__label__0	study interventions are recombinant CD40-ligand . melanoma skin diagnosis and no active cns metastases by ct scan or mri
__label__0	study interventions are Liposomal doxorubicin . colorectal cancer diagnosis and cardiovascular
__label__0	study interventions are BI 836909 . multiple myeloma diagnosis and indwelling central venous cateder or willingness to undergo intra venous central line placement
__label__0	study interventions are Immunoglobulins . recurrent fallopian tube carcinoma diagnosis and patients are allowed to receive but are not required to receive two additional cytotoxic regimens for management of recurrent or persistent disease with no more than one non platinum non taxane regimen
__label__0	study interventions are Paclitaxel . stage ovarian cancer diagnosis and patients must have recovered from the effects of recent surgery radiotherapy or other therapy
__label__0	study interventions are Antibodies, Monoclonal . recurrent verrucous carcinoma of the oral cavity diagnosis and must have undergone radiotherapy as component of prior treatment
__label__0	study interventions are Hormones . prostate cancer diagnosis and imaging examinations including emission computed tomography ect positron_emission tomography pet computed tomography ct and magnetic resonance imaging mri revealed non regional lymph node metastasis bone metastasis or visceral metastasis
__label__0	study interventions are Bendamustine Hydrochloride . diffuse large cell lymphoma diagnosis and no previous treatment
__label__0	study interventions are Nivolumab . recovered from all toxicities associated with prior treatment to acceptable baseline status for laboratory toxicity see below limits for inclusion or national cancer institute common terminology criteria for adverse events nci ctcae version doc three grade of zero or one except for toxicities not considered safety risk alopecia or vitiligo
__label__0	study interventions are Thalidomide . kidney cancer diagnosis and no diabetes mellitus
__label__0	study interventions are study of high risk factors . precancerous condition diagnosis and able to understand the procedures and the potential risks involved as determined by clinic staff
__label__0	study interventions are Androgens . prostate cancer diagnosis and patient characteristics
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and renal insufficiency s
__label__0	study interventions are Prednisone . testicular lymphoma diagnosis and bulky disease greater_than equal_than five cm in at least one dimension
__label__0	study interventions are Razoxane . unspecified adult solid tumor protocol specific diagnosis and platelet count greater_than one hundred zero mm³
__label__0	study interventions are Fludarabine . natural_killer cell lymphoblastic leukemia lymphoma diagnosis and bilirubin no more than doc mg dl alanine aminotransferase alt aspartate aminotransferase ast and alkaline phosphatase alp no more than five times the upper limit of normal uln
__label__0	study interventions are Fludarabine phosphate . stage iv adult immunoblastic large cell lymphoma diagnosis and unrelated donor
__label__0	study interventions are Interferon-gamma . lung cancer diagnosis and endocrine therapy
__label__0	study interventions are Antibodies . intraocular lymphoma diagnosis and may be treated in first cr
__label__0	study interventions are Pharmacological Study . dermatofibrosarcoma_protuberans diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Antibodies . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and must have undergone cranial irradiation
__label__0	study interventions are Oxaliplatin . stage iib gastric cancer diagnosis and bilirubin must be less_than upper limit of normal uln unless the patient has chronic grade one bilirubin elevation due to gilbert disease or similar syndrome due to slow_conjugation of bilirubin
__label__0	study interventions are [Ga-68]PSMA PET/MR . prostate cancer diagnosis and patients who are currently pregnant or breast feeding
__label__0	study interventions are Isotretinoin . neuroblastoma diagnosis and cardiovascular
__label__0	study interventions are Interleukin-2 . cutaneous cell lymphoma diagnosis and eighteen and older
__label__0	study interventions are Acetaminophen . non hodgkin lymphoma nhl diagnosis and adequate venous access for peripheral apheresis or consent to use temporary central venous catheter for apheresis
__label__0	study interventions are Antibodies, Monoclonal . stage ivb hepatocellular carcinoma diagnosis and abnormal pt inr may be considered with documented principal investigator pi approval if it is due to the use of anticoagulants for such patients normal pt inr must be available from before the start of anticoagulation treatment
__label__0	study interventions are Bortezomib . anaplastic large cell lymphoma diagnosis and life expectancy must be greater than three months
__label__0	study interventions are Cetuximab . lung cancer diagnosis and no significant history of uncontrolled cardiac disease including but not limited to any of the following
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent childhood spinal cord neoplasm diagnosis and at least six months since prior total body irradiation tbi craniospinal radiotherapy or radiotherapy to greater_than fifty of the pelvis
__label__0	study interventions are sPESI . symptomatic pulmonary embolism objectively confirmed according to the european society of cardiology criteria
__label__0	study interventions are Cisplatin . bladder cancer diagnosis and no clinically significant cardiac arrhythmia
__label__0	study interventions are Cediranib . recurrent adult primary liver cancer diagnosis and nyha class iii or iv heart disease
__label__0	study interventions are Irinotecan . breast cancer diagnosis and lesions on chest ray are allowed provided they are clearly defined and surrounded by aerated lung
__label__0	study interventions are Maytansine . tumor tissue blocks or fifteen twenty unstained tissue slides for confirmatory central laboratory hertwo status testing and other exploratory assessments
__label__0	study interventions are questionnaire administration . gastrointestinal cancer diagnosis and lost no more than ten of pre illness stable body weight
__label__0	study interventions are Antibodies . stage ivc lip and oral cavity squamous cell carcinoma diagnosis and platelets greater_than one hundred zero mcl
__label__0	study interventions are Pazopanib Hydrochloride . stage ivb thyroid gland medullary carcinoma diagnosis and uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness social situations that would or might reasonably be expected to limit compliance with study requirements
__label__0	study interventions are Immunoglobulins . stage iii midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and no evidence of active cns hemorrhage
__label__0	study interventions are Rituximab . diffuse large cell lymphoma dlbcl diagnosis and histologically confirmed aggressive cell dlbcl including fl transforming to dlbcl grade iii fl
__label__0	study interventions are Antibodies . stage iiia melanoma diagnosis and women of childbearing potential wocbp must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to twenty-six weeks after the last dose of investigational product in such manner that the risk of pregnancy is minimized in general the decision for appropriate methods to prevent pregnancy should be determined by discussions between the investigator and the study subject wocbp include any female who has experienced menarche and who has not undergone successful surgical sterilization hysterectomy bilateral tubal ligation or bilateral oophorectomy or is not post menopausal post menopause is defined as
__label__0	study interventions are Vorinostat . recurrent colon cancer diagnosis and bilirubin normal
__label__0	study interventions are Lenograstim . stage iii primary peritoneal cancer diagnosis and patient can read and understand sufficient english to be able to respond to questions posed by the study instruments
__label__0	study interventions are Cabozantinib S-malate . recurrent renal cell carcinoma diagnosis and patients with grade one prolonged qtc forty-five negative four hundred and eighty msec at the time of study enrollment should have correctable causes of prolonged qtc addressed if possible electrolytes medications
__label__0	study interventions are pharmacological study . childhood grade iii lymphomatoid granulomatosis diagnosis and serum albumin greater_than equal_than two dl
__label__0	study interventions are Antibodies, Monoclonal . undifferentiated fallopian tube carcinoma diagnosis and neuropathy sensory and motor less than or equal to ctep ctcae version doc grade one
__label__0	study interventions are Vitamin D . stage iii colon cancer diagnosis and participants must have normal organ and marrow function as defined below
__label__0	study interventions are Fluorouracil . adenocarcinoma of the stomach diagnosis and no serious medical or psychiatric illnesses which would prevent informed consent or otherwise limit survival to less than two years no history of refractory congestive heart failure or cardiomyopathy
__label__0	study interventions are Ganciclovir triphosphate . stage adult diffuse small cleaved cell lymphoma diagnosis and must have already been determined to be eligible for hct at city of hope_coh
__label__0	study interventions are Blood test: CA-125 biomarker . ovarian neoplasms diagnosis and diarrhoea constipation bowel or rectum feels full change in bowel habits constant urge to have bowel movement painful or burning bowel movements rectal pain painful defecation
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and no pregnant or breastfeeding individuals
__label__0	study interventions are Fluorouracil . stage iv lymphoepithelioma of the nasopharynx diagnosis and no history of allergic reaction attributed to compounds of similar chemical or biologic composition to docetaxel cisplatin carboplatin fluorouracil bevacizumab or other agents used in this study
__label__0	study interventions are Antibodies, Monoclonal . colorectal cancer diagnosis and capable of understanding and complying with the protocol requirements and has signed the informed consent document
__label__0	study interventions are microarray analysis . breast cancer diagnosis and hormone receptor status not specified
__label__0	study interventions are Everolimus . angiofibroma diagnosis and patients or his her guardian who agree to use the test drug npc twelveg gel or who want to participate in the trial again following participation in phase iii trial npc twelveg one
__label__0	study interventions are Mitomycins . squamous cell carcinoma head and neck diagnosis and histologically or cytologically confirmed incurable hnscc of the oral cavity oropharynx larynx hypopharynx and or level one three neck node with non cutaneous scc and unknown primary
__label__0	study interventions are Axitinib . malignant advanced solid tumors diagnosis and ecog performance status ps zero one
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and not specified
__label__0	study interventions are Vincristine . neuroblastoma diagnosis and patients must have performance status of zero one or two appendix i
__label__0	study interventions are Gefitinib . stage iva squamous cell carcinoma of the larynx diagnosis and platelet count of greater_than equal_than one hundred zero ul
__label__0	study interventions are Sirolimus . recurrent digestive system neuroendocrine tumor gone diagnosis and hemoglobin greater_than equal_than ninety l or greater_than equal_than nine dl
__label__0	study interventions are Ascorbic Acid . multiple myeloma and plasma cell neoplasm diagnosis and radiotherapy
__label__0	study interventions are Interferon-alpha . metastatic cancer diagnosis and gastrointestinal
__label__0	study interventions are Antibodies . stage iii ovarian epithelial cancer diagnosis and cytogenetic progression as evidenced by an increase in the percentage of philadelphia_chromosome ph one positive metaphases or phone positive cells by fluorescent in situ hybridization from complete cytogenetic response zero phone positive cells to partial response one thirty-four phone positive cells pr to minor response thirty-five ninety-four phone positive cells or mr to no response ninety-five onezerozero phone positive cells
__label__0	study interventions are Gemcitabine . neuroendocrine cancer diagnosis and must be able to achieve positive results on preliminary tests
__label__0	study interventions are Cyclosporins . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and marrow fibrosis
__label__0	study interventions are nonmyeloablative allogeneic hematopoietic stem cell transplantation . diagnosis by bone marrow biopsy not acceptable for follicular lymphomas
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and eighteen years of age
__label__0	study interventions are Oxaliplatin . stage iv extragonadal seminoma diagnosis and pulmonary embolism
__label__0	study interventions are Cetuximab . stage ivc oropharyngeal squamous cell carcinoma diagnosis and life expectancy of greater than eight weeks
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and who performance status of zero or one
__label__0	study interventions are Cyclophosphamide . patients must have precursor lymphoblastic leukemia or lymphoma
__label__0	study interventions are Pazopanib Hydrochloride . stage iv renal cell cancer diagnosis and double barrier method
__label__0	study interventions are Antibodies, Monoclonal . regional urothelial carcinoma of the renal pelvis and ureter diagnosis and no arterial thrombotic events within six months of registration including transient ischemic attack tia cerebrovascular accident cva peripheral arterial thrombus unstable angina or angina requiring surgical or medical intervention in the past six months or myocardial infarction mi patients with clinically significant peripheral artery disease claudication on less than one block are ineligible
__label__0	study interventions are Ifosfamide . leiomyosarcoma diagnosis and ten to less_than thirteen years doc mg dl male doc mg dl female
__label__0	study interventions are Hormones . prostate cancer diagnosis and at least four weeks since prior flutamide or ketoconazole six weeks for bicalutamide or nilutamide
__label__0	study interventions are Sirolimus . kaposiform_hemangioendotheliomas diagnosis and coagulopathy
__label__0	study interventions are Docetaxel . laryngeal neoplasms diagnosis and nutritional status appropriate
__label__0	study interventions are Immunoglobulin G . histologically confirmed high grade glioma who grade iii or iv at any site within the brain including the following
__label__0	study interventions are sargramostim . metastatic cancer diagnosis and no active psychotic disorder requiring pharmacotherapy
__label__0	study interventions are Protein Kinase Inhibitors . breast cancer diagnosis and inr normal provided the patient is not on warfarin therapy
__label__0	study interventions are Fludarabine phosphate . stage iii adult immunoblastic large cell lymphoma diagnosis and when evaluating patients for unrelated donor transplant higher degree of matching is preferred due to minimize the risk of gvhd the b drbone and dq loci comprising one0 possible alleles will be typed routinely for all unrelated transplants given the higher risk of trm in mismatched transplants rit is often the best way to mitigate the risk evolving data from the national marrow donor program now makes it possible to estimate the risks of donor recipient hla mismatch at the allele or antigen level the higher risk from hla mismatching must be carefully assessed with respect to the clinical urgency and the patient risk by the transplant physician antigen level mismatches at dq are inconsequential to transplant outcomes and are ignored with respect to donor selection for the purposes of this protocol with matching requirements confined to the eight loci involving hla b and drbone for the purpose of this protocol single antigen mismatch at hla b or with or without additional single allele level mismatch may participate in this protocol for voluntary unrelated donors blood or marrow patients must be at least antigen level matched at drbone
__label__0	study interventions are Exercise Education . pancreatic adenocarcinoma diagnosis and age eighteen years or older
__label__0	study interventions are Panobinostat . multiple myeloma diagnosis and must have achieved at least partial response pr prior to autologous hct and must not have progressive disease pd prior to the initiation of maintenance therapy
__label__0	study interventions are Camptothecin . progesterone receptor negative breast cancer diagnosis and her two not amplified by fluorescence in situ hybridization
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiic breast cancer diagnosis and the patient must have completed one of the procedures for evaluation of pathologic nodal status listed below
__label__0	study interventions are Ergocalciferols . stage iiic breast cancer diagnosis and prior documented bilateral oophorectomy or history of at least twelve months without spontaneous menstrual bleeding or have persistently postmenopausal estradiol in the past six months without menses and clinically in menopause at the judgment of the treating physician or age six0 or older with prior hysterectomy without oophorectomy or age less than six0 with prior hysterectomy without oophorectomy or in whom the status of the ovaries is unknown with documented fsh level demonstrating confirmatory elevation in the postmenopausal range for the lab
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and no evidence of severe or uncontrolled pulmonary disease
__label__0	study interventions are Antibodies . adult giant cell glioblastoma diagnosis and willing to provide mandatory blood and tissue samples for correlative research purposes phase and ii
__label__0	study interventions are Arsenic trioxide . multiple myeloma and plasma cell neoplasm diagnosis and hepatic
__label__0	study interventions are Vidarabine . t cell non hodgkin lymphoma diagnosis and adequate renal function defined as creatinine equal_than less_than doc mg dl adults or creatinine clearance greater_than forty ml min pediatrics
__label__0	study interventions are Medroxyprogesterone Acetate . breast cancer diagnosis and no concurrent chemotherapy
__label__0	study interventions are Heparin . hepatocellular carcinoma diagnosis and child pugh class or b
__label__0	study interventions are Mycophenolic Acid . stage ii contiguous adult diffuse large cell lymphoma diagnosis and donor
__label__0	study interventions are Leucovorin . recurrent rectal cancer diagnosis and no myocardial infarction within the past six months
__label__0	study interventions are Oxaliplatin . stage iii pancreatic cancer diagnosis and for advanced disease allowed as above
__label__0	study interventions are Capecitabine . locally advanced malignant neoplasm diagnosis and serum albumin greater_than doc gm dl
__label__0	study interventions are Sirolimus . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and fhcrc matching allowed will be grades doc to doc
__label__0	study interventions are Immunoglobulins . stage iiib non small cell lung cancer diagnosis and patients must not have had hemoptysis greater_than equal_than one two teaspoon within three months prior to registration
__label__0	study interventions are Dexamethasone acetate . mantle cell lymphoma diagnosis and absolute neutrophil count anc greater_than equal_than one thousand, five hundred cells microlitre
__label__0	study interventions are Gemcitabine . recurrent adenocarcinoma of the pancreas diagnosis and two observers will be required to assess kps
__label__0	study interventions are Antibodies . brain and central nervous system tumors diagnosis and no gross hemoptysis greater_than ½_teaspoon within the past two months
__label__0	study interventions are Immunoglobulin G . ovarian transitional cell carcinoma diagnosis and primary surgery and neoadjuvant chemotherapy with interval cytoreductive surgery patients
__label__0	study interventions are Methylprednisolone Hemisuccinate . splenic marginal zone lymphoma diagnosis and donor
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and absolute neutrophil count greater than or equal to doc ul
__label__0	study interventions are Antibodies, Monoclonal . recurrent adult liver carcinoma diagnosis and international normalized ratio inr equal_than less_than doc unless the patient is on full dose warfarin
__label__0	study interventions are Fludarabine . mantle cell lymphoma diagnosis and failed flu cyclophosphamide cy rituximab fcr combination chemotherapy at any time point or
__label__0	study interventions are DNA ploidy analysis . brain tumors diagnosis and biologic therapy
__label__0	study interventions are Vorinostat . stage grade two follicular lymphoma diagnosis and patients should have extinguished standard of care options prior to being considered eligible for this trial
__label__0	study interventions are Succinylcholine . recurrent gallbladder carcinoma diagnosis and arm cohort two
__label__0	study interventions are Cyclosporine . angioimmunoblastic cell lymphoma diagnosis and myelodysplastic syndrome equal_than less_than fifty years
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and at least four weeks since prior hormonal therapy radiotherapy
__label__0	study interventions are Celecoxib . recurrent non small cell lung cancer diagnosis and no evidence of coagulopathy defined as pt and or ptt equal_than less_than doc uln or platelets greater_than equal_than one hundred zero
__label__0	study interventions are Cyclophosphamide . small intestine lymphoma diagnosis and patients eligible for this trial will have high risk diseases that include but are not limited to
__label__0	study interventions are Methotrexate . a transitional cell component is not required in the setting of pure or extensive micropapillary tumors
__label__0	study interventions are counseling intervention . stage iv adult lymphoblastic lymphoma diagnosis and has internet and email access indicated by logon to site for consent and assessment
__label__0	study interventions are Liposomal doxorubicin . breast neoplasms diagnosis and negative pregnancy test urine or serum within seven days prior to registration for all women of childbearing potential
__label__0	study interventions are Immunoglobulins . stage iii verrucous carcinoma of the larynx diagnosis and women of childbearing potential and male participants who are sexually active must agree to use medically effective means of birth control
__label__0	study interventions are Liposomal doxorubicin . childhood nodular lymphocyte predominant hodgkin lymphoma diagnosis and doc mg dl one to five months
__label__0	study interventions are Antibodies, Monoclonal . neuroblastoma diagnosis and patients of childbearing or child fathering potential must be willing to use medically acceptable form of birth control which includes abstinence while they are being treated on this study and for sixty days following the last dose
__label__0	study interventions are Mechlorethamine . refractory non hodgkin lymphoma diagnosis and after induction chemotherapy
__label__0	study interventions are Fludarabine phosphate . diffuse large cell lymphoma transformed from follicular lymphoma diagnosis and normal cardiac ejection fraction and no evidence of pericardial effusion as determined by an echocardiogram
__label__0	study interventions are Prednisone . prostate cancer diagnosis and hematopoietic
__label__0	study interventions are Gemcitabine . stage iv gallbladder cancer diagnosis and patients must be able to comprehend and provide written informed consent
__label__0	study interventions are Capecitabine . palpable breast tumor size of greater_than two cm without involvement of the skin or muscle or evidence of inflammatory disease ttwo three
__label__0	study interventions are Staurosporine . recurrent squamous cell carcinoma of the hypopharynx diagnosis and hemoglobin greater_than ten dl
__label__0	study interventions are Gefitinib . stage ib non small cell lung cancer diagnosis and initiation of protocol treatment must begin within ten working days of patient randomization
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and men must practice complete abstinence or agree to use condom during sexual contact with fcbp even if they have had successful vasectomy
__label__0	study interventions are Methylprednisolone Hemisuccinate . multiple myeloma and plasma cell neoplasm diagnosis and in early relapse
__label__0	study interventions are Sorafenib . recurrent fallopian tube carcinoma diagnosis and renal
__label__0	study interventions are Nivolumab . ebv related non hodgkin lymphoma diagnosis and n negative or lymphoproliferative disease in first relapse and or refractory to at least one salvage chemotherapy or with primary refractory disease after at least two lines of therapy or in second or subsequent relapse
__label__0	study interventions are Interleukin-2 . stage iii small lymphocytic lymphoma diagnosis and no new york heart association class iii or iv congestive heart failure
__label__0	study interventions are Tacrolimus . recurrent adult diffuse large cell lymphoma diagnosis and partial cytogenetic remission
__label__0	study interventions are Mitogens . non melanomatous skin cancer diagnosis and no active gastrointestinal disease inflammatory bowel disease
__label__0	study interventions are Carboplatin . ovarian carcinosarcoma diagnosis and albumin greater than or equal to doc dl
__label__0	study interventions are diagnostic laboratory biomarker analysis . recurrent refractory childhood hodgkin lymphoma diagnosis and creatinine clearance or radioisotope gfr greater_than equal_than seventy ml min doc three two or serum creatinine based on age gender as follows
__label__0	study interventions are Cyclosporins . recurrent adult immunoblastic large cell lymphoma diagnosis and donor
__label__0	study interventions are Immunoglobulins . recurrent rectal cancer diagnosis and no history of allergic reactions hypersensitivity or intolerance to cetuximab and or compounds of similar chemical or biologic composition to pertuzumab or cetuximab other monoclonal antibodies such as bevacizumab that led to discontinuation of the drug
__label__0	study interventions are Everolimus . carcinoma non small cell lung diagnosis and one hundred and eighty-six times scr
__label__0	study interventions are Capecitabine . adenocarcinoma of the rectum diagnosis and not pregnant or nursing
__label__0	study interventions are Cyclophosphamide . recurrent childhood hodgkin lymphoma diagnosis and donor
__label__0	study interventions are Prednisolone acetate . lymphoma diagnosis and surgery
__label__0	study interventions are Vorinostat . recurrent childhood medulloblastoma diagnosis and biologic anti neoplastic agent
__label__0	study interventions are Bevacizumab . stage verrucous carcinoma of the larynx diagnosis and negative pregnancy test
__label__0	study interventions are Estradiol . malignant mesothelioma diagnosis and are able to swallow capsules
__label__0	study interventions are Etoposide . relapsed solid tumors diagnosis and prior therapy
__label__0	study interventions are alvespimycin hydrochloride . unspecified adult solid tumor protocol specific diagnosis and standard curative or palliative measures do not exist or are no longer effective or patient refused such measures
__label__0	study interventions are Rituximab . recurrent mantle cell lymphoma diagnosis and females of reproductive potential must adhere to the scheduled pregnancy testing as required in the revlimid risk evaluation and mitigation_strategy rems program
__label__0	study interventions are laboratory biomarker analysis . stage iii basal cell carcinoma of the lip diagnosis and hypericin
__label__0	study interventions are Anastrozole . solid tumors diagnosis and paclitaxel arm
__label__0	study interventions are Paclitaxel . stage iva uterine corpus cancer diagnosis and creatinine less than doc mg dl
__label__0	study interventions are Pharmaceutical Solutions . multiple myeloma and plasma cell neoplasm diagnosis and tachypnea defined as respiratory rate greater_than twenty breaths minute
__label__0	study interventions are Albumin-Bound Paclitaxel . adenocarcinoma of the lung diagnosis and maximum dose greater_than sixty-six gy allowed in only one lobar bronchus
__label__0	study interventions are Albumin-Bound Paclitaxel . lymphoma diagnosis and radiotherapy
__label__0	study interventions are endoscopic biopsy . lung cancer diagnosis and ecog zero two
__label__0	study interventions are High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox . non small cell lung cancer diagnosis and bone metastases index lesion in the ribs clavicle scapula upper extremities pelvis or posterior aspects of the lumbar vertebra lthree lfive or sacral sone sfive
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and ecog zero two life expectancy
__label__0	study interventions are Thalidomide . partial response of multiple myeloma or plasma cell leukemia diagnosis and absolute lymphocyte count greater_than equal_than one thousand mm three
__label__0	study interventions are Cisplatin . primary diagnosis of histologically proven adenocarcinoma of the stomach the gastro esophageal junction or an adenocarcinoma of the lower third of the esophagus
__label__0	study interventions are Dexamethasone acetate . myelodysplastic myeloproliferative neoplasms diagnosis and alkaline phosphatase less_than three times uln
__label__0	study interventions are Topotecan . unspecified adult solid tumor protocol specific diagnosis and greater than three months hematopoietic
__label__0	study interventions are Vidarabine . recurrent childhood large cell lymphoma diagnosis and acute myeloid leukemia with high risk features as defined by
__label__0	study interventions are Vinblastine . transitional cell cancer of the renal pelvis and ureter diagnosis and not specified hematopoietic
__label__0	study interventions are Tacrolimus . recurrent plasma cell myeloma diagnosis and deletion thirteenq by conventional karyotyping fish only not acceptable
__label__0	study interventions are Trebananib . mucinous adenocarcinoma
__label__0	study interventions are Antibodies, Monoclonal . recurrent prostate carcinoma diagnosis and hormones administered for nondisease related conditions insulin for diabetes allowed
__label__0	study interventions are Liposomal doxorubicin . b lymphoblastic lymphoma diagnosis and eastern cooperative oncology group ecog performance status zero to two
__label__0	study interventions are Erlotinib Hydrochloride . stage iii squamous cell carcinoma of the larynx diagnosis and negative pregnancy test
__label__0	study interventions are Everolimus . recurrent bladder carcinoma diagnosis and eligibility for phase one and phase two components
__label__0	study interventions are Vaccines . advanced melanoma diagnosis and clinically medically indicated procedure biopsy of lesions of recurrent disease palliative management via resection thoracentesis etc
__label__0	study interventions are Capecitabine . breast cancer diagnosis and negative pregnancy test
__label__0	study interventions are Pyridoxine . ovarian cancer diagnosis and recovered from prior surgery
__label__0	study interventions are Myomectomy . polyps plus up to two type zero or type myomas with at least one of the myomas being greater_than doc cm and less_than doc cm
__label__0	study interventions are Tacrolimus . adult grade iii lymphomatoid granulomatosis diagnosis and chronic myelogenous leukemia at the following stages
__label__0	study interventions are Cytarabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and relapsed or refractory acute lymphoblastic leukemia
__label__0	study interventions are Erlotinib Hydrochloride . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and protein less_than one on twenty-four hour urine collection
__label__0	study interventions are Gemcitabine . subjects with recurrent disease stage iii iv diagnosis of epithelial ovarian cancer fallopian tube cancer or primary peritoneal carcinoma
__label__0	study interventions are Endothelial Growth Factors . stage iiia breast cancer diagnosis and history of venous thrombosis in last twelve weeks
__label__0	study interventions are Vorinostat . recurrent childhood visual pathway glioma diagnosis and more than three weeks since prior myelosuppressive chemotherapy six weeks for nitrosourea
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and ecog zero three greater_than twelve years of age
__label__0	study interventions are Gemcitabine . cervical squamous cell carcinoma diagnosis and no concurrent clinically significant infection
__label__0	study interventions are Sapanisertib . glioblastoma diagnosis and hemoglobin greater_than equal_than nine dl
__label__0	study interventions are Prednisolone . diffuse large cell lymphoma diagnosis and hemoglobin greater_than nine dl absolute neutrophil count anc greater_than one five hundred mmthree and platelet count greater_than seventy-five zero mmthree
__label__0	study interventions are Brostallicin . myxoid liposarcoma diagnosis and life expectancy of at least three months
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and creatinine greater_than doc mg dl
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and renal function creatinine clearance greater_than thirtyml min based on cockroff
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and anemia hemoglobin less_than ten dl or two less_than normal
__label__0	study interventions are Sodium thiosulfate . extragonadal germ cell tumor diagnosis and at least six months since prior hematopoietic stem cell transplantation
__label__0	study interventions are Maleic acid . periampullary adenocarcinoma diagnosis and negative pregnancy test
__label__0	study interventions are Cortisone . cognitive side effects of cancer therapy diagnosis and any wbc with
__label__0	study interventions are Fludarabine phosphate . gastric cancer diagnosis and fertile patients must use effective contraception four weeks prior to during and for six months after completion of study therapy male patients must use barrier method contraception
__label__0	study interventions are Memory Intervention . cancer survivor diagnosis and able to comprehend and speak english
__label__0	study interventions are Tacrolimus . recurrent cutaneous cell non hodgkin lymphoma diagnosis and donor
__label__0	study interventions are Immunoglobulin G . recurrent breast carcinoma diagnosis and beta hcg negative in premenopausal women
__label__0	study interventions are alvespimycin hydrochloride . recurrent squamous cell carcinoma of the oropharynx diagnosis and more than four weeks since prior radiotherapy
__label__0	study interventions are Confocal Micro Endoscopy . malignant pharyngo laryngeal tumors diagnosis and eighteen years
__label__0	study interventions are Immunoglobulins . salivary gland squamous cell carcinoma diagnosis and no uncontrolled hypertension
__label__0	study interventions are Albumin-Bound Paclitaxel . erbbtwo positive stage iii breast cancer diagnosis and karnofsky performance status of seventy or higher
__label__0	study interventions are PNT2258 . prostate cancer diagnosis and platelets one hundred zero µl
__label__0	study interventions are Fludarabine phosphate . metastatic cutaneous melanoma diagnosis and the experimental treatment being evaluated in this protocol depends on an intact immune system
__label__0	study interventions are Gemcitabine . metastatic breast cancer diagnosis and patients may have had prior chest wall irradiation or palliative radiation to bony sites for control of pain or fracture
__label__0	study interventions are lonafarnib . brain and central nervous system tumors diagnosis and radiotherapy
__label__0	study interventions are Letrozole . breast cancer diagnosis and underwent prior bilateral oophorectomy
__label__0	study interventions are Cisplatin . patients must have had two or fewer cycles doses of induction chemotherapy and must have had tumor response to the induction therapy
__label__0	study interventions are BB 1101 . childhood cancer diagnosis and carboplatin
__label__0	study interventions are tanespimycin . kidney cancer diagnosis and karnofsky seventy one hundred
__label__0	study interventions are gene expression analysis . kidney cancer diagnosis and not specified
__label__0	study interventions are Sorafenib . gastrointestinal stromal tumor diagnosis and rifampin
__label__0	study interventions are Gemcitabine . kidney cancer diagnosis and at least four weeks since prior chemotherapy and recovered
__label__0	study interventions are Abemaciclib . rhabdomyosarcoma recurrent refractory diagnosis and participants must have fully recovered from the acute toxic effects of chemotherapy immunotherapy or radiotherapy prior to entering this study
__label__0	study interventions are Romidepsin . metastatic gastrointestinal carcinoid tumor diagnosis and no left ventricular hypertrophy by ekg
__label__0	study interventions are Cyclosporins . stage adult immunoblastic large cell lymphoma diagnosis and chronic myelogenous leukemia
__label__0	study interventions are Gemcitabine . peritoneal cavity cancer diagnosis and chemotherapy
__label__0	study interventions are Gemcitabine . symptomatic congestive heart failure
__label__0	study interventions are Carboplatin . histologically confirmed primary lung carcinoma
__label__0	study interventions are Cisplatin . histologic cytologic or radiologic documentation of metastatic squamous cell carcinoma or adenocarcinoma of the esophagus or gastroesophageal junction
__label__0	study interventions are Levoleucovorin . adenocarcinoma of the colon diagnosis and no serious non healing wound ulcer or bone fracture
__label__0	study interventions are Niacinamide . women affected by histologically proven metastatic breast cancer
__label__0	study interventions are Dacarbazine . should woman become pregnant or suspect she is pregnant while participating in this protocol study she will inform her treating physician immediately
__label__0	study interventions are Cetuximab . colorectal cancer diagnosis and bilirubin less_than doc uln
__label__0	study interventions are Pemetrexed . carcinoma non small cell lung diagnosis and no prior chemotherapy biologic or targeted therapy for any malignancy
__label__0	study interventions are Pentetic Acid . colon cancer diagnosis and
__label__0	study interventions are Metronidazole . head and neck cancer diagnosis and received prior therapy with possible survival benefit or refused such therapy
__label__0	study interventions are Camptothecin . recurrent lymphoepithelioma of the oropharynx diagnosis and must have undergone prior therapy with an anthracycline and taxane either in the adjuvant or metastatic setting
__label__0	study interventions are Bevacizumab . stage iva nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and no known brain metastases
__label__0	study interventions are Staurosporine . must have had tumor progression following blockade of both testicular and adrenal androgens
__label__0	study interventions are Sorafenib . cancer diagnosis and life expectancy of at least twelve weeks
__label__0	study interventions are O(6)-benzylguanine . recurrent childhood cerebral astrocytoma diagnosis and dexamethasone
__label__0	study interventions are Cognitive Assessment . limited stage small cell lung carcinoma diagnosis and patients must sign study specific informed consent prior to study entry
__label__0	study interventions are Hydroxyurea . stage iii inverted papilloma of the paranasal sinus and nasal cavity diagnosis and no known brain metastases
__label__0	study interventions are Prednisone . prostate cancer diagnosis and disease progression is defined as development of new metastatic lesions or greater_than two consecutive rises in prostate specific antigen psa over reference value
__label__0	study interventions are Niacinamide . stage iv rectal cancer diagnosis and progressive disease during or within six months of most recent prior chemotherapy regimen bevacizumab fluoropyrimidine oxaliplatin or irinotecan based treatment or considered ineligible for standard therapy
__label__0	study interventions are Cisplatin . bladder cancer diagnosis and ttwo gthree only or tthree four any nzero two or any none two mzero
__label__0	study interventions are Citric Acid . multiple myeloma diagnosis and platelets greater_than fifty zero mmthree independent of transfusion
__label__0	study interventions are Cetuximab . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional upper limit of normal
__label__0	study interventions are Dexamethasone 21-phosphate . relapsed and refractory multiple myeloma diagnosis and hemoglobin greater_than doc dl
__label__0	study interventions are Low dose total body irradiation . non hodgkin lymphoma diagnosis and good performance status and normal initial normal blood count
__label__0	study interventions are Cyclophosphamide . brain and central nervous system tumors diagnosis and ecog zero three except patients with posterior_fossa syndrome
__label__0	study interventions are Interleukin-2 . stage iii grade two follicular lymphoma diagnosis and at least four weeks since prior radiotherapy
__label__0	study interventions are Lenalidomide . recurrent cutaneous cell non hodgkin lymphoma diagnosis and measurable and or evaluable disease per lugano classification
__label__0	study interventions are Methotrexate . lymphoma diagnosis and non investigational antiretroviral and antiviral medications medications for mycobacterium_avium disease characteristics
__label__0	study interventions are ß-elemene . anaplastic oligoastrocytoma diagnosis and secondary outcome measure
__label__0	study interventions are Liver Extracts . cholangiocarcinoma diagnosis and patients with none disease metastasis to lymph nodes within hepatoduodenal ligament will remain eligible for the protocol
__label__0	study interventions are Mycophenolic Acid . stage ii contiguous adult burkitt lymphoma diagnosis and fhcrc matching allowed will be grades doc to doc
__label__0	study interventions are Fluorouracil . gastric cancer diagnosis and see appendix for tnm staging guide
__label__0	study interventions are Lenalidomide . stage multiple myeloma diagnosis and step ii
__label__0	study interventions are Pazopanib . small cell lung cancer diagnosis and disease must be measurable according to recist doc
__label__0	study interventions are Bendamustine Hydrochloride . multiple myeloma diagnosis and haemoglobin greater_than eight dl
__label__0	study interventions are Albumin-Bound Paclitaxel . women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation should woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study for the duration of study participation and four months after completion of bmn six hundred and seventy-three administration
__label__0	study interventions are BB 1101 . stage multiple myeloma diagnosis and not currently prescribed zidovudine or stavudine
__label__0	study interventions are Sorafenib . patients with relapsed or refractory solid tumors with no viable treatment options
__label__0	study interventions are Lomustine . glioblastoma multiforme diagnosis and treatment for active peptic ulcer disease in the past six months
__label__0	study interventions are Interleukin-4 . breast cancer diagnosis and at least four weeks since prior chemotherapy six weeks for nitrosoureas or mitomycin
__label__0	study interventions are Cyclophosphamide . recurrent adult diffuse large cell lymphoma diagnosis and preservation of renal function serum creatinine did not increase by more than two fold above the normal range
__label__0	study interventions are Camptothecin . liver cancer diagnosis and creatinine no greater than doc mg dl cardiovascular
__label__0	study interventions are Laboratory Biomarker Analysis . recurrent adult diffuse large cell lymphoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and white blood cell count wbc greater_than three zero mm three
__label__0	study interventions are gamma-secretase/Notch signalling pathway inhibitor RO4929097 . superficial spreading malignant melanoma diagnosis and patients must not have qtcf greater_than four hundred and fifty msec males or qtcf greater_than four hundred and seventy msec females
__label__0	study interventions are Temozolomide . lung cancer diagnosis and karnofsky performance status sixty one hundred
__label__0	study interventions are Rituximab . stage iii adult diffuse small cleaved cell lymphoma diagnosis and note
__label__0	study interventions are Dexamethasone acetate . recurrent adult lymphoblastic lymphoma diagnosis and creatinine clearance crcl greater than fifty ml per minute all tests must be performed within twenty-eight days prior to registration
__label__0	study interventions are Gemcitabine . must have measurable disease that can be assessed using response evaluation in solid tumors recist doc defined as the presence of at least one lesion on mri or ct scan that can be accurately measured with the longest diameter of ten mm in at least one dimension
__label__0	study interventions are Gemcitabine . primary peritoneal cavity cancer diagnosis and prior concurrent therapy
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and serum component absolute increase must be greater_than doc one hundred ml and or urine component absolute increase must be greater_than two hundred mg per twenty-four and or
__label__0	study interventions are Mesna . supra_tentorial primative_neuro ectodermal tumor pnet diagnosis and pulmonary
__label__0	study interventions are Antibodies . lung cancer diagnosis and at least two weeks since prior thoracic or other major surgery and recovered
__label__0	study interventions are Etoposide phosphate . stage ii childhood hodgkin lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Dasatinib . lung cancer diagnosis and phase ii only
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and subjects must have the following laboratory values
__label__0	study interventions are Fludarabine . lymphoma diagnosis and doc to seventy
__label__0	study interventions are Cyclosporins . stage iv grade three follicular lymphoma diagnosis and myelodysplastic syndrome mds myeloproliferative disorder mpd
__label__0	study interventions are Erlotinib Hydrochloride . pancreatic ductal adenocarcinoma diagnosis and women of childbearing potential and male participants must practice adequate contraception
__label__0	study interventions are Carboplatin . ovary cancer diagnosis and written informed consent
__label__0	study interventions are Vitamins . refractory anaplastic large cell lymphoma diagnosis and patients can be enrolled up through day one of cycle three of therapy this includes the following disease types
__label__0	study interventions are Mitomycins . unresectable intrahepatic cholangiocarcinoma diagnosis and albumin greater_than doc mg dl
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and all patients must have developed progressive disease pd while receiving or within six months after discontinuing palliative gemcitabine based chemotherapy
__label__0	study interventions are Bevacizumab . liver cancer diagnosis and proteinuria less_than two positive by urine dipstick or urine protein less_than one by two4 hour urine collection
__label__0	study interventions are BB 1101 . stage iiib primary peritoneal cancer diagnosis and patients with gog performance status of zero one or two
__label__0	study interventions are Leucovorin . recurrent rectal cancer diagnosis and no psychiatric illness or social situation that would preclude study compliance
__label__0	study interventions are Maleic acid . recurrent laryngeal squamous cell carcinoma diagnosis and peripheral vascular disease
__label__0	study interventions are Interleukin-2 . lymphoma diagnosis and doc to sixty-five performance status
__label__0	study interventions are Cyclophosphamide . recurrent small lymphocytic lymphoma diagnosis and serum glutamic oxaloacetic transaminase sgot less_than two times the normal or clearance by ccf physician
__label__0	study interventions are Paclitaxel . stage iiib non small cell lung cancer diagnosis and patients with history of hypertension must be well controlled less_than one hundred and fifty one hundred on stable regimen of anti hypertensive therapy
__label__0	study interventions are Romidepsin . splenic marginal zone lymphoma diagnosis and if currently not on anticoagulation medication willing and able to take aspirin three hundred and twenty-five mg daily note
__label__0	study interventions are Camptothecin . stage iiic rectal cancer diagnosis and sgot ast equal_than less_than three uln obtained equal_than less_than four weeks prior to randomization
__label__0	study interventions are Computed Tomography . neoplasm diagnosis and they are over eighteen years of age
__label__0	study interventions are Fludarabine . lymphoma diagnosis and patients must have performance status of zubrod three or better
__label__0	study interventions are Carboplatin . stage iv ovarian cancer diagnosis and prothrombin time pt such that international normalized ratio inr is equal_than less_than doc or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus and partial prothrombin time ptt less_than doc times the upper limit of normal heparin lovenox or alternative anticoagulants are acceptable
__label__0	study interventions are questionnaire administration . medullary ductal breast carcinoma with lymphocytic infiltrate diagnosis and exclusion
__label__0	study interventions are Asparaginase . lymphoma participants without bone marrow involvement must have
__label__0	study interventions are Bevacizumab . lung cancer diagnosis and disease characteristics
__label__0	study interventions are Dasatinib . stage iia pancreatic cancer diagnosis and asat sgot and alat sgpt equal_than less_than doc unl
__label__0	study interventions are Fludarabine phosphate . recurrent grade one follicular lymphoma diagnosis and toxicity related to prior therapy must either have returned to equal_than less_than grade three baseline or deemed irreversible
__label__0	study interventions are Immunoglobulins . recurrent squamous cell carcinoma of the larynx diagnosis and prior therapy with agents targeting blocking the epidermal growth factor receptor cetuximab and erlotinib is allowable
__label__0	study interventions are Etanercept . adenocarcinoma diagnosis and any concurrent illness that would constitute hazard to participation in study
__label__0	study interventions are Sirolimus . recurrent childhood large cell lymphoma diagnosis and waldenstrom macroglobulinemia must have failed two courses of therapy
__label__0	study interventions are Niacinamide . gliosarcoma diagnosis and history physical examination within fourteen days prior to study registration
__label__0	study interventions are Melphalan . stage iii adult immunoblastic large cell lymphoma diagnosis and unrelated donor
__label__0	study interventions are Carboplatin . stage iib ovarian cancer diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred mcl
__label__0	study interventions are proteomic profiling . breast cancer diagnosis and endocrine therapy
__label__0	study interventions are Sirolimus . sarcoma diagnosis and antifungals voriconazole itraconazole or ketoconazole
__label__0	study interventions are Laboratory Biomarker Analysis . recurrent mantle cell lymphoma diagnosis and prior to administration of ibrutinib day sixty to day ninety post hematopoietic cell transplant
__label__0	study interventions are Paclitaxel . urethral cancer diagnosis and cardiovascular
__label__0	study interventions are GM-CSF . melanoma skin diagnosis and life expectancy greater than four months in the opinion of the study clinician
__label__0	study interventions are Lidocaine . have an automatic implantable_cardioverter defibrillator_aicd or cardiac pacemaker
__label__0	study interventions are Doxorubicin . parameningeal and paraspinal tumors allowed
__label__0	study interventions are Cyclosporins . hodgkin or non hodgkin lymphoma beyond first complete remission cr or in first cr with features of high risk disease including but not limited to
__label__0	study interventions are Bevacizumab . colorectal cancer metastatic diagnosis and life expectancy greater_than six months
__label__0	study interventions are Antibodies, Monoclonal . stage ivc lip and oral cavity squamous cell carcinoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt less_than doc institutional upper limit of normal
__label__0	study interventions are Cyclophosphamide . sarcoma diagnosis and not specified
__label__0	study interventions are Antibodies, Monoclonal . stage iv salivary gland cancer diagnosis and prior cetuximab is permitted if it was given for no more than nine doses in combination with radiation therapy or chemoradiation therapy for initial treatment of locally advanced disease
__label__0	study interventions are Fludarabine phosphate . hepatocellular carcinoma diagnosis and ability to receive oral medication
__label__0	study interventions are Pentostatin . myelodysplastic myeloproliferative neoplasm diagnosis and donor must be medically fit to undergo the apheresis procedure institutional guidelines for apheresis
__label__0	study interventions are Immunoglobulins . contiguous stage ii adult diffuse mixed cell lymphoma diagnosis and ecog performance status of equal_than less_than two at study entry karnofsky performance status of greater_than equal_than seventy at study entry
__label__0	study interventions are Folic Acid . primary peritoneal serous adenocarcinoma diagnosis and creatinine equal_than less_than doc mg dl
__label__0	study interventions are Fludarabine . lymphoma diagnosis and no progressive or refractory disease
__label__0	study interventions are Vidarabine . metastatic melanoma diagnosis and chemistry
__label__0	study interventions are Cyclosporine . noncontiguous stage ii grade three follicular lymphoma diagnosis and donor
__label__0	study interventions are Melphalan . multiple myeloma and plasma cell neoplasm diagnosis and stem cell mobilization allowed
__label__0	study interventions are Cortisol succinate . prostate cancer diagnosis and no concurrent terfenadine_astemizole cisapride or other medicines known to interact with ketoconazole
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and evidence of evolution to aml refractory anemia with excess blasts raeb or raeb in transformation
__label__0	study interventions are Medical Chart Review . cancer risk diagnosis and limited to those patients who are registered for outpatient or inpatient care at university of southern california usc norris
__label__0	study interventions are Erlotinib Hydrochloride . stage iv verrucous carcinoma of the oral cavity diagnosis and no cardiac arrhythmia
__label__0	study interventions are Pemetrexed . colorectal cancer metastatic diagnosis and patients must have normal organ and marrow function as defined below
__label__0	study interventions are cilengitide . stage iii prostate cancer diagnosis and bilirubin within normal limits
__label__0	study interventions are Liposomal doxorubicin . ovarian cancer diagnosis and ast alt less_than two times upper limit of normal uln
__label__0	study interventions are Fulvestrant . metastatic breast cancer diagnosis and ambulatory outpatient with eastern cooperative oncology group ecog performance status of zero to two at study entry
__label__0	study interventions are Fluorouracil . pancreatic cancer diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Levoleucovorin . stage ivb colon cancer diagnosis and ast sgot alt sgpt equal_than less_than doc institutional upper limit of normal equal_than less_than five institutional upper limit of normal for patients with liver metastatsis
__label__0	study interventions are Imatinib Mesylate . breast cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Hormones . malignant tumor of breast diagnosis and able to swallow and retain oral medication
__label__0	study interventions are AUY922 . gastrointestinal stromal tumor diagnosis and women of childbearing potential and men must agree to use accepted methods of contraception during the course of the study and at least three months after last dose of treatment
__label__0	study interventions are Fludarabine . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and subjects must be ineligible for conventional myeloablative transplantation
__label__0	study interventions are Fludarabine phosphate . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and fhcrc matching allowed will be grade doc to doc
__label__0	study interventions are Capecitabine . pancreatic cancer diagnosis and endocrine therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . esophageal cancer diagnosis and no grade two or greater peripheral neuropathy
__label__0	study interventions are Paclitaxel . undifferentiated ovarian carcinoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Camptothecin . high grade glioma diagnosis and one four cmthree
__label__0	study interventions are Camptothecin . adult gliosarcoma diagnosis and patient must be able to understand and be willing to sign written informed consent document
__label__0	study interventions are Docetaxel . metastatic advanced gastric cancer diagnosis and histologically confirmed metastatic or recurrent agc
__label__0	study interventions are Niacinamide . recurrent pancreatic cancer diagnosis and platelets greater_than equal_than one hundred zero cells mm three
__label__0	study interventions are Docetaxel . ductal adenocarcinoma of the prostate is included
__label__0	study interventions are Antibodies, Monoclonal . neuroblastoma diagnosis and donor is hiv negative
__label__0	study interventions are Carboplatin . non small cell lung cancer diagnosis and patients who are suitable for treatment with radical intent using concurrent chemotherapy and radiation
__label__0	study interventions are Methotrexate . brain tumor recurrent diagnosis and life expectancy of at least twelve weeks in the opinion of the pi
__label__0	study interventions are Busulfan . precursor myeloid neoplasms diagnosis and human leukocyte antigen hla identical sibling donor or matched unrelated min
__label__0	study interventions are Trametinib . stage iv skin melanoma diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than doc iuln or less_than five iuln for patients with known liver metastases
__label__0	study interventions are Carboplatin . epithelial ovarian cancer diagnosis and laboratory requirements
__label__0	study interventions are Niacinamide . neoplasms diagnosis and absolute neutrophil count anc greater_than or equal to one five hundred mmthree
__label__0	study interventions are Fludarabine phosphate . hodgkin lymphoma diagnosis and these stem cells may have been collected from pbsc pheresis bone marrow harvest or the combination
__label__0	study interventions are cytology specimen collection procedure . precancerous condition diagnosis and disease characteristics
__label__0	study interventions are FlexHD . breast neoplasm diagnosis and no diabetes mellitus iddm and non iddm
__label__0	study interventions are Imatinib Mesylate . recurrent grade three follicular lymphoma diagnosis and no evidence of biliary sepsis
__label__0	study interventions are Docetaxel . head and neck cancer diagnosis and isoniazid
__label__0	study interventions are Pemetrexed . gestational_trophoblastic tumor diagnosis and no other prior chemotherapy
__label__0	study interventions are Observation/Standard Therapy . malignant neoplasm of breast diagnosis and also participants in this situation would not be required to have additional post mastectomy radiation therapy
__label__0	study interventions are external beam radiation therapy . stage iv prostate cancer diagnosis and white blood cell wbc greater_than equal_than two five hundred cells ul
__label__0	study interventions are Antibodies . unspecified childhood solid tumor protocol specific diagnosis and at least four months since prior craniospinal radiotherapy
__label__0	study interventions are Fluorouracil . islet cell tumor diagnosis and no medically uncontrolled seizures
__label__0	study interventions are Bevacizumab . recurrent rectal cancer diagnosis and no uncontrolled intercurrent illness including but not limited to any of the following
__label__0	study interventions are Everolimus . malignant mesothelioma diagnosis and recovered from all prior therapy
__label__0	study interventions are Capecitabine . cervical adenosquamous carcinoma diagnosis and see disease characteristics
__label__0	study interventions are Antibodies, Monoclonal . adult lymphocyte predominant hodgkin lymphoma diagnosis and baseline left ventricular ejection fraction lvef by multi gated acquisition scan muga or echocardiogram echo must be greater_than equal_than forty-five
__label__0	study interventions are Antibodies . lymphoma diagnosis and cranial neuropathies secondary to underlying malignancy
__label__0	study interventions are Azacitidine . melanoma diagnosis and prior treatment with vemurafenib will be allowed must not have taken hypomethylating agent
__label__0	study interventions are Everolimus . advanced gastric cancer diagnosis and measurable disease lesions must be accurately measured in at least one dimension with longest diameter greater_than twenty mm using conventional techniques or greater_than ten mm with spiral ct scan with minimum lesion size no less than double the slice_thickness
__label__0	study interventions are Guanabenz . bone cancer diagnosis and females of childbearing potential must have negative pregnancy test less_than equal_than twenty-eight days prior to registration
__label__0	study interventions are Bevacizumab . recurrent primary peritoneal carcinoma diagnosis and prothrombin time pt such that international normalized ratio inr is less than or equal to doc uln or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin and partial thromboplastin time ptt less than or equal to doc uln
__label__0	study interventions are U3-1784 . hepatocellular cancer hcc diagnosis and doc institutional uln
__label__0	study interventions are Doxorubicin . soft tissue sarcoma diagnosis and three or more lung lesions in total
__label__0	study interventions are Dacarbazine . adult anaplastic oligodendroglioma diagnosis and no concurrent full dose anticoagulants warfarin or low molecular weight heparin
__label__0	study interventions are O(6)-benzylguanine . brain and central nervous system tumors diagnosis and evaluable residual disease by contrast enhanced mri or ct scan
__label__0	study interventions are Fludarabine phosphate . stage iii grade three follicular lymphoma diagnosis and unrelated donor
__label__0	study interventions are Pembrolizumab . metastatic triple negative breast cancer diagnosis and previously treated with an anthracycline and or taxane in the neoadjuvant adjuvant or metastatic setting
__label__0	study interventions are Immunoglobulin G . recurrent melanoma diagnosis and immunotherapy
__label__0	study interventions are Albumin-Bound Paclitaxel . cervical cancer diagnosis and calgb zero two hematopoietic
__label__0	study interventions are Staurosporine . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and no concurrent granulocyte colony stimulating factors filgrastim csf or sargramostim gm csf during the first course of study
__label__0	study interventions are Doxorubicin . breast cancer stage iv diagnosis and fna or core biopsy of node is cytologically or histologically suspicious or positive
__label__0	study interventions are Histone Deacetylase Inhibitors . small intestine lymphoma diagnosis and any contraindication to safely using prophylactic anticoagulation
__label__0	study interventions are Hydroxyurea . recurrent squamous cell carcinoma of the oropharynx diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab or other agents used in this study
__label__0	study interventions are Paclitaxel . ovarian cancer diagnosis and subjects with one of the following relapsed and or refractory cell malignancies with disease progression following up to three prior systemic treatment regimens
__label__0	study interventions are Rituximab . recurrent marginal zone lymphoma diagnosis and patients must have an expected survival of greater_than sixty days and must be free of major infection including human immunodeficiency virus hiv
__label__0	study interventions are Bevacizumab . chromophobe carcinoma
__label__0	study interventions are Lenograstim . recurrent grade one follicular lymphoma diagnosis and donor
__label__0	study interventions are Freund's Adjuvant . non melanomatous skin cancer diagnosis and no known hiv positivity
__label__0	study interventions are Mechlorethamine . refractory plasma cell myeloma diagnosis and no concurrent medications that are strong inducers inhibitors or substrates of cypthreeafour
__label__0	study interventions are Vidarabine . recurrent grade two follicular lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are 1.2.Laser Ablation Device . organ confined clinical tonec or clinical ttwoa prostate cancer that is visualized on mr imaging
__label__0	study interventions are Everolimus . ovarian sarcoma diagnosis and negative pregnancy test
__label__0	study interventions are Nefopam . breast neoplasm diagnosis and american society of anesthesiologists physical status or ii
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Ketoconazole . prostate cancer diagnosis and patients receiving bicalutamide or nilutamide must have had greater_than one of the psa values obtained greater_than six weeks after antiandrogen discontinuation
__label__0	study interventions are Cyclophosphamide . wilms tumor diagnosis and zero to less_than four years male and female maximum cpk
__label__0	study interventions are Etoposide phosphate . recurrent plasma cell myeloma diagnosis and any abnormal karyotype by metaphase analysis except for isolated eleven fourteen
__label__0	study interventions are Vorinostat . stage iv adult immunoblastic large cell lymphoma diagnosis and myelodysplastic syndrome unclassified
__label__0	study interventions are Vidarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and hodgkin disease hd
__label__0	study interventions are Goserelin . recurrent prostate cancer diagnosis and performance status less_than two
__label__0	study interventions are Doxorubicin . localized transitional cell cancer of the renal pelvis and ureter diagnosis and absence of metastatic disease on radiographic imaging
__label__0	study interventions are Antibodies, Monoclonal . rhabdomyosarcoma diagnosis and has uncontrolled brain or leptomeningeal metastases
__label__0	study interventions are Gemcitabine . progesterone recepto negative negative breast cancer diagnosis and human epidermal growth factor receptor two hertwo negative as per american society of clinical oncology
__label__0	study interventions are Dexamethasone 21-phosphate . breast cancer diagnosis and signed informed consent
__label__0	study interventions are Trastuzumab . stage ia breast cancer diagnosis and be chemotherapy naïve
__label__0	study interventions are Aldesleukin . ovarian cancer diagnosis and standard curative or palliative measures do not exist are no longer effective have been completed or have been refused
__label__0	study interventions are Fludarabine phosphate . mixed lineage leukemia mll rearranged nine twenty-two qthirty-four qone doc complex cytogenetics five or more chromosomal abnormalities high white blood cell wbc at diagnosis greater_than equal_than thirty zero for lineage or greater_than equal_than five0 zero for lineage
__label__0	study interventions are Methylprednisolone acetate . hiv associated lymphoma
__label__0	study interventions are Tirapazamine . stage iia cervical cancer diagnosis and no uncontrolled hypertension
__label__0	study interventions are Pharmacogenomic studies . peripheral cell lymphoma diagnosis and patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug
__label__0	study interventions are Oxaliplatin . pancreatic cancer diagnosis and endocrine therapy
__label__0	study interventions are Floxuridine . resected liver metastases from colorectal cancer diagnosis and total bilirubin twomg dl direct bilirubin equal or less than doc times upper limit of normal uln alanine aminotransferase alt no greater than doc times uln aspartate aminotransferase ast no greater than doc times uln serum creatinine no greater than uln or glomerular filtration rate equal or greater than sixty ml min doc threem two
__label__0	study interventions are Epothilone B . recurrent prostate cancer diagnosis and creatinine equal_than less_than doc mg dl
__label__0	study interventions are Paclitaxel . pancreatic cancer diagnosis and tumour free margins could be achieved
__label__0	study interventions are Prednisolone . lymphoma diagnosis and performance status
__label__0	study interventions are Epothilone B . ovarian neoplasms diagnosis and must have life expectancy of greater than three three months
__label__0	study interventions are Interleukin-12 . recurrent malignant testicular germ cell tumor diagnosis and adequate hematopoietic cardiac renal and hepatic function
__label__0	study interventions are Melphalan . patients with multiple myeloma mm or systemic light chain amyloidosis who are receiving high dose melphalan hdm and autologous peripheral blood stem cell transplantation asct
__label__0	study interventions are Salvage stereotactic radiosurgery arm . neoplasm metastasis diagnosis and surgical resection for the largest brain metastases has achieved
__label__0	study interventions are Gemcitabine . biliary tract cancer diagnosis and creatinine
__label__0	study interventions are Topotecan . rhabdomyosarcoma diagnosis and patients must be greater than or equal to one year of age but less than or equal to twenty-five years of age
__label__0	study interventions are alpha-Tocopherol . colorectal cancer diagnosis and affiliated to french national health insurance
__label__0	study interventions are Fludarabine phosphate . non hodgkins lymphoma diagnosis and two ucb units selected according to current mskcc unit selection algorithm
__label__0	study interventions are quality-of-life assessment . stage iii lymphoepithelioma of the nasopharynx diagnosis and patients must sign study specific informed consent form
__label__0	study interventions are becatecarin . recurrent small cell lung cancer diagnosis and performance status
__label__0	study interventions are Cisplatin . melanoma skin diagnosis and liver function tests less_than three times the upper limit of normal
__label__0	study interventions are questionnaire administration . seeking care at the ireland cancer center university hospitals and all other satellite sites
__label__0	study interventions are Podophyllotoxin . stage diffuse large cell lymphoma diagnosis and patients with hbsag negative but hbcab positive regardless of hbsab status should have hepatitis virus hbv deoxyribonucleic acid dna testing done and protocol eligibility determined as follows
__label__0	study interventions are Fludarabine phosphate . myelodysplastic myeloproliferative neoplasms diagnosis and chemotherapy
__label__0	study interventions are Cyclophosphamide . splenic marginal zone lymphoma diagnosis and normal karyotype who are fltthree_itd negative and npmone positive in the absence of kit mutations
__label__0	study interventions are Methotrexate . small intestine lymphoma diagnosis and persistent thrombocytosis greater_than one thousand ten nine l
__label__0	study interventions are TB-403 100mg/kg . relapsed or refractory medulloblastoma mb part also include neuroblastoma nb ewing sarcoma es and alveolar rhabdomyosarcoma arms diagnosis and have no symptoms of cranial hypertension or convulsions within fourteen days before cycle one day one anti epileptic drugs and corticoids are allowed to control any preexisting symptoms
__label__0	study interventions are Laparoscopic surgery . gastrointestinal stromal tumor diagnosis and the informed consent has been obtained from the patient
__label__0	study interventions are Antibodies . stage ii grade two contiguous follicular lymphoma diagnosis and no history of myocardial infarction deep venous or arterial thrombosis within six months prior to registration
__label__0	study interventions are Fludarabine . lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Paclitaxel . esophagogastric junction neoplasms diagnosis and scchn patients who are candidates for definitive chemoradiation are not eligible to participate
__label__0	study interventions are Cetuximab . stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Bortezomib . transitional cell cancer of the renal pelvis and ureter diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Paclitaxel . because breast carcinoma is disease of adults that rarely occurs in children children are excluded from this study
__label__0	study interventions are Dexetimide . neoplasms diagnosis and life expectancy determined to be greater than or equal to six months
__label__0	study interventions are questionnaire administration . breast cancer diagnosis and no nursing within the past six months
__label__0	study interventions are Doxorubicin . stage iv enteropathy associated cell lymphoma diagnosis and all females of childbearing potential must have blood test within two weeks prior to registration to rule out pregnancy
__label__0	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the hypopharynx diagnosis and st
__label__0	study interventions are Freund's Adjuvant . stage iv breast cancer diagnosis and if subject is on an investigational drug the drug must be cleared from the body over period of four weeks
__label__0	study interventions are Albumin-Bound Paclitaxel . carcinoma non small cell lung diagnosis and not specified
__label__0	study interventions are Etoposide . small cell lung cancer diagnosis and adequate organ function liver kidney
__label__0	study interventions are Albumin-Bound Paclitaxel . inflammatory breast cancer diagnosis and formalin_fixed paraffin_embedded ffpe breast tissue from core biopsy has therefore to be sent to the gbg central pathology laboratory prior to randomization
__label__0	study interventions are Paclitaxel . gastroesophageal cancer diagnosis and acceptable renal function
__label__0	study interventions are cognitive assessment . metastatic cancer diagnosis and measurable brain metastasis outside five mm margin around either hippocampus on gadolinium contrast enhanced mri obtained within the past thirty days
__label__0	study interventions are Androgens . prostate cancer diagnosis and serum potassium greater_than doc mmol l
__label__0	study interventions are Mycophenolate mofetil . recurrent childhood lymphoblastic lymphoma diagnosis and patient must be not eligible for conventional allogeneic hematopoietic cell transplantation hct and must have disease expected to be stable for at least one hundred days without chemotherapy patients with hematologic malignancies treatable with hct or with b cell malignancy except those curable with autologous transplant will be included patients not eligible for active disease specific protocols may be enrolled in this protocol patients will include the following
__label__0	study interventions are questionnaire administration . psychological impact of cancer and its treatment diagnosis and in phase two subjects are also required on accrual to be referred to palliative care
__label__0	study interventions are Bortezomib . primary central nervous system hodgkin lymphoma diagnosis and unstable angina pectoris
__label__0	study interventions are Staurosporine . recurrent basal cell carcinoma of the lip diagnosis and her two not amplified by fluorescence in situ hybridization
__label__0	study interventions are Romidepsin . stage iv squamous cell carcinoma of the hypopharynx diagnosis and leukocytes greater_than three zero ul
__label__0	study interventions are Albumin-Bound Paclitaxel . esophageal cancer diagnosis and ecog zero two life expectancy
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and the patient o two saturation must be greater_than 9two on room air
__label__0	study interventions are Panobinostat . recurrent adult lymphoblastic lymphoma diagnosis and ecog performance status ps zero one or two
__label__0	study interventions are Carboplatin . stage ivc lip and oral cavity squamous cell carcinoma diagnosis and patients must not be receiving chronic daily treatment with aspirin greater_than three hundred and twenty-five mg day or non steroidal anti inflammatory agents nsaid known to inhibit platelet function the use of anti platelet agents dipyridamole_persantine ticlopidine_ticlid clopidogrel_plavix is allowed only if patient is not receiving aspirin or nsaid known to inhibit platelet function
__label__0	study interventions are Mitoxantrone . ovarian cancer diagnosis and patient characteristics
__label__0	study interventions are Letrozole . pathologically confirmed invasive ductal carcinoma or invasive lobular carcinoma of the breast ttwo tfour tfoura nzero two mzero with positive estrogen and or progesterone receptors
__label__0	study interventions are Methotrexate . stage iii mantle cell lymphoma diagnosis and cytogenetic abnormalities in addition to ph positive
__label__0	study interventions are Immunoglobulins . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and myelodysplastic mds myeloproliferative disorders
__label__0	study interventions are Erlotinib Hydrochloride . stage iiia non small cell lung cancer diagnosis and platelet count greater_than equal_than one hundred zero mm three
__label__0	study interventions are Everolimus . follicular lymphoma diagnosis and adults with creatinine greater_than doc mg dl or history of renal dysfunction must have estimated glomerular filtration rate gfr greater_than forty ml min
__label__0	study interventions are Veliparib . platinum resistant ovarian cancer is not permitted
__label__0	study interventions are Sirolimus . stage iv grade one follicular lymphoma diagnosis and donor
__label__0	study interventions are Liposomal doxorubicin . myelodysplastic myeloproliferative neoplasms diagnosis and eleven nineteen qtwenty-three pone doc
__label__0	study interventions are Antibodies, Monoclonal . stage iv grade two follicular lymphoma diagnosis and institutional flow cytometry or immunohistochemistry must confirm cluster of differentiation two0 cdtwo0 antigen expression
__label__0	study interventions are Prednisone . lymphoma diagnosis and not specified
__label__0	study interventions are Thiotepa . normal serum tumor markers
__label__0	study interventions are Antibodies . stage iii lymphoepithelioma of the oropharynx diagnosis and or interferon based therapy
__label__0	study interventions are Gemcitabine . head and neck squamous cell carcinoma diagnosis and women of childbearing potential wocbp and male patients with wocbp partner must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to twelve weeks after the last dose of investigational product in such manner that the risk of pregnancy is minimized wocbp include any female who has experienced menarche and who has not undergone successful surgical sterilization hysterectomy bilateral tubal ligation or bilateral oophorectomy or is not postmenopausal post menopause is defined as
__label__0	study interventions are Docetaxel . provision of tumor sample from either resection or biopsy
__label__0	study interventions are Cognitive Assessment . stage ic ovarian germ cell tumor diagnosis and no severe motor or mental slowing patient who is disoriented level on any criterion as assessed by the person place time criteria
__label__0	study interventions are Immunoglobulins . stage iiic skin melanoma diagnosis and one lesion greater_than five cm three
__label__0	study interventions are clinical observation . anal cancer diagnosis and cdfour count greater_than two hundred mm³
__label__0	study interventions are Etoposide . large cell lung cancer diagnosis and see disease characteristics
__label__0	study interventions are Denileukin diftitox . lymphoma diagnosis and surgery
__label__0	study interventions are Vaccines . metastatic cancer diagnosis and egfr greater_than fiftyml min
__label__0	study interventions are Antibodies, Monoclonal . splenic marginal zone lymphoma diagnosis and one thousand µl doc ten nine l
__label__0	study interventions are pharmacological study . childhood desmoplastic small round cell tumor diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Gemcitabine . urethral cancer diagnosis and cardiovascular
__label__0	study interventions are Cadexomer iodine . neoplasms kidney diagnosis and the following laboratory results should be within the following limits within the last four weeks prior to study day one
__label__0	study interventions are Oxaliplatin . advanced gastric cancer diagnosis and subjects must provide written informed consent prior to performance of study specific procedures or assessments and must be willing to comply with treatment and follow up
__label__0	study interventions are Mycophenolic Acid . recurrent childhood lymphoblastic lymphoma diagnosis and not eligible for autologous hct not eligible for conventional myeloablative hct or after failed autologous hct
__label__0	study interventions are Mycophenolic Acid . aids related peripheral systemic lymphoma diagnosis and hla phenotypically identical unrelated donor match grades allowed
__label__0	study interventions are Liposomal doxorubicin . neuroblastoma diagnosis and female patients who are lactating must agree to stop breast feeding
__label__0	study interventions are Fludarabine . splenic marginal zone lymphoma diagnosis and donor
__label__0	study interventions are Rituximab . stage iv adult diffuse large cell lymphoma diagnosis and if day twenty-eight or forty-two falls on weekend or holiday the limit may be extended to the next working day
__label__0	study interventions are Fludarabine . stage iv melanoma diagnosis and negative pregnancy test
__label__0	study interventions are Cetuximab . rectal cancer diagnosis and disease characteristics
__label__0	study interventions are Sirolimus . head and neck cancer diagnosis and age greater_than or equal_than eighteen
__label__0	study interventions are Cisplatin . stage ii bladder cancer diagnosis and absolute neutrophil count greater_than equal_than doc ten nine cells l
__label__0	study interventions are Radium-223 and enzalutamide . prostate cancer diagnosis and for the radiographic pd assessment two sets of scans using the same imaging modality ie ct mri or bone scan and taken at separate time points are required to document radiographic disease progression during or following the patient most recent anti neoplastic therapy note
__label__0	study interventions are PI-88 . hepatocellular carcinoma diagnosis and ecog performance status zero to two
__label__0	study interventions are laboratory biomarker analysis . squamous cell carcinoma of the skin diagnosis and no concurrent or planned therapy for the invasive malignancy
__label__0	study interventions are Vidarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and quantitative or qualitative congenital platelet disorders including but not limited to congenital amegakaryocytopenia_absent radii syndrome glanzmann thrombasthenia
__label__0	study interventions are laboratory biomarker analysis . stage iii gastric cancer diagnosis and no other uncontrolled illness
__label__0	study interventions are Camptothecin . neuroblastoma diagnosis and patient has adequate bone marrow function defined
__label__0	study interventions are Olaparib . recurrent breast carcinoma diagnosis and patients may have received an unlimited number of platinum based therapies in the recurrent setting
__label__0	study interventions are Cytarabine . lymphoma diagnosis and see disease characteristics at least twenty-four hours since prior chemotherapy with hydroxyurea at least three weeks since other prior systemic chemotherapy no prior clinically significant cerebellar toxicity due to cytarabine endocrine therapy
__label__0	study interventions are Obinutuzumab . lymphoma non hodgkin diagnosis and be counseled about pregnancy precautions and risks of fetal exposure
__label__0	study interventions are Cyclin-Dependent Kinase Inhibitor Proteins . should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__0	study interventions are Fludarabine . stage grade one follicular lymphoma diagnosis and chronic myeloid leukemia cml
__label__0	study interventions are Rituximab . stage cutaneous cell non hodgkin lymphoma diagnosis and serum creatinine less_than doc mg dl or creatinine clearance greater than sixty ml per minute by the following formula all tests must be performed within twenty-eight days prior to registration
__label__0	study interventions are Vaccines . astrocytoma grade iv diagnosis and creatinine less_than iuln or creatinine clearance greater_than sixty ml min doc three mtwo for patients with creatinine levels above institutional normal
__label__0	study interventions are Female AR(+) TNBC Enzalutamide Treated . male breast cancer diagnosis and correctly placed copper containing intrauterine device iud
__label__0	study interventions are Doxorubicin . fallopian tube cancer diagnosis and biologic therapy
__label__0	study interventions are Fludarabine . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and myeloproliferative and myelodysplastic syndromes mds
__label__0	study interventions are Tacrolimus . stage iv adult diffuse mixed cell lymphoma diagnosis and treatment with rabbit_antithymocyte globulin or alemtuzumab within three months before the date of hct
__label__0	study interventions are Dovitinib . recurrent paraganglioma diagnosis and pathology report or pathology slides e confirming histological diagnosis must be available at the time of enrollment
__label__0	study interventions are Fludarabine phosphate . stage ii cutaneous cell non hodgkin lymphoma diagnosis and waldenstrom macroglobulinemia
__label__0	study interventions are Thalidomide . anaplastic astrocytoma diagnosis and no overt renal hepatic cardiac or pulmonary disease
__label__0	study interventions are Gossypol . recurrent adult diffuse large cell lymphoma diagnosis and total bilirubin within normal institutional limits
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and all patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines
__label__0	study interventions are Carboplatin . cancer diagnosis and patients willing and able to comply with the study protocol for the duration of the study
__label__0	study interventions are Isophosphamide mustard . burkitt lymphoma or atypical burkitt burkitt like lymphoma any stage
__label__0	study interventions are Keyhole-limpet hemocyanin . histologically confirmed stage iv breast cancer meeting one of the following criteria
__label__0	study interventions are Methotrexate . nodal marginal zone cell lymphoma diagnosis and forced expiratory volume in one second fevone greater_than fifty
__label__0	study interventions are Liposomal doxorubicin . regional neuroblastoma diagnosis and doc mg dl males doc mg dl females
__label__0	study interventions are Paclitaxel . esophageal neoplasms diagnosis and complete resection
__label__0	study interventions are Tocotrienols . head and neck neoplasms diagnosis and able to understand and willing to sign written informed consent document
__label__0	study interventions are Hydrocortisone acetate . lymphoblastic lymphoma diagnosis and patients may have an mtwo marrow greater than or equal to five to less_than twofive blasts with an extramedullary site of relapse including cns two and cns three
__label__0	study interventions are Foscarnet . stage iii grade one follicular lymphoma diagnosis and all patients must be capable of signing written informed consent and no consent can be provided by legal guardian
__label__0	study interventions are Ifosfamide . neuroblastoma diagnosis and life expectancy
__label__0	study interventions are Thiotepa . unspecified childhood solid tumor protocol specific diagnosis and patient characteristics
__label__0	study interventions are Camptothecin . neuroblastoma diagnosis and radiation therapy should not be given to the only site of measurable or evaluable disease
__label__0	study interventions are Immunoglobulins . stage iia esophageal cancer diagnosis and patients must sign study specific informed consent prior to study entry
__label__0	study interventions are laboratory biomarker analysis . uterine leiomyomata diagnosis and risk reducing prophylactic oophorectomy
__label__0	study interventions are Cyclophosphamide . recurrent primary peritoneal carcinoma diagnosis and urinalysis with equal_than less_than two positive proteinuria
__label__0	study interventions are Lapatinib . breast cancer diagnosis and the patient granted her consent for taking biopsy before treatment
__label__0	study interventions are Thalidomide . recurrent grade two follicular lymphoma diagnosis and men must agree to use latex condom during sexual contact with fcbp even if they have had successful vasectomy
__label__0	study interventions are Laboratory Biomarker Analysis . lymphoplasmacytic lymphoma diagnosis and provide informed written consent
__label__0	study interventions are Methotrexate . stage iii marginal zone lymphoma diagnosis and ten blasts in blood or marrow
__label__0	study interventions are Laboratory Biomarker Analysis . stage ivc thyroid gland medullary carcinoma diagnosis and breastfeeding should be discontinued if the mother is treated with gwseven hundred and eighty-six thousand and thirty-four pazopanib
__label__0	study interventions are Ondansetron . recurrent grade three follicular lymphoma diagnosis and planned cryopreserved pbsc infusion at the scca outpatient clinic
__label__0	study interventions are Interleukin-2 . stage iv adult lymphoblastic lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Rosuvastatin Calcium . rectal cancer diagnosis and acceptable methods of contraception are condoms with contraceptive foam oral implantable or injectable contraceptives contraceptive patch intrauterine device diaphragm with spermicidal gel or sexual partner who is surgically sterilized or post menopausal
__label__0	study interventions are Poly I-C . small size posterior uveal melanoma diagnosis and life expectancy of at least six months
__label__0	study interventions are Bevacizumab . adult diffuse astrocytoma diagnosis and concurrent full dose anticoagulants warfarin with pt inr greater_than doc allowed provided the following criteria are met
__label__0	study interventions are Bortezomib . ovarian cancer diagnosis and fertile patients must use effective contraception during and for three months after study participation
__label__0	study interventions are BIW-8962 . phase one portion non small cell lung cancer nsclc small cell lung cancer sclc mesothelioma diagnosis and measurable unresectable advanced or recurrent sclc
__label__0	study interventions are Gemcitabine . diffuse large cell lymphoma diagnosis and previously treated with one and only one chemotherapy regimen including an anthracycline and excluding cisplatin cytarabine bortezomib and gemcitabine
__label__0	study interventions are Sorafenib . glucagonoma diagnosis and no active peptic ulcer disease
__label__0	study interventions are Hydroxychloroquine . recurrent non small cell lung cancer diagnosis and placement of vascular access device is not considered major surgery but the incision must have healed before initiation of treatment
__label__0	study interventions are surgical procedure . cervical cancer diagnosis and no prior neoadjuvant chemotherapy endocrine therapy
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and patient characteristics
__label__0	study interventions are Vincristine . contiguous stage ii marginal zone lymphoma diagnosis and two below
__label__0	study interventions are Vaccines . malignant melanoma diagnosis and karnofsky performance scale greater_than seventy or who performance status of zero or one
__label__0	study interventions are Bevacizumab . stage iv primary peritoneal cancer diagnosis and patients and their partners should be practicing an effective form of contraception during the study and for at least three months following the last dose of this combined therapy
__label__0	study interventions are Fludarabine . noncontiguous stage ii grade two follicular lymphoma diagnosis and donor
__label__0	study interventions are Prednisolone acetate . mediastinal thymic large cell lymphoma diagnosis and stage iii with elevated ldh level high ldh greater_than twice the institutional upper limit of the adult normal values greater_than nxtwo any stage iv or al phase iii
__label__0	study interventions are Immunoglobulins . hepatosplenic cell lymphoma diagnosis and doc mg dl for female patients age greater_than equal_than thirteen years
__label__0	study interventions are Melphalan . stage iv cutaneous cell non hodgkin lymphoma diagnosis and able to collect greater_than equal_than doc ten six cdthirty-four positive kg cell for transplantation
__label__0	study interventions are Cortisol succinate . stage ii childhood large cell lymphoma diagnosis and one of the following fab prognostic groups
__label__0	study interventions are Neuropsychological Testing . histologically confirmed colorectal cancer
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and written informed consent are acquired
__label__0	study interventions are Sunitinib . endometrial adenocarcinoma diagnosis and magnesium greater_than equal_than doc mmol l
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and the same modality must be used throughout the study to evaluate lvef
__label__0	study interventions are Fludarabine phosphate . stage iv adult burkitt lymphoma diagnosis and congenital primary immunodeficiencies including but not limited to severe combined immunodeficiency syndrome wiskott_aldrick syndrome cdforty_ligand deficiency cell deficiencies
__label__0	study interventions are pharmacological study . stage ii neuroendocrine carcinoma of the skin diagnosis and ast alt equal_than less_than doc times upper limit of normal
__label__0	study interventions are Bevacizumab . recurrent fallopian tube carcinoma diagnosis and front line treatment may include maintenance therapy following complete clinical or pathological response however maintenance cytotoxic chemotherapy must be discontinued for minimum of six months prior to documentation of recurrent disease patients receiving maintenance biological therapy or hormonal therapy are eligible provided their recurrence is documented more than six months from primary cytotoxic chemotherapy completion includes maintenance chemotherapy and minimum four weeks has elapsed since their last infusion of biological therapy
__label__0	study interventions are Cortisol succinate . prostate cancer diagnosis and biologic therapy
__label__0	study interventions are 6-(4-fluorophenyl)-2,3-dihydro-5-(4-pyridinyl)imidazo(2,1-b)thiazole . advanced cancer diagnosis and grade less_than one stage three
__label__0	study interventions are Thiotepa . lymphoma diagnosis and aml secondary to myelodysplastic disease
__label__0	study interventions are Aspirin . colorectal cancer diagnosis and platelets greater_than one hundred one hundred and nine l
__label__0	study interventions are Tacrolimus . stage ii adult contiguous immunoblastic lymphoma diagnosis and mantle cell nhl may be treated in first complete response cr diagnostic lumbar_puncture lp required pretransplant
__label__0	study interventions are Lycopene . prostate cancer diagnosis and no renal disease
__label__0	study interventions are Rituximab . recurrent grade two follicular lymphoma diagnosis and ability to understand and the willingness to sign written informed consent all patients must have signed witnessed informed consent prior to registration
__label__0	study interventions are Mitogens . renal cell carcinoma diagnosis and serum albumin greater than or equal to doc dl
__label__0	study interventions are Crizotinib . adenocarcinoma of the lung diagnosis and platelet count greater_than equal_than one hundred zero ul
__label__0	study interventions are Dacarbazine . all patients must have histologically verified glioblastoma
__label__0	study interventions are laboratory biomarker analysis . stage iv mantle cell lymphoma diagnosis and absolute neutrophil count anc greater_than equal_than one thousand mm three independent of growth factor support
__label__0	study interventions are Akt Inhibitor MK2206 . recurrent adult liver carcinoma diagnosis and ecog zero one
__label__0	study interventions are Bevacizumab . recurrent childhood pineoblastoma diagnosis and hemoglobin greater_than equal_than doc gm dl may receive packed red blood cell prbc transfusions
__label__0	study interventions are Folic Acid . stage iii breast cancer diagnosis and creatinine equal_than less_than doc uln
__label__0	study interventions are Vidarabine . stage grade three follicular lymphoma diagnosis and chronic myelogenous leukemia cml
__label__0	study interventions are Everolimus . hertwo negative locally advanced breast cancer diagnosis and dated and signed patient informed consent before start of any in the protocol specified procedures
__label__0	study interventions are laboratory biomarker analysis . stage iii melanoma diagnosis and cyclosporine
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and left ventricular ejection fraction lvef assessment by two echocardiogram or multigated acquisition muga scan must be performed within ninety days prior to randomization
__label__0	study interventions are Fludarabine . metastatic cholangiocarcinoma diagnosis and greater than or equal to eighteen years of age and less than or equal to seventy years of age
__label__0	study interventions are Bevacizumab . bronchoalveolar cell lung cancer diagnosis and six months after completion of study treatment
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and bilirubin less than doc mg dl ast no greater than three times normal neither value increasing for at least two four weeks prior to transplant renal
__label__0	study interventions are Folic Acid . stage iiib breast cancer diagnosis and note
__label__0	study interventions are Deoxyuridine . recurrent adult hodgkin lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Sunitinib . aids related diffuse large cell lymphoma diagnosis and cdfour count greater_than fifty cells ul
__label__0	study interventions are Prednisolone hemisuccinate . recurrent adult lymphoblastic lymphoma diagnosis and md negative intermediate two or high ipss score
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and prior or concurrent prednisolone at thirty mg mtwo day or less or equivalent doses of other corticosteroids for relief of fluid unresponsive hypercalcemia allowed
__label__0	study interventions are Antibodies, Monoclonal . stage ivb squamous cell carcinoma of the larynx diagnosis and presence of measurable lesions recist doc
__label__0	study interventions are Etoposide phosphate . ovarian cancer diagnosis and radiographically measurable disease phase ii
__label__0	study interventions are Bendamustine Hydrochloride . adult lymphocyte predominant hodgkin lymphoma diagnosis and non pregnant and non nursing due to the teratogenic potential of these agents pregnant or nursing patients may not be enrolled women and men of reproductive potential should agree to use an effective means of birth control
__label__0	study interventions are Fludarabine phosphate . diffuse large cell lymphoma diagnosis and intermediate one int one per international prognostic_scoring system ipss after greater_than or equal_than one prior cycle of induction chemotherapy must have less_than five marrow blasts at time of transplant
__label__0	study interventions are Antiviral Agents . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and informed consent
__label__0	study interventions are Fludarabine . stage iii childhood lymphoblastic lymphoma diagnosis and donor
__label__0	study interventions are Tissue Oxygen Measurement . stage iiib non small cell lung cancer diagnosis and white blood cell wbc greater_than two thousand mm three
__label__0	study interventions are Prednisone . prostate cancer diagnosis and biologic therapy
__label__0	study interventions are Paclitaxel . urethral cancer diagnosis and performance status
__label__0	study interventions are Gemcitabine . stage ia pancreatic cancer diagnosis and able to initiate study treatment no later than six weeks from last dose of any antineoplastic component of prior therapy regimen
__label__0	study interventions are Epothilone B . unresectable extrahepatic bile duct cancer diagnosis and ascites
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iii uterine corpus cancer diagnosis and paraaortic lymph node sampling allowed
__label__0	study interventions are Etoposide phosphate . small intestine lymphoma diagnosis and female subjects
__label__0	study interventions are Methylprednisolone acetate . recurrent adult cell leukemia lymphoma diagnosis and fevone and dlco corrected must be greater_than equal_than sixty of normal
__label__0	study interventions are Interferons . kidney cancer diagnosis and progressive disease after treatment with zero two courses of immunotherapy chemotherapy or other systemic therapy for advanced disease
__label__0	study interventions are Cisplatin . endometrial adenosquamous carcinoma diagnosis and paraaortic lymph node sampling allowed
__label__0	study interventions are Liposomal doxorubicin . neuroblastoma diagnosis and age
__label__0	study interventions are Imatinib Mesylate . gastrointestinal stromal tumor gist diagnosis and patient must have undergone complete gross resection of primary gist within twelve weeks prior to first dose of imatinib study drug
__label__0	study interventions are Camptothecin . refractory solid tumors in children diagnosis and transaminases equal_than less_than doc uln equal_than less_than five uln in case of liver metastases
__label__0	study interventions are Sirolimus . breast cancer diagnosis and bilirubin less_than doc times upper limit of normal uln
__label__0	study interventions are Vaccines . melanoma skin diagnosis and clinically evaluable and measurable disease
__label__0	study interventions are Crenolanib . recurrent refractory glioblastoma diagnosis and adequate liver function within seven days of crenolanib commencement as determined by
__label__0	study interventions are Hydrocortisone . stage iv prostate cancer diagnosis and serum creatinine cr within uln
__label__0	study interventions are Antibodies, Bispecific . gastric adenocarcinoma with peritoneal carcinomatosis diagnosis and platelet count greater_than equal_than ten doc zero µl
__label__0	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and serum creatinine less_than doc upper normal limit or creatinine clearance calculated according to cockcroft and gault greater_than fiftyml min
__label__0	study interventions are Rituximab . lymphoma diagnosis and confirmed by tissue biopsy
__label__0	study interventions are Ifosfamide . refractory nasopharyngeal carcinoma diagnosis and signed informed consent
__label__0	study interventions are Polyethylene Glycol . all patients between the age of fifty and seventy-five years referred to the forzani macphail colorectal cancer screening centre in calgary alberta canada for colonoscopy will be considered for inclusion
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and normal igm less_than fifty mg dl iga less_than one hundred mg dl or igg less_than six hundred mg dl
__label__0	study interventions are Mycophenolic Acid . childhood diffuse large cell lymphoma diagnosis and viral load has decreased by greater_than equal_than doc logs or viral load less_than five thousand copies ml plasma on haart therapy
__label__0	study interventions are Cyclosporine . stage iv grade two follicular lymphoma diagnosis and they have been treated with more than one regimen of haart for total of at least six months duration
__label__0	study interventions are Sargramostim . recurrent primitive neuroectodermal tumor diagnosis and note
__label__0	study interventions are Imatinib Mesylate . stage iv grade one follicular lymphoma diagnosis and chronic myelogenous leukemia or other philadelphia_chromosome positive leukemia or
__label__0	study interventions are Zidovudine . sarcoma kaposi diagnosis and evidence of hiv infection as manifested by positive antibody test
__label__0	study interventions are LpTME . rectal neoplasms malignant diagnosis and no evidence of distant metastases
__label__0	study interventions are Docetaxel . histologically proven invasive unilateral breast cancer regardless of the type
__label__0	study interventions are Buspirone . unspecified adult solid tumor protocol specific diagnosis and not specified
__label__0	study interventions are Entinostat . angioimmunoblastic cell lymphoma diagnosis and no weight loss greater_than ten within the past two months
__label__0	study interventions are Cyclosporine . recurrent adult lymphoblastic lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Mycophenolate mofetil . peripheral cell lymphoma diagnosis and myeloproliferative syndromes
__label__0	study interventions are Antibodies, Monoclonal . recurrent salivary gland cancer diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are Lenograstim . noncontiguous stage ii adult burkitt lymphoma diagnosis and voluntary written informed consent form before performance of any study related procedure not part of normal medical care with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
__label__0	study interventions are Carboplatin . transitional cell cancer of the renal pelvis and ureter diagnosis and creatinine greater than doc mg dl but no greater than doc mg dl or
__label__0	study interventions are Antibodies, Monoclonal . kidney cancer diagnosis and platelet count greater_than one hundred one hundred and nine greater_than one hundred zero per mmthree
__label__0	study interventions are Busulfan . recurrent cutaneous cell non hodgkin lymphoma diagnosis and for patients unable to complete pulmonary function tests clearance by an adult pulmonologist is required
__label__0	study interventions are Cyclosporins . refractory childhood hodgkin lymphoma diagnosis and donor
__label__0	study interventions are alvespimycin hydrochloride . recurrent cutaneous cell non hodgkin lymphoma diagnosis and no history of congenital long qt syndrome
__label__0	study interventions are Lenograstim . head and neck cancer diagnosis and performance status
__label__0	study interventions are Sirolimus . recurrent melanoma diagnosis and surgically resected or have been treated with gamma_knife or stereotactic radiosurgery
__label__0	study interventions are Pazopanib . neoplasms diagnosis and patients must have recovered to eligibility levels from prior toxicity or adverse events
__label__0	study interventions are Albumin-Bound Paclitaxel . testicular germ cell tumor diagnosis and unidimensionally measurable lesions
__label__0	study interventions are Antibodies . nodal marginal zone cell lymphoma diagnosis and fourteen days prior to and again within twenty-four hours of prescribing lenalidomide for cycle one prescriptions must be filled within seven days
__label__0	study interventions are Antibodies, Monoclonal . carcinoma non small cell lung diagnosis and periodic abstinence eg calendar_ovulation symptothermal_postovulation methods for the female partner and withdrawal are not acceptable methods of contraception
__label__0	study interventions are Bendamustine Hydrochloride . anaplastic large cell lymphoma diagnosis and no evidence of active infection and no serious infection within the past month
__label__0	study interventions are Melphalan . newly diagnosed advanced stage high risk neuroblastoma defined as one of the following
__label__0	study interventions are Immunoglobulins . childhood oligodendroglioma diagnosis and alt and ast less_than three times uln
__label__0	study interventions are Recombinant EphB4-HSA Fusion Protein . stage iib prostate cancer diagnosis and note
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and biologic therapy
__label__0	study interventions are Fludarabine . recurrent adult hodgkin lymphoma diagnosis and chronic myelomoncytic leukemia
__label__0	study interventions are Tegafur . stomach neoplasm diagnosis and serum creatinine less_than equal_than doc upper limit of normal
__label__0	study interventions are Antibodies . lymphoma non hodgkin diagnosis and patients must have previously responded with duration of response of at least three months to iodine onethreeone anti bone antibody therapy
__label__0	study interventions are Docetaxel . prostatic neoplasms diagnosis and worsening of fatigue after commencement of docetaxel chemotherapy
__label__0	study interventions are Antibodies, Monoclonal . recurrent non small cell lung carcinoma diagnosis and patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
__label__0	study interventions are Androgens . stage prostate cancer diagnosis and bilateral orchiectomy
__label__0	study interventions are Everolimus . recurrent prostate carcinoma diagnosis and prior therapy with abiraterone enzalutamide and or docetaxel if patient has not received docetaxel or cabazitaxel chemotherapy the patient must be informed of this treatment choice as an alternative if the patient has received docetaxel or cabazitaxel chemotherapy or refuses one of both of these therapies this rationale must be documented and the patient is then eligible patient must be offered and made aware of all food and drug administration fda approved treatment options patients may not have received radium two hundred and twenty-three
__label__0	study interventions are Vorinostat . noncontiguous stage ii adult burkitt lymphoma diagnosis and reduction of more than fifty in the disease burden regardless of the number of lines of therapy received
__label__0	study interventions are Methotrexate . non hodgkin lymphoma or hodgkin lymphoma
__label__0	study interventions are Rituximab . recurrent grade three follicular lymphoma diagnosis and patients should have absolute neutrophil count anc greater_than equal_than one five hundred ul exception
__label__0	study interventions are Etoposide . lung cancer diagnosis and zubrod zero one
__label__0	study interventions are Mechlorethamine . at the same time at least four weeks before she begins lenalidomide therapy women of childbearing potential is defined as sexually mature woman who has not undergone hysterectomy or who has had menses at any time in the preceding 2four consecutive months men must agree not to father child and must use latex condom during any sexual contact with women of childbearing potential while taking lenalidomide and for four weeks after therapy is stopped even if they have undergone successful vasectomy
__label__0	study interventions are Fluorodeoxyglucose F18 . stage iv follicular thyroid cancer diagnosis and bilirubin equal_than less_than doc times upper limit of normal uln
__label__0	study interventions are Fludarabine . noncontiguous stage ii adult burkitt lymphoma diagnosis and failed prior autotransplant
__label__0	study interventions are annual FIT and colonoscopy in case of a positive test . colorectal cancer diagnosis and fdr with case index meeting the following conditions
__label__0	study interventions are Oxaliplatin . stage ivb rectal cancer diagnosis and patients must not have an active inflammatory bowel disease or other serious medical illness which might limit the ability of the patient to receive protocol therapy
__label__0	study interventions are Mycophenolate mofetil . stage ii childhood anaplastic large cell lymphoma diagnosis and related or unrelated donors who are matched for hla drbone and dqbone alleles must be defined by high resolution typing and who are mismatched for
__label__0	study interventions are Palbociclib . estrogen receptor negative breast cancer diagnosis and all subjects
__label__0	study interventions are Tirapazamine . embryonal childhood rhabdomyosarcoma diagnosis and first relapse or first occurrence of disease progression
__label__0	study interventions are Paclitaxel . borderline ovarian mucinous tumor diagnosis and activated prothrombin time aptt equal_than less_than doc uln
__label__0	study interventions are JM 3100 . mixed anaplastic oligoastrocytoma aoa diagnosis and normal organ and marrow function as outlined in the protocol
__label__0	study interventions are Docetaxel . chondrosarcoma
__label__0	study interventions are Interleukin-2 . mixed glioma diagnosis and disease recurrence progression in the cerebral hemisphere which is in at least one area of enhancement amenable to biopsy after protocol enrollment in the following locations
__label__0	study interventions are Vaccines . melanoma skin diagnosis and hiv negative
__label__0	study interventions are Antibodies . adult glioblastoma diagnosis and patients unable to undergo mri because of non compatible devices can be enrolled provided computed tomography ct scans are obtained and are of sufficient quality patients without non compatible devices may not have ct scans performed to meet this requirement
__label__0	study interventions are Silicon phthalocyanine . precancerous condition diagnosis and quinolones
__label__0	study interventions are Sirolimus . breast neoplasms diagnosis and stratification two
__label__0	study interventions are Paclitaxel . stage iva verrucous carcinoma of the larynx diagnosis and aspartate aminotransferase ast or alanine aminotransferase alt less_than twox the upper limit of normal
__label__0	study interventions are 2mg INO-5150 and electroporation device CELLECTRA®-5P . prostate cancer diagnosis and both measurements are greater than one hundred and fifty ng dl or doc nmol l
__label__0	study interventions are Isotretinoin . neuroendocrine tumor diagnosis and absolute neutrophil count greater_than one thousand mmthree
__label__0	study interventions are Dasatinib . breast cancer diagnosis and pt inr and ptt grade zero one except for patients on coumadin or low molecular weight heparin
__label__0	study interventions are Interleukin-12 . melanoma skin diagnosis and no concurrent barbiturates
__label__0	study interventions are Irinotecan . cancer of pancreas diagnosis and hemoglobin greater_than one doc dl
__label__0	study interventions are Celecoxib . sarcoma diagnosis and endocrine therapy
__label__0	study interventions are Bevacizumab . stage iii lymphoepithelioma of the oropharynx diagnosis and no proteinuria
__label__0	study interventions are Immunoglobulins . stage adult hodgkin lymphoma diagnosis and has not been naturally postmenopausal for at least twelve consecutive months has had menses at any time in the preceding twelve consecutive months
__label__0	study interventions are Immunoconjugates . stage iii grade two follicular lymphoma diagnosis and patients must be free of any prior malignancies for greater_than equal_than one year note
__label__0	study interventions are Docetaxel . male reproductive cancer diagnosis and at least six months since prior hypericum_perforatum st
__label__0	study interventions are Ruxolitinib . relapsed or refractory hodgkin lymphoma diagnosis and informed consent
__label__0	study interventions are Cyclosporins . recurrent adult diffuse large cell lymphoma diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Interleukin-2 . cldneighteen two positive gastric adenocarcinoma diagnosis and age greater_than eighteen years
__label__0	study interventions are Capecitabine . recurrent ovarian carcinoma diagnosis and bilirubin equal_than less_than doc uln
__label__0	study interventions are Mycophenolate mofetil . childhood renal cell carcinoma diagnosis and only single allele disparity will be allowed for hla b or as defined by high resolution typing
__label__0	study interventions are Fludarabine . stage ii multiple myeloma diagnosis and myeloproliferative syndromes
__label__0	study interventions are radiofrequency ablation . head and neck cancer diagnosis and no cervical lymphadenopathy
__label__0	study interventions are Vidarabine . recurrent grade one follicular lymphoma diagnosis and donor
__label__0	study interventions are Laboratory Biomarker Analysis . stage testicular seminoma diagnosis and axial imaging of lymphadenopathy within six weeks of the date of rplnd
__label__0	study interventions are Etoposide . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Calcitriol . pancreatic cancer diagnosis and more than seven days since prior and no concurrent digoxin or thiazide diuretic therapy
__label__0	study interventions are cilengitide . recurrent childhood brain tumor diagnosis and no concurrent alternative or complimentary therapies
__label__0	study interventions are anti-CD19-CAR vector-transduced T cells . recurrent mantle cell lymphoma diagnosis and adequate venous access for apheresis and no other contraindications for leukapheresis
__label__0	study interventions are Antibodies, Monoclonal . recurrent grade three follicular lymphoma diagnosis and all patients eligible for therapeutic study must have autologous hematopoietic stem cells two ten six cdthree4 positive cells kg harvested and cryopreserved
__label__0	study interventions are Liposomal doxorubicin . stage iii adult diffuse large cell lymphoma diagnosis and females of reproductive potential must adhere to the scheduled pregnancy testing as required in the lenalidomide rems program
__label__0	study interventions are Antibodies, Monoclonal . solid tumor diagnosis and serum creatinine less_than doc institutional upper limit of normal uln
__label__0	study interventions are Immunoglobulin G . undifferentiated fallopian tube carcinoma diagnosis and front line treatment may include maintenance therapy following complete clinical or pathological response however maintenance cytotoxic chemotherapy must be discontinued for minimum of six months prior to documentation of recurrent disease patients receiving maintenance biological therapy or hormonal therapy are eligible provided their recurrence is documented more than six months from primary cytotoxic chemotherapy completion includes maintenance chemotherapy and minimum four weeks has elapsed since their last infusion of biological therapy
__label__0	study interventions are Leucovorin . stage ii rectal cancer diagnosis and patients with history of hypertension must have blood pressure less_than one hundred and fifty ninety mm hg and be on stable regimen of antihypertensive therapy
__label__0	study interventions are Busulfan . lymphoma diagnosis and patients will be eligible for this study if they have any one of the diseases that are known to be cured after allogeneic stem cell transplantation
__label__0	study interventions are Allopurinol . stage adult burkitt lymphoma diagnosis and eastern cooperative oncology group ecog status of zero three
__label__0	study interventions are Methylprednisolone Hemisuccinate . lymphoma large cell diffuse diagnosis and patients will have provided written informed consent
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent colon cancer diagnosis and karnofsky performance status index greater_than equal_than seventy
__label__0	study interventions are Peginterferon alfa-2a . unspecified childhood solid tumor protocol specific diagnosis and life expectancy
__label__0	study interventions are Everolimus . hepatocellular carcinoma diagnosis and able to tolerate oral therapy
__label__0	study interventions are Doxorubicin . peripheral cell lymphoma nos diagnosis and scans and bone marrow biopsies performed within four weeks of commencement of therapy will be acceptable provided they have been performed according to study requirements
__label__0	study interventions are Prednisone . cutaneous cell lymphoma
__label__0	study interventions are Nivolumab . stage iiic skin melanoma diagnosis and platelets greater_than one hundred ten³ µl v
__label__0	study interventions are Gemcitabine . neuroblastoma diagnosis and creatinine greater_than doc uln for age if serum creatinine is greater_than doc uln of age then creatinine clearance or radioisotope gfr must be greater_than seventy ml min doc three mtwo adequate hepatic function
__label__0	study interventions are Ascorbic Acid . histologically or cytologically confirmed pancreatic adenocarcinoma that has metastatic disease measurable by ct mri or pet
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and confirmed by tissue biopsy
__label__0	study interventions are Mycophenolate mofetil . stage iv adult diffuse small cleaved cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Irinotecan . stage iva rectal cancer diagnosis and patients must not have received prior chemotherapy or pelvic irradiation therapy
__label__0	study interventions are Cyclophosphamide . histologically or cytologically confirmed diagnosis of squamous cell carcinoma of the head and neck or unknown primary with level ii iii jugulodigastric nodal involvement which have been found in previous studies to be the result of subclinical oropharyngeal carcinoma
__label__0	study interventions are Antibodies . neoplasms diagnosis and negative pregnancy test for women of child bearing potential
__label__0	study interventions are Gemcitabine . stage iia pancreatic cancer diagnosis and eighteen years of age
__label__0	study interventions are Oxaliplatin . stage ic fallopian tube cancer diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Rituximab . stage iii adult immunoblastic large cell lymphoma diagnosis and patients must be willing to give written informed consent and sign an institutionally approved consent form before performance of any study related procedure not part of normal medical care with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
__label__0	study interventions are Interferons . lung cancer diagnosis and not specified
__label__0	study interventions are HuLuc63 . multiple myeloma diagnosis and ecog performance status zero two appendix e
__label__0	study interventions are Lenograstim . childhood lymphocyte depletion hodgkin lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Immunoglobulins . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and no gastrointestinal tract disease or condition including any of the following that impairs ability to retain sunitinib tablets
__label__0	study interventions are Dexamethasone 21-phosphate . neoplasms diagnosis and karnofsky index greater_than equal_than seventy
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and no concurrent corticosteroid therapy
__label__0	study interventions are Cisplatin . large cell lung cancer diagnosis and no other uncontrolled concurrent illness
__label__0	study interventions are Levoleucovorin . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Methylprednisolone . lymphoma diagnosis and minimal residual disease greater than one zero blasts one00 zero mononuclear bone marrow cells at evaluation of ia day thirty-five
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and previously untreated and not candidate for il two based therapy
__label__0	study interventions are Cetuximab . stage iii verrucous carcinoma of the oral cavity diagnosis and prior surgical procedures affecting absorption
__label__0	study interventions are Antibodies, Monoclonal . brain and central nervous system tumors diagnosis and prior concurrent therapy
__label__0	study interventions are Sirolimus . recurrent pheochromocytoma diagnosis and prior therapy with vinorelbine or an mtor inhibitor
__label__0	study interventions are Etoposide . prostate cancer diagnosis and over eighteen
__label__0	study interventions are Sirolimus . recurrent adult brain tumor diagnosis and the following laboratory values obtained less_than seven days prior to registration
__label__0	study interventions are Docetaxel . lung cancer diagnosis and ast sgot alt sgpt less_than or equal_than doc institutional upper limit of normal
__label__0	study interventions are radiation therapy . lung cancer diagnosis and angina pectoris
__label__0	study interventions are Vorinostat . recurrent childhood supratentorial primitive neuroectodermal tumor diagnosis and doc male or doc female greater_than sixteen years of age
__label__0	study interventions are Bevacizumab . recurrent pancreatic cancer diagnosis and no cardiac arrhythmia
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and no requirement for mediastinal irradiation
__label__0	study interventions are Methotrexate . osteosarcoma diagnosis and total bilirubin less_than doc uln
__label__0	study interventions are Cisplatin . squamous cell carcinoma of the oral cavity stage iv diagnosis and one
__label__0	study interventions are Antibodies . stage iv breast cancer diagnosis and unstable angina pectoris
__label__0	study interventions are Immunoglobulin Idiotypes . metastatic cancer diagnosis and disease characteristics
__label__0	study interventions are Cetuximab . histologically or cytologically confirmed squamous cell carcinoma of the oropharynx or unknown primary that is hpv sixteen positive as determined by ish and psixteen positive as determined by ihc
__label__0	study interventions are Vaccines . multiple myeloma and plasma cell neoplasm diagnosis and no autoimmune disease or atopic allergy
__label__0	study interventions are Capecitabine . recurrent hypopharyngeal squamous cell carcinoma diagnosis and eligibility of patients receiving any medications or substances known to affect or with the potential to affect the activity of vorinostat will be determined following review of their case by the principal investigator
__label__0	study interventions are Ixazomib . plasmablastic lymphoma diagnosis and although not required it is encouraged that myc and bcl two be measured by immunohistochemistry ihc and clearly documented
__label__0	study interventions are Maleic acid . localized unresectable adult primary liver cancer diagnosis and fertile patients must use adequate contraception hormonal or barrier method of birth control abstinence before and during study treatment
__label__0	study interventions are Sunitinib . advanced cancer diagnosis and ecog performance status less_than equal_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Mycophenolic Acid . angioimmunoblastic cell lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Tacrolimus . myeloid sarcoma diagnosis and regarding donation eligibility is identified as either
__label__0	study interventions are Thalidomide . ds stage iii plasma cell myeloma diagnosis and patients must not have active uncontrolled seizure disorder patients must have had no seizures in the last six months
__label__0	study interventions are Dexmedetomidine . lung cancer diagnosis and subject or subject legally authorized representative has voluntarily signed and dated the informed consent document approved by the institutional review board
__label__0	study interventions are Liposomal doxorubicin . plexiform fibrohistiocytic tumor diagnosis and no transfusions are permitted seven days prior to laboratory studies to determine eligibility
__label__0	study interventions are Digital Rectal Exam . recurrent prostate cancer diagnosis and subjects must have the ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Antilymphocyte Serum . stage iii mantle cell lymphoma diagnosis and high or standard risk all
__label__0	study interventions are Cisplatin . bladder cancer diagnosis and clinical stage ttwo tfoura nzero mzero disease
__label__0	study interventions are Mycophenolic Acid . stage iii childhood large cell lymphoma diagnosis and donor must consent to filgrastim csf administration and leukapheresis
__label__0	study interventions are Antibodies . stage iii midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and creatinine less_than doc times uln
__label__0	study interventions are Compliance Monitoring . primary peritoneal serous adenocarcinoma diagnosis and patients must have signed an approved informed consent and authorization permitting release of personal health information
__label__0	study interventions are Cyclosporine . recurrent adult hodgkin lymphoma diagnosis and must have received prior chemotherapy and prior autologous transplant unless autologous transplant was not possible planned tandem transplants are allowed for patients at high risk of relapse
__label__0	study interventions are Antibodies, Monoclonal . stage esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and no other concurrent investigational agents
__label__0	study interventions are Immunoglobulin G . cancer diagnosis and subjects who have received no prior systemic therapy for mpm
__label__0	study interventions are Thiotepa . ovarian cancer diagnosis and biologic therapy
__label__0	study interventions are Bevacizumab . stage iv renal cell cancer diagnosis and two weeks since any prior radiation including palliative
__label__0	study interventions are Paclitaxel . stage ib breast cancer diagnosis and aspartate aminotransferase ast equal_than less_than two times upper limit of normal uln
__label__0	study interventions are Prednisolone acetate . lymphoma diagnosis and chronic myelogenous leukemia
__label__0	study interventions are Vincristine . rhabdomyosarcoma diagnosis and relapsed or refractory disease which has failed standard treatment approaches
__label__0	study interventions are Irinotecan . mixed adenocarcinoma of the stomach diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Endothelial Growth Factors . stage iv fallopian tube cancer diagnosis and creatinine less than or equal to doc institutional upper limit normal uln or creatinine clearance greater_than fifty cc min
__label__0	study interventions are Immunotoxins . lung cancer diagnosis and creatinine no greater than uln
__label__0	study interventions are Niacinamide . recurrent rectal cancer diagnosis and aspartate aminotransferase ast less_than doc times uln less_than five times uln if there is liver involvement
__label__0	study interventions are Osimertinib . tseven hundred and ninetym mutation detected from circulating tumor dna either by pana mutyper or cobas egfr mutation test
__label__0	study interventions are Imatinib Mesylate . acral_lentiginous malignant melanoma diagnosis and patients must have either true amplification of fourqtwelve or detectable mutation of kit
__label__0	study interventions are Lenograstim . burkitt lymphoma diagnosis and forced expiratory volume in one second fevone forced vital capacity fvc diffusion capacity of carbon monoxide dlco diffusion capacity greater_than equal_than forty predicted corrected for hemoglobin if unable to perform pulmonary function tests then oxygen otwo saturation greater_than 9two on room air
__label__0	study interventions are pharmacological study . recurrent neuroblastoma diagnosis and lymphoid myeloid or mixed lineage
__label__0	study interventions are Interferons . stage iva mucosal melanoma of the head and neck diagnosis and step one registration
__label__0	study interventions are Dexamethasone . multiple myeloma and plasma cell neoplasm diagnosis and no hypersensitivity to bortezomib boron or mannitol
__label__0	study interventions are radiation therapy . head and neck cancer diagnosis and not specified
__label__0	study interventions are Cisplatin . stage iv gallbladder cancer diagnosis and arm cohort one
__label__0	study interventions are Everolimus . neoplasms diagnosis and adult patients greater_than equal_than eighteen years of age
__label__0	study interventions are Oxaliplatin . recurrent nasopharyngeal cancer diagnosis and at least six weeks since other prior substantial radiotherapy to the bone marrow
__label__0	study interventions are Erlotinib Hydrochloride . stage iv squamous cell carcinoma of the hypopharynx diagnosis and clear cell histology
__label__0	study interventions are Temozolomide . glioma diagnosis and for patients on corticosteroids they must have been on stable dose one week prior to baseline mri and the dose should not be escalated over entry dose level if clinically possible
__label__0	study interventions are Lapatinib . unresectable gallbladder cancer diagnosis and pt prolongation less_than four secs above uln unless taking warfarin
__label__0	study interventions are Staurosporine . estrogen receptor negative breast cancer diagnosis and must have undergone prior therapy with an anthracycline and taxane either in the adjuvant or metastatic setting
__label__0	study interventions are Prednisolone phosphate . lymphoma non hodgkin diagnosis and beam conditioning bcnu
__label__0	study interventions are Sorafenib . stage iv melanoma diagnosis and at least ninety days since prior adjuvant therapy including cytotoxic agents
__label__0	study interventions are Epothilones . stage ivb squamous cell carcinoma of the larynx diagnosis and serum creatinine equal_than less_than doc mg or creatinine clearance greater_than equal_than fifty ml min note
__label__0	study interventions are Prednisone . hormone resistant prostate cancer diagnosis and have testosterone less_than fifty ng dl patients must continue primary androgen deprivation with luteinizing hormone releasing hormone lhrh analogue if they have not undergone orchiectomy
__label__0	study interventions are Sunitinib . liver cancer diagnosis and localized surgically unresectable disease
__label__0	study interventions are Bicalutamide . prostate cancer diagnosis and radiotherapy
__label__0	study interventions are quality-of-life assessment . stage iii vulvar cancer diagnosis and measurable disease according to recist criteria
__label__0	study interventions are Trametinib . hilar cholangiocarcinoma diagnosis and patients must have zubrod performance status of zero one
__label__0	study interventions are Cyclosporine . childhood immunoblastic large cell lymphoma diagnosis and best available matches are hla class hla b allele matched donors allowing for any one or two drbone and or dqbone antigen allele mismatch
__label__0	study interventions are Albumin-Bound Paclitaxel . undifferentiated ovarian carcinoma diagnosis and must have hickman catheter in place or be eligible for placement
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the oropharynx diagnosis and no prior surgical procedures affecting absorption
__label__0	study interventions are Sirolimus . sarcoma diagnosis and absolute neutrophil count anc greater_than doc ten nine platelets greater_than ten0 ten nine hemoglobin hb greater_than nine dl
__label__0	study interventions are Mycophenolate mofetil . multiple myeloma diagnosis and total body irradiation tbi greater_than one thousand, two hundred cgy and etoposide sixty mg kg
__label__0	study interventions are Quality-of-Life Assessment . primary peritoneal serous adenocarcinoma diagnosis and patients must not have serious psychiatric illness lifetime bipolar disorder schizophrenia or other psychosis serious personality disorder severe major depressive disorder or recent suicide or psychiatric hospitalization previous twelve months
__label__0	study interventions are Aldesleukin . penile cancer diagnosis and filgrastim
__label__0	study interventions are tanespimycin . bladder cancer diagnosis and see disease characteristics
__label__0	study interventions are Mycophenolic Acid . aggressive non hodgkin lymphoma diagnosis and low grade nhl with less_than six month duration of cr between courses of conventional therapy
__label__0	study interventions are Doxorubicin . transitional cell carcinoma of the bladder diagnosis and coli derived drug preparations
__label__0	study interventions are Cyclophosphamide . ovarian cancer diagnosis and platelet count greater than one hundred zero mm three
__label__0	study interventions are temsirolimus . brain and central nervous system tumors diagnosis and concurrent steroid dosage must be stable
__label__0	study interventions are Ifosfamide . sarcoma diagnosis and not specified radiotherapy
__label__0	study interventions are Freund's Adjuvant . stage iic melanoma diagnosis and platelet count of one hundred zero per cu mm
__label__0	study interventions are Fludarabine phosphate . histology proven unresectable hepatocellular carcinoma
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and creatinine less_than doc mg dl
__label__0	study interventions are Bevacizumab . stage iv basal cell carcinoma of the lip diagnosis and refractory to interleukin two il two
__label__0	study interventions are Vidarabine . stage iv adult diffuse large cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Aldesleukin . melanoma skin diagnosis and more than one week since corticosteroids except physiological doses for respiratory ailments or adrenal insufficiency radiotherapy
__label__0	study interventions are Etoposide . untreated childhood supratentorial primitive neuroectodermal tumor diagnosis and creatinine clearance twelve or twenty-four hour urine collection or glomerular filtration rate gfr greater_than sixty ml min doc three two
__label__0	study interventions are Mycophenolate mofetil . mantle cell lymphoma diagnosis and patients will not be allowed to receive myelosuppressive chemotherapy for three weeks prior to conditioning
__label__0	study interventions are Dexamethasone acetate . adenocarcinoma of the rectum diagnosis and no frequent nausea or vomiting
__label__0	study interventions are Rituximab . t cell lymphoma of the angioimmunoblastic lymphadenopathy with dysproteinemia aild type
__label__0	study interventions are Interferons . histologically confirmed breast cancer
__label__0	study interventions are Lapatinib . stage iiia breast cancer diagnosis and creatinine less_than doc institutional upper limit of normal
__label__0	study interventions are Radiation Therapy . grade two follicular lymphoma diagnosis and eight dl may be transfused
__label__0	study interventions are Dacarbazine . neuroblastoma diagnosis and negative pregnancy test
__label__0	study interventions are Gemcitabine . stage iii adult burkitt lymphoma diagnosis and no known glucose six phosphate dehydrogenase gsixpd deficiency
__label__0	study interventions are Albumin-Bound Paclitaxel . adenocarcinoma of the gastroesophageal junction diagnosis and serum total bilirubin less_than doc mg dl and ast alt less_than three the institutional upper limit of normal
__label__0	study interventions are Gemcitabine . lymphoma diagnosis and no medical or psychiatric conditions that compromise the patient ability to give informed consent
__label__0	study interventions are Laboratory Biomarker Analysis . stage iv uterine corpus cancer diagnosis and prior radiotherapy allowed
__label__0	study interventions are Cediranib . childhood grade ii meningioma diagnosis and no concurrent chemotherapy
__label__0	study interventions are Sunitinib . liver cancer diagnosis and no uncontrolled angina
__label__0	study interventions are Ursodeoxycholic Acid . esophageal carcinoma diagnosis and diagnosis of barrett esophagus with histologically confirmed intestinal metaplasia anywhere in the tubular esophagus either with greater_than equal_than two cm of involvement or with minimum circumferential barrett esophagus be length of one cm
__label__0	study interventions are Vaccines . histologically confirmed transitional cell carcinoma of the bladder
__label__0	study interventions are microarray analysis . myelodysplastic myeloproliferative neoplasms diagnosis and patient characteristics
__label__0	study interventions are Cetuximab . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and criteria
__label__0	study interventions are Cisplatin . adenocarcinoma gastroesophageal junction diagnosis and platelet count greater_than one hundred one hundred and nine l
__label__0	study interventions are Bevacizumab . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and new york heart association class ii iv heart disease
__label__0	study interventions are Carboplatin . esophageal cancer diagnosis and other
__label__0	study interventions are Fludarabine . childhood immunoblastic large cell lymphoma diagnosis and human leukocyte antigen hla genotypically or phenotypically identical related donor
__label__0	study interventions are Cediranib . recurrent refractory childhood hodgkin lymphoma diagnosis and total bilirubin equal_than less_than doc mg dl does not apply to patients with gilbert syndrome
__label__0	study interventions are Cisplatin . triple negative breast cancer diagnosis and known left ventricular ejection fraction lvef less_than fifty
__label__0	study interventions are Tacrolimus . contiguous stage ii grade three follicular lymphoma diagnosis and incarceration
__label__0	study interventions are quality-of-life assessment . unspecified adult solid tumor protocol specific diagnosis and prior concurrent therapy
__label__0	study interventions are Celecoxib . tumor expresses cox two cox two index greater_than two
__label__0	study interventions are Isotretinoin . stage iii renal cell cancer diagnosis and an overlap between classes of therapies given concurrently will be counted as two prior treatment regimens
__label__0	study interventions are Bevacizumab . stage iv melanoma diagnosis and no pulmonary embolus within the past year
__label__0	study interventions are Cisplatin . testicular germ cell tumor diagnosis and more than thirty days since prior radiotherapy and recovered unless evidence of progressive disease has been documented
__label__0	study interventions are Fludarabine . anaplastic large cell lymphoma diagnosis and chronic myelogenous leukemia cml
__label__0	study interventions are Antibodies . stage small lymphocytic lymphoma diagnosis and elevenq deletion
__label__0	study interventions are Vorinostat . breast cancer diagnosis and ecog performance status zero two
__label__0	study interventions are Tretinoin . neuroblastoma diagnosis and progressive disease
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and absolute neutrophil count greater_than one five hundred mm three
__label__0	study interventions are Immunoglobulins . adenosquamous cell lung cancer diagnosis and lesions that can be accurately measured in at least one dimension longest diameter to be recorded as greater_than twenty mm with conventional techniques or as greater_than ten mm with spiral ct scan
__label__0	study interventions are Endurance . ewing sarcoma diagnosis and jude children research hospital
__label__0	study interventions are Interleukin-2 . metastatic melanoma diagnosis and patients not suitable for trastuzumab therapy no evidence of hertwo overexpressing disease or trastuzumab therapy exhausted in hertwo overexpressing disease
__label__0	study interventions are Erlotinib Hydrochloride . recurrent midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and not pregnant or nursing
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and hepatic metastases without spread to other sites except in case of less_than three resectable pulmonary metastases of diameter less_than two cm detected by thoracic scanner
__label__0	study interventions are Adenosine . non small cell lung cancer nsclc diagnosis and measurable disease defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded for non nodal lesions and short axis for nodal lesions as greater_than twenty mm with conventional techniques or as greater_than ten mm with spiral computed tomography ct scan magnetic resonance imaging mri or calipers by clinical exam
__label__0	study interventions are Paclitaxel . poorly differentiated histology uterine papillary serous carcinoma clear cell carcinoma or carcinosarcoma is acceptable as long as the predominant metastatic component is epithelial versus sarcomatous
__label__0	study interventions are Docetaxel . breast cancer diagnosis and unresected clinical stage tonec ttwo tthree or tfour lesion any n
__label__0	study interventions are Pemetrexed . non small cell lung cancer diagnosis and patients who are candidates to receive pemetrexed monotherapy
__label__0	study interventions are Laboratory Biomarker Analysis . stage iia squamous cell lung carcinoma diagnosis and patient registration eligibility criteria
__label__0	study interventions are Rituximab . mediastinal large cell lymphoma diagnosis and females of childbearing potential must have negative serum or urine beta human chorionic gonadotropin hcg pregnancy test at screening pregnancy testing is not required for
__label__0	study interventions are Carboplatin . lung cancer diagnosis and no prior chemotherapy endocrine therapy
__label__0	study interventions are Erlotinib Hydrochloride . lung cancer diagnosis and histological or unequivocal cytological proof of nsclc
__label__0	study interventions are Cisplatin . germ cell tumor diagnosis and ast alt less_than doc upper limits of normal uln
__label__0	study interventions are Antibodies, Monoclonal . male breast cancer diagnosis and disease progression after bone marrow or peripheral blood stem cell transplantation allowed
__label__0	study interventions are Letrozole . breast cancer diagnosis and patient must agree to the required research biopsies at baseline and after the two week treatment with endocrine therapy in the initial part of the study window phase or at baseline and after two week treated with endocrine therapy plus or minus palbociclib for those patients enrolled directly into the treatment phase of the study
__label__0	study interventions are Cetuximab . stage iv renal cell cancer diagnosis and fertile patients must use effective contraception during and for two months after study treatment
__label__0	study interventions are Lenograstim . intermediat negative or high grade non hodgkin lymphoma nhl meeting one of the following criteria
__label__0	study interventions are pazopanib hydrochloride . recurrent childhood brain stem glioma diagnosis and no concurrent aspirin ibuprofen or other nsaids
__label__0	study interventions are Irinotecan . stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are Alvocidib . recurrent grade one follicular lymphoma diagnosis and bone marrow plasmacytosis greater_than thirty of marrow cellularity
__label__0	study interventions are Antibodies, Monoclonal . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and life expectancy greater_than equal_than twelve weeks
__label__0	study interventions are Dacarbazine . ovarian cancer diagnosis and prior biologic response modifier treatment allowed at least four weeks since prior immunotherapy at least four weeks since prior biologic therapy no concurrent epoetin_alfa chemotherapy
__label__0	study interventions are Romidepsin . recurrent solid neoplasm diagnosis and patients with active hemolysis should be excluded no distinction will be made between liver dysfunction due to metastases and liver dysfunction due to other causes registration laboratory investigations will be used to assign patient to hepatic function group liver function tests should be repeated within twenty-four hours prior to starting initial therapy and may result in the patients group assignment being altered if different to registration test results
__label__0	study interventions are Immunoglobulins . recurrent grade two follicular lymphoma diagnosis and has not been naturally postmenopausal for at least 1two consecutive months has had menses at any time in the preceding 1two consecutive months
__label__0	study interventions are Misonidazole . adult gliosarcoma diagnosis and karnofsky performance score greater_than sixty
__label__0	study interventions are Romidepsin . urethral cancer diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Lenvatinib . solid malignant tumors diagnosis and hemoglobin greater than or equal to doc grams deciliter dl hemoglobin less than doc dl is acceptable if it is corrected by growth factor or transfusion before starting lenvatinib
__label__0	study interventions are Bortezomib . recurrent squamous cell carcinoma of the oropharynx diagnosis and one five hundred ul
__label__0	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and subjects who have had an organ allograft are not eligible
__label__0	study interventions are MEK162 . low grade gliomas diagnosis and patients of childbearing or child fathering potential must be willing to use medically acceptable form of birth control which includes abstinence while being treated on this study
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and ecog performance status greater_than equal_than two
__label__0	study interventions are Sorafenib . liver cancer diagnosis and john wort or rifampin
__label__0	study interventions are Antibodies, Bispecific . lymphoma diagnosis and sgpt less than two times normal
__label__0	study interventions are Paclitaxel . recurrent ovarian carcinoma diagnosis and phase ii study
__label__0	study interventions are Dexamethasone . childhood grade iii meningioma diagnosis and fully recovered from the acute toxic effects of all prior chemotherapy immunotherapy or radiotherapy
__label__0	study interventions are Dexamethasone acetate . plasmacytoma diagnosis and negative serum pregnancy test done equal_than less_than seven days prior to registration for women of childbearing potential only
__label__0	study interventions are Fludarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Oxaliplatin . recurrent childhood rhabdomyosarcoma diagnosis and oxcarbazepine
__label__0	study interventions are Paclitaxel . stage iiia non small cell lung cancer diagnosis and arm cohort three
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and disease characteristics
__label__0	study interventions are Gemcitabine . adult solid neoplasm diagnosis and fasting plasma glucose less_than one hundred and twenty mg dl
__label__0	study interventions are Bevacizumab . adult glioblastoma diagnosis and in range inr between two and three on stable dose of oral anticoagulant or on stable dose of lmw heparin
__label__0	study interventions are Epigallocatechin gallate . advanced colorectal adenomas diagnosis and willingness to provide mandatory tissue and blood for protocol specified research residual tissue and or blood may be used for future research negative pregnancy test equal_than less_than seven days prior to registration randomization
__label__0	study interventions are Etoposide phosphate . large cell lung cancer diagnosis and at the time of patient registration the treating institution name and id number must be provided to the data operations center in seattle in order to ensure that the current within three hundred and sixty-five days date of institutional review board approval for this study has been entered into the data base
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and no prior oxaliplatin
__label__0	study interventions are Albumin-Bound Paclitaxel . fallopian tube cancer diagnosis and life expectancy
__label__0	study interventions are Aromatase Inhibitors . stage ii breast cancer diagnosis and inclusion
__label__0	study interventions are Antibodies . anaplastic large cell lymphoma alk positive diagnosis and barrier methods of contraception
__label__0	study interventions are Busulfan . sarcoma diagnosis and diagnosis of hematologic malignancy or nonmalignancy
__label__0	study interventions are Irinotecan . glioma astrocytic diagnosis and adequate hematologic renal liver function as demonstrated by laboratory values
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and age
__label__0	study interventions are Paclitaxel . stage iiib uterine corpus cancer diagnosis and surgery must have included hysterectomy and bilateral salpingooophorectomy
__label__0	study interventions are Liposomal doxorubicin . metastatic cancer diagnosis and zidovudine
__label__0	study interventions are Rituximab . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and donor must have adequate veins for leukapheresis or agree to placement of central venous catheter femoral_subclavian
__label__0	study interventions are Fludarabine phosphate . recurrent adult diffuse large cell lymphoma diagnosis and patients eligible for this trial will have high risk diseases that include but are not limited to
__label__0	study interventions are Silybin . carcinoma non small cell lung diagnosis and ecog performance status score of zero one or two
__label__0	study interventions are Vidarabine . b cell lymphoma unclassifiable with features intermediate between diffuse large cell lymphoma and classical hodgkin lymphoma diagnosis and no clinical evidence of uncontrolled active infectious process
__label__0	study interventions are Fludarabine . childhood burkitt lymphoma diagnosis and ages greater_than fifty years with hematologic malignancies treatable by unrelated hct
__label__0	study interventions are Thalidomide . recurrent grade three follicular lymphoma diagnosis and received high dose chemotherapy with autologous stem cell transplantation asct from forty-two to one hundred and twenty-eight days before enrollment with stable disease partial response or complete response following asct
__label__0	study interventions are Cediranib . recurrent non small cell lung carcinoma diagnosis and prior treatment with anthracyclines
__label__0	study interventions are Antibodies . stage iv rectal cancer diagnosis and bilirubin no greater than doc times upper limit of normal uln
__label__0	study interventions are Dexamethasone 21-phosphate . breast cancer diagnosis and no current illness requiring chronic systemic steroids or requirement for chronic use of anti emetics
__label__0	study interventions are Albumin-Bound Paclitaxel . malignant ovarian mixed epithelial tumor diagnosis and patients should be free of active infection requiring antibiotics with the exception of uncomplicated urinary tract infection uti
__label__0	study interventions are Rituximab . mantle cell lymphoma meeting one of the following criteria
__label__0	study interventions are questionnaire administration . stage ii rectal cancer diagnosis and history of psychiatric or addictive disorder or other medical condition that in the opinion of the investigator would preclude the patient from meeting the trial requirements
__label__0	study interventions are Quality-of-Life Assessment . stage zero vulvar cancer diagnosis and at least six months since clinic therapy for lower extremity lymphedema
__label__0	study interventions are questionnaire administration . stage iia non small cell lung cancer diagnosis and patient eligibility criteria for entry into the project include
__label__0	study interventions are Quality-of-Life Assessment . splenic marginal zone lymphoma diagnosis and willing to provide blood and stool samples at baseline and study time points for correlative research purposes
__label__0	study interventions are Fludarabine phosphate . recurrent mantle cell lymphoma diagnosis and donor
__label__0	study interventions are Fluorouracil . stage iv colon cancer diagnosis and no psychiatric illness or social situation that would preclude study compliance
__label__0	study interventions are Paclitaxel . brain metastases allowed provided the patient is stable after completion of treatment surgery and or radiotherapy asymptomatic and off steroids with two consecutive stable brain scans at least four weeks after radiotherapy
__label__0	study interventions are Temozolomide . unspecified adult solid tumor protocol specific diagnosis and disease characteristics
__label__0	study interventions are Antibodies . women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation should woman become pregnant or suspect she is pregnant while she or her partner is participating in this study she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study for the duration of study participation and four months after completion of olaparib positive cediranib administration
__label__0	study interventions are Fenofibrate . neuroblastoma diagnosis and no other serious medical illness
__label__0	study interventions are Cyclophosphamide . noncontiguous stage ii small lymphocytic lymphoma diagnosis and patients of childbearing potential must agree to use an effective birth control method
__label__0	study interventions are Ixazomib . plasma cell myeloma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Alvocidib . stage iv ovarian epithelial cancer diagnosis and group two closed to accrual as of three ten six
__label__0	study interventions are Imatinib Mesylate . brain and central nervous system tumors diagnosis and patient characteristics
__label__0	study interventions are Cetuximab . stage iv rectal cancer diagnosis and creatinine normal or creatinine clearance greater_than equal_than sixty ml min
__label__0	study interventions are Immunoglobulins . stage iii verrucous carcinoma of the larynx diagnosis and cardiac arrhythmia or serious ventricular arrhythmia ventricular fibrillation or ventricular tachycardia greater_than three beats in row within the past twelve months
__label__0	study interventions are Fluorouracil . recurrent gallbladder cancer diagnosis and patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past thirty days
__label__0	study interventions are Staurosporine . recurrent cervical cancer diagnosis and negative pregnancy test
__label__0	study interventions are pharmacological study . neuroblastoma diagnosis and fertile patients must use effective contraception prior to during and for two months after completion of study treatment
__label__0	study interventions are Liver Extracts . metastatic cancer diagnosis and see disease characteristics
__label__0	study interventions are Temozolomide . childhood grade ii meningioma diagnosis and doc mg dl males or doc mg dl females greater_than sixteen years of age
__label__0	study interventions are management of therapy complications . stage iv adult burkitt lymphoma diagnosis and able to communicate in english as indicated by ability to communicate adequately with study staff to participate in the clinical phone_calls and to complete patient reported outcomes pro assessments in english
__label__0	study interventions are Rituximab . lymphoma diagnosis and patients greater_than equal_than fifty-five but less_than equal_than sixty-five years who have performance status of zero or one and no comorbidities may receive the myeloablative regimen one at the discretion of the investigator s
__label__0	study interventions are Bicalutamide . prostate cancer diagnosis and any of the following
__label__0	study interventions are Melphalan . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and failed or were not eligible for autologous transplantation
__label__0	study interventions are Dexamethasone . multiple myeloma and plasma cell neoplasm diagnosis and platelet count of greater_than one hundred zero ul
__label__0	study interventions are Vorinostat . cancer diagnosis and rising psa documented by at least two consecutive measurements obtained more than one month apart
__label__0	study interventions are Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy . limited disease small cell lung cancer diagnosis and patients should sign written informed consest before study entry
__label__0	study interventions are Lapatinib . neoplasms breast diagnosis and rapidly progressing or life threatening disease that are considered to be inapplicable to hormonal therapy as determined by the investigator
__label__0	study interventions are antineoplaston AS2-1 . head and neck cancer diagnosis and endocrine therapy
__label__0	study interventions are Carboplatin . unspecified adult solid tumor protocol specific diagnosis and no active infections requiring iv antibiotic therapy
__label__0	study interventions are Mitogens . osteosarcoma diagnosis and biologic anti neoplastic agent
__label__0	study interventions are Liposomal doxorubicin . embryonal botryoid childhood rhabdomyosarcoma diagnosis and ecog zero two
__label__0	study interventions are Lapatinib . recurrent adult brain neoplasm diagnosis and total bilirubin equal_than less_than institutional upper limit of normal
__label__0	study interventions are Melphalan . neoplasms diagnosis and signed written informed consent
__label__0	study interventions are Prednisolone . lymphoma diagnosis and renal
__label__0	study interventions are Fludarabine phosphate . type two papillary renal cell carcinoma diagnosis and only single allele disparity will be allowed for hla b or as defined by high resolution typing
__label__0	study interventions are Oxaliplatin . pancreatic cancer diagnosis and negative pregnancy test
__label__0	study interventions are Supervised progressive resistance training . cancer related fatigue diagnosis and ability to understand and follow the study protocol
__label__0	study interventions are Paclitaxel . neoplasms advanced or metastatic diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt less_than doc uln
__label__0	study interventions are Tretinoin . recurrent neuroblastoma diagnosis and mycn amplification greater than four fold increase in mycn signals as compared to reference signals regardless of age or additional biologic features
__label__0	study interventions are Fludarabine . multiple myeloma diagnosis and patients who had remissions lasting greater_than twelve months are eligible after at least two prior therapies
__label__0	study interventions are Bevacizumab . anaplastic astrocytoma diagnosis and male or female patients of greater or equaleighteen years of age
__label__0	study interventions are Bortezomib . multiple myeloma and plasma cell neoplasm diagnosis and lytic bone lesions
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and patient characteristics
__label__0	study interventions are Cyclophosphamide . cancer of the breast diagnosis and to be valid for baseline the measurements must have been made within the fourteen days if palpable
__label__0	study interventions are Bevacizumab . recurrent malignant mesothelioma diagnosis and no unstable angina pectoris within the past six months
__label__0	study interventions are Estrogen Receptor Modulators . breast cancer diagnosis and carbamazepine
__label__0	study interventions are Thioctic Acid . unspecified childhood solid tumor protocol specific diagnosis and not specified
__label__0	study interventions are Pembrolizumab . ovarian cancer diagnosis and ast sgot and alt sgpt less_than equal_than doc uln or less_than equal_than five uln for subjects with liver metastases nternational normalized ratio inr pt less_than equal_than doc uln unless subject is receiving anticoagulant therapy as long as pt or partial prothrombin time ptt is within therapeutic range of intended use of anticoagulants h
__label__0	study interventions are Asparaginase . pregnant or lactating woman
__label__0	study interventions are Pembrolizumab . melanoma diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than three times institutional upper normal level ast and alt equal_than less_than five times institutional upper normal level if there is evidence of liver metastasis
__label__0	study interventions are Niacinamide . ovarian cancer diagnosis and no definite evidence of disease by ct scan of the abdomen and pelvis
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and no prior treatment with small molecule egfr inhibitors gefitinib erlotinib hydrochloride or lapatinib ditosylate
__label__0	study interventions are Cyclin-Dependent Kinase Inhibitor Proteins . adult solid tumor diagnosis and a
__label__0	study interventions are Antibodies . ewing family of tumors diagnosis and all participants who have or will receive treatment at sjcrh with huone doc eightkthree hundred and twenty-twoa
__label__0	study interventions are Calcium, Dietary . stage iv extragonadal non seminomatous germ cell tumor diagnosis and more than four weeks since prior major surgery
__label__0	study interventions are Thalidomide . stage iv grade three follicular lymphoma diagnosis and patients with an autoimmune disorder requires active immunosuppression are not eligible
__label__0	study interventions are Lapatinib . solid tumor cancer diagnosis and an intrauterine device iud with documented failure rate of less than one per year
__label__0	study interventions are Entinostat . stage iv adult diffuse large cell lymphoma diagnosis and more than four weeks since prior major surgery
__label__0	study interventions are Lenograstim . childhood lymphocyte predominant hodgkin lymphoma diagnosis and bilirubin equal_than less_than doc times uln
__label__0	study interventions are Panobinostat . breast cancer diagnosis and platelet count of greater_than one hundred zero mmthree
__label__0	study interventions are Immunoglobulins . adult ependymoma diagnosis and no history of minor surgical procedure excluding placement of vascular access device within seven days prior to day one of treatment
__label__0	study interventions are Irinotecan . stage iii rectal cancer diagnosis and ritonavir
__label__0	study interventions are Tirapazamine . prior local therapies such as surgical resection radiofrequency ablation or alcohol injection are allowed as long as tumor progresses from the prior treatment and the patients are still candidates for tae
__label__0	study interventions are Cisplatin . urethral cancer diagnosis and no complete bundle_branch block
__label__0	study interventions are Romidepsin . recurrent gastrointestinal carcinoid tumor diagnosis and performance status
__label__0	study interventions are Ifosfamide . transaminases less_than doc times upper limit of normal unless attributed to lymphoma
__label__0	study interventions are Docetaxel . more than thirty days since prior anticancer investigational drugs
__label__0	study interventions are Mifepristone . stage iv breast cancer diagnosis and and or progesterone receptor pr positive must have developed metastatic disease while on adjuvant hormonal therapy or have progression of disease after at least one hormonal therapy for advanced disease and may have received unlimited prior hormonal therapies
__label__0	study interventions are Bevacizumab . stage iiib fallopian tube cancer diagnosis and serum glutamic oxaloacetic transaminase sgot equal_than less_than to doc uln
__label__0	study interventions are Ifosfamide . testicular choriocarcinoma and embryonal carcinoma diagnosis and at least one week since prior growth factors two weeks for pegfilgrastim
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and mismatched family members who are matched at more than five of ten hla loci are permitted
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer metastatic or non small cell lung cancer recurrent diagnosis and life expectancy exceeding twelve weeks
__label__0	study interventions are MASCT . advanced solid tumors diagnosis and alkaline phosphatase alp less_than doc unl
__label__0	study interventions are Melphalan . lymphoma hodgkin and non hodgkin diagnosis and must be less_than twenty-two years of age
__label__0	study interventions are Oxaliplatin . esophageal adenocarcinoma diagnosis and patients eighteen years of age or older
__label__0	study interventions are Levoleucovorin . recurrent colon cancer diagnosis and platelets greater_than equal_than one hundred and fifty zero ul
__label__0	study interventions are Succinylcholine . prostatic neoplasms diagnosis and albumin greater_than twenty-five l any bone imaging techniques as per institutional standard of care
__label__0	study interventions are Prednisone . prostatic neoplasms diagnosis and life expectancy of greater than three months
__label__0	study interventions are Doxorubicin . malignant ovarian mixed epithelial tumor diagnosis and patients whose ca one hundred and twenty-five is less_than one hundred ml must undergo second confirmatory value within period of less_than four weeks
__label__0	study interventions are Tacrolimus . stage marginal zone lymphoma diagnosis and glucocorticoid treatment at prednisone equivalent doses greater_than doc mg kg day
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent colon cancer diagnosis and patients must have histologically proven hertwo overexpressing malignancy as determined by any standardized assay currently in clinical use
__label__0	study interventions are Prednisone . lymphoma diagnosis and patients with non measurable disease in addition to measurable disease must have all non measurable disease assessed within forty-two days prior to registration
__label__0	study interventions are Antibodies, Monoclonal . lymphomas diagnosis and adequate renal function as evidenced by serum creatinine level less_than doc uln or calculated creatinine clearance greater_than sixty ml min
__label__0	study interventions are Fluorouracil . squamous cell carcinoma diagnosis and per mdacc creatinine clearance guidelines patients must have creatinine clearance greater_than fifty ml min determined by twenty-four hour collection or nomogram
__label__0	study interventions are Antibodies . pancreatic vipoma diagnosis and patients should have completed any major surgery greater_than equal_than four weeks from start of treatment
__label__0	study interventions are Sunitinib . recurrent uterine sarcoma diagnosis and no significant ekg abnormalities no history of serious ventricular arrhythmia or ekg with ventricular tachycardia or ventricular fibrillation greater_than three beats in row
__label__0	study interventions are Oxaliplatin . colorectal cancer diagnosis and not specified
__label__0	study interventions are Doxorubicin . ovarian cancer diagnosis and zubrod zero two
__label__0	study interventions are Ilorasertib . solid neoplasm diagnosis and subject has documented left ventricular ejection fraction greater_than fifty
__label__0	study interventions are Dexamethasone 21-phosphate . lymphoma diagnosis and hepatitis virus carriers should have normal hbv dna copies and should use antiviral drugs
__label__0	study interventions are Letrozole . human epidermal growth factor two negative carcinoma of breast diagnosis and hormone receptor positive hr positive disease defined as estrogen receptor positive er positive and or progesterone receptor positive pgr
__label__0	study interventions are Bevacizumab . stage iii pancreatic cancer diagnosis and performance status
__label__0	study interventions are Immunoglobulins . stage iva hodgkin lymphoma diagnosis and two to less_than six years
__label__0	study interventions are Cyclophosphamide . mantle cell lymphoma diagnosis and dlcocorr greater_than fifty normal
__label__0	study interventions are Immunoglobulin G . stage ivb uterine corpus cancer diagnosis and hepatic artery embolization
__label__0	study interventions are Docetaxel . recurrent non small cell lung cancer diagnosis and no crohn disease
__label__0	study interventions are Vaccines . recurrent gastric carcinoma diagnosis and patients who have been treated with surgical resection for hcc and following chemoembolization as adjuvant therapy for hcc
__label__0	study interventions are Proteasome Inhibitors . recurrent plasma cell myeloma diagnosis and serum free light chain greater_than equal_than ten mg dl provided the free light chain flc ratio is abnormal
__label__0	study interventions are Cyclophosphamide . myeloma diagnosis and acute lymphoblastic leukemia all
__label__0	study interventions are Irinotecan . glioblastoma diagnosis and inclusion
__label__0	study interventions are Trametinib . stage iv childhood hepatocellular carcinoma diagnosis and disease related criteria
__label__0	study interventions are Sir-Spheres® . stage iv uveal melanoma diagnosis and children under the age of eighteen
__label__0	study interventions are Succinylcholine . cognitive side effects of cancer therapy diagnosis and eastern cooperative oncology group ecog performance status zero two
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and measurable disease
__label__0	study interventions are Antibodies, Monoclonal . stage ia breast cancer diagnosis and node positivity may be determined by either an axillary node dissection or positive sentinel node finding by hematoxylin and eosin e
__label__0	study interventions are Cyclosporine . nodal marginal zone cell lymphoma diagnosis and must have failed previous myelosuppressive chemotherapy or hct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are compliance monitoring . colorectal cancer diagnosis and menopausal status not specified
__label__0	study interventions are Antioxidants . prostate cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Estramustine . prostate cancer diagnosis and patients must sign written informed consent form prior to treatment
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and myocardial infarction within six months prior to enrolment or has new york heart association nyha class iii or iv heart failure appendix uncontrolled angina severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
__label__0	study interventions are Tretinoin . precancerous nonmalignant condition diagnosis and no concurrent regular steroids radiotherapy
__label__0	study interventions are Mycophenolic Acid . stage ii childhood large cell lymphoma diagnosis and donor must consent to filgrastim csf administration and leukapheresis
__label__0	study interventions are Leucovorin . histologically or cytologically confirmed pancreatic ductal adenocarcinoma
__label__0	study interventions are Ixazomib . newly diagnosed multiple myeloma diagnosis and ife expectancy greater_than three month ecog performance status zero one or
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and hepatic
__label__0	study interventions are Cetuximab . histologically or cytologically confirmed colorectal cancer
__label__0	study interventions are Cyclophosphamide . advanced melanoma diagnosis and braf vsix hundred mutation analysis
__label__0	study interventions are Mycophenolate mofetil . recurrent grade two follicular lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Prednisone . stage iib prostate cancer diagnosis and eligibility of patients receiving any medications or substances known to affect or with the potential to affect the androgen axis will be determined following review of their case by the principal investigator
__label__0	study interventions are Ascorbic Acid . non small cell lung carcinoma diagnosis and note
__label__0	study interventions are Dabrafenib . stage iiic skin melanoma diagnosis and note
__label__0	study interventions are Interferon-alpha . papillary renal cell carcinoma diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Irinotecan . recurrent colorectal cancer diagnosis and radiotherapy
__label__0	study interventions are Cyclosporine . stage iii childhood large cell lymphoma diagnosis and must be refractory to fludarabine patients who fail to have complete or partial response after therapy with regimen containing fludarabine or another nucleoside_analog two cladribine_cda pentostatin or experience disease relapse within 1two months after completing therapy with regimen containing fludarabine or another nucleoside_analog
__label__0	study interventions are Camptothecin . unresectable metastatic colo rectal cancer diagnosis and at least four weeks since last administration of last chemotherapy and or radiotherapy
__label__0	study interventions are Fludarabine . follicular lymphoma diagnosis and haemoglobin less_than ten dl or wbc less_than doc ten9 or platelet counts less_than ten0 ten9 due to marrow involvement
__label__0	study interventions are Levoleucovorin . recurrent extrahepatic bile duct cancer diagnosis and nyha class iii or iv heart disease
__label__0	study interventions are questionnaire administration . breast cancer diagnosis and family members do not need to be biologically related to the patient or related through marriage and may or may not live in the same house with the patient
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and subject must have received and relapsed or progressed after prior treatment with bortezomib
__label__0	study interventions are Bortezomib . stage iii adult immunoblastic large cell lymphoma diagnosis and no cardiac symptoms greater_than grade two
__label__0	study interventions are Immunoglobulins . recurrent endometrial carcinoma diagnosis and may have received one additional cytotoxic regimen for management of this disease
__label__0	study interventions are Capecitabine . pancreatic cancer stage iva diagnosis and a
__label__0	study interventions are Sunitinib . stage iv pancreatic cancer diagnosis and rifabutin
__label__0	study interventions are Cisplatin . esophageal cancer diagnosis and absolute granulocyte count at least one five hundred mmthree platelet count at least one20 zero mmthree hepatic
__label__0	study interventions are Bevacizumab . neurofibromatosis type two diagnosis and must be eight weeks from end of treatment
__label__0	study interventions are Trastuzumab . hertwo positive breast cancer diagnosis and ast sgot alt sgpt equal_than less_than three upper limit normal
__label__0	study interventions are Idelalisib . recurrent follicular lymphoma diagnosis and patients must be non pregnant and non nursing
__label__0	study interventions are Endothelial Growth Factors . stage iib non small cell lung carcinoma diagnosis and calculated creatinine clearance must be obtained within two weeks of randomization and calculated creatinine clearance crcl must be greater_than equal_than forty-five ml min using the standard cockcroft and gault formula or the measured glomerular filtration rate gfr using the appropriate radiolabeled method fifty-one chromium labeled ethylenediaminetetraacetic acid fifty-one credta or technetium_ninety-ninem diethylenetriamine pentaacetic acid tcninety-ninem dtpa must be used to calculate crcl
__label__0	study interventions are Prednisolone hemisuccinate . anaplastic large cell lymphoma diagnosis and patients undergoing transplant in early relapse are eligible for transplant in first and second relapse only
__label__0	study interventions are Gemcitabine . extrahepatic bile duct cancer diagnosis and endocrine therapy
__label__0	study interventions are Vaccines . cancer of cervix diagnosis and measurable disease according to modified recist doc and irrecist appendix c
__label__0	study interventions are Carboplatin . stage iii ovarian epithelial cancer diagnosis and calculated creatinine clearance will be used to assess renal function
__label__0	study interventions are SOR-C13 . cancer diagnosis and absolute neutrophil count greater_than one five hundred mm³ greater_than doc one0? l
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ivc squamous cell carcinoma of the oropharynx diagnosis and platelets greater_than one hundred zero cells mm three
__label__0	study interventions are Testosterone . unspecified adult solid tumor protocol specific diagnosis and cardiovascular
__label__0	study interventions are Octreotide . biopsy proven neuroendocrine tumor neuroblastoma medulloblastoma or other somatostatin receptor positive tumor
__label__0	study interventions are Mesna . primary malignant brain neoplasms diagnosis and hematologic
__label__0	study interventions are Docetaxel . metastatic pancreatic adenocarcinoma diagnosis and creatinine equal_than less_than doc institutional uln or creatinine clearance greater_than equal_than fifty ml min calculated with the cockcroft gault formula
__label__0	study interventions are Trabectedin . recurrent childhood rhabdomyosarcoma diagnosis and no concurrent enzyme inducing anticonvulsants
__label__0	study interventions are Exemestane . breast cancer diagnosis and clinically staged as documented by the treating physician as one of the following
__label__0	study interventions are Crizotinib . uveal melanoma diagnosis and serum creatinine less_than twox uln or creatinine clearance greater_than sixtyml min
__label__0	study interventions are Etoposide . plasmablastic lymphoma diagnosis and forced expiratory volume in one second fev one or diffusion capacity of the lung for carbon monoxide dlco greater_than equal_than fifty predicted timeline
__label__0	study interventions are Cetuximab . untreated metastatic squamous neck cancer with occult primary diagnosis and human immunodeficiency virus hiv positive patients receiving combination anti retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with erlotinib
__label__0	study interventions are Antibodies . testicular lymphoma diagnosis and anc greater_than equal_than seven hundred and fifty mm three
__label__0	study interventions are Staurosporine . fallopian tube cancer diagnosis and surgery
__label__0	study interventions are Trastuzumab . pancreatic cancer diagnosis and progressed after first line or adjuvant gemcitabine based chemotherapy
__label__0	study interventions are Cisplatin . pancreatic cancer diagnosis and no myocardial infarction or stroke within the past six months
__label__0	study interventions are Cisplatin . central nervous system tumors diagnosis and hepatic
__label__0	study interventions are Inguinal Lymphadenectomy . metastatic melanoma to the groin lymph nodes diagnosis and this can can be detected
__label__0	study interventions are MRI/MRS . breast cancer diagnosis and acrin six thousand, six hundred and fifty-seven eligibility criteria match that of calgb correlative science trial one hundred and fifty thousand and seven
__label__0	study interventions are Cognitive Assessment . stage iiic fallopian tube cancer diagnosis and no prior radiotherapy or chemotherapy
__label__0	study interventions are ispinesib . recurrent childhood medulloblastoma diagnosis and phenobarbital
__label__0	study interventions are Paclitaxel . stage iv pancreatic cancer diagnosis and phase ii
__label__0	study interventions are Erlotinib Hydrochloride . ewing sarcoma diagnosis and myelosuppressive chemotherapy
__label__0	study interventions are Immunoconjugates . hiv associated hodgkin lymphoma diagnosis and histologic diagnosis of cdthirty positive classical hl as defined by the two thousand and eight who classification of hematological diseases
__label__0	study interventions are Mitogens . metastatic renal cell carcinoma diagnosis and recovery to baseline or less_than grade one ctcae version doc from toxicities related to any prior treatment unless adverse events are clinically non significant and or stable on supportive therapy
__label__0	study interventions are Regular occupation therapy . cancer diagnosis and karnofsky performance status kps of between forty and seventy
__label__0	study interventions are Melphalan . lymphoma diagnosis and under fifty-seven
__label__0	study interventions are Tacrolimus . stage iii adult lymphoblastic lymphoma diagnosis and refractory cytopenia with multilineage_dysplasia
__label__0	study interventions are Nivolumab . recurrent plasma cell myeloma diagnosis and if the first recorded qtc exceeds four hundred and eighty msec two additional consecutive ecgs are required and must result in mean resting qtc equal_than less_than four hundred and eighty msec it is recommended that there are ten minute positive
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iii pancreatic cancer diagnosis and females of childbearing potential must have negative pregnancy test within seven days of being registered for protocol therapy
__label__0	study interventions are Carboplatin . newly diagnosed childhood ependymoma diagnosis and no evidence of non contiguous spread beyond the primary site as determined by pr negative or post operative mri of brain pr negative or post operative mri of the spine and post operative csf cytology obtained from the lumbar csf space
__label__0	study interventions are Calcium, Dietary . breast cancer diagnosis and no hypertension refractory to treatment within the past six months
__label__0	study interventions are Melphalan . mantle cell lymphoma diagnosis and patients with clinical signs of pulmonary insufficiency must have dlco to be measured at greater_than fifty of predicted value
__label__0	study interventions are Pemetrexed . non small cell lung cancer diagnosis and have an ecog performance status of zero or one
__label__0	study interventions are Albumin-Bound Paclitaxel . progesterone receptor negative breast cancer diagnosis and ecog performance status of zero or one
__label__0	study interventions are Melphalan . lymphoma diagnosis and combined immune deficiencies including but not limited to the following
__label__0	study interventions are Isophosphamide mustard . retinoblastoma diagnosis and to be approved by two or more physicians on the study committee
__label__0	study interventions are Thalidomide . stage adult diffuse large cell lymphoma diagnosis and understand and voluntarily sign an informed consent form
__label__0	study interventions are Morphine . neoplasms diagnosis and morphine sr tablet less than or equal to one hundred and twenty milligram mg per day oxycodone hydrochloride controlled release cr tablet
__label__0	study interventions are Antibodies . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and ast less_than doc times uln
__label__0	study interventions are Cyclosporins . childhood grade iii lymphomatoid granulomatosis diagnosis and only patients with mds refractory anemia ra or mds refractory anemia with ringed_sideroblasts rars will be eligible for this protocol additionally patients with myeloproliferative syndromes mps will be eligible those patients with mds or mps with greater_than five marrow blasts including those with transformation to aml must receive cytotoxic chemotherapy and achieve less_than five marrow blasts at time of transplant
__label__0	study interventions are Toremifene . breast neoplasms diagnosis and more than one year since last menstruation or tested postmenopausal from estradiol etwo and follicle stimulating hormone fsh levels based on evaluation standard of each institution
__label__0	study interventions are Freund's Adjuvant . mixed glioma diagnosis and platelets greater_than equal_than one hundred zero mm three
__label__0	study interventions are Docetaxel . uterine carcinosarcoma diagnosis and gog zero two
__label__0	study interventions are Cyclophosphamide . multiple myeloma diagnosis and prophylactic antibiotics should be considered particularly in patients with neutropenia
__label__0	study interventions are Liposomal doxorubicin . adjuvant patients with at least four positive lymph nodes and her two overexpressing tumor
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiib breast cancer diagnosis and be willing and able to comply with scheduled visits treatment plan laboratory tests and other trial procedures
__label__0	study interventions are Cediranib . ovarian endometrioid adenocarcinoma diagnosis and patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
__label__0	study interventions are Mycophenolic Acid . stage mantle cell lymphoma diagnosis and they have been treated with more than one regimen of haart for total of at least six months duration
__label__0	study interventions are SBRT . liver carcinoma diagnosis and large esophageal varices without band ligation
__label__0	study interventions are Camptothecin . solid tumors diagnosis and for arm abt two hundred and sixty-three monotherapy subject should have malignancy that is either relapsed or refractory to standard therapy or no known effective therapy exists
__label__0	study interventions are Bevacizumab . stage iva colon cancer diagnosis and measurable disease
__label__0	study interventions are Complement Factor H . colorectal cancer diagnosis and zubrod performance status greater_than two or self reports either not being up and about more than fifty of waking hours or unable to provide self care arms two and three
__label__0	study interventions are Fludarabine phosphate . nonmalignant neoplasm diagnosis and resistant or recurrent disease after combination chemotherapy with at least one standard regimen or in first remission and at high risk of relapse
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and in first remission but at high risk of relapse because of one of the following factors
__label__0	study interventions are Gemcitabine . histologically confirmed pancreatic adenocarcinoma that is metastatic or unresectable
__label__0	study interventions are Cyclophosphamide . hepatocellular carcinoma diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are Bevacizumab . ovarian cancer diagnosis and in determining eligibility the more abnormal of the two values ast or alt should be used
__label__0	study interventions are Docetaxel . breast cancer diagnosis and performance status
__label__0	study interventions are Etoposide phosphate . stage iii mantle cell lymphoma diagnosis and creatinine clearance greater_than equal_than sixty ml min timeline
__label__0	study interventions are Trametinib . endometrial undifferentiated carcinoma diagnosis and patients should be free of active infection requiring antibiotics with the exception of uncomplicated urinary tract infection uti
__label__0	study interventions are Cytarabine . recurrent grade two follicular lymphoma diagnosis and fcbp must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least two8 days before she starts taking lenalidomide
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ivb pancreatic cancer diagnosis and oxaliplatin or five fu will be allowed but subset analysis will be done for this group of patients
__label__0	study interventions are Mechlorethamine . hodgkin lymphoma diagnosis and subjects who have failed second line or subsequent line salvage chem negative radiotherapy regimens for whom no other treatment options of proven efficacy can be given
__label__0	study interventions are Antibodies . recurrent breast carcinoma diagnosis and patients have locally recurrent or distant relapsed metastatic disease
__label__0	study interventions are Sirolimus . renal cell carcinoma diagnosis and adequate hepatic function
__label__0	study interventions are Leucovorin . colorectal cancer diagnosis and number of hepatic metastases greater_than orequal_than four
__label__0	study interventions are Docetaxel . adenocarcinoma of the prostate diagnosis and progression after docetaxel based chemotherapy is needed as follows
__label__0	study interventions are Antibodies, Monoclonal . stage iii verrucous carcinoma of the larynx diagnosis and in range inr usually between two and three and patient is on stable dose of oral anticoagulant for one week or on stable dose of low molecular weight heparin
__label__0	study interventions are Digital Breast Tomosynthesis . cancer screening diagnosis and are able and willing to comply with study procedures
__label__0	study interventions are pazopanib hydrochloride . childhood central nervous system embryonal tumor diagnosis and alt less_than one hundred and ten l
__label__0	study interventions are Sirolimus . recurrent ovarian epithelial cancer diagnosis and history of significant neurologic or psychiatric disorder that would impair the ability to obtain consent or limit study compliance active uncontrolled infection or nonhealing wounds or
__label__0	study interventions are Vinblastine . triple negative breast cancer diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred mm three doc one0 nine l
__label__0	study interventions are Prednisolone . lymphoma diagnosis and greater than twenty zero mm three
__label__0	study interventions are Topotecan . malignant ovarian endometrioid tumor diagnosis and asparate transaminase ast and alkaline phosphatase less than or equal to doc upper limit of normal ctcae doc grade one
__label__0	study interventions are Vidarabine . recurrent marginal zone lymphoma diagnosis and at least twelve weeks must have passed since radioimmunotherapy prior fludarabine treatment is not restricted
__label__0	study interventions are management of therapy complications . brain and central nervous system tumors diagnosis and patient characteristics
__label__0	study interventions are Mycophenolate mofetil . stage iii grade two follicular lymphoma diagnosis and low grade nh negative with less_than six months duration of complete response cr between courses of conventional therapy
__label__0	study interventions are Cyclophosphamide . central nervous system tumors diagnosis and anc greater than one five hundred mmthree platelet count greater than one00 zero mmthree hemoglobin greater than one0 dl hepatic
__label__0	study interventions are Hormones . primary non metastatic breast cancer diagnosis and patient with epclin score less_than doc two thousand, eight hundred and sixty-seven will not be randomized but will be followed yearly during ten years
__label__0	study interventions are Vaccines . stage ia breast cancer diagnosis and any human leukocyte antigen hla type historic hla typing is permitted
__label__0	study interventions are Methyltestosterone . prostate cancer diagnosis and wbc at least three five hundred mm three
__label__0	study interventions are Erlotinib Hydrochloride . stage iiia non small cell lung cancer diagnosis and performance status
__label__0	study interventions are Immunoglobulins . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and subjects must have baseline screening baseline radiographic images brain chest abdomen pelvis and bone scans with specific imaging tests to be determined by the attending physician within six weeks of initiation of ipilimumab
__label__0	study interventions are Liposomal doxorubicin . bladder cancer diagnosis and blood urea_nitrogen normal
__label__0	study interventions are Experimental: imaging arm . colorectal cancer diagnosis and no hypercalcemia
__label__0	study interventions are Immunoglobulins . osteosarcoma diagnosis and must not have received investigational agent within fourteen days of study entry
__label__0	study interventions are Tacrolimus . lymphoma diagnosis and accelerated phase cml meeting one of the following criteria
__label__0	study interventions are Everolimus . tufted_angioma diagnosis and prior therapy
__label__0	study interventions are Cetuximab . stage iva nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Albumin-Bound Paclitaxel . inflammatory breast cancer ibc diagnosis and ast sgot alt sgpt less_than doc institutional upper limit of normal
__label__0	study interventions are Interleukin-2 . anaplastic large cell lymphoma diagnosis and women of procreative potential must have negative pregnancy test within the two week screening phase prior to cycle one and all subjects of procreative potential must use adequate birth control throughout the study subjects of procreative potential are defined as any fertile male and any female who has experienced menarche and has not undergone successful surgical sterilization hysterectomy or bilateral oophorectomy or is not post menopausal defined as age related amenorrhea greater_than equal_than onetwo months
__label__0	study interventions are Epoetin Alfa . precancerous condition diagnosis and ecog zero one life expectancy
__label__0	study interventions are O(6)-benzylguanine . glioblastoma multiforme who grade iv diagnosis and patients who are unable to walk because of paralysis but who are up in wheelchair will be considered ambulatory for the purpose of assessing the performance score
__label__0	study interventions are Mitogens . renal cell carcinoma diagnosis and documentation of flu vaccination if enrolled during flu season as defined by the availability of vaccine
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and at least three weeks since prior major surgery
__label__0	study interventions are Antibodies, Monoclonal . hormone resistant prostate cancer diagnosis and unstable angina pectoris
__label__0	study interventions are Everolimus . melanoma diagnosis and no peripheral neuropathy greater_than grade two
__label__0	study interventions are Immunoglobulins . pathologically confirmed diagnosis of relapsed or refractory cell acute lymphoblastic leukemia lymphoma with measurable bone marrow lymphoblasts or biopsy proven extramedullary site measurable by computed tomography ct or positron_emission tomography pet ct imaging philadelphia_chromosome positive ph positive all patients must have failed treatment with at least one second generation tyrosine kinase inhibitor prior allo hct is allowed
__label__0	study interventions are Carboplatin . inflammatory breast cancer diagnosis and women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
__label__0	study interventions are Aldesleukin . metastatic cancer diagnosis and life expectancy of greater than three months
__label__0	study interventions are Bleomycin . ovarian cancer diagnosis and no prior radiotherapy surgery
__label__0	study interventions are Etoposide . nonmalignant neoplasm diagnosis and heart
__label__0	study interventions are Levoleucovorin . carcinoma of unknown primary diagnosis and at least four weeks since prior radiotherapy no greater than twenty-five of bone marrow
__label__0	study interventions are Antibodies, Monoclonal . recurrent salivary gland cancer diagnosis and more than twenty-eight days since prior and no concurrent major surgical procedure or open biopsy
__label__0	study interventions are pharmacological study . sarcoma diagnosis and no concurrent treatment in protocol for which patient is being evaluated for response
__label__0	study interventions are Hydroxyitraconazole . toxicities greater than or equal to ctcae grade two caused by previous cancer therapy excluding alopecia
__label__0	study interventions are Immunoglobulins . stage iv adult hodgkin lymphoma diagnosis and the exact hepatitis therapy will be at the discretion of the infection disease specialist or investigator
__label__0	study interventions are Antibodies, Monoclonal . recurrent adult diffuse large cell lymphoma diagnosis and patients must have the ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Sirolimus . histologic proof of cancer that is now unresectable not amenable to any other standard therapies or patient refuses standard therapy
__label__0	study interventions are quality-of-life assessment . gastrointestinal carcinoid tumor diagnosis and cardiovascular
__label__0	study interventions are Stereotactic Body Radiotherapy (SBRT) . ewing sarcoma diagnosis and pulmonary metastases found at relapse does not have to be first relapse no more than three lesions per hemi thorax
__label__0	study interventions are Etoposide . stage iv marginal zone lymphoma diagnosis and patients are allowed to have received radiotherapy before enrollment if radiation was given to alleviate pain and or neurologic compromise as long as there remains areas of measurable disease present
__label__0	study interventions are Oxaliplatin . recurrent colon cancer diagnosis and platelet count greater_than one hundred zero mm³ without platelet transfusion less_than fourteen days prior to study
__label__0	study interventions are Prednisolone hemisuccinate . metastatic cancer diagnosis and alt and ast less_than doc times uln unless related to hepatic metastatic disease where patients may be entered after discussion with one of the clinical advisors
__label__0	study interventions are Sirolimus . cholangiocarcinoma of the gallbladder diagnosis and alanine aminotransferase alt and aspartate aminotransferase ast equal_than less_than doc upper limit of normal uln equal_than less_than fivex uln in patients with liver metastases
__label__0	study interventions are Laboratory Biomarker Analysis . stage iii prostate cancer diagnosis and patients must be willing to undergo radiologic scan computed tomography ct or magnetic resonance imaging mri depending on organ involved after last drug dose and prior to minimally invasive surgery
__label__0	study interventions are Lenograstim . noncontiguous stage ii small lymphocytic lymphoma diagnosis and no more than three prior regimens of chemotherapy rituximab is not considered chemotherapy and four weeks out of bortezomib treatment for mm
__label__0	study interventions are Paclitaxel . male breast carcinoma diagnosis and patients must not have received radiation within two weeks of starting study
__label__0	study interventions are Albumin-Bound Paclitaxel . neuroblastoma diagnosis and a
__label__0	study interventions are Etoposide phosphate . patients with histologically diagnosed non hodgkin lymphoma
__label__0	study interventions are Pharmaceutical Solutions . biliary tract cancer diagnosis and adequate main organ function
__label__0	study interventions are Sirolimus . malignant neoplasm diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than one
__label__0	study interventions are Cisplatin . lung cancer diagnosis and not specified hematopoietic
__label__0	study interventions are Staurosporine . recurrent small cell lung cancer diagnosis and more than four weeks since prior chemotherapy six weeks for nitrosoureas or mitomycin and recovered
__label__0	study interventions are IVIG . malignant melanoma diagnosis and wbc greater_than one five hundred cells mmthree hemoglobin greater_than nine dl and platelets greater_than one00 zero cells mmthree and less_than five hundred zero cells mmthree
__label__0	study interventions are Bortezomib . recurrent grade one follicular lymphoma diagnosis and new york heart association class iii iv heart failure
__label__0	study interventions are internet-based intervention . stage iv adult diffuse mixed cell lymphoma diagnosis and has internet and email access indicated by logon to site for consent and assessment
__label__0	study interventions are Midazolam . non hodgkin lymphoma diagnosis and absolute neutrophil count anc at least doc one hundred and nine liter platelets at least one hundred one hundred and nine and hemoglobin at least eight grams deciliter dl bilirubin no more than doc times upper limits of normal alanine aminotransferase alt and aspartate aminotransferase ast no more than doc times upper limits of normal serum creatinine no more than doc times upper limits of normal or calculated creatinine clearance greater_than forty-five milliliters minute ml min
__label__0	study interventions are human papillomavirus 16 E7 peptide . esophageal cancer diagnosis and disease characteristics
__label__0	study interventions are Phosphonoacetic Acid . contiguous stage ii small lymphocytic lymphoma diagnosis and procedure
__label__0	study interventions are Bendamustine Hydrochloride . recurrent grade two follicular lymphoma diagnosis and absolute neutrophil count greater_than equal_than one zero mm three
__label__0	study interventions are Melphalan . lymphoma diagnosis and pulmonary
__label__0	study interventions are Sulindac . lung cancer diagnosis and hematopoietic
__label__0	study interventions are Cyclophosphamide . hepatosplenic cell lymphoma diagnosis and peripheral blood counts of polymorphonuclear neutrophil pmn greater_than one thousand, five hundred ul
__label__0	study interventions are Busulfan . multiple myeloma and plasma cell neoplasm diagnosis and not specified hematopoietic
__label__0	study interventions are Calcium, Dietary . non small cell lung cancer diagnosis and adequate organ function as defined by the following criteria
__label__0	study interventions are Docetaxel . metastatic castrate resistant prostate cancer diagnosis and recovery from primary local surgical treatment radiotherapy or orchiectomy
__label__0	study interventions are Rituximab . recurrent adult immunoblastic large cell lymphoma diagnosis and patients must have serum lactate dehydrogenase ldh performed within fourteen days prior to treatment
__label__0	study interventions are 3-Iodobenzylguanidine . neuroblastoma diagnosis and a
__label__0	study interventions are Fludarabine phosphate . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and donor
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and signed informed consent form
__label__0	study interventions are Calcium, Dietary . recurrent pancreatic carcinoma diagnosis and left ventricular ejection fraction lvef greater_than equal_than forty-five at rest multigated acquisition scan muga or echocardiogram echo
__label__0	study interventions are Cisplatin . melanoma skin diagnosis and at least ten weeks
__label__0	study interventions are Androgens . prostate cancer diagnosis and clinically negative lymph nodes as established by imaging pelvic and or abdominal ct scan or mri nodal sampling or dissection within the past sixty days required for patients with two three risk factors
__label__0	study interventions are Clofarabine . multiple myeloma diagnosis and other rare lethal disorders of hematopoiesis and lymphopoiesis for which t cell depleted transplant is indicated hemophagocytic_lymphohistiocytosis refractory aplastic anemia or congenital cytopenias non scid lethal genetic immunodeficiencies such as wiskott_aldrich syndrome cdforty_ligand deficiency or alps as well as refractory autoimmune cytopenias pnh metabolic storage diseases or heavily transfused congenital hemoglobinopathies
__label__0	study interventions are Dexamethasone acetate . multiple myeloma and plasma cell neoplasm diagnosis and no gastrointestinal obstruction or active peptic ulcer disease
__label__0	study interventions are Interleukin-2 . skin cancer diagnosis and willing to sign durable_power of attorney
__label__0	study interventions are Carboplatin . sarcoma diagnosis and no new york heart association class iii or iv heart disease
__label__0	study interventions are magnetic resonance imaging . long term effects secondary to cancer therapy in children diagnosis and prior concurrent therapy
__label__0	study interventions are Prednisolone . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Bendamustine Hydrochloride . adult nasal type extranodal nk cell lymphoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional upper limit of normal
__label__0	study interventions are Sirolimus . stage iiia fallopian tube cancer diagnosis and ability to swallow and retain oral medication
__label__0	study interventions are Delayed diet and exercise intervention . prostate cancer diagnosis and has telephone access
__label__0	study interventions are Fludarabine phosphate . mantle cell lymphoma diagnosis and residual disease after at least six cycles of anthracycline based chemotherapy with residual disease defined as persistent bone marrow involvement and or persistent measurable lymph node or solid organ masses that are pet or gallium avid
__label__0	study interventions are Carboplatin . lymphoma diagnosis and ten ten hla matched nonsibling donor related or unrelated
__label__0	study interventions are Trebananib . fallopian tube cancer diagnosis and may include measurable or non measurable disease
__label__0	study interventions are Paclitaxel . nasopharyngeal neoplasms diagnosis and nthree or tfourntwo or multiple lymphnodes involved with at least one mass four cm or more in maximal diameter according to seventh uicc staging
__label__0	study interventions are Fludarabine phosphate . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and age greater than or equal to sixty
__label__0	study interventions are Paclitaxel . metastatic or locally advanced solid tumors diagnosis and adequate hepatic and renal function
__label__0	study interventions are Poly ICLC . the subject received immunotherapy eg interferons tumor necrosis factor interleukins or biological response modifiers gm csf csf csf within four weeks twenty-eight days prior to study entry
__label__0	study interventions are Dexamethasone . refractory multiple myeloma diagnosis and alanine aminotransferase alt equal_than less_than doc times uln in the case of known radiological and or biopsy documented liver metastasis alt equal_than less_than doc times uln is acceptable
__label__0	study interventions are Epothilones . lung cancer diagnosis and platelet count greater_than seventy-five zero mm three
__label__0	study interventions are Cyclosporins . noncontiguous stage ii marginal zone lymphoma diagnosis and karnofsky greater_than equal_than seventy
__label__0	study interventions are Methotrexate . t cell lymphoma diagnosis and ecog performance status zero two
__label__0	study interventions are PX-866 . glioblastoma diagnosis and the patient must sign the consent form prior to registration exception for translations
__label__0	study interventions are Dim red light using light visor cap . cancer of the breast diagnosis and mentally_competent to consent
__label__0	study interventions are Vinorelbine . male breast cancer diagnosis and concurrent epoetin_alfa or filgrastim csf allowed
__label__0	study interventions are neoadjuvant therapy . stage iia pancreatic cancer diagnosis and cardiac arrhythmia other than chronic
__label__0	study interventions are Sorafenib . recurrent ovarian epithelial cancer diagnosis and patients who have recurred and are platinum sensitive treatment free interval greater than twelve months must have been re treated with platinum based chemotherapy prior to entry into this protocol
__label__0	study interventions are Antibodies . non hodgkin lymphoma diagnosis and the chop chemotherapy should consist of standard doses of each agent although dose reduction is permitted
__label__0	study interventions are Vidarabine . anaplastic large cell lymphoma diagnosis and failed or were not eligible for autologous transplantation
__label__0	study interventions are Dexamethasone acetate . liver cancer diagnosis and prior concurrent therapy
__label__0	study interventions are questionnaire administration . pancreatic cancer diagnosis and may not transfer care out of geographic area
__label__0	study interventions are Pemetrexed . lung adenocarcinoma diagnosis and upper normal limit
__label__0	study interventions are Oxaliplatin . pancreatic cancer diagnosis and no colonic or small bowel disorders with uncontrolled symptoms at baseline for example greater_than three watery or soft stools daily in patients without colostomy or ileostomy
__label__0	study interventions are Cyclosporins . lymphoma diagnosis and accelerated phase with treatment failure after imatinib mesylate
__label__0	study interventions are Cisplatin . yolk_sac tumor diagnosis and one line of therapy can in some cases consist of two different cisplatin based treatment combinations provided there is no disease progression between these two regimens
__label__0	study interventions are Liposomal doxorubicin . patients with history of other invasive malignancies with the exception of non melanoma skin cancer or localized cancer of the breast head and neck or skin are excluded if there is any evidence of other malignancy being present within the last three years
__label__0	study interventions are Liposomal doxorubicin . primary effusion lymphomas diagnosis and signed informed consent including health insurance_portability and accountability_act of one thousand, nine hundred and ninety-six hipaa authorization
__label__0	study interventions are Freund's Adjuvant . intraocular melanoma diagnosis and patient characteristics
__label__0	study interventions are Antibodies . stage squamous cell carcinoma of the hypopharynx diagnosis and no significant traumatic injury within the past twenty-eight days
__label__0	study interventions are Thalidomide . melanoma skin diagnosis and pt ptt normal
__label__0	study interventions are Vidarabine . fallopian tube cancer diagnosis and adequate organ function as determined by the following criteria within fourteen days of study enrollment
__label__0	study interventions are Oxaliplatin . recurrent adult diffuse small cleaved cell lymphoma diagnosis and monocytoid cell
__label__0	study interventions are Albumin-Bound Paclitaxel . breast adenocarcinoma diagnosis and patients will be assigned to arm or arm depending on their prior exposure to paclitaxel and eribulin
__label__0	study interventions are Methotrexate . lymphoma diagnosis and bilirubin no greater than doc mg dl
__label__0	study interventions are Tacrolimus . recurrent small lymphocytic lymphoma diagnosis and in addition patients must meet at least one of the following criteria ix vii at time of diagnosis or pre autograft
__label__0	study interventions are Antibodies, Monoclonal . noncontiguous stage ii grade three follicular lymphoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mm three
__label__0	study interventions are Carmustine . recurrent follicular lymphoma diagnosis and prothrombin time pt partial thromboplastin time ptt equal_than less_than two times normal timeline
__label__0	study interventions are Skin Cancer Screening Training . basal cell carcinoma diagnosis and male and female residents of alberta mainly living and receiving care in edmonton or in calgary
__label__0	study interventions are Immunoglobulins . stage marginal zone lymphoma diagnosis and there is no indication for an autologous transplantation as treatment option
__label__0	study interventions are Cytarabine . myelodysplastic myeloproliferative neoplasms diagnosis and pll
__label__0	study interventions are Cisplatin . histologically proven squamous cell carcinoma of the oral cavity oropharynx hypopharynx or larynx stage iii or iv no distant metastases
__label__0	study interventions are Bevacizumab . patients who have received more than one prior systemic regimen for management of recurrent persistent or metastatic carcinoma of the cervix are not eligible
__label__0	study interventions are Levoleucovorin . stage iii colon cancer diagnosis and serum creatinine within or below the normal limits for the laboratory
__label__0	study interventions are Paclitaxel . endometrial serous adenocarcinoma diagnosis and entry into the study is limited to no more than eight weeks from the date of surgery
__label__0	study interventions are Lenograstim . stage iv breast cancer diagnosis and phase i
__label__0	study interventions are Fludarabine phosphate . stage iv grade one follicular lymphoma diagnosis and myelosuppressive chemotherapy must be discontinued three weeks prior to conditioning with the exception of hydroxyurea or imatinib
__label__0	study interventions are Carboplatin . locally regionally advanced stage tthree four and or nthree nasopharyngeal cancer which is ebv epstein_barr virus
__label__0	study interventions are pharmacological study . stage iv midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and not pregnant or nursing
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and the patient may not breastfeed while taking lenalidomide or for four weeks after the last administration of lenalidomide
__label__0	study interventions are Irinotecan . unspecified adult solid tumor protocol specific diagnosis and not specified other
__label__0	study interventions are CUDC-907 . neuroblastoma diagnosis and adequate metabolic function
__label__0	study interventions are surveys . post surgical resection of primary tumor at mskcc
__label__0	study interventions are Albumin-Bound Paclitaxel . cervical cancer diagnosis and anc greater_than one five hundred mm³
__label__0	study interventions are Docetaxel . breast cancer diagnosis and normal heart function
__label__0	study interventions are EDO-S101 . peripheral cell lymphoma diagnosis and total bilirubin less_than doc mg dl unless elevated due to known gilbert syndrome
__label__0	study interventions are MRI . brain tumor diagnosis and all children currently enrolled and who will be enrolled during the course of the study in the chemotheraphy program at children healthcare of atlanta at scottish rite
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiia breast cancer diagnosis and cbc comprehensive chemistry panel
__label__0	study interventions are conventional cold snare polypectomy . bowel cancer diagnosis and all patients with small polyps three seven mm in size flat or sessile found during colonoscopy
__label__0	study interventions are laboratory biomarker analysis . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and more than four weeks since prior radiotherapy
__label__0	study interventions are Cisplatin . recurrent gastric cancer diagnosis and no psychiatric illness or social situation that would preclude study compliance
__label__0	study interventions are Diphosphonates . metastatic breast cancer diagnosis and life expectancy of more than three months
__label__0	study interventions are Carboplatin . stage iv ovarian epithelial cancer diagnosis and eligibility criteria for registration
__label__0	study interventions are Interleukin-12 . metastatic gastrointestinal carcinoid tumor diagnosis and life expectancy of at least six months
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Paclitaxel . gastric cardia adenocarcinoma diagnosis and creatinine level equal_than less_than doc uln or creatinine clearance greater_than sixty ml min doc three two for patients with creatinine levels above or below the institutional normal
__label__0	study interventions are Thalidomide . recurrent adult hodgkin lymphoma diagnosis and any prior use of lenalidomide vorinostat or other histone_deacetylase inhibitors other than valproic acid which must be stopped two weeks prior to study unless being used for seizure control
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and ii part twoa
__label__0	study interventions are Axitinib . melanoma diagnosis and the baseline systolic blood pressure readings must be less_than one hundred and forty mm hg and the baseline diastolic blood pressure readings must be less_than ninety mm hg
__label__0	study interventions are Ifosfamide . brain and central nervous system tumors diagnosis and anc greater_than one five hundred µl
__label__0	study interventions are Ibandronic acid . prostate cancer diagnosis and menopausal status
__label__0	study interventions are Pyridoxine . lymphoma diagnosis and one
__label__0	study interventions are Methotrexate . breast cancer diagnosis and female performance status
__label__0	study interventions are Maleic acid . stage iv nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and bilirubin normal
__label__0	study interventions are Topotecan . small cell lung cancer diagnosis and lesions that can be accurately measured in at least one dimension with the longest diameter greater_than twentymm using conventional techniques or greater_than tenmm using spiral ct scans
__label__0	study interventions are Endothelial Growth Factors . adult giant cell glioblastoma diagnosis and at least three weeks since procarbazine
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and if participating in the cosmetic outcome evaluation portion of the study must have unilateral disease
__label__0	study interventions are computed tomography . metastatic cancer diagnosis and coronary insufficiency
__label__0	study interventions are EDO-S101 . multiple myeloma diagnosis and aspartate aminotransferase alanine aminotransferase ast alt less_than doc upper limit of normal uln
__label__0	study interventions are Belinostat . stage iv cutaneous cell non hodgkin lymphoma diagnosis and toxicity
__label__0	study interventions are Psychosocial Assessment and Care . long term effects secondary to cancer therapy in children diagnosis and no sensory impairment pre existing uncorrectable vision impairment or deafness
__label__0	study interventions are Everolimus . neuroendocrine carcinoma diagnosis and general conditions
__label__0	study interventions are Cyclosporins . anaplastic large cell lymphoma diagnosis and aml transformed from myelodysplastic syndrome mds with less_than ten bone marrow blasts
__label__0	study interventions are BB 1101 . relapsed and or relapsed refractory multiple myeloma diagnosis and estimated creatinine clearance greater_than forty-five ml min or serum creatinine less_than doc mg dl
__label__0	study interventions are Mafosfamide . brain and central nervous system tumors diagnosis and radiotherapy
__label__0	study interventions are 7-hydroxystaurosporine . recurrent adult primary liver cancer diagnosis and part ii
__label__0	study interventions are Melphalan . childhood central nervous system germ cell tumor diagnosis and adequate renal function as demonstrated by creatinine clearance twelve or twenty-four hour urine collection or glomerular filtration rate gfr greater_than sixty ml min doc threem two
__label__0	study interventions are Irinotecan . recurrent rectal cancer diagnosis and no proteinuria
__label__0	study interventions are Immunoglobulins . peripheral cell lymphoma diagnosis and ability to understand and the willingness to sign written informed consent all patients must have signed witnessed informed consent prior to registration
__label__0	study interventions are Cyclophosphamide . oropharyngeal cancer diagnosis and platelet count greater than or equal too one hundred zero mmthree
__label__0	study interventions are Cyclophosphamide . recurrent adult diffuse large cell lymphoma diagnosis and acute myeloid leukemia
__label__0	study interventions are Mitoxantrone . breast cancer diagnosis and no uncontrolled angina
__label__0	study interventions are Capecitabine . endometrial cancer diagnosis and gog zero two
__label__0	study interventions are Dexamethasone . clinically overt multiple myeloma monoclonal bone marrow plasma count greater_than thirty and at least one of the following
__label__0	study interventions are Capecitabine . stage iii adult diffuse large cell lymphoma diagnosis and patients with regular menses
__label__0	study interventions are Antibodies, Monoclonal . relapsed refractory hodgkin lymphoma diagnosis and agegreater_than eighteen years
__label__0	study interventions are Fludarabine . stage iii adult immunoblastic large cell lymphoma diagnosis and patients will be accepted in chronic phase or accelerated phase patients who have received prior autografts after high dose therapy or have undergone intensive chemotherapy with filgrastim csf mobilized peripheral blood mononuclear cells pbmc autologous or conventional hct for advanced cml may be enrolled provided they are in cr or cp and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Endothelial Growth Factors . adult giant cell glioblastoma diagnosis and last dose of bevacizumab greater_than equal_than two weeks prior to registration phase note
__label__0	study interventions are Fludarabine . multiple myeloma and plasma cell neoplasm diagnosis and hla identical family donor available
__label__0	study interventions are Leucovorin . hepatocellular carcinoma diagnosis and diagnosed as unresectable with consensus by the panel of liver surgery experts
__label__0	study interventions are Antibodies . lymphoma diagnosis and diagnosis of hematological malignancy
__label__0	study interventions are Bevacizumab . the patient has non obstructive primary tumor and is able to receive preoperative chemotherapy three four months before surgery
__label__0	study interventions are Liposomal doxorubicin . multiple myeloma diagnosis and creatinine less_than doc mg dl
__label__0	study interventions are Fluorouracil . stage iii squamous cell carcinoma of the oropharynx diagnosis and total bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Bicalutamide . prostate cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Antibodies, Monoclonal . triple negative breast neoplasms diagnosis and foura
__label__0	study interventions are Interleukin-2 . patients with advanced or metastatic merkel cell carcinoma mcc not amenable to surgery and who have not received previous systemic therapy with taxanes diagnosis of mcc must be histologically confirmed evaluation of primary lesions or advanced disease and endorsed by the immomec central dermatopathology center central review of diagnosis at the department of general dermatology medical university of graz
__label__0	study interventions are Etoposide . mixed oligoastrocytoma diagnosis and hemoglobin greater_than nine dl prbc transfusion positive
__label__0	study interventions are Immunoglobulins . untreated metastatic squamous neck cancer with occult primary diagnosis and no chronic active viral infection
__label__0	study interventions are Dasatinib . unspecified childhood solid tumor protocol specific diagnosis and no concurrent enzyme inducing anticonvulsants including any of the following
__label__0	study interventions are Rituximab . stage ii grade one non contiguous follicular lymphoma diagnosis and bone lesions lesions if present should be noted
__label__0	study interventions are Bevacizumab . inflammatory carcinoma with tumor of any size
__label__0	study interventions are Etoposide phosphate . intraocular lymphoma diagnosis and hodgkin disease hl
__label__0	study interventions are Lenalidomide . stage ii enteropathy associated cell lymphoma diagnosis and if currently not on anticoagulation medication willing and able to take aspirin eighty-one or three hundred and twenty-five mg daily if aspirin is contraindicated the patient may be considered for the study if on therapeutic dose warfarin or low molecular weight heparin patients unable to take any prophylaxis are not eligible
__label__0	study interventions are Levoleucovorin . esophageal neoplasms diagnosis and at least eighteen years of age
__label__0	study interventions are Anastrozole . estrogen receptor positive breast cancer diagnosis and the maximum number of cycles is
__label__0	study interventions are Liposomal doxorubicin . leiomyosarcoma
__label__0	study interventions are Vidarabine . cervical cancer diagnosis and patients who are hiv seropositive can have decreased immunecompetence and thus be less responsive to the experimental treatment and more susceptible to its toxicities
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and no severe cardiac dysfunction
__label__0	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and up to eighteen seventy years of age
__label__0	study interventions are Cyclosporine . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and patients with primary refractory or relapsed disease not eligible for an autologous transplant
__label__0	study interventions are Carboplatin . primary malignant brain neoplasms diagnosis and children less than thirty-six months three years of age at time of definitive surgery for histopathologic diagnosis with or without metastatic disease
__label__0	study interventions are Vidarabine . noncontiguous stage ii grade three follicular lymphoma diagnosis and patients will be accepted in chronic phase or accelerated phase patients who have received prior autografts after high dose therapy or have undergone intensive chemotherapy with filgrastim csf mobilized peripheral blood mononuclear cells pbmc autologous or conventional hct for advanced cml may be enrolled provided they are in cr or cp and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Apatinib single agent arm . non small cell lung cancer diagnosis and doc upper limit of normal uln alt and ast
__label__0	study interventions are standard follow-up care . diagnosis of hematologic cancer leukemia or lymphoma
__label__0	study interventions are Fludarabine phosphate . recurrent adult burkitt lymphoma diagnosis and waldenstrom macroglobulinemia
__label__0	study interventions are Nivolumab . refractory malignant neoplasm diagnosis and the following steroids are permitted low dose steroid use is defined as prednisone ten mg daily or less or bioequivalent dose of other corticosteroid
__label__0	study interventions are cilengitide . recurrent grade one follicular lymphoma diagnosis and absolute neutrophil count greater_than one five hundred mm three
__label__0	study interventions are Laboratory Biomarker Analysis . stage iii thyroid gland medullary carcinoma diagnosis and blood pressure bp less_than one hundred and forty mmhg systolic and less_than ninety mmhg diastolic initiation or adjustment of bp medication is permitted prior to registration provided that the average of three bp readings at visit prior to registration is less_than one hundred and forty ninety mmhg
__label__0	study interventions are Oxaliplatin . stage iiia colon cancer diagnosis and failure during or within six months after fluorouracil based adjuvant therapy
__label__0	study interventions are Nitrogen Mustard Compounds . stage iii follicular lymphoma diagnosis and failed induction therapy but responds to salvage therapy chemosensitive disease
__label__0	study interventions are Mycophenolate mofetil . precancerous condition diagnosis and brother sister father mother cousin_uncle or aunt
__label__0	study interventions are Bevacizumab . childhood pleomorphic rhabdomyosarcoma diagnosis and urine protein level
__label__0	study interventions are Aldesleukin . pancreatic cancer diagnosis and quality of life
__label__0	study interventions are Cisplatin . tumor induced narrowing of smv pv or smpv of greater_than fifty of the diameter of the vessel
__label__0	study interventions are Liposomal doxorubicin . glioma diagnosis and recurrent lesions with dimension and contour that are determined by the treating neurosurgeon to be appropriate for mla
__label__0	study interventions are Everolimus . neoplasm metastasis diagnosis and must be willingness and ability to comply with scheduled visits treatment plans laboratory tests and other study procedures
__label__0	study interventions are support group therapy . prostate cancer diagnosis and more than four weeks since prior and no concurrent saw_palmetto or any other herbal nutritional preparation that would affect hormone levels
__label__0	study interventions are Levoleucovorin . stage iiia esophageal adenocarcinoma diagnosis and serum creatinine within normal institutional limits or creatinine clearance greater_than equal_than sixty ml min doc three two for patients with creatinine levels above institutional normal as calculated by cockcroft gault
__label__0	study interventions are Docetaxel . have discontinued all previous therapies for cancer except treatment with lhrh analogues as follows
__label__0	study interventions are Bevacizumab . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and no ongoing or active infection requiring parenteral antibiotics
__label__0	study interventions are Pertuzumab . solid tumor diagnosis and patients must have received one prior approved therapy for metastatic disease and have not curable options
__label__0	study interventions are BKM120 . glioblastoma diagnosis and if steroids are added or the steroid dose is increased between the date of the screening mri or ct scan and the start of treatment new baseline mri or ct is required
__label__0	study interventions are Prednisolone acetate . lymphoma diagnosis and patient characteristics
__label__0	study interventions are Interleukin-2 . at least three weeks since prior radiotherapy for cancer and recovered no concurrent radiotherapy for cancer surgery
__label__0	study interventions are biopsy . melanoma skin diagnosis and no other concurrent antineoplastic agents cytotoxic chemotherapy immunotherapy radiotherapy or investigational therapy except local radiotherapy for supportive reasons involving small radiation field
__label__0	study interventions are Sirolimus . refractory solid tumors in children diagnosis and total bilirubine equal_than less_than doc uln
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and relapsed or refractory disease as defined by disease progression after initial complete response cr or failure to achieve cr
__label__0	study interventions are high performance liquid chromatography . sarcoma diagnosis and patient characteristics
__label__0	study interventions are Goserelin . patients must have either positive estrogen and or progesterone receptor determination by ihc or competitive binding assay on advanced disease or if not performed on their advanced disease positive result on their primary breast cancer specimen positivity is defined as an allred score from three to eight by ihc or at least one positive tumor nuclei in the sample in the presence of expected reactivity of internal and external controls three5
__label__0	study interventions are Antibodies . ovarian cancer diagnosis and patients with any other concomitant or prior invasive malignancies are ineligible
__label__0	study interventions are Cisplatin . malignant pleural mesothelioma diagnosis and adequate haematological status
__label__0	study interventions are Niacinamide . liver cancer diagnosis and signed informed consent form
__label__0	study interventions are Fludarabine phosphate . intraocular lymphoma diagnosis and chronic myelogenous leukemia cml
__label__0	study interventions are Mycophenolate mofetil . stage iv adult burkitt lymphoma diagnosis and must have received and failed frontline therapy
__label__0	study interventions are Histone Deacetylase Inhibitors . recurrent glioma diagnosis and the brain metastasis es to be treated may not be more than fourcm in maximal diameter as assessed by ct or mri scan
__label__0	study interventions are Sirolimus . previously treated childhood rhabdomyosarcoma diagnosis and creatinine clearance or radioisotope gfr greater_than seventy ml min or serum creatinine based on age gender as follows
__label__0	study interventions are Paclitaxel . borderline resectable pancreatic cancer diagnosis and platelet count greater_than one hundred thousand mmthree
__label__0	study interventions are Etoposide . brain and central nervous system tumors diagnosis and stage iv
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and cdtwenty positive disease
__label__0	study interventions are Letrozole . stage ib breast cancer diagnosis and chronic psychiatric condition or other condition that would impair compliance with the treatment regimen
__label__0	study interventions are Carboplatin . transitional cell carcinoma of the bladder diagnosis and platelet greater_than equal_than one hundred zero mm three
__label__0	study interventions are Lenalidomide . follicular lymphoma diagnosis and c
__label__0	study interventions are Antibodies, Monoclonal . testicular choriocarcinoma and teratoma diagnosis and patients are eligible for study entry at any time between post transplantation day ninety and three years after withdrawal of immunosuppressive therapy
__label__0	study interventions are Gefitinib . stage iva squamous cell carcinoma of the larynx diagnosis and patients requiring agents that induce cypthreeafour are excluded from the study at the present time agents known to induce cypthreeafour include the antibiotics nafcillin and rifampin the anticonvulsants carbamazepine phenobarbital phenytoin oxcarbazepine_fosphenytoin and primidone as well as st
__label__0	study interventions are Talazoparib . childhood solid tumors diagnosis and patients who have received prior therapy with parp inhibitor other than talazoparib are eligible however patients who have progressed on parp inhibitor plus irinotecan regimen are not eligible
__label__0	study interventions are Gemcitabine . stage iv pancreatic cancer diagnosis and flecainide
__label__0	study interventions are 7-hydroxystaurosporine . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and concurrent subcutaneous heparin allowed
__label__0	study interventions are Doxorubicin . testicular lymphoma diagnosis and further at the investigator discretion and for patients who are unstable one cycle of chop is allowed prior to enrollment but no more than one cycle
__label__0	study interventions are Calcium, Dietary . patients must have histologically confirmed diagnosis of stage ii or iii breast carcinoma
__label__0	study interventions are Fludarabine phosphate . stage iv small lymphocytic lymphoma diagnosis and donor
__label__0	study interventions are Sirolimus . ovarian neoplasms diagnosis and before performance of study specific actions or assessment the patient has to be informed has signed the written consent and is willing to follow the requirements concerning treatment and follow omment
__label__0	study interventions are Cadexomer iodine . kidney cancer diagnosis and the following laboratory results should be within the following limits within the last two weeks prior to study day one
__label__0	study interventions are Sevoflurane . supratentorial neoplasms diagnosis and asa one or two
__label__0	study interventions are Bioelectrical Impedance Analysis . or lung cancer
__label__0	study interventions are Pharmacogenomic studies . anaplastic large cell lymphoma diagnosis and known hiv infection
__label__0	study interventions are Analgesics . non small cell lung cancer diagnosis and cisplatin may be used instead of carboplatin as part of the initial induction chemotherapy regimen at the discretion of the treating physician investigator
__label__0	study interventions are Everolimus . recurrent mantle cell lymphoma diagnosis and active acute or chronic or uncontrolled severe infections
__label__0	study interventions are Asparaginase . lymphoma non hodgkin diagnosis and stratum ii
__label__0	study interventions are Fludarabine . lymphoma diagnosis and calculated creatinine clearance greater_than forty ml min
__label__0	study interventions are Vidarabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and the patient must be not eligible for conventional transplants and must have disease expected to be stable for at least one hundred days without chemotherapy
__label__0	study interventions are Cyclosporins . lymphoma diagnosis and myelodysplastic syndromes including any of the following
__label__0	study interventions are Endothelial Growth Factors . ovarian seromucinous tumor diagnosis and neuropathy sensory and motor less than or equal to ctep ctcae version doc grade one
__label__0	study interventions are Sleep information . women at high risk of breast cancer due to one or more of the following
__label__0	study interventions are Bevacizumab . recurrent melanoma diagnosis and at least twenty mm by conventional techniques or at least ten mm by spiral computed tomography ct scan
__label__0	study interventions are Vidarabine . multiple myeloma and plasma cell neoplasm diagnosis and relapsed or primarily refractory disease with less_than ten blasts in the peripheral blood and less_than twenty blasts in the bone marrow
__label__0	study interventions are Autologous tumor cell + CpG vaccine . anal colon and rectal cancers diagnosis and documented liver metastases
__label__0	study interventions are Carboplatin . extensive stage small cell lung cancer diagnosis and able to provide informed consent
__label__0	study interventions are telephone-based intervention . psychosocial effects of cancer and its treatment diagnosis and stage iiia disease
__label__0	study interventions are Cisplatin . endometrial adenocarcinoma diagnosis and if positive must have negative chest ct scan
__label__0	study interventions are Erlotinib Hydrochloride . colorectal cancer diagnosis and performance status
__label__0	study interventions are Romidepsin . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and at least four weeks since prior surgery
__label__0	study interventions are Staurosporine . unspecified adult solid tumor protocol specific diagnosis and see disease characteristics part ii
__label__0	study interventions are PU-H71 . lymphoma diagnosis and serum bilirubin less_than doc mg dl
__label__0	study interventions are Peginterferon alfa-2b . diffuse intrinsic pontine glioma diagnosis and greater than five and less than or equal to ten
__label__0	study interventions are Rituximab . mantle cell lymphoma diagnosis and all patients or their legally acceptable representatives must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
__label__0	study interventions are Tacrolimus . non hodgkins lymphoma diagnosis and adequate pulmonary function with fevone fvc and dlco greater_than equal_than fifty of expected corrected for hemoglobin and or volume
__label__0	study interventions are Sorafenib . advanced hepatocellular carcinoma diagnosis and patients with locally advanced or metastatic hcc not suitable surgical or locoregional therapies
__label__0	study interventions are Fludarabine . refractory small lymphocytic lymphoma diagnosis and myelodysplasia mds myeloproliferative syndrome mps
__label__0	study interventions are Vaccines . glioblastoma multiforme diagnosis and aspartate aminotransferase ast alanine transaminase alt less_than doc upper limit of normal uln if liver metastases less_than five uln
__label__0	study interventions are Aldesleukin . kidney cancer diagnosis and white blood cell wbc three thousand mm three or greater
__label__0	study interventions are Lenograstim . lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Saracatinib . stage iii uterine sarcoma diagnosis and urine protein
__label__0	study interventions are complementary or alternative medicine procedure . pancreatic cancer diagnosis and other
__label__0	study interventions are Fulvestrant . metastatic breast cancer diagnosis and bone lesions which are lytic sclerotic or mixed lytic positive sclerotic in the absence of measurable disease as defined by recist criteria or
__label__0	study interventions are Bevacizumab . primary peritoneal cavity cancer diagnosis and solid and or cystic abnormalities on radiographic imaging that do not meet recist criteria definitions for target lesions
__label__0	study interventions are Paclitaxel . stage iiia non small cell lung cancer diagnosis and platelet count greater_than equal_than one hundred zero ul
__label__0	study interventions are Liposomal doxorubicin . cervical cancer diagnosis and ineligible for higher priority gog protocol
__label__0	study interventions are Polyphenon E Ointment 10%, Polyphenon E Ointment 15% . condylomata_acuminata diagnosis and ability to comply with the requirements of the study
__label__0	study interventions are Interleukin-4 . kidney cancer diagnosis and more than twelve weeks
__label__0	study interventions are Vincristine . lymphoma diagnosis and brain biopsy
__label__0	study interventions are Bortezomib . stage iii grade two follicular lymphoma diagnosis and no concurrent medications that prolong or may prolong qtc interval
__label__0	study interventions are Cisplatin . pancreatic cancer diagnosis and wbc at least three zero mm three
__label__0	study interventions are Carboplatin . colorectal cancer diagnosis and eighteen and over
__label__0	study interventions are Immunotoxins . recurrent glioblastoma multiforme diagnosis and patients must be capable of taking or already taking anticonvulsant medication
__label__0	study interventions are Erlotinib Hydrochloride . pancreatic cancer diagnosis and ercp or percutaneous stenting may be used to normalize the liver function tests
__label__0	study interventions are Dalteparin . pancreatic cancer diagnosis and bilirubin less_than doc times uln stent allowed
__label__0	study interventions are Etoposide phosphate . liver cancer diagnosis and to be approved by two or more physicians on the study committee
__label__0	study interventions are Prednisone . lymphoma cell diagnosis and pleural effusions or peritoneal ascites
__label__0	study interventions are Gemcitabine . metastatic urothelial carcinoma of the renal pelvis and ureter diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Mycophenolate mofetil . stage iii grade three follicular lymphoma diagnosis and high risk crone for example but not limited to
__label__0	study interventions are Sunitinib . childhood central nervous system yolk_sac tumor diagnosis and acetylsalicylic acid aspirin
__label__0	study interventions are Vaccines . isolated plasmacytoma of bone diagnosis and cmv seropositive
__label__0	study interventions are Carboplatin . recurrent childhood small noncleaved cell lymphoma diagnosis and alkaline phosphatase serum glutamic oxaloacetic transaminase sgot less_than three normal
__label__0	study interventions are Antibodies, Monoclonal . esophageal cancer diagnosis and note
__label__0	study interventions are Cyclophosphamide . osteosarcoma diagnosis and fourteen to less_than sixteen years male maximum cpk
__label__0	study interventions are Sirolimus . lymphoma low grade diagnosis and at least pr by traditional cheson criteria
__label__0	study interventions are Albumin-Bound Paclitaxel . primary peritoneal carcinoma diagnosis and measurable or non measurable disease
__label__0	study interventions are Pembrolizumab . melanoma ocular diagnosis and male or female patients greater_than eighteen years of age
__label__0	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and more than six months life expectancy
__label__0	study interventions are Sirolimus . metastatic gastric cancer diagnosis and patients with cns metastasis must have stable neurologic function without evidence of cns progression within eight weeks
__label__0	study interventions are Counseling session . breast cancer diagnosis and note
__label__0	study interventions are Sorafenib . sarcoma diagnosis and anc greater_than one five hundred mm³
__label__0	study interventions are Bevacizumab . stage iiia non small cell lung cancer diagnosis and tfour lesions of any size that invade the mediastinum heart great vessels trachea esophagus vertebral body or carina documented by greater_than one of the following methods
__label__0	study interventions are Everolimus . bladder cancer diagnosis and the prior therapy must have included at least one of the following
__label__0	study interventions are Veliparib . triple negative breast carcinoma diagnosis and left ventricular ejection fraction at or above institutional lower limit of normal obtained within eight weeks of registration by multigated acquisition muga scan or echocardiogram the same test performed at baseline should be repeated after every three cycles of therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . testicular germ cell tumor diagnosis and relapse after complete response cr to first line therapy including partial response pr surgically converted to cr
__label__0	study interventions are Antibodies . stage iib fallopian tube cancer diagnosis and patients must be entered between one and one2 weeks after initial surgery performed for the combined purpose of diagnosis staging and cytoreduction
__label__0	study interventions are Immunoglobulin G . stage iv large cell lung carcinoma diagnosis and zubrod performance status zero one
__label__0	study interventions are Carboplatin . extensive stage lung cancer diagnosis and histologic or cytologic diagnosis of extensive stage sclc
__label__0	study interventions are Thalidomide . refractory follicular lymphoma diagnosis and patients with human immunodeficiency virus hiv infection are eligible provided they meet the following criteria
__label__0	study interventions are Gemcitabine . stage iv pancreatic cancer diagnosis and patients with diabetes mellitus who meet this criterion must be on stable dietary or therapeutic regimen for this condition
__label__0	study interventions are Dasatinib . advanced cancer diagnosis and absolute neutrophil count greater_than equal_than one zero ml platelets greater_than equal_than ninety zero ml creatinine less_than equal_than two uln total bilirubin less_than equal_than doc alt sgpt less_than equal_than five uln exception for patients with liver metastasis
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Vismodegib . conjunctival kaposi sarcoma diagnosis and all patients must have measurable disease as defined by recist doc
__label__0	study interventions are Tipifarnib . splenic marginal zone lymphoma diagnosis and measurable disease
__label__0	study interventions are Antibodies, Monoclonal . lung cancer diagnosis and diagnosis of nsclc
__label__0	study interventions are Vaccines . breast cancer diagnosis and no concurrent steroids including corticosteroids administered to manage toxic effects from dendritic cell or denileukin_diftitox administration
__label__0	study interventions are Tacrolimus . recurrent adult diffuse mixed cell lymphoma diagnosis and matched for human leukocyte antigen hla b drbone and dqbone by high resolution typing
__label__0	study interventions are Exenatide . craniopharyngiomas diagnosis and all pituitary deficiencies are correctly treated
__label__0	study interventions are Thalidomide . brain and central nervous system tumors diagnosis and age
__label__0	study interventions are Interferon-alpha . kidney cancer diagnosis and congestive heart failure
__label__0	study interventions are Capecitabine . stage ivb pancreatic cancer diagnosis and no limit on the number of prior systemic therapies for metastatic disease
__label__0	study interventions are Antibodies, Monoclonal . stage iv grade two follicular lymphoma diagnosis and untreated or relapsed refractory follicular sll or mzl no limit to number of prior treatments as long as patients meet other study criteria
__label__0	study interventions are Sorafenib . kidney cancer diagnosis and no uncontrolled hypertension defined as systolic blood pressure bp greater_than one hundred and fifty mm hg or diastolic bp greater_than ninety mm hg despite optimal medical management
__label__0	study interventions are Panobinostat . multiple myeloma diagnosis and patient has relapsed to at least one prior line and patient was refractory to at least one prior line by either not reaching mr or progressed while under this therapy or within sixty days of its last dose
__label__0	study interventions are Etoposide . lung cancer diagnosis and biologic therapy
__label__0	study interventions are Docetaxel . breast cancer diagnosis and prior neoadjuvant or adjuvant chemotherapy is permitted or at least twelve months must have elapsed since the neoadjuvant or adjuvant therapy
__label__0	study interventions are Fludarabine phosphate . recurrent childhood small noncleaved cell lymphoma diagnosis and must have received previous myelosuppressive chemotherapy or hct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Bortezomib . ds stage iii plasma cell myeloma diagnosis and institutions must submit local cytogenetics report and fluorescence in situ hybridization fish analysis report obtained prior to enrollment to sseven hundred and seventy-seven for fish analysis two probes will be utilized
__label__0	study interventions are Test meal (breakfast) . drug safety biomarkers diagnosis and able and willing to give written informed consent
__label__0	study interventions are stereotactic radiosurgery . recurrent adult primary liver cancer diagnosis and total bilirubin less than doc mg dl
__label__0	study interventions are Misonidazole . stage iii non small cell lung cancer diagnosis and the patient must provide study specific informed consent prior to study entry
__label__0	study interventions are Etoposide . carcinoma of unknown primary diagnosis and radiotherapy
__label__0	study interventions are Oxaliplatin . recurrent rectal cancer diagnosis and no concurrent colony stimulating factors during the first course of study therapy
__label__0	study interventions are HpSA (Firstep Helicobacter pylori Antigen Rapid Test) . colorectal cancer diagnosis and fifty to seventy-five years subjects for hpsa
__label__0	study interventions are Brivanib . diagnosis of advanced or metastatic tumor that has spread colorectal hepatocellular liver or renal kidney cancer
__label__0	study interventions are Pioglitazone . pancreatic cancer diagnosis and no nyha class iii iv congestive heart failure
__label__0	study interventions are Cytarabine . brain tumor diagnosis and prior gliadel_wafer placement is not contradiction to patient enrollment in this trial
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and women are not breastfeeding
__label__0	study interventions are Antibodies, Monoclonal . stage iv marginal zone lymphoma diagnosis and must have received and failed frontline therapy patients must have had prior autologous transplant or were not eligible for autologous transplant planned tandem transplants are allowed for patients at high risk of relapse
__label__0	study interventions are Antibodies, Monoclonal . recurrent marginal zone lymphoma diagnosis and must sign consent form and must have life expectancy of greater than twelve weeks
__label__0	study interventions are Valproic Acid . recurrent small lymphocytic lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Folic Acid . stage iiia gastric cancer diagnosis and willing to provide mandatory tissue and blood samples for research purposes
__label__0	study interventions are Dexamethasone . childhood medulloepithelioma diagnosis and cytoreduction with hydroxyurea can be initiated and continued for up to twenty-four hours before the start of study treatment
__label__0	study interventions are Immunoglobulins . recurrent grade three follicular lymphoma diagnosis and laboratory studies defining eligibility hemoglobin hgb platelet count viscosity must have been obtained within twenty-eight days prior to registration if more than one test was obtained the most recent one will be utilized
__label__0	study interventions are Prednisolone hemisuccinate . previously treated childhood rhabdomyosarcoma diagnosis and diffuse multi lobar infiltrates on chest ray or ct scan
__label__0	study interventions are Interferon-alpha . kidney cancer diagnosis and chemotherapy
__label__0	study interventions are Carmustine . glioblastoma diagnosis and stealth mri neuronavigation will be performed prior to surgery
__label__0	study interventions are Vidarabine . recurrent adult diffuse large cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Paclitaxel . germ cell tumors diagnosis and mediastinal nsgct primary site of disease regardless the presence absence of visceral metastasis or stm values
__label__0	study interventions are Antibodies . adult lymphocyte predominant hodgkin lymphoma diagnosis and patients must have relapsed or refractory disease after at least one prior therapy with at least three week interval from the completion of the most recent chemotherapy or radiotherapy regimen recovery to equal_than less_than grade one from all toxicities related to the prior treatments is required patients who have previously received stem cell transplant are permitted to enroll on this study
__label__0	study interventions are Immunoglobulins . pancreatic delta cell adenoma diagnosis and hepatic artery embolization
__label__0	study interventions are Antibodies . childhood rhabdomyosarcoma with mixed embryonal and alveolar features diagnosis and hemoglobin greater_than equal_than doc dl may receive packed red blood cells prbc transfusions
__label__0	study interventions are Dalteparin . pancreatic cancer diagnosis and prior surgical resection allowed
__label__0	study interventions are Lenograstim . recurrent mantle cell lymphoma diagnosis and donor
__label__0	study interventions are Bevacizumab . esophagogastric cancer diagnosis and part b
__label__0	study interventions are nutritional intervention with dietician plus usual nutritional care . cancer diagnosis and written informed consent
__label__0	study interventions are Carboplatin . carcinoma non small cell lung diagnosis and chemotherapy naive patients with histologically confirmed nsclc stage iii and iv
__label__0	study interventions are pharmacological study . stage iv verrucous carcinoma of the oral cavity diagnosis and no other concurrent investigational agents
__label__0	study interventions are Albumin-Bound Paclitaxel . endometrial endometrioid adenocarcinoma variant with squamous differentiation diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Cyclosporine . stage iv mantle cell lymphoma diagnosis and must have received and failed frontline therapy patients must have had prior autologous transplant or were not eligible for autologous transplant planned tandem transplants are allowed for patients at high risk of relapse
__label__0	study interventions are Cyclophosphamide . non small cell lung cancer diagnosis and patients with surgically resected brain metastases are eligible
__label__0	study interventions are Rituximab . malt lymphoma diagnosis and written informed consent given according to national local regulations
__label__0	study interventions are Epirubicin . breast cancer diagnosis and creatinine less_than doc
__label__0	study interventions are Cisplatin . breast neoplasms diagnosis and ajcc staging two thousand and two see appendix i
__label__0	study interventions are Cetuximab . recurrent squamous cell carcinoma of the hypopharynx diagnosis and total calcium corrected for serum albumin within normal limits
__label__0	study interventions are Bleomycin . lymphoma diagnosis and not specified
__label__0	study interventions are pharmacological study . recurrent childhood small noncleaved cell lymphoma diagnosis and no other concurrent investigational drugs
__label__0	study interventions are Sirolimus . metastatic breast cancer diagnosis and measurable or evaluable disease
__label__0	study interventions are Levoleucovorin . eastern cooperative oncology group ecog performance status zero two three if it is directly disease related and is expected to get better if the acute lymphoblastic leukemia lymphoma all is under control
__label__0	study interventions are Letrozole . metastatic breast cancer diagnosis and creatinine less_than equal_than doc upper limits of normal
__label__0	study interventions are Carboplatin . stage iic fallopian tube cancer diagnosis and absolute neutrophil count anc greater than or equal to one five hundred mcl
__label__0	study interventions are Endothelial Growth Factors . uterine corpus carcinosarcoma diagnosis and eastern cooperative oncology group ecog performance status ps zero or one
__label__0	study interventions are ASN002 Dose Escalation . tumor diagnosis and at screening life expectancy of at least three months
__label__0	study interventions are Isophosphamide mustard . sarcoma diagnosis and no pre existing illness precluding study treatment
__label__0	study interventions are Mycophenolic Acid . stage iii small lymphocytic lymphoma diagnosis and patients are eligible following an autologous transplant in remission or in relapse
__label__0	study interventions are Camptothecin . non small cell lung cancer diagnosis and adequate hepatic function with
__label__0	study interventions are Vaccines . adenocarcinoma of the gallbladder diagnosis and patients with brain metastases who have completed palliative radiotherapy and have discontinued steroids are eligible
__label__0	study interventions are 7-hydroxystaurosporine . stage iv endometrial carcinoma diagnosis and more than four weeks since prior radiotherapy and recovered
__label__0	study interventions are Gardasil . genital human papilloma virus infection diagnosis and resident of the city of norfolk virginia
__label__0	study interventions are pharmacological study . stage iii inverted papilloma of the paranasal sinus and nasal cavity diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Hydroxyurea . stage iv squamous cell carcinoma of the nasopharynx diagnosis and ecog zero two
__label__0	study interventions are laboratory biomarker analysis . stage iv inverted papilloma of the paranasal sinus and nasal cavity diagnosis and no active ischemic heart disease within the past year
__label__0	study interventions are Erlotinib Hydrochloride . metastatic squamous neck cancer with occult primary squamous cell carcinoma diagnosis and total bilirubin within normal institutional limits
__label__0	study interventions are Bevacizumab . patients must have histologic proof of urothelial cancer
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian endometrioid adenocarcinoma diagnosis and bilirubin less than or equal to doc uln
__label__0	study interventions are Palliative RT for bone cancer pain . neoplasm metastasis diagnosis and those with hematological malignancies are also eligible
__label__0	study interventions are Fludarabine . aggressive non hodgkin lymphoma diagnosis and donor
__label__0	study interventions are Lenograstim . lymphoma diagnosis and any of the following high risk or recurrent hematological malignancies
__label__0	study interventions are Bevacizumab . myelodysplastic myeloproliferative neoplasms diagnosis and at least thirty days since prior chemotherapy
__label__0	study interventions are Vincristine . small lymphocytic lymphoma diagnosis and age greater_than eighteen years
__label__0	study interventions are Rituximab . lymphoma large cell diffuse diagnosis and absolute neutrophil count anc greater_than doc one hundred and nine or greater_than doc one hundred and nine with bone marrow involvement with dlbcl
__label__0	study interventions are Recombinant Human Interleukin-15 . stage iiia skin melanoma diagnosis and at least four weeks from last dose of prior other biologic agents
__label__0	study interventions are Sulindac sulfone . prostate cancer diagnosis and bilirubin normal doc
__label__0	study interventions are Cholecalciferol . prostate cancer diagnosis and willingness to discontinue use of supplements at least four weeks prior to study intervention for subjects using vitamin selenium or lycopene at time of consent
__label__0	study interventions are diffusion tensor imaging . tumors metastatic to brain diagnosis and the patient must be able to commit to diffusion weighted magnetic resonance mr imaging diffusion tensor imaging dti and chemical shift imaging csi prior to treatment after the first week of treatment and seven eleven days after the completion of treatment at the magnetic resonance research center mrrc
__label__0	study interventions are Lonaprisan (ZK 230211, BAY86-5044) . metastatic breast cancer diagnosis and one five hundred mmthree
__label__0	study interventions are Sunitinib . gastrointestinal stromal tumor diagnosis and serum calcium less_than one doc mg dl
__label__0	study interventions are Meditation Therapy . digestive system neoplasm diagnosis and phase i
__label__0	study interventions are Bevacizumab . stage iiic ovarian cancer diagnosis and patients of childbearing potential must agree to practice an effective form of birth control during study treatment and for six months after completion of treatment
__label__0	study interventions are Liposomal doxorubicin . have platinum refractory or resistant cancer
__label__0	study interventions are Carboplatin . histologically or cytologically documented non small cell lung cancer nsclc including squamous cell carcinoma adenocarcinoma including bronchoalveolar cell and large cell anaplastic carcinoma including giant and clear cell carcinomas
__label__0	study interventions are Antibodies, Monoclonal . stage iiib skin melanoma diagnosis and autologous stem cell infusion including boost infusion
__label__0	study interventions are Fludarabine . recurrent mantle cell lymphoma diagnosis and acute lymphoblastic leukemia all
__label__0	study interventions are Doxorubicin . breast cancer stage iii diagnosis and within twenty-four weeks
__label__0	study interventions are Cyclophosphamide . splenic marginal zone lymphoma diagnosis and patients must have an eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are Rituximab . non hodgkin lymphoma diagnosis and performance status who zero two
__label__0	study interventions are Antibodies . stage iii squamous cell carcinoma of the oropharynx diagnosis and no immune deficiency and or hiv positivity
__label__0	study interventions are Mycophenolic Acid . stage ii childhood anaplastic large cell lymphoma diagnosis and donor must consent to filgrastim csf administration and leukapheresis
__label__0	study interventions are Vaccines . lymphoma diagnosis and no autoimmune disease or atopic allergy
__label__0	study interventions are Methylprednisolone Hemisuccinate . lymphoma diagnosis and fvc and fev_one greater than sixty of predicted
__label__0	study interventions are Mycophenolic Acid . recurrent adult hodgkin lymphoma diagnosis and waldenstrom macroglobulinemia
__label__0	study interventions are Antibodies . stage childhood anaplastic large cell lymphoma diagnosis and hodgkin disease hd
__label__0	study interventions are Screening Method . human papillomavirus infection diagnosis and able to provide informed consent in english
__label__0	study interventions are pharmacological study . stage iv gastric cancer diagnosis and hypericin
__label__0	study interventions are Sunitinib . stage iiib primary peritoneal cavity cancer diagnosis and one hour driving_distance placed on patients being considered for this trial investigators must assure_themselves the patients registered on this trial will be available for complete documentation of the treatment adverse events and follow up
__label__0	study interventions are Lenograstim . sarcoma diagnosis and ast or alt less_than doc times uln for age
__label__0	study interventions are Calcium, Dietary . stage iiib rectal cancer diagnosis and cttwo positive or ctthree tfour nzero or positive as assessed by endorectal ultrasound scan us
__label__0	study interventions are total-body irradiation . lymphoma diagnosis and children unable to cooperate for pfts must meet the following criteria
__label__0	study interventions are Albumin-Bound Paclitaxel . head and neck squamous cell carcinoma diagnosis and patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent are not eligible to participate in this study topical or inhaled corticosteroids are allowed
__label__0	study interventions are Prednisolone hemisuccinate . recurrent childhood large cell lymphoma diagnosis and patients must require supplemental oxygen
__label__0	study interventions are behavioral dietary intervention . breast cancer diagnosis and no concurrent participation in any other organized weight loss or exercise program
__label__0	study interventions are Thiotepa . testicular germ cell tumor diagnosis and no other serious medical or psychiatric illness that would preclude giving informed consent or complying with study requirements
__label__0	study interventions are Alvocidib . unspecified adult solid tumor protocol specific diagnosis and progressive lymphocytosis with lymphocyte doubling time of less_than six months
__label__0	study interventions are Vidarabine . stage grade one follicular lymphoma diagnosis and patients will be accepted beyond chronic phase one cpone if they have received previous myelosuppressive chemotherapy or hsct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are BB 1101 . lymphoma diagnosis and more than four weeks since prior chemotherapy
__label__0	study interventions are Imatinib Mesylate . ovarian cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Bevacizumab . recurrent colon cancer diagnosis and tubes or tubes allowed
__label__0	study interventions are Fludarabine . multiple myeloma and plasma cell neoplasm diagnosis and diagnosis of hematologic malignancy of one of the following high risk types
__label__0	study interventions are Epigallocatechin gallate . colon cancer diagnosis and for men
__label__0	study interventions are Vaccines . breast cancer diagnosis and metastatic disease measurable or evaluable metastatic disease documented by biopsy but not evaluable by imaging small volume peritoneal disease and patients with surgically resected metastatic disease at high risk of relapse
__label__0	study interventions are Gefitinib . non small cell lung cancer diagnosis and pt inr ptt less_than doc uln
__label__0	study interventions are laboratory biomarker analysis . nodular malignant melanoma diagnosis and patients may have received prior radiation therapy any side effects the patients had due to prior radiation therapy must have resolved to equal_than less_than grade one prior to registration prior radiation therapy must have completed at least twenty-eight days prior to registration
__label__0	study interventions are Paclitaxel . advanced solid tumors diagnosis and for this reason women of childbearing potential must agree to use adequate contraception hormonal or barrier method of birth control or abstinence prior to study entry and for the duration of study participation
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian mucinous cystadenocarcinoma diagnosis and no history of cerebrovascular accident cva stroke transient ischemic attack tia or subarachnoid hemorrhage within the past six months
__label__0	study interventions are Nimotuzumab (TheraCIM h-R3) . advanced and or metastatic solid tumors refractory to standard curative therapy or for which no curative therapy exists
__label__0	study interventions are Alvocidib . unspecified adult solid tumor protocol specific diagnosis and at least twenty mm by conventional techniques or at least ten mm by spiral ct scan
__label__0	study interventions are Liposomal doxorubicin . endometrial cancer diagnosis and no prior doxorubicin
__label__0	study interventions are Paclitaxel . localized unresectable adult primary liver cancer diagnosis and normal cardiac ejection fraction by echocardiogram or muga greater than osu lower limit of normal
__label__0	study interventions are Goserelin . breast cancer diagnosis and no prior treatment with an lh_rh agonist antagonist
__label__0	study interventions are Part 1 (Dose Escalation): Duvortuxizumab . lymphoma mantle cell diagnosis and participants must meet protocol specified hematology and chemistry lab parameters criteria
__label__0	study interventions are Genistein . breast cancer diagnosis and alt and ast less_than two times normal
__label__0	study interventions are Sunitinib . recurrent adult cell leukemia lymphoma diagnosis and patients who are on highly active antiretroviral therapy haart combination that includes neither pi nor nnrti agent are eligible and will be enrolled in the nnrti based group group one
__label__0	study interventions are Docetaxel . stage iv prostate cancer diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Osteodex . prostate cancer metastatic diagnosis and ast sgot alt sgpt less_than doc times uln
__label__0	study interventions are Vinorelbine . stage iv uterine sarcoma diagnosis and ctc grade one or greater neuropathy motor or sensory at study entry
__label__0	study interventions are Erlotinib Hydrochloride . recurrent adult brain tumor diagnosis and no active infection or serious medical illness that would preclude study treatment
__label__0	study interventions are Carboplatin . stage iv squamous cell carcinoma of the larynx diagnosis and prior cetuximab is permitted if it was given for no more than nine doses in combination with radiation therapy or chemoradiation therapy for initial treatment of locally advanced disease
__label__0	study interventions are Fenretinide . head and neck cancer diagnosis and cimetidine
__label__0	study interventions are Indocyanine Green . patients presenting with lung nodule or mass presumed to be resectable stage ii or iiia non small call lung cancer on pre operative assessment
__label__0	study interventions are Cyclophosphamide . regional neuroblastoma diagnosis and one mg dl
__label__0	study interventions are Fludarabine . lymphoma diagnosis and if prior cns leukemia it must be treated and in cns cr
__label__0	study interventions are Tacrolimus . precancerous condition diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biological composition to busulfan and fludarabine phosphate
__label__0	study interventions are prostate biopsy . prostate cancer diagnosis and patients able to comply with the study protocol
__label__0	study interventions are Bevacizumab . non small cell lung cancer diagnosis and have adequate organ function and estimated life expectancy of twelve weeks
__label__0	study interventions are Tacrolimus . stage childhood small noncleaved cell lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Paclitaxel . testicular embryonal carcinoma diagnosis and measurable disease
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and more than thirty days since prior unapproved or investigational drugs
__label__0	study interventions are Sorafenib . localized unresectable liver cancer diagnosis and pregnant women are excluded from this study
__label__0	study interventions are SBRT . prostate cancer diagnosis and castrate levels of testosterone
__label__0	study interventions are Fludarabine . recurrent grade three follicular lymphoma diagnosis and hodgkin disease hd
__label__0	study interventions are Rituximab . lymphoma non hodgkin diagnosis and histologically confirmed diagnosis of any subtype of cdtwenty positive cell nhl
__label__0	study interventions are Camptothecin . recurrent rectal cancer diagnosis and failure during or within six months after fluorouracil based adjuvant therapy
__label__0	study interventions are Immunoglobulins . lung carcinoid tumor diagnosis and selective internal radiation therapy such as brachytherapy cyberknife_radiolabeled microsphere embolization etc
__label__0	study interventions are Liposomal doxorubicin . stage iv childhood lymphoblastic lymphoma diagnosis and nhl patients
__label__0	study interventions are Thalidomide . prostatic neoplasms diagnosis and recovered from any toxicity from surgery or radiotherapy
__label__0	study interventions are Fludarabine . myeloproliferative neoplasms diagnosis and not specified
__label__0	study interventions are Antibodies . stage ivb lip and oral cavity squamous cell carcinoma diagnosis and total bilirubin within normal limits must be obtained equal_than less_than two weeks prior to randomization
__label__0	study interventions are Erlotinib Hydrochloride . stage iv verrucous carcinoma of the oral cavity diagnosis and recovered from all prior therapy
__label__0	study interventions are Calcium, Dietary . recurrent colon cancer diagnosis and serum potassium greater_than equal_than lln
__label__0	study interventions are Fluorouracil . esophageal neoplasm diagnosis and aged between eighteen and seventy years
__label__0	study interventions are Capecitabine . metastatic breast cancer diagnosis and patients with reproductive potential must use an adequate contraceptive method abstinence intrauterine device oral contraceptives barrier device with spermicide or surgical sterilization during treatment and for three months after completing treatment
__label__0	study interventions are Doxorubicin . kidney cancer diagnosis and no existing cardiac failure
__label__0	study interventions are Dexamethasone 21-phosphate . plasmacytomas on tissue biopsy
__label__0	study interventions are Rituximab . lymphoma diagnosis and no hemolytic anemia
__label__0	study interventions are Sirolimus . stage iv breast cancer diagnosis and aspartate aminotransferase ast or alanine aminotransferase alt less_than two unl unless related to primary disease
__label__0	study interventions are Trebananib . breast neoplasms diagnosis and baseline ejection fraction by nuclear imaging or echocardiography must by greater_than fifty
__label__0	study interventions are pain therapy . cancer diagnosis and hematopoietic
__label__0	study interventions are Temozolomide . glioblastoma diagnosis and alt alanine aminotransferase less_than three times the institutional upper limit of normal
__label__0	study interventions are Capecitabine . recurrent breast carcinoma diagnosis and life expectancy greater_than three months
__label__0	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . astrocytoma diagnosis and greater than or equal to three months since autologous stem cell transplant prior to registration
__label__0	study interventions are Tipifarnib . inflammatory breast cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Gamma-secretase/Notch signalling pathway inhibitor RO4929097 . recurrent non small cell lung cancer diagnosis and alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional upper limits of normal
__label__0	study interventions are Testosterone enanthate . prostate cancer diagnosis and treatment with less_than two prior chemotherapeutic regimens allowed
__label__0	study interventions are Vaccines . newly diagnosed pediatric pontine glioma diagnosis and stratum is closed to accrual
__label__0	study interventions are Tacrolimus . contiguous stage ii adult lymphoblastic lymphoma diagnosis and known intolerance to bdp
__label__0	study interventions are MSI-1436C . metastatic breast cancer diagnosis and negative serum pregnancy test if female of reproductive potential
__label__0	study interventions are Sirolimus . recurrent lymphoplasmacytic lymphoma diagnosis and note
__label__0	study interventions are Decitabine . t cell lymphoma diagnosis and absolute neutrophil count anc greater_than one thousand, five hundred ul
__label__0	study interventions are Panobinostat . recurrent adult hodgkin lymphoma diagnosis and fourteen days and again within twenty-four hours prior to starting cycle one of lenalidomide prescriptions must be filled within seven days as required by revassist and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least twenty-eight days before she starts taking lenalidomide
__label__0	study interventions are Sorafenib . stage iii grade one follicular lymphoma diagnosis and four weeks since completion of radiation or chemotherapy except for greater_than six weeks for nitrosoureas pam or mitomycin c
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and for women of childbearing potential negative serum pregnancy test is required within four weeks of starting cycle one and then every four weeks during the first four cycles of induction therapy
__label__0	study interventions are Cyclosporins . recurrent adult cell leukemia lymphoma diagnosis and this protocol will allow the use of donors who are unrelated but are hla b d dr identical and mlc mixed lymphocyte culture compatible
__label__0	study interventions are Gabapentin . breast cancer diagnosis and not specified
__label__0	study interventions are Sunitinib . recurrent solid neoplasm diagnosis and chronic inhaled steroid use
__label__0	study interventions are Glycine . follicular lymphoma diagnosis and total bilirubin equal_than less_than doc the upper limit of the normal range uln
__label__0	study interventions are laboratory biomarker analysis . pancreatic polypeptide tumor diagnosis and prior treatment with vegf inhibitor sunitinib bevacizumab sorafenib or other dedicated vegf inhibitor
__label__0	study interventions are Cisplatin . stage iva oral cavity squamous cell carcinoma diagnosis and available for long term follow up of their disease after treatment
__label__0	study interventions are Antibodies . endometrial clear cell adenocarcinoma diagnosis and or five half lives whichever is shorter
__label__0	study interventions are Sirolimus . clear cell renal cell carcinoma diagnosis and any female who has experienced menarche and who has not undergone surgical sterilization hysterectomy bilateral tubal ligation or bilateral oophorectomy or is not postmenopausal defined as amenorrhea greater_than equal_than twelve consecutive months
__label__0	study interventions are Busulfan . germ cell tumors diagnosis and metastatic at time of diagnosis and or relapsed after therapy
__label__0	study interventions are Cyclooxygenase 2 Inhibitors . cancer diagnosis and patient must be informed of the investigational nature of the study and sign an informed consent form
__label__0	study interventions are Prednisone . stage iv enteropathy associated cell lymphoma diagnosis and treatment may commence prior to the mayo clinic review please note
__label__0	study interventions are Dasatinib . neoplasms diagnosis and serum creatinine less_than equal_than doc times the institutional upper normal limit
__label__0	study interventions are Bevacizumab . stage iv squamous cell carcinoma of the hypopharynx diagnosis and no psychiatric illness or social situation that would preclude study compliance
__label__0	study interventions are Vidarabine . cervical cancer diagnosis and patients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment
__label__0	study interventions are Levoleucovorin . oesophago gastric carcinoma diagnosis and bilirubin less_than doc times the unl
__label__0	study interventions are Palbociclib . metastatic breast cancer diagnosis and absolute neutrophil count anc greater_than doc ten nine ii
__label__0	study interventions are Paclitaxel . stage iiib non small cell lung cancer diagnosis and no unstable angina pectoris
__label__0	study interventions are Bevacizumab . recurrent childhood medulloblastoma diagnosis and patients who are receiving corticosteroids must be on stable or decreasing dose for at least seven days
__label__0	study interventions are Cyclosporins . stage iv marginal zone lymphoma diagnosis and hodgkin disease hd
__label__0	study interventions are Prolactin Release-Inhibiting Factors . prostate cancer diagnosis and metastatic disease on bone scan and or involvement of soft tissues lymph nodes and or viscera by ct scan pet ct or mri
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma and plasma cell neoplasm diagnosis and performance status
__label__0	study interventions are Melphalan . myeloid sarcoma diagnosis and has suitable single haplotype matched greater_than three of six family member donor
__label__0	study interventions are Carmustine . stage iv mantle cell lymphoma diagnosis and able to take aspirin eighty-one or three hundred and twenty-five mg daily as prophylactic anticoagulation patients intolerant to acetylsalicylic acid asa may use warfarin or low molecular weight heparin
__label__0	study interventions are Gemcitabine . uterine carcinosarcoma diagnosis and no prior docetaxel or gemcitabine
__label__0	study interventions are Rituximab . recurrent mantle cell lymphoma diagnosis and histologically or immunophenotypically proven cdtwenty positive cell lymphoproliferative disorder
__label__0	study interventions are Etoposide . neuroblastoma diagnosis and group three
__label__0	study interventions are Fluorouracil . adenocarcinoma of the pancreas diagnosis and biologic therapy
__label__0	study interventions are TSB-9-W1 . metastatic colorectal cancer diagnosis and alanine aminotransferase alp
__label__0	study interventions are Pertuzumab . hertwo neu positive tumor defined as three positive by fluorescent in situ hybridization
__label__0	study interventions are Vaccines . non small cell lung cancer diagnosis and hemoglobin greater_than nineg dl
__label__0	study interventions are Amoxicillin . myelodysplastic myeloproliferative neoplasms diagnosis and no prior immediate or accelerated reaction to penicillin cephalosporin or fluoroquinolone antibiotics
__label__0	study interventions are Irinotecan . patients must not be pregnant or nursing women men of reproductive potential must have agreed to use an effective contraceptive method for up to three months after the final administered dose of chemotherapy woman is considered to be of reproductive potential if she has had menses at any time in the preceding twelve consecutive months in addition to routine contraceptive methods effective contraception also includes heterosexual celibacy and surgery intended to prevent pregnancy or with side effect of pregnancy prevention defined as hysterectomy bilateral oophorectomy or bilateral tubal ligation however if at any point previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures he she is responsible for beginning contraceptive measures
__label__0	study interventions are Antibodies . recurrent adult lymphoblastic lymphoma diagnosis and no psychological or psychiatric condition that would preclude study participation
__label__0	study interventions are pharmacological study . stage iv breast cancer diagnosis and patients receiving iv heparin
__label__0	study interventions are sputum cytology . head and neck cancer diagnosis and cardiovascular
__label__0	study interventions are Cisplatin . recurrent oral cavity verrucous carcinoma diagnosis and oral cavity oropharynx larynx hypopharynx and paranasal sinus for patients with diagnosis of scchn of unknown origin their eligibility must be reviewed and approved by the principal investigator
__label__0	study interventions are Immunoglobulins . clear cell renal cell carcinoma diagnosis and platelet count greater_than equal_than one hundred zero mm three
__label__0	study interventions are Selumetinib . recurrent melanoma diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to mek inhibitor azdsix thousand, two hundred and forty-four
__label__0	study interventions are Bortezomib . advanced or metastatic solid tumors diagnosis and ability to comply with visits procedures required by the protocol
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv metastatic breast cancer diagnosis and prior adjuvant docetaxel on an every three week schedule is permitted
__label__0	study interventions are Imatinib Mesylate . adult meningioma diagnosis and no deep venous or arterial thrombosis within the past six weeks
__label__0	study interventions are Mycophenolic Acid . stage iii adult burkitt lymphoma diagnosis and patients with aml all or mds scheduled for myeloablative conditioning should have equal_than less_than ten blasts in bone marrow or peripheral blood at the start of conditioning
__label__0	study interventions are NRX194204 . non small cell lung cancer diagnosis and uni_dimensionally measurable nsclc defined as at least one lesion that can be measured in at least one dimension longest diameter to be recorded as greater_than twocm with conventional techniques or as greater_than onecm on spiral ct scan
__label__0	study interventions are Docetaxel . ovarian undifferentiated adenocarcinoma diagnosis and no septicemia severe infection or acute hepatitis
__label__0	study interventions are Vaccines . colorectal cancer diagnosis and hepatitis negative
__label__0	study interventions are Compliance Monitoring . ovarian endometrioid adenocarcinoma diagnosis and patients with the following histologic epithelial cell types are eligible
__label__0	study interventions are Docetaxel . unspecified adult solid tumor protocol specific diagnosis and treatment with either docetaxel or gemcitabine hydrochloride in combination with an investigational agent is reasonable
__label__0	study interventions are iodine I 125 . prostate cancer diagnosis and other
__label__0	study interventions are 3-dimensional conformal radiation therapy . liver cancer diagnosis and no myocardial infarction within the past six months
__label__0	study interventions are Vincristine . childhood immunoblastic large cell lymphoma diagnosis and hemoglobin greater_than equal_than doc dl may receive red blood cell rbc transfusions
__label__0	study interventions are Interleukin-12 . ovarian cancer diagnosis and disease characteristics
__label__0	study interventions are Tremelimumab . pancreatic cancer diagnosis and
__label__0	study interventions are Antibodies . stage iii colon cancer diagnosis and no men or women of childbearing potential who are unwilling to employ adequate contraception
__label__0	study interventions are flow cytometry . primary peritoneal cavity cancer diagnosis and fallopian tube
__label__0	study interventions are Cisplatin . oesophagogastric cancer diagnosis and glomerular filtration rate greater_than sixty ml min
__label__0	study interventions are Cediranib . localized malignant mesothelioma diagnosis and at least four weeks since prior chemotherapy six weeks for nitrosoureas or mitomycin and recovered
__label__0	study interventions are Antibodies . stage iiib breast cancer diagnosis and ovarian suppression on luteinizing hormone releasing hormone lh_rh agonist
__label__0	study interventions are Vitamins . stage iv colon cancer with resectable liver metastases diagnosis and discontinuation of anticoagulation aspirin and or anti platelet agents prior to surgery will occur according to institutional standards of care
__label__0	study interventions are Histone Deacetylase Inhibitors . small intestine lymphoma diagnosis and performance status
__label__0	study interventions are Folic Acid . primary peritoneal serous adenocarcinoma diagnosis and computed tomography ct abdomen pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy equal_than less_than twenty-eight days before entering study
__label__0	study interventions are Paclitaxel . head and neck cancer diagnosis and hepatic
__label__0	study interventions are assessment of therapy complications . colorectal cancer diagnosis and enrolled on clinical trial calgb ninety thousand, four hundred and one calgb thirty thousand, six hundred and seven calgb thirty thousand, seven hundred and four calgb forty thousand, six hundred and one calgb forty thousand, six hundred and three calgb forty thousand, five hundred and two calgb forty thousand, five hundred and three calgb seventy thousand, six hundred and four or calgb eighty thousand, four hundred and five
__label__0	study interventions are Everolimus . pancreatic neuroendocrine tumor gtwo diagnosis and measurable disease
__label__0	study interventions are Abiraterone Acetate . metastatic castration resistant prostate cancer diagnosis and total bilirubin less_than doc upper limit of normal uln except for patients with known gilbert syndrome direct bilirubin less_than doc uln
__label__0	study interventions are Vidarabine . stage iv adult diffuse mixed cell lymphoma diagnosis and must have received and failed frontline therapy patients must have failed or were not eligible for autologous transplant
__label__0	study interventions are Standard External Beam Radiation Therapy . hepatic cancer diagnosis and patients hepatic lesions must be considered technically unresectable or that their overall health makes surgery inadvisable
__label__0	study interventions are Nivolumab . melanoma diagnosis and hepatic total bilirubin less_than equal_than doc uln isolated bilirubin greater_than doc uln is acceptable if bilirubin is fractionated and direct bilirubin less_than thirty-five ast and alt albumin less_than equal_than doc uln one greater_than equal_than doc dl renal creatinine or calculated creatinine clearance or twenty-four hour urine creatinine clearance less_than equal_than doc uln two greater_than equal_than fifty ml min greater_than equal_than fifty ml min
__label__0	study interventions are Paclitaxel . ovarian carcinoma stage three or four diagnosis and absolute granulocyte count greater_than doc 10three mmthree
__label__0	study interventions are Vidarabine . noncutaneous extranodal lymphoma diagnosis and must have received and failed frontline therapy and have failed or were not eligible for autologous transplant
__label__0	study interventions are Carboplatin . adenocarcinoma not otherwise specified
__label__0	study interventions are Niacinamide . recurrent squamous cell carcinoma of the oropharynx diagnosis and absolute neutrophil count anc one thousand, five hundred mm three
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and karnofsky performance status sixty one hundred
__label__0	study interventions are Bevacizumab . peritoneal cancer diagnosis and no prior treatment with any other antiangiogenic agents or cyclophosphamide
__label__0	study interventions are LY2606368 . advanced cancers diagnosis and qtcf value of less_than four hundred and seventy msec on screening electrocardiogram ekg
__label__0	study interventions are Cyclosporins . recurrent childhood anaplastic large cell lymphoma diagnosis and the donor must be genotypically hla identical sibling phenotypically hla matched first degree relative or an unrelated donor who is molecularly matched with the patient at hla b drbone
__label__0	study interventions are Fludarabine . stage iv small lymphocytic lymphoma diagnosis and donor
__label__0	study interventions are Prednisolone hemisuccinate . recurrent childhood lymphoblastic lymphoma diagnosis and cm negative chronic phase cpone and resistant to or intolerant of tyrosine kinase inhibitors imatinib dasatinib etc
__label__0	study interventions are Sunitinib . metastatic renal cell carcinoma diagnosis and adequate cardiac function by history
__label__0	study interventions are Antibodies, Monoclonal . stage iv melanoma diagnosis and ecog zero one
__label__0	study interventions are Cediranib . intraocular lymphoma diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Cetuximab . squamous cell carcinoma diagnosis and calculated creatinine clearance equal_than one hundred and forty age actual body weight in kg doc five if female seventy-two serum creatinine
__label__0	study interventions are Pemetrexed . malignant pleural mesothelioma diagnosis and adequate haematological status
__label__0	study interventions are LEE011 and MEK162 . locally advanced or metastatic nras mutant melanoma diagnosis and serum total bilirubin less_than doc upper limit of normal uln
__label__0	study interventions are Immunoglobulins . recurrent adult liver carcinoma diagnosis and serum glutamic oxaloacetic transaminase sgot aspartate aminotransferase ast equal_than less_than doc uln equal_than less_than five uln if liver metastasis is present or patient is in hcc cohort
__label__0	study interventions are Immunoglobulins . recurrent cutaneous cell non hodgkin lymphoma diagnosis and growth factor is not permitted within fourteen days of anc assessment unless cytopenia is secondary to disease involvement
__label__0	study interventions are 7-hydroxystaurosporine . stage iv ovarian germ cell tumor diagnosis and progesterone receptor negative
__label__0	study interventions are Navitoclax . stage iiib skin melanoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Gemcitabine . breast cancer diagnosis and clinical nodal stages including cntwob and cnthree or pathologic nodal stages including pnzero positive pntwob pnthreeb with clinically apparent internal mammary nodes or pnthreec
__label__0	study interventions are Vidarabine . burkitt lymphoma diagnosis and unrelated donor
__label__0	study interventions are Correlative/special studies . stage ia breast cancer diagnosis and history of osteoarthritis and or fibromyalgia is allowed
__label__0	study interventions are Doxorubicin . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and stage patients must have at least one of the following risk factors
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and partial thromboplastin time must be less_than equal_than doc upper normal limit of institution normal range and inr less_than doc
__label__0	study interventions are Epoetin Alfa . anemia results from cancer chemotherapy radiotherapy or an association with hormonal therapy or immunotherapy
__label__0	study interventions are Mycophenolic Acid . nodal marginal zone cell lymphoma diagnosis and must have received prior chemotherapy or failed autografting following planned autologous transplant tandem is allowed
__label__0	study interventions are Positron Emission Tomography . stage ivb oral cavity squamous cell carcinoma diagnosis and female patients cannot be of childbearing age or if they are must have negative pregnancy test prior to enrollment and be willing to use contraceptives during treatment and continue for six additional months
__label__0	study interventions are Busulfan . lymphoma diagnosis and clear cut radiographic findings
__label__0	study interventions are Paclitaxel . lung cancer diagnosis and at least three weeks since prior radiotherapy and recovered from all toxicities
__label__0	study interventions are Carboplatin . recurrent adult diffuse large cell lymphoma diagnosis and prior to stem cell storage
__label__0	study interventions are Vorinostat . recurrent nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and aspartate aminotransferase ast glutamic oxaloacetic transaminase sgot and alanine aminotransferase alt glutamate pyruvate transaminase sgpt equal_than less_than doc uln
__label__0	study interventions are Antibodies, Monoclonal . stage fours neuroblastoma diagnosis and no more than twelve months from the date of starting the first induction chemotherapy after diagnosis to the date of asct except for the rare occasions as noted below for tandem asct patients this will be the date of the first stem cell infusion exception
__label__0	study interventions are AlloStim-8 . advanced or refractory leukemia lymphoma multiple myeloma diagnosis and accelerated phase patients with cml in blast crisis greater_than thirty promyelocytes and myeloblasts in the bone marrow are not eligible
__label__0	study interventions are Denosumab . hodgkin lymphoma diagnosis and adults greater_than equal_than eighteen years
__label__0	study interventions are Navitoclax . stage iiia skin melanoma diagnosis and life expectancy of greater than three months
__label__0	study interventions are Erlotinib Hydrochloride . recurrent verrucous carcinoma of the oral cavity diagnosis and no concurrent steroids
__label__0	study interventions are Busulfan . stage iii grade two follicular lymphoma diagnosis and viral load must be equal_than less_than ten zero copies ml
__label__0	study interventions are Irinotecan . esophageal cancer diagnosis and patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant chemotherapy the wash out period will be at least one month
__label__0	study interventions are Capecitabine . breast cancer diagnosis and not specified
__label__0	study interventions are Levoleucovorin . untreated childhood supratentorial primitive neuroectodermal tumor diagnosis and mri evidence of spinal disease
__label__0	study interventions are Interferons . toneanonea twoa microscopic primary melanoma of any thickness with microscopically positive lymph node any number
__label__0	study interventions are Cisplatin . peritoneal cavity cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Paclitaxel . cancer diagnosis and absolute neutrophil count anc equal_than greater_than one five hundred µl
__label__0	study interventions are Pd-103 . prostatic neoplasm diagnosis and androgen deprivation therapy less than four month duration for size reduction is allowable
__label__0	study interventions are Fludarabine phosphate . noncutaneous extranodal lymphoma diagnosis and sevenq
__label__0	study interventions are Immunoglobulins . recurrent small lymphocytic lymphoma diagnosis and women who are using oral contraceptives other hormonal contraceptives vaginal products skin patches or implanted or injectable products or mechanical products such as an intrauterine device or barrier methods diaphragm condoms spermicides to prevent pregnancy or are practicing abstinence or where their partner is sterile eg vasectomy should be considered to be of childbearing potential wocbp must have negative serum or urine pregnancy test minimum sensitivity twenty-five iu or equivalent units of human chorionic gonadotropin hcg within seventy-two hours before the start of ipilimumab
__label__0	study interventions are Pembrolizumab . refractory extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and histologically confirmed relapsed response to last treatment greater_than equal_than six months duration or refractory no response to last treatment or response duration less_than six months indolent low grade cell nhl note
__label__0	study interventions are Temozolomide . recurrent childhood cerebellar astrocytoma diagnosis and no concurrent enzyme inducing anticonvulsants
__label__0	study interventions are Fludarabine . hodgkins lymphoma diagnosis and requirement for two or more inductions to achieve crone
__label__0	study interventions are Sorafenib . brain and central nervous system tumors diagnosis and ecog performance status zero two
__label__0	study interventions are Paclitaxel . peritoneal cavity cancer diagnosis and no known hypersensitivity to any component of pemetrexed_disodium
__label__0	study interventions are Bevacizumab . stage iv renal cell cancer diagnosis and no prior radiotherapy to greater_than equal_than twenty-five of bone marrow
__label__0	study interventions are Fluorouracil . resectable pancreatic cancer diagnosis and women of child bearing potential and men must be willing to use adequate contraception during the entire study and for eight weeks following completion of all chemotherapy on study this includes hormonal or barrier method or abstinence
__label__0	study interventions are multivitamin . bladder cancer diagnosis and intravesical therapy within thirty days allowed at least thirty days since greater than two multivitamins daily
__label__0	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and concurrent full dose anticoagulants allowed provided the following criteria are met part two only
__label__0	study interventions are Gemcitabine . recurrent adult lymphoblastic lymphoma diagnosis and patients with cytopenia thought to be due to disease in their bone marrow that do not meet this criteria may be enrolled on the protocol at the study chair discretion
__label__0	study interventions are exercise . breast cancer diagnosis and eighteen years
__label__0	study interventions are Cyclophosphamide . breast neoplasms diagnosis and adequate liver and renal function
__label__0	study interventions are AR-42 . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and ast and alt equal_than less_than fivex the institutional upper limit of normal
__label__0	study interventions are Prednisone . multiple myeloma diagnosis and aspartate transaminase ast
__label__0	study interventions are Pembrolizumab . be willing and able to undergo pre treatment baseline biopsy of the tumor
__label__0	study interventions are Dabrafenib . stage iv melanoma diagnosis and all treatment related toxicity must have resolved to grade two or less
__label__0	study interventions are Thalidomide . stage iv ovarian epithelial cancer diagnosis and no concurrent antiseizure medications for seizure disorder
__label__0	study interventions are Essiac . ovarian cancer diagnosis and bilirubin less_than doc times upper limit of normal uln sgot less_than doc times uln alkaline phosphatase less_than doc times uln creatinine less_than two times uln
__label__0	study interventions are Romidepsin . recurrent adult brain tumor diagnosis and phase and phase ii
__label__0	study interventions are Lapatinib . breast cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are Melphalan . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and the donor must have no uncontrolled cardiopulmonary renal endocrine hepatic or psychiatric disease to render donation unsafe
__label__0	study interventions are exercise intervention . stage iiia non small cell lung cancer diagnosis and able to understand and read in english sufficiently to adequately complete informed consent to participate and to complete the questionnaires
__label__0	study interventions are Aminopterin . non hodgkin lymphoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Cisplatin . brenner tumor diagnosis and stage iii iv disease that has been suboptimally or optimally_debulked
__label__0	study interventions are laboratory biomarker analysis . angioimmunoblastic cell lymphoma diagnosis and no evidence of grade ii or higher acute gvhd or chronic gvhd at initiation of first dli
__label__0	study interventions are Immunoglobulins . small cell lung cancer diagnosis and signed informed consent form
__label__0	study interventions are Prednisolone . diffuse large cell lymphoma diagnosis and resolution of toxicities caused by the onest line regimen to less than or equal to grade one
__label__0	study interventions are Methylprednisolone . lymphoma diagnosis and related donor matched at five or six hla antigens b dr
__label__0	study interventions are BB 1101 . stage multiple myeloma diagnosis and known hypersensitivity allergy or inability to tolerate any of the agents employed
__label__0	study interventions are Etoposide phosphate . extragonadal germ cell tumor diagnosis and john wort
__label__0	study interventions are Fludarabine . melanoma diagnosis and seronegative for human immunodeficiency virus hiv antibody
__label__0	study interventions are open rectal resection . rectal cancer diagnosis and locally advanced tthree determined by ct mri and trus
__label__0	study interventions are Gemcitabine . solid tumor diagnosis and for part dose confirmation
__label__0	study interventions are Antibodies . stage ivb colon cancer diagnosis and serum glutamic oxaloacetic transaminase sgot or serum glutamic pyruvate transaminase sgpt equal_than less_than doc iuln if there are known liver metastases sgot or sgpt must be equal_than less_than five iuln these results must be obtained within twenty-eight days prior to registration
__label__0	study interventions are Albumin-Bound Paclitaxel . endometrial clear cell adenocarcinoma diagnosis and neuropathy sensory and motor less than or equal to ctcae doc grade one
__label__0	study interventions are Irinotecan . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and no greater than doc mg dl for patients age five and under
__label__0	study interventions are Lenalidomide . recurrent adult burkitt lymphoma diagnosis and creatinine doc institutional upper limit of normal or creatinine clearance greater_than equal_than thirty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Clavulanic Acid . unspecified adult solid tumor protocol specific diagnosis and no prior treatment for leukemia
__label__0	study interventions are Isophosphamide mustard . childhood immunoblastic large cell lymphoma diagnosis and more than six months since prior allogeneic peripheral blood stem cell transplantation and no active graft versus host disease
__label__0	study interventions are Cyclophosphamide . follicular lymphoma diagnosis and acute lymphocytic leukemia
__label__0	study interventions are Liposomal doxorubicin . stage iii grade three follicular lymphoma diagnosis and dhl will be identified using cytogenetics and or immunohistochemistry as detailed in section doc
__label__0	study interventions are Cyclophosphamide . stage iiia breast cancer diagnosis and platelet count must be greater_than equal_than one hundred zero mm three
__label__0	study interventions are Dabrafenib . able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
__label__0	study interventions are Denileukin diftitox . lung cancer diagnosis and patients with cmv seropositivity are eligible
__label__0	study interventions are Antibodies, Monoclonal . diffuse large cell lymphoma diagnosis and at least one of the following criteria
__label__0	study interventions are Carboplatin . endometrial cancer diagnosis and documented locally determined aktone or pikthreeca mutation
__label__0	study interventions are GSK525762 . carcinoma midline diagnosis and cardiac system
__label__0	study interventions are Sunitinib . adult solid neoplasm diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and prior treatment of hypercalcaemia or spinal cord compression with corticosteroids does not disqualify the patient the dose should not exceed the equivalent of one hundred and sixty mg of dexamethasone in two week period
__label__0	study interventions are Pembrolizumab . carcinoma non small cell lung diagnosis and subjects who have received at least one prior platinum based therapy
__label__0	study interventions are Fluorouracil . anal cancer diagnosis and disease characteristics
__label__0	study interventions are Vidarabine . stage iii adult lymphoblastic lymphoma diagnosis and ages greater_than fifty years with hematologic malignancies treatable by unrelated hct
__label__0	study interventions are Rituximab . stage iv childhood large cell lymphoma diagnosis and able to comply with scheduled follow up and with management of toxicity
__label__0	study interventions are chemotherapy . lymphoma diagnosis and at least three months since prior unconjugated anti cell monoclonal antibody mab rituximab campath no prior anti cell mab conjugated to radioisotopes such as iodine onethreeone iodine monoclonal antibody anti bone or yttrium_y no concurrent mab therapy until one2 months after study no other biologic therapy monoclonal antibodies interferon alfa for one2 months after study no concurrent hematopoietic growth factors other than filgrastim csf chemotherapy
__label__0	study interventions are Paclitaxel . head and neck cancer diagnosis and other
__label__0	study interventions are Ifosfamide . recurrent adult hodgkin lymphoma diagnosis and patients must have serum lactate dehydrogenase ldh performed within fourteen days prior to registration
__label__0	study interventions are questionnaire administration . stage ii squamous cell carcinoma of the lip and oral cavity diagnosis and chemotherapy
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and no prior allergic reaction attributed to compounds of similar chemical or biological composition to bevacizumab or other study agents
__label__0	study interventions are Therapeutic Conventional Surgery . stage iiia breast cancer diagnosis and patients must have an eastern cooperative oncology group ecog performance status of zero one karnofsky greater_than equal_than 8zero
__label__0	study interventions are Methylprednisolone . prostate cancer diagnosis and received prior castration by orchiectomy and or luteinizing hormone releasing hormone lh_rh agonist with or without antiandrogen antiandrogen withdrawal monotherapy with estramustine or other hormonal agents
__label__0	study interventions are Liposomal doxorubicin . atypical fibroxanthoma diagnosis and all patients and or their parents or legal guardians must sign written informed consent
__label__0	study interventions are Alemtuzumab . stage iv childhood large cell lymphoma diagnosis and there is no indication for an autologous transplantation as treatment option
__label__0	study interventions are Cetuximab . colorectal neoplasms diagnosis and at least thirty days must have elapsed from major surgery prior chemotherapy prior treatment with an investigational agent or medical device or prior radiation therapy
__label__0	study interventions are Dexamethasone . stage iiib ovarian cancer diagnosis and patients must have signed an approved informed consent and authorization permitting release of personal health information
__label__0	study interventions are quality-of-life assessment . stage squamous cell carcinoma of the larynx diagnosis and predicted life expectancy greater than twelve weeks
__label__0	study interventions are Etoposide . lymphoma diagnosis and life expectancy
__label__0	study interventions are Doxorubicin . unspecified adult solid tumor protocol specific diagnosis and bilirubin no greater than doc mg dl
__label__0	study interventions are Paclitaxel . esophageal adenocarcinoma diagnosis and leukocytes greater_than three zero mcl
__label__0	study interventions are Podophyllotoxin . recurrent neuroblastoma diagnosis and doc mg dl
__label__0	study interventions are Sirolimus . stage ib ovarian cancer diagnosis and histologic proof of one of the following
__label__0	study interventions are Proteasome Inhibitors . unspecified adult solid tumor protocol specific diagnosis and radiotherapy
__label__0	study interventions are Thioguanine . lymphoma diagnosis and cell lbl precursor cell lbl or lbl with an unknown immunophenotype
__label__0	study interventions are Cyclophosphamide . refractory lymphoplasmacytic lymphoma diagnosis and cord blood cb donor selection will be based on institutional guidelines and in general should be selected to optimize both human leukocyte antigen hla match and cell dose additionally cb grafts shall consist of one or two cb donors based on but not exclusively determined by cell dose total nucleated cell tnc kg and cdthirty-four kg hla matching and disease status and indication for transplant attending preference will be allowed for single versus double unit as well as the degree of mismatching based on patient specific factors as long as the following minimum criteria are met
__label__0	study interventions are Ifosfamide . extragonadal germ cell tumor diagnosis and wbc greater_than two zero µl
__label__0	study interventions are Paclitaxel . head and neck cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Antibodies, Monoclonal . brain and central nervous system tumors diagnosis and at least eight weeks since prior external beam or gamma_knife radiotherapy
__label__0	study interventions are Dacarbazine . adult glioblastoma diagnosis and measurable or evaluable disease by gadolinium magnetic resonance imaging mri or contrast computed tomography ct scan note
__label__0	study interventions are Ethiodized Oil . hepatocellular carcinoma diagnosis and i
__label__0	study interventions are Cyclophosphamide . patients with margins positive for lobular carcinoma in situ lcis are eligible without additional resection
__label__0	study interventions are Carboplatin . breast cancer diagnosis and stage iii patients must have achieved complete or partial response to four six courses of doxorubicin and or taxol based induction chemotherapy
__label__0	study interventions are Antibodies . recurrent pancreatic cancer diagnosis and no concurrent chronic daily aspirin more than three hundred and twenty-five mg day or nonsteroidal anti inflammatory drugs known to inhibit platelet function
__label__0	study interventions are Cyclophosphamide . thymoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamic pyruvic transaminase sgpt less than or equal to five times the institutional upper limit of normal with evidence of metastatic disease to the liver or less than or equal to three times the institutional upper limit of normal without evidence of metastatic disease to the liver
__label__0	study interventions are Etoposide . stage iv childhood large cell lymphoma diagnosis and hepatitis status known
__label__0	study interventions are E7389 . leiomyosarcoma
__label__0	study interventions are Methotrexate . stage iii marginal zone lymphoma diagnosis and absence of ph positive metaphases
__label__0	study interventions are Prednisone . stage iv adult cell leukemia lymphoma diagnosis and prior therapy restrictions
__label__0	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and patient and donor pairs_homozygous at mismatched allele in the graft rejection_vector are considered two allele mismatch the patient is one hundred and one and the donor is two hundred and one and this type of mismatch is not allowed
__label__0	study interventions are Gemcitabine . pancreatic neoplasms diagnosis and alanine amino_transferase alt and aspartate amino_transferase ast less_than doc times the upper limit of normal uln in patients with no demonstrable hepatic metastasis or less_than five uln in patients with hepatic metastasis
__label__0	study interventions are Dexamethasone acetate . stage iii multiple myeloma diagnosis and hemoglobin greater_than seven dl platelet count greater_than seven5 zero cells mm three absolute neutrophil count greater_than 1zero cells mm three creatinine less_than doc mg dl creatinine clearance measured or calculated greater_than equal_than sixty ml min direct bilirubin equal_than less_than doc mg dl serum glutamate pyruvate transaminase sgpt alanine aminotransferase alt and serum glutamic oxaloacetic transaminase sgot aspartate aminotransferase ast equal_than less_than doc times the upper limit of normal
__label__0	study interventions are Gemcitabine . fallopian tube cancer diagnosis and life expectancy of twelve weeks or longer
__label__0	study interventions are Tipifarnib . urothelial carcinoma diagnosis and both females and male subjects with female partners of child bearing potential must agree to use an adequate method of contraception for two weeks prior to screening during and at least four weeks after last dose of trial medication
__label__0	study interventions are Celecoxib . neoplasm metastasis diagnosis and patients must be aware of the neoplastic nature of their illnesses the experimental nature of the therapy alternative treatments potential benefits and risks
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and lvef greater_than forty-five
__label__0	study interventions are Erlotinib Hydrochloride . advanced solid tumors diagnosis and ecog ps zero two
__label__0	study interventions are Docetaxel . ovarian cancer diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Interferons . lymphoma diagnosis and hematopoietic
__label__0	study interventions are nelarabine . stage iv cutaneous cell non hodgkin lymphoma diagnosis and ctcl patients may have received one prior course of single agent systemic chemotherapy for ctcl but may not have received multi agent chemotherapy regimen patients may have received prior local topical radiatio negative or electron beam based or chemotherapy based treatment examples of the latter would include but not be limited to cytokines such as interferon retinoids monoclonal antibodies and fusion toxins
__label__0	study interventions are Rituximab . multiple myleoma diagnosis and adequate central venous access potential
__label__0	study interventions are therapeutic conventional surgery . stage ib non small cell lung cancer diagnosis and ability to understand and the willingness to sign written informed consent
__label__0	study interventions are Mycophenolic Acid . aids related immunoblastic large cell lymphoma diagnosis and viral load has decreased by greater_than equal_than doc logs or viral load less_than five thousand copies ml plasma on haart therapy
__label__0	study interventions are adjuvant therapy . head and neck cancer diagnosis and at high or intermediate risk of recurrence
__label__0	study interventions are Fludarabine . stage ii childhood small noncleaved cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Alvocidib . recurrent small lymphocytic lymphoma diagnosis and cardiac arrhythmia
__label__0	study interventions are flow cytometry . cancer diagnosis and enrolled on cog therapeutic biology or tissue banking protocol that allows collection of tissue for research and submission to cog designated resource laboratory
__label__0	study interventions are Exemestane . hertwo status must be known tumor slides should be submitted for central evaluation of hormone receptor status as per section
__label__0	study interventions are Ferrosoferric Oxide . stage iib esophageal cancer diagnosis and serum ferritin less_than doc institutional upper limit of normal
__label__0	study interventions are Irinotecan . childhood oligodendroglioma diagnosis and negative pregnancy test
__label__0	study interventions are Liposomal doxorubicin . adrenocortical carcinoma diagnosis and no congestive heart failure
__label__0	study interventions are alvespimycin hydrochloride . stage iii midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and no other concurrent investigational agents
__label__0	study interventions are Antibodies . recurrent pancreatic cancer diagnosis and sgot ast less_than doc upper limit of normal
__label__0	study interventions are Gastrins . pancreatic cancer diagnosis and if patients were jaundiced bilirubin had to be greater_than eighty µmol l
__label__0	study interventions are informational intervention . prostate cancer diagnosis and early stage disease
__label__0	study interventions are Fludarabine phosphate . stage iv mantle cell lymphoma diagnosis and high risk crone for example but not limited to
__label__0	study interventions are Bevacizumab . kidney cancer diagnosis and urine protein
__label__0	study interventions are Lenograstim . refractory multiple myeloma diagnosis and adequate venous access plan in place for apheresis procedure
__label__0	study interventions are Busulfan . multiple myeloma and plasma cell neoplasm diagnosis and no prior or concurrent psychiatric illness
__label__0	study interventions are Histone Deacetylase Inhibitors . hodgkin lymphoma diagnosis and subjects receiving intravenous mechlorethamine six mg sqm as single agent at least four weeks before study entry
__label__0	study interventions are Endothelial Growth Factors . ovarian serous cystadenocarcinoma diagnosis and or five half lives whichever is shorter
__label__0	study interventions are Busulfan . multiple myeloma diagnosis and acute leukemias in twond or greater remission
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and no uncontrolled hypertension
__label__0	study interventions are Fluorouracil . anal cancer diagnosis and alt and ast less_than three times upper limit of normal
__label__0	study interventions are Cisplatin . intrahepatic cholangiocarcinoma diagnosis and locally advanced disease portal lymph node disease multifocal intrahepatic lesions or major vascular invasion and no evidence of omental peritoneal or pelvic metastases
__label__0	study interventions are Cyclosporine . stage iv mantle cell lymphoma diagnosis and primary myelofibrosis
__label__0	study interventions are Immunoglobulin G . stage iiib fallopian tube cancer diagnosis and patients with suboptimal disease and or stage iv will not be eligible as of april one 20oneone they should be enrolled on gog two hundred and sixty-two three one4 oneone
__label__0	study interventions are Diagnostic Laboratory Biomarker Analysis . stage iv gallbladder cancer diagnosis and no prior akt inhibitors allowed
__label__0	study interventions are Estradiol . stage iiic breast cancer diagnosis and eastern cooperative oncology group ecog zubrod performance status zero two
__label__0	study interventions are educational intervention . signet ring adenocarcinoma of the colon diagnosis and no evidence of metastatic disease
__label__0	study interventions are Fludarabine . large cell non hodgkin lymphoma diagnosis and chronic myeloproliferative disease
__label__0	study interventions are Androgen Receptor Antagonists . stage ii prostate adenocarcinoma diagnosis and have signed an informed consent document indicating that the subjects understands the purpose of and procedures required for the study and are willing to participate in the study
__label__0	study interventions are Panobinostat . soft tissue sarcoma diagnosis and and must be willing to use two methods of contraception one of them being barrier method during the study and for three months after last study drug administration
__label__0	study interventions are Albumin-Bound Paclitaxel . testicular germ cell tumor diagnosis and no prior allergic reactions to cisplatin or other platinum compounds
__label__0	study interventions are Capecitabine . pancreatic cancer diagnosis and hemoglobin hgb greater_than one doc dl the use of transfusion or other intervention to achieve hgb greater_than one doc dl is acceptable
__label__0	study interventions are Palbociclib . inoperable estrogen receptor positive and hertwo negative breast cancer
__label__0	study interventions are Cyclophosphamide . metastatic melanoma diagnosis and note
__label__0	study interventions are Isophosphamide mustard . breast cancer diagnosis and not specified
__label__0	study interventions are Docetaxel . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and chest ct scan with or without contrast or ct pet that includes the chest with or without contrast either within eighty-four days prior to surgery or within one hundred and twenty days prior to registration note
__label__0	study interventions are Endothelial Growth Factors . stage iiia breast cancer diagnosis and eastern cooperative oncology group ecog performance status zero one
__label__0	study interventions are Paclitaxel . ovarian cancer diagnosis and urine protein creatinine
__label__0	study interventions are Temozolomide . liver cancer diagnosis and sgpt less_than doc times uln
__label__0	study interventions are Gemcitabine . stage iii pancreatic cancer diagnosis and eastern cooperative oncology group ecog performance status ps zero one or two
__label__0	study interventions are Cetuximab . stage iv colon cancer diagnosis and nefazodone
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and age
__label__0	study interventions are Panobinostat . nasopharyngeal carcinoma lymphomas any ebv positive solid tumour diagnosis and negative pregnancy test urinary hcg at screening applicable to women of child bearing potential who are sexually active
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and patients who are seropositive because of hepatitis virus vaccine are eligible
__label__0	study interventions are Etoposide . relapsed refractory sarcomas diagnosis and patient must have no persistent toxicities from prior therapy greater_than or equal_than to grade two with the exception of hematologic indices hemoglobin wbc anc alc
__label__0	study interventions are Irinotecan . colon adenocarcinoma diagnosis and phase ii
__label__0	study interventions are Vidarabine . recurrent childhood lymphoblastic lymphoma diagnosis and must have received prior chemotherapy consolidation of chemotherapy by autografting prior to nonmyeloablative hct is permitted
__label__0	study interventions are Oxaliplatin . stage iv rectal cancer diagnosis and no prior operative ultrasound during resection of hepatic metastases
__label__0	study interventions are Vincristine . lymphoma diagnosis and bone marrow biopsy in cases where results influence the duration of chemotherapy only
__label__0	study interventions are MDV9300 . primary mediastinal large cell lymphoma diagnosis and for post autologous stem cell transplant asct patients salvage therapy plus asct just prior to mdvnine thousand, three hundred treatment must have resulted in pr or stable disease
__label__0	study interventions are Rituximab . stage iv mantle cell lymphoma diagnosis and male subject agrees to use an acceptable method for contraception for the duration of the study
__label__0	study interventions are Vaccines . breast cancer diagnosis and bisphosphonates
__label__0	study interventions are MSC2490484A . solid tumors diagnosis and women of childbearing potential must have negative serum pregnancy test at the screening visit
__label__0	study interventions are Fluorodeoxyglucose F18 . use of an investigational anti cancer drug within twenty-eight days or five half lives whichever is shorter prior to the first dose of gsktwo million, one hundred and forty-one thousand, seven hundred and ninety-five
__label__0	study interventions are alvespimycin hydrochloride . stage iii melanoma diagnosis and no concurrent administration of any of the following herbal remedies
__label__0	study interventions are Antibodies, Monoclonal . metastatic squamous neck cancer with occult primary squamous cell carcinoma diagnosis and magnesium greater_than equal_than the lower limit of normal for the institution
__label__0	study interventions are Androgens . castration resistant prostate cancer diagnosis and no prior radiotherapy twenty-five or more of the bone marrow
__label__0	study interventions are Irinotecan . should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__0	study interventions are Docetaxel . unresectable or metastatic histologically confirmed adenocarcinoma of the stomach gastro oesophageal junction or lower third of the oesophagus with measurable disease on ct scanning see recist criteria appendix of the protocol for definition of measureable disease
__label__0	study interventions are Citric Acid . stage iiia breast cancer diagnosis and chromogenic in situ hybridization cish is performed the result must indicate hertwo gene copy number of less_than six per nucleus or
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent childhood anaplastic astrocytoma diagnosis and partial thromboplastin time ptt less_than doc institutional upper limits of normal
__label__0	study interventions are Antibodies, Monoclonal . stage iib fallopian tube cancer diagnosis and bilirubin less than or equal to doc uln
__label__0	study interventions are Immunoglobulins . cutaneous cell non hodgkin lymphoma diagnosis and doc mg dl for male patients age greater_than equal_than sixteen years
__label__0	study interventions are Metronidazole . stage iv primary peritoneal cavity cancer diagnosis and patient or legal representative must understand the investigational nature of this study and sign an independent ethics committee institutional review board approved written informed consent form prior to receiving any study related procedure
__label__0	study interventions are Tamoxifen . stage iv breast cancer diagnosis and patients who have not fully recovered from acute reversible effects of prior therapy regardless of interval since last treatment are not eligible to participate in this study
__label__0	study interventions are Melphalan . childhood immunoblastic large cell lymphoma diagnosis and donors who have poor peripheral venous access may require central venous line placement for stem cell apheresis
__label__0	study interventions are Immunoglobulins . stage iv midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and no clinically significant peripheral artery disease
__label__0	study interventions are Epacadostat . stage iiia ovarian cancer diagnosis and patients must be willing and able to undergo ascites fluid collection pr negative and post study treatment if adequate ascites is present patients without adequate ascites may also participate in the trial
__label__0	study interventions are Cyclosporine . stage iii grade one follicular lymphoma diagnosis and patients should have extinguished standard of care options prior to being considered eligible for this trial
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and histologically confirmed nsclc
__label__0	study interventions are Cetuximab . stage ivb salivary gland cancer diagnosis and fasting serum cholesterol less_than three hundred and fifty mg l and triglycerides less_than four hundred mg l
__label__0	study interventions are Dacarbazine . neuroectodermal tumor diagnosis and at least seven days must have elapsed since completion of therapy with biologic agent
__label__0	study interventions are Vaccines . prostate cancer diagnosis and no indication or resistance to irradiation and or surgery
__label__0	study interventions are Carboplatin . prostate adenocarcinoma diagnosis and must have pre study psa within twenty-eight days prior to registration note
__label__0	study interventions are Albumin-Bound Paclitaxel . ihc must be performed and the ihc staining results must indicate score of one positive in situ hybridization ish testing is not required or two positive ish must also be performed and must indicate that the tumor is hertwo low as described below
__label__0	study interventions are Pembrolizumab . stage ia breast cancer diagnosis and site must verify that there is no known change in the step one eligibility since initial registration
__label__0	study interventions are Antibodies . childhood immunoblastic large cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Methylprednisolone . childhood nasal type extranodal nk cell lymphoma diagnosis and md negative intermediate two or high ipss score
__label__0	study interventions are Docetaxel . lung cancer diagnosis and phase patients
__label__0	study interventions are Levoleucovorin . pancreatic cancer diagnosis and platelet count equal to or greater than fifty zero mm three
__label__0	study interventions are Belinostat . follicular lymphoma diagnosis and total bilirubin less_than two institutional upper limit of normal
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and must have completed first randomization therapy without disease progression
__label__0	study interventions are Allopurinol . lymphoblastic lymphoma diagnosis and patients in crtwo prtwo with initial short remission less_than six months are eligible
__label__0	study interventions are Aldesleukin . lymphoma diagnosis and granulocyte count at least one five hundred mm three
__label__0	study interventions are Dacarbazine . cancer diagnosis and women of child bearing potential must have negative pregnancy test within fourteen days prior to the first dose of study treatment
__label__0	study interventions are Liposomal doxorubicin . childhood nasal type extranodal nk cell lymphoma diagnosis and karnofsky greater_than equal_than fifty for patients greater_than sixteen years of age and lansky greater_than equal_than fifty for patients equal_than less_than sixteen years of age
__label__0	study interventions are Sirolimus . ovarian clear cell cystadenocarcinoma diagnosis and partial thromboplastin time ptt less_than doc times the upper limit of normal
__label__0	study interventions are Leucovorin . carcinoma squamous cell of head and neck diagnosis and scchn patients who are candidates for definitive chemoradiation are not eligible to participate
__label__0	study interventions are Doxycycline . cutaneous cell lymphoma diagnosis and adequate hepatic function as determined by total bilirubin less_than doc uln unless known gilbert syndrome alanine transaminase alt and aspartate transaminase ast less_than doc uln
__label__0	study interventions are Antibodies, Monoclonal . recurrent adult brain tumor diagnosis and clinically significant peripheral vascular disease
__label__0	study interventions are Methylprednisolone Hemisuccinate . myelodysplastic myeloproliferative neoplasms diagnosis and negative serum pregnancy test
__label__0	study interventions are Etoposide . stage iv grade three follicular lymphoma diagnosis and breaks in bcl two via cytogenetic studies or
__label__0	study interventions are Antilymphocyte Serum . b cell lymphoma diagnosis and five six or six six related donor match or seven eight eight hla b drbone allele matched unrelated donor marrow and or pbsc donor match per current institutional guidelines related donors will be evaluated and collected per mt20one2 one4c unrelated donors will be identified and collected per usual procedures
__label__0	study interventions are Albumin-Bound Paclitaxel . cervical squamous cell carcinoma diagnosis and evidence of distant metastases
__label__0	study interventions are Immunoglobulins . stage grade two follicular lymphoma diagnosis and myelodysplastic mds myeloproliferative disorders
__label__0	study interventions are Tirapazamine . stage iva cervical cancer diagnosis and no new york heart association class iii iv heart failure
__label__0	study interventions are Gefitinib . mucinous adenocarcinoma of the rectum diagnosis and no other prior malignancy unless curatively treated and no evidence of recurrence
__label__0	study interventions are Dexamethasone acetate . multiple myeloma and plasma cell neoplasm diagnosis and less than eleven dl in men
__label__0	study interventions are Fluorouracil . stage ii squamous cell carcinoma of the nasopharynx diagnosis and absolute neutrophil count greater_than one five hundred mm³
__label__0	study interventions are Everolimus . stage iii endometrial carcinoma diagnosis and no hearing loss greater_than equal_than grade two from any cause
__label__0	study interventions are Etoposide phosphate . neuroectodermal tumor diagnosis and diseases
__label__0	study interventions are Gefitinib . adenosquamous cell lung cancer diagnosis and right lower lobe
__label__0	study interventions are Oxaliplatin . resectable pancreatic carcinoma diagnosis and sites must seek additional patient consent for the future use of specimens
__label__0	study interventions are becatecarin . colorectal cancer diagnosis and no prior radiotherapy to only site of measurable disease
__label__0	study interventions are Akt Inhibitor MK2206 . recurrent adult liver carcinoma diagnosis and creatinine within normal institutional limits or creatinine clearance greater_than equal_than sixty ml min
__label__0	study interventions are Mycophenolic Acid . stage iii marginal zone lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Iodine . thyroid cancer diagnosis and participants must be iodine one hundred and thirty-one refractory resistant as defined by at least one of the following
__label__0	study interventions are Thalidomide . intraocular lymphoma diagnosis and ecog performance status zero two karnofsky 6zero_1zerozero
__label__0	study interventions are Dexamethasone acetate . lymphoma extranodal nk cell diagnosis and transminaseless_than two times the normal value
__label__0	study interventions are Cyclosporine . lymphoma diagnosis and no concurrent serious illness
__label__0	study interventions are Fludarabine phosphate . melanoma diagnosis and turnstile ii
__label__0	study interventions are Everolimus . metastatic renal cell cancer diagnosis and provide written informed consent
__label__0	study interventions are multi-herbal agent ACAPHA . precancerous condition diagnosis and atypical sputum cells as determined by computer assisted image analysis
__label__0	study interventions are Endothelial Growth Factors . stage iiia fallopian tube cancer diagnosis and albumin greater than or equal to doc dl
__label__0	study interventions are Paclitaxel . ovarian cancer diagnosis and life expectancy of at least three months
__label__0	study interventions are Paclitaxel . unresectable gallbladder carcinoma diagnosis and arm cohort one
__label__0	study interventions are bowel obstruction management . small intestine cancer diagnosis and not specified
__label__0	study interventions are Calcifediol . melanoma diagnosis and during the project time period potential pregnancy of women volunteers would change the risk category of the participants and that is reportable event to unm hsc hrrc and the clinical trial office
__label__0	study interventions are Thiotepa . testicular germ cell tumor diagnosis and no concurrent chemotherapy except for dexamethasone for antiedema effects
__label__0	study interventions are Cetuximab . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and see disease characteristics
__label__0	study interventions are Niacinamide . stage iii rectal cancer diagnosis and diltiazem
__label__0	study interventions are Abiraterone Acetate . prostate neoplasms diagnosis and agrees to protocol defined use of effective contraception
__label__0	study interventions are Fludarabine phosphate . stage iv adult immunoblastic large cell lymphoma diagnosis and must have received previous myelosuppressive chemotherapy or hct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Oxaliplatin . curatively treated cervical carcinoma in situ
__label__0	study interventions are Levoleucovorin . myelodysplastic myeloproliferative neoplasms diagnosis and no major illness or organ failure
__label__0	study interventions are Doxorubicin . childhood fibrosarcoma diagnosis and non metastatic disease
__label__0	study interventions are Fludarabine phosphate . metastatic melanoma diagnosis and lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible
__label__0	study interventions are Liposomal doxorubicin . recurrent ovarian carcinoma diagnosis and the patient or legally authorized representative must provide study specific informed consent prior to study entry and for patients treated in the united_states authorization permitting release of personal health information
__label__0	study interventions are Rituximab . contiguous stage ii grade three follicular lymphoma diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least fifty miu ml within ten
__label__0	study interventions are Fludarabine phosphate . stage iv adult burkitt lymphoma diagnosis and permissible hla matching
__label__0	study interventions are Fludarabine . melanoma diagnosis and more than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen and patients toxicities must have recovered to grade one or less except for toxicities such as alopecia or vitiligo
__label__0	study interventions are Dexamethasone 21-phosphate . stage iib fallopian tube cancer diagnosis and partial thromboplastin time ptt less_than doc times the upper limit of normal heparin lovenox or alternative anticoagulants are acceptable
__label__0	study interventions are Doxorubicin . breast neoplasms diagnosis and patients who have failed neoadjuvant endocrine therapy will also be eligible
__label__0	study interventions are Albumin-Bound Paclitaxel . premenopausal or postmenopausal breast cancer patients with measurable or non measurable lesions who are candidates for chemotherapy
__label__0	study interventions are Cisplatin . transitional cell carcinoma of the bladder diagnosis and no active seizure or history of seizure disorder
__label__0	study interventions are Antibodies, Monoclonal . non hodgkin lymphoma diagnosis and absolute granulocyte count less_than five hundred mmthree
__label__0	study interventions are Ifosfamide . sarcoma diagnosis and has undergone diagnostic surgery within the past eight weeks
__label__0	study interventions are Levoleucovorin . stage ii rectal cancer diagnosis and patients with history of cerebrovascular accident cva transient ischemic attack tia at any time or myocardial infarction unstable angina within twelve months of study entry are not eligible
__label__0	study interventions are Maytansine . recurrent rhabdomyosarcoma diagnosis and note
__label__0	study interventions are Immunoglobulins . recurrent squamous cell carcinoma of the oropharynx diagnosis and no deep venous thrombosis
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and ecog performance status less_than two
__label__0	study interventions are Etoposide . childhood lymphocyte depleted classical hodgkin lymphoma diagnosis and creatinine clearance greater than forty ml min
__label__0	study interventions are Bevacizumab . stage iv renal cell cancer diagnosis and at least four weeks since prior chemotherapy for metastatic disease
__label__0	study interventions are Cyclin-Dependent Kinase Inhibitor Proteins . familial testicular germ cell tumor diagnosis and female subjects of childbearing potential must have negative pregnancy test at screening
__label__0	study interventions are Sirolimus . estrogen receptor er negative with positive lymph nodes er negative with negative nodes if tumor greater_than two cm er positive with positive lymph nodes and er positive with negative lymph nodes and tumor greater_than five cm
__label__0	study interventions are Methotrexate . lymphoma diagnosis and hematopoietic
__label__0	study interventions are Cortisol succinate . recurrent prostate carcinoma diagnosis and creatine
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and patients must qualify for neoadjuvant treatment
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent ovarian germ cell tumor diagnosis and no active graft versus host disease
__label__0	study interventions are Melphalan . liver neoplasm diagnosis and patients must not have an active infection
__label__0	study interventions are Therapeutic conventional surgery . invasive lobular breast carcinoma diagnosis and appropriate stage for protocol entry including no clinical evidence for distant metastases based upon the following minimum diagnostic workup
__label__0	study interventions are Lenvatinib . advanced cancer diagnosis and written informed consent prior to any study specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice
__label__0	study interventions are Freund's Adjuvant . stage iv melanoma diagnosis and willingness to return to mayo clinic institution for follow up
__label__0	study interventions are Cisplatin . cervical adenocarcinoma diagnosis and unplanned surgery
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and no concurrent radiotherapy
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and urine protein greater_than two hundred mg twenty-fourh
__label__0	study interventions are Sterotactic radiosurgery . stage iv peripheral primitive neuroectodermal tumor diagnosis and more than three months hematopoietic
__label__0	study interventions are laboratory biomarker analysis . lymphoma diagnosis and no untreated brain or meningeal metastases
__label__0	study interventions are Rituximab . primary effusion lymphoma
__label__0	study interventions are Fludarabine phosphate . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Cyclophosphamide . prostate cancer diagnosis and total bilirubin less_than doc upper limit of laboratory normal unless due to gilbert disease
__label__0	study interventions are Glycine . multiple myeloma diagnosis and women of childbearing potential must follow pregnancy testing requirements as outlined in the revlimid_rems program material
__label__0	study interventions are Surgical resection . carcinoma of parotid gland diagnosis and patients greater_than eighteen years old
__label__0	study interventions are Etoposide . cancer diagnosis and bilirubin less than doc mg dl
__label__0	study interventions are Etoposide . untreated childhood pineoblastoma diagnosis and serum creatinine equal_than less_than doc times upper limit of institutional normal for age or glomerular filtration rate gfr greater_than equal_than seventy ml min doc threem two or estimated gfr schwartz bedside that is greater_than ninety-nine ml min doc threem two
__label__0	study interventions are pharmacological study . stage iii renal cell cancer diagnosis and no left bundle_branch block
__label__0	study interventions are Lapatinib . head and neck cancer diagnosis and left ventricular ejection fraction lvef must be greater_than the lower limit of normal lln per institutional standards by either echocardiography or radionuclide based multiple gated acquisition muga
__label__0	study interventions are Immunoglobulins . melanoma in situ diagnosis and patient is able to comply with appointments including follow up appointments
__label__0	study interventions are Everolimus . stage multiple myeloma diagnosis and no other concurrent investigational agents
__label__0	study interventions are BB 1101 . refractory multiple myeloma diagnosis and known active infection requiring parenteral or oral anti infective treatment
__label__0	study interventions are Antilymphocyte Serum . multiple myeloma and plasma cell neoplasm diagnosis and age
__label__0	study interventions are Cetuximab . pancreatic cancer diagnosis and no uncontrolled serious medical or psychiatric illness
__label__0	study interventions are Trastuzumab . recurrent plasma cell myeloma diagnosis and note
__label__0	study interventions are Antibodies, Monoclonal . adenocarcinoma of the gastroesophageal junction diagnosis and pt inr equal_than less_than doc
__label__0	study interventions are Vincristine . mantle cell lymphoma diagnosis and contraindication for rituximab treatment
__label__0	study interventions are Exemestane . male breast carcinoma diagnosis and transaminases alanine aminotransferase alt aspartate aminotransferase ast equal_than less_than doc institutional upper limit normal
__label__0	study interventions are Camptothecin . primary peritoneal cavity cancer diagnosis and prior hormonal therapy allowed
__label__0	study interventions are questionnaire administration . stage rectal cancer diagnosis and clinical or radiological evidence of metastatic spread
__label__0	study interventions are Paclitaxel . primary peritoneal cavity cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Vaccines . colorectal cancer diagnosis and menopausal status
__label__0	study interventions are Fluorouracil . salivary gland squamous cell carcinoma diagnosis and creatinine clearance of greater_than equal_than sixty ml min creatinine clearance may be measured or calculated if calculating creatinine clearance use the cockroft gault formula
__label__0	study interventions are Endothelial Growth Factors . cervical squamous cell carcinoma not otherwise specified diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt less_than equal_than three uln ast and or alt equal_than less_than five uln for patients with liver involvement
__label__0	study interventions are Nivolumab . bronchioloalveolar carcinoma diagnosis and patients must not have known active hepatitis virus hbv or hepatitis virus hcv infection at time of registration patients with hbv or hcv that have an undetectable viral load or in the opinion of the treating investigator is well controlled are eligible
__label__0	study interventions are Dihematoporphyrin Ether . brain and central nervous system tumors diagnosis and bilirubin and lfts less than two times uln
__label__0	study interventions are Melphalan . lymphoma diagnosis and only if transformed to aml or mds
__label__0	study interventions are Ketoconazole . prostate cancer diagnosis and not specified hematopoietic
__label__0	study interventions are Interferons . melanoma skin diagnosis and no prior mart one
__label__0	study interventions are Antibodies . stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Doxorubicin . diffuse large cell lymphoma dlbcl diagnosis and concurrent malignancy
__label__0	study interventions are Cyclin-Dependent Kinase Inhibitor Proteins . recurrent melanoma diagnosis and for subjects with liver metastases
__label__0	study interventions are Thiotepa . non hodgkins lymphoma diagnosis and patients with excess blasts less than or equal to ten blasts in the bone marrow at work up
__label__0	study interventions are Tacrolimus . recurrent grade one follicular lymphoma diagnosis and chronic myeloid leukemia cml in accelerated phase ap
__label__0	study interventions are Vincristine . lymphoblastic lymphoma diagnosis and age eighteen fifty-five yrs
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and note
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv endometrial carcinoma diagnosis and no abdominal fistula gi perforation or intra abdominal abscess within the past six months
__label__0	study interventions are DDP . esophageal squamous cell carcinoma diagnosis and presence of at least one index lesion measurable by ct scan or mri according to recist doc
__label__0	study interventions are Capecitabine . advanced gastric carcinoma diagnosis and kps greater_than seventy
__label__0	study interventions are Doxorubicin . localized resectable neuroblastoma diagnosis and no known contraindication to peripheral blood stem cell pbsc collection examples of contraindications might be weight or size less than the collecting institution finds feasible or physical condition that would limit the ability of the child to undergo apheresis catheter placement if necessary and or the apheresis procedure
__label__0	study interventions are Interferons . histologically confirmed high grade osteosarcoma including second malignancies
__label__0	study interventions are Immunoglobulins . adult anaplastic astrocytoma diagnosis and concurrent dexamethasone allowed provided patient is on stable dose for greater_than equal_than one week prior to study entry
__label__0	study interventions are Cyclosporine . refractory hodgkin lymphoma diagnosis and if two cb units are used the total cell dose of the combined units must be at least doc ten seven tnc per kilogram recipient weight based on pre cryopreservation numbers with each cb unit containing minimum of doc ten seven tnc kg
__label__0	study interventions are Immunoglobulin G . recurrent non small cell lung carcinoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Analgesics, Opioid . lymphoma diagnosis and concurrent tricyclic_antidepressants nonsteroidal antiinflammatory drugs nsaids anticonvulsants or other adjuvant analgesics or psychostimulants allowed provided therapy was initiated greater_than two weeks ago
__label__0	study interventions are Everolimus . recurrent osteosarcoma diagnosis and fasting triglycerides equal_than less_than three hundred mg dl patients with neutropenia on familial basis may still be enrolled on study please contact the pi who will discuss the patient with ctep
__label__0	study interventions are Cyclophosphamide . triple negative breast neoplasms diagnosis and er pr positive is defined as greater_than one stained cells and hertwo positive is defined as ihc three positive or in situ hybridisation ish ratio greater_than doc
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and no prior chemotherapy
__label__0	study interventions are Capecitabine . breast cancer diagnosis and no psychologic disorder
__label__0	study interventions are Vaccines . head and neck cancer diagnosis and biologic therapy
__label__0	study interventions are Tacrolimus . stage iv mantle cell lymphoma diagnosis and rapid doubling of wbc less_than five days
__label__0	study interventions are Pancreatin . pancreatic cancer diagnosis and greater than one hundred and eighty degrees sma or celiac encasement or unreconstructible smv portal occlusion or aortic invasion
__label__0	study interventions are Recombinant Human Interleukin-15 . stage iv skin melanoma diagnosis and no history of pulmonary disease such as emphysema or chronic obstructive pulmonary disease copd forced expiratory volume in one second fevone greater_than twol or greater_than equal_than fifty of predicted for height and age pulmonary function tests pfts are required in patients with significant pulmonary or smoking history
__label__0	study interventions are targeted fusion protein therapy . anaplastic astrocytoma diagnosis and no patients who are receiving any concurrent chemotherapy or any other investigational agent corticosteroids are permitted
__label__0	study interventions are Melphalan . lymphoma diagnosis and must have an indication for autologous stem cell transplantation
__label__0	study interventions are Cyclophosphamide . recurrent adult burkitt lymphoma diagnosis and no previous radiation history that negates the ability to safely receive two gy of tbi as determined by the radiation oncologist and the study co investigator responsible for the patient
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and life expectancy
__label__0	study interventions are ispinesib . recurrent childhood brain stem glioma diagnosis and itraconazole
__label__0	study interventions are Metronidazole . lung cancer diagnosis and able to avoid close household contact with the following individuals for at least three weeks after vaccinia vaccination
__label__0	study interventions are Liposomal doxorubicin . multiple myeloma and plasma cell neoplasm diagnosis and accelerated phase with treatment failure after imatinib mesylate
__label__0	study interventions are Palbociclib . metastatic breast cancer mbc diagnosis and hertwo normal ihc zero one fish less_than doc
__label__0	study interventions are Dactinomycin . stage iii wilms tumor diagnosis and patients transferring from arenthreebtwo with loh onep and one6q allowed
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ib gastric cancer diagnosis and note
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and not specified hepatic
__label__0	study interventions are Interferons . pleural mesothelioma diagnosis and must have ecog performance status of two
__label__0	study interventions are Mitoxantrone . lymphoma diagnosis and patients will be previously untreated
__label__0	study interventions are Cyclosporins . refractory multiple myeloma diagnosis and all patients with mds will be eligible for this protocol however those patients with mds and frank aml greater_than thirty blasts in bone marrow aspirate by morphology or flow cytometry will require induction chemotherapy to obtain complete remission marrow blasts less_than five and remain in complete remission at time of transplant
__label__0	study interventions are Vorinostat . stage iii adult diffuse mixed cell lymphoma diagnosis and myelodysplastic syndromes at any of the following stages
__label__0	study interventions are Antibodies, Monoclonal . recurrent childhood pineoblastoma diagnosis and biologic anti neoplastic agent
__label__0	study interventions are Carmustine . stage iii mantle cell lymphoma diagnosis and within three weeks prior to start of trial
__label__0	study interventions are Rituximab . aids related lymphoma diagnosis and anc greater than or equal one thousand mm three
__label__0	study interventions are Interleukin-12 . recurrent breast cancer diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Fosbretabulin . platinum resistant ovarian cancer diagnosis and ecog ps of zero one
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma and plasma cell neoplasm diagnosis and ast less than doc times upper limit of normal
__label__0	study interventions are Camptothecin . stage ivb colon cancer diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than two uln
__label__0	study interventions are Dasatinib . hodgkin lymphoma diagnosis and performance status greater_than equal_than sixty
__label__0	study interventions are Leucovorin . stage iiia gastric cancer diagnosis and note
__label__0	study interventions are Liposomal doxorubicin . small intestine lymphoma diagnosis and shortening fraction of greater_than equal_than twenty-seven by echocardiogram or ejection fraction of greater_than equal_than fifty by gated radionuclide study
__label__0	study interventions are Irinotecan . signet ring adenocarcinoma of the colon diagnosis and no active brain metastasis previously surgically treated or irradiated lesions are allowed if not clinically active
__label__0	study interventions are educational intervention . stage iiia uterine sarcoma diagnosis and living within fifty mile_radius of the city of hope
__label__0	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the nasopharynx diagnosis and active peptic ulcer disease
__label__0	study interventions are Cisplatin . ovary neoplasms diagnosis and hepatic function
__label__0	study interventions are Gemcitabine . histologically confirmed metastatic recurrent or unresectable locally advanced solid tumor including one of the following
__label__0	study interventions are Niacinamide . adenocarcinoma diagnosis and child pugh class a
__label__0	study interventions are Thalidomide . recurrent small lymphocytic lymphoma diagnosis and previously untreated disease and refuse or are ineligible for approved chem negative and or immunotherapy options for untreated cll sll pll
__label__0	study interventions are Fludarabine phosphate . recurrent grade one follicular lymphoma diagnosis and hematopoietic cell transplant comorbidity index hct ci score less_than four points for patients greater_than sixty years old or less_than five points for patients less_than sixty
__label__0	study interventions are MK-0752 . histologically confirmed primary cns tumor
__label__0	study interventions are Interferons . breast cancer diagnosis and at least three months since prior interferon alfa or interferon beta
__label__0	study interventions are Interleukin-2 . unspecified adult solid tumor protocol specific diagnosis and menopausal status
__label__0	study interventions are Capecitabine . histologically or cytologically confirmed adenocarcinoma of the colon or rectum
__label__0	study interventions are alvespimycin hydrochloride . recurrent colon cancer diagnosis and no clinically significant pulmonary comorbidity severe chronic obstructive pulmonary disease
__label__0	study interventions are Irinotecan . stage iv squamous cell carcinoma of the oropharynx diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are Carboplatin . brain and central nervous system tumors diagnosis and no prior chemotherapy
__label__0	study interventions are Fludarabine phosphate . patients with relapsed multiple myeloma following previous autologous stem cell transplant
__label__0	study interventions are Vivofit watch . stage ib pancreatic cancer diagnosis and able to read and understand english
__label__0	study interventions are Foscarnet . adult nasal type extranodal nk cell lymphoma diagnosis and hematologic malignancies disorders including aplastic anemia and myelodysplastic syndrome
__label__0	study interventions are Vaccines . solid tumors diagnosis and men that are sexually active with wocbp must follow instructions for birth control for period of ninety days plus the time required for the investigational drug to undergo five half lives sixty days
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and radiotherapy
__label__0	study interventions are Pembrolizumab . stage iii skin melanoma diagnosis and patients must in the opinion of the treating physician be candidates for intralesional administration into cutaneous subcutaneous or nodal lesions patients must have at least two injectable lesions
__label__0	study interventions are Radiopharmaceuticals . neuroendocrine tumors diagnosis and any full craniospinal radiation whether or not target lesion is included in the field must have occurred more than three months prior to study drug administration
__label__0	study interventions are Epothilones . histologically or cytologically confirmed solid tumor or lymphoma for which standard curative or palliative measures do not exist or are no longer effective
__label__0	study interventions are Metronidazole . stage ii pancreatic cancer diagnosis and myasthenia_gravis
__label__0	study interventions are Paclitaxel . recurrent ovarian cancer diagnosis and negative serum pregnancy test within seventy-two hours before starting study treatment in women with childbearing potential defined as sexually mature women who have not undergone hysterectomy or who have had amenorrhea for at least twelve consecutive months or women who have had six months of spontaneous amenorrhea with serum fsh levels greater_than forty miu ml and estradiol less_than twenty pg ml
__label__0	study interventions are Antibodies . metastatic cancer diagnosis and not specified
__label__0	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and adequate bone marrow function
__label__0	study interventions are Paclitaxel . recurrent fallopian tube cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Isophosphamide mustard . childhood nodular lymphocyte predominant hodgkin lymphoma diagnosis and no serious intercurrent illnesses
__label__0	study interventions are Liposomal doxorubicin . stage iiia breast cancer diagnosis and total bilirubin less_than upper limit of normal uln
__label__0	study interventions are Vitamin B 6 . lymphoma diagnosis and ps less_than two
__label__0	study interventions are Ethanol . clinically and histologically verified orl cancer required surgery
__label__0	study interventions are Mitomycins . carcinoma of the appendix diagnosis and alkaline phosphatase equal_than less_than three institutional upper limit of normal
__label__0	study interventions are BB 1101 . metastatic cancer diagnosis and new york heart association class ii iv congestive heart failure
__label__0	study interventions are Niacinamide . recurrent renal cell carcinoma diagnosis and urinary protein equal_than less_than one hundred mg dl in urinalysis or equal_than less_than one positive on dipstick unless quantitative protein is less_than one hundred0 mg in twenty-four urine sample
__label__0	study interventions are EVA-Online . breast cancer survivors diagnosis and treatment induced menopause due to at least one of the following treatment regimens
__label__0	study interventions are Bortezomib . stage iii multiple myeloma diagnosis and step i
__label__0	study interventions are BB 1101 . stage ii contiguous mantle cell lymphoma diagnosis and neutrophils greater_than one thousand ul
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and metastatic disease
__label__0	study interventions are Floxuridine . metastatic cancer diagnosis and anastomotic disease
__label__0	study interventions are Maytansine . wilms tumor diagnosis and radiotherapy
__label__0	study interventions are Virtual Reality Headset . cancer diagnosis and able to wear vr headset and move head in cervical rotation extension and flexion
__label__0	study interventions are Antibodies, Monoclonal . ovarian mucinous adenocarcinoma diagnosis and patients who have received prior anti programmed death one pd one or anti programmed death ligand one pd lone therapy are not eligible other immunotherapy is permitted
__label__0	study interventions are Vaccines . cancer of the prostate diagnosis and age eighteen years or older
__label__0	study interventions are Melphalan . sarcoma diagnosis and platelet count greater than one hundred and fifty zero mm three
__label__0	study interventions are Palbociclib . childhood ependymoblastoma diagnosis and patients should have received their last dose of biologic agent greater_than equal_than seven days prior to enrollment in the event the patient has received another biologic agent and has experienced greater_than equal_than grade two myelosuppression then at least three three weeks must have elapsed prior to enrollment if the investigational or biologic agent has prolonged half life then at least three three weeks interval is required
__label__0	study interventions are Aldesleukin . kidney cancer diagnosis and other
__label__0	study interventions are Gemcitabine . urethral cancer diagnosis and no hypertension not controlled by medical therapy systolic blood pressure greater_than one hundred and sixty mm hg or diastolic blood pressure greater_than one hundred mm hg
__label__0	study interventions are Paclitaxel . stage ii pancreatic cancer diagnosis and bilirubin less than doc mg dl
__label__0	study interventions are Antibodies, Bispecific . stage iiib fallopian tube cancer diagnosis and appropriate slides of the primary lesion will be available for future review if available hertwo neu positivity will be recorded
__label__0	study interventions are Vidarabine . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and minimum goal for peripheral blood stem cells pbsc dose is two ten six cdthirty-four positive cells kg of recipient weight minimum goal for the marrow dose is one ten eight nucleated cells kg of recipient weight
__label__0	study interventions are ziv-aflibercept . squamous cell carcinoma of the bladder diagnosis and bilirubin equal_than less_than doc times upper limit of normal uln
__label__0	study interventions are Arsenic trioxide . stage multiple myeloma diagnosis and prior steroid therapy allowed for patients with relapsed or refractory mm
__label__0	study interventions are Antibodies, Monoclonal . recovery from all reversible adverse events of previous anti cancer therapies to baseline or common terminology criteria for adverse events ctcae grade one except for alopecia any grade and less_than equal_than two sensory peripheral neuropathy
__label__0	study interventions are Paclitaxel . lymphoma diagnosis and over eighteen
__label__0	study interventions are Mycophenolic Acid . multiple myeloma and plasma cell neoplasm diagnosis and mantle cell
__label__0	study interventions are Tacrolimus . recurrent adult hodgkin lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Cyclosporine . stage iv small lymphocytic lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Celecoxib . lung cancer diagnosis and renal
__label__0	study interventions are Bortezomib . stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and radiographic findings are acceptable providing that clear cut measurement can be made
__label__0	study interventions are Cyclosporine . stage iii adult diffuse small cleaved cell lymphoma diagnosis and related or unrelated donors who are matched for hla drbone and dqbone alleles must be defined by high resolution typing and who are mismatched for
__label__0	study interventions are Interferons . lymphoma diagnosis and radiotherapy
__label__0	study interventions are Laser Interstitial Thermal Therapy . prostate cancer diagnosis and roi located proximal to the external sphincter by margin of at least two cm
__label__0	study interventions are laboratory biomarker analysis . recurrent adult diffuse large cell lymphoma diagnosis and pulmonary disease requiring medication
__label__0	study interventions are Antibodies, Monoclonal . melanoma diagnosis and wbc greater_than equal_than two thousand µl b
__label__0	study interventions are Albumin-Bound Paclitaxel . gastric cancer diagnosis and patients may not have received prior chemotherapy or immunotherapy regimen except in the adjuvant therapy that ended at least six months prior to registration on this study
__label__0	study interventions are Albumin-Bound Paclitaxel . histologically confirmed stage iii ovarian epithelial fallopian tube or primary peritoneal carcinoma
__label__0	study interventions are CAT-8015 . lymphoma diagnosis and measurable disease
__label__0	study interventions are Staurosporine . recurrent anal cancer diagnosis and no other concurrent investigational agents
__label__0	study interventions are Irinotecan . triple negative breast cancer diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Paclitaxel . squamous cell lung cancer diagnosis and other concurrent nonsteroidal anti inflammatory drugs allowed
__label__0	study interventions are BL-8040 . non hodgkin lymphoma diagnosis and female subjects must have negative urine or serum pregnancy test within ten days prior to taking study medication if of childbearing potential or must be of non childbearing potential
__label__0	study interventions are Antibodies . patients with pancreatic adenocarcinoma cytologically or histologically proven not suitable for potentially curative resection
__label__0	study interventions are Etoposide . recurrent adult cell leukemia lymphoma diagnosis and serum creatinine less_than doc mg dl
__label__0	study interventions are CX5461 . cancer diagnosis and exceptions may be made for low dose non myelosuppressive radiotherapy after consultation with cctg
__label__0	study interventions are Immunoglobulins . recurrent verrucous carcinoma of the larynx diagnosis and more than twenty-eight days since prior major surgery or open biopsy
__label__0	study interventions are Nivolumab . stage iv non small cell lung cancer diagnosis and serum creatinine equal_than less_than doc mg dl or creatinine clearance greater_than equal_than sixty ml min
__label__0	study interventions are conventional surgery . endometrial cancer diagnosis and must be fit to undergo lymphadenectomy and external beam radiotherapy
__label__0	study interventions are Decitabine . recurrent adult burkitt lymphoma diagnosis and platelets greater_than one hundred zero mm three
__label__0	study interventions are Antibodies, Monoclonal . histologic proof of epithelial cervical endometrial ovarian fallopian or primary peritoneal cancers allowable histologies for cervical cancer include squamous cell carcinoma adenocarcinoma and mixed adenosquamous carcinoma allowable histologies for endometrial cancer include endometrioid serous clear cell mucinous squamous transitional cell undifferentiated mixed and carcinosarcoma this is considered poorly differentiated epithelial tumor allowable histologies for ovarian fallopian and peritoneal cancer include serous clear cell endometrioid mucinous transitional cell undifferentiated mixed and carcinosarcoma
__label__0	study interventions are Bevacizumab . adenocarcinoma of the colon diagnosis and not pregnant or nursing
__label__0	study interventions are Fludarabine phosphate . lymphoma non hodgkin diagnosis and in general this encompasses all haematological disorders where volunteer unrelated donor transplant is clinically indicated
__label__0	study interventions are Amifostine . pleural mesothelioma diagnosis and ejection fraction greater_than forty-five
__label__0	study interventions are Fludarabine . small lymphocytic lymphoma diagnosis and fhcrc matching allowed will be grades doc to doc
__label__0	study interventions are Arsenic trioxide . multiple myeloma and plasma cell neoplasm diagnosis and no history of grand mal seizures other than infantile febrile seizures
__label__0	study interventions are temsirolimus . brain and central nervous system tumors diagnosis and sgot less than doc times uln
__label__0	study interventions are Capecitabine . ovarian neoplasms diagnosis and female participants should be of non child bearing potential either physiologic or by using adequate contraception have negative serum pregnancy test and refrain from breast feeding
__label__0	study interventions are Androgens . estrogen receptor negative neoplasm diagnosis and adequate organ and marrow function as defined below
__label__0	study interventions are Temozolomide . melanoma diagnosis and life expectancy of greater than six months
__label__0	study interventions are Antibodies . noncontiguous stage ii grade two follicular lymphoma diagnosis and any combination of two hla b or alleles if prospectively typed at molecular level
__label__0	study interventions are Docetaxel . stage iiia non small cell lung cancer diagnosis and urine protein
__label__0	study interventions are Mitogens . stage iiia breast cancer diagnosis and hertwo positive disease defined as immunohistochemistry ihc three positive or amplification by fluorescent in situ hybridization fish hertwo chromosome seventeen centromere cepseventeen ratio greater_than equal_than two or an average of greater_than equal_than six hertwo gene copies per nucleus confirmed by central pathology review mayo clinic rochester prior to patient being registered to begin protocol therapy
__label__0	study interventions are Mycophenolate mofetil . recurrent childhood lymphoblastic lymphoma diagnosis and life threatening cytopenia and or red cell or platelet transfusion dependence
__label__0	study interventions are Androgens . adenocarcinoma of the prostate diagnosis and initiation of androgen ablation of less than eight weeks duration prior to study entry is permitted
__label__0	study interventions are Celecoxib . breast cancer diagnosis and see disease characteristics
__label__0	study interventions are Sorafenib . head and neck cancer diagnosis and coagulation
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and ast and alt less_than five times upper limit of normal uln
__label__0	study interventions are Etoposide phosphate . iv disease and must be entered within eight weeks from surgery they may have either measurable residual disease by response evaluation criteria in solid tumors recist criteria or they may have no measurable residual disease or they must have biopsy proven recurrent disease of any stage and have never received cytotoxic chemotherapy
__label__0	study interventions are Magnetic Resonance Imaging (MRI) . prostate cancer diagnosis and performance status
__label__0	study interventions are pazopanib hydrochloride . metastatic childhood soft tissue sarcoma diagnosis and at least three months since prior total body irradiation craniospinal radiotherapy or greater_than fifty radiotherapy to the pelvis
__label__0	study interventions are Pirfenidone . precancerous condition diagnosis and negative pregnancy test
__label__0	study interventions are Albumin-Bound Paclitaxel . fallopian tube cancer diagnosis and no medical or social factors that would interfere with compliance not pregnant or nursing negative pregnancy test fertile patients must use effective contraception no serious concurrent illness requiring immediate therapy
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and females of childbearing potential must have two negative pregnancy tests prior to starting study drug
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and urine protein greater_than two hundred mg twenty-fourh
__label__0	study interventions are Fludarabine . recurrent grade two follicular lymphoma diagnosis and acute leukemia in onest or twond cr
__label__0	study interventions are Nivolumab . nasal cavity adenocarcinoma diagnosis and platelets greater_than equal_than seventy-five zero mcl
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and amyloidosis
__label__0	study interventions are Antibodies, Monoclonal . adult grade ii meningioma diagnosis and no history of stroke or transient ischemic attack
__label__0	study interventions are THEYA Recovery Range . breast cancer diagnosis and as this cohort are the principal users of post surgery bras
__label__0	study interventions are polymerase chain reaction . diagnosis of hodgkin lymphoma hl meeting the following criteria
__label__0	study interventions are Intraoperative radiofrequency ablation . uterine myoma diagnosis and desire for uterine preservation
__label__0	study interventions are Vinblastine . adult mixed cellularity hodgkin lymphoma diagnosis and concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic reactions
__label__0	study interventions are Vidarabine . stage iii mantle cell lymphoma diagnosis and mantle cell nh negative may be treated in first cr
__label__0	study interventions are Cetuximab . stage iii salivary gland cancer diagnosis and poorly controlled hypertension systolic blood pressure bp greater_than one hundred and forty mm hg or diastolic bp greater_than ninety mm hg
__label__0	study interventions are Isophosphamide mustard . lymphoma diagnosis and hepatic
__label__0	study interventions are Vidarabine . intraocular lymphoma diagnosis and donor must consent to filgrastim csf administration and leukapheresis
__label__0	study interventions are Melphalan . multiple myeloma and plasma cell neoplasm diagnosis and in first or second chronic phase or accelerated phase
__label__0	study interventions are Mycophenolate mofetil . follicular lymphoma diagnosis and patients less_than twenty-one years however are eligible with mtwo marrow with less_than two5 blasts in marrow after having failed one or more cycles of chemotherapy
__label__0	study interventions are Carmustine . brain and central nervous system tumors diagnosis and not specified
__label__0	study interventions are Doxorubicin . lymphoma cell diagnosis and at least one bi_dimensionally measurable lesion defined as greater_than doc cm in its largest dimension by ct scan
__label__0	study interventions are Vaccines . stage iv melanoma diagnosis and note
__label__0	study interventions are Cetuximab . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Cyclophosphamide . sarcoma diagnosis and clinically normal pulmonary function
__label__0	study interventions are psychosocial assessment and care . brain and central nervous system tumors diagnosis and confirmed late stage disease refractory to standard primary therapy
__label__0	study interventions are Mycophenolic Acid . multiple myeloma and plasma cell neoplasm diagnosis and age
__label__0	study interventions are Fludarabine . splenic marginal zone lymphoma diagnosis and chronic myelogenous leukemia cml
__label__0	study interventions are Bevacizumab . patients may have receive prior radiation therapy for treatment of endometrial carcinoma prior radiation therapy may have included pelvic radiation therapy extended field pelvic para aortic radiation therapy and or intravaginal brachytherapy all radiation therapy must be completed at least four weeks prior to the first date of study therapy the prior radiation field radiation dose number of fractions and prior radiation start and stop dates must be provided on the fast fact sheet ffs at registration
__label__0	study interventions are CT Scans . lung cancer diagnosis and has normal coagulation profile
__label__0	study interventions are Antibodies, Monoclonal . malignant mesothelioma diagnosis and adequate hematologic hepatic and renal function
__label__0	study interventions are Thalidomide . stage ii multiple myeloma diagnosis and upep on twenty-four hour collection is required no substitute method is acceptable urine must be followed monthly if the baseline urine spike is greater_than equal_than two hundred mg twenty-four hr please note that if both serum and urine components are present both must be followed in order to evaluate response
__label__0	study interventions are Lenograstim . prostate cancer diagnosis and disease characteristics
__label__0	study interventions are Immunoglobulins . adenocarcinoma of the lung diagnosis and patients must be willing to provide prior smoking history as required on the sfive hundred and thirty-six prestudy form form fifty-four thousand, six hundred and fifty-five
__label__0	study interventions are Lapatinib . ovarian cancer diagnosis and no concurrent participation in another study involving pharmacologic agent drugs biologics immunotherapy gene therapy for symptom control or therapeutic intent
__label__0	study interventions are Mycophenolic Acid . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Hormones . breast cancer stage iv diagnosis and if biopsy requires general anesthesia then biopsy of that site for research purposes only without coexisting clinical indication is not allowed on this protocol
__label__0	study interventions are Trastuzumab . confirmed diagnosis of metastatic breast cancer bc with hertwo neu overexpression
__label__0	study interventions are Prednisone . metastatic prostate cancer diagnosis and patients must agree to use adequate contraception abstinence hormonal or barrier method of birth control prior to the study during the study and at least six months after completion
__label__0	study interventions are Dacarbazine . astrocytoma grade iv diagnosis and age between eighteen and seventy years of age
__label__0	study interventions are Paclitaxel . stage iiib ovarian cancer diagnosis and patients must be entered between one and one2 weeks after initial surgery performed for the combined purpose of diagnosis staging and cytoreduction
__label__0	study interventions are Topotecan . recurrent extragonadal non seminomatous germ cell tumor diagnosis and dlco greater_than fifty predicted
__label__0	study interventions are Nelfinavir . head and neck neoplasms diagnosis and ecog performance status zero two karnofsky greater_than 5zero see appendix a
__label__0	study interventions are Gemcitabine . colon cancer diagnosis and age greater than or equal to eighteen years
__label__0	study interventions are Calcium, Dietary . colorectal cancer diagnosis and one hundred zero mmthree
__label__0	study interventions are No Media . infiltrating ductal carcinoma
__label__0	study interventions are Vismodegib . adult extraskeletal myxoid chondrosarcoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Irinotecan . metastatic colorectal cancer diagnosis and seventy-five years
__label__0	study interventions are Rituximab . stage grade one follicular lymphoma diagnosis and no more than three prior treatments for disease not including steroids alone
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and abdominal and pelvic ct scans and chest ct or ray within six weeks prior to registration
__label__0	study interventions are Stereotactic Radiosurgery . localized non resectable adult liver carcinoma diagnosis and hcc diagnosed by either of the following approaches
__label__0	study interventions are Cisplatin . squamous cell lung cancer diagnosis and histologic or cytologic diagnosis of nthree lymph node involvement or
__label__0	study interventions are Vincristine . metastatic malignant neoplasm in the bone diagnosis and for the purpose of this study metastatic disease is defined as one or more of the following
__label__0	study interventions are Albumin-Bound Paclitaxel . prior therapy with carboplatin and or paclitaxel allowed provided the patient has no persistent related toxicity greater_than equal_than grade one and retreatment with the combination is clinically indicated second line therapy for ovarian cancer with greater_than six month treatment free interval
__label__0	study interventions are Cetuximab . breast cancer diagnosis and not specified
__label__0	study interventions are Dihematoporphyrin Ether . cholangiocarcinoma of the gallbladder diagnosis and no clinically significant acute or chronic medial or psychological illness that would preclude study treatment
__label__0	study interventions are Cytarabine . cognitive side effects of cancer therapy diagnosis and organ function requirements for patients with ph like all and predicted tki sensitive mutation patients identified as ph like with dasatinib sensitive kinase mutation must have assessment of organ function performed within three days of study entry to be eligible for the dasatinib arm of aall11three1
__label__0	study interventions are Ifosfamide . ovarian yolk_sac tumor diagnosis and alt less_than doc times uln for age
__label__0	study interventions are HSV1716 . non cns solid tumors diagnosis and subject must have one three lesions amenable to hsvone7one6 administration by needle if superficial by needle and or catheter if deep or pulmonary via interventional radiology without undue risk
__label__0	study interventions are Cyclosporins . childhood diffuse large cell lymphoma diagnosis and one two
__label__0	study interventions are Etoposide . stage iii marginal zone lymphoma diagnosis and karnofsky performance status greater_than equal_than seventy
__label__0	study interventions are Busulfan . multiple myeloma and plasma cell neoplasm diagnosis and performance status
__label__0	study interventions are Azacitidine . stage iii grade three follicular lymphoma diagnosis and clinically or radiologically documented disease
__label__0	study interventions are Dacarbazine . childhood high grade cerebellar astrocytoma diagnosis and life expectancy greater_than eight weeks
__label__0	study interventions are Tacrolimus . lymphoma diagnosis and in first remission with poor prognosis cytogenetics five fiveq seven sevenq and greater_than two cytogenetic abnormalities six nine nine eleven or philadelphia_chromosome
__label__0	study interventions are Prednisolone hemisuccinate . lymphoma diagnosis and prior corticosteroids for up to one week allowed for the relief of local compressive symptoms
__label__0	study interventions are Flutamide . stage iii prostate cancer diagnosis and hepatic
__label__0	study interventions are survey administration . lymphoma diagnosis and no substitutions are permitted once this decision has been made
__label__0	study interventions are Liposomal doxorubicin . recurrent fallopian tube carcinoma diagnosis and myocardial infarction or unstable angina within six months of the first date of treatment on this study
__label__0	study interventions are Dexamethasone . childhood atypical_teratoid rhabdoid tumor diagnosis and fertile patients must use effective double method contraception one highly effective method and one additional effective method for greater_than four weeks before during and for greater_than twelve months after completion of study treatment
__label__0	study interventions are Cyclosporins . stage mantle cell lymphoma diagnosis and must have less_than five blasts at the time of transplant
__label__0	study interventions are Sunitinib . metastatic renal cell carcinoma diagnosis and advanced not amenable to curative surgery or radiation therapy or metastatic ajcc stage iv rcc
__label__0	study interventions are Radium 223 . prostate cancer diagnosis and creatinine less_than doc uln
__label__0	study interventions are Temozolomide . ependymoma diagnosis and the dose must be in stable range or decreasing for at least fourteen days
__label__0	study interventions are Dexrazoxane . recurrent childhood lymphoblastic lymphoma diagnosis and stratum two mixed lineage leukemia mll positive leukemia
__label__0	study interventions are Cabozantinib S-malate . recurrent childhood central nervous system neoplasm diagnosis and two to less_than six years
__label__0	study interventions are Thalidomide . neuroectodermal tumors primitive diagnosis and patient or legally authorized representative must be able to understand and willing to sign written informed consent document
__label__0	study interventions are Bevacizumab . lung cancer diagnosis and no concurrent therapeutic anticoagulation group one
__label__0	study interventions are Camptothecin . gastric cancer diagnosis and platelet count one hundred zero mmthree
__label__0	study interventions are biological therapy . merkel cell carcinoma diagnosis and metastatic disease
__label__0	study interventions are Trastuzumab . estrogen receptor er progesterone receptor pr and hertwo neu status documented by core needle biopsy of the primary tumor and or regional lymph node must be known prior to beginning systemic therapy
__label__0	study interventions are Tipifarnib . recurrent childhood medulloblastoma diagnosis and danazol
__label__0	study interventions are Melphalan . islet cell tumor diagnosis and pt no greater than two seconds above upper limit of normal
__label__0	study interventions are Carboplatin . breast cancer diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are Dactinomycin . sarcoma diagnosis and stage ii clinical group ii nzero nx
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and those associated with mds complex karyotype greater_than three abnormalities any of the following
__label__0	study interventions are Prednisolone . unspecified childhood solid tumor protocol specific diagnosis and not specified
__label__0	study interventions are Topotecan . unspecified adult solid tumor protocol specific diagnosis and disease characteristics
__label__0	study interventions are Histone Deacetylase Inhibitors . stage ii papillary thyroid cancer diagnosis and no history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drug
__label__0	study interventions are Antibodies . childhood immunoblastic large cell lymphoma diagnosis and waldenstrom macroglobulinemia
__label__0	study interventions are 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide . unspecified adult solid tumor protocol specific diagnosis and bilirubin normal ast and alt less than doc times upper limit of normal renal
__label__0	study interventions are Vidarabine . recurrent childhood small noncleaved cell lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Fludarabine . adult solid neoplasm diagnosis and platelets greater_than equal_than one hundred ten nine l
__label__0	study interventions are Interferon-alpha . lymphoma diagnosis and other concurrent antiretroviral therapy for hiv hepatitis or hepatitis infection or other indication allowed at investigator discretion for patients receiving therapy prior to study initiation
__label__0	study interventions are Cetuximab . stage iii midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and uncontrolled hypertension blood pressure greater_than one hundred and fifty eighty-five mm hg despite medication
__label__0	study interventions are Bevacizumab . stage iiia primary peritoneal cancer diagnosis and patients in this trial may receive ovarian estrogen positive
__label__0	study interventions are Testosterone . unspecified adult solid tumor protocol specific diagnosis and prior concurrent therapy
__label__0	study interventions are Antibodies . histologically or cytologically confirmed pancreatic adenocarcinoma
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and patient characteristics
__label__0	study interventions are Fludarabine . recurrent adult diffuse mixed cell lymphoma diagnosis and no previous radiation history that negates the ability to safely receive two gy of tbi as determined by the radiation oncologist and the study co investigator responsible for the patient
__label__0	study interventions are Antibodies . recurrent mantle cell lymphoma diagnosis and note
__label__0	study interventions are Everolimus . mantle cell lymphoma diagnosis and received at least one prior rituximab containing chemotherapy regimen separate lines of therapy are defined as single or combination therapies that are either separated by disease progression or by greater_than six month treatment free interval
__label__0	study interventions are Topotecan . rhabdomyosarcoma diagnosis and patients with second malignancy following previous therapy will be excluded
__label__0	study interventions are Tacrolimus . noncontiguous stage ii small lymphocytic lymphoma diagnosis and first complete remission crone confirmed
__label__0	study interventions are Mycophenolic Acid . recurrent diffuse large cell lymphoma diagnosis and acute lymphoblastic leukemia in high risk first complete remission crone as defined by at least one of the following
__label__0	study interventions are Fludarabine . ovarian cancer diagnosis and aspartate aminotransferase ast alanine transaminase alt total bilirubin alkaline phosphatase less_than five times upper limit of institutional normal uln
__label__0	study interventions are Cyclosporine . lymphoma non hodgkin diagnosis and doc
__label__0	study interventions are Antibodies . gastric cancer diagnosis and absolute neutrophil count anc greater_than one thousand, five hundred mmthree platelet count greater_than one hundred one hundred and nine hemoglobin greater_than nine dl
__label__0	study interventions are Asparaginase . cognitive side effects of cancer therapy diagnosis and age one three doc nine years
__label__0	study interventions are alvespimycin hydrochloride . recurrent squamous cell carcinoma of the nasopharynx diagnosis and wbc greater_than equal_than three zero mm three
__label__0	study interventions are Decitabine . stage ivc papillary thyroid cancer diagnosis and more than eighteen months since prior cumulative one hundred and thirty-onei activity of at least five hundred mci
__label__0	study interventions are Cyclophosphamide . stage iva pancreatic cancer diagnosis and if female of child bearing potential have negative pregnancy test equal_than less_than fourteen days prior to registration
__label__0	study interventions are Dexamethasone . lymphoma non hodgkin diagnosis and stratum ii
__label__0	study interventions are Goserelin . stage iib prostate cancer diagnosis and patients cannot have evidence of immunosuppression
__label__0	study interventions are microarray analysis . colorectal cancer diagnosis and patients do not need to be receiving protocol therapy
__label__0	study interventions are Interferons . carcinoma in situ diagnosis and patients must have no evidence of muscle invasive disease
__label__0	study interventions are Endothelial Growth Factors . stage ivc laryngeal squamous cell carcinoma diagnosis and patients who refuse radical resection for recurrent disease are eligible note
__label__0	study interventions are Vaccines . unspecified adult solid tumor protocol specific diagnosis and patients must have recovered from the reversible side effects of prior therapy
__label__0	study interventions are Camptothecin . neuroendocrine neoplasm diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional upper limit of normal equal_than less_than five upper limit of normal uln is acceptable if liver metastases are present
__label__0	study interventions are radiation therapy . squamous cell or undifferentiated carcinoma
__label__0	study interventions are Dexamethasone acetate . lymphoma diagnosis and see disease characteristics hepatic
__label__0	study interventions are Interferons . stage multiple myeloma diagnosis and patient must be less than seventy years old
__label__0	study interventions are Mycophenolic Acid . recurrent adult cell leukemia lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Pembrolizumab . ovarian neoplasms diagnosis and has received front line platinum based regimen administered via either intravenous or intraperitoneal route per local standard of care or treatment guideline following the primary or interval debulking surgery with documented disease recurrence note
__label__0	study interventions are Iodine . lymphoma diagnosis and hematopoietic
__label__0	study interventions are Celecoxib . recurrent non small cell lung cancer diagnosis and subjects who require treatment with fluconazole or lithium
__label__0	study interventions are Low-dose computed tomography Annual scan x3 . mesothelioma diagnosis and age fifty
__label__0	study interventions are Oophorectomy . premenopausal women with documented deleterious mutation in one of the following eleven eleven ovarian cancer genes
__label__0	study interventions are Sorafenib . patients with non medullary thyroid carcinoma
__label__0	study interventions are Mitogens . stage iii adult hodgkin lymphoma diagnosis and able and willing to give informed consent
__label__0	study interventions are hMN14 (labetuzumab) . colorectal neoplasms diagnosis and cardiovascular
__label__0	study interventions are Carmustine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and hodgkin disease hl
__label__0	study interventions are Bevacizumab . head and neck cancer diagnosis and patients with known hypersensitivity of chinese_hamster ovary cell products or other recombinant human antibodies
__label__0	study interventions are Cyclosporins . stage iii multiple myeloma diagnosis and the patient must have the capacity to give informed consent
__label__0	study interventions are IC+CCRT . malignant neoplasm of other specified site of nasopharynx diagnosis and with complete medical records
__label__0	study interventions are BB 1101 . plasma cell neoplasm diagnosis and prior concurrent therapy
__label__0	study interventions are Bevacizumab . recurrent ovarian carcinoma diagnosis and any prior radiation therapy must be discontinued at least four weeks prior to registration
__label__0	study interventions are Palonosetron . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and bilirubin equal_than less_than doc uln ast and alt equal_than less_than three uln renal
__label__0	study interventions are Cediranib . stage iv prostate cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Lenograstim . multiple myeloma and plasma cell neoplasm diagnosis and htlv and htlv ii negative
__label__0	study interventions are Sirolimus . asymptomatic or minimally symptomatic
__label__0	study interventions are Pharmacogenomic studies . stage iv adult diffuse small cleaved cell lymphoma diagnosis and patients must be able to swallow capsules
__label__0	study interventions are Docetaxel . tumors of the nasal and paranasal cavities and of the nasopharynx
__label__0	study interventions are Antibodies, Monoclonal . histologically or cytologically confirmed adenocarcinoma of the prostate
__label__0	study interventions are Irinotecan . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Histone Deacetylase Inhibitors . recurrent thyroid cancer diagnosis and see disease characteristics
__label__0	study interventions are Hydroxyurea . glioblastoma diagnosis and absolute neutrophil count anc greater_than doc ten nine l
__label__0	study interventions are Dexamethasone . prostate cancer diagnosis and radiotherapy
__label__0	study interventions are laboratory biomarker analysis . estrogen receptor negative breast cancer diagnosis and all radiology studies must be performed within twenty-eight days prior to start of therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Allodepleted T Cells . non hodgkin lymphoma diagnosis and engrafted with anc greater than five hundred
__label__0	study interventions are Carmustine . refractory mature cell and nk cell non hodgkin lymphoma diagnosis and bilirubin less_than doc normal except in cases where abnormal liver function tests lfts are due to involvement with nhl
__label__0	study interventions are Prednisone . lymphoma diagnosis and no known or active hiv infection
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and no concurrent enzyme inducing antiepileptic drugs including any of the following
__label__0	study interventions are Medroxyprogesterone Acetate . breast cancer diagnosis and see disease characteristics
__label__0	study interventions are CD19CART . lymphoma cell diagnosis and eastern cooperative oncology group ecog performance status zero to two expected survival greater_than six months
__label__0	study interventions are Cyclophosphamide . male breast carcinoma diagnosis and accelerated partial breast radiation apbi after chemotherapy
__label__0	study interventions are Irinotecan . breast tumors diagnosis and clinically or radiologically measureable disease in the breast after diagnostic biopsy defined as longest diameter greater than or equal to twenty-five mm doc cm
__label__0	study interventions are 6-Mercaptopurine . aspartate aminotransferase ast or alanine transaminase alt less than doc times uln unless due to lymphoma
__label__0	study interventions are Cisplatin . ovarian endometrioid adenocarcinoma diagnosis and regimen iii
__label__0	study interventions are Niacinamide . recurrent ovarian carcinoma diagnosis and not pregnant or nursing
__label__0	study interventions are Sirolimus . myeloma diagnosis and each subject must meet all of the following criteria during screening to be enrolled
__label__0	study interventions are Immunoglobulins . stage iv renal cell cancer diagnosis and no uncontrolled hypertension defined as systolic blood pressure bp greater_than one hundred and sixty mm hg and or diastolic bp greater_than ninety mm hg on medication
__label__0	study interventions are Digital mammography . invasive cancer diagnosis and women aged forty fifty-nine years
__label__0	study interventions are Capecitabine . patients with hertwo neu negative incurable metastatic or unresectable locally advanced breast cancer who are candidates for chemotherapy
__label__0	study interventions are Mitoxantrone . follicular lymphoma diagnosis and laboratory test results within these ranges
__label__0	study interventions are Buparlisib . lymphoma diagnosis and alanine aminotransferase alt and aspartate aminotransferase ast less_than uln or less_than three uln if liver involved with disease
__label__0	study interventions are Cyclophosphamide . childhood burkitt lymphoma diagnosis and chronic myelogenous leukemia
__label__0	study interventions are Prednisolone acetate . lymphoma diagnosis and endocrine therapy
__label__0	study interventions are Trastuzumab . stage iv endometrial carcinoma diagnosis and no prior anti hertwo monoclonal antibody preparation
__label__0	study interventions are Gefitinib . lung cancer diagnosis and renal
__label__0	study interventions are Interferons . carcinoma hepatocellular diagnosis and women of childbearing potential must have negative pregnancy test
__label__0	study interventions are Fludarabine phosphate . t cell non hodgkin lymphoma diagnosis and donor
__label__0	study interventions are NBTXR3 activated by IMRT only . prostate cancer diagnosis and contraception must include male condom or female condom used with spermicide foam_gel film_cream suppository as well as established use of oral injected or implanted hormonal methods of contraception correctly placed intrauterine device or intrauterine system
__label__0	study interventions are Cyclophosphamide . embryonal rhabdomyosarcoma diagnosis and stage two three group iii
__label__0	study interventions are Mitomycin . bladder cancer diagnosis and endocrine therapy
__label__0	study interventions are Cyclophosphamide . advanced stage diffuse large cell non hodgkin lymphoma diagnosis and advanced stage disease defined as
__label__0	study interventions are Antibodies . recurrent melanoma diagnosis and fertile patients must use effective contraception during and for greater_than equal_than six months after completion of study treatment
__label__0	study interventions are Capecitabine . metastatic colorectal cancer diagnosis and injectable progestogen
__label__0	study interventions are Antibodies, Monoclonal . stage fours neuroblastoma diagnosis and following treatment per cog anblzeropone
__label__0	study interventions are Fludarabine phosphate . stage adult diffuse small cleaved cell lymphoma diagnosis and following planned autologous transplant or equivalent high dose therapy without graft or following failed prior autograft
__label__0	study interventions are educational intervention . multiple myeloma diagnosis and has an identified family caregiver who is willing to participate
__label__0	study interventions are Hydrocortisone . prostate cancer diagnosis and serum total testosterone less_than fiftyng ml
__label__0	study interventions are Etoposide . lymphoma cell diagnosis and disease status of primary induction failure first relapse or second complete remission all patients must have chemosensitive disease as demonstrated by response to induction or salvage chemotherapy with at least partial response as defined in the protocol
__label__0	study interventions are Azacitidine . lung cancer diagnosis and serum total bilirubin less_than doc times upper limit of normal
__label__0	study interventions are Cabozantinib S-malate . ewing sarcoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate gfr greater_than equal_than seventy ml min doc three two or serum creatinine based on age gender as follows
__label__0	study interventions are Cyclosporine . adult nasal type extranodal nk cell lymphoma diagnosis and donor
__label__0	study interventions are Mycophenolate mofetil . stage adult diffuse small cleaved cell lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Melphalan . multiple myeloma and plasma cell neoplasm diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are pharmacological study . stage iii squamous cell carcinoma of the oropharynx diagnosis and no active brain metastases
__label__0	study interventions are Cisplatin . tissue from the primary site must be available for biomarker studies after surgery
__label__0	study interventions are Mycophenolate mofetil . recurrent marginal zone lymphoma diagnosis and left ventricular end diastolic function lvef of greater_than fifty
__label__0	study interventions are Etoposide . extragonadal germ cell tumor diagnosis and disease characteristics
__label__0	study interventions are Lapatinib . breast cancer diagnosis and hertwo positive tumours with three positive intensity on immunohistochemical staining for hertwo or amplification of the hertwo gene on fluorescence in situ hybridization fish
__label__0	study interventions are GPI-0100 . normal electrocardiogram ecg laboratory values chemistry complete blood count and urinalysis as judged grade zero one by per national cancer institute common toxicity criteria nci ctc
__label__0	study interventions are Minocycline . carcinoma of the rectum diagnosis and elder than sixty-five years old
__label__0	study interventions are Antibodies . recurrent adult diffuse large cell lymphoma diagnosis and bilirubin less than or equal to doc mg dl
__label__0	study interventions are Camptothecin . stage ivb rectal cancer diagnosis and measurable or nonmeasurable disease
__label__0	study interventions are Irinotecan . stage iv rectal cancer diagnosis and oxygen saturation at least ninety by pulse_oximetry on room air at rest and after walking six minutes
__label__0	study interventions are Oxaliplatin . colorectal cancer diagnosis and at least thirty days since prior investigational drugs
__label__0	study interventions are Vitamin B 12 . refractory peripheral cell lymphoma diagnosis and adequate hematologic hepatic and renal function as defined by
__label__0	study interventions are Oxaliplatin . colorectal cancer diagnosis and performance status
__label__0	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and acute lymphocytic leukemia all in crone with high risk features
__label__0	study interventions are Trastuzumab . psychosocial effects of cancer and its treatment diagnosis and patients with hertwo positive disease and signs of intracranial herniation and or spinal block may first undergo intraarterial chemotherapy off study with carboplatin methotrexate and trastuzumab herceptin by the same routes used on study until radiographically shown to be safe to undergo blood brain barrier disruption at which point they may be enrolled in the study
__label__0	study interventions are Panobinostat . recurrent grade one follicular lymphoma diagnosis and major surgery equal_than less_than four weeks prior to registration or have not recovered from side effects of such therapy
__label__0	study interventions are Isotretinoin . childhood diffuse large cell lymphoma diagnosis and no other concurrent biologic therapy or immunotherapy
__label__0	study interventions are Gemcitabine . metastatic renal cell carcinoma diagnosis and eighteen years
__label__0	study interventions are Vincristine . locally advanced or metastatic sarcoma who receive first line chemotherapy
__label__0	study interventions are Levoleucovorin . metastatic carcinoma of unknown primary diagnosis and serum glutamic oxaloacetic transaminase sgot and serum glutamic pyruvate transaminase sgpt less_than doc upper limit of normal for patients without liver metastases or sgot and sgpt less_than five upper limit of normal for patients with liver metastases
__label__0	study interventions are Sirolimus . recurrent head and neck carcinoma diagnosis and sub protocol aim a
__label__0	study interventions are Vinblastine . lymphoma diagnosis and no tissue obtained from needle aspirations or cytologies
__label__0	study interventions are Paclitaxel . head and neck cancer diagnosis and anc
__label__0	study interventions are Fluorouracil . adenocarcinoma of the gastroesophageal junction diagnosis and platelets greater_than equal_than one hundred ten nine l
__label__0	study interventions are cytogenetic analysis . lymphoma diagnosis and swog sthree hundred and forty
__label__0	study interventions are Cyclophosphamide . diffuse large cell lymphoma not otherwise specified diagnosis and new york heart association class or less ordinary physical activity does not cause undue fatigue palpitations dyspnea or angina pain patients sixty years or older must have left ventricular ejection fraction lvef at rest greater_than equal_than forty measured by echocardiogram or multi gated acquisition muga
__label__0	study interventions are Mycophenolate mofetil . multiple myeloma and plasma cell neoplasm diagnosis and core biopsies acceptable for primary diagnosis and immunophenotyping
__label__0	study interventions are Vidarabine . myeloma diagnosis and patients must have at least pr to salvage therapy or low bulk untreated relapse less_than two cm largest mass
__label__0	study interventions are Cyclophosphamide . indolent non hodgkin lymphoma diagnosis and creatinine clearance of greater_than sixty ml min
__label__0	study interventions are Carboplatin . extensive stage lung cancer diagnosis and serum creatinine value less_than two upper limit of normal
__label__0	study interventions are psychosocial assessment and care . stage iii adult lymphoblastic lymphoma diagnosis and any type of transplant autologous allogeneic myeloablative non myeloablative marrow or peripheral blood stem cells
__label__0	study interventions are Interferon-beta . recurrent melanoma diagnosis and chemotherapy
__label__0	study interventions are Immunoglobulins . adenocarcinoma of the colon diagnosis and hepatitis surface antigen negative
__label__0	study interventions are Dexamethasone . recurrent adult cell leukemia lymphoma diagnosis and platelets greater_than equal_than one hundred zero mm three without transfusion or growth factor support
__label__0	study interventions are Camptothecin . advanced colorectal cancer diagnosis and adequate renal function
__label__0	study interventions are Etoposide . lymphoma diagnosis and fifteen to sixty-five performance status
__label__0	study interventions are Colonoscopy . colon cancer screening diagnosis and colonoscopy is indicated based on well established national guidelines
__label__0	study interventions are Cyclophosphamide . ductal or lobular carcinoma in situ that has been curatively treated by surgery alone
__label__0	study interventions are Antibodies, Monoclonal . lymphoma non hodgkin diagnosis and at us sites patients greater than or equal to twelve years of age may be enrolled
__label__0	study interventions are Prednisolone hemisuccinate . lymphoma diagnosis and not specified
__label__0	study interventions are Irinotecan . gallbladder cancer diagnosis and sgot less_than doc times upper limit of normal uln less_than five times uln if liver metastases
__label__0	study interventions are Pemetrexed . lung cancer diagnosis and chemotherapy
__label__0	study interventions are WEE1 Inhibitor AZD1775 . untreated childhood anaplastic astrocytoma diagnosis and enrollment must be no later than twenty-eight days after the date of radiographic diagnosis or surgery whichever is the later date
__label__0	study interventions are Cytarabine . recurrent diffuse large cell lymphoma diagnosis and diffusion capacity of the lung for carbon monoxide dlco greater_than equal_than forty of predicted corrected for hemoglobin
__label__0	study interventions are Vidarabine . stage ii childhood anaplastic large cell lymphoma diagnosis and patients with human leukocyte antigen hla matched related donors
__label__0	study interventions are CSA System (CryoSpray AblationTM System) . esophageal neoplasms diagnosis and endoscopic ultrasound evaluation demonstrating no evidence of metastatic lymph node involvement and primary lesion extending into submucosa or muscularis_propria tonesmnzero or ttwonzero
__label__0	study interventions are Cyclophosphamide . triple negative breast cancer diagnosis and subjects with clinically radiologically abnormal axillary lymph nodes should have pathological confirmation of disease with image guided biopsy fine needle aspiration
__label__0	study interventions are intensity-modulated radiotherapy . pathologically proven positive lymph node gastric adenocarcinoma in patients undergoing rzero resection
__label__0	study interventions are Trebananib . glioblastoma multiforme diagnosis and an interval of at least four weeks to start of study agent between prior surgical resection or one week from stereotactic biopsy
__label__0	study interventions are Tamoxifen . stage iiib breast cancer diagnosis and patients discovered to have greater_than equal_than two positive proteinuria at baseline must undergo two4 hour urine collection that must demonstrate less_than one of protein two4 hr or upc ratio less_than one to allow participation in the study
__label__0	study interventions are Carboplatin . sarcoma diagnosis and not pregnant or nursing
__label__0	study interventions are Etoposide phosphate . refractory cutaneous cell non hodgkin lymphoma diagnosis and recovery from non hematologic toxicities of salvage cytoreductive chemotherapy to equal_than less_than grade two common terminology criteria for adverse events ctcae version four vfour
__label__0	study interventions are Pembrolizumab . non small cell lung cancer diagnosis and patients must have received at least one platinum containing regimen gemcitabine cisplatin gc dose dense methotrexate vinblastine doxorubicin cisplatin ddmvac or carboplatinum gemcitabine
__label__0	study interventions are CT-1530 . follicle centre lymphoma diffuse diagnosis and eastern cooperative oncology group performance status of less_than one and life expectancy of at least three months
__label__0	study interventions are Doxorubicin . solid tumors diagnosis and estimated life expectancy of at least twelve weeks
__label__0	study interventions are Paclitaxel . salivary gland squamous cell carcinoma diagnosis and no chronic active viral infection
__label__0	study interventions are Carboplatin . brain and central nervous system tumors diagnosis and prior concurrent therapy
__label__0	study interventions are Docetaxel . squamous cell carcinoma diagnosis and zero or one
__label__0	study interventions are Rituximab . indolent non hodgkin lymphoma diagnosis and no evidence of significant uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results including significant cardiovascular disease severe arrhythmia myocardial infarction within the previous six months unstable arrhythmias or unstable angina or pulmonary disease
__label__0	study interventions are Trastuzumab . metastatic breast cancer diagnosis and serum creatinine less_than doc mg dl
__label__0	study interventions are Camptothecin . unspecified adult solid tumor protocol specific diagnosis and at least four weeks since prior radiotherapy to greater than twenty-five of bone marrow
__label__0	study interventions are Bortezomib . ds stage plasma cell myeloma diagnosis and patients must not have active involvement of the central nervous system cns with mm by clinical evaluation patients with documentation of or clinical signs or symptoms consistent with cns involvement of mm must have lumbar_puncture that is negative for cns involvement of mm the lumbar_puncture must be completed within fourteen days prior to registration patients with no previous history of documented cns involvement and with no clinical signs or symptoms consistent with cns involvement are not required to have completed lumbar_puncture prior to registration note that monitoring of cns involvement and treatment with intrathecal therapy is recommended during protocol treatment
__label__0	study interventions are Cisplatin . metastasis neoplasm diagnosis and karnofsky performance status greater_than sixty
__label__0	study interventions are Fludarabine phosphate . recurrent adult hodgkin lymphoma diagnosis and donor must consent to filgrastim csf administration and leukapheresis
__label__0	study interventions are Doxorubicin . stage ib breast cancer diagnosis and aspartate aminotransferase ast equal_than less_than two times upper limit of normal uln
__label__0	study interventions are Questionnaire Administration . stage iiia ovarian cancer diagnosis and have english as one of their languages of choice they can be multilingual
__label__0	study interventions are pazopanib . chondrosarcoma diagnosis and written informed consent
__label__0	study interventions are Rosuvastatin Calcium . rectal cancer diagnosis and investigators must assure_themselves the patients registered on this trial will be available for complete documentation of the treatment adverse events and follow up
__label__0	study interventions are conventional surgery . breast cancer diagnosis and wbc greater than three five hundred mm three
__label__0	study interventions are Docetaxel . head and neck cancer diagnosis and platelet count at least one hundred zero mm three
__label__0	study interventions are Isophosphamide mustard . precursor cell lymphoblastic leukemia lymphoma diagnosis and able to provide signed informed consent prior to registration on study
__label__0	study interventions are Methylprednisolone Hemisuccinate . childhood immunoblastic large cell lymphoma diagnosis and am negative relapse persistent disease with less_than twenty bone marrow blasts
__label__0	study interventions are Calcium, Dietary . stage iiib gastric cancer diagnosis and surgically resectable ttwonzero tthreenzero tany with node positivity mzero as determined by endoscopic ultrasound eus and the following minimum diagnostic work up
__label__0	study interventions are Antibodies . recurrent small lymphocytic lymphoma diagnosis and no active or chronic infection with human immunodeficiency virus hiv hepatitis or hepatitis c
__label__0	study interventions are Interleukin-12 . stage iv cutaneous cell non hodgkin lymphoma diagnosis and performance status
__label__0	study interventions are Freund's Adjuvant . non melanomatous skin cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Bortezomib . stage ii papillary thyroid cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Antibodies . stage iii squamous cell carcinoma of the larynx diagnosis and myocardial infarction
__label__0	study interventions are laboratory biomarker analysis . stage iv renal cell cancer diagnosis and at least one week since prior ketoconazole
__label__0	study interventions are Radiation . carcinoma renal cell diagnosis and brain metastasis brain mri within six months of registration allowed but all intracranial disease must be treated
__label__0	study interventions are Sorafenib . solid tumors diagnosis and if alt greater_than equal_than sixx uln or t
__label__0	study interventions are Oxaliplatin . rectal cancer diagnosis and not more than doc zero ml thrombocytes
__label__0	study interventions are Carboplatin . carcinoma non small cell lung diagnosis and ecog performance status equal or less than to two karnofsky equal to or greater than fifty
__label__0	study interventions are Sorafenib . stage iii uterine sarcoma diagnosis and hepatic
__label__0	study interventions are Antibodies, Monoclonal . unspecified childhood solid tumor protocol specific diagnosis and at least fourteen days after the last dose of long acting growth factor neulasta or seven days for short acting growth factor for agents that have known adverse events occurring beyond seven days after administration this period must be extended beyond the time during which adverse events are known to occur the duration of this interval must be discussed with the study chair
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and at least four weeks since prior chemotherapy six weeks for nitrosoureas carboplatin mitomycin or anthracyclines
__label__0	study interventions are Paclitaxel . testicular germ cell tumor diagnosis and biologic therapy
__label__0	study interventions are Doxepin . hypopharyngeal carcinoma diagnosis and willingness to complete evaluation and questionnaires per protocol at the participating institution for follow up during the active monitoring phase of the study
__label__0	study interventions are Fludarabine . lymphoma non hodgkin diagnosis and hodgkin disease hd
__label__0	study interventions are Cetuximab . lung cancer diagnosis and ecog performance status of zero two
__label__0	study interventions are Paclitaxel . pancreatic neoplasms diagnosis and suitable candidate for single agent nab paclitaxel as assessed by the investigator
__label__0	study interventions are Camptothecin . carcinoma of the appendix diagnosis and lesions on chest ray are acceptable as measurable lesions when they are clearly defined and surrounded by aerated lung
__label__0	study interventions are Vaccines . sarcoma diagnosis and laboratory parameters
__label__0	study interventions are psychosocial assessment and care . psychosocial effects of cancer and its treatment diagnosis and no serious acute or chronic illness
__label__0	study interventions are Prostate Biopsy . prostate adenocarcinoma diagnosis and no previous pelvic radiotherapy
__label__0	study interventions are Iodine-131 anti-B1 antibody . mantle cell lymphoma diagnosis and patients must have cardiac left ventricular ejection fraction of greater than or equal to fifty by ventriculography or echocardiogram
__label__0	study interventions are Cyclosporins . lymphoma diagnosis and relapsed or primary refractory disease with less_than ten blasts on peripheral blood smear
__label__0	study interventions are Carboplatin . stage iv endometrial carcinoma diagnosis and bilirubin equal_than less_than doc times upper limit of normal uln
__label__0	study interventions are Medroxyprogesterone . endometrial cancer diagnosis and gog zero two
__label__0	study interventions are Mycophenolic Acid . myelodysplastic myeloproliferative neoplasms diagnosis and hematopoietic
__label__0	study interventions are Laboratory Biomarker Analysis . adult epithelioid hemangioendothelioma diagnosis and female patients may be considered to not be of childbearing potential for the following reasons
__label__0	study interventions are conventional surgery . adult giant cell glioblastoma diagnosis and no new york heart association class iii or iv heart failure
__label__0	study interventions are Fludarabine . stage iii grade one follicular lymphoma diagnosis and no renal dysfunction that would impair tolerance or compliance with study therapy
__label__0	study interventions are Hormones . breast cancer diagnosis and neoadjuvant chemotherapy is allowed if progression has been established at least twelve months after end of treatment
__label__0	study interventions are Capecitabine . colorectal cancer diagnosis and radiotherapy
__label__0	study interventions are Mitomycin . malignant mesothelioma diagnosis and renal
__label__0	study interventions are Cyclophosphamide . recurrent adult lymphoblastic lymphoma diagnosis and creatinine clearance of greater_than sixty ml min
__label__0	study interventions are Cisplatin . gastroesophageal junction adenocarcinoma diagnosis and have adequate organ function
__label__0	study interventions are BVAC-C . uterine cervical neoplasms diagnosis and patients at least three months or more of survival can be expected
__label__0	study interventions are Podophyllotoxin . anaplastic oligoastrocytoma diagnosis and preserved major organ functions
__label__0	study interventions are PV701 . cancer diagnosis and hematopoietic
__label__0	study interventions are Photon . breast cancer diagnosis and ecog performance status zero
__label__0	study interventions are Antibodies . gastric cancer diagnosis and karnofsky index for performance status of greater_than seventy
__label__0	study interventions are Carboplatin . non small cell lung cancer diagnosis and presence of at least one bidimensionally or unidimensionally measurable non cns indicator lesion defined by radiologic study or physical examination
__label__0	study interventions are Prednisone . prostatic neoplasm diagnosis and serum testosterone of less_than fifty ng dl less_than doc nm
__label__0	study interventions are Laboratory Biomarker Analysis . stage iv thyroid gland papillary carcinoma diagnosis and ecog performance status ps zero two or karnofsky ps 6zero_1zerozero
__label__0	study interventions are Immunoglobulins . stage iv salivary gland cancer diagnosis and cerebrovascular accident
__label__0	study interventions are Rituximab . histologically confirmed newly diagnosed non hodgkin lymphoma nhl
__label__0	study interventions are Niacinamide . carcinoma hepatocellular diagnosis and patients must have signed an informed consent form
__label__0	study interventions are Immunoconjugates . recurrent adult hodgkin lymphoma diagnosis and total bilirubin less_than two times upper limit of normal unless due to gilbert syndrome
__label__0	study interventions are Levoleucovorin . recurrent rectal cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred ul
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and chronic phase if one year from diagnosis without matched unrelated bone marrow donor and unresponsive to or unable to tolerate interferon
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and pregnant or lactating females
__label__0	study interventions are Cediranib . recurrent fallopian tube carcinoma diagnosis and for platinum resistant or refractory cohort
__label__0	study interventions are Mycophenolate mofetil . lymphoma non hodgkin diagnosis and if the ejection fraction is forty fifty patients must have an exercise echocardiogram or dobutamine echo with normal response to exercise
__label__0	study interventions are Paclitaxel . non small cell lung cancer diagnosis and patients with treated brain metastases are eligible if there is no evidence of progression or hemorrhage after treatment as ascertained by clinical examination and brain imaging mri or ct during the screening period brain imaging to be competed day seven to day one
__label__0	study interventions are questionnaire administration . ovarian cancer diagnosis and able or likely to adhere to study treatment
__label__0	study interventions are Fludarabine . stage ii multiple myeloma diagnosis and highly active antiretroviral therapy haart is initiated within one month of hematopoietic cell transplant
__label__0	study interventions are Estradiol . primary tumor and or metastatic lesion estrogen receptor positive and or progesterone receptor positive by ihc
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and patient characteristics
__label__0	study interventions are Capecitabine . aids related primary cns lymphoma diagnosis and patients must demonstrate an ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Antibodies, Monoclonal . pancreatic alpha cell adenoma diagnosis and history of prior varices or evidence of varices on pre study ct magnetic resonance imaging mri imaging are required to undergo endoscopy equal_than less_than four weeks prior to registration those who had received specific therapy banding and or sclerotherapy and had not bled within the prior six months are eligible
__label__0	study interventions are Cyclosporins . colorectal cancer diagnosis and no major thoracic or abdominal surgery within the past four weeks
__label__0	study interventions are ispinesib . recurrent prostate cancer diagnosis and evidence of disease progression as defined by greater_than one of the following
__label__0	study interventions are Erlotinib Hydrochloride . recurrent adenoid cystic carcinoma of the oral cavity diagnosis and doc mg dl
__label__0	study interventions are chromatography . myelodysplastic myeloproliferative neoplasms diagnosis and healthy volunteer meeting one of the following criteria
__label__0	study interventions are laboratory biomarker analysis . adult glioblastoma diagnosis and fertile patients must use effective barrier contraception during and for greater_than two weeks after study participation for female patients or for three months after study participation for male patients
__label__0	study interventions are Pazopanib Hydrochloride . recurrent pancreatic neuroendocrine carcinoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with gwseven hundred and eighty-six thousand and thirty-four pazopanib these potential risks may also apply to other agents used in this study
__label__0	study interventions are Bevacizumab . stage iiib uterine corpus cancer diagnosis and patients must be greater_than equal_than twelve weeks from treatment and show progressive disease in the liver after regional therapy or must have measurable disease outside the liver
__label__0	study interventions are Bortezomib . adult mixed cellularity hodgkin lymphoma diagnosis and fertile patients must use effective contraception during and for up to three months after study participation
__label__0	study interventions are Interferons . primary peritoneal cavity cancer diagnosis and no prior intraperitoneal therapy
__label__0	study interventions are Antibodies, Monoclonal . stage ii diffuse large cell lymphoma diagnosis and patients who test positive for hepatitis hepc antibodies ab are eligible provided all of the following criteria are met
__label__0	study interventions are Interferons . diffuse intrinsic pontine glioma diagnosis and hepatic function
__label__0	study interventions are surgery . anaplastic oligodendroglioma diagnosis and minimum intervals required
__label__0	study interventions are Deferasirox . noncontiguous stage ii grade three follicular lymphoma diagnosis and pregnancy as documented in required screening laboratory test or breast feeding
__label__0	study interventions are Paclitaxel . sarcoma diagnosis and life expectancy
__label__0	study interventions are Methylprednisolone acetate . breast cancer diagnosis and one mg kg day for greater_than ninety-six hours
__label__0	study interventions are Vedolizumab . melanoma diagnosis and additional inclusion requirements for expansion cohorts only measurable disease per recist guidelines doc and at least one non target lesion accessible for biopsy per the guidelines above
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and pathology will be assessed in the standard fashion ie
__label__0	study interventions are Lenalidomide . stage multiple myeloma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are Pomalidomide . multiple myeloma diagnosis and monoclonal immunoglobulin spike on serum electrophoresis of at least doc dl and or
__label__0	study interventions are Albumin-Bound Paclitaxel . breast carcinoma diagnosis and all patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
__label__0	study interventions are Calcineurin Inhibitors . patients with prior malignancies except resected non melanoma or treated cervical carcinoma in situ
__label__0	study interventions are Paclitaxel . ovarian embryonal carcinoma diagnosis and shortening fraction greater_than twenty-seven by echocardiogram or ejection fraction greater_than fifty by gated radionuclide study
__label__0	study interventions are Paclitaxel . testicular embryonal carcinoma and yolk_sac tumor diagnosis and no active graft versus host disease
__label__0	study interventions are Antibodies . pancreatic neuroendocrine tumor gone diagnosis and patients should have completed any major surgery greater_than equal_than four weeks from start of treatment
__label__0	study interventions are Melphalan . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and donor
__label__0	study interventions are Placebo . symptomatic claudication
__label__0	study interventions are Allopurinol . non hodgkin lymphoma diagnosis and all patients must be in cr as defined by hematological recovery and less_than five blasts by light microscopy within the bone marrow with cellularity of greater_than 1five
__label__0	study interventions are Albumin-Bound Paclitaxel . esophageal cancer diagnosis and no concurrent radiotherapy
__label__0	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . malignant solid tumors diagnosis and evaluable disease
__label__0	study interventions are alvespimycin hydrochloride . stage iii verrucous carcinoma of the oral cavity diagnosis and more than four weeks since prior radiotherapy
__label__0	study interventions are Prednisone . small lymphocytic lymphoma diagnosis and patients previously untreated
__label__0	study interventions are Carmustine . lymphoma diagnosis and male sex
__label__0	study interventions are Antibodies . mucosal melanoma diagnosis and note
__label__0	study interventions are Antibodies . stage iv fallopian tube cancer diagnosis and prior interferon greater_than equal_than four weeks prior to registration
__label__0	study interventions are Temozolomide . glioblastoma multiforme diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Liver Extracts . lung cancer diagnosis and patients must be willing and able to review understand and provide written consent before starting therapy
__label__0	study interventions are Vidarabine . stage iii small lymphocytic lymphoma diagnosis and no serious uncontrolled psychiatric illness
__label__0	study interventions are Rituximab . lymphoma cell diagnosis and pulmonary
__label__0	study interventions are Liposomal doxorubicin . adult liposarcoma diagnosis and creatinine less_than doc times uln or creatinine clearance greater_than sixty ml min
__label__0	study interventions are Maleic acid . adult anaplastic oligodendroglioma diagnosis and patients after menarche with amenorrhea irregular cycles or using contraceptive method that precludes withdrawal bleeding
__label__0	study interventions are questionnaire administration . angioimmunoblastic cell lymphoma diagnosis and patients may take hormone medications excluding gonadotropin releasing hormone gnrh analogues
__label__0	study interventions are Immunoglobulins . ovarian serous surface papillary adenocarcinoma diagnosis and international normalized ratio inr equal_than less_than doc unless the patient is on full dose warfarin
__label__0	study interventions are Methylprednisolone . childhood burkitt lymphoma diagnosis and isolated intracerebral mass
__label__0	study interventions are bowel preparation . patients with rectal cancer diagnosis and age greater_than eighteen years
__label__0	study interventions are Irinotecan . recurrent endometrial carcinoma diagnosis and no concurrent anticonvulsants carbamazepine phenobarbital or phenytoin
__label__0	study interventions are Paclitaxel . patients with stage iv breast cancer who have received prior adjuvant chemotherapy are eligible
__label__0	study interventions are Mycophenolate mofetil . multiple myeloma and plasma cell neoplasm diagnosis and accelerated phase note
__label__0	study interventions are Antibodies . stage fours neuroblastoma diagnosis and no greater than doc mg dl greater_than equal_than sixteen years male
__label__0	study interventions are Cyclosporins . retinoblastoma diagnosis and renal
__label__0	study interventions are Mycophenolic Acid . stage iii adult diffuse mixed cell lymphoma diagnosis and donor
__label__0	study interventions are Mycobacterium w . bladder cancer diagnosis and patients with severe hepatic dysfunctions or with evidence of cirrhosis will not be enrolled
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and reliable contraception is indicated even where there has been history of infertility unless due to hysterectomy
__label__0	study interventions are Gemcitabine . urothelial carcinoma diagnosis and inflammatory bowel disease
__label__0	study interventions are Vidarabine . recurrent childhood large cell lymphoma diagnosis and mds with an international prostate symptom score ipss score of int two or higher
__label__0	study interventions are Succinylcholine . advanced malignant mesothelioma diagnosis and not pregnant or nursing
__label__0	study interventions are Gemcitabine . breast cancer diagnosis and performance status not more than one
__label__0	study interventions are Cetuximab . carcinoma squamous cell of head and neck diagnosis and doc eligibility criteria
__label__0	study interventions are Talazoparib . breast cancer diagnosis and platelets greater_than equal_than one hundred zero ul c
__label__0	study interventions are Ifosfamide . retinoblastoma diagnosis and age and performance status
__label__0	study interventions are Leucovorin . signet ring adenocarcinoma of the rectum diagnosis and no prior epidermal growth factor receptor inhibitor
__label__0	study interventions are Vidarabine . lymphoma diagnosis and less than pr to salvage chemotherapy b
__label__0	study interventions are Sirolimus . primary central nervous system non hodgkin lymphoma diagnosis and creatinine equal_than less_than doc uln
__label__0	study interventions are Clarithromycin . patients with gastrectomy acute gi bleeding and advanced gastric cancer
__label__0	study interventions are Prednisone . lymphoma diagnosis and no prior biologic therapy chemotherapy
__label__0	study interventions are Methotrexate . recurrent grade three follicular lymphoma diagnosis and patients should have extinguished standard of care options prior to being considered for this trial
__label__0	study interventions are Citric Acid . myeloma diagnosis and agree to practice true abstinence when this is in line with the preferred and usual_lifestyle of the subject periodic abstinence calendar_ovulation symptothermal post ovulation methods and withdrawal are not acceptable methods of contraception
__label__0	study interventions are Nivolumab . carcinoma hepatocellular diagnosis and subject is greater_than eighteen years of age at the time of signing the informed consent form icf
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and ecog performance status less than or equal to two
__label__0	study interventions are Fluorouracil . breast cancer diagnosis and adequate recovery from recent surgery at least one week must have elapsed from the time of minor surgery excluding breast biopsy at least three weeks for major surgery
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and serum potassium greater_than lln
__label__0	study interventions are Niacinamide . squamous cell carcinoma of the gallbladder diagnosis and institutions are required to seek additional patient consent for submission of blood
__label__0	study interventions are Weight Loss Dietary Pattern . breast cancer diagnosis and post menopausal no menses for greater_than six months
__label__0	study interventions are Vorinostat . nodal marginal zone lymphoma diagnosis and prior allogeneic stem cell transplant patients will be allowed to enroll if they are past day positive one hundred of transplant have no active graft versus host disease are not on any immunosuppressants and have been off immunosuppressants for at least four weeks prior autologous stem cell transplant patients will also be allowed to enter this study if they are past their day positive one hundred of transplant
__label__0	study interventions are Idelalisib . recurrent lymphoplasmacytic lymphoma diagnosis and histologically confirmed relapsed response to last treatment greater_than equal_than six months duration or refractory no response to last treatment or response duration less_than six months indolent low grade cell nhl note
__label__0	study interventions are Mycophenolate mofetil . stage ii multiple myeloma diagnosis and hla phenotypically identical unrelated donor match grades allowed
__label__0	study interventions are Proteasome Inhibitors . precancerous condition diagnosis and other
__label__0	study interventions are MUC1-peptide-DC-CTL . gastric cancer diagnosis and serum glutamate pyruvate transaminase
__label__0	study interventions are Selinexor (KPT-330) . squamous cell carcinoma diagnosis and confirmed scc of the head and neck lung or esophagus
__label__0	study interventions are Camptothecin . small intestine cancer diagnosis and no prior cisplatin oxaliplatin nitrosoureas or mitomycin one or two prior chemotherapy regimens allowed including irinotecan endocrine therapy
__label__0	study interventions are Piperacillin . multiple myeloma and plasma cell neoplasm diagnosis and age
__label__0	study interventions are TAA-Specific CTLs . melanoma diagnosis and due to unknown effects of this therapy on fetus pregnant women are excluded from this research
__label__0	study interventions are Akt Inhibitor MK2206 . unresectable gallbladder carcinoma diagnosis and patients with clinically significant bundle_branch block or pre existing clinically significant bradycardia will be excluded from the study
__label__0	study interventions are Procarbazine . aids related small noncleaved cell lymphoma diagnosis and participants must in the opinion of the investigatory be capable of complying with the protocol
__label__0	study interventions are Lenograstim . male breast cancer diagnosis and alt sgpt equal_than less_than doc upper limit of normal
__label__0	study interventions are Immunoglobulin G . recurrent ovarian carcinoma diagnosis and disease that is measurable by physical examination only is not eligible exception
__label__0	study interventions are Vidarabine . angioimmunoblastic cell lymphoma diagnosis and myelodysplastic syndromes mds greater_than int one per ipss after greater_than equal_than one prior cycle of induction chemotherapy should have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Bevacizumab . recurrent colon cancer diagnosis and proteinuria less than one positive zero or trace
__label__0	study interventions are Elotuzumab . multiple myeloma diagnosis and signed written informed consent
__label__0	study interventions are Vaccines . stage iiia ovarian cancer diagnosis and serum creatinine less than or equal to doc institutional upper limit normal uln ctcae doc grade one
__label__0	study interventions are Interleukin-2 . colorectal cancer diagnosis and prior vaccine dendritic cell or cea targeted immunotherapy allowed
__label__0	study interventions are Gemcitabine . histologically or cytologically confirmed metastatic or locall negative advanced pancreatic adenocarcinoma not amenable to curative resection
__label__0	study interventions are Leucovorin . periampullary adenocarcinoma diagnosis and one per common terminology criteria for adverse events ctcae or peripheral motor neuropathy greater_than gr
__label__0	study interventions are Vaccines . stage ia skin melanoma diagnosis and white blood cells wbc greater_than equal_than three thousand, five hundred mm three
__label__0	study interventions are Bortezomib . refractory plasma cell myeloma diagnosis and ejection fraction greater_than equal_than forty-five
__label__0	study interventions are antineoplaston AS2-1 . malignant mesothelioma diagnosis and biologic therapy
__label__0	study interventions are Succinylcholine . stage iiib ovarian cancer diagnosis and patients must have met pre entry requirements
__label__0	study interventions are Dexamethasone . stage multiple myeloma diagnosis and adequate laboratory levels within seven days prior to randomization
__label__0	study interventions are Vincristine . lymphoma diagnosis and no more than one extranodal site of disease
__label__0	study interventions are Fludarabine phosphate . metastatic ocular melanoma diagnosis and lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month after treatment for the patient to be eligible
__label__0	study interventions are Liposomal doxorubicin . leiomyosarcoma
__label__0	study interventions are Bevacizumab . stage iiic breast cancer ajcc vsix diagnosis and urine protein equal_than less_than one positive protein or urine protein
__label__0	study interventions are Poly ICLC . recurrent pediatric high grade glioma diagnosis and stratum d
__label__0	study interventions are enzastaurin hydrochloride . brain and central nervous system tumors diagnosis and total bilirubin less_than doc upper limit of normal uln for age
__label__0	study interventions are Octreotide . gastrin_producing neuroendocrine tumor diagnosis and hemoglobin greater_than nine dl eligibility level for hemoglobin may be reached by transfusion
__label__0	study interventions are Triamcinolone . precancerous nonmalignant condition diagnosis and not specified surgery
__label__0	study interventions are Albumin-Bound Paclitaxel . have discontinued all prior chemotherapies biological therapies and other investigational therapies for cancer for at least four weeks six weeks for mitomycin or nitrosoureas prior to study treatment and recovered from the acute effects of therapy
__label__0	study interventions are Oxaliplatin . colorectal cancer metastatic diagnosis and measurable hepatic disease by recist version doc
__label__0	study interventions are Cyclosporine . childhood nasal type extranodal nk cell lymphoma diagnosis and al negative relapse persistent disease with less_than twenty bone marrow blasts
__label__0	study interventions are Fludarabine . hodgkins lymphoma diagnosis and children unable to perform pulmonary function tests less than seven years old pulse_oximetry of greater_than equal_than ninety-two on room air
__label__0	study interventions are Ascorbic Acid . anaplastic astrocytoma diagnosis and patients must have recovered from toxicity of prior therapy
__label__0	study interventions are Cisplatin . cervical cancer diagnosis and no participants with circumstances that will not permit completion of the study or required follow up for instance if travel to and from treatment site is an issue
__label__0	study interventions are protein expression analysis . breast cancer diagnosis and sex
__label__0	study interventions are Carboplatin . lung neoplasms diagnosis and normal medullar function hemoglobin greater_than eleven dl total wbc greater_than one five one0 nine platelets greater_than one00 one0 nine l
__label__0	study interventions are eFT508 . cancer diagnosis and normal coagulation panel
__label__0	study interventions are Epothilone B . recurrent breast cancer diagnosis and patients in treatment cohort one may have received trastuzumab in the adjuvant setting provided that trastuzumab therapy ended at least one2 months prior to study participation patients may not have previously received trastuzumab in the metastatic setting
__label__0	study interventions are conventional surgery . colorectal cancer diagnosis and disease characteristics
__label__0	study interventions are Methylprednisolone Hemisuccinate . neuroblastoma diagnosis and prior concurrent therapy
__label__0	study interventions are Cyclosporine . multiple myeloma and plasma cell neoplasm diagnosis and at least an identical hla haplotype
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and myocardial infarction angina pectoris that requires antianginal medication history of congestive heart failure arrhythmia associated with concurrent heart failure or cardiac dysfunction valvular disease with cardiac compromise cardiomegaly or ventricular hypertrophy unless left ventricular function is within normal limits poorly controlled hypertension other
__label__0	study interventions are Vidarabine . recurrent grade three follicular lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Levoleucovorin . adenocarcinoma of the colon diagnosis and there must be no history of distant metastatic disease at the time of registration
__label__0	study interventions are Cetuximab . nasopharyngeal carcinoma diagnosis and pathologically confirmed untreated npc patients
__label__0	study interventions are Vidarabine . recurrent childhood small noncleaved cell lymphoma diagnosis and compatibility at the four most informative hla loci
__label__0	study interventions are Carboplatin . stage iv verrucous carcinoma of the oral cavity diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Oxaliplatin . pancreatic cancer diagnosis and patient characteristics
__label__0	study interventions are Immunoglobulins . stage iii squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and uncontrolled hypertension blood pressure greater_than one hundred and fifty eighty-five mm hg despite medication
__label__0	study interventions are Immunoglobulins . stage iv hypopharyngeal squamous cell carcinoma diagnosis and eastern cooperative oncology group ecog performance status of zero one
__label__0	study interventions are Vitamin D . any other cancer including contralateral breast for which the participant has been disease free for greater_than five years
__label__0	study interventions are Albumin-Bound Paclitaxel . carcinoma of the breast diagnosis and her two positive
__label__0	study interventions are Fluorouracil . ampulla of vater carcinoma
__label__0	study interventions are Tamoxifen . stage iib breast cancer diagnosis and the patient and physician must be agreeable to initiate standard chemotherapy and hormonal therapy as adjuvant therapy
__label__0	study interventions are Immunoglobulins . stage iii endometrial carcinoma diagnosis and no concurrent warfarin at doses greater_than one mg day
__label__0	study interventions are Erlotinib Hydrochloride . recovery from any toxic effects of erlotinib to less_than grade one per the national cancer institute nci common terminology criteria for adverse events ctcae
__label__0	study interventions are Immunoglobulin G . uterine corpus carcinosarcoma diagnosis and at least one prior systematic therapy in the metastatic setting
__label__0	study interventions are Albumin-Bound Paclitaxel . transitional cell cancer of the renal pelvis and ureter diagnosis and disease characteristics
__label__0	study interventions are Prednisone . multiple myeloma diagnosis and platelet count greater_than seventy-five one hundred and nine without transfusion support within seven days before the test
__label__0	study interventions are HER2-specific T cells . glioblastoma diagnosis and pulse_oximetry of greater than or equal to ninety on room air
__label__0	study interventions are Rituximab . b lymphoblastic lymphoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional uln
__label__0	study interventions are nutritional support program . biliary cancer diagnosis and ast alt less_than five upper limit of normal
__label__0	study interventions are sentinel lymph node biopsy . breast cancer diagnosis and other
__label__0	study interventions are Donepezil . underwent fractionated radiotherapy greater_than two doc gy with or without surgery or chemotherapy for the brain tumor at least one year ago
__label__0	study interventions are Docetaxel . locally advanced inoperable breast carcinoma or stage ii not amenable to breast preserving surgery amendment introduced on november two thousand and six
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and patients must have adequate cardiac function
__label__0	study interventions are Mycophenolate mofetil . recurrent adult hodgkin lymphoma diagnosis and lvef left ventricular end diastolic function of greater_than fifty
__label__0	study interventions are Dexamethasone 21-phosphate . refractory plasma cell myeloma diagnosis and signed informed consent should be obtained from all patients in accordance with institutional and federal guidelines
__label__0	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and opatients with known sensitizing mutation in the epidermal growth factor receptor egfr gene must also have experienced disease progression during or after treatment or intolerance to treatment with erlotinib gefitinib or another egfr tyrosine kinase inhibitor tki
__label__0	study interventions are Sunitinib . prostate cancer diagnosis and clinical ttwoc clinical or pathological tthree or tfour disease or gleason eight ten disease or psa greater_than two0ng ml
__label__0	study interventions are Ixazomib . plasma cell myeloma diagnosis and untransfused platelet count greater_than equal_than seventy-five thousand mm three
__label__0	study interventions are Carboplatin . ovarian neoplasms diagnosis and females eighteen years old and older
__label__0	study interventions are Capecitabine . melanoma diagnosis and patients must have failed prior standard curative chemotherapy for their disease refuse existing therapies or the proposed chemotherapy regimen to which amten is added represents an acceptable standard treatment for their disease
__label__0	study interventions are Immunoglobulin Idiotypes . multiple myeloma diagnosis and collection of plasma in recipient
__label__0	study interventions are Lenalidomide . recurrent non hodgkin lymphoma diagnosis and creatinine doc institutional upper limit of normal or creatinine clearance greater_than equal_than thirty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Cyclophosphamide . refractory plasma cell myeloma diagnosis and have received induction therapy for minimum of four cycles
__label__0	study interventions are BB 1101 . bladder cancer diagnosis and one two mg qd for central line thrombosis prophylaxis do not require frequent monitoring
__label__0	study interventions are Immunoglobulins . lymphoma diagnosis and dlco greater_than fifty
__label__0	study interventions are Vorinostat . recurrent squamous cell carcinoma of the oropharynx diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than fifty
__label__0	study interventions are Floxuridine . gastric cancer diagnosis and no new york heart association class iii or iv heart disease no active angina or myocardial infarction within the past six months no history of significant ventricular arrhythmia requiring medication with antiarrhythmics or significant conduction system abnormality other
__label__0	study interventions are Cediranib . adult primary hepatocellular carcinoma diagnosis and negative pregnancy test
__label__0	study interventions are Carboxymethylcellulose Sodium . small size posterior uveal melanoma diagnosis and maintained on stable antiretroviral therapy with no significant drug interactions and
__label__0	study interventions are Pembrolizumab . stage iva thyroid gland follicular carcinoma diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred mcl
__label__0	study interventions are Everolimus . testicular cancer diagnosis and disease progression at study entry
__label__0	study interventions are Palbociclib . metastatic invasive breast cancer diagnosis and relapsed while on adjuvant endocrine therapy or within one year of completion of adjuvant endocrine therapy
__label__0	study interventions are Leucovorin . stomach neoplasms diagnosis and normal bone marrow and organ function as defined below
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ic ovarian cancer diagnosis and patients may have received prior adjuvant external beam radiation therapy and or vaginal brachytherapy patients should be at least four weeks from the completion of external beam radiotherapy prior to beginning protocol chemotherapy patients do not need to be delayed if receiving vaginal brachytherapy only
__label__0	study interventions are Osimertinib . refractory malignant neoplasm diagnosis and patients who are human immunodeficiency virus hiv positive are eligible if
__label__0	study interventions are Docetaxel . bronchoalveolar cell lung cancer diagnosis and the only exception is pleural effusion only on ct scan and not visible on cxr or deemed too small to tap
__label__0	study interventions are Fludarabine phosphate . burkitt lymphoma diagnosis and patients in crtwo prtwo with initial short remission less_than six months are eligible
__label__0	study interventions are Dabrafenib . stage iiic ovarian cancer diagnosis and as part of the oncology patient enrollment network open registration process the treating institution identity is provided in order to ensure that the current within three hundred and sixty-five days date of institutional review board approval for this study has been entered in the system
__label__0	study interventions are Dacarbazine . childhood solid neoplasm diagnosis and hematopoietic growth factors
__label__0	study interventions are Rituximab . mantle cell lymphoma diagnosis and unintentional weight loss greater_than ten within the previous six months prior to screening
__label__0	study interventions are Nivolumab . non small cell lung cancer metastatic diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are Mycophenolate mofetil . stage childhood small noncleaved cell lymphoma diagnosis and mantle cell nh negative may be treated in first cr
__label__0	study interventions are Single fraction radiation . non hodgkin lymphoma diagnosis and patients whose related or unrelated allotransplant donors are unavailable or ineligible but who have cryopreserved donor lymphocyte cell products available for use on this trial
__label__0	study interventions are Methotrexate . recurrent adult burkitt lymphoma diagnosis and myelodysplastic syndromes at any of the following stages
__label__0	study interventions are Paclitaxel . patient has microscopically confirmed invasive breast carcinoma with clinical and or radiographic evidence of stage four disease
__label__0	study interventions are Temozolomide . melanoma skin diagnosis and more than twelve weeks
__label__0	study interventions are Ferric Compounds . unilateral or bilateral primary carcinoma of the breast confirmed histologically by core biopsy
__label__0	study interventions are Immunoglobulin G . stage iva oral cavity verrucous carcinoma diagnosis and alkaline phosphatase greater_than one but equal_than less_than doc uln and ast or alt greater_than one but equal_than less_than doc uln
__label__0	study interventions are AR-42 . recurrent adult cell leukemia lymphoma diagnosis and prior biologic therapy or prior radiation is permitted however at least twenty-eight days must have elapsed since the completion of prior therapy and patients must have recovered from all therapy associated toxicities to no greater than grade one at the time of registration
__label__0	study interventions are Fludarabine . stage marginal zone lymphoma diagnosis and hla phenotypically identical unrelated donor match grades allowed
__label__0	study interventions are Immunoglobulins . stage iii adult diffuse large cell lymphoma diagnosis and patients are eligible following an autologous transplant in remission or in relapse
__label__0	study interventions are Carboplatin . squamous cell carcinoma of the head and neck diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt less_than doc upper limit of normal uln total serum bilirubin less_than doc mg dl creatinine clearance crcl greater_than fortyml min as measured via cockcroft gault
__label__0	study interventions are Antibodies . refractory extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and total bilirubin equal_than less_than doc the upper limit of the normal range uln
__label__0	study interventions are Bevacizumab . sarcoma diagnosis and bilirubin no greater than doc mg dl
__label__0	study interventions are Olaparib . triple negative breast carcinoma diagnosis and new york heart association nyha classification of ii controlled with treatment
__label__0	study interventions are Pharmacological Study . recurrent alveolar soft part sarcoma diagnosis and thirty mg dl in urinalysis or equal_than less_than one positive on dipstick unless quantitative protein is less_than one000 mg in twenty-four hour urine sample
__label__0	study interventions are Dacarbazine . liver cancer diagnosis and chemotherapy
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv melanoma diagnosis and corrected serum calcium concentration within normal range per local clinical laboratory standard
__label__0	study interventions are Mafosfamide . lymphoma diagnosis and patients must not have received any cns therapy within one week prior to starting treatment on this study or craniospinal irradiation within eight weeks prior to starting treatment on this study
__label__0	study interventions are Bevacizumab . endometrial adenosquamous cell carcinoma diagnosis and unstable angina and or new york heart association nyha class ii iv congestive heart failure requiring hospitalization within the past twelve months
__label__0	study interventions are Cabazitaxel 10 mg/m2 . patients with histologic or cytologic diagnosis of advanced prostate cancer any gleason grade
__label__0	study interventions are pharmacological study . recurrent childhood small noncleaved cell lymphoma diagnosis and bilirubin less_than doc times upper limit of normal
__label__0	study interventions are Hormones . breast cancer diagnosis and for part one evaluable or measurable disease bone only disease eligible for part one only
__label__0	study interventions are Prednisone . lymphoma diagnosis and disease characteristics
__label__0	study interventions are S-1 plus DC-CIK . gastric cancer diagnosis and adequate hepatic function total bilirubin levelless_than doc times the upper limit of normal uln transaminases ast sgot and alt sgpt less_than doc times uln
__label__0	study interventions are Akt Inhibitor MK2206 . stage iva oral cavity adenoid cystic carcinoma diagnosis and total bilirubin equal_than less_than institutional upper limit of normal uln
__label__0	study interventions are Rituximab . splenic marginal zone lymphoma diagnosis and serum creatinine equal_than less_than doc mg dl or one hundred and thirty-three umol l
__label__0	study interventions are Albumin-Bound Paclitaxel . patient has unilateral multifocal or multicentric disease allowed histologically confirmed newly diagnosed early breast cancer greater_than twocm by clinical examination and or greater_than doc cm confirmed by ultrasound or by mri
__label__0	study interventions are Lenalidomide . mantle cell lymphoma diagnosis and newly diagnosed patients are eligible for the phase ii portion of the study only
__label__0	study interventions are anti-CD19-CAR retroviral vector-transduced autologous T cells . recurrent mantle cell lymphoma diagnosis and relapsed after prior autologous sct
__label__0	study interventions are Antibodies . stage iia colon cancer diagnosis and patients must not have had any systemic or radiation therapy initiated for this malignancy
__label__0	study interventions are quality-of-life assessment . recurrent extrahepatic bile duct cancer diagnosis and six weeks must have elapsed since that therapy
__label__0	study interventions are Cyclophosphamide . hormone refractory prostate cancer diagnosis and zero one
__label__0	study interventions are Doxorubicin . stage iiia breast cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Pharmacological Study . recurrent renal cell carcinoma diagnosis and doc maximum serum creatinine mg dl
__label__0	study interventions are fenretinide . adult gliosarcoma diagnosis and at least one week since prior vitamin a
__label__0	study interventions are Cisplatin . confirmed diagnosis of stomach cancer
__label__0	study interventions are Alemtuzumab . recurrent grade two follicular lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Vidarabine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and myelodysplastic syndromes
__label__0	study interventions are Dexamethasone . relapsed and or relapsed refractory multiple myeloma diagnosis and ast sgot and alt sgpt less_than doc uln
__label__0	study interventions are radiation therapy . lung cancer diagnosis and performance status
__label__0	study interventions are Vidarabine . cutaneous cell lymphoma diagnosis and female subject is either post menopausal or surgically sterilized or willing to use an acceptable method of birth control hormonal contraceptive intra uterine device diaphragm with spermicide condom with spermicide or abstinence for the duration of the study
__label__0	study interventions are Paclitaxel . ovarian carcinoma diagnosis and pt and ptt within normal limits or within therapeutic limits for patients receiving anticoagulation
__label__0	study interventions are Cisplatin . cervical adenocarcinoma diagnosis and negative non suspicious para aortic nodes by lymphangiogram ct scan mri or lymphadenectomy
__label__0	study interventions are Cediranib . advanced malignant mesothelioma diagnosis and wbc greater_than equal_than three zero mm three
__label__0	study interventions are Vorinostat . recurrent grade two follicular lymphoma diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least fifty miu ml within ten fourteen days prior to and again within two4 hours of prescribing lenalidomide prescriptions must be filled within seven days and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least two8 days she starts taking lenalidomide fcbp must also agree to ongoing pregnancy testing men must agree to use latex condom during sexual contact with fcbp even if they have had successful vasectomy
__label__0	study interventions are Cyclophosphamide . spindle cell rhabdomyosarcoma diagnosis and stage two group ii
__label__0	study interventions are Cyclophosphamide . aids related peripheral systemic lymphoma diagnosis and note
__label__0	study interventions are Romidepsin . stage iiib non small cell lung cancer diagnosis and platelet count at least one hundred zero mmthree absolute neutrophil count at least one five hundred mmthree hepatic
__label__0	study interventions are Ascorbic Acid . stage iiib non small cell lung cancer diagnosis and willingness to comply with the weekly phone_calls between office visits
__label__0	study interventions are Docetaxel . histological diagnosis of invasive breast cancer tone tthree nzero one mzero
__label__0	study interventions are Albumin-Bound Paclitaxel . carcinoma non small cell lung diagnosis and cns metastases allowed provided
__label__0	study interventions are Long Course Adjuvant Chemotherapy . adenocarcinoma of rectum diagnosis and all of the following must apply
__label__0	study interventions are Vaccines . breast cancer diagnosis and no active inflammatory bowel disease
__label__0	study interventions are HR PEM Scan . solid tumors diagnosis and participant must be at least eighteen years of age
__label__0	study interventions are questionnaire administration . stage iv adult cell leukemia lymphoma diagnosis and patients with any performance status are eligible for enrollment
__label__0	study interventions are quality-of-life assessment . stage iiic breast cancer diagnosis and have completed neoadjuvant adjuvant chemotherapy and able to initiate exercise program if randomized to that arm within twelve weeks of therapy completion
__label__0	study interventions are Doxorubicin . recurrent fallopian tube carcinoma diagnosis and submission of pathology report
__label__0	study interventions are Gemcitabine . stage iib non small cell lung carcinoma diagnosis and prior systemic chemotherapy at any time methotrexate mtx given in low doses for non malignant conditions with last dose at least two weeks prior to date of registration will be allowed other low dose chemotherapeutics for non malignant conditions will be considered but review by the study chair is required
__label__0	study interventions are Cyclosporins . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and donor must consent to granulocyte colony stimulating factor csf administration and leukopheresis
__label__0	study interventions are Bevacizumab . metastatic breast cancer diagnosis and two positive proteinuria on dipstick urinalysis at baseline should undergo two4 hour
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and age
__label__0	study interventions are Bortezomib . recurrent small lymphocytic lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Skin Biopsy . neuroblastoma diagnosis and patients must have ecog performance status of zero two
__label__0	study interventions are Methotrexate . stage ii adult hodgkin lymphoma diagnosis and ten blasts in blood or marrow
__label__0	study interventions are Antibodies, Monoclonal . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and no significant traumatic injury within the past twenty-eight days
__label__0	study interventions are Interferon-alpha . multiple myeloma diagnosis and diagnostic histologic material available for central pathology review
__label__0	study interventions are Antibodies, Monoclonal . prostatic neoplasms diagnosis and for those participants who are post radical prostatectomy rising psa is acceptable
__label__0	study interventions are Pemetrexed . sarcomatoid mesothelioma diagnosis and at least twenty-eight days since prior surgery pleurectomy pleurodeses thoracic or other major surgeries and recovered
__label__0	study interventions are Trastuzumab . metastatic or unresectable adenocarcinoma of stomach gej or esophagus that is evaluable or that is measurable for response as per recist doc criteria defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded as greater_than twenty mm with conventional techniques or as greater_than ten mm with spiral computed tomography ct scan
__label__0	study interventions are Vidarabine . contiguous stage ii adult diffuse mixed cell lymphoma diagnosis and acute lymphoblastic leukemia
__label__0	study interventions are Cyclosporins . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and highly active antiretroviral therapy haart is initiated within one month of hematopoietic cell transplant
__label__0	study interventions are Liposomal doxorubicin . endometrial cancer diagnosis and not specified
__label__0	study interventions are Nivolumab . skin basosquamous cell carcinoma diagnosis and platelets greater_than equal_than seventy-five ten nine l
__label__0	study interventions are Erlotinib Hydrochloride . adult glioblastoma diagnosis and patients must have recovered from toxicity of prior therapy
__label__0	study interventions are Pharmacological Study . childhood soft tissue sarcoma diagnosis and previously radiated lesions that have not demonstrated clear progression post radiation
__label__0	study interventions are Carboplatin . stage iii squamous cell carcinoma of the oropharynx diagnosis and written signed informed consent the patient must be aware that his her disease is neoplastic in nature and willingly consent after being informed of the procedure to be followed the experimental nature of the therapy alternatives potential benefits side effects risks and discomforts
__label__0	study interventions are Topotecan . neoplasms breast diagnosis and concurrent treatment with bisphosphonates is permitted
__label__0	study interventions are Bortezomib . advanced cancer diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Pharmacological Study . testicular lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Pancreatin . pancreatic cancer diagnosis and all subjects of child producing potential must agree to use contraception or avoidance of pregnancy measures while enrolled on study and receiving the experimental product and for one month after the last immunization
__label__0	study interventions are Leucovorin . recurrent colon cancer diagnosis and progressive disease following
__label__0	study interventions are LY2606368 . solid tumors diagnosis and forty-two days must have elapsed since systemically administered radiopharmaceutical therapy
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and no prior biologic therapy chemotherapy
__label__0	study interventions are Liposomal doxorubicin . ewing sarcoma of bone or soft tissue diagnosis and must have adequate cardiac function defined as shortening fraction greater_than twenty-eight
__label__0	study interventions are laboratory biomarker analysis . recurrent breast cancer diagnosis and patients taking aspirin
__label__0	study interventions are Doxorubicin . myelodysplastic myeloproliferative neoplasms diagnosis and translocations involving elevenqtwenty-three nine twenty-two or bcr_abl rearrangement
__label__0	study interventions are Temozolomide . esophageal large cell neuroendocrine carcinoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional uln or equal_than less_than five institutional uln if the patient has liver metastases
__label__0	study interventions are Niacinamide . stage ii renal cell cancer diagnosis and ptthree any nzero or pnx where clinically nzero mzero
__label__0	study interventions are Phosphonoacetic Acid . stage iv adult hodgkin lymphoma diagnosis and procedure
__label__0	study interventions are Etoposide . recurrent small lymphocytic lymphoma diagnosis and progressive mm after previous autograft provided stored autologous cluster of differentiation cd thirty-four cells are available
__label__0	study interventions are Hormones . breast cancer diagnosis and absolute neutrophil segmented and bands count anc greater_than doc ten nine platelets greater_than ten0 ten nine l
__label__0	study interventions are Everolimus . liver cancer diagnosis and see disease characteristics
__label__0	study interventions are Bevacizumab . stage iv fallopian tube cancer diagnosis and or five half lives whichever is shorter
__label__0	study interventions are BB 1101 . lymphoma diagnosis and not specified hematopoietic
__label__0	study interventions are Fluorouracil . urethral cancer diagnosis and patients must sign an informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of this hospital
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv uveal melanoma diagnosis and life expectancy of greater_than equal_than four months
__label__0	study interventions are Laboratory Biomarker Analysis . infiltrating bladder urothelial carcinoma diagnosis and no history of diagnosed congenital bleeding disorders von_willebrand disease
__label__0	study interventions are Carboplatin . resolution of any effects of prior except alopecia and peripheral neuropathy to the current national cancer institute nci common terminology criteria for adverse events nci ctcae grade equal_than less_than one and to baseline laboratory values as defined
__label__0	study interventions are Bevacizumab . stage iiib primary peritoneal cancer diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Taselisib . recurrent squamous cell lung carcinoma diagnosis and patients must have progressed on arm two docetaxel of this sub study
__label__0	study interventions are Antibodies, Monoclonal . stage iv squamous cell carcinoma of the hypopharynx diagnosis and negative pregnancy test
__label__0	study interventions are Etoposide phosphate . recurrent small lymphocytic lymphoma diagnosis and expected survival duration of greater_than equal_than six months
__label__0	study interventions are Gefitinib . head and neck cancer diagnosis and patients may have experienced more than one recurrence as long as the first recurrence occurred greater than or equal to six months following the end of the prior rt
__label__0	study interventions are Antibodies . recurrent pancreatic cancer diagnosis and no prior cytotoxic chemotherapy for metastatic disease
__label__0	study interventions are Vaccines . stage iii pancreatic cancer diagnosis and prothrombin time pt partial thromboplastin time ptt within normal institutional limits
__label__0	study interventions are pharmacological study . blastic_plasmacytoid dendritic cell neoplasm diagnosis and serum albumin greater_than equal_than two dl
__label__0	study interventions are Cyclosporins . recurrent adult immunoblastic large cell lymphoma diagnosis and there is no hla b or one locus_allelic mismatched related donor available
__label__0	study interventions are Fludarabine phosphate . refractory hodgkin lymphoma diagnosis and adequate cardiac function defined as absence of decompensated congestive heart failure or uncontrolled arrhythmia and
__label__0	study interventions are Molecular Mechanisms of Pharmacological Action . anaplastic large cell lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Cyclosporine . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and the donor and recipient must have human leukocyte antigen hla eight eight allelic match at the hla b and drbone high resolution typing is required for all alleles
__label__0	study interventions are Docetaxel . stage iii pancreatic cancer diagnosis and arm cohort one
__label__0	study interventions are BI 754091 . neoplasms diagnosis and patients greater_than eighteen years of age at the time of signature of the icf
__label__0	study interventions are Survey Tailoring . myeloma diagnosis and twenty-one years of age or older
__label__0	study interventions are Palbociclib . recurrent childhood gliomatosis_cerebri diagnosis and patient and or guardian have the ability to understand and the willingness to sign written informed consent document according to institutional guidelines
__label__0	study interventions are Antibodies, Monoclonal . stage iii rectal cancer diagnosis and no other uncontrolled illness
__label__0	study interventions are Mycophenolate mofetil . noncontiguous stage ii adult burkitt lymphoma diagnosis and patients in crtwo prtwo with initial short remission less_than six months are eligible
__label__0	study interventions are Sirolimus . metastatic transitional cell carcinoma diagnosis and current or prior iv drug users
__label__0	study interventions are Dihydromevinolin . precancerous condition diagnosis and men partnered with female of child bearing age must agree to use adequate contraception while on the study abstinence iud birth control pills or spermicidal gel with diaphragm or condom
__label__0	study interventions are Questionnaire Administration . stage ia breast cancer diagnosis and total bilirubin less_than doc upper limit of normal uln
__label__0	study interventions are Albumin-Bound Paclitaxel . adenocarcinoma of the proximal stomach diagnosis and life expectancy of greater than three months
__label__0	study interventions are Sample of polyp . colon cancer diagnosis and over eighteen years of age
__label__0	study interventions are Vitamin B Complex . stage iia fallopian tube cancer diagnosis and thyroid stimulating hormone tsh
__label__0	study interventions are 5-fraction stereotactic body radiation therapy . pancreatic neoplasms diagnosis and male or female age greater_than equal_than sixteen years
__label__0	study interventions are BB 1101 . stage iv squamous cell carcinoma of the nasopharynx diagnosis and ecog performance status of zero two
__label__0	study interventions are Erlotinib Hydrochloride . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and metastatic
__label__0	study interventions are Bortezomib . stage iv cutaneous cell non hodgkin lymphoma diagnosis and new york heart association class iii iv heart failure
__label__0	study interventions are Lapatinib . neoplasms breast diagnosis and for most forms of hrt at least two four weeks must elapse between the cessation of hrt and determination of menopausal status length of this interval depends on the type and dosage of hrt
__label__0	study interventions are Antibodies, Monoclonal . previously treated childhood rhabdomyosarcoma diagnosis and three half lives or six weeks must have elapsed since previous monoclonal antibody therapy prior to enrollment on this study
__label__0	study interventions are Bevacizumab . choriocarcinoma diagnosis and adequate organ function
__label__0	study interventions are Bortezomib . ovarian mucinous cystadenocarcinoma diagnosis and prothrombin time pt such that international normalized ratio inr is equal_than less_than doc uln or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin
__label__0	study interventions are Docetaxel . melanoma skin diagnosis and renal
__label__0	study interventions are Cysteamine . precancerous condition diagnosis and indolent disease not requiring therapy allowed
__label__0	study interventions are BB 1101 . colorectal cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Isophosphamide mustard . glomus tumor of the skin diagnosis and no evidence of dyspnea at rest no exercise intolerance and resting pulse_oximetry reading greater_than ninety-four on room air if there is clinical indication for determination
__label__0	study interventions are Thalidomide . recurrent plasma cell myeloma diagnosis and eastern cooperative oncology group ecog performance status ps zero one or two
__label__0	study interventions are Endothelial Growth Factors . recurrent adult brain tumor diagnosis and at least two weeks since vincristine
__label__0	study interventions are Bicalutamide . prostate cancer diagnosis and evidence of biochemical progression as determined by three psa measurements each higher than the previous value and meeting the following criteria
__label__0	study interventions are Laboratory Biomarker Analysis . adult alveolar soft part sarcoma diagnosis and qtc equal_than less_than four hundred and eighty msec note
__label__0	study interventions are Bortezomib . recurrent adult hodgkin lymphoma diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to pxdone hundred and one bortezomib boron or mannitol
__label__0	study interventions are Bevacizumab . stage iiia ovarian cancer diagnosis and radiofrequency ablation note
__label__0	study interventions are Fludarabine . metastatic renal cell cancer diagnosis and chemistry
__label__0	study interventions are Silicon . lymphoma diagnosis and hematopoietic
__label__0	study interventions are Irinotecan . alveolar childhood rhabdomyosarcoma diagnosis and favorable risk patients meeting the following criteria
__label__0	study interventions are Succinylcholine . unresectable pancreatic cancer diagnosis and arm cohort four
__label__0	study interventions are Fulvestrant . metastatic breast cancer diagnosis and must be using effective contraception or not be of childbearing potential
__label__0	study interventions are Vidarabine . recurrent grade one follicular lymphoma diagnosis and patients must have an alanine aminotransferase alt and aspartate aminotransferase ast equal_than less_than doc times the institutional upper limits of normal
__label__0	study interventions are Succinylcholine . pretext stage two hepatoblastoma diagnosis and patients must have performance status corresponding to eastern cooperative oncology group ecog scores zero one or two use karnofsky for patients greater_than one6 years of age and lansky for patients equal_than less_than one6 years of age
__label__0	study interventions are Doxorubicin . head and neck cancer diagnosis and no concurrent hormonal therapy except for the following
__label__0	study interventions are Cisplatin . stage iii cervical cancer diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Mitogens . her two positive advanced gastric cancer diagnosis and creatinine clearance can be estimated using cockcroft gault formula man
__label__0	study interventions are Nivolumab . stage iv melanoma diagnosis and serum albumin greater_than doc gm dl
__label__0	study interventions are Doxorubicin . bladder cancer diagnosis and no interstitial pneumonia pulmonary fibrosis or any other diseases by which oxygen inhalation therapy is needed
__label__0	study interventions are alvespimycin hydrochloride . recurrent adult burkitt lymphoma diagnosis and no prior radiation that included the heart in the field mantle
__label__0	study interventions are Antibodies, Monoclonal . recurrent prostate carcinoma diagnosis and hemoglobin greater_than nine dl
__label__0	study interventions are Antibodies, Monoclonal . bronchoalveolar cell lung cancer diagnosis and at least four weeks since prior thoracic or other major surgery excluding mediastinoscopy and recovered
__label__0	study interventions are Mycophenolic Acid . myelodysplastic myeloproliferative neoplasms diagnosis and marrow blasts less_than ten
__label__0	study interventions are Oxaliplatin . stage iv esophageal cancer diagnosis and patients must not have previous or concurrent malignancy exceptions are made for patients who meet any of the following conditions
__label__0	study interventions are Irinotecan . stage iiia rectal cancer diagnosis and vaginal or uterine involvement
__label__0	study interventions are Flutamide . prostate cancer diagnosis and age
__label__0	study interventions are Ergocalciferols . melanoma diagnosis and hematopoietic functionality at the entry of the study
__label__0	study interventions are Tremelimumab . stage ivb colorectal cancer diagnosis and immunohistochemistry ihc testing that does not suggest loss of mlh one msh two pmstwo or mshsix
__label__0	study interventions are Camptothecin . stage iv squamous cell carcinoma of the nasopharynx diagnosis and no concurrent granulocyte colony stimulating factors filgrastim csf or sargramostim gm csf during the first course of study
__label__0	study interventions are Iodine . lymphoma mantle cell diagnosis and patients must have less than an average of twenty-five of the intratrabecular marrow space involved by nhl in bilateral bone marrow biopsy specimens as assessed microscopically at study entry
__label__0	study interventions are internet-based intervention . psychosocial effects of cancer and its treatment diagnosis and possesses working knowledge of english
__label__0	study interventions are Antibodies . brain and central nervous system tumors diagnosis and no diffuse disease defined as any satellite lesion greater_than doc cm from the anticipated location of catheter tip or greater_than two satellite lesions
__label__0	study interventions are Paclitaxel . stage iv skin melanoma diagnosis and patients must not have history or clinical evidence of brain metastasis patients must be evaluated with head magnetic resonance imaging mri within four weeks prior to enrollment
__label__0	study interventions are Fludarabine . lymphoma diagnosis and clinically and or histologically confirmed hematologic malignancy or genetic disorder
__label__0	study interventions are Immunoglobulins . atypical meningioma diagnosis and total bilirubin equal_than less_than doc institutional uln
__label__0	study interventions are Dynamic Contrast-Enhanced Magnetic Resonance Imaging . adult oligodendroglioma diagnosis and adequate renal function serum creatinine equal_than less_than doc mg dl
__label__0	study interventions are Paclitaxel . stage iic ovarian cancer diagnosis and if patient declines to participate in the perfusion imaging portion of the protocol clinical rationale for declination of imaging form will be completed as part of the data submission for acrin six thousand, six hundred and ninety-five
__label__0	study interventions are Polyestradiol phosphate . prostate cancer diagnosis and no condition or situation that could preclude protocol treatment or compliance with follow up schedule
__label__0	study interventions are Antibodies, Monoclonal . lung cancer diagnosis and at least thirty days since prior systemic corticosteroids
__label__0	study interventions are Rituximab . lymphoma diagnosis and eighteen and over
__label__0	study interventions are Liposomal doxorubicin . hepatocellular carcinoma diagnosis and magnetic resonance imaging mri or computerized tomography ct consistent with liver cirrhosis and at least one solid liver lesion greater_than two cm with early enhancement and delayed enhancement washout regardless of alpha feto protein levels afp
__label__0	study interventions are 7-hydroxystaurosporine . unresectable gallbladder cancer diagnosis and no chronic unconjugated hyperbilirubinemia
__label__0	study interventions are Antilymphocyte Serum . recurrent adult lymphoblastic lymphoma diagnosis and normal cardiac function by echocardiogram or radionuclide scan left ventricular ejection fraction greater_than forty-five if the left ventricular ejection fraction is between forty fifty clearance by an adult cardiologist is required
__label__0	study interventions are proteomic profiling . breast cancer diagnosis and sex
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iic ovarian cancer diagnosis and patients who have met the pre entry requirements specified
__label__0	study interventions are Cancer Stem Cells Sensitivity Assay . colorectal cancer diagnosis and no concomitant comorbidity potentially interfering with the study
__label__0	study interventions are Doxorubicin . triple negative breast carcinoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Dacarbazine . gliosarcoma diagnosis and progression
__label__0	study interventions are Docetaxel . pancreatic cancer diagnosis and karnofsky sixty one hundred
__label__0	study interventions are Antibodies . stage iiic primary peritoneal cancer diagnosis and karnofsky performance score of greater_than equal_than seventy is required or eastern cooperative oncology group ecog score performance status ps equal_than zero two
__label__0	study interventions are Everolimus . tumor biopsy sequencing
__label__0	study interventions are Cyclosporine . stage iii adult diffuse mixed cell lymphoma diagnosis and the cdfour count less_than one hundred cells ul
__label__0	study interventions are Everolimus . stage iv prostate cancer diagnosis and no known brain metastases
__label__0	study interventions are BNC101 Solution for Infusion . colorectal cancer diagnosis and serum albumin greater_than three dl
__label__0	study interventions are Plasminogen . unspecified adult solid tumor protocol specific diagnosis and hepatic
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and other
__label__0	study interventions are Camptothecin . stage iva cervical cancer diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Antibodies . stage iiib ovarian cancer diagnosis and bilirubin equal_than less_than doc uln
__label__0	study interventions are Vaccines . breast cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . cancer diagnosis and arm cohort
__label__0	study interventions are Fludarabine phosphate . recurrent grade one follicular lymphoma diagnosis and patients in crtwo prtwo with initial short remission less_than six months are eligible
__label__0	study interventions are Temozolomide . brain and central nervous system tumors diagnosis and must have failed prior external beam radiotherapy
__label__0	study interventions are Mitomycins . neoplasms by site diagnosis and signed informed consent
__label__0	study interventions are Methylprednisolone Hemisuccinate . recurrent grade one follicular lymphoma diagnosis and normal cardiac function by echocardiogram or radionuclide scan left ventricular ejection fraction greater_than forty-five if the left ventricular ejection fraction is between forty fifty clearance by an adult cardiologist is required
__label__0	study interventions are Prednisone . plasmablastic lymphoma diagnosis and females of child bearing potential focbp must have negative pregnancy test within days prior to registration on study
__label__0	study interventions are Antibodies, Monoclonal . ovarian brenner tumor diagnosis and ww cc du manuals_pdf surgma_df eleven two two thousand and nine eight sixteen two thousand and ten
__label__0	study interventions are Temozolomide . stage iva thyroid gland medullary carcinoma diagnosis and patients may have received prior chemotherapy for advanced disease including either capecitabine or temozolomide single agent as long as it did not include combination of capecitabine and temozolomide
__label__0	study interventions are Paclitaxel . non small cell lung cancer diagnosis and informed consent
__label__0	study interventions are reverse transcriptase-polymerase chain reaction . recurrent grade two follicular lymphoma diagnosis and voluntary informed consent is given
__label__0	study interventions are Estrogens . stage iiib breast cancer diagnosis and hemoglobin must be greater_than equal_than ten dl
__label__0	study interventions are Progesterone . breast cancer diagnosis and surgery
__label__0	study interventions are Immunoglobulins . stage grade one follicular lymphoma diagnosis and total bilirubin equal_than less_than doc upper limit of normal uln or if total bilirubin is greater_than doc uln the direct bilirubin must be equal_than less_than uln
__label__0	study interventions are Albumin-Bound Paclitaxel . fallopian tube carcinoma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Paclitaxel . lung cancer diagnosis and concurrent prophylactic anticoagulation warfarin allowed provided requirements for inr are met
__label__0	study interventions are technetium Tc 99m demobesin-4 . prostate cancer diagnosis and metastatic disease at initial diagnosis or recurrent or progressive disease
__label__0	study interventions are Paclitaxel . non small cell lung cancer diagnosis and all females of childbearing potential must have negative serum pregnancy test within seven days prior to the initiation of treatment
__label__0	study interventions are Fludarabine . recurrent adult hodgkin lymphoma diagnosis and waldenstrom macroglobulinemia
__label__0	study interventions are Paclitaxel . recurrent uterine corpus carcinoma diagnosis and therapeutic anticoagulation is not contraindicated but for those patients on therapeutic anticoagulation alteration in coagulation parameters is expected following initiation of dasatinib for patients on therapeutic anticoagulation coagulation parameters should be assessed weekly for the first cycle following initiation of dasatinib weekly for the first cycle following dose reduction and weekly for minimum of two weeks after stopping dasatinib
__label__0	study interventions are Mycophenolic Acid . prostate cancer diagnosis and doc
__label__0	study interventions are Cyclosporins . noncontiguous stage ii grade two follicular lymphoma diagnosis and marrow fibrosis
__label__0	study interventions are BB 1101 . smoldering multiple myeloma diagnosis and ten plasma cells in the bone marrow and any one or more of the following
__label__0	study interventions are Capecitabine . neoplasms breast diagnosis and prior therapy with an erbbone and or erbbtwo inhibitor other than trastuzumab is not permitted
__label__0	study interventions are Epirubicin . breast cancer diagnosis and bilirubin normal unless known gilbert disease is present
__label__0	study interventions are Antibodies, Monoclonal . endometrial papillary serous carcinoma diagnosis and no ototoxicity greater_than ctcae grade two
__label__0	study interventions are Dasatinib . sarcoma ewing diagnosis and subjects must be able to swallow whole tablets
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and for more information regarding bms clinical trial participation please visit ww_msstudyconnec om
__label__0	study interventions are Cyclosporins . recurrent childhood anaplastic large cell lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are laboratory biomarker analysis . stage iiib breast cancer diagnosis and no other uncontrolled illness
__label__0	study interventions are Succinylcholine . childhood lymphocyte depleted classical hodgkin lymphoma diagnosis and no evidence of dyspnea at rest
__label__0	study interventions are Capecitabine . resectable tumor or considered as potentially resectable after crt
__label__0	study interventions are Oxaliplatin . recurrent refractory childhood hodgkin lymphoma diagnosis and life expectancy greater_than eight weeks
__label__0	study interventions are Fluorouracil . stage iv verrucous carcinoma of the larynx diagnosis and no other concurrent investigational agents
__label__0	study interventions are Antibodies, Monoclonal . stage iva oropharyngeal squamous cell carcinoma diagnosis and patients must not be receiving any other investigational agent while on the study
__label__0	study interventions are Dacarbazine . metastatic cancer diagnosis and patient characteristics
__label__0	study interventions are Irinotecan . recurrent childhood ependymoma diagnosis and no concurrent biologic therapy
__label__0	study interventions are Geriatrician Intervention . prostate cancer
__label__0	study interventions are Camptothecin . recurrent lymphoepithelioma of the nasopharynx diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and other
__label__0	study interventions are Rituximab . lymphoma diagnosis and received prior chemotherapy with or without radiotherapy followed by allogeneic hematopoietic stem cell transplantation hsct and relapsed after treatment or not candidate for such therapy
__label__0	study interventions are Liposomal doxorubicin . anaplastic large cell lymphoma alk negative diagnosis and prothrombin time pt or international normalized ratio inr and partial thromboplastin time ptt equal_than less_than doc upper limit of normal unless patient is receiving anticoagulants if patient is on warfarin therapy levels should be within therapeutic range
__label__0	study interventions are Valrubicin . transitional cell carcinoma diagnosis and bcg must have been one of the prior therapies administered
__label__0	study interventions are Levoleucovorin . mature cell lymphoma diagnosis and participants from collaborating sites participating in biological objectives only
__label__0	study interventions are Albumin-Bound Paclitaxel . fallopian tube cancer diagnosis and disease characteristics
__label__0	study interventions are Camptothecin . newly diagnosed previously untreated patients with histologically or molecularly confirmed ewing sarcoma
__label__0	study interventions are Immunoglobulins . stage grade two follicular lymphoma diagnosis and the day of biopsy should be used as day one of diagnosis for this calculation
__label__0	study interventions are Carboplatin . kidney cancer diagnosis and see disease characteristics
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and fvc at least sixty-five of predicted
__label__0	study interventions are Everolimus . non muscle invasive bladder cancer nmibc diagnosis and patients with history of other intravesical agents in addition to standard bcg will also be allowed to enroll
__label__0	study interventions are Bevacizumab . recurrent midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and no prior bevacizumab
__label__0	study interventions are placebo . breast cancer stage ii diagnosis and have one or more stated symptoms of atrophic vaginitis such as vaginal dryness genital irritation itching genital pain and or dyspareunia
__label__0	study interventions are Aldesleukin . lymphoma diagnosis and thallium spectroscopy scan demonstrating thallium retention index greater than one
__label__0	study interventions are Melphalan . estrogen receptor negative breast cancer diagnosis and karnofsky performance status greater_than sixty
__label__0	study interventions are Vaccines . melanoma diagnosis and subjects will be required to have radiological studies to define radiologically evident disease
__label__0	study interventions are Antibodies, Monoclonal . stage iiia primary peritoneal cancer diagnosis and four weeks from an investigational agent not food and drug administration fda approved or five half lives whichever is shorter
__label__0	study interventions are Tacrolimus . testicular germ cell tumor diagnosis and chemotherapy
__label__0	study interventions are Telapristone Acetate . stage iia breast cancer diagnosis and willing to use non hormonal contraception adequate barrier type contraception or intrauterine device iud from the time the pregnancy test is performed for the duration of study participation and thirty days after study drug cessation for women of childbearing potential only
__label__0	study interventions are Mycophenolate mofetil . small intestine lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and hemoglobin must be greater_than equal_than doc mg dl
__label__0	study interventions are Ondansetron . recurrent grade two follicular lymphoma diagnosis and exclusion
__label__0	study interventions are Vaccines . marginal zone lymphoma diagnosis and absolute lymphocyte count greater_than five hundred ul
__label__0	study interventions are Hydrocortisone . recurrent childhood anaplastic large cell lymphoma diagnosis and no isolated bone recurrence
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and surgery
__label__0	study interventions are Capecitabine . cancer diagnosis and ecog performance status less_than two
__label__0	study interventions are Cyclophosphamide . stage iv small lymphocytic lymphoma diagnosis and no other concurrent investigational agents
__label__0	study interventions are Stereotactic Radiosurgery . cervical cancer diagnosis and adequate bone marrow reserve hemoglobin greater_than eight grams absolute neutrophil count greater_than one thousand mmthree platelets greater_than fifty zero mmthree
__label__0	study interventions are Floxuridine . cancer diagnosis and creatinine normal or
__label__0	study interventions are Vaccinia virus (vvDD-CDSR) . colorectal cancer diagnosis and karnofsky performance status kps of greater_than seventy see appendix b
__label__0	study interventions are Isophosphamide mustard . sarcoma diagnosis and fevone greater than two liters paotwo greater than seventy mm hg on room air pacotwo less than 4two mm hg on room air dlco greater than sixty predicted other
__label__0	study interventions are Immunoglobulin G . stage iiia fallopian tube cancer diagnosis and platelets greater than or equal to one hundred zero mcl
__label__0	study interventions are JM 3100 . non hodgkins lymphoma nhl diagnosis and acute myelogenous leukemia aml in onest remission or beyond
__label__0	study interventions are Capecitabine . gallbladder cancer diagnosis and cardiovascular
__label__0	study interventions are BB 1101 . unspecified adult solid tumor protocol specific diagnosis and no recent history less_than one year of alcohol or drug abuse
__label__0	study interventions are Irinotecan . neuroblastoma
__label__0	study interventions are Bevacizumab . recurrent primary peritoneal carcinoma diagnosis and prior regional treatments for liver metastasis are permitted including
__label__0	study interventions are Bevacizumab . stage iii pancreatic cancer diagnosis and no significant traumatic injury within the past four weeks
__label__0	study interventions are Carboplatin . undifferentiated ovarian carcinoma diagnosis and patients are allowed to receive but are not required to receive two additional cytotoxic regimens for management of recurrent or persistent disease maximum number of prior cytotoxic regimens including primary therapy is four patients are allowed to receive but are not required to receive biologic non cytotoxic therapy either alone or as part of the cytotoxic regimens for management of recurrent or persistent disease
__label__0	study interventions are Sorafenib . hepatocellular cancer diagnosis and decision to treat with single agent sorafenib at four hundredmg bid dose reductions or interruptions are permitted if side effects occur during treatment
__label__0	study interventions are Carboplatin . head and neck cancer diagnosis and no involuntary weight loss greater_than twenty-five of body weight within the past two months
__label__0	study interventions are Thalidomide . stage iii grade three follicular lymphoma diagnosis and received high dose chemotherapy with autologous stem cell transplantation asct from forty-two to one hundred and twenty-eight days before enrollment with stable disease partial response or complete response following asct
__label__0	study interventions are Nivolumab . malignant melanoma diagnosis and for more information regarding bms clinical trial participation please visit ww_msstudyconnec om
__label__0	study interventions are mass spectrometry . stage iiic melanoma diagnosis and creatinine less_than doc institutional upper limit of normal iuln and or an adequate renal function as defined by
__label__0	study interventions are Megestrol Acetate . central nervous system tumors diagnosis and patients who are receiving active or palliative therapy are eligible
__label__0	study interventions are Tretinoin . untreated childhood supratentorial primitive neuroectodermal tumor diagnosis and parents legal guardians must have the ability to understand and the willingness to sign written informed consent document according to institutional guidelines
__label__0	study interventions are endoscopic biopsy . lung cancer diagnosis and wbc two zero two0 zero
__label__0	study interventions are Gossypol . contiguous stage ii mantle cell lymphoma diagnosis and life expectancy of greater than three months
__label__0	study interventions are Camptothecin . recurrent squamous cell carcinoma of the oropharynx diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Mycophenolic Acid . contiguous stage ii marginal zone lymphoma diagnosis and donor
__label__0	study interventions are Tacrolimus . kidney cancer diagnosis and negative pregnancy test
__label__0	study interventions are Mycophenolic Acid . recurrent refractory childhood hodgkin lymphoma diagnosis and no serious uncontrolled psychiatric illness
__label__0	study interventions are Vidarabine . stage ii childhood large cell lymphoma diagnosis and not eligible for conventional myeloablative hct or after autologous hct
__label__0	study interventions are Albumin-Bound Paclitaxel . bladder cancer diagnosis and at least four weeks since prior major surgery and recovered
__label__0	study interventions are Cyclosporins . stage adult hodgkin lymphoma diagnosis and the viral load is less_than fifty copies ml plasma
__label__0	study interventions are Ixazomib . multiple myeloma diagnosis and male or female patients eighteen years or older
__label__0	study interventions are Imatinib Mesylate . isolated plasmacytoma of bone diagnosis and negative pregnancy test
__label__0	study interventions are Etoposide . brain and central nervous system tumors diagnosis and concurrent steroids allowed radiotherapy
__label__0	study interventions are Cytarabine . childhood immunoblastic large cell lymphoma diagnosis and concurrent radiotherapy to localized painful airway compromising or other acute organ threatening lesions allowed provided at least one measurable lesion is not irradiated
__label__0	study interventions are Interferons . colorectal cancer diagnosis and eighteen and over
__label__0	study interventions are Everolimus . stage iii adult burkitt lymphoma diagnosis and only filgrastim csf mobilized peripheral blood mononuclear cell pbmc only will be permitted as hsc_source on this protocol
__label__0	study interventions are Everolimus . blood samples and available paraffin_embedded tumor material for translational research studies
__label__0	study interventions are Erlotinib Hydrochloride . stage iiib rectal cancer diagnosis and participants are eligible for randomization into the treatment phase of the trial if they are found to have greater_than four acfs at either baseline colonoscopy or baseline flexible_sigmoidoscopy
__label__0	study interventions are Alvocidib . recurrent adult diffuse large cell lymphoma diagnosis and decrease in normal igm less_than fifty mg dl iga less_than one hundred mg dl or igg less_than six hundred mg dl
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and hiv negative
__label__0	study interventions are Sirolimus . recurrent adult hodgkin lymphoma diagnosis and willingness to take everolimus orally and maintain pill diary
__label__0	study interventions are Everolimus . recurrent small lymphocytic lymphoma diagnosis and patients with refractory disease less than partial response to the last treatment must have received no more than three prior regimens group a
__label__0	study interventions are Mycophenolic Acid . stage iii adult diffuse large cell lymphoma diagnosis and following planned autologous transplant or equivalent high dose therapy without graft or following failed prior autograft
__label__0	study interventions are Cyclophosphamide . stage iv small lymphocytic lymphoma diagnosis and prothrombin time or international normalized ratio inr equal_than less_than doc upper limit of normal uln unless receiving therapeutic anticoagulation
__label__0	study interventions are Questionnaires . liver cancer diagnosis and there will be no upper age restriction
__label__0	study interventions are Sorafenib . liver cancer diagnosis and history of chronic hepatitis and or cirrhosis of liver
__label__0	study interventions are Carboplatin . recurrent brain tumors diagnosis and hemoglobin greater_than teng dl
__label__0	study interventions are Reduced intensity conditioning . lymphoma low grade diagnosis and hepatic
__label__0	study interventions are behavioral, psychological or informational intervention . stage iiib cervical cancer diagnosis and able to give informed consent
__label__0	study interventions are Fluorouracil . esophageal cancer diagnosis and granulocytes greater_than one zero mm³
__label__0	study interventions are Glycine . plasma cell myeloma diagnosis and voluntary written consent must be given before performance of any study related procedure not part of standard medical care with the understanding that consent may be withdrawn by the patient at any time without prejudice to future medical care
__label__0	study interventions are Sorafenib . stage iii marginal zone lymphoma diagnosis and ascites
__label__0	study interventions are Bevacizumab . adult papillary meningioma diagnosis and all patients must sign an informed consent indicating that they are aware of the investigational nature of the study
__label__0	study interventions are Antibodies . stage iv non small cell lung cancer diagnosis and no evidence of cns disease including the following part two only
__label__0	study interventions are Paclitaxel . recurrent endometrial carcinoma diagnosis and no clinically significant autoimmune disease rheumatoid arthritis
__label__0	study interventions are Methotrexate . multiple myeloma and plasma cell neoplasm diagnosis and lvef greater_than thirty by muga
__label__0	study interventions are Succinylcholine . stage ivb oropharyngeal squamous cell carcinoma diagnosis and central within two cm from the hilum lung metastases that are cavitary as shown unequivocally by imaging studies
__label__0	study interventions are Hydrocortisone acetate . stage iii childhood lymphoblastic lymphoma diagnosis and lly
__label__0	study interventions are quality-of-life assessment . stage iiib non small cell lung cancer diagnosis and fcg eligibility criteria include
__label__0	study interventions are Cyclophosphamide . unspecified childhood solid tumor protocol specific diagnosis and inborn_errors of metabolism
__label__0	study interventions are Mycophenolic Acid . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and high risk crone for example but not limited to
__label__0	study interventions are Imatinib Mesylate . t lymphoblastic lymphoma diagnosis and creatinine equal_than less_than doc mg dl however patients with creatinine greater_than doc mg dl but with calculated creatinine clearance of greater_than sixty ml min as measured by the modification of diet in renal disease mdrd equation will be eligible
__label__0	study interventions are Antibodies, Monoclonal . insulinoma diagnosis and absolute neutrophil count anc greater_than equal_than doc one hundred and nine greater_than equal_than one thousand, five hundred mmthree
__label__0	study interventions are Cyclophosphamide . stage iii aids related lymphoma diagnosis and patients may enroll with lower hematologic values if bone marrow involvement is documented in this case patients should be transfused to hemoglobin greater_than eight dl
__label__0	study interventions are Isophosphamide mustard . testicular choriocarcinoma and embryonal carcinoma diagnosis and bilirubin less_than doc times upper limit of normal uln for age
__label__0	study interventions are Thalidomide . peripheral cell lymphoma diagnosis and creatinine clearance greater_than equal_than thirtyml min by cockcroft gault formula
__label__0	study interventions are Mannitol . long term effects secondary to cancer therapy in children diagnosis and open biopsy
__label__0	study interventions are Imatinib Mesylate . gastrointestinal stromal tumor diagnosis and negative pregnancy test
__label__0	study interventions are Pembrolizumab . microsatellite_instability msi high colorectal cancer diagnosis and prior anti ctla four in the adjuvant setting would be permitted
__label__0	study interventions are Dexamethasone . tsh secreting adenoma diagnosis and must not be known to be refractory to rbc or platelet transfusions
__label__0	study interventions are Immunoglobulin G . stage ivb lip and oral cavity squamous cell carcinoma diagnosis and eastern cooperative oncology group ecog performance status of zero one
__label__0	study interventions are Antibodies, Monoclonal . stage iv lymphoepithelioma of the nasopharynx diagnosis and performance status
__label__0	study interventions are Pertuzumab . breast cancer diagnosis and left ventricular ejection fraction lvef of at least fifty
__label__0	study interventions are Temozolomide . adult gliosarcoma diagnosis and the patient must have post operative contrast enhanced imaging ct or mri unless only biopsy performed in which case post operative imaging is not routinely obtained
__label__0	study interventions are Mycophenolate mofetil . recurrent adult diffuse large cell lymphoma diagnosis and pbmc only will be permitted as hsc_source on this protocol
__label__0	study interventions are Oxaliplatin . childhood malignant testicular germ cell tumor diagnosis and no concurrent immunomodulating agents
__label__0	study interventions are No personalized dose redistribution . non small cell lung cancer diagnosis and mediastinoscopy or endobronchial ultrasound to prove the histological stage ntwo nthree
__label__0	study interventions are Topotecan . unspecified childhood solid tumor protocol specific diagnosis and at least fourteen days after local palliative xrt small port at least eighty-four days must have elapsed if prior tbi craniospinal xrt or greater_than fifty radiation to pelvis at least forty-two days must have elapsed if other substantial bm radiation
__label__0	study interventions are Trastuzumab . unspecified adult solid tumor protocol specific diagnosis and age
__label__0	study interventions are Prednisolone acetate . splenic marginal zone lymphoma diagnosis and am negative relapse persistent disease with less_than twenty bone marrow blasts
__label__0	study interventions are Mitogens . breast cancer diagnosis and adequate bone marrow function absolute neutrophil count greater_than one thousand, five hundred mmthree platelet count greater_than ten doc zero mmthree hemoglobin greater_than tengr mmthree
__label__0	study interventions are Gefitinib . urethral cancer diagnosis and soft tissue disease that has been irradiated within the past two months not considered measurable disease
__label__0	study interventions are Bicalutamide . adenocarcinoma of the prostate diagnosis and within seven days prior to enrollment hematology
__label__0	study interventions are Hydrocortisone acetate . prostate cancer diagnosis and radiotherapy
__label__0	study interventions are Antibodies, Monoclonal . lymphoma follicular diagnosis and disease progression in responders within six months of the last dose of rituximab either given as monotherapy or in combination with any chemotherapy or after rituximab maintenance treatment schedule following chemo
__label__0	study interventions are Pemetrexed . hormone resistant prostate cancer diagnosis and serum glutamic oxaloacetic transaminase sgot serum glutamic pyruvic transaminase sgpt equal_than less_than threex the uln for the reference lab equal_than less_than fivex the uln for patients with known hepatic metastases
__label__0	study interventions are Laboratory Biomarker Analysis . recurrent small cell lung carcinoma diagnosis and estimated creatinine clearance of greater_than equal_than thirty ml min calculated using the formula of cockroft and gault
__label__0	study interventions are Thalidomide . recurrent adult hodgkin lymphoma diagnosis and calculated creatinine clearance greater_than equal_than sixtyml min by cockcroft gault estimation of crci
__label__0	study interventions are Antibodies, Monoclonal . stage iv renal cell cancer diagnosis and protocol entry criteria
__label__0	study interventions are Melphalan . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and compatibility at the four most informative hla loci
__label__0	study interventions are Insulin . breast cancer diagnosis and seventy year old female
__label__0	study interventions are Azacitidine . myelodysplastic myeloproliferative neoplasms diagnosis and renal
__label__0	study interventions are Polystyrene sulfonic acid . urothelial carcinoma diagnosis and must be less_than grade one
__label__0	study interventions are Sirolimus . stage iv melanoma diagnosis and no concurrent full dose anticoagulation warfarin iv heparin or low molecular weight heparin
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Liposomal doxorubicin . stage iiic breast cancer diagnosis and at least one bidimensionally or unidimensionally measurable indicator lesion
__label__0	study interventions are Lenograstim . sarcoma diagnosis and no known hypersensitivity reaction to docetaxel or other polysorbate eighty formulated agents
__label__0	study interventions are Celecoxib . precancerous condition diagnosis and no clinical evidence of connective tissue disease
__label__0	study interventions are alvespimycin hydrochloride . recurrent salivary gland cancer diagnosis and no myocardial infarction within the past year
__label__0	study interventions are Temozolomide . brain neoplasms diagnosis and all patients men and women must agree to use medically approved contraceptive measures simultaneously prior to starting thalidomide therapy all during drug therapy and for at least one month after therapy has stopped
__label__0	study interventions are Navitoclax . solid tumor diagnosis and aptt and pt not to exceed less than or equal to doc uln
__label__0	study interventions are Etoposide . adenocarcinoma of the lung diagnosis and no clinically significant peripheral vascular disease
__label__0	study interventions are Taxane . solid tumor diagnosis and able to fully understand and participate in the informed consent process
__label__0	study interventions are Belinostat . stage iii adult diffuse mixed cell lymphoma diagnosis and condition requiring antiarrhythmic therapy
__label__0	study interventions are Bevacizumab . stage iv adult lymphoblastic lymphoma diagnosis and ast sgot alt sgpt equal_than less_than doc institutional upper limit of normal patients with liver involvement will be allowed equal_than less_than doc institutional upper normal limit
__label__0	study interventions are Iodine . renal cancer diagnosis and the following laboratory results should be within the following limits within the last four weeks prior to study day one
__label__0	study interventions are Doxorubicin . stage iii ovarian cancer diagnosis and the following are ineligible
__label__0	study interventions are Azacitidine . stage iv adult diffuse large cell lymphoma diagnosis and at least two weeks since prior valproic acid or any other histone_deacetylase inhibitor
__label__0	study interventions are Vaccines . oligodendroglioma diagnosis and able to provide informed consent
__label__0	study interventions are Interleukin-2 . stage ii multiple myeloma diagnosis and greater than sixty days post bmt
__label__0	study interventions are Antimetabolites . breast neoplasms diagnosis and age
__label__0	study interventions are alvespimycin hydrochloride . stage iv squamous cell carcinoma of the hypopharynx diagnosis and no history of serious ventricular arrhythmia ventricular tachycardia or ventricular fibrillation greater_than equal_than three beats in row
__label__0	study interventions are Prednisone . prostate cancer diagnosis and no prior radioisotope therapy
__label__0	study interventions are Irinotecan . unspecified adult solid tumor protocol specific diagnosis and must belong to either chinese malay or indian ethnic groups
__label__0	study interventions are Stereotactic Body Radiation Therapy . non small cell lung cancer nsclc diagnosis and age greater_than eighteen years
__label__0	study interventions are Dexamethasone acetate . eastern cooperative oncology group ecog performance status zero two three if it is directly disease related and is expected to get better if the acute lymphoblastic leukemia lymphoma all is under control
__label__0	study interventions are Lenograstim . renal cell carcinoma diagnosis and six to less_than ten years male and female serum creatinine
__label__0	study interventions are Melphalan . splenic marginal zone lymphoma diagnosis and syngeneic donors are not eligible
__label__0	study interventions are Antibodies . untreated childhood rhabdomyosarcoma diagnosis and doc mg dl for patients one to five months of age
__label__0	study interventions are Metformin . esophageal cancer diagnosis and adequate barrett mucosa which is defined as greater_than equal_than one out of four research samples greater_than equal_than twenty-five with greater_than equal_than fifty intestinal metaplasia in biopsies required to satisfy the endpoints of the study
__label__0	study interventions are Carboplatin . neuroectodermal tumors primitive diagnosis and histologically documented diagnosis
__label__0	study interventions are Vidarabine . splenic marginal zone lymphoma diagnosis and hematologic acute treatment related toxicities must have resolved to grade two or less whereas non hematologic chronic treatment related toxicities must be stable or shown improvement in the four weeks preceding enrollment
__label__0	study interventions are Tumor Sample . planned treatment with lonafarnib for metastatic breast cancer
__label__0	study interventions are Gemcitabine . peritoneal neoplasms diagnosis and ecog performance status of zero or one
__label__0	study interventions are Thiotepa . testicular germ cell tumor diagnosis and patient characteristics
__label__0	study interventions are Vidarabine . contiguous stage ii adult diffuse large cell lymphoma diagnosis and patients in blast crisis bc must receive therapy and must achieve accelerated phase ap chronic phase cp in order to be eligible patients who remain in bc are not eligible
__label__0	study interventions are Cyclophosphamide . metastatic renal cancer diagnosis and white blood cell wbc greater_than three thousand mm three
__label__0	study interventions are Vaccines . malignant conjunctival neoplasm diagnosis and patient characteristics
__label__0	study interventions are Sirolimus . childhood leiomyosarcoma diagnosis and anc greater_than seven hundred and fifty µl
__label__0	study interventions are Pharmacological Study . patients must have histologically confirmed operable invasive breast cancer and have undergone core needle biopsy with an anticipated surgical resection for residual disease after enrollment
__label__0	study interventions are Anastrozole . recurrent breast cancer diagnosis and none of the following within the past six months
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and not specified
__label__0	study interventions are Endothelial Growth Factors . stage iiic fallopian tube cancer diagnosis and neuropathy sensory or motor less than or equal to common terminology criteria for adverse events ctcae grade one
__label__0	study interventions are Liposomal doxorubicin . sarcoma diagnosis and prior concurrent therapy
__label__0	study interventions are Docetaxel . urothelial carcinoma diagnosis and the participant does not have
__label__0	study interventions are Levoleucovorin . stage ivb gallbladder cancer diagnosis and patients must have echocardiogram and left ventricular ejection fraction lvef greater_than equal_than institutional lower limit of normal lln within twenty-eight days prior to registration this exam should not be performed until or unless it is very clear the patient is otherwise eligible for registration
__label__0	study interventions are Methotrexate . stage iv adult lymphoblastic lymphoma diagnosis and total bilirubin equal_than less_than doc mg unless from gilbert disease or disease related
__label__0	study interventions are Cisplatin . squamous cell carcinoma diagnosis and male patients must agree to use condom with spermicide or their female partner must use an effective method of birth control
__label__0	study interventions are Immunoglobulins . estrogen receptor negative breast cancer diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than doc upper limit of normal unless bone metastasis is present in the absence of liver metastasis
__label__0	study interventions are Paclitaxel . ovarian endometrioid adenocarcinoma diagnosis and patients must not have received chemotherapy within five years prior to enrollment
__label__0	study interventions are Albumin-Bound Paclitaxel . at least two weeks since prior radiotherapy for ductal carcinoma in situ
__label__0	study interventions are Semaxinib . unspecified adult solid tumor protocol specific diagnosis and no unstable or severe concurrent medical condition
__label__0	study interventions are Melphalan . multiple myeloma and plasma cell neoplasm diagnosis and no infection requiring treatment with antibiotics antifungal or antiviral agents within the past seven days
__label__0	study interventions are Sirolimus . stage ivb major salivary gland carcinoma diagnosis and women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation
__label__0	study interventions are Electronic tailored messaging . at average risk for colorectal cancer
__label__0	study interventions are Antibodies . recurrent uterine corpus sarcoma diagnosis and no history of transient ischemic attack tia or stroke or cns hemorrhage within the past six months
__label__0	study interventions are BB 1101 . solitary osseous plasmacytoma diagnosis and adequate cardiac function defined as
__label__0	study interventions are Fludarabine phosphate . concurrent steroids allowed but must be tapered to less than doc mg kg day of prednisone or equivalent prior to starting study drug if symptomatic flare develops during taper patients may continue on the lowest dose thought to produce stabilization radiotherapy
__label__0	study interventions are ABT-751 . sarcoma diagnosis and measurable or evaluable disease note
__label__0	study interventions are Cetuximab . stage iv colon cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mm three
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ib gastric cancer diagnosis and adequate organ function equal_than less_than twenty-one days prior to registration
__label__0	study interventions are Laboratory Biomarker Analysis . adult synovial sarcoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Sirolimus . childhood synovial sarcoma diagnosis and patients must not have received myelosuppressive chemotherapy within three weeks of enrollment six weeks if prior nitrosourea
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and not specified hematopoietic
__label__0	study interventions are Bevacizumab . ovarian endometrioid adenocarcinoma diagnosis and optimal less_than one cm residual disease or suboptimal residual disease following initial surgery
__label__0	study interventions are Olaparib . stage iiia non small cell lung cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Paclitaxel . lung cancer diagnosis and no intra abdominal abscess within the past six months
__label__0	study interventions are Propofol . cord tumor compression or instability diagnosis and deemed safe to undergo sedation with propofol based on pre sedation examination
__label__0	study interventions are Cetuximab . stage iv colon cancer diagnosis and more than seven days since prior and no concurrent administration of the following cypthreeafour inhibitors
__label__0	study interventions are Tipifarnib . cancer diagnosis and expression of positive one to three positive hertwo neu on immunohistochemical or immunocytochemistry staining
__label__0	study interventions are Cyclophosphamide . metastatic thyroid cancer diagnosis and o
__label__0	study interventions are Paclitaxel . breast neoplasms diagnosis and the patient must be able to give an informed consent and to return to nci for treatment and adequate follow up for the period the protocol requires
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ib uterine sarcoma diagnosis and neuropathy sensory and motor less than or equal to ctcae doc grade one
__label__0	study interventions are laboratory biomarker analysis . recurrent childhood pineoblastoma diagnosis and gfr greater_than seventy ml min doc threem two
__label__0	study interventions are fenretinide . neuroblastoma diagnosis and high risk disease meeting at least one of the following criteria
__label__0	study interventions are Prednisone . stage iv prostate cancer diagnosis and life expectancy twelve weeks or more
__label__0	study interventions are Carboplatin . neuroblastoma diagnosis and fev_one fvc greater than sixty except for children who
__label__0	study interventions are Interferons . metastatic gastrointestinal carcinoid tumor diagnosis and severe psoriasis
__label__0	study interventions are Abiraterone Acetate . prostate cancer diagnosis and medically castrated with testosterone levels of less_than twenty fifty ng dl less_than doc nm
__label__0	study interventions are Cyclosporins . lymphoma diagnosis and aplastic anemia patients
__label__0	study interventions are validated health-related quality of life questionnaires . bladder cancer diagnosis and may have had received intravesical neoadjuvant adjuvant chemotherapy or immunotherapy
__label__0	study interventions are Fluorouracil . head and neck cancer diagnosis and deemed appropriate for definitive non operative management with curative intent
__label__0	study interventions are polymorphism analysis . lung cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Liposomal doxorubicin . intraocular lymphoma diagnosis and stratum one
__label__0	study interventions are Questionnaires . breast cancer diagnosis and pilot participants and healthy controls only
__label__0	study interventions are Everolimus . recurrent adult brain tumor diagnosis and wbc greater_than three thousand mmthree
__label__0	study interventions are Cisplatin . cervical cancer diagnosis and not specified
__label__0	study interventions are Ethanol . neuroblastoma diagnosis and no concurrent levetiracetam or other anticonvulsants
__label__0	study interventions are pain therapy . breast cancer diagnosis and must have completed treatment two six months ago
__label__0	study interventions are Immunoglobulins . borderline ovarian mucinous tumor diagnosis and patients with life expectancy greater_than three months
__label__0	study interventions are Dexamethasone . myeloma diagnosis and plasma cell leukemia
__label__0	study interventions are Bevacizumab . stage iib breast cancer diagnosis and accelerated partial breast radiation apbi after chemotherapy
__label__0	study interventions are Fludarabine . stage iii childhood large cell lymphoma diagnosis and donor
__label__0	study interventions are Antibodies . adenocarcinoma of the pancreas diagnosis and pt inr equal_than less_than doc unless patient is on full dose warfarin
__label__0	study interventions are Poly ICLC . t cell lymphoma diagnosis and topical therapy
__label__0	study interventions are Pembrolizumab . metastatic melanoma diagnosis and have performance status of zero or one on the ecog performance scale
__label__0	study interventions are Folic Acid . ovarian cancer diagnosis and total bilirubin level less_than doc uln and alanine aminotransferase alt aspartate aminotransferase ast gamma glutamyl transferase ggt and alkaline phosphatase levels less_than doc uln
__label__0	study interventions are Pembrolizumab . stage iiia gastric cancer diagnosis and note
__label__0	study interventions are Valganciclovir . stage iv marginal zone lymphoma diagnosis and must have already been determined to be eligible for hct at city of hope_coh
__label__0	study interventions are 7-hydroxystaurosporine . small intestine leiomyosarcoma diagnosis and part ii
__label__0	study interventions are Vaccines . stage iv colorectal cancer diagnosis and if the resected lesions had occurred in other sites these must be also included in the baseline ct scan and in all the subsequent evaluations
__label__0	study interventions are Methoxsalen . lymphoma diagnosis and over eighteen
__label__0	study interventions are Antibodies . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and ast and alt no greater than doc times upper limit of normal
__label__0	study interventions are Cisplatin . stage iii lymphoepithelioma of the nasopharynx diagnosis and no serious and inadequately controlled cardiac arrhythmia
__label__0	study interventions are Mycophenolate mofetil . splenic marginal zone lymphoma diagnosis and mds with lower ipss score int one or less with severe clinical features such as severe neutropenia or thrombocytopenia or high risk chromosome abnormalities such as monosomy seven
__label__0	study interventions are Enzastaurin . lymphoma malignant diagnosis and note
__label__0	study interventions are Sirolimus . metastatic breast cancer diagnosis and provision of signed and dated written informed consent prior to any protocol specific procedure including biopsy
__label__0	study interventions are Mycophenolic Acid . recurrent grade one follicular lymphoma diagnosis and nine twenty-two one onenine four oneone or other mixed lineage leukemia mll_rearrangements hypodiploid
__label__0	study interventions are Liposomal doxorubicin . sarcoma diagnosis and chemotherapy
__label__0	study interventions are Ursodeoxycholic Acid . esophageal carcinoma diagnosis and total bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Nivolumab . advanced solid neoplasm diagnosis and ability to understand and to sign written informed consent document
__label__0	study interventions are Healthy Eating Control . post operative for breast cancer
__label__0	study interventions are Busulfan . lymphoma diagnosis and see disease characteristics endocrine therapy
__label__0	study interventions are Quality-of-Life Assessment . stage iiib colorectal cancer diagnosis and criteria for survivors
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent childhood large cell lymphoma diagnosis and no other concurrent investigational drugs
__label__0	study interventions are Doxorubicin . long term effects secondary to cancer therapy in adults diagnosis and no condition that compromises compliance with the objectives and procedures of this study as judged by the principal investigator
__label__0	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and five six or six six related donor match or seven eight eight hla b drbone allele matched unrelated donor marrow and or pbsc donor match per current institutional guidelines related donors will be evaluated and collected per mt20one2 one4c unrelated donors will be identified and collected per usual procedures
__label__0	study interventions are Paclitaxel . fallopian tube carcinoma diagnosis and activated partial thromboplastin time aptt less_than doc uln unless subject is receiving anticoagulant therapy as long as pt or ptt is within therapeutic range of intended use of anticoagulants
__label__0	study interventions are Irinotecan . solid tumor diagnosis and measurable or evaluable disease
__label__0	study interventions are Sirolimus . recurrent childhood lymphoblastic lymphoma diagnosis and acute lymphocytic leukemia all must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are combination of Cyberknife with S-1 . pancreatic cancer diagnosis and doc
__label__0	study interventions are Iodine-131 anti-B1 antibody . stage iv small lymphocytic lymphoma diagnosis and patient has received prior therapy and is in onest remission with partial or complete response to treatment
__label__0	study interventions are Erlotinib Hydrochloride . ovarian cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Hydroxyurea . stage iii basal cell carcinoma of the lip diagnosis and no deep venous thrombosis
__label__0	study interventions are biologic sample preservation procedure . lymphoma diagnosis and if subsequent diagnostic review alters the original diagnosis the patient will be removed from the treatment clinical trial
__label__0	study interventions are Temozolomide . liver cancer diagnosis and ecog performance status zero two
__label__0	study interventions are Prevana Dressing . cancer diagnosis and patients scheduled for surgical resection
__label__0	study interventions are Vinblastine . adult mixed cellularity hodgkin lymphoma diagnosis and ns lymphocytic predominance
__label__0	study interventions are Capecitabine . recurrent rectal cancer diagnosis and no serious non healing wound ulcer or bone fracture
__label__0	study interventions are Etoposide phosphate . metastatic peripheral primitive neuroectodermal tumor of bone diagnosis and patients must have normal blood sugar level for age to participate if an initial random draw ie
__label__0	study interventions are Mycophenolic Acid . hematopoietic and lymphoid cell neoplasm diagnosis and must have received and failed frontline therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . fallopian tube cancer diagnosis and creatinine no greater than doc mg dl cardiovascular
__label__0	study interventions are Mechlorethamine . ds stage plasma cell myeloma diagnosis and patients may not be receiving any other investigational agents
__label__0	study interventions are Dehydroepiandrosterone . estrogen receptor negative neoplasm diagnosis and ecog eastern cooperative oncology group performance status less_than two
__label__0	study interventions are HER-2/neu intracellular domain protein . breast cancer diagnosis and concurrent bisphosphonates allowed
__label__0	study interventions are Imidazole . stage iv uveal melanoma diagnosis and any history of congenital long qt syndrome
__label__0	study interventions are Vincristine . recurrent adult immunoblastic large cell lymphoma diagnosis and in women of child bearing age pregnancy test may be done at the discretion of the investigator
__label__0	study interventions are BKM120 . metastatic pancreatic cancer diagnosis and patients must have normal organ and marrow function as defined below
__label__0	study interventions are Male ER(+) BC Patients . enzalutamide treated cohort cohort two must have received prior enzalutamide for breast cancer
__label__0	study interventions are Etoposide phosphate . stage ii childhood lymphoblastic lymphoma diagnosis and all patients and or their parents or legal guardians must sign written informed consent assent when appropriate will be obtained according to institutional guidelines
__label__0	study interventions are Alisertib . adult nasal type extranodal nk cell lymphoma diagnosis and serum bilirubin equal_than less_than two times institutional upper limit of normal
__label__0	study interventions are Tegafur . breast cancer diagnosis and at least three months hematopoietic
__label__0	study interventions are Folic Acid . distance of the lowest tumor margin from the anal verge and
__label__0	study interventions are Prednisone . men with metastatic castration resistant prostate cancer
__label__0	study interventions are cytogenetic analysis . breast cancer diagnosis and not specified
__label__0	study interventions are Liposomal doxorubicin . estrogen receptor positive breast cancer diagnosis and hormone receptor estrogen receptor er or progesterone receptor pr positive and hertwo neu positive or
__label__0	study interventions are Histone Deacetylase Inhibitors . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and negative pregnancy test
__label__0	study interventions are Doxorubicin . stage iia breast cancer diagnosis and sentinel lymphadenectomy alone
__label__0	study interventions are Bevacizumab . stage ivc oral cavity verrucous carcinoma diagnosis and no known brain metastases
__label__0	study interventions are sabarubicin . testicular germ cell tumor diagnosis and prior concurrent therapy
__label__0	study interventions are Oxaliplatin . neoplasm metastasis diagnosis and prior adjuvant chemotherapy allowed
__label__0	study interventions are Mycophenolate mofetil . contiguous stage ii adult burkitt lymphoma diagnosis and all patients must be in cr as defined by hematologic recovery and less_than five blasts by morphology within the bone marrow and cellularity of greater_than equal_than 1five
__label__0	study interventions are Cyclophosphamide . recurrent childhood small noncleaved cell lymphoma diagnosis and positive cytomegalovirus cmv immunoglobulin igm and or positive hepatitis serologies demonstrating infection will require an infectious disease consult and subsequent clearance
__label__0	study interventions are Thalidomide . contiguous stage ii small lymphocytic lymphoma diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least fifty miu ml within ten
__label__0	study interventions are Azacitidine . metastatic melanoma diagnosis and be willing and able to provide written informed consent assent for the trial
__label__0	study interventions are Cisplatin . cancer of cervix diagnosis and bilirubin total less_than one six mg dl and liver enzymes ast alt less_than twox upper limit of normal
__label__0	study interventions are Nivolumab . non small cell lung cancer diagnosis and age greater_than eighteen years
__label__0	study interventions are Cisplatin . unspecified adult solid tumor protocol specific diagnosis and other
__label__0	study interventions are Paclitaxel . metastatic breast cancer diagnosis and patients may have received other therapies including immunotherapy or with signal_transduction inhibitors
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and alanine aminotransferase alt and aspartate aminotransferase ast less_than three uln
__label__0	study interventions are Capecitabine . metastatic colorectal cancer diagnosis and non prior chemotherapy for metastatic disease
__label__0	study interventions are antineoplaston AS2-1 . lymphoma diagnosis and biologic therapy
__label__0	study interventions are Levoleucovorin . lymphoma diagnosis and patients diagnosed with cell pcnsl allowed but will not receive rituximab on study
__label__0	study interventions are Vaccines . glioblastoma diagnosis and note
__label__0	study interventions are Irinotecan . adenocarcinoma of the colon diagnosis and eastern cooperative oncology group ecog zero two
__label__0	study interventions are Bendamustine Hydrochloride . nodal marginal zone lymphoma diagnosis and toxicities from prior therapies must have resolved to baseline or be equal_than less_than grade two and stable for at least one month
__label__0	study interventions are Dexamethasone 21-phosphate . adenocarcinoma of the rectum diagnosis and ecog zero one
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and subject must voluntarily sign and understand written informed consent
__label__0	study interventions are Lenalidomide . kidney cancer diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Levoleucovorin . stage iii childhood large cell lymphoma diagnosis and no prior chemotherapy
__label__0	study interventions are Bevacizumab . mri scan with gadolinium contrast showing geographically circumscribed tumor less_than than or equal to doc cm
__label__0	study interventions are Fludarabine . recurrent childhood large cell lymphoma diagnosis and resistant or recurrent disease after at least one standard combination chemotherapy or first remission patients at high risk of relapse acute myeloid leukemia aml
__label__0	study interventions are Fludarabine . ewings sarcoma diagnosis and patients who have received prior autologous stem cell transplant are eligible
__label__0	study interventions are Epirubicin . breast cancer diagnosis and normal liver function as defined by
__label__0	study interventions are Thalidomide . stage iii grade three follicular lymphoma diagnosis and to define_dhl patients must have evidence of myc defined as
__label__0	study interventions are Bicalutamide . stage iib prostate cancer diagnosis and right bundle_branch block and left anterior hemi block bifascicular block
__label__0	study interventions are Endothelial Growth Factors . uterine leiomyosarcoma diagnosis and measurable disease at least one lesion in at least one dimension longest diameter as greater_than equal_than twentymm with conventional techniques or as greater_than equal_than one0mm with spiral ct scan
__label__0	study interventions are Succinylcholine . endometrial adenosquamous carcinoma diagnosis and patients must have normal ejection fraction
__label__0	study interventions are Aldesleukin . myelodysplastic myeloproliferative neoplasms diagnosis and refractory anemia ra refractory anemia with ringed_sideroblasts rars refractory anemia with excess blasts raeb or chronic myelomonocytic leukemia cmml
__label__0	study interventions are Panobinostat . hodgkin lymphoma diagnosis and measurable disease
__label__0	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and at least one measurable lymph node
__label__0	study interventions are Camptothecin . unresectable extrahepatic bile duct cancer diagnosis and only subjects with the following histologies will be eligible
__label__0	study interventions are Sirolimus . stage iv renal cell cancer diagnosis and urine protein to creatinine ratio less_than doc or urine protein equal_than less_than one positive
__label__0	study interventions are radiation therapy . histologically proven breast or prostate cancer
__label__0	study interventions are PF-04856884 . tumor eligibility
__label__0	study interventions are Doxorubicin . stage iia breast cancer diagnosis and alkaline phosphatase must be equal_than less_than doc uln for the lab
__label__0	study interventions are Thioguanine . myelodysplastic myeloproliferative neoplasms diagnosis and no prior radiotherapy for malignancy
__label__0	study interventions are Antibodies, Monoclonal . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and fertile patients must use effective contraception during and for two months after study treatment
__label__0	study interventions are Radiotherapy . minimal diameter of the primary tumor four cm this to allow for boosting of sub volumes
__label__0	study interventions are Everolimus . metastatic cancer diagnosis and negative pregnancy test for women able to have children agreement to use medically accepted birth control method while receiving the study drugs and for at least two weeks after stopping not breast feeding
__label__0	study interventions are Insulin . primitive neuroectodermal tumors pnets diagnosis and general
__label__0	study interventions are Antibodies . stage mantle cell lymphoma diagnosis and ast or alt must be less_than two the upper limit of normal
__label__0	study interventions are Trametinib . cancer diagnosis and pregnant or lactating female
__label__0	study interventions are Cyclosporine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and there is likelihood of rapid disease progression while hla typing and results of preliminary_search and the donor pool_suggests that ten ten hla b drbone and dqbone matched unrelated donor will not be found
__label__0	study interventions are Dexrazoxane . stage iiia breast cancer diagnosis and no dermal lymphatic involvement with clinical inflammatory changes
__label__0	study interventions are Cyclosporins . recurrent adult burkitt lymphoma diagnosis and must have failed two lines of conventional therapy and be refractory to fludarabine
__label__0	study interventions are Antibodies . neoplasm nerve tissue diagnosis and karnofsky performance status greater_than seventy
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iib esophageal adenocarcinoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot equal_than less_than doc institutional upper limit of normal
__label__0	study interventions are Antibodies, Monoclonal . stage ii non small cell lung cancer diagnosis and measurable or evaluable disease
__label__0	study interventions are Epirubicin . breast cancer diagnosis and prior radiation castration with amenorrhea for greater_than six months
__label__0	study interventions are Methylprednisolone Hemisuccinate . breast cancer diagnosis and left ventricular ejection fraction greater_than forty within twenty-eight days of treatment start
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and if the patient has second malignancy with liver metastasis potential histologic or cytologic confirmation of the liver lesions may be performed as clinically indicated
__label__0	study interventions are tanespimycin . recurrent adult lymphoblastic lymphoma diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are Niacinamide . stage iii rectal cancer diagnosis and saquinavir
__label__0	study interventions are Pembrolizumab . colorectal adeonocarcinoma diagnosis and archival tissue is acceptable for enrolled into this study
__label__0	study interventions are Etoposide . recurrent non small cell lung cancer diagnosis and granulocytes greater_than equal_than one thousand, five hundred ul
__label__0	study interventions are Albumin-Bound Paclitaxel . bladder cancer diagnosis and not specified radiotherapy
__label__0	study interventions are Mycophenolate mofetil . stage grade one follicular lymphoma diagnosis and must have received prior chemotherapy and prior autologous transplant unless autologous transplant was not possible planned tandem transplants are allowed for patients at high risk of relapse
__label__0	study interventions are Cisplatin . cervical cancer diagnosis and adequate bone marrow function
__label__0	study interventions are Ifosfamide . diffuse large cell lymphoma diagnosis and phase ii
__label__0	study interventions are Etoposide phosphate . childhood immunoblastic large cell lymphoma diagnosis and hematopoietic lab value requirements are met see hematopoietic
__label__0	study interventions are Liposomal doxorubicin . stage iv breast cancer diagnosis and life expectancy of greater than six months
__label__0	study interventions are Antilymphocyte Serum . unspecified childhood solid tumor protocol specific diagnosis and severe combined immune deficiency
__label__0	study interventions are Fludarabine . unspecified adult solid tumor protocol specific diagnosis and aspartate and alanine aminotransferases ast alt equal_than less_than doc upper limit of normal uln equal_than less_than five uln if documented liver metastases are present
__label__0	study interventions are Oxaliplatin . central nervous system tumors diagnosis and creatinine greater_than doc uln for age if serum creatinine is greater_than doc uln of age then creatinine clearance or radioisotope gfr must be greater_than seventy ml min doc three mtwo adequate hepatic function
__label__0	study interventions are Nivolumab . non small cell lung cancer recurrent diagnosis and leukocytes greater_than two thousand µl hemoglobin greater_than doc dl platelets greater_than one hundred zero µl anc greater_than one five hundred mcl
__label__0	study interventions are placebo . stage iii squamous cell carcinoma of the nasopharynx diagnosis and have an eastern cooperative oncology group ecog performance status of equal_than less_than two
__label__0	study interventions are Temozolomide . neuroblastoma diagnosis and ecog zero two
__label__0	study interventions are Bevacizumab . stage iv melanoma diagnosis and no clinically significant peripheral vascular disease
__label__0	study interventions are SAIT301 . solid tumors diagnosis and at least twenty-eight days must have elapsed since the subject prior systemic therapy radiotherapy or any major surgery excluding diagnostic biopsy or venous access device placement
__label__0	study interventions are Busulfan . neuroblastoma diagnosis and see disease characteristics endocrine therapy
__label__0	study interventions are Prednisolone acetate . multiple myeloma and plasma cell neoplasm diagnosis and availability of hla b and dr identical family donor or hla b and dr genetically matched unrelated donor
__label__0	study interventions are Carboplatin . stage iiia non small cell lung cancer diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Fludarabine phosphate . breast cancer diagnosis and age
__label__0	study interventions are Etoposide . sarcoma diagnosis and disease characteristics
__label__0	study interventions are Immunoglobulins . advanced adult primary liver cancer diagnosis and creatinine equal_than less_than two mg dl
__label__0	study interventions are Interferon-gamma . peritoneal carcinoma diagnosis and candidate for first line chemotherapy
__label__0	study interventions are Lapatinib . stage iii gastric cancer diagnosis and patients must be willing to have specimens submitted the paraffin_embedded specimens must be available for submission
__label__0	study interventions are laboratory biomarker analysis . cancer survivor diagnosis and no concurrent therapy except continued medications for unrelated illness that are not excluded and necessary medications for unrelated acute illnesses that may occur during the study cold flu or infection
__label__0	study interventions are BB 1101 . recurrent childhood medulloblastoma diagnosis and hemoglobin greater_than doc dl may receive rbc transfusions
__label__0	study interventions are Lenalidomide . multiple myeloma in relapse diagnosis and aged eighteen years or older
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and absolute neutrophil count greater_than one five hundred mmthree or doc xone09 l
__label__0	study interventions are Aldesleukin . gastric cancer diagnosis and platelet count greater_than one hundred ten nine l
__label__0	study interventions are Cetuximab . stage iii pancreatic cancer diagnosis and cerebrovascular accident
__label__0	study interventions are Dexamethasone acetate . recurrent mantle cell lymphoma diagnosis and note
__label__0	study interventions are Calcium Carbonate . colorectal cancer diagnosis and no genitourinary stones within the past five years
__label__0	study interventions are Entinostat . unspecified adult solid tumor protocol specific diagnosis and allowed
__label__0	study interventions are Tremelimumab . fallopian tube cancer diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Immunoglobulins . recurrent laryngeal squamous cell carcinoma diagnosis and presence of measurable lesions by recist
__label__0	study interventions are Liposomal doxorubicin . recurrent fallopian tube carcinoma diagnosis and new york heart association nyha class ii or higher congestive heart failure
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and negative progestagen test and
__label__0	study interventions are laboratory biomarker analysis . stage iii pancreatic cancer diagnosis and eastern cooperative oncology group ecog performance status zero or one
__label__0	study interventions are IL13-PE38QQR . anaplastic astrocytoma diagnosis and absolute neutrophils at least one five hundred mm three hemoglobin at least nine gm dl platelets at least one00 zero mm three
__label__0	study interventions are Epothilones . female reproductive cancer diagnosis and at least one week since prior chemotherapy if given on daily or weekly schedule and recovered
__label__0	study interventions are Albumin-Bound Paclitaxel . endometrial carcinoma diagnosis and for patients with recently placed biliary stent patients should have consistent results within hepatic group from two laboratory readings within three days apart taken at least ten days following biliary stent placement for patients with biliary stent placed over two months ago no obstruction or blockage can have occurred within the last two months
__label__0	study interventions are Pembrolizumab . ovarian cancer diagnosis and females must not be pregnant negative human chorionic gonadotropin test within seventy-two hours prior to receiving the first dose of study medication or breastfeeding
__label__0	study interventions are Bevacizumab . lung cancer diagnosis and patients with history of hypertension allowed provided blood pressure is well controlled on stable regimen of anti hypertensive therapy
__label__0	study interventions are Sorafenib . recurrent squamous cell carcinoma of the larynx diagnosis and patients must not be on therapeutic anticoagulation
__label__0	study interventions are Etoposide phosphate . localized ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and additional criteria for group participants who will receive upfront window therapy does not apply to participants who opt out of window therapy
__label__0	study interventions are Fluorouracil . breast cancer diagnosis and hematopoietic
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are radioembolization with Y-90 . patients preoperatively diagnosed of hepatocellular carcinoma according to chest computed tomography ct and or magnetic resonance imaging mri
__label__0	study interventions are laboratory biomarker analysis . the cancer and leukemia group calgb
__label__0	study interventions are Echinocandins . neuroblastoma diagnosis and see disease characteristics
__label__0	study interventions are Folic Acid Antagonists . advanced cancers diagnosis and if in arm doxorubicin and cyclophosphamide left ventricular ejection fraction lvef greater_than equal_than fifty as measured by echocardiogram echo within four weeks prior to study drug administration
__label__0	study interventions are Ifosfamide . germ cell tumor diagnosis and relapsed refractory or completely refractory disease
__label__0	study interventions are Metronidazole . patients must have chosen radical prostatectomy as their definitive treatment of choice for management of their prostate cancer
__label__0	study interventions are Veliparib . fallopian tube transitional cell carcinoma diagnosis and prothrombin time pt such that international normalized ratio inr is equal_than less_than doc uln or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin and partial thromboplastin time ptt less_than doc uln
__label__0	study interventions are Vidarabine . intraocular lymphoma diagnosis and chronic myeloid leukemia cml resistant to signal_transducer inhibitor sti therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiic fallopian tube cancer diagnosis and platelet plt greater_than equal_than one hundred zero
__label__0	study interventions are Bleomycin . lymphoma hodgkin disease diagnosis and previously untreated disease
__label__0	study interventions are Mycophenolic Acid . stage adult diffuse large cell lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are placebo . advanced hepatocellular carcinoma diagnosis and for male subject or male partner of female subject vasectomy or other procedure resulting in infertility bilateral orchiectomy performed at least six months before screening
__label__0	study interventions are Bortezomib . islet cell tumor diagnosis and surgery
__label__0	study interventions are Dexamethasone acetate . intrahepatic cholangiocarcinoma diagnosis and radiographically measurable disease
__label__0	study interventions are Aspirin . prostate cancer diagnosis and oncotype_dx score of greater_than twenty-five
__label__0	study interventions are Gemcitabine . transitional cell carcinoma of the bladder diagnosis and not pregnant or nursing
__label__0	study interventions are external beam radiation therapy . prostate cancer diagnosis and patient has been classified as favorable risk as defined by the following
__label__0	study interventions are differentiation therapy . contiguous stage ii mantle cell lymphoma diagnosis and cardiovascular
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and ecog zero two
__label__0	study interventions are Cisplatin . cervical cancer diagnosis and see disease characteristics prior radiotherapy allowed to less than thirty of the bone marrow only recovered from toxic effects no concurrent radiotherapy surgery
__label__0	study interventions are Irinotecan . recurrent rectal cancer diagnosis and none of the following cardiac conditions
__label__0	study interventions are Antilymphocyte Serum . plasma cell neoplasm diagnosis and acute myeloid leukemia
__label__0	study interventions are Blood sampling . colorectal tumor diagnosis and aged greater_than seventy years
__label__0	study interventions are Aldesleukin . kidney cancer diagnosis and patients who have received previous low dose interleukin two il two less than six hundred zero iu kg food and drug administration fda approved dosing regimen will be eligible
__label__0	study interventions are Hydrocortisone 17-butyrate 21-propionate . adult lymphoblastic lymphoma diagnosis and ast sgot alt sgpt less_than three times institutional upper limit of normal unless due to all
__label__0	study interventions are diagnostic laboratory biomarker analysis . recurrent grade one follicular lymphoma diagnosis and part both schedules
__label__0	study interventions are Paclitaxel . ovarian cancer diagnosis and meets one of the following criteria
__label__0	study interventions are Romidepsin . neuroendocrine neoplasm diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Methotrexate . gastrointestinal cancers diagnosis and prior systemic chemotherapy immunotherapy or biological therapy radiation therapy and or surgery are allowed however prior use of methotrexate is not allowed
__label__0	study interventions are Angiogenesis Inhibitors . glioblastoma multiforme diagnosis and baseline mri ct is required on stable steroid dosage for at least five days
__label__0	study interventions are Semaxinib . sarcoma diagnosis and no uncompensated cad on electrocardiogram or physical examination
__label__0	study interventions are Capecitabine . colorectal cancer diagnosis and no partial or complete bowel obstruction
__label__0	study interventions are Liposomal doxorubicin . adrenal cortex neoplasms diagnosis and absolute neutrophil count greater than or equal to one thousand mm three
__label__0	study interventions are Irinotecan . esophageal cancer diagnosis and flurbiprofen
__label__0	study interventions are Dexamethasone . stage iii multiple myeloma diagnosis and cluster of differentiation cd four cell count greater_than equal_than three hundred and fifty mm three
__label__0	study interventions are Dactinomycin . sarcoma diagnosis and hepatic
__label__0	study interventions are laboratory biomarker analysis . stage ii squamous cell carcinoma of the oropharynx diagnosis and have no prior history of intolerance or allergy to berry or berry containing products
__label__0	study interventions are Positron emission tomography/x-ray computed tomography . breast cancer diagnosis and any number of lymph nodes with extranodal extension
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and no known positivity for hiv or infectious hepatitis b or c
__label__0	study interventions are Vindesine . lymphoma diagnosis and not specified
__label__0	study interventions are panitumumab . prostate cancer diagnosis and other
__label__0	study interventions are gene expression analysis . breast cancer diagnosis and patient characteristics
__label__0	study interventions are carfilzomib . recurrent small lymphocytic lymphoma diagnosis and anemia hemoglobin less_than eleven dl or thrombocytopenia platelets less_than one hundred ten nine l
__label__0	study interventions are Antibodies . recurrent cell non hodgkin lymphoma diagnosis and patients must have performance status of zero one or two according to eastern cooperative oncology group
__label__0	study interventions are Melphalan . renal cell cancer diagnosis and adequate major organ functions see section doc negative doc zero
__label__0	study interventions are Leucovorin . patients must have histologically or cytologically confirmed advanced metastatic colorectal cancer
__label__0	study interventions are Immunoglobulins . stage iiic fallopian tube cancer diagnosis and patients who have met the pre entry requirements
__label__0	study interventions are Brachytherapy boost with external beam radiotherapy . prostate cancer diagnosis and psa between ten ng ml and twenty ng ml and or gleason score of seven and or ttwob
__label__0	study interventions are radiation therapy . breast cancer diagnosis and renal
__label__0	study interventions are Erlotinib Hydrochloride . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and no significant traumatic injury within the past twenty-one days
__label__0	study interventions are Topotecan . lymphoma diagnosis and ecog zero or one
__label__0	study interventions are Lapatinib . metastatic breast cancer diagnosis and herceptin treatment in the neoadjuvant or adjuvant setting is permitted provide that at least twelve months has elapsed since the last dose of herceptin therapy
__label__0	study interventions are Mycophenolic Acid . recurrent grade one follicular lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Fludarabine phosphate . adult nasal type extranodal nk cell lymphoma diagnosis and absolute neutrophil count greater_than seven hundred and fifty ul
__label__0	study interventions are Oxaliplatin . histologically verified rectal carcinoma
__label__0	study interventions are magnetic resonance imaging . recurrent prostate cancer diagnosis and evidence of castration resistance defined as disease progression despite testosterone level less_than fiftyng dl or surgical castration
__label__0	study interventions are Nivolumab . stage iiib skin melanoma diagnosis and peripheral absolute neutrophil count anc greater_than equal_than seven hundred and fifty mm three
__label__0	study interventions are Melphalan . previously untreated and symptomatic multiple myeloma
__label__0	study interventions are Freund's Adjuvant . unspecified adult solid tumor protocol specific diagnosis and patients receiving il two only
__label__0	study interventions are Gemcitabine . recurrent transitional cell cancer of the renal pelvis and ureter diagnosis and d
__label__0	study interventions are alpha-Tocopherol . head and neck cancer diagnosis and at least four weeks since prior chemotherapy and recovered
__label__0	study interventions are Dactinomycin . untreated childhood rhabdomyosarcoma diagnosis and foxoone_fusion status
__label__0	study interventions are Levoleucovorin . liver cancer diagnosis and uncontrolled hypertension
__label__0	study interventions are Temozolomide . adult glioblastoma diagnosis and patients must have baseline evaluation including history and physical examination with neurological evaluation and magnetic resonance imaging mri of the brain with and without gadolinium based contrast all completed within thirty days prior to initiation of treatment
__label__0	study interventions are Everolimus . stage iiia uterine corpus cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Tazemetostat and [14C] Tazemetostat . marginal zone lymphoma diagnosis and laboratory results obtained during screening should be used to determine eligibility criteria
__label__0	study interventions are Vorinostat . noncontiguous stage ii grade three follicular lymphoma diagnosis and the recipient has achieved second or subsequent complete response but has persistent radiographic abnormalities of unknown significance
__label__0	study interventions are Everolimus . adult glioblastoma diagnosis and more than four weeks since prior chemotherapy six weeks for nitrosoureas
__label__0	study interventions are Methotrexate . lymphoma diagnosis and see disease characteristics prior biologic therapy allowed chemotherapy
__label__0	study interventions are Fluorouracil . head and neck cancer diagnosis and no prior chemotherapy immunotherapy or epidermal growth factor receptor inhibitors for any disease patients who have had previous definitive surgery or radiation therapy for this malignancy and patients who have had any previous chemotherapy immunotherapy or egf receptor inhibition for any disease are ineligible
__label__0	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and if the patient chooses to not undergo repeat biopsy aside from biopsy for diagnostic purposes the patient will still be eligible to enroll on two thousand and fourteen
__label__0	study interventions are Bevacizumab . prostate cancer diagnosis and no uncontrolled hypertension
__label__0	study interventions are Itraconazole . prostate cancer diagnosis and ecog performance status of zero or one
__label__0	study interventions are Rituximab . hemoglobin greater_than nine dl absolute neutrophil count greater_than one five hundred µl and platelet count greater_than seventy-five zero µl unless abnormalities are due to bone marrow involvement by lymphoma
__label__0	study interventions are Hydrocortisone acetate . prostate cancer diagnosis and no myocardial infarction within six months no nyha class iii iv status no history of thromboembolic or hemorrhagic cerebrovascular accident no disseminated_intravascular coagulation no anticoagulant therapy aspirin allowed for other uses other
__label__0	study interventions are Quality-of-Life Assessment . atypical carcinoid tumor diagnosis and port placement laparoscopy thoracoscopy bronchoscopy mediastinoscopy skin biopsies incisional biopsies imaging guided biopsy for diagnostic purposes and dental extraction procedures
__label__0	study interventions are autologous hematopoietic stem cell transplantation . recurrent grade one follicular lymphoma diagnosis and city of hope_coh pathology review confirms that research participant diagnostic material is consistent with the history of intermediate grade cell nhl dlbcl mcl or transformed nhl
__label__0	study interventions are laboratory biomarker analysis . stage iii colon cancer diagnosis and no standard curative or palliative therapy exists or is no longer effective
__label__0	study interventions are Leucovorin . colorectal cancer diagnosis and vascular involvement and or poor site that prevent complete resection of hepatic disease and or require resection with the remaining liver mass less than twenty-five thirty of functional liver
__label__0	study interventions are Chemo Plus Far . peritoneal neoplasms diagnosis and life expectancy greater than or equal to six months as estimated by the investigator
__label__0	study interventions are Irofulven . endometrial cancer diagnosis and patient characteristics
__label__0	study interventions are Methotrexate . wegener granulomatosis diagnosis and written informed consent
__label__0	study interventions are Carboplatin . lung cancer diagnosis and bone lesions
__label__0	study interventions are Antibodies . stage iv marginal zone lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are Fluorouracil . stage ivb laryngeal squamous cell carcinoma diagnosis and alkaline phosphatase normal and ast or alt equal_than less_than five upper limit of normal uln
__label__0	study interventions are radiotherapy . sarcoma diagnosis and no serious infection
__label__0	study interventions are Oxaliplatin . histologically or cytologically documented advanced or metastatic solid tumors for which established therapy either does not exist or has proven ineffective or intolerable with the following exceptions
__label__0	study interventions are Capecitabine . extrahepatic bile duct cancer diagnosis and able to swallow and or receive medications via gastrostomy feeding tube
__label__0	study interventions are Paclitaxel . ovarian cancer diagnosis and chemotherapy
__label__0	study interventions are Sirolimus . refractory hurthle cell thyroid cancer diagnosis and patients who have received greater than six hundred mci of radioactive iodine in their lifetime or
__label__0	study interventions are Carboplatin . cancer of unknown primary diagnosis and hemoglobin greater_than ten
__label__0	study interventions are Vidarabine . recurrent mantle cell lymphoma diagnosis and quantitative or qualitative congenital platelet disorders including but not limited to congenital amegakaryocytopenia_absent radii syndrome glanzmann thrombasthenia
__label__0	study interventions are Resistance Training . breast cancer diagnosis and capable of participating in moderate vigorous unsupervised exercise
__label__0	study interventions are Molecular Mechanisms of Pharmacological Action . multiple myeloma diagnosis and serum monoclonal protein greater_than doc dl by protein electrophoresis
__label__0	study interventions are Bevacizumab . adult giant cell glioblastoma diagnosis and patients must have baseline evaluation including history and physical examination with neurological evaluation and magnetic resonance imaging mri of the brain with and without gadolinium based contrast all completed within thirty days prior to initiation of treatment
__label__0	study interventions are Dasatinib . localized non resectable adult liver carcinoma diagnosis and patients with ongoing cardiac dysrhythmias of nci common terminology criteria for adverse events ctcae grade greater_than equal_than two atrial fibrillation of any grade or qtc interval greater_than four hundred and seventy msec for females or greater_than four hundred and fifty msec for males are not eligible
__label__0	study interventions are Vorinostat . contiguous stage ii small lymphocytic lymphoma diagnosis and refractory anemia
__label__0	study interventions are Immunoglobulins . stage iiic fallopian tube cancer diagnosis and regimen iii
__label__0	study interventions are Liposomal doxorubicin . multiple myeloma diagnosis and patients must have newly diagnosed active mm requiring treatment
__label__0	study interventions are Antineoplaston therapy (Atengenal + Astugenal) . malignant brain tumors diagnosis and no other cardiovascular conditions that contraindicate high dosages of sodium
__label__0	study interventions are Ascorbic Acid . stage iii multiple myeloma diagnosis and previously untreated disease with poor prognosis meeting one of the following criteria
__label__0	study interventions are Fatigue Inventory . recurrent adult diffuse mixed cell lymphoma diagnosis and platelet count greater_than equal_than fifty zero ul
__label__0	study interventions are EC1169 . prostate cancer diagnosis and lvef must be evaluated within seven to ten days prior to beginning study therapy iii cardiac troponin within normal limit as per local institution hepatic
__label__0	study interventions are Fludarabine . unspecified childhood solid tumor protocol specific diagnosis and chronic lymphocytic leukemia cll greater_than twenty marrow involvement
__label__0	study interventions are Cisplatin . stage iib ovarian germ cell tumor diagnosis and intermediate risk disease
__label__0	study interventions are Liposomal doxorubicin . stage iv adult diffuse large cell lymphoma diagnosis and breaks in bcl two via cytogenetic studies or
__label__0	study interventions are Vidarabine . recurrent grade two follicular lymphoma diagnosis and renal function
__label__0	study interventions are Antibodies, Monoclonal . colorectal cancer diagnosis and effective forms of contraception include abstinence hormonal contraceptive in conjunction with barrier method or double barrier method
__label__0	study interventions are Oxaliplatin . colon cancer diagnosis and patients must have life expectancy of greater than three months
__label__0	study interventions are Carboxymethylcellulose Sodium . melanoma diagnosis and the requirements for inclusion are as follows
__label__0	study interventions are Akt inhibitor MK2206 . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and doc mg dl
__label__0	study interventions are Interleukin-2 . melanoma skin diagnosis and no asthma requiring active treatment within the past five years
__label__0	study interventions are Cyclophosphamide . high risk er positive breast cancer defined as grade three invasive ductal or mixed ductal lobular cancers or grade two with kisixty-seven greater_than two0 node positive as evidenced by physical exam or imaging evaluation or histological evaluation
__label__0	study interventions are Cetuximab . stage iva salivary gland cancer diagnosis and absolute neutrophil count greater_than equal_than doc mm three
__label__0	study interventions are Temozolomide . wild type braf stage iv melanoma diagnosis and history of congestive heart failure greater than new york heart association nyha class ii unstable angina uncontrolled hypertension despite optimal treatment myocardial infarction or stroke within six months of the first dose of study drug or cardiac arrhythmia requiring medical treatment
__label__0	study interventions are Romidepsin . solid tumors diagnosis and women of childbearing potential should be advised to avoid becoming pregnant and men should be advised to not father child while receiving treatment with five azacitidine
__label__0	study interventions are Immunoglobulins . stage ii grade three non contiguous follicular lymphoma diagnosis and no known human anti chimeric antibody haca positivity
__label__0	study interventions are Docetaxel . untreated metastatic squamous cell carcinoma to neck with occult primary diagnosis and no prior chemotherapy or biologic molecular targeted therapy for recurrent or metastatic scchn
__label__0	study interventions are Podophyllotoxin . peripheral primitive neuroectodermal tumor of soft tissues diagnosis and this study utilizes whole body fdg pet scans to screen patients for bone metastases areas suspicious for bone metastasis based on fdg pet scans require confirmatory anatomic imaging with either mri or computed tomography ct whole body fdg pet ct or fdg pet magnetic resonance mr scan acceptable whole body technetium bone scans may be performed at the discretion of the investigator and are not required for patients without other sites of metastatic disease whose sole metastatic site to qualify for study entry is single area suspicious for bone metastasis identified by fdg pet confirmatory biopsy or anatomic imaging evidence of an associated soft tissue mass at that site is required for study entry
__label__0	study interventions are PX-866 . prostate cancer diagnosis and serum creatinine less_than doc unl total bilirubin less_than doc unl alt and ast less_than doc unl glucose less_than doc mmol less_than grade one psa greater_than fiveng ml
__label__0	study interventions are Epirubicin . breast cancer diagnosis and eighteen to sixty-five
__label__0	study interventions are Cyclophosphamide . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and any active infection will require an infectious disease consult and subsequent clearance
__label__0	study interventions are Antibodies, Monoclonal . stage iv verrucous carcinoma of the oral cavity diagnosis and negative pregnancy test
__label__0	study interventions are Immunoglobulins . stage iii squamous cell carcinoma of the oropharynx diagnosis and no known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies part two only
__label__0	study interventions are Bortezomib . stage iii grade one follicular lymphoma diagnosis and no evidence of co infection with hepatitis or cdfour positive count greater_than four00 ul no evidence of resistant strains of hiv on anti hiv therapy with an hiv viral load less_than fifty copies hiv rna ml no history of acquired immunodeficiency syndrome aids defining conditions no zidovudine or stavudine are allowed owing to overlapping toxicity with chemotherapy
__label__0	study interventions are Letrozole . metastatic or locally advanced unresectable breast cancer diagnosis and these include but not limited to st
__label__0	study interventions are Liposomal doxorubicin . astrocytoma diagnosis and arm a
__label__0	study interventions are Dexamethasone acetate . patient has previous diagnosis of multiple myeloma
__label__0	study interventions are pharmacological study . small intestine cancer diagnosis and recovered from all prior therapy
__label__0	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and central pathology review is mandatory but is retrospective in nature slides should be submitted within thirty days of enrollment patients can be enrolled prior to submission of slides
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ib uterine sarcoma diagnosis and surgical staging to include total abdominal hysterectomy bilateral salpingo oophorectomy peritoneal washings and lymph node samplings
__label__0	study interventions are Modified Measles Virus Lumbar Puncture . medulloblastoma recurrent diagnosis and three months since autologous bone marrow stem cell prior to registration
__label__0	study interventions are Imatinib Mesylate . lung cancer diagnosis and cardiac arrhythmia requiring therapy
__label__0	study interventions are Rituximab . stage iii grade one follicular lymphoma diagnosis and all study participants must be registered into the mandatory revassist program and be willing and able to comply with the requirements of revassist
__label__0	study interventions are Bevacizumab . stage iv mantle cell lymphoma diagnosis and patients must be willing and able to review understand and provide written consent before starting therapy
__label__0	study interventions are Irinotecan . ewing sarcoma family of tumors diagnosis and patients who are unable to walk because of paralysis or motor weakness but who are up in wheelchair will be considered ambulatory for the purpose of calculating the performance score
__label__0	study interventions are Antibodies, Monoclonal . testicular embryonal carcinoma and yolk_sac tumor with seminoma diagnosis and no prior anti cytotoxic lymphocyte associated antigen four monoclonal antibody mdx ten
__label__0	study interventions are Vaccines . prostate cancer diagnosis and other
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and creatinine less_than doc uln
__label__0	study interventions are Temozolomide . adult glioblastoma diagnosis and no other concurrent chemotherapy agents investigational agents or biologic therapy
__label__0	study interventions are Erlotinib Hydrochloride . ovarian cancer diagnosis and no cardiac arrhythmia
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and hematopoietic
__label__0	study interventions are Cisplatin . histological or cytological proof of non small cell lung cancer nsclc
__label__0	study interventions are Testosterone . prostate cancer diagnosis and karnofsky performance status kps greater_than _seventy
__label__0	study interventions are Immunoglobulins . recurrent adult immunoblastic large cell lymphoma diagnosis and must have less_than five blasts at the time of transplant
__label__0	study interventions are Paclitaxel . stage iv salivary gland cancer diagnosis and women of childbearing potential and sexually active males must use an accepted and effective method of contraception while on treatment and for three months after the completion of treatment
__label__0	study interventions are Melphalan . testicular cancer diagnosis and first relapse or progression or second response with an intermediate or high risk according to the beyer model
__label__0	study interventions are Gossypol acetic acid . recurrent small cell lung cancer diagnosis and gossypol
__label__0	study interventions are Podophyllotoxin . stage ivb hodgkin lymphoma diagnosis and patients with newly diagnosed pathologically confirmed chl meeting one of the following ann_arbor stages are eligible
__label__0	study interventions are Isotretinoin . stage iv adult hodgkin lymphoma diagnosis and no concurrent valproic acid
__label__0	study interventions are 6,8-bis(benzylthio)octanoic acid . stage iii pancreatic cancer diagnosis and mentally_competent ability to understand and willingness to sign the informed consent form
__label__0	study interventions are Antibodies . recurrent osteosarcoma diagnosis and platelets greater_than equal_than one hundred ten nine l
__label__0	study interventions are Thalidomide . lymphomatous involvement of non cutaneous extranodal site diagnosis and no uncontrolled infection requiring intravenous therapy or poorly controlled diabetes mellitus
__label__0	study interventions are Cisplatin . brain and central nervous system tumors diagnosis and creatinine normal for age
__label__0	study interventions are Leuprolide . prostate cancer diagnosis and systemic congestive heart failure
__label__0	study interventions are Sirolimus . recurrent prostate carcinoma diagnosis and sub protocol aim a
__label__0	study interventions are positron emission tomography . sarcoma diagnosis and cardiovascular
__label__0	study interventions are Isotretinoin . patients with newly diagnosed high risk neuroblastoma
__label__0	study interventions are Thalidomide . glioblastoma diagnosis and patients receiving steroids must be on stable or decreasing doses for at least five days prior to entry
__label__0	study interventions are Etoposide . recurrent childhood lymphoblastic lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two at time of consent
__label__0	study interventions are Thiotepa . multiple myeloma and plasma cell neoplasm diagnosis and no congestive heart failure
__label__0	study interventions are Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter . metastatic malignant peripheral nerve sheath tumor diagnosis and eastern cooperative oncology group ecog performance status ps zero one or two
__label__0	study interventions are fenretinide . ovarian cancer diagnosis and at least eight weeks since prior oral injectable or implantable contraceptives
__label__0	study interventions are Staurosporine . stage iv breast cancer diagnosis and no gilbert disease
__label__0	study interventions are Visica 2 Treatment System . breast cancer diagnosis and hertwo negative
__label__0	study interventions are Sirolimus . diffuse large cell lymphoma diagnosis and the following diseases will be permitted although other diagnoses can be considered if approved by patient care conference pcc or the participating institutions patient review committees and the principal investigators
__label__0	study interventions are Irinotecan . colon cancer diagnosis and one prior therapy for metastatic disease is permitted
__label__0	study interventions are Cyclophosphamide . recurrent grade three follicular lymphoma diagnosis and no uncontrolled infections other medical or psychological social conditions or required medications that might increase the likelihood of patient or donor adverse effects or poor outcomes
__label__0	study interventions are Tipifarnib . recurrent childhood cerebellar astrocytoma diagnosis and quinine
__label__0	study interventions are Vorinostat . stage small lymphocytic lymphoma diagnosis and alkaline phosphatase equal_than less_than doc uln
__label__0	study interventions are Cetuximab . adenocarcinoma of the rectum diagnosis and irinotecan hydrochloride or oxaliplatin
__label__0	study interventions are Doxorubicin . neuroblastoma diagnosis and pts can be enrolled but receive standard etoposide bolus dosing based on clinical conditions at diagnosis need for emergency intervention because of renal neurologic or airway compromise
__label__0	study interventions are Thalidomide . recurrent plasma cell myeloma diagnosis and females of childbearing potential fcbp must have negative serum pregnancy test with sensitivity of at least fifty miu ml within ten
__label__0	study interventions are Immunoconjugates . stage iia hodgkin lymphoma diagnosis and all stages except ia not bulky disease if involved field is considered radiotherapy rt curative
__label__0	study interventions are Melphalan . stage iii small lymphocytic lymphoma diagnosis and patients greater_than age sixty or with clinical signs of heart disease must have ejection fraction greater_than equal_than forty-five left ventricular ejection fraction lvef
__label__0	study interventions are [18F]fluoroestradiol (FES) . recurrent breast cancer diagnosis and patient or patient legally acceptable representative do not provide written informed consent
__label__0	study interventions are Docetaxel . pancreatic cancer diagnosis and ecog zero two life expectancy
__label__0	study interventions are Erlotinib Hydrochloride . stage iv lymphoepithelioma of the oropharynx diagnosis and no ongoing or active infection
__label__0	study interventions are Carboplatin . stage iv non small cell lung cancer diagnosis and female patients with childbearing potential should agree to use effective non hormonal means of contraception intrauterine contraceptive device barrier method of contraception in conjunction with spermicidal_jelly or surgically sterile during the study and for period of at least six months following the last administration of study drugs
__label__0	study interventions are Methylprednisolone Hemisuccinate . multiple myeloma and plasma cell neoplasm diagnosis and patients not in remission at day twenty-eight of first induction
__label__0	study interventions are Dexamethasone 21-phosphate . stage iiib fallopian tube cancer diagnosis and stage ii iii or iv disease with optimal equal_than less_than one cm residual disease or suboptimal residual disease
__label__0	study interventions are tailored education . adult patient has been diagnosed breast cancer age greater_than twenty
__label__0	study interventions are Talazoparib . triple negative breast carcinoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are POL6326 . non hodgkin lymphoma nhl or hodgkin disease hd in twond or greater complete remission partial remission diagnosis and recipient must have adequate neurologic function as defined by no evidence of severe central or peripheral neurologic abnormality
__label__0	study interventions are Bevacizumab . stage iiia uterine sarcoma diagnosis and anc count greater than or equal to one five hundred mm three
__label__0	study interventions are Gemcitabine . stage iv pancreatic cancer diagnosis and absolute neutrophil count anc greater_than one thousand, five hundred cells mm three
__label__0	study interventions are Interferon-alpha . kidney cancer diagnosis and surgery
__label__0	study interventions are Tacrolimus . nodal marginal zone cell lymphoma diagnosis and syngeneic donors are not eligible donor
__label__0	study interventions are Cyclophosphamide . alveolar rhabdomyosarcoma diagnosis and doc mg dl male doc mg dl female
__label__0	study interventions are Etoposide phosphate . gastric cancer diagnosis and normal hepatic renal and bone marrow function gptless_than two fold of upper limit value white blood cell countgreater_than four thousand dl tbilless_than doc mg dl crless_than doc fold of upper limit value
__label__0	study interventions are hyperfractionated radiation therapy . invasive lobular breast carcinoma with predominant in situ component diagnosis and the use of transfusion or other intervention to achieve hemoglobin hgb greater_than equal_than doc dl is acceptable
__label__0	study interventions are Busulfan . lymphoma diagnosis and polymorphonuclear leukocyte count greater than one five hundred mm three
__label__0	study interventions are Dexamethasone acetate . stage iiic fallopian tube cancer diagnosis and patients must have met pre entry requirements
__label__0	study interventions are Immunoglobulins . pancreatic beta cell adenoma diagnosis and radiofrequency ablation note
__label__0	study interventions are Mitomycin . squamous cell carcinoma head and neck diagnosis and ecog performance status less_than three
__label__0	study interventions are O(6)-benzylguanine . ovarian cancer diagnosis and absolute granulocyte count greater than one five hundred mm three
__label__0	study interventions are Akt inhibitor MK2206 . recurrent grade three follicular lymphoma diagnosis and corrected qt interval qtc equal_than less_than four hundred and fifty msec
__label__0	study interventions are Bevacizumab . stage iiib ovarian cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and pulmonary
__label__0	study interventions are Gemcitabine . extrahepatic bile duct cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Albumin-Bound Paclitaxel . uterine carcinosarcoma diagnosis and patients must have signed an approved informed consent
__label__0	study interventions are positron emission tomography . neuroblastoma diagnosis and not specified
__label__0	study interventions are Vidarabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Bendamustine Hydrochloride . mantle cell lymphoma mcl diagnosis and treatment naive mcl patients requiring treatment with no exposure to prior therapies
__label__0	study interventions are magnetic resonance imaging . prostate cancer diagnosis and serum creatinine less_than doc times uln
__label__0	study interventions are Lapatinib . stage iv squamous cell carcinoma of the larynx diagnosis and more than three months
__label__0	study interventions are laboratory biomarker analysis . adult grade iii lymphomatoid granulomatosis diagnosis and research participant without clinically significant encephalopathy new focal deficits
__label__0	study interventions are Gemcitabine . cholangiocarcinoma diagnosis and creatinine clearance greater_than thirty ml min
__label__0	study interventions are Cediranib . lung cancer diagnosis and suitable for treatment with capecitabine
__label__0	study interventions are radiation therapy . prostate cancer diagnosis and not specified
__label__0	study interventions are Etoposide . ewing sarcoma peripheral primitive neuroectodermal tumor pnet diagnosis and low or high risk in first or greater response stable disease or better or for responding patients at first progression
__label__0	study interventions are Thiotepa . renal tumors diagnosis and central nervous system
__label__0	study interventions are Bortezomib . recurrent grade three follicular lymphoma diagnosis and lvef greater_than forty by echocardiogram
__label__0	study interventions are Immunoglobulins . recurrent lymphoepithelioma of the oropharynx diagnosis and calcium less_than ten mg dl hypocalcemic agents allowed
__label__0	study interventions are Erlotinib Hydrochloride . tumors metastatic to brain diagnosis and neurologic function status zero two
__label__0	study interventions are mutation analysis . head and neck cancer diagnosis and historical material available from excess tissues at the vanderbilt pathology department
__label__0	study interventions are autologous hematopoietic stem cell transplantation . recurrent grade two follicular lymphoma diagnosis and city of hope_coh pathology review confirms that research participant diagnostic material is consistent with the history of intermediate grade cell nhl dlbcl mcl or transformed nhl
__label__0	study interventions are Dasatinib . limited stage small cell lung cancer diagnosis and progressive or recurrent disease after an initial response to first line treatment with platinum based chemotherapy with or without concurrent definitive radiotherapy to the chest chemotherapy must have been completed at least ninety days prior to documentation of relapse
__label__0	study interventions are Doxorubicin . hertwo negative breast cancer diagnosis and patients with either unexplained skeletal pain or alkaline phosphatase that is greater_than uln but less than or equal to doc uln are eligible for inclusion in the study if bone scan pet ct scan or pet scan performed within four weeks prior to randomization does not demonstrate metastatic disease
__label__0	study interventions are Cyclosporins . multiple myeloma diagnosis and greater than or equal to forty predicted
__label__0	study interventions are Gefitinib . untreated childhood anaplastic oligodendroglioma diagnosis and karnofsky or lansky greater_than equal_than fifty assessed within two weeks prior to registration
__label__0	study interventions are Amantadine . either medical diagnosis of cancer or determination of general good health after medical check up within two weeks of participation in the study
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and at least one prior systemic therapy other than single agent corticosteroids
__label__0	study interventions are Cetuximab . stage iv squamous cell carcinoma of the nasopharynx diagnosis and no serious or non healing wound ulcer or bone fracture part two only
__label__0	study interventions are Bryostatin 1 . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Isophosphamide mustard . pecoma diagnosis and no evidence of dyspnea at rest no exercise intolerance and resting pulse_oximetry reading greater_than ninety-four on room air if there is clinical indication for determination
__label__0	study interventions are Interleukin-2 . stage iv grade three follicular lymphoma diagnosis and dlco and fevone at least fifty of predicted
__label__0	study interventions are Immunoglobulins . recurrent small lymphocytic lymphoma diagnosis and anemia hemoglobin less_than eleven dl or thrombocytopenia platelets less_than one hundred zero mm three
__label__0	study interventions are Doxorubicin . endometrial cancer diagnosis and at least four weeks since prior radiotherapy and recovered
__label__0	study interventions are Dexamethasone 21-phosphate . mantle cell lymphoma mcl blastoid_variant diagnosis and understand the teratogenic risk associated with the study therapy especially lenalidomide
__label__0	study interventions are Irinotecan . extrahepatic bile duct cancer diagnosis and not specified hematopoietic
__label__0	study interventions are assessment of therapy complications . colorectal cancer diagnosis and has undergone either sentinel lymph node dissection or axillary lymph node dissection with adequate tnm staging
__label__0	study interventions are sentinel lymph node biopsy . stage iia melanoma diagnosis and skin biopsy performed at least five days and no longer than ten weeks from the time of initial entry into the study
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and relapsed with less_than twenty blasts in the bone marrow and no circulating blasts
__label__0	study interventions are Estramustine . prostate cancer diagnosis and not specified hematopoietic
__label__0	study interventions are Antibodies, Monoclonal . stage iic ovarian cancer diagnosis and all patients enrolled into gog two hundred and sixty-two at sites where acrin six thousand, six hundred and ninety-five is open will be enrolled in the advanced imaging protocol patients receiving adjuvant or neoadjuvant chemotherapy are eligible for acrin six thousand, six hundred and ninety-five the following sentence does not apply to those patients entered after two eight two thousand and twelve
__label__0	study interventions are Docetaxel . ovarian cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Mitomycin . lung cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Azacitidine . lymphoma diagnosis and biologic therapy
__label__0	study interventions are Pemetrexed . recurrent non small cell lung cancer diagnosis and alanine aminotransferase alt and aspartate aminotransferase ast within normal range or equal_than less_than three upper limit of normal uln if liver metastases are present
__label__0	study interventions are Vaccines . ovarian transitional cell carcinoma diagnosis and computed tomography ct abdomen pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy equal_than less_than twenty-eight days before entering study
__label__0	study interventions are Gemcitabine . non small cell lung cancer recurrent diagnosis and any nthreemzero or tfourntwomzero or metastatic ajcc stage negative any any mone progressive recurrent or refractory nsclc
__label__0	study interventions are Dacarbazine . recurrent adult brain tumor diagnosis and patients must have recovered from the toxic effects of prior therapy including surgery
__label__0	study interventions are Fluorodeoxyglucose F18 . not pregnant or nursing fertile patients must use effective contraception able to fast for six hours able to lie still for positron_emission tomography imaging no second malignancy except previously treated nonmelanomatous skin cancer or carcinoma in situ of the cervix no active infection no inflammatory disease sarcoidosis or rheumatoid arthritis no allergy to shellfish or contrast dye used for ct imaging
__label__0	study interventions are Fluorouracil . recurrent extragonadal seminoma diagnosis and measurable or evaluable disease as defined by one of the following criteria
__label__0	study interventions are Hormones . recurrent breast carcinoma diagnosis and age less_than fifty-five with prior hysterectomy but intact ovaries with estradiol less_than twenty pg ml
__label__0	study interventions are Isophosphamide mustard . extranodal nk cell lymphoma diagnosis and serum creatinine less_than doc mg dl
__label__0	study interventions are Albumin-Bound Paclitaxel . patients assumed to have stageii iv epithelial ovarian fallopian tube or primary peritoneal cancer as pre surgery diagnosis
__label__0	study interventions are Pharmacogenomic Study . metastatic melanoma diagnosis and stage iv disease
__label__0	study interventions are Paclitaxel . stage iiib gallbladder cancer diagnosis and arm cohort three
__label__0	study interventions are Curcumin . breast carcinoma diagnosis and twenty-eight gy breast boost
__label__0	study interventions are Angiotensin I (1-7) . ovarian sarcoma diagnosis and estimated est
__label__0	study interventions are novel PET tracer FACBC . large primary hnscc cancer loco regional advanced greater_than or equal to ttwo by ct mri imaging or clinical exam without prior treatment none nthree
__label__0	study interventions are Paclitaxel . metastatic breast cancer diagnosis and life expectancy longer than twelve weeks
__label__0	study interventions are Pembrolizumab . metastatic cancers diagnosis and this lesion if it is close to the radiated lesion must receive no more than ten of the dose prescribed to the target lesion
__label__0	study interventions are Floxuridine . resected liver metastases from colorectal cancer diagnosis and no serious complication occurred during or after metastases resection and affected subsequent treatment
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and voluntary written informed consent before performance of any study related procedure not part of normal medical care with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
__label__0	study interventions are Antibodies . histologically or cytologically confirmed adenocarcinoma of the prostate previously treated with surgery and or radiotherapy
__label__0	study interventions are Fludarabine . adult nasal type extranodal nk cell lymphoma diagnosis and lvef left ventricular end diastolic function of greater_than fifty
__label__0	study interventions are high performance liquid chromatography . breast cancer diagnosis and oral contraceptives
__label__0	study interventions are Dexamethasone acetate . lymphoma large cell diffuse diagnosis and total bilirubin less_than doc uln
__label__0	study interventions are Antibodies, Monoclonal . recurrent lymphoepithelioma of the oropharynx diagnosis and not amenable to standard therapy
__label__0	study interventions are Sirolimus . stage adult diffuse mixed cell lymphoma diagnosis and acute lymphocytic leukemia all must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Retinol acetate . recurrent adrenocortical carcinoma diagnosis and fertile patients must use effective contraception prior to during and for greater_than one month after completion of study treatment
__label__0	study interventions are Metronidazole . cholangiocarcinoma of the gallbladder diagnosis and no frequent vomiting or severe anorexia
__label__0	study interventions are Cisplatin . cervical adenosquamous carcinoma diagnosis and at least twenty mm by palpation_plain ray ct scan or mri or at least ten mm by spiral ct scan
__label__0	study interventions are Cyclophosphamide . non small cell lung cancer metastatic to the pleura previously treated with at least one prior treatment regimen chemotherapy or targeted agent and documented progression of disease
__label__0	study interventions are Etoposide phosphate . neuroblastoma diagnosis and regimen nb nine doc
__label__0	study interventions are Fludarabine phosphate . follicular lymphoma diagnosis and platelet count greater_than one hundred one hundred and nine l
__label__0	study interventions are Cyclophosphamide . recurrent childhood small noncleaved cell lymphoma diagnosis and there is no restriction on the number of prior chemotherapeutic regimens or radiation exposure with the exception of prior autologous or allogeneic stem cell transplantation
__label__0	study interventions are Cisplatin . malignant mesothelioma diagnosis and hematopoietic
__label__0	study interventions are Veliparib . triple negative breast cancer diagnosis and hormonal contraceptives oral parenteral or transdermal for at least three months prior to study drug administration
__label__0	study interventions are tyrosinase peptide . melanoma skin diagnosis and karnofsky eighty one hundred life expectancy
__label__0	study interventions are Fluorouracil . unspecified adult solid tumor protocol specific diagnosis and not pregnant or nursing
__label__0	study interventions are Antibodies . lymphoma diagnosis and patients must have relapsed after achieving complete or partial response to prior therapy have never responded to prior therapy or have poor risk disease
__label__0	study interventions are Glycine . multiple myeloma diagnosis and female subjects unless postmenopausal for at least one year before the screening visit or surgically sterilized agree to practice two two effective methods of contraception at the same time or agree to practice true abstinence when this is in line with the preferred and usual_lifestyle of the subject periodic abstinence eg calendar_ovulation symptothermal post ovulation methods and withdrawal are not acceptable methods of contraception through ninety days after the last dose of maintenance therapy see section doc
__label__0	study interventions are Sulforafan . breast cancer diagnosis and confirmed diagnosis of dcis on core or excisional incisional biopsy and scheduled for definitive surgery
__label__0	study interventions are Irinotecan . recurrent verrucous carcinoma of the oral cavity diagnosis and patients must have had no prior invasive malignancy unless the disease free interval is five years or more
__label__0	study interventions are Fludarabine phosphate . noncontiguous stage ii small lymphocytic lymphoma diagnosis and the donor must be able to give informed consent for peripheral blood stem cell collection or bone marrow collection
__label__0	study interventions are Sorafenib . hepatocellular cancer diagnosis and must have normal organ and marrow function
__label__0	study interventions are Fludarabine . stage ii childhood small noncleaved cell lymphoma diagnosis and patients with renal failure are eligible however patients with renal compromise serum creatinine greater_than doc will likely have further compromise in renal function and may require hemodialysis which may be permanent due to the need to maintain adequate serum tacrolimus levels
__label__0	study interventions are Camptothecin . liver cancer diagnosis and no prior organ allograft
__label__0	study interventions are Fluorodeoxyglucose F18 . hematopoietic lymphoid cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Fluorodeoxyglucose F18 . stage iia cervical cancer diagnosis and ferritin levels equal_than less_than six hundred ng ml or saturation of transferrin level equal_than less_than fifty
__label__0	study interventions are Albumin-Bound Paclitaxel . mixed germ cell tumor diagnosis and calculated creatinine clearance greater_than fifty ml min
__label__0	study interventions are Cisplatin . sarcoma diagnosis and albumin at least three dl
__label__0	study interventions are Hydrocortisone . lymphoma diagnosis and performance status
__label__0	study interventions are Immunoglobulins . recurrent refractory childhood hodgkin lymphoma diagnosis and patient current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
__label__0	study interventions are Vidarabine . stage grade two follicular lymphoma diagnosis and at least one measurable node greater than two cm by computed tomography ct scan or measurable disease in lymphoid structure spleen
__label__0	study interventions are Calcium polycarbophil . breast cancer diagnosis and be post menopausal as defined by any of the following
__label__0	study interventions are NanoKnife IRE System . unresectable pancreatic cancer diagnosis and must have an inr less_than doc
__label__0	study interventions are Cetuximab . stage ivc laryngeal verrucous carcinoma diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least twenty-five miu ml within ten
__label__0	study interventions are Albumin-Bound Paclitaxel . endometrial cancer diagnosis and no prior doxorubicin
__label__0	study interventions are Fludarabine . stage iv grade one follicular lymphoma diagnosis and creatinine no greater than doc mg dl
__label__0	study interventions are Beclomethasone . isolated plasmacytoma of bone diagnosis and cord blood transplant recipients
__label__0	study interventions are TAK-659 . patients must have recovered from the reversible effects of prior anticancer therapy to grade less_than one
__label__0	study interventions are Doxorubicin . diffuse large cell lymphoma diagnosis and adequate liver functions
__label__0	study interventions are Vitamin B 12 . relapsed peripheral cell lymphoma diagnosis and at least eighteen years of age
__label__0	study interventions are Hypofractionation . breast cancer diagnosis and willing to sign consent onto evaluation of cardiac function in patients undergoing proton beam or photon radiotherapy irb number fifteen seven thousand, four hundred and forty-three
__label__0	study interventions are Staurosporine . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and no prior allergic reactions attributed to compounds of similar chemical or biological composition to ucn one or irinotecan
__label__0	study interventions are Tacrolimus . stage ii adult hodgkin lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco greater_than fifty dlco should be corrected for hemoglobin
__label__0	study interventions are Pembrolizumab . esophagogastric junction carcinoma diagnosis and measurable disease
__label__0	study interventions are Paclitaxel . able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels
__label__0	study interventions are Paclitaxel . subjects with measurable or non measurable disease following the response evaluation criteria in solid tumors recist doc appendix one for phase one part of the study
__label__0	study interventions are Paclitaxel . malignant neoplasms of female genital organs diagnosis and e
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and no angina pectoris
__label__0	study interventions are Endothelial Growth Factors . stage iib ovarian cancer diagnosis and platelets greater than or equal to one hundred zero mm three
__label__0	study interventions are Lenalidomide . smoldering multiple myeloma diagnosis and age greater_than eighteen years
__label__0	study interventions are OMP-59R5 . solid tumors diagnosis and women of childbearing potential must have had prior hysterectomy or have negative serum pregnancy test and be using adequate contraception prior to study entry and must agree to use adequate contraception from study entry through at least six months after discontinuation of study drug
__label__0	study interventions are Antibodies, Monoclonal . stage iii grade two follicular lymphoma diagnosis and ascites
__label__0	study interventions are Vaccines . breast cancer diagnosis and chemotherapy
__label__0	study interventions are Doxorubicin . diffuse large cell lymphoma diagnosis and
__label__0	study interventions are Anastrozole . women with histological diagnosis of invasive breast cancer completely removed by surgery any any n
__label__0	study interventions are Tipifarnib . multiple myeloma and plasma cell neoplasm diagnosis and persistent thrombocytosis
__label__0	study interventions are Prednisolone hemisuccinate . testicular germ cell tumor diagnosis and age
__label__0	study interventions are Antibodies, Monoclonal . recurrent colon cancer diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Cetuximab . recurrent mucoepidermoid carcinoma of the oral cavity diagnosis and negative pregnancy test
__label__0	study interventions are Niacinamide . kidney cancer diagnosis and no concurrent palliative radiotherapy
__label__0	study interventions are LEAD RT . prostate cancer diagnosis and n
__label__0	study interventions are Antibodies . recurrent adult diffuse mixed cell lymphoma diagnosis and one allele or
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and two prior lines of therapy which must have included at least two consecutive cycles of lenalidomide and proteosome inhibitor alone or in combination
__label__0	study interventions are Fludarabine phosphate . contiguous stage ii adult diffuse mixed cell lymphoma diagnosis and all patients must be in cr as defined by hematologic recovery and less_than five blasts by morphology within the bone marrow and cellularity of greater_than equal_than 1five
__label__0	study interventions are Rituximab . stage iv adult diffuse small cleaved cell lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Mitomycins . colorectal cancer diagnosis and not specified
__label__0	study interventions are Mycophenolate mofetil . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and chronic phase intolerant or unresponsive to imatinib and or other tyrosine kinase inhibitors second chronic phase or accelerated phase who are ineligible for conventional myeloablative transplantation
__label__0	study interventions are Vinblastine . stage iiia breast cancer diagnosis and inclusion
__label__0	study interventions are Mycophenolic Acid . multiple myeloma and plasma cell neoplasm diagnosis and has two umbilical cord blood units available that are matched at greater_than four six hla b and drbone with the patient and with each other hla and dq will not be used in the match strategy
__label__0	study interventions are polymerase chain reaction . breast cancer diagnosis and no prior radiotherapy to the breast to be studied
__label__0	study interventions are Carboplatin . bladder cancer diagnosis and see disease characteristics
__label__0	study interventions are Rituximab . anaplastic large cell lymphoma diagnosis and creatinine within normal institutional limits or creatinine clearance greater_than equal_than sixty ml min for patients with creatinine levels above institutional normal
__label__0	study interventions are Iodine . histologically or cytologically confirmed prostate cancer
__label__0	study interventions are O(6)-benzylguanine . recurrent grade two follicular lymphoma diagnosis and hiv plasma viral load has decreased by doc logs or viral load less_than five thousand copies ml
__label__0	study interventions are Doxorubicin . plasmablastic lymphoma diagnosis and patients must have myc rearrangement as determined by fluorescent in situ hybridization fish does not require central review
__label__0	study interventions are Hydroxyitraconazole . cancer diagnosis and disease characteristics
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and cerebrovascular accident
__label__0	study interventions are Mitogens . diagnosis histologically confirmed by gynecologic pathologist as containing greater_than ten uterine papillary serous adenocarcinoma in the specimen
__label__0	study interventions are Everolimus . kaposiform_hemangioendotheliomas
__label__0	study interventions are Trans- Arterial Chemoembolization . hepatocellular carcinoma hcc diagnosis and male or female patients of any ethnic group
__label__0	study interventions are Maleic acid . triple negative breast carcinoma diagnosis and new york heart association classification of ii controlled with treatment
__label__0	study interventions are Fludarabine phosphate . mantle cell lymphoma diagnosis and diffusion capacity for carbon monoxide corrected dlcocorr greater_than fifty normal
__label__0	study interventions are Gossypol acetic acid . stage adult immunoblastic large cell lymphoma diagnosis and total bilirubin within normal institutional limits
__label__0	study interventions are Histone Deacetylase Inhibitors . recurrent mantle cell lymphoma diagnosis and primary cutaneous type
__label__0	study interventions are Paclitaxel . germinoma diagnosis and prior treatment with carboplatin as adjuvant therapy is allowed provided patients meet other eligibility criteria the patient has also received three four cycles of cisplatin based chemotherapy
__label__0	study interventions are biopsy . willing to provide existing and or future paraffin_embedded tumor samples
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and no hiv or hepatitis positivity
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and eastern cooperative oncology group ecog performance status score less_than two
__label__0	study interventions are Quality-of-Life Assessment . stage iiic ovarian germ cell tumor diagnosis and more than six months since prior epoetin_alfa darbepoetin or any investigational forms of erythropoietin
__label__0	study interventions are Sirolimus . cervical cancer diagnosis and ecog performance status zero two
__label__0	study interventions are Isophosphamide mustard . transitional cell cancer of the renal pelvis and ureter diagnosis and zero two
__label__0	study interventions are Etoposide phosphate . ovarian sex cord stromal tumor of mixed or unclassified cell types diagnosis and patients must have signed an approved informed consent and authorization permitting release of personal health information
__label__0	study interventions are Docetaxel . head and neck cancer diagnosis and anc greater_than one thousand pltgreater_than seventy-five zero serum creatinineless_than doc mg dl bilirubin less_than doc upper limits of normal uln
__label__0	study interventions are Dexamethasone 21-phosphate . myeloma diagnosis and age greater_than equal_than eighteen years
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and not specified
__label__0	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and hemoglobingreater_than nineg l
__label__0	study interventions are Antibodies, Monoclonal . cutaneous lymphomas diagnosis and to be eligible lyp patients must be in need of systemic therapy ie have scarring or active lesions greater_than equal_than ten per month or any number of active lesions on face hands or feet
__label__0	study interventions are Paclitaxel . primary peritoneal cavity cancer diagnosis and treatment free interval of less than six months duration after treatment with prior platinum or
__label__0	study interventions are Albumin-Bound Paclitaxel . urethral neoplasms diagnosis and fully recovered from any previous surgery
__label__0	study interventions are Capecitabine . cervical cancer diagnosis and hepatic
__label__0	study interventions are Trastuzumab . stage iv breast cancer diagnosis and platelets greater_than equal_than one hundred zero mm three
__label__0	study interventions are Eltrombopag . treatment with thrombomimetic agents in the past three months rtpo peg rhumgdf nplate or promacta
__label__0	study interventions are Capecitabine . rectal neoplasms diagnosis and no co morbid illnesses or other concurrent disease that in the judgment of the clinician obtaining informed consent would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__0	study interventions are Fludarabine phosphate . chronic granulomatous disease diagnosis and cgd patients as documented by an abnormal nbt assay in male patient and or abnormal nadph enzyme mutation confirmed by genetic analysis with abnormal nbt
__label__0	study interventions are Paclitaxel . teratoma diagnosis and other
__label__0	study interventions are Doxorubicin . liposarcoma diagnosis and six to less_than ten years one mg dl male one mg dl female
__label__0	study interventions are Cyclophosphamide . non hodgkin lymphoma diagnosis and cmml one and cmml two advanced polycythemia_vera and myelofibrosis
__label__0	study interventions are Isophosphamide mustard . testicular choriocarcinoma diagnosis and meets one of the following disease criteria
__label__0	study interventions are Proteasome Inhibitors . stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and note
__label__0	study interventions are Trastuzumab . stage iiic breast cancer diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Chinese Herb Huanglian (Coptis chinesis) . unspecified adult solid tumor protocol specific diagnosis and not specified
__label__0	study interventions are Entinostat . cancer diagnosis and performance status
__label__0	study interventions are alvespimycin hydrochloride . recurrent inverted papilloma of the paranasal sinus and nasal cavity diagnosis and no left bundle_branch block
__label__0	study interventions are Busulfan . recurrent adult diffuse mixed cell lymphoma diagnosis and diffusion capacity of the lung for carbon monoxide dlco of greater_than equal_than forty-five predicted or clearance by ccf physician
__label__0	study interventions are Glucocorticoids . castration resistant prostate cancer diagnosis and able to swallow the study drug whole as tablet
__label__0	study interventions are Cyclophosphamide . ependymoma neuroepithelioma
__label__0	study interventions are Cytarabine . cns lymphoma diagnosis and adequate hematological function
__label__0	study interventions are Oxaliplatin . cholangiolar carcinoma diagnosis and wbc greater_than two zero cells mmthree
__label__0	study interventions are Transarterial Chemoembolization . hepatocellular carcinoma diagnosis and adequate clinical condition to undergo laparoscopic or robot_assisted laparoscopic transarterial chemoembolization tace and or microwave ablation mwa as treatment for hcc
__label__0	study interventions are Antibodies . ovarian endometrioid adenocarcinoma diagnosis and willing to return to enrolling institution for follow up two four weeks after treatment discontinuation
__label__0	study interventions are Cyclophosphamide . ds stage ii plasma cell myeloma diagnosis and donor
__label__0	study interventions are Etoposide phosphate . solitary nodule greater_than equal_than doc cm or multiple nodules of greater_than equal_than doc cm unless lesion is biopsied and negative for tumor
__label__0	study interventions are Bupropion . head and neck cancer diagnosis and no other clinical contraindication
__label__0	study interventions are Tacrolimus . anaplastic large cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Mycophenolate mofetil . recurrent adult diffuse mixed cell lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Carboplatin . stage iv fallopian tube cancer diagnosis and serum glutamic oxaloacetic transaminase sgot serum glutamate pyruvate transaminase sgpt less_than doc institutional upper limit of normal uln
__label__0	study interventions are Cisplatin . ovarian cancer diagnosis and no disorder which leads to the condition that contraindicates the use of the investigational drugs or that may affect the patient compliance with the study requirements
__label__0	study interventions are Histone Deacetylase Inhibitors . angioimmunoblastic cell lymphoma diagnosis and absolute neutrophil count of greater_than one thousand ten nine cells l
__label__0	study interventions are Prednisolone . lymphoma diagnosis and toxic effects of prior therapy or surgery must be resolved to less_than grade two
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and pretreatment lab values must be performed within fourteen days of patient registration and other baseline studies with the exception of mammogram must be performed within thirty days of patient registration
__label__0	study interventions are Tacrolimus . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Palbociclib . human epidermal growth factor two negative carcinoma of breast diagnosis and or
__label__0	study interventions are differentiation therapy . stage iv mantle cell lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Exemestane . advanced or metastatic breast cancer
__label__0	study interventions are Liposomal doxorubicin . cdtwenty positive cells in lymph node biopsy or other lymphoma pathology specimen
__label__0	study interventions are Liposomal doxorubicin . recurrent childhood rhabdomyosarcoma diagnosis and performance status
__label__0	study interventions are Carboplatin . non seminomatous germ cell tumor diagnosis and in rare circumstances patients will be allowed to enroll even if pathologic diagnosis may not have been established
__label__0	study interventions are Immunoglobulins . neoplasm metastasis diagnosis and bilirubin less than doc except in cases of gilbert disease
__label__0	study interventions are Etoposide phosphate . adenocarcinoma of the lung diagnosis and patients with two or more parenchymal lesions on same or opposite sides of the lung are ineligible
__label__0	study interventions are Etoposide phosphate . stage iii grade two follicular lymphoma diagnosis and cardiac ejection fraction greater_than equal_than forty-five or clearance by cleveland clinic ccf physician
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and absolute neutrophil count greater_than one zero mm three
__label__0	study interventions are Doxorubicin . mesotheliomas diagnosis and these patients would ordinarily choose to have twelve cycles of taxol given after standard first line surgery and chemotherapy and instead choose one course of iphc as their cc
__label__0	study interventions are management of therapy complications . lung cancer diagnosis and patient characteristics
__label__0	study interventions are Irinotecan . kidney cancer diagnosis and no other concurrent chemotherapy
__label__0	study interventions are reflexology procedure . psychosocial effects of cancer and its treatment diagnosis and lymphedema
__label__0	study interventions are antineoplaston A10 . melanoma skin diagnosis and at least two months
__label__0	study interventions are Antibodies . refractory childhood hodgkin lymphoma diagnosis and patients with prior autologous or allogeneic stem cell transplant sct are excluded from this study
__label__0	study interventions are Prednisolone hemisuccinate . lymphoma diagnosis and accelerated phase blasts less than twenty
__label__0	study interventions are Isophosphamide mustard . ovarian cancer diagnosis and bilirubin less_than doc times uln for age
__label__0	study interventions are Cyclophosphamide . childhood nodular sclerosis classical hodgkin lymphoma diagnosis and radioisotope glomerular filtration rate greater than seventy ml min
__label__0	study interventions are Bicalutamide . prostate cancer diagnosis and gleason score greater than seven
__label__0	study interventions are Paclitaxel . carcinoma non small cell lung diagnosis and ast sgot less_than two uln
__label__0	study interventions are Liposomal doxorubicin . psychosocial effects of cancer and its treatment diagnosis and no unremovable body jewelry
__label__0	study interventions are Mycophenolic Acid . childhood diffuse large cell lymphoma diagnosis and must have failed previous myelosuppressive chemotherapy or hsct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Alvocidib . unspecified adult solid tumor protocol specific diagnosis and no prior enrollment in this study
__label__0	study interventions are Fosaprepitant . unspecified adult solid tumor protocol specific diagnosis and no chronic alcoholism as determined by the investigator
__label__0	study interventions are Bevacizumab . stage iii renal cell cancer diagnosis and no known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__0	study interventions are Calcium, Dietary . recurrent rectal cancer diagnosis and more than ten days since prior full dose aspirin three hundred and twenty-five mg
__label__0	study interventions are Aldesleukin . head and neck cancer diagnosis and disease characteristics
__label__0	study interventions are Bevacizumab . metastatic pancreatic cancer diagnosis and patients with recurrent disease who had completed adjuvant therapy in the form of radiation with or without radiosensitizing five fluorouracil five fu six months prior to recurrence may be included
__label__0	study interventions are Taxane . breast cancer diagnosis and adequate organ and bone marrow function
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and platelet count greater_than one hundred zero mm³
__label__0	study interventions are Vaccines . breast cancer diagnosis and chemistry paramters
__label__0	study interventions are Pembrolizumab . refractory extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and cll patients with richter transformation or hodgkin transformation do not need prior therapy to enroll
__label__0	study interventions are Busulfan . progesterone receptor positive breast cancer diagnosis and patient has received cytoxan four gm two one and taxol twofifty mg two one per fhcrc protocol fifty doc three cytoxan taxol must be given after all other chemotherapy is completed and before transplant
__label__0	study interventions are therapeutic allogeneic lymphocytes . noncutaneous extranodal lymphoma diagnosis and the clinical trial will be offered to all high risk defined three below patients with hematologic malignancies who require stem cell transplants as part of their standard of care using matched related or unrelated donors
__label__0	study interventions are Lenalidomide . solid tumors diagnosis and cont
__label__0	study interventions are Sirolimus . refractory hodgkin lymphoma diagnosis and unrelated donors who are prospectively
__label__0	study interventions are Ergocalciferols . mucinous adenocarcinoma of the rectum diagnosis and eastern cooperative oncology group ecog performance status of equal_than less_than two
__label__0	study interventions are Smartphone . cancer diagnosis and willing to listen to potentially scary or sad story that includes violence
__label__0	study interventions are Methylprednisolone Hemisuccinate . adult nasal type extranodal nk cell lymphoma diagnosis and acute non lymphocytic leukemia fab types mone mseven in first or second remission or early first or second bone or marrow relapse greater_than 3one marrow blasts and no circulating peripheral blasts
__label__0	study interventions are alvespimycin hydrochloride . stage iv salivary gland cancer diagnosis and john wort
__label__0	study interventions are Fludarabine . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and high risk first complete remission crone as evidenced by preceding myelodysplastic syndromes mds high risk cytogenetics for example monosomy five or seven or hr as defined by referring institution treatment protocol greater_than equal_than two cycles to obtain complete remission cr erythroblastic or megakaryocytic leukemia greater_than equal_than second complete remission crtwo
__label__0	study interventions are Alemtuzumab . neuroblastoma diagnosis and age
__label__0	study interventions are Doxorubicin . stage ii childhood large cell lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Vaccines . breast cancer diagnosis and see disease characteristics
__label__0	study interventions are Everolimus . cholangiocarcinoma of the gallbladder diagnosis and women of childbearing potential only
__label__0	study interventions are Cisplatin . gastric cancer diagnosis and biologic therapy
__label__0	study interventions are Busulfan . lymphoma diagnosis and diabetes or serious infection
__label__0	study interventions are Sunitinib . untreated metastatic squamous neck cancer with occult primary diagnosis and erythromycin
__label__0	study interventions are Docetaxel . prostatic neoplasms diagnosis and increase of psa greater_than five ng ml on two occasions despite castrate levels of testosterone before screening
__label__0	study interventions are Palbociclib . human epidermal growth factor two negative carcinoma of breast diagnosis and these participants must remain on the gnrh agonist for the duration of protocol treatment
__label__0	study interventions are Dexamethasone . recurrent childhood brain stem glioma diagnosis and measurable or evaluable disease
__label__0	study interventions are Fludarabine . small lymphocytic lymphoma diagnosis and patients in crtwo prtwo with initial short remission less_than six months are eligible
__label__0	study interventions are Floxuridine . metastatic colorectal cancer diagnosis and patients have provided signed informed consent form
__label__0	study interventions are Azacitidine . recurrent rectal cancer diagnosis and measurable disease
__label__0	study interventions are Computed Tomography . stage iva hypopharyngeal squamous cell carcinoma diagnosis and karnofsky performance status ps greater_than forty
__label__0	study interventions are Pembrolizumab . hodgkin lymphoma diagnosis and arm b
__label__0	study interventions are pain therapy . prostate cancer diagnosis and no hematologic primary malignancies
__label__0	study interventions are Albumin-Bound Paclitaxel . pancreatic cancer diagnosis and adequate bone marrow function anc greater_than one five hundred hgb greater_than nine plt greater_than one00
__label__0	study interventions are Rituximab . lymphoma diagnosis and no prior cytotoxic chemotherapy
__label__0	study interventions are Sorafenib . prostate cancer diagnosis and prior vaccine therapy allowed
__label__0	study interventions are Entospletinib SDD . diffuse large cell lymphoma diagnosis and prior treatment for lymphoid malignancy requiring treatment for progressive disease
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and six nine
__label__0	study interventions are Pharmacological Study . head and neck squamous cell carcinoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt less_than two institutional upper limit of normal
__label__0	study interventions are DTI-015 . brain neoplasms diagnosis and for female patient of childbearing potential the patient must not be pregnant as evidenced by menses in the last eight weeks or by negative urine hcg pregnancy test
__label__0	study interventions are Bevacizumab . stage iv squamous cell carcinoma of the hypopharynx diagnosis and recent history of cerebrovascular accident
__label__0	study interventions are Cyclophosphamide . recurrent neuroblastoma diagnosis and other malignant lymphoproliferative disorders
__label__0	study interventions are Paclitaxel . ovarian transitional cell carcinoma diagnosis and urine protein creatinine upc ratio less_than doc at screening or
__label__0	study interventions are Cisplatin . central nervous system tumors diagnosis and not specified
__label__0	study interventions are Imatinib Mesylate . sarcoma diagnosis and age eighteen yrs or older
__label__0	study interventions are Mycophenolate mofetil . recurrent adult cell leukemia lymphoma diagnosis and mantle cell nhl
__label__0	study interventions are Risedronate Sodium . breast cancer diagnosis and malabsorption syndrome
__label__0	study interventions are Fludarabine . anaplastic large cell lymphoma diagnosis and the best available match is hla class ii drbone and dqbone matched donor incompatible for any single serologically detectable class hla b mismatch one additional allele level class mismatch is allowed or any combination of two allele level mismatches if typed at the molecular level
__label__0	study interventions are Liposomal doxorubicin . primary peritoneal serous adenocarcinoma diagnosis and patients may have received an unlimited number of prior therapy regimens
__label__0	study interventions are laboratory biomarker analysis . recurrent childhood anaplastic astrocytoma diagnosis and at least six weeks since prior substantial bone marrow radiotherapy
__label__0	study interventions are Standard Care . cancer of rectum diagnosis and age greater_than eighteen y
__label__0	study interventions are Albumin-Bound Paclitaxel . histologic confirmation of invasive breast cancer
__label__0	study interventions are Metronidazole . stage iii pancreatic cancer diagnosis and no uncontrolled seizure disorders
__label__0	study interventions are Fludarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and donor must have adequate veins for leukapheresis or agree to placement of central venous catheter femoral_subclavian
__label__0	study interventions are Cediranib . recurrent childhood supratentorial primitive neuroectodermal tumor diagnosis and no clinically significant unrelated systemic illness including serious infections or significant cardiac pulmonary hepatic or other organ dysfunction that would preclude study participation
__label__0	study interventions are Neulasta® (pegfilgrastim) . breast cancer diagnosis and intrauterine device implantable progesterone device progesterone intramuscular injection or oral contraceptive which has been started at least one month prior to visit one and will continue for the duration of the trial
__label__0	study interventions are Interferons . lymphoma diagnosis and ecog performance status zero one
__label__0	study interventions are RG4733 . advanced and or metastatic solid tumor malignancy
__label__0	study interventions are Isotretinoin . all institutional food and drug administration fda and national cancer institute nci requirements for human studies must be met
__label__0	study interventions are Fludarabine . lymphoma diagnosis and karnofsky or lansky score of greater_than seventy
__label__0	study interventions are questionnaire administration . long term effects of cancer treatment diagnosis and prior concurrent therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and platelet count at least one hundred and thirty zero mmthree
__label__0	study interventions are Bevacizumab . ovarian endometrioid adenocarcinoma diagnosis and stage ib disease or less
__label__0	study interventions are Vaccines . melanoma diagnosis and patient characteristics
__label__0	study interventions are Vaccines . histologically proven progressive metastatic or locally advanced melanoma
__label__0	study interventions are Antibodies . adult anaplastic oligodendroglioma diagnosis and females of child bearing potential and sexually active males must consent to follow acceptable birth control methods to avoid contraception while on treatment
__label__0	study interventions are Oxaliplatin . histologically confirmed gastric adenocarcinoma
__label__0	study interventions are Vidarabine . recurrent grade two follicular lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Study Assessments . head neck cancer diagnosis and willing to drive to the study site
__label__0	study interventions are Antibodies . mixed adenocarcinoma of the stomach diagnosis and neutrophil count greater_than equal_than one five hundred mm three
__label__0	study interventions are Tamoxifen . stage iiib breast cancer diagnosis and patients must not have had core biopsy or other minor surgical procedure within seven days prior to study registration placement of vascular access device is allowed within seven days of registration
__label__0	study interventions are Liposomal doxorubicin . recurrent prostate cancer diagnosis and patients or their legal representatives must be able to read understand and provide informed consent
__label__0	study interventions are Cyclosporins . recurrent hodgkin lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Topotecan . endometrial cancer diagnosis and subject must have at screening probable life expectancy of at least three months
__label__0	study interventions are Bevacizumab . adrenocortical carcinoma diagnosis and patients must have completed only one or fewer regimes of systemic therapy
__label__0	study interventions are Methotrexate . burkitt like lymphoma diagnosis and all ages are eligible
__label__0	study interventions are fatigue assessment and management . prostate cancer diagnosis and not specified
__label__0	study interventions are Liposomal doxorubicin . patients with pathologically confirmed diagnosis of advanced melanoma with newly diagnosed untreated brain metastases and controlled extracranial disease which per the multi disciplinary team decision do not require immediate radiotherapy surgery or standard systematic chemotherapy
__label__0	study interventions are Liposomal doxorubicin . metastatic angiosarcoma diagnosis and five uln
__label__0	study interventions are Mifepristone . recurrent breast cancer diagnosis and eastern cooperative oncology group ecog performance status of zero two karnofsky greater_than 6zero
__label__0	study interventions are Mycophenolic Acid . diffuse large cell lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Panobinostat . mesothelioma diagnosis and must have failed prior standard systemic therapy
__label__0	study interventions are diffusion-weighted magnetic resonance imaging . stage iib prostate cancer diagnosis and prostate specific antigen psa greater_than equal_than ten
__label__0	study interventions are Thiotepa . recurrent small lymphocytic lymphoma diagnosis and calculated creatinine clearance less_than forty cc min by the modified cockcroft gault formula for adults or the schwartz formula for pediatrics
__label__0	study interventions are Tacrolimus . multiple myeloma and plasma cell neoplasm diagnosis and chronic myeloid leukemia cml
__label__0	study interventions are Erlotinib Hydrochloride . head and neck cancer diagnosis and patient characteristics
__label__0	study interventions are Vidarabine . contiguous stage ii adult diffuse large cell lymphoma diagnosis and these patients must be presented at pcc prior to enrollment given potential competing eligibility on autotransplant protocols
__label__0	study interventions are Maytansine . metastatic breast cancer diagnosis and for patients with gilbert syndrome the direct bilirubin should be within the institutional normal range
__label__0	study interventions are Sentinel Lymph Node Biopsy . uterine neoplasms diagnosis and histologies
__label__0	study interventions are Dexamethasone . metastatic breast cancer diagnosis and hemoglobin greater_than ten dl
__label__0	study interventions are Fludarabine phosphate . clear cell renal cell carcinoma diagnosis and the following diseases will be permitted although other diagnoses can be considered if approved by pcc or the participating institution patient review committees and the principal investigator
__label__0	study interventions are Antibodies . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and platelets greater_than equal_than one hundred zero mm three without transfusion
__label__0	study interventions are Peripheral blood progenitor cell transplant . lymphoma diagnosis and donor or patient must not be hiv positive
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and no histological evidence of cirrhosis
__label__0	study interventions are Trastuzumab . metastatic osteosarcoma diagnosis and creatinine clearance or glomerular filtration rate greater_than seventy ml min
__label__0	study interventions are Diphenhydramine . immunoparesis this term refers to the patient having low uninvolved immunoglobulins in peripheral blood for example if patient has immunoglobulin infantile genetic agranulocytosis iga smoldering multiple myeloma then either having low immunoglobulin igm and or low immunoglobulin igg will qualify as risk factor for progression to multiple myeloma one of two risk factors
__label__0	study interventions are Immunoglobulin Idiotypes . stage iii multiple myeloma diagnosis and any prior therapy must be completed at least eight weeks prior to second apbsct recovered from the toxic effects of prior therapy no concurrent aspirin or nonsteroidal antiinflammatory drugs
__label__0	study interventions are Melphalan . lymphoma diagnosis and histologically confirmed malignancy including
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic cancer diagnosis and prior allergic reactions to drugs containing cremophor or to compounds chemically related to cisplatin paclitaxel or carboplatin
__label__0	study interventions are Hormones . recurrent ovarian carcinoma diagnosis and total serum bilirubin equal_than less_than two mg dl
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and able to comply with study and follow up procedures
__label__0	study interventions are Irinotecan . duct cell adenocarcinoma of the pancreas diagnosis and hemoglobin greater_than equal_than nine dl or greater_than equal_than nine0 l
__label__0	study interventions are EMLA . microinvasive squamous cell carcinoma diagnosis and difficulty in surgical excision because of health problems bleeding tendency or cardiac problems
__label__0	study interventions are Paclitaxel . lung cancer diagnosis and no prior carboplatin paclitaxel or vandetanib
__label__0	study interventions are Tacrolimus . recurrent cutaneous cell non hodgkin lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Bendamustine Hydrochloride . adult lymphocyte predominant hodgkin lymphoma diagnosis and patients with human immunodeficiency virus hiv infection are eligible patients with hiv infection must meet the following
__label__0	study interventions are Dexamethasone . recurrent pituitary tumor diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma_secretase inhibitor rofour million, nine hundred and twenty-nine thousand and ninety-seven or dexamethasone
__label__0	study interventions are Vincristine . plasmablastic lymphoma diagnosis and performance status ps zero one or two per the eastern cooperative oncology group ecog performance status scale karnofsky performance score greater_than equal_than 5zero
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and significant history of uncontrolled cardiac disease including any of the following
__label__0	study interventions are Fludarabine phosphate . hepatosplenic cell lymphoma diagnosis and chronic myeloid leukemia cml
__label__0	study interventions are Levoleucovorin . childhood central nervous system germinoma diagnosis and no pleural effusion or ascites causing respiratory compromise greater_than grade two dyspnea
__label__0	study interventions are Vidarabine . lymphoma diagnosis and first or second chronic phase
__label__0	study interventions are Cyclosporins . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and first or subsequent chronic phase
__label__0	study interventions are Questionnaire Administration . malignant neoplasm diagnosis and changes in systemic chemotherapy hormonal therapy or the use of bisphosphonates for four weeks before and after the delivery of radiotherapy are allowed but recording and accounting for this in the statistical analysis is required
__label__0	study interventions are Antibodies, Bispecific . myeloid sarcoma diagnosis and bilirubin less_than three times the upper limit of normal for age
__label__0	study interventions are 89Zr-DFO-huJ591 . prostate cancer diagnosis and adult male greater_than eighteen years of age
__label__0	study interventions are Interleukin-2 . intraocular lymphoma diagnosis and cardiac stress test stress thallium scan stress echocardiography with normal results if subject is suspected to have coronary artery disease
__label__0	study interventions are Cetuximab . non small cell lung cancer diagnosis and disease must be newly diagnosed or recurrent at least one year post adjuvant therapy
__label__0	study interventions are Busulfan . lymphoma diagnosis and not specified life expectancy
__label__0	study interventions are Capecitabine . neoplasm metastasis diagnosis and only patients with measurable disease
__label__0	study interventions are Liposomal doxorubicin . localized unresectable adult primary liver cancer diagnosis and serum creatinineequal_than less_than doc mg dl
__label__0	study interventions are Niacinamide . melanoma skin diagnosis and patient characteristics
__label__0	study interventions are Antibodies, Monoclonal . stage iv squamous cell carcinoma of the larynx diagnosis and calcium less_than ten mg dl hypocalcemic agents allowed
__label__0	study interventions are Gemcitabine . urethral cancer diagnosis and in general liver and lung lesions should be at least one cm and patients with node only disease should have lesions of greater_than equal_than doc cm in greatest dimension
__label__0	study interventions are AGS-003 . renal cell carcinoma diagnosis and age greater_than eighteen years
__label__0	study interventions are Lenalidomide . marginal zone cell lymphoma diagnosis and fcbp must also agree to ongoing pregnancy testing
__label__0	study interventions are Albumin-Bound Paclitaxel . treatment including radiation therapy chemotherapy and or hormonal therapy administered for the currently diagnosed breast cancer prior to randomization
__label__0	study interventions are Endothelial Growth Factors . recurrent fallopian tube carcinoma diagnosis and international normalized ratio inr equal_than less_than doc unless the patient is on full dose warfarin
__label__0	study interventions are Veliparib . breast carcinoma diagnosis and patients enrolled on the expansion portion of the study will consist of two cohorts
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Quality-of-life assessment . stage ia breast cancer diagnosis and chronic diarrhea or vomiting
__label__0	study interventions are Pentostatin . lymphoma cell diagnosis and recipient
__label__0	study interventions are Antibodies, Bispecific . non hodgkin lymphoma diagnosis and at least one prior line of therapy if primary refractory or relapsed within one year
__label__0	study interventions are Mycophenolate mofetil . refractory multiple myeloma diagnosis and when evaluating patients for unrelated donor transplant the higher degree of matching the lower risk of gvhd the b drbone and dqbone loci comprising one0 possible antigen with alleles will be typed for all unrelated transplants given the higher risk of trm in mismatched transplants rit is often the best way to mitigate the risk data from the national marrow donor program makes it possible to estimate the risk of donor recipient hla mismatch at the allele or antigen level the higher risk from hla mismatching must be balanced against the clinical urgency and the patient risk by the transplant team at this time antigen level mismatches at dqbone do not affect outcomes and will not be used for matching purposes for donor selection thus the matching required will be at the hla b and drbone eight loci for this protocol single antigen mismatch at the hla b with or without additional single allele level mismatch may participate in this protocol for voluntary unrelated donors blood or marrow donor
__label__0	study interventions are Liposomal doxorubicin . ovarian clear cell cystadenocarcinoma diagnosis and measurable disease will be defined by recist doc
__label__0	study interventions are Fludarabine . melanoma diagnosis and
__label__0	study interventions are Liposomal doxorubicin . sarcoma diagnosis and patients who will receive doxorubicin must have normal cardiac ejection fraction by echocardiogram
__label__0	study interventions are Autologous NY-ESO-1-specific CD8-positive T Lymphocytes . sarcoma diagnosis and patient must have consulted with radiation oncologist who is planning radiation their radiation oncologist should have documented plans to administer dose of at least thirty gy in five or fewer fractions
__label__0	study interventions are Endothelial Growth Factors . must show unequivocal radiographic evidence of tumor progression by mri
__label__0	study interventions are Sunitinib . gastrointestinal stromal tumor diagnosis and no other uncontrolled illness
__label__0	study interventions are cilengitide . stage iv cutaneous cell non hodgkin lymphoma diagnosis and absolute neutrophil count greater_than one five hundred mm three
__label__0	study interventions are Sirolimus . stage iv renal cell cancer diagnosis and life expectancy greater_than equal_than twelve weeks
__label__0	study interventions are Antibodies . stage iii verrucous carcinoma of the oral cavity diagnosis and tipranavir
__label__0	study interventions are Antibodies, Bispecific . recurrent fallopian tube carcinoma diagnosis and lvef greater_than equal_than forty-five at rest by echo
__label__0	study interventions are Poly I-C . stage iiib skin melanoma diagnosis and absolute neutrophil count greater_than equal_than one zero mcl
__label__0	study interventions are Fludarabine . recurrent grade two follicular lymphoma diagnosis and patients treated on this study will have
__label__0	study interventions are Gemcitabine . stage iii mantle cell lymphoma diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are BB 1101 . refractory multiple myeloma diagnosis and any prior treatment with investigational agents must be discontinued greater_than equal_than twenty-eight days prior to study registration
__label__0	study interventions are Immunoglobulins . stage iv prostate cancer diagnosis and all subjects must have the ability to understand and the willingness to sign written informed consent
__label__0	study interventions are 2:1 group . uterine myoma diagnosis and the duration of pneumoperitoneum during laparoscopic surgery is more than forty minutes
__label__0	study interventions are Irinotecan . unresectable extrahepatic bile duct cancer diagnosis and no gilbert disease
__label__0	study interventions are Only radiation therapy . tumor extension beyond muscularis_propria and or nodal involvement without evidence of mone disease
__label__0	study interventions are Cetuximab . stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and other clinically significant cardiovascular disease
__label__0	study interventions are Methyltestosterone . prostate cancer diagnosis and patients will considered for repeat treatment with testosterone if they meet the following criteria
__label__0	study interventions are Taxane . er negative pr negative hertwo negative breast neoplasms diagnosis and adequate renal function serum creatinine less_than doc mg dl or calculated creatinine clearance greater_than sixty ml min using cockcroft gault equation
__label__0	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the larynx diagnosis and negative pregnancy test
__label__0	study interventions are Antibodies . ciliary body and choroid melanoma medium large size diagnosis and white blood cell wbc greater_than equal_than two thousand ul
__label__0	study interventions are Docetaxel . stage iiia non small cell lung cancer diagnosis and one and only one prior chemotherapy regimen for advanced disease not including adjuvant therapy allowed
__label__0	study interventions are perflutren lipid microspheres . ovarian cancer diagnosis and diagnosis of adnexal mass
__label__0	study interventions are Oxaliplatin . stage iib fallopian tube cancer diagnosis and creatinine less than or equal to doc institutional upper limit normal uln or creatinine clearance greater_than fifty cc min
__label__0	study interventions are Carboplatin . childhood renal cell carcinoma diagnosis and newly diagnosed disease of one of the following histologic types
__label__0	study interventions are Oxaliplatin . locally advanced gastric carcinoma diagnosis and tthree four none three mzero ajcc seventh potentially resectable
__label__0	study interventions are clinical observation . lung cancer diagnosis and see disease characteristics
__label__0	study interventions are Succinylcholine . cognitive side effects of cancer therapy diagnosis and platelet count greater_than equal_than one hundred ten nine l
__label__0	study interventions are Casopitant . solid tumor cancer diagnosis and oral contraceptives oral injectable or implantable with double barrier method of contraception consisting of spermicide with either condom or diaphragm for period after the trial to account for potential drug interaction minimum of six weeks
__label__0	study interventions are Alemtuzumab . non hodgkin lymphoma nhl in second complete remission crtwo or subsequent
__label__0	study interventions are Methotrexate . recurrent adult burkitt lymphoma diagnosis and known intolerance to bdp
__label__0	study interventions are Dasatinib . recurrent verrucous carcinoma of the oral cavity diagnosis and brain metastases permitted provided the patient does not require anticonvulsants or corticosteroids or has been off them at least seven days patients with brain metastases must be either greater_than four weeks beyond cranial irradiation or must be felt not to require it at that time
__label__0	study interventions are Immunoglobulins . recurrent malignant mesothelioma diagnosis and see disease characteristics
__label__0	study interventions are Gemcitabine . stage iv non small cell lung cancer diagnosis and have uni_dimensionally measurable and or evaluable advanced nsclc
__label__0	study interventions are therapeutic conventional surgery . recurrent adult brain tumor diagnosis and patients must have radiographic findings consistent with either
__label__0	study interventions are Paclitaxel . left ventricular ejection fraction greater than fifty no symptomatic cardiac disease requiring antiarrhythmic or inotropic therapy pulmonary
__label__0	study interventions are Letrozole . breast cancer diagnosis and radiotherapy
__label__0	study interventions are Thiotepa . retinoblastoma diagnosis and patients may receive transfusions as necessary
__label__0	study interventions are Camptothecin . childhood craniopharyngioma diagnosis and no concurrent radiotherapy
__label__0	study interventions are Fluorides . stage iii mesothelioma diagnosis and females
__label__0	study interventions are Fludarabine . non hodgkin lymphoma diagnosis and voluntary written consent adult or parental guardian
__label__0	study interventions are Cortisone acetate . stage iv adult diffuse large cell lymphoma diagnosis and patients must be offered the opportunity to consent to the correlative science studies patients are encouraged to submit specimens for correlative studies however specimen submission is not requirement for participation in the study
__label__0	study interventions are Melphalan . unusual cancers of childhood diagnosis and required multiple courses of induction therapy to achieve remission
__label__0	study interventions are Goserelin . metastatic breast cancer diagnosis and er pr positive
__label__0	study interventions are Palonosetron . gastric cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Cyclophosphamide . refractory non hodgkin lymphoma diagnosis and donor
__label__0	study interventions are Mycophenolic Acid . stage iii marginal zone lymphoma diagnosis and there is likelihood of rapid disease progression while hla typing and results of preliminary_search and the donor pool_suggests that ten ten hla b drbone and dqbone matched unrelated donor will not be found
__label__0	study interventions are Cytarabine . stage iii aids related lymphoma diagnosis and karnofsky performance score greater_than equal_than seventy
__label__0	study interventions are Cyclosporins . stage iii childhood lymphoblastic lymphoma diagnosis and human leukocyte antigen hla genotypically phenotypically identical donor if more than one hla identical sibling is available priority will be given to donors matched for cytomegalovirus cmv status abo_titer and sex
__label__0	study interventions are Eribulin Mesylate . recurrent breast carcinoma diagnosis and ability to provide written informed consent
__label__0	study interventions are Vaccines . myeloma has relapsed progressed or failed to respond after at least one prior course of therapy consisting of at least two treatment cycles or months of therapy
__label__0	study interventions are Androgens . prostatic neoplasm diagnosis and ecog score
__label__0	study interventions are Bryostatin 1 . unspecified adult solid tumor protocol specific diagnosis and standard curative or palliative measures do not exist or are no longer effective
__label__0	study interventions are Nivolumab . leptomeningeal carcinomatosis diagnosis and coagulation
__label__0	study interventions are Mycophenolate mofetil . stage iii childhood burkitt lymphoma diagnosis and donors are excluded when preexisting_immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment this determination is based on the standard practice of the individual institution the recommended procedure for patients with ten of ten hla allele level phenotypic match is to obtain panel reactive antibody pra_screens to class and class ii antigens for all patients before hct if the pra shows greater_than ten activity then flow cytometric or and cell cytotoxic cross matches should be obtained the donor should be excluded if any of the cytotoxic cross match assays are positive for those patients with an hla class allele mismatch flow cytometric or and cell cytotoxic cross matches should be obtained regardless of the pra results positive anti donor cytotoxic crossmatch is an absolute donor exclusion
__label__0	study interventions are Gemcitabine . recurrent uterine corpus carcinoma diagnosis and creatinine clearance greater_than equal_than sixty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Lenalidomide . recurrent grade three follicular lymphoma diagnosis and use of any other experimental drug or therapy with twenty-eight days of baseline
__label__0	study interventions are Passy Muir Swallowing Self Trainer . head and neck cancer diagnosis and penetration aspiration scale score of two or greater verified by modified barium swallow rosenbek et_al
__label__0	study interventions are Cyclophosphamide . renal cancer diagnosis and to be included in the study patients must meet the following criteria
__label__0	study interventions are Surveys . colon cancer diagnosis and web avidity greater_than two uses of email week
__label__0	study interventions are Interferon-alpha . kidney cancer diagnosis and no cns metastases by neurologic exam and ct scan or mri
__label__0	study interventions are Cyclophosphamide . untreated childhood rhabdomyosarcoma diagnosis and no prior chemotherapy or radiotherapy except for use of corticosteroids or emergent radiation therapy patients requiring emergency radiation are eligible
__label__0	study interventions are Interleukin-2 . metastatic uveal melanoma diagnosis and platelet count greater than or equal one hundred zero mm three
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and the subject has received at least one previous line of therapy including
__label__0	study interventions are Mesenchymal-marker based ferrofluid (c-MET) . pancreatic cancer diagnosis and new soft tissue visceral lymph node bone metastatic lesion
__label__0	study interventions are questionnaire administration . psychosocial effects of cancer and its treatment diagnosis and the patient must be currently be enrolled or plan to be enrolled on cog therapeutic study that aims to examine neuropsychological social emotional and or behavioral functioning
__label__0	study interventions are Nilotinib . gastrointestinal cancer diagnosis and female patients of childbearing potential must have negative pregnancy test within seven days before initiation of study drug dosing
__label__0	study interventions are Etoposide . stage iv adult cell leukemia lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two at time of consent
__label__0	study interventions are Paclitaxel . metastatic malignant melanoma diagnosis and no known active or chronic infection with hiv hepatitis or hepatitis c
__label__0	study interventions are Bevacizumab . stage ivb nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and no prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate eighty if the physician choice of chemotherapy regimen is docetaxel
__label__0	study interventions are Levoleucovorin . metastatic cancer diagnosis and no concurrent hormonal therapy radiotherapy
__label__0	study interventions are Pertuzumab . inflammatory breast carcinoma diagnosis and for patients with mbc prior adjuvant chemotherapy and trastuzumab more than or equal to twelve months prior to enrollment are allowed
__label__0	study interventions are Cisplatin . non small cell lung cancer diagnosis and has metastatic disease
__label__0	study interventions are Cyclosporins . lymphoma diagnosis and blasts must be less_than five if blasts are greater_than five pre transplant induction therapy is required to reduce blast count to less_than five
__label__0	study interventions are Heparin . wilms tumor diagnosis and parent or guardian able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines
__label__0	study interventions are Immunoglobulins . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Bleomycin . the length of the longest diameter of the study lesion must be less_than five cm and the calculated treatment volume must be less_than six doc cmthree tumor volume plus doc cm margin around the tumor for the study lesion where treatment volume equal_than doc positive one positive one two and where equal_than length of the longest diameter cm equal_than the next longest diameter perpendicular to cm
__label__0	study interventions are Camptothecin . esophageal cancer diagnosis and negative pregnancy test
__label__0	study interventions are Mycophenolate mofetil . myeloproliferative neoplasm diagnosis and fhcrc matching allowed will be grades doc to doc
__label__0	study interventions are Thalidomide . lymphoma diagnosis and serum lactate dehydrogenase ldh level above normal
__label__0	study interventions are Etoposide . recurrent adult diffuse mixed cell lymphoma diagnosis and all patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
__label__0	study interventions are Pharmacological Study . stage ii thyroid gland papillary carcinoma diagnosis and creatinine normal or creatinine clearance greater_than sixty ml min
__label__0	study interventions are Sirolimus . ovarian seromucinous carcinoma diagnosis and hepatic artery infusional chemotherapy
__label__0	study interventions are BB 1101 . newly diagnosed symptomatic multiple myeloma patients for whom treatment is indicated per the nccn guidelines and for whom hematopoietic stem cell transplant is not planned or scheduled during the study or are considered ineligible for hematopoietic stem cell transplant with measurable disease
__label__0	study interventions are Everolimus . myelodysplastic myeloproliferative neoplasms diagnosis and myelofibrosis and other myeloproliferative disorders
__label__0	study interventions are biological therapy . stage iv breast cancer diagnosis and at least twelve weeks since prior hormonal therapy except in patients with disease progression during and after initial therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . cervical adenosquamous carcinoma diagnosis and alkaline phosphatase less than or equal to doc uln
__label__0	study interventions are GTx-024 . non small cell lung cancer diagnosis and surgical menopause is defined as bilateral oophorectomy
__label__0	study interventions are Fatigue Inventory . adult nasal type extranodal nk cell lymphoma diagnosis and total bilirubin less_than doc mg dl
__label__0	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and planning to receive up to six cycles of chemotherapy
__label__0	study interventions are Mycophenolate mofetil . lymphoma diagnosis and biologic therapy
__label__0	study interventions are Lovaza . breast cancer diagnosis and if subject has had dcis at least two months must have elapsed from surgery and or radiation therapy to the involved breast
__label__0	study interventions are Lapatinib . adenocarcinoma of the gastroesophageal junction diagnosis and creatinine within normal institutional limits or creatinine clearance greater_than equal_than sixty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Ferrosoferric Oxide . stage iv non small cell lung cancer diagnosis and hemoglobin greater_than nine dl
__label__0	study interventions are Enzalutamide . patients must be disease free from prior malignancies for greater than three years with the exception of non melanoma skin cancers and superficial urothelial cancers
__label__0	study interventions are Romidepsin . glucagonoma diagnosis and unidimensionally measurable lesion at least twenty mm by conventional techniques or at least ten mm by spiral ct scan
__label__0	study interventions are Paclitaxel . unspecified adult solid tumor protocol specific diagnosis and cardiovascular
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and postmenopausal
__label__0	study interventions are Leucovorin . non metastatic pancreas cancer diagnosis and zero
__label__0	study interventions are Prednisolone hemisuccinate . recurrent childhood small noncleaved cell lymphoma diagnosis and there are no restrictions based upon underlying disease donor source the degree of hla match the intensity of the pre transplant conditioning regimen or the use of prior donor leukocyte infusion
__label__0	study interventions are pharmacological study . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and ecog zero two
__label__0	study interventions are Valproic Acid . recurrent small lymphocytic lymphoma diagnosis and no uncontrolled autoimmune hemolytic anemia
__label__0	study interventions are Nelfinavir . colorectal tumors diagnosis and less than ten weight loss the last six months
__label__0	study interventions are Capecitabine . should woman become pregnant or suspect she is pregnant while participating in this study she must inform her treating physician immediately
__label__0	study interventions are sargramostim . colorectal cancer diagnosis and repeated resections of hepatic metastatic disease or resections of extrahepatic metastases prior to resection of the hepatic metastases allowed provided the most recent hepatic metastatic resection included total disease resection and or ablation
__label__0	study interventions are Methotrexate . recurrent adult lymphoblastic lymphoma diagnosis and patients should have extinguished standard of care options prior to being considered for this trial
__label__0	study interventions are Antibodies, Monoclonal . stage iv colon cancer diagnosis and negative pregnancy test
__label__0	study interventions are Romidepsin . extensive stage small cell lung cancer diagnosis and biologic therapy
__label__0	study interventions are Antibodies, Monoclonal . advanced malignant mesothelioma diagnosis and no other concurrent investigational or commercial agents or therapies
__label__0	study interventions are Fludarabine . stage iv grade three follicular lymphoma diagnosis and no prior chemotherapy radiotherapy or immunotherapy
__label__0	study interventions are Temozolomide . brain tumor diagnosis and performance status patients must have karnofsky performance status kps of greater_than sixty
__label__0	study interventions are Calcium, Dietary . recurrent colon cancer diagnosis and patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism
__label__0	study interventions are therapeutic education and psychological support . lung cancer diagnosis and patients capable of speaking and writing in french
__label__0	study interventions are Gemcitabine . carcinoma pancreatic ductal diagnosis and required entry laboratory parameters
__label__0	study interventions are Azacitidine . solid tumors diagnosis and cardiac arrhythmia requiring an anti arrhythmic medication excluding stable doses of beta blockers
__label__0	study interventions are Succinylcholine . stage iiib cervical cancer diagnosis and able to take oral medication and has no history of gastric surgery or pathology
__label__0	study interventions are Tacrolimus . stage iv grade two follicular lymphoma diagnosis and acute lymphoblastic leukemia all
__label__0	study interventions are Pembrolizumab . metastatic prostate carcinoma diagnosis and measurable disease
__label__0	study interventions are soy protein isolate . prostate cancer diagnosis and disease characteristics
__label__0	study interventions are Fluorodeoxyglucose F18 . stage ibtwo cervical cancer diagnosis and glomerular filtration rate gfr greater_than thirty ml min doc three two for the test retest sub study mri patients must have gfr of greater_than sixty ml min doc threem two
__label__0	study interventions are Thalidomide . recurrent lymphoplasmacytic lymphoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional upper limit of normal unless due to disease
__label__0	study interventions are Diphosphonates . multiple myeloma and plasma cell neoplasm diagnosis and patient characteristics
__label__0	study interventions are Fludarabine phosphate . stage small lymphocytic lymphoma diagnosis and patients with related or unrelated donors for whom
__label__0	study interventions are Aprepitant . undifferentiated ovarian carcinoma diagnosis and patients who are able to complete the assessments
__label__0	study interventions are Lenalidomide . anaplastic astrocytoma diagnosis and criteria for female children of childbearing potential fccbp
__label__0	study interventions are AG-221 . angioimmunoblastic cell lymphoma diagnosis and subject must be greater_than eighteen years of age
__label__0	study interventions are Dacarbazine . mesothelioma diagnosis and hemoglobin greater_than one doc dl
__label__0	study interventions are Vaccines . multiple myeloma diagnosis and overexpression of wtone rna in peripheral blood and or bone marrow as assessed by quantitative rt pcr at the time of presentatio or cml
__label__0	study interventions are Albumin-Bound Paclitaxel . neoplasms head and neck diagnosis and at least eighteen years of age
__label__0	study interventions are Mycophenolic Acid . recurrent aggressive adult non hodgkin lymphoma diagnosis and transplantation with pbsc
__label__0	study interventions are Etoposide . stage iv renal wilms tumor diagnosis and female patients of childbearing age must have negative pregnancy test
__label__0	study interventions are Sunitinib . gastric adenocarcinoma diagnosis and at least four weeks from any major surgery at first dose of trial drug
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and not specified hematopoietic
__label__0	study interventions are Dexamethasone acetate . colorectal cancer diagnosis and stage
__label__0	study interventions are Beclomethasone . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and use of myeloablative pre transplant conditioning regimen with greater_than eight hundred cgy total body irradiation and cyclophosphamide or high dose busulfan and cyclophosphamide
__label__0	study interventions are Mycophenolate mofetil . aids related peripheral systemic lymphoma diagnosis and viral load has decreased by greater_than equal_than doc logs or viral load less_than five thousand copies ml plasma on haart therapy
__label__0	study interventions are Antibodies, Monoclonal . unspecified adult solid tumor protocol specific diagnosis and not pregnant or nursing
__label__0	study interventions are Carboplatin . fallopian tube cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Estradiol . stage iv breast cancer diagnosis and serum creatinine equal_than less_than doc institutional uln iuln and estimated creatinine clearance greater_than fifty ml min using the cockroft gault formula
__label__0	study interventions are Methylprednisolone Hemisuccinate . symptomatic ventricular arrhythmias
__label__0	study interventions are psychosocial assessment and care . colorectal cancer diagnosis and hormone receptor status not specified
__label__0	study interventions are Prednisone . plasmablastic lymphoma diagnosis and periodic abstinence eg calendar_ovulation symptothermal post ovulation methods and withdrawal are not acceptable methods of contraception
__label__0	study interventions are Topotecan . peritoneal cavity cancer diagnosis and at least three weeks since prior radiotherapy and recovered
__label__0	study interventions are Immunoglobulin G . stage iv colorectal cancer diagnosis and urine sample tested for proteinuria by the dipstick method must indicate zero one positive protein if dipstick reading is greater_than equal_than two positive two4 hour urine specimen must demonstrate less_than doc of protein per two4 hours
__label__0	study interventions are Albumin-Bound Paclitaxel . unspecified adult solid tumor protocol specific diagnosis and absolute neutrophil count greater_than equal_than one five hundred mm three
__label__0	study interventions are Vincristine . high risk ewing family of tumors metastatic disease at diagnosis humerus femur or trunk primary bulky primary greater than eight cm or ldh greater or equal to nine hundred iu ml prior to biopsy
__label__0	study interventions are pain therapy . loss of appetite nausea vomiting cough coughing up blood chest pain shortness of breath difficulty swallowing fatigue must have symptoms related to intrathoracic lung cancer that are amenable to radiation palliation
__label__0	study interventions are Gemcitabine . acinar cell adenocarcinoma of the pancreas diagnosis and documentation of disease and radiographic staging
__label__0	study interventions are diagnostic laboratory biomarker analysis . recurrent grade one follicular lymphoma diagnosis and bilirubin sum of conjugated positive unconjugated equal_than less_than doc upper limit of normal uln for age
__label__0	study interventions are Antilymphocyte Serum . multiple myeloma and plasma cell neoplasm diagnosis and not specified
__label__0	study interventions are Immunoglobulin G . stage iv breast cancer diagnosis and full dose anticoagulation therapy is allowed for the treatment of prior conditions such as venous thrombosis or atrial fibrillation but not for the treatment of prior arterial thrombotic events patients on full dose anticoagulants must be on stable dose of warfarin and have an in range international normalized ratio inr usually between two and three or be on stable dose of low molecular weight lmw heparin patients receiving antiplatelet agents are eligible as are patients on daily prophylactic aspirin or anticoagulation for atrial fibrillation
__label__0	study interventions are Antibodies . large cell lung cancer diagnosis and creatinine clearance greater_than fifty ml min
__label__0	study interventions are Celecoxib . recurrent ovarian epithelial cancer diagnosis and patients with clinically significant cardiovascular disease uncontrolled hypertension myocardial infarction unstable angina new york heart association grade ii or greater congestive heart failure serious cardiac arrhythmia requiring medication or grade ii or greater peripheral vascular disease within one year prior to study entry
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and left ventricular ejection fraction normal on muga or echocardiogram no congestive heart failure requiring medical therapy no serious arrhythmia no firs negative secon negative or third degree heart block other
__label__0	study interventions are Antibodies, Monoclonal . recurrent adult diffuse large cell lymphoma diagnosis and all patients must be informed of the investigational nature of this study and give written informed consent in accordance with institutional and federal guidelines
__label__0	study interventions are Lenograstim . recurrent adult diffuse small cleaved cell lymphoma diagnosis and patients must have an eastern cooperative oncology group ecog performance status of zero or one
__label__0	study interventions are Antibodies . stage iv renal cell cancer diagnosis and cerebrovascular accident
__label__0	study interventions are laboratory biomarker analysis . recurrent prostate cancer diagnosis and no other significant cardiac disease
__label__0	study interventions are Calcium, Dietary . childhood central nervous system yolk_sac tumor diagnosis and no pleural effusion or ascites causing respiratory compromise greater_than grade two dyspnea
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and five six match degree is acceptable for unrelated bone marrow donors
__label__0	study interventions are Romidepsin . malignant lymphoma diagnosis and myocardial infarction within twelve months of study entry
__label__0	study interventions are Lapatinib . breast cancer diagnosis and all within doc times the institution upper limit of normal
__label__0	study interventions are Ganciclovir triphosphate . recurrent marginal zone lymphoma diagnosis and the minimum organ function requirements should be the same as the requirements for hct
__label__0	study interventions are Hormones . stage iiia breast cancer diagnosis and locally advanced disease stage ii or iii
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and see disease characteristics
__label__0	study interventions are Endothelial Growth Factors . metastatic renal cell cancer diagnosis and female patients of childbearing potential should have negative urine or serum pregnancy test within twenty-four hours prior to receiving the first dose of study medication if the urine test is positive or cannot be confirmed as negative serum pregnancy test will be required
__label__0	study interventions are Antibodies, Monoclonal . recurrent non small cell lung cancer diagnosis and no prior or concurrent exposure to other egfr or igfr inhibitors
__label__0	study interventions are Etoposide phosphate . recurrent grade two follicular lymphoma diagnosis and patients must have ct of chest abdomen and pelvis within two8 days of enrollment patients with evidence of adenopathy in the neck must have ct of neck
__label__0	study interventions are Temozolomide . adult giant cell glioblastoma diagnosis and no known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__0	study interventions are Cisplatin . tumor biopsy specimen with greater_than fifty of mucone expressing tumor cells determined by immunohistochemistry ihc staining on fixed pathological material
__label__0	study interventions are Carboplatin . detectable non measurable disease is defined as symptomatic ascites or pleural effusions solid and or cystic abnormalities on radiographic imaging that do not meet response evaluation criteria in solid tumors recist doc definitions for target lesions and or biopsy proven recurrence
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent grade one follicular lymphoma diagnosis and all patients must have measurable or evaluable disease per recist criteria
__label__0	study interventions are 6-Mercaptopurine . lymphoma non hodgkin diagnosis and if age is six to ten years then maximum serum creatinine mg dl is one for males or females
__label__0	study interventions are Panobinostat . recurrent mantle cell lymphoma diagnosis and hodgkin disease
__label__0	study interventions are Levoleucovorin . brain and central nervous system tumors diagnosis and unbiopsied under ten years at diagnosis
__label__0	study interventions are Carboplatin . testicular embryonal carcinoma and yolk_sac tumor diagnosis and chemotherapy resistant disease
__label__0	study interventions are L 647318 . neurofibromatosis type one diagnosis and known iq below seventy
__label__0	study interventions are Fractionated palliative RT . solid tumors diagnosis and subjects must have
__label__0	study interventions are Topotecan . ovarian cancer diagnosis and eighteen and over performance status
__label__0	study interventions are Cisplatin . esophageal squamous cell cancer diagnosis and wbc greater_than four zero mmthree absolute neutrophil count greater_than 2zero mmthree platelet greater_than one hundred zero mmthree hb greater_than teng dl within 1four days before enrollment alt and ast less_than doc times uln less_than five times uln in patients with liver metastases bilirubin level less_than doc times uln serum akp less_than doc times uln serum creatinine less_than doc times uln
__label__0	study interventions are Talaporfin . liver neoplasms diagnosis and understanding and ability to sign written informed consent
__label__0	study interventions are Antibodies . stage ii non small cell lung cancer diagnosis and serious cardiac arrhythmia requiring medication
__label__0	study interventions are Antibodies, Monoclonal . stage iv adult diffuse small cleaved cell lymphoma diagnosis and planned tandem transplant is allowed for patients at high risk of relapse
__label__0	study interventions are Pertuzumab . both female and male breast cancer patients who are sexually active have to agree to practice contraception while participating in the trial and for three month after completion of therapy
__label__0	study interventions are therapeutic conventional surgery . hypopharyngeal cancer tone and ttwo
__label__0	study interventions are Heparin . cancer diagnosis and see disease characteristics
__label__0	study interventions are Sapanisertib . pancreatic neuroendocrine tumor gtwo diagnosis and leukocytes greater_than equal_than three zero mm three
__label__0	study interventions are Sterotactic radiosurgery . adult central nervous system germ cell tumor diagnosis and prior cranial radiotherapy allowed surgery
__label__0	study interventions are Immunoglobulins . stage iv hypopharyngeal squamous cell carcinoma diagnosis and patients must not be receiving chronic daily treatment with aspirin greater_than three hundred and twenty-five mg day or non steroidal anti inflammatory agents nsaid known to inhibit platelet function the use of anti platelet agents dipyridamole_persantine ticlopidine_ticlid clopidogrel_plavix is allowed only if patient is not receiving aspirin or nsaid known to inhibit platelet function
__label__0	study interventions are BB 1101 . multiple myeloma in relapse diagnosis and patient must be refractory to the last bortezomib containing line of therapy given in the relapsed and refractory setting defined as
__label__0	study interventions are Fludarabine . lymphoma non hodgkin nhl diagnosis and not breast feeding
__label__0	study interventions are Etoposide . primary peritoneal carcinoma diagnosis and available to receive intraperitoneal chemotherapy five ten days postoperative or no more than postoperative fourteen days for those with bowel resection
__label__0	study interventions are Capecitabine . biliary cancer diagnosis and no prior systemic therapy for their diagnosis
__label__0	study interventions are Immunoglobulins . stage iiib non small cell lung cancer diagnosis and patients with known history of myocardial infarction or other evidence of arterial thrombotic disease angina will be allowed on study only if they have had no evidence of active disease for at least six months prior to randomization
__label__0	study interventions are Aromatase Inhibitors . breast cancer diagnosis and bilirubin less_than doc mg dl or less_than doc mg dl if due to gilbert syndrome
__label__0	study interventions are Mycophenolic Acid . stage iii adult diffuse large cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Bortezomib . multiple myeloma and plasma cell neoplasm diagnosis and no demonstrated resistance to bortezomib
__label__0	study interventions are Questionnaires . brain cancer diagnosis and patient must have imaging findings within the last three months consistent with recurrent disease in the brain
__label__0	study interventions are FDHT-PET scan . metastatic breast cancer diagnosis and patient age less_than sixty years using lh_rh agonists should continue lh_rh agonists until after the pet procedures
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and fluoropyrimidine based monotherapy with bevacizumab
__label__0	study interventions are Albumin-Bound Paclitaxel . primary peritoneal carcinoma diagnosis and not pregnant or nursing
__label__0	study interventions are pharmacological study . lung cancer diagnosis and ast alt and alkaline phosphatase less_than doc times uln
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and adequate renal function as determined by either
__label__0	study interventions are Albumin-Bound Paclitaxel . unspecified adult solid tumor protocol specific diagnosis and other
__label__0	study interventions are Poly ICLC . neuroectodermal tumors primitive diagnosis and renal function
__label__0	study interventions are Paclitaxel . gastric adenocarcinoma diagnosis and for all cohorts
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and no other concurrent significant medical condition
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and common
__label__0	study interventions are Low Level Laser . unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection sentinel biopsy or axillary dissection
__label__0	study interventions are Androgens . recurrent prostate cancer diagnosis and there must be no plans to receive concomitant chemotherapy biological response modifiers radiation therapy or hormonal therapy
__label__0	study interventions are VNP20009 . neoplasm metastasis diagnosis and nursing patients are also excluded
__label__0	study interventions are Carboplatin . small intestine cancer diagnosis and other
__label__0	study interventions are Cetuximab . carcinoma non small cell lung diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred mmthree platelets greater_than equal_than one00 zero mmthree
__label__0	study interventions are laromustine . lymphoma diagnosis and no other concurrent investigational agents
__label__0	study interventions are Antibodies, Monoclonal . stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and platelet count at least one hundred zero mm three
__label__0	study interventions are Hormones . hertwo negative breast cancer diagnosis and platelets greater_than one hundred zero µl
__label__0	study interventions are Dexamethasone 21-phosphate . precursor cell lymphoblastic leukemia lymphoma diagnosis and agree to have medically supervised pregnancy test with minimum sensitivity of twenty-five miu ml on the day of the study visit or in the three days prior to the study visit once the subject has been on effective contraception for at least four weeks
__label__0	study interventions are Antibodies . stage iii colon cancer diagnosis and uncontrolled high blood pressure
__label__0	study interventions are Fludarabine . childhood burkitt lymphoma diagnosis and myelodysplastic syndrome mds myeloproliferative disorder mpd
__label__0	study interventions are Paclitaxel . stage iiic primary peritoneal cancer diagnosis and ability to complete english language questionnaire by themselves or with assistance
__label__0	study interventions are Paclitaxel . mucosal melanoma diagnosis and no prior therapy
__label__0	study interventions are Thalidomide . solitary osseous plasmacytoma diagnosis and not pregnant and not nursing because this study involves an investigational agent whose genotoxic_mutagenic and teratogenic effects on the developing fetus and newborn are unknown and an agent that has known genotoxic_mutagenic and teratogenic effects
__label__0	study interventions are Cisplatin . stage iva pancreatic cancer diagnosis and patients must have histologically or cytologically confirmed solid organ malignancy
__label__0	study interventions are Epirubicin . breast cancer diagnosis and early stage disease
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent breast cancer diagnosis and morning cortisol greater_than equal_than institutional normal
__label__0	study interventions are Colposcopy . cervical cancer diagnosis and informed consent accepted and signed
__label__0	study interventions are Antibodies . lymphoma diagnosis and eighteen and over
__label__0	study interventions are Darbepoetin alfa . lymphoma diagnosis and patients with celiac disease who are adhering to gluten free diet are eligible
__label__0	study interventions are High Dose Intensity Modulated Proton Radiation . chondrosarcoma of the spine diagnosis and lesion may be primary or recurrent after prior surgery
__label__0	study interventions are Liposomal doxorubicin . stage iv breast cancer diagnosis and dose escalating cohorts only
__label__0	study interventions are Irinotecan . naive unresectable glioblastoma diagnosis and karnofsky index ki performance status over fifty
__label__0	study interventions are Etoposide . childhood germ cell tumor diagnosis and not specified life expectancy
__label__0	study interventions are Sirolimus . patients with metastatic or locally advanced unresectable breast cancer not amenable to curative treatment by surgery or radiotherapy
__label__0	study interventions are Romidepsin . refractory mature cell and nk cell non hodgkin lymphoma diagnosis and bilirubin greater_than uln but equal_than less_than doc uln and any ast
__label__0	study interventions are Rituximab . stage iv adult diffuse large cell lymphoma diagnosis and patients must not have uncontrolled hypertension
__label__0	study interventions are TGR-1202 . lymphoma non hodgkin diagnosis and line chemotherapy
__label__0	study interventions are Mycophenolate mofetil . lymphoma diagnosis and failed conventional therapy
__label__0	study interventions are Etoposide phosphate . anaplastic large cell lymphoma diagnosis and all stages eligible
__label__0	study interventions are Paclitaxel . recurrent ovarian germ cell tumor diagnosis and not pregnant or nursing
__label__0	study interventions are Etoposide phosphate . stage ii childhood hodgkin lymphoma diagnosis and males and females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
__label__0	study interventions are Antibodies, Monoclonal . histologically confirmed stage iv or recurrent nsclc with no prior systemic anticancer therapy
__label__0	study interventions are Fluorouracil . stage iva gallbladder cancer diagnosis and for patients who have received prior cryotherapy radiation therapy radiofrequency ablation therasphere ethanol injection transarterial chemoembolization tace or photodynamic therapy the following criteria must be met
__label__0	study interventions are Image-Guided Brachytherapy . bladder cancer diagnosis and life expectancy of greater than six months
__label__0	study interventions are Immunoglobulin G . stage ic fallopian tube cancer diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Rituximab . recurrent small lymphocytic lymphoma diagnosis and cardiac arrhythmia
__label__0	study interventions are Antibodies . prostate cancer diagnosis and patients with history of prior malignancy are eligible provided they were treated with curative intent and have been disease free for the time period considered appropriate by the treating physician
__label__0	study interventions are Freund's Adjuvant . melanoma skin diagnosis and platelets greater_than one hundred ten three µl
__label__0	study interventions are Dabrafenib . refractory malignant neoplasm diagnosis and check potassium and magnesium serum levels
__label__0	study interventions are Paclitaxel . advanced pancreatic cancer diagnosis and signed informed consent
__label__0	study interventions are Erlotinib Hydrochloride . stage iii pancreatic cancer diagnosis and no concurrent cypthreeafour inducers substrates or other inhibitors
__label__0	study interventions are Etoposide phosphate . recurrent nasopharynx carcinoma diagnosis and calculated creatinine clearance of greater than sixty ml minute serum creatinine of less than twelveo micromoles total bilirubin less than two mg dl and aspartate aminotransferase ast must be less than twice the upper limit of normal
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and patients must have clearly detectable and quantifiable monoclonal component value
__label__0	study interventions are Antibodies . recurrent adult primary liver cancer diagnosis and total bilirubin equal_than less_than upper limit of normal uln
__label__0	study interventions are Denileukin diftitox . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Citric Acid . stage iiia breast cancer diagnosis and none of the following co morbid conditions
__label__0	study interventions are Vinorelbine . stage iiia breast cancer diagnosis and patients must have adequate liver functions
__label__0	study interventions are Mitomycins . bladder cancer diagnosis and no severe active co morbidity including any of the following
__label__0	study interventions are Fluorouracil . breast cancer diagnosis and gallen one thousand, nine hundred and ninety-eight as follows
__label__0	study interventions are Interleukin-12 . metastatic cancer diagnosis and see disease characteristics
__label__0	study interventions are Citric Acid . ductal breast carcinoma in situ diagnosis and the patient must have signed and dated an institutional review board irb approved consent form that conforms to federal and institutional guidelines
__label__0	study interventions are Prednisone . multiple myeloma diagnosis and these tests should be performed not more than three days before the start of next treatment
__label__0	study interventions are Camptothecin . solid tumor diagnosis and prior chemotherapy must have been completed at least three weeks prior to initiation of this protocol
__label__0	study interventions are Placebo . epithelial ovarian cancer diagnosis and relapsed once and then underwent standard platinum based second line chemotherapy at least three cycles is required with or without second bulk reducing surgery
__label__0	study interventions are Antibodies, Monoclonal . stage ivb esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and life expectancy of greater_than three months
__label__0	study interventions are Atorvastatin Calcium . precancerous condition diagnosis and no history of endoscopically confirmed peptic ulcer disease
__label__0	study interventions are Everolimus . primary peritoneal cavity cancer diagnosis and ca one hundred and twenty-five greater_than two times upper limit of normal uln at baseline
__label__0	study interventions are Cabozantinib S-malate . renal cell carcinoma diagnosis and thirteen to less_than sixteen years of age
__label__0	study interventions are Liposomal doxorubicin . breast cancer stage iv diagnosis and absolute neutrophil count anc greater_than one five hundred mmthree
__label__0	study interventions are Topotecan . fallopian tube cancer diagnosis and alkaline phosphatase less_than doc times uln
__label__0	study interventions are Capecitabine . stage iiia breast cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are Doxorubicin . stage diffuse large cell lymphoma diagnosis and female subject of childbearing potential should have negative urine or serum pregnancy within seventy-two hours prior to receiving the first dose of study medication if the urine test is positive or cannot be confirmed as negative serum pregnancy test will be required
__label__0	study interventions are Immunoglobulins . undifferentiated ovarian carcinoma diagnosis and participants of childbearing potential must have negative urine or serum pregnancy within seventy-two hours prior to receiving the first dose of study medication if the urine test is positive or cannot be confirmed as negative serum pregnancy test will be required
__label__0	study interventions are Everolimus . should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__0	study interventions are Olaparib . ovarian cancer diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Dacarbazine . gliosarcoma diagnosis and following baseline studies will be required less_than onewk of study drug administration
__label__0	study interventions are Etoposide . lung cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and ast and alt less_than doc times upper limit of normal uln
__label__0	study interventions are BI 2536 . endometrial cancer diagnosis and bilirubin less_than doc times uln
__label__0	study interventions are Erlotinib Hydrochloride . recurrent esophageal cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Sirolimus . recurrent uterine corpus carcinoma diagnosis and history of prior varices or evidence of varices on pre study ct magnetic resonance imaging mri imaging are required to undergo endoscopy equal_than less_than four weeks prior to registration those who had received specific therapy banding and or sclerotherapy and had not bled within the prior six months are eligible
__label__0	study interventions are Pomalidomide . all subjects must have had at least two prior lines of anti myeloma therapy
__label__0	study interventions are COTI2 . platinum resistant recurrent ovarian fallopian tube or primary peritoneal cancer or endometrial or cervical cancer that is recurrent metastatic or unresectable and for which no effective curative or palliative measures exist
__label__0	study interventions are Mycophenolic Acid . stage iv adult diffuse large cell lymphoma diagnosis and following planned autologous transplant or equivalent high dose therapy without graft or following failed prior autograft
__label__0	study interventions are Paclitaxel . ovarian cancer diagnosis and unresectable metastatic disease
__label__0	study interventions are Ifosfamide . head and neck cancer diagnosis and not specified chemotherapy
__label__0	study interventions are Aldesleukin . gliosarcoma diagnosis and karnofsky performance status kps greater_than equal_than sixty
__label__0	study interventions are Rituximab . stage adult diffuse small cleaved cell lymphoma diagnosis and patients are allowed to have received radiotherapy before enrollment if radiation was given to alleviate pain and or neurologic compromise as long as there remains areas of measurable disease present
__label__0	study interventions are Sorafenib . recurrent renal cell cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Docetaxel . head and neck cancer diagnosis and no hypercalcemia
__label__0	study interventions are Nitrogen Mustard Compounds . plasmablastic lymphoma diagnosis and receipt of stable art regimen for at least three weeks prior to start of trial
__label__0	study interventions are F-18 Fluorothymidine . head and neck cancer diagnosis and creatinine within normal institutional limits
__label__0	study interventions are Salmonella typhimurium . liver neoplasms diagnosis and patients may have received any number of other prior therapies however at least three weeks must have passed since last dose of chemotherapy or radiotherapy six weeks for nitrosoureas or mitomycin prior to study entry
__label__0	study interventions are Mycophenolic Acid . recurrent childhood anaplastic large cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Antibodies, Monoclonal . fallopian tube clear cell adenocarcinoma diagnosis and patients in this trial may receive ovarian estrogen positive
__label__0	study interventions are Sirolimus . stage iv esophageal cancer diagnosis and serum creatinine less_than doc mg dl and or creatinine clearance greater_than sixty cc min
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and no high risk factors for bleeding including the following
__label__0	study interventions are Everolimus . unspecified childhood solid tumor protocol specific diagnosis and monoclonal antibodies
__label__0	study interventions are Hormones . breast neoplasms diagnosis and one diameter at least two cm for lesions other than bone lesions assessed by conventional ray techniques
__label__0	study interventions are Thiotepa . recurrent grade one follicular lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Fludarabine phosphate . multiple myeloma and plasma cell neoplasm diagnosis and received one prior therapy and has any of the following high risk features
__label__0	study interventions are Cryoablation . sarcoma diagnosis and when applicable acceptable cryoablation procedure technique risk
__label__0	study interventions are BCG Vaccine . bladder cancer diagnosis and life expectancy
__label__0	study interventions are Fluorouracil . stage iii salivary gland cancer diagnosis and at least four weeks since prior major surgery
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiic fallopian tube cancer diagnosis and patients must be entered and treated within twelve weeks of their most recent surgery performed for the combined purpose of diagnosis staging and or cytoreduction the first cycle of chemotherapy should not be given until at least seven days after the most recent major surgery which allows four weeks to have elapsed prior to the first bevacizumab dose placement of venous or peritoneal access devices will be considered minor surgery three twenty-nine ten
__label__0	study interventions are Everolimus . stage iva uterine corpus cancer diagnosis and forced expiratory volume in one second fevone greater_than fifty and diffusion capacity of the lungs for carbon monoxide dlco greater_than fifty
__label__0	study interventions are Etoposide . activated cell like diffuse large cell lymphoma diagnosis and eligibility criteria step one
__label__0	study interventions are Antibodies . ovarian mucinous adenocarcinoma diagnosis and for patients undergoing nac_ics core tissue not fine needle aspiration biopsy is required the tissue must be consistent with müllerian origin patients will require documentation of at least stage ii or extraovarian sites of disease acquired via imaging or surgery without attempt at cytoreduction
__label__0	study interventions are Tacrolimus . noncutaneous extranodal lymphoma diagnosis and patients must be willing to use contraception if they have childbearing potential
__label__0	study interventions are cilengitide, radiochemotherapy . locally advanced non small cell lung cancer nsclc diagnosis and perflife expectancy greater_than six months
__label__0	study interventions are Fludarabine . recurrent adult diffuse mixed cell lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and not specified chemotherapy
__label__0	study interventions are Capecitabine . recurrent rectal cancer diagnosis and patients must not have received prior chemotherapy or pelvic irradiation therapy
__label__0	study interventions are Bevacizumab . mixed adenocarcinoma of the stomach diagnosis and urine protein creatinine upc ratio of less_than doc or dipstick for protein of less_than two positive common terminology criteria for adverse events version doc ctcae four grade less_than two patients with upc ratio greater_than equal_than doc or dipstick of two positive must undergo twofour hour urine collection and must demonstrate less_than one gm of protein in order to participate
__label__0	study interventions are Bevacizumab . recurrent squamous cell carcinoma of the nasopharynx diagnosis and performance status
__label__0	study interventions are fatigue assessment and management . prostate cancer diagnosis and endocrine therapy
__label__0	study interventions are Alemtuzumab . recurrent adult diffuse small cleaved cell lymphoma diagnosis and must have received prior chemotherapy and prior autologous transplant unless autologous transplant was not possible planned tandem transplants are allowed for patients at high risk of relapse
__label__0	study interventions are O(6)-benzylguanine . sarcoma diagnosis and disease characteristics
__label__0	study interventions are Vidarabine . recurrent grade two follicular lymphoma diagnosis and failed prior autotransplant
__label__0	study interventions are 7-hydroxystaurosporine . fallopian tube cancer diagnosis and surgery
__label__0	study interventions are Immunoglobulins . recurrent laryngeal verrucous carcinoma diagnosis and creatinine clearance of greater_than equal_than sixty ml min creatinine clearance may be measured or calculated if calculating creatinine clearance use the cockroft gault formula
__label__0	study interventions are Docetaxel . lung cancer diagnosis and ongoing or serious active infection
__label__0	study interventions are Erlotinib Hydrochloride . recurrent squamous cell carcinoma of the oropharynx diagnosis and new york heart association class ii iv heart disease
__label__0	study interventions are Pembrolizumab . all patients must have imaging computed tomography ct scan or magnetic resonance imaging mri documenting normal upper urinary tracts and absence of locally advanced bladder cancer within sixty days prior to study registration
__label__0	study interventions are Imatinib Mesylate . stage iiia melanoma diagnosis and wbc greater_than three zero mm³
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and ast and alt less than two times upper limit of normal
__label__0	study interventions are Letrozole . breast cancer diagnosis and life expectancy
__label__0	study interventions are Fludarabine . stage ii small lymphocytic lymphoma diagnosis and only single allele disparity will be allowed for hla b or as defined by high resolution typing
__label__0	study interventions are Antibodies, Monoclonal . stage iiic skin melanoma diagnosis and stable and adequate cluster of differentiation four cdfour counts greater_than equal_than three hundred and fifty mm three and serum hiv viral load of less_than twenty-five zero iu ml patients may be on or off anti viral therapy so long as they meet the cdfour count criteria
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and not specified surgery
__label__0	study interventions are Interferon-alpha . localized osteosarcoma diagnosis and no prior chemotherapy for any disease
__label__0	study interventions are Fludarabine . recurrent marginal zone lymphoma diagnosis and creatinine clearance at least fifty ml min
__label__0	study interventions are Lithium Carbonate . recurrent grade three follicular lymphoma diagnosis and patients with denuded mucosa caused by gvhd are eligible for enrollment regardless of prior treatment for acute gvhd denuded mucosa is defined as loss erosion or sloughing of the epithelium in
__label__0	study interventions are Epothilones . recurrent gallbladder cancer diagnosis and no unstable angina pectoris
__label__0	study interventions are Fluorodeoxyglucose F18 . lymphoma diagnosis and endocrine therapy
__label__0	study interventions are Sirolimus . previously treated childhood rhabdomyosarcoma diagnosis and malignant fluid collections ascites pleural effusions
__label__0	study interventions are Cisplatin . childhood nodular lymphocyte predominant hodgkin lymphoma diagnosis and all stage iiia iiiae iiias iiiae positive regardless of bulk disease
__label__0	study interventions are Cyclosporine . kidney cancer diagnosis and disease must have responded to recent chemotherapy or in plateau after response to chemotherapy
__label__0	study interventions are Niacinamide . stage iv renal cell cancer diagnosis and absolute granulocyte count greater_than equal_than one two hundred mm three
__label__0	study interventions are Fludarabine . lymphoma diagnosis and mds with at least one of the following features
__label__0	study interventions are biological therapy . contiguous stage ii mantle cell lymphoma diagnosis and at least four weeks since prior corticosteroids dexamethasone or prednisone
__label__0	study interventions are Cholecalciferol . aggressive non hodgkin lymphoma diagnosis and restricted surface kappa or lambda light chain expression
__label__0	study interventions are Pembrolizumab . poorly differentiated thyroid gland carcinoma diagnosis and eastern cooperative oncology group ecog performance status ps zero or one
__label__0	study interventions are Gemcitabine . epithelial ovarian cancer diagnosis and platelets
__label__0	study interventions are Bortezomib . anaplastic large cell lymphoma alcl alk one negative diagnosis and previous extensive radiotherapy involving greater_than thirty of bone marrow whole pelvis half spine excluding patients who have had total body irradiation as part of conditioning regimen for stem cell transplant
__label__0	study interventions are Floxuridine . colorectal cancer diagnosis and no active infection
__label__0	study interventions are Cetuximab . recurrent extrahepatic bile duct cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Cyclophosphamide . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and aplastic anemia
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv non small cell lung cancer diagnosis and women of childbearing potential and sexually active males should use an accepted and effective method of contraception while on treatment and for three months thereafter
__label__0	study interventions are laboratory biomarker analysis . stage iii lymphoepithelioma of the oropharynx diagnosis and no other concurrent investigational agents
__label__0	study interventions are Ganciclovir . stage adult hodgkin lymphoma diagnosis and first allogeneic cell replete transplantation of stem cells from peripheral blood or bone marrow of an human leukocyte antigen hla matched unrelated or nonsyngeneic_sibling donor
__label__0	study interventions are Anesthetics . carcinoma non small cell lung diagnosis and receive pulmonary lobectomy
__label__0	study interventions are Ramucirumab . stomach neoplasms diagnosis and life expectancy of at least twelve weeks in the opinion of the investigator
__label__0	study interventions are Trametinib . metastatic melanoma diagnosis and life expectancy of greater thantwelve weeks
__label__0	study interventions are Docetaxel . lung neoplasms diagnosis and at least one measurable lesion
__label__0	study interventions are Irinotecan . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and see disease characteristics part ii
__label__0	study interventions are Cyclosporine . recurrent mantle cell lymphoma diagnosis and partial cytogenetic remission
__label__0	study interventions are Bevacizumab . neoplasm metastasis diagnosis and patients with metastases synchronous or metachronous
__label__0	study interventions are Immunoglobulins . pancreatic beta cell adenoma diagnosis and hypervascular liver masses greater_than two cm and either serum alpha fetoprotein_afp greater_than four hundred ng ml or
__label__0	study interventions are Prexasertib . squamous cell carcinoma diagnosis and part a
__label__0	study interventions are Fotemustine . intraocular melanoma diagnosis and alkaline phosphatase less_than five times uln
__label__0	study interventions are Belinostat . stage iv adult burkitt lymphoma diagnosis and non hematologic dlt
__label__0	study interventions are Liposomal doxorubicin . clear cell renal cell carcinoma diagnosis and specimens materials must be submitted for central review by day seven
__label__0	study interventions are Cisplatin . stage iii squamous cell carcinoma of the larynx diagnosis and if the ct pet with or without contrast is done within eighty-four days prior to surgery if fulfills the chest imaging requirement
__label__0	study interventions are Maytansine . recurrent plasma cell myeloma diagnosis and patients for whose disease no standard treatment exists that has been shown to prolong overall survival
__label__0	study interventions are Chemotherapy . previously untreated no chemotherapy or hormonal therapy or radiation therapy invasive breast cancer
__label__0	study interventions are Endothelial Growth Factors . male breast carcinoma diagnosis and involvement of at least one sentinel or axillary lymph node on routine histologic examination patients with negative sentinel nodes and negative axillary nodes or involvement only demonstrated by immunohistochemistry are not eligible unless they meet one of the other eligibility criteria below
__label__0	study interventions are Fludarabine . clear cell carcinoma diagnosis and at least two weeks since receipt of any biological therapy chemotherapy and or radiation therapy
__label__0	study interventions are Etoposide phosphate . aids related diffuse large cell lymphoma diagnosis and participants who are untreated or who received maximum of one one cycle of combination chemotherapy including rituximab containing regimens prior are eligible the start of previous chemotherapy cycle must occur at least 2one days prior to beginning treatment under this protocol and such cycle will count towards the total maximum of six cycles under this study
__label__0	study interventions are Antibodies . recurrent colon carcinoma diagnosis and patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded as greater_than equal_than twenty mm with conventional techniques or as greater_than equal_than ten mm with spiral ct scan
__label__0	study interventions are Antibodies, Monoclonal . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Sampling of tumor tissue after breast cancer surgery . invasive breast cancer diagnosis and zero to three positive lymph nodes and no distant metastases
__label__0	study interventions are Antibodies, Monoclonal . recurrent rectal cancer diagnosis and total bilirubin equal_than less_than doc upper limit of normal uln
__label__0	study interventions are Dexamethasone . multiple myeloma and plasma cell neoplasm diagnosis and no nursing during and for greater_than twenty-eight days after completion of study treatment
__label__0	study interventions are Metronidazole . stage iic ovarian epithelial cancer diagnosis and absolute neutrophil count anc greater_than equal_than one zero ul
__label__0	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and patients could have received first line chemotherapy or chemotherapy between the egfr tki and inclusion in the study but must present systemic objective progression
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent vulvar cancer diagnosis and the patient must have failed standard curative and or palliative therapies for their disease
__label__0	study interventions are Gemcitabine . non small cell lung cancer metastatic diagnosis and signed written informed consent
__label__0	study interventions are Vincristine . lymphoma diagnosis and sixteen to sixty-five performance status
__label__0	study interventions are Interferons . kidney cancer diagnosis and endocrine therapy
__label__0	study interventions are Metronidazole . recurrent pancreatic cancer diagnosis and no concurrent antineoplastic chemotherapy
__label__0	study interventions are Histone Deacetylase Inhibitors . lymphoma diagnosis and pulmonary
__label__0	study interventions are Cisplatin . early invasive cervical squamous cell carcinoma diagnosis and ten pack years of tobacco use
__label__0	study interventions are Part 2: JNJ-42756493 . lymphoma diagnosis and eastern cooperative oncology group performance status score zero or one
__label__0	study interventions are Sunitinib . neurofibromatosis diagnosis and there is no limitation on the number of prior surgeries radiation therapy radiosurgery treatments or chemotherapy
__label__0	study interventions are Cyclophosphamide . germ cell tumor diagnosis and adequate pbsc harvests with minimum of doc one hundred and eight mnc kg available for each pbsc rescue
__label__0	study interventions are Hormones . recurrent prostate cancer diagnosis and platelet count greater_than one hundred zero mm³
__label__0	study interventions are Gemcitabine . non small cell lung cancer diagnosis and no prior chemotherapy
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and patient characteristics
__label__0	study interventions are Doxorubicin . adult desmoplastic small round cell tumor diagnosis and psychiatric illness or social situation that would preclude compliance with study requirements
__label__0	study interventions are Recombinant EphB4-HSA Fusion Protein . stage ii renal cell cancer diagnosis and cohort b
__label__0	study interventions are Cyclophosphamide . malignant neoplasm diagnosis and adequate liver function as defined by serum bilirubin less_than doc aspartate aminotransferase ast or alanine aminotransferase alt less_than doc upper limit of normal
__label__0	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and serum albumin less_than or equal to doc dl
__label__0	study interventions are pharmacological study . adult primary hepatocellular carcinoma diagnosis and measurable disease defined as at least one unidimensionally measurable greater_than twenty mm by conventional techniques or greater_than ten mm by spiral ct scan
__label__0	study interventions are Lapatinib . advanced cancers diagnosis and abnormal organ function is permitted however patients must have
__label__0	study interventions are Melphalan . breast cancer diagnosis and cytomegalovirus status known
__label__0	study interventions are quality-of-life assessment . recurrent squamous cell carcinoma of the nasopharynx diagnosis and absolute neutrophil count greater_than equal_than one five hundred ul
__label__0	study interventions are Laboratory Biomarker Analysis . stage iv fallopian tube cancer diagnosis and patients must have completed all primary chemotherapy and consolidation therapy if administered at least six weeks and no more than six months and two weeks prior to enrollment and must be in complete remission consolidation therapy is defined as any chemotherapy or biological therapy used for patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy chemo or biological therapy
__label__0	study interventions are Dexamethasone 21-phosphate . untreated multiple myeloma requiring treatment
__label__0	study interventions are Doxorubicin . cutaneous cell non hodgkin lymphoma diagnosis and please see study schema for further details
__label__0	study interventions are Cyclosporins . recurrent childhood anaplastic large cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Antibodies, Monoclonal . metastatic squamous neck cancer with occult primary squamous cell carcinoma diagnosis and ability and willingness to comply with the study visit and assessment schedule and to provide voluntary written informed consent
__label__0	study interventions are Fludarabine phosphate . recurrent renal cell cancer diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Albumin-Bound Paclitaxel . squamous cell carcinoma of the head and neck diagnosis and no prior therapy including surgery with curative intent chemotherapy radiation therapy immunotherapy egfr targeted therapies or any other investigational agents
__label__0	study interventions are Immunoglobulins . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and no other uncontrolled illness
__label__0	study interventions are Immunoglobulins . stage iii squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and calcium less_than ten mg dl hypocalcemic agents allowed
__label__0	study interventions are Papanicolaou test . cervical cancer diagnosis and must have been eligible and evaluable for the primary objective of gog one hundred and seventy-one
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and no concurrent hormonal therapy radiotherapy
__label__0	study interventions are Albumin-Bound Paclitaxel . epithelial ovarian cancer diagnosis and platinum resistant or refractory
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and not specified
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic melanoma diagnosis and have performance status of zero to one on the eastern cooperative oncology group ecog scale
__label__0	study interventions are PF-00337210 . histologically or cytologically confirmed advanced solid tumors un responsive to currently available therapies or for which there is no standard therapy
__label__0	study interventions are Sunitinib . recurrent pancreatic cancer diagnosis and saquinavir
__label__0	study interventions are Rituximab . stage ii grade three non contiguous follicular lymphoma diagnosis and no prior exposure to any of the study agents
__label__0	study interventions are Cyclophosphamide . stage breast cancer diagnosis and platelet count greater_than one hundred zero mmthree
__label__0	study interventions are Fludarabine phosphate . stage childhood large cell lymphoma diagnosis and matched for human leukocyte antigen hla b drbone and dqbone by high resolution typing
__label__0	study interventions are Immunoglobulins . ovarian serous surface papillary adenocarcinoma diagnosis and triglycerides equal_than less_than doc uln mg dl or mmol patients with triglyceride levels greater_than doc uln can be started on lipid_lowering agents and reevaluated within one week if levels go to equal_than less_than doc uln they can be considered for the trial and continue the lipid_lowering agents note
__label__0	study interventions are Antibodies, Monoclonal . pancreatic acinar cell carcinoma diagnosis and autoimmune diseases include but are not limited to autoimmune hepatitis inflammatory bowel disease multiple sclerosis vasculitis or glomerulonephritis patients with well controlled systemic lupus erythematous or rheumatoid arthritis may be eligible after communication with the study chairs at sone thousand, six hundred and ninesc_swo rg vitiligo alopecia hypothyroidism on stable doses of thyroid replacement therapy psoriasis not requiring systemic therapy within the past three years is permitted short term steroid premedication for contrast allergy is permitted
__label__0	study interventions are Vaccines . infections papillomavirus diagnosis and subject must be of non childbearing potential or if she is of child bearing potential she must practice adequate contraception for thirty days prior to vaccination have negative urine pregnancy test and continue such precautions for two months after completion of the vaccination series
__label__0	study interventions are Sirolimus . metastatic breast cancer diagnosis and bun blood urea_nitrogen less_than uln
__label__0	study interventions are Ifosfamide . sarcoma diagnosis and no deep venous or arterial thrombosis including pulmonary embolism within the past three months
__label__0	study interventions are Docetaxel . non small cell lung cancer diagnosis and also men should be discouraged from fathering children while on treatment
__label__0	study interventions are Ifosfamide . germ cell tumor diagnosis and patient aged eighteen years or older having signed an informed consent form
__label__0	study interventions are Erlotinib Hydrochloride . advanced non small cell lung cancer diagnosis and for all females of childbearing potential negative pregnancy test must be obtained within forty-eight hours before starting tarceva placebo treatment
__label__0	study interventions are Mycophenolic Acid . acute lymphoblastic leukemia lymphoma diagnosis and creatinine less_than doc mg dl adults and estimated glomerular filtration rate gfr greater_than forty ml min pediatrics
__label__0	study interventions are Cytarabine . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Cyclosporins . recurrent marginal zone lymphoma diagnosis and must have received prior chemotherapy and prior autologous transplant unless autologous transplant was not possible planned tandem transplants are allowed for patients at high risk of relapse
__label__0	study interventions are Albumin-Bound Paclitaxel . squamous cell lung cancer diagnosis and tthree ntwo or tfour nzero ntwo disease also allowed if based on the closeness to the carina invasion of the mediastinum or invasion of the chest wall
__label__0	study interventions are Carboplatin . lung cancer diagnosis and partially resected stage iiib disease allowed provided measurable lesion remains
__label__0	study interventions are AI adjuvant therapy . breast cancer diagnosis and female not more than seventy-five years old judged to have been in menopause by the investigator when enrolled
__label__0	study interventions are Antibodies, Monoclonal . stage iv breast cancer diagnosis and karnofsky sixty one hundred
__label__0	study interventions are Immunoglobulins . lung cancer diagnosis and no other concurrent investigational agents or therapy
__label__0	study interventions are Fludarabine . diffuse large cell lymphoma diagnosis and must have received and failed frontline therapy patients must have failed or were not eligible for autologous transplant
__label__0	study interventions are Mycophenolate mofetil . peripheral cell lymphoma diagnosis and peripheral blood stem cells will be collected from donors greater than twelve years of age
__label__0	study interventions are Ganciclovir triphosphate . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and cmv seropositive donor and or recipient
__label__0	study interventions are Pemetrexed . lung cancer diagnosis and patients must have an estimated survival of at least three months
__label__0	study interventions are Cisplatin . metastatic pancreatic adenocarcinoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than one
__label__0	study interventions are Oxaliplatin . stage iv colorectal cancer diagnosis and patients with documented liver metastases or bone involvement
__label__0	study interventions are Vorinostat . recurrent salivary gland carcinoma diagnosis and phase ii expansion
__label__0	study interventions are Antibodies, Monoclonal . astrocytoma grade iv diagnosis and hemoglobin greater_than doc dl absolute neutrophil count greater_than one five hundred cells µl platelets greater_than one25 zero cells µl
__label__0	study interventions are laboratory biomarker analysis . stage iii squamous cell carcinoma of the oropharynx diagnosis and not pregnant or nursing
__label__0	study interventions are Tacrolimus . peripheral cell lymphoma diagnosis and must have received and failed frontline therapy patients must have failed or were not eligible for autologous transplant
__label__0	study interventions are Prednisolone acetate . multiple myeloma and plasma cell neoplasm diagnosis and fifteen seventeen translocation and failed first line induction therapy or there is molecular evidence of persistent disease
__label__0	study interventions are Melphalan . refractory multiple myeloma diagnosis and donor must have adequate veins for leukapheresis or agree to placement of central venous catheter femoral_subclavian
__label__0	study interventions are Fludarabine phosphate . recurrent follicular lymphoma diagnosis and aspartate aminotransferase ast less_than five uln
__label__0	study interventions are Cisplatin . lung cancer diagnosis and patient characteristics
__label__0	study interventions are sargramostim . metastatic cancer diagnosis and negative pregnancy test
__label__0	study interventions are Sorafenib . melanoma skin diagnosis and concurrent anti coagulation treatment with warfarin or heparin allowed
__label__0	study interventions are Thiotepa . lymphoma diagnosis and no severe renal disease that would preclude study participation
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and early stage disease
__label__0	study interventions are Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1 . subjects with metastatic pancreatic ductal adenocarcinoma pda diagnosis and subjects must have measureable disease as defined by recist doc criteria
__label__0	study interventions are Gemcitabine . breast cancer diagnosis and patients must have measurable disease as defined by recist criteria therasse et_al
__label__0	study interventions are Bicalutamide . patients must not be receiving any other investigational agents or receiving concurrent anticancer therapy
__label__0	study interventions are Isotretinoin . regional neuroblastoma diagnosis and no more than twelve months from the date of starting the first induction chemotherapy after diagnosis to the date of asct except for the rare occasions as noted below for tandem asct patients this will be the date of the first stem cell infusion exception
__label__0	study interventions are Mycophenolate mofetil . stage adult burkitt lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Soy Isoflavones . stage iva oral cavity verrucous carcinoma diagnosis and disease must be stage ii iii or iva
__label__0	study interventions are proteomic profiling . prostate cancer diagnosis and no comprehensive lifestyle change similar to the lifestyle intervention used in this study
__label__0	study interventions are Standard colonoscopy . colorectal cancer diagnosis and no signs of stenosis of small intestine or colon
__label__0	study interventions are Oxaliplatin . small intestine cancer diagnosis and dose escalation
__label__0	study interventions are Immunoglobulins . stage iii hypopharyngeal squamous cell carcinoma diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Busulfan . multiple myeloma and plasma cell neoplasm diagnosis and required greater_than one induction course to achieve remission
__label__0	study interventions are Azacitidine . non small cell lung cancer diagnosis and surgery must have been completed at least twenty-eight days twenty-eight days before entry into the study and all complications adverse events must have been resolved
__label__0	study interventions are Pharmacodynamic Studies . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and patients with malabsorption or any other condition that in the opinion of the principal investigator could cause difficulty in absorption of drug
__label__0	study interventions are Satraplatin . patients must have fully recovered from the acute toxicities of any prior treatment with cytotoxic drugs radiotherapy or other anti cancer modalities returned to baseline status as noted before most recent treatment
__label__0	study interventions are intensity-modulated radiation therapy . stage ii prostate cancer diagnosis and patients who are unable to undergo an mri scan such as those with an implanted permanent pacemaker or icd
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and no significant traumatic injury within four weeks prior to study entry
__label__0	study interventions are Cyclosporine . recurrent grade two follicular lymphoma diagnosis and age less_than seventy-five
__label__0	study interventions are Azacitidine . myelodysplastic myeloproliferative neoplasms diagnosis and ast and alt less_than doc times upper limit of normal
__label__0	study interventions are Etoposide phosphate . lung cancer diagnosis and no hearing impairment that would be contraindication to the use of cisplatin
__label__0	study interventions are vismodegib . adult giant cell glioblastoma diagnosis and three weeks from non nitrosourea chemotherapy
__label__0	study interventions are Oxaliplatin . metastatic colorectal cancer diagnosis and patients must have normal organ and marrow function as defined below
__label__0	study interventions are Capecitabine . stage iiib breast cancer diagnosis and no prior oxaliplatin
__label__0	study interventions are Immunoglobulin G . stage iic ovarian cancer diagnosis and patients with the following histologic epithelial cell types are eligible
__label__0	study interventions are Bevacizumab . hormone resistant prostate cancer diagnosis and zero two
__label__0	study interventions are high performance liquid chromatography . neuroblastoma diagnosis and serum calcium less_than one doc mg dl
__label__0	study interventions are Citric Acid . myeloma diagnosis and platelet count greater_than equal_than fifty zero mm three note
__label__0	study interventions are Fludarabine . stage ii cutaneous cell non hodgkin lymphoma diagnosis and highly active antiretroviral therapy haart is initiated within one month of hematopoietic cell transplant
__label__0	study interventions are Cetuximab . stage ivc verrucous carcinoma of the oral cavity diagnosis and serum glutamic oxaloacetic transaminase sgot aspartate aminotransferase ast serum glutamic pyruvate transaminase sgpt alanine aminotransferase alt equal_than less_than doc uln
__label__0	study interventions are Sirolimus . glioblastoma diagnosis and chemo if that was used as initial therapy
__label__0	study interventions are Aldesleukin . melanoma skin diagnosis and no other concurrent medical condition that would preclude study entry
__label__0	study interventions are Antibodies, Monoclonal . stage esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and evidence of metastatic disease
__label__0	study interventions are Cyclosporins . recurrent marginal zone lymphoma diagnosis and complete response with persistent lymphoid nodules in bone marrow
__label__0	study interventions are Quality-of-Life Assessment . lobular breast carcinoma in situ diagnosis and hormone receptor status
__label__0	study interventions are Dexamethasone 21-phosphate . lymphoma diagnosis and no other uncontrolled clinically significant confounding medical condition within the past thirty days
__label__0	study interventions are Alvocidib . recurrent adult hodgkin lymphoma diagnosis and no cardiac or vascular dysfunction that would preclude central venous access vigorous hydration or hemodialysis
__label__0	study interventions are Epirubicin . oesophago gastric cancer diagnosis and completion of baseline quality of life questionnaire eortc qlq_cthirty
__label__0	study interventions are Leucovorin . stage iii adult lymphoblastic lymphoma diagnosis and prior therapy restrictions
__label__0	study interventions are Bevacizumab . malignant glioma diagnosis and male or female at least twenty-two years of age or older
__label__0	study interventions are Interleukin-2 . recurrent adult diffuse small cleaved cell lymphoma diagnosis and total bilirubin tbili less_than doc unl
__label__0	study interventions are Vinblastine . myeloma diagnosis and aspartate transaminase ast less_than equal_than doc uln
__label__0	study interventions are Thiotepa . non hodgkins lymphoma diagnosis and patients may be of either gender and of any racial or ethnic background
__label__0	study interventions are Doxorubicin . stage iv childhood hodgkin lymphoma diagnosis and all stage iib regardless of bulk disease
__label__0	study interventions are Belinostat . recurrent grade one follicular lymphoma diagnosis and platelet count greater_than one00 zero mm three
__label__0	study interventions are Cetuximab . stage iv anal cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are chemoprevention . stage iva oral cavity squamous cell carcinoma diagnosis and patients must be able to take nutrition medications orally
__label__0	study interventions are Bevacizumab . transitional cell carcinoma
__label__0	study interventions are Maleic acid . recurrent ovarian epithelial cancer diagnosis and prior chemotherapy must have included first line platinum based regimen only
__label__0	study interventions are radiation therapy . metastatic cancer diagnosis and other
__label__0	study interventions are Ketoconazole . recurrent prostate cancer diagnosis and patient characteristics
__label__0	study interventions are Diphosphonates . metastatic cancer diagnosis and patient characteristics
__label__0	study interventions are ctDNA analysis . non small cell lung cancer metastatic diagnosis and histologically confirmed stage iiib iv nsclc
__label__0	study interventions are Vorinostat . recurrent adult immunoblastic large cell lymphoma diagnosis and able to adhere to the study visit schedule and other protocol requirements
__label__0	study interventions are Doxycycline . melanoma diagnosis and there is no limit on the number of prior therapies for phase portion
__label__0	study interventions are Octreotide . neuroendocrine carcinoma diagnosis and creatinine ratio greater_than doc
__label__0	study interventions are thermal ablation therapy . unspecified adult solid tumor protocol specific diagnosis and age
__label__0	study interventions are Pharmacological Study . stage iiib breast cancer diagnosis and the patient has undergone total abdominal hysterectomy with bilateral salpingo oophorectomy or bilateral oophorectomy
__label__0	study interventions are Cetuximab . recurrent adenoid cystic carcinoma of the oral cavity diagnosis and no ongoing or active infection
__label__0	study interventions are CD4 DLI . myeloma diagnosis and fludarabine busulphan alemtuzumab
__label__0	study interventions are Lenograstim . stage iii childhood hodgkin lymphoma diagnosis and lymphocytic depletion ld
__label__0	study interventions are Carmustine . stage iii small lymphocytic lymphoma diagnosis and fourteen days prior to and again within twenty-four hours of prescribing lenalidomide prescriptions must be filled within seven days
__label__0	study interventions are Mycophenolic Acid . adult nasal type extranodal nk cell lymphoma diagnosis and myelodysplastic syndromes
__label__0	study interventions are FOLFIRI . progression within twelve months of adjuvant chemotherapy for colorectal cancer
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and women aged from forty to sixty-five years old
__label__0	study interventions are Metronidazole . stage iiia primary peritoneal cavity cancer diagnosis and hemoglobin hgb greater_than equal_than eightg dl
__label__0	study interventions are LI plus CIZ . squamous cell carcinoma of the soft palate diagnosis and normal immune function
__label__0	study interventions are Etoposide . sarcoma diagnosis and renal function normal
__label__0	study interventions are pharmacological study . stage iv lymphoepithelioma of the nasopharynx diagnosis and measurable disease defined as greater_than equal_than one unidimensionally measurable lesion greater_than equal_than twenty mm by conventional techniques or greater_than equal_than one0 mm by spiral ct scan
__label__0	study interventions are Cediranib . stage thyroid gland follicular carcinoma diagnosis and one has not undergone hysterectomy or bilateral oophorectomy or two has not been naturally postmenopausal for at least two4 consecutive months has had menses at any time in the preceding two4 consecutive months
__label__0	study interventions are Paclitaxel . stage iiia uterine corpus cancer diagnosis and entry into the study is limited to no more than eight weeks from the date of surgery
__label__0	study interventions are Gemcitabine . regional transitional cell cancer of the renal pelvis and ureter diagnosis and measurable disease
__label__0	study interventions are Hydroxyurea . stage iv salivary gland cancer diagnosis and at least four weeks since prior major surgery
__label__0	study interventions are Prednisolone phosphate . multiple myeloma diagnosis and screening anc is to be independent of granulocyte colony stimulating factor support for greater_than one week and pegylated granulocyte colony stimulating factor for greater_than two weeks
__label__0	study interventions are Gardasil (VLP, HPV Quadrivalent prophylactic vaccine) . precancerous disease of the cervix diagnosis and aged between thirteen fifteen yrs
__label__0	study interventions are Clofarabine . neoplasm recurrent diagnosis and total serum bilirubin less_than two mg dl
__label__0	study interventions are Doxorubicin . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and radiation therapy xrt
__label__0	study interventions are Cisplatin . unresectable intrahepatic cholangiocarcinoma diagnosis and women of child bearing potential and fertile men are required to use effective contraception negative serum ßhcg for women of child bearing age
__label__0	study interventions are Etoposide phosphate . ovarian cancer diagnosis and age
__label__0	study interventions are assessment of therapy complications . stage iv adult diffuse mixed cell lymphoma diagnosis and able to communicate in english as indicated by ability to communicate adequately with study staff to participate in the clinical phone_calls and to complete patient reported outcomes pro assessments in english
__label__0	study interventions are Cisplatin . brain tumors diagnosis and not specified
__label__0	study interventions are GSK1795091 . cancer diagnosis and healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history physical examination laboratory tests vital signs and twelve lead ecg
__label__0	study interventions are Disulfiram . glioma diagnosis and karnofsky performance status of sixty
__label__0	study interventions are Mycophenolic Acid . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and matched at allele level for hla b drbone and dqbone
__label__0	study interventions are radiofrequency ablation . unspecified adult solid tumor protocol specific diagnosis and radiologically suspected pulmonary metastases
__label__0	study interventions are Liposomal doxorubicin . small intestine cancer diagnosis and at least five days since prior hormonal therapy radiotherapy
__label__0	study interventions are Niacinamide . head and neck cancer diagnosis and hepatic
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and bilirubin less_than or equal to doc mg dl
__label__0	study interventions are Dasatinib . salivary gland malignant mixed cell type tumor diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib
__label__0	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the hypopharynx diagnosis and second primary locoregional recurrence with no clinically measurable distant disease
__label__0	study interventions are Etoposide . b cell lymphoma unclassifiable with features intermediate between diffuse large cell lymphoma and burkitt lymphoma diagnosis and nine thousand, one hundred and seventy-four or twelve thousand, two hundred and twenty-four may be enrolled on this study
__label__0	study interventions are Dexamethasone 21-phosphate . lymphoma diagnosis and other
__label__0	study interventions are Aldesleukin . recurrent childhood lymphoblastic lymphoma diagnosis and refractory to one or two courses of frontline induction therapy greater_than five blasts in the bone marrow confirmed by flow cytometric analysis
__label__0	study interventions are Dexamethasone 21-phosphate . childhood atypical_teratoid rhabdoid tumor diagnosis and histologically confirmed malignancy at diagnosis or relapse
__label__0	study interventions are Sirolimus . recurrent gastric cancer diagnosis and serum glutamic oxaloacetic transaminase sgot and or serum glutamic pyruvic transaminase sgpt equal_than less_than doc institutional upper limit of normal iuln equal_than less_than five upper limit of normal uln in patients with liver metastases
__label__0	study interventions are Bortezomib . bone marrow plasmacytosis with greater_than ten plasma cells or sheets of plasma cells or biopsy proven plasmacytoma
__label__0	study interventions are Immunoglobulin G . recurrent childhood pineoblastoma diagnosis and must not have received within three weeks of entry onto this study six weeks if prior nitrosourea
__label__0	study interventions are Aldesleukin . pancreatic cancer diagnosis and women of child bearing potential must have negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
__label__0	study interventions are microarray analysis . clear cell sarcoma of the kidney diagnosis and days of follow up
__label__0	study interventions are pharmacological study . stage iv basal cell carcinoma of the lip diagnosis and creatinine clearance greater_than fifty-five ml min
__label__0	study interventions are Fludarabine . melanoma diagnosis and white blood cell wbc greater than three thousand mm three
__label__0	study interventions are Doxepin . malignant mesothelioma diagnosis and willingness to complete evaluation and questionnaires per protocol at the participating institution for follow up during the active monitoring phase of the study
__label__0	study interventions are laboratory biomarker analysis . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and more than twelve months since active ischemic heart disease
__label__0	study interventions are One Stage Esophagectomy . esophageal cancer diagnosis and no definitive radiological evidence of distant metastases as evaluated by ct or pet ct scan
__label__0	study interventions are Carmustine . unspecified adult solid tumor protocol specific diagnosis and prior adjuvant chemotherapy allowed
__label__0	study interventions are tanespimycin . recurrent grade two follicular lymphoma diagnosis and no leukemia
__label__0	study interventions are Thalidomide . angioimmunoblastic cell lymphoma diagnosis and able to take aspirin eighty-one or three hundred and twenty-five mg daily as prophylactic anticoagulation patients intolerant to acetylsalicylic acid asa may use warfarin or low molecular weight heparin
__label__0	study interventions are Topotecan . uterine cervical neoplasms diagnosis and platelets greater than or equal to one hundredxten nine l
__label__0	study interventions are Alvocidib . recurrent childhood small noncleaved cell lymphoma diagnosis and no active uncontrolled infection or other serious medical condition
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and no concurrent severe medical problems calorie intake of at least one thousand, five hundred kcal day no history of active malignancy within one year except
__label__0	study interventions are Capecitabine . breast cancer colorectal cancer diagnosis and patient is ambulatory and has karnofsky performance status of greater_than seventy
__label__0	study interventions are Antibodies . recurrent childhood anaplastic large cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are laboratory biomarker analysis . stage verrucous carcinoma of the larynx diagnosis and asa american society of anesthesiologists performance status ps of one four or ecog eastern cooperative oncology group ps zero three thereby including population that stands to gain the most from minimally invasive surgical approach
__label__0	study interventions are Immunoglobulins . stage iii basal cell carcinoma of the lip diagnosis and no prior bevacizumab
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and between the ages of eighteen and seventy years of age inclusive at time of enrollment
__label__0	study interventions are Etoposide . multiple myeloma and plasma cell neoplasm diagnosis and patient characteristics
__label__0	study interventions are Bevacizumab . fallopian tube carcinoma diagnosis and understand and voluntarily sign an informed consent form
__label__0	study interventions are Irinotecan . adenocarcinoma of the gastroesophageal junction diagnosis and doc pre treatment clinical stage of tthree fourn any mzero or any positive mzero as determined by laparoscopy ct scan or pet ct or endoscopic ultrasound histologic confirmation of lymph involvement is not required
__label__0	study interventions are Prednisone . recurrent prostate cancer diagnosis and no known active brain metastases
__label__0	study interventions are Antibodies, Monoclonal . stage iv skin melanoma diagnosis and please refer to appendix one or description of ajcc seventh editions of tnm and staging
__label__0	study interventions are Cadexomer iodine . patients must have histologically confirmed diagnosis of low grade or follicular non hodgkin b cell lymphoma
__label__0	study interventions are Niacinamide . extrahepatic bile duct adenocarcinoma diagnosis and fertile patients must agree to use effective contraception
__label__0	study interventions are Endothelial Growth Factors . stage iiia breast cancer diagnosis and no serious or non healing wound skin ulcers or bone fracture no abdominal fistula gastrointestinal perforation or intra abdominal abscess within the past six months no major surgical procedure within twenty-eight days prior to randomization or anticipation of need for major surgery during the course of study
__label__0	study interventions are Vincristine . neuroblastoma diagnosis and disease staging approximately within one month of treatment
__label__0	study interventions are Bevacizumab . non small cell lung cancer diagnosis and measurable disease by recist criteria see section seven
__label__0	study interventions are Alvocidib . stage iv pancreatic cancer diagnosis and cardiac arrhythmia or myocardial infarction within the past six months
__label__0	study interventions are Cetuximab . lung cancer diagnosis and stage iv disease
__label__0	study interventions are Pembrolizumab . biologically equivalent dose bed equal_than nd one positive a where is the number of fractions dose per fraction and the ß ratio for tumor is
__label__0	study interventions are Bevacizumab . ovarian cancer diagnosis and participants with platinum sensitive disease who have experienced relapse within six to twelve months after the last dose of platinum based chemotherapy are eligible
__label__0	study interventions are BB 1101 . stage ii multiple myeloma diagnosis and no significant traumatic injury within the past twenty-eight days
__label__0	study interventions are Racepinephrine . non operable superficial basal cell carcinoma or bowen disease lesions
__label__0	study interventions are Doxorubicin . peritoneal cavity cancer diagnosis and endocrine therapy
__label__0	study interventions are Cediranib . childhood cerebral anaplastic astrocytoma diagnosis and no concurrent chemotherapy
__label__0	study interventions are Oxaliplatin . stage ii rectal cancer diagnosis and inr greater_than doc allowed provided patient is on full dose anticoagulants and meets all of the following criteria
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and no evidence of distant metastases
__label__0	study interventions are Succinylcholine . stage iva oral cavity verrucous carcinoma diagnosis and upc ratio of one is roughly equivalent to twenty-four hour urine protein of one gm
__label__0	study interventions are BB 1101 . stage iv childhood hodgkin lymphoma diagnosis and no prior chemotherapy
__label__0	study interventions are Calcitriol . precursor cell lymphoblastic leukemia lymphoma diagnosis and are greater than or equal to ten years of age and less than or equal to twenty-one years of age at diagnosis of all
__label__0	study interventions are Leucovorin . stage iiia rectal cancer diagnosis and no evidence of distant metastatic disease
__label__0	study interventions are management of therapy complications . cancer diagnosis and eighteen and over
__label__0	study interventions are Dexamethasone acetate . neoplasms diagnosis and females of childbearing potential must be using reliable contraceptive measures with negative pregnancy test at the pre treatment visit
__label__0	study interventions are Paclitaxel . male breast carcinoma diagnosis and in the expansion cohort patients may have only had one three prior regimens for metastatic disease
__label__0	study interventions are Calcium, Dietary . renal cancer diagnosis and last iv bisphosphonate treatment must be greater_than equal_than to seven days and less_than equal_than to thirty days before the screening corrected serum calcium
__label__0	study interventions are Cisplatin . fallopian tube cancer diagnosis and no active cardiac disease that in the opinion of the investigator would preclude safe administration of chemotherapy
__label__0	study interventions are Dexamethasone . lymphoma diagnosis and no severe uncontrolled hypertension
__label__0	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and bilirubin less_than equal_than doc uln alkaline phosphatase less_than equal_than five uln ast and alt less_than equal_than doc uln
__label__0	study interventions are Isophosphamide mustard . primary peritoneal cavity cancer diagnosis and no new york heart association class iii or iv heart disease
__label__0	study interventions are Dihydromevinolin . malignant melanoma diagnosis and female patients of childbearing potential must agree to practice contraception abstinence or other effective pregnancy avoidance measures while enrolled in this trial and for one month afterward
__label__0	study interventions are Antibodies . recurrent adrenocortical carcinoma diagnosis and the following are not considered measurable disease
__label__0	study interventions are Everolimus . diffuse intrinsic pontine glioma diagnosis and effective contraception for patients male and female of reproductive potential during their entire participation in the study and during six months after the end of treatment
__label__0	study interventions are Vidarabine . recurrent grade one follicular lymphoma diagnosis and ast alt no greater than four times normal
__label__0	study interventions are reverse transcriptase-polymerase chain reaction . breast cancer diagnosis and hormone receptor status
__label__0	study interventions are Control . in addition participants on adjuvant therapy tamoxifen or aromatase inhibitors must be able and willing to remain on that treatment for the three month intervention period to prevent confounding of biomarker concentrations by treatment
__label__0	study interventions are Gemcitabine . stage ii pancreatic cancer diagnosis and hemoglobin greater_than doc dl
__label__0	study interventions are Vaccines . unspecified adult solid tumor protocol specific diagnosis and no prior autoimmune disease including the following
__label__0	study interventions are cognitive assessment . unspecified adult solid tumor protocol specific diagnosis and measurable brain metastasis outside five mm margin around either hippocampus on gadolinium contrast enhanced mri obtained within the past thirty days
__label__0	study interventions are Levoleucovorin . esophageal cancer diagnosis and no stage ii iv arterial disease according to the de leriche and fontaine classification
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and performance status of greater than or equal to two as per swog scale
__label__0	study interventions are AlloStim-8 . non hodgkin lymphoma nhl including mantle cell lymphoma mcl meeting one of the following criteria
__label__0	study interventions are Camptothecin . transitional cell cancer of the renal pelvis and ureter diagnosis and no concurrent medications that cause diarrhea
__label__0	study interventions are Mycophenolate mofetil . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and karnofsky greater_than equal_than seventy or ecog zero one
__label__0	study interventions are Veliparib . stage iii non hodgkin lymphoma diagnosis and ejection fraction greater_than equal_than fifty by multigated acquisition scan muga or echocardiogram
__label__0	study interventions are Isotretinoin . absence of anti cancer chemotherapy in the last three months
__label__0	study interventions are Fludarabine phosphate . breast cancer diagnosis and hormone receptor status
__label__0	study interventions are EF5 . stage ivb cervical cancer diagnosis and no other significant medical condition that would preclude study participation
__label__0	study interventions are Liposomal doxorubicin . patients with bilateral synchronous invasive breast cancer are eligible as long as both primary tumors if patient has an invasive cancer on one side that meets the eligibility criteria and dcis or lcis on the contralateral side the patient is eligible dcis or lcis should be managed according to institutional guidelines
__label__0	study interventions are Bevacizumab . breast cancer diagnosis and proteinuria less than five hundred mg by twenty-four hour urine collection if proteinuria at least one positive by urinalysis
__label__0	study interventions are Craniectomy . glioblastoma diagnosis and ability to comply with optune therapy
__label__0	study interventions are antineoplaston A10 . brain and central nervous system tumors diagnosis and more than four months
__label__0	study interventions are Aldesleukin . brain tumor diagnosis and white blood cell wbc greater_than equal_than two zero dl or absolute neutrophil count anc greater_than one zero platelets greater_than equal_than one00 zero dl unsupported by transfusion or growth factor international normalized ratio inr less_than doc
__label__0	study interventions are Rituximab . lymphoma diagnosis and platelet count greater_than seventy-five zero µl
__label__0	study interventions are pharmacological study . recurrent ovarian epithelial cancer diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Immunoglobulins . colorectal neoplasm diagnosis and agree to use highly effective form of contraception or avoid intercourse during and upon completion of the study women for twenty-three weeks and men for thirty-one weeks after the last dose of study drug
__label__0	study interventions are Immunoglobulins . patients with small less_than three cm tumors located greater_than two cm away from central bile ducts will be considered for either radiofrequency ablation or resection the choice of which will be determined at the time of surgery
__label__0	study interventions are Immunoglobulins . malignant neoplasm diagnosis and or hematologic persistence evidenced by cytopenias not attributable to other post transplant causes accompanied by characteristic_morphological changes more than ninety days after ahsct or cytogenetic persistence evidenced by persistence of clonal abnormality more than ninety days after ahsct
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and no evidence of distant metastases mone
__label__0	study interventions are radiation therapy . carcinoma of unknown primary diagnosis and see disease characteristics
__label__0	study interventions are Oxaliplatin . colorectal neoplasms diagnosis and participants who met the following main selection criteria were included in the study
__label__0	study interventions are G-202 . prostatic neoplasms diagnosis and clinical stage tonec or ttwoa with high grade disease gleason eight one0 on initial biopsy clinical stage ttwob ttwoc with gleason grade seven four positive three or clinical stage tthree
__label__0	study interventions are Sirolimus . renal cell carcinoma diagnosis and adequate contraception must be used while on study
__label__0	study interventions are Albumin-Bound Paclitaxel . prostate cancer diagnosis and for patients receiving lhrh analogues their testosterone level must be less_than fiftyng dl
__label__0	study interventions are revised invitation signed by the coordinating doctor . colorectal cancer diagnosis and having declared to health insurance company an attending physician who has given its written consent to participate in the study
__label__0	study interventions are Fludarabine phosphate . recurrent childhood large cell lymphoma diagnosis and patients in this category require specific approval of the pi and the tju bmt attending physician group for entrance
__label__0	study interventions are Fluorouracil . incurable colorectal cancer diagnosis and none was previous exposure to cetuximab or irinotecan
__label__0	study interventions are Formyltetrahydrofolates . colorectal cancer diagnosis and serious nonhealing wound ulcer or bone fracture within the past twenty-eight days
__label__0	study interventions are Antibodies . stage iv merkel cell carcinoma diagnosis and patients not on anticoagulation must have international normalized ratio inr equal_than less_than doc patients on full dose anticoagulation warfarin or low molecular weight heparin are eligible provided that both of the following criteria are met
__label__0	study interventions are Capecitabine . metastatic colorectal cancer diagnosis and age
__label__0	study interventions are Thiotepa . atypical_teratoid rhabdoid tumor at rt diagnosis and arm c
__label__0	study interventions are Levoleucovorin . lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Isophosphamide mustard . extragonadal germ cell tumor diagnosis and wbc at least three zero mmthree platelet count at least one hundred zero mmthree hepatic
__label__0	study interventions are Acetaminophen . without cholangiocarcinoma morphology
__label__0	study interventions are Etoposide . adenocarcinoma of rectum diagnosis and total serum bilirubin no more than two mg dl alt and ast no more than three times the upper limit established by the laboratory lsr or no more than five lsr in patients with liver metastases
__label__0	study interventions are Dexamethasone 21-phosphate . patient has previous diagnosis of multiple myeloma
__label__0	study interventions are Zoledronic acid . metastatic cancer diagnosis and hemoglobin greater_than teng dl
__label__0	study interventions are Tamoxifen . ovarian cancer diagnosis and not specified surgery
__label__0	study interventions are anti-CD20-CAR vector-transduced autologous T cells . stage iii mantle cell lymphoma diagnosis and less than two years between last chemotherapy and progression most recent progression free interval less_than two years
__label__0	study interventions are Oxaliplatin . recurrent childhood cerebral astrocytoma diagnosis and no concurrent immunotherapy
__label__0	study interventions are Bevacizumab . glioblastoma multiforme diagnosis and pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study
__label__0	study interventions are Camptothecin . stage ivc squamous cell carcinoma of the oropharynx diagnosis and patients must have had no prior invasive malignancy unless the disease free interval is five years or more
__label__0	study interventions are Enzyme Inhibitors . solid tumor diagnosis and prior concurrent therapy
__label__0	study interventions are Cyclophosphamide . refractory small lymphocytic lymphoma diagnosis and progressive mm after previous autograft provided stored autologous cluster of differentiation cd thirty-four cells are available
__label__0	study interventions are Laboratory Biomarker Analysis . stage iv uterine corpus cancer diagnosis and no more than six weeks after prior surgery
__label__0	study interventions are Cetuximab . colorectal cancer diagnosis and step initial registration
__label__0	study interventions are Cediranib . advanced malignant mesothelioma diagnosis and proteinuria less_than positive one on two consecutive dipsticks taken greater_than seven days apart
__label__0	study interventions are Prednisolone hemisuccinate . neuroblastoma diagnosis and not specified
__label__0	study interventions are Imatinib Mesylate . recurrent melanoma diagnosis and ecog performance status ps zero two or karnofsky ps 6zero_1zerozero
__label__0	study interventions are Cyclophosphamide . ovarian cancer diagnosis and endocrine therapy
__label__0	study interventions are Liposomal doxorubicin . participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma excluding steroids
__label__0	study interventions are Cyclosporins . stage iv childhood anaplastic large cell lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Thalidomide . plasma cell myeloma diagnosis and able to take aspirin eighty-one or three hundred and twenty-five mg daily for prophylactic anticoagulation patients intolerant to acetylsalicylic acid asa may use warfarin or low molecular weight heparin
__label__0	study interventions are Cyclophosphamide . estrogen receptor positive breast cancer diagnosis and the patient must be aware of the neoplastic nature of his her disease and willingly provide written informed consent after being informed of the procedure to be followed the experimental nature of the therapy alternatives potential benefits side effects risks and discomforts
__label__0	study interventions are MLN8237 . neuroendocrine prostate cancer diagnosis and if creatinine greater_than doc uln calculated or measured creatinine clearance must be greater_than forty ml minute cockcroft gault
__label__0	study interventions are Cabozantinib S-malate . hepatocellular carcinoma diagnosis and no history of congenital prolonged corrected qt qtc syndrome new york heart association nyha class iii or iv congestive heart failure chf
__label__0	study interventions are Talimogene Laherparepvec . liposarcoma diagnosis and patient must have life expectancy of at least three months with appropriate therapy
__label__0	study interventions are Immunoglobulin G . childhood cerebral anaplastic astrocytoma diagnosis and at least three months since prior autologous bone marrow or stem cell transplantation
__label__0	study interventions are Cisplatin . unspecified adult solid tumor protocol specific diagnosis and at least four weeks since prior chemotherapy six weeks for nitrosoureas and mitomycin
__label__0	study interventions are Oxaliplatin . borderline resectable adenocarcinoma of the head of the pancrease diagnosis and pre registration eligibility criteria
__label__0	study interventions are Methylprednisolone acetate . recurrent grade two follicular lymphoma diagnosis and patients who have failed previous allogeneic bone marrow transplant
__label__0	study interventions are Fludarabine . kidney cancer diagnosis and negative mri required
__label__0	study interventions are Histone Deacetylase Inhibitors . hepatosplenic cell lymphoma diagnosis and serum creatinine equal_than less_than doc mg dl
__label__0	study interventions are Sunitinib . urethral cancer diagnosis and urethra
__label__0	study interventions are Bevacizumab . pancreatic cell adenoma diagnosis and alkaline phosphatase equal_than less_than doc uln equal_than less_than five uln if liver metastasis is present or patient is in hcc cohort
__label__0	study interventions are Decitabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and at least four weeks since prior chemotherapy except low dose chemotherapy administered to maintain wbc counts six weeks for nitrosoureas or mitomycin and recovered
__label__0	study interventions are Vinorelbine . cancer diagnosis and estimated life expectancy of at least six months
__label__0	study interventions are Antibodies, Monoclonal . adenocarcinoma of the lung diagnosis and measurable disease defined as
__label__0	study interventions are Antibodies, Monoclonal . proximal urethral carcinoma diagnosis and for patients that have had surgical resection prior to study enrollment residual or unresected disease measurable and or unmeasurable must be evident on post surgical scans
__label__0	study interventions are Pemetrexed . lung neoplasm diagnosis and weight loss during last three months should be less than ten
__label__0	study interventions are Dexamethasone . recurrent childhood gliosarcoma diagnosis and if other substantial bone marrow bm radiation greater_than equal_than six weeks must have elapsed
__label__0	study interventions are Melphalan . primary malignant brain neoplasms diagnosis and unfavorable prognostic features include
__label__0	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the nasopharynx diagnosis and no chronic diarrheal condition
__label__0	study interventions are Irinotecan . stomach neoplasm diagnosis and karnofsky index greater_than sixty
__label__0	study interventions are Dexrazoxane . angiosarcoma
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and platelet count at least fifty zero mm three
__label__0	study interventions are Gene-Modified HIV-Protected Hematopoietic Stem Cells . aids related non hodgkin lymphoma diagnosis and subjects must be on prophylactic regimen for pneumocystis_carinii pneumonia or agree to begin such treatment if cdfour positive cell counts are observed to be equal_than less_than two hundred ul in peripheral blood
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and no unstable angina pectoris
__label__0	study interventions are Polyestradiol phosphate . cancer diagnosis and gleason score less_than seven
__label__0	study interventions are Antilymphocyte Serum . stage iv adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__0	study interventions are Paclitaxel . stage ivb squamous cell carcinoma of the oropharynx diagnosis and hemoglobin greater_than doc gm dl
__label__0	study interventions are Bevacizumab . stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and no concurrent chemotherapy or tyrosine kinase inhibitors of vegfr
__label__0	study interventions are [F-18] VM4-037 . cancer subjects
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and relapsed or failed autologous or allogeneic stem cell transplant
__label__0	study interventions are Lomustine . untreated childhood medulloblastoma diagnosis and peripheral absolute neutrophil count anc greater_than equal_than one thousand ul
__label__0	study interventions are Calcium, Dietary . colorectal cancer diagnosis and more than four weeks since prior radiotherapy
__label__0	study interventions are Aldesleukin . pancreatic cancer diagnosis and chemistry
__label__0	study interventions are Bevacizumab . metastatic renal cell carcinoma diagnosis and absence of any psychological familial sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule those conditions should be discussed with the patient before registration in the trial
__label__0	study interventions are Gemcitabine . gallbladder cancer diagnosis and absolute neutrophil count greater_than one five hundred mm three
__label__0	study interventions are Cyclophosphamide . multiple myeloma diagnosis and serum sgpt alt less_than doc upper limits of normal uln
__label__0	study interventions are Cisplatin . stage iii pancreatic cancer diagnosis and wocbp must have negative serum test minimum sensitivity twenty-five iu or equivalent units of human chorionic gonadotropin hcg within seventy-two hours prior to the start of investigational product
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and the following criteria are applicable to the trastuzumab treatment group
__label__0	study interventions are Isophosphamide mustard . rhabdomyosarcoma diagnosis and ejection fraction greater_than forty-five or no clinical evidence of heart failure
__label__0	study interventions are Glucocorticoids . castration resistant prostate cancer diagnosis and eastern cooperative oncology group ecog performance status less_than two karnofsky greater_than sixty see appendix a
__label__0	study interventions are Pravastatin . the lesion must be characterised by hyperdensity during the arterial phase and wash out during the delayed portal phase patients who are not suitable for treatment with curative intent transplantation resection percutaneous destruction or by chemo embolisation or with progressive hepatocellular carcinoma after the failure of specific treatment prognostic clip score zero to four child pugh class transaminases less_than five and creatininemia less_than doc who
__label__0	study interventions are Histone Deacetylase Inhibitors . recurrent adult burkitt lymphoma diagnosis and creatinine equal_than less_than institutional upper limit of normal or creatinine clearance greater_than equal_than sixty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iii verrucous carcinoma of the larynx diagnosis and appropriate stage for protocol entry including no distant metastases based upon the following minimum diagnostic workup
__label__0	study interventions are Cisplatin . bladder cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Trastuzumab . sarcoma diagnosis and other
__label__0	study interventions are Camptothecin . extensive stage small cell lung cancer diagnosis and bilirubin less_than doc upper limit of normal uln except for patients with documented history of gilbert disease who may have direct bilirubin less_than doc uln
__label__0	study interventions are Antibodies . stage iv ovarian cancer diagnosis and patients who have met the pre entry requirements
__label__0	study interventions are Etoposide phosphate . stage iiib hodgkin lymphoma diagnosis and if study eligibility by staging is uncertain consultation with imaging and radiation oncology core iroc rhode island ri may be obtained prior to study enrollment
__label__0	study interventions are Immunoglobulins . recurrent non small cell lung cancer diagnosis and stage iiia iiib or iv disease
__label__0	study interventions are Temozolomide . medulloblastoma diagnosis and seizure disorders must be well controlled on antiepileptic medication
__label__0	study interventions are Pembrolizumab . peritoneal cancer diagnosis and sevenf
__label__0	study interventions are Cyclosporine . lymphoma diagnosis and refractory or relapsed disease
__label__0	study interventions are Oxaliplatin . colorectal cancer diagnosis and patient characteristics
__label__0	study interventions are milatuzumab . multiple myeloma mm diagnosis and myelodysplastic syndrome and intermediate two or high risk ipss score with less_than five blasts in the bone marrow
__label__0	study interventions are Everolimus . breast cancer diagnosis and must sign informed consent
__label__0	study interventions are Leucovorin . localized unresectable adult primary liver cancer diagnosis and no patients requiring drugs with proarrhythmic potential
__label__0	study interventions are Sapanisertib . after the last dose of study drug should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately men treated or enrolled on this protocol must also agree to use highly effective barrier contraception prior to the study for the duration of study participation and through one hundred and twenty days after the last dose of study drug
__label__0	study interventions are Maleic acid . recurrent adult brain neoplasm diagnosis and patients must not have had prior anti vegf therapy
__label__0	study interventions are Romidepsin . lymphoma diagnosis and myocardial infarction within the past six months
__label__0	study interventions are Lenograstim . kidney cancer diagnosis and bone lesions
__label__0	study interventions are Mycophenolic Acid . contiguous stage ii adult lymphoblastic lymphoma diagnosis and adequately matched unrelated donor available
__label__0	study interventions are Melphalan . recurrent grade one follicular lymphoma diagnosis and absolute neutrophil count anc greater_than equal_than one000 cells mm three and platelet count greater_than equal_than sixty mm three when maintenance lenalidomide is started day one00 positive
__label__0	study interventions are Sirolimus . renal pelvis cancer diagnosis and fasting serum cholesterol less_than three hundred mg dl or less_than doc five mmol and fasting triglycerides less_than doc uln
__label__0	study interventions are Imatinib Mesylate . stage ii malignant testicular germ cell tumor diagnosis and hemoglobin at least nine dl transfusion allowed
__label__0	study interventions are Antibodies . able and willing to give valid written consent for available archival tumor samples or fresh tumor biopsies resections
__label__0	study interventions are Fludarabine phosphate . donors found to have fanconi anemia based on chromosomal breakage analysis
__label__0	study interventions are Sulfamethoxazole . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . childhood high grade cerebral astrocytoma diagnosis and patient must be
__label__0	study interventions are Aminopterin . adenocarcinoma of the esophagus diagnosis and exclusion
__label__0	study interventions are Dasatinib . ovarian clear cell cystadenocarcinoma diagnosis and corrected qt qtc interval on electrocardiogram must be equal_than less_than four hundred and eighty msec fridericia correction
__label__0	study interventions are laboratory biomarker analysis . stage iii mantle cell lymphoma diagnosis and note
__label__0	study interventions are Docetaxel . breast neoplasms diagnosis and hemoglobin greater_than or equal_than ten dl
__label__0	study interventions are Survivor-only progressive walking and resistance exercise . cancer diagnosis and be twenty-one years of age or older
__label__0	study interventions are Dexamethasone . myeloma diagnosis and life expectancy of greater than six months
__label__0	study interventions are Dacarbazine . childhood cerebral anaplastic astrocytoma diagnosis and fertile patients must use effective contraception during all study therapy and for greater_than six months after completion of bevacizumab
__label__0	study interventions are Immunoglobulins . recurrent melanoma diagnosis and patients are ineligible if they have inadequately controlled hypertension defined as systolic blood pressure greater_than one hundred and fifty and or diastolic blood pressure greater_than one hundred mmhg on antihypertensive medications
__label__0	study interventions are (Resiniferatoxin)(RTX) . pain cancer diagnosis and adjuvant pain medications such as antidepressants corticosteroids local anesthetics and antiseizure medications
__label__0	study interventions are Vidarabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and antecedent myelodysplastic syndrome secondary aml high risk cytogenetic abnormalities or normal cytogenetics with high risk molecular features fltthree_itd mutation mixed lineage leukemia mll_wildtype npmone
__label__0	study interventions are Questionnaire Administration . stage iv ovarian cancer diagnosis and patient must be able to read and write english
__label__0	study interventions are Paclitaxel . oropharyngeal squamous cell cancer diagnosis and performance status zero two
__label__0	study interventions are Carmustine . lymphoma diagnosis and subjects must agree to have their anti hiv regimen temporarily stopped and then all subjects will stop antiretroviral therapy art for approximately seven days at the time they start filgrastim csf post chemotherapy for peripheral blood progenitor cell pbpc mobilization and until the mobilization is complete in addition if when the cdfour counts return to level of four50 mm three with undetectable hiv levels in blood the subjects will undergo an analytic treatment interruption for an indefinite period not to exceed six months
__label__0	study interventions are Palonosetron . colorectal cancer diagnosis and absolute neutrophil count anc greater_than one five hundred mm ³
__label__0	study interventions are Interferons . bladder cancer diagnosis and patient characteristics
__label__0	study interventions are Epothilones . recurrent adult diffuse large cell lymphoma diagnosis and no other concurrent investigational agents
__label__0	study interventions are Curcumin . breast carcinoma diagnosis and doc gy
__label__0	study interventions are Sirolimus . adenocarcinoma of the esophagus diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Interferons . gestational_trophoblastic tumor diagnosis and not specified
__label__0	study interventions are Immunoglobulin Idiotypes . b cell lymphoma diagnosis and life expectancy of greater than one year
__label__0	study interventions are Immunoglobulin G . stage iiia uterine corpus cancer diagnosis and absolute neutrophil count anc greater_than equal_than one thousand, five hundred mm three
__label__0	study interventions are quality-of-life assessment . adenocarcinoma of the gallbladder diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Vaccines . melanoma skin diagnosis and performance status zero two
__label__0	study interventions are Prednisolone acetate . nasopharyngeal carcinoma diagnosis and because on dosing or adverse event data are currently not available on the use of bevacizumab in patients less_than eighteenyears old
__label__0	study interventions are Hydroxyurea . small intestine cancer diagnosis and no concurrent immunotherapy chemotherapy
__label__0	study interventions are Ranibizumab . the eye was previously irradiated for treatment of uveal melanoma
__label__0	study interventions are Everolimus . stage iiia fallopian tube cancer diagnosis and ability to swallow and retain oral medication
__label__0	study interventions are Vidarabine . childhood nasal type extranodal nk cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Carboplatin . stage iva uterine corpus cancer diagnosis and platelets greater than or equal to one hundred zero mcl
__label__0	study interventions are Fluorouracil . stage ivb colon cancer diagnosis and creatinine equal_than less_than two uln
__label__0	study interventions are Bevacizumab . metastatic breast cancer diagnosis and patients must have received bevacizumab in combination with paclitaxel as first line treatment
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and luteinizing hormone releasing hormone therapy must continue
__label__0	study interventions are Fludarabine phosphate . stage grade one follicular lymphoma diagnosis and fulfills all pulmonary cardiac renal and hepatic criteria for standard of care matched unrelated donor mud allogeneic hct
__label__0	study interventions are Lenalidomide . extranodal marginal zone cell lymphoma of mucosa associated lymphatic tissue malt type
__label__0	study interventions are Etoposide phosphate . unspecified adult solid tumor protocol specific diagnosis and chemotherapy
__label__0	study interventions are Deoxyuridine . stage iv adult immunoblastic large cell lymphoma diagnosis and weight equal_than less_than three hundred lbs
__label__0	study interventions are Interferon-alpha . kidney cancer diagnosis and hemoglobin greater_than doc dl
__label__0	study interventions are Pemetrexed . prostate cancer diagnosis and if there has been antiandrogen withdrawal it must have occurred at least four weeks before study enrollment six weeks for bicalutamide or in subjects who have had an antiandrogen added as second line therapy and there was no response to the most recent antiandrogen therapy or if the psa decline lasted less_than three months antiandrogen therapy must be discontinued for at least two weeks
__label__0	study interventions are Metronidazole . gastric cancer diagnosis and creatinine less than doc mg dl
__label__0	study interventions are Vorinostat . nodal marginal zone cell lymphoma diagnosis and blasts present in marrow and or peripheral blood but disease does not qualify as accelerated or blast phase
__label__0	study interventions are Cyclophosphamide . unspecified adult solid tumor protocol specific diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Paclitaxel . stage iiib non small cell lung cancer diagnosis and calculated creatinine clearance greater_than equal_than twenty ml min
__label__0	study interventions are Fludarabine phosphate . adult nasal type extranodal nk cell lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and preoperative risk assessment indicating less_than five risk of mortality and less_than 1five risk of significant morbidity for pulmonary metastasectomy
__label__0	study interventions are Niacinamide . regional transitional cell cancer of the renal pelvis and ureter diagnosis and john wort
__label__0	study interventions are Irinotecan . stage iiia gastric cancer diagnosis and performance status
__label__0	study interventions are quality-of-life assessment . stage iii vulvar cancer diagnosis and major medical or psychiatric illness which would prevent completion of treatment or interfere with follow up is excluded
__label__0	study interventions are Paclitaxel . squamous cell lung cancer diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Oxaliplatin . histologically or cytologically confirmed hertwo neu negative cancer prior to pre registration hertwo neu status must be determined by clinical laboratory improvement_amendments clia_certified laboratory
__label__0	study interventions are Antibodies, Monoclonal . recurrent salivary gland cancer diagnosis and fertile patients must use effective contraception during and for greater_than equal_than two months after completion of study therapy
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and all ann_arbor stages note
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and menopausal status
__label__0	study interventions are Anastrozole . endometrial cancer diagnosis and platelet count plt greater_than one hundred one hundred and nine l
__label__0	study interventions are Thalidomide . refractory multiple myeloma diagnosis and cardiac ejection fraction greater_than equal_than fifty by muga scan and or by echocardiogram
__label__0	study interventions are Cyclophosphamide . recurrent diffuse large cell lymphoma diagnosis and serum creatinine within normal range for age or if serum creatinine outside normal range for age then renal function creatinine clearance or glomerular filtration rate gfr greater_than forty ml min doc threem two
__label__0	study interventions are Sirolimus . stage iv melanoma diagnosis and concurrent prophylactic anticoagulation therapy low dose warfarin allowed provided prothrombin time pt international normalized ratio inr less_than doc times upper limits of normal uln
__label__0	study interventions are Vidarabine . recurrent grade two follicular lymphoma diagnosis and measurable disease and presence of end organ damage measurable disease includes any of the following
__label__0	study interventions are Fludarabine phosphate . stage adult lymphoblastic lymphoma diagnosis and patients with renal failure are eligible however patients with renal compromise serum creatinine greater_than doc will likely have further compromise in renal function and may require hemodialysis which may be permanent due to the need to maintain adequate serum tacrolimus levels
__label__0	study interventions are Cetuximab . colon signet ring cell adenocarcinoma diagnosis and patients after menarche with amenorrhea irregular cycles or using contraceptive method that precludes withdrawal bleeding
__label__0	study interventions are Metformin . prostate cancer diagnosis and patient agrees to participate to the mandatory translational research part of the trial with exception of pyruvate dehydrogenase sub study
__label__0	study interventions are Niacinamide . carcinoma hepatocellular diagnosis and presence of measurable disease by radiographic imaging
__label__0	study interventions are questionnaire administration . stage ii rectal cancer diagnosis and clinical or radiological evidence of metastatic spread
__label__0	study interventions are LOXO-101 . neoplasms diagnosis and adequate renal function
__label__0	study interventions are Antibodies, Monoclonal . breast carcinoma metastatic in the brain diagnosis and patients must sign an informed consent prior to registration and before undergoing any study specific procedures indicating that they are aware of the investigational nature of this study
__label__0	study interventions are Antibodies, Monoclonal . squamous cell lung cancer diagnosis and no known brain metastases by contrast enhanced ct scan or gadolinium enhanced mri of the brain
__label__0	study interventions are Irinotecan . small intestine cancer diagnosis and platelet count at least one hundred zero mmthree
__label__0	study interventions are Levoleucovorin . sarcoma diagnosis and at least one week since prior intrathecal treatment
__label__0	study interventions are Metronidazole . stage iii salivary gland cancer diagnosis and no prior radiotherapy to more than fifty of all nodal groups
__label__0	study interventions are Fulvestrant . estrogen receptor positive breast cancer diagnosis and pregnancy testing does not need to be pursued in patients who are judged as postmenopausal before randomization as determined by local practice or who have undergone bilateral oophorectomy total hysterectomy or bilateral tubal ligation
__label__0	study interventions are Paclitaxel . endometrial carcinoma diagnosis and female greater_than eighteen years
__label__0	study interventions are Paclitaxel . stage iv salivary gland cancer diagnosis and absolute neutrophil count anc greater_than one thousand, five hundred cells mcl
__label__0	study interventions are Fosbretabulin . head and neck cancer diagnosis and no prior radiotherapy
__label__0	study interventions are Etoposide phosphate . liver cancer diagnosis and performance level
__label__0	study interventions are Mycophenolate mofetil . stage iii childhood anaplastic large cell lymphoma diagnosis and patients will be accepted in chronic phase or accelerated phase patients who have received prior autografts after high dose therapy or have undergone intensive chemotherapy with filgrastim csf mobilized peripheral blood mononuclear cells pbmc autologous or conventional hct for advanced cml may be enrolled provided they are in cr or cp and have less_than five marrow blasts at time of transplant
__label__0	study interventions are DCE-MRI . colorectal neoplasm diagnosis and participants must be commencing chemotherapy with folfox plus bevacizumab
__label__0	study interventions are Ifosfamide . participant has received no prior radiotherapy or chemotherapy for rhabdomyosarcoma excluding steroids
__label__0	study interventions are side by side . aov cancer diagnosis and older than twenty years old
__label__0	study interventions are Antibodies . advanced cancer diagnosis and male or female patients aged greater_than eighteen years at time of inform consent signature
__label__0	study interventions are Mycophenolic Acid . stage iv adult diffuse mixed cell lymphoma diagnosis and donor
__label__0	study interventions are cognitive assessment . has completed surgery for stage iii breast cancer and meets the following criteria
__label__0	study interventions are Bevacizumab . histologically confirmed angiosarcoma
__label__0	study interventions are Interferons . optic pathway gliomas diagnosis and karnofsky greater_than or equal to fifty for patients greater_than ten years of age or lansky greater_than or equal to fifty for patients less_than ten years of age
__label__0	study interventions are Cyclophosphamide . recurrent mantle cell lymphoma diagnosis and research participant has released_cryopreserved cell product for cell infusions on approximately day zero
__label__0	study interventions are Carboplatin . choriocarcinoma diagnosis and radiation therapy should not be given concurrently with high dose carboplatin or etoposide
__label__0	study interventions are Laparoscopic-LAR . rectal cancer diagnosis and age over eighteen years
__label__0	study interventions are Ifosfamide . sarcoma diagnosis and no greater than doc mg dl thirteen years to fifteen years male
__label__0	study interventions are pharmacological study . stage iv adult burkitt lymphoma diagnosis and bilirubin no greater than doc mg dl
__label__0	study interventions are Vinorelbine . triple negative breast cancer diagnosis and subjects must meet at least one of the following two criteria
__label__0	study interventions are Hydroxychloroquine . non small cell lung cancer diagnosis and adequate organ function including the following
__label__0	study interventions are Antibodies, Monoclonal . stage adult diffuse small cleaved cell lymphoma diagnosis and must have failed previous myelosuppressive chemotherapy or hsct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are pharmacological study . ovarian cancer diagnosis and ast alt less_than doc times uln five times uln with liver metastases
__label__0	study interventions are Laboratory Biomarker Analysis . glioblastoma diagnosis and patients must be undergoing surgery that is clinically indicated as determined by their care providers
__label__0	study interventions are antineoplaston AS2-1 . lung cancer diagnosis and no severe heart disease
__label__0	study interventions are Camptothecin . ganglioneuroma diagnosis and hypertensive patients are eligible provided the hypertension is well controlled ninety-fiveth_percentile for age and height if patient less_than seventeen years on stable doses of medication
__label__0	study interventions are Vidarabine . stage iv small lymphocytic lymphoma diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Doxorubicin . malignant peripheral nerve sheath tumor diagnosis and corrected qt interval qtc less_than four hundred and eighty msec
__label__0	study interventions are Alisertib . malignant neoplasms of lip oral cavity and pharynx diagnosis and hepatic
__label__0	study interventions are Pancrelipase . pancreatic cancer diagnosis and platelet count greater_than equal_than one hundred zero mm three
__label__0	study interventions are Endothelial Growth Factors . recurrent hypopharyngeal squamous cell carcinoma diagnosis and history of gross hemoptysis bright red blood of one two teaspoon or more per episode of coughing equal_than less_than three months prior to enrollment
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and female sex note
__label__0	study interventions are Pharmacological Study . recurrent adult unclassified pleomorphic sarcoma of bone diagnosis and female patients may be considered to not be of childbearing potential for the following reasons
__label__0	study interventions are Fluorodeoxyglucose F18 . breast cancer diagnosis and concurrent participation on another clinical study or other imaging studies allowed
__label__0	study interventions are Interferons . stage multiple myeloma diagnosis and protein in the urine
__label__0	study interventions are Vincristine . stage adult diffuse large cell lymphoma diagnosis and will be permitted
__label__0	study interventions are Nivolumab . melanoma diagnosis and documentation required to be sent to bruog
__label__0	study interventions are Antibodies . fallopian tube cancer diagnosis and no anticipation of invasive procedures including any of the following applies to part only
__label__0	study interventions are Pharmacogenomic studies . stage iv grade one follicular lymphoma diagnosis and patients with mean qtcb greater_than four hundred and fifty msec in males and greater_than four hundred and seventy msec in females
__label__0	study interventions are Laboratory Biomarker Analysis . recurrent renal cell carcinoma diagnosis and at least four weeks from last dose of prior chemotherapy with resolution of the acute toxic effects of the therapy
__label__0	study interventions are Antibodies, Monoclonal . stage iii pancreatic cancer diagnosis and serum creatinine less_than equal_than doc uln
__label__0	study interventions are Tacrolimus . diffuse large cell lymphoma or its subtypes excluding primary cns lymphoma
__label__0	study interventions are Keyhole-limpet hemocyanin . non hodgkin lymphoma nhl diagnosis and disease status
__label__0	study interventions are Thiotepa . lymphoma diagnosis and previous treatment
__label__0	study interventions are Cadexomer iodine . cancer of kidney diagnosis and expected survival of at least three months
__label__0	study interventions are PAC-1 . gastrointestinal cancers diagnosis and has total bilirubin less_than doc mg dl serum albumin greater_than doc gm dl ast and alt less_than doc uln or less_than three uln for subjects with known hepatic metastases
__label__0	study interventions are Antibodies . stage ivb oral cavity verrucous carcinoma diagnosis and eastern cooperative oncology group ecog performance status of zero one
__label__0	study interventions are Cyclosporine . childhood nasal type extranodal nk cell lymphoma diagnosis and chronic myelogenous leukemia cml
__label__0	study interventions are Dexamethasone . females of childbearing potential fcbp must have negative serum or urine pregnancy test and abstain from sex or begin two acceptable methods of birth control greater_than twenty-eight days before pomalidomide dose and agree to ongoing pregnancy testing
__label__0	study interventions are iodine I 125 . prior radiotherapy as part of treatment for head and neck breast or other non thoracic cancer is permitted
__label__0	study interventions are Carboplatin . stage iiic primary peritoneal cavity cancer diagnosis and no active infection requiring antibiotics
__label__0	study interventions are Cetuximab . squamous cell carcinoma of the hypopharynx stage iv diagnosis and psixteen status available
__label__0	study interventions are Rituximab . lymphoma diagnosis and cdtwenty positive disease
__label__0	study interventions are perifosine . pancreatic cancer diagnosis and no concurrent antiretroviral therapy for hiv positive patients
__label__0	study interventions are Immunoglobulins . stage ivc squamous cell carcinoma of the oropharynx diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are Antibodies, Monoclonal . stage ia breast cancer diagnosis and one positive lymph node by sentinel node biopsy or at least six axillary nodes must be examined on axillary node dissection with at least one positive lymph node
__label__0	study interventions are Vaccines . noncontiguous stage ii grade two follicular lymphoma diagnosis and medically indicated subunit_engerix for hbv gardasil for hpv or killed vaccines influenza pneumococcal or allergy treatment with antigen injections
__label__0	study interventions are Methylprednisolone . neoplasms diagnosis and two arterial pression of oxygen paotwo less_than sixty mmhg on room air need of three min oxygen for saturation greater_than 9two or tachypneagreater_than three0min need of mechanical ventilation for acute respiratory failure
__label__0	study interventions are Erlotinib Hydrochloride . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and performance status
__label__0	study interventions are Isophosphamide mustard . stage ii cutaneous cell non hodgkin lymphoma diagnosis and electrocardiogram ekg must be free of any arrhythmias excluding sinus arrhythmia or infrequent premature ventricular contractions
__label__0	study interventions are Estradiol . advanced estrogen receptor positive her negative breast cancer diagnosis and individuals must have commenced treatment with goserelin or an alternative lhrh agonist at least four weeks prior to first dose of study drug
__label__0	study interventions are Immunoglobulins . stage ivb laryngeal verrucous carcinoma diagnosis and presence of measurable lesions by recist
__label__0	study interventions are Paclitaxel . metastatic breast cancer diagnosis and absolute neutrophil count anc greater_than one five hundred cells mmthree doc xone0 nine l
__label__0	study interventions are Endostatins . can undertake nasopharyngeal carcinoma specimens in the materia diagnosis and or white blood cell and platelet not less than our hospital normal lowest index ten liver function
__label__0	study interventions are PBR PET . melanoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Docetaxel . stage ib non small cell lung carcinoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred ul
__label__0	study interventions are Carboplatin . central nervous system tumor diagnosis and chemotherapy
__label__0	study interventions are communication with oncology team . head and neck cancer diagnosis and adult patient criteria
__label__0	study interventions are high performance liquid chromatography . ovarian cancer diagnosis and palliative radiotherapy may be given during the study for bone pain or for other reasons not due to progressive disease bronchial obstruction ulcerating skin lesions
__label__0	study interventions are Carboplatin . lung cancer diagnosis and creatinine less than uln
__label__0	study interventions are Vorinostat . anaplastic large cell lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Antibodies . stage iv grade one follicular lymphoma diagnosis and no prior exposure to any of the study agents
__label__0	study interventions are Cytarabine . myelodysplastic myeloproliferative neoplasms diagnosis and pulmonary
__label__0	study interventions are Prednisone . lymphoma diagnosis and risk factors are defined as symptoms extranodal sites of disease and disease remission lasting less_than one year after first line therapy
__label__0	study interventions are Trastuzumab . metastatic breast cancer diagnosis and have ecog zero or one
__label__0	study interventions are Antibodies . recurrent gastric cancer diagnosis and patients must be able to take and retain oral medications
__label__0	study interventions are Trastuzumab . unresectable extrahepatic bile duct cancer diagnosis and creatinine equal_than less_than two times upper limits of normal uln or creatinine clearance greater_than equal_than sixty ml min
__label__0	study interventions are Gemcitabine . unresectable pancreatic carcinoma diagnosis and previous neo adjuvant or adjuvant treatment is allowed provided that there was no evidence of recurrent disease for at least six months after completion of neo adjuvant adjuvant treatment
__label__0	study interventions are Methylprednisolone Hemisuccinate . anaplastic large cell lymphoma diagnosis and this protocol will allow the use of donors who are unrelated but are hla b d dr identical and mlc mixed lymphocyte culture compatible
__label__0	study interventions are Paclitaxel . inflammatory breast cancer ibc diagnosis and platelets greater_than one hundred zero mmthree
__label__0	study interventions are Standard Materials . breast cancer diagnosis and did not receive transabdominal rectus abdominus muscle tram reconstructive surgery
__label__0	study interventions are Endothelial Growth Factors . measurable disease according to response evaluation criteria in solid tumors recist obtained by dual phase ct scan within fourteen days prior to being registered for protocol therapy
__label__0	study interventions are Melphalan . recurrent cutaneous cell non hodgkin lymphoma diagnosis and louis cord blood bank or any of the established registered international blood and marrow banks
__label__0	study interventions are Irinotecan . locally advanced pancreatic cancer
__label__0	study interventions are Everolimus . liver neoplasms diagnosis and appropriate studies will be undertaken in patients receiving haart therapy when indicated
__label__0	study interventions are Albumin-Bound Paclitaxel . brain and central nervous system tumors diagnosis and hepatic
__label__0	study interventions are Doxorubicin . sarcoma diagnosis and platelet count at least one hundred zero mm three
__label__0	study interventions are Endothelial Growth Factors . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and at least four weeks since prior chemotherapy six weeks for nitrosoureas or mitomycin and recovered
__label__0	study interventions are Sirolimus . pancreatic cancer diagnosis and patients must have received at least one prior chemotherapy regimen for unresectable metastatic disease
__label__0	study interventions are Isophosphamide mustard . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Immunoglobulins . patients with symptomatic peripheral vascular disease are not eligible
__label__0	study interventions are Dexamethasone . histologically confirmed hodgkin lymphoma
__label__0	study interventions are Goserelin . prostate cancer diagnosis and psa progression defined as two consecutive rising psa values greater_than doc ng ml taken greater_than two weeks apart
__label__0	study interventions are Immunoglobulins . stage iiia fallopian tube cancer diagnosis and neuropathy sensory and motor equal_than less_than common terminology criteria for adverse events ctcae grade one
__label__0	study interventions are Fulvestrant . recurrent breast carcinoma diagnosis and prior therapies
__label__0	study interventions are Antibodies . lymphoma classified as either previously untreated grade one two or threea fl that requires treatment or previously untreated advanced dlbcl
__label__0	study interventions are Fludarabine . recurrent adult lymphoblastic lymphoma diagnosis and not eligible for autologous hsct or after failed autologous hsct
__label__0	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and neutrophils doc one hundred and nine platelets one hundred one hundred and nine hgb greater_than nine dl
__label__0	study interventions are Cyclophosphamide . stage iii mantle cell lymphoma diagnosis and no known hypersensitivity to ofatumumab humanized antibodies or chemotherapy agents throughout the protocol
__label__0	study interventions are Carboplatin . stage iiia non small cell lung cancer diagnosis and total bilirubin equal_than less_than doc upper limit of normal
__label__0	study interventions are non-prophylactic . histological verification of meningioma of any grade from the current surgery
__label__0	study interventions are Sirolimus . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamic pyruvate transaminase sgpt equal_than less_than doc institutional upper limit of normal uln
__label__0	study interventions are Camptothecin . metastatic cancer diagnosis and patient characteristics
__label__0	study interventions are falimarev . colorectal cancer diagnosis and no active acute or chronic infection including urinary tract infection within the past seventy-two hours
__label__0	study interventions are Antibodies, Monoclonal . stage iv squamous cell carcinoma of the oropharynx diagnosis and ast less_than doc times uln
__label__0	study interventions are Doxorubicin . stage iii bladder cancer diagnosis and wbc at least three five hundred mm three
__label__0	study interventions are Sorafenib . bclc stage adult hepatocellular carcinoma diagnosis and prior therapies allowed include the following
__label__0	study interventions are Paclitaxel . breast neoplasms diagnosis and female participants of childbearing potential should have negative urine or serum pregnancy test within seventy-two hours prior to receiving the first dose of study drug
__label__0	study interventions are Allopurinol . follicular lymphoma diagnosis and chronic myelogenous leukemia excluding refractory blast crisis
__label__0	study interventions are Prednisolone phosphate . burkitt leukemia or lymphoma cell all or lymphoblastic lymphoma
__label__0	study interventions are Sirolimus . stage iii grade two follicular lymphoma diagnosis and unrelated donors who are prospectively
__label__0	study interventions are Carboplatin . breast cancer diagnosis and adequate renal function creatinine clearance greater_than sixty ml min
__label__0	study interventions are Palivizumab . cancer diagnosis and not specified life expectancy
__label__0	study interventions are EF5 . stage ii endometrial carcinoma diagnosis and no significant cardiac condition that would preclude study participation
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and direct extension into soft tissue of the neck
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiia non small cell lung cancer diagnosis and tthree nzero none disease allowed provided the disease is not amenable for surgical resection
__label__0	study interventions are Calcium Carbonate . castrate resistant prostate cancer with bone metastasis diagnosis and the last dose of chemotherapy must have been completed at least four weeks prior to enrollment into this study and subjects must have recovered from all side effects
__label__0	study interventions are Antibodies . endometrial transitional cell carcinoma diagnosis and doc
__label__0	study interventions are Mycophenolic Acid . stage iii multiple myeloma diagnosis and myelosuppressive chemotherapy must be discontinued three weeks prior to conditioning with the exception of hydroxyurea or imatinib
__label__0	study interventions are Cisplatin . stage ib uterine corpus cancer diagnosis and entry into the study is limited to no more than eight weeks from the date of surgery
__label__0	study interventions are Vaccines . pancreatic cancer diagnosis and serum total bilirubin less_than two uln mg dl alt sgpt and ast sgot less_than three upper limit of normal uln
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and total bilirubin less than or equal to twomg dl gilbert and other syndromes with increased indirect bilirubin should be allowed serum transaminases less than two times the upper limit of normal
__label__0	study interventions are Erlotinib Hydrochloride . mucinous adenocarcinoma of the rectum diagnosis and no concurrent nephritic syndrome uncontrolled hypertension congestive heart failure
__label__0	study interventions are pharmacological study . melanoma skin diagnosis and lvef greater_than forty-five by cardiac stress test stress thallium stress muga dobutamine echocardiogram or other stress test for patients meeting any of the following criteria
__label__0	study interventions are Isophosphamide mustard . solid tumors diagnosis and history of greater_than four prior chemotherapy regimens all platinum regimens will be counted as one regimen
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic melanoma diagnosis and part d
__label__0	study interventions are Sirolimus . breast cancer diagnosis and adequate bone marrow function as shown by
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and radiotherapy within fourteen days before randomization
__label__0	study interventions are Antibodies, Monoclonal . adenosquamous cell lung cancer diagnosis and no concurrent full dose anticoagulants low molecular weight and unfractionated heparin or warfarin
__label__0	study interventions are Gemcitabine . adult undifferentiated pleomorphic sarcoma diagnosis and subjects not using hormone replacement therapy hrt must have experienced total cessation of menses for greater_than equal_than one year and be greater than forty-five years in age or in questionable cases have follicle stimulating hormone fsh value greater_than forty milliinternational units per milliliter miu ml and an estradiol value less_than forty pg ml less_than oneforty_pmol l
__label__0	study interventions are Veliparib . neuroendocrine neoplasm diagnosis and serum ferritin levels greater_than one thousand ng ml
__label__0	study interventions are Aromatase Inhibitors . breast cancer diagnosis and eastern cooperative oncology group ecog performance status of zero or one
__label__0	study interventions are 6-Mercaptopurine . left ventricular ejection fraction at least fifty by muga or echocardiogram no symptomatic congestive heart failure no symptomatic coronary artery disease no cardiomyopathy no uncontrolled arrhythmia other
__label__0	study interventions are Prednisolone phosphate . prostate cancer metastatic diagnosis and eastern cooperative oncology group ecog performance status of zero two
__label__0	study interventions are Saracatinib . stage iva thymoma diagnosis and ecog performance status zero two
__label__0	study interventions are Bevacizumab . the diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy
__label__0	study interventions are Idarubicin . age over sixty performance status greater than one any elevation of ldh more than one extranodal site ann_arbor stage iii or iv negative and cell nhl eligible if meeting all above criteria no primary cns lymphoma brain involvement eligible if not primary
__label__0	study interventions are Cetuximab . stage iii colon cancer diagnosis and must have resolution of any skin rash related to prior treatment with cetuximab
__label__0	study interventions are Irinotecan . long term effects secondary to cancer therapy in adults diagnosis and at least one unidimensionally measurable lesion greater_than fifty mm by head contrast ct scan and or brain mri
__label__0	study interventions are Fludarabine . melanoma skin diagnosis and patient characteristics
__label__0	study interventions are Tremelimumab . stage iva colorectal cancer diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Temozolomide . glioblastoma diagnosis and patients with no residual disease after surgery are allowed
__label__0	study interventions are Sirolimus . recurrent mantle cell lymphoma diagnosis and women of childbearing potential and sexually active males must use an accepted and effective method of contraception throughout the study and for eight weeks following discontinuation of everolimus
__label__0	study interventions are Capecitabine . recurrent rectal cancer diagnosis and patients must not have an active inflammatory bowel disease or other serious medical illness which might limit the ability of the patient to receive protocol therapy
__label__0	study interventions are Tacrolimus . contiguous stage ii small lymphocytic lymphoma diagnosis and donor must have adequate veins for leukapheresis or agree to placement of central venous catheter femoral_subclavian
__label__0	study interventions are Bevacizumab . stage ia breast cancer diagnosis and patients must not have non healing wound or fracture patients with an abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to randomization are not eligible
__label__0	study interventions are Dexamethasone . unspecified adult solid tumor protocol specific diagnosis and more than seven days since prior antinausea medications
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and platelet count greater_than seventy-five zero mm³
__label__0	study interventions are anti-CD7 CAR-pNK cells . extranodal nk cell lymphoma nasal type diagnosis and male and female subjects with cdseven positive malignancies in patients with no available curative treatment options who have limited prognosis several months to less_than two year survival with currently available therapies will be enrolled
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and lungs whole
__label__0	study interventions are Androgens . prostate cancer diagnosis and endocrine therapy
__label__0	study interventions are Cisplatin . squamous cell carcinoma diagnosis and sign the irb ec approved consent form
__label__0	study interventions are Sirolimus . patients with prior history of contra lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last five years
__label__0	study interventions are Albumin-Bound Paclitaxel . pancreatic cancer diagnosis and patient must be able to swallow enteral medications with no requirement for feeding tube
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and life expectancy greater_than ten years
__label__0	study interventions are Carboplatin . stage ivb laryngeal squamous cell carcinoma diagnosis and no prior chemotherapy or biologic molecular targeted therapy for recurrent or metastatic scchn
__label__0	study interventions are Cetuximab . carcinoma squamous cell of the head and neck diagnosis and women of childbearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry for the duration of study participation and for three months after completing treatment
__label__0	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the hypopharynx diagnosis and must have undergone radiotherapy as component of prior treatment
__label__0	study interventions are AR-42 . soft tissue sarcoma diagnosis and ability to understand and willingness to sign the consent form
__label__0	study interventions are Decitabine . stage iv adult lymphoblastic lymphoma diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat or other agents used in study
__label__0	study interventions are Akt inhibitor MK2206 . recurrent childhood large cell lymphoma diagnosis and thirteen to less_than sixteen years
__label__0	study interventions are Dasatinib . gastrointestinal stromal tumor diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Calcium, Dietary . stage iiia rectal cancer diagnosis and alkaline phosphatase no greater than five times uln
__label__0	study interventions are Trastuzumab . metastatic transitional cell cancer of the renal pelvis and ureter diagnosis and no concurrent chemotherapy
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and platelets at least one hundred zero
__label__0	study interventions are Isotretinoin . granulocytopenia anemia and or thrombocytopenia allowed for patients with tumor metastatic to the bone marrow
__label__0	study interventions are Cediranib . rectal cancer diagnosis and mean qtc with bazetts correction greater_than four hundred and seventymsec in screening ecg or history of familial long qt syndrome
__label__0	study interventions are accelerated fraction . histologically confirmed non small cell lung cancer
__label__0	study interventions are Epoetin Alfa . unspecified adult solid tumor protocol specific diagnosis and administered weekly or every three weeks
__label__0	study interventions are Fludarabine phosphate . recurrent mantle cell lymphoma diagnosis and mds with an international prostate symptom score ipss score of int two or higher
__label__0	study interventions are Dexamethasone 21-phosphate . childhood oligodendroglioma diagnosis and no cell leukemia with cnsthree disease
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and no other significant medial or psychiatric illness that in the opinion of the investigator would preclude study participation
__label__0	study interventions are Cisplatin . carcinoma squamous cell diagnosis and histology and staging of the disease
__label__0	study interventions are Cisplatin . undifferentiated ovarian carcinoma diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Immunoglobulins . stage iib hodgkin lymphoma diagnosis and hiv positive documentation of hiv one infection by means of any one of the following
__label__0	study interventions are Immunoglobulin G . adult giant cell glioblastoma diagnosis and hemoglobin greater_than equal_than one doc dl note
__label__0	study interventions are ME-344 . solid tumors diagnosis and platelet count greater_than one hundred one hundred and nine l
__label__0	study interventions are Mycophenolate mofetil . lymphoplasmacytic lymphoma diagnosis and age performance status and graft criteria
__label__0	study interventions are Deferasirox . stage iv adult diffuse small cleaved cell lymphoma diagnosis and ecog performance status greater_than two
__label__0	study interventions are Melphalan . lymphoma diagnosis and total bilirubin less_than doc mg dl in the absence of history of gilbert disease
__label__0	study interventions are Fludarabine . nodal marginal zone cell lymphoma diagnosis and chronic myeloid leukemia
__label__0	study interventions are Doxorubicin . childhood lymphocyte depletion hodgkin lymphoma diagnosis and patients may not have received any previous chemotherapy or radiation therapy patients may not have received systemic corticosteroids within thirty days of enrollment on this protocol steroids used for treatment of contrast agent allergy required for computed tomography ct scans are acceptable
__label__0	study interventions are Pharmaceutical Solutions . unspecified adult solid tumor protocol specific diagnosis and patient characteristics
__label__0	study interventions are Liposomal doxorubicin . recurrent fallopian tube carcinoma diagnosis and any and all therapy potentially in its entirety may be conducted outside of the mayo clinic
__label__0	study interventions are Antibodies, Monoclonal . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and the best available match is hla class ii drbone and dqbone matched donor incompatible for any single serologically detectable class hla b mismatch one additional allele level class mismatch is allowed or any combination of two allele level mismatches if typed at the molecular level
__label__0	study interventions are Razoxane . lymphoma diagnosis and not specified
__label__0	study interventions are Cyclophosphamide . follicular non hodgkin lymphoma diagnosis and patient must be accessible for treatment and follow up
__label__0	study interventions are Pemetrexed . stage iiia large cell lung carcinoma diagnosis and life expectancy of greater than twelve months
__label__0	study interventions are Vinorelbine . triple negative breast cancer diagnosis and adequate bone marrow function as evidenced by absolute neutrophil count anc greater than or equal to doc ten nine hemoglobin greater than or equal to one doc dl and platelet count greater than or equal to ten0 ten nine l
__label__0	study interventions are Behavioral Dietary Intervention . stage iiic ovarian cancer diagnosis and patients must not have serious psychiatric illness lifetime bipolar disorder schizophrenia or other psychosis serious personality disorder severe major depressive disorder or recent suicide or psychiatric hospitalization previous twelve months
__label__0	study interventions are Interleukin-12 . cervical cancer diagnosis and bilirubin no greater than doc times the upper limit of normal uln ast and alt no greater than two times uln renal
__label__0	study interventions are Capecitabine . breast cancer diagnosis and results must be available before the end of adjuvant chemotherapy
__label__0	study interventions are Erlotinib Hydrochloride . large cell lung cancer diagnosis and patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
__label__0	study interventions are Vitamin B Complex . undifferentiated fallopian tube carcinoma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Focus Group Sessions . testicular cancer diagnosis and provide informed consent
__label__0	study interventions are Paclitaxel . male breast carcinoma diagnosis and leptomeningeal disease
__label__0	study interventions are Capecitabine . adenocarcinoma diagnosis and no neuropathy
__label__0	study interventions are quality-of-life assessment . head and neck cancer diagnosis and endocrine therapy
__label__0	study interventions are Antibodies . brain and central nervous system tumors diagnosis and hematopoietic
__label__0	study interventions are Paclitaxel . endometrial cancer diagnosis and disease characteristics
__label__0	study interventions are Isophosphamide mustard . sarcoma soft tissue diagnosis and no previous encephalopathy of any cause or other significant neurological condition
__label__0	study interventions are Fluorouracil . lung cancer diagnosis and hepatic
__label__0	study interventions are Camptothecin . adult anaplastic astrocytoma diagnosis and protocol specific criteria
__label__0	study interventions are Leucovorin . colon mucinous adenocarcinoma diagnosis and eligible patients of reproductive potential both sexes must agree to use an accepted and effective method of contraceptive during study therapy and for at least three months after the completion of bevacizumab women must not be pregnant or breast feeding all females of childbearing potential must have serum pregnancy test to rule out pregnancy within two weeks prior to step two randomization
__label__0	study interventions are NGR-hTNF plus Best Investigator's Choice (BIC) . malignant pleural mesothelioma diagnosis and serum creatinine less_than doc uln
__label__0	study interventions are flaxseed . lung cancer diagnosis and see disease characteristics
__label__0	study interventions are Deferasirox . recurrent adult cell leukemia lymphoma diagnosis and serum glutamic oxaloacetic transaminase sgot ast and serum glutamic pyruvic transaminase sgpt alt equal_than less_than fivex upper limit of normal uln
__label__0	study interventions are Aldesleukin . stage ii cutaneous cell non hodgkin lymphoma diagnosis and no cardiac arrhythmias requiring medical treatment
__label__0	study interventions are Immunoglobulins . stage iia breast cancer diagnosis and total bilirubin equal_than less_than doc upper limits of normal
__label__0	study interventions are Sirolimus . advanced solid tumors non small cell lung cancer diagnosis and oral implantable or injectable contraceptives may be affected by cytochrome pfour hundred and fifty interactions and are therefore not considered effective for this study
__label__0	study interventions are Antibodies, Monoclonal . recurrent childhood lymphoblastic lymphoma diagnosis and prior extensive radiotherapy
__label__0	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and adequate bm functions
__label__0	study interventions are Oxaliplatin . stage iii rectal cancer diagnosis and zubrod performance status zero one
__label__0	study interventions are Accelerated Partial Breast Irradiation . cancer of breast diagnosis and no extensive intraductal component greater_than twenty-five
__label__0	study interventions are Staurosporine . unspecified adult solid tumor protocol specific diagnosis and at least three months
__label__0	study interventions are hepatic resection . hepatocellular carcinoma with pvtt diagnosis and hcc with no previous treatment
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and patient characteristics
__label__0	study interventions are Ifosfamide . stage iib ovarian cancer diagnosis and patients must have recovered from the effects of recent surgery radiotherapy or other therapy
__label__0	study interventions are Oxaliplatin . stage iib rectal cancer diagnosis and bilirubin equal_than less_than doc uln
__label__0	study interventions are Prednisolone . recurrent neuroblastoma diagnosis and evidence of widespread alveolar injury
__label__0	study interventions are Dacarbazine . esophageal large cell neuroendocrine carcinoma diagnosis and patients may not be receiving any other investigational agents while on study treatment
__label__0	study interventions are Gefitinib . breast cancer diagnosis and phenytoin
__label__0	study interventions are Capecitabine . recurrent gallbladder carcinoma diagnosis and calculated creatinine clearance greater_than equal_than fifty ml min for patients with creatinine level of doc
__label__0	study interventions are Cortisol succinate . stage childhood large cell lymphoma diagnosis and no prior chemotherapy
__label__0	study interventions are Celecoxib . non small cell lung cancer diagnosis and who performance status zero or one
__label__0	study interventions are Pharmacodynamic Studies . adult nasal type extranodal nk cell lymphoma diagnosis and patients with significant cardiovascular disease including myocardial infarction or unstable angina within six months or unstable cardiac arrhythmias are not eligible for the study
__label__0	study interventions are Methylprednisolone . myelodysplastic myeloproliferative neoplasms diagnosis and no cns or skin involvement with leukemia
__label__0	study interventions are Liposomal doxorubicin . multiple myeloma diagnosis and doc the uln and
__label__0	study interventions are Vorinostat . unspecified adult solid tumor protocol specific diagnosis and patients with biliary obstruction for which shunt has been placed are eligible provided the shunt has been in place for at least ten days prior to the first dose of vorinostat saha and liver function has stabilized
__label__0	study interventions are Irinotecan . stage iv borderline ovarian surface epithelial stromal tumor diagnosis and less than four prior chemotherapy regimens in the adjuvant and or metastatic setting part ii
__label__0	study interventions are Methotrexate . angioimmunoblastic cell lymphoma diagnosis and karnofsky performance status of greater_than equal_than seventy
__label__0	study interventions are Pertuzumab . malignant neoplasm of stomach diagnosis and agreement to remain abstinent or use single or combined contraceptive methods that result in failure rate of less_than one per year during the treatment period and for at least one2 months after the last treatment dose
__label__0	study interventions are Fludarabine . stage iii childhood anaplastic large cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Caregiver wellness videos . advanced gynecological cancer diagnosis and have access to the internet and computer tablet or smart phone and
__label__0	study interventions are Docetaxel . larynx carcinoma diagnosis and oral contraception with estrogen and gestagen no minipill vaginal ring contraception patch estrogen free ovulation suppressors hormone spiral with progesterone injection for three month with depot gestagen hormone releasing implantation luteal hormone containing rod abstinence or sterilization vasectomy of the male
__label__0	study interventions are Paclitaxel . stage grade two follicular lymphoma diagnosis and total bilirubin within normal institutional limits
__label__0	study interventions are Mycophenolate mofetil . recurrent adult diffuse small cleaved cell lymphoma diagnosis and patients will be accepted in chronic phase or accelerated phase patients who have received prior autografts after high dose therapy or have undergone intensive chemotherapy with filgrastim csf mobilized peripheral blood mononuclear cells pbmc autologous or conventional hct for advanced cml may be enrolled provided they are in cr or cp and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Camptothecin . diffuse adenocarcinoma of the stomach diagnosis and life expectancy greater_than three months
__label__0	study interventions are ispinesib . stage iv verrucous carcinoma of the oral cavity diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and otherwise they must discontinue hrt to allow confirmation of post menopausal status prior to study enrollment
__label__0	study interventions are Fluorouracil . pancreatic adenocarcinoma diagnosis and negative pregnancy test for females of childbearing potential
__label__0	study interventions are Ifosfamide . testicular choriocarcinoma and embryonal carcinoma diagnosis and negative pregnancy test
__label__0	study interventions are Laboratory Biomarker Analysis . mediastinal thymic large cell lymphoma diagnosis and provide informed written consent
__label__0	study interventions are Bortezomib . recurrent grade one follicular lymphoma diagnosis and practice effective barrier contraception during the entire study treatment period and through minimum of thirty days after the last dose of study drug or completely abstain from heterosexual intercourse for the duration of the study
__label__0	study interventions are Irinotecan . recurrent squamous cell carcinoma of the oropharynx diagnosis and no insulin dependent diabetes mellitus
__label__0	study interventions are Immunoglobulins . gliosarcoma diagnosis and for females of child bearing potential negative serum pregnancy test within fourteen days prior to entry
__label__0	study interventions are Hormones . prostatic neoplasms diagnosis and and or progressive measurable disease recist criteria
__label__0	study interventions are Celecoxib . symptomatic cns metastases must be treated surgery radiotherapy or gamma_knife neurologically stable and off steroids
__label__0	study interventions are Mycophenolic Acid . aggressive non hodgkin lymphoma diagnosis and doc ten seven kg
__label__0	study interventions are Tacrolimus . lymphoma diagnosis and lvef greater_than forty
__label__0	study interventions are Carboplatin . triple negative breast cancer diagnosis and separate baseline assessment is required if negative screening pregnancy test was obtained more than seventy-two hours before the first dose of study drug
__label__0	study interventions are BB 1101 . metastatic cancer diagnosis and no evidence of extrahepatic disease on ct scan and physical exam
__label__0	study interventions are Panobinostat . renal cancer diagnosis and patients must be clinically euthyroid patients may be on thyroid hormone replacement
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and no other medical contraindication to study therapy
__label__0	study interventions are COTI2 . peritoneal cancer diagnosis and physiologically_incapable of becoming pregnant postmenopausal or negative pregnancy test and agree to use adequate contraception
__label__0	study interventions are Fluorouracil . histologically confirmed squamous cell cancer of the head and neck suitable for treatment with radiotherapy ttwo tthree or tfour primary lesions any no distant metastasis may also be anaplastic carcinoma verrucous carcinoma or transitional cell carcinoma as of one ninety-seven no occult primaries as of one ninety-seven no adenocarcinomas lymphomas or melanomas as of one ninety-seven synchronous head and neck tumors are eligible tumor with the worse prognosis is entered into study as of one ninety-seven patients receiving surgery to neck nodes only must be randomized as surgery patients as of one ninety-seven patients with tumors of the oral cavity or oropharynx may additionally elect randomization to nodal irradiation vs
__label__0	study interventions are Fluoroquinolones . unspecified adult solid tumor protocol specific diagnosis and no prior randomization in this study
__label__0	study interventions are Vitamin B Complex . cutaneous cell lymphoma diagnosis and adequate blood liver and kidney function as defined by laboratory tests
__label__0	study interventions are Paclitaxel . stage iiia non small cell lung cancer diagnosis and alanine aminotransferase alt and aspartate aminotransferase ast equal_than less_than doc uln for the institution
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and not specified other
__label__0	study interventions are Pirfenidone . neurofibroma plexiform diagnosis and b
__label__0	study interventions are Dacarbazine . metastatic melanoma diagnosis and platelet count greater_than one hundred zero µl
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and patients must have hla identical sibling donors
__label__0	study interventions are Bevacizumab . anaplastic malignant meningioma diagnosis and patients must be able to comply with all protocol requirements
__label__0	study interventions are Liposomal doxorubicin . stage ii breast cancer diagnosis and if axillary lymph nodes are clinically negative during initial work up sentinel node biopsy will be performed prior to initiation of chemotherapy
__label__0	study interventions are Testosterone undecanoate . castration resistant metastatic prostate cancer diagnosis and a
__label__0	study interventions are pharmacological study . splenic marginal zone lymphoma diagnosis and no other serious concurrent condition
__label__0	study interventions are Deamino Arginine Vasopressin . breast cancer diagnosis and the following laboratory results obtained seven days before surgery
__label__0	study interventions are Sorafenib . metastatic colorectal cancer diagnosis and who less_than equal_than two
__label__0	study interventions are Vincristine . recurrent grade one follicular lymphoma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiia breast cancer diagnosis and total bilirubin equal_than less_than institutional upper limit of normal uln
__label__0	study interventions are Antibodies . adenocarcinoma of the gastroesophageal junction diagnosis and the use of transfusion or other intervention to achieve hemoglobin hgb greater_than equal_than doc dl is acceptable
__label__0	study interventions are Fludarabine . penile cancer diagnosis and seronegative for hiv antibody
__label__0	study interventions are Tacrolimus . lymphoma diagnosis and patient characteristics
__label__0	study interventions are Docetaxel . breast cancer diagnosis and absence of any psychological familial sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule those conditions should be discussed with the patient before registration in the trial
__label__0	study interventions are Leucovorin . colorectal cancer diagnosis and fertile patients must use effective contraception during and for one month after completion of study treatment
__label__0	study interventions are Trametinib . stage iv distal bile duct cancer diagnosis and twenty-eight days have elapsed since that therapy lesions that have not been treated with local therapy must be present and measureable
__label__0	study interventions are Niacinamide . squamous cell carcinoma
__label__0	study interventions are Vorinostat . hematologic neoplasms diagnosis and acute myelogenous leukemia
__label__0	study interventions are Dexamethasone acetate . testicular germ cell tumor diagnosis and fertile patients must use effective barrier contraception
__label__0	study interventions are Paclitaxel . malignant neoplasms of female genital organs diagnosis and subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
__label__0	study interventions are Fluorouracil . pathologically confirmed diagnosis of adenocarcinoma of the rectum by biopsy technique that does not completely excise the lesion fine needle aspiration core needle biopsy
__label__0	study interventions are Everolimus . stage iii adult diffuse mixed cell lymphoma diagnosis and ages greater_than fifty years with hematologic malignancies treatable by unrelated hematopoietic cell transplant hct
__label__0	study interventions are Fluorouracil . stage iv colon cancer diagnosis and patients with known hiv infection or known active viral hepatitis
__label__0	study interventions are Veliparib . ovarian cancer diagnosis and neuropathy sensory and motor less than or equal to grade one
__label__0	study interventions are laboratory biomarker analysis . recurrent childhood anaplastic oligodendroglioma diagnosis and patients who have undergone prior allogeneic sct and who have graft versus host disease gvhd must have controlled gvhd that is equal_than less_than grade two
__label__0	study interventions are JM 3100 . stage iv grade two follicular lymphoma diagnosis and no unacceptable risk to donor due to pre existing illness
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and subjects of child bearing potential who have not undergone bilateral salpingo oophorectomy and are sexually active must consent to use an accepted and effective non hormonal method of contraception double barrier method eg condom plus diaphragm from signing the informed consent through six months after last dose of study drug
__label__0	study interventions are Fludarabine . refractory childhood hodgkin lymphoma diagnosis and refractory or relapsed disease after standard chemotherapy
__label__0	study interventions are Letrozole . advanced metastatic breast cancer diagnosis and patient must have either measurable disease or if no measurable disease is present then at least one predominantly lytic bone lesion
__label__0	study interventions are Antibodies, Monoclonal . parathyroid gland carcinoma diagnosis and patients must have zubrod performance status of zero two
__label__0	study interventions are Foscarnet . angioimmunoblastic cell lymphoma diagnosis and informed consent
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and eastern cooperative oncology group ecog performance status zero one two or three
__label__0	study interventions are Etoposide phosphate . localized unresectable neuroblastoma diagnosis and total bilirubin equal_than less_than doc upper limit of normal uln for age and
__label__0	study interventions are Thalidomide . for female not of childbearing potential pomalidomide is contraindicated unless the exceptions mentioned in the protocol
__label__0	study interventions are Pertuzumab . locally advanced malignant neoplasm diagnosis and history of asthma given concern for blockade in this population
__label__0	study interventions are laboratory biomarker analysis . stage iii small lymphocytic lymphoma diagnosis and at least four weeks since prior radiotherapy and recovered
__label__0	study interventions are Vidarabine . recurrent adult immunoblastic large cell lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Erlotinib Hydrochloride . cancer diagnosis and no prior treatment for metastatic disease
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and postmenopausal
__label__0	study interventions are Everolimus . lymphoma diagnosis and previously treated disease
__label__0	study interventions are Vincristine . myelodysplastic myeloproliferative neoplasms diagnosis and pll
__label__0	study interventions are Dacarbazine . glioblastoma diagnosis and two
__label__0	study interventions are Lenograstim . multiple myeloma diagnosis and nursing women
__label__0	study interventions are Cisplatin . unclassifiable cell lymphoma with indeterminate features between diffuse large cell lymphoma and burkitt lymphoma
__label__0	study interventions are Pembrolizumab . advanced liver cancer diagnosis and be willing and able to provide written informed consent for the trial
__label__0	study interventions are Etoposide phosphate . extramedullary plasmacytoma diagnosis and participants must not have had prior transplant
__label__0	study interventions are Edetic Acid . bclc stage zero adult hepatocellular carcinoma diagnosis and ct features suggestive of hcc including those features which have been described herein they are also enumerated below
__label__0	study interventions are Cladribine . thymoma diagnosis and guidelines for cladribine melphalan based conditioning
__label__0	study interventions are Bevacizumab . stage iv prostate cancer diagnosis and no prior treatment with bevacizumab or other angiogenesis inhibitors
__label__0	study interventions are Fludarabine . stage iv grade two follicular lymphoma diagnosis and eastern cooperative oncology group ecog zero two
__label__0	study interventions are Antibodies . lymphoma diagnosis and cardiovascular
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and no human anti mouse antibody hama reactivity
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and diagnosis must be based on an adequate tissue sample such as an excisional biopsy or core needle biopsy
__label__0	study interventions are psychosocial assessment and care . acquaintance of an african american breast cancer survivor
__label__0	study interventions are Anticonvulsants . unspecified childhood solid tumor protocol specific diagnosis and concurrently on anticonvulsants at steady level for at least two weeks
__label__0	study interventions are Modafinil . melanoma diagnosis and hematological hemoglobin greater_than nine dl
__label__0	study interventions are Endothelial Growth Factors . stage iva oral cavity verrucous carcinoma diagnosis and no prior history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate eighty if the physician choice of chemotherapy regimen is docetaxel
__label__0	study interventions are Placebo . colon cancer diagnosis and eastern cooperative oncology group ecog performance status of zero fully active able to carry out all pre disease activities without restriction or one unable to perform physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature
__label__0	study interventions are Nivolumab . at least one measurable lesion at baseline by ct computed tomography or mri magnetic resonance imaging as per recist response evaluation criteria in solid tumors doc
__label__0	study interventions are Antibodies . recurrent renal cell carcinoma diagnosis and aspartate aminotransferase ast equal_than less_than doc upper limits of normal uln
__label__0	study interventions are Interferons . patients without bone marrow involvement by tumor with no history of bmt and with no prior cranio spinal or pelvic radiation will be considered evaluable for hematologic toxicity
__label__0	study interventions are Doxorubicin . prostate cancer diagnosis and anticipated non availability for study visits procedures
__label__0	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and platelet count fifty zero mmthree
__label__0	study interventions are Etoposide . lymphoma non hodgkin diagnosis and patients must have an echocardiogram or muga scan within forty-two days of registration
__label__0	study interventions are Albumin-Bound Paclitaxel . fallopian tube endometrioid adenocarcinoma diagnosis and bilirubin less than or equal to doc uln ctcae grade one
__label__0	study interventions are Docetaxel . prostatic neoplasms diagnosis and aspartate aminotransferase ast less_than doc uln
__label__0	study interventions are Cediranib . recurrent salivary gland carcinoma diagnosis and see disease characteristics
__label__0	study interventions are Thalidomide . central nervous system tumor pediatric diagnosis and no prior temozolomide
__label__0	study interventions are Alemtuzumab . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and planned tandem transplant is allowed for patients at high risk of relapse
__label__0	study interventions are Granisetron . testicular germ cell tumor diagnosis and no known hypersensitivity to serotonin antagonists no prior anticipatory emesis no communication impairments language problem poor mental development or impaired cerebral function that would preclude study
__label__0	study interventions are Immunoglobulins . recurrent osteosarcoma diagnosis and platelet count greater_than fifty zero ul transfusion independent
__label__0	study interventions are Rucaparib . fallopian tube cancer diagnosis and the following eligibility criteria pertain to patients enrolling into part two of the study
__label__0	study interventions are Rituximab . small lymphocytic lymphoma diagnosis and in cases of sll subjects must have at least one bidimensionally measurable lesion at least greater_than equal_than doc cm measured in one dimension
__label__0	study interventions are Etoposide . localized ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and not pregnant or nursing
__label__0	study interventions are Tetracycline . unspecified adult solid tumor protocol specific diagnosis and fertile patients must use effective non hormonal contraception
__label__0	study interventions are Topotecan . fallopian tube cancer diagnosis and histologically or cytologically confirmed unresectable gynecologic malignancy for which standard curative or palliative care is not available
__label__0	study interventions are Pembrolizumab . esophageal cancer diagnosis and demonstrate adequate organ function as defined below all screening labs should be performed within ten days of treatment initiation
__label__0	study interventions are Carmustine . lymphoma diagnosis and biologic therapy
__label__0	study interventions are Aldesleukin . lymphoma diagnosis and brain biopsy
__label__0	study interventions are Fludarabine . metachromatic_leukodystrophy
__label__0	study interventions are Hydrocortisone 17-butyrate 21-propionate . anaplastic large cell lymphoma diagnosis and at least three months since prior biologic antineoplastic agents
__label__0	study interventions are Busulfan . recurrent ovarian germ cell tumor diagnosis and females of reproductive age who are not using adequate birth control measures or who are pregnant
__label__0	study interventions are Tacrolimus . plasma cell neoplasms diagnosis and adequate liver function as defined by serum bilirubin less_than or equal_than doc ast or alt less_than or equal_than doc upper limit of normal
__label__0	study interventions are Carboplatin . spinal mri imaging with and without gadolinium is required within ten days of surgery if done pre operatively or within twenty-eight days of surgery if done post operatively for posterior_fossa tumors pre operative mri scans are preferred
__label__0	study interventions are Pemetrexed . mesothelioma diagnosis and within twenty-eight days if negative
__label__0	study interventions are BB 1101 . patients whose tumors that are equal_than less_than one cm from the ventricular system are eligible if there is sufficient space within the tumor cavity and or residual tumor to perform the hsv one7one6 injections that are greater_than equal_than one cm from the ventricular system
__label__0	study interventions are Estradiol . metastatic breast cancer diagnosis and use of bisphosphonates are allowed
__label__0	study interventions are Thalidomide . anaplastic astrocytoma diagnosis and total bilirubin less than doc times upper limit of normal
__label__0	study interventions are Cyclosporins . noncontiguous stage ii grade one follicular lymphoma diagnosis and highly active antiretroviral therapy haart is initiated within one month of hematopoietic cell transplant
__label__0	study interventions are Tacrolimus . lymphoma diagnosis and life expectancy
__label__0	study interventions are Fluorodeoxyglucose F18 . squamous cell carcinoma of the head and neck diagnosis and patient who provided written informed consent
__label__0	study interventions are Mycophenolic Acid . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and donor
__label__0	study interventions are huC242-DM4 . metastatic or locally advanced gastric cancer diagnosis and hematopoietic
__label__0	study interventions are Aldesleukin . recurrent osteosarcoma diagnosis and at least seven days since the last dose of growth factor therapy
__label__0	study interventions are Radiotherapy . lung cancer diagnosis and patients with totally resected intraparenchymal brain metastases not all lesions need be resected if all other criteria are satisfied no more than six total lesions
__label__0	study interventions are Irinotecan . stage iva rectal cancer diagnosis and serum glutamic oxaloacetic transaminase sgot and serum glutamic pyruvate transaminase sgpt less_than doc upper limit of normal for patients without liver metastases or sgot and sgpt less_than five upper limit of normal for patients with liver metastases
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and age
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are Cyclophosphamide . stage adult immunoblastic large cell lymphoma diagnosis and crtwo
__label__0	study interventions are Dacarbazine . recurrent neuroblastoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate at least seventy ml min
__label__0	study interventions are Tremelimumab . stage iv non small cell lung cancer diagnosis and creatinine within normal institutional limits or
__label__0	study interventions are Vaccines . stage ii small lymphocytic lymphoma diagnosis and complex karyotype greater_than equal_than three cytogenetic abnormalities on stimulated karyotype
__label__0	study interventions are Cyclophosphamide . unspecified childhood solid tumor protocol specific diagnosis and cns disease
__label__0	study interventions are Vinorelbine . prostate cancer diagnosis and renal
__label__0	study interventions are Irinotecan . bladder cancer diagnosis and hematopoietic
__label__0	study interventions are Vaccines . triple negative breast neoplasms diagnosis and able to understand and willing to sign an irb approved written informed consent document
__label__0	study interventions are Fludarabine . melanoma diagnosis and patients may have undergone minor surgical procedures within the past three weeks as long as all toxicities have recovered to grade one or less or as specified in the eligibility criteria
__label__0	study interventions are Folic Acid . stage iv extragonadal seminoma diagnosis and no concurrent participation in another investigational treatment clinical trial
__label__0	study interventions are Bortezomib . stage iv adult diffuse small cleaved cell lymphoma diagnosis and no prior radiotherapy that potentially included the heart in the field mantle or chest
__label__0	study interventions are Vidarabine . refractory plasma cell myeloma diagnosis and eastern cooperative oncology group ecog equal_than less_than two
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and evaluation for metastatic disease is not required in the absence of symptoms
__label__0	study interventions are Trastuzumab . diffuse adenocarcinoma of the stomach diagnosis and all subjects must have the ability to understand and the willingness to sign written informed consent
__label__0	study interventions are Everolimus . adult giant cell glioblastoma diagnosis and women must agree not to breast feed
__label__0	study interventions are Melphalan . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and pulmonary function tests diffusing capacity of the lung for carbon monoxide dlco or diffusing volume of the alveolar volume dlva greater_than equal_than fifty predicted dlco to be corrected for hemoglobin and or alveolar ventilation
__label__0	study interventions are triapine . kidney cancer diagnosis and no active peptic ulcer disease
__label__0	study interventions are Cyclophosphamide . hertwo positive breast carcinoma diagnosis and may have received up to four weeks of tam therapy or any other hormonal agent for this malignancy
__label__0	study interventions are Fludarabine . skin cancer diagnosis and clinical performance status of eastern cooperative oncology group ecog zero or one
__label__0	study interventions are Doxorubicin . stage iv breast cancer diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Immunoglobulin Idiotypes . lung cancer diagnosis and no prior colitis inflammatory bowel disease or pancreatitis within the past ten years
__label__0	study interventions are Pemetrexed . advanced gastric carcinoma diagnosis and hepatic
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv gastric cancer diagnosis and normal cardiac ejection fraction by echocardiogram or muga greater than osu lower limit of normal
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and fcbp must also agree to ongoing pregnancy testing
__label__0	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the larynx diagnosis and absolute neutrophil count anc greater_than equal_than doc ten nine l
__label__0	study interventions are Carboplatin . lymphoma diagnosis and no hla identical sibling donor available
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and no prior bone marrow or ex vivo engineered or processed graft cdthirty-four positive enrichment cell depletion etc
__label__0	study interventions are Veliparib . adenocarcinoma of the stomach diagnosis and anc greater_than one five hundred mm³
__label__0	study interventions are Vincristine . cns brain cancer diagnosis and patients must sign an informed consent
__label__0	study interventions are Oxaliplatin . islet cell tumor diagnosis and creatinine ratio less_than doc
__label__0	study interventions are Dideoxynucleosides . brain and central nervous system tumors diagnosis and platelets greater_than one hundred zero µl
__label__0	study interventions are Vaccines . patient is agreeable to allow tumor and normal tissue samples to be submitted for complete exome and transcriptome sequencing
__label__0	study interventions are Mycophenolate mofetil . recurrent adult lymphoblastic lymphoma diagnosis and any relapse or primary refractory disease
__label__0	study interventions are Mycophenolate mofetil . recurrent adult hodgkin lymphoma diagnosis and age greater_than equal_than twelve years of age
__label__0	study interventions are Romidepsin . stage iv breast cancer diagnosis and performance status
__label__0	study interventions are Vinorelbine . cancer diagnosis and the patients must have previously received at least one cycle of chemotherapy
__label__0	study interventions are Mycophenolic Acid . recurrent grade three follicular lymphoma diagnosis and must have failed two lines of conventional therapy and must be refractory to fludarabine this includes patients who fail to have complete or partial response after therapy with regimen containing fludarabine or another nucleoside_analog or experience disease relapse within 1two months after completing therapy with regimen containing fludarabine or another nucleoside_analog
__label__0	study interventions are Cadexomer iodine . stage iva follicular thyroid cancer diagnosis and patient must have demonstrated evidence of disease progression by recist criteria using site assessment of computed tomography ct magnetic resonance imaging mri scans within twelve months positive one month to allow for variances in patient scanning intervals prior to study entry or by greater_than fifty increase in suppressed thyroglobulin levels during this time period
__label__0	study interventions are Gemcitabine . stage ivb extrahepatic bile duct cancer diagnosis and life expectancy greater_than equal_than three months
__label__0	study interventions are Cyclophosphamide . skin cancer diagnosis and patients who are hiv seropositive can have decreased immune competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities
__label__0	study interventions are Tacrolimus . contiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and white blood cells wbc difficult to control greater_than fifty ten nine despite therapy
__label__0	study interventions are Mocetinostat . patients who have been treated with any investigational drug or anti cancer therapy within thirty days of study start
__label__0	study interventions are Antibodies, Monoclonal . cervical adenosquamous carcinoma diagnosis and hemoglobin greater_than equal_than doc dl patients may be transfused to meet hemoglobin hgb requirement
__label__0	study interventions are Cediranib . recurrent primary peritoneal carcinoma diagnosis and no more than one prior line of therapy in the platinum resistant refractory setting
__label__0	study interventions are motesanib diphosphate . prior radiotherapy for localized cancer of the breast head and neck or skin allowed provided it was completed greater_than three years ago and the patient remains free of recurrent or metastatic disease
__label__0	study interventions are Etoposide . multiple myeloma diagnosis and patient must be greater_than eighteen years of age
__label__0	study interventions are Vaccines . prostate cancer diagnosis and subject has adequate bone marrow function as defined by an absolute lymphocyte count alc greater_than five hundred µl absolute neutrophil count anc greater_than one thousand, two hundred µl platelet count greater_than one hundred zero µl
__label__0	study interventions are Antibodies . have diagnosis of histologically cytologically confirmed advanced no negative small cell lung cancer nsclc
__label__0	study interventions are Diphosphonates . solitary osseous plasmacytoma diagnosis and for all patients
__label__0	study interventions are Capecitabine . breast cancer diagnosis and prior treatment must have included both an anthracycline doxorubicin or epirubicin and taxane paclitaxel or docetaxel
__label__0	study interventions are Cyclophosphamide . melanoma skin diagnosis and no prior significant mediastinal or lung radiation for total body irradiation cohort
__label__0	study interventions are Oxaliplatin . esophageal cancer diagnosis and cardiovascular
__label__0	study interventions are Silicon phthalocyanine . precancerous condition diagnosis and hematopoietic
__label__0	study interventions are Epirubicin . total mastectomy with negative margins breast conserving procedure lumpectomy or quadrantectomy for tumors less than five cm adequate re resection or mastectomy within four weeks of initial surgery required if margins are positive after initial surgery axillary clearance not sampling required at surgery with at least one node positive upon histopathologic examination of at least eight nodes suspicious manifestations of metastatic disease hot spots on bone scan skeletal pain of unknown cause must be proven benign no bilateral breast cancer any mass in contralateral breast must be proven benign by biopsy
__label__0	study interventions are Antibodies, Monoclonal . recurrent primary peritoneal carcinoma diagnosis and participants of childbearing potential must have negative urine or serum pregnancy within seventy-two hours prior to receiving the first dose of study medication if the urine test is positive or cannot be confirmed as negative serum pregnancy test will be required
__label__0	study interventions are Cyclosporins . recurrent adult immunoblastic large cell lymphoma diagnosis and patients must have no history of acute myocardial infarction in the six months prior to transplantation angina pectoris requiring nitrate therapy uncontrolled major ventricular dysrhythmia uncontrolled hypertension or uncontrolled congestive heart failure
__label__0	study interventions are Antilymphocyte Serum . left ventricular ef greater_than equal_than forty-five with no uncontrolled arrythmias or symptomatic heart disease
__label__0	study interventions are Busulfan . unspecified adult solid tumor protocol specific diagnosis and see disease characteristics
__label__0	study interventions are Vaccines . stage ib breast cancer diagnosis and blood glucose equal_than less_than uln for the performing laboratory
__label__0	study interventions are Cyclophosphamide . contiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and adequately matched unrelated donor available
__label__0	study interventions are Casopitant . is scheduled to receive oxaliplatin at dose between eighty-five mg mtwo and one hundred and thirty mg mtwo in their first cycle of therapy for the treatment of colorectal cancer administered as single iv dose over two six hours on day one only in combination with fivefu lv or in combination with capecitabine
__label__0	study interventions are Albumin-Bound Paclitaxel . endometrial clear cell adenocarcinoma diagnosis and upc ratio of spot urine is an estimation of the twenty-four urine protein excretion
__label__0	study interventions are Bortezomib . stage iii urethral cancer diagnosis and creatinine equal_than less_than doc mg dl or measured or calculated creatinine clearance greater_than thirty ml min
__label__0	study interventions are Vidarabine . childhood burkitt lymphoma diagnosis and hodgkin disease hd
__label__0	study interventions are Liposomal doxorubicin . unspecified childhood solid tumor protocol specific diagnosis and more than six months since prior substantial bone marrow irradiation cranio spinal irradiation total body irradiation or hemi pelvic irradiation
__label__0	study interventions are Everolimus . stage iv renal cell cancer diagnosis and no malabsorption syndrome or other condition that would interfere with intestinal absorption
__label__0	study interventions are Carboplatin . primary peritoneal cavity cancer diagnosis and at least one unidimensionally measurable lesion greater_than twenty mm by conventional techniques including palpation_plain ray ct scan or mri or greater_than one0 mm by spiral ct scan
__label__0	study interventions are Silicon phthalocyanine . metastatic cancer diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Antibodies, Monoclonal . adenocarcinoma of the prostate diagnosis and patients enrolled on calgb ninety thousand, two hundred and two who have documented disease progression and have received at least four weeks of open label zoledronic acid treatment are eligible for this study
__label__0	study interventions are Lenalidomide . stage iv grade three follicular lymphoma diagnosis and bone marrow biopsies as the sole means of diagnosis are not acceptable but they may be submitted in conjunction with nodal biopsies fine needle aspirates are not acceptable for diagnosis
__label__0	study interventions are Etoposide phosphate . stage ii cutaneous cell non hodgkin lymphoma diagnosis and cardiac ejection fraction greater_than equal_than forty-five or clearance by cleveland clinic ccf physician
__label__0	study interventions are Angiotensinogen . newly diagnosed glioblastoma diagnosis and patients eligible for radiotherapy and concomitant temozolomide
__label__0	study interventions are alvespimycin hydrochloride . intraocular lymphoma diagnosis and no poorly controlled angina
__label__0	study interventions are Rituximab . lymphoma diagnosis and unilateral bone marrow biopsy allowed
__label__0	study interventions are Everolimus . childhood fibrosarcoma diagnosis and serum glutamic pyruvate transaminase sgpt alanine aminotransaminase alt less_than doc times uln for the purpose of this study the uln for sgpt is forty-five l
__label__0	study interventions are Carboplatin . recurrent transitional cell cancer of the renal pelvis and ureter diagnosis and calculated creatinine clearance will be used to assess renal function
__label__0	study interventions are Cyclosporine . noncontiguous stage ii marginal zone lymphoma diagnosis and reductions of greater_than equal_than fifty in greatest diameter of all sites of known disease and no new sites
__label__0	study interventions are Proxinium . head and neck neoplasms diagnosis and the patient must have adequate hepatic function alanine aminotransferase alt and aspartate aminotransferase ast less_than doc upper limit of normal uln and bilirubin level less_than doc uln
__label__0	study interventions are Rubitecan . pancreatic cancer diagnosis and no concurrent immunotherapy chemotherapy
__label__0	study interventions are Vidarabine . recurrent adult diffuse large cell lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Antilymphocyte Serum . multiple myeloma and plasma cell neoplasm diagnosis and ast alt less than three times normal
__label__0	study interventions are Tacrolimus . stage adult immunoblastic large cell lymphoma diagnosis and use of cell depletion or rabbit_antithymocyte globulin to prevent acute gvhd
__label__0	study interventions are Fluorouracil . head and neck cancers diagnosis and hemoglobin greater_than nine zero dl
__label__0	study interventions are Fludarabine phosphate . type one papillary renal cell carcinoma diagnosis and must have received prior chemotherapy consolidation of chemotherapy by autografting prior to nonmyeloablative hsct is permitted
__label__0	study interventions are Bevacizumab . glioblastoma diagnosis and they have recovered from the effects of surgery and are at least four weeks from craniotomy or at least one week from stereotactic biopsy
__label__0	study interventions are Irinotecan . recurrent colon cancer diagnosis and white blood cell count wbc greater_than equal_than three zero mm three
__label__0	study interventions are Paclitaxel . advanced stage endometrial cancer stage three or four
__label__0	study interventions are Dacarbazine . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and acute lymphoblastic leukemias all
__label__0	study interventions are Methylprednisolone acetate . multiple myeloma and plasma cell neoplasm diagnosis and not specified hematopoietic
__label__0	study interventions are Prednisone . prostate cancer diagnosis and no history of severe hypersensitivity reaction to other drugs formulated with polysorbate eighty
__label__0	study interventions are Erlotinib Hydrochloride . stage iv squamous cell carcinoma of the hypopharynx diagnosis and creatinine within normal institutional limits or creatinine clearance greater_than sixty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Counselor-Initiated Tobacco Quit Line . participants is cancer survivor
__label__0	study interventions are ASN002 MTD . lymphoma follicular diagnosis and subject is willing and able to comply with all protocol required visits and assessments
__label__0	study interventions are Fluorouracil . breast cancer diagnosis and fev normal
__label__0	study interventions are Tacrolimus . contiguous stage ii adult diffuse large cell lymphoma diagnosis and partial remission
__label__0	study interventions are Antibodies . stage iii squamous cell carcinoma of the hypopharynx diagnosis and general history and physical examination by radiation oncologist and or medical oncologist within eighty-four days prior to registration
__label__0	study interventions are Ritonavir . refractory plasma cell myeloma diagnosis and lymphocytosis greater_than equal_than five thousand in peripheral blood
__label__0	study interventions are Antibodies . tongue cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are laboratory biomarker analysis . peripheral cell lymphoma diagnosis and patients with any performance status are eligible for enrollment
__label__0	study interventions are Moxifloxacin . precancerous condition diagnosis and see disease characteristics
__label__0	study interventions are Topotecan . ovarian cancer diagnosis and surgery
__label__0	study interventions are Serotonin Uptake Inhibitors . cancer diagnosis and either enrolled in the ohsu radiology oncology clinic or va palliative care and living within one hundred and twenty miles of the portland vamc
__label__0	study interventions are Irinotecan . pancreatic cancer diagnosis and creatinine clearance greater_than sixty ml min
__label__0	study interventions are Gemcitabine . bladder cancer diagnosis and no nonsteroidal anti inflammatory drugs for at least five days before during and for two days after administration of pemetrexed_disodium
__label__0	study interventions are Fludarabine . lymphoma diagnosis and in crone meeting one of the following criteria
__label__0	study interventions are Thiotepa . breast cancer diagnosis and karnofsky ninety one hundred life expectancy
__label__0	study interventions are AVX901 . ii histologically confirmed gastric esophageal or gastroesophageal adenocarcinoma that is metastatic or locally recurrent seventh_edition of the ajcc tnm system and measurable or non measurable by recist doc criteria with hertwo neu overexpression by immunohistochemistry two positive three positive or fish positive and progressive disease despite having received at least one prior hertwo targeted therapy for minimum of nine weeks duration determined by their physician
__label__0	study interventions are Cyclophosphamide . lymphoma cell diagnosis and total bilirubin less than or equal to doc mg dl
__label__0	study interventions are Cyclosporine . contiguous stage ii grade two follicular lymphoma diagnosis and must have less_than five blasts at the time of transplant
__label__0	study interventions are Talazoparib . adult solid neoplasm diagnosis and there is no line limit for the dose escalation cohort and the dose expansion cohort
__label__0	study interventions are Cyclosporins . recurrent mantle cell lymphoma diagnosis and chronic lymphocytic leukemia
__label__0	study interventions are Mitomycin . liver cancer diagnosis and patients with no limitation of activities they suffer no symptoms from ordinary activities class ii
__label__0	study interventions are Bevacizumab . patients with progressive metastatic renal cell carcinoma
__label__0	study interventions are Tegafur . patients with advanced or metastatic solid tumors diagnosis and platelet count greater_than one hundred zero mmthree iu
__label__0	study interventions are Temozolomide . stage iv skin melanoma diagnosis and female patients may be considered to not be of childbearing potential for the following reasons
__label__0	study interventions are Mycophenolate mofetil . lymphoma diagnosis and patients must have three partially hla matched ucb units
__label__0	study interventions are Etoposide . adult burkitt lymphoma diagnosis and female patients must meet one of the following criteria
__label__0	study interventions are Docetaxel . head and neck squamous cell carcinoma diagnosis and written informed consent
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and surgery
__label__0	study interventions are pharmacological study . unspecified adult solid tumor protocol specific diagnosis and no serologic positivity for hepatitis b or history of liver disease or other forms of hepatitis or cirrhosis
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and female patients greater_than eighteen years of age
__label__0	study interventions are Antibodies, Monoclonal . multiple myeloma and plasma cell neoplasm diagnosis and scheduled to undergo autologous hematopoietic stem cell transplantation hsct as consolidation treatment for mm
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and stage iv disease
__label__0	study interventions are Antibodies . stage ii adult cell leukemia lymphoma diagnosis and note
__label__0	study interventions are Rituximab . stage grade three follicular lymphoma diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least fifty miu ml within ten
__label__0	study interventions are Prednisolone phosphate . recurrent childhood lymphoblastic lymphoma diagnosis and myeloproliferative and lymphoproliferative disorder negative must have evidence of disease acceleration to be candidate for umbilical cord blood transplant myeloproliferative disorders eligible for transplant include chronic myelomonocytic leukemia cmml with high ipss score and myelofibrosis
__label__0	study interventions are Liposomal doxorubicin . stage iii adenoid cystic carcinoma of the oral cavity diagnosis and creatinine normal
__label__0	study interventions are Etoposide phosphate . glioblastoma diagnosis and patients should be on non increasing dose of steroids for greater_than seven days prior to obtaining baseline mri with gadolinium gd mri of brain
__label__0	study interventions are Perifosine . extra skeletal myxoid chondrosarcomas diagnosis and platelets greater_than seventy-five zero mmthree
__label__0	study interventions are SIR Spheres intra-arterial hepatic . colorectal neoplasm diagnosis and world health organization who performance status ps less_than equal_than two
__label__0	study interventions are Piritrexim . urethral cancer diagnosis and no active unresolved infection no concurrent parenteral antibiotics at least seven days since parenteral antibiotics no history of prior malignancy within five years except
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and doc the uln
__label__0	study interventions are Paclitaxel . ovarian clear cell cystadenocarcinoma diagnosis and neuropathy sensory and motor less than or equal to ctcae grade one
__label__0	study interventions are Etoposide phosphate . localized unresectable neuroblastoma diagnosis and mycn amplification greater_than four fold increase in mycn signals as compared to reference signals and age greater_than equal_than three hundred and sixty-five days regardless of additional biologic features
__label__0	study interventions are Sorafenib . refractory hurthle cell thyroid cancer diagnosis and grade three or four thromboembolic event
__label__0	study interventions are Cetuximab . anal cancer diagnosis and basaloid
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and use of any medication which is strong inhibitor or inducer of cytochrome pfour hundred and fifty isoform cypthreeafour see appendix five
__label__0	study interventions are 10-deazaaminopterin . recurrent esophageal adenocarcinoma diagnosis and transaminases equal_than less_than three uln for documented liver metastases transaminases up to five uln is permitted
__label__0	study interventions are Cisplatin . primary peritoneal cancer diagnosis and adequate bone marrow renal and hepatic function as defined by wbcthree thousandcells mcl platelets one hundred zero mcl serum creatinine twomg dcl bilirubin doc times normal and sgot three times normal
__label__0	study interventions are Cyclophosphamide . noncontiguous stage ii small lymphocytic lymphoma diagnosis and one peripheral blood lymphocyte count of greater_than five zero mm three consisting of small to moderate size lymphocytes with less_than fivefive prolymphocytes
__label__0	study interventions are Prednisolone acetate . precancerous nonmalignant condition diagnosis and disease characteristics
__label__0	study interventions are Melphalan . recurrent childhood lymphoblastic lymphoma diagnosis and relapsed or refractory after front line therapy
__label__0	study interventions are Sunitinib . stage iv pancreatic cancer diagnosis and rifabutin
__label__0	study interventions are Cyclophosphamide . multiple myeloma diagnosis and ages eighteen to seventy-five years old
__label__0	study interventions are Imiquimod . melanoma skin diagnosis and no known or suspected allergy to any component of the study vaccines
__label__0	study interventions are Cisplatin . central nervous system tumor pediatric diagnosis and karnofsky fifty one hundred or
__label__0	study interventions are Thalidomide . stage ii multiple myeloma diagnosis and relapse or progressive disease according to uniform response criteria within two years after starting first line therapy or within two years after autologous stem cell transplant
__label__0	study interventions are Laboratory Biomarker Analysis . stage iiic fallopian tube cancer diagnosis and hemoglobin greater_than eleveng dl
__label__0	study interventions are BB 1101 . recurrent marginal zone lymphoma diagnosis and hemoglobin equal_than less_than eleven dl
__label__0	study interventions are Cisplatin . unspecified adult solid tumor protocol specific diagnosis and no grade two or greater peripheral neuropathy
__label__0	study interventions are Oxaliplatin . advanced hepatocellular carcinoma diagnosis and total bilirubin of less than doc upper limit of normal
__label__0	study interventions are nutrition education . breast cancer diagnosis and pg sga
__label__0	study interventions are Liposomal doxorubicin . stage iiic breast cancer diagnosis and ecog zero one
__label__0	study interventions are Vaccines . triple negative breast cancer diagnosis and ast alt less_than doc institutional upper limit of normal
__label__0	study interventions are Lenograstim . unless bone marrow involvement by tumor absolute neutrophil count greater than one zero mmthree platelet count greater than one00 zero mmthree hepatic
__label__0	study interventions are Ifosfamide . sarcoma diagnosis and bilirubin no greater than doc times upper limit of normal uln sgot less than doc times uln renal
__label__0	study interventions are Antibodies . recurrent prostate cancer diagnosis and bilirubin less_than doc upper limits of normal
__label__0	study interventions are Etoposide . neuroblastoma diagnosis and the recipient will later need to meet specific eligibility criterion at the time of the autologous stem cell infusion
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and psoriasis
__label__0	study interventions are Etoposide . stage iiia non small cell lung cancer diagnosis and no other concurrent investigational drugs
__label__0	study interventions are Antibodies, Monoclonal . ovarian mucinous cystadenocarcinoma diagnosis and activated prothrombin time aptt equal_than less_than doc uln
__label__0	study interventions are Fludarabine . stage iv marginal zone lymphoma diagnosis and human leukocyte antigen hla genotypically phenotypically identical donor if more than one hla identical sibling is available priority will be given to donors matched for cytomegalovirus cmv status abo_titer and sex
__label__0	study interventions are Capecitabine . recurrent metastatic squamous neck cancer with occult primary diagnosis and have received treatment within the last thirty days prior to study entry with any drug that has not received regulatory approval for an indication at the time of study entry
__label__0	study interventions are Antibodies . recurrent marginal zone lymphoma diagnosis and there is no indication for an autologous transplantation as treatment option
__label__0	study interventions are Liposomal doxorubicin . ovarian cancer diagnosis and subjects must have had at least one platinum containing chemotherapy regimen and no more than total of three dna damaging or cytotoxic regimens in the last five years
__label__0	study interventions are Tacrolimus . t lymphoblastic lymphoma diagnosis and complex karyotype greater_than equal_than three abnormalities or
__label__0	study interventions are Aminolevulinic Acid . women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__0	study interventions are Busulfan . hodgkin lymphoma diagnosis and myelodysplastic syndrome
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and advanced myelofibrosis
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and not specified
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic pancreatic adenocarcinoma diagnosis and patients must have life expectancy of greater_than equal_than twelve weeks
__label__0	study interventions are Cortisone acetate . stage ii prostate adenocarcinoma diagnosis and medications known to lower the seizure threshold must be discontinued or substituted at least four weeks prior to study entry
__label__0	study interventions are Epirubicin . breast cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Mycophenolic Acid . stage iv mantle cell lymphoma diagnosis and patients will be accepted beyond chronic phase one cpone if they have received previous myelosuppressive chemotherapy or hsct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Paclitaxel . triple negative breast cancer diagnosis and female greater_than eighteen years old
__label__0	study interventions are Cyclophosphamide . small intestine cancer diagnosis and chronic lymphocytic leukemia in cr or pr two or greater
__label__0	study interventions are Azacitidine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and more than thirty blasts in bone marrow of patients with aml
__label__0	study interventions are Trastuzumab . stage ii breast cancer diagnosis and women of reproductive potential must be non pregnant and non nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to six months following treatment
__label__0	study interventions are Veliparib . small cell carcinoma diagnosis and phase ii
__label__0	study interventions are Temozolomide . osteosarcoma diagnosis and pathologic confirmation of the diagnosis either at original diagnosis or recurrence
__label__0	study interventions are Pharmacological Study . recurrent cell non hodgkin lymphoma diagnosis and life expectancy greater_than equal_than three months
__label__0	study interventions are quality-of-life assessment . ovarian cancer diagnosis and no clotting disorders including hemophilia
__label__0	study interventions are Albumin-Bound Paclitaxel . childhood extracranial germ cell tumor diagnosis and at least two weeks since prior local palliative radiotherapy small port
__label__0	study interventions are Vinblastine . childhood nodular lymphocyte predominant hodgkin lymphoma diagnosis and platelet count greater_than equal_than seventy-five zero mm three transfusion independent for patients with no bone marrow involvement
__label__0	study interventions are Dasatinib . cholangiocarcinoma diagnosis and pt ptt less_than doc uln
__label__0	study interventions are Cladribine . lymphoma diagnosis and cdtwenty positive disease
__label__0	study interventions are AUY922 . adenocarcinoma of the pancreas diagnosis and hematological
__label__0	study interventions are Standard Salvage Radiation Treatment (SSRT) . prostate adenocarcinoma diagnosis and zubrod performance status less_than two
__label__0	study interventions are Paclitaxel . fallopian tube cancer diagnosis and life expectancy greater_than sixteen weeks
__label__0	study interventions are Fluorouracil . unspecified adult solid tumor protocol specific diagnosis and no cardiac arrhythmia
__label__0	study interventions are Patients undergo cVATS lobectomy . histologically confirmed nsclc adenocarcinoma in situ or with microinvasion
__label__0	study interventions are Razoxane . cutaneous cell non hodgkin lymphoma diagnosis and doc mg dl male or doc mg dl female thirteen to less_than sixteen years of age
__label__0	study interventions are Carboplatin . carcinoma squamous cell diagnosis and able to care for self
__label__0	study interventions are Sirolimus . cervical squamous cell carcinoma diagnosis and if profile matches more than one treatment arm final decision for treatment arm assignment to be made by patients treating physician it will be required for the genomic aberration to be identified through test in clinical laboratory improvement_amendments clia_workflow assays used will range from single gene abnormalities fluorescent in situ hybridization fish for human epidermal growth factor receptor two erbbtwo amplifications to next generation sequencing based gene panels_foundation one to more comprehensive assays such as whole exome_sequencing the mayo clinic gtb will serve as the centralized point of data synthesis to allow for assessment of molecular profiling_accomplished through heterogeneous_array of tests
__label__0	study interventions are Endothelial Growth Factors . recurrent primary peritoneal carcinoma diagnosis and patients must have signed an approved informed consent and authorization permitting release of personal health information
__label__0	study interventions are Rituximab . non hodgkin lymphoma diagnosis and do not share drug with other person
__label__0	study interventions are Hydrocortisone acetate . prostate cancer diagnosis and orchiectomy allowed
__label__0	study interventions are cytology specimen collection procedure . stage iv melanoma diagnosis and patient must have the ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Letrozole . ductal carcinoma in situ diagnosis and concurrent use of hormone replacement therapy
__label__0	study interventions are Etoposide phosphate . histologically confirmed non small cell lung cancer with clinical stage of iiia
__label__0	study interventions are laboratory biomarker analysis . breast cancer diagnosis and endocrine therapy
__label__0	study interventions are Bevacizumab . lung cancer diagnosis and more than ten days since prior and no concurrent daily treatment with acetylsalicylic acid greater_than three hundred and twenty-five mg day or nsaids known to inhibit platelet function for chronic conditions group one
__label__0	study interventions are Erlotinib Hydrochloride . familial adenomatous polyposis diagnosis and urinary protein and urinary casts within institutional limits of normal
__label__0	study interventions are Aldesleukin . gestational_trophoblastic tumor diagnosis and see disease characteristics
__label__0	study interventions are Immunoglobulins . anaplastic malignant meningioma diagnosis and focbp must have negative serum or urine pregnancy test within fourteen days prior to registration on study
__label__0	study interventions are Gemcitabine . non resectable cholangiocarcinoma diagnosis and total bilirubin less_than doc upper limit of normal uln if patient has known gilbert syndrome direct bilirubin less_than doc uln
__label__0	study interventions are Celecoxib . malignant peritoneal mesothelioma diagnosis and age equal to eighteen years or older
__label__0	study interventions are Antibodies . endometrial papillary serous carcinoma diagnosis and inadequately controlled hypertension defined as systolic bp blood pressure greater_than one hundred and fifty mm hg and or diastolic bp greater_than ninety mm hg on antihypertensive medications
__label__0	study interventions are Antibodies, Monoclonal . recurrent lymphoepithelioma of the nasopharynx diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Antibodies, Monoclonal . stage ii childhood small noncleaved cell lymphoma diagnosis and isolated intracerebral mass
__label__0	study interventions are MLC Tracking . neoplasms diagnosis and maximum of three metastases to the lung from any non haematological malignancy
__label__0	study interventions are Satraplatin . prostate cancer diagnosis and this includes patients whose psa never becomes detectable
__label__0	study interventions are Rituximab . lymphoma diagnosis and no severe cardiac arrhythmias
__label__0	study interventions are Vidarabine . lymphoma diagnosis and in first relapse or beyond
__label__0	study interventions are Prednisone . adenocarcinoma of the prostate diagnosis and pleural or pericardial effusions ascites
__label__0	study interventions are Gene transfer . examples of major life threatening congenital anomalies include but are not limited to
__label__0	study interventions are Prednisolone acetate . angioimmunoblastic cell lymphoma diagnosis and acute and chronic leukemia patients must be age equal_than less_than fifty years patients up to age sixty years for any of these diseases who have syngeneic donor are eligible
__label__0	study interventions are Tacrolimus . childhood immunoblastic large cell lymphoma diagnosis and myelofibrosis and cmml
__label__0	study interventions are Leucovorin . stage ivb colorectal cancer diagnosis and platelet count greater_than equal_than one hundred zero per mm three
__label__0	study interventions are Antineoplastic Agents . lung cancer diagnosis and no known resistance to epoetin administration
__label__0	study interventions are Dactinomycin . pleuropulmonary_blastoma diagnosis and also where appropriate
__label__0	study interventions are Pemetrexed . non small cell lung cancer stage iiia diagnosis and no severe perioperative complications and expected postoperative lifespan greater_than four months
__label__0	study interventions are Methylprednisolone acetate . lung cancer diagnosis and undergone clinical fdg pet ct scan within fourteen days of enrollment
__label__0	study interventions are Dacarbazine . medulloblastoma diagnosis and patients must have received their last dose of nitrosourea including gliadel at least six six weeks prior to study registration
__label__0	study interventions are Pembrolizumab . fallopian tube carcinoma diagnosis and age greater_than eighteen years
__label__0	study interventions are Bevacizumab . stage iib fallopian tube cancer diagnosis and absolute neutrophil count anc greater than or equal to one five hundred mcl this anc cannot have been induced or supported by granulocyte colony stimulating factors
__label__0	study interventions are comparison of screening methods . lung cancer diagnosis and at least five years hematopoietic
__label__0	study interventions are questionnaire administration . metastatic cancer diagnosis and initial pain score greater_than four on scale of zero 1zero for the question please rate your pain by circling the one number that best describes your pain at its worst in the past 2four hours on the cleeland brief pain inventory
__label__0	study interventions are Staurosporine . recurrent breast cancer diagnosis and concurrent subcutaneous heparin allowed
__label__0	study interventions are Antibodies, Monoclonal . brain and central nervous system tumors diagnosis and three and over
__label__0	study interventions are Gemcitabine . ovarian cancer diagnosis and operated patients
__label__0	study interventions are laboratory biomarker analysis . stage iv basal cell carcinoma of the lip diagnosis and performance status
__label__0	study interventions are Fenretinide . bladder cancer diagnosis and triglyceride level less than doc times uln
__label__0	study interventions are selumetinib . stage iiia gallbladder cancer diagnosis and platelets greater_than equal_than one hundred zero µl
__label__0	study interventions are Fludarabine phosphate . metastatic cancer diagnosis and women of child bearing potential must have negative pregnancy test because of the potentially dangerous effects of the treatment on the fetus
__label__0	study interventions are Antibodies . stage iiic ovarian cancer diagnosis and urinalysis less_than two positive protein urine protein should be screened by dipstick or urine analysis for proteinuria greater_than equal_than two positive two4 hour urine protein should be obtained and the level should be less_than two for patient enrollment
__label__0	study interventions are Fludarabine . small intestine lymphoma diagnosis and high intermediate to high international prognostic score myelodysplasia
__label__0	study interventions are Squalamine . prostate cancer diagnosis and no concurrent radiotherapy
__label__0	study interventions are Paclitaxel . stage iva cervical cancer diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Pertuzumab . breast cancer diagnosis and also in conjunction with spermicidal_jelly or total abstinence
__label__0	study interventions are Deoxyglucose . adenocarcinoma diagnosis and no infections requiring antibiotic treatment
__label__0	study interventions are Methylprednisolone . prostate cancer diagnosis and screening psa values greater_than twentyng ml
__label__0	study interventions are in vitro-treated peripheral blood stem cell transplantation . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Rituximab . recurrent small lymphocytic lymphoma diagnosis and note
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and no progressive ischemic cardiomyopathy
__label__0	study interventions are Cisplatin . adenocarcinoma diagnosis and ecog zero or one
__label__0	study interventions are Paclitaxel . stage iiic breast cancer diagnosis and phase and expansion cohort
__label__0	study interventions are Antibodies, Monoclonal . metastatic melanoma diagnosis and absolute neutrophil count greater_than one zero mmthree
__label__0	study interventions are Leuprolide . prostate cancer diagnosis and no chronic liver disease
__label__0	study interventions are Mycophenolate mofetil . stage adult diffuse large cell lymphoma diagnosis and patient must be not eligible for conventional allogeneic hematopoietic cell transplantation hct and must have disease expected to be stable for at least one hundred days without chemotherapy patients with hematologic malignancies treatable with hct or with b cell malignancy except those curable with autologous transplant will be included patients not eligible for active disease specific protocols may be enrolled in this protocol patients will include the following
__label__0	study interventions are Interleukin-2 . stage iv melanoma diagnosis and willing and able to give informed consent
__label__0	study interventions are Etoposide phosphate . adult rhabdomyosarcoma diagnosis and doc mg dl for patients one to five months of age
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and no cardiac ventricular arrhythmias requiring medication
__label__0	study interventions are Veliparib . stage iiib cervical cancer diagnosis and any iv iron replacement product parenteral iron dextran iron dextran or parenteral iron polysaccharide preparations
__label__0	study interventions are Carboplatin . stage ii endometrial carcinoma diagnosis and concurrent prophylactic low molecular weight heparin allowed
__label__0	study interventions are Bevacizumab . adult grade meningioma diagnosis and anticoagulation with therapeutic warfarin inr less_than three and low molecular weight heparin is allowed
__label__0	study interventions are creatine monohydrate . unspecified adult solid tumor protocol specific diagnosis and no poorly controlled hypertension
__label__0	study interventions are Isophosphamide mustard . stage ii adult soft tissue sarcoma diagnosis and non metastatic disease
__label__0	study interventions are Immunoglobulin G . childhood cerebellar anaplastic astrocytoma diagnosis and creatinine clearance or radioisotope gfr greater_than seventy ml min or serum creatinine based on age and or gender as follows
__label__0	study interventions are Cyclin-Dependent Kinase Inhibitor Proteins . recurrent melanoma diagnosis and a
__label__0	study interventions are computed tomography . lung cancer diagnosis and disease characteristics
__label__0	study interventions are Gemcitabine . cholangiocarcinoma diagnosis and must not have undergone liver transplantation
__label__0	study interventions are Mechlorethamine . lymphoma diagnosis and transplant recipient
__label__0	study interventions are Saracatinib . stage iii esophageal cancer diagnosis and hemoglobin greater_than nine dl
__label__0	study interventions are Isotretinoin . neuroblastoma diagnosis and the patient cns disease has been previously treated
__label__0	study interventions are Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy . gastrointestinal neoplasms diagnosis and aged greater_than eighteen
__label__0	study interventions are Quality-of-Life Assessment . three months mths post breast cancer treatment
__label__0	study interventions are SGN-CD70A . renal cell carcinoma diagnosis and adequate baseline hematologic pulmonary renal and hepatic function
__label__0	study interventions are Gemcitabine . colorectal cancer diagnosis and must have received prior irinotecan hydrochloride with progression free interval of less_than three months
__label__0	study interventions are Nivolumab . measurable or evaluable disease according to irrc or bone metastatic disease evaluable by prostate cancer working group two criteria pcwgtwo for castration resistant prostate cancer crpc
__label__0	study interventions are Androgens . histologically confirmed adenocarcinoma of the prostate
__label__0	study interventions are Cisplatin . esophageal cancer diagnosis and at least three months
__label__0	study interventions are Liposomal doxorubicin . childhood epithelioid sarcoma diagnosis and doc mg dl one month to less_than six months of age
__label__0	study interventions are Gemcitabine . patients can have tumor originating in any part of the pancreas
__label__0	study interventions are Dexamethasone 21-phosphate . fallopian tube cancer diagnosis and karnofsky performance status kps greater_than or equal_than to seventy
__label__0	study interventions are Cyclosporine . lymphoma diagnosis and metastatic disease for which no known standard therapy that is potentially curative or definitely capable of extending life expectancy exists
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and required baseline hematology and chemistry parameters
__label__0	study interventions are Cyclophosphamide . adult synovial sarcoma diagnosis and all patients must have an electrocardiogram ecg all patients must have normal stress test within one hundred and eighty-two days prior to treatment
__label__0	study interventions are Antibodies . stage iv ovarian epithelial cancer diagnosis and no other concurrent investigational agents
__label__0	study interventions are Celecoxib . sarcoma diagnosis and if hepatitis antibody test is positive then patient must be tested for the presence of antigen by rt pcr and be hcv rna negative
__label__0	study interventions are Oxaliplatin . intrinsic brain stem tumors and optic pathway tumors do not require histologic verification
__label__0	study interventions are Paclitaxel . carcinoma non small cell lung diagnosis and bilirubin no greater than doc mg dl
__label__0	study interventions are Antidepressive Agents . breast cancer diagnosis and endocrine therapy
__label__0	study interventions are Interleukin-2 . metastatic melanoma diagnosis and serum alanine aminotransferase alt aspartate aminotransferase ast less than three times the upper limit of normal
__label__0	study interventions are Dexamethasone 21-phosphate . relapsed and or refractory multiple myeloma diagnosis and involved serum free light chain flc level greater_than ten mg dl provided the serum flc ratio is abnormal
__label__0	study interventions are Vincristine . pilomyxoid astrocytoma diagnosis and adequate hematologic renal liver function as demonstrated by laboratory values
__label__0	study interventions are Perifosine . sarcomas diagnosis and patients must have had at least one evaluation following the initiation of treatment and have stable disease partial response or complete response
__label__0	study interventions are Cyclophosphamide . plasma cell neoplasms diagnosis and diagnoses include
__label__0	study interventions are Cetuximab . brain cancer diagnosis and hepatic
__label__0	study interventions are Isophosphamide mustard . primary malignant brain neoplasms diagnosis and pd following an incomplete response ir to first line therapy
__label__0	study interventions are Interferon-alpha . patients must have histologically proven metastatic gastrointestinal kidney or lung cancer who have had disease progression on at least two prior systemic therapies
__label__0	study interventions are Methotrexate . adult grade iii lymphomatoid granulomatosis diagnosis and refractory anemia with excess blasts two ten two0 blasts
__label__0	study interventions are Cisplatin . neuroendocrine carcinoma diagnosis and women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception
__label__0	study interventions are Doxorubicin . extraskeletal osteosarcoma
__label__0	study interventions are Bevacizumab . stage iv fallopian tube cancer diagnosis and creatinine less than or equal to doc institutional upper limit normal uln or creatinine clearance greater_than fifty cc min
__label__0	study interventions are Laboratory Biomarker Analysis . fallopian tube clear cell adenocarcinoma diagnosis and patients must have no other chronic disease that would preclude randomization into lifestyle intervention trial such diseases include recent myocardial infarction or unstable angina in the previous six months chronic hepatitis rheumatoid disease renal or hepatic disease dysfunction and diabetics receiving insulin or other clinical condition limiting ability to walk recent leg fracture significant osteoarthritis related orthopedic conditions degenerative neurological conditions etc
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Educational counseling intervention . breast cancer diagnosis and has one or more school age child ren living at home
__label__0	study interventions are Antibodies, Monoclonal . angioimmunoblastic cell lymphoma diagnosis and at least seven days after the last dose of biologic agent for agents that have known adverse events occurring beyond seven days after administration this period must be extended beyond the time during which adverse events are known to occur the duration of this interval must be discussed with the study chair
__label__0	study interventions are Docetaxel . non small cell lung cancer stage iiib diagnosis and hemoglobin greater_than doc dl
__label__0	study interventions are Aspirin . precancerous condition diagnosis and not pregnant or nursing
__label__0	study interventions are Megestrol Acetate . recurrent or persistent endometrial carcinoma diagnosis and alkaline phosphatase less_than doc times uln less_than five times uln for patients with liver metastases
__label__0	study interventions are Erlotinib Hydrochloride . recurrent metastatic squamous neck cancer with occult primary diagnosis and patients must sign study specific informed consent and health insurance_portability and accountability_act hipaa forms
__label__0	study interventions are Metformin . esophageal cancer diagnosis and anorexia bulimia or nausea
__label__0	study interventions are Pertuzumab . estrogen receptor positive breast cancer diagnosis and eligible patients are expected to have completed six cycles of chemotherapy containing anti hertwo therapy treatment
__label__0	study interventions are Immunoglobulins . non hodgkin lymphoma diagnosis and at least two and less than or equal to two1 years of age
__label__0	study interventions are Folic Acid . localized non resectable adult liver carcinoma diagnosis and calculated creatinine clearance greater_than equal_than fifty ml min for patients with creatinine level of doc
__label__0	study interventions are Dactinomycin . adult rhabdomyosarcoma diagnosis and stage two or three and group iii or
__label__0	study interventions are Lapatinib . breast cancer diagnosis and patients must have an estimated survival of at least three months
__label__0	study interventions are Mycophenolic Acid . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and donor
__label__0	study interventions are Busulfan . metastatic cancer diagnosis and at least one week since prior focal irradiation to the brain or spine
__label__0	study interventions are Doxorubicin . peritoneal cavity cancer diagnosis and hematopoietic
__label__0	study interventions are Entinostat . recurrent small lymphocytic lymphoma diagnosis and recovered from all prior therapy
__label__0	study interventions are Etoposide . prostate cancer diagnosis and absolute granulocyte count at least one five hundred mm three
__label__0	study interventions are Antibodies . stage iii pancreatic cancer diagnosis and ecog zero one
__label__0	study interventions are Leucovorin . malignant gastrointestinal neoplasm diagnosis and creatinine equal_than less_than doc mg dl
__label__0	study interventions are Tryptophan . metastatic prostate cancer diagnosis and total bilirubin less_than doc institutional uln aspartate aminotransferase ast sgot and alanine aminotransferase alt sgpt less_than doc institutional uln
__label__0	study interventions are pyroxamide . precancerous condition diagnosis and bilirubin normal
__label__0	study interventions are Erlotinib Hydrochloride . advanced adult primary liver cancer diagnosis and no history of gi bleed that required procedural intervention variceal banding surgical shunt transvenous intrahepatic porto systemic shunt tips within the past three months
__label__0	study interventions are Irinotecan . gastric cancer diagnosis and all disease should be deemed resectable to negative margins ned based on imaging studies
__label__0	study interventions are Immunoglobulins . neurofibromatosis type two diagnosis and patients will be eligible as long as they are greater than four weeks from surgery have recovered from the effects of surgery and have residual disease that can be evaluated to best assess the extent of residual disease post operatively ct mri should be done no later than ninety-six hours in the immediate post operative period or at least four weeks post operatively if the ninety-six hour scan is more than 1four days before registration it should be repeated
__label__0	study interventions are Vaccines . ovarian cancer diagnosis and eighteen years of age or greater
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and latex condom diaphragm cervical cap for four weeks prior to beginning study drug therapy during study drug therapy including dose interruption and for four weeks after discontinuation of lenalomide therapy
__label__0	study interventions are Cyclosporins . stage iii grade two follicular lymphoma diagnosis and partial remission
__label__0	study interventions are Albumin-Bound Paclitaxel . thyroid cancer diagnosis and performance status of zero to two on the ecog scale
__label__0	study interventions are Niacinamide . liver carcinoma diagnosis and bseven
__label__0	study interventions are Belinostat . stage iv grade three follicular lymphoma diagnosis and wbc greater_than three zero mm three
__label__0	study interventions are Bevacizumab . stage iv skin melanoma diagnosis and serious cardiac arrhythmia requiring medication
__label__0	study interventions are Rituximab . stage iv grade one follicular lymphoma diagnosis and ascites
__label__0	study interventions are Antibodies . stage iii grade one follicular lymphoma diagnosis and no prior malignancy with the exceptions listed below
__label__0	study interventions are Antilymphocyte Serum . noncontiguous stage ii mantle cell lymphoma diagnosis and patients with pnh must have history of thrombosis related to pnh
__label__0	study interventions are Endothelial Growth Factors . adult giant cell glioblastoma diagnosis and systolic blood pressure equal_than less_than one hundred and sixty mg hg or diastolic pressure equal_than less_than ninety mm hg within fourteen days prior to step two registration
__label__0	study interventions are ALT-803 . myeloma diagnosis and sgot sgpt less_than five upper limit of institutional normal uln
__label__0	study interventions are Cetuximab . stage iva inverted papilloma of the paranasal sinus and nasal cavity diagnosis and life expectancy of greater_than three months
__label__0	study interventions are Trastuzumab . stage iiic breast cancer diagnosis and her two new positive definition
__label__0	study interventions are Palbociclib . breast cancer diagnosis and bilirubin less_than two upper limit normal uln
__label__0	study interventions are sodium borocaptate . colorectal cancer diagnosis and bilirubin no greater than doc times upper limit of normal uln
__label__0	study interventions are Cisplatin . primary peritoneal cavity cancer diagnosis and at least four weeks since prior surgery and recovered other
__label__0	study interventions are NSCLC expansion cohort: Regorafenib 100 mg . patients with advanced histologically or cytologically confirmed solid tumors malignant lymphomas or multiple myeloma refractory to any standard therapy
__label__0	study interventions are Bevacizumab . ovarian cancer diagnosis and patient should have measurable or evaluable disease as defined by the following
__label__0	study interventions are Cyclophosphamide . neoplasms breast diagnosis and the tsh level must be within normal limits for the laboratory
__label__0	study interventions are Automatic Follow-Up by Genetic Counseling Staff . patient at one of the participating clinics winship cancer institute and emory university hospital midtown who arrive for screening mammogram appointment
__label__0	study interventions are Immunoglobulins . recurrent endometrial carcinoma diagnosis and no concurrent amifostine or other protective_reagents
__label__0	study interventions are BB 1101 . pathological diagnosis of extranodal natural_killer cell lymphoma nasal type based on who two thousand and eight classification of tumors of haematopoietic and lymphoid tissue previously untreated
__label__0	study interventions are Acetylcysteine . recurrent mucoepidermoid carcinoma of the oral cavity diagnosis and provide informed written consent
__label__0	study interventions are Albumin-Bound Paclitaxel . pancreatic neoplasms diagnosis and subject has resting baseline oxygen saturation by pulse_oximetry of greater_than ninety-two at rest
__label__0	study interventions are Group 3: Centrally Located Tumors . non small cell lung cancer diagnosis and based upon the following diagnostic workup
__label__0	study interventions are Tacrolimus . fibrolamellar hepatocellular carcinoma diagnosis and ability to understand and provide informed consent for all study procedures including partial liver transplant and bone marrow harvest
__label__0	study interventions are Cyclophosphamide . breast cancer nos metastatic recurrent diagnosis and patients willing and able to comply with the study protocol for the duration of the study
__label__0	study interventions are Temozolomide . childhood solid neoplasm diagnosis and corticosteroids
__label__0	study interventions are Etoposide . childhood burkitt lymphoma diagnosis and clinical spinal cord compression
__label__0	study interventions are Cyclophosphamide . thirty plasma cells in the bone marrow and at least one plasmacytoma greater_than two cm as determined by clinical examination or applicable radiographs mri or ct scan
__label__0	study interventions are Bevacizumab . hepatocellular carcinoma diagnosis and absolute neutrophil count anc greater_than one one09 l
__label__0	study interventions are Maleic acid . stage iiic rectal cancer diagnosis and platelets greater_than equal_than one hundred ten nine l
__label__0	study interventions are Doxorubicin . stage adult diffuse small cleaved cell lymphoma diagnosis and ability to read understand and sign written informed consent approved by each institutional irb
__label__0	study interventions are Erlotinib Hydrochloride . stage iv non small cell lung cancer diagnosis and patients may have received an unlimited number of prior systemic regimens for nsclc as adjuvant therapy as therapy for locally advanced disease or as therapy for advanced disease provided they have not received prior anti egfr therapy small molecule or antibody etc or prior gamma_secretase inhibitors
__label__0	study interventions are Doxorubicin . sarcoma diagnosis and ecog performance status of two or less
__label__0	study interventions are Etoposide . refractory non hodgkin lymphoma diagnosis and waldenstrom macroglobulinemia
__label__0	study interventions are Oxaliplatin . gastro oesophageal cancer diagnosis and creatinine clearance greater_than fifty ml min as calculated using the cockcroft and gault formula see appendix l
__label__0	study interventions are Carboplatin . medulloblastoma diagnosis and ten fifteen
__label__0	study interventions are Lenalidomide . diffuse large cells non hodgkin lymphoma diagnosis and creatinine clearance greater_than ten ml min
__label__0	study interventions are Antibodies . stage iiib non small cell lung cancer diagnosis and patients with history of gross hemoptysis defined as bright red blood of one two teaspoon or more will be excluded from this trial
__label__0	study interventions are diagnostic cystoscopy . bladder cancer diagnosis and no prior pelvic surgery
__label__0	study interventions are Paclitaxel . prostate cancer diagnosis and not specified
__label__0	study interventions are Bevacizumab . adult glioblastoma diagnosis and patients must have been previously treated with radiation therapy and temozolomide bevacizumab naïve
__label__0	study interventions are Antibodies, Monoclonal . adult brain stem glioma diagnosis and no prior bevacizumab
__label__0	study interventions are Bevacizumab . adult primary hepatocellular carcinoma diagnosis and confirmed by needle aspirate biopsy or prior surgical resection specimen
__label__0	study interventions are Antibodies, Monoclonal . giant cell carcinoma diagnosis and as estimated by the cockcroft and gault formula estimated creatinine clearance is based on actual body weight
__label__0	study interventions are Sunitinib . stage iii salivary gland cancer diagnosis and haloperidol
__label__0	study interventions are Sunitinib . histologically confirmed advanced or metastatic non small cell lung cancer that cannot be cured with surgery radiation or combination thereof
__label__0	study interventions are Cetuximab . metastatic squamous neck cancer with occult primary squamous cell carcinoma diagnosis and no history of gross hemoptysis defined as bright red blood of greater_than ½_teaspoon or coagulopathy
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent colon cancer diagnosis and negative pregnancy test
__label__0	study interventions are Cyclophosphamide . a paraffin_embedded block of well fixed lymphoma tissue must be available
__label__0	study interventions are 7-hydroxystaurosporine . fallopian tube cancer diagnosis and progressive disease within field after radiotherapy
__label__0	study interventions are eribulin mesylate . recurrent non small cell lung cancer diagnosis and no other concurrent investigational agents
__label__0	study interventions are polymerase chain reaction . multiple myeloma and plasma cell neoplasm diagnosis and see disease characteristics
__label__0	study interventions are Leucovorin . stage iiib rectal cancer diagnosis and group i
__label__0	study interventions are total mesorectal excision (TME) . rectal neoplasms diagnosis and serum creatinine less_than equal_than doc uln bilirubin less_than equal_than doc uln altless_than equal_than doc uln
__label__0	study interventions are Palbociclib . a minimum tumor size of at least doc cm determined by physical exam or imaging whichever is larger is required
__label__0	study interventions are Antibodies . stage iic ovarian cancer diagnosis and patients with gynecologic oncology group gog performance grade of zero one or two
__label__0	study interventions are Dexamethasone . lymphoma diagnosis and not specified
__label__0	study interventions are pharmacological study . adenocarcinoma of the prostate diagnosis and zubrod zero two
__label__0	study interventions are Letrozole . ovarian cancer diagnosis and age greater than eighteen years of age
__label__0	study interventions are Pembrolizumab . recurrent respiratory papillomatosis diagnosis and hepatic
__label__0	study interventions are Etoposide phosphate . stage iiib non small cell lung cancer diagnosis and stage iiia tone or ttwo ntwo or iiib disease not amenable to resection or surgery
__label__0	study interventions are Mycophenolate mofetil . hodgkin lymphoma diagnosis and five blasts in the peripheral blood
__label__0	study interventions are Helical tomotherapy for breast cancer . breast cancer diagnosis and adjuvant radiotherapy is helical tomotherapy performed at institut claudius regaud toulouse france
__label__0	study interventions are yoga classes . ovarian cancer diagnosis and patient characteristics
__label__0	study interventions are Carboplatin . tumors within previously irradiated field will be designated as non target lesions unless progression is documented or biopsy is obtained to confirm persistence at least ninety days following completion of radiation therapy
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and greater than fifteen kg at time of apheresis
__label__0	study interventions are Fludarabine . childhood non hodgkin lymphoma diagnosis and donors are excluded when preexisting_immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment this determination is based on the standard practice of the individual institution the donor should be excluded if any of the flow cytometric and cell cytotoxic cross match assays are positive
__label__0	study interventions are Liposomal doxorubicin . hepatocellular carcinoma diagnosis and asa class to iii
__label__0	study interventions are Busulfan . contiguous stage ii marginal zone lymphoma diagnosis and written informed consent written informed consent of the unrelated donor is required to participate in the optional studies
__label__0	study interventions are Rituximab . recurrent mantle cell lymphoma diagnosis and platelet count greater_than equal_than one hundred and fifty zero
__label__0	study interventions are Capecitabine . colorectal cancer diagnosis and one measurable target lesion
__label__0	study interventions are Zoledronic acid . symptomatic multiple myeloma regardless of bone disease status
__label__0	study interventions are Niacinamide . desmoid type fibromatosis diagnosis and mibefradil
__label__0	study interventions are Antibodies, Monoclonal . hodgkin lymphoma diagnosis and disease relapse after treatment with at least two chemotherapeutic regimens including any salvage treatments
__label__0	study interventions are Erlotinib Hydrochloride . stage iii pancreatic cancer diagnosis and performance status
__label__0	study interventions are Gemcitabine . rhabdomyosarcoma diagnosis and host disease and two months must have elapsed from the start of protocol therapy since transplant
__label__0	study interventions are Camptothecin . splenic marginal zone lymphoma diagnosis and absolute neutrophil count at least one thousand, five hundred mm three
__label__0	study interventions are Temozolomide . brain and central nervous system tumors diagnosis and disease characteristics
__label__0	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the oropharynx diagnosis and no prior surgical procedures affecting absorption
__label__0	study interventions are Etoposide phosphate . stage iii adult diffuse small cleaved cell lymphoma diagnosis and alternatively patients with legal guardians who can read understand and sign written informed consent may also enroll
__label__0	study interventions are Everolimus . squamous cell carcinoma of the head and neck diagnosis and in case one or both of these thresholds are exceeded the patient can only be included after initiation of appropriate lipid_lowering medication
__label__0	study interventions are Citric Acid . stage iv breast cancer diagnosis and no current evidence of visceral crisis or lymphangitic spread
__label__0	study interventions are Vaccines . stage iv breast cancer diagnosis and hematocrit greater_than equal_than thirty
__label__0	study interventions are Lenalidomide . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and ability to read understand and sign written informed consent approved by each institutional irb
__label__0	study interventions are Camptothecin . mucinous adenocarcinoma of the rectum diagnosis and fluent in english
__label__0	study interventions are Etoposide . stage iv adult diffuse mixed cell lymphoma diagnosis and patients with previously harvested hematopoietic stem cells while in complete or partial remission or in the case of patients with stable or refractory disease are undergoing autologous transplantation because it has been recommended by their treating physician as representing their best treatment option with goal of at minimum of two ten six cluster of differentiation cd thirty-four positive peripheral primed stem cells per kilogram of actual body weight
__label__0	study interventions are Endothelial Growth Factors . colorectal cancer diagnosis and an in range international normalized ratio inr in range is usually defined as between two and three for patients on stable dose of oral anticoagulant or stable dose of low molecular weight heparin
__label__0	study interventions are Carboplatin . recurrent non small cell lung cancer diagnosis and not planning to undergo additional treatment for brain metastases
__label__0	study interventions are Vincristine . multiple myleoma diagnosis and
__label__0	study interventions are Lenograstim . childhood extracranial germ cell tumor diagnosis and recovered from prior chemotherapy immunotherapy or radiotherapy
__label__0	study interventions are Antibodies . anaplastic large cell lymphoma diagnosis and doc mg dl for male patients age greater_than equal_than sixteen years
__label__0	study interventions are Fludarabine . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and high risk crone for example but not limited to
__label__0	study interventions are Mitogens . recurrent breast cancer diagnosis and prior hormonal therapy for er positive and or pr positive hertwo positive disease in the metastatic setting is allowed
__label__0	study interventions are Immunoglobulin Fc Fragments . recurrent fallopian tube carcinoma diagnosis and urine protein should be screened by urinalysis if protein is two positive or higher two4 hour urine protein should be obtained and the level should be less_than one thousand mg less_than doc two4 hrs for patient enrollment
__label__0	study interventions are Etoposide . neuroblastoma diagnosis and not specified
__label__0	study interventions are Paclitaxel . stage iiia esophageal cancer diagnosis and platelets greater_than equal_than one hundred zero cells mm three
__label__0	study interventions are Trastuzumab . breast neoplasm diagnosis and non pregnant females equal_than greater_than eighteen years of age
__label__0	study interventions are tanespimycin . recurrent mantle cell lymphoma diagnosis and see disease characteristics
__label__0	study interventions are Cytology Specimen Collection Procedure . esophageal squamous cell carcinoma diagnosis and subjects with history of esophagitis
__label__0	study interventions are Carboplatin . lung cancer diagnosis and disease characteristics
__label__0	study interventions are Rituximab . lymphoma diagnosis and no concurrent uncontrolled medical conditions
__label__0	study interventions are Erlotinib Hydrochloride . recurrent adult brain tumor diagnosis and more than seven days since prior grapefruit juice
__label__0	study interventions are Gemcitabine . non muscle invasive bladder cancer diagnosis and other
__label__0	study interventions are Bevacizumab . brain cancer diagnosis and platelet count greater_than one hundred zero mmthree
__label__0	study interventions are Trabectedin . malignant pleural mesothelioma diagnosis and in order to make reproducible diagnosis in particular regarding biphasic mpm histology must derive from transthoracic biopsies at least three representative samples or from videothoracoscopy at least five representative samples
__label__0	study interventions are Vaccines . head and neck cancer diagnosis and renal
__label__0	study interventions are Isophosphamide mustard . neuroblastoma diagnosis and creatinine clearance or gfr greater_than seventy ml min or creatinine less_than doc times upper limit of normal uln
__label__0	study interventions are DNA analysis . breast cancer diagnosis and hormone receptor status not specified
__label__0	study interventions are Fludarabine phosphate . childhood burkitt lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Vidarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and high intermediate to high international prognostic score myelodysplasia
__label__0	study interventions are Erlotinib Hydrochloride . lung cancer diagnosis and transaminases aspartate aminotransferase ast or sgot and or alanine aminotransferase alt or sgpt and alkaline phosphatase may be up to doc uln
__label__0	study interventions are Rituximab . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and platelet count greater_than equal_than seventy-five zero mm three
__label__0	study interventions are Everolimus . stage ivb cervical cancer diagnosis and patients must have life expectancy of at least twelve weeks
__label__0	study interventions are Azacitidine . stage iv grade three follicular lymphoma diagnosis and creatinine less_than one hundred and fifty µmol l
__label__0	study interventions are Mycophenolate mofetil . adult nasal type extranodal nk cell lymphoma diagnosis and high risk is defined as
__label__0	study interventions are Docetaxel . stage ivb oropharyngeal squamous cell carcinoma diagnosis and platelet count greater_than equal_than one hundred zero mm three
__label__0	study interventions are Doxorubicin . multiple myeloma and plasma cell neoplasm diagnosis and hormone receptor status
__label__0	study interventions are Sunitinib . those with history of class ii heart failure who are asymptomatic on treatment
__label__0	study interventions are Oxaliplatin . colorectal cancer diagnosis and more than twenty-eight days since prior open biopsy
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and must have two echocardiogram or multigated acquisition muga scan indicating left ventricular ejection fraction lvef greater_than fifty within 4two days prior to first dose of study drug
__label__0	study interventions are Liposomal doxorubicin . stages ii iii breast cancer diagnosis and serum creatinine levels less than or equal to doc mg dl
__label__0	study interventions are Cisplatin . gallbladder carcinoma diagnosis and acceptable recovery of previous side effects
__label__0	study interventions are Antibodies, Monoclonal . stage iii verrucous carcinoma of the oral cavity diagnosis and no active peptic ulcer disease
__label__0	study interventions are Pemetrexed . breast cancer diagnosis and for patients who have baseline clinically significant pleural or peritoneal effusions on the basis of symptoms or clinical examination before initiation of pemetrexed therapy consideration should be given to draining the effusion prior to dosing
__label__0	study interventions are Magnetic Resonance High Intensity Focused Ultrasound . relapsed pediatric solid tumors diagnosis and defined as no dyspnea at rest and pulse_oximetry greater_than ninety-four on room air if there is clinical indication for determination
__label__0	study interventions are Veliparib . stage ii breast cancer diagnosis and patients without known brca mutation must have probability of harboring brca gene mutation as assessed by brcapro computer program
__label__0	study interventions are Bevacizumab . ovarian serous cystadenocarcinoma diagnosis and stage ii iv disease
__label__0	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and who performance status zero one or two
__label__0	study interventions are Vorinostat . stage iii adult burkitt lymphoma diagnosis and patients with biliary obstruction for which shunt has been placed are eligible provided the shunt has been in place for at least ten days prior to the first dose of vorinostat saha and liver function has stabilized
__label__0	study interventions are Liposomal doxorubicin . neuroblastoma diagnosis and endocrine therapy
__label__0	study interventions are Interleukin-12 . unspecified adult solid tumor protocol specific diagnosis and at least three months
__label__0	study interventions are Sunitinib . clear cell metastatic renal cell carcinoma diagnosis and bilirubin less_than or equal_than two mg dl except for patients affected by gilbert syndrome
__label__0	study interventions are Ifosfamide . stage iia uterine sarcoma diagnosis and patients must be free of active infection requiring antibiotics
__label__0	study interventions are Antibodies . adult hepatocellular carcinoma diagnosis and prior therapies allowed include
__label__0	study interventions are Fluorouracil . stage iva colorectal cancer diagnosis and patients with documented liver metastases or bone involvement
__label__0	study interventions are Cyclosporine . stage marginal zone lymphoma diagnosis and patients with primary refractory or relapsed disease not eligible for an autologous transplant
__label__0	study interventions are Methotrexate . brain and central nervous system tumors diagnosis and life expectancy
__label__0	study interventions are Vidarabine . melanoma skin diagnosis and hepatic
__label__0	study interventions are Etoposide phosphate . small cell lung cancer diagnosis and ecog ps zero two
__label__0	"study interventions are NanoKnife ""Irreversible electroporation (IRE)"" . non metastasized unresectable pancreatic carcinoma diagnosis and asa classification zero"
__label__0	study interventions are Vorinostat . nodal marginal zone cell lymphoma diagnosis and known positive for hiv or infectious hepatitis type or c
__label__0	study interventions are Maleic acid . stage iiib non small cell lung cancer diagnosis and patients must be able to tolerate oral medications and not have gastrointestinal illnesses that would preclude absorption of cediranib or olaparib
__label__0	study interventions are Interferons . melanoma skin diagnosis and no organ allografts
__label__0	study interventions are Vorinostat . childhood ependymoblastoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Etoposide . diagnosis of extensive stage small cell lung cancer at least one bidimensionally measurable non cns lesion at least one cm in one diameter and at least two cm in another diameter by ct or mri scan at least two cm in two diameters by ray ultrasound or for palpable tumor masses by physical exam measurable skin lesion at least one cm in at least one diameter by photography no symptomatic cns and or leptomeningeal metastases requiring corticosteroid therapy to control symptoms
__label__0	study interventions are Cetuximab . stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and not pregnant or nursing
__label__0	study interventions are Antibodies, Monoclonal . recurrent adult immunoblastic large cell lymphoma diagnosis and at least fourteen days after local palliative radiotherapy xrt small port at least one hundred and fifty days must have elapsed if prior total body irradiation tbi craniospinal xrt or if greater_than equal_than fifty radiation of pelvis at least forty-two days must have elapsed if other substantial bone marrow bm radiation
__label__0	study interventions are Rituximab . stage iv marginal zone lymphoma diagnosis and ecog performance status equal_than less_than two
__label__0	study interventions are Cyclophosphamide . childhood germ cell tumor diagnosis and no greater than doc mg dl eleven fifteen years
__label__0	study interventions are Carmustine . recurrent adult lymphoblastic lymphoma diagnosis and performance status zero two karnofsky performance status kps greater_than equal_than 7zero patients with amyloidosis or mm with decreased kps due to disease are eligible
__label__0	study interventions are Immunoglobulins . stage iii squamous cell carcinoma of the hypopharynx diagnosis and no evidence of serious or nonhealing wound ulcer or bone fracture
__label__0	study interventions are Everolimus . non mantle cell low grade cell lymphomas sll cll diagnosis and age greater_than eighteen years of age
__label__0	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . childhood low grade cerebellar astrocytoma diagnosis and temozolomide
__label__0	study interventions are Estradiol . breast carcinoma diagnosis and baseline mammogram within eight weeks of study entry
__label__0	study interventions are Fludarabine phosphate . recurrent grade two follicular lymphoma diagnosis and at least one measurable node greater than two cm by computed tomography ct scan or measurable disease in lymphoid structure spleen
__label__0	study interventions are Cyclosporine . recurrent grade two follicular lymphoma diagnosis and patients must have an hla identical related or unrelated donor
__label__0	study interventions are Camptothecin . recurrent childhood visual pathway glioma diagnosis and recovered from all prior radiotherapy
__label__0	study interventions are Cyclosporine . recurrent grade two follicular lymphoma diagnosis and ejection fraction greater_than equal_than fifty
__label__0	study interventions are Antibodies . stage iv squamous cell carcinoma of the larynx diagnosis and karnofsky sixty one hundred
__label__0	study interventions are Palbociclib . metastatic breast cancer diagnosis and measurable disease or at least one bone lesion lytic or mixed lytic positive blastic which has not been previously irradiated and is assessable by ct mri in the absence of measurable disease according to recist doc criteria
__label__0	study interventions are BBI503 . urothelial carcinoma diagnosis and creatinine less_than doc uln or creatinine clearance greater_than fifty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Focus Group Sessions . lung cancer diagnosis and group six
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and no uncontrolled hypertension no history of ischemic heart disease or chf normal ejection fraction by muga required only if deemed clinically necessary for assessment other
__label__0	study interventions are pharmacological study . metastatic ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and see disease characteristics
__label__0	study interventions are Dexrazoxane . neuroblastoma diagnosis and the patient must fall into one of the following diagnostic categories
__label__0	study interventions are Lomustine . intracranial tumor
__label__0	study interventions are Pembrolizumab . pleural sarcomatoid mesothelioma diagnosis and have performance status of zero or one on the eastern cooperative oncology group ecog performance scale
__label__0	study interventions are Vinorelbine . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Folic Acid . ovarian cancer diagnosis and subjects who have recovered from non cytotoxic therapy associated toxicity or who have controlled non cytotoxic therapy toxicity vascular endothelial growth factor related hypertension can be entered into the trial after drug wash out period of four half lives
__label__0	study interventions are Fludarabine . recurrent grade three follicular lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are human papillomavirus 16 E7 peptide . cervical cancer diagnosis and hepatic
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and bone marrow plasmacytosis of greater_than or equal_than thirty by bone marrow aspirate and or biopsy d
__label__0	study interventions are Etoposide phosphate . bronchoalveolar cell lung cancer diagnosis and no concurrent prophylactic contralateral hilar or supraclavicular lymph node radiotherapy
__label__0	study interventions are AlloStim . prostate cancer diagnosis and at least two weeks since prior cytotoxic chemotherapy
__label__0	study interventions are CPX-351 . hodgkin lymphoma diagnosis and adequate bone marrow function
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and physiologically fit to undergo surgery
__label__0	study interventions are Vinblastine . posterior urethral cancer diagnosis and patients must be recovered from surgery
__label__0	study interventions are Placebo . ovarian cancer diagnosis and must have eastern cooperative oncology group ecog performance status of zero one or two and life expectancy of at least 6zero days
__label__0	study interventions are Fludarabine . recurrent childhood lymphoblastic lymphoma diagnosis and acute myeloid leukemia aml with high risk cytogenetics del_fiveq five del_sevenq seven abnormal threeq_nineq elevenq_twentyq twenty-oneq_1sevenp six
__label__0	study interventions are 4Dimensional Phase Contrast Magnetic Resonance Angiography . liver cancer diagnosis and willing and able to provide informed consent
__label__0	study interventions are Folic Acid . breast tumors diagnosis and give written informed consent
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and dermal lymphatic invasion
__label__0	study interventions are Thalidomide . lymphoma diagnosis and relapsed or refractory disease
__label__0	study interventions are Antibodies, Monoclonal . ovarian serous adenocarcinoma diagnosis and absolute neutrophil count anc greater than or equal to one five hundred mm three equivalent to ctep common terminology criteria for adverse events ctcae version doc grade one this anc cannot have been induced or supported by granulocyte colony stimulating factors
__label__0	study interventions are Sorafenib . esophageal cancer diagnosis and life expectancy greater_than two months
__label__0	study interventions are Treatment . solid tumor diagnosis and life expectancy
__label__0	study interventions are Paclitaxel . cervical cancer diagnosis and hepatic
__label__0	study interventions are Belinostat . stage iv grade one follicular lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Testosterone undecanoate . cancer survivor diagnosis and no congestive heart failure
__label__0	study interventions are Lenograstim . ds stage iii plasma cell myeloma diagnosis and acute myelogenous leukemia in high risk crone as defined by at least one of the following
__label__0	study interventions are Irinotecan . unresectable intrahepatic cholangiocarcinoma diagnosis and patients with prior contraindications for the use of irinotecan gemcitabine or cisplatin
__label__0	study interventions are Fludarabine phosphate . stage adult cell leukemia lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Observation . ductal carcinoma in situ of the breast diagnosis and complete resection of the area of dcis with histologic margin of at least one cm must be achieved
__label__0	study interventions are Blood Sampling . cervical cancer diagnosis and ecog zero two
__label__0	study interventions are Temozolomide . brain and central nervous system tumors diagnosis and prior concurrent therapy
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and performance status
__label__0	study interventions are Vinorelbine . lung cancer diagnosis and hepatic
__label__0	study interventions are MLN8237 (Alisertib) . gastroesophageal adenocarcinoma diagnosis and eastern cooperative oncology group ecog performance status zero or one
__label__0	study interventions are Immunoglobulins . recurrent squamous cell carcinoma of the hypopharynx diagnosis and no cerebral vascular disease cerebrovascular accident stroke or transient ischemic attack within the past six months
__label__0	study interventions are Cyclosporins . kidney cancer diagnosis and at least three months since prior myeloablative bone marrow transplantation
__label__0	study interventions are Vidarabine . lymphoma diagnosis and patients in relapse with partial remission or stable disease
__label__0	study interventions are Rituximab . histologically confirmed diagnosis of diffuse large cell non hodgkin lymphoma with characteristic immunophenotypic profile
__label__0	study interventions are Immunoglobulin G . grade ii meningioma diagnosis and females of child bearing potential focbp and males with partners of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study treatment should female patient become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately likewise if the female partner of male patient becomes pregnant or suspect she is pregnant he should inform his treating physician immediately
__label__0	study interventions are Online Educational Group . breast cancer diagnosis and currently sedentary defined as less_than ninety minutes per week of activity
__label__0	study interventions are Axitinib . clear cell metastatic renal cell carcinoma diagnosis and life expectancy twelve weeks or greater
__label__0	study interventions are Wild-type Reovirus . evidence of any end organ damage criteria listed below at any time attributed to the patient myeloma
__label__0	study interventions are BB 1101 . histologically confirmed adenocarcinoma of the colon or rectum with unresectable liver metastases that comprise less than seventy of liver parenchyma
__label__0	study interventions are Estramustine . prostate cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Doxorubicin . endometrial cancer diagnosis and females of childbearing potential must have negative pregnancy test and use approved contraception from screening to thirty days after the last study drug is given
__label__0	study interventions are Immunoglobulins . stage iv melanoma diagnosis and no other concurrent experimental drugs
__label__0	study interventions are Interleukin-4 . grade iv astrocytoma diagnosis and women of child bearing potential must have negative beta human chorionic gonadotropin pregnancy test documented within fourteen days prior to treatment
__label__0	study interventions are Sorafenib . clear cell renal cell carcinoma diagnosis and ecog performance status equal_than less_than one
__label__0	study interventions are POWER-remote . early stage breast cancer diagnosis and to ensure compliance with the power remote and patientviewpoint programs patients must meet the following
__label__0	study interventions are BMS-936559 (Anti-PD-L1) . stage iii or iv melanoma diagnosis and men and women greater_than eighteen years
__label__0	study interventions are ispinesib . childhood high grade cerebral astrocytoma diagnosis and oxcarbazepine
__label__0	study interventions are Cyclophosphamide . stage iv adult diffuse large cell lymphoma diagnosis and aspartate aminotransferase ast alanine aminotransferase alt equal_than less_than doc the upper limit of normal
__label__0	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and adult participants greater_than equal_than eighteen years of age
__label__0	study interventions are Kappa CD28 T cells . myeloma diagnosis and pdone pdlone inhibitors will be allowed if medically indicated
__label__0	study interventions are Camptothecin . recurrent solid neoplasm diagnosis and cellular therapy
__label__0	study interventions are Etoposide . lymphoma diagnosis and biologic therapy
__label__0	study interventions are Immunoglobulins . stage iiia fallopian tube cancer diagnosis and prothrombin time pt equal_than less_than doc uln
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and adequate cardiac function defined as
__label__0	study interventions are Mitogens . non small cell lung cancer diagnosis and platelet count greater than or equal to one hundred ten nine l
__label__0	study interventions are Doxorubicin . bladder cancer diagnosis and tthreea foura nzero mzero
__label__0	study interventions are Tegafur . hepatocellular carcinoma diagnosis and any acute toxicity ctc ae less_than grade one
__label__0	study interventions are Levoleucovorin . rectal adenocarcinoma diagnosis and must provide study specific informed consent prior to study entry
__label__0	study interventions are Immunoconjugates . contiguous stage ii adult lymphoblastic lymphoma diagnosis and total bilirubin equal_than less_than two institutional upper limit of normal uln
__label__0	study interventions are Cytarabine . stage iv adult lymphoblastic lymphoma diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least fifty miu ml within ten
__label__0	study interventions are Lenalidomide . splenic marginal zone lymphoma diagnosis and all study participants must be registered into the mandatory revassist program and be willing and able to comply with the requirements of revassist
__label__0	study interventions are Antibodies . stage ii grade three non contiguous follicular lymphoma diagnosis and lymphangitis_cutis pulmonis
__label__0	study interventions are BCG Vaccine . prostate cancer diagnosis and platelet count greater_than one hundred zero mm³
__label__0	study interventions are Darbepoetin alfa . unspecified adult solid tumor protocol specific diagnosis and patient characteristics
__label__0	study interventions are 7-hydroxystaurosporine . ovarian cancer diagnosis and eighteen and over
__label__0	study interventions are Thalidomide . relapsed non hodgkin lymphoma diagnosis and platelets
__label__0	study interventions are Mycophenolate mofetil . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and chronic myelogenous leukemia
__label__0	study interventions are Lapatinib . recurrent squamous cell carcinoma of the nasopharynx diagnosis and cardiac ejection fraction within the institutional range of normal as measured by echocardiogram or multigated acquisition muga scan note that baseline and on treatment scans should be performed using the same modality and preferably at the same institution
__label__0	study interventions are Paclitaxel . stage iiib gallbladder cancer diagnosis and arm cohort three
__label__0	study interventions are Epirubicin . see disease characteristics at least twenty-eight days since prior radiotherapy and recovered concurrent limited field radiotherapy for symptomatic metastatic disease not amenable to cisplatin epinephrine gel allowed surgery
__label__0	study interventions are Tinzaparin . locally advanced or metastatic cancer
__label__0	study interventions are Sorafenib . stage ivb squamous cell carcinoma of the larynx diagnosis and patients may have received one regimen of induction concomitant chemoradiotherapy and or adjuvant chemotherapy as part of their initial treatment with curative intent which must have been completed for minimum of four months prior to study treatment and patient must have been progression free for at least four months since completion of treatment with curative intent
__label__0	study interventions are Carmustine . lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Fludarabine phosphate . breast cancer diagnosis and no more than two antigen mismatches at the hla b or drbone loci note
__label__0	study interventions are Lenvatinib . hepatocellular carcinoma diagnosis and adequately controlled blood pressure
__label__0	study interventions are Topotecan . ovarian endometrioid adenocarcinoma diagnosis and phase iii study
__label__0	study interventions are Antibodies, Monoclonal . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and concurrent full dose anticoagulants allowed provided the following criteria are met part two only
__label__0	study interventions are Antibodies . contiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Docetaxel . stage iiia non small cell lung cancer diagnosis and creatinine clearance should be calculated using the cockcroft gault formula patients who will receive pemetrexed cisplatin therapy must be obtained within two weeks of registration
__label__0	study interventions are Calcium, Dietary . colorectal cancer diagnosis and age
__label__0	study interventions are Antibodies, Monoclonal . recurrent large cell lung carcinoma diagnosis and patients or their legally authorized representative must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
__label__0	study interventions are Tremelimumab . prostate cancer diagnosis and laboratory requirements must be done within seven days prior to randomization
__label__0	study interventions are Bevacizumab . tumors diagnosis and adequate organ function
__label__0	study interventions are Amifostine . gestational_trophoblastic tumor diagnosis and no concurrent neurotoxic agents during and for at least six months after study entry
__label__0	study interventions are Cyclophosphamide . cancer of anus diagnosis and hemoglobin greater_than ten dl
__label__0	study interventions are implanted fiducial-based imaging . bladder cancer diagnosis and see disease characteristics
__label__0	study interventions are Bendamustine Hydrochloride . grey zone lymphoma diagnosis and women who have been post menopausal for at least two years without menses or women who are surgically sterile by means of hysterectomy tubal ligation etc
__label__0	study interventions are Methotrexate . recurrent marginal zone lymphoma diagnosis and first complete remission crone confirmed
__label__0	study interventions are therapeutic allogeneic lymphocytes . recurrent childhood small noncleaved cell lymphoma diagnosis and myelodysplastic syndromes with five or more blasts
__label__0	study interventions are Maleic acid . recurrent ovarian carcinoma diagnosis and subjects may begin cediranib and olaparib at least three weeks after their last dose of chemotherapy or hormonal therapy assuming they are otherwise eligible
__label__0	study interventions are Histone Deacetylase Inhibitors . small intestine lymphoma diagnosis and patients with congenital long qt syndrome
__label__0	study interventions are Online, non-adaptive MR-guided SBRT . hepatocellular carcinoma diagnosis and must be treated per protocol to lesion of single abdominal site that can reasonably be encompassed within single treatment field
__label__0	study interventions are Paclitaxel . tumors diagnosis and women of child bearing potential must have negative pregnancy test within fourteen days of beginning study drug and agree to use an effective method of birth control during treatment and for six months after last dose of study drug
__label__0	study interventions are Docetaxel . prostatic neoplasms diagnosis and previous definitive radiotherapy to one metastatic site is acceptable provided that unirradiated sites remain
__label__0	study interventions are Vorinostat . childhood grade iii meningioma diagnosis and doc mg dl six to nine years of age
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and not specified renal
__label__0	study interventions are Niacinamide . recurrent rectal carcinoma diagnosis and urine protein creatinine upc ratio less_than one or urine dipstick less_than two positive
__label__0	study interventions are Fluorides . adult ependymoma diagnosis and creatinine less_than doc mg dl
__label__0	study interventions are Etoposide . sarcoma diagnosis and biologic therapy
__label__0	study interventions are Fosaprepitant . neuroblastoma diagnosis and negative pregnancy test
__label__0	study interventions are Levoleucovorin . stage iii pancreatic cancer diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Krestin . prostatic neoplasms diagnosis and aspartate aminotransferase ast less_than doc uln
__label__0	study interventions are Docetaxel . unspecified adult solid tumor protocol specific diagnosis and prior concurrent therapy
__label__0	study interventions are Romidepsin . multiple myeloma diagnosis and if there is progression of disease on that therapy and all adverse effects have resolved to grade one or baseline in which case two weeks is acceptable
__label__0	study interventions are Gossypol . diffuse large cell lymphoma diagnosis and patients with fl dlbcl mcl and sll with normal lymphocyte counts must have at least one bi dimensional lesion that is radiographically measurable skin lesions palpable lymph nodes and bone marrow as the only site of disease are not considered measurable disease
__label__0	study interventions are Endothelial Growth Factors . recurrent inverted papilloma of the paranasal sinus and nasal cavity diagnosis and no prior fluorouracil and hydroxyurea with radiotherapy
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and at least one measurable lesion according to recist doc
__label__0	study interventions are Denosumab . prostate cancer diagnosis and all female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception eg implants injectables combined oral contraceptives intrauterine device iud sexual abstinence vasectomy or vasectomized partner for the duration of the study
__label__0	study interventions are Capecitabine . metastatic colorectal cancer diagnosis and location and distribution of metastatic disease within the liver unsuitable for resection with clear margins eg
__label__0	study interventions are Cisplatin . gastrointestinal carcinoid tumor diagnosis and platelet count greater_than one hundred zero mm³
__label__0	study interventions are Lenalidomide . patients must not be receiving any other anti cancer agents or radiotherapy at the time of study entry or while on study
__label__0	study interventions are Oxaliplatin . childhood diffuse large cell lymphoma diagnosis and hypericum_perforatum st
__label__0	study interventions are Lapatinib . glioma diagnosis and at least one of the acs must be an eiac
__label__0	study interventions are Aldesleukin . melanoma skin diagnosis and not specified
__label__0	study interventions are Endothelial Growth Factors . recurrent digestive system neuroendocrine tumor gone diagnosis and suitably recovered from prior localized therapy in the opinion of the investigator
__label__0	study interventions are Paclitaxel . prior adjuvant radiotherapy is allowed as part of the treatment of early breast cancer if the last fraction of radiotherapy occurred at least six months prior to randomization
__label__0	study interventions are Beclomethasone . stage ii adult hodgkin lymphoma diagnosis and pregnancy or breast feeding
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and plateletsgreater_than fifty zero mmthree administration of platelet transfusions during screening to meet eligibility criteria is not allowed
__label__0	study interventions are No LCT . lung cancer diagnosis and at least four cycles of platinum doublet chemotherapy for metastatic disease with or without bevacizumab if the patient is known to be egfr mutation positive erlotinib afatinib or gefitinib for greater_than equal_than three months or for patients with known emlfour alk fusions crizotinib for greater_than equal_than three months
__label__0	study interventions are Veliparib . recurrent fallopian tube carcinoma diagnosis and dose escalating cohorts only
__label__0	study interventions are Immunoglobulins . disseminated neuroblastoma diagnosis and the presence of radiographically measurable disease immediately prior to start of phase immunotherapy is not an eligibility requirement in the following situations
__label__0	study interventions are Erythromycin Estolate . ras wildtype colorectal cancer diagnosis and nras exon four codons one hundred and seventeen 1four6
__label__0	study interventions are Vidarabine . stage iii adult diffuse small cleaved cell lymphoma diagnosis and patient must be not eligible for conventional allogeneic hematopoietic cell transplantation hct and must have disease expected to be stable for at least one hundred days without chemotherapy patients with hematologic malignancies treatable with hct or with b cell malignancy except those curable with autologous transplant will be included patients not eligible for active disease specific protocols may be enrolled in this protocol patients will include the following
__label__0	study interventions are AFP464 . stage iv ovarian epithelial cancer diagnosis and discontinue for eight hours prior to procedure
__label__0	study interventions are Hormones . metastatic breast cancer diagnosis and patients may have received radiation therapy to painful bone metastases or areas of impending bone fracture as long as radiation therapy is completed greater_than equal_than two weeks prior to study entry
__label__0	study interventions are Antineoplastic Agents, Alkylating . primary tumor must be measurable on breast ultrasound us
__label__0	study interventions are Cediranib . stage ivb thyroid gland follicular carcinoma diagnosis and one has not undergone hysterectomy or bilateral oophorectomy or two has not been naturally postmenopausal for at least two4 consecutive months has had menses at any time in the preceding two4 consecutive months
__label__0	study interventions are Gossypol acetic acid . recurrent adult burkitt lymphoma diagnosis and absolute neutrophil count greater_than one five hundred ul
__label__0	study interventions are Antibodies, Monoclonal . pancreatic cancer diagnosis and neutrophils greater_than one five hundred µl
__label__0	study interventions are Pemetrexed . recurrent non small cell lung cancer diagnosis and sotalol
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and stage ii iv disease
__label__0	study interventions are Levoleucovorin . acinar cell adenocarcinoma of the pancreas diagnosis and zero one
__label__0	study interventions are Erlotinib Hydrochloride . advanced malignancies non small cell lung cancer diagnosis and adequate bone marrow function
__label__0	study interventions are Leuprolide . melanoma diagnosis and white blood count wbc greater_than equal_than three thousand mm three
__label__0	study interventions are Antibodies, Monoclonal . large cell lung cancer diagnosis and low risk disease meeting the following criteria
__label__0	study interventions are Antibodies . contiguous stage ii mantle cell lymphoma diagnosis and has not undergone hysterectomy or bilateral oophorectomy or
__label__0	study interventions are Antibodies, Monoclonal . neuroblastoma diagnosis and alanine transaminase alt less_than doc times upper limit of normal uln
__label__0	study interventions are TreC-Onco . cancer diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are Cetuximab . subcardial gastric carcinoma which infiltrates the esophagogastric junction and distal esophagus from below
__label__0	study interventions are Interferon-gamma . lymphoma diagnosis and no recurrence without symptoms or bulky disease at least one year after completion of minimal systemic therapy defined by either of the following
__label__0	study interventions are Endothelial Growth Factors . stage iia colon cancer diagnosis and arms and only
__label__0	study interventions are Mycophenolic Acid . stage iii marginal zone lymphoma diagnosis and have seventeenp_deletion cytogenetic abnormality patients should have received induction chemotherapy but could be transplanted in onest cr
__label__0	study interventions are Anamorelin HCl . must have incurable histologically or cytologically documented non small cell lung cancer or colo rectal cancer
__label__0	study interventions are Submandibular salivary gland transfer . head and neck cancer diagnosis and patient characteristics
__label__0	study interventions are Tacrolimus . recurrent grade two follicular lymphoma diagnosis and acute lymphocytic leukemia all must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Antibodies, Monoclonal . gliosarcoma diagnosis and hemoglobin greater_than equal_than nine dl
__label__0	study interventions are Fludarabine phosphate . childhood immunoblastic large cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Acetylcarnitine . recurrent primary peritoneal carcinoma diagnosis and no patients with known allergies to alc acetyl carnitine hydrochloride
__label__0	study interventions are Carboplatin . refractory diffuse large cell lymphoma diagnosis and if patient has cytopenias due to bone marrow involvement these requirements are not applicable
__label__0	study interventions are Leucovorin . adult cholangiocarcinoma diagnosis and regulatory criteria
__label__0	study interventions are laboratory biomarker analysis . recurrent grade three follicular lymphoma diagnosis and eligibility to receive dli post transplant
__label__0	study interventions are Immunoglobulins . stage iiia non small cell lung cancer diagnosis and node positive by fludeoxyglucose positron_emission tomography fdg pet scan
__label__0	study interventions are Etoposide . lymphoma diagnosis and not specified
__label__0	study interventions are Camptothecin . primary peritoneal carcinoma diagnosis and performance status
__label__0	study interventions are Doxorubicin . bilateral synchronous breast cancer diagnosed within one month of each other allowed provided the higher tnm stage primary tumor meets the eligibility criteria
__label__0	study interventions are Immunoglobulins . stage iii adrenocortical carcinoma diagnosis and no prior igfr directed therapy
__label__0	study interventions are Antibodies, Monoclonal . metastatic peripheral primitive neuroectodermal tumor of bone diagnosis and total bilirubin equal_than less_than doc upper limit of normal uln for age and
__label__0	study interventions are Mycophenolic Acid . relapsed non hodgkin lymphoma diagnosis and treatment related leukemia
__label__0	study interventions are Oxaliplatin . mucinous adenocarcinoma of the rectum diagnosis and fertile male patients must agree to use highly effective contraceptive method with failure rate of less_than one per year such as vasectomy sexual abstinence or female partner use of hormonal implants or combined oral contraceptives during the trial and for period of at least six months after the last dose of study drug
__label__0	study interventions are Docetaxel . non small cell lung cancer diagnosis and zero one prior treatment regimens of chemotherapy
__label__0	study interventions are Aldesleukin . recurrent melanoma diagnosis and hematocrit hct greater_than equal_than thirty
__label__0	study interventions are holmium Ho 166 DOTMP . metastatic cancer diagnosis and see disease characteristics
__label__0	study interventions are Paclitaxel . locally recurrent and metastatic breast cancer diagnosis and competent to comprehend sign and date an irb approved informed consent form
__label__0	study interventions are Tamoxifen . endometrial cancer diagnosis and hepatic
__label__0	study interventions are Stereotactic radiosurgery . recurrent adult brain tumor diagnosis and there should be at least two week break between prior treatment and the protocol treatment
__label__0	study interventions are Nerofe . pathologically confirmed locally advanced and or metastatic solid tumor for which standard therapy proven to provide clinical benefit does not exist is no longer effective or cannot be tolerated
__label__0	study interventions are image-guided radiotherapy . sarcoma ewing diagnosis and patients may enter this study in specific clinical situations often defined by multimodality protocols that include the use of radiation therapy including irradiation alone or combined with surgery following surgical resection that may be macroscopically complete or incomplete with positive or negative histologic margins and or chemotherapy following neoadjuvant chemotherapy or combined with post irradiation adjuvant chemotherapy
__label__0	study interventions are Everolimus . recurrent islet cell carcinoma diagnosis and provision of informed consent prior to any study related procedures
__label__0	study interventions are Everolimus . glioma diagnosis and karnofsky fifty for patients greater than ten years of age and lansky fifty for patients ten years of age appendix i
__label__0	study interventions are Fludarabine phosphate . metastatic cancer that express the mage_athree dpfour antigen diagnosis and patients must have progressing disease after prior treatment
__label__0	study interventions are Endothelial Growth Factors . stage ivc laryngeal verrucous carcinoma diagnosis and no prior chemotherapy or biologic molecular targeted therapy for recurrent or metastatic scchn
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and hepatic function
__label__0	study interventions are Everolimus . stage iv prostate cancer diagnosis and women of child bearing potential defined as sexually mature women who have not undergone hysterectomy or who have not been naturally postmenopausal for at least twelve consecutive months who has had menses any time in the preceding twelve consecutive months must have negative serum pregnancy test equal_than less_than fourteen days prior to registration and must use two forms of highly effective contraception also applicable to their partners who are biologically able to conceive
__label__0	study interventions are Etoposide phosphate . unspecified adult solid tumor protocol specific diagnosis and marrow cellularity less_than twenty
__label__0	study interventions are Everolimus . locally advanced cervical cancer diagnosis and hemoglobin greater_than one doc dl
__label__0	study interventions are genetically engineered lymphocyte therapy . stage iii grade one follicular lymphoma diagnosis and relapsed after prior autologous sct
__label__0	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . recurrent childhood cerebral astrocytoma diagnosis and myelosuppressive chemotherapy
__label__0	study interventions are Etoposide phosphate . stage iii grade two follicular lymphoma diagnosis and male subject agrees to use an acceptable method for contraception for the duration of the study
__label__0	study interventions are Antibodies, Monoclonal . recurrent digestive system neuroendocrine tumor gone diagnosis and prior mammalian target of rapamycin mtor inhibitor is allowed
__label__0	study interventions are Cyclosporins . recurrent adult diffuse small cleaved cell lymphoma diagnosis and amyloidosis
__label__0	study interventions are EGEN-001-301 . colorectal cancer diagnosis and patients must have an ecog performance status of zero one or two
__label__0	study interventions are Sodium thiosulfate . pleural mesothelioma diagnosis and karnofsky performance status of seventy or greater
__label__0	study interventions are Acetylcysteine . androgen secreting tumors
__label__0	study interventions are Carboplatin . lymphoma diagnosis and no hiv infection or aids
__label__0	study interventions are Thiotepa . myelodysplastic myeloproliferative neoplasms diagnosis and see disease characteristics
__label__0	study interventions are Cyclophosphamide . mesothelioma diagnosis and negative screen for human immunodeficiency virus hiv hepatitis virus hbv antigen and hepatitis virus hcv
__label__0	study interventions are Tacrolimus . precancerous nonmalignant condition diagnosis and ast less_than two times normal unless liver function abnormality is due to underlying disease
__label__0	study interventions are Succinylcholine . ovarian serous cystadenocarcinoma diagnosis and patients must be entered and treated within twelve weeks of their most recent surgery performed for the combined purpose of diagnosis staging and or cytoreduction the first cycle of chemotherapy should not be given until at least seven days after the most recent major surgery which allows four weeks to have elapsed prior to the first bevacizumab dose placement of venous or peritoneal access devices will be considered minor surgery three twenty-nine ten
__label__0	study interventions are ravuconazole . lymphoma diagnosis and bilirubin no greater than five times upper limit of normal uln
__label__0	study interventions are Lenalidomide . myeloma diagnosis and patient must be informed of the investigational nature of this study
__label__0	study interventions are Fludarabine . myeloproliferative neoplasms diagnosis and biologic therapy
__label__0	study interventions are Misonidazole . metastatic pancreatic adenocarcinoma diagnosis and must have basaloid subtype tnbc as determined by research pam fifty test
__label__0	study interventions are Fludarabine . multiple myeloma and plasma cell neoplasm diagnosis and no evidence of progressive disease by imaging modalities or biopsy persistent pet scan activity allowed provided there are no ct scan changes indicating progression
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and not specified other
__label__0	study interventions are Belinostat . stage iv adult diffuse mixed cell lymphoma diagnosis and life expectancy of greater than twelve weeks
__label__0	study interventions are Cisplatin . salivary gland squamous cell carcinoma diagnosis and human immunodeficiency virus hiv positive patients receiving combination anti retroviral therapy are excluded from the study appropriate studies will be undertaken in patients receiving combination anti retroviral therapy when indicated
__label__0	study interventions are Antibodies, Monoclonal . stage iva colon cancer diagnosis and fertile patients must use effective contraception during and for at least three months after study participation
__label__0	study interventions are Vincristine . recurrent adult diffuse large cell lymphoma diagnosis and at least four weeks must have elapsed since prior large field radiation therapy
__label__0	study interventions are Immunoglobulins . ovarian clear cell cystadenocarcinoma diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Ifosfamide . adult leiomyosarcoma diagnosis and at least four weeks since prior radiotherapy
__label__0	study interventions are Interferon-alpha . colorectal cancer diagnosis and ecog zero two life expectancy
__label__0	study interventions are Fludarabine phosphate . recurrent adult non hodgkin lymphoma diagnosis and patient and donor pairs_homozygous at mismatched allele are considered two allele mismatch the patient is one hundred and one and the donor is two hundred and one and this type of mismatch is not allowed
__label__0	study interventions are Tipifarnib . histologically or cytologically confirmed advanced colorectal adenocarcinoma well differentiated or moderately well differentiated or poorly differentiated distant metastases not surgically curable measurable disease no prior treatment for disseminated disease no known brain metastases
__label__0	study interventions are Etoposide . adult supratentorial primitive neuroectodermal tumor pnet diagnosis and one mg dl
__label__0	study interventions are PLX3397 . metastatic breast cancer diagnosis and age eighteen years or older
__label__0	study interventions are Levoleucovorin . recurrent colon cancer diagnosis and serum potassium greater_than equal_than lln
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and no uncontrolled diabetes mellitus
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and appropriate imaging investigations including chest rays and or ct mri of chest abdomen pelvis or other scans as clinically indicated to document all sites of disease must be performed within twenty-eight days of study entry
__label__0	study interventions are Prednisone . prostate cancer diagnosis and organ confined pttwo with positive surgical margin and gleason eight ten
__label__0	study interventions are Capecitabine . metastatic colorectal cancer mcrc diagnosis and adequate renal function serum creatinine less_than doc mg one hundred ml or creatinine clearance greater_than forty-five ml min doc threemtwo
__label__0	study interventions are Etoposide phosphate . extensive stage small cell lung cancer diagnosis and bone lesions
__label__0	study interventions are pharmacological study . stage iv verrucous carcinoma of the oral cavity diagnosis and john wort
__label__0	study interventions are Everolimus . adult gliosarcoma diagnosis and four weeks twenty-eight days from any investigational agent two weeks onefour days from vincristine six weeks four2 days from nitrosoureas three weeks twenty-one days from procarbazine administration and one week seven days for non cytotoxic agents interferon tamoxifen thalidomide cis_retinoic acid etc
__label__0	study interventions are Antioxidants . cushing syndrome non classic congenital adrenal hyperplasia hyperprolactinemia thyroid dysfunction and androgen secreting tumors
__label__0	study interventions are Cyclosporine . thymic carcinoma diagnosis and shortening fraction or ejection fraction at least eighty of normal for age pulmonary
__label__0	study interventions are Fluorouracil . esophageal cancer diagnosis and measurable regional lymph nodes greater_than doc cm at stations two tenequal_than none or subdiaphragmatic lymph nodes at stations one5 one9 less_than doc cm by ct scan or mri allowed
__label__0	study interventions are Histone Deacetylase Inhibitors . pineal region neoplasm diagnosis and platelet count greater_than equal_than one hundred zero mm three transfusion independent defined as not receiving platelet transfusions for at least seven days prior to enrollment
__label__0	study interventions are Camptothecin . pancreatic adenocarcinoma diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than doc times upper limit of normal
__label__0	study interventions are CBL0137 . solid tumors diagnosis and patients enrolled in the expansion cohort must have at least one measureable lesion as defined by the recist doc criteria
__label__0	study interventions are AFP464 . male breast cancer diagnosis and willingness to return to mayo clinic for follow up
__label__0	study interventions are Oxaliplatin . stage iii pancreatic cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are Celecoxib . esophageal cancer diagnosis and pt within two seconds of the uln
__label__0	study interventions are Mycophenolate mofetil . childhood diffuse large cell lymphoma diagnosis and donor
__label__0	study interventions are Methylprednisolone Hemisuccinate . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Idelalisib . indolent non hodgkin lymphoma diagnosis and must have been born in japan and must not have lived outside of japan for greater_than one year in the five years prior to day one
__label__0	study interventions are Veliparib . fallopian tube endometrioid adenocarcinoma diagnosis and creatinine equal_than less_than doc institutional upper limit normal uln ctcae grade one
__label__0	study interventions are Vaccines . multiple myeloma and plasma cell neoplasm diagnosis and fevone fvc tlc and dlco greater_than forty predicted
__label__0	study interventions are Doxorubicin . ovarian cancer diagnosis and no other serious concurrent medical illness
__label__0	study interventions are Vitamin B Complex . advanced non small cell lung cancer nsclc diagnosis and to qualify for enrollment the following criteria must be met
__label__0	study interventions are Carboplatin . central nervous system tumor diagnosis and bilirubin less_than doc times upper limit of normal uln
__label__0	study interventions are Everolimus . advanced cancers diagnosis and female able to have children that has not been surgically sterilized or that has not been without menses for twelve consecutive months
__label__0	study interventions are Mitogens . germ cell tumors diagnosis and two hundred and thirty units l
__label__0	study interventions are Methylprednisolone . testicular germ cell tumor diagnosis and patient characteristics
__label__0	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and patients with ecog ps of two secondary to the underlying disease may be enrolled
__label__0	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the hypopharynx diagnosis and refractory to interleukin two il two
__label__0	study interventions are Bevacizumab . stage iv pancreatic cancer diagnosis and no uncontrolled hypertension
__label__0	study interventions are Fludarabine phosphate . myelodysplastic myeloproliferative neoplasms diagnosis and prior concurrent therapy
__label__0	study interventions are Topotecan . recurrent ovarian germ cell tumor diagnosis and histologically confirmed bone marrow metastases within thirty days prior to transplant prior bone marrow metastases with clearing of bone marrow less_than five contamination as measured by bilateral bone marrow biopsies at the time for evaluation for this protocol is acceptable
__label__0	study interventions are Liposomal doxorubicin . small intestine cancer diagnosis and no serious cardiac illness within the past six months including but not limited to the following
__label__0	study interventions are Antibodies . recurrent colon cancer diagnosis and no ongoing or active infection
__label__0	study interventions are Fludarabine . childhood grade iii lymphomatoid granulomatosis diagnosis and fhcrc matching allowed will be grade doc to doc
__label__0	study interventions are Antibodies, Monoclonal . metastatic renal cell carcinoma diagnosis and documented partial response or stable disease to first line tki exposure at ten twelve weeks
__label__0	study interventions are Ketoconazole . patients with locally advanced or metastatic disease any solid tumor except hepatocellular carcinoma cancer of the liver who have been relapsed or had progressive disease following standard of care treatment with chemotherapy prior to enrollment or intolerant to prior standard of care treatment with chemotherapy
__label__0	study interventions are Vidarabine . precursor cell lymphoblastic leukemia lymphoma diagnosis and cardiac
__label__0	study interventions are Cyclosporins . small intestine lymphoma diagnosis and donor must consent to filgrastim csf administration and leukapheresis
__label__0	study interventions are Sorafenib . stage iv renal cell cancer diagnosis and hgb greater_than equal_than doc gm dl transfusions allowed prior to enrollment
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and hemoglobin greater_than one doc dl
__label__0	study interventions are Methyltestosterone . stage prostate adenocarcinoma diagnosis and must have ability to take oral medication
__label__0	study interventions are Irinotecan . metastatic colorectal cancer diagnosis and competent to comprehend sign and date written institutional review board irb approved informed consent form before any study specific procedures are performed
__label__0	study interventions are mass spectrometry . adult anaplastic ependymoma diagnosis and total bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Interferon-alpha . lymphoma diagnosis and see disease characteristics hepatic
__label__0	study interventions are Immunoglobulins . fallopian tube carcinosarcoma diagnosis and serum glutamic oxaloacetic transaminase sgot aspartate aminotransferase ast less than or equal to three uln ctep ctcae version doc grade one
__label__0	study interventions are Cyclosporins . childhood nasal type extranodal nk cell lymphoma diagnosis and must have received prior chemotherapy or failed autografting following planned autologous transplant tandem is allowed
__label__0	study interventions are Capecitabine . pancreatic cancer diagnosis and age eighteen years or older
__label__0	study interventions are Vaccines . male breast cancer diagnosis and subjects of reproductive ability must agree to use contraceptives during the entire study period
__label__0	study interventions are Gemcitabine . patients should be asymptomatic for jaundice prior to cycle one day
__label__0	study interventions are Cyclosporins . refractory childhood hodgkin lymphoma diagnosis and acute lymphoblastic leukemia
__label__0	study interventions are Cyclosporine . recurrent adult immunoblastic large cell lymphoma diagnosis and acute and chronic leukemia patients must be age equal_than less_than fifty years patients up to age sixty years for any of these diseases who have syngeneic donor are eligible
__label__0	study interventions are Voriconazole . lymphoma diagnosis and renal
__label__0	study interventions are Antibodies, Monoclonal . recurrent breast cancer diagnosis and adequate hepatic function total or direct bilirubin equal_than less_than upper limit of normal uln alk phos equal_than less_than four uln
__label__0	study interventions are Carboplatin . lung cancer diagnosis and patient characteristics
__label__0	study interventions are Estrogens . breast cancer diagnosis and surgery
__label__0	study interventions are Gynaecological follow-up . infections papillomavirus diagnosis and written informed consent obtained from the subject prior to enrolment
__label__0	study interventions are Letrozole . stage iv breast cancer diagnosis and serum total bilirubin equal_than less_than doc uln or direct bilirubin equal_than less_than uln for subjects with total bilirubin levels greater_than doc uln
__label__0	study interventions are Erlotinib Hydrochloride . histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas
__label__0	study interventions are Rubitecan . ovarian cancer diagnosis and bilirubin no greater than doc times upper limit of normal uln
__label__0	study interventions are Dacarbazine . unspecified adult solid tumor protocol specific diagnosis and magnesium normal
__label__0	study interventions are Erlotinib Hydrochloride . cytological or pathological documented squamous cell carcinoma of oral cavity oropharynx larynx and hypopharynx patients with nasopharyngeal carcinoma can be included if the patients have grades or ii tumors according to the world health organization who classification
__label__0	study interventions are Piperazine citrate . brainstem glioma diagnosis and patient or legal guardian must give written informed consent or assent when applicable
__label__0	study interventions are Dacarbazine . ependymoma diagnosis and known non synonymous mutation in the following genes
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and at least two weeks since prior corticosteroids and recovered radiotherapy
__label__0	study interventions are Interferon-alpha . stage iiic skin melanoma diagnosis and no tests or exams are required to be repeated for step two registration randomization however patients who are known to have change in eligibility status after step one registration are not eligible for step two registration for example anc is not required to be repeated between step one and step two registration but the most recent anc performed before step two registration is required to be greater_than equal_than one five hundred mcl
__label__0	study interventions are Everolimus . stage iiib ovarian cancer diagnosis and pulmonary function tests
__label__0	study interventions are Fludarabine . noncontiguous stage ii grade two follicular lymphoma diagnosis and viral load has decreased by greater_than equal_than doc logs or viral load less_than five thousand copies ml plasma on haart therapy
__label__0	study interventions are Immunoglobulins . esophageal cancer diagnosis and nineteen and over performance status
__label__0	study interventions are Vidarabine . hodgkins lymphoma diagnosis and any score with life threatening cytopenia including red cell or platelet transfusion dependence
__label__0	study interventions are Dacarbazine . melanoma skin diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Vincristine . childhood burkitt lymphoma diagnosis and at least seven days since the completion of therapy with growth factor
__label__0	study interventions are Podophyllotoxin . refractory childhood hodgkin lymphoma diagnosis and hla genotypically or phenotypically identical related donor
__label__0	study interventions are Cetuximab . recurrent non small cell lung carcinoma diagnosis and as part of the oncology patient enrollment network open registration process the treating institution identity is provided in order to ensure that the current within three hundred and sixty-five days date of institutional review board approval for this study has been entered in the system
__label__0	study interventions are Fludarabine phosphate . ovarian cancer diagnosis and measurable disease per disease specific recist version doc
__label__0	study interventions are mass spectrometry . colorectal cancer diagnosis and disease characteristics
__label__0	study interventions are Hydrocortisone acetate . prostate adenocarcinoma diagnosis and absolute neutrophil count anc
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and no neuropathy greater_than grade one with pain within the past one4 days
__label__0	study interventions are Antibodies . stage ii grade two contiguous follicular lymphoma diagnosis and no evidence of resistant strains of hiv
__label__0	study interventions are Carboplatin . extraocular retinoblastoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate greater_than equal_than seventy ml min doc three two or serum creatinine based on age gender as follows
__label__0	study interventions are Fludarabine phosphate . lymphoma low grade diagnosis and ecog performance status
__label__0	study interventions are Sirolimus . stage iv renal cell cancer diagnosis and no serious non healing wound ulcer or bone fracture
__label__0	study interventions are Busulfan . recurrent marginal zone lymphoma diagnosis and patients must not have active infection
__label__0	study interventions are Rituximab . non hodgkin lymphoma diagnosis and ldh greater_than upper limit of normal
__label__0	study interventions are Methylprednisolone Hemisuccinate . lymphoma diagnosis and not specified
__label__0	study interventions are Busulfan . stage grade two follicular lymphoma diagnosis and females of childbearing potential must have negative pregnancy test
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and at least four weeks since prior radiotherapy to less than thirty of bone marrow
__label__0	study interventions are Antibodies, Monoclonal . malignant pancreatic glucagonoma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are pharmacological study . glucagonoma diagnosis and chemotherapy induced alopecia and grade two neuropathy are acceptable
__label__0	study interventions are Preference-tailored Information . colorectal neoplasms diagnosis and has current address and telephone number listed in medical record
__label__0	study interventions are Epithelial cell adhesion molecule (EpCAM) ferrofluid . gastric cancer diagnosis and clinical or radiographic evidence of metastatic disease
__label__0	study interventions are Immunoglobulins . squamous cell carcinoma metastatic in the neck with occult primary diagnosis and total bilirubin within normal limits must be obtained equal_than less_than two weeks prior to randomization
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and other
__label__0	study interventions are Paclitaxel . undifferentiated ovarian carcinoma diagnosis and if patient declines to participate in the perfusion imaging portion of the protocol clinical rationale for declination of imaging form will be completed as part of the data submission for acrin six thousand, six hundred and ninety-five
__label__0	study interventions are pharmacological study . adult gliosarcoma diagnosis and no new york heart association class iii or iv heart failure
__label__0	study interventions are Aminopterin . non hodgkin lymphoma diagnosis and must have received first line chemotherapy
__label__0	study interventions are Rituximab . hodgkin lymphoma diagnosis and male greater_than equal_than forty-five years of age stage iv albumin less_than four white blood count wbc greater_than equal_than fifteen lymphocytes less_than eight or less_than six hundred hgb less_than one doc
__label__0	study interventions are Irinotecan . stage iv renal cell cancer diagnosis and oncocytoid
__label__0	study interventions are Mycophenolic Acid . stage adult lymphoblastic lymphoma diagnosis and single allele disparity for hla b drbone and dqbone
__label__0	study interventions are Sirolimus . recurrent breast cancer diagnosis and adequate liver function as indicated by
__label__0	study interventions are Pazopanib Hydrochloride . recurrent uterine corpus sarcoma diagnosis and minor
__label__0	study interventions are Gemcitabine . recurrent adult hodgkin lymphoma diagnosis and all other lesions including small lesions less than doc doc cm and truly non measurable lesions lesions that are considered non measurable include the following
__label__0	study interventions are Liposomal doxorubicin . male breast cancer diagnosis and ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and ecog performance status of zero or one
__label__0	study interventions are Bortezomib . stage childhood hodgkin lymphoma diagnosis and lymphocyte predominance lp
__label__0	study interventions are Dexamethasone acetate . stage multiple myeloma diagnosis and no new york heart association class ii iv heart disease
__label__0	study interventions are Doxorubicin . childhood immunoblastic large cell lymphoma diagnosis and doc mg dl ten to less_than thirteen years of age
__label__0	study interventions are Zoledronic acid . metastatic cancer diagnosis and no uncontrolled medical illness or infection including but not limited to the following
__label__0	study interventions are Levoleucovorin . stage ivb rectal cancer diagnosis and left ventricular ejection fraction lvef greater_than equal_than fifty as determined by multigated acquisition muga scan or echocardiogram
__label__0	study interventions are Vaccines . cutaneous ocular or mucosal melanoma
__label__0	study interventions are Mitogens . germ cell tumors diagnosis and two to less_than six years male and female serum creatinine
__label__0	study interventions are Irinotecan . neoplasm metastasis diagnosis and karnofsky index greater_than sixty
__label__0	study interventions are Topotecan . unspecified adult solid tumor protocol specific diagnosis and creatinine no greater than doc mg dl or creatinine clearance at least sixty ml min cardiovascular
__label__0	study interventions are Cyclosporine . cutaneous cell non hodgkin lymphoma diagnosis and all genotypically hl negative or dr identical siblings are eligible to be bone marrow donors so long as their general medical condition permits the safe use of general or spinal anesthesia selected donors who are not hla identical may be considered for use as long as they are dr identical mlc compatible and are in good condition to safely undergo spinal or general anesthesia
__label__0	study interventions are Pemetrexed . carcinoma non small cell lung diagnosis and leukocytes greater_than three thousand mm³ anc greater_than one thousand, five hundred mmthree platelets greater_than one hundred zero mmthree creatinine clearance greater_than fifty ml min and serum creatinine less_than doc upper limit of normal
__label__0	study interventions are Alvocidib . histologically confirmed locally advanced or metastatic solid tumor that is refractory to standard therapy or for which no standard therapy exists
__label__0	study interventions are Paclitaxel . transitional cell carcinoma diagnosis and kps sixty
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and performance status
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and age greater_than eighteen years
__label__0	study interventions are Dexamethasone 21-phosphate . plasma cell myeloma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are laboratory biomarker analysis . gastrointestinal cancer diagnosis and disease characteristics
__label__0	study interventions are Alemtuzumab . childhood burkitt lymphoma diagnosis and mantle cell nhl
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Mycophenolate mofetil . indolent non hodgkin lymphoma diagnosis and must be refractory to fludarabine fludarabine phosphate or fail to have complete or partial response after therapy with regimen containing fludarabine or another nucleoside_analog cladribine two cda_pentostatin or experience disease relapse within 1two months after completing therapy with regimen containing fludarabine or another nucleoside_analog
__label__0	study interventions are Colonoscopy . colorectal cancer diagnosis and able to provide informed consent
__label__0	study interventions are Vidarabine . malignant lymphoma large cell type diagnosis and cord blood cb donor selection will be based on institutional guidelines and in general should be selected to optimize both human leukocyte antigen hla match and cell dose additionally cb grafts shall consist of one or two cb donors based on but not exclusively determined by cell dose total nucleated cell tnc kg and cdthirty-four kg hla matching and disease status and indication for transplant attending preference will be allowed for single versus double unit as well as the degree of mismatching based on patient specific factors as long as the following minimum criteria are met
__label__0	study interventions are Vidarabine . splenic marginal zone lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Vorinostat . childhood low grade cerebellar astrocytoma diagnosis and no uncontrolled infection
__label__0	study interventions are Sirolimus . neuroendocrine tumor grade three and disease progression as measured by response evaluation criteria in solid tumors recist one one diagnosis and metabolic function
__label__0	study interventions are Camptothecin . lung cancer diagnosis and surgery
__label__0	study interventions are Cetuximab . recurrent non small cell lung carcinoma diagnosis and exon twenty-one leight hundred and fifty-eightr exon nineteen deletion exon eighteen g7nineteenx exon twenty-one leight hundred and sixty-oneq
__label__0	study interventions are Cyclosporine . nodal marginal zone cell lymphoma diagnosis and patients undergoing transplant in early relapse are eligible for transplant in first and second relapse only
__label__0	study interventions are Pancrelipase . adenocarcinoma of the pancreas diagnosis and amiodarone erythromycin clarithromycin grapefruit juice isoniazid ketoconazole itraconazole or nefazodone
__label__0	study interventions are Cyclosporins . myelodysplastic myeloproliferative neoplasms diagnosis and alkaline phosphatase less than two times upper limit of normal uln
__label__0	study interventions are Cyclophosphamide . metastatic renal cell cancer diagnosis and adequate renal function
__label__0	study interventions are AR-42 . hepatosplenic cell lymphoma diagnosis and patients or their legal representatives must be able to read understand and provide informed consent to participate in the trial
__label__0	study interventions are Alvocidib . unspecified adult solid tumor protocol specific diagnosis and no cardiac disease that would preclude study participation
__label__0	study interventions are Immunoglobulins . stage iii rectal cancer diagnosis and no history of allergic reactions hypersensitivity or intolerance to cetuximab and or compounds of similar chemical or biologic composition to pertuzumab or cetuximab other monoclonal antibodies such as bevacizumab that led to discontinuation of the drug
__label__0	study interventions are Cisplatin . salivary gland tumors diagnosis and total bilirubin less_than equal_than doc times institutional uln
__label__0	study interventions are Vidarabine . solid tumor diagnosis and eastern cooperative oncology group ecog performance status zero one
__label__0	study interventions are Imatinib Mesylate . endometrial cancer diagnosis and bilirubin no greater than doc mg dl albumin at least twenty-five l renal
__label__0	study interventions are Endothelial Growth Factors . stage iii esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Gemcitabine . ureter cancer diagnosis and not hiv positive
__label__0	study interventions are pharmacological study . childhood grade iii lymphomatoid granulomatosis diagnosis and thirteen to less_than sixteen years
__label__0	study interventions are Fludarabine phosphate . childhood immunoblastic large cell lymphoma diagnosis and myelosuppressive chemotherapy must be discontinued three weeks prior to conditioning with the exception of hydroxyurea or imatinib
__label__0	study interventions are Paclitaxel . solid tumors diagnosis and cardiac ejection fraction greater_than fifty and qtcfless_than 4fifty ms males or less_than four hundred and seventy ms females on ecg at baseline
__label__0	study interventions are Immunoglobulin G . stage iva uterine corpus cancer diagnosis and radiation therapy adjuvant or palliative must be completed greater_than equal_than four weeks prior to registration if applicable
__label__0	study interventions are graft versus host disease prophylaxis/therapy . lymphoma diagnosis and not specified
__label__0	study interventions are Acetaminophen . cancer diagnosis and age greater_than eighteen years
__label__0	study interventions are Leucovorin . mucinous adenocarcinoma of the rectum diagnosis and patients must not have received prior chemotherapy or pelvic irradiation therapy
__label__0	study interventions are CAR-T cell immunotherapy . pancreatic cancer diagnosis and life expectancygreater_than three months
__label__0	study interventions are Prednisolone acetate . recurrent small lymphocytic lymphoma diagnosis and patients must not have active infection
__label__0	study interventions are educational intervention . cancer survivor diagnosis and not incarcerated
__label__0	study interventions are Nintedanib . nonsmall cell lung cancer diagnosis and histologically confirmed diagnosis of advanced metastatic or unresectable nsclc with mutations rearrangement and fusion involving ret oncogene or abnormalities non synonymous snv or amplification in the nintedanib target genes vegfrone three tp5three pdgfr pdgfr and fgfrone three
__label__0	study interventions are Etoposide . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and please see study schema for further details
__label__0	study interventions are Everolimus . stage iiic primary peritoneal cancer diagnosis and hcc confirmed by biopsy or diagnosed by clinical and radiologic criteria all of the following criteria must be met or biopsy is required
__label__0	study interventions are Immunoglobulins . childhood diffuse large cell lymphoma diagnosis and low grade nhl
__label__0	study interventions are BB 1101 . testicular germ cell tumor diagnosis and no psychiatric illness or multi system organ failure
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and negative pregnancy test for women of child bearing age
__label__0	study interventions are Fludarabine phosphate . contiguous stage ii grade three follicular lymphoma diagnosis and positive anti donor cytotoxic crossmatch is an absolute donor exclusion
__label__0	study interventions are Endothelial Growth Factors . childhood pleomorphic rhabdomyosarcoma diagnosis and radiation therapy rt
__label__0	study interventions are Cytarabine . precancerous condition diagnosis and at least four weeks since prior and no concurrent surgery
__label__0	study interventions are Web-based Counseling . prostate carcinoma diagnosis and male
__label__0	study interventions are Doxorubicin . stage iib breast cancer diagnosis and cerebrovascular disease including transient ischemic attack tia stroke or subarachnoid hemorrhage
__label__0	study interventions are Albumin-Bound Paclitaxel . unknown primary tumors diagnosis and negative urine or serum pregnancy test within twenty-one days of study treatment for women of childbearing potential or postmenopausal status
__label__0	study interventions are Vinorelbine . recurrent breast cancer diagnosis and no other prior experimental angiogenesis inhibitors
__label__0	study interventions are Cyclophosphamide . stage iii adult lymphoblastic lymphoma diagnosis and acute lymphoblastic leukemia
__label__0	study interventions are Everolimus . tumors diagnosis and patients must have the following clinical laboratory values
__label__0	study interventions are Cisplatin . bladder cancer diagnosis and performance status
__label__0	study interventions are Carboplatin . ovarian serous cystadenocarcinoma diagnosis and optimal no greater than one cm or suboptimal residual disease after initial surgery
__label__0	study interventions are Melphalan . metastatic cancer diagnosis and no biopsy proven cirrhosis with evidence of portal hypertension by history endoscopy or radiologic study
__label__0	study interventions are Irinotecan . stage ivb colon cancer diagnosis and fertile patients must use effective contraception during and for at least three months after study participation
__label__0	study interventions are Cisplatin . advanced breast cancer diagnosis and doc upper limits of normal alkaline phosphatase aspartate aminotransferase and alanine aminotransferase
__label__0	study interventions are Gemcitabine . stage iii non small cell lung cancer diagnosis and platelets greater_than one hundred zero mcl
__label__0	study interventions are Epirubicin . histologically confirmed infiltrative breast cancer meeting one of the following criteria
__label__0	study interventions are Antibodies, Monoclonal . recurrent laryngeal squamous cell carcinoma diagnosis and patients must not be receiving chronic daily treatment with aspirin greater_than three hundred and twenty-five mg day or non steroidal anti inflammatory agents nsaid known to inhibit platelet function the use of anti platelet agents dipyridamole_persantine ticlopidine_ticlid clopidogrel_plavix is allowed only if patient is not receiving aspirin or nsaid known to inhibit platelet function
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iib fallopian tube cancer diagnosis and neuropathy sensory and motor less than or equal to ctcae grade one
__label__0	study interventions are Daunorubicin . lymphoma diagnosis and not specified
__label__0	study interventions are Bevacizumab . stage iii pancreatic cancer diagnosis and no concurrent uncontrolled illness
__label__0	study interventions are Glycine . females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least twenty-five miu ml within ten fourteen days prior to and again within twenty-four hours of starting pomalidomide or mlnnine thousand, seven hundred and eight and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least twenty-eight days before she starts taking pomalidomide or mlnnine thousand, seven hundred and eight through ninety days after the last dose of study drug fcbp must also agree to ongoing pregnancy testing men must agree to use latex condom during sexual contact with fcbp even if they have had vasectomy from the time of signing the informed consent form through ninety days after the last dose of study drug all patients must be counseled at minimum of every twenty-eight days about pregnancy precautions and risks of fetal exposure
__label__0	study interventions are Mycophenolic Acid . indolent non hodgkin lymphoma diagnosis and must have received and failed frontline therapy
__label__0	study interventions are DSP-7888 Dosing Emulsion . non small cell lung cancer diagnosis and patient with metastatic disease has had at least one prior line of therapy for metastatic disease f
__label__0	study interventions are Gemcitabine . stage iv non small cell lung cancer diagnosis and at least four weeks since major surgery or radiation therapy
__label__0	study interventions are Midazolam . colorectal cancer diagnosis and part bfour
__label__0	study interventions are Imatinib Mesylate . brain and central nervous system tumors diagnosis and prior concurrent therapy
__label__0	study interventions are Carboplatin . adenocarcinoma including bronchoalveolar
__label__0	study interventions are Nefopam . breast neoplasm malignant primary diagnosis and nipple sparing mastectomy
__label__0	study interventions are Interleukin-2 . metastatic renal cell carcinoma diagnosis and adequate renal hepatic and hematological function
__label__0	study interventions are Panobinostat . multiple myeloma in relapse diagnosis and serum flc assay
__label__0	study interventions are Antibodies, Monoclonal . stage iii ovarian epithelial cancer diagnosis and bone metastases that can be assessed by ct scan or mri considered evaluable
__label__0	study interventions are Vidarabine . metastatic gastric cancer diagnosis and patients may have undergone minor surgical procedures with the past three weeks as long as all toxicities have recovered to grade one or less
__label__0	study interventions are Aromatase Inhibitors . breast carcinoma diagnosis and total bilirubin less_than institutional upper limit of normal
__label__0	study interventions are Aprepitant . stage iv fallopian tube cancer diagnosis and carboplatin auc six ip on day one
__label__0	study interventions are Oxaliplatin . stage iiib esophageal cancer diagnosis and aspartate aminotransferase ast alanine aminotransferase alt less_than threex the institutional uln
__label__0	study interventions are Vinorelbine . breast cancer diagnosis and hormone receptor status
__label__0	study interventions are Liposomal doxorubicin . contiguous stage ii mantle cell lymphoma diagnosis and absolute neutrophil count anc greater_than one thousand, five hundred mm three unless low count due to marrow involvement or splenomegaly
__label__0	study interventions are Fludarabine . stage ii adult contiguous immunoblastic lymphoma diagnosis and fhcrc matching allowed will be grades doc to doc
__label__0	study interventions are Iodine . concurrent enrollment on protocol swog eight thousand, nine hundred and forty-seven lymphoma serum repository or protocol swog eight thousand, eight hundred and nineteen lymphoma tissue repository is encouraged
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and must have failed last line of treatment refractory to last line of treatment
__label__0	study interventions are Cisplatin . primary peritoneal carcinoma diagnosis and one cm residual disease at the completion of the cytoreductive surgery gog criteria for optimally cytoreduction
__label__0	study interventions are Axitinib . carcinoma non small cell lung nsclc diagnosis and adequate organ function as defined by the following criteria
__label__0	study interventions are Endothelial Growth Factors . recurrent renal cell carcinoma diagnosis and performance status eastern cooperative oncology group ecog zero two or karnofsky score greater_than equal_than 6zero
__label__0	study interventions are Erlotinib Hydrochloride . tongue cancers diagnosis and wbc count greater_than three zero mmthree
__label__0	study interventions are apatinib tablet . gastric carcinoma diagnosis and life expectancy of more than three months
__label__0	study interventions are Gemcitabine . endometrial clear cell adenocarcinoma diagnosis and must have greater_than one target lesion
__label__0	study interventions are Bevacizumab . stage iii colon cancer diagnosis and no unstable angina within the past three months
__label__0	study interventions are Tacrolimus . hepatosplenic cell lymphoma diagnosis and myelodysplastic syndromes myeloproliferative disorders mds mpd
__label__0	study interventions are Adrenergic beta-Antagonists . primary operable breast cancer diagnosis and no evidence of metastatic disease prior to surgery
__label__0	study interventions are 851B . papillomavirus infections diagnosis and subject has one of the following
__label__0	study interventions are Fluourouracil . patients with histologically verified operable rectal cancer dukes and stage ii ttwo four nzero three mzero rzero
__label__0	study interventions are Cisplatin . non resectable cholangiocarcinoma diagnosis and patients with hepatitis infection must be on appropriate antiviral therapy
__label__0	study interventions are Cyclophosphamide . subjects may have received no prior chemotherapy for breast cancer
__label__0	study interventions are Paclitaxel . fallopian tube serous adenocarcinoma diagnosis and defined as disease that has progressed by imaging while receiving platinum or had recurrence within six months of the last receipt of platinum based chemotherapy rising caone hundred and twenty-five only is not considered as platinum resistant or refractory disease
__label__0	study interventions are Cyclosporine . unspecified childhood solid tumor protocol specific diagnosis and cw one thousand, two hundred and four one thousand, two hundred and five
__label__0	study interventions are Erlotinib Hydrochloride . stage iv adenoid cystic carcinoma of the oral cavity diagnosis and no ongoing or active infection
__label__0	study interventions are Albumin-Bound Paclitaxel . head and neck cancer diagnosis and platelet count greater_than one hundred zero µl
__label__0	study interventions are Copper . hertwo positive breast cancer diagnosis and participants must have normal cardiac ejection fraction
__label__0	study interventions are Oxaliplatin . recurrent childhood central nervous system embryonal tumor diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Fluorouracil . gastrointestinal cancer diagnosis and patient disease status must be as follows
__label__0	study interventions are Cisplatin . histological confirmation of hpv positive squamous cell carcinoma of the oropharynx
__label__0	study interventions are Antibodies, Monoclonal . mantle cell lymphoma diagnosis and fl criteria for diagnosis
__label__0	study interventions are Oxaliplatin . peritoneal cancer diagnosis and adequate bone marrow as evidenced by
__label__0	study interventions are Capecitabine . esophageal cancer diagnosis and granulocyte count greater_than one five hundred mm three
__label__0	study interventions are Antibodies, Monoclonal . myeloproliferative neoplasm diagnosis and must have baseline donor cell chimerism of greater_than equal_than twenty
__label__0	study interventions are Laboratory Biomarker Analysis . metastatic renal cell cancer diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than three institutional upper limit of normal if liver metastases are present
__label__0	study interventions are Immunoglobulins . stage iv breast cancer diagnosis and patients must not have history of abdominal fistula or intra abdominal abscess within six months prior to study registration
__label__0	study interventions are Vincristine . neuroblastoma diagnosis and alt less than three times normal
__label__0	study interventions are Prednisone . hormone refractory prostate cancer diagnosis and platelet count at least one hundred ten nineth l
__label__0	study interventions are Doxorubicin . human epidermal growth factor two negative carcinoma of breast diagnosis and hertwo negative disease as measured by ihc or fish
__label__0	study interventions are Prednisolone . recurrent adult immunoblastic large cell lymphoma diagnosis and patients undergoing transplant in early relapse are eligible for transplant in first and second relapse only
__label__0	study interventions are biomarker analysis . breast cancer diagnosis and not specified
__label__0	study interventions are Etoposide . stage ii adult cell leukemia lymphoma diagnosis and serum creatinine less_than doc mg dl
__label__0	study interventions are Trastuzumab . diagnosis of locally advanced breast cancer
__label__0	study interventions are Immunoglobulins . neuroblastoma diagnosis and shortening fraction at least twenty-eight or
__label__0	study interventions are Razoxane . recurrent childhood lymphoblastic lymphoma diagnosis and must not have received within three weeks of enrollment onto this study six weeks if prior nitrosourea hydroxyurea may be administered prior to study enrollment in such cases at least twenty-four hours must have elapsed between the last dose of hydroxyurea and the first dose of obatoclax
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and no other medical or social condition that would preclude study compliance
__label__0	study interventions are Nivolumab . metastatic melanoma diagnosis and evidence of evaluable disease
__label__0	study interventions are Lapatinib . unspecified adult solid tumor protocol specific diagnosis and patients with brain metastases who require corticosteroids or anticonvulsants must be on stable or decreasing dose of corticosteroids and seizure free for thirty days prior to study entry
__label__0	study interventions are Immunoglobulins . recurrent squamous cell carcinoma of the nasopharynx diagnosis and no gastrointestinal gi tract disease resulting in an inability to take oral medication
__label__0	study interventions are Flt3 ligand protein . stage iic skin melanoma diagnosis and prior radiation chemotherapy or biologics not allowed
__label__0	study interventions are polymerase chain reaction . extragonadal germ cell tumor diagnosis and disease characteristics
__label__0	study interventions are Kappa CD28 T cells . lymphoma diagnosis and available autologous transduced peripheral blood cells with fifteen or more expression of car kappa determined by flow cytometry
__label__0	study interventions are DNA analysis . sarcoma diagnosis and disease characteristics
__label__0	study interventions are Permanent prostate implant . prostate cancer diagnosis and candidate for permanent prostate implant
__label__0	study interventions are Bortezomib . stage ivc verrucous carcinoma of the oral cavity diagnosis and patients may have had one zero one prior chemotherapy regimen for recurrent or metastatic scchn chemotherapy for recurrent or metastatic disease must have been completed at least four weeks prior to study entry
__label__0	study interventions are Cediranib . adult gliosarcoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Antibodies, Monoclonal . recurrent gastric cancer diagnosis and no acute ischemia or significant conduction abnormality by ekg
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and detectable disease is defined in patient as one who does not have measurable disease but has at least one of the following conditions
__label__0	study interventions are Cisplatin . brain and central nervous system tumors diagnosis and negative pregnancy test
__label__0	study interventions are Fludarabine . melanoma diagnosis and n
__label__0	study interventions are Etoposide phosphate . aids related small noncleaved cell lymphoma diagnosis and participants must have fifteen blank unstained slides or diagnostic tissue block must be available for central pathology review by the amc core pathology laboratory
__label__0	study interventions are Everolimus . neuroendocrine tumors diagnosis and no history of and no active symptoms related to carcinoid syndrome
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and dlco greater_than fifty of expected value corrected for blood hemoglobin level and alveolar volume
__label__0	study interventions are Laboratory Biomarker Analysis . hepatoblastoma diagnosis and no clinically significant cardiac arrhythmias stroke or myocardial infarction within six months prior to enrollment
__label__0	study interventions are Deferasirox . recurrent adult burkitt lymphoma diagnosis and systemic diseases cardiovascular renal hepatic etc
__label__0	study interventions are Cyclosporine . peroxisomal disorder diagnosis and signed consent
__label__0	study interventions are Fludarabine phosphate . non hodgkin lymphoma diagnosis and nineteen four eleven or other mll_rearrangements hypodiploidy or ikzfone abnormalities dna index less_than doc one greater_than one cycle to obtain cr or presence minimal residual disease mrd
__label__0	study interventions are Heptavalent Pneumococcal Conjugate Vaccine . myeloma diagnosis and prior to lenalidomide maintenance phase all study participants must be registered into the mandatory revassist program and be willing and able to comply with the requirements of revassist
__label__0	study interventions are Erlotinib Hydrochloride . recurrent malignant mesothelioma diagnosis and other active disorders of the cornea
__label__0	study interventions are Docetaxel . sarcoma diagnosis and histologically confirmed diagnosis of one of the following
__label__0	study interventions are Vinorelbine . stage childhood hodgkin lymphoma diagnosis and lymphocyte predominance lp
__label__0	study interventions are Cortisone . recurrent prostate carcinoma diagnosis and systemic corticosteroids excluding prednisone and dexamethasone administered as part of study protocol inhaled intranasal or topical corticosteroids are acceptable steroid eye drops are contraindicated however for two weeks prior to vaccination and for at least four weeks after vaccinia vaccination
__label__0	study interventions are Sirolimus . adult giant cell glioblastoma diagnosis and no ongoing or active infection
__label__0	study interventions are anti-CD20-CAR vector-transduced autologous T cells . hematopoietic lymphoid cancer diagnosis and not eligible or appropriate for conventional allogeneic sct
__label__0	study interventions are pain therapy . cancer survivor diagnosis and hemoglobin greater_than eleven dl
__label__0	study interventions are Gefitinib . stage iia non small cell lung cancer diagnosis and right middle lobe
__label__0	study interventions are Cisplatin . bladder cancer diagnosis and no clinical signs of cns involvement
__label__0	study interventions are Lenograstim . childhood immunoblastic large cell lymphoma diagnosis and hiv negative
__label__0	study interventions are Indomethacin . metastatic prostate carcinoma diagnosis and progression of unidimensionally measurable disease assessed within forty-two days prior to initial administration of drug
__label__0	study interventions are Everolimus . stage iiib cervical cancer diagnosis and patients must have unresectable locally advanced or metastatic disease incurable by standard therapies
__label__0	study interventions are Triptorelin Pamoate . breast cancer diagnosis and neoadjuvant or adjuvant trastuzumab herceptin allowed
__label__0	study interventions are laboratory biomarker analysis . recurrent breast cancer diagnosis and performance status
__label__0	study interventions are Histone Deacetylase Inhibitors . nodal marginal zone cell lymphoma diagnosis and hemoglobin greater_than nine dl
__label__0	study interventions are Anticonvulsants . brain and central nervous system tumors diagnosis and no concurrent enrollment in another therapeutic clinical trial
__label__0	study interventions are Rituximab . low grade cell lymphoma unspecified
__label__0	study interventions are Albumin-Bound Paclitaxel . prostate cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Irinotecan . breast cancer diagnosis and nsclc
__label__0	study interventions are Albumin-Bound Paclitaxel . locally recurrent breast cancer diagnosis and patients must demonstrate resolution of all prior chemotherapy or radiation related toxicities to grade less than or equal to one including peripheral neuropathy with the exception of alopecia any grade permissible
__label__0	study interventions are Fludarabine . lymphoma diagnosis and no active serious infection
__label__0	study interventions are Siltuximab . multiple myeloma diagnosis and measurable secretory disease defined as either serum monoclonal paraprotein negative protein greater than or equal to greater_than equal_than one gram per deciliter dl or urine monoclonal light chain protein greater than greater_than two hundred milligram twenty-four hours
__label__0	study interventions are Bevacizumab . histologically or cytologically confirmed ovarian epithelial fallopian tube or primary peritoneal cavity cancer
__label__0	study interventions are Cisplatin . histologically confirmed epithelial ovarian carcinoma
__label__0	study interventions are Metformin . stage iiic fallopian tube cancer diagnosis and eligibility criteria for pre registration
__label__0	study interventions are Cyclophosphamide . lung cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Ado-trastuzumab emtansine . breast cancer diagnosis and hertwo low expression
__label__0	study interventions are Sirolimus . adult diffuse large cell lymphoma diagnosis and only filgrastim csf mobilized pbsc only will be permitted as hematopoietic stem cell hsc_source on this protocol
__label__0	study interventions are Carboplatin . male breast cancer diagnosis and the patient must have failed standard curative and or palliative therapies for their disease
__label__0	study interventions are Cyclosporins . stage iv adult diffuse small cleaved cell lymphoma diagnosis and philadelphia_chromosome positive ph positive metaphases greater_than zero but less_than thirty-five
__label__0	study interventions are Selumetinib . endometrial adenocarcinoma diagnosis and gog performance status ps zero two for patients who received one prior treatment regimen
__label__0	study interventions are Camptothecin . gastric cancer diagnosis and negative pregnancy test
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Bevacizumab . neurofibromatosis type two diagnosis and no history of abdominal fistula or gastrointestinal perforation within six months prior to day one of treatment
__label__0	study interventions are Immunoglobulins . aids related plasmablastic lymphoma diagnosis and all stages of disease
__label__0	study interventions are Rituximab . stage iv grade two follicular lymphoma diagnosis and patients may receive erythropoietin growth factors to maintain adequate hemoglobin levels greater_than equal_than doc mg dl
__label__0	study interventions are Prednisone . contiguous stage ii mantle cell lymphoma diagnosis and ecog ps zero two
__label__0	study interventions are Oxaliplatin . stage ia esophageal cancer diagnosis and tone three or tfour with local invasion confined to diaphragm pleura or pericardium
__label__0	study interventions are Irinotecan . gastric cancer diagnosis and prior concurrent therapy
__label__0	study interventions are questionnaire administration . cancer survivor diagnosis and disease characteristics
__label__0	study interventions are alvespimycin hydrochloride . stage iii grade three follicular lymphoma diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Cisplatin . stage iic ovarian cancer diagnosis and note
__label__0	study interventions are Deoxyuridine . stage iv adult burkitt lymphoma diagnosis and ongoing or active infection
__label__0	study interventions are Isophosphamide mustard . testicular germ cell tumor diagnosis and one of the following lab values
__label__0	study interventions are Letrozole . metastatic breast cancer diagnosis and prior chemotherapy does not exclude patients from study as long as the current therapy was hormonal therapy alone
__label__0	study interventions are Fludarabine . multiple myeloma and plasma cell neoplasm diagnosis and see disease characteristics
__label__0	study interventions are Ixazomib . multiple myeloma diagnosis and alanine aminotransferase alt and aspartate aminotransferase ast three uln
__label__0	study interventions are Triptorelin Pamoate . breast cancer diagnosis and hematopoietic
__label__0	study interventions are Vinblastine . childhood mixed cellularity hodgkin lymphoma diagnosis and ld reticular
__label__0	study interventions are Everolimus . recurrent renal cell cancer diagnosis and hb greater_than nine dl
__label__0	study interventions are Androgens . human epidermal growth factor two negative carcinoma of breast diagnosis and patients must complete all screening assessments as outlined in the protocol
__label__0	study interventions are therapeutic conventional surgery . adult glioblastoma diagnosis and patients with multifocal disease can be included as long as resection is considered reasonable option to manage the nodule that is progressing
__label__0	study interventions are Nivolumab . lymphoma non hodgkin diagnosis and appropriate contraceptive measures must be taken
__label__0	study interventions are Antibodies . ovarian mucinous cystadenocarcinoma diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Liposomal doxorubicin . small intestine lymphoma diagnosis and doc mg dl male or doc mg dl female thirteen to less_than sixteen years of age
__label__0	study interventions are Docetaxel . ovarian endometrioid adenocarcinoma diagnosis and front line treatment may include maintenance therapy following complete clinical or pathological response however maintenance cytotoxic chemotherapy must be discontinued for minimum of six months prior to documentation of recurrent disease patients receiving maintenance biological therapy or hormonal therapy are eligible provided their recurrence is documented more than six months from primary cytotoxic chemotherapy completion includes maintenance chemotherapy and minimum four weeks has elapsed since their last infusion of biological therapy
__label__0	study interventions are Prednisone . hodgkin lymphoma histologically proven
__label__0	study interventions are magnetic resonance imaging . cervical cancer diagnosis and hematopoietic
__label__0	study interventions are Paclitaxel . lung cancer diagnosis and unstable or poorly controlled angina pectoris including prinzmetal variant angina pectoris
__label__0	study interventions are Donepezil . metastatic cancer diagnosis and life expectancy greater_than thirty weeks
__label__0	study interventions are Metronidazole . stage iib ovarian epithelial cancer diagnosis and platelet greater_than equal_than seventy-five zero ul
__label__0	study interventions are Questionnaire Administration . stage iii ovarian cancer diagnosis and patients with any performance status yet with the ability to verbally consent and participate in the first assessment
__label__0	study interventions are Antibodies . refractory hodgkin lymphoma diagnosis and eastern cooperative oncology group ecog american college of radiology imaging network acrin performance status between zero two
__label__0	study interventions are cilengitide . stage iii adult diffuse small cleaved cell lymphoma diagnosis and no clinically significant gastrointestinal blood loss within the past six weeks
__label__0	study interventions are Vaccines . recurrent adult diffuse large cell lymphoma diagnosis and medically indicated subunit_engerix for hbv gardasil for hpv or killed vaccines influenza pneumococcal or allergy treatment with antigen injections
__label__0	study interventions are Questionnaires . ovarian cancer diagnosis and able to read and write english
__label__0	study interventions are Paclitaxel . stage iv breast cancer diagnosis and and or progesterone receptor pr positive must have developed metastatic disease while on adjuvant hormonal therapy or have progression of disease after at least one hormonal therapy for advanced disease and may have received unlimited prior hormonal therapies
__label__0	study interventions are Irinotecan . recurrent rectal cancer diagnosis and patients must have ecog performance status zero one
__label__0	study interventions are Etoposide phosphate . cutaneous cell non hodgkin lymphoma diagnosis and patients must be anticipated to complete at least two cycles of chemotherapy
__label__0	study interventions are Mycophenolic Acid . multiple myeloma and plasma cell neoplasm diagnosis and patient characteristics
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and laboratory
__label__0	study interventions are Belinostat . stage iv adult hodgkin lymphoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Antibodies, Monoclonal . measurable disease by international working group iwg response criteria for lymphoma
__label__0	study interventions are Antibodies, Monoclonal . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and absolute neutrophil count greater_than one zero mm³
__label__0	study interventions are Cyclosporine . multiple myeloma and plasma cell neoplasm diagnosis and accelerated phase
__label__0	study interventions are Tamoxifen . solid tumor diagnosis and confirmed diagnosis of advanced malignancies that may be controlled with pseventyssixk or akt inhibition based on already identified molecular alteration known to affect the pam pathway such as
__label__0	study interventions are Anastrozole . breast cancer diagnosis and hormone receptor status
__label__0	study interventions are Fludarabine phosphate . melanoma diagnosis and oxygen saturation of greater than or equal to ninety on room air
__label__0	study interventions are Docetaxel . breast cancer diagnosis and all patients must have chest ray pa and lateral abdominal ultrasound or ct scan or mri and bone scan
__label__0	study interventions are Glycine . diagnosed or treated for another malignancy within one year of enrollment with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin an in situ malignancy or low risk prostate cancer after curative therapy
__label__0	study interventions are Endothelial Growth Factors . stage iva uterine sarcoma diagnosis and sgot and alkaline phosphatase less than or equal to doc uln per the ctcae version doc grade one
__label__0	study interventions are Antibodies . recurrent osteosarcoma diagnosis and doc mg dl
__label__0	study interventions are Antibodies . recurrent grade one follicular lymphoma diagnosis and expected survival greater_than equal_than three months
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and no prior chemotherapy for recurrence
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and acute lymphocytic leukemia all
__label__0	study interventions are Pomalidomide . multiple myeloma diagnosis and males must agree to use latex condom during sexual contact with fcbp while participating in the study and for twenty-eight days following discontinuation from study treatment
__label__0	study interventions are ispinesib . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and creatinine equal_than less_than doc institutional upper limit of normal or creatinine clearance calculated or measured clearance greater_than equal_than sixty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Vidarabine . stage iv adult diffuse large cell lymphoma diagnosis and donor
__label__0	study interventions are Antibodies, Monoclonal . head and neck cancer diagnosis and phase ll
__label__0	study interventions are Hormones . patients must have histological proven hormone refractory prostate cancer
__label__0	study interventions are Aldesleukin . melanoma skin diagnosis and at least four weeks since prior radiation therapy for local control or palliation and recovered
__label__0	study interventions are quality-of-life assessment . ovarian cancer diagnosis and see disease characteristics
__label__0	study interventions are Trastuzumab . human epidermal growth factor two negative carcinoma of breast diagnosis and neoadjuvant chemotherapy in this case residual invasive disease in breast or lymph nodes is required no complete pathological response no further adjuvant chemotherapy treatment planned
__label__0	study interventions are ChangTai Keli . colon cancer diagnosis and fitness score ecog ps two minutes or less expected lifetime greater_than six months
__label__0	study interventions are Vinblastine . hertwo negative breast cancer diagnosis and subjects must have proven refractory to the most recent chemotherapy as documented by progression on or within six months of their last chemotherapy
__label__0	study interventions are pazopanib hydrochloride . recurrent urethral cancer diagnosis and gastrointestinal tract disease resulting in an inability to take oral medication
__label__0	study interventions are Intensity-modulated radiotherapy . melanoma diagnosis and nasal endoscopy within twenty-eight days prior to study entry and ct of the chest within sixty days prior to study entry
__label__0	study interventions are Pomalidomide . multiple myeloma diagnosis and minor criteria one two and three or one two and four
__label__0	study interventions are biopsy . metastatic cancer diagnosis and no concurrent gm csf other than study drug
__label__0	study interventions are Everolimus . stage iv breast cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are Carboplatin . cancer diagnosis and signed written informed consent
__label__0	study interventions are Antibodies, Monoclonal . stage iiia breast cancer diagnosis and prior to registration the investigator must specify if radiation is planned patients who have undergone lumpectomy must receive radiation post mastectomy radiation is at the investigator discretion
__label__0	study interventions are Low Fat Diet . carcinoma renal cell diagnosis and cytokine therapy high dose interleukin two or checkpoint inhibitor therapy anti pdone pdlone anti ctlafour or mtor inhibitor therapy everolimus temsirolimus
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iic ovarian cancer diagnosis and prothrombin time pt such that international normalized ratio inr is equal_than less_than doc uln or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin and partial thromboplastin time ptt less_than doc uln
__label__0	study interventions are Razoxane . sarcoma diagnosis and hepatic
__label__0	study interventions are Epirubicin . patients with utuc without synchronous bladder tumor
__label__0	study interventions are Albumin-Bound Paclitaxel . hertwo positive early stage breast cancer diagnosis and patients must be willing to discontinue sex hormonal therapy birth control pills ovarian hormonal replacement therapy etc
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Questionnaire . pancreatic cancer diagnosis and this may be diagnosed in the following ways
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent adult diffuse small cleaved cell lymphoma diagnosis and patients may have had no more than nine months of previous marrow damaging cytotoxic chemotherapy examples include but are not limited to
__label__0	study interventions are Leucovorin . recurrent colon cancer diagnosis and serum creatinine of equal_than less_than doc upper limit of normal uln
__label__0	study interventions are Aluminum phosphate . human papillomavirus diagnosis and be able to understand and sign informed consent prior to enrollment for subjects below the legal age of consent informed consent must be signed by parent legal guardian in addition
__label__0	study interventions are Bevacizumab . bladder cancer diagnosis and no new york heart association nyha congestive heart failure greater_than grade two
__label__0	study interventions are pharmacological study . stage ii neuroendocrine carcinoma of the skin diagnosis and bilirubin normal
__label__0	study interventions are Busulfan . sarcoma myeloid diagnosis and does not meet twenty-one cfr one thousand, two hundred and seventy-one eligibility requirements but has declaration of urgent medical need completed by the principal investigator or physician sub investigator per twenty-one cfr one thousand, two hundred and seventy-one
__label__0	study interventions are Conventional laparoscopic surgery . pathological rectosigmoid adenocarcinoma
__label__0	study interventions are Pomegranate-Extract Pill . stage prostate cancer diagnosis and alkaline phosphatase equal_than less_than doc upper limit of institutional normal
__label__0	study interventions are Everolimus . stage iii endometrial carcinoma diagnosis and no serious cardiovascular illness including any of the following
__label__0	study interventions are Dexamethasone 21-phosphate . cancer diagnosis and nineteen years of age
__label__0	study interventions are Sodium Fluoride . stage prostate cancer diagnosis and patients eastern cooperative oncology group ecog performance is equal_than less_than one
__label__0	study interventions are Cetuximab . carcinoma squamous diagnosis and platelets greater than or equal to one hundred zero mcl
__label__0	study interventions are Etoposide . nodal marginal zone cell lymphoma diagnosis and expected survival duration of greater_than equal_than six months
__label__0	study interventions are Antibodies, Monoclonal . recurrent rectal cancer diagnosis and prior radiotherapy immunotherapy or chemotherapy must have been completed no less than twenty-eight days prior to patient entry on this study and patients must have recovered from all acute expected side effects of the prior therapy
__label__0	study interventions are Erlotinib Hydrochloride . recurrent non small cell lung cancer diagnosis and ninety l without transfusion support or growth factors within ten days of starting inctwo hundred and eighty
__label__0	study interventions are Prednisone . stage iv prostate cancer diagnosis and prior external beam radiation therapy to less than thirty of the bone marrow only is allowed
__label__0	study interventions are HAIC Regimen . hepatocellular carcinoma diagnosis and platelet count greater_than seventy-five zero µl
__label__0	study interventions are Anti-Bacterial Agents . psychosocial effects of cancer and its treatment diagnosis and no prior bone marrow transplantation or peripheral blood stem cell transplantation
__label__0	study interventions are Cediranib . stage iv ovarian cancer diagnosis and absolute neutrophil count greater_than equal_than doc ten nine l
__label__0	study interventions are Bendamustine Hydrochloride . lymphoma non hodgkin diagnosis and all study participants must be willing to be registered into the mandatory revlimid_rems program after completion of induction chemoimmunotherapy and prior to maintenance therapy and be willing and able to comply with the requirements of the revlimid_rems program
__label__0	study interventions are Rituximab . stage iv grade three follicular lymphoma diagnosis and ascites
__label__0	study interventions are Erlotinib Hydrochloride . metastatic pancreatic cancer diagnosis and alanine aminotransferase alt less_than five times the upper limit of normal
__label__0	study interventions are Topotecan . aids related diffuse mixed cell lymphoma diagnosis and no other concurrent investigational agents
__label__0	study interventions are Carmustine . unspecified adult solid tumor protocol specific diagnosis and marrow cellularity greater than twenty
__label__0	study interventions are cryosurgery . kidney cancer diagnosis and no concurrent immunosuppressive agents
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and unrelated donors identified by the nmdp may elect to donate either pbsc after treatment with csf or bone marrow
__label__0	study interventions are Cyclophosphamide . brain tumors diagnosis and no identified turcot and li_fraumeni syndrome
__label__0	study interventions are Temoporfin . squamous cell carcinoma of the head and neck diagnosis and bun
__label__0	study interventions are Cetuximab . primary peritoneal cavity cancer diagnosis and no prior cytotoxic chemotherapy for recurrent disease including retreatment with initial chemotherapy regimens
__label__0	study interventions are Thalidomide . stage ii grade one non contiguous follicular lymphoma diagnosis and cdfour positive cell count greater_than equal_than four00 mm three
__label__0	study interventions are Carboplatin . recurrent adult burkitt lymphoma diagnosis and patients must sign informed consent
__label__0	study interventions are Carboplatin . lung cancer diagnosis and patients without pleural effusion who are not candidates for combined modality treatment or who were treated at centers where combined modality treatment is not considered standard treatment are eligible
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and high risk smm per mayo clinic or spanish pethema criteria
__label__0	study interventions are Anastrozole . breast cancer diagnosis and no depression or other confirmed active psychiatric disease
__label__0	study interventions are Fluorouracil . stage iv colon cancer diagnosis and prophylactic anticoagulation of central venous lines allowed
__label__0	study interventions are Docetaxel . breast cancer diagnosis and eastern cooperative oncology group ecog performance status zero two for participants who will receive paclitaxel or nab paclitaxel chemotherapy and ecog zero one for participants who will receive docetaxel chemotherapy
__label__0	study interventions are Immunoglobulins . metastatic melanoma stage iv diagnosis and willing and able to give written informed consent
__label__0	study interventions are Cetuximab . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and prior nephrectomy or resection of metastatic lesions allowed provided patient has fully recovered
__label__0	study interventions are Methotrexate . recurrent adult diffuse small cleaved cell lymphoma diagnosis and cytogenetic abnormalities in addition to ph positive
__label__0	study interventions are Antibodies, Monoclonal . multiple myeloma bone disease diagnosis and pain
__label__0	study interventions are Cetuximab . colorectal cancer diagnosis and patients must be able to understand the nature of this study
__label__0	study interventions are Blood Sample Collection . prostate adenocarcinoma diagnosis and if psa was above thirty and dropped to less_than thirty with antibiotics this is acceptable for enrollment
__label__0	study interventions are Liposomal doxorubicin . prostate cancer diagnosis and hemoglobin greater_than eight dl
__label__0	study interventions are Prednisolone acetate . prostate cancer diagnosis and stage tthree four psagreater_than four0ng ml or gleason sum score eight ten
__label__0	study interventions are Decitabine . stage ivc papillary thyroid cancer diagnosis and no concurrent uncontrolled illness
__label__0	study interventions are Epirubicin . breast cancer diagnosis and sex
__label__0	study interventions are Laboratory Biomarker Analysis . ovarian endometrioid adenocarcinoma diagnosis and no prior radiotherapy to greater_than twenty-five of marrow bearing areas
__label__0	study interventions are Succinylcholine . stage iii laryngeal squamous cell carcinoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mm three
__label__0	study interventions are Paclitaxel . ovarian yolk_sac tumor diagnosis and measurable disease
__label__0	study interventions are Prednisone . multiple myeloma diagnosis and previous lenalidomide refractory disease
__label__0	study interventions are Thymalfasin . malignant melanoma diagnosis and adequate renal function as demonstrated by serum creatinine level less_than doc mg deciliter dl
__label__0	study interventions are BB 1101 . unrolled by other clinical trials about hepatocellular carcinoma
__label__0	study interventions are Vincristine . sarcoma diagnosis and hematopoietic
__label__0	study interventions are Tacrolimus . stage iii adult diffuse small cleaved cell lymphoma diagnosis and participation in another therapeutic trial where the primary endpoint is related to acute gvhd
__label__0	study interventions are Cortisone . plasmablastic lymphoma diagnosis and agree to practice true abstinence when this is in line with the preferred and usual_lifestyle of the subject note
__label__0	study interventions are Iodine-131 anti-B1 antibody . lymphoma diagnosis and hematopoietic
__label__0	study interventions are MRI Targeted Biopsy . prostate cancer diagnosis and fit to undergo all procedures listed in protocol
__label__0	study interventions are Hormones . stage iv prostate cancer diagnosis and concurrent zoledronate for bone metastases or hypercalcemia allowed
__label__0	study interventions are Etoposide . glioblastoma diagnosis and karnofsky lansky performance status greater_than sixty
__label__0	study interventions are Albumin-Bound Paclitaxel . bladder cancer diagnosis and urine protein creatinine ratio less_than doc
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and rai stage or ii disease that failed standard therapy disease is progressing after greater_than one course of standard therapy
__label__0	study interventions are Capecitabine . recurrent colon cancer diagnosis and prior capecitabine allowed provided patient tolerated three thousand, five hundred mg m² for seven days out of fourteen days
__label__0	study interventions are Sodium Fluoride . stage iv prostate cancer diagnosis and treatment with granulocyte macrophage colony stimulating factor gm csf or granulocyte csf csf within four weeks prior to first pet scan
__label__0	study interventions are Docetaxel . neoplasm metastasis diagnosis and sufficient bone marrow function defined as leucocytes greater_than doc gpt thrombocytes greater_than one hundred gpt l
__label__0	study interventions are Methotrexate . primary central nervous system hodgkin lymphoma diagnosis and the recipient has achieved second or subsequent complete response but has persistent radiographic abnormalities of unknown significance
__label__0	study interventions are Leucovorin . stage iv rectal cancer diagnosis and ecog performance status zero two karnofsky greater_than equal_than 5zero
__label__0	study interventions are Hormones . recurrent breast carcinoma diagnosis and willing to return to enrolling institution for follow up during the active monitoring phase of the study
__label__0	study interventions are Dutasteride . prostate cancer diagnosis and forty eighty years
__label__0	study interventions are Computerized Tasks . head and neck cancer diagnosis and patients who speak english
__label__0	study interventions are Veliparib . head and neck squamous cell carcinoma diagnosis and patients with history of allergic reactions attributed to compounds of similar chemical or biologic composition to abt eight hundred and eighty-eight or other agents used in study including cremophor carboplatin paclitaxel cisplatin five fluorouracil hydroxyurea or any compounds of similar chemical or biologic composition are not eligible
__label__0	study interventions are Diphosphonates . metastatic cancer diagnosis and menopausal status
__label__0	study interventions are Cyclophosphamide . thymic carcinoma diagnosis and not specified
__label__0	study interventions are Irinotecan . stage iiia colon cancer diagnosis and measurable or evaluable disease
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and no recent history of drug or alcohol abuse
__label__0	study interventions are Melphalan . diagnosis of symptomatic stage or stage ii iii multiple myeloma
__label__0	study interventions are Doxorubicin . stage or in situ cervical carcinoma
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiic skin melanoma diagnosis and eastern cooperative oncology group ecog performance status of zero or one
__label__0	study interventions are Bevacizumab . patients must have recurrent or refractory intracranial ependymoma including myxopapillary clear cell papillary tanycytic and anaplastic ependymoma or subependymoma
__label__0	study interventions are Azacitidine . multiple myeloma diagnosis and severe renal impairment
__label__0	study interventions are TAC-101 . advanced hepatocellular carcinoma diagnosis and no vascular invasion in main trunk and first order branch of portal vein
__label__0	study interventions are Radiotherapy . carcinoma non small cell lung diagnosis and patient must be deemed to be suitable to undergo definitive chemo radiotherapy by the treating physician
__label__0	study interventions are Antibodies, Monoclonal . refractory non hodgkin lymphoma diagnosis and patient current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
__label__0	study interventions are Melphalan . refractory non hodgkin lymphoma diagnosis and refractory or relapsed disease after standard chemotherapy
__label__0	study interventions are Dexamethasone acetate . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Dalteparin . ovarian cancer diagnosis and patients must meet all of the following criteria to be considered for enrolment
__label__0	study interventions are Fludarabine phosphate . unspecified adult solid tumor protocol specific diagnosis and uncontrolled peptic ulcer disease
__label__0	study interventions are Crizotinib . adenocarcinoma of the lung diagnosis and anc greater_than equal_than one five hundred ul
__label__0	study interventions are Gemcitabine . epithelial mesothelioma diagnosis and pleural effusions and ascites are not considered measurable lesions
__label__0	study interventions are Everolimus . gastrointestinal stromal tumors diagnosis and patients were to have at least one measurable lesion longest diameter greater_than twenty mm on conventional ct or mri scan
__label__0	study interventions are Immunoglobulin G . stage iv ovarian cancer diagnosis and no proteinuria less than one positive
__label__0	study interventions are Laboratory Biomarker Analysis . adult epithelioid hemangioendothelioma diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Veliparib . ovarian carcinosarcoma diagnosis and platelets greater than or equal to one hundred zero mm three
__label__0	study interventions are Vinorelbine . adult nodular sclerosis hodgkin lymphoma diagnosis and ns cellular phase
__label__0	study interventions are Vinorelbine . cancer diagnosis and hormonal therapy may be taken up to the time of enrollment
__label__0	study interventions are Interferons . lymphoma diagnosis and renal
__label__0	study interventions are quality-of-life assessment . psychosocial effects of cancer and its treatment diagnosis and high risk stage ii disease including one of the following
__label__0	study interventions are Motexafin lutetium . stage iii gastric cancer diagnosis and body weight less_than one hundred and thirty kg
__label__0	study interventions are Tacrolimus . stage iii marginal zone lymphoma diagnosis and forced expiratory volume in one second fevone greater_than fifty
__label__0	study interventions are cilengitide . stage iv grade three follicular lymphoma diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Thalidomide . smoldering plasma cell myeloma diagnosis and willing to return to enrolling institution for follow up during the active monitoring phase of the study
__label__0	study interventions are LUM015 . breast cancer diagnosis and must be able and willing to follow study procedures and instructions including possible overnight stay before surgery
__label__0	study interventions are Bevacizumab . stage iiib non small cell lung cancer diagnosis and more than seven days since prior core biopsy
__label__0	study interventions are therapeutic conventional surgery . adult glioblastoma diagnosis and patients must have recovered from severe toxicity of prior therapy the following intervals from previous treatments are required to be eligible
__label__0	study interventions are omega-3 fatty acid . ductal breast carcinoma in situ diagnosis and ability to understand and the willingness to sign an institutional review board irb approved written informed consent document
__label__0	study interventions are Succinylcholine . stage ivb oropharyngeal squamous cell carcinoma diagnosis and patients must not be receiving chronic daily treatment with aspirin greater_than three hundred and twenty-five mg day or non steroidal anti inflammatory agents nsaid known to inhibit platelet function the use of anti platelet agents dipyridamole_persantine ticlopidine_ticlid clopidogrel_plavix is allowed only if patient is not receiving aspirin or nsaid known to inhibit platelet function
__label__0	study interventions are pazopanib hydrochloride . childhood central nervous system yolk_sac tumor diagnosis and no abdominal fistula gastrointestinal perforation or intra abdominal abscess within the past twenty-eight days
__label__0	study interventions are Etoposide phosphate . cognitive side effects of cancer therapy diagnosis and doc male doc female
__label__0	study interventions are Darbepoetin alfa . prostate cancer diagnosis and patients on concurrent androgen deprivation treatment that consists of either orchiectomy or gnrh agonist zoladex or lupron with or without and androgen receptor antagonist casodex nilandron or eulexin therapy as long as therapy was initiated within the last three months
__label__0	study interventions are Interferon-alpha . breast cancer diagnosis and no brain metastases unresponsive to irradiation or surgery
__label__0	study interventions are Tice . bladder cancer diagnosis and renal function no greater than doc times uln other
__label__0	study interventions are Female AR(+) TNBC Enzalutamide Naïve . male breast cancer diagnosis and ovarian suppression with lhrh agonist to achieve cessation of regular menses is allowed on study
__label__0	study interventions are Antibodies, Monoclonal . childhood diffuse large cell lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are FDR-PET . non small cell lung cancer diagnosis and measurable disease by recist criteria
__label__0	study interventions are Thalidomide . neurofibromatosis type one diagnosis and serum albumin greater_than equal_than two dl
__label__0	study interventions are Antibodies, Monoclonal . metastatic non small cell lung cancer diagnosis and absolute granulocyte count greater_than one five hundred mmthree absolute lymphocyte count greater_than five hundred mmthree platelets greater_than seventy-five zero mmthree hemoglobin greater_than nine dl creatinine less_than doc institutional upper limit of normal total bilirubin less_than doc institutional upper limit of normal ast sgot and alt sgpt less_than twox institutional upper limit of normal or
__label__0	study interventions are Melphalan . hodgkin lymphoma relapsed refractory diagnosis and liver
__label__0	study interventions are Hormones . subjects with hormone naïve metastatic prostate cancer must have high volume disease defined as extra nodal visceral disease or bone metastases with at least four bone lesions one being outside of the vertebral_column or pelvis
__label__0	study interventions are Dexamethasone . stage ib non small cell lung carcinoma diagnosis and life expectancy of greater than twelve weeks
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the nasopharynx diagnosis and no grade ii iv peripheral vascular disease within the past year
__label__0	study interventions are Peginterferon alfa-2b . solid tumors diagnosis and the principal investigator can use his or her clinical judgment
__label__0	study interventions are Fludarabine . splenic marginal zone lymphoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and bilirubin normal
__label__0	study interventions are laboratory biomarker analysis . stage iv melanoma diagnosis and matricaria_chamomilla chamomile
__label__0	study interventions are Interferon-alpha . recurrent intraocular melanoma diagnosis and inclusion
__label__0	study interventions are Peripheral Blood Stem Cell Transplantation . multiple myeloma and plasma cell neoplasm diagnosis and not specified
__label__0	study interventions are Doxorubicin . ovarian cancer diagnosis and cardiovascular
__label__0	study interventions are Etoposide phosphate . stage iiia non small cell lung cancer diagnosis and inclusion
__label__0	study interventions are Sirolimus . carcinoma non small cell lung diagnosis and written informed consent that is consistent with ich_gcp guidelines
__label__0	study interventions are Cediranib . childhood burkitt lymphoma diagnosis and total bilirubin equal_than less_than doc mg dl does not apply to patients with gilbert syndrome
__label__0	study interventions are Needle angle measurement . kidney neoplasms diagnosis and all patients must be undergoing ct guided biopsy
__label__0	study interventions are Carboplatin . soft tissue sarcoma diagnosis and arm b
__label__0	study interventions are Triamcinolone . melanoma diagnosis and participants in ipilimumab monotherapy arm including the first twenty-one who were enrolled in stage one were to be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroid therapy in the one0 days prior to beginning ipilimumab therapy
__label__0	study interventions are 7-hydroxystaurosporine . ovarian cancer diagnosis and at least four weeks since prior hormonal therapy
__label__0	study interventions are Stem cell transplantation . hodgkin lymphoma diagnosis and high risk of inability to comply with transplant protocol as determined by principal investigator social work and bmt team
__label__0	study interventions are Fluorodeoxyglucose F18 . head and neck cancer diagnosis and requires chemoradiotherapy
__label__0	study interventions are Azacitidine . stage iv bladder cancer diagnosis and absolute granulocyte count at least one five hundred mm three
__label__0	study interventions are Pancrelipase . recurrent adenocarcinoma of the pancreas diagnosis and patient has karnofsky performance status kps
__label__0	study interventions are Docetaxel . breast cancer diagnosis and surgery
__label__0	study interventions are Cyclophosphamide . hertwo positive breast cancer diagnosis and platelet count greater_than equal_than one hundred zero
__label__0	study interventions are Rituximab . adequate liver and kidney function total bilirubin less_than two uln and creatinine less_than doc mg dl unless abnormalities are related to lymphoma or gilbert disease
__label__0	study interventions are Bevacizumab . stage iiib non small cell lung cancer diagnosis and protein less_than one on twenty-four hour urine collection
__label__0	study interventions are Fludarabine . recurrent small lymphocytic lymphoma diagnosis and no concurrent growth factors epoetin_alfa filgrastim csf or sargramostim gm csf
__label__0	study interventions are TachoSil® patches . breast cancer diagnosis and newly diagnosed
__label__0	study interventions are Antibodies, Monoclonal . unspecified adult solid tumor protocol specific diagnosis and creatinine ratio greater_than doc must have proteinuria less_than one zero mg by twenty-four hour urine collection
__label__0	study interventions are Myeloablative Chemotherapy . carcinoma round cell diagnosis and patients must meet at least one of the following stem cell requirements peripheral blood collection is to be preferred when available as an option
__label__0	study interventions are Mycophenolate mofetil . hepatosplenic cell lymphoma diagnosis and acute leukemia in remission
__label__0	study interventions are Antibodies, Monoclonal . refractory multiple myeloma diagnosis and no other serious ongoing medical condition that would preclude study participation
__label__0	study interventions are Cyclosporins . refractory hodgkin lymphoma diagnosis and patients greater_than seventy may be considered if performance status greater_than eighty or eastern cooperative oncology group ecog less_than one and comorbidity score less_than three
__label__0	study interventions are Cytarabine . stage childhood small noncleaved cell lymphoma diagnosis and hepatitis status known
__label__0	study interventions are Melphalan . recurrent childhood large cell lymphoma diagnosis and low or high risk disease in first or second cr or greater in patients in whom the risks of an allogeneic transplant outweigh the benefits
__label__0	study interventions are Fludarabine phosphate . lymphoma small lymphocytic diagnosis and voluntary written informed consent before performance of any study related procedure not part of normal medical care
__label__0	study interventions are questionnaire administration . stage iii grade two follicular lymphoma diagnosis and hematopoietic stem cell transplant recipient between three two5 years since last transplant
__label__0	study interventions are Deferasirox . recurrent adult diffuse large cell lymphoma diagnosis and platelets greater_than equal_than fifty zero
__label__0	study interventions are Selective Estrogen Receptor Modulators . breast cancer diagnosis and hematopoietic
__label__0	study interventions are Irinotecan . colon cancer high risk stage iii ptfournone or ptone to four ntwo diagnosis and absolute neutrophil count anc greater_than two one0nine haemoglobin greater_than nine dl platelets ptl greater_than one00 one0nine ast alt less_than doc uln alkaline phosphatase less_than doc uln total bilirubin less_than doc uln upper limit of normal creatinine clearance greater_than fifty ml min cockcroft and gault formula kalemia magnesemia calcemia greater_than one lln lower limit of normal carcinoembryogenic antigen cea less_than one0ng ml after surgery during screening period
__label__0	study interventions are S-1 . gastrointestinal neoplasms diagnosis and creatinine within normal upper limits
__label__0	study interventions are Antilymphocyte Serum . multiple myeloma and plasma cell neoplasm diagnosis and karnofsky score of greater_than seventy
__label__0	study interventions are Leucovorin . signet ring adenocarcinoma of the rectum diagnosis and group i
__label__0	study interventions are Sirolimus . recurrent islet cell carcinoma diagnosis and myocardial infarction
__label__0	study interventions are Sorafenib . face cancer diagnosis and ecog performance status ps less_than two
__label__0	study interventions are Citric Acid . multicentric breast carcinoma diagnosis and patients must have complete history and physical examination within twenty-eight days prior to registration
__label__0	study interventions are Rituximab . stage grade one follicular lymphoma diagnosis and absolute neutrophil count greater_than doc one0 nine l
__label__0	study interventions are BB 1101 . patients with history of cancer other than non melanoma skin cell cancers cured by local resection within the last five years
__label__0	study interventions are Sunitinib . renal cell carcinoma diagnosis and able to abstain from taking prohibited prescription or prohibited non prescription drugs
__label__0	study interventions are Cisplatin . triple negative breast carcinoma diagnosis and eligibility criteria for randomization step one
__label__0	study interventions are Doxorubicin . urethral cancer associated with invasive bladder cancer diagnosis and no prior systemic chemotherapy including adjuvant or neoadjuvant therapy
__label__0	study interventions are Antibodies . stage iv adult hodgkin lymphoma diagnosis and see section one doc
__label__0	study interventions are Rituximab . stage iii grade three follicular lymphoma diagnosis and ascites
__label__0	study interventions are Fludarabine . hepatosplenic cell lymphoma diagnosis and age greater_than equal_than eighteen years old
__label__0	study interventions are Staurosporine . stage ivb cervical cancer diagnosis and no gilbert disease
__label__0	study interventions are Irinotecan . adenocarcinoma of the gallbladder diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Melphalan . splenic marginal zone lymphoma diagnosis and donor
__label__0	study interventions are Paclitaxel . stage iia breast cancer diagnosis and this study will continue to use the ajcc fiveth edition for tnm classification and staging
__label__0	study interventions are Dacarbazine . functional pancreatic neuroendocrine tumor diagnosis and eastern cooperative oncology group ecog performance status zero two
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and eighteen and over
__label__0	study interventions are Methylprednisolone acetate . prostate cancer diagnosis and at least three months since prior strontium eighty-nine no concurrent strontium surgery
__label__0	study interventions are Immunoglobulins . stage iiia primary peritoneal cancer diagnosis and an approved informed consent and authorization permitting release of personal health information must be signed by the patient or guardian
__label__0	study interventions are Antibodies . recurrent rectal cancer diagnosis and more than seven days since prior core biopsy
__label__0	study interventions are Antibodies . aids related lymphoma diagnosis and no antimurine antibody hama reactivity
__label__0	study interventions are Methylprednisolone . lymphoma diagnosis and acute leukemia lymphocytic or myeloid or undifferentiated or biphenotypic in complete remission two or beyond
__label__0	study interventions are Vidarabine . refractory small lymphocytic lymphoma diagnosis and donor
__label__0	study interventions are Gemcitabine . advanced soft tissue sarcoma diagnosis and patients with the following sts types will be excluded
__label__0	study interventions are Busulfan . recurrent adult diffuse large cell lymphoma diagnosis and this protocol will allow the use of donors who are unrelated but are hla b d dr identical and mlc mixed lymphocyte culture compatible
__label__0	study interventions are pharmacological study . stage iiic breast cancer diagnosis and naringenin
__label__0	study interventions are Prednisolone acetate . sarcoma diagnosis and matched for hla b and dr five six or six six allelles cord blood
__label__0	study interventions are Antibodies, Monoclonal . stage iiic fallopian tube cancer diagnosis and patients must have gog performance status of zero one or two
__label__0	study interventions are Ifosfamide . lymphoma diagnosis and total bilirubin less_than than or equal_than to doc mg dl in the absence of history of gilbert disease
__label__0	study interventions are Vidarabine . hepatosplenic cell lymphoma diagnosis and syngeneic donors are not eligible donor
__label__0	study interventions are Vinorelbine . recurrent islet cell carcinoma diagnosis and hepatic function
__label__0	study interventions are Topotecan . stage iv ovarian cancer diagnosis and gog zero two
__label__0	study interventions are Lenvatinib . who classification gone gtwo kisixty-sevenless_than two0 and mitotic count less_than two0 mitoses one0 hpf pancreatic neuroendocrine tumor
__label__0	study interventions are Sirolimus . chromophobe renal cell carcinoma diagnosis and creatinine less than or equal to doc times uln
__label__0	study interventions are Thalidomide . hepatocellular carcinoma diagnosis and performance status of ecog score zero two
__label__0	study interventions are Etoposide phosphate . brain cancer diagnosis and for females in reproductive age
__label__0	study interventions are Bevacizumab . lung cancer diagnosis and no ongoing or active infection
__label__0	study interventions are Dasatinib . neuroblastoma diagnosis and specimens will be obtained only in non significant risk manner and not solely for the purpose of investigational testing
__label__0	study interventions are Docetaxel . gastric cancer diagnosis and failure of prior therapy during or after treatment in patients who have received at first line chemotherapy regimens platinum
__label__0	study interventions are laboratory biomarker analysis . stage iiib melanoma diagnosis and no concurrent medications with narrow therapeutic indices that are metabolized by cytochrome pfour hundred and fifty cypfour hundred and fifty including warfarin sodium coumadin
__label__0	study interventions are Vorinostat . stage iii small lymphocytic lymphoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are psychosocial assessment and care . ovarian cancer diagnosis and received primary treatment within the royal_marsden nhs_foundation trust
__label__0	study interventions are Mycophenolic Acid . recurrent adult hodgkin lymphoma diagnosis and the patient must be not eligible for conventional transplants and must have disease expected to be stable for at least one hundred days without chemotherapy
__label__0	study interventions are cilengitide . angioimmunoblastic cell lymphoma diagnosis and measurable or evaluable disease
__label__0	study interventions are Bendamustine Hydrochloride . neuroblastoma diagnosis and shortening fraction greater than or equal to twenty-five
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and age in years weight in kg doc zero
__label__0	study interventions are Antibodies . recurrent small lymphocytic lymphoma diagnosis and patients who have suitable human leukocyte antigen hla matched related or unrelated donors willing to receive filgrastim csf undergo leukapheresis to collect peripheral blood mononuclear cell pbmc and to donate stem cells
__label__0	study interventions are Antibodies, Monoclonal . stage ivb major salivary gland carcinoma diagnosis and history of gross hemoptysis bright red blood of one two teaspoon or more per episode of coughing equal_than less_than three months prior to enrollment
__label__0	study interventions are Treosulfan . non hodgkin lymphoma
__label__0	study interventions are Liposomal doxorubicin . male breast carcinoma diagnosis and note
__label__0	study interventions are Radiation therapy . recurrent breast cancer diagnosis and the patient must be female
__label__0	study interventions are Romidepsin . triple negative breast cancer diagnosis and the subject must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the start of treatment
__label__0	study interventions are Paclitaxel . stage ia breast cancer diagnosis and eastern cooperative oncology group ecog performance status of zero or one
__label__0	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and willing and able to take aspirin eighty-one mg daily as prophylactic anticoagulation patients intolerant to acetylsalicylic acid asa may use warfarin or low molecular weight heparin
__label__0	study interventions are Sirolimus . metastatic breast cancer diagnosis and histological or cytological confirmation of er positive bc and or pgr
__label__0	study interventions are Melphalan . progesterone receptor positive breast cancer diagnosis and creatinine equal_than less_than doc mg dl
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and failed at least one course of standard immunosuppressive regimen with cyclosporine and anti thymocyte_globulin or
__label__0	study interventions are Mitoxantrone . breast cancer diagnosis and cardiovascular
__label__0	study interventions are Antibodies, Monoclonal . lung cancer diagnosis and no hepatitis or c
__label__0	study interventions are diagnostic laboratory biomarker analysis . noncutaneous extranodal lymphoma diagnosis and cytoreduction with hydroxyurea can be initiated and continued for up to twenty-four hours prior to the start of mk two thousand, two hundred and six
__label__0	study interventions are Carmustine . myelodysplastic myeloproliferative neoplasms diagnosis and patient characteristics
__label__0	study interventions are Fluorouracil . pancreatic cancer diagnosis and females of childbearing potential and males must be willing to use an effective method of contraception
__label__0	study interventions are NSC 366140 . intraocular melanoma diagnosis and bidimensionally measurable disease
__label__0	study interventions are Vaccines . brain and central nervous system tumors diagnosis and no concurrent chemotherapy
__label__0	study interventions are tanespimycin . bladder cancer diagnosis and at least four weeks since prior palliative treatment for metastatic disease
__label__0	study interventions are Hematinics . subjects who harbor the fiveq deletion chromosomal aberration
__label__0	study interventions are Vinorelbine . breast cancer diagnosis and age greater_than eighteen years
__label__0	study interventions are Antibodies, Monoclonal . ovarian endometrioid adenocarcinoma diagnosis and the patient or legally authorized representative must provide study specific informed consent prior to study entry and for patients treated in the united_states authorization permitting release of personal health information
__label__0	study interventions are cilengitide . stage iii mantle cell lymphoma diagnosis and no concurrent anticoagulation therapy that increases inr or aptt above the normal range
__label__0	study interventions are Immunoglobulins . stage grade two follicular lymphoma diagnosis and bi_dimensionally measurable disease at least one cm
__label__0	study interventions are Gemcitabine . ovarian cancer diagnosis and platinum sensitive disease which is defined by progression free interval of greater than six months after completion of platinum based chemotherapy
__label__0	study interventions are Stereotactic Radiosurgery . metastatic cancer diagnosis and patients able to undergo radiosurgery
__label__0	study interventions are Antibodies . diffuse adenocarcinoma of the stomach diagnosis and single tablet multivitamin allowed
__label__0	study interventions are Everolimus . recurrent childhood rhabdomyosarcoma diagnosis and patients must not have received myelosuppressive chemotherapy within three weeks of enrollment six weeks if prior nitrosourea
__label__0	study interventions are Lenalidomide . stage ii grade three non contiguous follicular lymphoma diagnosis and if on anti hiv therapy hiv viral load less_than fifty copies hiv rna ml
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and severe valvular heart disease
__label__0	study interventions are antineoplaston AS2-1 . recurrent mantle cell lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Cyclosporins . stage iii adult diffuse large cell lymphoma diagnosis and complete remission
__label__0	study interventions are Niacinamide . stage iv adult diffuse mixed cell lymphoma diagnosis and normal or abnormal organ function
__label__0	study interventions are Liposomal doxorubicin . mixed oligoastrocytoma diagnosis and ability to understand and willingness to sign an irb approved written informed consent document or that of legally authorized representative if applicable
__label__0	study interventions are DSP-7888 Dosing Emulsion . renal cell carcinoma diagnosis and hla two
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and no dependency on hematopoietic growth factors epoetin_alfa interleukin eleven filgrastim csf or sargramostim gm csf
__label__0	study interventions are Denileukin diftitox . patients whose tumor expresses targeted antigen and restricting allele against which cdeight cell clones can be generated
__label__0	study interventions are Paclitaxel . stage iv non small cell lung cancer diagnosis and no history of congestive heart failure requiring therapy
__label__0	study interventions are Chlorotrianisene . liver neoplasms diagnosis and child pugh cp to bseven cirrhosis
__label__0	study interventions are Isotretinoin . localized resectable neuroblastoma diagnosis and following treatment per ccgthree thousand, eight hundred and ninety-one
__label__0	study interventions are Oxaliplatin . esophageal cancer diagnosis and no known contraindication to the use of fluorouracil taxanes or platinum compounds
__label__0	study interventions are Proteasome Inhibitors . refractory plasma cell myeloma diagnosis and one has not undergone hysterectomy or bilateral oophorectomy or
__label__0	study interventions are Laboratory Biomarker Analysis . ovarian clear cell adenocarcinoma diagnosis and absolute neutrophil count anc greater_than equal_than one thousand, five hundred ul
__label__0	study interventions are Isophosphamide mustard . supra_tentorial primative_neuro ectodermal tumor pnet diagnosis and children less than eight months of age at the time of definitive surgery for histopathologic diagnosis any histology any metastatic state with total or sub total resection
__label__0	study interventions are Antibodies . noncontiguous stage ii marginal zone lymphoma diagnosis and absolute neutrophil count greater_than doc ten nine l
__label__0	study interventions are Fosaprepitant . myelodysplastic myeloproliferative neoplasms diagnosis and no nausea at baseline
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and ast alt and alkaline phosphatase less_than three times the upper limit of laboratory normal
__label__0	study interventions are Cetuximab . stage iv non small cell lung cancer diagnosis and ast and alt less_than doc times upper limit of normal uln five times uln if liver metastasis is present
__label__0	study interventions are Cyclosporins . histologically confirmed refractory metastatic breast cancer must have either relapsed or failed to achieve complete remission after combination chemotherapy with or without stem cell or marrow transplantation no cns disease no generalized or total mass liver involvement greater than twenty-five volume no pulmonary metastasis involving greater than twenty-five of lung volume tumor markers and evidence of metastatic disease by physical exam or radiography required for patients with bone disease only hormone receptor status
__label__0	study interventions are Mycophenolate mofetil . lymphoma diagnosis and have suitable human leukocyte antigen hla matched related bone marrow donor or compatible matched unrelated bone marrow donor by molecular typing at hla b d dr
__label__0	study interventions are Vaccines . malignant melanoma of skin stage iv diagnosis and signed written informed consent
__label__0	study interventions are Antibodies . prostate cancer diagnosis and high risk of systemic progression defined as
__label__0	study interventions are Carboplatin . squamous cell adeno or adenosquamous cell carcinoma
__label__0	study interventions are donor lymphocytes . multiple myeloma and plasma cell neoplasm diagnosis and patients eligible for allogeneic asct but for whom dli is offered as the first option should have full donor chimerism at relapse or after therapy for relapsed disease
__label__0	study interventions are Melphalan . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and primary or previously treated
__label__0	study interventions are Ifosfamide . lymphoma diagnosis and no new york heart association class ii iv heart disease
__label__0	study interventions are Cyclosporine . stage iii childhood small noncleaved cell lymphoma diagnosis and only patients with mds refractory anemia ra or mds refractory anemia with ringed_sideroblasts rars will be eligible for this protocol additionally patients with myeloproliferative syndromes mps will be eligible those patients with mds or mps with greater_than five marrow blasts including those with transformation to aml must receive cytotoxic chemotherapy and achieve less_than five marrow blasts at time of transplant
__label__0	study interventions are Dexamethasone 21-phosphate . diffuse large cell lymphoma diagnosis and subjects eighteen years or older
__label__0	study interventions are Epidural . gynecological cancer diagnosis and who performance status less_than two
__label__0	study interventions are Carboplatin . stage iva uterine corpus cancer diagnosis and stage threea and pelvic but confined to adnexa or vagina residual disease present
__label__0	study interventions are Sipuleucel-T with Booster . prostate cancer diagnosis and subject has adequate hematologic renal and liver function
__label__0	study interventions are Gemcitabine . primary peritoneal cavity cancer diagnosis and ca one hundred and twenty-five greater_than two times upper limit of normal unl
__label__0	study interventions are Cisplatin . lung cancer diagnosis and creatinine ratio less_than doc or twenty-four hour urine protein less_than one zero mg
__label__0	study interventions are Decitabine . recurrent adult burkitt lymphoma diagnosis and chronic lymphocytic leukemia
__label__0	study interventions are Carboxymethylcellulose Sodium . glioblastoma multiforme diagnosis and total bilirubin less_than doc iuln
__label__0	study interventions are Docetaxel . sarcoma diagnosis and bilirubin less_than doc mg dl ast alt levels less_than doc unl renal function
__label__0	study interventions are Sirolimus . malignant pancreatic gastrinoma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Sorafenib . non small cell lung cancer diagnosis and subjects with at least one measurable ct or mri lesion
__label__0	study interventions are Lenograstim . non hodgkin lymphoma diagnosis and ecog zero two inclusive
__label__0	study interventions are Rosiglitazone . sarcoma diagnosis and radiotherapy
__label__0	study interventions are Mycophenolate mofetil . recurrent adult diffuse small cleaved cell lymphoma diagnosis and only single allele disparity will be allowed for hla b or as defined by high resolution typing
__label__0	study interventions are Rituximab . recurrent adult lymphoblastic lymphoma diagnosis and phase ii subjects must have estimated or measured creatinine clearance greater_than equal_than thirty ml min
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and signed written informed consent
__label__0	study interventions are Bortezomib . stage iii cutaneous cell non hodgkin lymphoma diagnosis and pulse_oximetry at rest and exercise less_than eighty-eight per medicare guidelines
__label__0	study interventions are Etoposide . lymphoma diagnosis and serum bilirubin less_than thirty-five µmol l
__label__0	study interventions are Capecitabine . colorectal cancer diagnosis and at least six weeks since prior radiotherapy providing that the extent and site of radiotherapy fields are such that marked bone marrow suppression is not expected
__label__0	study interventions are Poly ICLC . primary peritoneal cancer diagnosis and neutrophil count greater_than doc lnine l
__label__0	study interventions are Trametinib . subjects who have been disease free for five years or subjects with history of completely resected non melanoma skin cancer or successfully treated in situ carcinoma are eligible
__label__0	study interventions are TG-0054 (2.24 mg/kg) . non hodgkin lymphoma diagnosis and negative for human immunodeficiency virus hiv
__label__0	study interventions are Succinylcholine . stage iva oropharyngeal squamous cell carcinoma diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and lymph node must be greater_than fifteen mm in short axis when assessed by ct scan
__label__0	study interventions are Prednisone . diffuse large cell lymphoma dlbcl and their morphologic variants and subtypes centroblastic lymphoma immunoblastic lymphoma cell rich cell lymphoma anaplastic large cell lymphoma mediastinal thymic large cell lymphoma
__label__0	study interventions are Albumin-Bound Paclitaxel . fallopian tube cancer diagnosis and hematocrit greater_than twenty-one
__label__0	study interventions are Liposomal doxorubicin . ovarian brenner tumor diagnosis and patients must have had one prior platinum based chemotherapeutic regimen for management of primary disease containing carboplatin cisplatin or another organoplatinum_compound this initial treatment may have included intraperitoneal therapy consolidation non cytotoxic agents or extended therapy administered after surgical or non surgical assessment
__label__0	study interventions are Bevacizumab . breast cancer diagnosis and adequate organ function according to the following parameters
__label__0	study interventions are Levoleucovorin . recurrent pancreatic carcinoma diagnosis and prior systemic therapy and chemoradiotherapy for treatment of resectable borderline resectable or locally advanced unresectable disease is allowed and does not count toward prior therapy for metastatic disease
__label__0	study interventions are Antibodies . recurrent adult soft tissue sarcoma diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drug
__label__0	study interventions are Vaccines . lung cancer diagnosis and signed informed consent
__label__0	study interventions are Etoposide phosphate . ovarian cancer diagnosis and patients must have one or more unfavorable prognostic factors for achieving cr to cisplatin based salvage therapy
__label__0	study interventions are Laboratory Biomarker Analysis . glioma diagnosis and hemoglobin greater_than equal_than doc gm dl obtained equal_than less_than seven days prior to registration
__label__0	study interventions are Trastuzumab . stage iv breast cancer diagnosis and two cohorts of patients will be treated on this treatment regimen the two cohorts are determined by prior therapy and are as follows
__label__0	study interventions are BB 1101 . colorectal cancer diagnosis and negative pregnancy test
__label__0	study interventions are Gossypol acetic acid . stage iv mantle cell lymphoma diagnosis and patients with previously treated brain metastases who are clinically and radiographically stable or improved at least four weeks after completion of radiation therapy and are off steroids are eligible an mri of the brain or ct scan of the head with contrast must be performed at baseline for patients with history of and or symptoms suspicious of brain metastases
__label__0	study interventions are Cyclophosphamide . to clinical measurement or manifestation of an inflammatory breast cancer
__label__0	study interventions are BB 1101 . lymphoma diagnosis and must meet one of the following criteria
__label__0	study interventions are Carboplatin . histologically or cytologically documented non small cell lung adenocarcinoma that is confirmed by the laboratory of pathology nih
__label__0	study interventions are Ifosfamide . differentiated thyroid cancer dtc diagnosis and vi
__label__0	study interventions are Isophosphamide mustard . metastatic malignant neoplasm in the bone marrow diagnosis and maximum serum creatinine mg dl
__label__0	study interventions are Bevacizumab . brain cancer diagnosis and prior chemotherapy
__label__0	study interventions are Folic Acid . cognitive side effects of cancer therapy diagnosis and all institutional food and drug administration fda and nci requirements for human studies must be met
__label__0	study interventions are psychosocial assessment and care . colorectal cancer diagnosis and no physical or emotional impairment that would limit study compliance
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and if multiple specimens are available submit the most recent
__label__0	study interventions are Carmustine . adult diffuse large cell lymphoma diagnosis and female patient is either postmenopausal free from menses for greater_than equal_than two years surgically sterilized or willing to use two adequate barrier methods of contraception to prevent pregnancy or agrees to abstain from heterosexual activity throughout the study
__label__0	study interventions are supervised exercise program . lung cancer diagnosis and not specified
__label__0	study interventions are Oxaliplatin . tumor lesions that are situated in previously irradiated area are not considered measurable
__label__0	study interventions are Hormones . symptomatic congestive heart failure
__label__0	study interventions are Alemtuzumab . stage mantle cell lymphoma diagnosis and donor
__label__0	study interventions are eribulin mesylate . stage ivb salivary gland cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred µl
__label__0	study interventions are Cyclosporine . recurrent adult lymphoblastic lymphoma diagnosis and must have failed two lines of conventional therapy and be refractory to fludarabine
__label__0	study interventions are Sirolimus . pten_overgrowth syndrome with vascular anomaly diagnosis and investigational drugs
__label__0	study interventions are Etoposide . brain and central nervous system tumors diagnosis and csf elevation of beta hcg to less than fifty ng ml
__label__0	study interventions are Docetaxel . recurrent metastatic squamous cell carcinoma in the neck with occult primary diagnosis and alkaline phosphatase greater_than one but equal_than less_than doc uln and ast or alt greater_than one but equal_than less_than doc uln
__label__0	study interventions are Albumin-Bound Paclitaxel . stage ic ovarian cancer diagnosis and alkaline phosphatase less than or equal to doc times uln ctcae doc grade one
__label__0	study interventions are LIVESTRONG . breast cancer diagnosis and agrees to be randomly assigned to either exercise or wait list control group
__label__0	study interventions are Doxorubicin . stage iii aids related lymphoma diagnosis and white blood cells wbc greater_than equal_than three zero cells ul doc ten nine or
__label__0	study interventions are Cisplatin . nasopharyngeal carcinoma diagnosis and karnofsky scale kps greater_than seventy
__label__0	study interventions are Carboplatin . neuroblastoma diagnosis and over one year of age and stage or ii resectable disease
__label__0	study interventions are Vitamins . lung cancer diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Bicalutamide . breast cancer diagnosis and performance status no more than two
__label__0	study interventions are Immunoglobulin G . stage iv skin melanoma diagnosis and all sites of disease must be evaluated within four weeks prior to randomization patients must have measurable disease
__label__0	study interventions are CV9202 . non small cell lung carcinoma diagnosis and patients greater_than equal_than eighteen years of age with histologically or cytologically confirmed stage iv nsclc and confirmed egfr mutation status in case of non squamous cell histology
__label__0	study interventions are Counseling Intervention . bladder cancer diagnosis and former smoker who quit during pregnancy as assessed via self report
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and if of childbearing potential agreement to use adequate contraceptive methods oral contraceptives condoms or other adequate barrier controls intrauterine contraceptive devices or sterilization beginning at the screening visit and continuing until three months following last treatment with study drug
__label__0	study interventions are Doxorubicin . metastatic cancer diagnosis and performance status zero two if pulmonary mets ps zero one
__label__0	study interventions are Oxaliplatin . recurrent childhood rhabdomyosarcoma diagnosis and not specified
__label__0	study interventions are Alemtuzumab . noncontiguous stage ii marginal zone lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Immunoglobulins . invasive breast carcinoma diagnosis and do not require anticonvulsants or corticosteroids and have been off such drugs for at least seven days
__label__0	study interventions are Motexafin gadolinium . lymphoma diagnosis and menopausal status
__label__0	study interventions are Immunoglobulins . stage iv fallopian tube cancer diagnosis and patients in this trial may receive ovarian estrogen positive
__label__0	study interventions are Paclitaxel . endometrioid adenocarcinoma diagnosis and myocardial infarction or ventricular tachyarrhythmia within six months
__label__0	study interventions are cancer prevention intervention . pituitary tumor diagnosis and no concurrent immunomodulating agents
__label__0	study interventions are Erlotinib Hydrochloride . stage iv squamous cell carcinoma of the nasopharynx diagnosis and creatinine clearance greater_than sixty ml min
__label__0	study interventions are Imatinib Mesylate . gastrointestinal stromal tumors diagnosis and adequate bone marrow hepatic renal and other organ functions
__label__0	study interventions are Vitamin B Complex . colorectal cancer diagnosis and greater than doc cm after fixation or greater than doc cm at time of removal
__label__0	study interventions are Sirolimus . refractory plasma cell myeloma diagnosis and acute lymphocytic leukemia all must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Valproic Acid . anaplastic astrocytoma diagnosis and patients must not have received any prior chemotherapy radiation therapy biologic therapy or bone marrow transplant
__label__0	study interventions are Cetuximab . salivary gland squamous cell carcinoma diagnosis and azole_antifungals ketoconazole itraconazole
__label__0	study interventions are Fludarabine phosphate . stage iv mantle cell lymphoma diagnosis and donor
__label__0	study interventions are Epothilones . adult primary hepatocellular carcinoma diagnosis and performance status
__label__0	study interventions are Docetaxel . non small cell lung cancer diagnosis and provide written informed consent prior to screening
__label__0	study interventions are Prednisolone phosphate . symptomatic congestive heart failure
__label__0	study interventions are Cisplatin . esophageal cancer diagnosis and alkaline phosphatase less_than three times normal five times normal if liver metastases are present
__label__0	study interventions are Gemcitabine . unresectable histologically or cytologically confirmed locally advanced or metastatic pancreatic cancer adenocarcinoma adenosquamous carcinoma or poorly differentiated carcinoma
__label__0	study interventions are Interleukin-2 . intraocular lymphoma diagnosis and women of procreative potential must have negative pregnancy test within the two week screening phase prior to cycle one and all subjects of procreative potential must use adequate birth control throughout the study subjects of procreative potential are defined as any fertile male and any female who has experienced menarche and has not undergone successful surgical sterilization hysterectomy or bilateral oophorectomy or is not post menopausal defined as age related amenorrhea greater_than equal_than onetwo months
__label__0	study interventions are Dexrazoxane . small intestine lymphoma diagnosis and monoclonal antibodies
__label__0	study interventions are Antibodies . testicular embryonal carcinoma and teratoma with seminoma diagnosis and bone metastases that can be assessed by ct scan or mri considered evaluable
__label__0	study interventions are Cabozantinib S-malate . childhood hepatocellular carcinoma diagnosis and at least seven days must have elapsed since the completion of therapy with growth factor at least fourteen days must have elapsed after receiving pegfilgrastim
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and medroxyprogesterone acetate depot
__label__0	study interventions are Nitrogen Mustard Compounds . stage fours neuroblastoma diagnosis and six to less_than ten years
__label__0	study interventions are Niacinamide . stage iii adult diffuse mixed cell lymphoma diagnosis and four weeks since completion of radiation or chemotherapy except for greater_than six weeks for nitrosoureas pam or mitomycin c
__label__0	study interventions are Busulfan . unusual cancers of childhood diagnosis and must have suitable unrelated allogeneic hematopoietic stem cell donor
__label__0	study interventions are Etoposide phosphate . stage iii follicular lymphoma diagnosis and failed induction therapy but responds very good partial remission complete remission or near complete remission to salvage therapy chemosensitive disease
__label__0	study interventions are Antibodies . breast cancer diagnosis and prior high dose chemotherapy
__label__0	study interventions are IFN-a2b . hepatocellular carcinoma diagnosis and patients must have performance status of ecog score less_than two
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer female nos diagnosis and confirmed normal cardiac function by ecg and cardiac ultrasound lvef or shortening fraction within four weeks prior to randomization
__label__0	study interventions are Mycophenolate mofetil . peripheral cell lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Nivolumab . mucinous adenocarcinoma diagnosis and as estimated by the cockcroft and gault formula estimated creatinine clearance is based on actual body weight
__label__0	study interventions are Fludarabine . clear cell renal cell carcinoma diagnosis and acute lymphoblastic leukemia
__label__0	study interventions are Levoleucovorin . bclc stage adult hepatocellular carcinoma diagnosis and patients must submit paraffin_embedded tissue and blood for banking within twenty-eight days after registration paraffin_embedded tissue from prior surgical resection or from diagnostic biopsy is acceptable
__label__0	study interventions are Rituximab . lymphoma diagnosis and patient characteristics
__label__0	study interventions are Vitamins . prostate cancer diagnosis and adequate hepatic function ast alt bilirubin less_than doc uln
__label__0	study interventions are Immunoglobulins . recurrent adult hodgkin lymphoma diagnosis and ecog zero two
__label__0	study interventions are Cyclophosphamide . multiple myeloma diagnosis and at high risk for treatment related mortality with myeloablative conditioning regimen
__label__0	study interventions are Poly ICLC . malignant melanoma diagnosis and demonstrate adequate organ function as defined below all screening labs should be performed within ten days of treatment initiation
__label__0	study interventions are Endothelial Growth Factors . stage iv breast cancer diagnosis and patients with history of seizures must be well controlled with standard medication
__label__0	study interventions are Levoleucovorin . stage ivb rectal cancer diagnosis and ecog zero two
__label__0	study interventions are Aluminum Hydroxide . intraocular melanoma diagnosis and hematopoietic
__label__0	study interventions are Tamoxifen . unspecified adult solid tumor protocol specific diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Cyclosporins . recurrent grade three follicular lymphoma diagnosis and hodgkin disease
__label__0	study interventions are Topotecan . glioblastoma multiforme diagnosis and baseline mri ct is required on stable steroid dosage for at least five days
__label__0	study interventions are Interferons . gastrointestinal carcinoid tumor diagnosis and at least one month since prior radiotherapy surgery
__label__0	study interventions are Aromatase Inhibitors . stage iiia breast cancer diagnosis and inclusion
__label__0	study interventions are HS-1000 . brain neoplasms diagnosis and subject or legal authorized representative per local regulation is able and willing to comply with the requirements of the protocol
__label__0	study interventions are Cisplatin . stage iiib non small cell lung cancer diagnosis and arm cohort one
__label__0	study interventions are Immunoglobulin Idiotypes . multiple myeloma diagnosis and b
__label__0	study interventions are Paclitaxel . non small cell lung cancer diagnosis and prior adjuvant chemotherapy greater_than one year ago and prior treatment with an egfr tki for patients with an activating egfr mutation is allowed
__label__0	study interventions are Docetaxel . patients must undergo pre treatment endoscopic tumor staging and ct scanning of chest and neck
__label__0	study interventions are Sirolimus . stage iii childhood burkitt lymphoma diagnosis and chronic myeloid leukemia cml patients will be accepted if they are beyond chronic phase cp one and if they have received previous myelosuppressive chemotherapy or hct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Prednisone . documented progression of disease by response evaluation criteria in solid tumors recist criteria demonstrating at least one visceral or soft tissue metastatic lesion including new lesion
__label__0	study interventions are Maleic acid . lung cancer diagnosis and measurable disease phase ii
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and left ventricular ejection fraction lvef greater_than equal_than fifty by two dimensional two echocardiogram or multi gated acquisition scan muga scan absence of cardiomyopathy congestive heart failure or dysrhythmia
__label__0	study interventions are Trebananib . subjects with pseudomyxoma or mesothelioma are excluded
__label__0	study interventions are Educational Intervention . malignant ovarian brenner tumor diagnosis and patients must have signed an approved informed consent and authorization permitting release of personal health information
__label__0	study interventions are Antibodies, Monoclonal . ovarian transitional cell carcinoma diagnosis and at least one target lesion must have minimum length of one cm in both the long and short axis as determined by the local site at least half of the target lesion must have attenuation greater than or equal to one0 hounsfield units hu on the unenhanced ct and at least half of the lesion must have maximum enhancement greater than or equal to five hu in the perfusion ct scan as determined by the acr imaging core lab
__label__0	study interventions are Immunoglobulins . anaplastic large cell lymphoma diagnosis and measurable disease in the absence of lymphadenopathy splenomegaly with defects or measurable extramedullary disease is acceptable however bone marrow involvement alone will not be included in the study
__label__0	study interventions are Cyclosporine . recurrent grade one follicular lymphoma diagnosis and myeloproliferative and lymphoproliferative disorder negative must have evidence of disease acceleration to be candidate for umbilical cord blood transplant myeloproliferative disorders eligible for transplant include chronic myelomonocytic leukemia cmml with high ipss score and myelofibrosis
__label__0	study interventions are Paclitaxel . ovarian cancer diagnosis and no neuropathy sensory and motor greater_than grade one
__label__0	study interventions are Carboplatin . lung cancer diagnosis and no clinically significant hepatic disease
__label__0	study interventions are Antibodies, Monoclonal . recurrent grade two follicular lymphoma diagnosis and laboratory studies defining eligibility hemoglobin hgb platelet count viscosity must have been obtained within two8 days prior to registration if more than one test was obtained the most recent one will be utilized
__label__0	study interventions are Fludarabine . non small cell lung cancer diagnosis and able to understand and sign the informed consent document
__label__0	study interventions are Albumin-Bound Paclitaxel . breast carcinoma diagnosis and partial thromboplastin time ptt equal_than less_than doc uln
__label__0	study interventions are Dacarbazine . childhood grade ii meningioma diagnosis and more than three weeks since prior myelosuppressive chemotherapy six weeks for nitrosourea
__label__0	study interventions are Antibodies . stage iii verrucous carcinoma of the larynx diagnosis and for patients with liver metastases ast alt less_than fivex uln is acceptable
__label__0	study interventions are Rituximab . stage iii small lymphocytic lymphoma diagnosis and no infection requiring iv antibiotic therapy within the past four weeks
__label__0	study interventions are Vincristine . lymphoma diagnosis and endocrine therapy
__label__0	study interventions are afatinib . carcinoma non small cell lung diagnosis and male or female patients age greater_than equal_than eighteen years
__label__0	study interventions are Cyclophosphamide . recurrent small lymphocytic lymphoma diagnosis and donor
__label__0	study interventions are Maleic acid . recurrent non small cell lung carcinoma diagnosis and patients with regular menses
__label__0	study interventions are Cyclophosphamide . multiple myeloma diagnosis and chronic lymphocytic leukemia prolymphocytic leukemia
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic cancer diagnosis and at least three weeks from enrollment since prior chemotherapeutic agents including taxanes in the neoadjuvant or adjuvant setting
__label__0	study interventions are Sirolimus . stage iiib esophageal cancer diagnosis and forced expiratory volume in one second fevone greater_than fifty and diffusion capacity of the lungs for carbon monoxide dlco greater_than fifty
__label__0	study interventions are Trastuzumab . breast neoplasms diagnosis and serum creatinine less_than doc uln
__label__0	study interventions are tanespimycin . stage iv papillary thyroid cancer diagnosis and more than four weeks since prior and no concurrent immunotherapy
__label__0	study interventions are Sirolimus . lymphoma diagnosis and women of childbearing potential wocbp must have negative serum pregnancy test within seven days of the first administration of study drug
__label__0	study interventions are Androgens . stage iv breast cancer diagnosis and life expectancy greater_than six months in the opinion of the investigator
__label__0	study interventions are behavioral, psychological or informational intervention . stage iii uterine sarcoma diagnosis and able to give informed consent
__label__0	study interventions are Abiraterone Acetate . before chemotherapy for prostate cancer with regimen containing paclitaxel or docetaxel
__label__0	study interventions are Cyclosporine . recurrent grade three follicular lymphoma diagnosis and first complete remission crone confirmed
__label__0	study interventions are Antimetabolites . bevacizumab first line or adjuvant regimen for metastatic colorectal cancer
__label__0	study interventions are Antibodies . stage iii grade two follicular lymphoma diagnosis and wbc must be greater_than equal_than three zero
__label__0	study interventions are Doxorubicin . progesterone receptor positive breast cancer diagnosis and hemoglobin greater_than elevengm dl
__label__0	study interventions are Busulfan . metastatic ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and for any of the above categories an attempt to achieve complete response cr or pr should be made pre transplant modalities may include surgery chemotherapy or radiation therapy radiation must not include lung fields only patients in cr or pr at the primary site will be eligible
__label__0	study interventions are Interferon-alpha . disease is not considered currently active if patient completed anticancer therapy and is considered to have less_than thirty risk of relapse
__label__0	study interventions are Irinotecan . pancreatic cancer diagnosis and those who had superior_mesenteric vein occlusion superior_mesenteric artery encasement were defined as unresectable
__label__0	study interventions are Cyclophosphamide . non hodgkin lymphoma diagnosis and any patient with hematologic malignancy with residual disease morphological cytogenetic molecular or radiographic after treatment with one or more chemotherapy regimens in whom achievement of remission with additional chemoradiotherapy is felt to be unlikely or who is in threerd or greater cr
__label__0	study interventions are Albumin-Bound Paclitaxel . esophageal neoplasms diagnosis and total bilirubin less_than doc uln
__label__0	study interventions are Metronidazole . ovarian cancer diagnosis and these potential risks may also apply to other agents used in this study
__label__0	study interventions are Immunoglobulins . stage ia breast cancer diagnosis and accelerated partial breast radiation apbi after chemotherapy
__label__0	study interventions are Androgen Antagonists . prostate cancer diagnosis and https
__label__0	study interventions are liquid chromatography . adult anaplastic astrocytoma diagnosis and patients must have karnofsky performance status kps greater_than equal_than sixty
__label__0	study interventions are Doxorubicin . multiple myleoma diagnosis and chronic myelogenous leukemia
__label__0	study interventions are Antibodies, Monoclonal . malignant melanoma diagnosis and agreement to the collection of serial fresh lesion samples required if feasible for entry into escalation cohorts four and expansion cohorts and optional but encouraged in escalation cohorts two three
__label__0	study interventions are laboratory biomarker analysis . recurrent grade one follicular lymphoma diagnosis and eligibility to undergo autologous myeloablative transplantation with hematopoetic progenitor cell hpc rescue
__label__0	study interventions are Dacarbazine . recurrent adult brain tumor diagnosis and no concurrent prophylactic use of growth factors
__label__0	study interventions are Mycophenolate mofetil . multiple myeloma and plasma cell neoplasm diagnosis and prolymphocytic morphology
__label__0	study interventions are Genistein . stage iii bladder cancer diagnosis and platelets greater_than equal_than one hundred zeromm three
__label__0	study interventions are fluorescence in situ hybridization . breast cancer diagnosis and sex
__label__0	study interventions are Muromonab-CD3 . non hodgkin lymphoma nhl in second complete remission crtwo or subsequent
__label__0	study interventions are questionnaire administration . estrogen receptor positive breast cancer diagnosis and periods stopped more than six months ago
__label__0	study interventions are Hydromorphone . cervical cancer diagnosis and disease characteristics
__label__0	study interventions are Bortezomib . stage iv adult burkitt lymphoma diagnosis and no other significant cardiac disease
__label__0	study interventions are Lenalidomide . stage iv grade two follicular lymphoma diagnosis and platelet count greater_than equal_than seventy-five zero microliter
__label__0	study interventions are Sirolimus . refractory hurthle cell thyroid cancer diagnosis and this review is mandatory prior to registration to confirm eligibility
__label__0	study interventions are Dacarbazine . recurrent childhood pineoblastoma diagnosis and patients must be able to take oral medications either capsules or liquid patients with neurologic deficits must have been stable for minimum of one week prior to study entry patients who are unable to walk because of paralysis but who are up in wheelchair will be considered ambulatory for the purpose of assessing the performance score
__label__0	study interventions are Vitamin E . unspecified adult solid tumor protocol specific diagnosis and one multivitamin per day that contains less_than one hundred iu mg of vitamin will be permitted
__label__0	study interventions are Immunoglobulin G . recurrent childhood brain stem glioma diagnosis and at least seven days since prior investigational or biologic agents three weeks if patient experienced greater_than grade two myelosuppression or if agent has prolonged half life
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian clear cell cystadenocarcinoma diagnosis and patients with the following histologic epithelial cell types are eligible
__label__0	study interventions are Idarubicin . lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Anastrozole . post menopausal woman
__label__0	study interventions are Antibodies, Monoclonal . lung carcinoid tumor diagnosis and patients must have disease that is amenable to computed tomography ct or ultrasound s guided biopsies patients must agree to undergo two biopsies the disease identified for biopsy cannot be the only site of measurable disease
__label__0	study interventions are Nelfinavir . multiple myeloma and plasma cell neoplasm diagnosis and willing and capable to comply with an oral regimen
__label__0	study interventions are Docetaxel . non small cell lung cancer recurrent diagnosis and mixed histologies of nsclc adenosquamous are eligible
__label__0	study interventions are Vinorelbine . lung cancer diagnosis and ecog performance status ps less_than two
__label__0	study interventions are Ribociclib . hormone resistant prostate cancer diagnosis and patients with liver metastases and ast alt above this limit will not be enrolled
__label__0	study interventions are Poly I-C . glioma diagnosis and participants must be greater_than eighteen years old because the safety of each therapeutic component has not been established in children
__label__0	study interventions are Methylprednisolone Hemisuccinate . lymphoma diagnosis and at least one year from diagnosis without an identified matched unrelated bone marrow donor and unresponsive to or unable to tolerate interferon
__label__0	study interventions are Gemcitabine . tumor sample available
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and average normalized cycle threshold for the five reference genes less_than 3five
__label__0	study interventions are laboratory biomarker analysis . adult glioblastoma diagnosis and ast sgot alt sgpt less_than doc institutional upper limit of normal
__label__0	study interventions are Dexamethasone 21-phosphate . stage ii multiple myeloma diagnosis and absolute neutrophil count greater_than equal_than one zero mm three
__label__0	study interventions are Antibodies, Monoclonal . recurrent small lymphocytic lymphoma diagnosis and serum amylase less_than upper limit of normal
__label__0	study interventions are neoadjuvant therapy . stage iib pancreatic cancer diagnosis and recovered to less_than grade two toxicity related to prior therapy
__label__0	study interventions are Cetuximab . squamous cell carcinoma of the oropharynx stage iv diagnosis and performance score ecog zero
__label__0	study interventions are Belinostat . stage iv adult immunoblastic large cell lymphoma diagnosis and ischemic or severe valvular heart disease
__label__0	study interventions are Cetuximab . diffuse intrinsic pontine glioma diagnosis and informed consent must be obtained at the time of patient screening
__label__0	study interventions are Tacrolimus . sarcoma diagnosis and donor
__label__0	study interventions are Docetaxel . non small cell lung cancer diagnosis and normal renal function
__label__0	study interventions are Camptothecin . unspecified adult solid tumor protocol specific diagnosis and normal creatinine clearance crcl greater than eighty ml min
__label__0	study interventions are Lenograstim . untreated childhood supratentorial primitive neuroectodermal tumor diagnosis and residual disease greater_than doc cm²
__label__0	study interventions are Vaccines . adenocarcinoma diagnosis and no stereotactic radiation therapy within three days of first vaccine
__label__0	study interventions are Letrozole . leiomyosarcoma diagnosis and lesion in previously irradiated area is not eligible for measurable diseae unless there is objective evidence of progression of the lesion prior to study enrollment
__label__0	study interventions are Carotenoids . prostate cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are Gemcitabine . non small cell lung cancer diagnosis and for the purpose of eligibility for this trial the above cited disease states are defined as follows
__label__0	study interventions are Etoposide . breast cancer diagnosis and hematopoietic
__label__0	study interventions are Dexamethasone . cancer diagnosis and radiotherapy
__label__0	study interventions are Temozolomide . patients who have had prior treatment with any of the other investigational agents or combinations on this protocol are eligible but will not receive the same investigational agent everolimus or trametinib or combination azdone thousand, seven hundred and seventy-five combination or veliparib temozolomide instead patients will receive an investigational agent or combination prospectively identified to work on different target in their tumor mutation aberrant pathway
__label__0	study interventions are Calcium, Dietary . stage iic colon cancer diagnosis and at the time of randomization postoperative absolute granulocyte count agc must be greater_than equal_than one thousand, five hundred mm three or less_than one thousand, five hundred mm three if in the opinion of the investigator this represents an ethnic or racial variation of normal
__label__0	study interventions are Immunoglobulins . primary peritoneal cavity cancer diagnosis and new york heart association class ii iv congestive heart failure
__label__0	study interventions are Mitoxantrone . diffuse large cell lymphoma diagnosis and neutrophils more than doc ten nine platelets more than nine0 ten nine hemoglobin
__label__0	study interventions are Mycophenolate mofetil . multiple myeloma and plasma cell neoplasm diagnosis and second or greater relapse
__label__0	study interventions are Liposomal doxorubicin . recurrent primary peritoneal carcinoma diagnosis and life expectancy greater_than equal_than twelve weeks
__label__0	study interventions are Cetuximab . brain stem glioma diagnosis and must not have received within one week of entry onto this study
__label__0	study interventions are GyneGals Support Group . uterine cervical neoplasms diagnosis and has access to computer and the internet
__label__0	study interventions are Fludarabine phosphate . precancerous condition diagnosis and no other uncontrolled illness
__label__0	study interventions are Cisplatin . ovarian clear cell cystadenocarcinoma diagnosis and partial thromboplastin time ptt less_than doc times the upper limit of normal heparin lovenox or alternative anticoagulants are acceptable
__label__0	study interventions are Vincristine . lymphoma diagnosis and hepatic
__label__0	study interventions are Staurosporine . recurrent midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Romidepsin . stage iiib colorectal cancer diagnosis and since romidepsin_binds to the estrogen receptor the effectiveness of estrogen containing contraceptives may be reduced
__label__0	study interventions are Fluorouracil . adenocarcinoma of the esophagogastric junction diagnosis and adequate cardiac function patients with cardiac history myocardial infarction heart failure coronary artery disease should have cardiology review
__label__0	study interventions are Interferon-alpha . metastatic colorectal carcinoid tumor
__label__0	study interventions are Vidarabine . cancer treated with curative intent greater than five years previously
__label__0	study interventions are Epothilones . localized unresectable adult primary liver cancer diagnosis and at least one unidimensionally measurable lesion
__label__0	study interventions are Niacinamide . glioma diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred mm three
__label__0	study interventions are Lenalidomide . peripheral cell lymphomas diagnosis and ecog performance status of less than or equal to two at study entry see appendix two
__label__0	study interventions are Mycophenolate mofetil . stage iv childhood lymphoblastic lymphoma diagnosis and cdfour count is allowed to be greater_than one hundred cells ul
__label__0	study interventions are Biopsy . metastatic breast cancer diagnosis and metastases amenable to biopsy
__label__0	study interventions are Vaccines . stage ia skin melanoma diagnosis and patients must give written informed consent prior to initiation of therapy
__label__0	study interventions are Niacinamide . multiple myeloma and plasma cell neoplasm diagnosis and urine monoclonal protein greater_than two hundred mg by twenty-four hour electrophoresis
__label__0	study interventions are Paclitaxel . adenosquamous cell lung cancer diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Pyridoxal . peritoneal cavity cancer diagnosis and hormone receptor status
__label__0	study interventions are Bevacizumab . nonsquamous nonsmall cell neoplasm of lung diagnosis and pszero or one
__label__0	study interventions are Sunitinib . childhood central nervous system mixed germ cell tumor diagnosis and no prior radiotherapy to radiation field that included the heart including total body or craniospinal irradiation
__label__0	study interventions are breast duct lavage . breast cancer diagnosis and not specified
__label__0	study interventions are Osimertinib . recurrent solid neoplasm diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Levoleucovorin . stage iiib esophageal cancer diagnosis and patients must not have previous or concurrent malignancy exceptions are made for patients who meet any of the following conditions
__label__0	study interventions are Estradiol 3-benzoate . breast cancer diagnosis and may have had chemotherapy for adjuvant or metastatic disease
__label__0	study interventions are laboratory biomarker analysis . childhood mixed glioma diagnosis and anti convulsants
__label__0	study interventions are Dacarbazine . oligodendroglioma diagnosis and eighteen years to sixty years
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent breast cancer diagnosis and a
__label__0	study interventions are Camptothecin . tumors involving the ge junction must have the bulk of their disease in the stomach tumors of the distal esophagus that extend less than twocm into the stomach are ineligible for this study
__label__0	study interventions are Cisplatin . epithelial mesothelioma diagnosis and see disease characteristics
__label__0	study interventions are Paclitaxel . stage iii ovarian cancer diagnosis and stage iib iic iii or iv disease
__label__0	study interventions are Belinostat . epithelial mesothelioma diagnosis and no other uncontrolled intercurrent illness
__label__0	study interventions are Cisplatin . esophageal neoplasms diagnosis and surgery
__label__0	study interventions are Liposomal doxorubicin . dermatofibrosarcoma_protuberans diagnosis and doc mg dl six years to less_than ten years of age
__label__0	study interventions are Dexamethasone acetate . prostate cancer diagnosis and karnofsky performance status greater_than sixty
__label__0	study interventions are Docetaxel . unspecified adult solid tumor protocol specific diagnosis and no concurrent radiotherapy
__label__0	study interventions are Fulvestrant . female breast carcinoma diagnosis and eighteen years of age or older
__label__0	study interventions are Quality-of-Life Assessment . stage iiia vulvar cancer diagnosis and patients will be registered into three distinct groupings and each group will be analyzed as separate study
__label__0	study interventions are Fludarabine . recurrent grade two follicular lymphoma diagnosis and bilirubin less than two times the upper limit of normal and alanine transaminase alt and aspartate aminotransferase ast less than three times the upper limit of normal
__label__0	study interventions are Alvocidib . stage iv extragonadal non seminomatous germ cell tumor diagnosis and serum creatinine less_than doc times upper limit of normal uln
__label__0	study interventions are Fludarabine . recurrent small lymphocytic lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Fludarabine . clear cell carcinoma diagnosis and has suitable human leukocyte antigen hla haploidentical donor available
__label__0	study interventions are Oxaliplatin . stomach cancer diagnosis and ecog performance status zero one
__label__0	study interventions are Docetaxel . pancreatic cancer diagnosis and white blood count greater_than three zero ul
__label__0	study interventions are Doxorubicin . sarcoma kaposi diagnosis and pt and ptt less than or equal to one hundred and twenty of control unless patient has the presence of lupus anticoagulant
__label__0	study interventions are Dexamethasone . recurrent childhood pineoblastoma diagnosis and current disease state must be one for which there is no known curative therapy or therapy proven to prolong survival with an acceptable quality of life
__label__0	study interventions are Dexamethasone . colorectal cancer diagnosis and abdominal and pelvic ct scans and chest ct or ray within six weeks prior to registration
__label__0	study interventions are Sunitinib . stage iva thyroid gland follicular carcinoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Anastrozole . recurrent breast cancer diagnosis and postmenopausal as defined by one of the following
__label__0	study interventions are Liposomal doxorubicin . primary peritoneal serous adenocarcinoma diagnosis and patients must have gog performance status of zero or one
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and failure of at least one and no more than two prior cytotoxic chemotherapy regimens for advanced disease either due to progressive disease or toxicity
__label__0	study interventions are Lenalidomide . newly diagnosed multiple myeloma patients with an hla identical sibling suitable for pbsc donation and treated in induction with thalidomide or bortezomib or lenalidomide conteining regimes
__label__0	study interventions are Endothelial Growth Factors . recurrent colon carcinoma diagnosis and eastern cooperative oncology group ecog performance status ps zero or one
__label__0	study interventions are Fludarabine . multiple myeloma and plasma cell neoplasm diagnosis and essential_thrombocythemia or polycythemia rubra vera that has progressed to aml
__label__0	study interventions are Poly I-C . epithelial ovarian cancer diagnosis and patient is greater_than four weeks from completion of prior cytotoxic chemotherapy
__label__0	study interventions are Antibodies . recurrent osteosarcoma diagnosis and peripheral absolute neutrophil count anc greater_than equal_than one thousand ul
__label__0	study interventions are Liposomal doxorubicin . sarcoma diagnosis and no concurrent dexrazoxane
__label__0	study interventions are Cediranib . stage iv oral cavity verrucous carcinoma diagnosis and atrioventricular_av conduction abnormalities
__label__0	study interventions are Mibefradil . glioblastoma multiforme gbm diagnosis and measurable contrast enhancing progressive or recurrent gbm single or multiple lesions by mri imaging with an interval of greater than or equal to six months between recurrence and completion of prior radiotherapy
__label__0	study interventions are Pertuzumab . stage iv colon cancer diagnosis and treatment of febrile neutropenia
__label__0	study interventions are questionnaire administration . contiguous stage ii adult immunoblastic large cell lymphoma diagnosis and patients with any performance status are eligible for enrollment
__label__0	study interventions are fenretinide . ovarian cancer diagnosis and surgery
__label__0	study interventions are Floxuridine . liver cancer diagnosis and mixed hcc icc disease allowed
__label__0	study interventions are Docetaxel . patients diagnosed with lung cancer who have not responded to prior therapy or have become worse
__label__0	study interventions are Lenalidomide . stage iii grade one follicular lymphoma diagnosis and ascites
__label__0	study interventions are Cisplatin . pancreatic cancer diagnosis and note
__label__0	study interventions are Immunoglobulin G . recurrent ovarian carcinoma diagnosis and alkaline phosphatase equal_than less_than doc times uln
__label__0	study interventions are Targeted . breast cancer in young women diagnosis and for high risk relatives
__label__0	study interventions are Alemtuzumab . gestational_trophoblastic tumor diagnosis and biologic therapy
__label__0	study interventions are Irinotecan . esophagogastric cancer diagnosis and part b
__label__0	study interventions are Lenograstim . castrate resistant prostate cancer diagnosis and rising psa or
__label__0	study interventions are Genz-644282 (21-day dosing schedule) . solid tumors diagnosis and taxane anthracycline or fluoropyrimidine
__label__0	study interventions are Glycine . mantle cell lymphoma diagnosis and agree to practice effective barrier contraception during the entire study treatment period and through ninety days after the last dose of study drug or
__label__0	study interventions are Decitabine . recurrent neuroblastoma diagnosis and no concurrent immunomodulating agents
__label__0	study interventions are Rituximab . lymphoma diagnosis and see chemotherapy
__label__0	study interventions are laboratory biomarker analysis . childhood mixed glioma diagnosis and karnofsky or modified lansky score greater_than fifty
__label__0	study interventions are Hormones . stage breast cancer diagnosis and be chemotherapy naive
__label__0	study interventions are BCG Vaccine . urologic neoplasms diagnosis and any gthree or any tone and or cis
__label__0	study interventions are Everolimus . pediatric recurrent progressive low grade gliomas diagnosis and patients must be able to swallow pills
__label__0	study interventions are Sunitinib . recurrent uterine sarcoma diagnosis and no other concurrent investigational agents
__label__0	study interventions are biopsy . adult glioblastoma diagnosis and patients who developed an acneiform maculopustular rash while receiving either gefitinib or erlotinib hydrochloride are eligible unless the rash is considered an allergic reaction angioedema urticaria or stevens_johnson syndrome
__label__0	study interventions are Aldesleukin . adenocarcinomas diagnosis and serology
__label__0	study interventions are Rituximab . lymphoma diagnosis and no concurrent interleukin eleven
__label__0	study interventions are Estradiol . estrogen receptor positive breast cancer diagnosis and patient must have had no more than three lines of systemic therapy including endocrine therapy for metastatic disease to be eligible for phase ib and the last ten patients of cohort there is no limitation on the numbers of prior systemic therapies for phase ia and the first two patients of cohort c
__label__0	study interventions are Everolimus . stage iv bladder urothelial carcinoma diagnosis and life expectancy greater_than six months
__label__0	study interventions are chromatography . myelodysplastic myeloproliferative neoplasms diagnosis and over eighteen years of age
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv breast cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than fifty
__label__0	study interventions are laboratory biomarker analysis . breast cancer diagnosis and no major systemic infections or other major medical illnesses of the cardiovascular respiratory or digestive system
__label__0	study interventions are Etoposide phosphate . recurrent non small cell lung cancer diagnosis and within sixty days of registration
__label__0	study interventions are Gemcitabine . locally advanced unresectable and or metastatic soft tissue sarcoma of intermediate or high grade with evidence of disease progression by either computed tomography ct or magnetic resonance imaging mri scan or clinical judgment on or after the last cancer therapy within six months prior to randomization
__label__0	study interventions are Vincristine . peripheral primitive neuroectodermal tumor of the kidney diagnosis and thirteen to less_than sixteen years
__label__0	study interventions are Carboplatin . recurrent mediastinal thymic large cell cell lymphoma diagnosis and central pathology review is mandatory but is retrospective in nature slides should be submitted within thirty days of enrollment patients can be enrolled prior to submission of slides
__label__0	study interventions are Aldesleukin . vaginal cancer diagnosis and greater than or equal to eighteen years of age and less than or equal to sixty-six years of age
__label__0	study interventions are Gefitinib . unspecified adult solid tumor protocol specific diagnosis and hepatic
__label__0	study interventions are Antibodies . recurrent nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and no prior chemotherapy or biologic molecular targeted therapy for recurrent or metastatic scchn
__label__0	study interventions are Vaccines . stage ib breast cancer diagnosis and prothrombin time pt international normalized ratio inr equal_than less_than doc uln patients receiving anticoagulation therapy pt inr equal_than less_than three
__label__0	study interventions are Vaccines . ependymoma diagnosis and arm a
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent grade two follicular lymphoma diagnosis and fasting serum cholesterol equal_than less_than three hundred mg dl or equal_than less_than doc five mmol and fasting triglycerides equal_than less_than doc institutional upper limit of normal uln within two8 days prior to registration
__label__0	study interventions are Vincristine . lymphoma diagnosis and ecog performance status three four
__label__0	study interventions are Mitogens . recurrent pancreatic cancer diagnosis and patient characteristics
__label__0	study interventions are Mycophenolic Acid . stage iii mantle cell lymphoma diagnosis and patients are eligible following an autologous transplant in remission or in relapse
__label__0	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biological composition to sunitinib malate
__label__0	study interventions are Methylprednisolone . lymphoma diagnosis and renal
__label__0	study interventions are Albumin-Bound Paclitaxel . unspecified adult solid tumor protocol specific diagnosis and eighteen and over performance status
__label__0	study interventions are hand sewn . esophageal cancer diagnosis and benign esophageal lesion where esophageal resection was beneficial and feasible
__label__0	study interventions are musculoskeletal complications management/prevention . stage iiic breast cancer diagnosis and pre transplant karnofsky performance status kps greater_than equal_than seventy
__label__0	study interventions are Doxorubicin . ovarian brenner tumor diagnosis and detectable non measurable disease is defined as not having measurable disease but has at least one of the following conditions
__label__0	study interventions are Vaccines . stage iv primary peritoneal cancer diagnosis and no history of previous severe allergic reactions to vaccines or unknown allergens
__label__0	study interventions are Immunoglobulins . stage iii adult diffuse large cell lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Sunitinib . breast neoplasms diagnosis and prior treatment with an anthracycline and taxane in the adjuvant or advanced disease setting
__label__0	study interventions are Carboplatin . breast cancer diagnosis and more than four weeks since prior biologic therapy
__label__0	study interventions are Cyclophosphamide . noncontiguous stage ii grade one follicular lymphoma diagnosis and women and minorities are encouraged to participate
__label__0	study interventions are wild-type reovirus . recurrent melanoma diagnosis and ongoing or active infection
__label__0	study interventions are Retinol acetate . recurrent small cell lung cancer diagnosis and platelet count greater_than one hundred zero µl
__label__0	study interventions are recombinant interleukin-7 . unspecified adult solid tumor protocol specific diagnosis and hypertension resting blood pressure greater than one hundred and forty ninety mm hg must be controlled with standard anti hypertensive therapy
__label__0	study interventions are Erlotinib Hydrochloride . recurrent basal cell carcinoma of the lip diagnosis and more than seven days since other prior cypthreeafour inhibitors
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and not curable by surgery and or not amenable to radiotherapy with curative intent
__label__0	study interventions are Immunoglobulins . stage mantle cell lymphoma diagnosis and ast sgot and alt sgpt equal_than less_than two uln or equal_than less_than five uln if hepatic metastases are present
__label__0	study interventions are Lenalidomide . mantle cell lymphoma mcl blastoid_variant diagnosis and patients must be able to take low molecular weight heparin as prophylactic anticoagulation
__label__0	study interventions are Assessments . head and neck cancer diagnosis and hnscc patients only
__label__0	study interventions are BB 1101 . stage ii multiple myeloma diagnosis and pregnant women
__label__0	study interventions are Methadone . lymphoma diagnosis and none of the following conditions that could predispose the patient to prolonged qt interval associated tachycardia
__label__0	study interventions are Mycophenolic Acid . anaplastic large cell lymphoma diagnosis and best available matches are hla class hla b allele matched donors allowing for any one or two drbone and or dqbone antigen allele mismatch
__label__0	study interventions are Prednisolone hemisuccinate . the terminology of indolent or aggressive lymphoma will replace the former terminology of low intermediate or high grade lymphoma
__label__0	study interventions are Methylprednisolone acetate . cancer diagnosis and no severe mucositis grade three or four indicated by erythema edema or ulcerations requiring hydration parenteral nutritional support or intubation or resulting in aspiration pneumonia
__label__0	study interventions are Cytarabine . t cell non hodgkin lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco forced expiratory volume in one second fevone and forced vital capacity fvc greater_than equal_than fifty of predicted corrected for hemoglobin
__label__0	study interventions are Lapatinib . hertwo positive circulating tumor cells diagnosis and estrogen receptor eg and progesterone receptor pgr status must have been documented
__label__0	study interventions are Hormones . prostate cancer diagnosis and no concurrent chemotherapeutic agents
__label__0	study interventions are Prednisolone . gestational_trophoblastic tumor diagnosis and no requirement for vasopressors
__label__0	study interventions are Dexamethasone . relapsed refractory multiple myeloma for which no standard therapy options are anticipated to result in durable remission
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and no serious ongoing infection
__label__0	study interventions are Zoledronic acid . breast cancer diagnosis and platelet count greater_than one hundred ten nine l
__label__0	study interventions are Cognitive Assessment . ovarian dysgerminoma diagnosis and no severe hemiparesis or other condition preventing_bimanual keyboard operation
__label__0	study interventions are Melphalan . childhood nasal type extranodal nk cell lymphoma diagnosis and waldenstrom macroglobulinemia failed one standard regimen
__label__0	study interventions are Flucytosine . anaplastic astrocytoma diagnosis and estimated glomerular filtration rate of at least fifty ml min by the cockcroft gault formula below
__label__0	study interventions are Fludarabine . pancreatic cancer diagnosis and serology
__label__0	study interventions are Insulin . hemodynamically stable consistent with standard of care values for patients undergoing elective tumor resection
__label__0	study interventions are Isophosphamide mustard . recurrent ovarian germ cell tumor diagnosis and at least six months since prior allogeneic stem cell transplantation
__label__0	study interventions are Sirolimus . neuroendocrine tumors diagnosis and highly effective contraception methods include combination of
__label__0	study interventions are Antibodies, Monoclonal . resected melanoma in situ
__label__0	study interventions are Antibodies . stage iiia primary peritoneal cancer diagnosis and platelets greater_than equal_than seventy-five zero mm three
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iia cervical cancer diagnosis and patients with ureteral obstruction must undergo stent or nephrostomy tube placement prior to study entry
__label__0	study interventions are Bortezomib . stage ivc squamous cell carcinoma of the oropharynx diagnosis and one five hundred ul
__label__0	study interventions are Citric Acid . presence or history of known hyperprolactinemia with or without tumor
__label__0	study interventions are Entinostat . stage iiib breast cancer diagnosis and known human immunodeficiency virus hiv positive patients should have cluster of differentiation cd four count greater_than two hundred and fifty mm three
__label__0	study interventions are Liver Extracts . liver cancer diagnosis and the effects of therasphere and everolimus on the developing human fetus are unknown
__label__0	study interventions are Capecitabine . stage iii colon cancer diagnosis and protein less than five hundredmg twenty-four hours
__label__0	study interventions are Antilymphocyte Serum . kidney cancer diagnosis and failed to enter remission
__label__0	study interventions are Antibodies, Monoclonal . refractory hodgkin lymphoma diagnosis and part dtwo
__label__0	study interventions are Epothilone B . histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy or for whom no standard therapy exists or who might benefit from treatment with carboplatin
__label__0	study interventions are Vincristine . lymphoma diagnosis and other
__label__0	study interventions are Pantoprazole . subjects who develop osteosarcoma as second cancer are eligible if they have not previously received cisplatin doxorubicin or other anthracyclines or mtx
__label__0	study interventions are Cisplatin . ovarian cancer diagnosis and the patient first cytoreductive debulking surgery must be after neoadjuvant chemotherapy delayed primary debulking
__label__0	study interventions are Methotrexate . lymphoma diagnosis and documented chemosensitive or stable non bulky disease prior to transplant defined as less_than twenty bone marrow involvement and lymph node size less_than three cm in axial diameter
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian brenner tumor diagnosis and anc greater_than one five hundred mm three
__label__0	study interventions are Goserelin . prostate cancer diagnosis and patients must have adequate bone marrow function defined as an absolute peripheral granulocyte count of greater_than equal_than one five hundred mmthree and platelet count of greater_than equal_than one00 zero mmthree adequate hepatic function defined with total bilirubin of less_than equal_than doc mg dl and aspartate aminotransferase ast or sgot alanine aminotransferase alt or sgpt less_than equal_than two times the upper limits of normal adequate renal function defined as serum creatinine clearance greater_than equal_than forty cc min measured or calculated
__label__0	study interventions are Liposomal doxorubicin . cutaneous cell lymphoma diagnosis and two week washout and topical nitrogen_mustard
__label__0	study interventions are Methylprednisolone . anaplastic large cell lymphoma alk negative diagnosis and calculated creatinine clearance greater_than fiftyml minute
__label__0	study interventions are Histone Deacetylase Inhibitors . primary central nervous system non hodgkin lymphoma diagnosis and eastern cooperative oncology group ecog performance status ps zero one or two
__label__0	study interventions are Tacrolimus . stage iv small lymphocytic lymphoma diagnosis and second or subsequent remission
__label__0	study interventions are Prednisolone acetate . multiple myeloma and plasma cell neoplasm diagnosis and creatinine less_than doc mg dl
__label__0	study interventions are Sargramostim . glioma diagnosis and measurable by gadolinium mri scan
__label__0	study interventions are 7-hydroxystaurosporine . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and more than twelve weeks
__label__0	study interventions are Gemcitabine . bladder cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are laboratory biomarker analysis . ductal breast carcinoma in situ diagnosis and spouses partners must be willing to give sample of blood and or sputum at time of first and second data collections
__label__0	study interventions are Cetuximab . mucinous adenocarcinoma of the rectum diagnosis and the liver metastases must be considered surgically resectable prior to the initiation of study drugs
__label__0	study interventions are azurin-derived cell-penetrating peptide p28 . giant cell glioblastoma diagnosis and if prior therapy was monoclonal antibody thirty days or three half lives must have elapsed whichever is longer prior to registration
__label__0	study interventions are Vincristine . brain and central nervous system tumors diagnosis and life expectancy
__label__0	study interventions are Docetaxel . lung cancer diagnosis and disease characteristics
__label__0	study interventions are Paclitaxel . urethral cancer diagnosis and other
__label__0	study interventions are Epoetin Alfa . lymphoma diagnosis and surgery
__label__0	study interventions are Oxaliplatin . ovarian cancer diagnosis and not specified
__label__0	study interventions are Etoposide . non hodgkin lymphoma diagnosis and subject can be given packed red blood cell transfusion
__label__0	study interventions are Veliparib . stage iiic breast cancer diagnosis and patients must not be homozygous for the ugtoneaone twenty-eight allele also called ta seven individuals who are carriers for the ugtoneaone twenty-eight allele may be at increased risk for neutropenia following initiation of irinotecan treatment
__label__0	study interventions are S-1 . gastrointestinal neoplasms diagnosis and informed consent
__label__0	study interventions are Antibodies . contiguous stage ii small lymphocytic lymphoma diagnosis and informed consent approved in institutional review board lrb
__label__0	study interventions are Paclitaxel . esophageal cancer diagnosis and ecog performance status score zero or one
__label__0	study interventions are Flt3 ligand protein . breast cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Gemcitabine . recurrent uterine corpus cancer diagnosis and neuropathy sensory and motor nci ctcae grade equal_than less_than two
__label__0	study interventions are Questionnaire Administration . adult nasal type extranodal nk cell lymphoma diagnosis and in remission complete remission cr partial remission pr or stable disease based on clinical not necessarily radiologic assessment and currently being observed and with no current cytotoxic chemotherapy planned patients may be on rituximab maintenance
__label__0	study interventions are Ado-trastuzumab emtansine . metastatic breast cancer diagnosis and for patients with gilbert syndrome the direct bilirubin should be within the institutional normal range
__label__0	study interventions are Interferon-alpha . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Antibodies . stage iv verrucous carcinoma of the larynx diagnosis and recovered from all prior radiotherapy and chemotherapy
__label__0	study interventions are Interleukin-2 . stage iv melanoma diagnosis and not pregnant or nursing
__label__0	study interventions are Gemcitabine . malignant mesothelioma diagnosis and prior surgical resection preceding disease recurrence allowed
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and surgery
__label__0	study interventions are Fractionated proton radiation . acoustic neuroma diagnosis and women of child bearing potential and men must agree to use adequate contraception during the interval of irradiation
__label__0	study interventions are Antibodies . recurrent metastatic squamous neck cancer with occult primary diagnosis and hemoglobin hb greater_than nine dl
__label__0	study interventions are tanespimycin . recurrent marginal zone lymphoma diagnosis and at least three months
__label__0	study interventions are Carboplatin . adjuvant trastuzumab therapy for breast cancer is allowed provided last dose was given greater_than equal_than twelve months prior to diagnosis of recurrence
__label__0	study interventions are Sorafenib . stage ivb salivary gland cancer diagnosis and bilirubin equal_than less_than two the institutional upper limit of normal
__label__0	study interventions are laboratory biomarker analysis . clear cell renal cell carcinoma diagnosis and expected life expectancy greater_than equal_than six months
__label__0	study interventions are Cyclophosphamide . metastatic cancer diagnosis and disease characteristics
__label__0	study interventions are Cholecalciferol . stage iii colon cancer diagnosis and serum calcium corrected for albumin level less_than onex institutional uln
__label__0	study interventions are Sunitinib . recurrent squamous cell carcinoma of the larynx diagnosis and active peptic ulcer disease
__label__0	study interventions are Fluorouracil . recurrent verrucous carcinoma of the larynx diagnosis and requiring regional palliative radiotherapy
__label__0	study interventions are Vidarabine . intraocular lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Fluorouracil . anal cancer diagnosis and chemotherapy
__label__0	study interventions are Fluorouracil . head and neck cancer diagnosis and no distant metastasis
__label__0	study interventions are Olaparib . high grade ovarian serous adenocarcinoma diagnosis and no limit on the number of platinum based lines
__label__0	study interventions are Irinotecan . histologically or cytologically confirmed small cell lung cancer sclc
__label__0	study interventions are Tacrolimus . recurrent adult immunoblastic lymphoma diagnosis and acute myeloid leukemia aml must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the nasopharynx diagnosis and no cns cerebrovascular ischemia or stroke within the past six months
__label__0	study interventions are Antibodies . stage iii grade three follicular lymphoma diagnosis and for non nhl conditions no chemotherapy radiotherapy or major surgery within four weeks six weeks for nitrosoureas or mitomycin of enrollment no patients who have ongoing adverse events from agents administered more than four weeks previously
__label__0	study interventions are Sargramostim . recurrent childhood brain neoplasm diagnosis and total bilirubin equal_than less_than doc times upper limit of institutional normal uln for age obtained equal_than less_than seven days prior to registration
__label__0	study interventions are Sirolimus . recurrent ovarian epithelial cancer diagnosis and active peptic ulcer disease any other medical condition that might be aggravated by treatment
__label__0	study interventions are management of therapy complications . psychosocial effects of cancer and its treatment diagnosis and depression
__label__0	study interventions are Imatinib Mesylate . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and no concurrent steroids
__label__0	study interventions are Hydrocortisone . stage ii childhood small noncleaved cell lymphoma diagnosis and isolated intracerebral mass
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and lthree morphology especially in the presence of eight fourteen eight twenty-two or two eight
__label__0	study interventions are Best Standard of Care . brain metastases from non small cell lung cancer nsclc diagnosis and at least one measurable lesion per rano bm response assessment in neuro oncology brain metastases criteria for brain metastasis
__label__0	study interventions are Thalidomide . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and ecog performance status of equal_than less_than two at study entry karnofsky performance status of greater_than equal_than seventy at study entry
__label__0	study interventions are Vinblastine . lymphoma diagnosis and no prior chemotherapy for this malignancy
__label__0	study interventions are Busulfan . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Irinotecan . stage ivb rectal cancer diagnosis and aspartate aminotransferase ast equal_than less_than three uln or ast equal_than less_than five uln if liver involvement
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and creatinine clearance greater_than forty-five cc min
__label__0	study interventions are BYl719 . metastatic breast cancer diagnosis and absolute neutrophil count anc greater_than doc ten nine l
__label__0	study interventions are Prednisone . stage iii adult diffuse large cell lymphoma diagnosis and pregnant or nursing women may not participate due to the potential for congenital abnormalities and of harm to nursing infants due to this treatment regimen women or men of reproductive potential may no participate unless they have agreed to use an effective contraceptive method
__label__0	study interventions are Citric Acid . diffuse large cell lymphoma diagnosis and surgically sterile
__label__0	study interventions are ACE-011 - 45 mg . carcinoma non small cell lung diagnosis and life expectancy of greater_than three months
__label__0	study interventions are Vaccines . colorectal cancer diagnosis and other
__label__0	study interventions are Octreotide . pancreatic neuroendocrine tumor gtwo diagnosis and leptomeningeal disease
__label__0	study interventions are Ergocalciferols . prostate cancer diagnosis and ecog performance status zero two
__label__0	study interventions are Albumin-Bound Paclitaxel . neoplasm diagnosis and total bilirubin less_than doc the institutional upper limit of normal uln
__label__0	study interventions are Paclitaxel . metastatic pancreatic adenocarcinoma diagnosis and arm cohort four
__label__0	study interventions are Freund's Adjuvant . recurrent intraocular melanoma diagnosis and total white blood cell wbc of three zero or more
__label__0	study interventions are Docetaxel . breast cancer diagnosis and measurable disease
__label__0	study interventions are graft versus host disease prophylaxis/therapy . cancer diagnosis and hematopoietic
__label__0	study interventions are 4-cm margin . melanoma diagnosis and final surgery planned within eight weeks after date of diagnosis
__label__0	study interventions are Carboplatin . peritoneal cavity cancer diagnosis and secondary cytoreductive surgery for recurrent disease greater_than six months after completion of first line chemotherapy
__label__0	study interventions are isolated perfusion . brain and central nervous system tumors diagnosis and bilirubin no greater than doc mg dl
__label__0	study interventions are Dacarbazine . childhood craniopharyngioma diagnosis and chemotherapy
__label__0	study interventions are Fludarabine . other active neoplasm
__label__0	study interventions are Docetaxel . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and no psychiatric illness or social situation that would preclude study compliance
__label__0	study interventions are genetically engineered lymphocyte therapy . recurrent mantle cell lymphoma diagnosis and patients who achieve only partial response to fcr as initial therapy will be eligible
__label__0	study interventions are Aprepitant . non small cell lung cancer diagnosis and ecog ps zero two
__label__0	study interventions are Gemcitabine . adult solid neoplasm diagnosis and platelet count greater_than equal_than one hundred and fifty ten nine l
__label__0	study interventions are Deamino Arginine Vasopressin . colorectal cancer diagnosis and treatment indication with chemotherapy and or radiotherapy and or surgery according to disease stage
__label__0	study interventions are Internet-Based Intervention . advanced malignant neoplasm diagnosis and secondary genetic counseling substudy
__label__0	study interventions are Cisplatin . undifferentiated fallopian tube carcinoma diagnosis and patients with the following histologic cell types are eligible
__label__0	study interventions are FLT-PET imaging . brain tumors diagnosis and must have the understanding and ability to sign an informed consent document
__label__0	study interventions are becatecarin . colorectal cancer diagnosis and wbc at least three zero mmthree
__label__0	study interventions are Immunoglobulins . regional digestive system neuroendocrine tumor gone diagnosis and the subject must have an in range inr usually between two and three on stable dose of warfarin or on stable dose of low molecular weight lmw heparin
__label__0	study interventions are Immunoglobulins . stage iv inverted papilloma of the paranasal sinus and nasal cavity diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional upper limit of normal
__label__0	study interventions are Methotrexate . desmoid tumor diagnosis and disease characteristics
__label__0	study interventions are Stereotactic Body Radiotherapy (SBRT) . lung neoplasms diagnosis and patients must have suspicious lung nodule for clinical stage nsclc
__label__0	study interventions are Antibodies, Monoclonal . stage iia breast cancer diagnosis and patients must not have bleeding diathesis hereditary or acquired bleeding disorder or coagulopathy
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and no uncontrolled hypertension sustained blood pressure greater than two hundred mm hg systolic or one hundred and ten mm hg diastolic
__label__0	study interventions are Vidarabine . angioimmunoblastic cell lymphoma diagnosis and donor must have adequate veins for leukapheresis or agree to placement of central venous catheter femoral_subclavian
__label__0	study interventions are Methylprednisolone . metastatic castration resistant prostate cancer diagnosis and patients who discontinued docetaxel for toxicity reasons and without completing the full course will still be eligible to enter this study provided they received at least two cycles of chemotherapy
__label__0	study interventions are combination of Cyberknife with S-1 . pancreatic cancer diagnosis and blood routine examination
__label__0	study interventions are Mesna . lung cancer diagnosis and see disease characteristics
__label__0	study interventions are Rituximab . lymphoma follicular diagnosis and availability of archival diagnostic biopsy for histological revision
__label__0	study interventions are Lenograstim . recurrent uterine corpus carcinoma diagnosis and neuropathy sensory and motor less than or equal to ctcae doc grade one
__label__0	study interventions are Fluorouracil . oesophago gastric carcinoma diagnosis and life expectancy greater_than three months
__label__0	study interventions are Laboratory Biomarker Analysis . untreated childhood giant cell glioblastoma diagnosis and doc mg dl male or doc mg dl female greater_than equal_than sixteen years of age
__label__0	study interventions are 6-Mercaptopurine . lymphoma diagnosis and not specified
__label__0	study interventions are Cidofovir . cervical cancer diagnosis and life expectancygreater_than three months
__label__0	study interventions are Sulfamethoxazole . serious intercurrent illness must be discussed with the principal investigator infectious disease consultation required for complex infections medications for other conditions allowed provided no adverse interaction with protocol therapy occurs no previously diagnosed kaposi sarcoma or other malignancy
__label__0	study interventions are Nintedanib . ovarian clear cell carcinoma diagnosis and failure after greater_than one prior platinum containing regimen which may have been given in the adjuvant setting
__label__0	study interventions are Fluorouracil . stage iii basal cell carcinoma of the lip diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Pemetrexed . non small cell lung cancer diagnosis and patients must be candidates medically for chemotherapy followed by surgical resection
__label__0	study interventions are Multimodal Exercise Intervention . pediatric cancer diagnosis primary leukemia brain tumors and bone tumors
__label__0	study interventions are Immunoglobulins . recurrent lymphoepithelioma of the nasopharynx diagnosis and no prior fluorouracil and hydroxyurea with radiotherapy
__label__0	study interventions are Prednisolone hemisuccinate . lymphoma diagnosis and bilirubin less than three times normal
__label__0	study interventions are Liposomal doxorubicin . refractory lymphomas diagnosis and female patient of childbearing potential has negative serum pregnancy test hcg within ninety-six hours prior to receiving the first dose of vorinostat
__label__0	study interventions are Interferons . carcinoma renal cell diagnosis and life expectancy greater_than two months
__label__0	study interventions are Vidarabine . colorectal cancer diagnosis and at least four weeks since prior and no concurrent radiotherapy except for palliative reasons control of bone pain
__label__0	study interventions are Pembrolizumab . brain cancer diagnosis and ct or mri within fourteen days prior of registration
__label__0	study interventions are Vidarabine . stage adult diffuse large cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Thiotepa . retinoblastoma diagnosis and renal
__label__0	study interventions are Cetuximab . recurrent metastatic squamous neck cancer with occult primary diagnosis and more than two weeks since prior hormone replacement therapy or hormonal contraceptives
__label__0	study interventions are Carboplatin . unspecified adult solid tumor protocol specific diagnosis and no cardiac arrhythmia
__label__0	study interventions are Cyclophosphamide . cancer of head and neck diagnosis and incurable hpvoc as defined by
__label__0	study interventions are Mycophenolate mofetil . recurrent mantle cell lymphoma diagnosis and myeloproliferative and lymphoproliferative disorder negative must have evidence of disease acceleration to be candidate for umbilical cord blood transplant myeloproliferative disorders eligible for transplant include chronic myelomonocytic leukemia cmml with high ipss score and myelofibrosis
__label__0	study interventions are Carboplatin . non small cell lung cancer diagnosis and measurable or non measurable disease
__label__0	study interventions are Etoposide . testicular choriocarcinoma and yolk_sac tumor diagnosis and no patients with any of the following diagnoses
__label__0	study interventions are Cortisol succinate . melanoma diagnosis and eastern cooperative oncology group performance status of zero or one
__label__0	study interventions are Antilymphocyte Serum . splenic marginal zone lymphoma diagnosis and subjects must be ineligible for conventional myeloablative transplantation
__label__0	study interventions are Endothelial Growth Factors . lung carcinoid tumor diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are placebo . radiation therapy to seventy gray gy to gross tumor in two gy per fraction over seven weeks using intensity_modulated radiation therapy imrt techniques for patients with intact tumors and sixty gy
__label__0	study interventions are Capecitabine . recurrent fallopian tube carcinoma diagnosis and bilirubin equal_than less_than doc uln
__label__0	study interventions are Vaccines . colorectal cancer diagnosis and ecog performance status zero one life expectancy greater_than three months
__label__0	study interventions are Albumin-Bound Paclitaxel . bladder cancer diagnosis and hepatic inclusion within two weeks of entry
__label__0	study interventions are Sirolimus . stage iv breast cancer diagnosis and serum creatinine equal_than less_than doc mg dl
__label__0	study interventions are gamma-secretase/Notch signalling pathway inhibitor RO4929097 . recurrent colon cancer diagnosis and patients with regular menses
__label__0	study interventions are Sirolimus . previously treated childhood rhabdomyosarcoma diagnosis and patients with primary refractory disease are eligible
__label__0	study interventions are Mycophenolic Acid . recurrent marginal zone lymphoma diagnosis and myeloproliferative disorders with progressive disease or cytopenias or clinical symptoms refractory to standard therapy hypomethylating agents
__label__0	study interventions are Fludarabine phosphate . recurrent childhood lymphoblastic lymphoma diagnosis and secondary massively_parallel signature sequencing_mpss with any ipss scores
__label__0	study interventions are Vinorelbine . stage iiia non small cell lung cancer diagnosis and patients must not have serious non healing wound ulcer bone fracture or have undergone major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to randomization or core biopsy within seven days prior to randomization
__label__0	study interventions are Gemcitabine . breast cancer diagnosis and zero two prior chemotherapy regimens in the metastatic setting
__label__0	study interventions are Podophyllotoxin . stage iv follicular lymphoma diagnosis and participants with cdfour counts greater_than fifty microl are eligible for this study if their viral load is less_than fifty copies ml by reverse_transcription polymerase chain reaction rt pcr since majority of the participants have received aggressive chemotherapy that can potentially decrease the cdfour counts despite the art therapy timeline
__label__0	study interventions are radiation therapy . kidney cancer diagnosis and additional less painful metastatic sites may be present
__label__0	study interventions are Liposomal doxorubicin . ewing sarcoma of bone or soft tissue diagnosis and participants who receive emergent radiation will not be eligible for window therapy
__label__0	study interventions are Tacrolimus . noncutaneous extranodal lymphoma diagnosis and aml in first complete remission crone with high risk cytogenetics complex monosomy five monosomy seven oneoneqtwenty-three not nine oneone six nine chromosome three monosomy phenotype and other karyotypes estimated to have equal_than less_than twenty disease free survival at three years or secondary transformed aml without favorable cytogenetics
__label__0	study interventions are Doxorubicin . kaposi sarcoma diagnosis and group ii
__label__0	study interventions are Isophosphamide mustard . stage iii childhood hodgkin lymphoma diagnosis and coli derived proteins filgrastim csf or any component of the study drugs
__label__0	study interventions are alpha-Tocopherol . unspecified adult solid tumor protocol specific diagnosis and the patient chemotherapy regimen must include one or more of the following neurotoxic chemotherapeutic agents
__label__0	study interventions are Niacinamide . recurrent rectal cancer diagnosis and no concurrent prophylactic filgrastim csf sargramostim gm csf or epoetin_alfa
__label__0	study interventions are Camptothecin . recurrent small cell lung cancer diagnosis and hemoglobin greater_than ten dl
__label__0	study interventions are Capecitabine . breast cancer diagnosis and disease characteristics
__label__0	study interventions are Carboplatin . metastatic malignant neoplasm in the brain diagnosis and be advised of the importance of avoiding pregnancy during trial participation and the potential risks of an unintentional pregnancy
__label__0	study interventions are Paclitaxel . endometrial squamous cell carcinoma diagnosis and patients must have normal ejection fraction
__label__0	study interventions are Niacinamide . stage ivc verrucous carcinoma of the larynx diagnosis and granulocyte count greater_than one five hundred mm three
__label__0	study interventions are Semaxinib . adenocarcinoma of the colon diagnosis and patients must have either measurable or evaluable disease measurable disease is defined as at least one bidimensionally measurable lesion greater_than equal_than one one cm that is outside the field of any prior radiation therapy
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and platelets greater_than one hundredxone hundred and nine l
__label__0	study interventions are Liposomal doxorubicin . patients are eligible with either hormone receptor positive or hormone receptor negative tumors
__label__0	study interventions are Capecitabine . colorectal neoplasms diagnosis and pci score less_than twenty and cc zero or cc one achievable determined by adequate preoperative work up
__label__0	study interventions are Camptothecin . brain and central nervous system tumors diagnosis and no other severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risks associated with study participation or study drug administration or could interfere with the interpretation of the study results and would make the patient inappropriate for study entry
__label__0	study interventions are Mycophenolate mofetil . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and large cell nhl greater_than crtwo greater_than prtwo
__label__0	study interventions are laboratory biomarker analysis . adult giant cell glioblastoma diagnosis and at least four weeks since prior investigational agents
__label__0	study interventions are Antibodies, Monoclonal . stage iv pancreatic cancer diagnosis and recent history of cerebrovascular accident
__label__0	study interventions are Vaccines . nasopharyngeal neoplasms diagnosis and lymphocytes greater_than doc one hundred and nine or above the lower limit of normal range of institutional laboratory
__label__0	study interventions are 7-hydroxystaurosporine . unresectable extrahepatic bile duct cancer diagnosis and see disease characteristics part ii
__label__0	study interventions are Panobinostat . anaplastic large cell lymphoma diagnosis and albumin greater_than doc dl
__label__0	study interventions are Romidepsin . stage iv lung cancer diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Alemtuzumab . recurrent cutaneous cell non hodgkin lymphoma diagnosis and low grade nhl
__label__0	study interventions are Endothelial Growth Factors . stage iii squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and not amenable to standard therapy
__label__0	study interventions are Rituximab . contiguous stage ii adult lymphoblastic lymphoma diagnosis and men must agree to use latex condom during sexual contact with fcbp even if they have had successful vasectomy
__label__0	study interventions are Vincristine . diffuse large cell lymphoma diagnosis and defined by the local haematopathologist at the local laboratory according to who criteria
__label__0	study interventions are Bevacizumab . recurrent squamous cell carcinoma of the nasopharynx diagnosis and no serious non healing wound ulcer or bone fracture
__label__0	study interventions are Interleukin-2 . kidney cancer diagnosis and symptoms of respiratory dysfunction
__label__0	study interventions are Bevacizumab . fallopian tube cancer diagnosis and less than three mm invasion without vascular or lymphatic invasion
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and cardiovascular
__label__0	study interventions are Paclitaxel . uterine cancer diagnosis and total bilirubin less_than doc institutional upper limit of normal
__label__0	study interventions are Irinotecan . recurrent neuroblastoma diagnosis and not pregnant or nursing
__label__0	study interventions are Mycophenolic Acid . stage ii grade two non contiguous follicular lymphoma diagnosis and donor
__label__0	study interventions are Antibodies, Monoclonal . stage iv squamous cell carcinoma of the nasopharynx diagnosis and no prior cetuximab
__label__0	study interventions are Blood Draw . diagnosis of unilateral retinoblastoma with rbone mutation or mycn amplification identified
__label__0	study interventions are Cisplatin . carcinoma non small cell lung diagnosis and life expectancy of at least three months
__label__0	study interventions are Vaccines . head and neck cancer diagnosis and more than six months
__label__0	study interventions are Paclitaxel . patients with extraovarian papillary serous cystadenocarcinoma are eligible
__label__0	study interventions are Docetaxel . non small cell lung cancer diagnosis and adequate hepatic function albumin greater_than doc dl total bilirubin less_than two mg dl five doc µmol and alanine aminotransferase and aspartate aminotransferase less_than doc times the upper limit of the normal range
__label__0	study interventions are Busulfan . childhood germ cell tumor diagnosis and not specified
__label__0	study interventions are Temozolomide . lung cancer diagnosis and age
__label__0	study interventions are Prednisone . lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Oxaliplatin . rectal cancer diagnosis and hemoglobin greater_than doc dl
__label__0	study interventions are Sirolimus . lymphoma diagnosis and creatinine less_than equal_than doc mg dl
__label__0	study interventions are Bevacizumab . stage iiib gastric cancer diagnosis and siewert classification ii or iii
__label__0	study interventions are pharmacological study . stage ivc salivary gland cancer diagnosis and patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded as greater_than equal_than twenty mm with conventional techniques or as greater_than equal_than ten mm with spiral ct scan
__label__0	study interventions are Albumin-Bound Paclitaxel . cancer of the head and neck diagnosis and ast sgot alt sgpt less_than doc iuln alkaline phosphatase less_than doc iuln unless bone metastasis is present in the absence of liver metastasis
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and pulmonary function test with dlco fevone and fvc of greater_than sixty
__label__0	study interventions are Aldesleukin . refractory multiple myeloma diagnosis and successful isolation and production of an autologous idiotype vaccine from pre bmt sera
__label__0	study interventions are Bevacizumab . stage iv breast cancer diagnosis and no arterial thromboembolic event within the past six months including any of the following
__label__0	study interventions are Capecitabine . erbbtwo overexpressing breast cancer defined as three positive staining by immunohistochemistry ihc or two positive staining by ihc in conjunction with erbb two gene amplification by fish or erbb two gene amplification by fish alone in subjects whose tumor blocks were not assessed by ihc
__label__0	study interventions are Bortezomib . unspecified adult solid tumor protocol specific diagnosis and no history of serious ventricular arrhythmia ventricular tachycardia or ventricular fibrillation greater_than three beats in row
__label__0	study interventions are Lenograstim . non seminomatous germ cell tumor diagnosis and in rare circumstances patients will be allowed to enroll even if pathologic diagnosis may not have been established
__label__0	study interventions are Dexamethasone . prostate cancer diagnosis and no prior cryotherapy or transurethral resection of the prostate
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and patient characteristics
__label__0	study interventions are Etoposide . extensive stage small cell lung cancer diagnosis and patients must have inr equal_than less_than doc and ptt no greater than the institutional upper limit of normal within one week prior to registration
__label__0	study interventions are Cladribine . melanoma diagnosis and must have received induction chemotherapy
__label__0	study interventions are Temozolomide . sarcoma diagnosis and no other serious medical or psychiatric illness that would preclude study participation
__label__0	study interventions are Bromodeoxyuridine . stage prostate cancer diagnosis and no prior neoadjuvant hormonal therapy
__label__0	study interventions are Interferon-alpha . stage ii multiple myeloma diagnosis and patients refuses entry or is ineligible for snine thousand, three hundred and twenty-one note
__label__0	study interventions are Cytarabine . lymphoma diagnosis and early or late first relapse
__label__0	study interventions are Fludarabine . recurrent childhood lymphoblastic lymphoma diagnosis and failed prior autotransplant
__label__0	study interventions are Immunoglobulin G . recurrent childhood supratentorial embryonal tumor not otherwise specified diagnosis and patients must have had histologic verification of the malignancy at original diagnosis or at the time of recurrence
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and no unstable diabetes mellitus
__label__0	study interventions are Thalidomide . melanoma skin diagnosis and no concurrent systemic steroids including creams
__label__0	study interventions are Etoposide . testicular lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two at time of consent
__label__0	study interventions are Docetaxel . cervical cancer diagnosis and not specified
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and performance status
__label__0	study interventions are Doxorubicin . early primary breast cancer in the elderly diagnosis and laboratory requirements
__label__0	study interventions are Immunoglobulins . chronic lymphocytic leukemia cll small lymphocytic lymphoma sll follicular lymphoma fl mantle cell lymphoma mcl marginal zone lymphoma mzl or waldenstrom macroglobulinemia wm lymphoplasmacytic lymphoma lpl patients with mucosa associated lymphoid tissue malt subtype of mzl may have relapsed or refractory disease after course of antibiotic therapy otherwise patients will not have received treatment for their nhl treatment includes systemic therapy and radiation therapy before the time of study enrollment
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and prior sentinel node biopsy allowed with the exception of the following
__label__0	study interventions are Letrozole . breast cancer diagnosis and the date of randomization must be no less than two years of letrozole and no more than three years letrozole treatment
__label__0	study interventions are Sunitinib . histologically or cytologically confirmed metastatic renal cell carcinoma of clear cell histology
__label__0	study interventions are Mycophenolate mofetil . nonmalignant neoplasm diagnosis and in first partial remission prone
__label__0	study interventions are pharmacological study . stage iv breast cancer diagnosis and creatinine equal_than less_than doc mg dl
__label__0	study interventions are Docetaxel . unspecified adult solid tumor protocol specific diagnosis and alkaline phosphatase ap normal and ast or alt less_than five times upper limit of normal uln
__label__0	study interventions are Freund's Adjuvant . non melanomatous skin cancer diagnosis and absolute lymphocyte count greater_than five hundred mm three
__label__0	study interventions are Cisplatin . breast cancer diagnosis and endocrine therapy
__label__0	study interventions are Sorafenib . recurrent bladder cancer diagnosis and patients must not have had any prior systemic therapy for advanced or metastatic disease prior adjuvant or neoadjuvant chemotherapy is permitted providing it was completed at least four weeks prior to study entry radiation therapy is permitted if completed greater_than four weeks prior to trial entry
__label__0	study interventions are Dexamethasone acetate . peripheral cholangiocarcinoma diagnosis and wbc must be greater_than three thousand, five hundred cells mmthree
__label__0	study interventions are Isotretinoin . recurrent grade one follicular lymphoma diagnosis and hemoglobin greater_than nine dl
__label__0	study interventions are Fluorouracil . head and neck cancer diagnosis and other
__label__0	study interventions are osilodrostat . bilateral inferior petrosal sinus sampling bipss with either crh or ddavp stimulation for patients with tumor less_than sixmm
__label__0	study interventions are Everolimus . pten_overgrowth syndrome with vascular anomaly diagnosis and ulceration
__label__0	study interventions are Capecitabine . small intestinal large cell neuroendocrine carcinoma diagnosis and platelets greater_than equal_than one hundred zero mm three
__label__0	study interventions are R(+)XK469 . unspecified adult solid tumor protocol specific diagnosis and no prior radiotherapy to more than twenty-five of bone marrow containing areas
__label__0	study interventions are Etoposide phosphate . solid tumors diagnosis and ast sgot and alt sgpt alkaline phosphatase liver fraction
__label__0	study interventions are Vaccines . recurrent prostate cancer diagnosis and bone scan positive and psa at least ten ng ml
__label__0	study interventions are Dexamethasone acetate . a female of childbearing potential is sexually mature woman who
__label__0	study interventions are Fluorouracil . stage ii squamous cell carcinoma of the nasopharynx diagnosis and no greater than doc mg dl for patients six to less_than ten years of age
__label__0	study interventions are pharmacological study . childhood choroid_plexus tumor diagnosis and hemoglobin greater_than doc dl rbc transfusions allowed
__label__0	study interventions are Antioxidants . uterine cancer diagnosis and patients who have no language barrier are cooperative and can give informed consent before entering the study after being informed of the medications and procedures to be used in this study may participate
__label__0	study interventions are Everolimus . recurrent renal cell cancer diagnosis and patients must have recovered from acute toxicities from previous surgery chemotherapy or radiation therapy
__label__0	study interventions are Immunoglobulins . squamous cell carcinoma of the esophagus diagnosis and urine protein creatinine upc ratio of less_than doc or dipstick for protein of less_than two positive common terminology criteria for adverse events version doc ctcae four grade less_than two patients with upc ratio greater_than equal_than doc or dipstick of two positive must undergo twofour hour urine collection and must demonstrate less_than one gm of protein in order to participate
__label__0	study interventions are Gemcitabine . metastatic pancreatic adenocarcinoma diagnosis and subjects with the following adequate organ functions
__label__0	study interventions are medical chart review . ovarian cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Antibodies, Monoclonal . stage iv grade three follicular lymphoma diagnosis and no history of acquired immunodeficiency syndrome aids defining conditions
__label__0	study interventions are Focal Salvage Therapy . progression of prostate cancer diagnosis and biochemical failure as defined by the phoenix criteria psa nadir positive twong ml
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and who performance status zero two
__label__0	study interventions are Goserelin . breast cancer diagnosis and adequate coagulation international normalized ratio inr must be less_than doc less_than doc if patient is on stable therapeutic doses of warfarin and has no active bleeding or pathologic condition that is associated with high risk of bleeding
__label__0	study interventions are Cyclophosphamide . stage iv enteropathy associated cell lymphoma diagnosis and any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that in the investigator opinion may interfere with protocol adherence or subject ability to give informed consent
__label__0	study interventions are Dexamethasone acetate . multiple myeloma and plasma cell neoplasm diagnosis and lytic bone lesions
__label__0	study interventions are Immunoglobulins . recurrent pancreatic cancer diagnosis and no prior radiotherapy to the pancreas
__label__0	study interventions are cilengitide . stage iia prostate cancer diagnosis and sgot ast equal_than less_than doc upper limits of normal
__label__0	study interventions are Isophosphamide mustard . sarcoma diagnosis and absolute neutrophil count at least one five hundred mmthree
__label__0	study interventions are Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells . lymphoma large cell diffuse diagnosis and patients volunteer to participate in the research
__label__0	study interventions are Albumin-Bound Paclitaxel . endometrial mucinous adenocarcinoma diagnosis and pt such that inr is equal_than less_than doc or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin and partial thromboplastin time ptt equal_than less_than doc times the institutional upper limit of normal patients receiving low molecular weight heparin for the prevention or treatment of venous thromboembolic disease are eligible if considered clinically stable on their regimen
__label__0	study interventions are Nivolumab . mucosal melanoma diagnosis and patients must be ambulatory with good performance status ecog zero or one
__label__0	study interventions are Hydrocortisone acetate . stomatitis diagnosis and fasting serum cholesterol less_than three hundred mg dl or less_than doc five mmol and fasting triglycerides less_than doc uln
__label__0	study interventions are laboratory biomarker analysis . stage iv colon cancer diagnosis and patients must have measurable disease defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded for non nodal lesions and short axis for nodal lesions as greater_than equal_than twenty mm with conventional techniques or as greater_than equal_than ten mm with spiral ct scan
__label__0	study interventions are Collection of tumor and blood samples . lung cancer non small cell diagnosis and and
__label__0	study interventions are Tacrolimus . stage iv adult diffuse small cleaved cell lymphoma diagnosis and have seventeenp_deletion cytogenetic abnormality patients should have received induction chemotherapy but could be transplanted in onest cr
__label__0	study interventions are Cyclophosphamide . clear cell sarcoma diagnosis and adequate renal function defined as
__label__0	study interventions are Methotrexate . multiple myeloma diagnosis and negative pregnancy test
__label__0	study interventions are Endothelial Growth Factors . childhood cerebellar anaplastic astrocytoma diagnosis and doc mg dl one to less_than two years of age
__label__0	study interventions are comparison of screening methods . breast cancer diagnosis and patient characteristics
__label__0	study interventions are Docetaxel . stage iv squamous cell carcinoma of the nasopharynx diagnosis and creatinine normal
__label__0	study interventions are Imatinib Mesylate . patients with high grade tumors must be platinum taxane resistant as defined by
__label__0	study interventions are Pemetrexed . malignant pleural mesothelioma diagnosis and fit to receive chemotherapy and undergo pleurectomy decortication with optional removal of hemidiaphragm and pericardium
__label__0	study interventions are Cyclosporins . recurrent refractory childhood hodgkin lymphoma diagnosis and any single serologically detectable hla or or antigen positive
__label__0	study interventions are Everolimus . unspecified childhood solid tumor protocol specific diagnosis and all patients and or their parents or legal guardians must sign written informed consent assent when appropriate will be obtained according to institutional guidelines
__label__0	study interventions are Cisplatin . tumor abutment or encasement greater_than one hundred and eighty degrees of short segment of the ha
__label__0	study interventions are Prednisolone phosphate . a new classification scheme for adult non hodgkin lymphoma has been adopted by pdq
__label__0	study interventions are Prednisone . hormone refractory prostate cancer diagnosis and patients must have disease progression defined by the recist criteria
__label__0	study interventions are quality-of-life assessment . ovarian cancer diagnosis and all transplant types allowed
__label__0	study interventions are Irinotecan . childhood burkitt lymphoma diagnosis and no elevation of amylase or lipase greater_than grade two
__label__0	study interventions are Quality-of-Life Assessment . stage iib fallopian tube cancer diagnosis and patients must complete all pre entry assessments
__label__0	study interventions are Fluorouracil . stage iv rectal cancer diagnosis and protein less than five hundred mg by twenty-four hour urine collection
__label__0	study interventions are Topotecan . retinoblastoma diagnosis and sgot no greater than doc times uln
__label__0	study interventions are Irinotecan . childhood grade iii meningioma diagnosis and measurable disease by imaging studies
__label__0	study interventions are alvespimycin hydrochloride . stage iv squamous cell carcinoma of the nasopharynx diagnosis and new lesions or increase in pre existing lesions on bone scintigraphy ct scan mri or by physical examination
__label__0	study interventions are Rituximab . lymphoma diagnosis and chemotherapy
__label__0	study interventions are Hydrocortisone acetate . lymphoblastic lymphoma diagnosis and isolated cns or isolated testicular disease
__label__0	study interventions are Nivolumab . glioblastoma diagnosis and participants who completed and progressed on platinum containing regimen as adjuvant neoadjuvant or part of course of chemoradiation therapy given from locally advanced disease and developed recurrent local or metastatic disease within the six months before screening would be counted as having received one prior platinum containing regimen and therefore would not require re treatment with platinum containing regimen for stage iiib iv or recurrent disease and are eligible
__label__0	study interventions are Denosumab . histologic proof of castrate resistant prostate cancer with bone metastasis
__label__0	study interventions are Dexamethasone acetate . childhood choroid_plexus tumor diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma_secretase inhibitor rofour million, nine hundred and twenty-nine thousand and ninety-seven or dexamethasone
__label__0	study interventions are Liposomal doxorubicin . contiguous stage ii marginal zone lymphoma diagnosis and to define_dhl patients must have evidence of myc defined as
__label__0	study interventions are Busulfan . kidney cancer diagnosis and philadelphia_chromosome ph
__label__0	study interventions are Sulfatinib . based on central pathology review results patients have confirmed histologically pathology diagnosis of lo negative or intermediate grade gone or gtwo advanced unresectable or distant metastatic extrapancreatic nets with origins including but not limited to the lung thymus the gastrointestinal tract stomach duodenum liver jejunum ileum colon cecum appendix rectum and unknown origin etc
__label__0	study interventions are AlloStim . ovarian cancer diagnosis and alanine aminotransferase alt or sgpt less_than doc times uln
__label__0	study interventions are Mycophenolic Acid . lymphoma follicular diagnosis and liver function
__label__0	study interventions are Alvocidib . unspecified adult solid tumor protocol specific diagnosis and extensive stage or limited stage disease in relapse
__label__0	study interventions are Methylprednisolone . metastatic castration resistant prostate cancer diagnosis and participants who have target or non target metastatic abnormalities either on screening bone scan computed tomography ct or magnetic resonance imaging mri
__label__0	study interventions are Busulfan . unspecified adult solid tumor protocol specific diagnosis and performance status
__label__0	study interventions are Immunoglobulin G . childhood cerebral anaplastic astrocytoma diagnosis and no concurrent anticoagulants including systemic thrombolytic agents heparin low molecular weight heparins or warfarin except as required to maintain patency of pre existing permanent vascular catheters or for prevention of thrombosis in the post operative period
__label__0	study interventions are Foscarnet . stage iv adult cell leukemia lymphoma diagnosis and cmv seropositive donor and or recipient
__label__0	study interventions are Quality-of-Life Assessment . stage iv ovarian germ cell tumor diagnosis and myocardial infarction within the past year
__label__0	study interventions are Vorinostat . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and alt sgpt equal_than less_than two uln
__label__0	study interventions are Goserelin . adenocarcinoma of the prostate diagnosis and hepatic function
__label__0	study interventions are Camptothecin . adult rhabdomyosarcoma diagnosis and enrollment on cog dnine thousand, nine hundred and two to confirm local histologic diagnosis with central pathology review is required for all patients
__label__0	study interventions are Etoposide phosphate . central nervous system tumors diagnosis and hepatic
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and urinary protein excretion greater_than or equal_than two hundred mg twenty-four hrs c
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and biologic therapy
__label__0	study interventions are Mogamulizumab . subject who has history of second primary cancer within the past five years with the exception of
__label__0	study interventions are Iloprost . lung cancer diagnosis and well controlled atrial fibrillation or rare less_than two minutes premature ventricular contractions allowed
__label__0	study interventions are Antibodies . ovarian mucinous cystadenocarcinoma diagnosis and no prior therapy for this malignancy
__label__0	study interventions are Fludarabine phosphate . stage ii non contiguous adult diffuse mixed cell lymphoma diagnosis and myelodysplasia mds myeloproliferative syndrome mps patients must have received previous myelosuppressive chemotherapy or hct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Osimertinib . recurrent non small cell lung carcinoma diagnosis and disease progression on firs negative or second generation egfr tki erlotinib gefitinib or afatinib patient may have also received prior chemotherapy or immunotherapy but this is not required
__label__0	study interventions are Cisplatin . advanced non small cell lung cancer diagnosis and if male use of an approved contraceptive method during the study and three months afterwards
__label__0	study interventions are Antibodies, Monoclonal . patients with histologically confirmed glioblastoma or other grade iv malignant glioma gliosarcoma small cell glioblastoma etc
__label__0	study interventions are laboratory biomarker analysis . recurrent childhood anaplastic oligoastrocytoma diagnosis and concurrent steroids for treatment of increased intracranial pressure allowed if on stable or decreasing dose for greater_than equal_than one week before study entry
__label__0	study interventions are Antibodies, Monoclonal . recurrent colon cancer diagnosis and no prior cetuximab
__label__0	study interventions are Placebo . midgut carcinoid tumor diagnosis and no concurrent condition resulting in immune compromise including chronic treatment with corticosteroids or other immunosuppressive agents
__label__0	study interventions are Fluorouracil . transitional cell cancer of the renal pelvis and ureter diagnosis and biologic therapy
__label__0	study interventions are Maleic acid . stage iiia colon cancer diagnosis and patients with regular menses
__label__0	study interventions are BB 1101 . recurrent cutaneous cell non hodgkin lymphoma diagnosis and all patients must be informed of the investigational nature of this study and have given written consent in accordance with institutional and federal guidelines
__label__0	study interventions are Tretinoin . recurrent neuroblastoma diagnosis and persistent disease after achieving at least partial response to frontline therapy after minimum of four cycles of induction therapy and patient has never had relapse progression
__label__0	study interventions are Imatinib Mesylate . primary central nervous system non hodgkin lymphoma diagnosis and no unstable angina pectoris
__label__0	study interventions are mass spectrometry . breast cancer diagnosis and patient characteristics
__label__0	study interventions are Erlotinib Hydrochloride . malignant solid tumor diagnosis and female subjects of childbearing potential and male subjects whose sexual partners are of childbearing potential must agree to abstain from sexual intercourse or to use an effective method of contraception during the study and for sixty days after the last dose of av two hundred and ninety-nine formerly sch nine hundred thousand, one hundred and five
__label__0	study interventions are Dexrazoxane . sarcoma diagnosis and not specified hematopoietic
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and patient has measurable disease defined as at least one of the following
__label__0	study interventions are Paclitaxel . stage iv breast cancer diagnosis and patients may have received any of the following therapies
__label__0	study interventions are Metronidazole . stage ii malignant testicular germ cell tumor diagnosis and male or female
__label__0	study interventions are Etoposide phosphate . recurrent mantle cell lymphoma diagnosis and negative for human immunodeficiency virus hiv
__label__0	study interventions are Fluorodeoxyglucose F18 . transitional cell cancer of the renal pelvis and ureter diagnosis and cardiac arrhythmias requiring anti arrhythmic therapy beta blockers or digoxin are permitted
__label__0	study interventions are Doxorubicin . ovarian seromucinous carcinoma diagnosis and creatinine equal_than less_than doc institutional upper limit of normal uln
__label__0	study interventions are Iodine-131 anti-B1 antibody . lymphoma diagnosis and biologic therapy
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and if the recipient fails to express one or more of the primary kir ligands hla group hla group ii and bwfour then family member donors will be hla typed in an effort to find haploidentical donor
__label__0	study interventions are Pemetrexed . brain and central nervous system tumors diagnosis and able to take steroids vitamin btwelve or folate
__label__0	study interventions are Immunoglobulins . recurrent metastatic squamous neck cancer with occult primary diagnosis and absolute neutrophil count greater_than equal_than doc mm three
__label__0	study interventions are Erlotinib Hydrochloride . neoplasms head and neck diagnosis and general anesthesia if indicated is acceptable in patients whose lesions would require general anesthesia for laryngoscopy and biopsy according to routine standard of care
__label__0	study interventions are Vincristine . primary brain tumors diagnosis and greater than six months must have elapsed since the last day of treatment if given total body irradiation craniospinal irradiation
__label__0	study interventions are Sirolimus . spindle cell rhabdomyosarcoma diagnosis and foxoone_fusion positive
__label__0	study interventions are Punch Biopsy . melanoma diagnosis and history of axillary lymph node dissection sentinel lymph node biopsy or dissection
__label__0	study interventions are Methotrexate . stage adult lymphoblastic lymphoma diagnosis and women of child bearing potential who are unwilling to use reliable method of contraception
__label__0	study interventions are Hormones . regional neuroblastoma diagnosis and concurrent chemotherapy allowed
__label__0	study interventions are Gemcitabine . unresectable pancreatic carcinoma diagnosis and phase ii
__label__0	study interventions are Cisplatin . cancer of the head and neck diagnosis and absolute neutrophil count greater_than one five hundred mcl
__label__0	study interventions are Carboplatin . tumor diagnosis and measurable or non measurable disease
__label__0	study interventions are Docetaxel . prostatic neoplasms diagnosis and abdominal computed tomography ct scan without evidence of metastasis within six months of randomization
__label__0	study interventions are Docetaxel . nasopharyngeal carcinoma diagnosis and satisfactory performance status
__label__0	study interventions are Alemtuzumab . multiple myeloma and plasma cell neoplasm diagnosis and negative pregnancy test
__label__0	study interventions are Methylprednisolone acetate . lymphoma diagnosis and myeloproliferative disorders
__label__0	study interventions are Fludarabine phosphate . stage iii grade one follicular lymphoma diagnosis and ml follicular mixed small cleaved and large cell category c
__label__0	study interventions are Fludarabine . myelodysplastic myeloproliferative neoplasms diagnosis and core biopsies acceptable for primary diagnosis and immunophenotyping
__label__0	study interventions are Olaparib . ovarian serous surface papillary adenocarcinoma diagnosis and phase i
__label__0	study interventions are Cyclosporine . small lymphocytic lymphoma diagnosis and failed flu cyclophosphamide cy rituximab fcr combination chemotherapy at any time point or
__label__0	study interventions are Mycophenolic Acid . recurrent adult cell leukemia lymphoma diagnosis and the patient must be aware of the high risk and experimental nature of the treatment and provide informed consent
__label__0	study interventions are Liposomal doxorubicin . lymphoma diagnosis and ecog performance status zero two
__label__0	study interventions are Laboratory Biomarker Analysis . patients must have histologically confirmed relapsed refractory or previously untreated mantle cell lymphoma any stage
__label__0	study interventions are Pegylated Recombinant Human Arginase I . hepatocellular carcinoma diagnosis and progression of or non response of hcc lesions after treatments which are considered best standard of care
__label__0	study interventions are Regorafenib . pathologically confirmed metastatic adenocarcinoma of colon or rectum
__label__0	study interventions are Capecitabine . stage iiia breast cancer diagnosis and note
__label__0	study interventions are Irinotecan . mixed adenocarcinoma of the stomach diagnosis and inr in range two three while on stable dose of warfarin or low molecular weight heparin
__label__0	study interventions are Magnesium Sulfate . neoplasms diagnosis and eastern cooperative oncology group ecog performance status assessment of zero or one
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and creatinine clearance greater_than forty-five cc min
__label__0	study interventions are Epothilones . brain and central nervous system tumors diagnosis and other
__label__0	study interventions are BB 1101 . multiple myeloma and plasma cell neoplasm diagnosis and platelet count of greater_than one hundred zero ul
__label__0	study interventions are Isophosphamide mustard . metastatic ewing sarcoma diagnosis and for the purpose of this study metastatic disease is defined as one or more of the following
__label__0	study interventions are Sirolimus . stage iv non small cell lung cancer diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Tacrolimus . recurrent adult lymphoblastic lymphoma diagnosis and myelodysplastic syndromes mds greater_than int one per ipss after greater_than equal_than one prior cycle of induction chemotherapy should have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Gemcitabine . kidney cancer diagnosis and surgery
__label__0	study interventions are Carboplatin . recurrent primary peritoneal cancer diagnosis and prothrombin time pt such that international normalized ratio inr is less_than doc or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin or low molecular weight heparin and partial thromboplastin time ptt less_than doc times control
__label__0	study interventions are Stereotactic Radiosurgery . stage iv non small cell lung cancer diagnosis and after the required number of evaluable patients have been accrued for given dose level the accrual for that metastatic location will be temporarily suspended while the safety of that dose level is assessed patient can only be entered onto the trial if all of their metastatic locations are open to accrual if central lung is temporarily suspended for safety assessment and the patient has central lung metastases regardless of other metastases they cannot enroll until the safety of dose to central lung is determined
__label__0	study interventions are Fludarabine . myelodysplastic myeloproliferative neoplasms diagnosis and see disease characteristics
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iia breast cancer diagnosis and eastern cooperative oncology group ecog zubrod performance status zero one
__label__0	study interventions are Antibodies, Monoclonal . patients must have tumors that demonstrate er pr positive positivity by ihc staining greater_than equal_than one
__label__0	study interventions are study of socioeconomic and demographic variables . colorectal cancer diagnosis and no pap test within the past three years
__label__0	study interventions are Everolimus . non small cell lung cancer diagnosis and patients may not have had grade three hemorrhage within four weeks of study drug administration
__label__0	study interventions are Temozolomide . adult glioblastoma diagnosis and inr less_than equal_than doc
__label__0	study interventions are Carmustine . refractory childhood hodgkin lymphoma diagnosis and expected survival greater_than equal_than three months from study entry
__label__0	study interventions are CTX-4430 . the presence of known or suspicious unresolved dermatological cancerous or pre cancerous lesions
__label__0	study interventions are Fludarabine . recurrent childhood anaplastic large cell lymphoma diagnosis and failed or were not eligible for autologous transplantation
__label__0	study interventions are Bleomycin . breast cancer diagnosis and if treatment with trastuzumab herceptin can continue this treatment if there is no regression in cutaneous lesions
__label__0	study interventions are Carboplatin . progressive breast cancer diagnosis and prior trastuzumab is allowed
__label__0	study interventions are Fluorodeoxyglucose F18 . duct cell adenocarcinoma of the pancreas diagnosis and diaphragm always used with spermicide
__label__0	study interventions are Methylprednisolone Hemisuccinate . multiple myeloma and plasma cell neoplasm diagnosis and first complete remission with high risk karyotype
__label__0	study interventions are Fludarabine . contiguous stage ii grade one follicular lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Belinostat . advanced malignant mesothelioma diagnosis and no other uncontrolled intercurrent illness
__label__0	study interventions are Anti-LeY- scFv-CD28-? vector,. . multiple myeloma diagnosis and thirteenq deletion
__label__0	study interventions are laboratory biomarker analysis . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and progressive metastatic disease on imaging studies bone scan ct scan or mri or metastatic disease and rising prostate specific antigen psa allowed
__label__0	study interventions are human papillomavirus 16 E7 peptide . cervical cancer diagnosis and at least four weeks since prior chemotherapy and recovered
__label__0	study interventions are Cetuximab . stage ia pancreatic cancer diagnosis and arterial thrombembolic events
__label__0	study interventions are Vincristine . lymphoma non hodgkin diagnosis and if displaying systemic symptoms evaluation for concurrent opportunistic infections as follows
__label__0	study interventions are Epothilones . unspecified childhood solid tumor protocol specific diagnosis and no grade two or greater preexisting sensory neuropathy
__label__0	study interventions are Cytochrome P-450 CYP3A Inducers . unequivocal evidence for tumor progression by mri or ct scan if mri is contraindicated
__label__0	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and women of child bearing potential must be willing to use an effective contraceptive measure while on study
__label__0	study interventions are Bevacizumab . recurrent adult brain tumor diagnosis and transmural myocardial infarction or unstable angina within the past six months
__label__0	study interventions are Irinotecan . colorectal cancer diagnosis and patient characteristics
__label__0	study interventions are Capecitabine . stage iv breast cancer diagnosis and previous chemotherapy adjuvant and metastatic regimens and hormonal therapy allowed but chemotherapy must have been discontinued at least twenty-one days prior to starting study treatment and hormonal therapy at least seven days prior to starting study treatment patients must have recovered from acute common terminology criteria for adverse events ctcae doc grade greater_than equal_than two side effects of previous treatments
__label__0	study interventions are Bortezomib . recurrent adult diffuse large cell lymphoma diagnosis and no congenital long qt syndrome
__label__0	study interventions are Fosaprepitant . lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Antibodies, Monoclonal . stage iv melanoma diagnosis and performance status
__label__0	study interventions are Fluorouracil . signet ring adenocarcinoma of the colon diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Fludarabine . recurrent marginal zone lymphoma diagnosis and ages equal_than less_than fifty years of age with chronic lymphocytic leukemia cll these patients do not require patient review committee approvals
__label__0	study interventions are Paclitaxel . lung cancer diagnosis and patient characteristics
__label__0	study interventions are laboratory biomarker analysis . adult glioblastoma diagnosis and no major medical illnesses or psychiatric impairments that in the investigator opinion would prevent administration or completion of protocol therapy
__label__0	study interventions are Fludarabine . recurrent adult cell leukemia lymphoma diagnosis and absolute neutrophil count greater_than seven hundred and fifty ul
__label__0	study interventions are Bevacizumab . patients must not have received prior cytotoxic chemotherapy or hormonal therapy for this breast cancer prior treatment with an anthracycline anthracenedione or taxane for any condition is not allowed
__label__0	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and adequate hematologic and end organ function defined by the following laboratory results obtained within less_than fourteen days prior to eighty-ninezr mpdlthree thousand, two hundred and eightya injection
__label__0	study interventions are Interferon-alpha . cutaneous melanoma diagnosis and able and willing to give valid written informed consent
__label__0	study interventions are Carmustine . unspecified adult solid tumor protocol specific diagnosis and pulmonary
__label__0	study interventions are Robot assisted laparoscopic hysterectomy . endometrial cancer diagnosis and proficiency in swedish
__label__0	study interventions are Fludarabine phosphate . stage iv childhood lymphoblastic lymphoma diagnosis and viral load has decreased by greater_than equal_than doc logs or viral load less_than five thousand copies ml plasma on haart therapy
__label__0	study interventions are Busulfan . sarcoma diagnosis and severe aplastic anemia
__label__0	study interventions are Gemcitabine . unspecified adult solid tumor protocol specific diagnosis and bilirubin normal sgot sgpt no greater than doc times upper limit of normal renal
__label__0	study interventions are Mycophenolic Acid . refractory mantle cell lymphoma diagnosis and doc ten seven kg
__label__0	study interventions are Carboplatin . non small cell lung cancer diagnosis and lesions that are not considered measurable include the following
__label__0	study interventions are Mitomycins . lung cancer diagnosis and neutrophil count greater than one five hundred mm three
__label__0	study interventions are Laboratory Biomarker Analysis . stage iv squamous cell lung carcinoma diagnosis and patients with impaired decision making capacity are eligible as long as their neurological or psychological condition does not preclude their safe participation in the study tracking pill consumption and reporting adverse events to the investigator
__label__0	study interventions are Everolimus . stage iv ovarian epithelial cancer diagnosis and hematology and biochemistry laboratory results within the limits normally expected for the patient population without evidence of major organ failure
__label__0	study interventions are Fluorouracil . breast cancer diagnosis and other
__label__0	study interventions are Liposomal doxorubicin . bclc stage adult hepatocellular carcinoma diagnosis and no prior history of any allograft including but not limited to liver and bone marrow transplants
__label__0	study interventions are Lenalidomide . recurrent grade two follicular lymphoma diagnosis and patients must have measurable disease by ct scan pet scans are desirable but not mandatory so that patients with negative pet scans but measurable disease by ct are eligible
__label__0	study interventions are Neoadjuvant chemotherapy . breast cancer diagnosis and in determining eligibility the more abnormal of the two values ast or alt should be used as shown below
__label__0	study interventions are Cyclosporine . solid tumor diagnosis and if unable to perform pulmonary function tests then oxygen otwo saturation greater_than 9two in room air
__label__0	study interventions are Antibodies . stage iv endometrial carcinoma diagnosis and not nursing
__label__0	study interventions are Romidepsin . triple negative breast cancer diagnosis and serum magnesium greater_than doc mg dl
__label__0	study interventions are Cetuximab . patients must have histologically confirmed malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective histology can be based on either the primary tumor or metastases
__label__0	study interventions are Antibodies . stage ii pancreatic cancer diagnosis and patients with locally advanced disease must have disease that extends outside the boundaries of standard radiation port
__label__0	study interventions are Carboxymethylcellulose Sodium . oligoastrocytoma mixed diagnosis and off or low dose less_than four mg day by decadron corticosteroid at least two weeks before the first pre surgical vaccine
__label__0	study interventions are educational intervention . fallopian tube cancer diagnosis and mood swings
__label__0	study interventions are Semaxinib . multiple myeloma and plasma cell neoplasm diagnosis and no pulmonary embolism within past three months other
__label__0	study interventions are Busulfan . multiple myeloma and plasma cell neoplasm diagnosis and having an unrelated donor is considered high risk condition
__label__0	study interventions are Cisplatin . stage ivc major salivary gland carcinoma diagnosis and patients must not have any co existing condition that would preclude full compliance with the study
__label__0	study interventions are chemotherapy . colorectal cancer diagnosis and stage iii tone four nzero three mzero disease
__label__0	study interventions are Dexamethasone . bilirubin less than doc mg dl unless lymphoma involvement
__label__0	study interventions are Paclitaxel . see disease characteristics see biologic therapy no prior chemotherapy for metastatic breast cancer no prior gemcitabine or taxane no other concurrent chemotherapy endocrine therapy
__label__0	study interventions are physiologic testing . lung cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Paclitaxel . recurrent childhood malignant germ cell tumor diagnosis and no dyspnea at rest
__label__0	study interventions are N-monoacetylcystine . stage mucoepidermoid carcinoma of the oral cavity diagnosis and initiation of investigational agent equal_than less_than three days after initiation of radiotherapy
__label__0	study interventions are Aldesleukin . recurrent small lymphocytic lymphoma diagnosis and hemoglobin greater_than doc gm dl
__label__0	study interventions are Etoposide phosphate . recurrent non small cell lung cancer diagnosis and adequate baseline organ function obtained within thirty days of study registration
__label__0	study interventions are Antibodies, Monoclonal . fallopian tube serous adenocarcinoma diagnosis and patients with the following histologic epithelial cell types are eligible
__label__0	study interventions are Lopinavir . patients with previous low grade glioma who progressed after radiotherapy and chemotherapy and are biopsied and found to have high grade glioma are eligible
__label__0	study interventions are Methylprednisolone acetate . recurrent adult immunoblastic large cell lymphoma diagnosis and patients treated previously with radiation therapy in excess of one thousand cgy rads to any thoracic or abdominal port or in excess of three thousand cgy rads to cranial spinal ports who are not eligible for other protocols are eligible for this study
__label__0	study interventions are Ifosfamide . metastatic childhood soft tissue sarcoma diagnosis and doc mg dl for patients one year of age
__label__0	study interventions are Liposomal doxorubicin . stage iii adult diffuse large cell lymphoma diagnosis and no prior chemotherapy radiation therapy or immunotherapy for dlbcl short course less_than two weeks of corticosteroids is allowed for symptom control signed informed consent
__label__0	study interventions are Dexamethasone acetate . plasma cell myeloma diagnosis and serum potassium greater_than lln and serum magnesium greater_than lln electrolyte levels may be achieved with repletion or other supportive medications like potassium sparing diuretics
__label__0	study interventions are Pancreatin . adenocarcinoma diagnosis and no prior treatment with radiotherapy surgery chemotherapy or investigational treatment for the metastatic disease or no more than the three cycles of first line chemotherapy
__label__0	study interventions are Epothilone B . endometrial adenocarcinoma diagnosis and prothrombin time pt such that international normalized ratio inr is equal_than less_than doc uln or an in range inr usually between two and three if patient is on stable dose of therapeutic warfarin and partial thromboplastin time ptt equal_than less_than doc uln
__label__0	study interventions are BB 1101 . pituitary eosinophilic adenoma diagnosis and fertile patients must use effective double method contraception one highly effective method and one additional effective method for greater_than four weeks before during and for greater_than twelve months after completion of study treatment
__label__0	study interventions are Temozolomide . melanoma diagnosis and creatinine clearance measured or calculated greater_than thirty ml min
__label__0	study interventions are Immunoglobulins . cholangiocarcinoma of the extrahepatic bile duct diagnosis and no significant traumatic injury within the past twenty-eight days
__label__0	study interventions are Methodological trolley tokens . myeloproliferative neoplasm cases
__label__0	study interventions are Carboplatin . stage iv breast cancer diagnosis and at least one measurable lesion must be completely outside the radiation portal or there must be unequivocal radiologic or clinical exam proof of progressive disease within the radiation portal in accordance with recist doc guidelines
__label__0	study interventions are Tacrolimus . precancerous condition diagnosis and bone marrow blasts less_than twenty within four weeks of transplant and peripheral blood absolute blast count less_than five hundred µl on the day of initiation of conditioning for patients with non cr aml or all
__label__0	study interventions are 3-Iodobenzylguanidine . neuroblastoma diagnosis and non enzyme inducing anticonvulsants keppra etc
__label__0	study interventions are Antibodies . adenocarcinoma of the lung diagnosis and sixty ml min
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and agree to practice effective barrier contraception during the entire study treatment period and through twenty-eight days after the last dose of study treatment or
__label__0	study interventions are Oprelvekin . splenic marginal zone lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Liposomal doxorubicin . burkitt lymphoma
__label__0	study interventions are gp100 antigen . melanoma skin diagnosis and patient characteristics
__label__0	study interventions are Cyclosporine . recurrent plasma cell myeloma diagnosis and must have progressed with the most recent remission duration being less_than six months
__label__0	study interventions are Vorinostat . childhood central nervous system yolk_sac tumor diagnosis and alt less_than one hundred and ten l
__label__0	study interventions are Rituximab . testicular lymphoma diagnosis and age greater_than eighteen years
__label__0	study interventions are Gossypol . recurrent mantle cell lymphoma diagnosis and all patients must have measurable or evaluable disease per recist criteria
__label__0	study interventions are Levoleucovorin . metastatic cancer diagnosis and potentially resectable nodal disease
__label__0	study interventions are Cisplatin . recurrent fallopian tube cancer diagnosis and creatinine less_than doc uln or creatinine clearance greater_than sixty ml min according to cockcroft gault formula
__label__0	study interventions are Carboplatin . breast cancer diagnosis and hiv negative
__label__0	study interventions are Gemcitabine . ovarian stromal cancer diagnosis and patient has no major medical illnesses or psychiatric illnesses
__label__0	study interventions are Extensive Intraoperative Peritoneal Lavage . histologically proven primary gastric adenocarcinoma
__label__0	study interventions are laboratory biomarker analysis . breast cancer diagnosis and disease characteristics
__label__0	study interventions are assessment of therapy complications . breast cancer diagnosis and inclusion
__label__0	study interventions are Alemtuzumab . hodgkin lymphoma diagnosis and has not received prior allogeneic hematopoietic stem cell transplant
__label__0	study interventions are Dexamethasone . unspecified adult solid tumor protocol specific diagnosis and thiazides
__label__0	study interventions are Irinotecan . brain tumor diagnosis and serious and inadequately controlled cardiac arrhythmia
__label__0	study interventions are Cisplatin . squamous cell lung cancer diagnosis and no nursing during and for greater_than six months after the last dose of bevacizumab
__label__0	study interventions are Veliparib . stage iva pancreatic cancer diagnosis and bilirubin equal_than less_than doc uln
__label__0	study interventions are Vidarabine . stage ii multiple myeloma diagnosis and high risk all defined as
__label__0	study interventions are Niacinamide . stage iib pancreatic cancer diagnosis and women of childbearing potential and men must agree to use medically accepted form of birth control during the treatment and for two months following completion of study treatment
__label__0	study interventions are fatigue assessment and management . prostate cancer diagnosis and more than six months since prior regular aerobic or resistance exercise
__label__0	study interventions are Capecitabine . stage iv childhood hepatocellular carcinoma diagnosis and must not have known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or excipients or to dimethyl_sulfoxide dmso or other agents used in study
__label__0	study interventions are Tacrolimus . multiple myeloma diagnosis and patient or patient legal representative able to sign informed consent
__label__0	study interventions are Antibodies, Monoclonal . stage iiic ovarian cancer diagnosis and if patient declines to participate in the perfusion imaging portion of the protocol clinical rationale for declination of imaging form will be completed as part of the data submission for acrin six thousand, six hundred and ninety-five
__label__0	study interventions are laboratory biomarker analysis . stage iii adult diffuse mixed cell lymphoma diagnosis and ecog zero two
__label__0	study interventions are Anesthetics . lung cancer diagnosis and american society of anesthesiologists physical status class one or two
__label__0	study interventions are Antibodies . unspecified adult solid tumor protocol specific diagnosis and although not mandated by the protocol the results of the ct scan and labs complete blood count cbc comprehensive metabolic panel cmp that are performed as part of the standard work up should be available and should have been done within two months prior to study entry
__label__0	study interventions are Interferons . malignant melanoma diagnosis and treatment with ifn within study or analog treatment schedule with ifn a
__label__0	study interventions are Navitoclax . metastatic melanoma diagnosis and prior therapy is allowed
__label__0	study interventions are Everolimus . recurrent grade one follicular lymphoma diagnosis and if last regimen is with rituximab there must have been at least six months since last rituximab dose and if without rituximab there must have been at least three months since last regimen
__label__0	study interventions are counseling intervention . sarcoma diagnosis and patient characteristics
__label__0	study interventions are Paclitaxel . lung cancer diagnosis and alt less_than doc uln less_than five uln if liver metastases
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and lvef greater_than thirty by muga
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and if progression is documented as below prior to this time interval patients are eligible
__label__0	study interventions are Antibodies, Monoclonal . stage iva rectal cancer diagnosis and women of childbearing potential only
__label__0	study interventions are Isophosphamide mustard . recurrent childhood anaplastic large cell lymphoma diagnosis and no greater than doc mg dl thirteen years to fifteen years male
__label__0	study interventions are Phosphonoacetic Acid . stage adult immunoblastic large cell lymphoma diagnosis and informed consent
__label__0	study interventions are Oxaliplatin . stage iib esophageal adenocarcinoma diagnosis and platelet count greater_than equal_than one hundred zero mcl
__label__0	study interventions are Lenalidomide . recurrent grade three follicular lymphoma diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least fifty miu ml within ten
__label__0	study interventions are BB 1101 . recurrent childhood cerebellar astrocytoma diagnosis and baseline qtc less_than four hundred and fifty msec
__label__0	study interventions are Antilymphocyte Serum . stage iv marginal zone lymphoma diagnosis and waldenstroms macroglobulinemia failed one standard regimen
__label__0	study interventions are Vidarabine . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and patient has no existing zero one hla b drbone and dqbone matched related donor
__label__0	study interventions are reverse transcriptase-polymerase chain reaction . stage iv adult diffuse large cell lymphoma diagnosis and stage iii iv disease
__label__0	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasms diagnosis and total bilirubin less_than two mg dl
__label__0	study interventions are Immunoconjugates . stage iiia breast cancer diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than doc upper limit of normal uln
__label__0	study interventions are Alemtuzumab . nodal marginal zone cell lymphoma diagnosis and hodgkin disease hd
__label__0	study interventions are graft versus host disease prophylaxis/therapy . multiple myeloma and plasma cell neoplasm diagnosis and disease in complete remission cr
__label__0	study interventions are BCG+ALT-803 . non muscle invasive bladder cancer diagnosis and platelets greater_than one hundred zero ul
__label__0	study interventions are Cortisol succinate . stage childhood large cell lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Antibodies . recurrent diffuse large cell lymphoma diagnosis and provide informed written consent
__label__0	study interventions are Bevacizumab . stage ia gastric cancer diagnosis and serum creatinine cr equal_than less_than doc mg and or creatinine clearance greater_than equal_than sixty cc min
__label__0	study interventions are Sunitinib . tongue cancer diagnosis and ast and alt less_than doc times uln
__label__0	study interventions are Efatutazone . anaplastic thyroid cancer diagnosis and histologically or cytologically diagnosed advanced atc
__label__0	study interventions are Laboratory Biomarker Analysis . stage iv breast cancer diagnosis and maximum diameter of individual metastasis in any dimension equal_than less_than five cm
__label__0	study interventions are Pembrolizumab . mesothelioma diagnosis and radiation
__label__0	study interventions are Pancrelipase . pancreatic cancer diagnosis and men must agree not to father child and agree to use condom if his partner is of child bearing potential
__label__0	study interventions are Denileukin diftitox . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Cyclosporins . small intestine lymphoma diagnosis and absence of ph positive metaphases
__label__0	study interventions are Etoposide . squamous cell lung cancer diagnosis and no congenital abnormality fuch dystrophy
__label__0	study interventions are Pembrolizumab . stage iva hypopharyngeal squamous cell carcinoma diagnosis and direct bilirubin
__label__0	study interventions are Tremelimumab . recurrent glioblastoma diagnosis and patients must have given written signed and dated informed consent prior to registration on the study note
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and zero one
__label__0	study interventions are Temozolomide . brain and central nervous system tumors diagnosis and uncontrolled symptoms defined as any of the following
__label__0	study interventions are Carboplatin . lung cancer diagnosis and hepatic
__label__0	study interventions are Docetaxel . breast cancer diagnosis and women of child bearing potential must use effective non hormonal contraception while undergoing radiation therapy
__label__0	study interventions are Vaccines . peritoneal cavity cancer diagnosis and no concurrent systemic corticosteroids antihistamines non steroidal anti inflammatory drugs or other immunosuppressants
__label__0	study interventions are laboratory biomarker analysis . stage iv gastric cancer diagnosis and colon
__label__0	study interventions are Thiotepa . regional neuroblastoma diagnosis and bone marrow may be used in conjunction with blood progenitor cells
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and must have recovered from any treatment related toxicities prior to registration
__label__0	study interventions are Docetaxel . breast cancer diagnosis and all patients must be informed of the investigational nature of this study and given written informed consent in accordance with institutional and federal guidelines
__label__0	study interventions are Immunoglobulins . clear cell renal cell carcinoma diagnosis and new york heart association grade ii or greater congestive heart failure serious cardiac arrhythmia requiring medication unstable angina pectoris
__label__0	study interventions are Succinylcholine . stage iib fallopian tube cancer diagnosis and all patients must have procedure for determining diagnosis of epithelial ovarian fallopian tube primary peritoneal with appropriate tissue for histologic evaluation
__label__0	study interventions are Radical Cystectomy . stage iib prostate cancer diagnosis and no abnormalities no history of diagnosed acquired bleeding disorders within one year acquired anti factor viii antibodies of registration on protocol therapy
__label__0	study interventions are Docetaxel . breast cancer diagnosis and no uncontrolled hypertension systolic bp greater_than one hundred and fifty mm hg and or diastolic bp greater_than one hundred mm hg
__label__0	study interventions are Antibodies . recurrent rectal cancer diagnosis and measurable disease
__label__0	study interventions are Cadexomer iodine . renal cancer diagnosis and alanine aminotransferase alt less_than doc uln
__label__0	study interventions are Lenalidomide . newly diagnosed multiple myeloma diagnosis and have an understanding that the study drug could have potential teratogenic risk
__label__0	study interventions are Everolimus . adult glioblastoma diagnosis and at least twenty-one days since prior procarbazine or major surgery
__label__0	study interventions are Doxorubicin . liver cancer diagnosis and no contraindication to hepatic embolization procedures as indicated by any of the following
__label__0	study interventions are Trastuzumab . invasive ductal breast cancer diagnosis and written informed consent according to local regulatory requirements prior to beginning specific protocol procedures
__label__0	study interventions are Cyclophosphamide . stage iii multiple myeloma diagnosis and no other medical or psychosocial problems which in the opinion of the primary physician or principal investigator would place the patient at unacceptably high risk from this treatment regimen
__label__0	study interventions are X-Ray Imaging . head and neck cancer diagnosis and negative pregnancy test for women of child bearing potential
__label__0	study interventions are Endothelial Growth Factors . ovarian endometrioid adenocarcinoma diagnosis and platelets greater than or equal to one hundred zero µl ctcae grade zero one
__label__0	study interventions are laboratory biomarker analysis . recurrent lymphoepithelioma of the oropharynx diagnosis and no requirement for supplemental oxygen
__label__0	study interventions are Doxorubicin . histologically or pathologically confirmed stage iii breast cancer
__label__0	study interventions are Erlotinib Hydrochloride . recurrent adult brain tumor diagnosis and albumin less than doc dl
__label__0	study interventions are Camptothecin . histological or cytological documentation of adenocarcinoma of the colon or rectum
__label__0	study interventions are Anastrozole . progressing or progression at some point during breast cancer treatment on endocrine therapy with non steroidal ai co administration of targeted agent with the non steroidal ai is permitted providing all toxicities have recovered to ctcae grade one or below
__label__0	study interventions are Bevacizumab . stage iiib breast cancer diagnosis and prior endocrine therapy is not required
__label__0	study interventions are Pembrolizumab . invasive adenocarcinoma of the breast diagnosis and if imaging is suspicious or abnormal an fna or core biopsy of the questionable node on imaging is required
__label__0	study interventions are Antibodies, Monoclonal . cancer of kidney diagnosis and female subjects must either be of non reproductive potential post menopausal by history
__label__0	study interventions are Antibodies, Monoclonal . stage ivc oropharyngeal squamous cell carcinoma diagnosis and one has not undergone hysterectomy or bilateral oophorectomy or two has not been naturally postmenopausal for at least two4 consecutive months has had menses at any time in the preceding two4 consecutive months all patients must be counseled by trained_counselor every two8 days about pregnancy precautions and risks of fetal exposure
__label__0	study interventions are Gemcitabine . non small cell lung cancer diagnosis and histological or cytological confirmation of nsclc with stage iiib or iv disease not amenable to curative therapy
__label__0	study interventions are Carboplatin . testicular choriocarcinoma diagnosis and no allergy to cremophor_el or castor_oil
__label__0	study interventions are Dexamethasone acetate . recurrent ovarian carcinoma diagnosis and for study arm one female subjects of childbearing potential or less than two years postmenopausal agree to use an acceptable form of contraception from the time of signing informed consent until thirty days after study completion unless total hysterectomy performed at the time of original operation
__label__0	study interventions are SNS01-T . if neither of the above criteria are met the presence of plasmacytomata measurable radiographically ct pet or mri or by direct measurement
__label__0	study interventions are Methotrexate . recurrent adult burkitt lymphoma diagnosis and partial remission
__label__0	study interventions are Mammography . progesterone receptor negative breast cancer diagnosis and eligible for bct based on clinical examination mammography and if standard practice at given institution ultrasound and or tomogram
__label__0	study interventions are Bevacizumab . colorectal cancer diagnosis and no signet ring cell type
__label__0	study interventions are Cisplatin . untreated childhood medulloblastoma diagnosis and doc mg dl male or doc mg dl female thirteen to less_than sixteen years of age
__label__0	study interventions are Capecitabine . extrahepatic bile duct cancer diagnosis and measurable or nonmeasurable disease
__label__0	study interventions are Antibodies . primary peritoneal cavity cancer diagnosis and no prior anti vegf drug including bevacizumab
__label__0	study interventions are Sirolimus . malignant peripheral nerve sheath tumors diagnosis and allowable prior therapy
__label__0	study interventions are Poly ICLC . stage iic skin melanoma diagnosis and total bilirubin less_than doc institutional upper limit of normal bilirubin less_than three institutional upper limit of normal for gilbert syndrome
__label__0	study interventions are Belinostat . histologically or cytologically confirmed hepatocellular carcinoma that is not amenable to curative resection
__label__0	study interventions are Fluorouracil . head and neck cancer diagnosis and history of severe hypersensitivity reaction to docetaxel or to other drugs formulated with polysorbate eighty
__label__0	study interventions are Radiation Therapy . prior localized radiotherapy for skin cancer arising in the head and neck region is allowed
__label__0	study interventions are Paclitaxel . stage iv ovarian epithelial cancer diagnosis and total bilirubin equal_than less_than doc mg dl unless history of gilbert disease
__label__0	study interventions are Zoledronic acid . breast cancer diagnosis and biologic therapy
__label__0	study interventions are Vaccines . colorectal cancer diagnosis and no concurrent illegal drug use
__label__0	study interventions are Antiviral Agents . noncontiguous stage ii grade one follicular lymphoma diagnosis and must have already been determined to be eligible for hct at city of hope_coh
__label__0	study interventions are pazopanib hydrochloride . distal urethral cancer diagnosis and ergot_derivatives dihydroergotamine_ergonovine ergotamine or methylergonovine
__label__0	study interventions are Carboplatin . large cell lung cancer diagnosis and measurable or evaluable disease
__label__0	study interventions are Mycophenolic Acid . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and hodgkin disease
__label__0	study interventions are Cetuximab . stage iii pancreatic cancer diagnosis and no history of allergic reaction attributed to compounds of similar chemical or biologic composition to study drugs
__label__0	study interventions are Androgens . prostate cancer diagnosis and age greater_than eighteen and less_than eighty years
__label__0	study interventions are Gefitinib . in phase ib part lung cancer patients with disease progression after egfr tki and at least one line of chemotherapy
__label__0	study interventions are Liver Extracts . cancer of gallbladder diagnosis and positive transcatheter biopsy or brush cytology
__label__0	study interventions are Irofulven . melanoma skin diagnosis and disease characteristics
__label__0	study interventions are Irinotecan . gastric cancer diagnosis and no active inflammatory bowel disease
__label__0	study interventions are Nitrous Oxide . colorectal cancer diagnosis and subjects age eighteen eighteen
__label__0	study interventions are Paclitaxel . stage ia breast cancer diagnosis and eastern cooperation oncology group ecog performance status of zero or one
__label__0	study interventions are Antibodies, Monoclonal . adenocarcinoma of the colon diagnosis and no prior agents directed against egfr and or hertwo
__label__0	study interventions are OSI-906 . advanced hepatocellular carcinoma hcc diagnosis and international normalized ratio inr less_than doc
__label__0	study interventions are Antibodies . meningeal melanocytoma diagnosis and creatinine less_than doc times uln
__label__0	study interventions are Vitamin B Complex . stage iv fallopian tube cancer diagnosis and creatinine equal_than less_than doc upper limit of normal uln or twenty-four hour urine equal_than less_than grade two
__label__0	study interventions are Olaparib . stage iva pancreatic cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Mycophenolate mofetil . stage iv grade three follicular lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and no more than one prior induction or adjuvant chemotherapy regimen
__label__0	study interventions are Fludarabine phosphate . recurrent childhood large cell lymphoma diagnosis and myeloproliferative syndromes
__label__0	study interventions are tanespimycin . recurrent marginal zone lymphoma diagnosis and no concurrent drugs that interfere with hepatic cypthreeafour metabolism grapefruit juice ketoconazole fluconazole itraconazole cyclosporine erythromycin clarithromycin cimetidine terfenadine_astemizole indinavir or nelfinavir mesylate
__label__0	study interventions are Immunosuppressive Agents . multiple myeloma diagnosis and no contraindication to csf granulocyte colony stimulating factor stimulation
__label__0	study interventions are Oxaliplatin . gastrointestinal carcinoid tumor diagnosis and not pregnant or nursing
__label__0	study interventions are Dasatinib . recurrent non small cell lung cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mm three
__label__0	study interventions are Sirolimus . multiple myeloma and plasma cell neoplasm diagnosis and no evidence or history of serious bleeding diathesis or coagulopathy such as hemophilia or von_willebrand disease
__label__0	study interventions are Apixaban . cancer diagnosis and able to begin study medication less_than six weeks of starting either firs negative or second line chemotherapy
__label__0	study interventions are Interferon-alpha . multiple myeloma and plasma cell neoplasm diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are Metformin . metastatic breast cancer diagnosis and radiologic or clinical evaluation must have been performed within four weeks prior to registration
__label__0	study interventions are Decitabine . stage iva follicular thyroid cancer diagnosis and hepatic
__label__0	study interventions are Tocotrienols . unspecified adult solid tumor protocol specific diagnosis and ability to sign informed consent and understand the nature of placebo controlled trial
__label__0	study interventions are Estradiol . if tumor is hertwo positive three positive by immunohistochemistry or amplified by fluorescent in situ hybridization the patient must have received greater_than one prior trastuzumab herceptin containing regimen unless there is contraindication to trastuzumab
__label__0	study interventions are Tacrolimus . noncontiguous stage ii grade one follicular lymphoma diagnosis and forced expiratory volume in one second fevone greater_than fifty
__label__0	study interventions are Leucovorin . adenocarcinoma of the gastroesophageal junction diagnosis and not pregnant or nursing
__label__0	study interventions are Interleukin-12 . male breast cancer diagnosis and no clinically significant gastrointestinal bleeding
__label__0	study interventions are Immunoglobulins . adult oligodendroglioma diagnosis and karnofsky performance status sixty one hundred
__label__0	study interventions are Androgen Antagonists . prostate cancer diagnosis and leukocyte count greater_than three zero µl
__label__0	study interventions are Sorafenib . at least one tumor lesion should be assessable for biopsy to perform kinase activity analysis
__label__0	study interventions are Antibodies . stage iiia gastric cancer diagnosis and ptt equal_than less_than three seconds above uln
__label__0	study interventions are BB 1101 . sarcoma diagnosis and must be eighteen to sixty-five years of age
__label__0	study interventions are Hormones . metastatic breast cancer diagnosis and women are considered to be of childbearing potential unless they are postmenopausal for at least twelve consecutive months or surgically sterile bilateral tubal ligation bilateral oophorectomy or hysterectomy
__label__0	study interventions are Cisplatin . mesothelioma diagnosis and eligible stages
__label__0	study interventions are Immunoglobulins . recurrent small lymphocytic lymphoma diagnosis and doc mg dl for female patients age greater_than equal_than thirteen years
__label__0	study interventions are Vaccines . stage iiib breast cancer diagnosis and urine protein less than one zero mg twenty-four hour collection if proteinuria greater than positive one
__label__0	study interventions are Paclitaxel . advanced breast cancer diagnosis and patient must have received less_than three prior cytotoxic regimens in the metastatic setting
__label__0	study interventions are Trastuzumab . stomach neoplasms diagnosis and neutrophil count less_than doc one hundred and nine or platelet count less_than one hundred one hundred and nine l
__label__0	study interventions are Saracatinib . recurrent adult soft tissue sarcoma diagnosis and no more than two prior lines of chemotherapy for metastatic disease not including adjuvant chemotherapy
__label__0	study interventions are Androgens . prostate cancer diagnosis and patients must have either measurable disease or bone metastasis
__label__0	study interventions are Veliparib . triple negative breast carcinoma diagnosis and hemoglobin greater_than equal_than eight dl
__label__0	study interventions are Antibodies, Monoclonal . recurrent renal cell carcinoma diagnosis and cerebrovascular accident
__label__0	study interventions are Dasatinib . lymphoma diagnosis and john wort
__label__0	study interventions are Fludarabine . contiguous stage ii grade three follicular lymphoma diagnosis and patients with renal failure are eligible however patients with renal compromise serum creatinine greater_than doc will likely have further compromise in renal function and may require hemodialysis which may be permanent due to the need to maintain adequate serum tacrolimus levels
__label__0	study interventions are Vorinostat . cutaneous cell non hodgkin lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Heptavalent Pneumococcal Conjugate Vaccine . multiple myeloma diagnosis and treatment
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and no other concurrent investigational agents
__label__0	study interventions are Antibodies, Monoclonal . epithelioid trophoblastic tumor diagnosis and histologically proven trophoblastic neoplasia or clinically demonstrated trophoblastic neoplasia that has progressed following treatment with at least one chemotherapy regimen that included two or more chemotherapy agents
__label__0	study interventions are Carboplatin . lung cancer diagnosis and at least three weeks since other prior investigational agents or devices no prior rsr1three
__label__0	study interventions are Cisplatin . stage iiia ovarian epithelial cancer diagnosis and group two closed to accrual as of three ten six
__label__0	study interventions are Celecoxib . lung cancer diagnosis and doc
__label__0	study interventions are Aldesleukin . melanoma skin diagnosis and wbc greater_than three zero mm three
__label__0	study interventions are Levoleucovorin . stage ib gastric cancer diagnosis and tone three or tfour with local invasion confined to diaphragm pleura or pericardium
__label__0	study interventions are Penicillanic Acid . unspecified childhood solid tumor protocol specific diagnosis and see disease characteristics chemotherapy
__label__0	study interventions are Fludarabine phosphate . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and primary allogeneic hematopoietic stem cell transplantation hsct is appropriate for selected patients with severe aplastic anemia however patients with aplastic anemia must have failed at least one cycle of standard immunosuppressive therapy with calcineurin inhibitor plus anti thymocyte_globulin atg if fully matched donor is not available
__label__0	study interventions are Albumin-Bound Paclitaxel . pancreatic carcinoma non resectable diagnosis and gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct abutment of the hepatic artery without extension to the celiac axis
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and platelet count greater_than one hundred zero mcl
__label__0	study interventions are Sorafenib . primary peritoneal carcinoma diagnosis and at least one week since prior hormonal therapy for the malignancy
__label__0	study interventions are Sirolimus . recurrent cervical carcinoma diagnosis and longest diameter
__label__0	study interventions are Liposomal doxorubicin . kaposi sarcoma diagnosis and ast sgot alt sgpt less than or equal to doc institutional upper limit of normal
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian clear cell adenocarcinofibroma diagnosis and neoadjuvant chemotherapy nac with interval cytoreductive surgery ics patients
__label__0	study interventions are Everolimus . glioblastoma multiforme diagnosis and female patients must not breast feed
__label__0	study interventions are Flt3 ligand protein . recurrent renal cell cancer diagnosis and bilirubin no greater than doc mg dl ast and alt less than two times normal renal
__label__0	study interventions are Vaccines . advanced adult primary liver cancer diagnosis and graves disease
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and chronic myelogenous leukemia cml meeting one of the following criteria
__label__0	study interventions are Cyclophosphamide . hepatosplenic cell lymphoma diagnosis and cardiac ejection fraction greater_than equal_than forty-five or clearance by cleveland clinic ccf physician
__label__0	study interventions are Hydrocortisone 17-butyrate 21-propionate . lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Podophyllotoxin . patients must not have uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris uncontrolled cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__0	study interventions are quality-of-life assessment . extensive stage small cell lung cancer diagnosis and the target lesion is determined by ct or magnetic resonance imaging mri images to be in location where cryoablation is technically achievable based on the proximity of adjacent organs and structures
__label__0	study interventions are Antibodies, Monoclonal . stage iv verrucous carcinoma of the larynx diagnosis and erythromycin
__label__0	study interventions are Oxaliplatin . colon signet ring cell adenocarcinoma diagnosis and any non malignant systemic disease
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the nasopharynx diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Navitoclax . peripheral cell lymphoma diagnosis and absolute neutrophil count anc greater_than equal_than one thousand µl
__label__0	study interventions are Talazoparib . mantle cell lymphoma diagnosis and willing and able to provide written signed informed consent after the nature of the study has been explained and prior to any research related procedures
__label__0	study interventions are Cyclosporins . stage iii multiple myeloma diagnosis and donors must meet the selection criteria for administration of csf filgrastim and apheresis defined by the foundation for the accreditation of cell therapy fact and will be screened per the american association of blood banks_aabb
__label__0	study interventions are Fludarabine . ovarian cancer diagnosis and diagnosis will be confirmed by the laboratory of pathology nci
__label__0	study interventions are Endothelial Growth Factors . clear cell renal cell carcinoma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and cardiovascular
__label__0	study interventions are Imatinib Mesylate . adult meningioma diagnosis and newly diagnosed recurrent disease that requires surgical debulking allowed
__label__0	study interventions are Antibodies . stage iv squamous cell carcinoma of the hypopharynx diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Vincristine . brain and central nervous system tumors diagnosis and endocrine therapy
__label__0	study interventions are Gemcitabine . extrahepatic bile duct cancer diagnosis and no concurrent endoscopic or external biliary drainage as consequence of progressive malignant bile duct obstruction
__label__0	study interventions are Vorinostat . stage iii mantle cell lymphoma diagnosis and patients must have ct of chest abdomen and pelvis within twenty-eight days of enrollment patients with evidence of adenopathy in the neck must have ct of neck
__label__0	study interventions are Rituximab . lymphoma diagnosis and patients with seropositivity presumed to be due to prior vaccination against hepatitis virus or resolved infection are eligible
__label__0	study interventions are Arsenic trioxide . patients must have evaluable tumor and be potentially eligible for pre and post ato tumor biopsy
__label__0	study interventions are pharmacological study . adult giant cell glioblastoma diagnosis and patients after menarche with amenorrhea irregular cycles or using contraceptive method that precludes withdrawal bleeding
__label__0	study interventions are Imatinib Mesylate . recurrent adult diffuse large cell lymphoma diagnosis and at least four weeks since prior radiotherapy and recovered
__label__0	study interventions are Group 2: Peripherally Located Chest Wall Adjacent Tumors . non small cell lung cancer diagnosis and poor pulmonary function for resection including baseline forced expiratory volume in one second fevone fevone less_than fifty post operative predicted fevoneless_than thirty predicted diffusion capacity less_than fifty baseline hypoxemia and or hypercapnia
__label__0	study interventions are Camptothecin . metastatic colorectal cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are Lenograstim . ovarian choriocarcinoma diagnosis and must have received prior first line chemotherapy regimen that included cisplatin
__label__0	study interventions are Vaccines . stage iv fallopian tube cancer diagnosis and alkaline phosphatase less than or equal to doc uln
__label__0	study interventions are Cisplatin . cervical cancer diagnosis and no parametrial extension and negative resection margin
__label__0	study interventions are Aldesleukin . squamous cell carcinoma diagnosis and potentially dangerous effects of the treatment on the fetus
__label__0	study interventions are Immunotoxins . fallopian tube cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Arsenic trioxide . stage iii multiple myeloma diagnosis and bilirubin less_than two times uln unless clearly related to disease
__label__0	study interventions are Docetaxel . metastatic hormone sensitive prostate cancer diagnosis and partial thromboplastin time ptt less_than doc times uln unless on therapeutic anticoagulation
__label__0	study interventions are Fluorodeoxyglucose F18 . endometrial clear cell carcinoma diagnosis and appropriate surgical candidate to undergo extraperitoneal or laparoscopic lymph node sampling or hysterectomy and lymph node sampling
__label__0	study interventions are Methotrexate . multiple myeloma diagnosis and prior alkylating agent therapy allowed if no more than twelve months duration
__label__0	study interventions are Saracatinib . histologically or cytologically confirmed advanced carcinoma solid tumour of known primary site which is refractory to standard therapies or for which no standard therapy exists
__label__0	study interventions are Tacrolimus . stage iv grade one follicular lymphoma diagnosis and donor must have adequate veins for leukapheresis or agree to placement of central venous catheter femoral_subclavian
__label__0	study interventions are Gefitinib . lung cancer diagnosis and patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital
__label__0	study interventions are Mycophenolate mofetil . splenic marginal zone lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are EndoMAXX EVT . patient esophageal tumor length exceeds that which can be treated with single stent maximum lesion length doc cm
__label__0	study interventions are Antibodies, Monoclonal . stage iiib non small cell lung cancer diagnosis and one
__label__0	study interventions are therapeutic procedure . must agree to provide archival tissue for research purposes either archival paraffin tissue block or ten unstained slides of primary or metastatic melanoma lesion prior to enrollment samples should be shipped within one month after enrollment
__label__0	study interventions are Ribociclib . diffuse intrinsic pontine glioma diagnosis and patients diagnosed with dipg may choose to have stereotactic biopsy prior to starting radiation therapy
__label__0	study interventions are monosialotetrahexosylganglioside Sodium . colorectal cancer diagnosis and should have target lesions or non target lesions
__label__0	study interventions are Sorafenib . male breast cancer diagnosis and if hertwo gene amplified or strongly positive for hertwo by immunohistochemistry patient must have had prior treatment containing trastuzumab herceptin unless contraindicated
__label__0	study interventions are hyperfractionated accelerated radiotherapy . histologically proven squamous cell carcinoma
__label__0	study interventions are Etoposide phosphate . multiple myleoma diagnosis and however patients with lvef of between thirty-five and forty-four may also be eligible provided that such patients are cleared by cardiology consultation that must include cardiac stress test
__label__0	study interventions are Cediranib . recurrent breast carcinoma diagnosis and history of myocardial infarction within twelve months patients with history of myocardial infarction within six months are excluded from the study
__label__0	study interventions are Oxaliplatin . colorectal cancer diagnosis and prior concurrent therapy
__label__0	study interventions are radiotherapy . head and neck neoplasms diagnosis and histopathologically confirmed previously untreated hnscc of the oropharynx hypopharynx or larynx within six weeks forty-two days of registration
__label__0	study interventions are Fludarabine . lymphoma diagnosis and stage iv disease at presentation especially with marrow involvement
__label__0	study interventions are Rituximab . noncontiguous stage ii small lymphocytic lymphoma diagnosis and wbc must be greater_than equal_than three zero
__label__0	study interventions are Immunoconjugates . noncontiguous stage ii grade one follicular lymphoma diagnosis and has not been naturally postmenopausal for at least one2 consecutive months has had menses at any time in the preceding one2 consecutive months
__label__0	study interventions are Trastuzumab . stage iv breast cancer diagnosis and measurable disease defined as least one lesion that can be accurately measured in at least one dimension
__label__0	study interventions are Docetaxel . stage iii prostate cancer diagnosis and prior surgery allowed
__label__0	study interventions are Dabrafenib . recurrent melanoma diagnosis and all prior treatment related toxicities must be common terminology criteria for adverse events ctcae version doc equal_than less_than grade one at the time of enrollment
__label__0	study interventions are Tacrolimus . recurrent adult diffuse large cell lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Vorinostat . recurrent adult diffuse mixed cell lymphoma diagnosis and karnofsky sixty one hundred
__label__0	study interventions are Radium Ra 223 dichloride . metastatic prostate cancer diagnosis and anc greater_than doc one hundred and nine l
__label__0	study interventions are Sirolimus . patient previously treated with irradiation on the brainstem for another neoplasm
__label__0	study interventions are Cisplatin . metastatic breast cancer diagnosis and patient non previously treated by platinum salts
__label__0	study interventions are Capecitabine . rectal cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Sirolimus . stage adult immunoblastic lymphoma diagnosis and low grade nhl with less_than six month duration of cr between courses of conventional therapy
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and no prior systemic chemotherapy for metastatic disease
__label__0	study interventions are Sirolimus . endometrial cancer diagnosis and not pregnant or nursing
__label__0	study interventions are pharmacological study . recurrent childhood large cell lymphoma diagnosis and two weeks for local palliative radiation therapy xrt small port greater_than equal_than two4 weeks must have elapsed if prior total body irradiation tbi craniospinal xrt or if greater_than equal_than fifty radiation of pelvis greater_than equal_than six weeks must have elapsed if other substantial bone marrow bm radiation
__label__0	study interventions are Trifluridine . colorectal neoplasms diagnosis and patient able and willing to comply with study procedures as per protocol
__label__0	study interventions are Busulfan . stage iii multiple myeloma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are radiation therapy . central nervous system tumor diagnosis and see disease characteristics
__label__0	study interventions are Panobinostat . multiple myeloma diagnosis and total serum calcium corrected for serum albumin or ionized calcium greater_than lln for the institution
__label__0	study interventions are Fatigue Inventory . anaplastic large cell lymphoma diagnosis and breastfeeding should be discontinued if the mother is treated with ar forty-two
__label__0	study interventions are Milk fat globule . willingness to donate blood for biomarker studies
__label__0	study interventions are AbGn-107 . gastric colorectal and pancreatic adenocarcinoma diagnosis and wocp and men whose partners are wocp must agree to use highly effective method of birth control during the study and for six months following the last dose of study drug
__label__0	study interventions are Methotrexate . stage iii bladder cancer diagnosis and fertile patients must use effective contraception during and for six months after study
__label__0	study interventions are Antibodies, Monoclonal . recurrent urothelial carcinoma of the renal pelvis and ureter diagnosis and no significant history of bleeding events or gastrointestinal gi perforation
__label__0	study interventions are Mycophenolate mofetil . non hodgkin lymphoma diagnosis and very high risk pediatric patients with all
__label__0	study interventions are Immunostimulating Interstitial Laser Thermotherapy . neoplasms diagnosis and have given informed verbal and written consent to participation in the trial
__label__0	study interventions are Paclitaxel . stage iv pancreatic cancer diagnosis and arm cohort one
__label__0	study interventions are Succinylcholine . recurrent neuroblastoma diagnosis and doc mg dl
__label__0	study interventions are Everolimus . childhood gliosarcoma diagnosis and prior treatment with mtor inhibitors rapamycin temsirolimus everolimus deferolimus is not allowed
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and aged eighteen years and older
__label__0	study interventions are Dasatinib . non small cell lung cancer diagnosis and phase only
__label__0	study interventions are Fludarabine . large cell non hodgkin lymphoma diagnosis and the unrelated ucb donors must be four six six hla b drbone matched with the recipient hla matching using molecular techniques
__label__0	study interventions are Lenograstim . multiple myeloma diagnosis and co morbid condition which in the view of the investigators renders the patient at high risk from treatment complications
__label__0	study interventions are 6-Mercaptopurine . childhood lymphoblastic lymphoma diagnosis and all patients must be enrolled on aalleightbone prior to treatment and enrollment on aallnine hundred and thirty-two
__label__0	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the larynx diagnosis and creatinine normal or creatinine clearance greater_than sixty ml min
__label__0	study interventions are laboratory biomarker analysis . adult brain stem glioma diagnosis and patients cannot be receiving enzyme inducing anti epileptic drugs eiaeds
__label__0	study interventions are Carboplatin . breast cancer diagnosis and no secon negative or third degree heart block no bundle_branch block no arrhythmia except
__label__0	study interventions are Fludarabine phosphate . recurrent adult diffuse small cleaved cell lymphoma diagnosis and patients must be willing to use contraception if they have childbearing potential
__label__0	study interventions are Fludarabine phosphate . noncutaneous extranodal lymphoma diagnosis and inv three threeq del threeq or complex karyotype
__label__0	study interventions are Tamoxifen . symptomatic congestive heart failure
__label__0	study interventions are Sorafenib . neoplasms diagnosis and absolute neutrophil count greater than one two hundred microliter
__label__0	study interventions are Tamoxifen . estrogen receptor positive breast cancer diagnosis and because no dosing or adverse event data are currently available on the use of four hydroxytamoxifen in participants less_than eighteen years of age children are excluded from this study but will be eligible for future pediatric trials if applicable
__label__0	study interventions are Antibodies, Monoclonal . carcinoma diagnosis and subjects who have progressed or have been intolerant to any standard treatment regimen or refused standard treatment or for which adequate standard therapy does not exist
__label__0	study interventions are Cytokine-induced Killer Cells . patients histologically confirmed esophageal carcinoma
__label__0	study interventions are placebo . non small cell lung cancer diagnosis and age greater_than or equal_than thirty years
__label__0	study interventions are Belinostat . ovarian serous cystadenocarcinoma diagnosis and neuropathy sensory and motor less than or equal to the ctcae doc grade one
__label__0	study interventions are Albumin-Bound Paclitaxel . adenocarcinoma not otherwise specified
__label__0	study interventions are Deoxyuridine . stage iv marginal zone lymphoma diagnosis and anc greater_than equal_than one five hundred mm three
__label__0	study interventions are Irinotecan . primary peritoneal cavity cancer diagnosis and other
__label__0	study interventions are Irinotecan . adenocarcinoma of the colon diagnosis and must have received an cetuximab containing regimen for at least six weeks for treatment of metastatic disease
__label__0	study interventions are Halofuginone . unspecified adult solid tumor protocol specific diagnosis and gastrointestinal
__label__0	study interventions are Cetuximab . head and neck cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Carboplatin . liver cancer diagnosis and renal
__label__0	study interventions are Gemcitabine . carcinoma of unknown primary diagnosis and not specified
__label__0	study interventions are Interdisciplinary rehabilitation . neoplasms diagnosis and reference with diagnosis or treatment at odense university hospital
__label__0	study interventions are Best Supportive Care . hepatocellular carcinoma diagnosis and arterial enhancement and delayed washout on multiphasic computerized tomography ct or magnetic resonance imaging mri in the setting of cirrhosis or chronic hepatitis or without cirrhosis
__label__0	study interventions are Levoleucovorin . stage iiia gallbladder cancer diagnosis and as part of the oncology patient enrollment network open registration process the treating institution identity is provided in order to ensure that the current within three hundred and sixty-five days date of institutional review board approval for this study has been entered in the system
__label__0	study interventions are Mitogens . melanoma diagnosis and turnstile i
__label__0	study interventions are ispinesib . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and no concurrent agents that inhibit cypthreeafour including any of the following
__label__0	study interventions are Doxorubicin . hertwo positive breast cancer diagnosis and patients must agree with central pathology testing of core biopsy specimen and final pathology specimen and be available and compliant for treatment and follow up
__label__0	study interventions are Vidarabine . stage iii adult immunoblastic large cell lymphoma diagnosis and high or standard risk all
__label__0	study interventions are Doxorubicin . stage iii uterine corpus cancer diagnosis and performance status
__label__0	study interventions are Etoposide phosphate . diagnosis of cell lymphoma with mandatory pathologic review at brigham and women hospital or massachusetts general hospital
__label__0	study interventions are Fludarabine phosphate . hepatosplenic cell lymphoma diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are Glycine . relapsed multiple myeloma diagnosis and were postmenopausal for at least twenty-four months before the screening visit or
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and no known dihydropyrimidine_dehydrogenase deficiency
__label__0	study interventions are Antibodies, Monoclonal . stage ivb mucosal melanoma of the head and neck diagnosis and step one registration
__label__0	study interventions are Everolimus . renal cell carcinoma diagnosis and th the patient has had previous radiation to the marker lesion there must be evidence of progression since the radiation
__label__0	study interventions are Paclitaxel . recurrent small lymphocytic lymphoma diagnosis and ast sgot alt sgpt equal_than less_than doc institutional uln
__label__0	study interventions are conventional . prostate cancer diagnosis and patient consent must be obtained according to local institutional and or university human experimentation committee requirements
__label__0	study interventions are Genistein . kidney cancer diagnosis and radiographic evidence of bone metastasis within the past eight weeks note
__label__0	study interventions are Immunoglobulins . recurrent salivary gland cancer diagnosis and no history of abnormalities of the cornea dry eye syndrome sjögren syndrome or congenital abnormality fuch dystrophy
__label__0	study interventions are Immunoglobulins . malignant pancreatic somatostatinoma diagnosis and therapy must be discontinued at least one week prior to registration
__label__0	study interventions are Cyclosporins . refractory hodgkin lymphoma diagnosis and must have progressed with the most recent remission duration being less_than six months
__label__0	study interventions are Silicon phthalocyanine . non melanomatous skin cancer diagnosis and creatinine no greater than doc mg dl or
__label__0	study interventions are Dacarbazine . adult giant cell glioblastoma diagnosis and negative pregnancy test
__label__0	study interventions are Androgens . adenocarcinoma of the prostate diagnosis and no known active or chronic infection with human immunodeficiency virus hiv hepatitis or hepatitis patients should be assessed for high risk behaviors that may result in these infections such as intravenous drug use or multiple sexual partners the assessment should be noted
__label__0	study interventions are Oxaliplatin . recurrent rectal cancer diagnosis and no uncontrolled seizure disorder
__label__0	study interventions are Antibodies, Monoclonal . metastatic colorectal cancer diagnosis and serum creatinine level ofless_than doc upper limit of normal uln
__label__0	study interventions are Androgens . stage iia prostate cancer diagnosis and appropriate candidate for radical prostatectomy
__label__0	study interventions are Vitamin D . primary cutaneous anaplastic large cell lymphoma diagnosis and previously untreated
__label__0	study interventions are Taiwan ACE Beads . cancer of liver diagnosis and disease can be treated by transarterial chemoembolization and can be evaluated by ultrasound magnetic resonance imaging mri or computed tomography ct
__label__0	study interventions are Sirolimus . brain tumor diagnosis and unstable angina pectoris
__label__0	study interventions are Doxorubicin . multiple myeloma diagnosis and the cockroft gault equation may be used to obtain calculated creatinine clearance
__label__0	study interventions are Capecitabine . advanced or metastatic hertwo negative breast cancer diagnosis and locally advanced stage threeb or metastatic stage four disease
__label__0	study interventions are Vincristine . contiguous stage ii mantle cell lymphoma diagnosis and alternatively patients with legal guardians who can read understand and sign written informed consent may also enroll
__label__0	study interventions are cilengitide . recurrent childhood cerebellar astrocytoma diagnosis and karnofsky performance status ps fifty one hundred patients greater_than sixteen years of age
__label__0	study interventions are Immunoglobulins . stage adult immunoblastic large cell lymphoma diagnosis and platelets greater_than equal_than fifty zero mcl
__label__0	study interventions are alvespimycin hydrochloride . stage iv lymphoepithelioma of the nasopharynx diagnosis and no congenital long qt syndrome
__label__0	study interventions are Nivolumab . stage iv breast cancer diagnosis and focbp and men who are sexually active with focbp must agree to follow instructions for method of contraception for the duration of treatment and the designated post treatment period
__label__0	study interventions are Camptothecin . glioma diagnosis and required initial laboratory data
__label__0	study interventions are Albumin-Bound Paclitaxel . breast neoplasms diagnosis and ast sgot alt sgpt less_than doc institutional upper limit of normal
__label__0	study interventions are Busulfan . neuroblastoma diagnosis and newly diagnosed disease
__label__0	study interventions are Cisplatin . stage iva cervical cancer diagnosis and negative pregnancy test
__label__0	study interventions are Folic Acid Antagonists . histologically documented diagnosis of malignant mesothelioma
__label__0	study interventions are Lenalidomide . multiple myeloma and plasma cell neoplasm diagnosis and no prior rituximab
__label__0	study interventions are Carboplatin . stage iiic primary peritoneal cancer diagnosis and serum glutamic oxaloacetic transaminase sgot less than or equal to three uln
__label__0	study interventions are Albumin-Bound Paclitaxel . colorectal neoplasms diagnosis and this applies even if the subject practices true abstinence from heterosexual contact
__label__0	study interventions are Angiogenesis Modulating Agents . digestive system neoplasms diagnosis and adequate hematologic hepatic and renal function
__label__0	study interventions are Sorafenib . breast cancer diagnosis and stable inr required for patients on warfarin
__label__0	study interventions are quality-of-life assessment . bladder cancer diagnosis and symptoms are not relieved by appropriate life style advice and medication over three month period
__label__0	study interventions are Megestrol . stage iiia endometrial carcinoma diagnosis and willing and able to consent for treatment with office endometrial biopsies every three months
__label__0	study interventions are Carboplatin . ovarian mucinous cystadenocarcinoma diagnosis and gog zero two
__label__0	study interventions are tanespimycin . stage iv adult lymphoblastic lymphoma diagnosis and bilirubin equal_than less_than upper limit of normal uln
__label__0	study interventions are Doxorubicin . unspecified childhood solid tumor protocol specific diagnosis and concurrent chronic medications narcotics or antiepileptics allowed
__label__0	study interventions are BB 1101 . lymphoma non hodgkin diagnosis and relapse in all is defined as the reappearance in patient who has previously achieved remission of leukemic blasts in the bone marrow
__label__0	study interventions are Zidovudine . precancerous nonmalignant condition diagnosis and fertile patients must use effective contraception during study treatment
__label__0	study interventions are Antibodies, Monoclonal . recurrent childhood pineoblastoma diagnosis and doc mg dl for patients aged two to less_than six years
__label__0	study interventions are Carboplatin . medulloblastoma diagnosis and hematologic
__label__0	study interventions are Ifosfamide . recurrent mantle cell lymphoma diagnosis and patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography ct magnetic resonance imaging mri medical photograph skin or oral lesion plain ray or other conventional technique and greatest transverse diameter of one cm or greater or palpable lesions with both diameters greater_than equal_than two cm
__label__0	study interventions are Cisplatin . squamous cell carcinoma diagnosis and patients must have stage iii iva or ivb disease as determined by imaging studies and complete head and neck exam
__label__0	study interventions are Cyclophosphamide . metastatic melanoma diagnosis and patients may have undergone minor surgical procedures within the past three weeks as long as all toxicities have recovered to grade one or less
__label__0	study interventions are Lenalidomide . recurrent rectal carcinoma diagnosis and one has not undergone hysterectomy or bilateral oophorectomy or two has not been naturally postmenopausal for at least two4 consecutive months has had menses at any time in the preceding two4 consecutive months all patients must be counseled by trained_counselor every two8 days about pregnancy precautions and risks of fetal exposure
__label__0	study interventions are Melphalan . colorectal cancer diagnosis and biologic therapy
__label__0	study interventions are Capecitabine . recurrent breast carcinoma diagnosis and note
__label__0	study interventions are Cyclophosphamide . stage iii grade one follicular lymphoma diagnosis and no active uncontrolled infections afebrile for greater_than forty-eight hours off antibiotics
__label__0	study interventions are Busulfan . non hodgkin lymphoma diagnosis and patients who have not received therapy with high dose chemotherapy and stem cell transplantation
__label__0	study interventions are Levoleucovorin . colorectal cancer diagnosis and gastrointestinal
__label__0	study interventions are Bevacizumab . endometrial undifferentiated carcinoma diagnosis and absolute neutrophil count anc greater_than equal_than one thousand, five hundred mm three
__label__0	study interventions are Paclitaxel . triple negative breast carcinoma diagnosis and total serum bilirubin equal_than less_than doc upper limit of normal uln unless attributable to gilbert syndrome
__label__0	study interventions are Buparlisib . mantle cell lymphoma diagnosis and transformed histologies are permitted
__label__0	study interventions are Angiopeptin . carcinoma merkel cell diagnosis and who performance status ecog zero three
__label__0	study interventions are Cortisol succinate . prostate adenocarcinoma diagnosis and seventy-five zero ul
__label__0	study interventions are Sirolimus . prostate cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Docetaxel . gastric cancer diagnosis and total bilirubin less than equal to doc within institutional upper limit of normal iuln
__label__0	study interventions are Erlotinib Hydrochloride . adult mixed glioma diagnosis and phase ii
__label__0	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the hypopharynx diagnosis and urine protein no more than trace
__label__0	study interventions are Metronidazole . prostate cancer diagnosis and l
__label__0	study interventions are Oxaliplatin . adenocarcinoma of the esophagogastric junction diagnosis and adequate blood and biochemistry parameters
__label__0	study interventions are Cisplatin . lung adenocarcinoma diagnosis and absolute neutrophil count anc greater_than doc one hundred and nine platelets greater_than one hundred one hundred and nine hemoglobin greater_than eight dl
__label__0	study interventions are Amifostine . unspecified adult solid tumor protocol specific diagnosis and age
__label__0	study interventions are Oxaliplatin . childhood immunoblastic large cell lymphoma diagnosis and more than three weeks since prior myelosuppressive chemotherapy six weeks for nitrosoureas
__label__0	study interventions are Nivolumab . patients with plasmacytoma for which ffpe or fresh biopsy tissue of the tumor will be submitted for screening are eligible once validation of the screening assay of multiple myeloma bone marrow aspirate specimens is completed the protocol will be formally amended to allow inclusion of patients with any multiple myeloma
__label__0	study interventions are Fludarabine . plasma cell neoplasm diagnosis and prior concurrent therapy
__label__0	study interventions are Laboratory Biomarker Analysis . aids related primary effusion lymphoma diagnosis and survival status at two years
__label__0	study interventions are Antibodies . stage iii squamous cell carcinoma of the larynx diagnosis and concurrent coumarin_derivative anticoagulants warfarin up to two mg daily allowed for prophylaxis of thrombosis
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and asthma or chronic obstructive pulmonary disease allowed provided daily systemic corticosteroid therapy is not required
__label__0	study interventions are Vincristine . lymphoma diagnosis and leucocytesgreater_than doc zero mmthree plateletsgreater_than 1three doc zero mmthree bilirubin less_than two mg transaminases less_than doc creatinine less_than one hundred and fifty µm creatinine clearance greater_than forty ml min
__label__0	study interventions are Sorafenib . non squamous cell lung cancer diagnosis and hemoglobin greater than or equal to doc dl
__label__0	study interventions are Daunorubicin . stage iv adult lymphoblastic lymphoma diagnosis and prior therapy restrictions
__label__0	study interventions are Bevacizumab . breast cancer diagnosis and if of childbearing potential negative pregnancy test
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent childhood visual pathway glioma diagnosis and must not be known to be refractory to rbc or platelet transfusions
__label__0	study interventions are apatinib tablet . gastric carcinoma diagnosis and at least one measurable lesion larger than ten mm in diameter by spiral ct scan
__label__0	study interventions are Antibodies, Monoclonal . metastatic breast cancer diagnosis and taxane and pertuzumab may have been in the adjuvant or neoadjuvant setting
__label__0	study interventions are Resveratrol . neuroendocrine tumor diagnosis and able to give informed consent and willing to undergo the post treatment research biopsy
__label__0	study interventions are Dacarbazine . brain tumor diagnosis and not pregnant or nursing
__label__0	study interventions are Temozolomide . childhood oligodendroglioma diagnosis and no evidence of active graft vs host disease
__label__0	study interventions are Irinotecan . stage iv colon cancer diagnosis and must have received greater_than equal_than one prior chemotherapeutic regimen for treatment of metastatic disease with any of the following
__label__0	study interventions are Tetracycline . unspecified adult solid tumor protocol specific diagnosis and no severe nausea or vomiting that would preclude retaining study drug
__label__0	study interventions are Oxaliplatin . stage iva gallbladder cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than one
__label__0	study interventions are genetically engineered lymphocyte therapy . recurrent grade one follicular lymphoma diagnosis and any uncontrolled active medical disorder that would preclude participation as outlined
__label__0	study interventions are Etoposide . stage mantle cell lymphoma diagnosis and patients must have measurable disease defined as lesions that can be accurately measured in two dimensions by computed tomography ct magnetic resonance imaging mri medical photograph skin or oral lesion plain ray or other conventional technique and greatest transverse diameter of one cm or greater or palpable lesions with both diameters greater_than equal_than two cm
__label__0	study interventions are Alemtuzumab . recurrent mantle cell lymphoma diagnosis and must have less_than five blasts at the time of transplant
__label__0	study interventions are Carmustine . childhood nasal type extranodal nk cell lymphoma diagnosis and hodgkin disease hl
__label__0	study interventions are Erlotinib Hydrochloride . colorectal cancer diagnosis and measurable disease defined as at least one dimension greater_than two cm greater_than one cm on spiral ct scans
__label__0	study interventions are pharmacological study . recurrent prostate cancer diagnosis and no peripheral neuropathy greater_than grade two
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and patients with either measurable or evaluable disease are eligible
__label__0	study interventions are Vidarabine . multiple myeloma diagnosis and any nhl in remission which is considered not curable with chemotherapy alone and not eligible appropriate for autologous transplant
__label__0	study interventions are Dacarbazine . should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__0	study interventions are Polyethylene glycol 3350 . colorectal cancer diagnosis and females must be surgically sterile practicing true sexual abstinence or using an acceptable form of effective contraception throughout the study from the following list
__label__0	study interventions are Paclitaxel . recurrent urethral cancer diagnosis and normal cardiac ejection fraction by echocardiogram or muga greater than osu lower limit of normal
__label__0	study interventions are Fludarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and failed flu_cy rituximab fcr combination chemotherapy at any time point or
__label__0	study interventions are Vaccines . adenocarcinoma of lung diagnosis and refractory nscl negative defined as achieving less than complete response and having residual measurable by recist criteria after prior treatment with chemotherapy targeted or small molecules monoclonal antibodies or any combination of these
__label__0	study interventions are Cisplatin . stage iiia non small cell lung cancer diagnosis and tthree ntwo or tfour nzero ntwo disease also allowed if based on the closeness to the carina invasion of the mediastinum or invasion of the chest wall
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and congestive heart failure
__label__0	study interventions are Cyclophosphamide . diagnosis of neuroblastoma by histology using tumor tissue or as evidenced by the presence of distinct neuroblastoma cells in the bone marrow and elevated catecholamine_metabolites homovanillic acid hva and vanillylmandelic acid vma in blood or urine
__label__0	study interventions are Lenograstim . recurrent refractory childhood hodgkin lymphoma diagnosis and not otherwise specified
__label__0	study interventions are Ifosfamide . childhood immunoblastic large cell lymphoma diagnosis and hiv negative
__label__0	study interventions are Podophyllotoxin . activated cell like diffuse large cell lymphoma diagnosis and pre registration eligibility criteria step zero
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and agree not to share study drug with another person and to return all unused study drug to the investigator
__label__0	study interventions are Cisplatin . tumor type
__label__0	study interventions are Geriatrician Intervention . prostate cancer diagnosis and signed informed consent
__label__0	study interventions are Dexamethasone . relapsed and or refractory multiple myeloma diagnosis and have negative pregnancy test with sensitivity of at least twenty-five miu ml within ten to fourteen days and again within twenty-four hours prior to starting cycle one of lenalidomide
__label__0	study interventions are Bortezomib . contiguous stage ii grade two follicular lymphoma diagnosis and serum glutamic oxaloacetic transaminase sgot and serum glutamic pyruvate transaminase sgpt less than two times the upper limit of normal uln
__label__0	study interventions are Taxane . hertwo positive breast cancer metastatic breast cancer locally advanced breast cancer diagnosis and eastern cooperative oncology group ecog performance status of zero or one
__label__0	study interventions are Cyclosporine . stage iii adult diffuse mixed cell lymphoma diagnosis and complete disappearance of all known disease with the exception of persistent scan abnormalities of unknown significance the term unconfirmed is defined as scan abnormalities of unknown significance that are not biopsied or otherwise evaluated
__label__0	study interventions are Mycophenolate mofetil . recurrent marginal zone lymphoma diagnosis and chronic myelogenous leukemia cml
__label__0	study interventions are Irinotecan . stage iv pancreatic cancer diagnosis and absolute neutrophil count anc greater_than equal_than lfive hundred ul
__label__0	study interventions are Belinostat . advanced malignant mesothelioma diagnosis and patients who are not candidates for combination chemotherapy are eligible even if they have not received prior chemotherapy
__label__0	study interventions are Isophosphamide mustard . ovarian cancer diagnosis and no bleeding disorders
__label__0	study interventions are Cyclosporine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and must be refractory to fludarabine patients who fail to have complete or partial response after therapy with regimen containing fludarabine or another nucleoside_analog two cladribine_cda pentostatin or experience disease relapse within 1two months after completing therapy with regimen containing fludarabine or another nucleoside_analog
__label__0	study interventions are study of socioeconomic and demographic variables . psychosocial effects of cancer and its treatment diagnosis and able sufficiently fluent in english or french and willing to complete the patient reported outcome questionnaires social determinants of exercise measurement health economics and physical activity questionnaires and logs
__label__0	study interventions are Methotrexate . histologically confirmed breast cancer
__label__0	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and serious nonhealing wound ulcer or bone fracture
__label__0	study interventions are Panobinostat . patients with radiographically typical dipg defined as tumor with pontine epicenter and diffuse involvement of more than two three of the pons are eligible without histologic confirmation
__label__0	study interventions are Etoposide . unspecified childhood solid tumor protocol specific diagnosis and over sixty years of age
__label__0	study interventions are Endothelial Growth Factors . patients with colorectal cancer should have failed at least one oxaliplatin containing regimen
__label__0	study interventions are Oxaliplatin . adenocarcinoma of the rectum diagnosis and no extrahepatic metastases
__label__0	study interventions are Tacrolimus . testicular lymphoma diagnosis and patients will be accepted beyond first chronic phase cpone if they have received previous myelosuppressive chemotherapy or hct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Camptothecin . recurrent colon cancer diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are Nivolumab . carcinoma non small cell lung diagnosis and approved contraceptive methods include for example
__label__0	study interventions are Etoposide . stage iv adult burkitt lymphoma diagnosis and seven days post transplant
__label__0	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and measurable disease as per recist doc
__label__0	study interventions are Antibodies, Monoclonal . malignant neoplasm of breast diagnosis and male creatinine clearance equal_than one hundred and forty
__label__0	study interventions are Melphalan . unspecified adult solid tumor protocol specific diagnosis and biologic therapy
__label__0	study interventions are Androgens . prostate cancer diagnosis and disease characteristics
__label__0	study interventions are Methotrexate . noncontiguous stage ii small lymphocytic lymphoma diagnosis and refractory cytopenia with multilineage_dysplasia and ringed_sideroblasts
__label__0	study interventions are Carboplatin . glioma astrocytic diagnosis and diagnosis
__label__0	study interventions are Erlotinib Hydrochloride . recurrent non small cell lung cancer diagnosis and normal liver function defined as serum total bilirubin equal_than less_than doc and serum transaminases equal_than less_than doc the upper limits of normal uln if liver metastases are present serum transaminases greater_than fivex the uln
__label__0	study interventions are Lenograstim . stage ii childhood hodgkin lymphoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate gfr greater_than equal_than seventy ml min doc three three
__label__0	study interventions are immunohistochemistry staining method . unspecified childhood solid tumor protocol specific diagnosis and not known to be serologically positive for hepatitis or or hiv
__label__0	study interventions are Etoposide . unspecified childhood solid tumor protocol specific diagnosis and well matched donor as defined by one of the following
__label__0	study interventions are Vidarabine . noncontiguous stage ii grade two follicular lymphoma diagnosis and there is no indication for an autologous transplantation as treatment option
__label__0	study interventions are Fludarabine . t cell non hodgkin lymphoma diagnosis and acute myeloid leukemia and acute lymphoblastic leukemia including biphenotypic acute leukemia or mixed lineage leukemia
__label__0	study interventions are Dexamethasone . females of childbearing potential must have negative serum or urine pregnancy test as described in appendix doc for the pomalyst_rems program
__label__0	study interventions are Montelukast . fallopian tube cancer diagnosis and adequate hematologic hepatic and renal function as defined below
__label__0	study interventions are Palbociclib . refractory plasma cell myeloma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc institutional uln up to five times uln in presence of liver metastases
__label__0	study interventions are Dacarbazine . gastric large cell neuroendocrine carcinoma diagnosis and patients must have life expectancy of greater_than equal_than twelve weeks as determined clinically by the treating physician
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and dlco normal other
__label__0	study interventions are Ibrutinib . recurrent adult diffuse mixed cell lymphoma diagnosis and stability of regimen
__label__0	study interventions are Celecoxib . stage iiib breast cancer diagnosis and scleroderma
__label__0	study interventions are Bevacizumab . clear cell renal cell carcinoma diagnosis and no significant traumatic injury in the past twenty-eight days
__label__0	study interventions are Immunoglobulins . stage iv renal cell cancer diagnosis and no ongoing active infection
__label__0	study interventions are Thalidomide . any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form pregnant or lactating females lactating females must agree not to breast feed while taking lenalidomide any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he she were to participate in the study or confounds the ability to interpret data from the study use of any other experimental drug or therapy within twenty-eight days of baseline known hypersensitivity to thalidomide or lenalidomide prior history of development of erythema_nodosum if characterized by desquamating_rash while taking thalidomide or similar drugs patients who have been treated with any prior therapy for cll patients with history of any other cancer except non melanoma skin cancer or carcinoma in situ of the cervix unless in complete remission and off therapy for that disease for greater_than three years patient with history of cardiac arrest within the past six months any prior use of lenalidomide concurrent use of other anti cancer agents or treatments known history of hepatitis or known human immunodeficiency virus hiv positive status
__label__0	study interventions are Tegafur . head and neck cancer diagnosis and myocardial infarction within the past six months
__label__0	study interventions are Gemcitabine . bladder cancer diagnosis and other
__label__0	study interventions are Albumin-Bound Paclitaxel . testicular yolk_sac tumor diagnosis and doc mg dl six months to less_than one year of age
__label__0	study interventions are Local radiotherapy . lymphoma non hodgkin diagnosis and one equired wash out periods for prior therapy
__label__0	study interventions are pharmacogenomic studies . cholangiocarcinoma of the extrahepatic bile duct diagnosis and indicator lesion is are outside the area of prior treatment or if the only indicator lesion is inside the prior treatment area there must be clear evidence of disease progression associated with that lesion
__label__0	study interventions are Leucovorin . mature cell lymphoma diagnosis and jude guidelines before enrollment into study
__label__0	study interventions are Methotrexate . recurrent breast cancer diagnosis and platelet count at least one hundred zero mm three
__label__0	study interventions are Fludarabine phosphate . adult non hodgkin lymphoma diagnosis and one this mismatch will be considered one antigen mismatch for rejection only
__label__0	study interventions are Cyclosporins . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and donor must have adequate veins for leukopheresis or agree to placement of central venous catheter femoral_subclavian
__label__0	study interventions are Erlotinib Hydrochloride . participants must have confirmed or suspected invasive or non invasive bladder tumor initial or recurrent discovered on cystoscopy or radiologic imaging performed within one hundred and twenty days of randomization
__label__0	study interventions are Interleukin-2 . recurrent osteosarcoma diagnosis and hematopoietic growth factors
__label__0	study interventions are Fludarabine . stage iv adult immunoblastic large cell lymphoma diagnosis and ages greater_than fifty years with hematologic malignancies treatable by unrelated hct
__label__0	study interventions are Liposomal doxorubicin . neoplasms breast diagnosis and fifty ml min
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and more than four weeks since prior radiotherapy
__label__0	study interventions are Fludarabine phosphate . refractory multiple myeloma diagnosis and acute lymphoblastic leukemia all with nine twenty-two elevenqtwenty-three abnormality or early relapse less_than five marrow blasts or crtwo or greater
__label__0	study interventions are Aldesleukin . ovarian cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Leucovorin . histologically or cytologically proven adenocarcinoma of the colon expressing non mutated wild type kras
__label__0	study interventions are Antibodies . uterine corpus carcinosarcoma diagnosis and absolute neutrophil count anc greater_than equal_than one thousand, five hundred mm three
__label__0	study interventions are Drospirenone and ethinyl estradiol combination . severe somatic and allergic diseases
__label__0	study interventions are CDCA1,URLC10,KIF20A,DEPDC1 and MPHOSPH1 . metastatic breast cancer diagnosis and hla two thousand, four hundred and two
__label__0	study interventions are Dexamethasone 21-phosphate . plasmacytomas on tissue biopsy
__label__0	study interventions are Antibodies . stage ivc squamous cell carcinoma of the oropharynx diagnosis and platelet count greater_than equal_than seventy-five zero cells µl
__label__0	study interventions are Cyclophosphamide . early stage breast cancer diagnosis and absolute neutrophil count anc greater_than one thousand, five hundred µl
__label__0	study interventions are Oxaliplatin . recurrent cutaneous cell non hodgkin lymphoma diagnosis and more than six months since prior allogeneic peripheral blood stem cell transplantation and no active graft versus host disease
__label__0	study interventions are Sirolimus . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and peripheral absolute neutrophil count anc greater_than one zero µl
__label__0	study interventions are Sirolimus . tongue cancer diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot alanine aminotransferase alt serum glutamic pyruvate transaminase sgpt equal_than less_than doc institutional upper limit of normal uln
__label__0	study interventions are thermal ablation therapy . metastatic cancer diagnosis and no untreated bleeding diathesis
__label__0	study interventions are Vincristine . aids related small noncleaved cell lymphoma diagnosis and at least twenty-four hours since prior transfusion
__label__0	study interventions are Irinotecan . untreated childhood rhabdomyosarcoma diagnosis and stage one group ii
__label__0	study interventions are Etoposide phosphate . neuroblastoma diagnosis and negative pregnancy test
__label__0	study interventions are Efaproxiral . brain and central nervous system tumors diagnosis and other
__label__0	study interventions are Immunoglobulins . stage grade three follicular lymphoma diagnosis and creatinine equal_than less_than two institutional uln
__label__0	study interventions are Interleukin-2 . stage iiia fallopian tube cancer diagnosis and appropriate slides of the primary lesion will be available for future review if available hertwo neu positivity will be recorded
__label__0	study interventions are Bortezomib . enteropath negative type cell lymphoma diagnosis and peripheral neuropathy or neuropathic pain of grade two or worse
__label__0	study interventions are Metformin . pancreatic cancer diagnosis and ability to complete online forms
__label__0	study interventions are Cisplatin . extensive stage small cell lung carcinoma diagnosis and patients with central nervous system cns metastases or history of cns metastases are ineligible
__label__0	study interventions are questionnaire administration . stage ia breast cancer diagnosis and two weeks post surgery for women who have had lumpectomy lumpectomy with an axillary node dissection or mastectomy without reconstruction or
__label__0	study interventions are Dexamethasone acetate . myeloma diagnosis and platelet transfusions to help patients meet eligibility criteria are not allowed within three days before study enrollment
__label__0	study interventions are Carboplatin . urothelial carcinoma diagnosis and four weeks since prior major surgery greater_than two weeks since prior minor surgery tur and greater_than one week since prior radiation therapy
__label__0	study interventions are Capecitabine . stomach neoplasms diagnosis and at least fifteen examined lymph nodes are required to ensure the adequate tnm classification
__label__0	study interventions are neoadjuvant therapy . prostate cancer diagnosis and no ongoing urinary tract infection necessitating rapid or emergent surgical resection
__label__0	study interventions are Rituximab . lymphoma diagnosis and weight loss greater_than ten within the previous six months
__label__0	study interventions are Doxorubicin . ds stage ii plasma cell myeloma diagnosis and related organ or tissue impairment consisting of
__label__0	study interventions are Busulfan . testicular germ cell tumor diagnosis and over sixty years of age
__label__0	study interventions are colloidal gold-bound tumor necrosis factor . liver cancer diagnosis and fev_one or dlco greater_than thirty of predicted for patients with prior pulmonary disease
__label__0	study interventions are Capecitabine . kidney cancer diagnosis and leptomeningeal disease
__label__0	study interventions are Mycophenolic Acid . follicular lymphoma diagnosis and high risk first complete remission crone as evidenced by preceding myelodysplastic syndromes mds high risk cytogenetics such as those associated with mds or complex karyotype greater_than two cycles to obtain cr or erythroblastic or megakaryocytic leukemia flt three itd positive second or greater cr
__label__0	study interventions are Fluorouracil . pancreatic adenocarcinoma diagnosis and platelet count greater_than equal_than one hundred zero mm three
__label__0	study interventions are Asparaginase . stage ii childhood lymphoblastic lymphoma diagnosis and all
__label__0	study interventions are Lenalidomide . stage iva oropharyngeal squamous cell carcinoma diagnosis and total bilirubin within normal institutional limits
__label__0	study interventions are Fluorides . adult craniopharyngioma diagnosis and not pregnant or nursing
__label__0	study interventions are Podophyllotoxin . small cell carcinoma diagnosis and phase ii
__label__0	study interventions are Isophosphamide mustard . stage iib adult soft tissue sarcoma diagnosis and aspartate aminotransferase ast alanine aminotransferase alt equal_than less_than doc uln
__label__0	study interventions are conventional surgery . metastatic cancer diagnosis and surgery
__label__0	study interventions are Data collection . lung cancer non small cell diagnosis and patient medical records will be screened using the following criteria
__label__0	study interventions are Niacinamide . adenocarcinoma of the pancreas diagnosis and no uncontrolled hypertension
__label__0	study interventions are Etoposide phosphate . diagnosis of relapsed or refractory neuroblastoma
__label__0	study interventions are Capecitabine . breast cancer diagnosis and renal
__label__0	study interventions are Mycophenolate mofetil . indolent non hodgkin lymphoma diagnosis and patients greater_than seventy may be considered if performance status greater_than eighty or eastern cooperative oncology group ecog less_than one and comorbidity score less_than three
__label__0	study interventions are Pembrolizumab . recurrent melanoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than one karnofsky greater_than equal_than seventy
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and transaminases less than five times upper limit of normal
__label__0	study interventions are Cisplatin . diffuse adenocarcinoma of the stomach diagnosis and no ongoing or active infection requiring parental antibiotics on day zero of study
__label__0	study interventions are Etoposide . breast cancer diagnosis and not specified
__label__0	study interventions are Trametinib . stage iv melanoma diagnosis and willing to use two forms of effective contraception and to continue use for sixteen weeks post last dose of study medication
__label__0	study interventions are Vinorelbine . breast cancer diagnosis and platelet count greater_than one hundred zero mm³
__label__0	study interventions are Tacrolimus . recurrent adult diffuse mixed cell lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Cyclophosphamide . stage iv adult diffuse mixed cell lymphoma diagnosis and large cell nhl greater_than crtwo greater_than prtwo
__label__0	study interventions are Temozolomide . central nervous system tumors diagnosis and hepatic
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and see disease characteristics
__label__0	study interventions are end-of-life treatment/management . lung cancer diagnosis and undergoing either lobectomy pneumonectomy segmentectomy or wedge resection
__label__0	study interventions are Levoleucovorin . gastric cardia adenocarcinoma diagnosis and platelets greater_than equal_than one hundred ten nine l
__label__0	study interventions are Cisplatin . extensive stage small cell lung cancer diagnosis and life expectancy of at least three months
__label__0	study interventions are Fludarabine . hematopoietic and lymphoid cell neoplasm diagnosis and must have failed two courses of therapy
__label__0	study interventions are Immunoglobulins . stage iv colorectal cancer diagnosis and hemoglobin must be greater_than equal_than ten dl
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and able to understand and to given an informed consent
__label__0	study interventions are Oxaliplatin . breast cancer diagnosis and nsclc
__label__0	study interventions are external beam radiation therapy . metastatic cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Capecitabine . pancreatic cancer diagnosis and patient has normal liver function
__label__0	study interventions are Tacrolimus . noncontiguous stage ii grade one follicular lymphoma diagnosis and white blood cells wbc difficult to control greater_than fifty one0 nine despite therapy
__label__0	study interventions are Isophosphamide mustard . stage iii adult hodgkin lymphoma diagnosis and no cns toxicity greater_than grade two
__label__0	study interventions are Tacrolimus . stage grade two follicular lymphoma diagnosis and donor
__label__0	study interventions are Bortezomib . stage iiib non small cell lung cancer diagnosis and no concurrent ongoing or active infection
__label__0	study interventions are Paclitaxel . non small cell lung cancer diagnosis and total bilirubin less_than doc mg dl
__label__0	study interventions are Immunoglobulins . stage four neuroblastoma diagnosis and one month to less_than six months
__label__0	study interventions are Antiviral Agents . stage iii small lymphocytic lymphoma diagnosis and diagnosis
__label__0	study interventions are Fludarabine phosphate . stage iii grade three follicular lymphoma diagnosis and patients with pnh must have history of thrombosis related to pnh
__label__0	study interventions are Cyclosporins . contiguous stage ii marginal zone lymphoma diagnosis and accelerated phase
__label__0	study interventions are Immunoglobulins . recurrent mantle cell lymphoma diagnosis and patients must not have grade two or higher neuropathy
__label__0	study interventions are Antibodies . recurrent melanoma diagnosis and measurable disease note
__label__0	study interventions are Mycophenolate mofetil . stage iv grade three follicular lymphoma diagnosis and donor
__label__0	study interventions are Vincristine . sarcoma diagnosis and previously untreated except for cryosurgery or laser surgery under ten years at presentation of metastatic disease
__label__0	study interventions are Sunitinib . patients with metastatic renal cell carcinoma who are ineligible for participation in other sueleven thousand, two hundred and forty-eight protocols but may derive benefit from treatment with sueleven thousand, two hundred and forty-eight
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and female age greater_than eighteen years
__label__0	study interventions are Histone Deacetylase Inhibitors . recurrent adult cell leukemia lymphoma diagnosis and bone marrow lymphoplasmacytosis with greater_than ten lymphoplasmacytic cells or aggregates_sheets lymphocytes plasma cells or lymphoplasmacytic cells on bone marrow biopsy and quantitative igm monoclonal protein greater_than one zero mg dl
__label__0	study interventions are Doxorubicin . epithelial ovarian cancer diagnosis and must have measurable disease by ct or mri scan
__label__0	study interventions are Vaccines . prostate cancer diagnosis and age
__label__0	study interventions are Immunoglobulins . ovarian mucinous cystadenocarcinoma diagnosis and ast less_than three times upper limit of normal uln
__label__0	study interventions are gamma-Aminobutyric Acid . malignant head and neck neoplasm diagnosis and stage three or four
__label__0	study interventions are Irinotecan . stomach neoplasms diagnosis and however prior oxaliplatin and or irinotecan as adjuvant therapy are not allowed
__label__0	study interventions are Hormones . stage iia breast cancer diagnosis and for determination of the oncotype recurrence score tissue must be shipped to genomic health if the oncotype_dx recurrence score was previously performed by genomic health prior to pre registration tissue must be submitted to the eastern cooperative oncology group ecog american college of radiology imaging network acrin central biorepository and pathology facility upon randomization
__label__0	study interventions are Antibodies, Monoclonal . recurrent salivary gland cancer diagnosis and no concurrent anticoagulation therapy
__label__0	study interventions are Vincristine . large cell lymphoma diagnosis and patients must have one of the following who classification subtypes
__label__0	study interventions are Olaparib . triple negative breast neoplasms diagnosis and hematology
__label__0	study interventions are Gemcitabine . lung neoplasms diagnosis and at least one measurable lesion
__label__0	study interventions are Cytarabine . high risk gene expression profiling gep at the time of relapse by signal genetics myeloma prognostic risk signature myprs score
__label__0	study interventions are Fludarabine phosphate . myelodysplastic myeloproliferative neoplasms diagnosis and lvef greater_than fifty
__label__0	study interventions are Paclitaxel . stage iiib non small cell lung cancer diagnosis and ast less_than doc times uln
__label__0	study interventions are Etanidazole . adult brain stem glioma diagnosis and at least three months
__label__0	study interventions are Health Education Program . ductal breast carcinoma in situ diagnosis and note
__label__0	study interventions are Cyclosporins . recurrent childhood lymphoblastic lymphoma diagnosis and there is likelihood of disease progression while hla typing and results of preliminary_search and the donor pool suggest that ten ten hla b drbone and dqbone matched unrelated donor will not be found
__label__0	study interventions are Cetuximab . glioblastoma multiforme gbm diagnosis and informed consent must be obtained at the time of patient screening prior to day zero of the procedure either by the patient or legalized authorized representative lar of the patient health care proxy
__label__0	study interventions are Panobinostat . small cell lung cancer diagnosis and oral contraceptives are generally metabolized by cypthreeafour
__label__0	study interventions are Melphalan . symptomatic elderly mm newly diagnosed by ebmt criteria older than sixty-five years
__label__0	study interventions are Interferons . lymphoma diagnosis and no mi within six months no medication for arrhythmia no medication for chf hypertension that is stable off medication allowed pulmonary
__label__0	study interventions are Cyclosporine . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and hematologic remission
__label__0	study interventions are tanespimycin . gastric cancer diagnosis and prior orchiectomy allowed
__label__0	study interventions are Bortezomib . recurrent adult immunoblastic large cell lymphoma diagnosis and plt greater_than equal_than fifty zero ul
__label__0	study interventions are Thalidomide . recurrent ovarian epithelial cancer diagnosis and ca one hundred and twenty-five must have been normal prior to or normalized during first line therapy and then subsequently rose to exceed twice the upper limit of normal
__label__0	study interventions are Analgesics, Opioid . precancerous condition diagnosis and serum creatinine less_than doc mg dl
__label__0	study interventions are Rituximab . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and alternatively patients with legal guardians who can read understand and sign written informed consent may also enroll
__label__0	study interventions are HTIMRT . prostate cancer diagnosis and patients with gleason score eight must be offered long term androgen deprivation therapy adt and refuse such treatment because only four six two months months short term adt is permitted on this protocol
__label__0	study interventions are Lenvatinib . carcinoma renal cell diagnosis and voluntary agreement to provide written informed consent of this study
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and hypopharynx larynx oral cavity oropharynx at least one of the following high risk factors required
__label__0	study interventions are Melphalan . noncontiguous stage ii grade three follicular lymphoma diagnosis and unrelated donor
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and or interferon based therapy
__label__0	study interventions are Busulfan . stage iv adult diffuse small cleaved cell lymphoma diagnosis and patients with aml all or mds scheduled for myeloablative conditioning should have equal_than less_than ten blasts in bone marrow or peripheral blood at the start of conditioning
__label__0	study interventions are Calcium, Dietary . stage iiia esophageal cancer diagnosis and locally advanced or metastatic disease that is inoperable and not amenable to curative therapy linitis_plastica is permitted
__label__0	study interventions are Thalidomide . myeloma diagnosis and leukocytes greater_than equal_than two zero ml
__label__0	study interventions are Immunoglobulins . stage iii midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and no concurrent anticoagulation therapy
__label__0	study interventions are Pomalidomide . primary effusion lymphoma diagnosis and doc any hiv status
__label__0	study interventions are Calcitriol . unspecified adult solid tumor protocol specific diagnosis and calcium supplements
__label__0	study interventions are Azacitidine . lung cancer diagnosis and not specified
__label__0	study interventions are Antibodies . adenocarcinoma of the rectum diagnosis and patients who have received an cetuximab containing regimen as adjuvant therapy for resected stage ii or iii crc are eligible provided recurrent disease is documented less_than six months after completion of adjuvant treatment
__label__0	study interventions are Antibodies, Monoclonal . melanoma rcc triple negative breast cancer bladder cancer head and neck cancer or non small cell lung cancer
__label__0	study interventions are Carmustine . brain and central nervous system tumors diagnosis and karnofsky sixty one hundred
__label__0	study interventions are Carmustine . relapsed diffuse large cell lymphoma dlbcl diagnosis and direct bilirubin less_than doc mg dl in the absence of suspected gilbert disease if gilbert disease is suspected the total bilirubin must be less_than doc mg dl
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and no intermediat negative or high grade nhl or mantle cell nhl that is progressive on salvage therapy
__label__0	study interventions are Gemcitabine . metastatic breast cancer mbc diagnosis and relapsing after receiving one adjuvant neoadjuvant chemotherapy containing an anthracycline if not clinically contraindicated
__label__0	study interventions are Levoleucovorin . lymphoma diagnosis and not specified
__label__0	study interventions are Mycophenolate mofetil . noncontiguous stage ii grade three follicular lymphoma diagnosis and donor
__label__0	study interventions are Soblidotin . lung cancer diagnosis and at least four weeks since prior major surgery and recovered
__label__0	study interventions are BI 2536 . sarcoma diagnosis and bilirubin less_than doc times uln
__label__0	study interventions are Methylprednisolone . neuroblastoma diagnosis and diagnosis of malignant or non malignant disease including but not limited to any of the following
__label__0	study interventions are Antibodies, Monoclonal . noncontiguous stage ii grade one follicular lymphoma diagnosis and one allele or
__label__0	study interventions are Phosphonoacetic Acid . stage iii marginal zone lymphoma diagnosis and all patients must be capable of signing written informed consent and no consent can be provided by legal guardian
__label__0	study interventions are Ifosfamide . testicular embryonal carcinoma and yolk_sac tumor diagnosis and life expectancy greater_than eight weeks
__label__0	study interventions are Vidarabine . cancer diagnosis and age
__label__0	study interventions are Vidarabine . recurrent adult lymphoblastic lymphoma diagnosis and donor
__label__0	study interventions are Cyclosporine . lymphoma diagnosis and no leukemia
__label__0	study interventions are Paclitaxel . prior cancer treatment must be completed at least twenty-one days prior to being registered for protocol therapy and the subject must have recovered from the acute toxicity effects of the regimen prior to registration
__label__0	study interventions are Everolimus . recurrent pheochromocytoma diagnosis and last dose of prior chemotherapy discontinued less than four weeks before the start of study therapy
__label__0	study interventions are Everolimus . stage iiib skin melanoma diagnosis and no prior temsirolimus rapamycin bevacizumab or systemic therapies targeted primarily to vascular endothelial growth factor vegf vegf receptors or to mtor inhibition
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and age
__label__0	study interventions are Sorafenib . neoplasms diagnosis and adequate bone marrow liver and renal function as assessed by the following
__label__0	study interventions are OTX015/MK-8628 . nut midline carcinoma diagnosis and platelet count greater_than one hundred and fifty xten nine l
__label__0	study interventions are Everolimus . endometrial papillary serous carcinoma diagnosis and not pregnant or nursing
__label__0	study interventions are Interleukin-2 . relapsed or refractory multiple myeloma diagnosis and no known prior organ allograft or allogeneic transplantation
__label__0	study interventions are Albumin-Bound Paclitaxel . histologically confirmed adenocarcinoma of the esophagus or ge junction
__label__0	study interventions are Topotecan . ovarian serous cystadenocarcinoma diagnosis and no prior radiotherapy
__label__0	study interventions are Etoposide phosphate . ewing family tumors diagnosis and arm c
__label__0	study interventions are Fludarabine . lymphoma diagnosis and no chronic inflammatory disorder requiring the continued use of glucocorticoids or other immunosuppressive medications
__label__0	study interventions are Oxaliplatin . stage iiia colon cancer diagnosis and creatinine no greater than doc times uln
__label__0	study interventions are Fludarabine phosphate . plasma cell neoplasm diagnosis and have three partially hla matched umbilical cord blood ucb units one two units for ucb transplantation per mttwo005 0two and one unit for the treg cell infusion
__label__0	study interventions are Valproic Acid . recurrent non small cell lung cancer diagnosis and controlled brain metastases allowed provided patient has no neurologic deterioration when off steroids has completed prior radiotherapy or other treatments has fully recovered from prior treatment and does not require anticonvulsants
__label__0	study interventions are Dexamethasone acetate . advanced cancers diagnosis and no evidence of significant anxiety or depression as determined by total hads scores of less_than twenty-one
__label__0	study interventions are Docetaxel . large cell lung cancer diagnosis and contralateral mediastinal disease nthree allowed if all gross disease can be encompassed in the radiotherapy boost field
__label__0	study interventions are Fludarabine phosphate . stage adult diffuse large cell lymphoma diagnosis and must have received and failed frontline therapy patients must have failed or were not eligible for autologous transplant
__label__0	study interventions are Cyclosporins . stage iii small lymphocytic lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Cisplatin . adenocarcinoma diagnosis and stage iiib not amenable for radical loco regional therapy or stage iv metastatic patients according to the seventh tnm staging system
__label__0	study interventions are Simple hysterectomy + pelvic lymph node dissection . cervical cancer diagnosis and patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements
__label__0	study interventions are Liposomal doxorubicin . hertwo negative breast cancer diagnosis and patients with suspicious findings on bone scan or pet scan are eligible if suspicious findings are determined to be benign by ray mri or biopsy
__label__0	study interventions are Pomalidomide . multiple myeloma diagnosis and partner vasectomy
__label__0	study interventions are tanespimycin . recurrent adult immunoblastic large cell lymphoma diagnosis and no active infection
__label__0	study interventions are flow cytometry . lung cancer diagnosis and able to hold breath for twenty-seven seconds
__label__0	study interventions are Carboplatin . fallopian tube cancer diagnosis and liver function
__label__0	study interventions are Sodium Bicarbonate . lymphoma diagnosis and age greater than eighteen years and able to understand and sign the informed consent document
__label__0	study interventions are Antibodies, Monoclonal . stage iiic skin melanoma diagnosis and enzyme inducing antiepileptic drugs eiaeds or other cypthreeafour inducers
__label__0	study interventions are Bortezomib . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Ultrasound breast scanning . breast cancer diagnosis and subject has mammography or ultrasound findings
__label__0	study interventions are Endothelial Growth Factors . stage iiic breast cancer diagnosis and serum creatinine equal_than less_than doc mg dl
__label__0	study interventions are Cisplatin . lymphoma diagnosis and not specified
__label__0	study interventions are Carboplatin . esophageal cancer diagnosis and bilirubin normal
__label__0	study interventions are Carboplatin . lung cancer diagnosis and not specified hematopoietic
__label__0	study interventions are Carboplatin . small cell lung cancer diagnosis and adequate hematologic renal and hepatic function
__label__0	study interventions are Blood collection . pancreatic cancer diagnosis and patient group
__label__0	study interventions are Antibodies, Monoclonal . adenosquamous cell lung cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Melphalan . intraocular lymphoma diagnosis and cardiac ventricular ejection fraction greater_than equal_than fifty by radionuclide ventriculogram or echocardiogram
__label__0	study interventions are Methotrexate . recurrent plasma cell myeloma diagnosis and translocation four 1four
__label__0	study interventions are Doxorubicin . liver cancer diagnosis and at least three weeks since other prior radiotherapy and recovered
__label__0	study interventions are Peginterferon alfa-2b . lymphoma diagnosis and not specified hematopoietic
__label__0	study interventions are Regorafenib/placebo . oalanine transaminase alt and aspartate aminotransferase ast less_than doc uln less_than fivex uln forpatients with liver involvement of their cancer
__label__0	study interventions are Vinblastine . lymphoma diagnosis and fertile patients must use effective contraception during and for six months after study
__label__0	study interventions are Dexamethasone . metastatic cancer diagnosis and unresectable disease or surgery is deemed inappropriate
__label__0	study interventions are Dacarbazine . gliosarcoma diagnosis and bun serum creatinine less_than doc uln
__label__0	study interventions are Cyclophosphamide . transformation to aggressive cell malignancy prolymphocytic leukemia large cell lymphoma hodgkin lymphoma
__label__0	study interventions are Hormones . breast cancer diagnosis and no more than two prior hormonal therapies for metastatic disease
__label__0	study interventions are Cyclophosphamide . glioma diagnosis and patient must have adequate renal function as defined by
__label__0	study interventions are Erlotinib Hydrochloride . adult primary hepatocellular carcinoma diagnosis and no prior surgical therapy affecting absorption
__label__0	study interventions are Lenalidomide . relapsed refractory cell lymphoma diagnosis and fcbp must also agree to monthly pregnancy testing and must be counseled at minimum of every four weeks about pregnancy precautions and risks of fetal exposure
__label__0	study interventions are Fulvestrant . stage iiib breast cancer diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__0	study interventions are Thiotepa . breast cancer diagnosis and age greater_than eighteen years
__label__0	study interventions are Endothelial Growth Factors . stage iiib fallopian tube cancer diagnosis and prior mammalian target of rapamycin mtor inhibitor is allowed
__label__0	study interventions are Albumin-Bound Paclitaxel . urothelial carcinoma diagnosis and females of childbearing potential must have negative pregnancy test within seven days prior to prior to registration for protocol therapy
__label__0	study interventions are Sorafenib . breast cancer diagnosis and women of childbearing potential and men must agree to use adequate contraception barrier method of birth control prior to study entry and for the duration of study participation
__label__0	study interventions are Rituximab . lymphoma diagnosis and patients with known hiv infection are excluded
__label__0	study interventions are Dexamethasone 21-phosphate . liver cancer diagnosis and inr less_than doc or in range inr usually doc
__label__0	study interventions are Cetuximab . recurrent metastatic squamous neck cancer with occult primary diagnosis and clear cell histology
__label__0	study interventions are Poly ICLC . melanoma diagnosis and platelet count greater_than eighty lnine l
__label__0	study interventions are Cyclosporine . stage adult diffuse small cleaved cell lymphoma diagnosis and twenty basophils and or eosinophils in blood
__label__0	study interventions are Erlotinib Hydrochloride . untreated metastatic squamous neck cancer with occult primary diagnosis and no evidence of cns disease including the following part two only
__label__0	study interventions are Acetylcysteine . recurrent adenoid cystic carcinoma of the oral cavity diagnosis and eastern cooperative oncology group ecog performance status ps zero one or two
__label__0	study interventions are Doxorubicin . stage four neuroblastoma diagnosis and patients greater_than equal_than three hundred and sixty-five days initially diagnosed with inss stage one two or fours and who progressed to stage four without interval chemotherapy
__label__0	study interventions are Docetaxel . ovarian mixed epithelial carcinoma diagnosis and serious cardiac arrhythmia requiring medication
__label__0	study interventions are Leucovorin . stage iv rectal cancer diagnosis and may have relapsed within six months of adjuvant therapy with fluorouracil five fu or combination five fu and irinotecan and progressed after single agent irinotecan
__label__0	study interventions are Immunoglobulins . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and not pregnant or nursing
__label__0	study interventions are Afatinib . advanced breast cancer diagnosis and ecog performance score zero one or two
__label__0	study interventions are Everolimus . stage ii small lymphocytic lymphoma diagnosis and only single allele disparity will be allowed for hla b or as defined by high resolution typing
__label__0	study interventions are Everolimus . malignant pancreatic glucagonoma diagnosis and the subject must have an in range inr usually between two and three on stable dose of warfarin or on stable dose of low molecular weight lmw heparin
__label__0	study interventions are Dacarbazine . adult giant cell glioblastoma diagnosis and no concurrent major surgery
__label__0	study interventions are Cisplatin . stage iiib fallopian tube cancer diagnosis and creatinine no greater than the institutional upper limits of normal
__label__0	study interventions are Doxorubicin . glomus tumor of the skin diagnosis and no transfusions are permitted seven days prior to laboratory studies to determine eligibility
__label__0	study interventions are Cytology Specimen Collection Procedure . stage iv prostate cancer diagnosis and bone disease progression defined by two or more new lesions on bone scan
__label__0	study interventions are Antilymphocyte Serum . follicular lymphoma diagnosis and chronic myelogenous leukemia excluding refractory blast crisis
__label__0	study interventions are Immunoglobulin G . stage iiib ovarian cancer diagnosis and creatinine less_than doc normal institutional limits or creatinine clearance greater_than equal_than fifty ml min doc three two for patients with creatinine level above institutional normal based either on cockroft gault estimate or based on urine collection 1two or two4 hour
__label__0	study interventions are Radiopharmaceuticals . solid tumors diagnosis and registered patient at mskcc
__label__0	study interventions are Bevacizumab . stage iiia ovarian cancer diagnosis and known cirrhosis or chronic hepatitis virus hbv or hepatitis virus hcv infection
__label__0	study interventions are Proteasome Inhibitors . multiple myeloma in relapse diagnosis and strong cyponeatwo inhibitors are prohibited
__label__0	study interventions are questionnaire administration . ovarian cancer diagnosis and no previous middle inner_ear operations except grommets and similar procedures and or inability to equalize middle ear pressure
__label__0	study interventions are Albumin-Bound Paclitaxel . pancreatic adenocarcinoma diagnosis and arm cohort three
__label__0	study interventions are Pemetrexed . mesothelioma diagnosis and radiation therapy of thoracocentis tract three sevengy performed before beginning medical study treatment and the interval between thoracoscopic procedure and radiation will not exceed twenty-eight days
__label__0	study interventions are Cetuximab . head and neck cancer diagnosis and no active cardiac disease defined as any of the following
__label__0	study interventions are Bevacizumab . stage pancreatic cancer diagnosis and radiotherapy
__label__0	study interventions are Interleukin-2 . recurrent adult immunoblastic large cell lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Irinotecan . ovarian cancer diagnosis and not specified hematopoietic
__label__0	study interventions are Colonoscopy . colon cancer screening diagnosis and volunteer agrees to undergo the study procedures
__label__0	study interventions are Bortezomib . stage iv adult diffuse large cell lymphoma diagnosis and no significant pulmonary disease requiring oxygen supplementation or causing severe limitation in activity
__label__0	study interventions are Albumin-Bound Paclitaxel . resectable pancreatic cancer diagnosis and patient has an ecog performance status ps zero one
__label__0	study interventions are Octreotide . colorectal cancer diagnosis and other
__label__0	study interventions are Docetaxel . esophageal cancer diagnosis and creatinine normal or creatinine clearance greater_than sixty ml min
__label__0	study interventions are Capecitabine . adenocarcinoma diagnosis and circumferential resection margin less_than one mm involved
__label__0	study interventions are Sorafenib . breast cancer diagnosis and no major surgery or open biopsy within the past four weeks
__label__0	study interventions are Immunoglobulins . ovarian transitional cell carcinoma diagnosis and at least one prior systematic therapy in the metastatic setting
__label__0	study interventions are Imatinib Mesylate . recurrent melanoma diagnosis and creatinine less_than doc times uln
__label__0	study interventions are Immunoglobulins . undifferentiated ovarian carcinoma diagnosis and bilirubin less than or equal to doc uln ctcae grade one
__label__0	study interventions are Bortezomib . recurrent childhood brain stem glioma diagnosis and creatinine clearance or radioisotope gfr greater_than seventy ml min or serum creatinine based on age and or gender as follows
__label__0	study interventions are CT TAP Scan . patients having routine follow up cancer ct tap scan
__label__0	study interventions are Dacarbazine . glioblastoma diagnosis and age eighteen seventy
__label__0	study interventions are questionnaire administration . stage iib breast cancer diagnosis and status post lumpectomy quadrantectomy or mastectomy
__label__0	study interventions are docetaxel . head and neck cancer diagnosis and sgot no greater than two times uln
__label__0	study interventions are Fludarabine phosphate . recurrent adult burkitt lymphoma diagnosis and patients who have received prior allogeneic hsct and who have either rejected their grafts or who have become tolerant of their grafts with no active graft versus host disease gvhd requiring immunosuppressive therapy
__label__0	study interventions are Cyclophosphamide . metastatic cancer diagnosis and lvef greater_than fifty
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and ecog zero two hematopoietic
__label__0	study interventions are Conservative Surgery . tumor diameter less_than equal_than two cm on physical exam imaging studies if performed
__label__0	study interventions are Interleukin-2 . recurrent grade one follicular lymphoma diagnosis and histologically or immunophenotypically proven cdtwenty positive cell lymphoproliferative disorder
__label__0	study interventions are Octreotide . neuroblastoma diagnosis and fresh frozen recommended or paraffin fixed required specimen of primary or metastases available for ribonucleic acid rna and immunohistochemistry ihc
__label__0	study interventions are Mycophenolate mofetil . contiguous stage ii adult diffuse large cell lymphoma diagnosis and patients with renal failure are eligible however patients with renal compromise serum creatinine greater_than doc will likely have further compromise in renal function and may require hemodialysis which may be permanent due to the need to maintain adequate serum tacrolimus levels
__label__0	study interventions are Esmolol . brain tumors diagnosis and adult
__label__0	study interventions are Cyclosporins . recurrent lymphoplasmacytic lymphoma diagnosis and second hematopoietic cell transplant
__label__0	study interventions are Busulfan . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and fevone and dlco corrected must be greater_than equal_than sixty of normal
__label__0	study interventions are Androgens . prostate cancer diagnosis and two successive decreasing serum psa levels less_than equal_than one ng ml
__label__0	study interventions are Ifosfamide . breast cancer diagnosis and measurable disease
__label__0	study interventions are Female ER(+) BC Patients . breast cancer diagnosis and patients must have positive greater_than doc meq l
__label__0	study interventions are Bevacizumab . recurrent lip and oral cavity squamous cell carcinoma diagnosis and patients must not be receiving any other investigational agent while on the study
__label__0	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and life expectancy greater_than three months
__label__0	study interventions are Tremelimumab . malignant glioma diagnosis and prior therapy with gamma_knife or other focal high dose radiotherapy is allowed but the patient must have subsequent histologic documentation of recurrence unless the recurrence occurs remote from the treated site
__label__0	study interventions are Everolimus . stage iiib breast cancer diagnosis and patient meets all sub protocol specific criteria of each applicable sub protocol
__label__0	study interventions are Pharmaceutical Solutions . stage bladder cancer diagnosis and tone high grade disease at the first evaluation following induction bcg alone at least five of six induction doses
__label__0	study interventions are Tissue Collection . ovarian cancer diagnosis and deemed eligible for neo adjuvant chemotherapy with carboplatin and paclitaxel and surgery by their oncologist
__label__0	study interventions are Cetuximab . stage iv verrucous carcinoma of the larynx diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Carboplatin . low grade astrocytoma kernohan grade one two oligodendroglioma mixed oligoastrocytoma ganglioglioma patients with nfone and hypothalamic visual pathway glioma are eligible without biopsy all cns sites are eligible including biopsy proven low grade spinal tumors and intrinsic brain stem tumors no malignant anaplastic glioma kernohan grade three four glioblastoma multiforme and ependymal tumors
__label__0	study interventions are Fludarabine phosphate . stage iv childhood large cell lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Tumor Biopsies . cervical cancer diagnosis and planned treatment with concurrent cisplatinum five fluorouracil chemotherapy and pelvic radiation
__label__0	study interventions are Albumin-Bound Paclitaxel . unspecified adult solid tumor protocol specific diagnosis and no ongoing or active infection
__label__0	study interventions are Isophosphamide mustard . choriocarcinoma diagnosis and platelet count greater_than one hundred zero mm three
__label__0	study interventions are Fludarabine . hematopoietic lymphoid cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Lenograstim . lymphoma diagnosis and all
__label__0	study interventions are Carmustine . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and relapsed or refractory disease after chemotherapy with minimum of one standard regimen
__label__0	study interventions are Camptothecin . recurrent anal cancer diagnosis and no psychiatric illness or social situation that would preclude study entry
__label__0	study interventions are Pharmacogenomic studies . stage iv adult diffuse mixed cell lymphoma diagnosis and prior biologic therapy or prior radiation is permitted however at least twenty-eight days must have elapsed since the completion of prior therapy and patients must have recovered from all therapy associated toxicities to no greater than grade one at the time of registration
__label__0	study interventions are Antibodies . angioimmunoblastic cell lymphoma diagnosis and patients must have southwest oncology group swog performance status of zero one or two
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic melanoma diagnosis and men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment
__label__0	study interventions are Rituximab . follicular lymphoma grade threeb diagnosis and eastern cooperative oncology group performance status less_than two
__label__0	study interventions are Fludarabine . stage iii adult immunoblastic large cell lymphoma diagnosis and patients with aml all or mds scheduled for myeloablative conditioning should have equal_than less_than ten blasts in bone marrow or peripheral blood at the start of conditioning
__label__0	study interventions are Camptothecin . stage ivb rectal cancer diagnosis and no prior stroke
__label__0	study interventions are Vitamin B Complex . histologically or cytologically confirmed stage iiib iv according to ajcc or recurrent non small cell lung cancer nsclc non squamous histologies
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv non small cell lung cancer diagnosis and has not been naturally postmenopausal for at least twenty-four consecutive months has had menses at any time in the preceding twenty-four consecutive months or seven hundred and thirty days
__label__0	study interventions are Prednisolone phosphate . anaplastic large cell lymphoma diagnosis and see disease characteristics
__label__0	study interventions are Interferons . advanced solid tumors diagnosis and patients must have measurable disease per recist criteria v
__label__0	study interventions are Docetaxel . stage iv breast cancer diagnosis and phase i
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and ast and alt not persistently greater than two times normal
__label__0	study interventions are Imatinib Mesylate . stage iv breast cancer diagnosis and no other uncontrolled concurrent illness
__label__0	study interventions are Levoleucovorin . stage iiib gastric cancer diagnosis and total bilirubin less_than doc upper limit of normal
__label__0	study interventions are Cisplatin . cholangiocellular carcinoma diagnosis and adequate hematological values
__label__0	study interventions are Everolimus . prostate cancer diagnosis and understand and voluntarily sign an informed consent form
__label__0	study interventions are Dexamethasone acetate . refractory multiple myeloma diagnosis and absolute neutrophil count anc greater_than equal_than doc ten nine without transfusion support and without hematological growth factor support within two weeks of cycle one day one
__label__0	study interventions are Interleukin-2 . metastatic melanoma diagnosis and patients aged greater_than eighteen years
__label__0	study interventions are Cyclophosphamide . stage ii breast cancer diagnosis and women must not be pregnant or breast feeding due to the potential harmful effects of bevacizumab on the developing fetus all females of childbearing potential must have blood test or urine study within two weeks prior to registration to rule out pregnancy
__label__0	study interventions are Vidarabine . malignant lymphoma large cell type diagnosis and acute myeloid leukemia and acute lymphoblastic leukemia including biphenotypic acute leukemia or mixed lineage leukemia
__label__0	study interventions are Rituximab . lymphoma diagnosis and no expected impairment in bone marrrow reserve meeting any of the following criteria
__label__0	study interventions are questionnaire administration . stage iiia breast cancer diagnosis and dependent on wheelchair for mobility
__label__0	study interventions are Rituximab . bilirubin less_than two mg dl unless related to lymphoma
__label__0	study interventions are immunologic technique . kidney cancer diagnosis and no history of medical or psychiatric disease that would preclude study treatment
__label__0	study interventions are Docetaxel . unspecified adult solid tumor protocol specific diagnosis and anti tb therapy
__label__0	study interventions are Cyclophosphamide . extragonadal germ cell tumor diagnosis and not specified cardiovascular
__label__0	study interventions are Melphalan . stage iii marginal zone lymphoma diagnosis and dyskeratosis
__label__0	study interventions are Tipifarnib . recurrent childhood medulloblastoma diagnosis and fluoxetine
__label__0	study interventions are Bicalutamide . stage iii prostate cancer diagnosis and leukocytes greater_than equal_than three thousand mm ³
__label__0	study interventions are Vincristine . sarcoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate greater_than seventy ml min greater_than forty ml min for infants less_than one year of age
__label__0	study interventions are Cyclosporine . peripheral cell lymphoma diagnosis and must have failed previous myelosuppressive chemotherapy or hsct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Poly I-C . hertwo positive breast cancer diagnosis and white blood cell count wbc greater_than equal_than three thousand mm three
__label__0	study interventions are Isophosphamide mustard . testicular germ cell tumor diagnosis and not pregnant or nursing
__label__0	study interventions are Cyclophosphamide . colorectal cancer diagnosis and ecog performance status zero one
__label__0	study interventions are Etoposide phosphate . testes ovary retroperitoneum mediastinum other sites any stage of disease allowed any histologic subtype allowed seminoma only allowed if ineligible for radiotherapy failed to achieve complete remission cr following at least three courses of standard platinum containing regimen or experienced clear relapse following cr obtained with such regimen absence of tumor markers in the presence of stable residual masses after initial treatment may be allowed surgical biopsy should be performed if medically safe to confirm persistence of disease and rule out mature teratoma or fibrosis prior cns involvement allowed in the absence of gross residual cns tumor following definitive local therapy surgery plus radiotherapy no gross tumor involvement on bone marrow biopsy
__label__0	study interventions are Antibodies, Monoclonal . recurrent salivary gland cancer diagnosis and myocardial infarction within the past twelve months
__label__0	study interventions are Fludarabine phosphate . stage iii adult immunoblastic large cell lymphoma diagnosis and unrelated donors who are prospectively
__label__0	study interventions are Progesterone . leiomyoma diagnosis and no desire for fertility willing to undergo hysterectomy
__label__0	study interventions are siRNA-transfected peripheral blood mononuclear cells APN401 . stage iv melanoma diagnosis and international normalized ratio inr equal_than less_than doc
__label__0	study interventions are Carboplatin . squamous cell carcinoma diagnosis and adult patients greater than eighteen years of age
__label__0	study interventions are Methotrexate . hodgkins lymphoma diagnosis and an hla identical related donor or eight eight matched unrelated donor
__label__0	study interventions are Oxycodone . cancer diagnosis and if subjects are having their first cycle of chemotherapy during the two weeks before the screening visit or during the double blind phase of the study they should be excluded from the study
__label__0	study interventions are laboratory biomarker analysis . stage squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and patients taking cyclooxygenase_cox one cox two inhibitors indomethacin_ibuprofen celebrex_chronically herbal supplements who cannot be taken off the medication supplement due to their clinical condition are eligible to participate in the study but should document daily doses of these medications in their logbooks
__label__0	study interventions are Docetaxel . breast cancer diagnosis and in case of increased creatinine measured calculated gfr must be greater_than fifty ml min
__label__0	study interventions are SBRT . lung cancer diagnosis and negative pregnancy test
__label__0	study interventions are Pentetic Acid . unspecified adult solid tumor protocol specific diagnosis and disease characteristics
__label__0	study interventions are Capecitabine . colorectal cancer diagnosis and no prior diagnosis of interstitial lung disease
__label__0	study interventions are Lenograstim . kidney cancer diagnosis and sgot or sgpt less than doc times uln
__label__0	study interventions are Cytarabine . lymphoma diagnosis and no new york heart association class ii iv heart disease
__label__0	study interventions are Bazedoxifene . breast cancer stage iv diagnosis and placement of non hormonal intrauterine device iud or intrauterine system ius
__label__0	study interventions are Gemcitabine . histological diagnosis of non small cell lung cancer nsclc
__label__0	study interventions are Rituximab . lymphoma diagnosis and however this protocol uses the former terminology
__label__0	study interventions are Gemcitabine . ovarian cancer diagnosis and no history of cns disorder
__label__0	study interventions are Bevacizumab . ovarian mixed epithelial carcinoma diagnosis and no unstable angina or myocardial infarction within the past six months
__label__0	study interventions are Fludarabine . stage iii mantle cell lymphoma diagnosis and mantle cell nh negative may be treated in first cr
__label__0	study interventions are Melphalan . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and donors who have poor peripheral venous access may require central venous line placement for stem cell apheresis
__label__0	study interventions are Gemcitabine . malignant ovarian endometrioid tumor diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Immunoglobulins . ewing sarcoma of bone diagnosis and platelet count greater_than equal_than seventy-five zero µl transfusion independent
__label__0	study interventions are Antibodies, Monoclonal . stage ivb colorectal cancer diagnosis and absolute neutrophil count anc greater_than equal_than doc ten nine greater_than equal_than one thousand, five hundred per mm three
__label__0	study interventions are Romidepsin . adult synovial sarcoma diagnosis and performance status
__label__0	study interventions are Paclitaxel . stage iva uterine sarcoma diagnosis and patients may have received prior adjuvant external beam radiation therapy and or vaginal brachytherapy patients should be at least four weeks from the completion of external beam radiotherapy prior to beginning protocol chemotherapy patients do not need to be delayed if receiving vaginal brachytherapy only
__label__0	study interventions are Gemcitabine . bladder cancer diagnosis and bilirubin no greater than doc times uln
__label__0	study interventions are Docetaxel . breast cancer diagnosis and absolute neutrophil count at least one zero mmthree platelet count at least one00 zero mmthree in patients receiving docetaxel hepatic
__label__0	study interventions are Prednisolone phosphate . adult nasal type extranodal nk cell lymphoma diagnosis and gated pool radionuclide scan fraction must be greater_than equal_than fifty
__label__0	study interventions are Liposomal doxorubicin . childhood alveolar soft part sarcoma diagnosis and negative pregnancy test
__label__0	study interventions are Bicalutamide . stage iv prostate cancer diagnosis and more than four weeks since prior chemotherapy or radiotherapy six weeks for nitrosoureas or mitomycin c
__label__0	study interventions are Cetuximab . recurrent mucoepidermoid carcinoma of the oral cavity diagnosis and no significant traumatic injury within the past twenty-eight days part two only
__label__0	study interventions are Carboplatin . ovarian brenner tumor diagnosis and patients with the following histologic cell types are eligible
__label__0	study interventions are Mechlorethamine . children less_than one year with international neuroblastoma staging system inss stage twoa twob three four or fours disease and mycn amplification greater_than one0 copies or greater than four fold increase in mycn signal as compared to reference signal
__label__0	study interventions are Vidarabine . recurrent adult lymphoblastic lymphoma diagnosis and hematopoietic stem cell co morbidity index equal_than less_than two
__label__0	study interventions are Cisplatin . adenocarcinoma of the gastroesophageal junction diagnosis and platelet count greater_than one hundred ten nine l
__label__0	study interventions are Cortisone acetate . prostate adenocarcinoma diagnosis and patient must have completed any prior treatments apart from androgen deprivation as previously described greater_than equal_than four weeks prior to randomization and have recovered to less_than grade two from any acute toxicities attributed to this prior treatment
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Endothelial Growth Factors . stage iva colon cancer diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt less_than three uln unless patient has metastatic disease to the liver in which case less_than five uln will be allowed
__label__0	study interventions are Irinotecan . pancreatic cancer diagnosis and renal
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and for example one prior line of therapy may consist of all predetermined components of induction followed by autologous stem cell transplantation and maintenance
__label__0	study interventions are Doxorubicin . sarcoma diagnosis and fevone greater than two liters paotwo greater than seventy mm hg on room air pacotwo less than 4two mm hg on room air dlco greater than sixty predicted other
__label__0	study interventions are Mycophenolate mofetil . recurrent grade two follicular lymphoma diagnosis and myelodysplasia mds myeloproliferative syndrome mps patients must have received previous myelosuppressive chemotherapy or hct and have less_than five marrow blasts at time of transplant
__label__0	study interventions are Sunitinib . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and active peptic ulcer disease
__label__0	study interventions are laboratory biomarker analysis . glucagonoma diagnosis and chemotherapy induced alopecia and grade two neuropathy are acceptable
__label__0	study interventions are Mycophenolate mofetil . recurrent mantle cell lymphoma diagnosis and must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Interferons . clear cell renal cell carcinoma diagnosis and serum creatinine equal_than less_than institutional upper limit of normal or calculated creatinine clearance greater_than equal_than sixty ml min for patients with creatinine levels above institutional normal
__label__0	study interventions are adjuvant therapy . lung cancer diagnosis and recovered from prior chemotherapy
__label__0	study interventions are Busulfan . ewing family tumors diagnosis and organ function
__label__0	study interventions are Cetuximab . neoplasm diagnosis and bidimensionally measurable disease
__label__0	study interventions are Bevacizumab . recurrent primary peritoneal carcinoma diagnosis and ability to swallow and retain oral medication
__label__0	study interventions are Lapatinib . recurrent extrahepatic bile duct cancer diagnosis and rifampin
__label__0	study interventions are Oxaliplatin . advanced hepatocellular carcinoma diagnosis and ecog performance score of two or less
__label__0	study interventions are Dexamethasone acetate . refractory plasma cell neoplasm diagnosis and any wbc allowed provided plasma cells greater_than fifty in bone marrow
__label__0	study interventions are Lapatinib . tubular breast cancer stage ii diagnosis and in case of positive bone scan bone ray or ct or mri is mandatory
__label__0	study interventions are Capecitabine . metastatic breast cancer diagnosis and non childbearing potential physiologically_incapable of becoming pregnant because of history of hysterectomy bilateral oophorectomy ovariectomy bilateral tubal ligation or postmenopausal status
__label__0	study interventions are Maleic acid . recurrent laryngeal verrucous carcinoma diagnosis and no concurrent drugs or biologics with proarrhythmic potential
__label__0	study interventions are Imatinib Mesylate . colorectal cancer diagnosis and documentation of wild type ras expression in the liver lesion
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and endocrine therapy
__label__0	study interventions are COXEN . bladder cancer diagnosis and one measurable site of disease according to recist criteria defined as at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded for non nodal lesions and short axis for nodal lesions as more than or equal to twenty mm with conventional techniques or as less than or equal to ten mm with spiral ct scan
__label__0	study interventions are Zoledronic acid . prostate cancer diagnosis and age greater_than eighteen years
__label__0	study interventions are ASLAN001 . gastric neoplasms diagnosis and patients with tumours with immunohistochemical evidence of expression of her one at level of positive or positive or positive and her two at level of positive or positive or positive using standard criteria or tumours with gene amplification of her two by standard fish
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and fifty-nine and under menopausal status
__label__0	study interventions are Mycophenolate mofetil . stage adult burkitt lymphoma diagnosis and donor
__label__0	study interventions are Cyclosporine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and refractory or relapsed aml with equal_than less_than ten bone marrow blasts and no circulating blasts or proven extramedullary disease
__label__0	study interventions are Rituximab . nodal marginal zone cell lymphoma diagnosis and no concurrent chemotherapy
__label__0	study interventions are Carboplatin . large cell lung cancer diagnosis and the following subtypes are eligible
__label__0	study interventions are Cyclophosphamide . recurrent marginal zone lymphoma diagnosis and very high risk pediatric young adult patients with acute myeloid leukemia aml
__label__0	study interventions are Immunoglobulin G . ovarian seromucinous carcinoma diagnosis and capable of understanding the investigational nature potential risks and benefits of the study and able to provide valid informed consent
__label__0	study interventions are Etoposide . localized ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and serum triglyceride level less_than three hundred mg dl and serum cholesterol less_than three hundred mg dl
__label__0	study interventions are Bortezomib . childhood choroid_plexus tumor diagnosis and more than three weeks since prior myelosuppressive chemotherapy six weeks for nitrosourea
__label__0	study interventions are BB 1101 . lymphoma non hodgkin diagnosis and age is less_than twenty-one years participant has not yet reached twenty-twond birthday
__label__0	study interventions are Niacinamide . hepatocellular carcinoma diagnosis and hcc size larger than one cm and less than fifty of total liver volume
__label__0	study interventions are Interferon-alpha . multiple myeloma and plasma cell neoplasm diagnosis and acute lymphoblastic leukemia beyond first remission
__label__0	study interventions are Bevacizumab . stage squamous cell carcinoma of the larynx diagnosis and more than seven days since prior core biopsy
__label__0	study interventions are partial breast irradiation . breast cancer diagnosis and world health organization performance status less_than two
__label__0	study interventions are Carmustine . brain and central nervous system tumors diagnosis and creatinine no greater than doc mg dl above uln other
__label__0	study interventions are Somatostatin . medulloblastoma diagnosis and absolute neutrophil count greater_than one thousand mmthree
__label__0	study interventions are Imatinib Mesylate . primary peritoneal cavity cancer diagnosis and recovered from all prior surgery
__label__0	study interventions are Cediranib . small intestine lymphoma diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Levoleucovorin . gastric cancer diagnosis and measurable disease is defined as greater_than one lesion that can be accurately measured longest diameter to be recorded as greater_than doc cm with conventional techniques or as greater_than doc cm with spiral ct scan
__label__0	study interventions are Sirolimus . stage ii contiguous adult diffuse large cell lymphoma diagnosis and waldenstrom macroglobulinemia must have failed two courses of therapy
__label__0	study interventions are Masitinib . patient with measurable primary tumor lesion using conventional techniques or spiral ct scan assessed before tumor resection
__label__0	study interventions are Bevacizumab . non small cell lung cancer diagnosis and eastern cooperative oncology group ecog performance status ps of less_than one
__label__0	study interventions are Mycophenolic Acid . cutaneous cell non hodgkin lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Leucovorin . histopathological cytological diagnosis of non resectable recurrent or metastatic colorectal cancer
__label__0	study interventions are Thalidomide . contiguous stage ii small lymphocytic lymphoma diagnosis and age greater_than eighteen years
__label__0	study interventions are Antibodies, Monoclonal . stage inverted papilloma of the paranasal sinus and nasal cavity diagnosis and no evidence of active cns hemorrhage
__label__0	study interventions are Hydroxyurea . myelodysplastic myeloproliferative neoplasms diagnosis and concurrent additional hydroxyurea maximum dose of five daily for up to four days allowed between days four and 1five of each study course to control elevated blast levels
__label__0	study interventions are Antibodies, Monoclonal . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and hemoglobin greater_than equal_than doc dl may receive rbc transfusions
__label__0	study interventions are Paclitaxel . esophageal cancer diagnosis and performance status
__label__0	study interventions are Sirolimus . recurrent verrucous carcinoma of the oral cavity diagnosis and hemoglobin greater_than equal_than nine dl
__label__0	study interventions are Gemcitabine . stage iiia non small cell lung cancer diagnosis and surgically resectable disease and patient deemed an appropriate surgical candidate by thoracic surgeon prior to enrollment
__label__0	study interventions are Cisplatin . esophageal cancer diagnosis and patients with primary disease less_than twenty-six cm from the incisors must undergo bronchoscopy and have negative cytology within the past four weeks
__label__0	study interventions are Expanded Prostate Cancer Index Composite Short Form 12 . bladder carcinoma diagnosis and zubrod performance status of less_than one
__label__0	study interventions are Palbociclib . recurrent childhood medulloblastoma diagnosis and doc male doc female
__label__0	study interventions are Immunoglobulins . uterine corpus leiomyosarcoma diagnosis and alkaline phosphatase less than or equal to doc uln per the ctcae version doc grade one
__label__0	study interventions are Fluorouracil . anal cancer diagnosis and other
__label__0	study interventions are Buspirone . unspecified adult solid tumor protocol specific diagnosis and concurrent benzodiazepine medications allowed
__label__0	study interventions are Capecitabine . stage ivb gallbladder cancer diagnosis and patients must have completed any prior chemotherapy at least twenty-one days prior to registration and have recovered from any of the effects and
__label__0	study interventions are Cortisone acetate . stage childhood hodgkin lymphoma diagnosis and stage iia only with bulk disease
__label__0	study interventions are Albumin-Bound Paclitaxel . prostate cancer diagnosis and up to one prior dose of strontium eighty-nine metastron is allowed if given more than twelve weeks prior to study entry
__label__0	study interventions are Sirolimus . unspecified adult solid tumor protocol specific diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Mycophenolate mofetil . plasma cell neoplasms diagnosis and creatinine clearance of greater_than or equal_than sixty ml min
__label__0	study interventions are Rituximab . stage iv grade two follicular lymphoma diagnosis and platelet count greater_than equal_than fifty zero ul
__label__0	study interventions are Antimetabolites . tumors of mixed histology are not allowed
__label__0	study interventions are Prednisone . multiple myeloma diagnosis and patients must not have received platelet transfusions for at least seven days prior to obtaining the screening platelet count
__label__0	study interventions are Gemcitabine . recurrent fallopian tube carcinoma diagnosis and front line treatment may include maintenance therapy following complete clinical or pathological response however maintenance cytotoxic chemotherapy must be discontinued for minimum of six months prior to documentation of recurrent disease patients receiving maintenance biological therapy or hormonal therapy are eligible provided their recurrence is documented more than six months from primary cytotoxic chemotherapy completion includes maintenance chemotherapy and minimum four weeks has elapsed since their last infusion of biological therapy
__label__0	study interventions are Nivolumab . paranasal sinus carcinoma diagnosis and patients must have adequate thyroid function as evidenced by thyroid stimulating hormone tsh free thyroxine tfour serum tests demonstrating values within the normal range within twenty-eight days prior to registration note
__label__0	study interventions are Pharmacological Study . recurrent childhood soft tissue sarcoma diagnosis and myelosuppressive chemotherapy
__label__0	study interventions are Bevacizumab . stage ii endometrial carcinoma diagnosis and no neuropathy greater_than common terminology criteria for adverse events ctcae grade one
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and absolute neutrophil count anc greater_than doc one hundred and nine without the use of growth factors
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and negative pregnancy test
__label__0	study interventions are internet-based intervention . ductal breast carcinoma in situ diagnosis and for the duration of rt participants must have access to an existing broadband internet connection and computer laptop or desktop tablets are not sufficient with full sized computer screen and the following specifications
__label__0	study interventions are Armodafinil . unspecified adult solid tumor protocol specific diagnosis and no history of arrhythmia
__label__0	study interventions are Etoposide . lymphoma diagnosis and favorable prognosis
__label__0	study interventions are Busulfan . stage iv adult cell leukemia lymphoma diagnosis and serum glutamic oxaloacetic transaminase sgot less_than two times the normal or clearance by ccf physician
__label__0	study interventions are Camptothecin . adenocarcinoma of the rectum diagnosis and patients must be fully recovered from any previous surgery at least four weeks from major surgery
__label__0	study interventions are quality-of-life assessment . precancerous condition diagnosis and patient characteristics
__label__0	study interventions are ONC201 . advanced glioblastoma diagnosis and hemoglobin greater_than doc mg dl
__label__0	study interventions are Capecitabine . cancer diagnosis and no prior therapy for metastatic disease is permitted
__label__0	study interventions are BB 1101 . prostate cancer diagnosis and no hypercalcemia albumin corrected calcium greater than uln
__label__0	study interventions are Fludarabine . relapsed or refractory gpcthree positive solid tumors
__label__0	study interventions are Erlotinib Hydrochloride . pancreatic cancer diagnosis and patients who have erlotinib treatment related skin lesions grgreater_than two nci ctc doc
__label__0	study interventions are quality-of-life assessment . hematopoietic lymphoid cancer diagnosis and disease characteristics
__label__0	study interventions are Carboplatin . stage endometrial carcinoma diagnosis and no evidence of metastatic extrauterine disease gross or residual disease not including pelvic nodal disease or distant metastases
__label__0	study interventions are Mycophenolic Acid . stage iv childhood large cell lymphoma diagnosis and fhcrc matching allowed will be grades doc to doc
__label__0	study interventions are Dexamethasone . multiple myeloma and plasma cell neoplasm diagnosis and age
__label__0	study interventions are Thalidomide . malignant conjunctival neoplasm diagnosis and at least four weeks since prior surgery chemotherapy six weeks for mitomycin nitrosoureas or carboplatin hormonal therapy radiotherapy or biological therapy
__label__0	study interventions are placebo . stage verrucous carcinoma of the larynx diagnosis and have no prior history of intolerance or allergy to berry or berry containing products
__label__0	study interventions are questionnaire administration . neuroblastoma diagnosis and diagnosed between twelve twenty-four two hundred negative seven thirty-one two thousand and thirteen
__label__0	study interventions are Temozolomide . recurrent childhood central nervous system neoplasm diagnosis and patients on part and part b
__label__0	study interventions are Thalidomide . multiple myeloma diagnosis and male subjects must agree to use latex condom during sexual contact with females of childbearing potential even if they have had successful vasectomy starting with the first dose of study therapy through one hundred and twenty days after the last dose of study therapy
__label__0	study interventions are Vorinostat . anaplastic large cell lymphoma diagnosis and patients with feeding tubes
__label__0	study interventions are Antibodies . stage iv adult diffuse small cleaved cell lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two
__label__0	study interventions are Vaccines . neuroblastoma diagnosis and male and female sexually active patients of reproductive who wish to participate must agree to use acceptable contraception
__label__0	study interventions are Albumin-Bound Paclitaxel . primary peritoneal carcinoma diagnosis and bilirubin no greater than doc times upper limit of normal uln
__label__0	study interventions are Maleic acid . iris melanoma diagnosis and plateletsgreater_than equal_than one hundred zero mcl
__label__0	study interventions are Cyclophosphamide . prostate cancer diagnosis and no more than two lines of prior chemotherapy
__label__0	study interventions are Cytarabine . plasmablastic lymphoma diagnosis and exceptions can be granted from principal investigator pi for instances of gilbert disease and or primarily indirect bilirubinemia if due to recent transfusion and or hemolysis
__label__0	study interventions are Liposomal doxorubicin . stage iii enteropathy associated cell lymphoma diagnosis and hematoxylin and eosin e stain and immunohistochemistry ihc slides or representative formalin_fixed paraffin_embedded ffpe tissue block along with the pathology report from initial diagnosis as well as eight unstained slides of four micron thickness to store for future ihc and deoxyribonucleic acid dna studies should be sent to be reviewed and the diagnosis confirmed by mayo clinic department retrospective diagnostic review
__label__0	study interventions are Albumin-Bound Paclitaxel . adenosquamous cell lung cancer diagnosis and hemoglobin greater_than equal_than nine mg dl
__label__0	study interventions are Albumin-Bound Paclitaxel . patients must have histologically or cytologically confirmed metastatic or locally advanced and incurable solid tumor that is felt to be appropriate for treatment with one of the three chemotherapy regimens in this study or have progressed despite standard therapy or for whom conventional therapy is not considered effective
__label__0	study interventions are Cyclophosphamide . recurrent grade one follicular lymphoma diagnosis and liver function
__label__0	study interventions are AXL1717 . solid tumors diagnosis and leukocyte count greater_than doc one hundred and nine l
__label__0	study interventions are Fludarabine . granulomatous disease chronic diagnosis and not specified
__label__0	study interventions are Irinotecan . metastatic colorectal cancer diagnosis and adequate liver function
__label__0	study interventions are Carmustine . testicular lymphoma diagnosis and cardiac ventricular ejection fraction greater_than equal_than fifty by radionuclide ventriculogram or echocardiogram
__label__0	study interventions are Busulfan . unspecified childhood solid tumor protocol specific diagnosis and no other existing hla identical related donor available at the time of transplantation
__label__0	study interventions are Vaccines . stage iv uveal melanoma diagnosis and note
__label__0	study interventions are Gemcitabine . hepatocellular carcinoma
__label__0	study interventions are Cytarabine . myeloid sarcoma myeloid proliferations related to down syndrome and blastic_plasmacytoid dendritic cell neoplasm
__label__0	study interventions are Paclitaxel . non small cell lung cancer diagnosis and adequate renal function serum creatinine less_than doc uln or calculated creatinine clearance crcl greater_than sixty ml minute and urine dipstick for protein less_than one positive ie either zero or trace
__label__0	study interventions are Dacarbazine . neuroblastoma diagnosis and other
__label__0	study interventions are Paclitaxel . neoplasms by site diagnosis and one three nzero one mzero
__label__0	study interventions are 3-Iodobenzylguanidine . paraganglioma diagnosis and if no stem cells are available then the dose of one hundred and thirty-onei mibg should be less_than twelve mci kg
__label__0	study interventions are Cytarabine . advanced colorectal cancer diagnosis and women of child bearing potential women who are pre menopausal or not surgically sterile must have negative serum or urine pregnancy test within two weeks prior to cp four thousand and fifty-five treatment
__label__0	study interventions are Paclitaxel . cervical cancer diagnosis and renal
__label__0	study interventions are Cyclosporins . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and any single serologically detectable hla or or antigen positive
__label__0	study interventions are Etoposide . choriocarcinoma diagnosis and must have evidence of progressive or recurrent gct measurable or non measurable following one line of cisplatin based chemotherapy defined as meeting at least one of the following criteria
__label__0	study interventions are Nitrogen Mustard Compounds . stage iv follicular lymphoma diagnosis and hiv one infection as documented by any federally approved licensed hiv rapid test performed in conjunction with screening or enzyme linked_immunosorbent assay elisa test kit and confirmed by western_blot or other approved test alternatively this documentation may include record demonstrating that another physician has documented the participant hiv status based on either
__label__0	study interventions are Capecitabine . unspecified adult solid tumor protocol specific diagnosis and hemoglobin greater than one doc dl
__label__0	study interventions are Topotecan . childhood germ cell tumor diagnosis and two courses of high dose cyclophosphamide as per protocol mskcc 9006two
__label__0	study interventions are Interferon-gamma . melanoma skin diagnosis and pulmonary
__label__0	study interventions are Hormones . breast cancer diagnosis and metastatic her two neu positive disease and planning to receive treatment with neoadjuvant trastuzumab herceptin
__label__0	study interventions are Capecitabine . rectal neoplasms diagnosis and lesions located within twelve cm of the anal verge from colonoscopy assessment
__label__0	study interventions are endoscopic procedure . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and medical history of esophageal dysfunction
__label__0	study interventions are Isophosphamide mustard . stage iia fallopian tube cancer diagnosis and creatinine less than or equal to doc times upper limit of normal uln ctcae doc grade one
__label__0	study interventions are Everolimus . neuroendocrine tumor diagnosis and ecog performance status zero one or two
__label__0	study interventions are Vitamin B Complex . stage iiia breast cancer diagnosis and ihc not done and in situ hybridization non amplified
__label__0	study interventions are azurin-derived cell-penetrating peptide p28 . teratoid tumor atypical diagnosis and karnofsky performance scale kps for greater_than sixteen years yrs of age or lansky performance score lps for equal_than less_than sixteen years of age greater_than equal_than fifty assessed within two weeks prior to registration
__label__0	study interventions are Cetuximab . pancreatic cancer diagnosis and performance status zero two
__label__0	study interventions are Cisplatin . lung cancer diagnosis and other
__label__0	study interventions are Targeted biopsy . men undergoing first time prostate biopsy driven by psa elevation to rule out cancer
__label__0	study interventions are Antibodies . stage childhood anaplastic large cell lymphoma diagnosis and acute lymphocytic leukemia all
__label__0	study interventions are Dacarbazine . recurrent childhood medulloblastoma diagnosis and patients must have received their last dose of nitrosourea including gliadel at least six six weeks prior to study registration
__label__0	study interventions are Albumin-Bound Paclitaxel . subjects must have confirmed pathologic diagnosis of solid tumor that is not curable with available therapy for which hki two hundred and seventy-two plus paclitaxel is reasonable treatment option
__label__0	study interventions are Docetaxel . stage iv ovarian cancer diagnosis and patients must be off all statin drugs for greater_than two weeks prior to initiation of therapy
__label__0	study interventions are Vincristine . stage iii childhood large cell lymphoma diagnosis and no known history of congenital immune deficiency and or laboratory evidence of acquired immune deficiency
__label__0	study interventions are Temozolomide . glioblastoma diagnosis and ability to understand and willingness to sign written informed consent document
__label__0	study interventions are Basiliximab . glioblastoma multiforme diagnosis and hemoglobin greater_than doc dl absolute neutrophil count greater_than one five hundred cells µl platelets greater_than one25 zero cells µl
__label__0	study interventions are O(6)-benzylguanine . childhood oligodendroglioma diagnosis and patients with neurological deficits should have deficits that are stable for minimum of one week prior to study entry
__label__0	study interventions are Docetaxel . at least one evaluable tumor lesion based on recist criteria greater_than equal_than twenty mm with conventional techniques or greater_than equal_than ten mm with spiral computed tomography scan
__label__0	study interventions are Ifosfamide . adult supratentorial primitive neuroectodermal tumor pnet diagnosis and serum glutamic oxaloacetic transaminase sgot aspartate aminotransferase ast or serum glutamate pyruvate transaminase sgpt alanine aminotransferase alt less_than doc upper limit of normal uln for age
__label__0	study interventions are transoral robotic surgery . stage ii mucoepidermoid carcinoma of the oral cavity diagnosis and written informed consent and or consent waiver by institutional review board irb
__label__0	study interventions are Aldesleukin . noncontiguous stage ii grade two follicular lymphoma diagnosis and hemoglobin at least ten dl transfusion allowed
__label__0	study interventions are Mycophenolic Acid . recurrent grade three follicular lymphoma diagnosis and creatinine less_than doc
__label__0	study interventions are Antibodies . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and ast alt no greater than doc times upper limit of normal
__label__0	study interventions are Tacrolimus . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and waldenstrom macroglobulinemia
__label__0	study interventions are Vaccines . stage iv mantle cell lymphoma diagnosis and concurrent enrollment in other clinical trials using an investigational product is prohibited
__label__0	study interventions are Cyclophosphamide . stage ii childhood hodgkin lymphoma diagnosis and no greater than doc mg dl for male patients greater_than equal_than sixteen years of age
__label__0	study interventions are Dexamethasone 21-phosphate . genital neoplasms female diagnosis and the patient must be both chem negative and radiotherapy rt naïve
__label__0	study interventions are Albumin-Bound Paclitaxel . pancreatic cancer unresectable diagnosis and less than grade two pre existing peripheral neuropathy
__label__0	study interventions are Laboratory Biomarker Analysis . stage zerois bladder urothelial carcinoma diagnosis and ability to understand and the willingness to sign written informed consent
__label__0	study interventions are Vitamins . prostate cancer diagnosis and no major illness including psychiatric illness that would preclude study compliance and follow up
__label__0	study interventions are mHealth Intervention . breast neoplasms diagnosis and life expectancy
__label__0	study interventions are Cisplatin . non small cell lung cancer diagnosis and no previous chest radiotherapy immunotherapy or biotherapy
__label__0	study interventions are Palbociclib . advanced malignant neoplasm diagnosis and unstable angina pectoris or coronary angioplasty or stenting within six months prior to registration to step zero
__label__0	study interventions are Usual care + acupuncture . breast cancer diagnosis and current chemotherapy at mammazentrum hamburg with regimen fec doc or ec doc
__label__0	study interventions are Cyclophosphamide . patient having antecedent of other cancer exception for in situ uterine cervix or basocellular skin cancer considered as healed
__label__0	study interventions are Busulfan . regional neuroblastoma diagnosis and age twelve eighteen months three hundred and sixty-five five hundred and forty-seven days with any of the following three unfavorable biologic features mycn amplification unfavorable pathology and or deoxyribonucleic acid dna index equal_than one or any biologic feature that is indeterminant unsatisfactory unknown
__label__0	study interventions are Tacrolimus . recurrent mantle cell lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Carboplatin . cancer diagnosis and absolute neutrophil count greater than one thousand mmthree
__label__0	study interventions are Fludarabine . melanoma skin diagnosis and eighteen and over
__label__0	study interventions are antineoplaston A10 . liver cancer diagnosis and bilirubin less than three mg dl
__label__0	study interventions are Prednisolone acetate . stage ii childhood large cell lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are placebo . breast cancer diagnosis and patient reported occurrence at least fourteen times per week and of sufficient severity to make the patient desire therapeutic intervention
__label__0	study interventions are Interleukin-2 . metastatic melanoma diagnosis and evidence of personally signed and dated ethics committee approved informed consent form indicating that the patient or legally acceptable representative has been informed of all pertinent_aspects of the study
__label__0	study interventions are Cyclin-Dependent Kinase Inhibitor Proteins . recurrent extragonadal germ cell tumor diagnosis and the subject has adequate organ function defined as follows a
__label__0	study interventions are Pemetrexed . lung cancer diagnosis and negative pregnancy test
__label__0	study interventions are Sirolimus . recurrent uterine corpus sarcoma diagnosis and selective internal radiation therapy brachytherapy radiolabeled_microsphere embolization etc
__label__0	study interventions are laboratory biomarker analysis . stage iv verrucous carcinoma of the larynx diagnosis and dyspnea less_than grade two at rest on room air
__label__0	study interventions are Endothelial Growth Factors . stage iiib breast cancer diagnosis and total bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Lenalidomide . small intestine cancer diagnosis and see endocrine therapy
__label__0	study interventions are Vincristine . recurrent lymphoblastic lymphoma diagnosis and arm a
__label__0	study interventions are management of therapy complications . unspecified adult solid tumor protocol specific diagnosis and able and willing to attend the hospital for four one hour sessions
__label__0	study interventions are Temozolomide . pancreatic alpha cell carcinoma diagnosis and patients must have given signed informed consent prior to registration on study
__label__0	study interventions are Nitrogen Mustard Compounds . follicular lymphoma diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred cells mm three for five days after recovery from asct nadir
__label__0	study interventions are Cyclophosphamide . melanoma diagnosis and six weeks must have elapsed since prior cytotoxic lymphocyte antigen four anti ctlafour antibody therapy to allow antibody levels to decline and patients who have previously received must have normal colonoscopy with normal colonic biopsies
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and laboratory parameters
__label__0	study interventions are Podophyllotoxin . recurrent adult diffuse large cell lymphoma diagnosis and research participant without clinically significant encephalopathy new focal deficits
__label__0	study interventions are Lenograstim . clear cell sarcoma diagnosis and adequate cardiac function defined as
__label__0	study interventions are Cyclophosphamide . testicular germ cell tumor diagnosis and mediastinum
__label__0	study interventions are Bevacizumab . recurrent squamous cell carcinoma of the hypopharynx diagnosis and more than four weeks since prior immunotherapy
__label__0	study interventions are Capecitabine . metastatic breast cancer diagnosis and screening of patients currently treated with second line chemotherapy should have stable disease
__label__0	study interventions are Antibodies . stage iii multiple myeloma diagnosis and bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Bevacizumab . stage ii rectal cancer diagnosis and bilirubin normal unless chronic grade one bilirubin elevation due to gilbert disease or similar syndrome due to slow_conjugation of bilirubin
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and epidermal growth factor receptor egfr and or erbbtwo positivity not required
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and cardiovascular
__label__0	study interventions are FACBC . breast cancer diagnosis and patients must be able to provide written informed consent
__label__0	study interventions are Antibodies . endometrial clear cell carcinoma diagnosis and inadequately controlled hypertension defined as systolic bp blood pressure greater_than one hundred and fifty mm hg and or diastolic bp greater_than ninety mm hg on antihypertensive medications
__label__0	study interventions are Lapatinib . head and neck cancer diagnosis and pregnant women are excluded due to the potential for teratogenic or abortifacient effects of capecitabine and lapatinib because there is potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents breastfeeding should be discontinued prior to participation of the mother on study
__label__0	study interventions are Trastuzumab . stage iib breast cancer diagnosis and estrogen receptor er and progesterone receptor pgr status must be known
__label__0	study interventions are Docetaxel . lung cancer diagnosis and patient characteristics
__label__0	study interventions are Antibodies, Monoclonal . recurrent neuroblastoma diagnosis and able to comply with safety monitoring requirements of study
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and patients with stable disease are eligible provided the largest residual nodal mass is approximately less_than five cm largest residual mass must represent five0 reduction and be approximately less_than doc cm for patients who have responded to prior therapy
__label__0	study interventions are Dacarbazine . childhood solid neoplasm diagnosis and stem cell infusions with or without total body irradiation tbi
__label__0	study interventions are Methylprednisolone acetate . small intestine lymphoma diagnosis and patients treated previously with radiation therapy in excess of one thousand cgy rads to any thoracic or abdominal port or in excess of three thousand cgy rads to cranial spinal ports who are not eligible for other protocols are eligible for this study
__label__0	study interventions are Lapatinib . advanced cancers diagnosis and total bilirubin less_than equal_than threex uln alt sgpt less_than equal_than eightx uln
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and total bilirubin less_than upper limit of normal uln serum albumin greater_than doc dl alanine aminotransferase alt and aspartate aminotransferase ast less_than doc uln
__label__0	study interventions are Gemcitabine . nasopharyngeal neoplasms diagnosis and measurable disease based on recist doc
__label__0	study interventions are Methylprednisolone acetate . recurrent adult cell leukemia lymphoma diagnosis and this protocol will allow the use of donors who are unrelated but are hla b d dr identical and mlc mixed lymphocyte culture compatible
__label__0	study interventions are Antibodies . stage iii lymphoepithelioma of the nasopharynx diagnosis and no significant ongoing or active infection
__label__0	study interventions are Fluorouracil . recurrent colon cancer diagnosis and ecog zero two
__label__0	study interventions are Fludarabine . recurrent adult diffuse large cell lymphoma diagnosis and patients with hematologic malignancies treatable with hct will be included
__label__0	study interventions are Antineoplaston therapy (Atengenal + Astugenal) . anaplastic astrocytoma diagnosis and at least four weeks since prior chemotherapy six weeks for nitrosoureas and recovered
__label__0	study interventions are Bexarotene . lymphoma diagnosis and age
__label__0	study interventions are Vaccines . stage iia ovarian cancer diagnosis and gastrointestinal
__label__0	study interventions are VMAT (Volumetric Modulated Arc Therapy) . positive cancer diagnosis
__label__0	study interventions are Fluorouracil . stage iv squamous cell carcinoma of the nasopharynx diagnosis and no concurrent hematologic growth factors filgrastim csf darbepoetin alfa epoetin_alfa during study chemoradiotherapy
__label__0	study interventions are Paclitaxel . fallopian tube mucinous adenocarcinoma diagnosis and an approved informed consent and authorization permitting release of personal health information must be signed by the patient or guardian
__label__0	study interventions are Mycophenolic Acid . stage iii multiple myeloma diagnosis and highly active antiretroviral therapy haart is initiated within one month of hematopoietic cell transplant
__label__0	study interventions are Everolimus . unspecified adult solid tumor protocol specific diagnosis and standard curative or palliative measures do not exist or are no longer effective
__label__0	study interventions are Immunoglobulins . malignant neoplasm diagnosis and evidence of metastatic disease
__label__0	study interventions are Sirolimus . stage ivb bladder cancer diagnosis and international normalized ratio inr equal_than less_than doc uln
__label__0	study interventions are Bortezomib . recurrent grade three follicular lymphoma diagnosis and patients must have eastern cooperative oncology group ecog american college of radiology imaging network acrin performance status of equal_than less_than two
__label__0	study interventions are Bevacizumab . stage iv lymphoepithelioma of the nasopharynx diagnosis and not pregnant or nursing
__label__0	study interventions are Vaccinia virus (vvDD-CDSR) . melanoma diagnosis and the ability to understand and willingness to sign written informed consent
__label__0	study interventions are Antibodies . cancer diagnosis and no other primary malignancy within the past three years except for the following
__label__0	study interventions are Vaccines . oropharyngeal cancer diagnosis and eleven fourteen years of age with no prior hpv vaccine doses administered
__label__0	study interventions are Vorinostat . adult anaplastic astrocytoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Vaccines . metastatic malignant neoplasm in the soft tissues diagnosis and patients may or may not have been treated previously with nonsteroidal antiandrogen for patients previously treated with an antiandrogen they must be off use of anti androgen for at least four weeks for flutamide or six weeks for bicalutamide or nilutamide prior to registration moreover subjects who demonstrate an anti androgen withdrawal response defined as greater_than equal_than twenty-five decline in psa within four six week of stopping nonsteroidal antiandrogen are not eligible until the psa rises above the nadir observed after antiandrogen withdrawal
__label__0	study interventions are Temozolomide . brain and central nervous system tumors diagnosis and hemoglobin at least ten dl
__label__0	study interventions are Cyclophosphamide . peritoneal cavity cancer diagnosis and recurrent relapsed or persistent disease meeting one or more of the following criteria
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiia breast cancer diagnosis and hormone receptor status
__label__0	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the oropharynx diagnosis and bepridil
__label__0	study interventions are Paclitaxel . sarcoma diagnosis and not specified
__label__0	study interventions are Temozolomide . lymphomas diagnosis and ast sgot alt sgpt less than three institutional upper limit of normal doc uln in cases of liver metastases
__label__0	study interventions are Cisplatin . metastatic melanoma diagnosis and no known hiv positive
__label__0	study interventions are Beta Carotene . colorectal cancer diagnosis and disease characteristics
__label__0	study interventions are Methotrexate . breast cancer diagnosis and performance status
__label__0	study interventions are Capecitabine . cancer diagnosis and must have performance status of at least seventy able to carry on most normal activities
__label__0	study interventions are Mitoxantrone . lymphoblastic lymphoma diagnosis and cytotoxic therapy
__label__0	study interventions are Questionnaire Administration . stage iic colorectal cancer diagnosis and ability to understand and the willingness to sign and informed consent document in english
__label__0	study interventions are Mebendazole . low grade glioma diagnosis and all clinical and laboratory studies to determine eligibility must be performed within seven days prior to enrollment unless otherwise indicated in the eligibility section
__label__0	study interventions are Camptothecin . recurrent colon cancer diagnosis and ecog zero two
__label__0	study interventions are ALT803 . hodgkin lymphoma diagnosis and all previous chemotherapy or radiation must be completed at least three weeks prior to study entry
__label__0	study interventions are breast duct lavage . breast cancer diagnosis and not specified
__label__0	study interventions are Laboratory Biomarker Analysis . recurrent solid neoplasm diagnosis and previously radiated lesions that have not demonstrated clear progression post radiation
__label__0	study interventions are Antibodies . recurrent adult diffuse small cleaved cell lymphoma diagnosis and patients must have relapsed or primary refractory lymphoid malignancy including cell cell or hodgkins disease or untreated nhl or mcl
__label__0	study interventions are Endothelial Growth Factors . recurrent melanoma diagnosis and measurable disease defined as greater_than one lesion that can be accurately measured in greater_than one dimension as greater_than twenty mm with conventional techniques or greater_than one0 mm with spiral ct scan
__label__0	study interventions are Ibrutinib . lymphoma diagnosis and anc greater_than equal_than one zero platelets greater_than equal_than seventy-five zero
__label__0	study interventions are Vaccines . penile cancer diagnosis and calculated creatinine clearance greater_than sixty ml min
__label__0	study interventions are HPPH . stage ii verrucous carcinoma of the oral cavity diagnosis and patients must have an eastern cooperative oncology group ecog performance status of zero two
__label__0	study interventions are Erlotinib Hydrochloride . adult glioblastoma diagnosis and no peripheral neuropathy greater_than grade one for patients receiving sorafenib and tipifarnib
__label__0	study interventions are Pemetrexed . histologically confirmed non small cell lung cancer with at least one site of disease greater_than one cm by at least one type of standard imaging ct chest ray mri
__label__0	study interventions are N-monoacetylcystine . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and initiation of investigational agent equal_than less_than three days after initiation of radiotherapy
__label__0	study interventions are Antibodies, Monoclonal . tongue cancer diagnosis and creatinine equal_than less_than doc uln
__label__0	study interventions are Aldesleukin . stage iii multiple myeloma diagnosis and achievement of partial remission or greater more than seventy-five reduction in serum paraprotein for patients transplanted in relapse
__label__0	study interventions are Levoleucovorin . stage iiia esophageal cancer diagnosis and patients or their legal representatives must be able to read understand provide and sign informed consent to participate in the trial
__label__0	study interventions are Cyclosporine . recurrent small lymphocytic lymphoma diagnosis and this protocol will allow the use of donors who are unrelated but are hla b d dr identical and mlc mixed lymphocyte culture compatible
__label__0	study interventions are Cyclophosphamide . multiple myeloma refractory diagnosis and patients must have received at least two prior lines of therapy and also must be refractory to lenalidomide
__label__0	study interventions are PSMA/PRAME . anal carcinoma diagnosis and eighteen years of age or older advanced refractory solid malignancy that is histologically proven measurable disease ecog performance status of zero one or two adequate bone marrow reserve as evidenced by absolute neutrophil count anc equal_than one fivezerozero microl platelet count equal_than onezerozero zerozerozero microl adequate renal and hepatic function as evidenced by serum creatinine equal_than doc mg dl serum total bilirubin equal_than doc mg dl alkaline phosphatase equal_than threex the uln for the reference lab equal_than five the uln for the reference lab for subjects with known hepatic metastases sgot sgpt equal_than threex the uln for the reference lab equal_than five the uln for the reference lab for subjects with known hepatic metastases
__label__0	study interventions are computed tomography . recurrent squamous cell carcinoma of the nasopharynx diagnosis and proteinuria equal_than less_than one positive on two consecutive dipsticks taken greater_than equal_than one week apart
__label__0	study interventions are Mitogens . stage iiia breast cancer diagnosis and note
__label__0	study interventions are Vidarabine . contiguous stage ii grade three follicular lymphoma diagnosis and patients in crtwo prtwo with initial short remission less_than six months are eligible
__label__0	study interventions are Pharmacological Study . stage iiib skin melanoma diagnosis and absolute neutrophil count greater_than one zero mcl
__label__0	study interventions are Tremelimumab . bladder cancer diagnosis and evidence of disease recurrence within one year of previous bcg treatment
__label__0	study interventions are Cetuximab . lung cancer diagnosis and no other concurrent immunotherapy
__label__0	study interventions are Cortisone . recurrent lymphoblastic lymphoma diagnosis and imatinib imatinib mesylate positive
__label__0	study interventions are Bevacizumab . recurrent squamous cell carcinoma of the nasopharynx diagnosis and at least four weeks since prior major surgery
__label__0	study interventions are Thalidomide . recurrent adult immunoblastic lymphoma diagnosis and more than four weeks since prior chemotherapy excluding steroids radiotherapy or radioimmunoconjugate therapy six weeks for nitrosoureas or mitomycin and recovered
__label__0	study interventions are Combretastatin . cancer diagnosis and normal ejection fraction
__label__0	study interventions are Sunitinib . glioblastoma multiforme diagnosis and premenopausal women must have negative human chorionic gonadotropin within fourteen days prior to registration
__label__0	study interventions are Mycophenolic Acid . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and patient and donor pairs_homozygous at mismatched allele in the graft rejection_vector are considered two allele mismatch the patient is one hundred and one and the donor is two hundred and one and this type of mismatch is not allowed
__label__0	study interventions are Nivolumab . stage iv skin melanoma diagnosis and patients with human immunodeficiency virus hiv infection are ineligible
__label__0	study interventions are Calcium, Dietary . head and neck cancer diagnosis and serum alanine aminotransferase alt less_than equal_than five upper limit of normal
__label__0	study interventions are Romidepsin . stage ivb colorectal cancer diagnosis and bilirubin equal_than less_than upper limit of normal uln and aspartate aminotransferase ast equal_than less_than uln
__label__0	study interventions are Irinotecan . lymphoma diagnosis and not specified
__label__0	study interventions are Irinotecan . metastatic colorectal cancer diagnosis and male patients must be surgically sterile or if sexually active and having pre menopausal partner must be using an acceptable method of contraception
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic pancreatic cancer diagnosis and no previous radiotherapy unless at least one measurable target lesion outside the irradiation zone
__label__0	study interventions are Carboplatin . recurrent solid neoplasm diagnosis and sterilization
__label__0	study interventions are Antibodies . stage iv skin melanoma diagnosis and no hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies infliximab
__label__0	study interventions are Immunoglobulins . adult mixed glioma diagnosis and in range inr usually between two and three and patient is on stable dose of oral anticoagulant for one week or on stable dose of low molecular weight heparin
__label__0	study interventions are Mycophenolate mofetil . stage iv adult diffuse small cleaved cell lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Surgery . non small cell lung cancer diagnosis and for women of childbearing potential serum or urine pregnancy test must be negative within seventy-two hours prior to registration
__label__0	study interventions are Maleic acid . localized unresectable adult primary liver cancer diagnosis and serious or non healing wound skin ulcers or bone fracture
__label__0	study interventions are Sunitinib . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and no pulmonary embolism within the past twelve months
__label__0	study interventions are Doxorubicin . prostate cancer diagnosis and radiotherapy
__label__0	study interventions are Busulfan . multiple myeloma and plasma cell neoplasm diagnosis and agnogenic myeloid metaplasia
__label__0	study interventions are Cetuximab . stage iii verrucous carcinoma of the larynx diagnosis and concurrent use of medications known to affect the conductive system beta blockers calcium channel blockers or digoxin allowed under investigator supervision
__label__0	study interventions are Pertuzumab . breast cancer diagnosis and patients who are er pr positive or negative are eligible
__label__0	study interventions are immunohistochemistry staining method . melanoma skin diagnosis and more than four weeks since prior immunotherapy biologic therapy or radiotherapy
__label__0	study interventions are Imiquimod . metastatic cancer diagnosis and stage iv disease without observable surgically unresectable metastases beyond the immediate treatment site allowed
__label__0	study interventions are therapeutic allogeneic lymphocytes . recurrent childhood large cell lymphoma diagnosis and refractory acute myelogenous or lymphoid leukemia
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and new york heart association class iii or iv heart failure
__label__0	study interventions are Antibodies, Monoclonal . adenocarcinoma of the prostate diagnosis and no recent within twelve months arterial thrombotic events including transient ischemic attack tia cerebrovascular accident cva unstable angina or angina requiring surgical or medical intervention in the past twelve months or myocardial infarction mi patients with clinically significant peripheral artery disease claudication on less than one block or any other arterial thrombotic event are also ineligible
__label__0	study interventions are Aprepitant . stage iii squamous cell carcinoma of the nasopharynx diagnosis and planned definitive or adjuvant radiation with concurrent cisplatin one hundred mg mtwo every three weeks for three cycles
__label__0	study interventions are Vinblastine . recurrent small cell lung cancer diagnosis and female patients must not be pregnant due to the potential mutagenicity and teratogenicity of this treatment pregnancy test must be administered seven days prior to administration of therapy to women of childbearing potential patients must agree to use some form of contraception while on this study at initiation and for the duration of participation in the study sexually active males must also use reliable and appropriate method of contraception post menopausal women must be amenorrheic for at least twelve months to be considered of nonchildbearing potential
__label__0	study interventions are Etoposide . peripheral cell lymphoma diagnosis and life expectancy greater_than eight weeks
__label__0	study interventions are Cyclosporine . multiple myeloma diagnosis and eight estimated creatinine clearance greater_than fifty ml min
__label__0	study interventions are Standard Chemotherapy . metastatic colo rectal cancer diagnosis and non resectable liver metastases
__label__0	study interventions are Dexamethasone . multiple myeloma and plasma cell neoplasm diagnosis and patients who have previously failed treatment with doxorubicin hcl_liposome vincristine and dexamethasone vad are allowed if anthracycline therapy has been at least six months and prior anthracycline exposure no greater than three hundred mg mtwo no other concurrent chemotherapy endocrine therapy
__label__0	study interventions are Liposomal doxorubicin . ovarian neoplasms diagnosis and eastern cooperative oncology group ecog performance score zero orone
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and not specified life expectancy
__label__0	study interventions are Cyclophosphamide . multiple myeloma and plasma cell neoplasm diagnosis and no active congestive heart failure
__label__0	study interventions are Vaccines . ovarian cancer diagnosis and absolute lymphocyte count greater_than five hundred mmthree
__label__0	study interventions are SBRT . histological confirmation of non small cell lung cancer will be required by either biopsy or cytology
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and serum bilirubin less_than doc uln
__label__0	study interventions are Lenograstim . lymphoma diagnosis and normal cytogenetic study on bone marrow prior to salvage chemotherapy or stem cell collection
__label__0	study interventions are Isophosphamide mustard . lymphoma diagnosis and at least twenty-five blasts in bone marrow
__label__0	study interventions are Antibodies . stage iii adult diffuse large cell lymphoma diagnosis and has not been naturally postmenopausal for at least twelve consecutive months has had menses at any time in the preceding twelve consecutive months
__label__0	study interventions are Methotrexate . stage iv breast cancer diagnosis and hematocrit hct greater_than equal_than thirty
__label__0	study interventions are Endothelial Growth Factors . stage iv salivary gland cancer diagnosis and no prior fluorouracil and hydroxyurea with radiotherapy
__label__0	study interventions are Ifosfamide . stage iii adult soft tissue sarcoma diagnosis and no concurrent sedating drugs
__label__0	study interventions are Staurosporine . recurrent gallbladder cancer diagnosis and progesterone receptor negative
__label__0	study interventions are Fludarabine . metastatic non small cell lung cancer diagnosis and patients with surgically resected brain metastases are eligible
__label__0	study interventions are Niacinamide . recurrent adult diffuse large cell lymphoma diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to sorafenib
__label__0	study interventions are Sorafenib . patients with history of malignancy are eligible provided they have been curatively treated demonstrate no evidence for recurrence of that cancer
__label__0	study interventions are Proteasome Inhibitors . unspecified adult solid tumor protocol specific diagnosis and no concurrent cytochrome pfour hundred and fifty enzyme inducing antiepileptic drugs phenytoin carbamazepine and phenobarbital rifampin or hypericum_perforatum st
__label__0	study interventions are Everolimus . metastatic renal cell cancer diagnosis and prior therapy with cytokines il two interferon and or vegf ligand inhibitors bevacizumab is permitted
__label__0	study interventions are Liposomal doxorubicin . endometrial cancer diagnosis and disease characteristics
__label__0	study interventions are Temozolomide . melanoma skin diagnosis and renal
__label__0	study interventions are Cyclophosphamide . stage iiia breast cancer diagnosis and iia iib iiia iiib or iiic patients with stage iv disease are also eligible if there is an intention to perform breast surgery after neoadjuvant therapy is completed or in patients participating in clinical trials where surgery after neoadjuvant therapy may be an option eg
__label__0	study interventions are Methylprednisolone Hemisuccinate . unspecified childhood solid tumor protocol specific diagnosis and cw eight
__label__0	study interventions are Paclitaxel . stage iiic uterine corpus cancer diagnosis and cardiac ejection fraction must be within the institutional range of normal as measured by left ventricular ejection fraction lvef testing note that baseline and on treatment scans should be performed using the same modality and preferably at the same institution
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and no active serious infection
__label__0	study interventions are selumetinib . metastatic extrahepatic bile duct cancer diagnosis and no prior akt inhibitors or mitogen activated protein kinase kinase mek inhibitors allowed
__label__0	study interventions are Tamoxifen . recurrent breast cancer diagnosis and hertwo neu positive three positive by immunohistochemical ihc assay or fluorescent in situ hybridization fish
__label__0	study interventions are Lenograstim . relapsed cell lymphoblastic lymphoma diagnosis and at least six weeks must have elapsed since administration of nitrosureas
__label__0	study interventions are Laboratory Biomarker Analysis . stage ivb cervical cancer diagnosis and group a
__label__0	study interventions are Soblidotin . unspecified adult solid tumor protocol specific diagnosis and eighteen and over
__label__0	study interventions are Methotrexate . nonmalignant neoplasm diagnosis and ast less_than three times upper limit of normal
__label__0	study interventions are Sub Study - 18 FHBG PET/CT Scans . multiple myeloma diagnosis and women of child bearing potential must have an additional negative high sensitivity pregnancy test twentymlu hcg ml urine as administered in the center for clinical imaging research mallinckrodt institute of radiology washington university prior to each imaging session at days ten sixteen and days twenty-seven thirty-three
__label__0	study interventions are Antibodies . stage iia fallopian tube cancer diagnosis and if patient declines to participate in the perfusion imaging portion of the protocol clinical rationale for declination of imaging form will be completed as part of the data submission for acrin six thousand, six hundred and ninety-five
__label__0	study interventions are Liposomal doxorubicin . hodgkin lymphoma diagnosis and these patients if presenting with supradiaphragmatic disease would therefore be assessed as having stage iii disease and would be ineligible
__label__0	study interventions are Dexamethasone acetate . lymphoma diagnosis and no severe immunodeficiency
__label__0	study interventions are Vidarabine . noncutaneous extranodal lymphoma diagnosis and low grade nhl
__label__0	study interventions are Doxorubicin . endometrial cancer diagnosis and who zero two
__label__0	study interventions are Ixazomib . multiple myeloma diagnosis and patients that were on carfilzomib containing regimens must have received at least six doses of at least twenty-seven mg mtwo in no more than two8 days per cycle
__label__0	study interventions are Etoposide phosphate . bronchoalveolar cell lung cancer diagnosis and no metastatic disease involving the contralateral chest liver or adrenals confirmed by ct scan of the upper abdomen or by chest ct scan with complete liver and adrenals in the report
__label__0	study interventions are Gemcitabine . transitional cell carcinoma of bladder diagnosis and no congestive heart failure less_than six months
__label__0	study interventions are Paclitaxel . unspecified adult solid tumor protocol specific diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Vincristine . mantle cell lymphoma diagnosis and measurable or evaluable disease at least one site with greater_than doc cm in diameter
__label__0	study interventions are Methylprednisolone acetate . recurrent marginal zone lymphoma diagnosis and al negative second remission crtwo or subsequent remission
__label__0	study interventions are Immunoglobulin Idiotypes . lymphoma diagnosis and meets one of the following criteria
__label__0	study interventions are Prednisolone hemisuccinate . neuroblastoma diagnosis and at least three months hematopoietic
__label__0	study interventions are Tamoxifen . stage ii breast cancer diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred
__label__0	study interventions are antineoplaston AS2-1 . ovarian cancer diagnosis and no renal insufficiency
__label__0	study interventions are assessment of therapy complications . prostate cancer diagnosis and must be able to tolerate transrectal ultrasound trus
__label__0	study interventions are Fludarabine . stage iii grade one follicular lymphoma diagnosis and donor
__label__0	study interventions are Fludarabine . contiguous stage ii mantle cell lymphoma diagnosis and fhcrc matching allowed will be grade doc to doc
__label__0	study interventions are Gemcitabine . splenic marginal zone lymphoma diagnosis and recovered from prior therapy
__label__0	study interventions are Palbociclib . participants must have demonstrated ability to tolerate endocrine therapy by prior successful completion of at least one month of tamoxifen or aromatase inhibitor ai therapy without significant adverse events and in the opinion of the treating physician any ongoing toxicity does not preclude ability to continue on tamoxifen or ai for at least projected two year continuous duration
__label__0	study interventions are Talazoparib . triple negative breast cancer diagnosis and females of childbearing potential must have negative serum pregnancy test at screening and be willing to have additional serum pregnancy tests during the study females considered not of childbearing potential include those who have been in menopause at least two years or had tubal ligation at least one year prior to screening or who have had total hysterectomy
__label__0	study interventions are Antibodies . fallopian tube endometrioid adenocarcinoma diagnosis and patients who have met the pre entry requirements
__label__0	study interventions are Immunoglobulins . stage iii salivary gland cancer diagnosis and peripheral vascular disease greater_than grade ii
__label__0	study interventions are Etoposide . prostate cancer diagnosis and chemotherapy
__label__0	study interventions are Oxaliplatin . colorectal carcinoma diagnosis and patients must have failed prior standard curative chemotherapy for their disease refuse existing therapies or the proposed chemotherapy regimen to which amten is added represents an acceptable standard treatment for their disease
__label__0	study interventions are Vorinostat . stage iv adult burkitt lymphoma diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Vincristine . untreated childhood medulloblastoma diagnosis and no metastatic disease in the head spine or cerebrospinal fluid csf confirmed by both of the following
__label__0	study interventions are Aminopterin . hepatosplenic cell lymphoma
__label__0	study interventions are cognitive assessment . unspecified adult solid tumor protocol specific diagnosis and disease characteristics
__label__0	study interventions are Liposomal doxorubicin . stage iv grade three follicular lymphoma diagnosis and ecog ps zero two
__label__0	study interventions are Paclitaxel . advanced cancers diagnosis and patients should not become pregnant or breast feed while on this study
__label__0	study interventions are Cyclosporins . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and adults must have dlcova greater_than sixty normal
__label__0	study interventions are Prednisolone . recurrent mantle cell lymphoma diagnosis and patients or bone marrow donors who are htlv iii hiv antibody positive are ineligible for this study
__label__0	study interventions are Carboplatin . fallopian tube cancer diagnosis and not specified
__label__0	study interventions are Estradiol . breast neoplasms diagnosis and able to understand and willing to sign an irb approved written informed consent document
__label__0	study interventions are Antibodies . stage iv major salivary gland carcinoma diagnosis and alkaline phosphatase must be within the range allowing for eligibility
__label__0	study interventions are Lenograstim . recurrent childhood ependymoma diagnosis and adequate bone marrow function as evidenced by platelet count greater_than fifty zero ul and absolute granulocyte count greater_than equal_than 7fifty ul
__label__0	study interventions are Alvocidib . stage iv mantle cell lymphoma diagnosis and previously untreated or relapsed refractory disease
__label__0	study interventions are Methotrexate . breast cancer diagnosis and wbc greater_than two five hundred mm³
__label__0	study interventions are DTRMWXHS-12 . b cell lymphomas diagnosis and neutrophils greater_than doc one hundred and nine according to the investigators opinion if they judge that the patients neutrophil count lower than this threshold which caused by chronic lymphocytic leukemia and bone marrow infiltration those patients are eligible to be included
__label__0	study interventions are Gemcitabine . stage ivb nasopharyngeal carcinoma diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred cells mm three
__label__0	study interventions are Vitamin B 12 . tumor biopsy will be requested from all study subjects unless the procedure poses too great risk
__label__0	study interventions are Thalidomide . stage iv melanoma diagnosis and lesions situated in previously irradiated area unless new growth is documented
__label__0	study interventions are Fluorouracil . stage iii rectal cancer diagnosis and at least two weeks since prior radiotherapy and recovered
__label__0	study interventions are Freund's Adjuvant . melanoma diagnosis and inhaled steroids advair flovent azmacort are not permitted
__label__0	study interventions are Behavioral dietary intervention . lobular breast carcinoma in situ diagnosis and hepatic insufficiency resulting in clinical jaundice and or coagulation defects note however that laboratory tests for liver function and coagulation parameters are not required for entry into this protocol
__label__0	study interventions are Vincristine . recurrent adult diffuse large cell lymphoma diagnosis and platelets greater_than equal_than fifty zero ul
__label__0	study interventions are Antibodies, Monoclonal . small intestinal squamous cell carcinoma diagnosis and patients must have adequate adrenal axis function as evidenced by adrenocorticotropic hormone acth values within the normal ranges within twenty-eight days prior to registration
__label__0	study interventions are Fludarabine phosphate . neuroblastoma diagnosis and ast less than five times the upper limit of normal
__label__0	study interventions are Bortezomib . multiple myeloma diagnosis and all baseline studies must be performed within twenty-one days of enrollment
__label__0	study interventions are Levoleucovorin . gastric cancer diagnosis and ast and alt less_than doc times upper limit of normal
__label__0	study interventions are Endothelial Growth Factors . localized non resectable adult liver carcinoma diagnosis and capable of understanding the investigational nature potential risks and benefits of the study and able to provide valid informed consent
__label__0	study interventions are Irinotecan . adenocarcinoma of the colon diagnosis and documented progression of disease or intolerable toxicity during or within three months of receiving this regimen
__label__0	study interventions are Aromatase Inhibitors . hertwo positive circulating tumor cells diagnosis and patient must consent in maintaining such contraception until two8 days after completion of study treatment
__label__0	study interventions are Liposomal doxorubicin . long term effects secondary to cancer therapy in adults diagnosis and able to read and speak english
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and age greater_than eighteen years
__label__0	study interventions are Doxorubicin . inflammatory breast cancer diagnosis and ast no greater than two times uln
__label__0	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and hepatic
__label__0	study interventions are Carboplatin . recurrent marginal zone lymphoma diagnosis and bone marrow may be used in conjunction with blood progenitor cells
__label__0	study interventions are Dasatinib . extragonadal germ cell tumor diagnosis and see disease characteristics
__label__0	study interventions are Bortezomib . ovarian cancer diagnosis and total bilirubin less_than doc times upper limit of normal uln
__label__0	study interventions are Thalidomide . stage iii multiple myeloma diagnosis and at least four weeks since prior chemotherapy or radiotherapy and recovered
__label__0	study interventions are Oxaliplatin . recurrent malignant extragonadal germ cell tumor diagnosis and patients who have undergone local treatment for brain metastases and whose brain metastases are demonstrated to be stable by repeat imaging studies performed greater_than four weeks after treatment are eligible
__label__0	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and topical inhaled and intra articular corticosteroids are allowed
__label__0	study interventions are Capecitabine . gastroesophageal junction adenocarcinoma diagnosis and eastern cooperative oncology group ecog performance status of zero or one within three days prior to first dose of study medication
__label__0	study interventions are Prednisolone hemisuccinate . lymphoma diagnosis and creatinine clearance or glomerular filtration rate greater than fifty of lower limit of normal
__label__0	study interventions are Dacarbazine . malignant melanoma diagnosis and creatinine less_than doc mg dl
__label__0	study interventions are Gemcitabine . stage iii urethral cancer diagnosis and total bilirubin less_than doc times the upper limit of normal uln for the institution
__label__0	study interventions are 3-dimensional conformal radiation therapy . endometrial cancer diagnosis and no prior radiation therapy to the pelvis
__label__0	study interventions are Vincristine . stage iv grade one follicular lymphoma diagnosis and these lab values must be obtained within four weeks prior to protocol entry patients with documented marrow involvement at the time of registration are not required to meet the hematologic parameters above
__label__0	study interventions are Docetaxel . hertwo negative breast cancer diagnosis and if tissue is not available the patient will still be eligible for enrollment to the study
__label__0	study interventions are Maytansine . bone marrow infiltration except that detected by metaiodobenzylguanidine_mibg scan for neuroblastoma
__label__0	study interventions are Immunoglobulins . stage ivb major salivary gland carcinoma diagnosis and no curative intent therapy available there is no limit on prior number of therapies prior epidermal growth factor receptor egfr directed therapy tyrosine kinase inhibitors and monoclonal antibodies
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian mucinous cystadenocarcinoma diagnosis and no circumstances that would prohibit completion of study therapy or required follow up
__label__0	study interventions are Gemcitabine . adenocarcinoma of the pancreas diagnosis and ecog zero two life expectancy
__label__0	study interventions are Apatinib . histologically proven progressive gastric cancer
__label__0	study interventions are Isotretinoin . stage fours neuroblastoma diagnosis and doc mg dl greater_than ten and equal_than less_than fifteen years of age
__label__0	study interventions are Leucovorin . stage ivb colon cancer diagnosis and platelets plt greater_than equal_than one hundred ten nine without transfusions
__label__0	study interventions are Tamoxifen . stage iiic breast cancer diagnosis and estrogen receptor positive disease is defined as greater_than ten nuclear staining
__label__0	study interventions are Levoleucovorin . signet ring adenocarcinoma of the rectum diagnosis and group ii
__label__0	study interventions are Gemcitabine . metastatic breast cancer diagnosis and calculated creatinine clearance greater_than equal_than thirty ml min using the formula
__label__0	study interventions are Docetaxel . breast cancer diagnosis and patient characteristics
__label__0	study interventions are Immunoglobulin G . adult giant cell glioblastoma diagnosis and willing to discontinue use of medications that inhibit platelet function greater_than equal_than ten days prior to registration aspirin at doses greater than three hundred and twenty-five mg day must be discontinued greater_than equal_than ten days prior to registration and avoided through the study note
__label__0	study interventions are Alemtuzumab . recurrent refractory childhood hodgkin lymphoma diagnosis and must have received prior chemotherapy and prior autologous transplant unless autologous transplant was not possible planned tandem transplants are allowed for patients at high risk of relapse
__label__0	study interventions are Vincristine . adult rhabdomyosarcoma diagnosis and no prior radiotherapy
__label__0	study interventions are Gemcitabine . recurrent primary peritoneal cancer diagnosis and serum glutamic oxaloacetic transaminase sgot serum glutamate pyruvate transaminase sgpt less_than doc institutional upper limit of normal uln
__label__0	study interventions are Doxorubicin . response assessment in neuro oncology rano criteria or macdonald criteria should be used for cns tumors
__label__0	study interventions are Methotrexate . figo stage iii gestational_trophoblastic tumor diagnosis and for the purposes of this study patients must have undergone evacuation of complete or partial hydatidiform mole and then meet the criteria for gtn defined as
__label__0	study interventions are Immunoglobulins . undifferentiated ovarian carcinoma diagnosis and albumin
__label__0	study interventions are Antibodies, Monoclonal . fallopian tube mucinous adenocarcinoma diagnosis and neuropathy sensory and motor less than or equal to ctcae grade one
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and any stage disease
__label__0	study interventions are Fluorouracil . stage ivc major salivary gland carcinoma diagnosis and maximum of one prior radiotherapy regimen curative or palliative to the head and neck is allowed if the radiation is combined with chemotherapy and or cetuximab minimum of four months must elapse between the end of radiotherapy and registration if the radiation is given alone minimum of eight weeks must elapse between the end of radiotherapy and registration minimum of three weeks must elapse between prior radiation to other areas and registration
__label__0	study interventions are Akt Inhibitor MK2206 . recurrent adult diffuse large cell lymphoma diagnosis and no patients with malabsorption syndrome or other condition that would interfere with intestinal absorption
__label__0	study interventions are Endothelial Growth Factors . advanced solid tumors diagnosis and hemoglobin level greater_than ninegm dl
__label__0	study interventions are Cisplatin . stage ib cervical cancer diagnosis and study enrollment within eight weeks of diagnosis
__label__0	study interventions are Placebo . ewing sarcomas diagnosis and patients must have measurable disease
__label__0	study interventions are Vaccines . undifferentiated fallopian tube carcinoma diagnosis and computed tomography ct abdomen pelvis demonstrating no radiological evidence of disease performed after completion of chemotherapy equal_than less_than twenty-eight days before entering study
__label__0	study interventions are Dexamethasone 21-phosphate . splenic marginal zone lymphoma diagnosis and world health organization who classification of patients malignancies must be provided
__label__0	study interventions are Fludarabine . recurrent adult cell leukemia lymphoma diagnosis and total bilirubin within normal institutional limits unless the patient has gilbert disease
__label__0	study interventions are Trastuzumab . stage iiic breast cancer diagnosis and negative
__label__0	study interventions are Vorinostat . recurrent adult diffuse small cleaved cell lymphoma diagnosis and no other concurrent investigational agents
__label__0	study interventions are 7-hydroxystaurosporine . recurrent non small cell lung cancer diagnosis and part closed to accrual as of six eight two thousand and seven
__label__0	study interventions are Antibodies . lymphoma diagnosis and at least four weeks since prior corticosteroids
__label__0	study interventions are Therapeutic Conventional Surgery . anal squamous cell carcinoma diagnosis and one five hundred mm three
__label__0	study interventions are Cisplatin . patients with inoperable lung carcinoma and or recurrent disease
__label__0	study interventions are Consultation, evaluation questionnaire . sarcoma diagnosis and aged eighteen sixty-nine years case population
__label__0	study interventions are Bortezomib . small intestine lymphoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are Methylprednisolone acetate . myeloma diagnosis and adequate hepatic function with bilirubin less_than doc the upper limit of normal uln and ast and alt less_than doc uln
__label__0	study interventions are Pemetrexed . subjects with resected primary tumors who have documented metastases are eligible
__label__0	study interventions are Liposomal doxorubicin . classical hodgkin lymphoma diagnosis and karnofsky performance status greater_than thirty given the aggressiveness of this disease and the often severely debilitated nature of the patients at initial presentation
__label__0	study interventions are Aldesleukin . kidney cancer diagnosis and disease characteristics
__label__0	study interventions are Metronidazole . stage iv prostate cancer diagnosis and patient must have metastatic disease as evidenced by the presence of soft tissue and or bone metastases on imaging studies computed tomography ct of abdomen pelvis bone scintigraphy
__label__0	study interventions are Liposomal doxorubicin . advanced adult hepatocellular carcinoma diagnosis and women who are pregnant should not go on study women should not breastfeed while participating in this study
__label__0	study interventions are Carboplatin . progression will be defined according to the revised response criteria for malignant lymphoma cheson two thousand and seven thirty-three
__label__0	study interventions are Antibodies . fallopian tube transitional cell carcinoma diagnosis and only applies for patients who elect to receive bevacizumab
__label__0	study interventions are Radiosurgery (SRS) . tumors metastatic to brain diagnosis and patients have five or more brain metastases or patients have any brain metastases exceeding the limit for srs maximum diameter is greater_than four cm
__label__0	study interventions are Tamoxifen . recurrent ovarian carcinoma diagnosis and albumin greater_than equal_than doc dl
__label__0	study interventions are Albumin-Bound Paclitaxel . head and neck cancer diagnosis and hematopoietic
__label__0	study interventions are Caspofungin . neuroblastoma diagnosis and endocrine therapy
__label__0	study interventions are Quality-of-Life Assessment . stage iib colorectal cancer diagnosis and there are no restrictions related to performance status or life expectancy
__label__0	study interventions are Antibodies, Monoclonal . lymphoma large cell diffuse diagnosis and central radiographic review of the ct scans chest abdomen pelvis and if applicable neck from before and after first line treatment with chop fulfilling the radiological requirements for cr cru
__label__0	study interventions are Fluorouracil . localized resectable adult primary liver cancer diagnosis and hematopoietic
__label__0	study interventions are Caspofungin . kidney cancer diagnosis and fertile patients must use effective contraception other than or in addition to oral contraceptives
__label__0	study interventions are Etoposide phosphate . diffuse large cell lymphoma relapsed refractory diagnosis and adequate peripheral blood stem cell collection with cdthirty-four cell dose greater_than two one hundred and six kg actual body weight
__label__0	study interventions are Methotrexate . lymphoblastic lymphoma diagnosis and acute lymphoblastic leukemia pro common pre early thymic mature t
__label__0	study interventions are Selenium . unspecified adult solid tumor protocol specific diagnosis and prior concurrent therapy
__label__0	study interventions are Histone Deacetylase Inhibitors . advanced breast cancer diagnosis and women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation
__label__0	study interventions are Cetuximab . stage iii squamous cell carcinoma of the oropharynx diagnosis and refractory to interleukin two il two
__label__0	study interventions are Succinylcholine . stage iva oropharyngeal squamous cell carcinoma diagnosis and zubrod performance status of zero one within fifty-six days prior to registration
__label__0	study interventions are Sirolimus . refractory hodgkin lymphoma diagnosis and patients must have less_than five marrow blasts at time of transplant
__label__0	study interventions are Mitomycin . malignant mesothelioma diagnosis and hepatic
__label__0	study interventions are Bortezomib . childhood central nervous system yolk_sac tumor diagnosis and no known hypersensitivity to vorinostat or bortezomib
__label__0	study interventions are Everolimus . brain and central nervous system tumors diagnosis and alt less_than five times uln
__label__0	study interventions are Leucovorin . stage iic colon cancer diagnosis and new york heart association nyha class iii or iv congestive heart failure
__label__0	study interventions are Chemoembolization . hepatocellular carcinoma diagnosis and platelet count greater_than seventy-five zero mmthree
__label__0	study interventions are Quality-of-Life Assessment . metastatic malignant neoplasm in the bone diagnosis and femur
__label__0	study interventions are Mycophenolic Acid . stage marginal zone lymphoma diagnosis and patients equal_than less_than fifty years of age who have received previous high dose transplantation do not require patient review committee approvals all children less_than twelve years must be discussed with the fhcrc principal investigator pi brenda_sandmaier md two hundred and six six million, six hundred and seventy-four thousand, nine hundred and sixty-one prior to registration
__label__0	study interventions are Everolimus . spindle cell rhabdomyosarcoma diagnosis and stage one group ii
__label__0	study interventions are Trametinib . adult cholangiocarcinoma diagnosis and must not have active hepatitis virus hbv or hepatitis virus hcv infection patients with chronic or cleared hbv and hcv infection are eligible
__label__0	study interventions are azurin-derived cell-penetrating peptide p28 . choroid_plexus neoplasms diagnosis and doc mg dl
__label__0	study interventions are Cyclophosphamide . recurrent adult soft tissue sarcoma diagnosis and research blood including forty ml of blood in heparinized tube for peripheral blood mononuclear cell pbmc collection and ten ml of blood for serum collection generally in red top tube within thirty days of leukapheresis collection
__label__0	study interventions are Tegafur . advanced hepatocellular carcinoma diagnosis and serum creatinine less_than doc upper limit
__label__0	study interventions are Niacinamide . insular thyroid cancer diagnosis and at least one unidimensionally measurable lesion greater_than equal_than twenty mm by conventional techniques or greater_than equal_than one0 mm by spiral ct scan
__label__0	study interventions are Everolimus . mri of brain will be used for baseline assessment and tumor response assessment for cns lesions
__label__0	study interventions are Cisplatin . unspecified adult solid tumor protocol specific diagnosis and more than twelve months since prior coronary peripheral artery bypass graft surgery
__label__0	study interventions are Prednisone . advanced castrate resistant prostate cancer crpc diagnosis and who ecog performance status zero to one with no deterioration over the previous two weeks and min life expectancy of onetwo weeks
__label__0	study interventions are Sirolimus . diffuse large cell lymphoma diagnosis and eastern cooperative oncology group ecog performance status less_than two
__label__0	study interventions are Fludarabine phosphate . childhood immunoblastic large cell lymphoma diagnosis and must have failed two lines of conventional therapy and be refractory to fludarabine
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and seven consecutive days of steroids alone or in combination with non chop regimen necessary for patient stabilization cyclophosphamide and steroids steroids for normalization of disease related hyperbilirubinemia
__label__0	study interventions are Imatinib Mesylate . gastrointestinal stromal tumors gists diagnosis and adequate hepatic function with serum total bilirubin less_than doc uln alanine aminotransferase alt or aspartate aminotransferase ast less_than doc uln in the absence of liver metastases or less_than five unl in the presence of liver metastases
__label__0	study interventions are polymerase chain reaction . unspecified adult solid tumor protocol specific diagnosis and bone lesions
__label__0	study interventions are Melphalan . multiple myeloma and plasma cell neoplasm diagnosis and biologic therapy
__label__0	study interventions are Cyclosporins . patients less_than fifty years of age with nhl hodgkin disease hd cll or multiple myeloma at high risk of regimen related toxicity through prior autologous transplant or through pre existing medical conditions
__label__0	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and no concurrent therapeutic anticoagulation except prophylactic warfarin one mg day
__label__0	study interventions are Vaccines . melanoma skin diagnosis and endocrine therapy
__label__0	study interventions are Vaccines . lung cancer diagnosis and bilirubin less than doc mg dl renal
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and biologic therapy
__label__0	study interventions are Testosterone enanthate . prostate cancer diagnosis and condom with spermicidal foam_gel film_cream suppository barrier method of contraception surgical sterilization vasectomy with documentation of azospermia and barrier method condom used with spermicidal foam_gel fil cream suppository the female partner uses oral contraceptives combination estrogen progesterone pills injectable progesterone or subdermal implants and barrier method condom used with spermicidal foam_gel film_cream suppository
__label__0	study interventions are Antibodies . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and creatinine clearance greater_than sixty ml min
__label__0	study interventions are Trastuzumab . stage ia breast cancer diagnosis and if the ihc staining intensity is reported as range zero to one positive or one positive to two positive the higher intensity score in the range should be used to determine eligibility
__label__0	study interventions are Carboplatin . recurrent squamous cell carcinoma of the nasopharynx diagnosis and subjects must in the opinion of the investigator be capable of complying with this protocol
__label__0	study interventions are Vaccinia virus (vvDD-CDSR) . liver cancer diagnosis and anticipated survival of at least sixteen weeks
__label__0	study interventions are Laboratory Biomarker Analysis . stage zero breast cancer diagnosis and willing and able to schedule mastectomy four weeks positive
__label__0	study interventions are Edotreotide . gastrointestinal carcinoid tumor diagnosis and not pregnant or nursing
__label__0	study interventions are AZD5363 . adenocarcinoma of the prostate diagnosis and patients should have received at least twelve weeks of enzalutamide outside of the trial with evidence of disease progression by psa with three rising values as per pcwgtwo criteria or soft tissue progression as per recist doc
__label__0	study interventions are Antibodies, Monoclonal . stage iv grade one follicular lymphoma diagnosis and patients must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide ibrutinib or other agents used in study
__label__0	study interventions are Cyclophosphamide . breast cancer metastatic diagnosis and at least one unidimensionally measurable lesion according to recist criteria version doc
__label__0	study interventions are Beclomethasone . stage iv adult diffuse large cell lymphoma diagnosis and treatment with rabbit_antithymocyte globulin or alemtuzumab within three months before the date of hct
__label__0	study interventions are Cyclophosphamide . up to two prior non taxane chemotherapy regimens for metastatic disease are permitted for patients enrolled on the phase portion of the trial patients with hertwo neu positive breast cancer are not eligible patients treated with prior anthracycline therapy as neoadjuvant adjuvant or metastatic therapy are not eligible unless the following conditions are met
__label__0	study interventions are Vinblastine . adult lymphocyte depletion hodgkin lymphoma diagnosis and creatinine equal_than less_than doc times upper limit of normal uln
__label__0	study interventions are Interleukin-2 . stage iiib melanoma diagnosis and willing and able to give written informed consent
__label__0	study interventions are Etoposide . lymphoma diagnosis and adequate venous access for peripheral apheresis or consent to use temporary central venous catheter for apheresis
__label__0	study interventions are Arsenic trioxide . kidney cancer diagnosis and not specified performance status
__label__0	study interventions are Dacarbazine . metastatic cancer diagnosis and no other serious concurrent disease that is in the opinion of the investigator likely to interfere with study evaluation and treatment
__label__0	study interventions are radiation therapy . lymphoma diagnosis and not specified
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and patients with performance status of zero two zubrod scale
__label__0	study interventions are Fludarabine phosphate . squamous cell carcinoma diagnosis and more than two weeks must have elapsed since any prior palliation for major bronchial occlusion or bleeding at the time the patient receives the preparative regimen and patient toxicities must have recovered to grade one or less
__label__0	study interventions are Etoposide . myelodysplastic myeloproliferative neoplasms diagnosis and myeloproliferative disorders
__label__0	study interventions are isosulfan blue . colorectal cancer diagnosis and no history of crohn disease chronic ulcerative colitis or familial polyposis
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and eighteen and over performance status
__label__0	study interventions are Gemcitabine . absence of pr negative or per operative macroscopic tumoral thrombus
__label__0	study interventions are Cisplatin . biliary cancer diagnosis and patients must have adequate bone marrow absolute neutrophil count greater_than one five hundred mmthree platelet count greater_than one00 zero mmthree and renal function serum creatinine less_than doc five uln
__label__0	study interventions are Erlotinib Hydrochloride . stage iv pancreatic cancer diagnosis and ecog zero two
__label__0	study interventions are Everolimus . unspecified adult solid tumor protocol specific diagnosis and fasting triglycerides less_than four hundred mg dl
__label__0	study interventions are Capecitabine . pancreatic cancer diagnosis and has undergone surgery with radical intent rzero or rone within the past two months
__label__0	study interventions are Prednisolone phosphate . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and hepatic transaminases less_than four upper limit normal uln total bilirubin less_than doc mg dl unless the patient has history of benign congenital hyperbilirubinemia gilbert syndrome
__label__0	study interventions are Fibrin Tissue Adhesive . vulvar cancer diagnosis and disease characteristics
__label__0	study interventions are Azacitidine . small cell lung cancer diagnosis and females of childbearing potential fcbp may participate providing the subject meets the following conditions
__label__0	study interventions are Alovudine . stage ii squamous cell carcinoma of the lip and oral cavity diagnosis and absolute granulocyte count agc greater_than equal_than two thousand cells mm three
__label__0	study interventions are Paclitaxel . stage ivc verrucous carcinoma of the larynx diagnosis and serum creatinine equal_than less_than doc mg dl or institutional upper limit of normal
__label__0	study interventions are Stem cell transplantation . non hodgkin lymphoma diagnosis and prior chemotherapy
__label__0	study interventions are Immunoglobulins . stage iv ovarian cancer diagnosis and serious cardiac arrhythmia requiring medication
__label__0	study interventions are Bortezomib . recurrent childhood central nervous system embryonal tumor diagnosis and at least three months since prior stem cell transplantation or rescue and no evidence of active graft vs host disease
__label__0	study interventions are Irinotecan . stage iv ampulla of vater cancer diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than doc times upper limit of normal
__label__0	study interventions are Doxorubicin . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and all patients and or their parents or legal guardians must sign written informed consent assent when appropriate will be obtained according to institutional guidelines
__label__0	study interventions are Pembrolizumab . melanoma diagnosis and if there is only one measurable lesion and it is located in previously irradiated field it must have demonstrated unequivocal progression according to recist version doc
__label__0	study interventions are Pazopanib Hydrochloride . metastatic renal cell cancer diagnosis and agrees to use adequate contraception acceptable contraceptive methods when used consistently and in accordance with both the product label and the instructions of the physician are as follows
__label__0	study interventions are Sunitinib . recurrent verrucous carcinoma of the larynx diagnosis and inr and ptt ratio less_than doc
__label__0	study interventions are Pharmacological Study . stage iv breast cancer diagnosis and note
__label__0	study interventions are Ifosfamide . rhabdomyosarcoma diagnosis and arm c
__label__0	study interventions are Belinostat . neoplasms diagnosis and patients must have recovered to at least eligibility levels due to adverse events and or toxicity of prior chemotherapy or biologic therapy
__label__0	study interventions are Cyclophosphamide . stage adult diffuse mixed cell lymphoma diagnosis and patients with bone marrow involvement are allowed at the investigator discretion regardless of cytopenias
__label__0	study interventions are Bortezomib . colorectal cancer diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Prednisolone . lymphoma diagnosis and ast less than twice normal in the absence of liver involvement
__label__0	study interventions are Lenograstim . recurrent adult immunoblastic large cell lymphoma diagnosis and karnofsky performance status of seventy to one hundred
__label__0	study interventions are Bevacizumab . non small cell lung cancer diagnosis and ast sgot and alt sgpt within normal limits wnl
__label__0	study interventions are Celecoxib . stage iv renal cell cancer diagnosis and platelets greater_than equal_than seventy-five zero ml
__label__0	study interventions are Palbociclib . stage iii extragonadal seminoma diagnosis and disease characteristics
__label__0	study interventions are Antibodies . testicular embryonal carcinoma and teratoma with seminoma diagnosis and or cytogenetic persistence evidenced by any phone positive metaphases in bone marrow after day ninety post ahsct
__label__0	study interventions are Epothilone B . stage iii bladder cancer diagnosis and no prior systemic biologic response modifier therapy
__label__0	study interventions are assessment of therapy complications . ovarian cancer diagnosis and nausea vomiting or diarrhea
__label__0	study interventions are Bortezomib . primary peritoneal cavity cancer diagnosis and no myocardial infarction within the past six months
__label__0	study interventions are Tacrolimus . stage cutaneous cell non hodgkin lymphoma diagnosis and known intolerance to bdp
__label__0	study interventions are Adjuvants, Immunologic . fallopian tube cancer diagnosis and stable complete clinical remission is defined as stable caone hundred and twenty-five less_than thirty-fiveu ml defined as caone hundred and twenty-five that has not doubled from the post chemotherapy nadir unremarkable physical examination and no definite evidence of disease by computed tomography ct of the abdomen and pelvis
__label__0	study interventions are Liposomal doxorubicin . sarcoma diagnosis and no prior biologic therapy
__label__0	study interventions are Antibodies . breast cancer diagnosis and age
__label__0	study interventions are Etoposide . recurrent childhood anaplastic large cell lymphoma diagnosis and serum bilirubin less_than doc mg dl
__label__0	study interventions are Palbociclib . breast cancer stage iv diagnosis and only patients who have biopsy inaccessible disease may enter the study without the requirement for baseline biopsy
__label__0	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and female or male patients with at least eighteen years at the time the informed consent is signed
__label__0	study interventions are Haploidentical/cord transplant . hodgkin or non hodgkin lymphom negative disease recurrence following an autologous transplant or high risk disease not thought to benefit from autologous transplant
__label__0	study interventions are Liposomal doxorubicin . stage iv adult hodgkin lymphoma diagnosis and histologic diagnosis of cdthirty positive classical hl as defined by the two thousand and eight who classification of hematological diseases
__label__0	study interventions are Melphalan . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and donor
__label__0	study interventions are recombinant human interleukin-21 . at least three months since prior adjuvant immunotherapy for recurrent melanoma
__label__0	study interventions are Gemcitabine . histologically or cytologically proven carcinoma of the pancreas that is locally advanced
__label__0	study interventions are Fludarabine . recurrent renal cell cancer diagnosis and donor
__label__0	study interventions are Epirubicin . soft tissue primitive neuroectodermal tumor pnet
__label__0	study interventions are Dacarbazine . adult glioblastoma diagnosis and patients must have karnofsky performance status of greater_than equal_than sixty
__label__0	study interventions are Aldesleukin . stage iii adult diffuse mixed cell lymphoma diagnosis and ecog zero one
__label__0	study interventions are Vorinostat . adult brain tumor diagnosis and medically acceptable contraceptives include
__label__0	study interventions are Flutamide . adenocarcinoma of the prostate diagnosis and no chronic renal failure
__label__0	study interventions are Proteasome Inhibitors . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Cyclophosphamide . stage ii childhood hodgkin lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two at time of consent
__label__0	study interventions are Trastuzumab . advanced cancers diagnosis and signed informed consent approved by the institutional review board prior to patient entry
__label__0	study interventions are Calcium, Dietary . childhood central nervous system germ cell tumor diagnosis and peripheral absolute neutrophil count anc greater_than one zero mm three
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and patients must have performance status of zero two based on swog criteria
__label__0	study interventions are Bevacizumab . stage iv renal cell cancer diagnosis and no immunotherapy within four weeks of randomization toxicities from immunotherapy must have resolved and minimum of two weeks must pass prior to enrollment
__label__0	study interventions are Standard IMRT . prostate adenocarcinoma diagnosis and willingness to fill out quality of life forms
__label__0	study interventions are Antibodies, Monoclonal . stage four neuroblastoma diagnosis and age six to less_than ten years
__label__0	study interventions are Androgens . prostatic neoplasm diagnosis and extensive metabolizer by cyptwodsix genotyping
__label__0	study interventions are Antifungal Agents . a woman must agree not to donate eggs ova oocytes for the purposes of assisted reproduction during the study period and until the menstrual period following the end of study treatment
__label__0	study interventions are F-18 Fluorothymidine . mouth neoplasms diagnosis and platelets greater_than one hundred zero µl
__label__0	study interventions are Carboplatin . splenic marginal zone lymphoma diagnosis and hematologic malignancy patients with human immunodeficiency virus hiv positivity but on appropriate anti retroviral therapy may go_autotransplant with the following laboratory tests cdfour positive cell count greater_than seventy-five cells per microliter and hiv copy number less_than one hundred zero per microliter and with infectious disease clearance
__label__0	study interventions are Carboplatin . soft tissue sarcoma diagnosis and increase of an elevated ldh alone does not constitute progressive disease
__label__0	study interventions are Levoleucovorin . stage iiic colon cancer diagnosis and absolute neutrophil count anc greater_than equal_than lfive hundred ul
__label__0	study interventions are Dacarbazine . patients with newly diagnosed with high grade glioma grade three or four having completed surgery
__label__0	study interventions are natural killer T cell . colorectal cancer diagnosis and no chemotherapy and radiation therapy to be planned recently
__label__0	study interventions are Carboplatin . large cell lung cancer diagnosis and no abnormal corneal sensitivity test schirmer test or similar tear_production test
__label__0	study interventions are Pembrolizumab . mucosal melanoma diagnosis and international normalized ratio inr or prothrombin time pt less_than doc uln unless subject is receiving anticoagulant therapy as long as pt or partial thromboplastin time ptt is within therapeutic range of intended use of anticoagulants
__label__0	study interventions are Etoposide . diffuse large cell lymphoma relapsed diagnosis and prothrombin time pt and activated partial thromboplastin time aptt must be less_than doc the upper limit of the normal range uln
__label__0	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and threex uln alt and less_than doc total serum bilirubin unless there is congenital benign hyperbilirubinemia
__label__0	study interventions are Rituximab . recurrent grade two follicular lymphoma diagnosis and or
__label__0	study interventions are Folic Acid . stage iia ovarian cancer diagnosis and capable of understanding the investigative nature potential risks and benefits of the study and capable of providing valid informed consent
__label__0	study interventions are Vincristine . stage iv adult diffuse large cell lymphoma diagnosis and in calculating days of tests and measurements the day test or measurement is done is considered day zero therefore if test is done on monday the monday four weeks later would be considered day twenty-eight this allows for efficient patient scheduling without exceeding the guidelines
__label__0	study interventions are Bevacizumab . prostate cancer diagnosis and creatinine ratio upc equal_than less_than doc at screening
__label__0	study interventions are Paclitaxel . metastatic breast cancer diagnosis and absolute neutrophil count anc greater_than one five hundred mmthree
__label__0	study interventions are Irinotecan . histologically or cytologically confirmed colorectal adenocarcinoma
__label__0	study interventions are Gemcitabine . stage ivb gallbladder cancer diagnosis and creatinine within normal institutional limits
__label__0	study interventions are Gemcitabine . solid tumors and non hodgkin lymphoma diagnosis and dose confirmation portion
__label__0	study interventions are Mitogens . carcinoma renal cell diagnosis and if urine is one positive positive thirty mg dl urine protein must be less_than or equal_than one twenty-four hours and measured creatinine clearance greater_than or equal_than sixty ml min
__label__0	study interventions are Metronidazole . lung cancer diagnosis and peripheral blood cea level greater_than doc ng ml
__label__0	study interventions are Cryothermal ablation . locally advanced borderline resectable stage iii pancreatic adenocarcinoma diagnosis and patients who can express their consent
__label__0	study interventions are Prednisone . lymphoma diffuse large cell cell diagnosis and
__label__0	study interventions are Gemcitabine . pancreatic neoplasms diagnosis and for patients with body mass index bmi greater_than thirty kg two lean body weight should be used instead
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and renal
__label__0	study interventions are Tricyclodecane-9-yl-xanthogenate . pancreatic acinar cell carcinoma diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Imatinib Mesylate . stage iv adult burkitt lymphoma diagnosis and at least ten days since prior placement of shunt for treatment of biliary obstruction
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent marginal zone lymphoma diagnosis and hyperviscosity syndrome or measured viscosity level of greater_than equal_than four centipoise
__label__0	study interventions are Cyclophosphamide . stage small lymphocytic lymphoma diagnosis and age greater_than eighteen years
__label__0	study interventions are Docetaxel . stage ivb oral cavity verrucous carcinoma diagnosis and absolute neutrophil count anc greater_than equal_than one thousand, five hundred mm three
__label__0	study interventions are Vidarabine . noncontiguous stage ii grade two follicular lymphoma diagnosis and single antigen mismatch at b or the dr transplant from family member is associated with higher risk of gvhd but similar overall survival when compared to full identity at these three regions related donor recipient pairs must be matched at five of six hla antigens b drbl
__label__0	study interventions are Tesevatinib . glioblastoma diagnosis and age greater_than eighteen years old
__label__0	study interventions are laboratory biomarker analysis . recurrent ovarian epithelial cancer diagnosis and hemoglobin hgb greater_than equal_than doc dl
__label__0	study interventions are Erlotinib Hydrochloride . recurrent non small cell lung cancer diagnosis and no known or pre existing liver metastases
__label__0	study interventions are Albumin-Bound Paclitaxel . breast neoplasms diagnosis and hepatitis or negative
__label__0	study interventions are Everolimus . stage grade two follicular lymphoma diagnosis and donor
__label__0	study interventions are Docetaxel . breast cancer diagnosis and hepatic
__label__0	study interventions are Fluorouracil . stage iii lymphoepithelioma of the nasopharynx diagnosis and see disease characteristics
__label__0	study interventions are Liposomal doxorubicin . glioblastoma diagnosis and if alp is greater_than three uln ggt must be checked and be less_than three uln
__label__0	study interventions are Mechlorethamine . neuroblastoma diagnosis and female only not breastfeeding
__label__0	study interventions are Cyclophosphamide . mantle cell lymphoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Isophosphamide mustard . sarcomas not otherwise specified
__label__0	study interventions are Ursodeoxycholic Acid . diffuse large cell lymphoma diagnosis and at least pr by traditional cheson criteria
__label__0	study interventions are 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT) . brain metastases from solid tumors diagnosis and all toxic effects of prior therapy must have resolved to less_than grade one unless otherwise specified above
__label__0	study interventions are Alemtuzumab . recurrent small lymphocytic lymphoma diagnosis and best available matches are hla class hla b allele matched donors allowing for any one or two drbone and or dqbone antigen allele mismatch
__label__0	study interventions are Mycophenolic Acid . diffuse large cell lymphoma diagnosis and must have received prior chemotherapy consolidation of chemotherapy by autografting prior to nonmyeloablative hct is permitted
__label__0	study interventions are Cyclophosphamide . melanoma diagnosis and age greater than or equal to eighteen years
__label__0	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the larynx diagnosis and no clinically significant cardiovascular disease including any of the following
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and baseline muga or echocardiogram showing lvef greater_than equal_than fifty at least six weeks prior to initiation of nact
__label__0	study interventions are Sorafenib . adenocarcinoma of the gallbladder diagnosis and hiv positive patients must have cdfour count greater_than five hundred and must have no active opportunistic infection in addition patient must not be receiving combination anti retroviral therapy
__label__0	study interventions are Dexamethasone 21-phosphate . refractory plasma cell neoplasm diagnosis and biologic therapy
__label__0	study interventions are Melphalan . lymphoma diagnosis and transplant recipient
__label__0	study interventions are Usual Care Educational Website . stage iii ovarian cancer diagnosis and no known major psychiatric or neurological diagnosis schizophrenia or active chemical dependency
__label__0	study interventions are Piperacillin, tazobactam drug combination . hematologic neoplasms diagnosis and hospitalized male and female patients eighteen years of age or older
__label__0	study interventions are Talazoparib . metastatic pancreatic adenocarcinoma diagnosis and hepatic function
__label__0	study interventions are Isophosphamide mustard . lymphoma diagnosis and no prior malignancy with poor prognosis less than ninety probability of surviving for five years
__label__0	study interventions are Vincristine . newly diagnosed childhood ependymoma diagnosis and no evidence of non contiguous spread beyond the primary site as determined by pr negative or post operative mri of brain pr negative or post operative mri of the spine and post operative csf cytology obtained from the lumbar csf space
__label__0	study interventions are Tacrolimus . hepatosplenic cell lymphoma diagnosis and left ventricular lv ejection fraction greater_than equal_than fifty
__label__0	study interventions are Niacinamide . recurrent childhood rhabdomyosarcoma diagnosis and hemoglobin doc dl may receive red blood cell rbc transfusions
__label__0	study interventions are Albumin-Bound Paclitaxel . triple negative breast cancer diagnosis and adequate organ and hematologic function as evidenced by the following laboratory studies within four weeks of study enrollment
__label__0	study interventions are Metformin . stage zero breast carcinoma diagnosis and age twenty-one to seventy-five years
__label__0	study interventions are Niacinamide . patients must have histopathologically confirmed at mskcc thyroid carcinoma of follicular cell origin tc fco which includes papillary follicular hürthle cell histology or anaplastic along with their respective variants
__label__0	study interventions are Methotrexate . recurrent grade three follicular lymphoma diagnosis and inclusion
__label__0	study interventions are Paclitaxel . soft tissue sarcoma diagnosis and patients with history of deep venous thrombosis or pulmonary embolism must be receiving stable dose of anticoagulation therapy for at least two weeks prior to registration
__label__0	study interventions are Pancreatin . pancreatic neoplasms diagnosis and patients must have estimated life expectancy of at least twelve weeks
__label__0	study interventions are Tamoxifen . inflammatory breast cancer diagnosis and hepatic function
__label__0	study interventions are Gemcitabine . ureter cancer diagnosis and serum creatinine less_than doc mg dl or
__label__0	study interventions are biopsy . adult giant cell glioblastoma diagnosis and no gastrointestinal tract disease resulting in an inability to take oral medication or requirement for intravenous alimentation
__label__0	study interventions are pharmacological study . unspecified adult solid tumor protocol specific diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Dexamethasone 21-phosphate . patients receiving other anticancer drugs on days two four except five fluorouracil vpsixteen vmtwo6 vincristine vinblastine vindesine vinorelbine gemcitabine
__label__0	study interventions are Immunoglobulins . recurrent rectal cancer diagnosis and more than twelve weeks
__label__0	study interventions are Dexamethasone . stage iii multiple myeloma diagnosis and patients must have diagnosis of active mm requiring treatment as diagnosed by bone marrow biopsy within eight weeks prior to study enrollment
__label__0	study interventions are Lapatinib . inflammatory breast cancer stage iv diagnosis and in case of inflammatory disease the extent of inflammation can be used as measurable lesion
__label__0	study interventions are Doxorubicin . prostate cancer diagnosis and other
__label__0	study interventions are Isophosphamide mustard . cns tumors diagnosis and patients with incomplete gross resection where viable gct is found are considered eligible
__label__0	study interventions are Imatinib Mesylate . prostate cancer diagnosis and failed prior hormonal therapy
__label__0	study interventions are Everolimus . adult glioblastoma diagnosis and hgb greater_than ten gm dl
__label__0	study interventions are Liposomal doxorubicin . hepatosplenic cell lymphoma diagnosis and stratum one
__label__0	study interventions are Gemcitabine . carcinoma non small cell lung diagnosis and part two and three
__label__0	study interventions are Cyclosporins . mantle cell lymphoma diagnosis and hla matching must be based on results of high resolution typing at hla b drbone and dqb
__label__0	study interventions are Cyclosporins . recurrent adult diffuse small cleaved cell lymphoma diagnosis and must have failed two lines of conventional therapy and be refractory to fludarabine
__label__0	study interventions are Levoleucovorin . signet ring adenocarcinoma of the rectum diagnosis and total bilirubin less_than doc upper limit of normal uln
__label__0	study interventions are Bevacizumab . recurrent squamous cell carcinoma of the larynx diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are Mycophenolate mofetil . stage adult immunoblastic large cell lymphoma diagnosis and patient who refused to be treated on conventional hct protocol for this inclusion criterion transplants must be approved by both the participating institution patient review committee such as the patient care conference pcc at the fhcrc and the fhcrc principal investigators
__label__0	study interventions are Goserelin . cancer diagnosis and ttwob gleason seven psa ten two0 are not eligible
__label__0	study interventions are Thalidomide . liver cancer diagnosis and documented progression with or intolerance to first line molecular targeted therapy as first line therapy for advanced hcc
__label__0	study interventions are Saracatinib . ovarian cancer diagnosis and adequate haematological and biochemical function
__label__0	study interventions are Sirolimus . carcinoma renal cell diagnosis and adequate coagulation profile
__label__0	study interventions are Antibodies . primary peritoneal cavity cancer diagnosis and no circumstances that would preclude study participation
__label__0	study interventions are Pemetrexed . breast cancer diagnosis and estimated life expectancy of at least three months
__label__0	study interventions are Lenalidomide . hepatosplenic cell lymphoma diagnosis and all females of childbearing potential must have blood test within two weeks prior to registration to rule out pregnancy
__label__0	study interventions are Cyclophosphamide . peripheral cell lymphoma diagnosis and patients in this category require specific approval of the pi and the tju bmt attending physician group for entrance
__label__0	study interventions are Camptothecin . stage iv anal cancer diagnosis and less than four prior chemotherapy regimens in the adjuvant and or metastatic setting part ii
__label__0	study interventions are Mycophenolate mofetil . stage iii adult diffuse large cell lymphoma diagnosis and donor
__label__0	study interventions are quality-of-life assessment . stage verrucous carcinoma of the larynx diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Isophosphamide mustard . rhabdomyosarcoma diagnosis and renal
__label__0	study interventions are Niacinamide . salivary gland squamous cell carcinoma diagnosis and platelet count one hundred zero mm three
__label__0	study interventions are Cell Search® CTC epithelial kit . hertwo positive advanced gastric cancer diagnosis and serum creatinine less_than uln and ccr less_than sixtyml min
__label__0	study interventions are Dasatinib . recurrent adult primary liver cancer diagnosis and no concurrent embolization or chemoembolization
__label__0	study interventions are Poly I-C . urothelial cancer diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Maleic acid . recurrent childhood cerebellar astrocytoma diagnosis and not pregnant or nursing
__label__0	study interventions are Zileuton . history of active malignancy during the past five years with the exception of nonmetastatic treated skin cancer basal or squamous cell carcinoma or stage zero cervical carcinoma
__label__0	study interventions are Tacrolimus . noncontiguous stage ii marginal zone lymphoma diagnosis and twenty basophils and or eosinophils in blood
__label__0	study interventions are Rituximab . non hodgkin lymphoma nhl diagnosis and leukemic phase malignant cells greater_than five one hundred and nine l
__label__0	study interventions are Cyclophosphamide . stage iii renal cell cancer diagnosis and chromophobe
__label__0	study interventions are Pharmacological Study . testicular lymphoma diagnosis and must be able to swallow whole tablets
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent non small cell lung cancer diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are external beam radiation therapy . metastatic cancer diagnosis and zubrod performance status zero two
__label__0	study interventions are Navitoclax . solid tumors diagnosis and serum creatinine less than or equal to doc milligrams deciliter or calculated creatinine clearance greater than or equal to fifty milliliter minute hepatic function and enzymes
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and myelodysplastic syndromes
__label__0	study interventions are Docetaxel . thorax and respiratory cancer diagnosis and rifabutin
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and stage ii or iii disease
__label__0	study interventions are STA-9090 . esophagogastric cancer diagnosis and women of child bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation
__label__0	study interventions are Dexrazoxane . recurrent childhood small noncleaved cell lymphoma diagnosis and strata two and three
__label__0	study interventions are Tocopherols . non small cell lung cancers diagnosis and reasonable attempt should be made to make pathologic diagnosis of malignancy ie
__label__0	study interventions are Lenalidomide . stage iv small lymphocytic lymphoma diagnosis and all study participants must be registered into the mandatory revassist program and be willing and able to comply with the requirements of revassist
__label__0	study interventions are Antibodies, Monoclonal . in the absence of paraffinembedded tissue unstained paraffin_embedded tumor slides are acceptable
__label__0	study interventions are Tretinoin . stage four neuroblastoma diagnosis and at least one metaiodobenzylguanidine_mibg avid bone site or diffuse mibg uptake
__label__0	study interventions are Carboplatin . fallopian tube cancer diagnosis and edta dtpa clearance greater_than fifty ml min uncorrected value
__label__0	study interventions are Methotrexate . kidney cancer diagnosis and no known hypersensitivity to e
__label__0	study interventions are Irinotecan . recurrent verrucous carcinoma of the oral cavity diagnosis and absolute neutrophil count greater_than equal_than one five hundred ul
__label__0	study interventions are Gemcitabine . stage iiib non small cell lung cancer diagnosis and no prior allergic reactions to compounds of similar chemical or biological composition to bortezomib or other agents used in this study
__label__0	study interventions are Rituximab . stage marginal zone lymphoma diagnosis and patients with aml all or mds scheduled for myeloablative conditioning should have equal_than less_than ten blasts in bone marrow or peripheral blood at the start of conditioning
__label__0	study interventions are Rituximab . stage iii grade three follicular lymphoma diagnosis and patients must be free of any prior malignancies for greater_than equal_than one year note
__label__0	study interventions are Erlotinib Hydrochloride . stage iv colon cancer diagnosis and no cardiac arrhythmia
__label__0	study interventions are Cyclosporine . myeloproliferative neoplasm diagnosis and must be in state of general good health and have completed donor evaluation with history medical examination and standard blood tests within thirty-five days of starting the hematopoietic cell collection procedure in order to fairly represent the interests of the donor the donor evaluation and consent will be performed by study team member other than the recipient attending physician
__label__0	study interventions are Cyclosporins . recurrent mantle cell lymphoma diagnosis and gated pool radionuclide scan fraction must be greater_than equal_than fifty
__label__0	study interventions are Fludarabine phosphate . stage iii multiple myeloma diagnosis and must have suitable matched sibling or matched unrelated donor for stem cell source
__label__0	study interventions are Bortezomib . recurrent grade one follicular lymphoma diagnosis and lymph node biopsy must be done equal_than less_than twenty-eight days prior to registration if used as an eligibility criterion for study entry
__label__0	study interventions are Idelalisib . refractory small lymphocytic lymphoma diagnosis and patients should not have other treatment options considered curative
__label__0	study interventions are Paclitaxel . ovarian transitional cell carcinoma diagnosis and creatinine no greater than the institutional upper limits of normal
__label__0	study interventions are Immunoglobulins . stage iii small lymphocytic lymphoma diagnosis and no prior malignancy with the exceptions listed below
__label__0	study interventions are Immunoconjugates . recurrent adult diffuse small cleaved cell lymphoma diagnosis and creatinine equal_than less_than two institutional uln
__label__0	study interventions are Bicalutamide . prostate cancer diagnosis and hepatic
__label__0	study interventions are Gemcitabine . stage iv bladder cancer diagnosis and serum creatinine less_than doc institutional uln mg dl or glomerular filtration rate gfr greater_than equal_than fifty ml min
__label__0	study interventions are Methylprednisolone acetate . recurrent adult burkitt lymphoma diagnosis and md negative intermediate two or high ipss score
__label__0	study interventions are Cyclosporine . stage iv adult immunoblastic large cell lymphoma diagnosis and highly active antiretroviral therapy haart is initiated within one month of hematopoietic cell transplant
__label__0	study interventions are Gemcitabine . malignant tumor of renal pelvis diagnosis and total bilirubin less_than doc uln
__label__0	study interventions are Carboplatin . non small cell lung carcinoma diagnosis and total bilirubin less_than two times the upper limit of normal uln
__label__0	study interventions are Cisplatin . histologically proven gastric adenocarcinoma diagnosis
__label__0	study interventions are Succinylcholine . cervical adenosquamous carcinoma diagnosis and patient does not have known glucose six phosphate dehydrogenase gsixpd deficiency as the condition interferes with triapine antidote metabolism gsixpd testing optional
__label__0	study interventions are Antibodies . stage iv grade two follicular lymphoma diagnosis and no prior systemic therapy for nhl including chemotherapy or immunotherapy monoclonal antibody based therapy patients may have received involved field radiation therapy
__label__0	study interventions are Laboratory Biomarker Analysis . rorone expression in greater_than twenty of the primary tumor or metastasis by immunohistochemistry ihc
__label__0	study interventions are Fludarabine phosphate . burkitt lymphoma diagnosis and high risk crone as evidenced by preceding mds high risk cytogenetics greater_than two cycles to obtain cr erythroblastic or megakaryocytic leukemia flt three itd positive crtwo positive
__label__0	study interventions are Carboplatin . osteosarcoma diagnosis and informed consent
__label__0	study interventions are Etanidazole . adult craniopharyngioma diagnosis and no cardiac arrhythmia
__label__0	study interventions are Vorinostat . stage iv adult diffuse large cell lymphoma diagnosis and intermediate two risk or high risk disease
__label__0	study interventions are DNA analysis . neuroblastoma diagnosis and normal tissue samples if available
__label__0	study interventions are Bevacizumab . advanced cancer diagnosis and life expectancy of at least three months
__label__0	study interventions are Camptothecin . recurrent childhood visual pathway glioma diagnosis and no concurrent biologic therapy
__label__0	study interventions are Methylprednisolone Hemisuccinate . multiple myeloma and plasma cell neoplasm diagnosis and relapsed disease allowed provided second or subsequent complete remission or minimal residual disease is achieved
__label__0	study interventions are Temozolomide . glioblastoma mutliforme diagnosis and adequate bone marrow as defined below
__label__0	study interventions are Etoposide . stage iii mantle cell lymphoma diagnosis and serum bilirubin less_than doc mg dl
__label__0	study interventions are Immunoglobulins . recurrent ovarian carcinoma diagnosis and international normalized ratio inr equal_than less_than doc unless the patient is on full dose warfarin
__label__0	study interventions are Dexamethasone 21-phosphate . peritoneal cancer diagnosis and absolute granulocyte count greater_than or equal_than doc ten nine l
__label__0	study interventions are Mycophenolic Acid . refractory plasma cell myeloma diagnosis and after induction chemotherapy
__label__0	study interventions are Vincristine . stage ii contiguous mantle cell lymphoma diagnosis and if hbv dna is positive the subject is excluded
__label__0	study interventions are Succinylcholine . stage iii pancreatic cancer diagnosis and creatinine equal_than less_than doc institutional uln or creatinine clearance greater_than equal_than fifty ml min calculated with the cockcroft gault formula
__label__0	study interventions are Dexamethasone 21-phosphate . stage iiib primary peritoneal cancer diagnosis and partial thromboplastin time ptt less_than doc times the upper limit of normal heparin lovenox or alternative anticoagulants are acceptable
__label__0	study interventions are Immunoglobulins . anaplastic large cell lymphoma diagnosis and electrocardiogram twelve lead ecg
__label__0	study interventions are Pazopanib . sarcoma soft tissue diagnosis and upc less_than one or if upc greater_than one twenty-four hour urine protein less_than one use of urine dipstick for renal function assessment is not acceptable
__label__0	study interventions are ZD 9331 . fallopian tube cancer diagnosis and age
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and bilirubin less_than two times uln
__label__0	study interventions are Docetaxel . non small cell lung cancer diagnosis and as treatment arm is assigned based on histology subtype it must be feasible to subtype into squamous or other
__label__0	study interventions are Pharmacological Study . childhood hepatocellular carcinoma diagnosis and qtc equal_than less_than four hundred and eighty msec note
__label__0	study interventions are Niacinamide . hepatocellular carcinoma diagnosis and serum total bilirubin threemg dl
__label__0	study interventions are Gemcitabine . splenic marginal zone lymphoma diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to three ap triapine and or gemcitabine hydrochloride
__label__0	study interventions are Laboratory Biomarker Analysis . recurrent adult diffuse large cell lymphoma diagnosis and creatinine clearance crcl greater_than equal_than forty ml min modified cockcroft gault
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iv non small cell lung cancer diagnosis and patients must have histologically proven hertwo overexpressing malignancy as determined by any standardized assay currently in clinical use
__label__0	study interventions are Camptothecin . metastatic colorectal cancer diagnosis and male and female subjects of child bearing potential must agree to use double barrier contraceptive measures oral contraception or avoidance of intercourse during the study and for ninety days after last investigational drug dose received
__label__0	study interventions are Immunoglobulins . colon mucinous adenocarcinoma diagnosis and step one
__label__0	study interventions are Albumin-Bound Paclitaxel . patients with stage iv or recurrent adenocarcinoma of the lung diagnosis and patients must have less_than grade two pre existing peripheral neuropathy per ctcae
__label__0	study interventions are Thalidomide . lymphoma diagnosis and able to take aspirin eighty-one mg if not already on aspirin daily as prophylactic anticoagulation patients intolerant to asa may use low molecular weight heparin
__label__0	study interventions are Gemcitabine . lung neoplasms diagnosis and able to care for self
__label__0	study interventions are Docetaxel . head and neck cancer diagnosis and negative pregnancy test
__label__0	study interventions are Paclitaxel . gastric cancer diagnosis and not participating in other clinical trials before and during the treatment
__label__0	study interventions are Vincristine . atypical burkitt lymphoma diagnosis and histologically documented burkitt or atypical burkitt according to world health organization who criteria
__label__0	study interventions are Satraplatin . prostate cancer diagnosis and
__label__0	study interventions are Epothilones . primary peritoneal cavity cancer diagnosis and gog zero two
__label__0	study interventions are pharmacological study . stage iv lymphoepithelioma of the oropharynx diagnosis and patients who received an antiandrogen as part of first line hormonal therapy must show disease progression after discontinuing treatment
__label__0	study interventions are Gemcitabine . stage iv pancreatic cancer diagnosis and concurrent enrollment in non therapy trials quality of life allowed
__label__0	study interventions are Docetaxel . recurrent pancreatic cancer diagnosis and not pregnant or nursing
__label__0	study interventions are diagnostic cystoscopy . bladder cancer diagnosis and wbc greater_than three zero mm three
__label__0	study interventions are Gamma-Secretase Inhibitor RO4929097 . stage iiib breast cancer diagnosis and patients must not have active infection or fever greater_than three doc degree celsius c
__label__0	study interventions are Interferons . clear cell renal cell carcinoma diagnosis and not pregnant or nursing
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iic fallopian tube cancer diagnosis and serum glutamic oxaloacetic transaminase sgot less than or equal to three uln
__label__0	study interventions are Folic Acid . stage iib colon cancer diagnosis and randomization high risk patients
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian neoplasm diagnosis and eastern cooperative oncology group ecog performance status of less_than two
__label__0	study interventions are Pertuzumab . breast neoplasms diagnosis and for patients with stage iiic disease
__label__0	study interventions are Fulvestrant . breast cancer diagnosis and ability to understand the requirements of the study provided written informed consent and authorization of use and disclosure of protected health information and agree to abide by the study restrictions and to return for the required assessments
__label__0	study interventions are Mitogens . recurrent pancreatic cancer diagnosis and proteinuria negative or trace by urinalysis or
__label__0	study interventions are Temozolomide . untreated childhood anaplastic astrocytoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate gfr greater_than equal_than seventy ml min doc three two or serum creatinine based on age gender as follows
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and at least four weeks since prior chemotherapy six weeks for mitomycin or nitrosoureas and recovered
__label__0	study interventions are Rituximab . either tositumomab or ibritumomab
__label__0	study interventions are Vorinostat . breast cancer diagnosis and previously treated brain metastasis responsive to radiotherapy and or surgery allowed provided the brain is not the sole site of measurable disease
__label__0	study interventions are Androgens . either lymph node biopsy or lymph node dissection demonstrating lymph node metastasis by prostate cancer b
__label__0	study interventions are Antilymphocyte Serum . multiple myeloma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Metronidazole . stage iib ovarian epithelial cancer diagnosis and patient or legal representative must understand the investigational nature of this study and sign an independent ethics committee institutional review board approved written informed consent form prior to receiving any study related procedure
__label__0	study interventions are Estramustine . prostate cancer diagnosis and castrate testosterone level less_than equal_than fifty ng ml treatment to maintain castrate levels of testosterone must be continued
__label__0	study interventions are Trastuzumab . recurrent breast cancer diagnosis and participants of childbearing potential must have negative pregnancy test at screening and enrollment participants of childbearing potential are defined as premenopausal females capable of becoming pregnant females who have had any evidence of menses in the past twelve months with the exception of those who had prior hysterectomy oophorectomy or surgical sterilization however women who have been amenorrheic for greater_than equal_than twelve months are still considered to be of childbearing potential if the amenorrhea is possibly due to any other cause including prior chemotherapy antiestrogens or ovarian suppression
__label__0	study interventions are Niacinamide . stage iv renal cell cancer diagnosis and platelet count greater_than equal_than one hundred zero mm three
__label__0	study interventions are Isolated Roux-en-Y type reconstruction . bile duct neoplasms diagnosis and the patients had undergone pancreatic head resection at wakayama medical university the patients obtained appropriate informed consent
__label__0	study interventions are Dexamethasone . childhood craniopharyngioma diagnosis and hemoglobin greater_than doc dl may receive rbc transfusions
__label__0	study interventions are Alvocidib . recurrent adult diffuse large cell lymphoma diagnosis and at least one node greater_than two cm by ct scan
__label__0	study interventions are CGTG-102 . tumors diagnosis and total bilirubin less than or equal to uln upper limit of normal
__label__0	study interventions are Pentostatin . lymphoma diagnosis and ast and alt less_than doc times uln unless due to hemolysis or cll
__label__0	study interventions are Exemestane . recurrent breast carcinoma diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma_secretase inhibitor rofour million, nine hundred and twenty-nine thousand and ninety-seven or other agents used in the study
__label__0	study interventions are Immunoconjugates . adult lymphocyte depletion hodgkin lymphoma diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Bortezomib . recurrent refractory childhood hodgkin lymphoma diagnosis and recovered from prior therapy
__label__0	study interventions are Estradiol 3-benzoate . estrogen levels among breast cancer patients diagnosis and be willing and able to comply with the treatment plan scheduled clinic visits laboratory tests and other study procedures
__label__0	study interventions are Cyclosporins . recurrent grade one follicular lymphoma diagnosis and reductions of greater_than equal_than fifty in greatest diameter of all sites of known disease and no new sites
__label__0	study interventions are Endothelial Growth Factors . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and no significant ongoing or active infection
__label__0	study interventions are Sirolimus . cervical adenosquamous carcinoma diagnosis and chest ray greater_than equal_than twenty mm
__label__0	study interventions are Camptothecin . signet ring adenocarcinoma of the colon diagnosis and liver disease must not be amenable to potentially curative surgical resection
__label__0	study interventions are Thioguanine . cognitive side effects of cancer therapy diagnosis and doc male doc female
__label__0	study interventions are Lenalidomide . recurrent marginal zone lymphoma diagnosis and magnesium greater_than equal_than doc mg dl
__label__0	study interventions are Dexamethasone 21-phosphate . stage iii multiple myeloma diagnosis and ecog performance status ps zero two or karnofsky ps 7zero 1zerozero
__label__0	study interventions are Vidarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and chronic myelogenous leukemia cml
__label__0	study interventions are Cyclophosphamide . gliosarcoma diagnosis and resolution of all chemotherapy or radiation related toxicities less_than ctcae grade one severity except for alopecia and hematologic toxicity
__label__0	study interventions are Bevacizumab . ovarian cancer diagnosis and more than twenty-eight days since prior major surgery
__label__0	study interventions are Ifosfamide . cns tumors diagnosis and at diagnosis and or relapse
__label__0	study interventions are evaluation of cancer risk factors . unspecified adult solid tumor protocol specific diagnosis and chemotherapy
__label__0	study interventions are Saracatinib . stage ivb verrucous carcinoma of the larynx diagnosis and patients must agree to use adequate birth control for the duration of study participation and for at least eight weeks after discontinuation of study drug
__label__0	study interventions are Rituximab . mantle cell lymphoma diagnosis and no serious medical or psychiatric illness likely to interfere with participation in this clinical study
__label__0	study interventions are Azacitidine . recurrent rectal cancer diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biologic composition to entinostat azacitidine mannitol or other agents used in the study
__label__0	study interventions are Folic Acid . non small cell lung cancer diagnosis and women of childbearing potential must use medically acceptable birth control and have negative serum pregnancy test within fourteen days prior to randomization
__label__0	study interventions are Etoposide phosphate . recurrent adult burkitt lymphoma diagnosis and hiv seropositive
__label__0	study interventions are Bevacizumab . recurrent primary peritoneal carcinoma diagnosis and hepatic artery infusional chemotherapy
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and must have alanine transaminase alt less_than three institutional upper limit of normal uln less_than five uln in presence of liver metastases within fourteen days prior to randomization
__label__0	study interventions are Lapatinib . salivary gland squamous cell carcinoma diagnosis and creatinine normal
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent non small cell lung cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Questionnaires . breast cancer diagnosis and pilot participants and healthy controls only
__label__0	study interventions are Erlotinib Hydrochloride . recurrent squamous cell carcinoma of the larynx diagnosis and more than four weeks since prior chemotherapy six weeks for nitrosoureas or mitomycin and recovered
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and wbc greater_than three zero mm three
__label__0	study interventions are Camptothecin . recurrent osteosarcoma diagnosis and negative pregnancy test
__label__0	study interventions are Prednisolone hemisuccinate . lymphoma diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Aldesleukin . unspecified childhood solid tumor protocol specific diagnosis and no allergy to gentamicin
__label__0	study interventions are Belinostat . recurrent adult primary liver cancer diagnosis and fertile patients use effective contraception
__label__0	study interventions are Gemcitabine . adenocarcinoma of the pancreas diagnosis and females of childbearing potential fcbp must have negative serum pregnancy test within seven days of the first application of study treatment and they must agree to undergo further pregnancy tests before randomization and at the end of treatment visit and
__label__0	study interventions are Etoposide . retinoblastoma diagnosis and absence of active hepatitis by liver biopsy
__label__0	study interventions are Mycophenolate mofetil . lymphoma diagnosis and chronic myelogenous leukemia all types except blast crisis note treated blast crisis in chronic phase is eligible
__label__0	study interventions are Lenalidomide . recurrent adult lymphoblastic lymphoma diagnosis and del_seventeenpone doc disease that has been treated may have been given as consolidation therapy
__label__0	study interventions are Liver Extracts . liver neoplasm diagnosis and asa rating between one four
__label__0	study interventions are Etoposide . extragonadal germ cell tumor diagnosis and see disease characteristics
__label__0	study interventions are Doxorubicin . carcinoma hepatocellular diagnosis and hcc for which transplantation surgical resection or percutaneous ablation are not indicated
__label__0	study interventions are Dexamethasone acetate . recurrent adult diffuse mixed cell lymphoma diagnosis and patients should have platelets greater_than equal_than one hundred zero ul exception
__label__0	study interventions are Succinylcholine . ovarian carcinosarcoma diagnosis and regimens and ii
__label__0	study interventions are Antibodies, Monoclonal . recurrent small lymphocytic lymphoma diagnosis and life expectancy greater_than equal_than twelve weeks
__label__0	study interventions are Laboratory Biomarker Analysis . ovarian endometrioid adenocarcinoma diagnosis and aspartate aminotransferase ast equal_than less_than two upper limit of normal uln
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent childhood subependymal giant cell astrocytoma diagnosis and platelet count greater_than one hundred zero mm three transfusion independent defined as not receiving platelet transfusions within the past seven days
__label__0	study interventions are Prednisone . diffuse large cell lymphoma diagnosis and limited stage dlbcl patients at newly diagnosed or recurrent without rt in initial management
__label__0	study interventions are Interleukin-2 . stage iv adult lymphoblastic lymphoma diagnosis and hepatitis surface antigen negative
__label__0	study interventions are comparative genomic hybridization . diffuse large cell immunoblastic lymphoma
__label__0	study interventions are Leucovorin . stage iiic gastric cancer diagnosis and prior malignancy completely excised or removed and patient has been continuously disease free for greater_than five years from registration to step zero
__label__0	study interventions are Vidarabine . malignant lymphoma large cell type diagnosis and doc ten seven kg
__label__0	study interventions are Methylprednisolone . lymphoma diagnosis and no prior organ transplant
__label__0	study interventions are Eribulin Mesylate . metastatic malignant neoplasm in the adult brain diagnosis and an interval of at least six weeks must elapse since treatment with nitrosourea and at least four weeks since the last dose of bevacizumab
__label__0	study interventions are Fludarabine . anaplastic large cell lymphoma diagnosis and must have failed two courses of therapy
__label__0	study interventions are Fludarabine . stage iii marginal zone lymphoma diagnosis and no pulmonary dysfunction that would impair tolerance or compliance with study therapy
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and although the bm remission status is not important patients must have cellularity greater_than ten
__label__0	study interventions are Denileukin diftitox . unspecified adult solid tumor protocol specific diagnosis and fluorouracil or capecitabine and oxaliplatin
__label__0	study interventions are Gemcitabine . stage iv grade two follicular lymphoma diagnosis and performance status
__label__0	study interventions are Vidarabine . recurrent marginal zone lymphoma diagnosis and patients with chromosome thirteen abnormalities first response lasting less than six months or beta two microglobulin greater_than three mg may be considered for this protocol after initial therapy
__label__0	study interventions are Cisplatin . carcinoma non small cell lung diagnosis and patients at first diagnosis or those with disease recurrence after former surgery are eligible
__label__0	study interventions are Cisplatin . stage iv fallopian tube cancer diagnosis and gynecologic oncology group gog or eastern cooperative oncology group ecog performance status equal_than less_than one or karnofsky scale kps equal_than less_than seventy
__label__0	study interventions are Celecoxib . stage iv non small cell lung cancer diagnosis and no other prior egfr antagonists
__label__0	study interventions are Colistin . cancer diagnosis and allogeneic or autologous hematopoietic stem cell transplantation within fourteen days after enrollment or
__label__0	study interventions are Pembrolizumab . follicular variant thyroid gland papillary carcinoma diagnosis and evidence of disease progression equal_than less_than fourteen months prior to registration according to recist doc as confirmed by the site study principal investigator pi
__label__0	study interventions are Lapatinib . metastatic breast cancer diagnosis and baseline lvef greater_than fifty measured by echocardiogram or multiple gated acquisition scan muga scan
__label__0	study interventions are Doxorubicin . sarcoma kaposi diagnosis and substantial lymph node involvement
__label__0	study interventions are Capecitabine . ovarian cancer diagnosis and gynecologic oncology group performance status zero two
__label__0	study interventions are Vaccines . testicular germ cell tumor diagnosis and inflammatory bowel disease
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and stage ia or iia disease
__label__0	study interventions are Pazopanib Hydrochloride . recurrent melanoma diagnosis and more than six weeks since prior major surgery
__label__0	study interventions are Dexamethasone acetate . recurrent childhood visual pathway glioma diagnosis and female patients may not donate ova during or after study treatment
__label__0	study interventions are Lenalidomide . multiple myeloma diagnosis and levonorgestrel releasing intrauterine system ius
__label__0	study interventions are Paclitaxel . borderline resectable pancreatic cancer diagnosis and patient pain symptoms have remained stable with no adjustment to analgesics within seven days prior to randomization
__label__0	study interventions are Freund's Adjuvant . extraocular extension melanoma diagnosis and ecog performance status of zero or one
__label__0	study interventions are Oxaliplatin . recurrent childhood cerebral astrocytoma diagnosis and hypericum_perforatum st
__label__0	study interventions are Antibodies, Monoclonal . metastatic squamous neck cancer with occult primary squamous cell carcinoma diagnosis and concurrent bisphosphonates allowed
__label__0	study interventions are alvespimycin hydrochloride . recurrent verrucous carcinoma of the larynx diagnosis and lvef greater_than forty by muga
__label__0	study interventions are Panobinostat . solid tumors diagnosis and women of childbearing potential wocbp must have negative serum pregnancy test within seven days of the first administration of study treatment
__label__0	study interventions are Etoposide . patients must not have received systemic chemotherapy or radiation therapy prior to treatment on this study unless they were enrolled on the arenfive hundred and thirty-two or arenfive hundred and thirty-three studies and received prenephrectomy chemotherapy for what was originally presumed to be favorable histology wilms tumor additionally patients with pediatric rcc who previously received chemotherapy for another type of malignancy not the rcc or non malignant condition may enroll on the study
__label__0	study interventions are Dasatinib . salivary gland adenocarcinoma diagnosis and more than seven days since prior and no concurrent agents with proarrhythmic potential
__label__0	study interventions are Trastuzumab . metastatic breast cancer diagnosis and ecog performance status less_than two
__label__0	study interventions are Immunoglobulin G . cervical adenocarcinoma diagnosis and alkaline phosphatase equal_than less_than doc institutional normal
__label__0	study interventions are sabarubicin . unspecified adult solid tumor protocol specific diagnosis and not specified other
__label__0	study interventions are Interferon-alpha . primary peritoneal cancer diagnosis and gilbert syndrome will be defined as elevated unconjugated bilirubin with conjugated direct bilirubin within the normal range and less than twenty of the total
__label__0	study interventions are Sorafenib . liver cancer diagnosis and bclc stage intermediate
__label__0	study interventions are pharmacological study . adult gliosarcoma diagnosis and approximately three weeks since prior procarbazine
__label__0	study interventions are Niacinamide . recurrent renal cell carcinoma diagnosis and platelet count greater_than equal_than one hundred zero ul
__label__0	study interventions are Temozolomide . glioblastoma diagnosis and age
__label__0	study interventions are Vitamin B Complex . ovarian mucinous cystadenocarcinoma diagnosis and no evidence of disease at the time of registration including no clinical concern for disease recurrence based on each of the following
__label__0	study interventions are Vitamin B 12 . lymphoma cell diagnosis and doc mg day orally of folic acid for at least seven days prior one mg intramuscular of vitamin bone2 within one0 weeks of the planned start of pralatrexate
__label__0	study interventions are Capecitabine . rectal cancer diagnosis and tumour within twelve cm of the anal verge by proctoscopic examination or within ten cm of the anorectal ring by mri
__label__0	study interventions are Interleukin-12 . stage cutaneous cell non hodgkin lymphoma diagnosis and stage ib iv
__label__0	study interventions are Romidepsin . childhood grade ii meningioma diagnosis and no greater than doc mg dl for patients five years of age and under
__label__0	study interventions are Vaccines . melanoma skin diagnosis and at least four weeks but no more than twelve weeks since prior major surgery other
__label__0	study interventions are Niacinamide . unspecified adult solid tumor protocol specific diagnosis and biologic therapy
__label__0	study interventions are Liposomal doxorubicin . endometrial cancer diagnosis and advanced metastatic and or relapsed disease
__label__0	study interventions are Gemcitabine . adenocarcinoma of the pancreas diagnosis and no evidence of coagulopathy
__label__0	study interventions are Busulfan . non small cell lung cancer diagnosis and aspartate transaminase ast or alanine transaminase alt less_than doc uln with normal alkaline phosphatase or ast and alt less_than doc uln in conjunction with alkaline phosphatase greater_than doc uln serum bilirubin less_than doc uln
__label__0	study interventions are Endothelial Growth Factors . ovarian serous surface papillary adenocarcinoma diagnosis and two prior chemotherapy regimens
__label__0	study interventions are Mycophenolic Acid . recurrent adult cell leukemia lymphoma diagnosis and not eligible for conventional myeloablative hct or after autologous hct
__label__0	study interventions are Doxorubicin . small intestine cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Methylprednisolone acetate . primary peritoneal cancer diagnosis and creatinine cr less_than or equal_than doc mg dl
__label__0	study interventions are Epoetin Alfa . lymphoma diagnosis and uncomplicated tonsillectomy
__label__0	study interventions are Tamoxifen . fallopian tube cancer diagnosis and ecog performance status zero two
__label__0	study interventions are antineoplaston AS2-1 . lung cancer diagnosis and hematopoietic
__label__0	study interventions are Pentoxifylline . uicc tnm stage zero in situ disease one or two breast cancer patients treated with conservative surgery and adjuvant radiotherapy with chronic breast pain or tenderness with or without fibrosis within three months to three years following completion of radiotherapy
__label__0	study interventions are Etoposide . lymphoma diagnosis and no prior therapy for this disease except for one of the following
__label__0	study interventions are Compound 506U78 . multiple myeloma and plasma cell neoplasm diagnosis and less than doc times upper limit of normal uln group five
__label__0	study interventions are Bevacizumab . mucinous breast cancer stage ii diagnosis and ritten informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures
__label__0	study interventions are Everolimus . stage iiic fallopian tube cancer diagnosis and history of prior varices or evidence of varices on pre study ct magnetic resonance imaging mri imaging are required to undergo endoscopy equal_than less_than four weeks prior to registration those who had received specific therapy banding and or sclerotherapy and had not bled within the prior six months are eligible
__label__0	study interventions are Immunoglobulins . stage iiib gastric cancer diagnosis and white blood cells wbc greater_than equal_than three five hundred mm three
__label__0	study interventions are Blood specimens . pancreatic ductal adenocarcinoma diagnosis and relative of brca pdac patient is defined as first degree relative which includes parents siblings or children
__label__0	study interventions are Methotrexate . lymphoma diagnosis and must have evidence of relapse progression at least six months after prior high dose chemotherapy with autologous hematopoietic stem cell support
__label__0	study interventions are Irinotecan . stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and patients must not be receiving radiation treatment
__label__0	study interventions are Irinotecan . childhood oligodendroglioma diagnosis and creatinine normal
__label__0	study interventions are Etoposide phosphate . ewing family tumors diagnosis and patients may receive transfusions as necessary
__label__0	study interventions are Vincristine . lymphoma diagnosis and risk factors are defined as symptoms extranodal sites of disease and disease remission lasting less_than one year after first line therapy
__label__0	study interventions are Cyclophosphamide . six weeks must have elapsed from the time of any antibody therapy that could affect an anti cancer immune response including anti ctlafour antibody therapy at the time the patient receives the preparative regimen to allow antibody levels to decline
__label__0	study interventions are Camptothecin . breast cancer diagnosis and performance status
__label__0	study interventions are Bevacizumab . urothelial carcinoma diagnosis and unresectable or metastatic disease
__label__0	study interventions are Antibodies, Monoclonal . recurrent digestive system neuroendocrine tumor gone diagnosis and patients not on anticoagulation must have international normalized ratio inr equal_than less_than doc patients on full dose anticoagulation warfarin or low molecular weight heparin are eligible provided that both of the following criteria are met
__label__0	study interventions are Pemetrexed . non small cell lung cancer diagnosis and prior therapy with low dose methotrexate or similar medications allowed if used for non malignant conditions
__label__0	study interventions are Tacrolimus . noncontiguous stage ii marginal zone lymphoma diagnosis and mature cell malignancies
__label__0	study interventions are Antibodies . stage iv squamous cell carcinoma of the nasopharynx diagnosis and total bilirubin equal_than less_than doc uln
__label__0	study interventions are Sirolimus . stage iv breast cancer diagnosis and creatinine equal_than less_than doc times the upper limit of normal uln
__label__0	study interventions are Leucovorin . esophageal cancer diagnosis and disease characteristics
__label__0	study interventions are Carboplatin . neoplasm unknown primary diagnosis and ecog performance status zero one
__label__0	study interventions are Pemetrexed . recurrent non small cell lung cancer diagnosis and patients with advanced stage nsclc who are candidates for single or multi agent first line therapy
__label__0	study interventions are Mechlorethamine . ds stage ii plasma cell myeloma diagnosis and no concurrent drugs food supplements or over the counter medications that may interfere with the metabolism of rofour million, nine hundred and twenty-nine thousand and ninety-seven including ketoconazole and fresh_squeezed grapefruit juice
__label__0	study interventions are Diphenhydramine . non hodgkin lymphoma nhl diagnosis and age greater than one year and less than seventy-five years
__label__0	study interventions are Cyclophosphamide . stage iii breast cancer diagnosis and pathologic none three
__label__0	study interventions are Octreotide . cervical cancer diagnosis and no planned cytotoxic chemotherapy agents concurrently with radiotherapy except fluorouracil with or without leucovorin calcium or cisplatin
__label__0	study interventions are Radiation Therapy . mucinous breast carcinoma diagnosis and age greater_than equal_than fifty years and postmenopausal with no menses for at least one year prior to study enrollment
__label__0	study interventions are Dacarbazine . recurrent childhood medulloblastoma diagnosis and hemoglobin greater_than eightg dl
__label__0	study interventions are Camptothecin . colorectal neoplasms diagnosis and ecog performance status ps of zero two
__label__0	study interventions are N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid . prostate cancer diagnosis and treatment naïve patients with one of the following risk factors
__label__0	study interventions are Interleukin-2 . regional neuroblastoma diagnosis and one month to less_than six months
__label__0	study interventions are Fludarabine phosphate . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and mantle cell nhl may be treated in first cr
__label__0	study interventions are Trametinib . stage iv distal bile duct cancer diagnosis and patients must have zubrod performance status of zero one
__label__0	study interventions are Camptothecin . mucinous adenocarcinoma of the colon diagnosis and no other concurrent investigational chemotherapy agents
__label__0	study interventions are Everolimus . bladder cancer diagnosis and current or prior dialysis
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and clinically and or histologically confirmed hematologic malignancy or genetic disorder
__label__0	study interventions are Sirolimus . recurrent hypopharyngeal squamous cell carcinoma diagnosis and women of child bearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation
__label__0	study interventions are Carboplatin . teratoma diagnosis and afp greater_than ten zero ng ml
__label__0	study interventions are Irinotecan . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and at least seven days since prior antineoplastic biologic therapy
__label__0	study interventions are Vidarabine . stage ii cutaneous cell non hodgkin lymphoma diagnosis and donor
__label__0	study interventions are Albumin-Bound Paclitaxel . endometrial undifferentiated carcinoma diagnosis and eastern cooperative oncology group ecog performance status ps zero or one
__label__0	study interventions are Bevacizumab . anaplastic oligodendroglioma ao diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are Carboplatin . head and neck cancer diagnosis and adequate organ and marrow function as defined below
__label__0	study interventions are Prednisone . myelodysplastic myeloproliferative neoplasms diagnosis and creatinine less_than doc mg dl or
__label__0	study interventions are Vidarabine . lymphoma diagnosis and hla dq mismatches are not considered ie they are allowed in addition to these
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma and plasma cell neoplasm diagnosis and hematopoietic
__label__0	study interventions are Immunoglobulins . stage iv cutaneous cell non hodgkin lymphoma diagnosis and has not undergone hysterectomy or bilateral oophorectomy or
__label__0	study interventions are 7-hydroxystaurosporine . myelodysplastic myeloproliferative neoplasms diagnosis and abntwenty-oneq
__label__0	study interventions are Mycophenolic Acid . noncontiguous stage ii mantle cell lymphoma diagnosis and acute myeloid leukemia
__label__0	study interventions are Lenalidomide . stage iii adult burkitt lymphoma diagnosis and no serious disease or condition that in the opinion of the investigator would compromise the patient ability to participate in the study
__label__0	study interventions are Iniparib . non small cell lung cancer stage iv diagnosis and stage iv disease including stage iiib with pleural effusion with no prior systemic therapy
__label__0	study interventions are Camptothecin . recurrent colon cancer diagnosis and absolute neutrophil count anc greater_than equal_than one five hundred mmthree
__label__0	study interventions are Cyclosporine . stage iv childhood lymphoblastic lymphoma diagnosis and chronic myelogenous leukemia
__label__0	study interventions are Vidarabine . recurrent refractory childhood hodgkin lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Isophosphamide mustard . pheochromocytoma diagnosis and renal
__label__0	study interventions are Dexamethasone 21-phosphate . recurrent grade two follicular lymphoma diagnosis and serum bilirubin less than two times the upper limit of normal
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the larynx diagnosis and or interferon based therapy
__label__0	study interventions are Ganciclovir . primary peritoneal cavity cancer diagnosis and alkaline phosphatase no greater than four times uln
__label__0	study interventions are Vinblastine . metastatic breast cancer diagnosis and able to comply with the protocol
__label__0	study interventions are Mycophenolic Acid . refractory hodgkin lymphoma diagnosis and any subtype morphologic blasts must be less than five in an evaluable marrow greater_than 2five of normal cellularity for age if blasts are five or more patient requires induction chemotherapy pre transplant to reduce blast count to less than five patients who have hypocellular marrow in the absence of excess blasts that is related to the underlying disease or as result of treatment for mds may also be eligible with the approval of the pi or designee
__label__0	study interventions are Mycophenolic Acid . recurrent hodgkin lymphoma diagnosis and donor
__label__0	study interventions are Sirolimus . metastatic cancer diagnosis and no concurrent drugs or substances known to be inhibitors or inducers of the isoenzyme cypthreea
__label__0	study interventions are Antibodies . testicular choriocarcinoma and seminoma diagnosis and at least six weeks since prior and no concurrent immunosuppressive agents for clinically active graft versus host disease gvhd prophylaxis or treatment
__label__0	study interventions are Diphosphonates . prostate cancer diagnosis and documented disease progression defined by one of the following
__label__0	study interventions are Prednisone . childhood diffuse large cell lymphoma diagnosis and group intermediate risk
__label__0	study interventions are Bortezomib . mantle cell lymphoma diagnosis and attachment two
__label__0	study interventions are Fluorouracil . gastric cancer diagnosis and performance status
__label__0	study interventions are Antibodies . lymphoma diagnosis and disease characteristics
__label__0	study interventions are Albumin-Bound Paclitaxel . primary peritoneal cavity cancer diagnosis and gog zero two
__label__0	study interventions are Antibodies, Monoclonal . stage iv adult diffuse mixed cell lymphoma diagnosis and must also either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least twenty-eight days before she starts taking lenalidomide
__label__0	study interventions are Megestrol . unspecified childhood solid tumor protocol specific diagnosis and cachexia is defined as having one or more of the following
__label__0	study interventions are Gefitinib . lung cancer diagnosis and invades the visceral pleura
__label__0	study interventions are Cyclosporins . non hodgkin lymphoma diagnosis and cll with adverse cytogenetics mcl or cell nhl
__label__0	study interventions are Pemetrexed . esophagogastric cancer diagnosis and ecog performance status less_than two
__label__0	study interventions are Ofloxacin . unspecified adult solid tumor protocol specific diagnosis and no shock or hypotension supine systolic blood pressure less than eighty mmhg unresponsive to fluid challenge other
__label__0	study interventions are Phosphonoacetic Acid . angioimmunoblastic cell lymphoma diagnosis and cmv seropositive donor and or recipient
__label__0	study interventions are Mycophenolate mofetil . stage childhood small noncleaved cell lymphoma diagnosis and myelodysplastic syndrome mds myeloproliferative disorder mpd
__label__0	study interventions are Carboplatin . epithelial ovarian cancer diagnosis and bone marrow function
__label__0	study interventions are Everolimus . liver cancer diagnosis and healthy participant
__label__0	study interventions are Folic Acid . colorectal neoplasms diagnosis and no past or current history of malignancies except for the indication under this study and curatively treated
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and for patients with bone and visceral disease fulfilling any of the criteria in doc or doc is sufficient to define progression
__label__0	study interventions are Immunoglobulins . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and hodgkin disease hd
__label__0	study interventions are questionnaire administration . bladder cancer diagnosis and west midlands
__label__0	study interventions are Liposomal doxorubicin . stage iii mantle cell lymphoma diagnosis and patients must be tested for hepatitis surface antigen hbs ag within four weeks prior to registration note
__label__0	study interventions are Cediranib . stage iv prostate cancer diagnosis and qtc prolongation greater_than five hundred msec or other ecg abnormality noted within fourteen days of treatment
__label__0	study interventions are Paclitaxel . stage iiib non small cell lung cancer diagnosis and serum creatinine or measured or calculated creatinine clearance glomerular filtration rate gfr can also be used in place of creatinine or creatinine clearance rate crcl equal_than less_than doc upper limit of normal uln or greater_than equal_than sixty ml min for subject with creatinine levels greater_than doc institutional uln
__label__0	study interventions are Cyclophosphamide . stage iii grade three follicular lymphoma diagnosis and will be permitted
__label__0	study interventions are western blotting . colorectal cancer diagnosis and see disease characteristics
__label__0	study interventions are Irradiation: HA-PCI . small cell lung cancer diagnosis and age at registration eighteen to seventy-five years
__label__0	study interventions are Echinocandins . kidney cancer diagnosis and patient characteristics
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and adequate mental function to understand and sign the consent
__label__0	study interventions are Sirolimus . endometrial cancer diagnosis and a
__label__0	study interventions are magnetic resonance imaging . breast cancer diagnosis and no claustrophobia
__label__0	study interventions are Camptothecin . neuroblastoma diagnosis and the duration of this interval must be discussed with the study chair
__label__0	study interventions are Erlotinib Hydrochloride . unspecified adult solid tumor protocol specific diagnosis and performance status
__label__0	study interventions are Trastuzumab . stage iiic gastric cancer diagnosis and patients must be able to swallow whole tablets nasogastric or gastrostomy tube administration is not allowed tablets must not be crushed or chewed
__label__0	study interventions are Dacarbazine . adult glioblastoma diagnosis and no patients with severely impaired renal function estimated glomerular filtration rate less_than thirty ml min or on dialysis
__label__0	study interventions are Melphalan . localized unresectable neuroblastoma diagnosis and ten to less_than sixteen years
__label__0	study interventions are Glycine . plasma cell myeloma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are laboratory biomarker analysis . lung cancer diagnosis and ast and alt less_than doc times uln
__label__0	study interventions are quality-of-life assessment . lymphoma diagnosis and prior concurrent therapy
__label__0	study interventions are Antibodies . stage ii grade two contiguous follicular lymphoma diagnosis and no history of acquired immune deficiency syndrome aids defining conditions
__label__0	study interventions are alvespimycin hydrochloride . recurrent breast cancer diagnosis and no increase in biochemical markers carcinoembryonic antigen or ca fifteen three or symptoms as sole evidence of disease progression
__label__0	study interventions are Antibodies, Monoclonal . recurrent melanoma diagnosis and no concurrent radiotherapy
__label__0	study interventions are Etoposide . primary central nervous system neoplasms diagnosis and children treated with chemotherapy or radiotherapy prior to entering the study will be evaluated separately
__label__0	study interventions are Dacarbazine . recurrent childhood cerebellar astrocytoma diagnosis and recovered from all prior immunotherapy
__label__0	study interventions are Liposomal doxorubicin . classical hodgkin lymphoma diagnosis and for patients aged seventy years old and more mini nutritional assessment mna greater_than seventeen
__label__0	study interventions are Selinexor . symptomatic ischemia or
__label__0	study interventions are Oxaliplatin . stage ii pancreatic cancer diagnosis and radiographic evidence for metastatic disease in distant organs such as masses in distant organs or ascites
__label__0	study interventions are Interleukin-2 . stage iv adult diffuse mixed cell lymphoma diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Etoposide . lung cancer diagnosis and surgery
__label__0	study interventions are Trabedersen . glioblastoma diagnosis and the patient has life expectancy of at least three months
__label__0	study interventions are Cisplatin . testicular germ cell tumor diagnosis and retroperitoneum
__label__0	study interventions are Antibodies, Monoclonal . neuroblastoma diagnosis and no concurrent nonsteroidal anti inflammatory agents
__label__0	study interventions are Camptothecin . histologically confirmed malignant solid tumor
__label__0	study interventions are Temozolomide . melanoma skin diagnosis and prior temozolomide or sorafenib tosylate allowed
__label__0	study interventions are Tipifarnib . bladder cancer diagnosis and creatinine clearance at least sixty ml min
__label__0	study interventions are 7-hydroxystaurosporine . recurrent extrahepatic bile duct cancer diagnosis and ast alt no greater than three times upper limit of normal uln
__label__0	study interventions are Antibodies, Monoclonal . stage iiia skin melanoma diagnosis and uncontrolled hypertension hypertension despite maximal therapy
__label__0	study interventions are Androgens . stage iii prostate cancer diagnosis and able to adhere to the study visit schedule and other protocol requirements
__label__0	study interventions are Pembrolizumab . stage iva oropharyngeal squamous cell carcinoma diagnosis and platelets
__label__0	study interventions are BB 1101 . childhood lymphocyte depleted classical hodgkin lymphoma diagnosis and pulse_oximetry greater than ninety-four
__label__0	study interventions are Citric Acid . breast cancer diagnosis and no contraindication to tamoxifen citrate or letrozole
__label__0	study interventions are Paclitaxel . recurrent fallopian tube carcinoma diagnosis and patients are allowed to receive but are not required to receive two additional cytotoxic regimens for management of recurrent or persistent disease with no more than one non platinum non taxane regimen treatment with weekly paclitaxel for recurrent or persistent disease is not allowed
__label__0	study interventions are Fludarabine phosphate . lymphoma diagnosis and chronic lymphocytic leukemia
__label__0	study interventions are Liposomal doxorubicin . liver cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Fludarabine phosphate . non hodgkin lymphoma diagnosis and treatment
__label__0	study interventions are quality-of-life assessment . stage squamous cell carcinoma of the nasopharynx diagnosis and asa american society of anesthesiologists performance status ps of one four or ecog eastern cooperative oncology group ps zero three thereby including population that stands to gain the most from minimally invasive surgical approach
__label__0	study interventions are Prednisolone . previously treated childhood rhabdomyosarcoma diagnosis and radiographic finding of pulmonary edema does not exclude the diagnosis of ips provided the other criteria have been met and provided the treating physician concludes by clinical or echocardiographic criteria that the pulmonary edema is not secondary to cardiac dysfunction or iatrogenic fluid overload
__label__0	study interventions are Tacrolimus . recurrent adult cell leukemia lymphoma diagnosis and incarceration
__label__0	study interventions are Mitomycin . carcinoma hepatocellular diagnosis and eastern clinical oncology group performance status zero one or two
__label__0	study interventions are Cognitive Assessment . stage ii ovarian cancer diagnosis and uncontrolled hypertension
__label__0	study interventions are Antibodies . adult anaplastic oligodendroglioma diagnosis and bilirubin equal_than less_than doc upper limit of normal range uln
__label__0	study interventions are Sorafenib . should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__0	study interventions are Maleic acid . cholangiocarcinoma of the gallbladder diagnosis and not pregnant or nursing
__label__0	study interventions are Antibodies, Monoclonal . primary peritoneal cavity cancer diagnosis and more than one month since prior thrombolytic agents
__label__0	study interventions are Cytarabine . stage iii grade two follicular lymphoma diagnosis and able to adhere to the study visit schedule and other protocol requirements
__label__0	study interventions are Romidepsin . recurrent gastric cancer diagnosis and taxane paclitaxel or docetaxel
__label__0	study interventions are Bortezomib . fallopian tube serous adenocarcinoma diagnosis and patients must have had one prior platinum based chemotherapeutic regimen for management of primary disease containing carboplatin cisplatin or another organoplatinum_compound this initial treatment may have included non cytotoxic therapy intraperitoneal therapy consolidation or extended therapy administered after surgical or non surgical assessment
__label__0	study interventions are Vidarabine . stage ii multiple myeloma diagnosis and eighteen sixty years of age
__label__0	study interventions are Mycophenolate mofetil . contiguous stage ii grade one follicular lymphoma diagnosis and the cdfour count less_than one00 cells ul
__label__0	study interventions are Antibodies . recurrent prostate carcinoma diagnosis and at least four weeks since prior herbal products known to decrease psa levels pc_spes or saw_palmetto
__label__0	study interventions are Rituximab . splenic marginal zone lymphoma diagnosis and more than twelve weeks
__label__0	study interventions are Letrozole . breast cancer diagnosis and any age with documented bilateral oophorectomy
__label__0	study interventions are Vincristine . adult malignant mesenchymoma diagnosis and patients who have received prior chemotherapy excluding steroids or radiation therapy except for patients transferring from arstthree hundred and thirty-one low risk study are not eligible
__label__0	study interventions are Fludarabine phosphate . stage adult diffuse mixed cell lymphoma diagnosis and only patients with mds refractory anemia ra or mds refractory anemia with ringed_sideroblasts rars will be eligible for this protocol additionally patients with myeloproliferative syndromes mps will be eligible those patients with mds or mps with greater_than five marrow blasts including those with transformation to aml must receive cytotoxic chemotherapy and achieve less_than five marrow blasts at time of transplant
__label__0	study interventions are Prednisolone phosphate . multiple myeloma and plasma cell neoplasm diagnosis and patient characteristics
__label__0	study interventions are Laboratory Biomarker Analysis . recurrent solid neoplasm diagnosis and doc maximum serum creatinine mg dl
__label__0	study interventions are Etoposide . brain and central nervous system tumors diagnosis and any age
__label__0	study interventions are Fluorouracil . stage iiia gallbladder cancer diagnosis and platelets greater_than equal_than one hundred zero ul
__label__0	study interventions are Vinblastine . previously treated childhood rhabdomyosarcoma diagnosis and host disease
__label__0	study interventions are Vaccines . stage pancreatic cancer diagnosis and at least four weeks since prior steroids and recovered radiotherapy
__label__0	study interventions are quality-of-life assessment . lymphoma diagnosis and patient characteristics
__label__0	study interventions are Isotretinoin . stage four neuroblastoma diagnosis and following treatment per pog 96four0
__label__0	study interventions are Dexamethasone 21-phosphate . adenocarcinoma of the colon diagnosis and no prior systemic chemotherapy for metastatic disease
__label__0	study interventions are Rituximab . cognitive side effects of cancer therapy diagnosis and if last regimen is with rituximab there must have been at least six months since last rituximab dose and if without rituximab there must have been at least three months since last regimen
__label__0	study interventions are Nivolumab . recurrent non small cell lung carcinoma diagnosis and phase ii only
__label__0	study interventions are Cyclophosphamide . peripheral cell lymphoma diagnosis and acute leukemia in twond or greater cr cr greater_than equal_than two
__label__0	study interventions are Ofloxacin . lymphoma diagnosis and hematopoietic
__label__0	study interventions are Entinostat . stage iv breast cancer diagnosis and note
__label__0	study interventions are Etoposide phosphate . localized osteosarcoma diagnosis and ribs sternum clavicle or scapula
__label__0	study interventions are Endothelial Growth Factors . untreated metastatic squamous neck cancer with occult primary diagnosis and no psychiatric illness or social situation that would preclude study compliance
__label__0	study interventions are Docetaxel . prostate cancer diagnosis and anc greater_than one five hundred ml and platelet count of one00 zero ml
__label__0	study interventions are Carboplatin . head and neck cancer diagnosis and metastatic or recurrent lesions of the nasopharynx and sinus are excluded
__label__0	study interventions are Carboplatin . stage iiib ovarian cancer diagnosis and neuropathy sensory and motor less than or equal to ctep ctcae version doc grade one
__label__0	study interventions are Poly ICLC . melanoma diagnosis and ecog performance status of zero or one appendix three
__label__0	study interventions are Antibodies, Monoclonal . mixed adenocarcinoma of the stomach diagnosis and urine protein creatinine upc ratio of less_than doc or dipstick for protein of less_than two positive common terminology criteria for adverse events version doc ctcae four grade less_than two patients with upc ratio greater_than equal_than doc or dipstick of two positive must undergo twofour hour urine collection and must demonstrate less_than one gm of protein in order to participate
__label__0	study interventions are alvespimycin hydrochloride . recurrent gastric cancer diagnosis and more than four weeks since prior radiotherapy
__label__0	study interventions are Erlotinib Hydrochloride . adult grade ii meningioma diagnosis and measurable or evaluable disease
__label__0	study interventions are Immunoconjugates . anaplastic large cell lymphoma alk positive diagnosis and total abstinence when this is in line with the preferred and usual_lifestyle of the subject periodic abstinence calendar_ovulation symptothermal post ovulation methods and withdrawal are not acceptable methods of contraception
__label__0	study interventions are Cyclosporine . testicular lymphoma diagnosis and stable not hematologic remission
__label__0	study interventions are Vehicle - cohort 1 . basal cell carcinomas diagnosis and the subject must provide electronic informed consent prior to any study procedures
__label__0	study interventions are Bendamustine Hydrochloride . stage iv grade one follicular lymphoma diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than doc upper limits of normal uln
__label__0	study interventions are Doxorubicin . breast adenocarcinoma diagnosis and total bilirubin within normal institutional limits
__label__0	study interventions are Immunoglobulins . recurrent grade one follicular lymphoma diagnosis and electrocardiogram one2 lead ecg
__label__0	study interventions are Veliparib . lung adenocarcinoma mixed subtype diagnosis and platelets greater_than equal_than one hundred zero ml
__label__0	study interventions are Lenalidomide . patients must have low risk disease defined as an existing myeloma prognostic risk score risk score less_than five doc from prior bone marrow biopsy sample in which plasma cells were present
__label__0	study interventions are Bortezomib . stage iv non small cell lung cancer diagnosis and patients who are enrolled at the maximum tolerated dose must have chemotherapy naïve disease
__label__0	study interventions are Vorinostat . recurrent adult lymphoblastic lymphoma diagnosis and serum creatinine less_than doc mg dl or creatinine clearance greater than sixty ml per minute by the following formula all tests must be performed within twenty-eight days prior to registration
__label__0	study interventions are Fluorouracil . gastric adenocarcinoma with peritoneal carcinomatosis diagnosis and serum creatinine less_than doc upper limit of normal and creatinine clearance greater_than sixty ml min
__label__0	study interventions are Dexamethasone acetate . cholangiolar carcinoma diagnosis and prior chemotherapy is allowed
__label__0	study interventions are Antibodies . stage iiic ovarian cancer diagnosis and hepatic artery infusional chemotherapy
__label__0	study interventions are Muromonab-CD3 . melanoma skin diagnosis and patient characteristics
__label__0	study interventions are Fludarabine . small lymphocytic lymphoma diagnosis and adequate organ function to tolerate chemotherapy
__label__0	study interventions are Trastuzumab . breast cancer diagnosis and concurrent tamoxifen therapy allowed for estrogen receptor positive patients who have not received prior hormonal therapy no other concurrent hormonal therapy radiotherapy
__label__0	study interventions are Cisplatin . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and planned definitive or adjuvant radiation with concurrent cisplatin one hundred mg mtwo every three weeks for three cycles
__label__0	study interventions are Bevacizumab . hemangioblastomas diagnosis and kps greater_than or equal to sixty
__label__0	study interventions are laboratory biomarker analysis . adult gliosarcoma diagnosis and no re irradiation any technique is allowed
__label__0	study interventions are Everolimus . duct cell adenocarcinoma of the pancreas diagnosis and female condom
__label__0	study interventions are Ifosfamide . childhood teratoma diagnosis and one line of therapy can in some cases consist of two different cisplatin based treatment combinations provided there is no disease progression between these two regimens
__label__0	study interventions are Trimethoprim, Sulfamethoxazole Drug Combination . unspecified adult solid tumor protocol specific diagnosis and patient characteristics
__label__0	study interventions are Antibodies . stage iv adenoid cystic carcinoma of the oral cavity diagnosis and platelet count greater_than seventy-five zero mm three
__label__0	study interventions are Proteasome Inhibitors . multiple myeloma plasma cell leukemia diagnosis and confirmed relapsed or refractory mm measurable disease or pcl
__label__0	study interventions are Temozolomide . metastatic ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and cytochrome pfour hundred and fifty cypthreeafour active agents
__label__0	study interventions are Antibodies . stage ii small lymphocytic lymphoma diagnosis and patients must have documented cell lymphocytosis greater_than five ten nine at some point since initial diagnosis of cll
__label__0	study interventions are Vorinostat . stage iii adult diffuse mixed cell lymphoma diagnosis and ast alt less_than doc times upper limit of normal uln
__label__0	study interventions are Imatinib Mesylate . previous histologic diagnosis of lower grade of glioma allowed if there is histologic evidence of progression to diagnosis of malignant glioma
__label__0	study interventions are Tetrathiomolybdate . colorectal carcinoma diagnosis and patients must have adequate renal function as documented by serum creatinine less_than doc mg dl and have adequate hepatic function as documented by serum bilirubin less_than doc mg dl within two weeks of enrollment
__label__0	study interventions are Irinotecan . lung cancer diagnosis and anc greater_than one five hundred mm³
__label__0	study interventions are Antibodies . recurrent adult burkitt lymphoma diagnosis and fourteen days prior to and again within twenty-four hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least twenty-eight days before she starts taking lenalidomide fcbp must also agree to ongoing pregnancy testing men must agree to use latex condom during sexual contact with fcbp even if they have had successful vasectomy all patients must be counseled at minimum of every twenty-eight days about pregnancy precautions and risks of fetal exposure
__label__0	study interventions are Rituximab . aggressive marginal zone lymphoma mzl diagnosis and agree to have medically supervised pregnancy test with minimum sensitivity of twenty-five miu ml on the day of the study visit or in the three days prior to the study visit once the subject has been on effective contraception for at least four weeks
__label__0	study interventions are Cetuximab . recurrent midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and no prior cetuximab
__label__0	study interventions are Osimertinib . non small cell lung cancer diagnosis and treatment any of the following
__label__0	study interventions are Doxorubicin . stage ib breast cancer diagnosis and note
__label__0	study interventions are Sorafenib . liver cancer diagnosis and inr less_than doc or pt ptt within normal limits
__label__0	study interventions are Doxorubicin . recurrent primary peritoneal carcinoma diagnosis and normal cardiac function as determined by left ventricular ejection fraction lvef greater_than equal_than institutional lower limit of normal on echocardiogram or multi gated acquisition scan muga within one month of registration
__label__0	study interventions are Antibodies . adenocarcinoma of the colon diagnosis and no concurrent herbal remedies unless initiated prior to study entry
__label__0	study interventions are Cyclosporine . nonmalignant neoplasm diagnosis and no cr within four weeks of initial treatment
__label__0	study interventions are ixabepilone . extragonadal germ cell tumor diagnosis and no active infection
__label__0	study interventions are Aldesleukin . kidney cancer diagnosis and surgery
__label__0	study interventions are Digoxin . prostate cancer diagnosis and ecog less_than two or karnofsky performance status greater_than seventy within fourteen days before being registered for protocol therapy appendix b
__label__0	study interventions are Paclitaxel . stage iii ampulla of vater cancer diagnosis and women of childbearing potential and sexually active males must use an effective contraception method during treatment and for three months after completing treatment
__label__0	study interventions are Formyltetrahydrofolates . esophageal neoplasms diagnosis and women of childbearing potential and men must agree to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry and for the duration of study participation
__label__0	study interventions are Carboplatin . lung cancer diagnosis and not specified
__label__0	study interventions are Oxaliplatin . stage iii gastric cancer diagnosis and alanine aminotransferase alt aspartate aminotransferase ast less than twox uln for the reference laboratory
__label__0	study interventions are Olaparib . advanced solid tumors diagnosis and patients with measurable or non measurable disease according to recist
__label__0	study interventions are Sirolimus . squamous cell cancer diagnosis and adequate bone marrow reserve
__label__0	study interventions are counseling intervention . stage iiia breast cancer diagnosis and spouses and patients must have english as one of their languages of choice they can be multilingual
__label__0	study interventions are CoFactor and 5FU . colon cancer diagnosis and karnofsky performance status of sixty or greater
__label__0	study interventions are Camptothecin . recurrent solid neoplasm diagnosis and six to less_than ten years
__label__0	study interventions are Bexarotene . histologically confirmed cutaneous cell lymphoma
__label__0	study interventions are Mycophenolic Acid . stage ii childhood large cell lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Carboplatin . brain and central nervous system tumors diagnosis and life expectancy
__label__0	study interventions are Levoleucovorin . pancreatic cancer diagnosis and patient characteristics
__label__0	study interventions are Doxorubicin . the immunophenotype of tumor cells must be either cell or non cell non cell
__label__0	study interventions are Maleic acid . metastatic pancreatic adenocarcinoma diagnosis and for all patients
__label__0	study interventions are Lapatinib . stage iv squamous cell carcinoma of the oropharynx diagnosis and total bilirubin equal_than less_than two
__label__0	study interventions are Abiraterone Acetate . prostate cancer metastatic diagnosis and ecog performance status of zero two
__label__0	study interventions are Mesna . extragonadal germ cell tumor diagnosis and children who are uncooperative must meet all of the following criteria
__label__0	study interventions are Immunoglobulins . colorectal cancer diagnosis and no significant cardiac disease new york heart association class ii iv heart disease other
__label__0	study interventions are Vaccines . malignant mesothelioma diagnosis and completed chemotherapy surgery and or radiotherapy
__label__0	study interventions are Aldesleukin . stage ii cutaneous cell non hodgkin lymphoma diagnosis and absolute neutrophil count greater_than one five hundred mm three
__label__0	study interventions are Carboplatin . clear cell renal cell carcinoma diagnosis and renal medullary
__label__0	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and for each lesion such as mri or ct when measured by traditional methods should be at least twentymm spiral ct spiral ct have been measured to be less than tenmm when
__label__0	study interventions are Metronidazole . stage prostate cancer diagnosis and granulocytes greater_than equal_than one thousand, five hundred mm three
__label__0	study interventions are Antibodies, Monoclonal . solid neoplasm diagnosis and two weeks from administration of non cytotoxic fda approved agent erlotinib hydroxychloroquine etc
__label__0	study interventions are Rucaparib . advanced solid tumor with evidence of germline or somatic brca diagnosis and have evidence of measurable disease as defined by recist version doc
__label__0	study interventions are Cetuximab . recurrent squamous cell carcinoma of the nasopharynx diagnosis and refractory to interleukin two il two
__label__0	study interventions are Capecitabine . stage iv colon cancer diagnosis and tubes or tubes allowed
__label__0	study interventions are Antibodies, Monoclonal . rectal cancer diagnosis and hemoglobin greater_than nine dl
__label__0	study interventions are Everolimus . stage ivc salivary gland cancer diagnosis and leukocytes greater_than equal_than three mm three
__label__0	study interventions are Methotrexate . t cell lymphoma diagnosis and doc
__label__0	study interventions are Mycophenolic Acid . aggressive non hodgkin lymphoma diagnosis and hla class hla b allele matched donors allowing for any one or two drbone and or dqbone antigen allele mismatch
__label__0	study interventions are Camptothecin . sarcoma diagnosis and normal liver function
__label__0	study interventions are AZD9150 . gastrointestinal cancer diagnosis and for this reason women of child bearing potential should use reliable methods of contraception from the time of screening until six months after discontinuing study treatment
__label__0	study interventions are Aldesleukin . lymphoma diagnosis and not specified hematopoietic
__label__0	study interventions are Dasatinib . glioma diagnosis and hematocrit greater_than or equal_than to twenty-nine anc greater_than or equal_than to one five hundred mmthree platelet count greater_than or equal_than to one2five zero mmthree total bilirubin less_than or equal_than to doc uln alt and ast less_than or equal_than to doc the uln less_than or equal_than to five uln for patients with liver involvement inr less_than doc or pt ptt within normal limits unless on therapeutic anti coagulation
__label__0	study interventions are Methylprednisolone . testicular germ cell tumor diagnosis and no increasing levels of viremia by serial quantitative viral plasma polymerase chain reaction assays
__label__0	study interventions are Dexamethasone 21-phosphate . malignant ovarian mixed epithelial tumor diagnosis and partial thromboplastin time ptt less_than doc times the upper limit of normal heparin lovenox or alternative anticoagulants are acceptable
__label__0	study interventions are therapeutic conventional surgery . breast cancer diagnosis and patient characteristics
__label__0	study interventions are gp209-2M antigen . melanoma skin diagnosis and not specified hematopoietic
__label__0	study interventions are AZD6244 . non squamous cell lung cancer with wild type kras diagnosis and prior chemotherapy and or if indicated accessible egfr directed or alk directed therapy for advanced disease
__label__0	study interventions are Mycophenolate mofetil . examples include monosomy seven msix mseven six nine fltthree_itd or patients who have greater than or equal to twenty-five blasts by morphology after induction or who do not achieve cr after two courses of therapy includes myeloid sarcoma
__label__0	study interventions are Azacitidine . osteogenic sarcoma diagnosis and liver function
__label__0	study interventions are Aldesleukin . melanoma skin diagnosis and prior concurrent therapy
__label__0	study interventions are Fulvestrant . stage iiib breast cancer diagnosis and two positive by ihc and ish ratio hertwo gene copy chromosome seventeen less_than two
__label__0	study interventions are Olaparib . high grade fallopian tube serous adenocarcinoma diagnosis and leukocytes greater_than equal_than three zero mcl
__label__0	study interventions are Oxaliplatin . colorectal cancer diagnosis and performance status
__label__0	study interventions are Paclitaxel . stage iv ovarian epithelial cancer diagnosis and fasting serum cholesterol equal_than less_than doc mmol l
__label__0	study interventions are Cyclophosphamide . triple negative breast cancer diagnosis and no advanced metastasis or metastasis involving brain or liver
__label__0	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the hypopharynx diagnosis and no history of documented thrombosis pulmonary embolism within the past twelve months or deep vein thrombosis dvt within the past six months known coagulopathies or thrombophilia or evidence of dvt thromboembolic event
__label__0	study interventions are BB 1101 . diffuse large cell lymphoma diagnosis and patients must have received at least two cycles of anthracycline based chemotherapy administered with curative intent and one of the following
__label__0	study interventions are Liposomal doxorubicin . ovarian cancer diagnosis and at least sixty years of age or greater_than eighteen years of age if patient is not suitable for intensive combination chemotherapy treatments
__label__0	study interventions are laboratory biomarker analysis . stage iiia colon cancer diagnosis and patients must provide written informed consent and health insurance_portability and accountability_act hipaa consent prior to performance of study specific procedures or assessments and must be willing to comply with treatment and follow up
__label__0	study interventions are Capecitabine . breast cancer diagnosis and patients able to comply with treatment and study follow up
__label__0	study interventions are Dexamethasone . recurrent childhood small noncleaved cell lymphoma diagnosis and no uncontrolled infection
__label__0	study interventions are Antibodies . stage iia ovarian cancer diagnosis and regimens and ii
__label__0	study interventions are Irinotecan . follicular thyroid cancer diagnosis and confirmation of trop two expression by immunohistology or other means is not required but the sponsor will request tissue specimens from archived materials for determination of trop two expression
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and disease characteristics
__label__0	study interventions are Antibodies, Monoclonal . recurrent pancreatic cancer diagnosis and inr less_than doc less_than three for patients on warfarin
__label__0	study interventions are active surveillance . stage iib prostate cancer diagnosis and as the intent of serial biopsy is to ensure that the disease has not progressed to the stage or grade of requiring treatment the presence of negative biopsy following an initial positive biopsy coupled with clinically localized tonec or ttwoa psa less_than equal_than one0 and gleason less_than equal_than six for patient who has had no treatment will not render the patient ineligible
__label__0	study interventions are Dexrazoxane . not have been diagnosed with any subsequent malignancy with the exception of non melanomatous skin cancer patients with history of only subsequent non melanomatous skin cancers remain eligible
__label__0	study interventions are Paclitaxel . breast cancer diagnosis and disease characteristics
__label__0	study interventions are Erlotinib Hydrochloride . recurrent basal cell carcinoma of the lip diagnosis and previously untreated and not candidate for il two based therapy
__label__0	study interventions are Azacitidine . stage iia non small cell lung carcinoma diagnosis and platelets greater_than one hundred zero mcl
__label__0	study interventions are Everolimus . pathologically confirmed head and neck carcinoma any histology other than sarcoma lymphoma or melanoma
__label__0	study interventions are Enhanced Tailored . breast cancer diagnosis and survivor is willing to contact
__label__0	study interventions are Carboplatin . brain tumors diagnosis and no medical contraindication to radiotherapy or chemotherapy such as preexisting dna breakage syndromes fanconi anemia nijmegen breakage syndrome gorlin syndrome or other reasons as defined by patient clinician
__label__0	study interventions are Doxorubicin . mantle cell lymphoma blastoid
__label__0	study interventions are Docetaxel . stage iia breast cancer diagnosis and nodal status
__label__0	study interventions are Alemtuzumab . recurrent adult cell leukemia lymphoma diagnosis and patients must be not eligible for conventional transplants and must have disease expected to be stable for at least one hundred days without chemotherapy patients with hematologic malignancies treatable with hematopoietic stem cell transplant hsct or with b cell malignancy except those treatable with autologous transplant will be included
__label__0	study interventions are Sorafenib . stage iii colon cancer diagnosis and bilirubin normal
__label__0	study interventions are Misonidazole . stage iva cervical cancer diagnosis and psychiatric illness social situations that would limit compliance with study requirements
__label__0	study interventions are ACE-011 - 45 mg . uterine cervical cancer diagnosis and understand and voluntarily sign informed consent
__label__0	study interventions are Ad5CMV-p53 gene . stage zero oropharyngeal cancer diagnosis and clinically evident diffuse premalignant disease defined by one of the following mucosal abnormalities
__label__0	study interventions are Dexamethasone . stage multiple myeloma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Vitamin B Complex . primary peritoneal serous adenocarcinoma diagnosis and total bilirubin equal_than less_than two upper limit of normal uln unless patient has documented history of gilbert disease then direct bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Erlotinib Hydrochloride . fallopian tube cancer diagnosis and not pregnant
__label__0	study interventions are Sorafenib . reccurent metastatic solid tumor disease diagnosis and patients must be affiliated to the french social security system
__label__0	study interventions are Vidarabine . recurrent marginal zone lymphoma diagnosis and high intermediate to high international prognostic score myelodysplasia
__label__0	study interventions are Paclitaxel . bronchoalveolar cell lung cancer diagnosis and no cardiac arrhythmia
__label__0	study interventions are Antibodies . childhood diffuse large cell lymphoma diagnosis and host disease and at least fifty-six days must have elapsed after transplant or stem cell infusion
__label__0	study interventions are Methotrexate . lymphoma diagnosis and biologic therapy
__label__0	study interventions are Dacarbazine . small cell glioblastoma diagnosis and adult patients greater_than eighteen years old
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and no other serious underlying medical condition that would preclude study participation
__label__0	study interventions are Prednisone . neoplasm prostatic diagnosis and patients must have metastatic disease defined as at least one lesion on bone scan or at least one lesion that can be accurately measured in at least one dimension longest diameter to be recorded for non nodal lesions and short axis for nodal lesions as greater_than twenty mm with conventional techniques or as greater_than ten mm with spiral ct scan mri or calipers by clinical exam
__label__0	study interventions are Antibodies, Monoclonal . tumor tissue archival or recent tumor biopsy must be available for biomarker evaluation
__label__0	study interventions are Goserelin . recurrent prostate cancer diagnosis and no concurrent medications associated with the risk of qtc prolongation and or torsades de pointes
__label__0	study interventions are Pemetrexed . mesothelioma diagnosis and pulmonary function
__label__0	study interventions are Bortezomib . recurrent adult diffuse large cell lymphoma diagnosis and for patients with known human immunodeficiency virus hiv infection cluster of differentiation cd four count greater_than equal_than doc ten nine l
__label__0	study interventions are Tumor Removal . brain cancer diagnosis and doc cm in diameter
__label__0	study interventions are Gemcitabine . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and serum bilirubin less than two times the upper limit of normal
__label__0	study interventions are Docetaxel . breast cancer diagnosis and no prior severe hypersensitivity reaction to drugs formulated with polysorbate eighty
__label__0	study interventions are Camptothecin . triple negative breast cancer diagnosis and eighteen years of age or above
__label__0	study interventions are Antibodies, Monoclonal . splenic marginal zone lymphoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mm three
__label__0	study interventions are Vaccines . melanoma skin diagnosis and completed prior interferon alfa therapy or
__label__0	study interventions are Folic Acid . pathologically proven esophageal squamous cell or adenocarcinoma recurrence or metastasis measurable disease greater_than one one cm by cxr ct scan or mri age greater_than one8 kps greater_than sixty cre less_than doc mg dl ast alt less_than doc n bil less_than doc mg dl wbc greater_than four zero mmthree anc greater_than two zero mmthree plt greater_than one00 zero mmthree
__label__0	study interventions are Bortezomib . stage iii cutaneous cell non hodgkin lymphoma diagnosis and no significant cardiovascular disease including any of the following
__label__0	study interventions are educational intervention . recurrent ovarian germ cell tumor diagnosis and to be considered for the blood and saliva collection women must fulfill the following secondary criteria
__label__0	study interventions are Irinotecan . breast cancer diagnosis and at least twelve weeks hematopoietic
__label__0	study interventions are Cyclosporine . cutaneous cell non hodgkin lymphoma diagnosis and bone marrow will be collected from donors less than twelve years of age
__label__0	study interventions are Cabozantinib . carcinoid tumor diagnosis and participants must have adequate organ and marrow function as defined below
__label__0	study interventions are Prednisolone phosphate . recurrent small lymphocytic lymphoma diagnosis and cm negative chronic phase cpone and resistant to or intolerant of tyrosine kinase inhibitors imatinib dasatinib etc
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and hepatic
__label__0	study interventions are Albumin-Bound Paclitaxel . adenosquamous cell lung cancer diagnosis and no other prior malignancy is allowed except for the following
__label__0	study interventions are therapeutic allogeneic lymphocytes . hepatosplenic cell lymphoma diagnosis and eligibility to receive dli post transplant
__label__0	study interventions are Individual MBSR . breast cancer diagnosis and both members of the couple must have regular access to email and willingness to use the internet
__label__0	study interventions are Fludarabine phosphate . recurrent adult non hodgkin lymphoma diagnosis and age greater_than equal_than twelve years of age
__label__0	study interventions are Sirolimus . hormone resistant prostate cancer diagnosis and patients who have been treated with surgical resection for hcc and following chemoembolization as adjuvant therapy for hcc
__label__0	study interventions are gene expression analysis . specimens from patients with ewing sarcoma used for protocol cog aewseightbone
__label__0	study interventions are Carboplatin . lesions must be measured by ct scan or mri according to response evaluation criteria in solid tumors recist added with protocol global version four
__label__0	study interventions are Antibodies . localized resectable neuroblastoma diagnosis and total bilirubin equal_than less_than doc normal
__label__0	study interventions are Mycophenolic Acid . recurrent mantle cell lymphoma diagnosis and chronic myelogenous leukemia cml in twond chronic phase
__label__0	study interventions are Gossypol . small lymphocytic lymphoma diagnosis and must have histologically confirmed cell malignancy defined as fl any grade dlbcl mcl or sll cll
__label__0	study interventions are Cisplatin . small cell lung cancer sclc diagnosis and participants who have had cr after pre study therapy are not eligible for study
__label__0	study interventions are Methamphetamine . surgical evaluation by member of the liver tumor program must conclude the patient is not candidate for resection or ablation
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and physical score zero two grade who standard and able to comply with the visit time and protocol requirements
__label__0	study interventions are Pembrolizumab . rectal carcinoma diagnosis and absolute neutrophil count
__label__0	study interventions are Camptothecin . adenocarcinoma of the rectum diagnosis and locally advanced or metastatic disease
__label__0	study interventions are Vorinostat . recurrent melanoma diagnosis and total bilirubin within institutional limits
__label__0	study interventions are Bevacizumab . colorectal cancer diagnosis and one
__label__0	study interventions are Doxorubicin . lymphoma hodgkin diagnosis and endocrine therapy
__label__0	study interventions are Prednisolone . diffuse large cell lymphoma diagnosis and agree to abstain from donating blood while they are taking the treatment and after discontinuation of study drug therapy
__label__0	study interventions are Camptothecin . stage iii colon cancer diagnosis and new york heart association class iii or iv heart disease
__label__0	study interventions are Laboratory Biomarker Analysis . b lymphoblastic leukemia lymphoma diagnosis and able to deliver four fresh within twenty-four hours stool samples to mayo clinic rochester over four month period
__label__0	study interventions are Epigallocatechin gallate . human papilloma virus infection diagnosis and able and willing to return to clinic for study visits once every four weeks for the duration of the study
__label__0	study interventions are Antibodies, Monoclonal . marginal zone lymphoma
__label__0	study interventions are Paclitaxel . extragonadal germ cell tumor diagnosis and not specified
__label__0	study interventions are Gemcitabine . non small cell lung cancer diagnosis and subjects must have programmed death ligand one pd lone immunohistochemical ihc testing with results performed by the central lab during the screening period
__label__0	study interventions are Estrogens . disease refractory to non steroidal aromatase inhibitors nsai
__label__0	study interventions are Blood sampling . histologically proven breast carcinoma
__label__0	study interventions are Cortisone acetate . stage childhood hodgkin lymphoma diagnosis and no prior radiotherapy
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and men must agree not to father child and agree to use latex condom even if he has had successful vasectomy if partner is fcbp
__label__0	study interventions are Endostatins . head and neck neoplasms diagnosis and ecog performance status of zero to two
__label__0	study interventions are Pentostatin . adenocarcinoma of lung diagnosis and both men and women and members of all races and ethnic groups are eligible for this trial
__label__0	study interventions are S-1 plus DC-CIK . pancreatic cancer diagnosis and informed consent signed
__label__0	study interventions are Vaccines . breast cancer diagnosis and at least four weeks since prior and no concurrent chemotherapy
__label__0	study interventions are Levoleucovorin . unresectable extrahepatic bile duct cancer diagnosis and hemoglobin greater_than equal_than nineg dl
__label__0	study interventions are Pembrolizumab . melanoma diagnosis and subjects for whom newly obtained samples cannot be obtained inaccessible or patient safety concern may submit an archived specimen only upon agreement from the sponsor
__label__0	study interventions are Dexamethasone 21-phosphate . stage iii marginal zone lymphoma diagnosis and absolute neutrophil count greater_than equal_than one thousand mm three
__label__0	study interventions are Sorafenib . refractory solid tumors diagnosis and patients of child bearing potential should be using adequate contraceptive measures should not be breast feeding and must have negative pregnancy test prior to start of dosing
__label__0	study interventions are Bevacizumab . colorectal cancer diagnosis and wbc greater_than one five hundred mm three
__label__0	study interventions are Prednisone . multiple myeloma diagnosis and latex condom diaphragm cervical cap for four weeks prior to beginning study drug therapy during study drug therapy including dose interruption and for four weeks after discontinuation of lenalidomide therapy
__label__0	study interventions are Antibodies, Monoclonal . recurrent colon cancer diagnosis and hypertension must be well controlled less than one hundred and sixty ninety and on stable regimen of antihypertensive therapy
__label__0	study interventions are Bortezomib . recurrent squamous cell carcinoma of the larynx diagnosis and patients must have had no prior invasive malignancy unless the disease free interval is five years or more
__label__0	study interventions are Cytarabine . sarcoma diagnosis and at least six months since prior radiotherapy to greater_than fifty of the pelvis
__label__0	study interventions are Interleukin-12 . stage iii cutaneous cell non hodgkin lymphoma diagnosis and no htlv or htlv ii associated disease
__label__0	study interventions are Freund's Adjuvant . extrahepatic bile duct cancer diagnosis and white blood count wbc at least four zero mm three
__label__0	study interventions are Cyclophosphamide . long term effects secondary to cancer therapy in children diagnosis and no significant risk for general anesthesia
__label__0	study interventions are Edetic Acid . localized non resectable adult liver carcinoma diagnosis and ct features suggestive of hcc including those features which have been described herein they are also enumerated below
__label__0	study interventions are Camptothecin . stage iv gastric cancer diagnosis and full dose anticoagulants allowed provided the following criteria are met
__label__0	study interventions are Sirolimus . brain and central nervous system tumors diagnosis and serum total triglycerides less_than four hundred mg dl
__label__0	study interventions are Interleukin-12 . metastatic cancer diagnosis and fertile patients must use effective contraception during and for at least two months after completion of study treatment
__label__0	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and previous therapy with irinotecan oxaliplatin and fluoropyrimidine either alone or in any combination s
__label__0	study interventions are Celecoxib . breast cancer diagnosis and aluminum antacids
__label__0	study interventions are Sirolimus . patients must have had previous histological verification of rhabdomyosarcoma at original diagnosis
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent ovarian cancer diagnosis and female patients must be surgically sterile postmenopausal no menses for at least one year or using medically approved method of contraception excluding rhythm withdraw or abstinence
__label__0	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and alkaline phosphatase and ast must be less than three times the upper limit of normal
__label__0	study interventions are European Organization for Research and Treatment of Cancer (EORTC) QLQ-30 . pancreas cancer diagnosis and treatment of additional site outside of the abdomen while the patient is on trial is acceptable
__label__0	study interventions are DS-8273a . lymphoma diagnosis and has an eastern cooperative oncology group ecog performance status zero one
__label__0	study interventions are Vaccines . lymphoma diagnosis and patient characteristics
__label__0	study interventions are Samarium ethylenediaminetetramethylenephosphonate . metastatic osteosarcoma diagnosis and life expectancy greater_than eight weeks
__label__0	study interventions are Cyclosporine . multiple myeloma and plasma cell neoplasm diagnosis and disease characteristics
__label__0	study interventions are Sirolimus . adult diffuse large cell lymphoma diagnosis and mantle cell nhl
__label__0	study interventions are laboratory biomarker analysis . stage iii adenoid cystic carcinoma of the oral cavity diagnosis and no clinically significant pulmonary comorbidity severe chronic obstructive pulmonary disease
__label__0	study interventions are Fluorodeoxyglucose F18 . adenocarcinoma of the esophagus diagnosis and marrow
__label__0	study interventions are Fludarabine phosphate . chronic granulomatous disease diagnosis and single unrelated umbilical cord blood unit with zero two antigen mismatch and minimum cell dose of greater_than five 1zero seven nucleated cells kg as per current institutional guidelines
__label__0	study interventions are Albumin-Bound Paclitaxel . hertwo negative breast cancer diagnosis and female greater_than eighteen years old
__label__0	study interventions are Cyclosporins . recurrent cutaneous cell non hodgkin lymphoma diagnosis and acute leukemia with less_than ten blasts
__label__0	study interventions are Ganciclovir . stage iv adult lymphoblastic lymphoma diagnosis and all patients must be capable of signing written informed consent and no consent can be provided by legal guardian
__label__0	study interventions are 4SCAR-GD2 . neuroblastoma diagnosis and four at least four weeks must have elapsed since prior therapy that included monoclonal antibody
__label__0	study interventions are ASG-22CE . tumors diagnosis and gamma gt less_than doc uln
__label__0	study interventions are Daratumumab . multiple myeloma diagnosis and must have measurable disease as defined by protein or serum free light chain
__label__0	study interventions are Carboplatin . stage ii non small cell lung cancer diagnosis and granulocyte count
__label__0	study interventions are Vorinostat . recurrent adult diffuse large cell lymphoma diagnosis and patients with unstable or untreated non irradiated brain metastases should be excluded
__label__0	study interventions are Doxorubicin . stage iiic breast cancer diagnosis and patient must be willing and able to undergo mri as outlined in protocol
__label__0	study interventions are Fludarabine . multiple myeloma diagnosis and negative pregnancy test
__label__0	study interventions are Paclitaxel . neoplasms diagnosis and suitable for paclitaxel chemotherapy
__label__0	study interventions are Deferasirox . lymphoma diagnosis and adequate renal function defined as serum creatinine less_than or equal_than doc mg dl and creatinine clearance of greater_than or equal_than sixty ml min calculated using the crockcroft gault formula on two occasions within thirty days of enrollment
__label__0	study interventions are Sorafenib . prostate cancer diagnosis and patients on flutamide must have disease progression at least four weeks after withdrawal
__label__0	study interventions are Fludarabine phosphate . recurrent grade one follicular lymphoma diagnosis and the following diseases will be permitted although other diagnoses can be considered if approved by pcc or the participating institutions patient review committees and the principal investigators
__label__0	study interventions are Dabrafenib . brafvsix_hundrede melanoma patients diagnosis and creatinine less_than doc mg dl
__label__0	study interventions are Melphalan . ovarian mixed germ cell tumor diagnosis and high dose chemotherapy
__label__0	study interventions are Immunoglobulins . recurrent adult brain neoplasm diagnosis and willing to return to enrolling institution for follow up
__label__0	study interventions are Vaccines . stage iib breast cancer diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot equal_than less_than two times upper limit of normal uln
__label__0	study interventions are Paclitaxel . fallopian tube cancer diagnosis and eighteen years of age or above
__label__0	study interventions are Dexamethasone acetate . renal cancer diagnosis and patients are required to have received prior rituximab alone or combined with other treatment and are considered refractory to defined as no response or progression within six months of completing therapy or intolerant of continued rituximab
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and small cells in bone marrow allowed
__label__0	study interventions are Prednisolone acetate . nasopharyngeal carcinoma diagnosis and prior irradiation greater_than equal_than six months prior to study entry
__label__0	study interventions are Folic Acid . stage iii childhood hepatocellular carcinoma diagnosis and twenty-eight days have elapsed since that therapy lesions that have not been treated with local therapy must be present and measureable
__label__0	study interventions are Vaccines . male breast cancer diagnosis and no allergy to eggs
__label__0	study interventions are Rituximab . stage iii adult diffuse small cleaved cell lymphoma diagnosis and must also either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control one highly effective method and one additional effective method at the same time at least twenty-eight days before she starts taking lenalidomide
__label__0	study interventions are Carboxymethylcellulose Sodium . pancreatic adenocarcinoma non resectable diagnosis and patients do not need to demonstrate progression to be considered for this trial
__label__0	study interventions are Antibodies, Monoclonal . stage iii small lymphocytic lymphoma diagnosis and donor
__label__0	study interventions are Cyclophosphamide . recurrent refractory childhood hodgkin lymphoma diagnosis and able to give informed consent
__label__0	study interventions are therapeutic conventional surgery . adult anaplastic oligodendroglioma diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible
__label__0	study interventions are Amphotericin B . patients who participate in another clinical trial except anti cancer trials
__label__0	study interventions are Tacrolimus . multiple myeloma and malignant plasma cell neoplasms diagnosis and with poor risk cytogenetics
__label__0	study interventions are Oxaliplatin . breast neoplasms diagnosis and or metastatic settings concurrent sequential or combined with other drugs
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and adequate renal function as evidenced by serum creatinine less_than doc mg dl
__label__0	study interventions are Melphalan . high risk tumor diagnosis and female only is not breastfeeding
__label__0	study interventions are Fludarabine . stage iii adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__0	study interventions are Bortezomib . recurrent adult immunoblastic large cell lymphoma diagnosis and no history of pulmonary toxicity after receiving anthracyclines doxorubicin hydrochloride daunorubicin hydrochloride mitoxantrone hydrochloride bleomycin or carmustine
__label__0	study interventions are CI-1040 . colorectal cancer diagnosis and menopausal status
__label__0	study interventions are Erlotinib Hydrochloride . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and no prior bevacizumab
__label__0	study interventions are Aldesleukin . metastatic cancer that express the mage_athree hla aone antigen diagnosis and greater than or equal to eighteen years of age and less than or equal to age seventy
__label__0	study interventions are Alvocidib . stage iii small lymphocytic lymphoma diagnosis and nci grade two or three fatigue
__label__0	study interventions are Interleukin-2 . symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism
__label__0	study interventions are Tetrathiomolybdate . patients must have histologically proven adenocarcinoma primary to the colon or rectum and clinical or pathologic evidence of distant metastasis
__label__0	study interventions are BB 1101 . myelodysplastic myeloproliferative neoplasms diagnosis and prior concurrent therapy
__label__0	study interventions are Mycophenolic Acid . noncontiguous stage ii grade two follicular lymphoma diagnosis and myelodysplastic syndromes myeloproliferative disorders mds mpd
__label__0	study interventions are Ifosfamide . metastatic malignant neoplasm in the bone diagnosis and age greater_than equal_than sixteen years
__label__0	study interventions are Decitabine . stage ivc papillary thyroid cancer diagnosis and creatinine not elevated or
__label__0	study interventions are Fludarabine . stage mantle cell lymphoma diagnosis and patient and donor pairs_homozygous at mismatched allele in the graft rejection_vector are considered two allele mismatch the patient is one hundred and one and the donor is two hundred and one and this type of mismatch is not allowed
__label__0	study interventions are Cisplatin . stage iiic unresectable ovarian tubes or peritoneal primitive adenocarcinoma according to figo classification previously treated with six cycles of carboplatin cisplatin neoadjuvant chemotherapy with response allowing complete surgery after the six cycles
__label__0	study interventions are Antibodies, Monoclonal . recurrent pancreatic cancer diagnosis and absolute neutrophil count greater_than one two hundred and fifty mm three
__label__0	study interventions are BB 1101 . cancer of the breast diagnosis and signed informed consent
__label__0	study interventions are Prednisolone . lymphoma diagnosis and acquired severe aplastic anemia
__label__0	study interventions are polymerase chain reaction . sarcoma diagnosis and no known hiv positivity
__label__0	study interventions are Levoleucovorin . sarcoma diagnosis and incompletely resected all sites under ten years at diagnosis
__label__0	study interventions are Cyclosporine . type one papillary renal cell carcinoma diagnosis and chronic lymphocytic leukemia cll
__label__0	study interventions are gastrointestinal complications management/prevention . prostate cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Ramucirumab . stomach cancer diagnosis and adequate renal hematological and hepatic function
__label__0	study interventions are DS-2248 . non small cell lung carcinoma diagnosis and acquired resistance to reversible epidermal growth factor receptor tyrosine kinase inhibitor egfr tki which should meet the following criteria
__label__0	study interventions are Folic Acid . stage iiic breast cancer diagnosis and patient has at least one of the following
__label__0	study interventions are Deferasirox . stage iii multiple myeloma diagnosis and clinical or laboratory evidence of active hepatitis or hepatitis hbsag in the absence of hbsab or hcv ab positive with hcv rna positive and alt above the normal range
__label__0	study interventions are Cyclosporins . recurrent adult diffuse mixed cell lymphoma diagnosis and any phase of mds if patient is less_than twenty-one years of age
__label__0	study interventions are Cyclosporins . lymphoma diagnosis and not pregnant or lactating hiv negative no uncontrolled viral bacterial or fungal infection
__label__0	study interventions are Pembrolizumab . gastric adenocarcinoma diagnosis and performance status of zero or one on the eastern cooperative oncology group ecog performance scale within three days prior to first dose of study medication
__label__0	study interventions are Dacarbazine . brain tumors diagnosis and
__label__0	study interventions are Vorinostat . stage iii marginal zone lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Antibodies, Monoclonal . recurrent pancreatic neuroendocrine carcinoma diagnosis and patients who have had prior anthracycline must have normal ejection fraction on left ventricular ejection fraction lvef assessment by multigated acquisition scan muga or echocardiogram echo equal_than less_than four weeks prior to registration
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent primary peritoneal carcinoma diagnosis and strong inhibitors of cytochrome four hundred and fifty system cyp threeafour are prohibited
__label__0	study interventions are Denileukin diftitox . stage iii ovarian epithelial cancer diagnosis and white blood cell count wbc greater_than doc thou ul
__label__0	study interventions are Cyclophosphamide . stage iv mantle cell lymphoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two at time of consent
__label__0	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and significant vascular disease aortic aneurysm or history of aortic dissection
__label__0	study interventions are Cyclosporins . nodal marginal zone cell lymphoma diagnosis and the following diseases will be permitted although other diagnoses can be considered if approved by pcc or the participating institution patient review committees and the principal investigator
__label__0	study interventions are Cisplatin . stage iii ovarian epithelial cancer diagnosis and bilirubin equal_than less_than doc mg dl
__label__0	study interventions are coagulation study . unspecified adult solid tumor protocol specific diagnosis and no concurrent estrogen contraceptives or hormone replacement therapy
__label__0	study interventions are Prednisolone phosphate . myeloma diagnosis and ag negative must be at least eighteen years of age
__label__0	study interventions are internet-based intervention . recurrent marginal zone lymphoma diagnosis and has internet and email access indicated by logon to site for consent and assessment
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and recurrent disease
__label__0	study interventions are Palbociclib . stage iii extragonadal non seminomatous germ cell tumor diagnosis and however women who have been amenorrheic for twelve or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy antiestrogens or ovarian suppression
__label__0	study interventions are Antibodies, Monoclonal . untreated stage iii melanoma or stage iv melanoma diagnosis and wbc greater_than two thousand ul
__label__0	study interventions are Carboplatin . transitional cell cancer of the renal pelvis and ureter diagnosis and karnofsky sixty one hundred or
__label__0	study interventions are Carmustine . stage iv marginal zone lymphoma diagnosis and all study participants must be registered into the mandatory revassist program and be willing and able to comply with the requirements of revassist
__label__0	study interventions are Isotretinoin . stage iv grade one follicular lymphoma diagnosis and more than four weeks since prior major surgery
__label__0	study interventions are Alisertib . malignant neoplasms of male genital organs diagnosis and creatinine clearance greater_than equal_than fifty ml min based either on cockcroft gault estimate or based on urine collection twelve or twenty-four hour metabolic
__label__0	study interventions are Aldesleukin . melanoma skin diagnosis and no myocardial infarction within the past six months
__label__0	study interventions are Sunitinib . kidney neoplasms diagnosis and adjusted serum calcium less_than doc mmol l
__label__0	study interventions are Genistein . ewing sarcoma diagnosis and at least four consecutive cycles
__label__0	study interventions are Pembrolizumab . breast neoplasms diagnosis and eighteen years or older
__label__0	study interventions are Fludarabine . stage iii adult immunoblastic large cell lymphoma diagnosis and fulfills all pulmonary cardiac renal and hepatic criteria for standard of care matched unrelated donor mud allogeneic hct
__label__0	study interventions are Sorafenib . bladder cancer diagnosis and the patient must be informed that he has the right to withdraw from the study at any time without any kind of prejudice
__label__0	study interventions are Gemcitabine . head and neck squamous cell carcinoma diagnosis and arm cohort four
__label__0	study interventions are Antibodies, Monoclonal . recurrent childhood rhabdomyosarcoma diagnosis and no known type or ii diabetes mellitus
__label__0	study interventions are Romidepsin . childhood grade ii meningioma diagnosis and recovered from prior radiotherapy
__label__0	study interventions are endoscopic procedure . lung cancer diagnosis and fertile patients must use effective contraception during and for three months after the completion of study treatment
__label__0	study interventions are Interferons . kidney cancer diagnosis and other
__label__0	study interventions are Prednisolone acetate . intraocular lymphoma diagnosis and it is recommended but not required that acute leukemia patients undergoing transplantation in first remission must have received at least one course of consolidation therapy
__label__0	study interventions are Bevacizumab . melanoma skin diagnosis and significant traumatic injury within the past four weeks
__label__0	study interventions are Alvocidib . breast cancer diagnosis and disease characteristics
__label__0	study interventions are placebo . metastatic breast cancer diagnosis and platelets greater_than one hundred one hundred and nine µl
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and chronic phase patients must have failed or been intolerant to gleevec
__label__0	study interventions are Thiotepa . primary central nervous system lymphoma diagnosis and signature of informed consent
__label__0	study interventions are Antibodies, Monoclonal . pancreatic neuroendocrine tumor gtwo diagnosis and non measurable disease
__label__0	study interventions are Sirolimus . recurrent colorectal carcinoma diagnosis and esophageal
__label__0	study interventions are Pemetrexed . urogenital neoplasms diagnosis and patients must agree to this schedule in conjunction with every dose of pemetrexed
__label__0	study interventions are Cyclophosphamide . desmoplastic small round cell tumor
__label__0	study interventions are Carbamazepine . cancer diagnosis and eighteen years old at the time of informed consent
__label__0	study interventions are Leucovorin . adenocarcinoma of the gastroesophageal junction diagnosis and platelets greater_than equal_than one hundred zero mcl
__label__0	study interventions are Leuprolide . recurrent prostate carcinoma diagnosis and bilirubin equal_than less_than doc times the institutional upper limit of normal uln unless documented gilbert disease
__label__0	study interventions are Cisplatin . lung cancer diagnosis and ap less_than doc times uln and ast and alt less_than doc times uln
__label__0	study interventions are Albumin-Bound Paclitaxel . epithelial ovarian cancer diagnosis and patients with measurable disease
__label__0	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and no metastases accessible to complete surgical resection
__label__0	study interventions are Cyclosporins . stage adult hodgkin lymphoma diagnosis and karnofsky greater_than equal_than seventy
__label__0	study interventions are Antibodies, Monoclonal . head and neck cancer diagnosis and absolute neutrophil count greater_than one thousand ml hematocrit greater_than twenty-four and platelet count greater_than fifty zero ml
__label__0	study interventions are Thalidomide . multiple myeloma and plasma cell neoplasm diagnosis and no cardiac arrhythmia
__label__0	study interventions are Vincristine . lymphoma diagnosis and age of eighteen and over
__label__0	study interventions are Doxorubicin . hepatocellular cancer diagnosis and serum creatinine less_than doc normal or calculated creatinine clearance rate greater_than sixty ml min
__label__0	study interventions are Antibodies, Monoclonal . stage iiib ovarian cancer diagnosis and total bilirubin less_than doc institutional upper limit of normal with direct bilirubin within normal limits except for participants with gilbert disease
__label__0	study interventions are laboratory biomarker analysis . recurrent adult brain tumor diagnosis and approximately two weeks since prior vincristine
__label__0	study interventions are Pasireotide (SOM230) . pancreatic cancer diagnosis and signed informed consent
__label__0	study interventions are Vincristine . stage iv marginal zone lymphoma diagnosis and all study participants must be registered into the mandatory lenalidomide rems program and be willing and able to comply with the requirements of the rems program
__label__0	study interventions are Isophosphamide mustard . stage iv childhood hodgkin lymphoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate greater_than equal_than seventy ml min doc three two
__label__0	study interventions are Gossypol acetic acid . lung cancer diagnosis and ability to understand and the willingness to sign written informed consent form the consent form must be signed by the patient prior to any study specific procedures
__label__0	study interventions are Panobinostat . metastatic gastric cancer diagnosis and all women included in the trial must be surgically sterile or postmenopausal or agree to employ adequate birth control measures for the duration of the trial and six months post dosing
__label__0	study interventions are Interferon-alpha . pancreatic cancer diagnosis and at least one month since prior radiotherapy surgery
__label__0	study interventions are Antibodies . malignant pancreatic somatostatinoma diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Nivolumab . bladder adenocarcinoma diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt both equal_than less_than three iuln
__label__0	study interventions are Prednisone . multiple myeloma diagnosis and age greater_than sixty-five years or not eligible for high dose therapy and autologous stem cell transplant
__label__0	study interventions are DSA arteriogram- hepatic arteries . kidney renal cell cancer diagnosis and patients must have received an abdominal ct pet ct scan or mri completed prior to the tace procedure
__label__0	study interventions are Lapatinib . stage iv squamous cell carcinoma of the oropharynx diagnosis and no prior cumulative anthracycline therapy greater_than four hundred and fifty mg two of doxorubicin or equivalent
__label__0	study interventions are Mycophenolic Acid . recurrent grade one follicular lymphoma diagnosis and amyloidosis
__label__0	study interventions are Antibodies . stage iiib colon cancer diagnosis and leukocytes greater_than equal_than three zero ul
__label__0	study interventions are Camptothecin . lung neoplasms diagnosis and
__label__0	study interventions are Antibodies, Monoclonal . non hodgkin lymphoma diagnosis and female patients of childbearing potential must have negative serum pregnancy test within three days prior to enrollment
__label__0	study interventions are Lenalidomide . smoldering plasma cell myeloma diagnosis and patients must not have active uncontrolled infection
__label__0	study interventions are Irinotecan . esophageal cancer diagnosis and negative pregnancy test
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and chemotherapy
__label__0	study interventions are Laboratory Biomarker Analysis . stage iii renal cell cancer diagnosis and use of topical corticosteroids and or eye drops containing glucocorticosteroids is acceptable
__label__0	study interventions are biologically based therapies . recurrent breast cancer diagnosis and sex
__label__0	study interventions are Prednisolone . lymphoma diagnosis and life expectancy
__label__0	study interventions are Motexafin gadolinium . lymphoma diagnosis and endocrine therapy
__label__0	study interventions are Interleukin-2 . non hodgkin lymphoma diagnosis and able to be off prednisone or other immunosuppressive medications for at least three day prior to day zero excluding denileukin_diftitox pre medications
__label__0	study interventions are Cyclosporine . histologically confirmed recurrent metastatic or locally advanced cervical or vaginal carcinoma that is not curable with surgery or radiotherapy
__label__0	study interventions are TLR4 Agonist GLA-SE . stage iv adult soft tissue sarcoma diagnosis and partial thromboplastin time ptt equal_than less_than doc times the upper limit of normal
__label__0	study interventions are Cyclophosphamide . stage iiia breast cancer diagnosis and suspicious findings on bone scan must be confirmed as benign by ray mri or biopsy
__label__0	study interventions are Docetaxel . gastric cancer adjuvant chemotherapy xo diagnosis and patients who can be randomized within six weeks after surgery
__label__0	study interventions are Sunitinib . metastatic renal cell carcinoma diagnosis and adequate organ function as defined by the following criteria
__label__0	study interventions are Pemetrexed . pancreatic cancer diagnosis and part b
__label__0	study interventions are Dexamethasone . non hodgkin lymphoma nhl diagnosis and serum protein greater_than doc dl and or urine protein greater_than two hundred mg twenty-four hr
__label__0	study interventions are Levoleucovorin . stage iiia esophageal adenocarcinoma diagnosis and patients must have life expectancy of greater_than three months in the opinion of and as documented by the investigator
__label__0	study interventions are Trametinib . melanoma diagnosis and total serum bilirubin less_than three uln
__label__0	study interventions are Etoposide phosphate . lymphoma non hodgkin diagnosis and adequate cardiac function defined as shortening fraction of greater_than twenty-seven or ejection fraction greater_than forty-five
__label__0	study interventions are quality-of-life assessment . recurrent adult primary liver cancer diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Liposomal doxorubicin . hepatocellular carcinoma diagnosis and hcc amenable to tace
__label__0	study interventions are Interleukin-2 . recurrent adult diffuse large cell lymphoma diagnosis and ecog zero one
__label__0	study interventions are Paclitaxel . stage iv verrucous carcinoma of the larynx diagnosis and platelets greater_than one hundred zero cells mm three
__label__0	study interventions are Allopurinol . burkitt lymphoma diagnosis and plasma cell leukemia after initial therapy who achieved at least partial remission
__label__0	study interventions are Leucovorin . stage iii testicular cancer diagnosis and none of the following within the past six months
__label__0	study interventions are Fludarabine . stage iii small lymphocytic lymphoma diagnosis and failed fcr or pentostatin cyclophosphamide rituximab pcr combination chemotherapy at any time point
__label__0	study interventions are Maleic acid . spinal cord neurofibroma diagnosis and mean qtc less_than four hundred and seventy msec with bazett correction by ekg
__label__0	study interventions are Calcium, Dietary . stage ivb colon cancer diagnosis and no other concurrent investigational chemotherapy agents
__label__0	study interventions are Methylprednisolone Hemisuccinate . sarcoma diagnosis and wiskott_aldrich
__label__0	study interventions are Antibodies, Monoclonal . stage iv salivary gland cancer diagnosis and not candidate for surgical resection with curative intent
__label__0	study interventions are Methotrexate . stage grade one follicular lymphoma diagnosis and partial cytogenetic remission
__label__0	study interventions are Lenograstim . lymphoma diagnosis and lvef greater than forty-five no ischemic heart disease no myocardial infarction or congestive heart failure in past year other
__label__0	study interventions are Vaccines . melanoma skin diagnosis and hepatic
__label__0	study interventions are Pancreatectomy . pancreatic cancer diagnosis and no celiac trunk and superior_mesenteric artery invasion by loyer grading
__label__0	study interventions are Beclomethasone . kidney cancer diagnosis and able to swallow oral capsules no persistent vomiting of all oral intake no multiorgan failure no sepsis syndrome including positive bacterial or fungal cultures within seventy-two hours of study
__label__0	study interventions are Morphine . metastatic cancer diagnosis and more than two weeks since prior and no concurrent corticosteroid therapy
__label__0	study interventions are Antibodies, Monoclonal . adenocarcinoma of the prostate diagnosis and for patients with gilbert disease less_than doc uln is allowed
__label__0	study interventions are Fludarabine . indolent non hodgkin lymphoma diagnosis and acute lymphocytic leukemia all
__label__0	study interventions are diagnostic colonoscopy . colorectal cancer diagnosis and patient characteristics
__label__0	study interventions are Etoposide . multiple myeloma and plasma cell neoplasm diagnosis and bilirubin less than doc mg dl
__label__0	study interventions are Cyclosporins . stage iii grade two follicular lymphoma diagnosis and two0 blasts and or promyelocytes in blood or marrow
__label__0	study interventions are Melphalan . stage iii adult diffuse mixed cell lymphoma diagnosis and able to take aspirin eighty-one or three hundred and twenty-five mg daily as prophylactic anticoagulation patients intolerant to acetylsalicylic acid asa may use warfarin or low molecular weight heparin
__label__0	study interventions are Trastuzumab . lymphoma diagnosis and no other prior malignancy is allowed except for the following
__label__0	study interventions are Methotrexate . contiguous stage ii mantle cell lymphoma diagnosis and participation in another therapeutic trial where the primary endpoint is related to acute gvhd
__label__0	study interventions are Camptothecin . neuroblastoma diagnosis and no greater than doc mg dl two years five years
__label__0	study interventions are Etoposide . aids related diffuse large cell lymphoma diagnosis and eligibility criteria for hspc transplantation
__label__0	study interventions are OSI-906 . advanced solid tumors diagnosis and female subject of child bearing potential has negative pregnancy test at screening and day one
__label__0	study interventions are Cyclophosphamide . stage iiia breast cancer diagnosis and ipsilateral dcis treated by local excision with or without hormonal therapy allowed
__label__0	study interventions are Hormones . er positive hertwo negative breast cancer neoplasms diagnosis and able to swallow and retain oral medication
__label__0	study interventions are Antilymphocyte Serum . lymphoma diagnosis and no poor organ function
__label__0	study interventions are Standard therapy . supratentorial newly diagnosed inoperable gliobastoma diagnosis and subject with non resectable gbm
__label__0	study interventions are Fludarabine . recurrent grade one follicular lymphoma diagnosis and donor for allogeneic lymphocytes arm two only
__label__0	study interventions are Fluorouracil . acinar cell adenocarcinoma of the pancreas diagnosis and pregnancy nursing status
__label__0	study interventions are Ado-trastuzumab emtansine . breast cancer diagnosis and hertwo positive disease determined locally
__label__0	study interventions are Trametinib . breast cancer diagnosis and ecog performance status zero two
__label__0	study interventions are medical chart review . gastric cancer diagnosis and no bleeding disorder
__label__0	study interventions are Cyclosporine . anaplastic large cell lymphoma diagnosis and insulin dependent diabetes mellitus or uncompensated major thyroid or adrenal dysfunction render patients ineligible
__label__0	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and patients should be greater_than twenty-one less_than seventy-three years old
__label__0	study interventions are Paclitaxel . hertwo negative breast cancer diagnosis and absolute neutrophil count greater than or equal to one five hundred mcl
__label__0	study interventions are Akt inhibitor MK2206 . recurrent childhood small noncleaved cell lymphoma diagnosis and these patients are not evaluable for hematologic toxicity
__label__0	study interventions are management of therapy complications . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and hematopoietic stem cell transplant recipient between three twenty-five years since last transplant
__label__0	study interventions are Antibodies . recurrent grade three follicular lymphoma diagnosis and no prior myeloablative therapy with autologous or allogeneic bone marrow transplantation or peripheral blood stem cell support
__label__0	study interventions are Taxane . prostate cancer diagnosis and adequate renal and hepatic function defined as
__label__0	study interventions are Temozolomide . central nervous system neoplasms diagnosis and patients must have an ecog performance status between zero and two
__label__0	study interventions are Bicalutamide . gynaecomastia diagnosis and psa equal or above four ng ml
__label__0	study interventions are Estradiol . availability of representative formalin_fixed paraffin_embedded tumor tissue sample
__label__0	study interventions are Vincristine . neuroblastoma diagnosis and no prior biologic therapy
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and hematologic
__label__0	study interventions are Antibodies, Monoclonal . stage iii adrenal cortex carcinoma diagnosis and males who are sexually active with women of childbearing potential wocbp must agree to follow instructions for method of contraception hormonal or barrier method of birth control abstinence for the duration of treatment with nivolumab plus five halflives of the study drug nineteen weeks plus ninety days duration of sperm turnover for total of thirty-one weeks days post treatment completion
__label__0	study interventions are Irinotecan . childhood grade iii lymphomatoid granulomatosis diagnosis and performance status
__label__0	study interventions are Iniparib . breast cancer diagnosis and eastern cooperative oncology group ecog performance status zero one
__label__0	study interventions are Immunoglobulin G . stage iiic fallopian tube cancer diagnosis and hepatic artery chemoembolization
__label__0	study interventions are Cisplatin . stage iv squamous cell carcinoma of the hypopharynx diagnosis and ast and alt no greater than doc times upper limit of normal
__label__0	study interventions are pazopanib hydrochloride . unspecified childhood solid tumor protocol specific diagnosis and other venous thromboembolic event
__label__0	study interventions are Fludarabine . recurrent childhood anaplastic large cell lymphoma diagnosis and the donor must be able to give informed consent for peripheral blood stem cell collection or bone marrow collection
__label__0	study interventions are Bevacizumab . liver neoplasms diagnosis and measurable liver metastases on ct scan recist positive signal of liver metastases on fdg pet scan
__label__0	study interventions are Antibodies . neuroblastoma diagnosis and growth factors
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and agree to have medically supervised pregnancy test
__label__0	study interventions are Levoleucovorin . stage iii colon cancer diagnosis and no other severe acute or chronic medical condition or laboratory abnormality that would preclude study participation
__label__0	study interventions are NK Cell Infusion . lymphoma diagnosis and are ineligible to receive tyrosine kinase inhibitor tki therapy and myeloablative hsct
__label__0	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and no serious psychiatric or medical illness that would preclude study participation
__label__0	study interventions are Cisplatin . stage iv non small cell lung cancer diagnosis and prior pemetrexed is allowed except arm dose level four cisplatin seventy-five mg two
__label__0	study interventions are Everolimus . glioblastoma multiforme diagnosis and chemotherapy six weeks for nitrosoureas or mitomycin c
__label__0	study interventions are Cyclophosphamide . stage iv diffuse large cell lymphoma diagnosis and patients must not be receiving erythroid stimulating agents epo
__label__0	study interventions are Methotrexate . metastatic osteosarcoma diagnosis and shortening fraction greater_than twenty-eight by echocardiogram
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and not specified hematopoietic
__label__0	study interventions are conventional surgery . sarcoma diagnosis and surgery
__label__0	study interventions are Cyclosporine . stage iii adult immunoblastic large cell lymphoma diagnosis and patients in blast crisis bc must receive therapy and must achieve accelerated phase ap chronic phase cp in order to be eligible patients who remain in bc are not eligible
__label__0	study interventions are Cetuximab . stage iv squamous cell carcinoma of the larynx diagnosis and no immune deficiency and or hiv positivity
__label__0	study interventions are Testosterone enanthate . prostate cancer diagnosis and patient must have rising psa
__label__0	study interventions are Dexamethasone acetate . diffuse large cell lymphoma dlbcl diagnosis and wm
__label__0	study interventions are Bevacizumab . adult grade meningioma diagnosis and total serum bilirubin equal_than less_than doc
__label__0	study interventions are Prednisolone acetate . multiple myeloma and plasma cell neoplasm diagnosis and negative pregnancy test
__label__0	study interventions are Cortisone acetate . stage ii adult cell leukemia lymphoma diagnosis and patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and or it cytarabine
__label__0	study interventions are Cyclophosphamide . stage iv adult diffuse large cell lymphoma diagnosis and subjects must have the ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Carboplatin . stage four neuroblastoma diagnosis and doc mg dl
__label__0	study interventions are Prednisolone hemisuccinate . lymphoma diagnosis and not specified
__label__0	study interventions are Mifepristone . leiomyoma diagnosis and willing and able to comply with study requirements
__label__0	study interventions are Interleukin-12 . advanced solid tumors diagnosis and absolute neutrophil count greater_than equal_than doc ten nine l
__label__0	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . local irradiation to the primary tumors or other sites cumulative dose greater_than fortygy greater_than three months prior to registration
__label__0	study interventions are Mycophenolic Acid . stage iii grade three follicular lymphoma diagnosis and high risk crone for example but not limited to
__label__0	study interventions are adjuvant therapy . cervical cancer diagnosis and see disease characteristics
__label__0	study interventions are Irinotecan . stage iv squamous cell carcinoma of the nasopharynx diagnosis and patients must not be receiving radiation treatment
__label__0	study interventions are Tacrolimus . non hodgkin lymphoma in crtwo or subsequent
__label__0	study interventions are Antibodies . recurrent squamous cell carcinoma of the larynx diagnosis and ast and alt no greater than doc times upper limit of normal
__label__0	study interventions are Hydroxyitraconazole . cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Prednisolone phosphate . unusual cancers of childhood diagnosis and fev_one fvc greater_than sixty-five of predicted
__label__0	study interventions are Liposomal doxorubicin . neuroblastoma diagnosis and chemotherapy
__label__0	study interventions are Immunoglobulins . retinoblastoma diagnosis and must have recovered from all hematopoietic and neurologic side effects of prior chemotherapy
__label__0	study interventions are Carbendazim . lymphoma diagnosis and eighteen and over performance status
__label__0	study interventions are Levoleucovorin . unspecified adult solid tumor protocol specific diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Voriconazole . unspecified adult solid tumor protocol specific diagnosis and sirolimus
__label__0	study interventions are Carboplatin . stage iiia non small cell lung cancer diagnosis and granulocyte count
__label__0	study interventions are Idelalisib . recurrent lymphoplasmacytic lymphoma diagnosis and diagnosis of cll according to nci working group criteria as evidenced by all of the following
__label__0	study interventions are Prednisolone . recurrent adult immunoblastic large cell lymphoma diagnosis and life threatening cytopenia and or red cell or platelet transfusion dependence
__label__0	study interventions are Mycophenolate mofetil . stage iv mantle cell lymphoma diagnosis and crtwo
__label__0	study interventions are Pemetrexed . lung cancer diagnosis and other
__label__0	study interventions are Endurance . malignant fibrous_histiocytoma of the bone diagnosis and surgical intervention is planned primary mechanism of local control
__label__0	study interventions are Interleukin-2 . non hodgkin lymphoma diagnosis and if fertile patient male or female has agreed to use physician approved method of birth control to avoid pregnancy for the duration of the study and for period of three months thereafter
__label__0	study interventions are Liposomal doxorubicin . ovarian cancer diagnosis and subjects must have been treated and progressed following chemotherapy which includes platinum and paclitaxel
__label__0	study interventions are Cyclosporins . stage iii adult diffuse small cleaved cell lymphoma diagnosis and chronic myelomonocytic leukemia
__label__0	study interventions are Doxorubicin . previously treated childhood rhabdomyosarcoma diagnosis and cardiac arrhythmia
__label__0	study interventions are Antibodies, Monoclonal . pediatric cancers diagnosis and renal
__label__0	study interventions are Oxaliplatin . advanced gastric carcinoma diagnosis and disease at clinical stage of resectable or potentially resectable lagc tfoura n positive mzero
__label__0	study interventions are Nelfinavir . stage iii adult soft tissue sarcoma diagnosis and patients enrolled cannot be on the following medications
__label__0	study interventions are Mitomycin . hepatocellular carcinoma diagnosis and class i
__label__0	study interventions are Fluorodeoxyglucose F18 . recurrent pancreatic cancer diagnosis and willing to return to mayo clinic for follow up
__label__0	study interventions are Cisplatin . lung cancer diagnosis and not specified hematopoietic
__label__0	study interventions are Etoposide phosphate . recurrent adult lymphoblastic lymphoma diagnosis and life expectancy greater_than two months
__label__0	study interventions are Antibodies, Monoclonal . lymphoma large cell diffuse diagnosis and the expansion cohort includes patients with fl or dlbcl with relapsed or refractory disease
__label__0	study interventions are Disulfiram . prostate cancer diagnosis and for subjects in group with nepc previous use of at least one platinum containing chemotherapy regimen
__label__0	study interventions are Somatostatin . gastrointestinal carcinoid tumor diagnosis and age
__label__0	study interventions are Mycophenolic Acid . lymphoma diagnosis and see disease characteristics
__label__0	study interventions are laboratory biomarker analysis . tumors metastatic to brain diagnosis and history physical examination within eight weeks prior to registration
__label__0	study interventions are Cisplatin . gastrointestinal cancers diagnosis and patients desiring future fertility
__label__0	study interventions are Dexamethasone . multiple myeloma diagnosis and anc of greater_than one thousand mmthree independent of csf
__label__0	study interventions are Busulfan . sarcoma diagnosis and histiocytosis unresponsive to medical management
__label__0	study interventions are Vaccines . solid tumors diagnosis and be able and willing to sign informed consent document that has been approved by an institutional review board or independent ethics committee irb iec
__label__0	study interventions are Dexamethasone . hematologic neoplasms diagnosis and melphalan
__label__0	study interventions are Cisplatin . stage iv squamous cell carcinoma of the nasopharynx diagnosis and twelve lead electrocardiogram ecg with normal tracing or non clinically significant changes that do not require medical intervention
__label__0	study interventions are gastrointestinal complications management/prevention . unspecified adult solid tumor protocol specific diagnosis and is surgery for treatment of malignant bowel obstruction mbo being considered for this patient
__label__0	study interventions are Methylprednisolone acetate . lymphoma diagnosis and no hla abc dr identical related bone marrow or ucb donor
__label__0	study interventions are Vorinostat . recurrent adult burkitt lymphoma diagnosis and reductions of greater_than equal_than fifty in greatest diameter of all sites of known disease and no new sites
__label__0	study interventions are Docetaxel . lung neoplasms diagnosis and performance status
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and doc negative doc five
__label__0	study interventions are Trametinib . solid neoplasm diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Gemcitabine . fallopian tube serous adenocarcinoma diagnosis and patients must have gynecologic oncology group gog performance status of zero one or two
__label__0	study interventions are Leucovorin . recurrent rectal cancer diagnosis and patients who have had chemotherapy or radiotherapy within three weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from significant adverse events due to agents administered more than three weeks earlier
__label__0	study interventions are Lenalidomide . stage iii grade one follicular lymphoma diagnosis and no intracranial hemorrhage within the last six months
__label__0	study interventions are Erlotinib Hydrochloride . stage iii colon cancer diagnosis and recovered from all prior therapy
__label__0	study interventions are Rituximab . lymphoma diagnosis and creatinine no greater than doc mg dl or creatinine clearance greater than sixty ml min no chronic renal insufficiency cardiovascular
__label__0	study interventions are Prednisolone hemisuccinate . recurrent grade three follicular lymphoma diagnosis and myeloproliferative and lymphoproliferative disorder negative must have evidence of disease acceleration to be candidate for umbilical cord blood transplant myeloproliferative disorders eligible for transplant include chronic myelomonocytic leukemia cmml with high ipss score and myelofibrosis
__label__0	study interventions are Fluorouracil . stage iia gastric cancer diagnosis and albumin greater_than equal_than doc dl
__label__0	study interventions are Vidarabine . lymphoma diagnosis and failed to achieve complete cytogenetic remission at one year after initiation of therapy
__label__0	study interventions are Antibodies, Monoclonal . calculated creatinine clearance greater_than thirty ml min unless demonstrated hodgkin lymphoma involvement of the kidney
__label__0	study interventions are Temozolomide . metastatic cancer diagnosis and not pregnant or nursing
__label__0	study interventions are ECO-4601 . pancreatic cancer diagnosis and patients can be receiving stable or decreasing dose of steroids within two weeks prior to patient signature of the informed consent
__label__0	study interventions are Histamine H2 Antagonists . brain and central nervous system tumors diagnosis and no known hypersensitivity to the study treatment
__label__0	study interventions are Pertuzumab . stage iii colon cancer diagnosis and no psychiatric illness social situation that would limit compliance with study requirements
__label__0	study interventions are Gemcitabine . head and neck cancer diagnosis and the standard cockcroft and gault formula based on actual weight or the measured glomerular filtration rate gfr using the appropriate radiolabeled method fifty-one credta or tcninety-ninem dtpa must be used to calculate crcl for enrollment or dosing
__label__0	study interventions are laboratory biomarker analysis . recurrent prostate cancer diagnosis and zubrod zero two
__label__0	study interventions are Capecitabine . neoplasms breast diagnosis and the status of erbbtwo expression must be documented prior to study entry
__label__0	study interventions are Veliparib . childhood infratentorial ependymoma diagnosis and patients must have fully recovered from the acute toxic effects of all prior chemotherapy immunotherapy or radiotherapy prior to entering this study recovery is defined as all ae attributable to prior therapy having improved to grade two or better or as outlined below
__label__0	study interventions are Vincristine . hodgkin lymphoma diagnosis and cs ps iii iv
__label__0	study interventions are BB 1101 . childhood ependymoblastoma diagnosis and fully recovered from the acute toxic effects of all prior chemotherapy immunotherapy or radiotherapy
__label__0	study interventions are Cetuximab . stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and at least one month since prior surgery unless ambulatory within forty-eight hours
__label__0	study interventions are Levoleucovorin . adenocarcinoma of the rectum diagnosis and ecog performance status zero one
__label__0	study interventions are Busulfan . lymphoma diagnosis and doc
__label__0	study interventions are Cyclosporins . recurrent childhood small noncleaved cell lymphoma diagnosis and donor must consent to granulocyte colony stimulating factor csf administration and leukopheresis
__label__0	study interventions are Liposomal doxorubicin . epithelioid malignant peripheral nerve sheath tumor diagnosis and patients on low molecular weight heparin or coumadin with stable international normalized ratio inr are eligible
__label__0	study interventions are Vaccines . recurrent fallopian tube carcinoma diagnosis and any human leukocyte antigen hla type historic hla typing is permitted
__label__0	study interventions are Melphalan . stage iv marginal zone lymphoma diagnosis and donor
__label__0	study interventions are Tacrolimus . recurrent childhood lymphoblastic lymphoma diagnosis and donors who have poor peripheral venous access may require central venous line placement for stem cell apheresis
__label__0	study interventions are Carboplatin . histologically or cytologically confirmed small cell lung cancer
__label__0	study interventions are Carboplatin . anaplastic large cell lymphoma diagnosis and patients must have serum lactate dehydrogenase ldh performed within fourteen days prior to registration
__label__0	study interventions are Diphosphonates . multiple myeloma and plasma cell neoplasm diagnosis and no prior samarium_sm one hundred and fifty-three_lexidronam pentasodium or strontium_chloride sr_eighty-nine
__label__0	study interventions are Etoposide . metastatic malignant neoplasm in the lung diagnosis and this study utilizes whole body fdg pet scans to screen patients for bone metastases areas suspicious for bone metastasis based on fdg pet scans require confirmatory anatomic imaging with either mri or computed tomography ct whole body fdg pet ct or fdg pet magnetic resonance mr scan acceptable whole body technetium bone scans may be performed at the discretion of the investigator and are not required for patients without other sites of metastatic disease whose sole metastatic site to qualify for study entry is single area suspicious for bone metastasis identified by fdg pet confirmatory biopsy or anatomic imaging evidence of an associated soft tissue mass at that site is required for study entry
__label__0	study interventions are Bevacizumab . ovarian mucinous cystadenocarcinoma diagnosis and bilirubin less_than doc times normal
__label__0	study interventions are Antibodies, Monoclonal . stage iiib ovarian cancer diagnosis and known cirrhosis or chronic hepatitis virus hbv or hepatitis virus hcv infection
__label__0	study interventions are Gemcitabine . pancreatic cancer diagnosis and presence of measurable lesions in at least one site which have not been previously irradiated bone lesions ascites and pleural effusions are not considered as measurable described as any of the following
__label__0	study interventions are Dexamethasone 21-phosphate . lymphoma diagnosis and endocrine therapy
__label__0	study interventions are Docetaxel . pancreatic cancer diagnosis and no kidney stones within the past five years
__label__0	study interventions are Norgestimate, ethinyl estradiol drug combination . lymphoma diagnosis and radiotherapy
__label__0	study interventions are Erlotinib Hydrochloride . recurrent non small cell lung carcinoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Capecitabine . histologically or cytologically confirmed colorectal cancer
__label__0	study interventions are Vidarabine . metastatic malignant neoplasm diagnosis and patients must have previously received systemic standard care or effective salvage chemotherapy regimens for metastatic disease if known to be effective for that disease and have been either non responders progressive disease or have recurred
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and pulmonary
__label__0	study interventions are Immunoglobulin G . metastatic melanoma diagnosis and adequate contraception must be used by both patient and partner while receiving study drug and for twelve weeks after the last dose of study drug
__label__0	study interventions are Rituximab . lymphoma diagnosis and no chronic lung disease with hypoxemia
__label__0	study interventions are gamma-secretase/Notch signalling pathway inhibitor RO4929097 . stage ib pancreatic cancer diagnosis and grade one hyponatremia with sodium less_than one3one mg dl is permissible
__label__0	study interventions are laboratory biomarker analysis . lung cancer diagnosis and no concurrent darbepoetin alfa or epoetin_alfa
__label__0	study interventions are Gemcitabine . proximal urethral carcinoma diagnosis and calculated or measured creatinine clearance greater_than equal_than fifty ml minute
__label__0	study interventions are Gemcitabine . stage iv pancreatic cancer diagnosis and patients should have clinically measurable or evaluable malignant disease
__label__0	study interventions are Antibodies . follicular small cleaved cell or follicular mixed lymphoma with surface igm igg or iga phenotype with monoclonal heavy and light chain
__label__0	study interventions are Etoposide phosphate . lymphoma diagnosis and no more than ninety days since diagnosis
__label__0	study interventions are Immunoglobulins . adequately treated basal cell or squamous cell skin cancer in situ cervical cancer adequately treated stage or ii cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease free for five years
__label__0	study interventions are Cisplatin . stage ib cervical cancer diagnosis and uncontrolled arrhythmia
__label__0	study interventions are Vidarabine . recurrent hodgkin lymphoma diagnosis and only filgrastim csf mobilized pbsc only will be permitted as hematopoietic stem cell hsc_source on this protocol
__label__0	study interventions are HSV1716 . neuroblastoma diagnosis and subjects who are unable to walk because of paralysis but who are up in wheelchair will be considered ambulatory for the purpose of assessing the performance score
__label__0	study interventions are Paclitaxel . measurable disease defined as at least one lesion that can be accurately measured in at least one dimension by response evaluation criteria in solid tumors recist criteria doc
__label__0	study interventions are Long Course Radiotherapy . adenocarcinoma of rectum diagnosis and written informed consent
__label__0	study interventions are Tetrahydrofolates . recurrent pancreatic carcinoma diagnosis and platelets greater_than equal_than one hundred zero
__label__0	study interventions are Antibodies . adenocarcinoma of the lung diagnosis and the following subtypes are eligible
__label__0	study interventions are R(+)XK469 . localized unresectable neuroblastoma diagnosis and at least four weeks since prior chemotherapy six weeks for nitrosoureas or mitomycin c
__label__0	study interventions are Thalidomide . recurrent adult diffuse mixed cell lymphoma diagnosis and nucleoside_analog refractory disease or disease that relapsed after two prior regimens
__label__0	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and chemotherapy must have been completed at least four weeks prior to randomization
__label__0	study interventions are Camptothecin . histologically confirmed recurrent or refractory non hodgkin lymphoma
__label__0	study interventions are Maleic acid . recurrent metastatic squamous cell carcinoma in the neck with occult primary diagnosis and bilirubin normal
__label__0	study interventions are Dexamethasone 21-phosphate . subject is diagnosed with symptomatic multiple myeloma based on the international myeloma working group diagnostic criteria kyle two thousand and nine
__label__0	study interventions are Pertuzumab . female patients aged eighteen years or older with tumors suitable for neoadjuvant treatment
__label__0	study interventions are Maytansine . stage iiia breast cancer diagnosis and fluorescence in situ hybridization fish positive with an amplification ratio greater_than equal_than doc indicating positive status and or
__label__0	study interventions are Rituximab . stage iii adult diffuse large cell lymphoma diagnosis and patients without evidence of severe organ dysfunction as determined within two weeks of onest cycle of chop r
__label__0	study interventions are Antibodies . stage iv adult diffuse mixed cell lymphoma diagnosis and phase ii subjects must have estimated or measured creatinine clearance greater_than equal_than thirty ml min
__label__0	study interventions are Immunoglobulin G . recurrent hypopharyngeal squamous cell carcinoma diagnosis and patients must not be receiving chronic daily treatment with aspirin greater_than three hundred and twenty-five mg day or non steroidal anti inflammatory agents nsaid known to inhibit platelet function the use of anti platelet agents dipyridamole_persantine ticlopidine_ticlid clopidogrel_plavix is allowed only if patient is not receiving aspirin or nsaid known to inhibit platelet function
__label__0	study interventions are Mycophenolate mofetil . adult nasal type extranodal nk cell lymphoma diagnosis and for patients unable to complete pulmonary function tests clearance by an adult pulmonologist is required
__label__0	study interventions are Sirolimus . stage iiib cervical cancer diagnosis and sub protocol aim a
__label__0	study interventions are Racepinephrine . head and neck cancer diagnosis and prior concurrent therapy
__label__0	study interventions are Albumin-Bound Paclitaxel . metastatic melanoma diagnosis and patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry
__label__0	study interventions are Etoposide phosphate . stage iv childhood hodgkin lymphoma diagnosis and negative pregnancy test
__label__0	study interventions are Vidarabine . stage iii mantle cell lymphoma diagnosis and serum creatinine equal_than less_than doc mg dl adults and creatinine clearance greater_than sixty ml min pediatrics
__label__0	study interventions are Oxaliplatin . stage iva colorectal cancer diagnosis and female patients with childbearing potential should agree to use effective nonhormonal means of contraception intrauterine contraceptive device barrier method of contraception in conjunction with spermicidal_jelly or surgically sterile during the study and for period of at least three months following the last administration of study drug
__label__0	study interventions are Endothelial Growth Factors . disease that is measurable per response evaluation criteria in solid tumors version doc recist doc
__label__0	study interventions are Fludarabine . recurrent marginal zone lymphoma diagnosis and first second or third relapse
__label__0	study interventions are Taxane . ovarian cancer diagnosis and all patients must be considered platinu negative and taxan negative resistant
__label__0	study interventions are endoscopic surgery . male breast cancer diagnosis and not pregnant or breastfeeding
__label__0	study interventions are Silicon phthalocyanine . sarcoma diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Paclitaxel . pathologic evidence of small cell lung cancer or non small cell lung cancer
__label__0	study interventions are Lenalidomide . stage ii grade three contiguous follicular lymphoma diagnosis and non pregnant and non nursing females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least twenty-five miu ml within ten fourteen days prior to registration further they must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control
__label__0	study interventions are Endothelial Growth Factors . colon cancer diagnosis and if suspicion of bleeding diathesis exists bleeding time should be performed
__label__0	study interventions are Paclitaxel . stage iiic breast cancer diagnosis and able to give informed consent
__label__0	study interventions are Fluorodeoxyglucose F18 . high risk endometrial carcinoma meeting one of the following criteria
__label__0	study interventions are Immunoglobulin G . ovarian mucinous adenocarcinoma diagnosis and albumin greater than or equal to doc dl
__label__0	study interventions are Antibodies, Monoclonal . stage iv salivary gland cancer diagnosis and prior chemotherapy in the induction organ preservation or adjuvant setting is permitted if it was completed more than four months prior to enrollment on the current study
__label__0	study interventions are Fludarabine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and serum creatinine equal_than less_than doc mg dl adults and creatinine clearance greater_than sixty ml min pediatrics
__label__0	study interventions are Everolimus . mesothelioma diagnosis and measurable disease by recist criteria
__label__0	study interventions are laboratory biomarker analysis . stage ivb verrucous carcinoma of the oral cavity diagnosis and patient is deemed to be surgical candidate by ent
__label__0	study interventions are Camptothecin . those patients who are triple negative brca mutant positive and those patients who have triple negative non brca mutated breast cancer
__label__0	study interventions are Bevacizumab . unspecified adult solid tumor protocol specific diagnosis and metastatic or unresectable disease
__label__0	study interventions are SEA-CD40 . lymphoma follicular diagnosis and histologically confirmed advanced malignancy either
__label__0	study interventions are Thalidomide . multiple myeloma and plasma cell neoplasm diagnosis and hiv negative
__label__0	study interventions are Doxorubicin . transitional cell cancer of the renal pelvis and ureter diagnosis and patient characteristics
__label__0	study interventions are Immunoglobulins . nodal marginal zone cell lymphoma diagnosis and able to adhere to the study visit schedule and other protocol requirements
__label__0	study interventions are Cyclosporins . angioimmunoblastic cell lymphoma diagnosis and the donor must be genotypically hla identical sibling phenotypically hla matched first degree relative or an unrelated donor who is molecularly matched with the patient at hla b drbone
__label__0	study interventions are Citalopram . lung cancer diagnosis and not pregnant
__label__0	study interventions are Estrogens, Conjugated (USP) . patients currently receiving anticancer therapies or who have received anticancer therapies within four weeks of the start of study drug including chemotherapy radiation therapy antibody based therapy etc
__label__0	study interventions are Temozolomide . medulloblastoma diagnosis and patients must have life expectancy of three months
__label__0	study interventions are Fluorouracil . colorectal cancer diagnosis and negative pregnancy test
__label__0	study interventions are Prednisone . prostate cancer diagnosis and castrate levels of testosterone testosterone less_than fifty ng dl on androgen deprivation therapy adt with evidence of progression on adt
__label__0	study interventions are Topotecan . malignant ovarian serous tumor diagnosis and patients are allowed to receive but not required to receive biologic noncytotoxic therapy as part of their treatment regimen bevacizumab
__label__0	study interventions are Methylprednisolone acetate . fallopian tube cancer diagnosis and or
__label__0	study interventions are Liposomal doxorubicin . stage iva hodgkin lymphoma diagnosis and serum glutamic oxaloacetic transaminase sgot aspartate transaminase ast or serum glutamate pyruvate transaminase sgpt alanine transaminase alt less_than doc upper limit of normal uln for age
__label__0	study interventions are Rituximab . recurrent indolent adult non hodgkin lymphoma diagnosis and serum creatinine less_than doc mg dl or estimated glomerular filtration rate gfr greater_than sixty ml min
__label__0	study interventions are Fatigue Inventory . stage iv cutaneous cell non hodgkin lymphoma diagnosis and patients receiving concurrent corticosteroids less than one week prior to protocol therapy other than for physiologic maintenance treatment or control of aiha or itp
__label__0	study interventions are Paclitaxel . primary peritoneal serous adenocarcinoma diagnosis and patients must have gog performance status of zero or one
__label__0	study interventions are Immunoglobulins . contiguous stage ii grade one follicular lymphoma diagnosis and there is no indication for an autologous transplantation as treatment option
__label__0	study interventions are Goserelin . adenocarcinoma of the prostate diagnosis and absolute neutrophil count greater_than one five hundred mmthree
__label__0	study interventions are Thiotepa . csf cytology demonstrating malignant clonal nhl population consistent with lymphomatous leptomeningitis with or without radiographically or pathologically identifiable cns or systemic mass lesion
__label__0	study interventions are Docetaxel . sarcoma diagnosis and not specified
__label__0	study interventions are Cisplatin . hypopharynx cancer diagnosis and be willing and able to provide written informed consent for the trial
__label__0	study interventions are laboratory biomarker analysis . unspecified childhood solid tumor protocol specific diagnosis and no confusion_disorientation or psychiatric illness that may preclude study
__label__0	study interventions are Niacinamide . neuroendocrine tumor diagnosis and international normalized ratio inr normal
__label__0	study interventions are Vaccines . recurrent fallopian tube cancer diagnosis and total bilirubin equal_than less_than doc upper limit of normal uln
__label__0	study interventions are Citric Acid . ductal breast carcinoma in situ diagnosis and total bilirubin within normal institutional limits
__label__0	study interventions are magnetic resonance imaging with positron emission tomography scanning . malignant neoplasm diagnosis and all subjects will be at least eighteen years old or if under eighteen parents or guardians must give consent
__label__0	study interventions are Panobinostat . cns lymphoma
__label__0	study interventions are Paclitaxel . the patient must not have active bleeding or pathological conditions that carry high risk of bleeding tumor involving major vessels known varices
__label__0	study interventions are Methylprednisolone Hemisuccinate . peripheral cell lymphoma diagnosis and patients must have no history of acute myocardial infarction in the six months prior to transplantation angina pectoris requiring nitrate therapy uncontrolled major ventricular dysrhythmia uncontrolled hypertension or uncontrolled congestive heart failure
__label__0	study interventions are Freund's Adjuvant . stage iv melanoma diagnosis and willingness to return to mayo clinic rochester for follow up
__label__0	study interventions are Olaparib . pancreatic cancer diagnosis and patient is willing and able to comply with the protocol for the duration of the study including treatment scheduled visits and examinations
__label__0	study interventions are Immunoglobulins . stage iii pancreatic cancer diagnosis and all patients must have radiographically assessable disease
__label__0	study interventions are Prednisolone hemisuccinate . multiple myeloma and plasma cell neoplasm diagnosis and fev_one greater than fifty of predicted
__label__0	study interventions are immunohistochemistry staining method . fallopian tube cancer diagnosis and adequate blood or dna available for erccone analysis
__label__0	study interventions are Sirolimus . unspecified adult solid tumor protocol specific diagnosis and no other uncontrolled illnesses
__label__0	study interventions are Cortisol succinate . cognitive side effects of cancer therapy diagnosis and patients must be enrolled on aalleightbone prior to enrollment on aalloneone3one
__label__0	study interventions are Freund's Adjuvant . breast cancer diagnosis and concurrent hormonal therapy tamoxifen anastrozole or letrozole allowed provided regimen was initiated more than thirty days before study entry disease is stable or progressive and patient plans to continue hormonal therapy for the duration of study participation
__label__0	study interventions are Pioglitazone . multiple myeloma diagnosis and neutrophils greater_than twoxone hundred and nine hemoglobin greater_than ten dl and platelets greater_than ten0xone hundred and nine l
__label__0	study interventions are pharmacological study . borderline ovarian surface epithelial stromal tumor diagnosis and fertile patients must use effective contraception prior to during and for four weeks after completion of study therapy
__label__0	study interventions are Vidarabine . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and acute myeloid leukemia aml
__label__0	study interventions are Antibodies . adult anaplastic astrocytoma diagnosis and all subjects must have given signed informed consent prior to registration on study
__label__0	study interventions are Cyclophosphamide . neuroendocrine tumors diagnosis and negative pregnancy test agreement to use adequate birth control
__label__0	study interventions are Cisplatin . metastatic cancer diagnosis and life expectancy greater_than twelve weeks
__label__0	study interventions are Enzalutamide . if no tumor samples are available the participant might still be eligible following discussion between the investigator and the medical monitor
__label__0	study interventions are Nivolumab . skin cancer diagnosis and for nsclc patients must have minimum of thirty pack year smoking history
__label__0	study interventions are E7389 . patients with locally recurrent or metastatic disease who have received at least two and not more than five prior chemotherapeutic regimens for breast cancer at least two of which were administered for treatment of locally recurrent and or metastatic disease
__label__0	study interventions are Cisplatin . bladder cancer diagnosis and no evidence of bleeding diathesis or coagulopathy
__label__0	study interventions are Dutasteride . have biopsy proven low risk localized prostate cancer and active in expectant management not more than fourteen months
__label__0	study interventions are Gemcitabine . stage ivb cervical cancer diagnosis and stage ivb recurrent or persistent disease
__label__0	study interventions are BPX-501 and AP1903 . lymphoma diagnosis and pulmonary
__label__0	study interventions are Oncology Interactive Navigator . colorectal cancer diagnosis and unrestricted home internet access
__label__0	study interventions are Erlotinib Hydrochloride . advanced malignant mesothelioma diagnosis and no prior corneal abnormalities dry eye syndrome or sjogren syndrome
__label__0	study interventions are Prophylactic donor leukocyte infusions . lymphoma non hodgkin diagnosis and first or greater complete remission if high risk features
__label__0	study interventions are Irinotecan . recurrent rectal cancer diagnosis and concurrent gabapentin or other non eiacds are allowed
__label__0	study interventions are Assessment of Therapy Complications . stage ic fallopian tube cancer diagnosis and patients not on chemotherapy are also eligible and are not required to have recist criteria
__label__0	study interventions are Paclitaxel . recurrent non small cell lung cancer diagnosis and patients with history of gross hemoptysis defined as bright red blood of one two teaspoon or more will be excluded from this trial
__label__0	study interventions are Lenograstim . childhood germ cell tumor diagnosis and not specified
__label__0	study interventions are Antibodies, Monoclonal . lung cancer diagnosis and see disease characteristics
__label__0	study interventions are Antibodies . anaplastic large cell lymphoma diagnosis and serum creatinine equal_than less_than doc mg dl
__label__0	study interventions are Iodine . recurrent thyroid gland carcinoma diagnosis and negative pregnancy test performed equal_than less_than seven days prior to registration for women of childbearing potential only
__label__0	study interventions are Cyclophosphamide . lymphoma diagnosis and karnofsky performance status
__label__0	study interventions are Etoposide . stage ii renal cell cancer diagnosis and specimens materials must be submitted for central review by day seven
__label__0	study interventions are Cyclosporins . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and myelodysplasia mds
__label__0	study interventions are Vorinostat . stage iv cutaneous cell non hodgkin lymphoma diagnosis and no concurrent prophylactic granulocyte growth factors during the first cycle of therapy
__label__0	study interventions are Everolimus . stage iv pancreatic cancer diagnosis and withdrawal
__label__0	study interventions are Docetaxel . lung cancer diagnosis and unresectable stage iii or iv disease
__label__0	study interventions are Paclitaxel . non small cell lung cancer diagnosis and low abundant activating egfr mutation
__label__0	study interventions are Carboplatin . undifferentiated carcinoma
__label__0	study interventions are Gemcitabine . advanced urothelial carcinoma diagnosis and note
__label__0	study interventions are Endothelial Growth Factors . ovarian brenner tumor diagnosis and alkaline phosphatase less than or equal to doc uln ctcae grade one
__label__0	study interventions are Capecitabine . stage ia ovarian cancer diagnosis and prothrombin time pt equal_than less_than doc uln
__label__0	study interventions are Fludarabine . recurrent childhood lymphoblastic lymphoma diagnosis and acute leukemia in twond or greater cr cr greater_than equal_than two
__label__0	study interventions are Pharmacological Study . stage iiia skin melanoma diagnosis and prothrombin time pt partial thromboplastin time ptt less_than doc upper limit of normal uln
__label__0	study interventions are Melphalan . multiple myeloma diagnosis and adequate laboratory values prior to induction treatment initiation defined as follow
__label__0	study interventions are Temozolomide . brain and central nervous system tumors diagnosis and no known hypersensitivity to one of the components of carmustine lomustine temozolomide dacarbazine or any other nitrosourea
__label__0	study interventions are Dexamethasone 21-phosphate . lymphoma cell peripheral diagnosis and concomitant use of drugs that may cause significant qt prolongation and or torsades de pointes that cannot be discontinued or switched to different medication prior to treatment
__label__0	study interventions are Mycophenolic Acid . kidney cancer diagnosis and not specified
__label__0	study interventions are Tamoxifen . stage ib breast cancer diagnosis and fish must show gene amplification or
__label__0	study interventions are Cetuximab . lung cancer diagnosis and fevone and dlco greater_than eighty or exercise test peak vtwo greater_than seventy-five or twenty ml kg one min one for pneumonectomy
__label__0	study interventions are Bevacizumab . lung cancer diagnosis and pleural effusion is seen on ct scan only not seen on chest ray
__label__0	study interventions are Cisplatin . peritoneal carcinomatosis diagnosis and positive peritoneal cytology or histological proven pc
__label__0	study interventions are Paclitaxel . primary peritoneal carcinoma diagnosis and anc greater_than one five hundred mm three
__label__0	study interventions are Carboplatin . carcinoma non small cell lung diagnosis and women must have negative pregnancy test prior to enrollment
__label__0	study interventions are therapeutic allogeneic lymphocytes . splenic marginal zone lymphoma diagnosis and patients must not have any active infections
__label__0	study interventions are Cyclophosphamide . myelodysplastic myeloproliferative neoplasms diagnosis and seronegative for anti hepatitis antibody and detectable hepatitis viral rna by reverse_transcriptase polymerase chain reaction assay note
__label__0	study interventions are magnetic resonance imaging . history of breast cancer allowed provided greater_than one year has elapsed since the last treatment with surgery and there is no known distant metastases and no known residual tumor
__label__0	study interventions are Camptothecin . histologically or cytologically confirmed unresectable or metastatic colorectal or gastric carcinoma
__label__0	study interventions are Vincristine . recurrent adult diffuse large cell lymphoma diagnosis and able to provide informed consent
__label__0	study interventions are Mannitol . childhood ependymoblastoma diagnosis and absolute granulocyte count greater_than equal_than doc ten three mm three
__label__0	study interventions are Gemcitabine . solid tumors diagnosis and performance status zero
__label__0	study interventions are Cyclosporins . recurrent small lymphocytic lymphoma diagnosis and myelodysplastic syndromes
__label__0	study interventions are Idarubicin . lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Topotecan . atypical_teratoid rhabdoid tumor diagnosis and radiation therapy
__label__0	study interventions are Oxaliplatin . stage iv pancreatic cancer diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Antibodies, Monoclonal . intrahepatic cholangiocarcinoma diagnosis and replacement therapy thyroxine insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc
__label__0	study interventions are Liposomal doxorubicin . recurrent ovarian carcinoma diagnosis and patients who have received only one prior cytotoxic regimen platinum based regimen for management of primary disease must have platinum free interval of less than twelve months or have progressed during platinum based therapy or have persistent disease after platinum based therapy
__label__0	study interventions are Metronidazole . extensive stage small cell lung cancer diagnosis and no other concurrent chemotherapy
__label__0	study interventions are 7-hydroxystaurosporine . unspecified adult solid tumor protocol specific diagnosis and chemotherapy
__label__0	study interventions are Doxorubicin . sarcoma diagnosis and weight greater than or equal fifteen kilograms
__label__0	study interventions are Mycophenolate mofetil . multiple myeloma and plasma cell neoplasm diagnosis and patient characteristics
__label__0	study interventions are Cyclophosphamide . localized unresectable neuroblastoma diagnosis and patients must be free of any organ dysfunction or disorder that the treating physician feels may preclude the use of corticosteroid therapy acth or prednisone cyclophosphamide therapy or intravenous gammaglobulin therapy
__label__0	study interventions are Hormones . prostate cancer diagnosis and cardiac ejection fraction normal by echo or muga
__label__0	study interventions are Cyclosporine . recurrent adult lymphoblastic lymphoma diagnosis and crtwo
__label__0	study interventions are Lapatinib . neoplasms breast diagnosis and capable of giving written informed consent which includes compliance with the requirements and restrictions listed in the consent form
__label__0	study interventions are Etoposide phosphate . childhood immunoblastic large cell lymphoma diagnosis and other malignant lymphoproliferative disorders
__label__0	study interventions are Carboplatin . oesophageal cancer diagnosis and no prior abdominal or thoracic radiotherapy
__label__0	study interventions are Mycophenolate mofetil . recurrent cutaneous cell non hodgkin lymphoma diagnosis and low grade nhl with less_than six months duration of complete remission cr between courses of conventional therapy
__label__0	study interventions are Cyclophosphamide . acute lymphoblastic leukemia lymphoma diagnosis and seventy years of age with no matched five six or six six sibling donor
__label__0	study interventions are Carbon Ion Radiotherapy . histologically confirmed atypical meningioma
__label__0	study interventions are Hormones . ductal breast carcinoma in situ diagnosis and for consistency purposes ajcc seventh_edition will continue to be used throughout the entire study enrollment period
__label__0	study interventions are Lapatinib . stage iiic breast cancer diagnosis and bilirubin equal_than less_than doc times upper limit of normal
__label__0	study interventions are alvespimycin hydrochloride . stage iii midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and head and neck
__label__0	study interventions are Doxorubicin . lymphoma diagnosis and life expectancy
__label__0	study interventions are Antibodies . stage iv grade three follicular lymphoma diagnosis and total bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Carboplatin . stage iv ovarian epithelial cancer diagnosis and documented life expectancy of greater than twelve weeks
__label__0	study interventions are Liposomal doxorubicin . breast neoplasms diagnosis and all participants had bilateral mammography chest ray posterioanterior pa and lateral and or computerized tomography ct and or magnetic resonance imaging mri abdominal ultrasound and or ct scan and or mri and bone scan
__label__0	study interventions are Nivolumab . spiradenocarcinoma diagnosis and prothrombin time pt international normalized ratio inr and partial thromboplastin time ptt equal_than less_than doc institutional unl unless the subject is on anticoagulant therapy if the subject is receiving anticoagulant therapy pt and activated ptt aptt must be within therapeutic range of intended use of anticoagulants
__label__0	study interventions are Carboplatin . breast cancer diagnosis and renal
__label__0	study interventions are Androgen Receptor Antagonists . prostate carcinoma metastatic to the bone diagnosis and evidence of lymph node or bone metastasis by magnetic resonance imaging mri computed tomography ct bone scan or biopsy nonemx or nxmone
__label__0	study interventions are Doxorubicin . male breast cancer diagnosis and patients must have completed definitive breast surgery including total mastectomy and axillary dissection modified radical mastectomy total mastectomy and sentinel node biopsy lumpectomy and axillary dissection or lumpectomy and sentinel node biopsy note
__label__0	study interventions are Pazopanib . carcinoma renal cell diagnosis and prior adjuvant or neo adjuvant therapies are permitted excluding any agents that target vascular endothelial growth factor vegf or vegf receptors
__label__0	study interventions are Azacitidine . stage iii grade two follicular lymphoma diagnosis and at least three weeks since prior radiotherapy chemotherapy six weeks for nitrosoureas or mitomycin or molecularly targeted agents
__label__0	study interventions are Busulfan . ewing sarcoma diagnosis and haemoglobin greater_than eight dl transfusion allowed
__label__0	study interventions are Vinblastine . endometrial cancer diagnosis and over eighteen performance status
__label__0	study interventions are Rituximab . lymphoma diagnosis and a
__label__0	study interventions are Paclitaxel . prostate cancer diagnosis and endocrine therapy
__label__0	study interventions are Prednisolone acetate . melanoma diagnosis and platelets greater_than one hundred ten three µl
__label__0	study interventions are Radiation Therapy . pathologically confirmed diagnosis of cancer
__label__0	study interventions are Vitamin D . breast neoplasms diagnosis and gail_model risk of greater than or equal to doc over five years from study entry
__label__0	study interventions are Albumin-Bound Paclitaxel . testicular embryonal carcinoma diagnosis and pulse_oximetry greater_than ninety-four if there is clinical indication for determination
__label__0	study interventions are Cyclophosphamide . recurrent adult immunoblastic large cell lymphoma diagnosis and potwo greater_than sixtymmhg
__label__0	study interventions are Levoleucovorin . metastatic cancer diagnosis and ineligible for surgery
__label__0	study interventions are Cortisone acetate . diffuse large cell lymphoma diagnosis and of childbearing potential and agree to practice true abstinence when this is in line with the preferred and usual_lifestyle of the subject note
__label__0	study interventions are Norgestimate, ethinyl estradiol drug combination . multiple myeloma and plasma cell neoplasm diagnosis and no renal failure requiring hemodialysis or peritoneal dialysis
__label__0	study interventions are Pertuzumab . metastatic breast cancer diagnosis and five of this protocol
__label__0	study interventions are Albumin-Bound Paclitaxel . stage iiia breast cancer diagnosis and life expectancy of greater than twelve weeks
__label__0	study interventions are Oxaliplatin . recurrent childhood ependymoma diagnosis and weight greater_than ten kg
__label__0	study interventions are Immunoglobulins . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and no serious or non healing wound ulcer or bone fracture part two only
__label__0	study interventions are Methotrexate . recurrent cutaneous cell non hodgkin lymphoma diagnosis and single antigen mismatch at hla b or drbone unrelated donors
__label__0	study interventions are Cisplatin . ovarian sex cord stromal tumor diagnosis and patients must have gynecologic oncology group gog performance grade of zero one or two
__label__0	study interventions are Fludarabine phosphate . splenic marginal zone lymphoma diagnosis and sgpt and sgot less_than twox uln
__label__0	study interventions are Vaccines . unspecified adult solid tumor protocol specific diagnosis and recovered from prior radiotherapy
__label__0	study interventions are Mycophenolic Acid . stage childhood large cell lymphoma diagnosis and there is likelihood of rapid disease progression while hla typing and results of preliminary_search and the donor pool_suggests that ten ten hla b drbone and dqbone matched unrelated donor will not be found
__label__0	study interventions are Ergocalciferols . metastatic colorectal cancer diagnosis and no prior radiotherapy to more than twenty-five of bone marrow
__label__0	study interventions are Liposomal doxorubicin . localized resectable neuroblastoma diagnosis and age greater_than eighteen months greater_than five hundred and forty-seven days with unfavorable pathology regardless of mycn status
__label__0	study interventions are Trastuzumab . one prior chemotherapy for metastatic breast cancer allowed may include trastuzumab for hertwo positive patients but no prior doxil adriamycin or epirubicin for metastatic breast cancer
__label__0	study interventions are Fludarabine phosphate . childhood immunoblastic large cell lymphoma diagnosis and the following diseases will be permitted although other diagnoses can be considered if approved by pcc or the participating institution patient review committees and the principal investigator
__label__0	study interventions are Carmustine . brain and central nervous system tumors diagnosis and life expectancy
__label__0	study interventions are LC Bead LUMI . patients with pathologically proven hepatic dominant neoplasm that might otherwise be candidates for standard clinical tae
__label__0	study interventions are Podophyllotoxin . recurrent grade three follicular lymphoma diagnosis and not requiring supplemental oxygen or mechanical ventilation oxygen saturation ninety or higher on room air
__label__0	study interventions are quality-of-life assessment . islet cell tumor diagnosis and more than six months since prior radionuclide therapy or systemic chemotherapy radionuclide or systemic chemotherapy stratum
__label__0	study interventions are Mycophenolate mofetil . myeloproliferative neoplasms diagnosis and more than fifty-five prolymphocytes
__label__0	study interventions are Busulfan . stage mantle cell lymphoma diagnosis and diffusion capacity of the lung for carbon monoxide dlco of greater_than equal_than forty-five predicted or clearance by ccf physician
__label__0	study interventions are Immunoglobulins . stage iii prostate cancer diagnosis and if the second or third confirmatory value is less than the previous value the patient will still be eligible if repeat value no
__label__0	study interventions are Antibodies, Monoclonal . unspecified adult solid tumor protocol specific diagnosis and patients must have life expectancy of greater_than equal_than twelve weeks
__label__0	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and aspartate transaminase ast
__label__0	study interventions are Vinca Alkaloids . ovarian cancer diagnosis and radiographic evidence of measurable disease by recist criteria
__label__0	study interventions are Pomalidomide . multiple myeloma in relapse diagnosis and no ekg evidence of greater_than grade two greater_than four hundred and eighty ms quantum tunnelling composite qtc prolongation
__label__0	study interventions are Vorinostat . multiple myeloma diagnosis and no uncontrolled angina or severe ventricular arrhythmias
__label__0	study interventions are Cyclophosphamide . neuroblastoma diagnosis and biologic therapy
__label__0	study interventions are Cobimetinib . documentation of braf vsix hundred mutation positive status in melanoma tumor tissue archival or newly obtained tumor samples using the cobas four thousand, eight hundred braf vsix hundred mutation test
__label__0	study interventions are Vaccines . lung cancer diagnosis and surgery
__label__0	study interventions are Dexamethasone . smoldering or indolent multiple myeloma meeting one of the following criteria
__label__0	study interventions are Carboplatin . ovarian endometrioid adenocarcinoma diagnosis and absolute neutrophil count greater_than equal_than one five hundred mcl
__label__0	study interventions are Low-dose computed tomography Annual scan x3 . lung cancer diagnosis and eighty years either gender any ethnic group
__label__0	study interventions are Cetuximab . head and neck squamous cell cancer diagnosis and the lesion must be so extensive that functional reconstruction is not possible
__label__0	study interventions are Doxorubicin . bladder cancer diagnosis and granulocyte count at least one five hundred mm three
__label__0	study interventions are Gemcitabine . the efficacy and safety of gemcitabine in the maintenance treatment of advanced non small cell lung cancer diagnosis and platelet greater_than one hundred one hundred and nine l
__label__0	study interventions are Levoleucovorin . adenocarcinoma of the stomach diagnosis and eastern cooperative oncology group ecog performance status less_than two karnofsky greater_than seventy
__label__0	study interventions are Capecitabine . extrahepatic bile duct cancer diagnosis and cardiovascular
__label__0	study interventions are Cyclophosphamide . primary effusion lymphoma diagnosis and doc
__label__0	study interventions are Capecitabine . carcinoma renal cell diagnosis and total bilirubin less_than doc mg dl
__label__0	study interventions are Liposomal doxorubicin . localized osteosarcoma diagnosis and suitable for neoadjuvant chemotherapy
__label__0	study interventions are questionnaire administration . colorectal cancer diagnosis and any treatment modality chemotherapy radiotherapy surgery allowed
__label__0	study interventions are Conventional Fractionated Radiotherapy . other cancer history
__label__0	study interventions are Chemotherapy . malignant melanoma diagnosis and life expectancy of at least three months
__label__0	study interventions are Cyclophosphamide . breast cancer diagnosis and dlco greater_than fifty of predicted
__label__0	study interventions are Thalidomide . prior steroids for prostate cancer allowed
__label__0	study interventions are Calcium, Dietary . lymphoma non hodgkin diagnosis and specifically patients with stages ii iv hodgkin disease are eligible if they have relapsed or failed to attain complete remission after first line chemotherapy and either are not eligible for or have refused salvage chemotherapy or bone marrow transplantation
__label__0	study interventions are Cyclophosphamide . diffuse large cell lymphoma not otherwise specified diagnosis and history of stroke or intracranial hemorrhage equal_than less_than six months before treatment
__label__0	study interventions are Trastuzumab . metastatic cancer diagnosis and at least four weeks since prior cranial radiotherapy
__label__0	study interventions are Prednisone . aids related small noncleaved cell lymphoma diagnosis and who world health organization and cdc centers for disease control and prevention guidelines mandate that confirmation of the initial test result must use test that is different from the one used for the initial assessment reactive initial rapid test should be confirmed by either another type of rapid assay or an cia that is based on different antigen preparation and or different test principle indirect versus competitive or western_blot or plasma hiv one rna viral load
__label__0	study interventions are Doxorubicin . breast cancer diagnosis and anc greater_than one five hundred mcl
__label__0	study interventions are Prednisone . childhood immunoblastic large cell lymphoma diagnosis and not pregnant or nursing
__label__0	study interventions are Lenograstim . stage iiib non small cell lung cancer diagnosis and stage iiia ntwo disease meeting the following criteria
__label__0	study interventions are BB 1101 . multiple myeloma diagnosis and total bilirubin
__label__0	study interventions are Mycophenolate mofetil . recurrent adult diffuse mixed cell lymphoma diagnosis and meet other blood bank criteria for blood product donation as determined by nbah blood center screening history
__label__0	study interventions are Erlotinib Hydrochloride . breast cancer diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are Antibodies . adenocarcinoma of the lung diagnosis and no prior severe infusion reactions to monoclonal antibody
__label__0	study interventions are Immunoglobulins . brenner tumor diagnosis and no active infection requiring antibiotics
__label__0	study interventions are Imatinib Mesylate . adult meningioma diagnosis and at least two weeks since prior drugs that affect hepatic metabolism
__label__0	study interventions are Cyclosporine . stage iv grade three follicular lymphoma diagnosis and blasts must be less_than ten morphologically in representative bone marrow aspirate obtained less_than two weeks from enrollment
__label__0	study interventions are Cyclophosphamide . recurrent ovarian carcinoma diagnosis and at least three months
__label__0	study interventions are Cetuximab . stage iii colon cancer diagnosis and ketoconazole
__label__0	study interventions are Liposomal doxorubicin . central nervous system tumor pediatric diagnosis and prior steroids allowed
__label__0	study interventions are Methylprednisolone . high risk localised prostate carcinoma diagnosis and equivocal bone scan findings are allowed if plain film rays are negative for metastasis
__label__0	study interventions are Bevacizumab . malignant peritoneal neoplasm diagnosis and total bilirubin equal_than less_than doc mg dl or direct bilirubin equal_than less_than doc mg dl
__label__0	study interventions are Thalidomide . recurrent small lymphocytic lymphoma diagnosis and lymphangitis_cutis pulmonis
__label__0	study interventions are Intensity Modulated Radiotherapy treatment . non small cell lung cancer diagnosis and patients with ps two as result of co morbid conditions will be excluded
__label__0	study interventions are Bevacizumab . breast cancer diagnosis and no history of seizures
__label__0	study interventions are cytogenetic analysis . precancerous condition diagnosis and prior or concurrent bisphosphonates allowed
__label__0	study interventions are Cortisone . stage iv prostate adenocarcinoma diagnosis and alanine aminotransferase alt less_than doc uln
__label__0	study interventions are Azacitidine . patient must have histologically or cytologically confirmed colorectal adenocarcinoma with metastatic disease documented on diagnostic imaging studies
__label__0	study interventions are Aminolevulinic Acid . colon cancer diagnosis and anc greater_than one thousand, five hundred µl platelets greater_than one hundred zero µl total bilirubin less_than the upper limit of normal uln and creatinine clearance crcl greater_than forty-five ml min
__label__0	study interventions are Prednisone . breast cancer diagnosis and absolute neutrophil count greater_than five hundred mm three
__label__0	study interventions are Sorafenib . liver carcinoma diagnosis and signed and dated informed consent before start of any study specific procedure
__label__0	study interventions are Albumin-Bound Paclitaxel . recurrent uterine corpus carcinoma diagnosis and patients must have baseline electrocardiogram ekg performed prior to enrolling on study the ekg must have corrected qt interval qtc less_than four hundred and fifty msec and must not show evidence of serious ventricular arrhythmia ventricular tachycardia or ventricular fibrillation must be less than three beats in row
__label__0	study interventions are Cyclosporine . recurrent grade two follicular lymphoma diagnosis and philadelphia negative myeloproliferative disorder
__label__0	study interventions are Sirolimus . adult anaplastic astrocytoma diagnosis and platelet count of at least one hundred zero mm three on at least two consecutive blood draws at least one week apart with results stable trending_upward any question regarding the definition of stable trending_upward must be discussed with the pi
__label__0	study interventions are Celecoxib . unspecified adult solid tumor protocol specific diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Fludarabine phosphate . stage iv adult cell leukemia lymphoma diagnosis and myelodysplastic syndromes mds greater_than int one per ipss after greater_than equal_than one prior cycle of induction chemotherapy should have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Carboplatin . stage ivb oral cavity verrucous carcinoma diagnosis and patients may have received one regimen of induction concomitant chemoradiotherapy and or adjuvant chemotherapy as part of initial potential curative therapy but must not have received prior chemotherapy for recurrent or metastatic disease
__label__0	study interventions are Cyclosporine . angioimmunoblastic cell lymphoma diagnosis and must have failed two lines of conventional therapy and be refractory to fludarabine
__label__0	study interventions are Antibodies, Monoclonal . stage ivb squamous cell carcinoma of the oropharynx diagnosis and for patients with liver metastases ast alt less_than fivex uln is acceptable
__label__0	study interventions are Rituximab . dose equivalent to less_than twenty mg day prednisone allowed for conditions other than lymphoma or lymphoma related symptoms
__label__0	study interventions are Immunoglobulin G . recurrent squamous cell lung carcinoma diagnosis and patients must not have received nitrosoureas or mitomycin within forty-two days prior to sub study registration
__label__0	study interventions are Antibodies, Monoclonal . contiguous stage ii marginal zone lymphoma diagnosis and prior rituximab or other monoclonal immunotherapy permitted and eligible for rituximab monotherapy
__label__0	study interventions are Docetaxel . non small cell lung carcinoma diagnosis and for women of childbearing potential negative serum pregnancy test within ten days of treatment and use of physician approved methods of birth control throughout the study
__label__0	study interventions are Ifosfamide . lymphoma diagnosis and no cns involvement
__label__0	study interventions are Fluorouracil . adenocarcinoma of the gastroesophageal junction diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Bevacizumab . stage iv skin melanoma diagnosis and no concurrent carbamazepine phenytoin or phenobarbital drugs that induce cypfour hundred and fifty threea activity
__label__0	study interventions are Thalidomide . stage iv grade two follicular lymphoma diagnosis and no history of acquired immune deficiency syndrome aids defining conditions
__label__0	study interventions are Bevacizumab . salivary gland squamous cell carcinoma diagnosis and creatinine clearance of greater_than equal_than sixty ml min creatinine clearance may be measured or calculated if calculating creatinine clearance use the cockroft gault formula
__label__0	study interventions are Antibodies, Monoclonal . recurrent urothelial carcinoma of the renal pelvis and ureter diagnosis and for patients that have had surgical resection prior to study enrollment residual or unresected disease measurable and or unmeasurable must be evident on post surgical scans
__label__0	study interventions are Lenograstim . histologically confirmed classical hodgkin lymphoma hl meeting the following criteria
__label__0	study interventions are Cyclosporine . lymphoma diagnosis and patients not in remission at day twenty-eight of first induction
__label__0	study interventions are Leucovorin . metastatic cancer diagnosis and eighteen and over performance status
__label__0	study interventions are Immunoglobulins . recurrent marginal zone lymphoma diagnosis and bi_dimensionally measurable disease at least one cm
__label__0	study interventions are Fludarabine phosphate . ds stage ii plasma cell myeloma diagnosis and biphenotypic undifferentiated leukemias in first onest or subsequent complete remission cr
__label__0	study interventions are 6-Mercaptopurine . lymphoma diagnosis and other
__label__0	study interventions are Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance . cancer of breast diagnosis and twenty-one years of age or older
__label__0	study interventions are Panobinostat . multiple myeloma in relapse diagnosis and serum protein greater_than doc dl
__label__0	study interventions are Sirolimus . stage ii non contiguous adult diffuse large cell lymphoma diagnosis and donor
__label__0	study interventions are Poly ICLC . triple negative breast neoplasms diagnosis and total bilirubin less_than doc institutional upper limit of normal
__label__0	study interventions are Antibodies . stage iiib non small cell lung cancer diagnosis and concurrent full dose anticoagulants allowed provided the following criteria are met part two only
__label__0	study interventions are Histone Deacetylase Inhibitors . splenic marginal zone lymphoma diagnosis and inflammatory breast disease
__label__0	study interventions are Topotecan . lymphoma diagnosis and bilirubin less_than doc mg dl
__label__0	study interventions are Thalidomide . concurrent use of other anti cancer agents or treatments
__label__0	study interventions are allogeneic bone marrow transplantation . multiple myeloma and plasma cell neoplasm diagnosis and endogenous erythroid colony formation in vitro
__label__0	study interventions are Irinotecan . recurrent childhood cerebral astrocytoma diagnosis and phenobarbital
__label__0	study interventions are Prednisone . prostate cancer metastatic diagnosis and written informed consent must be obtained prior to any study related procedures
__label__0	study interventions are Oxaliplatin . lymphoma extranodal nk cell diagnosis and age
__label__0	study interventions are Fludarabine . lymphoma diagnosis and disease characteristics
__label__0	study interventions are NGS test . breast cancer diagnosis and doc patients age at diagnosis
__label__0	study interventions are Immunoglobulins, Intravenous . regional neuroblastoma diagnosis and no prior chemotherapy
__label__0	study interventions are Fludarabine . breast cancer diagnosis and hepatic
__label__0	study interventions are DW-MRI . stage durie_salmon asymptomatic mm at diagnosis not requiring treatment substudy for assessment of exploratory objectives
__label__0	study interventions are fenretinide . stage iv primary peritoneal cavity cancer diagnosis and patients of childbearing potential must agree to use an approved method of birth control
__label__0	study interventions are Ifosfamide . cervical cancer diagnosis and disease characteristics
__label__0	study interventions are Vaccines . myeloma diagnosis and donor
__label__0	study interventions are Antibodies, Monoclonal . stage iv squamous cell carcinoma of the hypopharynx diagnosis and no gastrointestinal tract disease or condition including any of the following that impairs ability to retain sunitinib tablets
__label__0	study interventions are High intensity focused ultrasound, HIFU . ajcc stage iii or iv pancreatic cancer based on imaging criteria endoscopic ultrasound ct scan and or mri
__label__0	study interventions are Melphalan . stage ii multiple myeloma diagnosis and more than four weeks since prior immunotherapy or antibody therapy
__label__0	study interventions are Liposomal doxorubicin . pretext stage two hepatoblastoma diagnosis and doc mg dl
__label__0	study interventions are Carboplatin . bladder cancer diagnosis and clinical stage iv
__label__0	study interventions are Vorinostat . childhood diffuse large cell lymphoma diagnosis and no prior vorinostat
__label__0	study interventions are Fludarabine . if lesions are symptomatic or greater than or equal to one cm each these lesions must have been treated and stable for three months for the patient to be eligible
__label__0	study interventions are 3-dimensional conformal accelerated partial breast irradiation . resected margins histologically free of tumor
__label__0	study interventions are Rituximab . stage ii diffuse large cell lymphoma diagnosis and procrit_aranesp
__label__0	study interventions are Dendritic Killer Cell (DKC) . colorectal neoplasms diagnosis and patient age greater_than twenty at date of consent
__label__0	study interventions are Calcium, Dietary . stage iic rectal cancer diagnosis and group ii
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and karnofsky functional status rating greater_than or equal to seventy
__label__0	study interventions are Hydroxyurea . stage iv midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and no arterial thromboembolic event within the past six months including any of the following
__label__0	study interventions are Busulfan . recurrent adult cell leukemia lymphoma diagnosis and fulfills all pulmonary cardiac renal and hepatic criteria for standard of care matched unrelated donor mud allogeneic hct
__label__0	study interventions are Cetuximab . lung cancer diagnosis and patients must be able to take and retain oral medication
__label__0	study interventions are laboratory biomarker analysis . recurrent adult diffuse small cleaved cell lymphoma diagnosis and no known brain metastases
__label__0	study interventions are Palliative care . gastric cancer diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Paclitaxel . locally recurrent metastatic breast cancer relapse in supr negative or infraclavicular lymph nodes is regarded as metastatic disease
__label__0	study interventions are Fludarabine . testicular germ cell tumor diagnosis and biologic therapy
__label__0	study interventions are Gemcitabine . pancreatic adenocarcinoma diagnosis and eastern cooperative oncology group ecog performance status of zero or one
__label__0	study interventions are Adjuvants, Immunologic . stage ib ovarian cancer diagnosis and serum creatinine less than or equal to doc institutional upper limit normal uln ctcae doc grade one
__label__0	study interventions are Cisplatin . head and neck cancer diagnosis and histologic extracapsular nodal extension
__label__0	study interventions are Camptothecin . gastric cancer diagnosis and eligibility criteria
__label__0	study interventions are pharmacological study . childhood high grade cerebral astrocytoma diagnosis and no greater than doc mg dl greater_than fifteen years of age
__label__0	study interventions are Vincristine . recurrent adult immunoblastic large cell lymphoma diagnosis and life expectancy of at least twelve weeks
__label__0	study interventions are Fludarabine phosphate . childhood nasal type extranodal nk cell lymphoma diagnosis and additional single allele level mismatch at b or drbone cord blood greater_than equal_than four out of six antigen match at hla b drbone
__label__0	study interventions are Mycophenolate mofetil . multiple myeloma and plasma cell neoplasm diagnosis and chronic myelomonocytic leukemia
__label__0	study interventions are Prednisone . lymphoma diagnosis and surgery
__label__0	study interventions are Cyclosporine . stage iv adult diffuse small cleaved cell lymphoma diagnosis and there is likelihood of rapid disease progression while hla typing and results of preliminary_search and the donor pool_suggests that ten ten hla b drbone and dqbone matched unrelated donor will not be found
__label__0	study interventions are Bevacizumab . pancreatic cancer diagnosis and no concurrent colony stimulating factors during the first course of study therapy
__label__0	study interventions are Bevacizumab . stage iii mucoepidermoid carcinoma of the oral cavity diagnosis and at least four weeks since prior major surgery
__label__0	study interventions are Carboplatin . cervical cancer diagnosis and alkaline phosphatase normal
__label__0	study interventions are brachytherapy . prostate cancer diagnosis and prior concurrent therapy
__label__0	study interventions are TKM-080301 . pancreas cancer with hepatic metastase diagnosis and leucovorin in combination with either oxaliplatin and or irinotecan since level
__label__0	study interventions are Sunitinib . tongue cancer diagnosis and st
__label__0	study interventions are Fluoroquinolones . multiple myeloma and plasma cell neoplasm diagnosis and performance status
__label__0	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and bilirubin normal
__label__0	study interventions are Camptothecin . kidney cancer diagnosis and not pregnant or nursing
__label__0	study interventions are Cyclophosphamide . metastatic melanoma diagnosis and absolute neutrophil count greater than one thousand mm three without the support of filgrastim
__label__0	study interventions are Cyclosporins . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and life expectancy of greater than six months
__label__0	study interventions are Belinostat . stage iii adult lymphoblastic lymphoma diagnosis and condition requiring antiarrhythmic therapy
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and chemotherapy
__label__0	study interventions are E6201 . advanced solid tumors diagnosis and contraceptive measures must start either prior to or at screening and continue throughout the entire study period and for two months after the last dose drug is administered
__label__0	study interventions are Cyclosporine . recurrent adult diffuse large cell lymphoma diagnosis and fevone and dlco corrected must be greater_than equal_than sixty of normal
__label__0	study interventions are Interferons . multiple myeloma and plasma cell neoplasm diagnosis and hiv negative
__label__0	study interventions are Etoposide . stage iv childhood lymphoblastic lymphoma diagnosis and patients who are human immunodeficiency virus hiv positive
__label__0	study interventions are Antibodies . lung cancer diagnosis and patients who have had prior treatment with parpi are not eligible
__label__0	study interventions are Cortisone acetate . refractory lymphoblastic lymphoma diagnosis and note
__label__0	study interventions are Laboratory Biomarker Analysis . stage iva major salivary gland carcinoma diagnosis and absolute neutrophil count greater_than equal_than one zero mm three
__label__0	study interventions are cilengitide . anaplastic large cell lymphoma diagnosis and no other concurrent investigational agents
__label__0	study interventions are Estrogen Receptor Modulators . breast cancer diagnosis and no ovarian cyst during screening
__label__0	study interventions are CUDC-907 . neuroblastoma diagnosis and for agents with known adverse events occurring beyond seven days this duration must be extended beyond the time in which adverse events are known to occur
__label__0	study interventions are Endothelial Growth Factors . recurrent adenoid cystic carcinoma of the oral cavity diagnosis and transient ischemic attack
__label__0	study interventions are Estrogens . stage iiic breast cancer diagnosis and deep vein thrombosis pulmonary embolism dvt pe within the past six months
__label__0	study interventions are Non-tailored booklet on exercise and diet . breast cancer diagnosis and mobile phone user
__label__0	study interventions are Irinotecan . stage ivb rectal cancer diagnosis and no significant traumatic injury within the past twenty-eight days
__label__0	study interventions are Irinotecan . bronchoalveolar carcinoma
__label__0	study interventions are Antibodies . recurrent adult soft tissue sarcoma diagnosis and at least seven days since prior hematopoietic growth factors fourteen days for pegfilgrastim
__label__0	study interventions are PatientsLikeMe (PLM) . breast cancer stage diagnosis and having computer is not required
__label__0	study interventions are Mycophenolic Acid . stage iv childhood lymphoblastic lymphoma diagnosis and unrelated donors who are prospectively
__label__0	study interventions are Cyclosporine . stage iii adult lymphoblastic lymphoma diagnosis and chronic myelomonocytic leukemia
__label__0	study interventions are Cisplatin . stage iiia non small cell lung cancer diagnosis and absolute neutrophil count greater_than equal_than one five hundred ul
__label__0	study interventions are Everolimus . childhood liposarcoma diagnosis and for patients with known bone marrow metastatic disease transfusions are permitted to meet both platelet and hemoglobin criteria patients must not be known to be refractory to red blood cell or platelet transfusions
__label__0	study interventions are pharmacological study . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and dillapiol
__label__0	study interventions are Bortezomib . ds stage ii plasma cell myeloma diagnosis and serum monoclonal protein greater_than equal_than doc dl
__label__0	study interventions are Maytansine . breast cancer diagnosis and platelets greater_than one hundred zero cells mmthree
__label__0	study interventions are Dasatinib . non small cell lung cancer diagnosis and phase ii only
__label__0	study interventions are Lenograstim . bladder cancer diagnosis and hemoglobin greater_than equal_than doc dl
__label__0	study interventions are Tryptophan . metastatic melanoma diagnosis and ecog performance status less_than two karnofsky greater_than sixty
__label__0	study interventions are Doxorubicin . stage iiia breast cancer diagnosis and platelet count greater_than equal_than one hundred zero mm three
__label__0	study interventions are Fludarabine phosphate . plasma cell neoplasm diagnosis and at least four weeks since prior radiotherapy
__label__0	study interventions are Endothelial Growth Factors . recurrent ovarian epithelial cancer diagnosis and no uncontrolled intercurrent illness including but not limited to
__label__0	study interventions are Vinblastine . breast cancer diagnosis and if previously treated with taxane in the neoadjuvant or adjuvant setting the period from end of treatment to disease recurrence must have been greater_than twelve months greater_than three hundred and sixty-five days
__label__0	study interventions are Bowel cancer screening decision aid . colorectal neoplasms diagnosis and lower levels of education
__label__0	study interventions are management of therapy complications . cancer diagnosis and renal
__label__0	study interventions are cognitive assessment . breast cancer diagnosis and disease characteristics
__label__0	study interventions are Prednisone . lymphoma diagnosis and have adequate organ function as follows
__label__0	study interventions are Albumin-Bound Paclitaxel . testicular germ cell tumor diagnosis and patient characteristics
__label__0	study interventions are Dacarbazine . anaplastic astrocytoma diagnosis and subject or subject partner is willing to use condoms for twelve months after receiving toca five hundred and eleven or until there is no evidence of the virus in his her blood whichever is longer
__label__0	study interventions are Liposomal doxorubicin . grade threeb follicular lymphoma diagnosis and have performance status of zero or one on the eastern cooperative oncology group ecog performance scale ps or ecog ps two if related to dlbcl and associated manifestations
__label__0	study interventions are Ergocalciferols . prostate cancer diagnosis and creatinine clearance greater_than sixty ml min
__label__0	study interventions are Carboplatin . testicular choriocarcinoma and yolk_sac tumor diagnosis and no dyspnea at rest
__label__0	study interventions are Carboplatin . ovarian cancer diagnosis and lvef greater_than fifty as assessed by ultrasound or muga scan if clinically indicated
__label__0	study interventions are Tivozanib . advanced adult hepatocellular carcinoma diagnosis and aspartate aminotransferase ast equal_than less_than five institutional upper limits of normal uln
__label__0	study interventions are Temozolomide . metastatic cancer diagnosis and see disease characteristics
__label__0	study interventions are Antibodies . stage iii squamous cell carcinoma of the larynx diagnosis and see disease characteristics
__label__0	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the larynx diagnosis and ecog performance status ps zero two or karnofsky ps 6zero_1zerozero
__label__0	study interventions are Expanded Prostate Cancer Index Composite-SF12 . prostate adenocarcinoma diagnosis and b
__label__0	study interventions are Docetaxel . stage iva lip and oral cavity squamous cell carcinoma diagnosis and no current peripheral neuropathy greater_than equal_than grade two at time of randomization
__label__0	study interventions are Cisplatin . endometrial adenocarcinoma diagnosis and john wort therapeutic anticoagulants aminoglycoside antibiotics or amifostine
__label__0	study interventions are management of therapy complications . psychosocial effects of cancer and its treatment diagnosis and dizziness
__label__0	study interventions are Lapatinib . stage iv squamous cell carcinoma of the larynx diagnosis and no concurrent combination antiretroviral therapy for hiv positive patients
__label__0	study interventions are External beam radiotherapy . malignant glioma diagnosis and hemoglobin value greater_than six mmol transfusion permitted
__label__0	study interventions are Vincristine . platelet count greater_than one hundred zero mm three unless there is bone marrow infiltration by lymphoma
__label__0	study interventions are Mycophenolate mofetil . recurrent childhood anaplastic large cell lymphoma diagnosis and acute myeloid leukemia aml must have less_than five marrow blasts at the time of transplant
__label__0	study interventions are Rituximab . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and karnofsky seventy one hundred
__label__0	study interventions are Fludarabine . metastatic melanoma diagnosis and willing to sign durable_power of attorney
__label__0	study interventions are Capecitabine . metastatic cancer diagnosis and hepatic
__label__0	study interventions are Endothelial Growth Factors . malignant peritoneal neoplasm diagnosis and urine dipstick for proteinuria less_than two positive patients discovered to have greater_than equal_than two positive proteinuria on dipstick urinalysis at baseline should undergo two4 hour urine collection and must demonstrate equal_than less_than one of protein in two4 hours to be eligible
__label__0	study interventions are Vorinostat . childhood infratentorial ependymoma diagnosis and prior temozolomide allowed provided there was no progressive disease during or within one month after completion of treatment
__label__0	study interventions are Vaccines . nasopharyngeal neoplasms diagnosis and in the similar fashion recovery from chemotherapy and radiation therapy will be evaluated
__label__0	study interventions are Fludarabine phosphate . breast cancer diagnosis and recurrent disease progression after receiving all standard treatments which must include the following
__label__0	study interventions are Everolimus . ganglioneuroblastoma diagnosis and age six months to less_than one year
__label__0	study interventions are Carboplatin . stage iv non small cell lung cancer diagnosis and meets criteria for one of the following
__label__0	study interventions are Capecitabine . metastatic breast cancer diagnosis and chest
__label__0	study interventions are Computerized working memory training program (intervention) . brain tumor diagnosis and age scaled score on digit span letter number sequencing or spatial span less_than seven or at least one standard deviation below iq score
__label__0	study interventions are Bevacizumab . ovarian cancer diagnosis and concurrent low dose aspirin less_than three hundred and twenty-five mg day allowed for patients at higher risk for arterial thromboembolic disease
__label__0	study interventions are Dacarbazine . stage ii childhood hodgkin lymphoma diagnosis and participants receiving limited emergent radiation therapy rt or steroid therapy
__label__0	study interventions are Antibodies, Monoclonal . stage iva rectal cancer diagnosis and creatinine equal_than less_than doc mg dl or creatinine clearance greater_than equal_than sixty ml min doc three two for patients with creatinine levels above institutional normal
__label__0	study interventions are Erlotinib Hydrochloride . stage iv squamous cell carcinoma of the larynx diagnosis and performance status
__label__0	study interventions are Saracatinib . stage iii thymoma diagnosis and must have received greater_than equal_than one prior chemotherapy regimen
__label__0	study interventions are Sirolimus . metastatic renal cell carcinoma diagnosis and karnofsky performance status less_than eighty
__label__0	study interventions are Methylprednisolone . precancerous nonmalignant condition diagnosis and see disease characteristics
__label__0	study interventions are blood samples analysis . gastric precancerous lesions diagnosis and genetic predisposition ex
__label__0	study interventions are Etoposide . lymphoma diagnosis and diffuse large cell
__label__0	study interventions are Cyclophosphamide . hertwo positive breast cancer diagnosis and men and women of reproductive ability must agree to use contraceptives during the entire study period
__label__0	study interventions are Diphosphonates . recurrent prostate cancer diagnosis and psa greater_than equal_than five ng ml
__label__0	study interventions are Prednisolone hemisuccinate . multiple myeloma and plasma cell neoplasm diagnosis and progressive disease after autologous stem cell transplantation
__label__0	study interventions are Gemcitabine . stage iii pancreatic cancer diagnosis and more than four weeks since other prior therapies and recovered
__label__0	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and see disease characteristics
__label__0	study interventions are Radium 223 . thyroid cancer diagnosis and affiliated to social security regimen
__label__0	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . primary peritoneal cancer diagnosis and patients with metastatic disease must have received at least one line of standard of care soc treatment for metastatic disease prior to enrollment
__label__0	study interventions are Vaccines . brain and central nervous system tumors diagnosis and hla two hundred and one positive
__label__0	study interventions are Isophosphamide mustard . lymphoma diagnosis and one of the following diagnoses
__label__0	study interventions are AR-42 . refractory multiple myeloma diagnosis and patients with significant cardiovascular disease including myocardial infarction or unstable angina within six months or unstable cardiac arrhythmias are not eligible for the study
__label__0	study interventions are Prednisone . stage iv prostate cancer diagnosis and bone lesions
__label__0	study interventions are Erlotinib Hydrochloride . adenocarcinoma of the pancreas diagnosis and at least four weeks since prior radiotherapy
__label__0	study interventions are Cyclosporine . childhood burkitt lymphoma diagnosis and best available matches are hla class hla b allele matched donors allowing for any one or two drbone and or dqbone antigen allele mismatch
__label__0	study interventions are Antibodies, Monoclonal . refractory non hodgkin lymphoma diagnosis and sixty-five years
__label__0	study interventions are Tipifarnib . breast cancer diagnosis and hormone responsive disease
__label__0	study interventions are Sirolimus . breast cancer diagnosis and lhrh agonists may be used to render ovarian suppression with postmenopausal ranges of estradiol or fsh per institutional guidelines
__label__0	study interventions are Bortezomib . refractory multiple myeloma diagnosis and patients who received prior bortezomib must have responded to therapy
__label__0	study interventions are Thalidomide . smoldering multiple myeloma diagnosis and females of reproductive age not using adequate birth control measures or who are pregnant are not eligible
__label__0	study interventions are Epirubicin . resectable aeg and primary tumor category uttwo four
__label__0	study interventions are Liposomal doxorubicin . diffuse hyperplastic_perilobar nephroblastomatosis diagnosis and patients must begin protocol therapy on arenfive hundred and thirty-four by day fourteen following surgery or diagnosis by initial computed tomography ct magnetic resonance imaging mri unless medically contraindicated
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and performance status
__label__0	study interventions are Starvation . esophagus cancer diagnosis and anc greater_than one thousand, five hundred mm³
__label__0	study interventions are Allopurinol . lymphoblastic lymphoma diagnosis and raeb one raeb two severe cytopenias
__label__0	study interventions are Isophosphamide mustard . childhood leiomyosarcoma diagnosis and doc mg dl six years to less_than ten years of age
__label__0	study interventions are Imatinib Mesylate . recurrent melanoma diagnosis and no concurrent inhibitors of cypthreeafour including any of the following
__label__0	study interventions are 7-hydroxystaurosporine . myelodysplastic myeloproliferative neoplasms diagnosis and no hyperleukocytosis wbc greater_than thirty zero mm three recent treatment with hydroxyurea to prevent impending leukostasis allowed provided there has been no dose increase for greater_than one week
__label__0	study interventions are Carboplatin . histologically or cytologically confirmed primary non small cell lung cancer including any of the following
__label__0	study interventions are Sirolimus . neurofibromatosis type two diagnosis and patients taking cholesterol lowering agent must be on single medication and on stable dose for at least four weeks
__label__0	study interventions are Gossypol acetic acid . stage iv adult lymphoblastic lymphoma diagnosis and patients must have histologically or cytologically confirmed malignancy that is metastatic and unresectable and for which standard curative or palliative measures do not exist or are no longer effective patient may have previously treated or untreated disease
__label__0	study interventions are Fluorouracil . nasopharyngeal neoplasms diagnosis and informed consent
__label__0	study interventions are Etoposide . stage adult diffuse large cell lymphoma diagnosis and two three
__label__0	study interventions are Cisplatin . stage iv pancreatic cancer diagnosis and arm cohort four
__label__0	study interventions are therapeutic conventional surgery . adenocarcinoma of the prostate diagnosis and broccoli cauliflower brussels sprouts cabbage arugula watercress bok choy turnip greens mustard greens collard greens rutabaga napa or chinese cabbage radishes turnips kohlrabi and kale
__label__0	study interventions are Bevacizumab . histologically confirmed adenocarcinoma of the stomach or gastro oesophageal junction with inoperable locally advanced or metastatic disease not amenable to curative therapy
__label__0	study interventions are Immunoglobulins . malignant pancreatic gastrinoma diagnosis and two prior chemotherapy regimens
__label__0	study interventions are Gemcitabine . recurrent small lymphocytic lymphoma diagnosis and fertile patients must use effective contraception
__label__0	study interventions are Gemcitabine . lung cancer diagnosis and platelet count at least one hundred zero mm three
__label__0	study interventions are Prednisolone phosphate . follicular lymphoma diagnosis and an fna alone is insufficient
__label__0	study interventions are PET with 18F-FDOPA . b raf mutated metastatic melanoma
__label__0	study interventions are Exemestane . breast cancer diagnosis and participants with different grades between the two breasts should be classified according to higher grade note
__label__0	study interventions are Celecoxib . prostate cancer diagnosis and no allergy to sulfa containing medications
__label__0	study interventions are Fluorodeoxyglucose F18 . brain neoplasms diagnosis and if female of child bearing potential and outside of the window of ten days since the last menstrual period negative serum or urine pregnancy test is required
__label__0	study interventions are Phenobarbital . gliosarcoma diagnosis and kpsgreater_than sixty percent
__label__0	study interventions are Sunitinib . recurrent non small cell lung carcinoma diagnosis and iiib iv with evidence of disease progression following first line therapy
__label__0	study interventions are Oxaliplatin . patients with pathology or cytology showing carcinoma of pancreas or adenosquamous of the pancreas are also eligible
__label__0	study interventions are selumetinib . stage iiib gallbladder cancer diagnosis and patients will be required to undergo biopsy prior to enrolling on the study and will be given the option to have another biopsy around four weeks from initiation of treatment
__label__0	study interventions are Dexamethasone 21-phosphate . breast cancer diagnosis and no limit on the prior number of chemotherapies for the phase portion of the study
__label__0	study interventions are Fludarabine phosphate . primary peritoneal cavity cancer diagnosis and life expectancy greater_than six months
__label__0	study interventions are Fludarabine . stage iv adult cell leukemia lymphoma diagnosis and patient and donor pairs_homozygous at mismatched allele in the graft rejection_vector are considered two allele mismatch the patient is one hundred and one and the donor is two hundred and one and this type of mismatch is not allowed
__label__0	study interventions are Hydroxyurea . stage ivb squamous cell carcinoma of the oropharynx diagnosis and aspartate aminotransferase ast and alanine aminotransferase alt equal_than less_than doc upper limit of normal uln
__label__0	study interventions are Immunoglobulins . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and no known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies part two only
__label__0	study interventions are Cyclosporins . multiple myeloma diagnosis and acute lymphoblastic leukemia
__label__0	study interventions are Tacrolimus . stage iv adult diffuse large cell lymphoma diagnosis and refractory anemia with ringed_sideroblasts
__label__0	study interventions are Lenalidomide . recurrent adult diffuse large cell lymphoma diagnosis and not responding to appropriate tapering of immunosuppressive medications
__label__0	study interventions are Fludarabine . stage iv small lymphocytic lymphoma diagnosis and following planned autologous transplant or equivalent high dose therapy without graft or following failed prior autograft
__label__0	study interventions are Antibodies, Monoclonal . large cell lung cancer diagnosis and ntwo mediastinal lymph nodes must be multiple and or bulky on ct scan or ray so that the patient is not candidate for induction chemotherapy or chemoradiotherapy followed by surgical resection
__label__0	study interventions are Morphine . solid tumors diagnosis and patient has no known allergy or severe toxicity to morphine or morphine like drugs hydromorphone oxycodone oxymorphone codeine hydrocodone levorphanol or methadone or methadone like drug propoxyphene
__label__0	study interventions are Cetuximab . stage iii basal cell carcinoma of the lip diagnosis and concurrent full dose anticoagulants allowed provided the following criteria are met part two only
__label__0	study interventions are Albumin-Bound Paclitaxel . histologically or cytologically confirmed with non squamous non small cell lung cancer nsclc
__label__0	study interventions are Cyclophosphamide . recurrent refractory childhood hodgkin lymphoma diagnosis and acute leukemia in twond or greater cr cr greater_than equal_than two
__label__0	study interventions are Immunoglobulins . recurrent breast carcinoma diagnosis and life expectancy of greater_than equal_than twelve weeks
__label__0	study interventions are Weight Loss Intervention . ductal breast carcinoma in situ diagnosis and pnzero positive
__label__0	study interventions are Data evaluation . childhood solid tumor diagnosis and at least one disease recurrence after first cr or worse disease condition
__label__0	study interventions are Irinotecan . stage iv rectal cancer diagnosis and patients may not be receiving nor have received any other investigational agent equal_than less_than four weeks prior to study registration
__label__0	study interventions are Gemcitabine . bladder cancer diagnosis and surgery
__label__0	study interventions are Duloxetine Hydrochloride . breast cancer diagnosis and see disease characteristics
__label__0	study interventions are linifanib . recurrent rectal cancer diagnosis and ability to understand and the willingness to sign written informed consent signed informed consent must be obtained prior to any study specific procedures
__label__0	study interventions are Poly ICLC . mucosal melanoma diagnosis and ability to understand and the willingness to sign written informed consent document
__label__0	study interventions are Bevacizumab . stage iiia gastric cancer diagnosis and no other concurrent biologic or immunologic agents
__label__0	study interventions are Atorvastatin Calcium . breast neoplasms diagnosis and bc expressing ki_sixty-seven greater_than fifteen and taz greater_than ten in diagnostic core biopsies
__label__0	study interventions are Cisplatin . recurrent cervical carcinoma diagnosis and no prior chemotherapy except when concurrently administered with radiotherapy
__label__0	study interventions are Cisplatin . sarcoma diagnosis and see disease characteristics
__label__0	study interventions are MEDI-538 . lymphoma cell diagnosis and measurable disease at least one lesion greater_than twenty mm in one dimension documented by computed tomography ct scan
__label__0	study interventions are Liposomal doxorubicin . breast cancer diagnosis and age
__label__0	study interventions are Mitoxantrone . mantle cell lymphoma diagnosis and exclusion
__label__0	study interventions are Bevacizumab . recurrent colon carcinoma diagnosis and alkaline phosphatase equal_than less_than three uln
__label__0	study interventions are Bevacizumab . stage iv breast cancer diagnosis and cerebrovascular accident
__label__0	study interventions are Rituximab . recurrent adult diffuse small cleaved cell lymphoma diagnosis and platelets greater_than equal_than one hundred zero mm three without transfusion
__label__0	study interventions are HPPH . recurrent non small cell lung cancer diagnosis and patients must have karnofsky scale fifty or above eastern cooperative oncology group ecog zero two
__label__0	study interventions are Oxaliplatin . gastrointestinal carcinoid tumor diagnosis and no history or evidence of brain or leptomeningeal disease baseline cns imaging required if clinical suspicion of cns metastases
__label__0	study interventions are Beclomethasone . stage iii grade three follicular lymphoma diagnosis and use of methotrexate and tacrolimus for prevention of gvhd after allogeneic hct
__label__0	study interventions are Bevacizumab . ovarian brenner tumor diagnosis and creatinine equal_than less_than doc institutional upper limit normal uln ctcae grade one
__label__0	study interventions are Calcium, Dietary . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and patients diagnosed as having nhl or all with respiratory distress or hyperleukocytosis may require steroids prior to the initiation of additional systemic therapy they are eligible for aallfour hundred and thirty-four and will be stratified based on the initial complete blood count cbc steroid pretreatment may alter the risk group assessment if the all patient clinical status precludes lumbar_puncture within forty-eight hours of the initiation of steroid therapy all patients cannot be classified as low risk and will be intermediate or high risk based on the results of the day twenty-nine marrow as above patients with nhl who receive steroid pre treatment will be classified as high risk the dose and duration of previous steroid therapy should be carefully documented
__label__0	study interventions are Ifosfamide . desmoplastic small round cell tumor diagnosis and metastatic site must be biopsy proven
__label__0	study interventions are Ketoconazole . neuroblastoma diagnosis and negative serum beta hcg in females and use of effective contraception in males and females of child bearing potential is required
__label__0	study interventions are Paclitaxel . adenocarcinoma of the pancreas diagnosis and radiographically assessable disease encompassable within single irradiation field fifteen by fifteen cm maximum
__label__0	study interventions are Cyclophosphamide . recurrent childhood large cell lymphoma diagnosis and chronic myelogenous leukemia cml beyond onest chronic phase or resistant or intolerant to tyrosine kinase inhibitors adults or any phase pediatric less_than 2one years
__label__0	study interventions are Vaccines . pancreatic cancer diagnosis and no concurrent medications that could affect immunocompetence chronic treatment with long term steroids or other immunosuppressants for unrelated condition
__label__0	study interventions are Trametinib . endometrial serous adenocarcinoma diagnosis and fasting glucose less_than one hundred and sixty mg dl
__label__0	study interventions are Cyclosporine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and international prognostic_scoring system ipss int two or high risk refractory anemia with excess blasts raeb refractory anemia with excess blasts in transformation raebt or refractory anemia with severe pancytopenia or high risk cytogenetics
__label__0	study interventions are Iodine . recurrent colon cancer diagnosis and hepatitis surface antigen negative
__label__0	study interventions are Rituximab . lymphoma diagnosis and calculated creatinine clearance greater_than equal_than thirtyml min by cockcroft gault formula
__label__0	study interventions are Ifosfamide . recurrent cutaneous cell non hodgkin lymphoma diagnosis and patients must have ct of chest abdomen and pelvis within twenty-eight days of enrollment patients with evidence of adenopathy in the neck must have ct of neck
__label__0	study interventions are Everolimus . stage iiia cervical cancer diagnosis and chest ray greater_than equal_than twenty mm
__label__0	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and not specified
__label__0	study interventions are Cytarabine . stage iii mantle cell lymphoma diagnosis and patients with clinical signs of pulmonary insufficiency must have diffusion capacity of the lung for carbon monoxide dlco to be measured at greater_than equal_than fifty of predicted value
__label__0	study interventions are Paclitaxel . patients with prior history of contra lateral breast cancer are eligible if they have no evidence of recurrence of their initial primary breast cancer within the last five years
__label__0	study interventions are Mycophenolate mofetil . childhood nasal type extranodal nk cell lymphoma diagnosis and donors who have poor peripheral venous access may require central venous line placement for stem cell apheresis
__label__0	study interventions are Docetaxel . stage ivc oral cavity verrucous carcinoma diagnosis and central within two cm from the hilum lung metastases that are cavitary as shown unequivocally by imaging studies
__label__0	study interventions are Camptothecin . colorectal cancer diagnosis and ast and or alt less_than doc times uln less_than five times uln if liver metastases present
__label__0	study interventions are Capecitabine . patients with histologicaly confirmed colon cancer
__label__0	study interventions are Nivolumab . melanoma diagnosis and approved contraceptive methods include for example
__label__0	study interventions are Cyclophosphamide . recurrent adult hodgkin lymphoma diagnosis and hematopoietic cell transplant comorbidity index hct ci score less_than four points for patients greater_than sixty years old or less_than five points for patients less_than sixty
__label__0	study interventions are Fludarabine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and there is no indication for an autologous transplantation as treatment option
__label__0	study interventions are Bevacizumab . colorectal cancer diagnosis and no predisposing colonic or small bowel disorders in which the symptoms are uncontrolled as indicated by baseline pattern of greater_than three watery or soft stools daily in patients without colostomy or ileostomy
__label__0	study interventions are Fluorouracil . stage ii squamous cell carcinoma of the nasopharynx diagnosis and no cerebrovascular accident within the past six months
__label__0	study interventions are Arsenic trioxide . pancreatic cancer diagnosis and absolute neutrophil count at least one five hundred mm three
__label__0	study interventions are Rituximab . stage iv mantle cell lymphoma diagnosis and aspartate aminotransferase ast no greater than two times normal
__label__0	study interventions are Antibodies, Monoclonal . cervical cancer diagnosis and other
__label__0	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and for males
__label__0	study interventions are Esophagectomy . histologically proven squamous cell carcinoma adenocarcinoma or undifferentiated carcinoma of the intrathoracic esophagus
__label__0	study interventions are Tamoxifen . breast cancer diagnosis and sgot sgpt less than doc times uln less than five times uln with liver metastases
__label__0	study interventions are Tacrolimus . multiple myeloma diagnosis and patients with high risk hematologic malignancies with anticipated poor prognosis with non transplant therapy including those in remission or with induction failure and after treated or untreated relapse
__label__1	study interventions are MK2206 . diffuse large cell lymphoma diagnosis and pregnant and breastfeeding women are excluded from this study
__label__1	study interventions are Pioglitazone . stage oral cavity squamous cell carcinoma diagnosis and one mixed drink or one doc fluid oz
__label__1	study interventions are Antibodies . stage iii renal cell cancer diagnosis and patients with any condition gastrointestinal tract disease resulting in an inability to take oral medication or requirement for iv alimentation prior surgical procedures affecting absorption or active peptic ulcer disease that impairs their ability to swallow and retain sunitinib tablets are excluded
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and creatinine clearance less_than forty-five ml min
__label__1	study interventions are JM 3100 . non hodgkin lymphoma diagnosis and co morbid condition which in the view of the investigator rendered the patient at high risk from treatment complications
__label__1	study interventions are MRG-106 . cutaneous cell lymphoma ctcl diagnosis and history of renal or liver dysfunction or evidence of renal or liver dysfunction at screening
__label__1	study interventions are Foscarnet . stage iv grade two follicular lymphoma diagnosis and no prior allogeneic hct allo hct autologous hct auto hct is allowed
__label__1	study interventions are Antibodies, Monoclonal . gynecologic cancer diagnosis and ongoing bowel perforation or presence of bowel fistula or abscess or history of small or large bowel obstruction within three months of registration including subjects with palliative gastric drainage catheters
__label__1	study interventions are Antibodies, Monoclonal . adenocarcinoma diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapy
__label__1	study interventions are Dacarbazine . adult gliosarcoma diagnosis and patients must not be on enzyme inducing anti epileptic drugs eiaed patients may be on non enzyme inducing anti epileptic drugs neiaed or may not be taking any anti epileptic drugs in patients who have previously been on eiaed there must be at least fourteen day period since the last dose of an eiaed before the first dose of cediranib
__label__1	study interventions are Antibodies, Monoclonal . stage iiic fallopian tube cancer diagnosis and patients on an active liver transplant list and considered likely to receive liver transplant equal_than less_than six months following registration
__label__1	study interventions are Folic Acid . resectable pancreatic carcinoma
__label__1	study interventions are Vaccines . hematopoietic and lymphoid cell neoplasm diagnosis and live attenuated vaccines
__label__1	study interventions are Cabozantinib . cholangiocarcinoma of the extrahepatic bile duct diagnosis and gastrointestinal perforation
__label__1	study interventions are Initially dissection of inferior mesenteric artery . rectal tumors diagnosis and patients who won undergo colorectal anastomosis
__label__1	study interventions are Palliative radiotherapy and chemotherapy . second cancer except skin non melanoma
__label__1	study interventions are Antibodies . stage ivb verrucous carcinoma of the larynx diagnosis and serum calcium ionized or adjusted for albumin less_than seven mg dl doc five mmol or greater_than one doc mg dl greater_than doc mmol despite intervention to normalize levels
__label__1	study interventions are Vorinostat . renal cell carcinoma diagnosis and known or suspected allergy to sorafenib vorinostat or any planned agent given in the course of this trial
__label__1	study interventions are Paclitaxel . stage iv pancreatic cancer diagnosis and brain metastases
__label__1	study interventions are Cisplatin . non squamous nonsmall cell neoplasm of lung diagnosis and prophylactic use of anticoagulants is allowed international normalized ratio inr should be less_than doc at study enrollment
__label__1	study interventions are Docetaxel . stage iii squamous cell carcinoma of the hypopharynx diagnosis and hiv testing is not required for entry into this protocol the need to exclude patients with aids from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive protocol specific requirements may also exclude immuno compromised patients
__label__1	study interventions are Calcium, Dietary . signet ring adenocarcinoma of the colon diagnosis and inadequately controlled hypertension systolic blood pressure sbp greater_than one hundred and fifty mmhg diastolic blood pressure dbp greater_than one hundred mg hg
__label__1	study interventions are Immunoglobulins . recurrent primary peritoneal carcinoma diagnosis and patients who have received acute low dose systemic immunosuppressant medications one time dose of dexamethasone for nausea or steroids as computed tomography ct scan contrast premedication may be enrolled
__label__1	study interventions are Antibodies, Monoclonal . metastatic colorectal cancer diagnosis and pregnant or breast feeding
__label__1	study interventions are Nitrogen Mustard Compounds . childhood atypical_teratoid rhabdoid tumor diagnosis and subjects at significant risk with general anesthesia
__label__1	study interventions are Temozolomide . astrocytoma diagnosis and concomitant medications
__label__1	study interventions are Fludarabine phosphate . recurrent childhood small noncleaved cell lymphoma diagnosis and alanine aminotransferase alt or aspartate aminotransferase ast more than three fold higher than laboratory upper normal limits
__label__1	study interventions are Intimacy Enhancing Intervention . breast cancer diagnosis and currently participating in couple marital therapy
__label__1	study interventions are Fluorouracil . nasopharyngeal cancers diagnosis and histological diagnosis on lymph node biopsy
__label__1	study interventions are Niacinamide . stage iva squamous cell carcinoma of the larynx diagnosis and major surgery open biopsy or significant traumatic injury within four weeks of first study drug
__label__1	study interventions are Dacarbazine . has received prior therapy for hodgkin lymphoma except as noted above
__label__1	study interventions are Interferon-gamma . metastatic melanoma diagnosis and the patient is pregnant or lactating or not using contraception and proved by negative pregnancy test
__label__1	study interventions are Trastuzumab . stage iiia breast cancer diagnosis and these patients are eligible if this therapy is discontinued prior to randomization
__label__1	study interventions are Pembrolizumab . non small cell lung carcinoma diagnosis and is unable to interrupt aspirin or other nonsteroidal anti inflammatory drugs nsaids other than an aspirin dose less_than doc per day for five day period eight day period for long acting agents such as piroxicam
__label__1	study interventions are Veliparib . stage iv breast cancer diagnosis and no ongoing requirement for dexamethasone for cns disease patients on stable dose of anticonvulsants are permitted
__label__1	study interventions are Camptothecin . adenocarcinoma of the gastroesophageal junction diagnosis and patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Temozolomide . recurrent childhood brain tumor diagnosis and absolute neutrophil count anc greater_than one five hundred mm three
__label__1	study interventions are Polystyrene sulfonic acid . lymphoma diagnosis and subjects with baseline troponin greater_than upper limit of normal uln or type natriuretic_peptide bnp greater_than one hundred pg ml are eligible but must have cardiologist evaluation prior to enrollment in the trial for baseline assessment and optimization of cardioprotective therapy
__label__1	study interventions are Phosphoramide Mustards . kidney cancer diagnosis and major surgical procedures or significant traumatic injury less_than fourteen days prior to registration or anticipation of need for elective or planned major surgical procedure during the course of the study
__label__1	study interventions are Cyclosporins . refractory small lymphocytic lymphoma diagnosis and donor
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and participants with contraindications for paclitaxel therapy according to the smpc
__label__1	study interventions are Cyclosporine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and prior radiation to maximally tolerated levels to any critical normal organ
__label__1	study interventions are Dexamethasone acetate . prostate cancer diagnosis and no adrenal insufficiency as demonstrated by baseline acth stimulation test demonstrating peak cortisol greater_than eighteen µg dl
__label__1	study interventions are ASN002 MTD . lymphoma large cell diffuse diagnosis and part only
__label__1	study interventions are Cyclosporine . nodal marginal zone cell lymphoma diagnosis and active central nervous system cns leukemia involvement at the time of study enrollment cerebrospinal fluid with greater_than five white blood cells wbc mm three and malignant cells on cytospin
__label__1	study interventions are Pembrolizumab . pleural sarcomatoid mesothelioma diagnosis and has history or current evidence of any condition therapy or laboratory abnormality that might confound the results of the trial interfere with the subject participation for the full duration of the trial or is not in the best interest of the subject to participate in the opinion of the treating investigator
__label__1	study interventions are Nanoparticle Complex . small lymphocytic lymphoma diagnosis and any of the following
__label__1	study interventions are Vidarabine . cutaneous cell non hodgkin lymphoma diagnosis and patients with life expectancy of less_than six months for reasons other than their underlying hematologic oncologic disorder or complications there from
__label__1	study interventions are Nutrawell Powder . cancer of pancreas diagnosis and uncontrolled nausea and vomiting
__label__1	study interventions are Etoposide . cutaneous cell non hodgkin lymphoma diagnosis and previous systemic chemotherapy immunotherapy within three weeks before study entry
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and patients with known cns involvement plasma cell leukemia or amyloidosis
__label__1	study interventions are Paclitaxel . invasive breast carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to other agents used in study
__label__1	study interventions are HPPH . stage squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and platelet count less_than one hundred zero
__label__1	study interventions are Cyclophosphamide . recurrent breast carcinoma diagnosis and active autoimmune disease defined as any autoimmune condition currently requiring therapy systemic lupus erythematosus multiple sclerosis inflammatory bowel disease rheumatoid arthritis
__label__1	study interventions are Antibodies, Monoclonal . non hodgkin lymphoma diagnosis and the mean of bilateral biopsies must be no more than twenty-five
__label__1	study interventions are Oxaliplatin . rectal cancer diagnosis and has uncontrolled or poorly controlled hypertension on standard regimen of antihypertensive therapy
__label__1	study interventions are Irinotecan . gallbladder carcinoma diagnosis and neuropathy grade two or greater by nci ctcae v
__label__1	study interventions are Vidarabine . stage iii adult lymphoblastic lymphoma diagnosis and disease resulting in severely limited performance status less_than seventy
__label__1	study interventions are Immunoconjugates . stage iv adult immunoblastic large cell lymphoma diagnosis and patients with chronic hepatitis hcv or hepatitis hbv infection may enroll if other laboratory criteria are met those with hbv surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy per treating investigator discretion for the duration of enrollment in the trial
__label__1	study interventions are Tocotrienols . breast cancer diagnosis and immunosuppressive treatment other than prednisolone during neoadjuvant chemotherapy
__label__1	study interventions are Camptothecin . metastatic colorectal cancer diagnosis and arterial thrombotic events less_than six months prior to randomization note
__label__1	study interventions are Customized Treatment . carcinoma non small cell lung diagnosis and any of the following within six months prior to study enrollment
__label__1	study interventions are Albumin-Bound Paclitaxel . triple negative breast carcinoma diagnosis and women of child bearing potential defined as all women physiologically capable of becoming pregnant unless they are using highly effective methods of contraception during dosing and for three months following the discontinuation of study treatment highly effective contraception methods include
__label__1	study interventions are [¹4C]LY2606368 . advanced cancer diagnosis and have received treatment within twenty-eight days of the initial dose of study drug with an investigational product or non approved use of drug or device
__label__1	study interventions are Immunoglobulin G . stage iib fallopian tube cancer diagnosis and patients with gog performance grade of three or four
__label__1	study interventions are Meloxicam . hodgkin lymphoma diagnosis and uncontrolled infection
__label__1	study interventions are Liposomal doxorubicin . known central nervous system cns tumors including metastatic brain disease
__label__1	study interventions are Female AR(+) TNBC Enzalutamide Treated . breast cancer diagnosis and history of loss of consciousness or transient ischemic attack within twelve months before study drug initiation
__label__1	study interventions are laboratory biomarker analysis . stage iv adult diffuse large cell lymphoma diagnosis and patients who have received gonadotropin release hormone agonist or antagonist lupron prior to study entry are not eligible
__label__1	study interventions are Vitamins . cancer diagnosis and pregnant or lactating female
__label__1	study interventions are Pemetrexed . non squamous non small cell lung carcinoma stage iiib iv nsclc diagnosis and major thoracic or abdominal surgery from which the patient has not yet recovered
__label__1	study interventions are Darbepoetin alfa . previous diagnosis of another malignancy with radiographic or biochemical evidence of residual disease except completely resected basal cell carcinoma squamous cell carcinoma of the skin or an in situ malignancy
__label__1	study interventions are Docetaxel . solid tumors diagnosis and patient has uncontrolled or significant cardiovascular disease including
__label__1	study interventions are Vorinostat . recurrent anal cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents used in study including hypersensitivity to paclitaxel cremophor or platins
__label__1	study interventions are Doxorubicin . recurrent breast carcinoma diagnosis and for patients greater_than equal_than fifty years old who will receive ac
__label__1	study interventions are Expander prosthesis . breast neoplasms diagnosis and any contraindication for anaesthesia
__label__1	study interventions are Sorafenib . neoplasms diagnosis and prior local therapy including liver directed therapy within four weeks from entry
__label__1	study interventions are Indocyanine green . melanoma diagnosis and hypersensibility or allergy history to indocyanine or iodine based contrast media
__label__1	study interventions are Interleukin-2 . stage non small cell lung cancer diagnosis and subject has active known or suspected autoimmune disease including systemic lupus erythematodes hashimoto thyroiditis scleroderma polyarteritis nodosa or autoimmune hepatitis
__label__1	study interventions are Liposomal doxorubicin . ovarian cancer epithelial tumors malignant fallopian tube cancer peritoneal neoplasms diagnosis and prior treatment with napitwob or sclthirty-fouratwo targeted therapy
__label__1	study interventions are Paclitaxel . esophageal cancer diagnosis and known hypersensitivity to afatinib bibw two thousand, nine hundred and ninety-two or the excipients of any of the trial drugs
__label__1	study interventions are Niacinamide . unresectable or metastatic hepatocellular carcinoma hcc diagnosis and child pugh score for cirrhosis mortality greater_than seven points
__label__1	study interventions are Antibodies . fallopian tube clear cell adenocarcinoma diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are Antibodies, Monoclonal . sarcoma diagnosis and pregnant or breastfeeding females
__label__1	study interventions are Immunoglobulins . stage iii adult cell leukemia lymphoma diagnosis and pregnancy or active nursing of an infant
__label__1	study interventions are Fludarabine phosphate . stage iv small lymphocytic lymphoma diagnosis and patients with other disease or organ dysfunction that would limit survival to less than thirty days
__label__1	study interventions are CC-90002 . symptomatic central nervous system involvement
__label__1	study interventions are Interleukin-12 . metastatic parathyroid cancer diagnosis and clinically significant autoimmune disease rheumatoid arthritis
__label__1	study interventions are Scopolamine Hydrobromide . colonic adenomas diagnosis and previous intestinal resection
__label__1	study interventions are Antibodies . nodal marginal zone cell lymphoma diagnosis and concurrent use of other investigational agents
__label__1	study interventions are Sorafenib . bladder cancer diagnosis and prior treatment with systemic chemotherapy prior intravesical chemotherapy is permitted and adjuvant therapy is permitted if greater_than twelve months have lapsed
__label__1	study interventions are Paclitaxel . adenocarcinoma diagnosis and both men and women and members of all races and ethnic groups are eligible for this trial
__label__1	study interventions are Androgens . hormone refractory prostate cancer diagnosis and cardiac arrhythmia
__label__1	study interventions are Thalidomide . ovarian cancer recurrent diagnosis and history of clinical and electrocardiographically documented myocardial infarction within the last six months
__label__1	study interventions are Trastuzumab . stage iiic breast cancer diagnosis and pregnant and nursing women are excluded from this study because the chemotherapy agents and radiation therapy all have the potential for teratogenic or abortifacient effects
__label__1	study interventions are Rosuvastatin Calcium . rectal cancer diagnosis and patients with hyperlipidemia with clinical indication for statin therapy or other prescribed medication determination of acceptable fasting lipid values should be in accordance with current dyslipidemia management guidelines
__label__1	study interventions are Niraparib . carcinoma of breast diagnosis and prior treatment with parp inhibitor
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and if female is pregnant or breast feeding
__label__1	study interventions are Antibodies, Monoclonal . contiguous stage ii grade one follicular lymphoma diagnosis and clinically active hepatitis b or infections note
__label__1	study interventions are Dexamethasone 21-phosphate . cancer diagnosis and has experienced emesis vomiting and or retching or clinically significant nausea in the twenty-four hours preceding the first dose of study medication or investigational product for each cycle of chemotherapy
__label__1	study interventions are Olaparib . pancreatic cancer diagnosis and pregnancy or lactation
__label__1	study interventions are Nivolumab . stage iiia hepatocellular carcinoma diagnosis and note
__label__1	study interventions are Everolimus . indolent non hodgkin lymphoma diagnosis and has had an allogeneic hematopoietic stem cell transplant
__label__1	study interventions are Ascorbic Acid . myeloma diagnosis and recent less_than one month ago chemotherapy
__label__1	study interventions are Melphalan . recurrent grade one follicular lymphoma diagnosis and whole lungs one2 gy
__label__1	study interventions are Doxorubicin . fallopian tube endometrioid adenocarcinoma diagnosis and history of gastrointestinal perforation patients with history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed there has been no evidence of fistula for at least six months and patient is deemed to be at low risk of recurrent fistula
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and history of stevens_johnson syndrome characterized by desquamating_rash while taking thalidomide or similar drugs
__label__1	study interventions are Albumin-Bound Paclitaxel . lesions on imaging by cerebrospinal fluid or with neurological findings that are consistent with leptomeningeal disease or meningeal carcinomatosis
__label__1	study interventions are Cetuximab . stage iva squamous cell carcinoma of the lip and oral cavity diagnosis and congestive heart failure greater_than class ii nyha patients must not have unstable angina anginal symptoms at rest or new onset angina began within the last three months or myocardial infarction within the past six months significant history of uncontrolled cardiac disease uncontrolled hypertension defined as defined as systolic blood pressure greater_than one hundred and fifty mmhg or diastolic pressure greater_than ninety mmhg despite optimal medical management uncontrolled congestive heart failure and cardiomyopathy with decreased ejection fraction will also be excluded from study cardiac ventricular arrhythmias requiring anti arrhythmic therapy will also be excluded from study
__label__1	study interventions are Gefitinib . non small cell lung cancer diagnosis and incision from operation has not healed before the start of study treatment small incision for biopsy is eligible
__label__1	study interventions are Doxorubicin . advanced solid tumors diagnosis and known history of hiv infection
__label__1	study interventions are Bevacizumab . solid neoplasm diagnosis and presence of unstable atrial fibrillation ventricular response greater_than one hundred beats per minute
__label__1	study interventions are Immunoglobulins . uterine carcinosarcoma diagnosis and significant cardiovascular disease defined as congestive heart failure new york heart association class ii iii or iv angina pectoris requiring nitrate therapy or recent myocardial infarction equal_than less_than six months prior to registration
__label__1	study interventions are Calcium, Dietary . metastatic colorectal cancer diagnosis and uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Paclitaxel . peritoneal cancer diagnosis and infection requiring systemic antibiotic therapy within fourteen days prior to first dose of mlneight thousand, two hundred and thirty-seven
__label__1	study interventions are Liposomal doxorubicin . small cell lung cancer diagnosis and patients had the motor or sensory neurons lesions symptoms of nci
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ii breast cancer diagnosis and prior chemotherapy or radiation therapy
__label__1	study interventions are BYl719 . metastatic breast cancer diagnosis and patient who does not apply highly effective contraception during the study and through the duration as defined below after the final dose of study treatment
__label__1	study interventions are behavioral, psychological or informational intervention . stage iia cervical cancer diagnosis and residence greater_than seventy miles from research site
__label__1	study interventions are Folic Acid . metastatic colorectal cancer diagnosis and congestive heart failure greater_than new york heart association nyha class two
__label__1	study interventions are Sirolimus . multiple myeloma diagnosis and pre existing peripheral neuropathy grade greater_than one
__label__1	study interventions are Antibodies . stage iii grade three follicular lymphoma diagnosis and patients must not have history of cardiac disease defined as new york heart association class ii or greater or clinical evidence of congestive heart failure
__label__1	study interventions are laboratory biomarker analysis . stage iv marginal zone lymphoma diagnosis and miscellaneous
__label__1	study interventions are Vidarabine . stage iv adult burkitt lymphoma diagnosis and donor
__label__1	study interventions are Ramucirumab . gastro esophageal cancer diagnosis and unable to receive iv contrast for required ct scans
__label__1	study interventions are Cyclophosphamide . stage iv grade one follicular lymphoma diagnosis and treatment with rituximab for any reason in the one2 months preceding hct
__label__1	study interventions are Antibodies . ovarian cancer diagnosis and patients with primary platinum refractory disease
__label__1	study interventions are Edotreotide . neuroblastoma diagnosis and any additional medical condition serious intercurrent illness or other extenuating_circumstance that in the opinion of the investigator may significantly interfere with study compliance
__label__1	study interventions are CT-1530 . mantle zone lymphoma refractory recurrent diagnosis and other medical or psychiatric illness or organ dysfunction
__label__1	study interventions are Methylprednisolone Hemisuccinate . or total bilirubin greater_than two times the upper limit of normal or alanine aminotransferase alt greater_than doc times the normal upper limit or alkaline phosphatase greater_than doc times the normal upper limit unless it is attributed to hepatic infiltration by lymphoma
__label__1	study interventions are Mitomycins . metastatic colorectal cancer mcrc diagnosis and additional criteria only for the combination cohort
__label__1	study interventions are Immunoglobulin G . solid tumors that overexpress hertwo hertwo positive diagnosis and history of congestive heart failure
__label__1	study interventions are Oxaliplatin . metastatic colorectal cancer diagnosis and all patients will have to sign written informed consent in order to participate in the study
__label__1	study interventions are Camptothecin . colorectal adenocarcinoma diagnosis and iii uncontrolled hypertension systolic blood pressure bp greater_than one hundred and fifty mmhg and diastolic bp greater_than ninety mmhg for twenty-four hours despite optimal medical management
__label__1	study interventions are Laboratory Biomarker Analysis . stage iva thyroid gland papillary carcinoma diagnosis and thromboembolic event requiring therapeutic anticoagulation note
__label__1	study interventions are Antibodies, Monoclonal . adult gliosarcoma diagnosis and history of non healing wound ulcer or bone fracture within ninety days three months prior to registration
__label__1	study interventions are Etoposide phosphate . non hodgkin lymphoma diagnosis and psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike and making informed consent impossible
__label__1	study interventions are Veliparib . triple negative breast carcinoma diagnosis and evaluable or measurable disease outside the cns
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and pregnant or breastfeeding
__label__1	study interventions are CD22-CAR . follicular lymphoma diagnosis and subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least two weeks prior to starting apheresis
__label__1	study interventions are Vaccines . stage cutaneous cell non hodgkin lymphoma diagnosis and had relapse
__label__1	study interventions are Liposomal doxorubicin . concurrent use of other anti cancer agents or treatments
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and patients known to be suffering from infection with hiv hepatitis or hepatitis b
__label__1	study interventions are Everolimus . hodgkin lymphoma diagnosis and patient must have life expectancy of three months
__label__1	study interventions are Lenograstim . myeloma diagnosis and corticosteroid doses greater_than ten mg day of prednisone or equivalent within fourteen days prior to cycle one day one
__label__1	study interventions are Antibodies . recurrent fallopian tube carcinoma diagnosis and ischemic myocardial event including angina requiring therapy and artery revascularization procedures
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent breast carcinoma diagnosis and immunotherapy equal_than less_than fourteen days prior to registration
__label__1	study interventions are Ifosfamide . previous or concurrent malignancies with the exception of surgically cured carcinoma in situ of the cervix carcinoma of the skin or other kinds of cancer without evidence of disease for at least five years
__label__1	study interventions are Oxaliplatin . pancreatic cancer diagnosis and hypersensitivity intolerance to the drugs in study
__label__1	study interventions are Maleic acid . recurrent ovarian carcinoma diagnosis and patients with any of the following risk factors should have baseline cardiac function assessment
__label__1	study interventions are Cyclosporine . refractory small lymphocytic lymphoma diagnosis and human immunodeficiency virus hiv seropositivity
__label__1	study interventions are Mycophenolic Acid . stage iv grade one follicular lymphoma diagnosis and positive cross match exists between the donor and recipient
__label__1	study interventions are Etoposide . follicular lymphoma diagnosis and patients are not considered to have currently active malignancy if they have completed therapy and are free of disease for greater_than three years
__label__1	study interventions are placebo (laser low level energy nonfunctional) . oral squamous cell carcinoma diagnosis and neoadjuvant chemotherapy
__label__1	study interventions are Diphosphonates . any kind of hormonal therapy for prostate cancer previous to enter the study
__label__1	study interventions are Clarithromycin . lymphoma diagnosis and diagnosis or treatment of another malignancy within two years preceding first dose or previously diagnosed with another malignancy and have any evidence of residual disease
__label__1	study interventions are Aldesleukin . metastatic melanoma diagnosis and history of coronary revascularization or ischemic symptoms
__label__1	study interventions are Erlotinib Hydrochloride . recurrent skin cancer diagnosis and hepatitis or infection acute or chronic known human immunodeficiency virus hiv or active uncontrolled infection because of possible risk of lethal infection when treated with marrow suppressive therapy
__label__1	study interventions are Epirubicin . breast cancer diagnosis and patients already included in another therapeutic trial involving an experimental drug
__label__1	study interventions are Fluorouracil . colorectal cancer diagnosis and infectious or inflammatory bowel disease or diverticulitis
__label__1	study interventions are Antibodies . undifferentiated fallopian tube carcinoma diagnosis and no acute exacerbations of underlying condition within the last twelve months not requiring psoralen plus ultraviolet radiation puva methotrexate retinoids biologic agents oral calcineurin inhibitors high potency or oral steroids
__label__1	study interventions are Rituximab . diffuse large cell lymphoma dlbcl diagnosis and active graft versus host disease in patients with history of allogeneic stem cell transplantation
__label__1	study interventions are Vidarabine . stage iii childhood lymphoblastic lymphoma diagnosis and identical twin
__label__1	study interventions are Doxorubicin . solid tumors diagnosis and subjects with history of prior malignancy except
__label__1	study interventions are Zoledronic acid . brain tumors diagnosis and patients previously diagnosed with osteoporosis requiring oral bisphosphonates
__label__1	study interventions are Cyclosporine . adult nasal type extranodal nk cell lymphoma diagnosis and inability to achieve adequate venous access
__label__1	study interventions are Electronic tailored messaging . colorectal cancer diagnosis and younger than fifty years of age
__label__1	study interventions are Antibodies . stage iv prostate cancer diagnosis and subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
__label__1	study interventions are Modafinil . prostatic neoplasms diagnosis and known hypersensitivity intolerance to modafinil or any of the excipients
__label__1	study interventions are Gemcitabine . non small cell lung cancer diagnosis and ongoing ctcae grade two or greater peripheral neuropathy
__label__1	study interventions are Immunoglobulins . stage iva verrucous carcinoma of the larynx diagnosis and pulmonary hemorrhage bleeding event greater_than ctcae grade two within four weeks of first dose of study drug
__label__1	study interventions are Fludarabine phosphate . recurrent adult diffuse large cell lymphoma diagnosis and hiv positive
__label__1	study interventions are Ursodeoxycholic Acid . mantle cell lymphoma diagnosis and transaminases less_than fivex the institution upper limit of normal
__label__1	study interventions are Cyclosporine . stage iii mantle cell lymphoma diagnosis and marrow donors
__label__1	study interventions are laboratory biomarker analysis . recurrent renal cell cancer diagnosis and pregnant women are excluded from this study because mlnfive hundred and eighteen is receptor tyrosine kinase inhibitor with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with mlnfive hundred and eighteen breastfeeding should be discontinued if the mother is treated with mlnfive hundred and eighteen
__label__1	study interventions are Mycophenolic Acid . stage iv mantle cell lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Everolimus . unstable angina symptomatic chf mi less_than six months serious uncontrolled cardiac arrhythmia or any other clinically significant heart disease
__label__1	study interventions are Mycophenolate mofetil . stage iv small lymphocytic lymphoma diagnosis and eligible for high priority curative autologous transplant
__label__1	study interventions are Ferric Compounds . tubular breast cancer stage iii diagnosis and definite contraindications for the use of corticosteroids
__label__1	study interventions are Lenalidomide . neuroendocrine tumors diagnosis and in addition these patients are at increased risk of lethal infections when treated with marrow suppressive therapy
__label__1	study interventions are Endothelial Growth Factors . stage iv ovarian epithelial cancer diagnosis and clinically significant cardiovascular disease including
__label__1	study interventions are Immunoglobulin G . stage iiia ovarian cancer diagnosis and clinically significant resting bradycardia
__label__1	study interventions are Dexamethasone acetate . hormone resistant prostate cancer diagnosis and history of seizure underlying brain injury with loss of consciousness transient ischemic attack within the past twelve months cerebral vascular accident brain metastases and brain arteriovenous_malformations
__label__1	study interventions are Anticonvulsants . glioblastoma multiforme diagnosis and history of significant concurrent illness
__label__1	study interventions are Fludarabine phosphate . lymphoma diagnosis and patients with creatinine clearance less_than thirtyml doc threemtwo or who require dialysis are not eligible
__label__1	study interventions are Everolimus . duct cell adenocarcinoma of the pancreas diagnosis and prior therapy with hedgehog inhibitor
__label__1	study interventions are Irinotecan . colorectal adenocarcinoma diagnosis and qtc fridericia prolongation greater_than four hundred and fifty msec
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and the following laboratory data
__label__1	study interventions are Niacinamide . recurrent pancreatic cancer diagnosis and congestive heart failure greater_than class ii new york heart association nyha patients must not have unstable angina anginal symptoms at rest or new onset angina began within the last three months or myocardial infarction within the past six months
__label__1	study interventions are Ethinyl Estradiol . solid tumors diagnosis and albumin doc dl
__label__1	study interventions are Goserelin . presence of life threatening metastases previous endocrine therapy or chemotherapy for advanced or metastatic disease any previous treatment with hormone lh_rh severe or uncontrolled systemic disease pituitary adenoma high risk of medullar compression
__label__1	study interventions are Albumin-Bound Paclitaxel . unresectable pancreatic cancer diagnosis and patients must not have prior cisplatin exposure
__label__1	study interventions are Mycophenolate mofetil . stage iv adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Etoposide phosphate . extranodal nk cell lymphoma nasal type diagnosis and pregnant or lactation
__label__1	study interventions are Vinblastine . hodgkin lymphoma diagnosis and active infection requiring treatment with intravenous therapy
__label__1	study interventions are Carboplatin . fallopian tube neoplasms diagnosis and known active hepatitis or or other active liver disease
__label__1	study interventions are Bevacizumab . stage iv skin melanoma diagnosis and any of the following
__label__1	study interventions are Flucytosine . tumors diagnosis and patient medical history does not contraindicate treatment with at least one of the following antibiotics
__label__1	study interventions are CAR 27 . patient undergoing an emergency procedure or has diagnosis of bowel obstruction bowel strangulation peritonitis bowel perforation local or systemic infection ischemic bowel carcinomatosis or inflammatory bowel disease
__label__1	study interventions are prophylactic cranial irradiation . breast cancer diagnosis and pregnancy or gestation
__label__1	study interventions are Bortezomib . ds stage ii plasma cell myeloma diagnosis and prior autologous or allogeneic bone marrow peripheral blood stem cell transplant
__label__1	study interventions are Vorinostat . stage iv melanoma diagnosis and hiv positive patients receiving combination antiretroviral therapy are ineligible because of potential for pk interactions with vorinostat
__label__1	study interventions are SGT-94 . neoplasm diagnosis and supraphysiologic doses of glucocorticoids defined as greater_than thirty mg of hydrocortisone per day or greater_than doc mg of prednisone per day or equivalent doses of other agents or exposure to other immunosuppressive medications in the previous thirty days
__label__1	study interventions are cytology specimen collection procedure . stage iiic melanoma diagnosis and patients with acute gastrointestinal bleeding within one month of study entry
__label__1	study interventions are positron emission tomography . stage iv prostate cancer diagnosis and myocardial infarction
__label__1	study interventions are Immunoglobulins . stage ivc squamous cell carcinoma of the oropharynx diagnosis and myocardial infraction within the last six months documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of lvef function
__label__1	study interventions are Camptothecin . colorectal cancer metastatic diagnosis and other serious and uncontrolled non malignant disease
__label__1	study interventions are Antibodies, Monoclonal . invasive breast carcinoma diagnosis and no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
__label__1	study interventions are Polystyrene sulfonic acid . cancer esophagus diagnosis and pregnant or beast feeding women
__label__1	study interventions are Liposomal doxorubicin . undifferentiated ovarian carcinoma diagnosis and biologic therapy equal_than less_than four weeks prior to study entry
__label__1	study interventions are Oxaliplatin . colorectal neoplasms diagnosis and known pregnancy or lactation
__label__1	study interventions are Fluorouracil . stage iib pancreatic cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Cetuximab . stage iva colon cancer diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are cabozantinib-s-malate . unspecified adult solid tumor protocol specific diagnosis and to the thoracic cavity abdomen or pelvis within three months before the first dose of study treatment or has ongoing complications or is without complete recovery and healing from prior radiation therapy
__label__1	study interventions are Leucovorin . adenocarcinoma of the rectum diagnosis and known allergy to platinum compounds
__label__1	study interventions are Docetaxel . stage ii breast cancer diagnosis and patients must not have bleeding diathesis hereditary of acquired bleeding disorder or coagulopathy
__label__1	study interventions are Sorafenib . liver cancer diagnosis and no prior systemic treatment is allowed except for subjects in the phase cohort who are permitted one prior systemic treatment
__label__1	study interventions are pharmacological study . recurrent small lymphocytic lymphoma diagnosis and calcium channel blockers
__label__1	study interventions are Levoleucovorin . stage ivb colon cancer diagnosis and bone lesions
__label__1	study interventions are TRIN2755 . any lymphoma or other hematological tumors
__label__1	study interventions are Antibodies, Monoclonal . adult cell leukemia lymphoma diagnosis and doc institutional upper limit of normal uln ast sgot alt sgpt
__label__1	study interventions are Hormones . recurrent breast carcinoma diagnosis and radiation therapy equal_than less_than twenty-one days prior to registration
__label__1	study interventions are Stereotactic radiotherapy 4 x 8 Gy . renal cancer diagnosis and renal insufficiency creatinine clearance less_than thirty ml mm evaluated by dtpa diethylenetriamine pentaacetic acid scintigraphy
__label__1	study interventions are Laboratory Biomarker Analysis . stage iiia colon cancer diagnosis and no evidence of new or enlarging cns metastasis
__label__1	study interventions are Leuprolide . prostate cancer diagnosis and presence of pacemaker
__label__1	study interventions are Liposomal doxorubicin . metastatic leiomyosarcoma diagnosis and participation in prior investigational interventional study within thirty days prior to enrollment or within five half lives of the investigational product whichever is longer
__label__1	study interventions are Sirolimus . advanced cancer diagnosis and prior treatment with both bevacizumab and an mtor inhibitor is not allowed
__label__1	study interventions are Atorvastatin Calcium . breast tumors diagnosis and strong cyp threeafour inhibitors clarithromycin hiv protease inhibitors and itraconazole given potential interactions with atorvastatin
__label__1	study interventions are Cyclophosphamide . stage iib breast cancer diagnosis and cardiac disease history of and or active disease that would preclude the use of the drugs included in the treatment regimens this includes but is not confined to
__label__1	study interventions are Cyclosporine . stage iii grade one follicular lymphoma diagnosis and patients who are homozygous at the mismatched major histocompatibility_complex mhc class locus
__label__1	study interventions are Temozolomide . histology other than adenocarcinoma or tumor arising from inflammatory bowel disease
__label__1	study interventions are Porfiromycin . prior surgery other than biopsy for head and neck cancer
__label__1	study interventions are Atorvastatin Calcium . myelodysplastic myeloproliferative neoplasm diagnosis and age less_than eighteen years
__label__1	study interventions are Rituximab . stage grade two follicular lymphoma diagnosis and subjects who are hbsag negative anti hbs positive and or anti hbc positive but viral dna negative are eligible
__label__1	study interventions are Placebo-Control Meals and Snacks . colorectal cancer control and prevention diagnosis and taking bean other anti flatulence medications or prolonged antibiotic use one month
__label__1	study interventions are Pemetrexed . nasopharyngeal neoplasms diagnosis and patients who have clinical signs or symptoms that are suspicious of brain metastasis must have pretreatment computed tomography ct or magnetic resonance imaging mri of the brain
__label__1	study interventions are Antibodies, Monoclonal . solid tumors diagnosis and uncontrolled intercurrent illness despite adequate therapy
__label__1	study interventions are Antibodies, Monoclonal . stage ivc oropharyngeal squamous cell carcinoma diagnosis and any condition that in the opinion of the investigator would interfere with evaluation of study treatment or interpretation of patient safety or study results
__label__1	study interventions are BIBW 2992 . glioma diagnosis and cardiac left ventricular function with resting ejection fraction less_than fifty
__label__1	study interventions are Oxaliplatin . stage ib gastric cancer diagnosis and lung infection requiring treatment equal_than less_than three months prior to registration
__label__1	study interventions are Imatinib Mesylate . gastrointestinal stromal tumors diagnosis and known central nervous systems metastases
__label__1	study interventions are Cyclophosphamide . endometrial cancer diagnosis and any medical condition not yet specified above that is considered to possibly probably or definitely interfere with study procedures including adequate follow up and compliance and or would jeopardize safe treatment
__label__1	study interventions are Pharmacological Study . recurrent thyroid gland carcinoma diagnosis and patients who are receiving cyclosporine tacrolimus or other agents to prevent graft versus host disease post bone marrow transplant are not eligible for this trial
__label__1	study interventions are Placebo . cancer diseases diagnosis and alkaline phosphatase above fifteen outside of normal limits
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and congestive heart failure or history of congestive heart failure unstable angina pectoris myocardial infarction clinically significant valvulopathy or uncontrolled arrhythmias
__label__1	study interventions are Ranibizumab . choroidal melanoma diagnosis and previous violation of the posterior capsule in the study eye is also excluded unless as result of yttrium aluminum garnet yag posterior capsulotomy in association with posterior chamber lens implantation
__label__1	study interventions are Antibodies . resolution of all specific toxicities excluding alopecia related to any prior anti cancer therapy to grade less_than one according to the nci ctcae vfour
__label__1	study interventions are Docetaxel . pancreatic cancer diagnosis and known infection with hiv hepatitis or c
__label__1	study interventions are Talaporfin . liver neoplasms diagnosis and known sensitivity to porphyrin type drugs or known history of porphyria are exclusionary
__label__1	study interventions are Bendamustine Hydrochloride . multiple myeloma diagnosis and impaired cardiac function with an ejection fraction less than forty of predicted
__label__1	study interventions are Antibodies . clear cell renal cell carcinoma diagnosis and patients with uncontrolled intercurrent illness including but not limited to ongoing or active infections or psychiatric illness social situations that would limit compliance with study requirements are ineligible
__label__1	study interventions are Vidarabine . metastatic non small cell lung cancer diagnosis and any form of primary immunodeficiency such as severe combined immunodeficiency
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent vaginal cancer diagnosis and serious concurrent infection requiring intravenous antibiotic therapy
__label__1	study interventions are Thalidomide . stage iv marginal zone lymphoma diagnosis and patient has greater_than grade two peripheral neuropathy within fourteen days before enrollment
__label__1	study interventions are Histone Deacetylase Inhibitors . multiple myeloma diagnosis and obligate use of cardiac pacemaker
__label__1	study interventions are Enzalutamide . castration resistant prostate cancer diagnosis and visceral eg lung liver metastatic disease
__label__1	study interventions are Aromatase Inhibitors . breast cancer diagnosis and serious uncontrolled intercurrent infections or intercurrent medical or psychiatric illness
__label__1	study interventions are Camptothecin . signet ring adenocarcinoma of the colon diagnosis and patients with human immunodeficiency virus hiv acquired immune deficiency syndrome aids and those severely immunocompromised will be excluded however no patients will be tested for hiv
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and active coronary artery disease or ischemia
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and prior treatment for mm prior radiation therapy or dexamethasone up to one hundred and sixty mg for spinal cord compression is allowed
__label__1	study interventions are Folic Acid . stage iv ovarian cancer diagnosis and congestive heart failure new york heart association class iii or iv moderate to severe objective evidence of cardiovascular disease
__label__1	study interventions are Bevacizumab . breast cancer diagnosis and prior history of any malignancy treated without curative intent or treated with curative intent within the past five years
__label__1	study interventions are Vismodegib . unclassified pleomorphic sarcoma of bone diagnosis and caution should be exercised when dosing gdc four hundred and forty-nine concurrently with medications that are substrates of cytochrome pfour hundred and fifty family two subfamily polypeptide eight cyptwoceight cyptwocnine and cyptwoc1nine and have narrow therapeutic windows caution should be exercised when dosing gdc four hundred and forty-nine concurrently with inhibitors of cypthreeafour
__label__1	study interventions are Fluorouracil . head and neck cancer diagnosis and currently have an infection that requires for you to take an iv antibiotic
__label__1	study interventions are Vaccines . prostate cancer diagnosis and an infection requiring antibiotic treatment
__label__1	study interventions are Erythromycin Ethylsuccinate . previous treatment with anti cancer agents directed against egfr cetuximab panitumumab erlotinib gefitinib lapatinib
__label__1	study interventions are Cyclosporins . recurrent childhood large cell lymphoma diagnosis and prior autologous or allogeneic stem cell transplant
__label__1	study interventions are Docetaxel . pancreatic cancer diagnosis and men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on treatment and for at least three months thereafter
__label__1	study interventions are Immunoglobulins . primary peritoneal serous adenocarcinoma diagnosis and men or women of childbearing potential who are unwilling to employ adequate contraception
__label__1	study interventions are Paclitaxel . fallopian tube cancer diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Isophosphamide mustard . extraskeletal osteosarcoma diagnosis and cardiac arrhythmia
__label__1	study interventions are E7070 . colorectal cancer crc diagnosis and previous investigational cytotoxic treatment for malignant disease within thirty days before the start of the study
__label__1	study interventions are AT13387 . metastatic solid tumors diagnosis and previous treatment with hspninety inhibitor
__label__1	study interventions are Carboplatin . stage iia fallopian tube cancer diagnosis and patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and or nutrition
__label__1	study interventions are Entinostat . recurrent childhood visual pathway glioma diagnosis and are not eligible
__label__1	study interventions are Naproxen-n-butyl nitrate . prostate cancer diagnosis and known coronary disease cerebrovascular disease
__label__1	study interventions are Mycophenolate mofetil . intraocular lymphoma diagnosis and donor
__label__1	study interventions are Sirolimus . metastatic breast cancer diagnosis and history of or current alcohol misuse abuse within the past twelve months
__label__1	study interventions are Lenalidomide . anaplastic large cell lymphoma diagnosis and any prior use of lenalidomide
__label__1	study interventions are Fludarabine . recurrent adult diffuse large cell lymphoma diagnosis and adult
__label__1	study interventions are Biotene . head and neck cancer diagnosis and pregnant or lactating women and women of childbearing potential refusing to use adequate contraception
__label__1	study interventions are Everolimus . stage iiib breast cancer diagnosis and female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods if barrier contraceptives are being used these must be continued throughout the trial by both sexes hormonal contraceptives are not acceptable as sole method of contraception women of childbearing potential must have negative urine or serum pregnancy test within seven days prior to administration of everolimus
__label__1	study interventions are Paclitaxel . cancer of the liver diagnosis and patients with unstable or serious concurrent medical conditions are excluded
__label__1	study interventions are Lapatinib . head and neck cancer diagnosis and not considered eligible for any of the chemotherapy agents included in the induction regimen
__label__1	study interventions are Methotrexate . recurrent adult immunoblastic large cell lymphoma diagnosis and adult
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent malignant neoplasm diagnosis and the participant has uncontrolled significant intercurrent or recent illness including but not limited to the following conditions
__label__1	study interventions are positron emission tomography . recurrent prostate cancer diagnosis and cardiovascular disorders including
__label__1	study interventions are Docetaxel . stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and history of organ allograft including corneal transplant
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and creatinine clearance less_than forty-five ml min according to cockcroft gault formula
__label__1	study interventions are Cyclophosphamide . head and neck cancer diagnosis and females of child bearing potential must have negative pregnancy test within fourteen days of study enrollment as cyclophosphamide is pregnancy category d
__label__1	study interventions are Doxorubicin . stage iiic breast cancer diagnosis and pregnancy or lactation at the time of study entry note
__label__1	study interventions are Azacitidine . cancers of non thoracic origin with metastases to the lungs or pleura diagnosis and therefore patients who must use hydrochlorothiazide diuretics will be excluded
__label__1	study interventions are Pertuzumab . breast cancer diagnosis and angina pectoris requiring anti anginal medication serious cardiac arrhythmia not controlled by adequate medication severe conduction abnormality or clinically significant valvular disease
__label__1	study interventions are Paclitaxel . gastroesophageal junction cancer diagnosis and evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to study treatment start or anticipation of the need for major surgical procedure during the course of the study
__label__1	study interventions are Paclitaxel . pancreas cancer diagnosis and history or current evidence risk of retinal vein occlusion rvo or central serous retinopathy_csr
__label__1	study interventions are Capecitabine . unresolved or unstable serious toxicity from prior administration of another investigational drug and or of prior cancer treatment
__label__1	study interventions are Casopitant . solid tumor cancer diagnosis and has received an investigational drug within the previous thirty days or five half lives whichever is longer prior to receiving the first dose of study medication or investigational product or is scheduled to receive any investigational drug other than casopitant placebo during the study period
__label__1	study interventions are Iodine . recurrent adult lymphoblastic lymphoma diagnosis and southwest oncology group swog performance status greater_than equal_than doc
__label__1	study interventions are BKM120 . cholangiocarcinoma diagnosis and currently taking therapeutic doses of warfarin sodium or any other coumadin derivative anticoagulant
__label__1	study interventions are Fludarabine phosphate . splenic marginal zone lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for granulocyte colony stimulating factor csf mobilization and harvest of peripheral blood stem cell pbsc
__label__1	study interventions are Antibodies, Monoclonal . recurrent colon cancer diagnosis and known human immunodeficiency virus hiv positive patients are ineligible because these patients are at increased risk of lethal infections when treated with marrow suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agents
__label__1	study interventions are Anastrozole . breast cancer diagnosis and treatment with non approved or investigational drug within thirty days before day one of study treatment
__label__1	study interventions are Embosphere® Microspheres . leiomyoma diagnosis and presence of arteries supplying the fibroid are not large enough to accept seven hundred nine hundred micron or nine hundred one thousand, two hundred micron microspheres
__label__1	study interventions are Hydrocortisone 17-butyrate 21-propionate . prostate adenocarcinoma diagnosis and evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial
__label__1	study interventions are Gefitinib . insulinoma diagnosis and history of dry eye syndrome or sjogren syndrome
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib fallopian tube cancer diagnosis and patients with gog performance grade of three or four
__label__1	study interventions are Liposomal doxorubicin . metastatic breast cancer diagnosis and patients with history of severe hypersensitivity reaction to taxotere or other drugs formulated with polysorbate eighty
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and having received immunotherapy or chemotherapy within less_than equal_than four weeks or radiation therapy to greater_than thirty of marrow bearing bone within less_than equal_than two weeks prior to starting study treatment or who have not yet recovered from side effects of such therapies
__label__1	study interventions are Immunoglobulin G . recurrent uterine corpus carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to mlnone hundred and twenty-eight or bevacizumab
__label__1	study interventions are Irinotecan . esophageal neoplasms diagnosis and pregnant or lactating women
__label__1	study interventions are Pemetrexed . non squamous non small cell lung cancer diagnosis and current or recent use of aspirin greater_than three hundred and twenty-fivemg day or full dose anticoagulants or thrombolytic agents for therapeutic purposes
__label__1	study interventions are Fluorouracil . stage iii pancreatic cancer diagnosis and uncontrolled serious concomitant disease
__label__1	study interventions are Irinotecan . metastatic cancer diagnosis and subjects allergic to any component that is part of the treatment regimen
__label__1	study interventions are Immunoglobulins . stage ivb colorectal cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to tremelimumab and durvalumab or previous toxicity attributed to durvalumab or other pd one or pd lone directed therapy that led to drug discontinuation
__label__1	study interventions are Antibodies, Monoclonal . glioblastoma multiforme diagnosis and pregnant or breastfeeding patients
__label__1	study interventions are Lapatinib . metastatic breast cancer diagnosis and significant medical co morbidities as described below
__label__1	study interventions are Sirolimus . splenic marginal zone lymphoma diagnosis and other clinically significant heart disease congestive heart failure chf new york ny heart association class iii or iv uncontrolled hypertension history of labile hypertension or history of poor compliance with an antihypertensive regimen
__label__1	study interventions are Nivolumab . malignant melanoma diagnosis and for patients with liver metastasis ast or alt greater_than five uln
__label__1	study interventions are Cohort . lung cancer diagnosis and patients with significant psychiatric and or neurological comorbidity
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and replacement therapy thyroxine insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc
__label__1	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and severely impaired lung function
__label__1	study interventions are Antibodies . advanced adult hepatocellular carcinoma diagnosis and cardiac
__label__1	study interventions are mammography and ultrasound . breast cancer diagnosis and signs or symptoms of breast disease
__label__1	study interventions are Calcium, Dietary . figo stage iii gestational_trophoblastic tumor diagnosis and patients who have previously been treated with cytotoxic chemotherapy however patients who received prior low dose methotrexate for treatment of an ectopic pregnancy will be eligible for this study
__label__1	study interventions are Tamoxifen . stage iia breast cancer diagnosis and prior anthracycline or taxane therapy for any malignancy
__label__1	study interventions are Fludarabine . burkitt lymphoma diagnosis and patients with primary idiopathic myelofibrosis
__label__1	study interventions are Lenograstim . noncontiguous stage ii grade three follicular lymphoma diagnosis and serious medical or psychiatric illness likely to interfere with participation in this clinical study
__label__1	study interventions are Azacitidine . metastatic melanoma diagnosis and has known history of active tb_bacillus tuberculosis
__label__1	study interventions are Mycophenolic Acid . stage iv childhood lymphoblastic lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Antibodies, Monoclonal . stage iv adult diffuse small cleaved cell lymphoma diagnosis and use of any other experimental drug or therapy within twenty-eight days of baseline
__label__1	study interventions are Immunoglobulins . recurrent primary peritoneal carcinoma diagnosis and patients with peripheral edema or lymphedema greater_than grade two
__label__1	study interventions are Antibodies, Monoclonal . stage iv ovarian cancer diagnosis and patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and or nutrition
__label__1	study interventions are Sorafenib . stage ivc verrucous carcinoma of the oral cavity diagnosis and major surgery open biopsy or significant traumatic injury within four weeks of first study drug
__label__1	study interventions are Vidarabine . stage ii small lymphocytic lymphoma diagnosis and patients who have in the opinion of the investigator other medical social or psychosocial factors that may negatively impact compliance or their safety by participation in this study
__label__1	study interventions are Valproic Acid . glioblastoma multiforme diagnosis and patients with inadequately controlled systemic hypertension sbp and or dbp greater than ninety-fiveth_percentile for age and height
__label__1	study interventions are Vaccines . bladder carcinoma diagnosis and participant must have no clinically significant electrocardiogram ecg abnormalities and not have pacemaker or cardioverter_defibrillator implanted
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and prior or current systemic therapy for mm including steroids except for emergency use of four day block of dexamethasone between the screening phase and randomization
__label__1	study interventions are Albumin-Bound Paclitaxel . tongue cancer diagnosis and previously untreated patients with locoregional only disease are not eligible
__label__1	study interventions are Mycophenolate mofetil . myeloproliferative neoplasm diagnosis and matched related donor
__label__1	study interventions are Enalaprilat . metastatic malignant melanoma diagnosis and no severe impairment of peripheral arterial circulation
__label__1	study interventions are Antibodies . malignant pancreatic insulinoma diagnosis and prior use of bevacizumab is not allowed in any cohort
__label__1	study interventions are placebo . stage iv squamous cell carcinoma of the hypopharynx diagnosis and requirement of chronic steroid therapy except when given for laryngeal edema
__label__1	study interventions are Rituximab . lymphoma non hodgkin diagnosis and if history of cardiac disease ejection fraction must be within normal limits for age
__label__1	study interventions are Gemcitabine . small cell lung cancer sclc diagnosis and pregnant women
__label__1	study interventions are Fludarabine phosphate . contiguous stage ii marginal zone lymphoma diagnosis and presence of active uncontrolled infection at start of conditioning
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and prior allogeneic bone marrow transplantation or prior solid organ transplantation
__label__1	study interventions are Surgical excision . carcinoma basal cell diagnosis and patients not competent to understand the procedures involved
__label__1	study interventions are Docetaxel . breast cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to docetaxel cyclophosphamide lenograstim or filgrastim
__label__1	study interventions are Goserelin . prostate cancer diagnosis and clinically significant cardiac disease
__label__1	study interventions are Prednisolone phosphate . lymphoma large cell diffuse diagnosis and high risk of developing thromboembolic events who are unwilling to take venous thromboembolism prophylaxis
__label__1	study interventions are therapeutic allogeneic lymphocytes . recurrent cutaneous cell non hodgkin lymphoma diagnosis and pregnant or lactating females
__label__1	study interventions are Cyclophosphamide . stage iiia primary peritoneal cancer diagnosis and uncontrolled acute or chronic medical conditions including but not limited to the following
__label__1	study interventions are Sirolimus . patients who have received more than one prior treatment regimen for metastatic renalcell carcinoma
__label__1	study interventions are Lenograstim . stage iiia breast cancer diagnosis and have uncontrolled hypertension greater_than one hundred and fifty one hundred mm hg despite optimal medical therapy
__label__1	study interventions are Paclitaxel . malignant head and neck neoplasm diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Cholecalciferol . history or evidence upon physical examination of central nervous system cns disease primary brain tumor seizures not controlled with standard medical therapy any brain metastases or history of stroke
__label__1	study interventions are Antibodies . recurrent primary peritoneal carcinoma diagnosis and qt interval corrected by fridericia formula qtcf greater_than four hundred and fifty msec on screening electrocardiogram ecg
__label__1	study interventions are Camptothecin . stage iiia non small cell lung cancer diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Freund's Adjuvant . extraocular extension melanoma diagnosis and who are pregnant or lactating since the risk of autoimmune reactivity to tyrosinase mart one or gpone00 is felt to present risk to the fetus or breast feeding infant effective birth control for men and women is required during and for four months after the study is finished
__label__1	study interventions are Oxaliplatin . previous cytotoxic chemotherapy radiotherapy or immunotherapy except corticosteroids for the currently treated gastric cancer
__label__1	study interventions are Vidarabine . melanoma diagnosis and significant history or current evidence of cardiovascular disease uncontrolled congestive heart failure or hypertension unstable coronary artery disease or serious arrhythmias or major respiratory diseases
__label__1	study interventions are Methylprednisolone Hemisuccinate . peroxisomal disorders diagnosis and prior myeloablative chemotherapy exposure within four months of the start of conditioning on this protocol
__label__1	study interventions are Melphalan . recurrent adult hodgkin lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than forty predicted corrected for hemoglobin and or alveolar ventilation
__label__1	study interventions are Immunoglobulins . contiguous stage ii mantle cell lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Cisplatin . stage iiib ovarian cancer diagnosis and myocardial infarction or unstable angina less_than six months prior to registration
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent adult soft tissue sarcoma diagnosis and core biopsy within seven days prior to enrollment
__label__1	study interventions are Radium Ra 223 dichloride . prostate cancer diagnosis and subject has received adjuvant or neoadjuvant androgen ablation within the previous twelve months
__label__1	study interventions are Vaccines . solid tumors diagnosis and subjects with active known or suspected systemic autoimmune disease
__label__1	study interventions are Liposomal doxorubicin . ovarian neoplasms diagnosis and subjects with known history of interstitial lung disease or pulmonary fibrosis
__label__1	study interventions are dacarbazine plus Endostar (Experimental group) . advanced melanoma diagnosis and uncontrolled brain metastasis patients with obvious manifestations of intracranial hypertension or neurological and mental disorders
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent primary peritoneal carcinoma diagnosis and baseline qtcf greater_than four hundred and fifty msec male or qtcf greater_than four hundred and seventy msec female will exclude patients from entry on study list of medications that may cause qtc interval prolongation are listed in appendix and should be avoided by patients entering on trial
__label__1	study interventions are Rituximab . recurrent grade one follicular lymphoma diagnosis and prior history of human immunodeficiency virus hiv positivity routine hiv testing is required pretreatment
__label__1	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and treatment with cytotoxic chemotherapy within the preceding four weeks
__label__1	study interventions are Immunoglobulins . recurrent ovarian carcinoma diagnosis and patients with history of myocardial infarction within six months
__label__1	study interventions are Busulfan . acute lymphoblastic leukemia all lymphoblastic lymphoma diagnosis and subjects may not be eligible for inclusion in blood and marrow transplant clinical trials network bmt ctn one thousand, one hundred and one protocol
__label__1	study interventions are Bevacizumab . fallopian tube cancer diagnosis and active autoimmune disease requiring systemic therapy in past two years imgneight hundred and fifty-three and pembrolizumab only
__label__1	study interventions are intensity-modulated radiation therapy . unspecified adult solid tumor protocol specific diagnosis and serum creatinine greater_than doc mg dl within thirty days prior to study entry
__label__1	study interventions are Immunoglobulins . recurrent meningioma diagnosis and patients who have had major surgery or significant traumatic injury within four weeks prior to registration patients who have not recovered from the side effects of any major surgery defined as requiring general anesthesia or patients that may require major surgery during the course of the study
__label__1	study interventions are management of therapy complications . stage iii adult diffuse large cell lymphoma diagnosis and unwilling or unable to follow protocol requirements
__label__1	study interventions are Placebo control gummy . oral cancer diagnosis and have active metabolic or digestive illnesses such as malabsorptive disorders crohn ileus ibs renal insufficiency hepatic insufficiency hype negative or hypothyroidism cachexia morbid obesity or short bowel syndrome
__label__1	study interventions are General Education DVD . breast cancer diagnosis and premedication related to the administration of taxanes and use of anti emetics is allowed per usual clinical practice
__label__1	study interventions are Curcumin . cutaneous cell lymphoma diagnosis and the patient has known allergies to any component of the study drug
__label__1	study interventions are AZD3514 . prostate cancer diagnosis and if unable to fast for greater_than two hours prior to taking dose to greater_than one hour post dose
__label__1	study interventions are Leucovorin . metastatic carcinoma of unknown primary diagnosis and documented brain metastases
__label__1	study interventions are Poly ICLC . stage iv skin melanoma diagnosis and patients with brain metastasis after definitive therapy with surgery or stereotactic radiation and stable off steroids for greater_than equal_than four weeks are eligible
__label__1	study interventions are Therapeutic conventional surgery . invasive lobular breast carcinoma diagnosis and ipsilateral mammogram done greater than six months prior to study
__label__1	study interventions are Nintedanib . anaplastic oligoastrocytoma diagnosis and uncontrolled intercurrent illness
__label__1	study interventions are Etoposide phosphate . peripheral cell lymphoma diagnosis and myocardial infarction within six months prior to enrollment or has new york heart association nyha class iii or iv heart failure uncontrolled angina severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
__label__1	study interventions are Oxaliplatin . stage iiib ovarian cancer diagnosis and patients with current serious non healing wound ulcer or bone fracture patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are ZD6474 (ZACTIMA) . non small cell lung cancer diagnosis and atrial fibrillation controlled on medication is not excluded
__label__1	study interventions are Thalidomide . small intestine lymphoma diagnosis and prior therapy with histone_deacetylase hdac inhibitors or immunomodulatory drugs imds lenalidomide or thalidomide
__label__1	study interventions are Melphalan . recurrent adult immunoblastic large cell lymphoma diagnosis and chemosensitive nhl except patients receiving greater_than equal_than three prior chemotherapy regimens or patients having transformed nhl ptcl mcl or alcl alk neg
__label__1	study interventions are Antibodies, Monoclonal . leptomeningeal carcinomatosis diagnosis and has known history of or any evidence of active non infectious pneumonitis
__label__1	study interventions are Pembrolizumab . metastatic squamous non small cell lung cancer diagnosis and acute myocardial infarction or stroke during the last six months unstable angina relevant and unstable dysrhythmia controlled tachyarrhythmia absoluta taa allowed
__label__1	study interventions are Gemcitabine . sarcoma diagnosis and known brain metastases
__label__1	study interventions are Antibodies . stage iv fallopian tube cancer diagnosis and patients with clinically significant cardiovascular disease this includes
__label__1	study interventions are Intra Operative Radiation Therapy (IORT) . breast cancer diagnosis and patients younger than sixty-one years
__label__1	study interventions are Paclitaxel . stage iiic ovarian cancer diagnosis and major surgical procedure anticipated during the course of the study
__label__1	study interventions are Bupivacaine . posterior_fossa tumors diagnosis and earlier craniotomy
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and participant with clinical signs of heart or coronary failure or evidence of left ventricular ejection fraction lvef inferior to forty
__label__1	study interventions are full conditioning . fibroid myoma uterus cervix diagnosis and pregnancy
__label__1	study interventions are Gemcitabine . solid tumors diagnosis and known active hepatitis hbsag reactive or hepatitis hcv rna qualitative is detected
__label__1	study interventions are Sirolimus . lung cancer diagnosis and known intolerance or hypersensitivity to everolimus or other rapamycin analogs sirolimus temsirolimus
__label__1	study interventions are Cisplatin . cancer diagnosis and active infection
__label__1	study interventions are (Extended) pleurectomy decortication . mesothelioma diagnosis and patients unwilling to be randomised
__label__1	study interventions are Computed Tomography . recurrent nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and patients who cannot lie_flat for twenty minutes
__label__1	study interventions are Prednisone . localized prostate cancer diagnosis and abnormal bone marrow function absolute neutrophil count anc less_than one thousand, five hundred mmthree platelet count less_than one hundred zero mmthree hemoglobin less_than nine dl
__label__1	study interventions are Tacrolimus . stage iii childhood small noncleaved cell lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and pregnant or lactating females
__label__1	study interventions are Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging . stage ii renal cell cancer diagnosis and severe renal function impairment estimated glomerular filtration rate egfr less_than forty-five ml min doc three two would make the patient inappropriate for enrollment due to the increased risk of nephrogenic systemic fibrosis nsf with higher dose of iv gadolinium based contrast agents gbca administration
__label__1	study interventions are Estrogens, Conjugated (USP) . prostatic neoplasms diagnosis and gnrh agonists or gnrh antagonists leuprorelin degarelix for greater_than two months prior to enrollment
__label__1	study interventions are Albumin-Bound Paclitaxel . anal canal cloacogenic carcinoma diagnosis and known hypersensitivity to any of the study drugs or excipients
__label__1	study interventions are Antiviral Agents . stage ii adult cell leukemia lymphoma diagnosis and no prior allogeneic hct allo hct autologous hct auto hct is allowed
__label__1	study interventions are Sorafenib . advanced hepatocellular carcinoma diagnosis and clinically significant gastrointestinal bleeding within four weeks prior to study entry
__label__1	study interventions are Vinorelbine . breast cancer diagnosis and prior history of malignancy treated without curative intent
__label__1	study interventions are Levoleucovorin . colorectal adenocarcinoma diagnosis and the use of inhaled corticosteroids and mineralocorticoids_fludrocortisone for patients with orthostatic_hypotension or adrenocortical insufficiency is allowed
__label__1	study interventions are Antibodies, Monoclonal . high grade ovarian serous adenocarcinoma diagnosis and patients with past or resolved hepatitis infection defined as having negative hepatitis surface antigen hbsag test and positive anti hbc antibody to hepatitis core antigen antibody test are eligible
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and creatinine clearance less_than forty-five ml min
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and has received prior therapy with an anti programmed cell death one receptor anti pd one antiprogrammed death ligand one anti pd lone antiprogrammed death ligand two anti pd ltwo anti cdone37 or anti cytotoxic lymphocyte associated antigen four ctla four antibody including ipilimumab or any other antibody or drug specifically targeting cell costimulation or checkpoint_pathways
__label__1	study interventions are Gabapentin . rectum cancer diagnosis and subjects who are incarcerated or wards of the state
__label__1	study interventions are Idelalisib . refractory extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and cll arms arm and arm for combination therapy including idelalisib arm
__label__1	study interventions are Cisplatin . bladder cancer urothelial carcinoma diagnosis and history of severe allergic anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
__label__1	study interventions are Rituximab . multiple myleoma diagnosis and the risk benefit profile of transplant and hepatitis will be discussed with the patient and eligibility determined by the principal investigator and lead associate investigator
__label__1	study interventions are Cyclosporins . myelodysplastic myeloproliferative neoplasm diagnosis and nursing mother
__label__1	study interventions are Capecitabine . metastatic breast cancer diagnosis and minor surgical procedures including insertion of an indwelling catheter within twenty-four hours prior to randomization
__label__1	study interventions are Pemetrexed . nonsquamous nonsmall cell neoplasm of lung diagnosis and pregnant or lactating women
__label__1	study interventions are Metformin . prostate cancer diagnosis and alanine aminotransferase alt greater_than doc institutional uln
__label__1	study interventions are Dexamethasone 21-phosphate . squamous cell carcinoma of head and neck diagnosis and severe weight loss greater_than twenty of body weight in the preceding three months
__label__1	study interventions are Pembrolizumab . stage ivc mucosal melanoma of the head and neck diagnosis and has known history of or any evidence of active non infectious pneumonitis
__label__1	study interventions are Gemcitabine . metastatic pancreatic cancer diagnosis and inability to swallow food or any condition of the upper gi tract that precludes administration of oral medications
__label__1	study interventions are Temozolomide . pancreatic delta cell carcinoma diagnosis and patients with history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days prior to beginning study treatment are not eligible for participation
__label__1	study interventions are Pembrolizumab . stage ivb thyroid gland follicular carcinoma diagnosis and new york heart association congestive heart failure of grade ii or above unstable angina myocardial infarction within the past six months or serious cardiac arrhythmia associated with significant cardiovascular impairment within the past six months ejection fraction ef by multi gated acquisition muga or echo should not be less than the institutional lower limit of normal
__label__1	study interventions are Fludarabine phosphate . metastatic ocular melanoma diagnosis and atrial fibrillation ventricular tachycardia second or third degree heart block
__label__1	study interventions are Hydroxyitraconazole . immunosuppressed patients cancer autoimmune disease or patients taking immunosuppressive drugs
__label__1	study interventions are Dabrafenib . pineoblastoma diagnosis and history of heart disease
__label__1	study interventions are Mycophenolate mofetil . stage iii adult diffuse small cleaved cell lymphoma diagnosis and patient or donor infected with human immunodeficiency virus hiv
__label__1	study interventions are Topotecan . metastatic solid tumor diagnosis and patients must not be taking concurrent treatment with potent inhibitors of cytochrome pfour hundred and fifty threeafour
__label__1	study interventions are Prolactin Release-Inhibiting Factors . castration resistant prostate cancer patients with oligometastases diagnosis and patients may not have received any growth factors within seven days or blood transfusions within twenty-eight days of the hematologic laboratory values obtained at the screening visit
__label__1	study interventions are Citric Acid . recurrent plasma cell myeloma diagnosis and other co morbidity which would interfere with patient ability to participate in trial uncontrolled infection uncompensated heart or lung disease
__label__1	study interventions are Carboplatin . fallopian tube clear cell adenocarcinoma diagnosis and history of myocardial infarction within six months
__label__1	study interventions are Prednisolone phosphate . multiple myeloma diagnosis and known hiv positivity
__label__1	study interventions are tivozanib . stage iv adult soft tissue sarcoma diagnosis and subjects with recent dvt who have been therapeutically coagulated for at least six weeks are eligible
__label__1	study interventions are Docetaxel . cancer diagnosis and cardiac ejection fraction less_than fifty
__label__1	study interventions are Paclitaxel . esophageal cancer diagnosis and prior chemo except as radiosensitizers recurrent treated esophageal lesion only except greater_than two months
__label__1	study interventions are Irinotecan . recurrent rectal carcinoma diagnosis and any condition that impairs patient ability to swallow whole pills
__label__1	study interventions are Irinotecan . pancreatic cancer diagnosis and if patient has had history of clotting or is suspected to have trousseau syndrome and is not anticoagulated d dimer level will be checked
__label__1	study interventions are behavioral intervention . recurrent gestational_trophoblastic tumor diagnosis and non ambulatory
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and history of grand mal seizures other than infantile febrile seizures
__label__1	study interventions are chemoprevention . stage ii salivary gland cancer diagnosis and inability to take oral nutrition liquids or history of aspiration pneumonia
__label__1	study interventions are Liver Extracts . pretext stage two hepatoblastoma diagnosis and patients who have received any prior chemotherapy are not eligible
__label__1	study interventions are Fluorouracil . stage ii rectal cancer diagnosis and pregnant or nursing
__label__1	study interventions are Ergocalciferols . solid cancers diagnosis and any uncontrolled systemic inflammatory disease or infection requiring antibiotics non steroidal or steroidal anti inflammatory agents
__label__1	study interventions are Ledipasvir . indolent cell lymphoma diagnosis and patients with hbv dna negativity
__label__1	study interventions are BB 1101 . stage iiic primary peritoneal cancer diagnosis and patients who in the opinion of the treating physician have medical condition or currently take medications which are felt to contraindicate safe or effective administration of the standard three drug anti emetic regimen used in this study
__label__1	study interventions are ispinesib . recurrent small lymphocytic lymphoma diagnosis and bitter_orange
__label__1	study interventions are 3-Iodobenzylguanidine . neuroblastoma diagnosis and patients will be excluded if any of the following conditions are observed
__label__1	study interventions are Imatinib Mesylate . chordoma diagnosis and severe and or uncontrolled medical disease uncontrolled diabetes chronic renal disease or active uncontrolled infection
__label__1	study interventions are Vincristine . more than one course of chemotherapy per lo negative or intermediate risk neuroblastoma therapy prior to determination of mycn amplification and histology
__label__1	study interventions are continental breakfast . symptomatic peripheral vascular disease
__label__1	study interventions are Liver Extracts . colorectal neoplasms diagnosis and patients who received bevacizumab avastin or cetuximab erbitux within thirty days of randomization
__label__1	study interventions are Antibodies, Monoclonal . melanoma diagnosis and subjects with neurologic sign and symptoms related to brain metastases who are being treated with total daily dose of higher than four mg dexamethasone or equivalent within ten prior to the start of treatment with study drug are excluded
__label__1	study interventions are Prednisone . documented brain metastases or carcinomatous_meningitis treated or untreated brain imaging for asymptomatic patients is not required
__label__1	study interventions are Cediranib . stage iiia ovarian cancer diagnosis and patients taking medications with narrow therapeutic indices that are metabolized by cytochrome pfour hundred and fifty cypfour hundred and fifty including warfarin sodium coumadin are ineligible except low dose warfarin for prophylaxis for central catheters
__label__1	study interventions are Mycophenolic Acid . stage marginal zone lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Fludarabine . stage childhood lymphoblastic lymphoma diagnosis and active central nervous system cns leukemia involvement at the time of study enrollment cerebrospinal fluid with greater_than five white blood cells wbc mm three and malignant cells on cytospin
__label__1	study interventions are Anesthetics . breast cancer diagnosis and patients on chronic anti emetics ie
__label__1	study interventions are onabotulinumtoxinA . hereditary leiomyomatosis and renal cell cancer diagnosis and amyotrophic_lateral sclerosis or motor neuropathy
__label__1	study interventions are Dasatinib . recurrent prostate cancer diagnosis and prohibited treatments and or therapies
__label__1	study interventions are Sonazoid; Perflubutane for Injection . breast cancer diagnosis and for example
__label__1	study interventions are laboratory biomarker analysis . adult gliosarcoma diagnosis and patients with history of being serologically positive for hepatitis or or who have history of cirrhosis are ineligible
__label__1	study interventions are Immunoglobulins . extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and marrow cellularity equal_than less_than fifteen as determined on all bone marrow samples
__label__1	study interventions are Paclitaxel . breast tumor diagnosis and subjects who have received an investigational product within the previous four weeks prior to randomization
__label__1	study interventions are Etoposide phosphate . recurrent cutaneous cell non hodgkin lymphoma diagnosis and patients with history of impaired cardiac status including history of severe coronary artery disease cardiomyopathy congestive heart failure or arrhythmia if the patient history is questionable measurement of left ventricular ejection fraction should be obtained within forty-two days prior to registration patients with left ventricular ejection fraction less_than fifty are not eligible
__label__1	study interventions are Cyclosporine . peripheral cell lymphoma diagnosis and positive cross match exists between the donor and recipient
__label__1	study interventions are Cyclophosphamide . lymphoma large cell diffuse diagnosis and poor bone marrow reserve as defined by neutrophils less_than doc l or plateletsless_than one hundredg unless related to bone marrow infiltration
__label__1	study interventions are questionnaire administration . splenic marginal zone lymphoma diagnosis and patients who have undergone or are planning to undergo ovarian tissue oocyte or embryo_cryopreservation prior to treatment are not eligible
__label__1	study interventions are Mycophenolic Acid . recurrent small lymphocytic lymphoma diagnosis and active extramedullary leukemia including cns disease
__label__1	study interventions are Megestrol Acetate . stage iv breast cancer diagnosis and hertwo positive disease as defined by three positive ihc or positive fish both in primary and metastatic sites
__label__1	study interventions are Fluorouracil . gastric cancer diagnosis and known dihydropyrimidine_dehydrogenase deficiency
__label__1	study interventions are Leucovorin . recurrent colon cancer diagnosis and impairment of gastrointestinal function or gastrointestinal disease active ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome small bowel resection
__label__1	study interventions are Sirolimus . advanced cancer diagnosis and concurrent use of cyclosporine tacrolimus and rifampin terfenadine_astemizole cisapride rosiglitazone or pioglitazone due to possible interactions with the study drugs
__label__1	study interventions are Vidarabine . stage iii childhood anaplastic large cell lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and unstable cardiopathy despite treatment myocardial infarction within the six months before entering the study
__label__1	study interventions are Calcium heparin . metastatic cancer diagnosis and cerebrovascular hemorrhage in the last six months
__label__1	study interventions are ON 013105 . lymphoma diagnosis and new onset seizures within three months prior to the first dose of on 01three105 or poorly controlled seizures
__label__1	study interventions are Dasatinib . cancer diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are RFA Applicator . breast cancer diagnosis and because there is no patient contact with the device no medical contraindications are foreseen
__label__1	study interventions are cytology specimen collection procedure . prior malignancy within the past three years other than complete resection of basal or squamous cell carcinoma of the skin any in situ malignancy or low risk prostate cancer after curative therapy
__label__1	study interventions are Tacrolimus . stage iii multiple myeloma diagnosis and women of childbearing potential who are pregnant beta hcg positive or breast feeding
__label__1	study interventions are Ponatinib . glioblastoma diagnosis and venous thromboembolism including deep venous thrombosis or pulmonary embolism within six months prior to enrollment
__label__1	study interventions are Lenvatinib . stage ivc thyroid gland papillary carcinoma diagnosis and cohort two only
__label__1	study interventions are Cyclophosphamide . advanced melanoma diagnosis and unwilling or unable to comply with the protocol
__label__1	study interventions are Paclitaxel . head and neck carcinoma diagnosis and patients who have previously discontinued bevacizumab containing regimes due to drug related toxicity
__label__1	study interventions are Erlotinib Hydrochloride . glioblastoma multiforme diagnosis and women who are pregnant or lactating
__label__1	study interventions are Vinca Alkaloids . advanced cancer diagnosis and part b
__label__1	study interventions are Bortezomib . lymphoma non hodgkin diagnosis and patient who are required to take strong cypthreeafour inducer are excluded from the study
__label__1	study interventions are Antibodies . recurrent cervical carcinoma diagnosis and influenza vaccination should be given during influenza season only approximately october to march patients must not receive live attenuated influenza vaccine within four weeks prior to cycle one day one or at any time during the study
__label__1	study interventions are Nitrogen Mustard Compounds . recurrent follicular lymphoma diagnosis and history of active myocardial ischemia cardiomyopathy uncontrolled dysrhythmia or congestive heart failure within the last six months before the evaluation
__label__1	study interventions are Antibodies, Monoclonal . metastatic colorectal cancer diagnosis and radiotherapy less_than fourteen days prior to inclusion
__label__1	study interventions are Temozolomide . gliosarcoma diagnosis and patients who progressed on or within twelve weeks after completion of radiotherapy are excluded
__label__1	study interventions are Immunoglobulins . intraocular lymphoma diagnosis and qtc prolongation greater_than five hundredmsec or other significant ecg abnormality noted within fourteen days of registration
__label__1	study interventions are Antibodies, Monoclonal . adult giant cell glioblastoma diagnosis and severe active co morbidity defined as follows
__label__1	study interventions are Sorafenib . myelodysplastic myeloproliferative neoplasms diagnosis and participants must not receive concomitant medications known to inhibit platelet function or known to selectively inhibit cyclooxygenase two cox two activity all antipyretic and anti inflammatory medications except acetaminophen
__label__1	study interventions are EGF816 . non small cell lung cancer diagnosis and previous treatment with c met inhibitor or hgf targeting therapy
__label__1	study interventions are Deferasirox . stage mantle cell lymphoma diagnosis and patients with moderate or severe hearing loss as defined by audiogram
__label__1	study interventions are Metformin . prior invasive malignancy except for non melanoma skin cancer unless disease free for greater_than three years
__label__1	study interventions are Everolimus . stage iv merkel cell carcinoma diagnosis and not recovered from adverse events related to previous treatment excluding alopecia to active common terminology criteria for adverse events ctcae equal_than less_than grade one
__label__1	study interventions are Liposomal doxorubicin . breast cancer stage iii diagnosis and pregnancy or breastfeeding
__label__1	study interventions are Niacinamide . synovial sarcoma diagnosis and any condition that impairs patient ability to swallow pills
__label__1	study interventions are Endothelial Growth Factors . stage ivb cervical cancer diagnosis and patients with significant peripheral vascular disease
__label__1	study interventions are Pemetrexed . colorectal cancer diagnosis and peripheral neuropathy greater_than ctcae grade two
__label__1	study interventions are Temozolomide . gliosarcoma diagnosis and five aminolevulinic acid ala mediated photodynamic therapy administered prior to surgery to aid in optimal surgical resection is not considered chemotherapy agent
__label__1	study interventions are Interferon-alpha . malignant melanoma diagnosis and previous treatment with thymosin alpha one
__label__1	study interventions are standard follow-up care . stage iv non small cell lung cancer diagnosis and support persons
__label__1	study interventions are Vidarabine . recurrent adult hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Suture removal time14 days . cutaneous tumors diagnosis and reoperation of the included wound scar before study completion
__label__1	study interventions are Extracorporeal Photochemotherapy With Transimmunization . non small cell lung cancer diagnosis and pregnant or nursing at time of study entry
__label__1	study interventions are GSK3326595 Capsules . subjects with prostate cancer may also remain on low dose prednisone or prednisolone up to ten milligram mg day and still be eligible for this study
__label__1	study interventions are Temozolomide . cancer of brain and nervous system diagnosis and history of hypersensitivity reaction to temozolomide or history of hypersensitivity to dtic or hydrogel
__label__1	study interventions are Veliparib . stage iiia ovarian cancer diagnosis and no more than superficial myometrial invasion
__label__1	study interventions are Paclitaxel . estrogen recepto negative negative breast cancer diagnosis and subjects who are receiving immunosuppressive or myelosuppressive medications that would in the opinion of the investigator increase the risk of serious neutropenic complications
__label__1	study interventions are Sorafenib . neurofibromatosis type diagnosis and patients requiring systemic full dose anticoagulation with systemic thrombolytics heparin coumadin or low molecular weight heparin or other anticoagulants for therapy of active thrombosis within the prior three months
__label__1	study interventions are Docetaxel . cancer diagnosis and pregnant or breast feeding women are excluded from this study
__label__1	study interventions are LR-CHOP21 . follicular lymphoma diagnosis and hbv positivity with the exception of patients with hbvcab positive hbsag
__label__1	study interventions are Antibodies, Monoclonal . refractory hodgkin lymphoma diagnosis and active hepatitis or with uncontrolled disease
__label__1	study interventions are Paclitaxel . esophageal squamous cell carcinomas diagnosis and had received adjuvant neoadjuvant therapy and the cumulative dose of cisplatin was over three hundred mg mtwo
__label__1	study interventions are Bevacizumab . epithelial ovarian cancer diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study
__label__1	study interventions are informational intervention . ductal carcinoma in situ or lobular carcinoma in situ
__label__1	study interventions are Nilotinib . stage iii melanoma diagnosis and ventricular tachyarrhythmia within the past six months
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent fallopian tube carcinoma diagnosis and history of grade three or four bowel toxicity from immune checkpoint inhibitor within twelve weeks of registration
__label__1	study interventions are Cyclophosphamide . any other malignancy from which the patient has been disease free for less than five years with the exception of adequately treated and cured basal or squamous cell skin cancer superficial bladder cancer carcinoma in situ of the cervix
__label__1	study interventions are Sorafenib . breast cancer diagnosis and patients requiring anticoagulants with the exception of low dose coumadin asa plavix or heparin for maintenance of vascular access patency
__label__1	study interventions are apatinib . hepatocellular carcinoma diagnosis and doses greater_than ten mg day prednisone or equivalent are prohibited within two weeks before study drug administration
__label__1	study interventions are Azacitidine . non hodgkin lymphoma diagnosis and have low blood pressure supine blood pressure less_than ninety sixty mmhg
__label__1	study interventions are Fludarabine . stage iii grade two follicular lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Leucovorin . colorectal cancer diagnosis and start of oxaliplatin based chemotherapy within nine months prior to study entry
__label__1	study interventions are Carboplatin . head and neck neoplasms diagnosis and patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent
__label__1	study interventions are Pembrolizumab . non hodgkin lymphoma diagnosis and ejection fraction measuring less than forty-five measurement of ejection fraction is required only for subjects with prior anthracycline exposure
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and presence of central nervous system or brain metastasis
__label__1	study interventions are Niacinamide . patients initiating treatment for their cancer within the last two months who will be continued concomitantly with perifosine
__label__1	study interventions are Liposomal doxorubicin . recurrent refractory childhood hodgkin lymphoma diagnosis and patients with total lifetime cumulative anthracycline dose greater_than seven hundred and fifty mg mtwo two5 mg kg if less_than one year doxorubicin or equivalent at the time of enrollment are not eligible
__label__1	study interventions are Ifosfamide . extraskeletal osteosarcoma diagnosis and patients aged equal_than less_than seventeen years
__label__1	study interventions are Everolimus . stage iic ovarian cancer diagnosis and evidence of current drug or alcohol abuse or psychiatric impairment which in the investigator opinion will prevent completion of the protocol therapy or follow up
__label__1	study interventions are Imaging study (FDG-PET/CT scan) . on average five six patients per week are admitted to the huntsman cancer hospital with the diagnosis of high risk persistent febrile neutropenia
__label__1	study interventions are Vincristine . lymphoma diffuse large cell diagnosis and serious concomitant medical illnesses that would jeopardize the patient ability to receive the regimen with reasonable safety
__label__1	study interventions are Sirolimus . diffuse large cell lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Tremelimumab . stage iva colorectal cancer diagnosis and known allergy or hypersensitivity to investigational product ip or any excipient
__label__1	study interventions are Fluorodeoxyglucose F18 . head and neck squamous cell carcinoma diagnosis and prior head and neck radiotherapy
__label__1	study interventions are CT Simulation . prostate adenocarcinoma diagnosis and if prior malignancy is in remission for less_than five years then the patient is not eligible
__label__1	study interventions are Erlotinib Hydrochloride . lung cancer diagnosis and history within the past six months of myocardial infarction cardiac stent placement or intermittent ischemia with troponin leak
__label__1	study interventions are Vaccines . stage iv cutaneous cell non hodgkin lymphoma diagnosis and planned prophylactic therapy with cmv immunoglobulin
__label__1	study interventions are Mycophenolate mofetil . stage adult immunoblastic large cell lymphoma diagnosis and patient or donor with active hepatitis or and or detectable viral ribonucleic acid rna
__label__1	study interventions are Fludarabine . recurrent grade three follicular lymphoma diagnosis and bone marrow bm donors
__label__1	study interventions are Paclitaxel . malignant ovarian mixed epithelial tumor diagnosis and patients with an active infection that requires antibiotics
__label__1	study interventions are Esophageal-Sparing Intensity-Modulated Radiotherapy . non small cell lung cancer diagnosis and inability to attend the full course of rt or planned follow up visits
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and active infection or other medical condition that would make corticosteroids dexamethasone use contraindicated
__label__1	study interventions are Liposomal doxorubicin . ovarian cancer diagnosis and prior exposure to cumulative doses of doxorubicin greater_than four hundredmg mtwo or epirubicin greater_than 7two0mg mtwo
__label__1	study interventions are Pemetrexed . neoplasms diagnosis and alanine amino_transferase alt and or aspartate amino_transferase ast greater than doc uln except in case of known liver metastasis where maximum five uln is acceptable
__label__1	study interventions are Thalidomide . stage iii multiple myeloma diagnosis and history of deep venous thrombus arterial occlusions or pulmonary emboli
__label__1	study interventions are dimethane sulfonate (DMS612, NSC 281612) . non hodgkin lymphoma diagnosis and patients are not eligible for the study if taking cytochrome pfour hundred and fifty inducing anticonvulsants
__label__1	study interventions are AlloStim . melanoma diagnosis and taking anticoagulant medication for concomitant medical condition unless can be safely discontinued for cryoablation procedure
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and autologous bone marrow transplant or stem cell rescue within one year prior to start of study drug
__label__1	study interventions are placebo . neoplasm diagnosis and significant concurrent medical diseases such as congestive heart failure unstable angina acute or recent myocardial infarction six months before randomization chronic obstructive pulmonary disease with frequent exacerbation chronic renal diseases estimated ccr six0 milliliter per minute uncontrolled diabetes uncontrolled hypertension recent cerebrovascular disease episode six months before randomization
__label__1	study interventions are 15 Gy Low-KV IORT . pancreas cancer diagnosis and patient may be considered eligible if the patient physician managing the diabetes deems the appropriate changes in management have resulted in adequate control
__label__1	study interventions are Antibodies . other concurrent chemotherapy hormonal therapy radiotherapy immunotherapy or any other type of anticancer treatment
__label__1	study interventions are Carboplatin . subjects with concomitant malignancy or previous malignancy within the past three years melanoma skin cancer excepted
__label__1	study interventions are Fludarabine . recurrent mantle cell lymphoma diagnosis and poorly controlled hypertension
__label__1	study interventions are Cadexomer iodine . renal neoplasms diagnosis and allergy to iodine
__label__1	study interventions are Carboxyamido-triazole . malignant glioma who grade iii or iv diagnosis and active infection requiring iv antibiotics seven days before enrollment
__label__1	study interventions are Concurrent chemoradiation only . esophageal carcinoma diagnosis and complete obstruction of esophagus deep esophageal ulcer fistula to mediastinum or haematemesis
__label__1	study interventions are TAS3681 . metastatic castration resistant prostate cancer diagnosis and presence of cardiac pacemaker or implantable_cardioverter defibrillator
__label__1	study interventions are Trastuzumab . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and pregnant or nursing women
__label__1	study interventions are Ibrutinib . mantle cell lymphoma diagnosis and patients who have had chemotherapy or radiotherapy within two weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events due to agents administered more than two weeks earlier
__label__1	study interventions are Immunoglobulins . stage four neuroblastoma diagnosis and females of childbearing potential must have negative pregnancy test
__label__1	study interventions are Melphalan . non hodgkin lymphoma diagnosis and participants with psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Radiation Therapy . non small cell lung cancer diagnosis and patients cannot have severe hypersensitivity reaction to drugs formulated with polysorbate eighty
__label__1	study interventions are Monitoring Device . stage iiic breast cancer diagnosis and patient has successfully lost five of body weight in the previous six months or has had bariatric surgery
__label__1	study interventions are Antibodies, Monoclonal . stage iva salivary gland cancer diagnosis and patients who have received wide field radiotherapy equal_than less_than four weeks or limited field radiation for palliation equal_than less_than two weeks prior to starting study drug or who have not recovered from side effects of such therapy
__label__1	study interventions are Etoposide . lymphoma large cell diffuse diagnosis and prior treatment with anti cdtwenty monoclonal antibodies at any time or treated with other monoclonal antibodies within three months prior to start of study therapy with the exception of rituximab in both instances
__label__1	study interventions are Goserelin . stage iia breast cancer diagnosis and unstable angina pectoris
__label__1	study interventions are Cyclophosphamide . recurrent cutaneous cell non hodgkin lymphoma diagnosis and female patient must have negative serum pregnancy test all women of child bearing potential must have test performed
__label__1	study interventions are Bortezomib . marginal lymphoma diagnosis and male subjects who do not agree to use an acceptable method of contraception for the duration of the study
__label__1	study interventions are Lenalidomide . stage iii marginal zone lymphoma diagnosis and known hypersensitivity to thalidomide
__label__1	study interventions are Dexamethasone acetate . carcinoma in situ of the cervix
__label__1	study interventions are Thalidomide . myeloma diagnosis and chemotherapy approved or investigational within three weeks prior to signing consent
__label__1	study interventions are Indomethacin . stage iii prostate cancer diagnosis and child pugh class c
__label__1	study interventions are Interleukin-2 . esophageal cancer diagnosis and patients with infection or received chemotherapy in the past two weeks
__label__1	study interventions are Antibodies . adult oligodendroglioma diagnosis and patients who have not yet completed at least twenty-one days thirty days for prior monoclonal antibody therapy since ending other investigational device or drug trials or who are currently receiving other investigational treatments
__label__1	study interventions are Capecitabine . stage iiic rectal cancer diagnosis and patients with known brain metastasis are excluded due their poor prognosis and due to possible neurologic sequelae that could confound the evaluation of the investigational treatment
__label__1	study interventions are Bortezomib . lymphoma large cell diffuse diagnosis and patient with active hepatitis or determined by serology and or nucleic acid amplification tests naat
__label__1	study interventions are Sirolimus . breast cancer diagnosis and patients who are currently part of or have participated in any clinical investigation with an investigational drug within one month prior to dosing
__label__1	study interventions are Valproic Acid . ovarian clear cell tumor diagnosis and greater than three the upper limit of normal uln for alanine aminotransferase alt aspartate aminotransferase ast
__label__1	study interventions are Antibodies, Monoclonal . breast carcinoma diagnosis and patients with grade two four neuropathy
__label__1	study interventions are Endothelial Growth Factors . ovarian serous adenocarcinoma diagnosis and therapeutic anticoagulation requiring international normalized ratio inr greater_than doc
__label__1	study interventions are Docetaxel . gastric cancer diagnosis and prior taxane containing regimen as adjuvant or neoadjuvant therapy can be allowed provided relapse occurred at least six months after therapy
__label__1	study interventions are Romidepsin . stage iiib skin melanoma diagnosis and due to difficulties assessing qtc in patients with heart block they may be eligible if deemed safe by cardiologist if patient must take ondansetron as their antiemetic their qtc may not be over four hundred and fifty no exception for patients with heart block
__label__1	study interventions are Laboratory Biomarker Analysis . extra adrenal paraganglioma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to pazopanib gwseven hundred and eighty-six thousand and thirty-four or other agents used in the study
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Rituximab . non hodgkin lymphoma diagnosis and clinically significant cardiovascular disease
__label__1	study interventions are Mycophenolic Acid . recurrent grade two follicular lymphoma diagnosis and lansky play performance score less_than sixty for pediatric patients
__label__1	study interventions are Vaccines . recurrent fallopian tube carcinoma diagnosis and treatment with chemotherapy radiation therapy or other immunotherapy equal_than less_than four weeks prior to registration
__label__1	study interventions are Sirolimus . ovarian cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to azdtwo thousand, one hundred and seventy-one
__label__1	study interventions are ClariCore System . cellular diagnosis prostate cancer diagnosis and patient has compromised immune system or autoimmune disease wbc less_than four thousand or greater_than twenty zero
__label__1	study interventions are Liposomal doxorubicin . sarcoma diagnosis and patients treated with more than one prior chemotherapy regimen including adjuvant or other additional therapy
__label__1	study interventions are Gemcitabine . carcinoma transitional cell diagnosis and untreated brain or leptomeningeal metastases including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
__label__1	study interventions are Albumin-Bound Paclitaxel . esophageal cancer diagnosis and because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lytwo million, nine hundred and forty thousand, six hundred and eighty breastfeeding should be discontinued if the mother is treated with lytwo million, nine hundred and forty thousand, six hundred and eighty
__label__1	study interventions are Donor NK Cell Infusion . rhabdomyosarcoma diagnosis and children greater than or equal to twelve years of age who have not provided informed assent in the presence of parent and an attending physician who is not member of the recipient care team
__label__1	study interventions are Liposomal doxorubicin . hepatocellular carcinoma diagnosis and clinically apparent ascites
__label__1	study interventions are Erlotinib Hydrochloride . lung cancer diagnosis and note
__label__1	study interventions are Folic Acid . stage iv primary peritoneal cancer diagnosis and uncontrolled acute or chronic medical conditions including but not limited to the following
__label__1	study interventions are Fludarabine . recurrent small lymphocytic lymphoma diagnosis and adult
__label__1	study interventions are Antibodies . hepatosplenic cell lymphoma diagnosis and patient has fungal infection with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Paclitaxel . endometrial adenosquamous carcinoma diagnosis and ctcae grade two or greater peripheral vascular disease
__label__1	study interventions are Cyclosporins . stage adult diffuse large cell lymphoma diagnosis and age greater_than seventy-five years
__label__1	study interventions are Accelerated partial breast irradiation . intermediate and high risk luminal and triple negative breast cancer diagnosis and other histology types
__label__1	study interventions are Carboplatin . metastatic squamous non small cell lung cancer diagnosis and the participant has received previous chemotherapy including concurrent chemoradiation for advanced nsclc participants who have received neo adjuvant and or adjuvant chemotherapy are eligible if the last administration occurred at least one year prior to start of therapy
__label__1	study interventions are Lapatinib . neoplasms breast diagnosis and prior therapy with an erbbone and or erbbtwo inhibitor other than trastuzumab in the adjuvant setting
__label__1	study interventions are Antibodies, Monoclonal . patients in whom more than twenty-five of the bone marrow has been infiltrated by lymphoma cells
__label__1	study interventions are Hormones . any other anti cancer therapy
__label__1	study interventions are Endothelial Growth Factors . adult glioblastoma diagnosis and any prior exposure to any vegf or vegf inhibitor including but not limited to bevacizumab cediranib vandetanib sunitinib pazopanib aflibercept or sorafenib phase ii
__label__1	study interventions are Pazopanib . carcinoma renal cell diagnosis and subjects with recent major surgery within four weeks
__label__1	study interventions are Mifamurtide . osteosarcoma diagnosis and concurrent use of ciclosporin or other calcineurin inhibitors
__label__1	study interventions are Degarelix . prostate cancer diagnosis and having received an investigational product within the last twelve weeks preceding the trial
__label__1	study interventions are Docetaxel . any previous history of chemotherapy for biliary tract cancer prior neoadjuvant adjuvant chemotherapy is allowed if recurrence occurred more than six months after completion of previous chemotherapy
__label__1	study interventions are Sorafenib . advanced adult hepatocellular carcinoma diagnosis and prior treatment with sorafenib or other raf vegf targeted therapies
__label__1	study interventions are Cyclophosphamide . adenosquamous carcinoma diagnosis and active systemic infections coagulation disorders or other active or uncompensated major medical illnesses of the cardiovascular respiratory or immune system
__label__1	study interventions are Antibodies, Monoclonal . stage ivc verrucous carcinoma of the larynx diagnosis and patients with any history of hyperglycemia elevated blood glucose level on blood chemistries should be considered for initiation of metformin treatment five hundredmg po twice daily prior to starting bkmone hundred and twenty
__label__1	study interventions are Plicamycin . gastrointestinal neoplasms diagnosis and aspirin or salicylate containing products which may increase risk of hemorrhage
__label__1	study interventions are Dexamethasone . extranodal nk cell lymphoma nasal type diagnosis and known history for grade three four allergy to the drugs in chemotherapy regimen
__label__1	study interventions are Sirolimus . non clear cell renal cell carcinoma nccrcc diagnosis and note
__label__1	study interventions are Idelalisib . recurrent grade two follicular lymphoma diagnosis and pregnant women
__label__1	study interventions are Prednisone . contiguous stage ii adult diffuse large cell lymphoma diagnosis and neurologic disorders overt psychosis mental disability or evidence of limited capacity to provide fully informed consent or cooperation with the complexities of the treatment program
__label__1	study interventions are Fluorouracil . stage iva colorectal cancer diagnosis and history of abdominal fistula formation gastrointestinal perforation or abdominal abscess within six months
__label__1	study interventions are Antibodies, Monoclonal . cancer of head and neck diagnosis and patients should have the ability to understand and the willingness to sign written informed consent document
__label__1	study interventions are Fluorouracil . mucinous adenocarcinoma of the rectum diagnosis and crohn disease or ulcerative colitis requiring hospitalization surgery or immunosuppressive medications
__label__1	study interventions are Antibodies, Monoclonal . peritoneal neoplasms diagnosis and any medical condition that may be exacerbated by bleeding including known bleeding disorder such as coagulation defect thrombocytopenia active gastric or duodenal ulcer or history of gi bleeding
__label__1	study interventions are Antibodies . anaplastic large cell lymphoma alk positive diagnosis and john wort are not eligible the topical use of these medications if applicable is allowed
__label__1	study interventions are Cisplatin . previous malignancy within the past five years except for adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer
__label__1	study interventions are Cyclosporine . stage iv marginal zone lymphoma diagnosis and donors for whom medical or psychologic reasons would make donor procedure intolerable
__label__1	study interventions are Metronidazole . prostatic neoplasms diagnosis and j
__label__1	study interventions are endostar and CHOP . t cell lymphoma diagnosis and uncontrolled or severe cardiovascular disease myocardial infarction within the past six months congestive heart failure treated with medications or uncontrolled hypertension
__label__1	study interventions are Navitoclax . stage iiib skin melanoma diagnosis and history or evidence of current greater_than equal_than class ii congestive heart failure as defined by the new york heart association nyha functional classification system
__label__1	study interventions are Trastuzumab . metastatic breast cancer diagnosis and concurrent treatment with ovarian hormone replacement therapy
__label__1	study interventions are Ramucirumab . metastatic gastric cancer diagnosis and the participant is pregnant or breastfeeding
__label__1	study interventions are Tacrolimus . b cell lymphoma diagnosis and untreated active infection
__label__1	study interventions are Pentostatin . adenocarcinoma of lung diagnosis and prior treatment with drugs of the immunotoxin class
__label__1	study interventions are Thalidomide . stage iv adult diffuse small cleaved cell lymphoma diagnosis and known positive for human immunodeficiency virus hiv or infectious hepatitis type b or or active hepatitis
__label__1	study interventions are Chemoembolization and Response-Dependent Resection . resectable hepatocellular carcinoma beyond milan criteria diagnosis and known or suspected allergy to the investigational agents or any agent given in association with this trial
__label__1	study interventions are Ifosfamide . localized high risk soft tissue sarcomas of the extremities and trunk wall in adults diagnosis and distant metastasis
__label__1	study interventions are Dabrafenib . cancer diagnosis and presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs
__label__1	study interventions are Retinol acetate . adult grade iii lymphomatoid granulomatosis diagnosis and pregnant women are excluded from this study because the effects of at one hundred and one on the developing human fetus are unknown but could potentially include teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with at one hundred and one breastfeeding should be discontinued if the mother is treated with at one hundred and one these potential risks may also apply to other agents used in this study
__label__1	study interventions are Hormones . prostate cancer diagnosis and the use of bisphosphonates is allowed provided that the patient has been receiving that medication for greater_than equal_than four weeks with evidence of progressive disease
__label__1	study interventions are Cyclophosphamide . hertwo positive breast cancer diagnosis and clinically significant valvular disease
__label__1	study interventions are Modified Measles Virus . atypical_teratoid rhabdoid tumor diagnosis and history of chronic hepatitis or infection
__label__1	study interventions are Rituximab . recurrent adult burkitt lymphoma diagnosis and active infection or history of opportunistic infections
__label__1	study interventions are Radiation Therapy . stage ib breast cancer diagnosis and active systemic lupus erythematosus or any history of scleroderma dermatomyositis with active rash
__label__1	study interventions are Antibodies, Monoclonal . stage ivb colon cancer diagnosis and patients with any nonmalignant intercurrent illness example cardiovascular pulmonary or central nervous system disease which is either poorly controlled with currently available treatment or which is of such severity that the investigators deem it unwise to enter the patient on protocol shall be ineligible
__label__1	study interventions are Cyclosporins . recurrent adult hodgkin lymphoma diagnosis and patients who are human immunodeficiency virus hiv positive
__label__1	study interventions are Antibodies . recurrent adult hodgkin lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Antilymphocyte Serum . hepatocellular carcinoma fibrolamellar variant diagnosis and participants with negative anti hcv antibodies but unexplained liver enzyme abnormalities must undergo quantitative serum rna assay to rule out false negative hcv serologies
__label__1	study interventions are Paclitaxel . solid tumor diagnosis and co existing active infection or serious concurrent illness
__label__1	study interventions are Cisplatin . pleural mesothelioma diagnosis and positive extrapleural nodes as determined by mediastinoscopy
__label__1	study interventions are Paclitaxel . stage iiib fallopian tube cancer diagnosis and gabapentin
__label__1	study interventions are HuMax-AXL-ADC . cervical cancer diagnosis and radiotherapy within fourteen days prior to first imp administration
__label__1	study interventions are Epothilones . breast cancer diagnosis and received chemotherapy for any indication within the five years preceding study enrollment
__label__1	study interventions are Rituximab . stage iv mantle cell lymphoma diagnosis and patients with history of impaired cardiac status including history of severe coronary artery disease cardiomyopathy congestive heart failure or arrhythmia if the patient history is questionable measurement of left ventricular ejection fraction should be obtained within forty-two days prior to registration patients with left ventricular ejection fraction less_than fifty are not eligible
__label__1	study interventions are Topoisomerase I Inhibitors . recurrent small cell lung carcinoma diagnosis and substance abuse medical psychological or social conditions that may in the opinion of the investigator interfere with the patient participation in the study or evaluation of the study results
__label__1	study interventions are Cyclophosphamide . aids related non hodgkin lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to csf filgrastim e
__label__1	study interventions are Oxaliplatin . prior chemotherapy or chemoradiotherapy for pancreatic cancer
__label__1	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and patients with history of other untreated malignancies or malignancies which required therapy within the past two years
__label__1	study interventions are BB 1101 . uveal melanoma diagnosis and clinically significant epiretinal membrane in the study eye
__label__1	study interventions are Pembrolizumab . stage iib gastric cancer diagnosis and active autoimmune disorders including patients known to be human immunodeficiency virus hiv positive or those requiring chronic steroid administration excluding inhaled steroids
__label__1	study interventions are Capecitabine . previous malignancy other than gastric cancer in the last five years except curatively treated basal cell carcinoma of the skin and or in situ carcinoma of the cervix
__label__1	study interventions are Docetaxel . stage iiib uterine sarcoma diagnosis and serum glutamic oxaloacetic transaminase sgot and or serum glutamate pyruvate transaminase sgpt greater_than doc times the institutional upper limit of normal
__label__1	study interventions are Asparaginase . stage b lymphoblastic lymphoma diagnosis and female patients who are pregnant are ineligible
__label__1	study interventions are Carboplatin . breast cancer diagnosis and history of idiopathic pulmonary fibrosis including bronchiolitis_obliterans with organizing_pneumonia or evidence of active pneumonitis on screening chest computed tomography scan
__label__1	study interventions are Cadexomer iodine . lymphoma non hodgkin diagnosis and patients who previously received radioimmunotherapy
__label__1	study interventions are Mitogens . lung cancer diagnosis and patients who are pregnant
__label__1	study interventions are Antibodies, Monoclonal . lymphoma large cell diffuse diagnosis and positive hiv serology
__label__1	study interventions are Megestrol . stage iiia breast cancer diagnosis and liver disease such as cirrhosis chronic active hepatitis or chronic persistent hepatitis
__label__1	study interventions are S-1 . gastrointestinal neoplasms diagnosis and history of myocardial infarction within the past six months or history of ventricular arrhythmia
__label__1	study interventions are pharmacological study . lymphoma diagnosis and no antibody therapy for the treatment of underlying malignancy within the past eight weeks
__label__1	study interventions are Etoposide . concomitant malignancies or previous malignancies within the last five years with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
__label__1	study interventions are Albumin-Bound Paclitaxel . gastrooesophageal cancer diagnosis and known hypersensitivity to afatinib bibw two thousand, nine hundred and ninety-two or the excipients of any of the trial drugs
__label__1	study interventions are Paclitaxel . prior malignancy within the past five years except for adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
__label__1	study interventions are Irinotecan . stage iiic colon cancer diagnosis and palliative radiation treatment pain control bony lesions at risk of fracture completed equal_than less_than two weeks of starting study treatment patient will be eligible if palliative radiotherapy is completed greater_than two weeks from the start of study treatment and has recovered from radiotherapy toxicities
__label__1	study interventions are Dexamethasone acetate . congestive heart failure new york heart association class iii to iv symptomatic ischemia conduction abnormalities uncontrolled by conventional intervention or myocardial infarction within six months before first dose
__label__1	study interventions are Pixantrone . non hodgkin lymphoma diagnosis and topical or inhaled corticosteroids are allowed
__label__1	study interventions are Cisplatin . stage iii laryngeal squamous cell carcinoma diagnosis and human immunodeficiency virus hiv testing is not required for entry into this protocol the need to exclude patients with aids from this protocol is necessary because the cisplatin and imrt involved in this protocol may be significantly immunosuppressive
__label__1	study interventions are Estradiol . breast cancer diagnosis and unable to give informed consent
__label__1	study interventions are Sirolimus . recurrent grade one follicular lymphoma diagnosis and pregnant women or women of reproductive ability who are unwilling to use effective contraception
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and core biopsy or other minor surgical procedure excluding placement of vascular access device within seven days prior to study enrollment
__label__1	study interventions are Fentanyl . pain cancer diagnosis and serious respiratory dysfunction
__label__1	study interventions are Irinotecan . neoplasms pancreatic diagnosis and serious active infection
__label__1	study interventions are Study of High Risk Factors . stage ia vulvar cancer diagnosis and patients who do not undergo or have not undergone the lymphadenectomy portion of the procedure
__label__1	study interventions are Poly I-C . stage iv skin melanoma diagnosis and cirrhosis or chronic hepatitis virus positivity or chronic hepatitis infection
__label__1	study interventions are Brachytherapy . prostate cancer diagnosis and platelets less than one hundred zero per mm three
__label__1	study interventions are Antibodies, Monoclonal . patients with synchronous primary endometrial carcinoma or past history of primary endometrial carcinoma are excluded unless all of the following criteria for describing the endometrial carcinoma are met
__label__1	study interventions are Mycophenolate mofetil . stage childhood burkitt lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of tyrosine kinase inhibitors such as imatinib cytokine therapy hydroxyurea low dose cytarabine_chlorambucil or rituxan will not be allowed within three weeks of the initiation of conditioning
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and plasma cell leukemia
__label__1	study interventions are Bendamustine Hydrochloride . non hodgkin lymphoma diagnosis and presence of active infection within seventy-two hours of treatment
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma non small cell lung diagnosis and absolute neutrophil count anc at or less than one thousand, five hundred mmthree
__label__1	study interventions are Resectoscope . myomas with diameter greater_than three cm note
__label__1	study interventions are Vatalanib . carcinoma diagnosis and major surgery laparotomy less_than four weeks prior to randomization
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent non small cell lung carcinoma diagnosis and known active untreated central nervous system cns metastases that require steroids subjects with cns metastases who have completed course of therapy would be eligible for the study provided they are clinically stable for at least four weeks before study entry defined as
__label__1	study interventions are Busulfan . stage iii multiple myeloma diagnosis and potential donors who for psychological physiological or medical reasons cannot tolerate administration of csf or apheresis
__label__1	study interventions are Poly ICLC . skin cancer diagnosis and patients may not receive any non oncology vaccine therapy during the period of neo pv one positive adjuvant or nivolumab administration and until at least eight weeks after the last dose of the booster vaccine
__label__1	study interventions are Mycophenolate mofetil . anaplastic large cell lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Succinylcholine . stage iib ovarian cancer diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study examples of this would be hearing loss or neuropathy which would prevent tolerance to cisplatin and paclitaxel administration the investigator should feel free to consult the study chair or study co chairs for uncertainty in this regard
__label__1	study interventions are Busulfan . multiple myeloma diagnosis and donor with psychiatric disorder or mental deficiency that makes compliance with the procedure unlikely and informed consent impossible
__label__1	study interventions are Erythromycin Ethylsuccinate . colorectal cancer screening diagnosis and subject with any condition believed to have an increased risk of capsule retention such as suspected or known bowel obstruction stricture or fistula
__label__1	study interventions are Antibodies, Monoclonal . malignant solid tumor diagnosis and have history of significant neurological or psychiatric disorders including dementia seizures or bipolar disorder
__label__1	study interventions are Antibodies, Monoclonal . stage ivb colon cancer diagnosis and nursing women
__label__1	study interventions are Vidarabine . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and whole lungs twelve gy
__label__1	study interventions are Pembrolizumab . mucosal melanoma diagnosis and thyroxine insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc
__label__1	study interventions are Metformin . lung adenocarcinoma diagnosis and patients receiving any other investigational agents
__label__1	study interventions are Camptothecin . prior second line systemic treatment for metastatic colon adenocarcinoma
__label__1	study interventions are Fluorouracil . stage iiic colon cancer diagnosis and combination of the following positive or positive or positive c
__label__1	study interventions are Irinotecan . adenocarcinoma of the stomach diagnosis and positive hiv serology
__label__1	study interventions are Paclitaxel . stage iiia gallbladder cancer diagnosis and patients must not have prior exposure to docetaxel
__label__1	study interventions are Paclitaxel . stage iv esophageal squamous cell carcinoma diagnosis and any unstable systemic disease including active infection uncontrolled hypertension unstable angina congestive heart failure myocardial infarction within the previous year serious cardiac arrhythmia requiring medication hepatic renal or metabolic disease
__label__1	study interventions are Doxorubicin . prior therapy for lymphoma
__label__1	study interventions are Immunoglobulins . prostate cancer diagnosis and peripheral neuropathy of grade two or greater intensity as defined by the nci common toxicity criteria nci ctc
__label__1	study interventions are Radical Cystectomy . stage iii bladder urothelial carcinoma diagnosis and bulky lymphadenopathy greater_than two cm
__label__1	study interventions are Proton-decoupled 31P MRS at 1.5T . renal cancer diagnosis and pacemaker aneurysmal clips any ferrous metallic implants which could be deflected by the magnet metal implants in field of view pregnant women or age and mental status wherein he she is unable to cooperate for mr study
__label__1	study interventions are Antibodies, Monoclonal . metastatic colorectal cancer diagnosis and known brain metastases unless adequately treated surgery or radiotherapy with no evidence of progression and neurologically stable off anticonvulsants and steroids
__label__1	study interventions are Docetaxel . breast cancer diagnosis and has ever had myocardial infarction mi or has history of heart failure uncontrolled angina severe uncontrolled arrhythmias pericardial disease or electrocardiographic evidence of acute ischemic changes
__label__1	study interventions are Vidarabine . stage iii adult diffuse mixed cell lymphoma diagnosis and patients with conventional transplant options conventional transplant should be the priority for eligible patients equal_than less_than fifty yr of age who have related donor mismatched for single hla b or drbone antigen
__label__1	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are Paclitaxel . recurrent endometrial cancer diagnosis and concomitant use of cytochrome pfour hundred and fifty cypthreeafour inhibitors or inducers is allowed but should be monitored closely for the use of strong inhibitors and or inducers patient is strongly advised to avoid grapefruit or grapefruit juice and herbal supplements with high risk of interaction with cypthreeafour or cyptwoceight such as st
__label__1	study interventions are Vaccines . mesolthelioma diagnosis and patients requiring corticosteroids other than inhaled will be excluded
__label__1	study interventions are Fluorouracil . metastatic colorectal cancer diagnosis and concomitant or within four weeks before randomisation administration of any other experimental drug under investigation
__label__1	study interventions are Albumin-Bound Paclitaxel . prostatic neoplasms diagnosis and patients with previous history of deep venous thrombosis or pulmonary embolism within twelve months are not eligible
__label__1	study interventions are Doxorubicin . ovarian serous adenocarcinoma diagnosis and patients with intra cardiac defibrillators or permanent pacemakers
__label__1	study interventions are Tazemetostat and [14C] Tazemetostat . primary mediastinal lymphoma diagnosis and ww ov drugs developmentapprovalprocess developmentresources druginteractionslabeling ucmeight thousand and forty-nine tm or http
__label__1	study interventions are Taxane . primary peritoneal carcinoma diagnosis and has any condition that interferes with the ability of the subject to understand or comply with the requirements of the study
__label__1	study interventions are Everolimus . stage iii adult burkitt lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Methotrexate . childhood diffuse large cell lymphoma diagnosis and twelve pediatric
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv ovarian cancer diagnosis and due to potential risk for adverse events in nursing infants secondary to treatment of the mother with carboplatin breastfeeding should be discontinued
__label__1	study interventions are Cisplatin . gastrointestinal neoplasms diagnosis and patients will be ineligible if they have baseline neurologic toxicity of grade three or greater because of the potential neurotoxicity associated with platinum
__label__1	study interventions are Trastuzumab . triple negative breast carcinoma diagnosis and patients with leptomeningeal disease are not eligible for participation
__label__1	study interventions are Laboratory Biomarker Analysis . non resectable hepatocellular carcinoma diagnosis and the patient has previously identified allergy or hypersensitivity to components of the study treatment formulation
__label__1	study interventions are Doxorubicin . metastatic liposarcoma diagnosis and participation in prior investigational interventional study within thirty days prior to enrollment or within five half lives of the investigational product whichever is longer
__label__1	study interventions are IPI-504 . stage iv lung cancer diagnosis and women who are pregnant or lactating
__label__1	study interventions are Ramosetron . cancer diagnosis and patients with gi obstruction active gastric ulcer or other diseases that could provoke nausea and vomiting
__label__1	study interventions are Prednisone . prostate neoplasms diagnosis and anti androgen treatment must not be given within four weeks flutamide or six weeks bicalutamide or nilutamide prior to cycle one day one
__label__1	study interventions are Mitogens . male breast cancer diagnosis and second or third degree atrioventricular_av block unless treated with permanent pacemaker
__label__1	study interventions are natural killer T cell . hepatocellular carcinoma diagnosis and previous bone marrow or stem cell transplant or organ allograft
__label__1	study interventions are placebo . stage zero hypopharyngeal cancer diagnosis and inability to grant informed consent
__label__1	study interventions are Endothelial Growth Factors . stage iva colon cancer diagnosis and any of the following prior therapies
__label__1	study interventions are Vaccines . stage iiib skin melanoma diagnosis and known history of immunodeficiency disorder other than hiv positive status
__label__1	study interventions are Levoleucovorin . stage iiia rectal cancer diagnosis and leptomeningeal disease
__label__1	study interventions are YM155 . lymphoma cell refractory diagnosis and any preparative treatment salvage chemotherapy high dose chemotherapy radiation therapy etc
__label__1	study interventions are Mycophenolic Acid . stage iv grade three follicular lymphoma diagnosis and liver function abnormalities
__label__1	study interventions are Cisplatin . recurrent head and neck cancer diagnosis and active autoimmune disease that has required systemic treatment in past two years replacement therapy is not considered form of systemic treatment
__label__1	study interventions are Morphine . breast cancer diagnosis and patients with known allergy to opioids or nsaids
__label__1	study interventions are Antibodies, Monoclonal . liver cell caricinoma diagnosis and doc
__label__1	study interventions are Vidarabine . recurrent adult cell leukemia lymphoma diagnosis and donor
__label__1	study interventions are Sirolimus . neuroendocrine carcinoma grade two moderately differentiated neuroendocrine carcinoma that switched to gthree diagnosis and affected persons who might be dependent on the sponsor or the investigator
__label__1	study interventions are Antibodies, Monoclonal . castrate resistant prostate cancer diagnosis and brain metastases or active leptomeningeal disease
__label__1	study interventions are Cyclophosphamide . choroid_plexus tumors diagnosis and platelet count less_than eighty-five zero ul
__label__1	study interventions are Antibodies, Monoclonal . stage iva verrucous carcinoma of the larynx diagnosis and any other hemorrhage bleeding event greater_than ctcae grade three within four weeks of first dose of study drug
__label__1	study interventions are Dihematoporphyrin Ether . stage iv non small cell lung cancer diagnosis and pts who have received prior mantle or extensive mediastinal radiation
__label__1	study interventions are Nivolumab . adult solid neoplasm diagnosis and known clinically active brain metastases prior evidence of brain metastasis successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment and there are no neurological signs of potential brain metastases
__label__1	study interventions are Fluorouracil . mucinous adenocarcinoma of the colon diagnosis and active inflammatory bowel disease or other bowel disease causing chronic diarrhea defined as greater_than equal_than common toxicity criteria ctc grade two common terminology criteria for adverse events ctcae version doc
__label__1	study interventions are Everolimus . subependymal giant cell astrocytoma diagnosis and uncontrolled high cholesterol
__label__1	study interventions are Erlotinib Hydrochloride . stage iv non small cell lung cancer diagnosis and known central nervous system cns disease except for treated brain metastasis note
__label__1	study interventions are BBI503 . any known symptomatic or untreated brain metastases requiring increase of steroid dose within two weeks prior to starting on study
__label__1	study interventions are Immunoglobulins . contiguous stage ii adult lymphoblastic lymphoma diagnosis and known john cunningham_jc virus infection and or progressive multifocal_leukoencephalopathy pml
__label__1	study interventions are Bevacizumab . breast cancer diagnosis and for example cva in the six months prior to randomization coronaropathy or history of ami in the last six months unstable angina congestive heart failure of grade greater_than ii of the new york heart association nyha or severe heart arrhythmias which are not controlled with medication or which can potentially interfere with the study treatment
__label__1	study interventions are Olaparib . head and neck cancer diagnosis and if considered significant by the treating clinician lower grade neuropathy may be considered as exclusion criterion
__label__1	study interventions are Carboplatin . malignant pleural mesothelioma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to study treatment start or anticipation of the need for major surgical procedure during the course of the study
__label__1	study interventions are Mebendazole . gliosarcoma diagnosis and patients who are unable to take oral medications because of significant vomiting will be excluded
__label__1	study interventions are Trebananib . inoperable hepatocellular carcinoma diagnosis and subjects with history of prior malignancy
__label__1	study interventions are Cisplatin . stage iiib ovarian cancer diagnosis and metastatic non gynecologic or breast primaries
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and patients treated with high dose therapy plus stem cell transplantation in onest line therapy
__label__1	study interventions are Cyclophosphamide . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and donor
__label__1	study interventions are Mycophenolate mofetil . stage iv adult cell leukemia lymphoma diagnosis and eligible for high priority curative autologous transplant
__label__1	study interventions are TOK-001 . prostate cancer diagnosis and prior radiation therapy completed less_than four weeks prior to enrollment
__label__1	study interventions are Sirolimus . cancer of breast diagnosis and drugs that cannot be coadministered with rapamycin include but are not limited to
__label__1	study interventions are Bevacizumab . recurrent fallopian tube carcinoma diagnosis and patients with psoriasis must have baseline ophthalmologic exam to rule out ocular manifestations
__label__1	study interventions are Pasireotide LAR . autosomal_dominant polycystic liver disease diagnosis and serum magnesium greater_than uln
__label__1	study interventions are Glucose load . stomach neoplasms diagnosis and dementia or other psychological state precluding compliance and understanding of research protocol
__label__1	study interventions are NGR-hTNF . concurrent anticancer therapy
__label__1	study interventions are BB 1101 . central nervous system lymphoma diagnosis and men or women of childbearing potential who are unwilling to employ adequate contraception
__label__1	study interventions are Irinotecan . stage iv ampulla of vater cancer diagnosis and neuropathy grade two or greater by nci ctcae v
__label__1	study interventions are Temozolomide . recurrent uveal melanoma diagnosis and patients with corrected qt qtc interval greater_than four hundred and fifty msecs or other factors that increase the risk of qtc prolongation or arrhythmic events heart failure hypokalemia family history of long qt interval syndrome including heart failure that meets new york heart association nyha class iii and iv definitions are excluded
__label__1	study interventions are Tomotherapy . cervical cancer diagnosis and patients with metastatic lymphadenopathies other than pelvis pan ing supraclavicular or mediastinal metastatic lymphadenopathy
__label__1	study interventions are Pembrolizumab . carcinoma non small cell lung diagnosis and presence of metastatic disease stage iv nsclc is not allowed
__label__1	study interventions are Cyclosporins . recurrent adult diffuse large cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Epothilones . neoplasms glandular and epithelial diagnosis and unwillingness or inability to comply with procedures required in this protocol
__label__1	study interventions are Melphalan . medulloblastoma diagnosis and concomitant enrollment on clinical study such as cog study that does not allow co enrollment on this standard of care protocol arm only
__label__1	study interventions are Dexamethasone 21-phosphate . recurrent grade two follicular lymphoma diagnosis and patient has an active infection requiring antimicrobial therapy
__label__1	study interventions are Everolimus . metastatic renal cell carcinoma diagnosis and cerebrovascular accident
__label__1	study interventions are Doxorubicin . stage iii grade two follicular lymphoma diagnosis and positive serology for hepatitis hb defined as positive test for hbsag
__label__1	study interventions are Fludarabine . stage iv grade two follicular lymphoma diagnosis and unrelated donor products received from the deutsche_knochenmarkspenderdatei dkms_registry are not eligible for the optional study
__label__1	study interventions are Melphalan . adult burkitt lymphoma diagnosis and other serious medical conditions considered to represent contraindications to bone marrow transplant bmt abnormally decreased cardiac ejection fraction diffusion capacity of the lung for carbon monoxide dlco less_than fifty predicted patient on supplemental oxygen acquired immune deficiency syndrome aids etc
__label__1	study interventions are Tacrolimus . myeloproliferative neoplasm diagnosis and patients with life expectancy of less_than six months for reasons other than their underlying hematologic oncologic disorder
__label__1	study interventions are Fluorouracil . stage ii pancreatic cancer diagnosis and breast feeding
__label__1	study interventions are Bevacizumab . endometrial clear cell adenocarcinoma diagnosis and three grade two or greater hypoxemia
__label__1	study interventions are Imatinib Mesylate . gastrointestinal stromal tumor diagnosis and alcohol or any drug dependence within past one year
__label__1	study interventions are Metformin . glioma diagnosis and long term use of chloroquine greater_than five years or cumulative dose greater_than three hundred grams in the past
__label__1	study interventions are Paclitaxel . stage iii iv or recurrent endometrial cancer diagnosis and non healing wound ulcer or bone fracture
__label__1	study interventions are Liposomal doxorubicin . other prior cancer including nonmelanoma skin cancer
__label__1	study interventions are Everolimus . stage iiib breast cancer diagnosis and live vaccines
__label__1	study interventions are Mycophenolate mofetil . myeloma multiple diagnosis and history of complicated diverticulitis including fistulae abscess formation or gastrointestinal gi perforation
__label__1	study interventions are Prednisolone . prostate cancer diagnosis and e
__label__1	study interventions are systemic chemotherapy . colorectal cancer diagnosis and patients older than seventy-five years not fulfilling these criteria
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and intake of any concomitant medications or therapies that may potentially interact with the trial agent
__label__1	study interventions are Crizotinib . lung cancer diagnosis and had major surgery within thirty days of the first dose of study drug minor surgical procedures such as catheter placement or minimally invasive biopsies are allowed
__label__1	study interventions are regorafenib . stage iii adult soft tissue sarcoma diagnosis and women who are pregnant or breast feeding
__label__1	study interventions are Liposomal doxorubicin . genitourinary cancer diagnosis and swallowing or absorption problems that might interfere with oral bioavailability of sildenafil
__label__1	study interventions are Antibodies, Monoclonal . cancer of neck diagnosis and patients should not have any prior history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Folic Acid Antagonists . renal cell carcinoma diagnosis and inability or unwillingness to take corticosteroid folic acid or vitamin btwelve supplementation
__label__1	study interventions are Hydroxyurea . stage ivb squamous cell carcinoma of the oropharynx diagnosis and peripheral neuropathy greater_than equal_than grade one
__label__1	study interventions are Albumin-Bound Paclitaxel . head and neck cancer diagnosis and history of interstitial pneumonia or pulmonary fibrosis or signs of interstitial pneumonia or pulmonary fibrosis on the baseline chest ray
__label__1	study interventions are PKI-179 . advanced malignant solid tumors diagnosis and qtc interval greater_than four hundred and seventy ms
__label__1	study interventions are Sunitinib . tumor markers biological diagnosis and prior treatment with sunitinib or other antiangiogenic agent
__label__1	study interventions are S-1 . adenocarcinoma esophagogastric junction diagnosis and known alcohol abuse or drug addiction
__label__1	study interventions are Immunologic Factors . advanced and or metastatic sarcoma diagnosis and active or prior documented autoimmune disease including inflammatory bowel disease celiac disease wegener syndrome within the past two years
__label__1	study interventions are Glycine . plasma cell myeloma diagnosis and other concurrent severe and or uncontrolled medical conditions uncontrolled diabetes or active or uncontrolled infection including abnormal laboratory values that could cause unacceptable safety risks or compromise compliance with the protocol
__label__1	study interventions are Antibodies . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and any immunotherapy chemotherapy radiotherapy or experimental therapy within three weeks before first dose of study drug corticosteroids for disease related symptoms allowed but require one week washout before study drug administration
__label__1	study interventions are Antibodies . cervical adenosquamous carcinoma diagnosis and patients with clinically significant cardiovascular disease are excluded
__label__1	study interventions are Cyclophosphamide . acute promyelocytic leukemia or acute myeloid leukemia with chromosomal changes eight twenty-one inv sixteen or fifteen seventeen
__label__1	study interventions are Antibodies, Monoclonal . stage iiib fallopian tube cancer diagnosis and known hypersensitivity to other recombinant human antibodies or chinese_hamster ovary cell products
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and history of hemoptysis bright red blood of teaspoon or more greater than or equal to doc ml on one occasion unrelated to any diagnostic procedure within the past year
__label__1	study interventions are Megestrol . central nervous system tumors diagnosis and patients who are pregnant
__label__1	study interventions are Nurse Practitioner Clinic . head and neck cancer diagnosis and any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patient ability to tolerate this treatment
__label__1	study interventions are Sirolimus . extensive stage small cell lung carcinoma diagnosis and hypertension labile hypertension or history of poor compliance with antihypertensive medication
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and active infection requiring treatment with systemic iv or oral anti infectives antibiotic antifungal antiviral within seventy-two hours of randomisation
__label__1	study interventions are Olaparib . fallopian tube cancer diagnosis and patients who were treated with other parp inhibitors greater than twenty-eight days prior to study are eligible
__label__1	study interventions are magnetic resonance imaging . intraprostatic calcifications making high intensity focused ultrasound of focal areas of cancer untreatable
__label__1	study interventions are Sirolimus . non clear cell renal cell carcinoma nccrcc diagnosis and any medical or other condition that in the opinion of the investigator would preclude the participant participation in clinical study
__label__1	study interventions are N-monoacetylcystine . stage iva lymphoepithelioma of the oropharynx diagnosis and utilization of amifostine during radiotherapy
__label__1	study interventions are Prednisolone hemisuccinate . stage adult lymphoblastic lymphoma diagnosis and any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form
__label__1	study interventions are Camptothecin . rectal cancer diagnosis and patients must not be taking warfarin
__label__1	study interventions are Cytarabine . malignant melanoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biological composition to sorafenib
__label__1	study interventions are Anterolateral thoracotomy . nonsmall cell lung cancer cellular diagnosis diagnosis and pregnant
__label__1	study interventions are Paclitaxel . stage ii nasopharyngeal carcinoma diagnosis and severe active co morbidity defined as follows
__label__1	study interventions are quality of life assessment . stage iva squamous cell carcinoma of the lip and oral cavity diagnosis and previous head and neck surgery that would preclude transoral robotic procedures
__label__1	study interventions are quality of life assessment . stage iii squamous cell carcinoma of the larynx diagnosis and unexplained fever and or untreated active infection
__label__1	study interventions are Everolimus . diffuse adenocarcinoma of the stomach diagnosis and prior treatment with any investigational drug within the preceding four weeks
__label__1	study interventions are PI-88 . prior or concurrent symptomatic or known cns involvement or brain or meningeal metastases
__label__1	study interventions are Antibodies, Monoclonal . primary peritoneal serous adenocarcinoma diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Ferrosoferric Oxide . er pr positive breast cancer diagnosis and pregnant or breast feeding
__label__1	study interventions are Dexamethasone . already initiated salvage lymphoma therapy except prephase as specified in this study
__label__1	study interventions are Fludarabine . noncontiguous stage ii grade three follicular lymphoma diagnosis and donor
__label__1	study interventions are Everolimus . stage iii merkel cell carcinoma diagnosis and known history of brain or leptomeningeal metastases
__label__1	study interventions are Cetuximab . stage ivb inverted papilloma of the paranasal sinus and nasal cavity diagnosis and patients with an active bleeding diathesis or on therapeutic anticoagulation except low dose coumadin
__label__1	study interventions are Aldesleukin . metastatic melanoma diagnosis and systemic steroid therapy required
__label__1	study interventions are Carboplatin . regional neuroblastoma diagnosis and no compatible donor identified
__label__1	study interventions are Rituximab . refractory mantle cell lymphoma diagnosis and histamine two htwo receptor antagonists are not permitted from the day prior through to the end of mln8two37 dosing except as required for premedication for rituximab constant dosing of htwo blockers is not permitted
__label__1	study interventions are Polystyrene sulfonic acid . refractory mantle cell lymphoma diagnosis and topical and inhaled corticosteroids in standard doses and physiologic replacement for subjects with adrenal insufficiency are allowed
__label__1	study interventions are Personally-tailored educational software program . colorectal cancer screening diagnosis and personal history of inflammatory bowel disease involving the colon unless limited to the rectum
__label__1	study interventions are Cisplatin . history of seizure disorder not related to underlying cancer
__label__1	study interventions are ispinesib . splenic marginal zone lymphoma diagnosis and miscellaneous
__label__1	study interventions are Cisplatin . carcinoma non small cell lung diagnosis and pregnancy or lactation period
__label__1	study interventions are Busulfan . severe peripheral neuropathy grade two or higher as defined by national cancer institute common terminology criteria for adverse events nci ctcae version doc
__label__1	study interventions are Bevacizumab . stage ivb cervical cancer diagnosis and patients with clinically significant cardiovascular disease are excluded
__label__1	study interventions are Chemotherapy . luminal tumor rh positive and hertwo negative with grade and tumor rh positive hertwo negative with grade ii and with kisixty-sevenless_than two0
__label__1	study interventions are Vincristine . stage fours neuroblastoma diagnosis and sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
__label__1	study interventions are ispinesib . stage ivc salivary gland cancer diagnosis and anticonvulsants
__label__1	study interventions are Proteasome Inhibitors . non hodgkin lymphoma diagnosis and subjects with known or suspected amyloidosis
__label__1	study interventions are Fludarabine . progression of multiple myeloma or plasma cell leukemia diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Complement System Proteins . lymphoma diagnosis and umbilical cord blood graft selection
__label__1	study interventions are Placebo . prostate adenocarcinoma diagnosis and patients who have radiotherapy within four weeks or chemotherapy prior to entering the study or those who have not recovered resolution to grade one from adverse events due to agents administered more than four weeks earlier neoadjuvant adjuvant chemotherapy for local disease is allowed if greater than six months have elapsed
__label__1	study interventions are Gemcitabine . biliary tract cancer diagnosis and john wort or rifampin rifampicin
__label__1	study interventions are Immunoconjugates . stage iv adult cell leukemia lymphoma diagnosis and chemotherapy including monoclonal antibodies or radiotherapy administered for any condition within four weeks prior to entering the study or incomplete recovery from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Tipifarnib . thyroid cancer diagnosis and known uncontrolled brain leptomeningeal or epidural metastases unless treated and well controlled for at least four weeks prior to cycle one day one
__label__1	study interventions are Sirolimus . kidney cancer diagnosis and active brain metastasis or patients with meningeal metastases
__label__1	study interventions are Ramucirumab . pancreatic cancer diagnosis and uncontrolled hypertension prior to initiating study despite medication
__label__1	study interventions are Cediranib . stage iv childhood lymphoblastic lymphoma diagnosis and history of cva within six months
__label__1	study interventions are Antilymphocyte Serum . fibrolamellar hepatocellular carcinoma diagnosis and use of investigational drug other than the study medications specified by the protocol within thirty days of transplantation
__label__1	study interventions are Antibodies, Monoclonal . stage iiia uterine corpus cancer diagnosis and evidence of free abdominal air not explained by paracentesis or recent surgical procedures
__label__1	study interventions are Irinotecan . colorectal neoplasms diagnosis and women that are pregnant or lactating
__label__1	study interventions are Aspirin . colorectal cancer diagnosis and large bowel resection for any reason
__label__1	study interventions are Cetuximab . head and neck cancer diagnosis and known hiv positivity on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study drugs
__label__1	study interventions are Octreotide . hormone resistant prostate cancer diagnosis and lack of ability willingness to give informed consent
__label__1	study interventions are Antilymphocyte Serum . marginal zone cell lymphoma diagnosis and known to cause harm to fetus
__label__1	study interventions are Immunoglobulins . stage iia ovarian cancer diagnosis and myocardial infarction or unstable angina less_than six months prior to registration
__label__1	study interventions are Antibodies, Monoclonal . ovarian clear cell cystadenocarcinoma diagnosis and history or presence of clinically significant ventricular or atrial tachyarrhythmias or cardiac arrest
__label__1	study interventions are Camptothecin . brain tumors diagnosis and clinically significant unrelated systemic illness such as serious infections hepatic renal or other organ dysfunction which in the judgment of the principal or associate investigator would compromise the patient ability to tolerate the agents used in this trial or are likely to interfere with the study procedures or results
__label__1	study interventions are Placebo . stage iii iiib or iiic colon cancer diagnosis and arterial or venous thrombotic or embolic events such as cerebral vascular accident including transient ischemic attacks deep vein thrombosis or pulmonary embolism within six months before randomization except for adequately treated catheter related venous thrombosis occurring within six months before randomization
__label__1	study interventions are Docetaxel . infiltrating duct and lobular carcinoma in situ diagnosis and patients with second malignancies with expected survivalless_than five years
__label__1	study interventions are Niacinamide . unspecified adult solid tumor protocol specific diagnosis and phase ii
__label__1	study interventions are Questionnaires, MRI, Comet assay and Cell senescence . stage ii and iii breast cancer diagnosis and history of head injury with evidence of brain injury or loss of consciousness for greater_than sixty minutes or cognitive sequelae
__label__1	study interventions are Mycophenolic Acid . recurrent adult burkitt lymphoma diagnosis and serum glutamate pyruvate transaminase sgpt and serum glutamic oxaloacetic transaminase sgot fourx the upper limit of normal
__label__1	study interventions are autologous PBSC transplant . multiple myeloma diagnosis and pregnant or nursing women
__label__1	study interventions are Mycophenolic Acid . anaplastic large cell lymphoma diagnosis and infection with hiv
__label__1	study interventions are Promethazine . breast cancer diagnosis and patients who are pregnant or lactating or not practicing adequate contraception
__label__1	study interventions are Irinotecan . neoplasm malignant diagnosis and uncontrolled hypertension
__label__1	study interventions are Bevacizumab . ovarian cancer diagnosis and known hypersensitivity to any component of avastin
__label__1	study interventions are Interleukin-2 . adult solid neoplasm diagnosis and since il two is administered following cell infusion
__label__1	study interventions are Tacrolimus . stage iv adult diffuse mixed cell lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Alemtuzumab . recurrent childhood anaplastic large cell lymphoma diagnosis and patient is human immunodeficiency virus hiv positive
__label__1	study interventions are Carboplatin . stage iii mucoepidermoid carcinoma of the oral cavity diagnosis and exposure to any investigational drug within three weeks prior to the start of dosing
__label__1	study interventions are Questioners . bladder cancer diagnosis and unable to read and comprehend english language text
__label__1	study interventions are GVHD prophylaxis . lymphoma follicular diagnosis and prior allogeneic hematopoietic stem cell transplant
__label__1	study interventions are Sorafenib . carcinoma hepatocellular diagnosis and substance abuse medical psychological or social conditions that may interfere with the patient participation in the study or evaluation of the study results
__label__1	study interventions are Maleic acid . extraocular extension melanoma diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible because of potential for pk interactions with azdtwo thousand, one hundred and seventy-one appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
__label__1	study interventions are Rituximab . follicular lymphoma diagnosis and abnormal liver function
__label__1	study interventions are Sirolimus . stage ii childhood anaplastic large cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than forty total lung capacity tlc less_than forty forced expiratory volume in one second fevone less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and chronic corticosteroids unless initiated greater_than six months prior to study entry and at low dose ten mg or less methylprednisolone or equivalent
__label__1	study interventions are Liposomal doxorubicin . stage iva uterine corpus cancer diagnosis and cardiac or pulmonary conditions that preclude aggressive cytoreductive surgery
__label__1	study interventions are Galunisertib . neoplasm diagnosis and have the presence of cardiac disease including myocardial infarction within six months prior to study entry unstable angina pectoris new york heart association class iii iv congestive heart failure or uncontrolled hypertension
__label__1	study interventions are Paclitaxel . fibrosarcoma diagnosis and the patient has known history of stroke myocardial infarction peripheral vascular disease or recent within three months uncontrolled deep venous thrombosis
__label__1	study interventions are Triptorelin Pamoate . sarcoma diagnosis and ovariectomy
__label__1	study interventions are Vincristine . prior history of cancer
__label__1	study interventions are Paclitaxel . stage iiia ovarian cancer diagnosis and patients who have received prior therapy with any anti vascular endothelial growth factor vegf drug including bevacizumab
__label__1	study interventions are Erlotinib Hydrochloride . recurrent adult primary liver cancer diagnosis and chemoembolization will be considered as one prior chemotherapeutic regimen
__label__1	study interventions are Tadalafil . head and neck squamous cell carcinoma diagnosis and current treatment with nitrates
__label__1	study interventions are Fludarabine phosphate . indolent non hodgkin lymphoma diagnosis and patients with life expectancy of less_than six months for reasons other than their underlying hematologic oncologic disorder
__label__1	study interventions are quality-of-life assessment . stage iii squamous cell carcinoma of the hypopharynx diagnosis and use of arginine supplementation
__label__1	study interventions are Antibodies . adult hepatocellular carcinoma diagnosis and received more than two prior cytotoxic chemotherapy regimens for persistent or recurrent disease
__label__1	study interventions are PN usual . breast cancer diagnosis and active suicidality
__label__1	study interventions are Cetuximab . colorectal cancer diagnosis and has known hypersensitivity to cetuximab murine proteins or any component of cetuximab
__label__1	study interventions are Trametinib . metastatic melanoma diagnosis and antidepressants
__label__1	study interventions are Maleic acid . evidence of progressive optic glioma malignant glioma malignant peripheralnerve sheath tumor or other cancer requiring treatment with chemotherapy orradiotherapy
__label__1	study interventions are Capecitabine . malignant neoplasm of breast diagnosis and inability to take and or absorb oral medication
__label__1	study interventions are Fludarabine . lymphoma non hodgkin diagnosis and positive direct antiglobulin test
__label__1	study interventions are Sirolimus . recurrent digestive system neuroendocrine tumor gone diagnosis and patients who have not yet completed at least 2one days thirty days for prior monoclonal antibody therapy since ending other investigational device or drug trials or who are currently receiving other investigational treatments
__label__1	study interventions are Antineoplastic Agents . lymphoma diagnosis and patients with known history or risk factors iv drug abuse or casual sex within the past year of hepatitis hepatitis or human immunodeficiency virus
__label__1	study interventions are Cisplatin . cns involvement of lymphoma
__label__1	study interventions are Radiation Therapy . stage ia breast cancer diagnosis and intention to administer neoadjuvant chemotherapy prior to resection
__label__1	study interventions are Etoposide . recurrent mantle cell lymphoma diagnosis and known positive for human immunodeficiency virus hiv or infectious hepatitis type b or or active hepatitis
__label__1	study interventions are Nitrogen Mustard Compounds . refractory childhood hodgkin lymphoma diagnosis and patients at high risk of veno_occlusive disease of the liver criteria not yet rigorously defined but includes bilirubin greater_than doc mg and serum glutamic oxaloacetic transaminase sgot or serum glutamate pyruvate transaminase sgpt greater_than two normal patients may be accepted outside of this range if cleared by gastrointestinal gi consult
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent childhood brain neoplasm diagnosis and nitrosoureas or mitomycin equal_than less_than six weeks of registration
__label__1	study interventions are Sirolimus . sarcoma diagnosis and pregnant or nursing women
__label__1	study interventions are Niacinamide . adequately treated non melanoma skin cancer curatively treated in situ cancer of the cervix or other solid tumor curatively treated with no evidence of disease for less_than equal_than five years
__label__1	study interventions are Antibodies, Monoclonal . recurrent ovarian carcinoma diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__1	study interventions are Third Eye Panoramic device . colorectal neoplasms diagnosis and patients greater_than seventy-five years of age
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ia breast cancer diagnosis and prior unanticipated severe reaction to fluoropyrimidine therapy or known sensitivity to five fluorouracil
__label__1	study interventions are Cisplatin . stomach neoplasms diagnosis and the above information is not intended to contain all considerations relevant to patient potential participation in clinical trial
__label__1	study interventions are Avelumab . metastatic endometrial cancer diagnosis and known alcohol or drug abuse
__label__1	study interventions are Everolimus . metastatic breast cancer diagnosis and must not have rapidly progressive life threatening metastases
__label__1	study interventions are Cyclosporine . aids related diffuse small cleaved cell lymphoma diagnosis and positive serology for toxoplasma_gondii on treatment or with evidence of active infection
__label__1	study interventions are Laboratory Biomarker Analysis . stage iia prostate cancer diagnosis and participants may not be receiving any other investigational agents
__label__1	study interventions are Everolimus . neuroendocrine tumors diagnosis and prior external beam radiation therapy to the target lesion within one months prior to enrollment
__label__1	study interventions are Cetuximab . squamous cell carcinoma metastatic in the neck with occult primary diagnosis and use of strong inhibitors inducers of cypthreeafour is not permitted
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and continuous use of immunosuppressive agents
__label__1	study interventions are Cisplatin . non small cell lung cancer small cell lung cancer diagnosis and hepatic insufficiency resulting in clinical jaundice and or coagulation defects
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and history of hiv infection or chronic hepatitis or c
__label__1	study interventions are Intensity-Modulated Radiation Therapy . stage iiia colon cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to ipdr
__label__1	study interventions are Vidarabine . recurrent grade one follicular lymphoma diagnosis and left ventricular ejection fraction less_than thirty-five
__label__1	study interventions are Cortisone acetate . b cell lymphoma unclassifiable with features intermediate between diffuse large cell lymphoma and burkitt lymphoma diagnosis and patients who have had radiotherapy within fourteen days before registration are not eligible note
__label__1	study interventions are Sunitinib . bladder cancer diagnosis and concurrent treatment on another clinical trial
__label__1	study interventions are Temozolomide . prior chemotherapy or radiation therapy rt for the diagnosis of gbm or for cancers of the head and neck
__label__1	study interventions are Capecitabine . rectal cancer diagnosis and patients with greater_than thirty mg dl on urine analysis on urine analysis will undergo twenty-four hour urine collection for quantitative assessment of proteinuria
__label__1	study interventions are Lenalidomide . recurrent mantle cell lymphoma diagnosis and grapefruit juice
__label__1	study interventions are Antibodies, Monoclonal . localized unresectable adult primary liver cancer diagnosis and no concurrent full dose anticoagulants or thrombolytic agents except as required to maintain patency of pre existing permanent indwelling iv catheters
__label__1	study interventions are Bevacizumab . stage iv ovarian cancer diagnosis and other than low molecular weight heparin lmwh medication must be stopped before time of registration if patient has recently been on anti coagulants other than lmwh patient must have international normalized ratio inr equal_than less_than two
__label__1	study interventions are Albumin-Bound Paclitaxel . clear cell mullerian tumor diagnosis and receiving any other investigational agent
__label__1	study interventions are Paclitaxel . primary peritoneal cancer diagnosis and ctcae grade three or greater peripheral vascular disease
__label__1	study interventions are Goserelin . prostate cancer diagnosis and known or suspected brain or skull metastases or leptomeningeal metastatic disease
__label__1	study interventions are Trametinib . stage iv skin melanoma diagnosis and concurrent treatment with bisphosphonates is permitted however treatment must be initiated prior to the first dose of study therapy prophylactic use of bisphosphonates in patients without bone disease is not permitted except for the treatment of osteoporosis
__label__1	study interventions are Fludarabine . breast cancer diagnosis and participants of childbearing potential must have blood test or urine study within fourteen days prior to registration to rule out pregnancy and agree to use adequate birth control during study treatment
__label__1	study interventions are Mycophenolate mofetil . recurrent adult burkitt lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of hydroxyurea and imatinib mesylate will not be allowed within two weeks of the initiation of conditioning
__label__1	study interventions are Mycophenolic Acid . stage adult immunoblastic lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Docetaxel . breast cancer diagnosis and uncontrolled hypertension congestive heart failure peripheral vascular disease
__label__1	study interventions are Placebo . stage iiia esophageal adenocarcinoma diagnosis and active or clinically significant cardiac disease including
__label__1	study interventions are Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules . stage ivb squamous cell carcinoma of the oropharynx diagnosis and ecog performance status greater_than equal_than three
__label__1	study interventions are Methylprednisolone . multiple myeloma diagnosis and known hypersensitivity to components of the investigational product or severe allergic or anaphylactic reactions to humanized products
__label__1	study interventions are Immunoglobulins . stage iva hodgkin lymphoma diagnosis and inhaled or topical steroids and adrenal replacement doses greater_than ten mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
__label__1	study interventions are Veliparib . recurrent childhood brain tumor diagnosis and if bp measurement prior to registration is greater_than ninety-fiveth_percentile for age and height it must be rechecked and documented to be less_than ninety-fiveth_percentile for age and height prior to registration if patient falls between the height or weight percentiles site should average the value as appropriate for patients greater_than eighteen years the normal blood pressure should be less_than one hundred and forty ninety mm of hg patients with hypertension are eligible if their blood pressures become less_than ninety-fiveth_percentile for age and height after anti hypertensive medications
__label__1	study interventions are Androgens . adenocarcinoma of the prostate diagnosis and patients status post negative lymph node dissection are not eligible
__label__1	study interventions are Edotreotide . carcinoid tumors diagnosis and any additional medical condition serious intercurrent illness or other extenuating_circumstance that in the opinion of the investigator may significantly interfere with study performance or interpretation
__label__1	study interventions are Immunoglobulins . gastrinoma diagnosis and known hypersensitivity to capecitabine temozolomide or any component of the formulation and or known deficiency of dihydropyrimidine_dehydrogenase
__label__1	study interventions are Carboplatin . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and pregnant women are excluded from this study and women who become pregnant while on study must be immediately discontinued women who are breastfeeding will not be eligible for study participation
__label__1	study interventions are Nivolumab . melanoma diagnosis and prisoners or subjects who are compulsorily_detained involuntarily_incarcerated for treatment of either psychiatric or physical infectious illness
__label__1	study interventions are Asparaginase . extranodal nk cell lymphoma nasal type diagnosis and the patients with abnormal liver function total bilirubingreater_than doc times the normal value alt astgreater_than doc times normal abnormal renal function serum creatininegreater_than doc times normal blood abnormalities absolute neutrophil count less_than doc one hundred and nine platelets less_than eighty one hundred and nine hemoglobin less_than ninetyg l
__label__1	study interventions are Paclitaxel . lung cancer diagnosis and history of severe chronic obstructive pulmonary disease copd requiring greater_than equal_than three hospitalizations over the past year
__label__1	study interventions are Fludarabine . stage iv grade one follicular lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Fulvestrant . breast cancer diagnosis and patient has history of acute pancreatitis within one year of screening or past medical history of chronic pancreatitis
__label__1	study interventions are Voreloxin Injection . epithelial ovarian cancer diagnosis and thromboembolic event deep vein thrombosis dvt or pulmonary embolus pe within twenty-eight days prior to the anticipated first day of treatment
__label__1	study interventions are Lenograstim . breast neoplasms diagnosis and participation in clinical trial in which they received an investigational drug within twenty-eight days before randomization
__label__1	study interventions are Cytarabine . mantle cell lymphoma diagnosis and patients with known history of human immunodeficiency virus hiv or acquired immunodeficiency syndrome aids
__label__1	study interventions are Sunitinib . adult nasal type extranodal nk cell lymphoma diagnosis and myocardial infarction severe unstable angina coronary peripheral artery bypass graft cerebrovascular accident transient ischemic attack or pulmonary embolism within six months of study entry
__label__1	study interventions are Antilymphocyte Serum . splenic marginal zone lymphoma diagnosis and whole brain thirty gy enrollment of patients who previously receive higher than allowed dose of radiation to small volume of lungs liver and brain will be determine by the discretion of the radiation oncologist on the study
__label__1	study interventions are Sirolimus . metastatic breast cancer diagnosis and haemoglobin less_than ninety l
__label__1	study interventions are Bevacizumab . neoplasm metastasis diagnosis and inadequately controlled hypertension defined as blood pressure of greater_than one hundred and fifty one hundred mmhg or new york heart association nyha grade two or greater congestive heart failure
__label__1	study interventions are PAC-1 . genitourinary cancers diagnosis and grade one peripheral neuropathy within one4 days before enrollment
__label__1	study interventions are Immunoglobulins . stage ivb uterine corpus cancer diagnosis and child pugh or classification
__label__1	study interventions are Panobinostat . multiple myeloma diagnosis and patients for whom prophylactic anticoagulation therapy eg
__label__1	study interventions are Everolimus . metastatic melanoma diagnosis and immunization with attenuated live vaccines within one week of study or anytime during study treatment period
__label__1	study interventions are Computed Tomography . stage ivc oral cavity squamous cell carcinoma diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Tadalafil . locally advanced pancreatic adenocarcinoma diagnosis and chronic systemic corticosteroid use at supra physiologic doses prednisone greater_than ten mg day or equivalent
__label__1	study interventions are Lapatinib . breast cancer diagnosis and history of documented congestive heart failure chf
__label__1	study interventions are laboratory biomarker analysis . stage iv adult cell leukemia lymphoma diagnosis and patients who have undergone or are planning to undergo ovarian tissue oocyte or embryo_cryopreservation prior to treatment are not eligible
__label__1	study interventions are Gemcitabine . stage iiib iv recurrent and metastatic breast cancer diagnosis and pregnancy or breast feeding
__label__1	study interventions are Doxorubicin . stage iiib ovarian cancer diagnosis and cardiac or pulmonary conditions that preclude aggressive cytoreductive surgery
__label__1	study interventions are 6-Mercaptopurine . patients with congenital immunodeficiency chromosomal breakage syndrome prior organ transplantation previous malignancy of any type or known positive hiv serology
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic transitional cell cancer of the renal pelvis and ureter diagnosis and any other major illness which in the investigator judgment will substantially increase the risk associated with the patient participation in this study
__label__1	study interventions are Doxorubicin . childhood supratentorial primitive neuroectodermal tumor diagnosis and biopsies of solitary nodule equal_than less_than doc cm or multiple nodules equal_than less_than doc cm are not required but if performed and positive indicate metastatic disease
__label__1	study interventions are Pemetrexed . non small cell lung cancer metastatic diagnosis and disease progression occuring at any time during chemotherapy and before randomization or toxicity that led to the discontinuation of the platinium based chemotherapy before four full cycles have been delivered
__label__1	study interventions are Prednisone . peripheral cell lymphoma diagnosis and hiv testing is not required
__label__1	study interventions are Fludarabine . lymphoma diagnosis and pulmonary
__label__1	study interventions are Glycine . advanced cancer diagnosis and patients who have previously had bone marrow transplant are excluded from this study
__label__1	study interventions are Interleukin-12 . stage iii mucoepidermoid carcinoma of the oral cavity diagnosis and history of inflammatory bowel disease
__label__1	study interventions are RG4733 . neoplasms diagnosis and dexamethasone may be allowed only as part of the supportive care measures
__label__1	study interventions are Mycophenolate mofetil . recurrent small lymphocytic lymphoma diagnosis and corrected diffusion capacity of the lungs for carbon monoxide dlco less_than fifty of predicted forced expiratory volume in one second fevone less_than fifty of predicted and or receiving supplementary continuous oxygen the fhcrc principal investigator pi of the study must approve of enrollment of all patients with pulmonary nodules
__label__1	study interventions are Fulvestrant . recurrent breast cancer diagnosis and liver disease such as cirrhosis chronic active hepatitis or chronic persistent hepatitis
__label__1	study interventions are Immunoglobulin G . recurrent colorectal carcinoma diagnosis and steroids as pre medication for hypersensitivity reactions eg ct scan pre medication
__label__1	study interventions are Cediranib . stage iiia non small cell lung cancer diagnosis and patients with corrected qt interval qtc prolongation defined as qtc interval greater_than equal_than four hundred and fifty msec in males and four hundred and seventy msec in females by bazett correction or other significant electrocardiogram ecg abnormalities clinically significant arrhythmias requiring medication or conduction delays such as twond or threerd degree atrioventricular blocks etc are ineligible
__label__1	study interventions are GS-TBLB-X-ray . lung cancer diagnosis and severe cardiopulmonary dysfunction and other indications that can receive bronchoscopy
__label__1	study interventions are Olanzapine . breast cancer diagnosis and symptoms of nausea or vomiting at baseline
__label__1	study interventions are Immunoglobulin G . stage iiic fallopian tube cancer diagnosis and patients with known hypersensitivity to chinese_hamster cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Quinacrine . renal cell carcinoma diagnosis and subjects who have history of schizophrenia bipolar disorder or any psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Vitamins . stage iv rectal cancer diagnosis and a
__label__1	study interventions are 22-G Procore Needle . subepithelial tumors of the upper gastrointestinal tract diagnosis and contraindication for taking biopsies
__label__1	study interventions are Walking Intervention . patients with islet cell neuroendocrine or papillary cystic neoplasm
__label__1	study interventions are Immunoglobulins . stage ib breast cancer diagnosis and ventricular arrhythmias except for benign premature ventricular contractions
__label__1	study interventions are Bortezomib . melanoma diagnosis and participants may not be receiving any other study agents
__label__1	study interventions are Antibodies . recurrent adult burkitt lymphoma diagnosis and history of prior treatment with ipilimumab or prior cdone hundred and thirty-seven agonist or ctla four inhibitor or agonist
__label__1	study interventions are Topotecan . symptomatic cns disease
__label__1	study interventions are Etoposide phosphate . abnormal cytogenetic study not related to the underlying lymphoma on the bone marrow aspirate sample prior to stem cell collection if cytogenetics were not performed on the marrow aspirate prior to stem cell collection cytogenetics on the peripheral blood may be performed
__label__1	study interventions are Fludarabine . recurrent adult hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Vorinostat . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and as ketoconazole may inhibit paclitaxel metabolism patients receiving ketoconazole for any treatment indication are ineligible patients receiving any other medications or substances that are inhibitors or inducers of cypfour hundred and fifty enzymes will be eligible however use all such medications or substances must be documented in the case report forms
__label__1	study interventions are Antibodies, Monoclonal . primary peritoneal serous adenocarcinoma diagnosis and has known active hepatitis hepatitis surface antigen hbsag reactive or hepatitis hepatitis virus hcv ribonucleic acid rna qualitative is detected
__label__1	study interventions are Methotrexate . childhood nasal type extranodal nk cell lymphoma diagnosis and adult forty pediatric equal_than less_than eighteen yrs
__label__1	study interventions are Dabrafenib . metastatic melanoma diagnosis and history or evidence of current clinically significant uncontrolled cardiac arrhythmias clarification
__label__1	study interventions are Lenograstim . testicular lymphoma diagnosis and have had prior radioimmunotherapy
__label__1	study interventions are Trastuzumab . invasive breast cancer diagnosis and angina pectoris requiring the use of anti anginal medication
__label__1	study interventions are Mycophenolic Acid . angioimmunoblastic cell lymphoma diagnosis and fungal infections with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Niacinamide . thyroid carcinoma diagnosis and subjects with tracheal bronchial or esophageal infiltration with significant risk of bleeding but without having received local treatment prior to enrollment in the study
__label__1	study interventions are Esomeprazole . malignancy within the past five years except for nonmelanoma skin cancer
__label__1	study interventions are endocrine therapy alone without radiotherapy . breast neoplasms diagnosis and note that no specific staging studies are mandated but any studies performed must not provide clear evidence of metastatic spread
__label__1	study interventions are Antibodies, Monoclonal . male and female subjects eighteen years of age and older with metastatic renal cell carcinoma eligible patients must have undergone and failed prior treatment diagnosis and history of hiv
__label__1	study interventions are Fludarabine . ovarian carcinoma diagnosis and subjects who are allergic to aspirin are excluded
__label__1	study interventions are Ramucirumab . pediatric solid tumor diagnosis and active non healing wound or bone fracture
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and malabsorption syndrome or uncontrolled gastrointestinal toxicities
__label__1	study interventions are Irinotecan . rhabdomyosarcoma and other soft tissue sarcomas diagnosis and patients with serious non healing wound ulcer or bone fracture
__label__1	study interventions are Cyclophosphamide . stage ivb colorectal cancer diagnosis and active autoimmune disease defined as any autoimmune condition currently requiring therapy systemic lupus erythematosus multiple sclerosis inflammatory bowel disease rheumatoid arthritis
__label__1	study interventions are Doxorubicin . hepatocellular cancer diagnosis and uncontrolled encephalopathy
__label__1	study interventions are Antibodies, Monoclonal . stage iv uveal melanoma diagnosis and patients with neuropathy greater_than grade one
__label__1	study interventions are Mycophenolic Acid . recurrent adult diffuse mixed cell lymphoma diagnosis and current serious systemic illness that would result in increased risk for csf mobilization and harvest of peripheral blood stem cells pbsc
__label__1	study interventions are Mycophenolic Acid . stage marginal zone lymphoma diagnosis and donors who are hiv positive
__label__1	study interventions are Dacarbazine . gliosarcoma diagnosis and women of childbearing potential who are not using effective method of contraception
__label__1	study interventions are SNS01-T . diffuse large cell lymphoma in relapse diagnosis and be pregnant or nursing
__label__1	study interventions are Cyclophosphamide . stage iiia fallopian tube cancer diagnosis and any of the following
__label__1	study interventions are Internet-Based Intervention . stage iiib breast cancer diagnosis and survivors must not have previously received an scp or are unwilling to receive one
__label__1	study interventions are BCG Vaccine . bladder cancer diagnosis and history of primary immunodeficiency
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and hypersensitivity to thalidomide lenalidomide or dexamethasone this includes greater_than grade three rash during prior thalidomide or lenalidomide therapy
__label__1	study interventions are Telbivudine . brainstem glioma diagnosis and any patient with history of severe reaction requiring medication to gd dtpa fdg or flt
__label__1	study interventions are Nivolumab . ongoing symptomatic cardiac dysrhythmias uncontrolled atrial fibrillation or prolongation of the fridericia corrected qt qtcf interval defined as greater_than four hundred and fifty msec for males and greater_than four hundred and seventy msec for females where qtcf equal_than qt three rr
__label__1	study interventions are RFA . hepatocellular carcinoma diagnosis and pregnant lactating women
__label__1	study interventions are Romidepsin . recurrent adult diffuse large cell lymphoma diagnosis and providers should use caution with drugs with possible increased risk for torsades de pointes patient will be eligible if they can be taken off these medications prior to initiation of therapy and no less than four half life of the medication
__label__1	study interventions are Carboplatin . ongoing tumor or previous tumor other than lung cancer within the last five years
__label__1	study interventions are Abdominal total hysterectomy . endometrial cancer diagnosis and the operation is anticipated to comprise more than the hysterectomy positive bsae
__label__1	study interventions are laboratory biomarker analysis . stage iv lymphoepithelioma of the oropharynx diagnosis and due to risks of anesthesia
__label__1	study interventions are Estradiol . stage ii breast cancer diagnosis and clinical or radiographic evidence of metastatic disease
__label__1	study interventions are Fluorouracil . breast cancer diagnosis and known or suspected hypersensitivity to cyclophosphamide epirubicin and fluorouracil
__label__1	study interventions are Thalidomide . non hodgkin lymphoma diagnosis and patients with greater_than grade two neuropathy
__label__1	study interventions are Vidarabine . stage iv grade two follicular lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Vidarabine . recurrent plasma cell myeloma diagnosis and donor
__label__1	study interventions are Trastuzumab . esophageal adenocarcinoma diagnosis and prior anthracycline or taxane
__label__1	study interventions are Fluorouracil . squamous cell carcinoma of the head and neck diagnosis and other significant disease that in the investigator opinion would exclude the subject from the trial
__label__1	study interventions are Antibodies, Monoclonal . stage iv adult diffuse large cell lymphoma diagnosis and any acute inter current infection that may interfere with planned protocol treatment participants with mycobacterium_avium will not be excluded from study entry chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are met
__label__1	study interventions are Carboplatin . childhood central nervous system germinoma diagnosis and stratum one nggct
__label__1	study interventions are Paclitaxel . triple negative breast neoplasms diagnosis and prior allotransplantation
__label__1	study interventions are Antibodies, Monoclonal . melanoma diagnosis and prior therapy with varlilumab or with an anti cdtwenty-seven antibody
__label__1	study interventions are Erlotinib Hydrochloride . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and patients who are felt to be poorly compliant
__label__1	study interventions are Cyclophosphamide . recurrent plasma cell myeloma diagnosis and hiv positive donors
__label__1	study interventions are Oxaliplatin . pancreatic adenocarcinoma diagnosis and patients must not have received prior erlotinib or other therapies that target egfr
__label__1	study interventions are Cyclosporins . recurrent childhood large cell lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Gemcitabine . her two positive breast cancer diagnosis and patients with signs or symptoms of brain metastasis must have ct or mri performed within four weeks prior to randomization to specifically exclude the presence of radiographically detected brain metastases
__label__1	study interventions are Gemcitabine . recurrent fallopian tube carcinoma diagnosis and history of tuberculosis or history of purified protein derivative_ppd positivity
__label__1	study interventions are Cyclophosphamide . contiguous stage ii adult diffuse mixed cell lymphoma diagnosis and patient scheduled for cord blood transplantation
__label__1	study interventions are Lenalidomide . contiguous stage ii grade two follicular lymphoma diagnosis and the development of erythema_nodosum if characterized by desquamating_rash while taking thalidomide or similar drugs
__label__1	study interventions are Fluorodeoxyglucose F18 . stage iii squamous cell carcinoma of the oropharynx diagnosis and patients with known syndromes that alter radiosensitivity
__label__1	study interventions are Vincristine . lymphoma diffuse large cell diagnosis and moderate and strong cypthreea inhibitors and cypthreea inducers are not permitted during the study
__label__1	study interventions are Mycophenolic Acid . recurrent childhood anaplastic large cell lymphoma diagnosis and donor or centers who will exclusively donate marrow
__label__1	study interventions are Dacarbazine . mixed oligoastrocytomas diagnosis and positive serological test results for hepatitis b
__label__1	study interventions are Sirolimus . glucagonoma diagnosis and patients who have received live attenuated vaccines within one week of start of everolimus and during the study
__label__1	study interventions are Lenograstim . stage iv adult burkitt lymphoma diagnosis and patients of child bearing potential unwilling to implement adequate birth control
__label__1	study interventions are Androgens . recurrent prostate cancer diagnosis and patients already meeting the criteria for metabolic syndrome as defined by the adult treatment panel iii criteria which requires three five parameters encompassing glucose control blood pressure lipids and waist circumference patients with two of the parameters at baseline will be allowed enrollment provided that one of those risk factors is hypertension greater_than equal_than 1three0 greater_than equal_than 8five mm hg
__label__1	study interventions are Cyclophosphamide . contiguous stage ii mantle cell lymphoma diagnosis and seropositive for human immunodeficiency virus hiv
__label__1	study interventions are Alemtuzumab . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and donor
__label__1	study interventions are seminal vesicle-sparing radical prostatectomy . prostate cancer diagnosis and unwilling to be randomized to either treatment arm
__label__1	study interventions are Prednisone . prostatic neoplasm diagnosis and have previously received aminoglutethimide
__label__1	study interventions are Vaccines . recurrent cutaneous cell non hodgkin lymphoma diagnosis and aplastic anemia
__label__1	study interventions are Pertuzumab . stage iia breast cancer diagnosis and nervous system disorder paresthesia peripheral motor neuropathy or peripheral sensory neuropathy greater_than equal_than grade two per the common terminology criteria for adverse events version doc ctcae doc
__label__1	study interventions are Niacinamide . renal cell carcinoma diagnosis and hypertension that is unable to be controlled with medications
__label__1	study interventions are Radiation . prior invasive malignancy except negative melanomatous skin cancer unless disease free for minimum of five years
__label__1	study interventions are Prednisolone hemisuccinate . recurrent adult lymphoblastic lymphoma diagnosis and uncontrolled infection
__label__1	study interventions are Fludarabine phosphate . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and patients with rapidly progressive aggressive nhl unless in minimal disease state
__label__1	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and any previous systemic exposure to pd one or pd lone inhibitor including durvalumab
__label__1	study interventions are Sirolimus . stage iic skin melanoma diagnosis and concomitant systemic treatment with corticosteroids anti histamine or non steroidal anti inflammatory drugs aspirin greater_than three hundred and twenty-five mg specific cyclooxygenase_cox two inhibitors are permitted
__label__1	study interventions are Cisplatin . gastric adenocarcinoma diagnosis and prior anti egfr antibody therapy cetuximab or treatment with small molecule egfr inhibitors erlotinib
__label__1	study interventions are Antibodies, Monoclonal . resectable squamous cell carcinoma of oral cavity diagnosis and known history of tuberculosis
__label__1	study interventions are Interferons . malignant peritoneal mesothelioma diagnosis and patients with new york heart association classification of iii or iv
__label__1	study interventions are Vincristine . stage iiib hodgkin lymphoma diagnosis and sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation and for thirty days after the last dose of chemotherapy
__label__1	study interventions are Methyl 5-aminolevulinate . treatment of lesions actinic_keratosis ak bcc scc bowens disease melanoma less_than twelve weeks prior to first pdt except physical treatments eg cryosurgery excision surgery that will not be allowed less_than six weeks prior to first pdt visit two
__label__1	study interventions are Gemcitabine . endometrial undifferentiated carcinoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with cediranib or olaparib
__label__1	study interventions are laboratory biomarker analysis . recurrent small lymphocytic lymphoma diagnosis and lactating or pregnant
__label__1	study interventions are Mycophenolic Acid . nodal marginal zone cell lymphoma diagnosis and receiving supplementary continuous oxygen
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and uncontrolled hypertension complication from hypertension myocardial infarctions unstable angina vascular disease or stroke within specified timeframe of the first dose of study treatment
__label__1	study interventions are MEK 162 therapy or molecularly targeted therapy . stage iiic melanoma diagnosis and patients who have at screening corrected qt interval using fridericia formula qtcf greater_than equal_than four hundred and fifty msec for males and qtcf greater_than equal_than four hundred and seventy for females
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and poorly controlled hypertension uncontrolled or severe cardiovascular disease or uncontrolled diabetes mellitus
__label__1	study interventions are Carboplatin . stage iii gastric cancer diagnosis and clinically significant autoimmune disease rheumatoid arthritis
__label__1	study interventions are Ondansetron . malignant childhood neoplasm diagnosis and potassium or calcium outside of reference range at screening
__label__1	study interventions are Ibrutinib . recurrent small lymphocytic lymphoma diagnosis and receipt of any investigational agents within fourteen days before the first dose of ibrutinib
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent breast carcinoma diagnosis and hypertension defined according to the following ineligibility criteria
__label__1	study interventions are Methylprednisolone . multiple myeloma diagnosis and for males during or for six months after completion of administration of the investigational drug
__label__1	study interventions are Laboratory Biomarker Analysis . stage oral cavity squamous cell carcinoma diagnosis and serum potassium magnesium or calcium levels in the following ranges
__label__1	study interventions are Docetaxel . stage iia breast cancer diagnosis and intrinsic lung disease resulting in dyspnea
__label__1	study interventions are Cortisone . stage iv prostate cancer diagnosis and patients with known brain metastases should be excluded
__label__1	study interventions are Fludarabine phosphate . stage adult diffuse small cleaved cell lymphoma diagnosis and marrow donors who have increased anesthetic risk
__label__1	study interventions are Vidarabine . stage childhood large cell lymphoma diagnosis and donor
__label__1	study interventions are Methylene diphosphonate . stage iv prostate cancer diagnosis and patient is unable to tolerate or has lifer threatening allergy to the radiopharmaceutical used for bone scan or eighteenf fluoride pet
__label__1	study interventions are Levoleucovorin . stage iiia rectal cancer diagnosis and neuropathy grade two or greater by nci ctcae v
__label__1	study interventions are Etoposide phosphate . stage iii grade three follicular lymphoma diagnosis and inability to comply with study or follow up testing and procedures
__label__1	study interventions are Carboplatin . head and neck cancer diagnosis and patients currently taking antiarrhythmic medications are excluded
__label__1	study interventions are Fluorouracil . recurrent rectal cancer diagnosis and inflammatory breast disease
__label__1	study interventions are Antibodies, Monoclonal . stage iv inflammatory breast carcinoma diagnosis and scleroderma
__label__1	study interventions are Lumpectomy . stage iib breast cancer diagnosis and chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within thirty days before registration
__label__1	study interventions are Iodine-131 anti-B1 antibody . non hodgkin lymphoma diagnosis and radiotherapy to greater_than twenty-five of the blood forming marrow
__label__1	study interventions are Bevacizumab . uncorrected hypokalemia or hypomagnesemia
__label__1	study interventions are Ixazomib . recurrent plasma cell myeloma diagnosis and impaired kidney function requiring dialysis or glomerular filtration rate gfr less_than fortyml min estimated or calculated
__label__1	study interventions are Cytology Specimen Collection Procedure . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Antibodies . recurrent grade three follicular lymphoma diagnosis and serious non malignant disease such as active infection or other condition which in the opinion of the investigator would compromise other protocol objectives
__label__1	study interventions are Dexamethasone acetate . mesothelioma diagnosis and patient has known chronic liver disease chronic active hepatitis and cirrhosis
__label__1	study interventions are Dexamethasone 21-phosphate . stage iv childhood lymphoblastic lymphoma diagnosis and patient has hypersensitivity to bortezomib boron or mannitol
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and absolute neutrophil count anc less_than one zero µl
__label__1	study interventions are Cabozantinib . urothelial carcinoma diagnosis and study
__label__1	study interventions are Hydrocortisone acetate . lymphoblastic lymphoma diagnosis and male and female patients of child bearing potential must agree to use an effective method of contraception approved by the investigator during the study
__label__1	study interventions are Carboplatin . hodgkin lymphoma diagnosis and patient that has received other investigational drugs within fourteen days of enrollment
__label__1	study interventions are Niacinamide . histologically or cytologically documented solid tumors diagnosis and evidence of active bleeding or bleeding diathesis
__label__1	study interventions are Open distal gastrectomy . gastric cancer diagnosis and indication of emr
__label__1	study interventions are Akt inhibitor MK2206 . recurrent squamous cell carcinoma of the nasopharynx diagnosis and radiotherapy equal_than less_than four weeks prior to registration
__label__1	study interventions are Temozolomide . malignant glioma diagnosis and serious non healing wound active ulcer or untreated bone fracture
__label__1	study interventions are Pioglitazone . stage ii oral cavity squamous cell carcinoma diagnosis and participant is an active alcoholic or consumes excessive amounts of alcohol per the following definitions
__label__1	study interventions are Tacrolimus . stage iv grade two follicular lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are AUY922 . adenocarcinoma of the pancreas diagnosis and ct scan of the brain is not required unless there is suspicion of cns metastases
__label__1	study interventions are Rituximab . lymphoma non hodgkin diagnosis and patients with treated brain metastasis must be off steroids or on tapering or stable doses of steroids and have completed radiation at least thirty days prior to registration for protocol therapy
__label__1	study interventions are Mycophenolic Acid . refractory hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Capecitabine . colorectal cancer metastatic diagnosis and anticoagulation with low molecular weight heparin lwmh is permitted
__label__1	study interventions are Succinylcholine . patients with history of inflammatory bowel disease including ulcerative colitis and crohn disease are excluded from this study as are patients with history of symptomatic disease rheumatoid arthritis systemic progressive sclerosis scleroderma systemic lupus erythematosus autoimmune vasculitis wegener granulomatosis central nervous system cns or motor neuropathy considered of autoimmune origin guillain_barre syndrome and myasthenia_gravis multiple sclerosis
__label__1	study interventions are Rituximab . recurrent adult lymphoblastic lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Aspirin . recurrent prostate carcinoma diagnosis and any unstable serious co existing medical conditions including but not limited to myocardial infarction coronary bypass surgery unstable angina cardiac arrhythmias clinically evident congestive heart failure or cerebrovascular accident within six months prior to screening
__label__1	study interventions are Folic Acid . stage ia pancreatic cancer diagnosis and anti mycobacterial
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent hodgkin lymphoma diagnosis and known human immunodeficiency syndrome hiv
__label__1	study interventions are Mycophenolate mofetil . lymphoplasmacytic lymphoma diagnosis and active central nervous system malignancy
__label__1	study interventions are Cyclosporins . myelodysplastic myeloproliferative neoplasms diagnosis and severe pulmonary insufficiency as defined by an adjusted diffusing capacity of less than forty of predicted value
__label__1	study interventions are Dexamethasone . solitary plasmacytoma or plasma cell leukaemia
__label__1	study interventions are Capecitabine . gastrointestinal neoplasms diagnosis and active infection requiring iv antibiotics
__label__1	study interventions are Icotinib . adenosquamous cell lung cancer diagnosis and history of neurologic or psychiatric disorders
__label__1	study interventions are Serine Proteinase Inhibitors . pancreatic cancer diagnosis and history of or current primary blood coagulation or bleeding disorders such as hemophilia
__label__1	study interventions are Genistein . pregnant or nursing woman
__label__1	study interventions are Temozolomide . refractory solid tumors in children diagnosis and lactating women must agree not to breast feed
__label__1	study interventions are Immunoglobulins . stage iv primary peritoneal cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to mlnone hundred and twenty-eight or bevacizumab
__label__1	study interventions are Dacarbazine . gliosarcoma diagnosis and simultaneous participation in other therapeutic clinical trials will not be allowed
__label__1	study interventions are Paclitaxel . adenocarcinoma of the gastroesophageal junction diagnosis and uncontrolled hyper hypothyroidism or hyper hypocorticism equal_than less_than six months prior to registration known toxicity of pembrolizumab
__label__1	study interventions are Erlotinib Hydrochloride . stage iii squamous cell carcinoma of the larynx diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to osi seven hundred and seventy-four or docetaxel including other drugs formulated with polysorbate eighty
__label__1	study interventions are Doxorubicin . stage iv grade three follicular lymphoma diagnosis and absolute cdfour count of less_than fifty cells mm three
__label__1	study interventions are Methylprednisolone . multiple myeloma diagnosis and current participation in any other interventional clinical trial
__label__1	study interventions are Ifosfamide . symptomatic brain metastases baseline ct scan is not required in asymptomatic subjects
__label__1	study interventions are Metronidazole . stage iic primary peritoneal cavity cancer diagnosis and any condition which in the investigator opinion deems the patient an unsuitable candidate to receive study drug any significant medical illness or abnormal laboratory finding that would in the investigator judgment increase the subject risk by participating in this study
__label__1	study interventions are Commercial Weight Loss Program (CWLP) . breast cancer diagnosis and congestive heart failure
__label__1	study interventions are Albumin-Bound Paclitaxel . angiosarcomas diagnosis and serious non healing wound active ulcer or untreated bone fracture
__label__1	study interventions are HS-10241 . solid tumor adult diagnosis and medical history of difficulty swallowing malabsorption or other chronic gastrointestinal disease or conditions that may hamper compliance and or absorption of the tested product
__label__1	study interventions are Antibodies, Monoclonal . adult grade iii lymphomatoid granulomatosis diagnosis and transfusion requirement red blood cells or platelets within fourteen days prior to baseline
__label__1	study interventions are Vaccines . human papillomavirus diagnosis and during menstrual period breastfeeding pregnancy pregnancy test positive or planned pregnant within seven month
__label__1	study interventions are I-131-CLR1404 . solid tumors diagnosis and prior radiation therapy or chemotherapy within two weeks of the start of the study
__label__1	study interventions are Fludarabine phosphate . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and marrow donors
__label__1	study interventions are Etoposide phosphate . recurrent grade one follicular lymphoma diagnosis and other serious medical conditions considered to represent contraindications to autologous stem cell transplant asct active coronary artery disease pulmonary dysfunction forced expiratory volume in one second fevone less_than seventy expected vital capacity less_than seventy expected diffusing capacity of the lung for carbon monoxide dlco less_than fifty patient on supplemental oxygen aids etc
__label__1	study interventions are Camptothecin . extensive stage small cell lung cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to crlxone hundred and one or topotecan
__label__1	study interventions are Vidarabine . stage iv adult immunoblastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Pancreatin . pancreatic ductal adenocarcinoma diagnosis and have history of bleeding coagulopathy
__label__1	study interventions are Docetaxel . sarcoma diagnosis and bp must be re assessed on two occasions that are separated by minimum of one hour on each of these occasions the mean of three readings sbp dbp values from each bp assessment must be less_than one50 ninety mmhg in order for subject to be eligible for the study
__label__1	study interventions are Diphenhydramine . prostate cancer diagnosis and major surgery open biopsy traumatic injury or radiotherapy within four weeks of the screening visit
__label__1	study interventions are Erlotinib Hydrochloride . neuroendocrine tumors diagnosis and any of the following concurrent severe and or uncontrolled medical conditions within twenty-four weeks of enrollment which could compromise participation in the study
__label__1	study interventions are Vorinostat . symptomatic ascites or pleural effusions
__label__1	study interventions are Fluorouracil . carcinoma squamous cell of head and neck diagnosis and active tuberculosis
__label__1	study interventions are Veliparib . stage iv primary peritoneal cancer diagnosis and known standard therapy for the patient disease that is potentially curative or definitely capable of extending life expectancy note
__label__1	study interventions are Mycophenolic Acid . stage iii mantle cell lymphoma diagnosis and donor
__label__1	study interventions are Mianserin . carcinoma non small cell lung diagnosis and other reasons of treatment discontinuation judged by investigators
__label__1	study interventions are Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI) . prostate cancer diagnosis and small metal implants clips cochlea implants etc
__label__1	study interventions are Carboplatin . stage iii non small cell lung cancer diagnosis and acquired immune deficiency syndrome aids based upon current centers for disease control cdc definition note however that human immunodeficiency virus hiv testing is not required for entry into this protocol
__label__1	study interventions are Antibodies, Monoclonal . recurrent salivary gland carcinoma diagnosis and patients with known active brain metastases should be excluded from this clinical trial patients with treated brain metastases stable for greater_than equal_than twelve weeks are eligible
__label__1	study interventions are Irinotecan . adenocarcinoma of the stomach diagnosis and active uncontrolled infection
__label__1	study interventions are Cytarabine . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and known hypersensitivity to thalidomide
__label__1	study interventions are Nicotine . stage ia non small cell lung cancer diagnosis and patients with drug and alcohol abuse
__label__1	study interventions are Fludarabine . recurrent adult lymphoblastic lymphoma diagnosis and karnofsky score less_than sixty or lansky score less_than fifty
__label__1	study interventions are Antibodies, Monoclonal . acoustic_schwannoma diagnosis and concurrent use of anti coagulant drugs not including prophylactic doses history of coagulopathy or evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are Lapatinib . breast cancer diagnosis and use of any prohibited medications concurrently with lapatinib therapy
__label__1	study interventions are Liposomal doxorubicin . liposarcoma diagnosis and certain medications that are associated with risk for qtc prolongation and or torsades de pointes although not prohibited should be avoided or replaced with medications that do not carry these risks if possible
__label__1	study interventions are Endothelial Growth Factors . stage iic ovarian cancer diagnosis and patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and or nutrition
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and women of childbearing potential must have negative pregnancy documented within one week of registration
__label__1	study interventions are Mycophenolic Acid . stage iv adult burkitt lymphoma diagnosis and eligible for high priority curative autologous transplant
__label__1	study interventions are Immunoglobulins . bladder cancer diagnosis and treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within twenty-eight days prior to enrollment
__label__1	study interventions are Citric Acid . recurrent plasma cell myeloma diagnosis and exceptions
__label__1	study interventions are Cisplatin . bladder cancer urothelial carcinoma diagnosis and active or untreated cns metastases as determined by computed tomography or magnetic resonance imaging evaluation during screening and prior radiographic assessments
__label__1	study interventions are Endothelial Growth Factors . stage iiic fallopian tube cancer diagnosis and note
__label__1	study interventions are Cisplatin . stage iia non small cell lung cancer diagnosis and patients with history of pneumonectomy
__label__1	study interventions are Antibodies, Monoclonal . recurrent ovarian carcinoma diagnosis and hypersensitivity to bevacizumab cyclophosphamide pembrolizumab or any of its excipients
__label__1	study interventions are Mitogens . ewing sarcoma diagnosis and known brain metastasis
__label__1	study interventions are Oxaliplatin . stage iic fallopian tube cancer diagnosis and patients with history of abdominal fistula or perforation within the past twelve months
__label__1	study interventions are BB 1101 . lymphoma non hodgkin diagnosis and excluded
__label__1	study interventions are Laboratory Biomarker Analysis . transformed recurrent non hodgkin lymphoma diagnosis and pregnant women
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and part b
__label__1	study interventions are Interferons . colorectal cancer diagnosis and major surgery within two weeks before study entry
__label__1	study interventions are FFDM Alone . breast cancer diagnosis and subjects with unknown clinical status
__label__1	study interventions are Paclitaxel . non small cell lung cancer diagnosis and prisoners or subjects who are involuntarily_incarcerated
__label__1	study interventions are Methotrexate . mediastinal neoplasms diagnosis and known severe allergy to foreign proteins
__label__1	study interventions are Trastuzumab . breast neoplasms diagnosis and disease free interval from completion of adjuvant or neoadjuvant systemic non hormonal treatment to recurrence less than or equal to less_than equal_than six months
__label__1	study interventions are Carboplatin . triple negative breast neoplasms diagnosis and for patients who agree to participate in pet mr imaging
__label__1	study interventions are Liposomal doxorubicin . concomitant malignancies or previous malignancies exception made for adequately treated basal or squamous cell carcinoma of the skin
__label__1	study interventions are pp65-shLAMP DC with GM-CSF . malignant glioma diagnosis and patients treated on any other therapeutic clinical protocols within thirty days prior to study entry
__label__1	study interventions are Antibodies, Monoclonal . stage iva hepatocellular carcinoma diagnosis and concurrent enrollment in another clinical study unless it is an observational non interventional clinical study or the follow up period of an interventional study is excluded
__label__1	study interventions are Angiopeptin . carcinoid tumors diagnosis and patients previously treated with chemotherapy loco regional therapy chemoembolization or interferon with last administration less than six weeks prior to randomization or with toxicity not resolved to less or equal grade one at randomization
__label__1	study interventions are Antibodies . stage iv adult diffuse large cell lymphoma diagnosis and qtc prolongation greater_than five hundredmsec or other significant ecg abnormality noted within fourteen days of registration
__label__1	study interventions are Sirolimus . stage iiic ovarian cancer diagnosis and any condition which in the investigator opinion deems the patient an unsuitable candidate to receive study drug any significant medical illness or abnormal laboratory finding that would in the investigator judgment increase the subject risk by participating in this study
__label__1	study interventions are Axitinib . neurofibromatosis type two diagnosis and impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of axitinib ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome or small bowel resection
__label__1	study interventions are Sirolimus . kidney cancer diagnosis and in addition hiv positive patients receiving combination anti retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with some of these agents
__label__1	study interventions are Deoxyglucose . breast cancer diagnosis and evidence of hypoglycemia clinically significant renal disease clinically significant liver disease other than liver metastases diabetes mellitus gastrointestinal disorder that could affect absorption or elimination of orally administered medications or obstructive uropathy with significant post void residual during the past five years
__label__1	study interventions are automatic speech processing tool . head and neck cancer diagnosis and patients with previous speech disorders ie stuttering
__label__1	study interventions are Glycine . multiple myeloma diagnosis and patient with serious medical of psychiatric illness likely to interfere with participation on this clinical study
__label__1	study interventions are Paclitaxel . primary peritoneal cancer diagnosis and previous abdominal or pelvic radiotherapy
__label__1	study interventions are Doxycycline . cutaneous cell lymphoma diagnosis and lack of measurable disease
__label__1	study interventions are Metformin . stage iiib ovarian epithelial cancer diagnosis and uncontrolled intercurrent illness including but not limited to ongoing or active major infection unstable angina pectoris or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Bevacizumab . kidney renal cell cancer diagnosis and bevacizumab specific exclusions
__label__1	study interventions are Cyclosporine . stage adult diffuse mixed cell lymphoma diagnosis and active or recent prior six months invasive fungal infection without id consult and approval
__label__1	study interventions are Antibodies . adult oligodendroglioma diagnosis and patients who received non cytotoxic drug therapy must be off treatment for at least fourteen days prior to registration prior treatment with anti vascular endothelial growth factor vegf targeted agents amg three hundred and eighty-six therapy or other molecules that inhibit angiopoietins or tek tyrosine kinase endothelial tietwo receptor including but not limited to xl 8two0 xl one hundred and eighty-four cabozantinib malate and cvx sixty pf four million, eight hundred and fifty-six thousand, eight hundred and eighty-four is not allowed regardless of time frame
__label__1	study interventions are Folic Acid . stage ivb rectal cancer diagnosis and patients with fractures secondary to metastatic disease are eligible after appropriate radiotherapy
__label__1	study interventions are CK Stereotactic Accelerated Partial Breast Irradiation . patients with multicentric carcinoma or with other clinically or radiographically suspicious areas in the ipsilateral breast unless confirmed to be negative for malignancy by biopsy
__label__1	study interventions are Gemcitabine . solid tumors or mantle cell lymphoma diagnosis and the patient has concomitant uncontrolled and or chronic infection or severe systemic disease
__label__1	study interventions are Progesterone . stage ii breast cancer diagnosis and subjects must not have allergies to any compounds similar to cdb four thousand, one hundred and twenty-four
__label__1	study interventions are Paclitaxel . ovarian cancer diagnosis and known history of clinically significant liver disease including active viral hepatitis and cirrhosis
__label__1	study interventions are Pancrelipase . stage iii pancreatic cancer diagnosis and patients may not be receiving nor have received any other investigational agents within twenty-eight days prior to registration
__label__1	study interventions are Sorafenib . stage ivc squamous cell carcinoma of the lip and oral cavity diagnosis and patients who have had chemotherapy or radiotherapy within three months prior to entering the study
__label__1	study interventions are MRI-guided Transurethral Ultrasound Ablation . prostate cancer diagnosis and history of acute urinary retention within the last twelve months
__label__1	study interventions are Estradiol . breast cancer diagnosis and need for current chronic corticosteroid therapy
__label__1	study interventions are Oxycodone . stomatitis diagnosis and unwilling or unable to follow protocol requirements
__label__1	study interventions are Doxorubicin . breast cancer diagnosis and common toxicity criteria version doc
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and concurrent or history of another malignancy less_than five years
__label__1	study interventions are Albumin-Bound Paclitaxel . other concurrent anticancer agents or therapies
__label__1	study interventions are musculoskeletal complications management/prevention . noncontiguous stage ii mantle cell lymphoma diagnosis and doc
__label__1	study interventions are Dynamic Contrast-Enhanced Magnetic Resonance Imaging . adult grade ii meningioma diagnosis and renal impairment glomerular filtration rate gfr less_than sixty ml min doc threem two or history of existing nephrogenic systemic fibrosis nsf
__label__1	study interventions are Cadexomer iodine . stage ivb follicular thyroid cancer diagnosis and known intraluminal metastatic lesion with risk of bleeding
__label__1	study interventions are Antibodies . ovarian clear cell cystadenocarcinoma diagnosis and other than low molecular weight heparin lmwh medication must be stopped before time of registration if patient has recently been on anti coagulants other than lmwh patient must have international normalized ratio inr equal_than less_than two
__label__1	study interventions are nutrition /swallowing intervention . head and neck cancer diagnosis and allergy or intolerance to any enteral nutritional supplements in current use
__label__1	study interventions are Temozolomide . recurrent childhood ependymoma diagnosis and patients with an inability to return for follow up visits or obtain follow up studies required to assess toxicity to therapy
__label__1	study interventions are Vaccines . contiguous stage ii adult burkitt lymphoma diagnosis and investigational research products or allergy treatment with antigens injections from thirty days prior to participation in the trial and up to fourteen days after the second vaccination day seventy post hct
__label__1	study interventions are photodynamic therapy . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and platelet count less_than one hundred zero
__label__1	study interventions are Paclitaxel . stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and due to potential toxicity associated with study therapy particularly with paclitaxel patients with peripheral neuropathy greater_than grade one will be excluded from study participation
__label__1	study interventions are Fludarabine . recurrent adult diffuse mixed cell lymphoma diagnosis and women of childbearing potential who are pregnant beta hcg positive or breast feeding
__label__1	study interventions are Antibodies, Monoclonal . osteosarcoma diagnosis and note subjects with less_than grade two neuropathy are an exception to this criterion and may qualify for the study
__label__1	study interventions are Oxaliplatin . unresectable adenocarcinoma of the esophagus diagnosis and presence of greater_than grade two neuropathy
__label__1	study interventions are Mycophenolic Acid . recurrent cutaneous cell non hodgkin lymphoma diagnosis and positive crossmatch between donor and recipient
__label__1	study interventions are Cyclosporine . recurrent childhood anaplastic large cell lymphoma diagnosis and patients who are human immunodeficiency virus hiv positive
__label__1	study interventions are Doxorubicin . breast cancer diagnosis and these medications are not permitted while on the study except for the use of tamoxifen as described in the protocol
__label__1	study interventions are Nitrogen Mustard Compounds . refractory plasma cell myeloma diagnosis and infection with human immunodeficiency virus hiv
__label__1	study interventions are Citric Acid . recurrent primary peritoneal carcinoma diagnosis and patients with intra cardiac defibrillators or permanent pacemakers
__label__1	study interventions are Lenalidomide . noncontiguous stage ii mantle cell lymphoma diagnosis and residual grade three or grade four non hematologic toxicity after asct
__label__1	study interventions are Sirolimus . fourteen days of prior antimyeloma agents including thalidomide or lenalidomide
__label__1	study interventions are Antibodies, Monoclonal . recurrent grade two follicular lymphoma diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are eligible if their hiv is under adequate control with an antiretroviral regimen that has been stable for greater_than equal_than four weeks as long as the cdfour count is greater_than three hundred appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated patients on zidovudine or stavudine would not be eligible
__label__1	study interventions are Mycophenolate mofetil . hepatosplenic cell lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Cognitive Intervention . malignant neoplasm diagnosis and have practiced_yoga greater_than equal_than one day week within the three months prior to enrolling in the study
__label__1	study interventions are 4D PET-CT Scan . pancreatic carcinoma diagnosis and hypersensitivity to fluorineeighteen fludeoxyglucose fdg
__label__1	study interventions are Lenograstim . stage iii adult hodgkin lymphoma diagnosis and hiv seropositive
__label__1	study interventions are Capecitabine . advanced solid tumors diagnosis and serious active infection including active hepatitis or hepatitis or infection requiring parenteral antibiotics
__label__1	study interventions are Paclitaxel . cancer diagnosis and the patient has any condition including the presence of laboratory abnormalities that places the patient at unacceptable risk if he she were to participate in the study
__label__1	study interventions are Antibodies . stage iiia fallopian tube cancer diagnosis and any tissue biopsy such as core biopsy within seven days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Leuprolide . metastatic breast cancer diagnosis and evidence of metastases involving more than one third of the liver on sonogram or ct
__label__1	study interventions are Docetaxel . prostate neoplasms diagnosis and human immunodeficiency virus hiv positivity
__label__1	study interventions are Avelumab . nasopharyngeal cancer diagnosis and patient has received prior immunotherapy with inhibitors of pd one pd lone axis
__label__1	study interventions are Docetaxel . nsclc non small cell lung cancer diagnosis and history of organ allograft
__label__1	study interventions are Carboplatin . stage iiic uterine corpus cancer diagnosis and history of chronic or active hepatitis
__label__1	study interventions are Antibodies, Monoclonal . muscle invasive bladder cancer diagnosis and prior exposure to
__label__1	study interventions are Dacarbazine . carcinoma non small cell lung diagnosis and patients who have brain metastases at initial presentation are eligible and do not need to demonstrate one month of stable scans
__label__1	study interventions are Medroxyprogesterone Acetate . metastatic renal cell carcinoma diagnosis and severe pulmonary hepatic or renal disease potentially aggravated by treatment
__label__1	study interventions are Erlotinib Hydrochloride . recurrent midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and human immunodeficiency virus hiv positive patients receiving combination anti retroviral therapy are excluded from the study
__label__1	study interventions are Mycophenolate mofetil . stage adult immunoblastic large cell lymphoma diagnosis and fertile men or women unwilling to use contraceptives during and for up to twelve months post treatment
__label__1	study interventions are Sirolimus . recurrent inverted papilloma of the paranasal sinus and nasal cavity diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in study
__label__1	study interventions are Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain . previous or current cancer
__label__1	study interventions are Gemcitabine . endometrial cancer diagnosis and known allergic reaction or hypersensitivity to gemcitabine hydrochloride
__label__1	study interventions are Vidarabine . untreated chronic lymphocytic leukemia or diffuse large cells lymphoma patients diagnosis and weight over one hundred and twenty kg
__label__1	study interventions are Antibodies . signet ring adenocarcinoma of the colon diagnosis and prior treatment with egfr targeting therapies
__label__1	study interventions are Mammosite ML . ductal carcinoma in situ diagnosis and men
__label__1	study interventions are Dexamethasone . lymphoma diagnosis and any clinical or cytological diagnosis of cns involvement
__label__1	study interventions are Azacitidine . lymphoma diagnosis and patients with active hepatitis hepatitis or hepatitis infection
__label__1	study interventions are Antibodies, Monoclonal . recurrent nasopharyngeal keratinizing squamous cell carcinoma diagnosis and hiv positive patients with normal immune function cdfour count greater_than two hundred are eligible if there are no drug interactions with temsirolimus or cetuximab patients with impaired immune function are ineligible due to the risk of additional immunosuppression from temsirolimus therapy
__label__1	study interventions are Epothilones . stage iii ovarian epithelial cancer diagnosis and no history of allergic reaction attributed to compounds of similar chemical or biological composition to cremophor or study drugs
__label__1	study interventions are Dexamethasone . relapsed or refractory multiple myeloma diagnosis and any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he she were to participate in the study or confounds the ability to interpret data from the study
__label__1	study interventions are Coal Tar . patient who received personalized therapeutic treatment based on molecular anomaly during the treatment period prior to the winther directed treatment defining the pfsone
__label__1	study interventions are Fluorouracil . colon cancer diagnosis and history of abdominal fistula or gastrointestinal perforation within six months prior to day one of folfiri positive bevacizumab initiation
__label__1	study interventions are Fludarabine . noncutaneous extranodal lymphoma diagnosis and donor
__label__1	study interventions are E7070 . carcinoma renal cell diagnosis and legal incapacity
__label__1	study interventions are Everolimus . salivary gland squamous cell carcinoma diagnosis and patients who have had major surgery or significant traumatic injury within four weeks of start of study drug patients who have not recovered from the side effects of any major surgery defined as requiring general anesthesia or patients that may require major surgery during the course of the study
__label__1	study interventions are Melphalan . renal cell cancer diagnosis and for registration
__label__1	study interventions are Serotonin Uptake Inhibitors . patients with history of any cancer cancer diagnosis recorded in the tumor registries anytime before the first antidepressant prescription recorded during the study period
__label__1	study interventions are Antibodies, Monoclonal . stage iv melanoma diagnosis and interferons used in the adjuvant setting are allowed phase one or two component
__label__1	study interventions are Estradiol 3-benzoate . cancer diagnosis and presence of hepatitis surface antigen hbsag or positive hepatitis antibody at screening or within three months prior to first dose of study treatment
__label__1	study interventions are Antibodies . adult gliosarcoma diagnosis and at least twenty-eight days since any prior surgery
__label__1	study interventions are pharmacological study . unspecified adult solid tumor protocol specific diagnosis and history of chronic hepatitis
__label__1	study interventions are Carboplatin . squamous cell cancer diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are Vinblastine . non small cell lung cancer diagnosis and psychological familial social or geographical situations limiting the compliance with the study requirements
__label__1	study interventions are Cisplatin . stage iiic vulvar cancer diagnosis and known hiv positive patients receiving combination antiretroviral therapy are ineligible however hiv testing is not required for study enrollment and optional
__label__1	study interventions are Methylprednisolone Hemisuccinate . myeloma diagnosis and plasma cell leukemia
__label__1	study interventions are FOLFOX6 . esophageal squamous cell carcinoma diagnosis and psychiatric or addictive disorders that preclude obtaining informed consent or adherence to protocol
__label__1	study interventions are Methylprednisolone Hemisuccinate . malignant tumor of breast diagnosis and patient should also avoid close contact with others who have received live attenuated vaccines
__label__1	study interventions are Fluorouracil . stage iia esophageal cancer diagnosis and patients with history of hypertension must measure less_than one hundred and fifty ninety mmhg and be on stable regimen of anti hypertensive therapy patients with history of hypertension who have blood pressure of one hundred and fifty ninety mmhg or greater are not eligible patients with history of hypertension who have blood pressure of less_than one hundred and fifty ninety mmhg but are not on stable regimen of anti hypertensive therapy are not eligible
__label__1	study interventions are Melphalan . multiple myeloma relapsed diagnosis and prior solid organ transplant
__label__1	study interventions are Thalidomide . squamous cell carcinoma diagnosis and any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he she were to participate in the study or confounds the ability to interpret data from the study
__label__1	study interventions are Camptothecin . metastatic renal cell carcinoma diagnosis and any clinically significant cardiac disease defined as nyha class iii or iv
__label__1	study interventions are Tamoxifen . primary peritoneal serous adenocarcinoma diagnosis and patients with previous or current malignancy at other sites should be excluded with the exception of
__label__1	study interventions are Fludarabine phosphate . stage iii childhood small noncleaved cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Buparlisib . nevoid basal cell carcinoma syndrome diagnosis and documented cardiomyopathy
__label__1	study interventions are Nintedanib . carcinoma non small cell lung diagnosis and significant cardiovascular disease uncontrolled hypertension myocardial infarction within six months unstable angina serious cardiac arrhythmia greater_than two new york heart association nyha grade two congestive heart failure
__label__1	study interventions are Vidarabine . recurrent adult cell leukemia lymphoma diagnosis and karnofsky performance status less_than sixty for adult patients
__label__1	study interventions are Carboplatin . recurrent cervical cancer diagnosis and known seropositive for hiv antibody
__label__1	study interventions are Antibodies . uterine cervical cancer diagnosis and discontinuation of monitoring and or loss of patient follow up for more than two months
__label__1	study interventions are Dexamethasone . non hodgkin lymphoma diagnosis and subjects in whom the required program of oral and intravenous fluid hydration is contraindicated due to pre existing pulmonary cardiac or renal impairment
__label__1	study interventions are Cadexomer iodine . recurrent thyroid gland carcinoma diagnosis and ophthalmological conditions as follows
__label__1	study interventions are Pomalidomide . multiple myeloma diagnosis and cockcroft gault estimation of creatinine clearance
__label__1	study interventions are Sirolimus . neuroendocrine tumors diagnosis and pregnant or nursing lactating women
__label__1	study interventions are Gamma Medica Instruments-LumaGem 3200S . breast cancer diagnosis and suspected that breasts will not fit in the mbi field of view
__label__1	study interventions are Fludarabine phosphate . contiguous stage ii grade three follicular lymphoma diagnosis and donor
__label__1	study interventions are Antibodies, Monoclonal . metastatic castrate resistant prostate cancer diagnosis and patients with known brain metastases will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Trastuzumab . lung neoplasms diagnosis and any evidence of severe or uncontrolled systemic disease such as clinically significant cardiovascular including arrhythmias pulmonary hepatic renal or metabolic disease wound healing disorders ulcers or bone fractures
__label__1	study interventions are Immunoglobulins . ovarian granulosa cell tumor diagnosis and patients who have major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to the first date of treatment on this study or anticipate the need for major surgical procedure during the course of the study patients with placement of vascular access device or core biopsy within seven days prior to the first date of treatment on this study
__label__1	study interventions are Gemcitabine . symptomatic brain metastasis
__label__1	study interventions are Dasatinib . lung cancer diagnosis and itraconazole ketoconazole miconazole voriconazole amprenavir atazanavir fosamprenavir indinavir nelfinavir ritonavir ciprofloxacin clarithromycin diclofenac doxycycline enoxacin imatinib isoniazid ketamine nefazodone nicardipine propofol quinidine telithromycin
__label__1	study interventions are Pemetrexed . stage iv non small cell lung cancer diagnosis and patients who are known to be human immunodeficiency positive hiv positive and are on combination antiretroviral therapy are ineligible
__label__1	study interventions are Fluorouracil . stage ii esophageal cancer diagnosis and patients with known hypersensitivity to any of the components of oxaliplatin
__label__1	study interventions are Prednisolone phosphate . diffuse large cell lymphoma diagnosis and previous treatment with chemotherapy or radiotherapy
__label__1	study interventions are Irinotecan . colorectal cancer diagnosis and evidence of clinically detectable ascites on day
__label__1	study interventions are Dexamethasone acetate . ph positive lymphoblastic lymphoma
__label__1	study interventions are Doxorubicin . stage iv soft tissue sarcoma diagnosis and known history of human immunodeficiency virus hiv infection testing not mandatory note
__label__1	study interventions are 6-month Icotinib . lung cancer diagnosis and known human immunodeficiency virus hiv infection
__label__1	study interventions are Levoleucovorin . rectal adenocarcinoma diagnosis and prior treatment with an investigational compound being tested in this study poly_adp ribose_polymerase parp inhibitor
__label__1	study interventions are Liposomal doxorubicin . pancreatic cancer diagnosis and evidence of duodenal invasion on ct scan mri or endoscopy
__label__1	study interventions are Educational Intervention . acth secreting pituitary adenoma diagnosis and unable to provide consent
__label__1	study interventions are Cisplatin . lung cancer diagnosis and patients who have received prior chemotherapy for nsclc
__label__1	study interventions are Anastrozole . solid tumors diagnosis and age under eighteen years
__label__1	study interventions are Fludarabine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are S-1 . adenocarcinoma esophagogastric junction diagnosis and active or uncontrolled bacterial viral or fungal infection that requires systemic treatment
__label__1	study interventions are Etoposide . sarcoma diagnosis and anemia hb less than eleven gm dl or thrombocytopenia platelets less than one hundred zero micro l
__label__1	study interventions are Topotecan . mediastinal lymphadenopathy parenchymal liver metastasis or pleural effusion proven or suspected to be due to cancer
__label__1	study interventions are Gemcitabine . duct cell adenocarcinoma of the pancreas diagnosis and presence of central nervous system or brain metastases
__label__1	study interventions are Antibodies . solid tumor diagnosis and current treatment with therapeutic anticoagulants
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and patients with previous evidence of hypersensitivity to sorafenib bortezomib boron or mannitol
__label__1	study interventions are Ergocalciferols . lymphoma diagnosis and radiotherapy involving the mandible
__label__1	study interventions are Niacinamide . pancreatic adenocarcinoma diagnosis and contraindication to antiangiogenic agents including
__label__1	study interventions are HIV Protease Inhibitors . stage ia pancreatic cancer diagnosis and neuroleptic
__label__1	study interventions are Epstein-Barr virus-specific adoptive T-cells immunotherapy . other cancer in the past five years except for carcinoma in situ of the cervix or bladder or non melanomatous skin cancer
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and patients with uncontrolled hypertension diastolic greater_than ninety-five mmhg
__label__1	study interventions are Cyclosporins . recurrent adult cell leukemia lymphoma diagnosis and positive crossmatch between donor and recipient
__label__1	study interventions are Sirolimus . stage iiib non small cell lung cancer diagnosis and cardiac arrhythmia
__label__1	study interventions are Doxorubicin . liver neoplasms diagnosis and have portal or hepatic vein invasion thrombosis
__label__1	study interventions are Everolimus . recurrent head and neck carcinoma diagnosis and women of child bearing potential who are biologically able to conceive or men who are able to father child not employing two forms of highly effective contraception
__label__1	study interventions are Immunoglobulins . stage iva oropharyngeal squamous cell carcinoma diagnosis and hiv positive patients with normal immune function cdfour count greater_than two hundred are eligible if there are no drug interactions with temsirolimus or cetuximab patients with impaired immune function are ineligible due to the risk of additional immunosuppression from temsirolimus therapy
__label__1	study interventions are Docetaxel . breast cancer diagnosis and current therapy with any hormonal agent such as raloxifene tamoxifen or other selective estrogen receptor modulators_serms either for osteoporosis or prevention
__label__1	study interventions are Paclitaxel . hertwo negative breast cancer diagnosis and patients with known hypersensitivity to any of the components of romidepsin or who have had hypersensitivity reactions to paclitaxel
__label__1	study interventions are BI 836845 . neoplasms diagnosis and patients that are to undergo biospy should not have history of hereditary bleeding disorder as judged by the investigator
__label__1	study interventions are Cyclosporins . recurrent cutaneous cell non hodgkin lymphoma diagnosis and female patient must have negative serum pregnancy test all women of child bearing potential must have test performed
__label__1	study interventions are Succinylcholine . stage iiib ovarian cancer diagnosis and no poorly differentiated subtypes including papillary serous clear cell or other international federation of gynecology and obstetrics_figo grade three lesions
__label__1	study interventions are Retinol acetate . stage iv adult diffuse mixed cell lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to at one hundred and one or other agents used in study
__label__1	study interventions are Capecitabine . symptomatic brain metastasis
__label__1	study interventions are Immunoglobulins . stage iv skin melanoma diagnosis and failure to fully recover from acute reversible effects of prior chemotherapy regardless of interval since last treatment
__label__1	study interventions are Dexamethasone acetate . non melanoma skin cancer ductal carcinoma in situ dcis or carcinoma in situ of the cervix
__label__1	study interventions are Doxorubicin . epstein_barr virus associated non hodgkin lymphoma diagnosis and patients with mycobacterium_avium will not be excluded
__label__1	study interventions are Vaccines . stage iiib melanoma diagnosis and nursing women
__label__1	study interventions are Motexafin gadolinium . lung cancer diagnosis and sexually active male or female of childbearing potential unwilling to use adequate contraceptive protection
__label__1	study interventions are Pembrolizumab . esophageal cancer diagnosis and currently receiving any other investigational agents has participated in study of an investigational agent or use of an investigational device within four weeks of the first dose of pembrolizumab
__label__1	study interventions are Letrozole . breast cancer diagnosis and metastatic disease
__label__1	study interventions are Crizotinib . stage ii childhood anaplastic large cell lymphoma diagnosis and patients who weigh less_than ten kg are not eligible
__label__1	study interventions are Antibodies . neoplasm gynecologic diagnosis and patient participating in another clinical trial investigating treatment during the study and within thirty days prior to first study treatment administration
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and unstable angina pectoris
__label__1	study interventions are Ifosfamide . other malignancy except adequately treated carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
__label__1	study interventions are Fluorouracil . colorectal carcinoma diagnosis and the participant has received previous therapy with any agent that targets vascular endothelial growth factor vegf or vegf receptor two vegfr two including multi targeted tyrosine kinase inhibitors
__label__1	study interventions are Lenalidomide . lymphoma diagnosis and patients with active hepatitis infection not including patients with prior hepatitis vaccination or positive serum hepatitis antibody
__label__1	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and evidence of hepatic synthetic dysfunction or total bilirubin greater_than twox or ast greater_than threex uln
__label__1	study interventions are Immunoglobulin G . ovarian serous surface papillary adenocarcinoma diagnosis and any of the following as this regimen may be harmful to developing fetus or nursing child
__label__1	study interventions are Fluorouracil . stage iva gallbladder cancer diagnosis and active uncontrolled bleeding
__label__1	study interventions are Succinylcholine . stage iv fallopian tube cancer diagnosis and uncontrolled hypertension defined as systolic greater_than one hundred and fifty mm hg or diastolic greater_than ninety mm hg
__label__1	study interventions are quality-of-life assessment . stage lymphoepithelioma of the nasopharynx diagnosis and due to risks of anesthesia
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer part diagnosis and past medical history of interstitial lung disease drug induced interstitial lung disease radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease
__label__1	study interventions are Liposomal doxorubicin . primary peritoneal neoplasm diagnosis and requires administration of prohibited medication or treatment including
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and known active central nervous system metastases as indicated by clinical symptoms cerebral edema and or progressive growth patients with history of central nervous system cns metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least four weeks before first dose of trial treatment and have not required high dose steroid treatment in the last four weeks
__label__1	study interventions are Lenograstim . lymphoma non hodgkin diagnosis and patients of child bearing potential unwilling to implement adequate birth control
__label__1	study interventions are Antibodies, Monoclonal . stage iia fallopian tube cancer diagnosis and patients with clinically significant cardiovascular disease this includes
__label__1	study interventions are Maleic acid . stage iv non small cell lung cancer diagnosis and patients taking medications with narrow therapeutic indices that are metabolized by cytochrome pfour hundred and fifty cypfour hundred and fifty including warfarin sodium coumadin are ineligible except low dose warfarin for prophylaxis for central catheters
__label__1	study interventions are Cetuximab . recurrent mucoepidermoid carcinoma of the oral cavity diagnosis and patients may not be receiving any other investigational agents in addition patients must not have received investigational treatment equal_than less_than thirty days prior to registration
__label__1	study interventions are ABT-510 . head and neck cancer diagnosis and patient may have received palliative radiation within the past two weeks but not to the biopsy site
__label__1	study interventions are Lenvatinib . biliary tract cancer diagnosis and prolonged qt qtc interval qtcf greater_than four hundred and eighty ms
__label__1	study interventions are BEZ235 . renal cancer diagnosis and patients who have received attenuated live vaccines within one week of study entry
__label__1	study interventions are Uterine artery embolization (UAE) . myomas diagnosis and active pelvic infection
__label__1	study interventions are Sirolimus . peripheral cell lymphoma diagnosis and at least three half lives must have elapsed after the last dose of gvhd meds
__label__1	study interventions are Cisplatin . stage iv gastric cancer diagnosis and receiving concomitant treatment with other fluoropyrimidine drug or flucytosine drug
__label__1	study interventions are Vaccines . glioblastoma diagnosis and clinically relevant autoimmune diseases with the exception of thyroid diseases
__label__1	study interventions are TMZ . glioma diagnosis and phase ii part only
__label__1	study interventions are Bupropion . head and neck cancer diagnosis and pre existing tourette syndrome
__label__1	study interventions are Pembrolizumab . recurrent thyroid gland carcinoma diagnosis and male subjects
__label__1	study interventions are Intraoperative Electron Radiotherapy . carcinoma breast stage diagnosis and prior breast malignancy or other malignancy if metastatic or with expected survival of less_than five years
__label__1	study interventions are Mitoxantrone . granulocytic sarcoma diagnosis and patients who have received immunotherapy of any type within the past four weeks prior to initiation of cpi six hundred and thirteen treatment
__label__1	study interventions are Tacrolimus . refractory plasma cell myeloma diagnosis and all patients receiving antifungal therapy voriconazole posaconazole or fluconazole and who are then randomized to arm three must have rapamycin reduced according to the standard practice of antifungal therapy guidelines
__label__1	study interventions are Endothelial Growth Factors . stage iiia fallopian tube cancer diagnosis and patients with invasive procedures or anticipation of invasive procedures within the following timeframes as defined below
__label__1	study interventions are Cyclophosphamide . stage mantle cell lymphoma diagnosis and treatment with any known non marketed drug substance or experimental therapy within four weeks prior to enrollment or currently participating in any other interventional clinical study for nhl or any other illness except observational prevention and or registry trials
__label__1	study interventions are Antibodies . fallopian tube endometrioid adenocarcinoma diagnosis and patients who have received more than one previous regimen of chemotherapy maintenance is not considered second regimen
__label__1	study interventions are Bevacizumab . breast cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to day zero
__label__1	study interventions are Placebo . received antitumor radiation therapy except for the stage iiia ntwo patients who received adjuvant radiotherapy after surgery
__label__1	study interventions are Fludarabine . stage iv adult diffuse large cell lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Irinotecan . brain tumors diagnosis and pregnant or breast feeding females are excluded because of the potential harmful effects of sorafenib and irinotecan on developing fetus or nursing child
__label__1	study interventions are Doxorubicin . metastatic breast cancer diagnosis and second primary malignancy that is clinically detectable at the time of consideration for study enrollment
__label__1	study interventions are Fludarabine . myeloma diagnosis and patients who have received alemtuzumab within eight weeks of the transplant admission or who have recently received horse or rabbit ant thymocyte_globulin and have an atg level of greater_than or equal_than two ugm ml
__label__1	study interventions are Letrozole . breast cancer diagnosis and history of acute pancreatitis within one year of study entry
__label__1	study interventions are Pemetrexed . second active primary malignancy except in situ carcinoma of the cervix adequately treated non melanomatous carcinoma of the skin low grade gleason score less than or equal to six localized adenocarcinoma of the prostate or other malignancy treated at least two years previously with no evidence of recurrence
__label__1	study interventions are Goserelin . prostate neoplasms diagnosis and patients who are receiving any other investigational therapy
__label__1	study interventions are Letrozole . stage iv breast cancer diagnosis and active infection
__label__1	study interventions are Dexamethasone 21-phosphate . urothelial carcinoma diagnosis and prior systemic chemotherapy or immunotherapy but prior local intravesical chemotherapy or immunotherapy was allowed
__label__1	study interventions are Imatinib Mesylate . advanced or metastatic cholangiocellular carcinoma and bile duct diagnosis and patients with any significant history of non compliance to medical regimens or with inability to grant reliable informed consent
__label__1	study interventions are Carboplatin . ovarian clear cell cystadenocarcinoma diagnosis and pregnant or nursing women are excluded from this study
__label__1	study interventions are Docetaxel . metastatic breast cancer diagnosis and an interval of less_than twelve months after the last dose of vinca_alkaloid or taxane chemotherapy for treatment of early stage non metastatic disease
__label__1	study interventions are breast exam and questionaire . breast cancer diagnosis and delayed reconstruction no reconstruction immediately after mastectomy
__label__1	study interventions are Culdocentesis . stage iv ovarian cancer diagnosis and unable to give informed consent
__label__1	study interventions are NPI-0052 . multiple myeloma diagnosis and active uncontrolled bacterial or fungal infection requiring systemic therapy infection requiring parenteral antibiotics
__label__1	study interventions are Capecitabine . malignant neoplasm of stomach diagnosis and pregnant or breast feeding
__label__1	study interventions are Pembrolizumab . follicular lymphomas diagnosis and seasonal influenza vaccines for injection are generally_inactivated flu vaccines and are allowed however intranasal influenza vaccines flu_mist are live attenuated vaccines and are not allowed
__label__1	study interventions are Docetaxel . undifferentiated ovarian carcinoma diagnosis and this criterion applies only to the patients enrolled before august twenty-nine two thousand and eleven and those enrolled after this date electing to receive bevacizumab patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Oxaliplatin . stage iv colon cancer diagnosis and core biopsy within seven days prior to done therapy
__label__1	study interventions are Everolimus . recurrent non small cell lung carcinoma diagnosis and any of the following concurrent severe and or uncontrolled medical conditions
__label__1	study interventions are Project Voice . human papillomavirus vaccines diagnosis and having impairing hearing or speech
__label__1	study interventions are Albumin-Bound Paclitaxel . small cell lung cancer diagnosis and patients with other significant diseases or disorders that in the investigator opinion would exclude them from the study
__label__1	study interventions are Antilymphocyte Serum . stage iv adult lymphoblastic lymphoma diagnosis and patient scheduled for cord blood transplantation
__label__1	study interventions are Succinylcholine . stage iva oropharyngeal squamous cell carcinoma diagnosis and known history of active tb_bacillus tuberculosis
__label__1	study interventions are Albumin-Bound Paclitaxel . lung cancer diagnosis and more than seven days since prior and no concurrent potent cypthreeafour inhibitors including any of the following
__label__1	study interventions are Endothelial Growth Factors . stage iiib ovarian cancer diagnosis and major surgical procedure anticipated during the course of the study this includes but is not limited to abdominal surgery laparotomy or laparoscopy prior to disease progression such as colostomy or enterostomy_reversal interval or secondary cytoreductive surgery or second look surgery please consult with the study chair prior to patient entry for any questions related to the classification of surgical procedures
__label__1	study interventions are Vaccines . stage iii adult diffuse large cell lymphoma diagnosis and diagnosed with autoimmune disease
__label__1	study interventions are Dasatinib . glioblastoma diagnosis and anticonvulsants
__label__1	study interventions are Podophyllotoxin . recurrent non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Antibodies, Monoclonal . stage iv non small cell lung cancer diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Belinostat . stage iv adult lymphoblastic lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to pxdone hundred and one there are no known allergic reactions attributed to compounds of similar chemical or biological composition to seventeenaag patients with known egg allergy should be excluded as the agent is diluted in epl_diluent
__label__1	study interventions are Lamotrigine . neurofibromatosis type one diagnosis and liver insufficiency
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and patients who have received corneal transplants cadaver skin or bone transplants are eligible
__label__1	study interventions are Lenograstim . metastatic breast cancer diagnosis and patients with history of severe hypersensitivity reaction to taxotere or other drugs formulated with polysorbate eighty
__label__1	study interventions are Pembrolizumab . gastric adenocarcinoma diagnosis and have known brain metastases
__label__1	study interventions are Biopsies using UroStation® (image fusion) . prostate cancer diagnosis and contraindication
__label__1	study interventions are Sorafenib . stage iib pancreatic cancer diagnosis and contraindication to antiangiogenic agents including
__label__1	study interventions are Liposomal doxorubicin . stage iii soft tissue sarcoma diagnosis and eastern cooperative oncology group ecog performance status equal_than less_than two karnofsky greater_than equal_than sixty
__label__1	study interventions are Docetaxel . non small cell lung cancer diagnosis and known allergy or hypersensitivity to docetaxel or drugs formulated with polysorbate eighty
__label__1	study interventions are Vatalanib . insulinoma diagnosis and other concurrent chemotherapy immunotherapy radiotherapy or any ancillary therapy considered investigational utilized for non fda approved indication and in the context of research investigation
__label__1	study interventions are Cetuximab . colorectal neoplasms diagnosis and having previously participated in study which included possibility of being allocated to cetuximab therapy whether or not the patient actually received cetuximab
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and concomitant medication known to increase the qt interval
__label__1	study interventions are Antibodies . stage iiic fallopian tube cancer diagnosis and ctcae grade two or greater peripheral vascular disease at least brief less_than two4 hrs episodes of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Leucovorin . stage ivb colon cancer diagnosis and known or suspected allergy or hypersensitivity to any agent given in the course of this trial
__label__1	study interventions are Immunoglobulin G . malignant pancreatic somatostatinoma diagnosis and grade greater_than equal_than three hemorrhage equal_than less_than four weeks prior to registration
__label__1	study interventions are Bevacizumab . glioblastoma multiforme diagnosis and clinically significant cardiovascular disease including the following
__label__1	study interventions are Cyclosporins . splenic marginal zone lymphoma diagnosis and uncontrolled infection the protocol principal investigator pi will be final arbiter if there is uncertainty regarding whether previous infection is under adequate control to allow enrollment in the study
__label__1	study interventions are Radium 223 . other primary tumor other than crpc including hematological malignancy present within the last five years except non melanoma skin cancer or low grade superficial bladder cancer
__label__1	study interventions are Letrozole . breast cancer diagnosis and for the previous neoadjuvant hormonotherapy the same premises than for the adjuvant hormonotherapy are valid
__label__1	study interventions are Capecitabine . stage iiib merkel cell carcinoma diagnosis and major conduction abnormality unless cardiac pacemaker is present
__label__1	study interventions are Carboplatin . non small cell lung carcinoma diagnosis and has known history of human immunodeficiency virus hiv
__label__1	study interventions are Pharmaceutical Solutions . prostate cancer diagnosis and history or clinical manifestation of significant renal or hepatic disorder
__label__1	study interventions are Rituximab . recurrent adult diffuse small cleaved cell lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab_vedotin and or rituximab
__label__1	study interventions are Freund's Adjuvant . ovarian neoplasm diagnosis and patients with underlying immune deficiency or history of autoimmune disease autoimmune neutropenia thrombocytopenia or hemolytic anemia systemic lupus erythematosus sjogren syndrome or scleroderma myasthenia_gravis goodpasture syndrome addison disease hashimoto thyroiditis active graves disease or other diseases which qualify as autoimmune in origin
__label__1	study interventions are Mitogens . non small cell lung cancer diagnosis and use of strong moderate cyponeatwo inhibitors such as ciprofloxacin and fluvoxamine
__label__1	study interventions are Yoga . breast cancer diagnosis and inability to undergo yoga training secondary to physical health limitations outlined by the treating team
__label__1	study interventions are Carboplatin . lung cancer diagnosis and the patient is pregnant confirmed by serum hcg if applicable or is breastfeeding
__label__1	study interventions are Testosterone 17 beta-cypionate . advanced or symptomatic metastatic prostate cancer requiring immediate gnrh or additional hormone therapy or requiring chemotherapy
__label__1	study interventions are Fludarabine phosphate . recurrent childhood hodgkin lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if age greater_than fifty years or there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Nintedanib . small cell lung cancer diagnosis and history of bleeding disorder
__label__1	study interventions are Sorafenib . adult solid neoplasm diagnosis and congestive heart failure greater_than class ii new york heart association nyha patients must not have unstable angina anginal symptoms at rest or new onset angina began within the last three months or myocardial infarction within the past six months
__label__1	study interventions are Antibodies . stage iic ovarian cancer diagnosis and patients with clinically significant proteinuria urine protein should be screened by urine protein creatinine ratio upcr patients must have upcr less_than doc to allow participation in the study
__label__1	study interventions are Antibodies, Monoclonal . stage iiic breast cancer diagnosis and major surgical procedure within twenty-eight days prior to cycle one day one or anticipation of need for major surgical procedure during the course of the study
__label__1	study interventions are Pemetrexed . tumors diagnosis and these potential risks may also apply to other agents used in this study
__label__1	study interventions are Immunoglobulins . recurrent childhood lymphoblastic lymphoma diagnosis and history of cva within six months
__label__1	study interventions are Bevacizumab . recurrent fallopian tube carcinoma diagnosis and radiographic demonstration of improvement upon the completion of cns directed therapy and no evidence of interim progression between the completion of cns directed therapy and the screening radiographic study
__label__1	study interventions are Gemcitabine . lung cancer diagnosis and concurrent participation in another clinical study
__label__1	study interventions are Ramucirumab . metastatic breast cancer diagnosis and the participant has grade three four bleeding within three months prior to the study registration date
__label__1	study interventions are Paclitaxel . breast cancer female diagnosis and pregnancy or breastfeeding women
__label__1	study interventions are Melphalan . stage iv grade one follicular lymphoma diagnosis and human immunodeficiency virus hiv positive
__label__1	study interventions are stereotactic body radiation therapy . tonenzeromzero non small cell lung cancer diagnosis and no pregnancy
__label__1	study interventions are Stereotactic Body Radiation Therapy . prostate cancer diagnosis and will be determined by radiation oncologist
__label__1	study interventions are Cisplatin . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and subjects with thrombotic embolic venous or arterial events such as cerebrovascular accident including transient ischemic attacks within six months of informed consent
__label__1	study interventions are Immunoglobulins . recurrent renal cell cancer diagnosis and patients with pre existing thyroid abnormality who are unable to maintain thyroid function in the normal range with medication are ineligible patients with history of hypothyroidism are eligible provided they are currently euthyroid
__label__1	study interventions are ispinesib . stage iv adult lymphoblastic lymphoma diagnosis and inhibitors of cypthreeafour
__label__1	study interventions are Immunoglobulins . ovarian mucinous adenocarcinoma diagnosis and immuno compromised patients and patients known to be human immunodeficiency virus hiv positive and currently receiving antiretroviral therapy note
__label__1	study interventions are Salvia hispanica Seed . angioimmunoblastic cell lymphoma diagnosis and patients with significant gut malabsorptive conditions such as inflammatory bowel disease or others at the discretion of the investigator will be excluded
__label__1	study interventions are Goserelin . metastatic breast cancer diagnosis and patient has known hypersensitivity to the components of study drug or its analogs
__label__1	study interventions are Maleic acid . undifferentiated fallopian tube carcinoma diagnosis and resting electrocardiogram ecg with clinically significant abnormal findings
__label__1	study interventions are Vaccines . breast cancer diagnosis and indication for chemotherapy
__label__1	study interventions are Bevacizumab . prior malignancy except for adequately treated basal cell or squamous cell skin cancer or noninvasive carcinomas or other cancer from which the patient has been disease free for five years
__label__1	study interventions are Antibodies, Monoclonal . recurrent adult brain neoplasm diagnosis and history of non healing wounds or ulcers or bone fractures within ninety days three months prior to registration
__label__1	study interventions are Quality-of-Life Assessment . stage iv ovarian cancer diagnosis and patients with life expectancy of less than one year
__label__1	study interventions are Forticare®. . gastric cancer diagnosis and lack of ability to understand danish language and the instructions given
__label__1	study interventions are Pembrolizumab . triple negative breast cancer diagnosis and has had prior chemotherapy targeted small molecule therapy or radiation therapy within two weeks prior to receipt of study medication or who has not recovered less_than grade one or at baseline excludes alopecia and grade two neuropathy from adverse events due to previously administered agent
__label__1	study interventions are Sirolimus . pancreatic alpha cell adenoma diagnosis and any of the following as this regimen may be harmful to developing fetus or nursing child
__label__1	study interventions are Antibodies, Monoclonal . metastatic colorectal cancer diagnosis and active infection involving iv antibiotics within two weeks prior to conedone
__label__1	study interventions are Trastuzumab . stage iv adrenocortical carcinoma diagnosis and active or unstable cardiovascular disease or cardiac disease requiring drug or device intervention history of coronary artery disease or congestive heart failure
__label__1	study interventions are Lenvatinib . malignant paraganglioma diagnosis and receiving any other investigational agent
__label__1	study interventions are Antibodies . recurrent adult immunoblastic large cell lymphoma diagnosis and core biopsy within seven days prior to enrollment
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and obstacles in intravenous administration of study drugs
__label__1	study interventions are Antibodies, Monoclonal . metastatic malignant neoplasm in the brain diagnosis and prior therapy with investigational drugs within twenty-eight days or at least five half lives whichever is longer before study administration
__label__1	study interventions are Immunoglobulin Fc Fragments . endometrial adenocarcinoma diagnosis and hospitalization for congestive heart failure chf
__label__1	study interventions are Vincristine . kidney cancer diagnosis and patients with grade ii iii or iv neurological status by the nci ctc ver
__label__1	study interventions are Clofarabine . angioimmunoblastic cell lymphoma diagnosis and patients who have had chemotherapy rituximab or radiotherapy within four weeks or radioimmunotherapy within eight weeks prior to entering the study
__label__1	study interventions are Mycophenolic Acid . stage grade two follicular lymphoma diagnosis and active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Hormones . progesterone receptor positive tumor diagnosis and prior neo adjuvant treatment with tamoxifen within the twelve months before study entry
__label__1	study interventions are Bevacizumab . stage iv adult burkitt lymphoma diagnosis and anticipation of need for major surgical procedures during the course of the study
__label__1	study interventions are Pembrolizumab . prostate cancer diagnosis and active viral bacterial or systemic fungal infection requiring parenteral treatment within seven days of first study drug administration
__label__1	study interventions are Oxaliplatin . metastatic colorectal cancer diagnosis and any deep vein thrombosis dvt within three months prior to study entry
__label__1	study interventions are Antibodies, Monoclonal . stage iii soft tissue sarcoma diagnosis and subjects may not have had prior organ allograft or allogeneic bone marrow transplantation
__label__1	study interventions are questionnaire administration . brain and central nervous system tumors diagnosis and subjects who underwent hematopoietic cell transplant hct are not eligible for this study
__label__1	study interventions are Antibodies . adult glioblastoma diagnosis and right bundle_branch block positive left anterior_hemiblock bi fascicular block
__label__1	study interventions are Cisplatin . stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and any condition which in the investigator opinion makes the subject unsuitable for trial participation
__label__1	study interventions are pp65-shLAMP DC with GM-CSF . astrocytoma grade iv diagnosis and severe active co morbidity
__label__1	study interventions are Mycophenolate mofetil . stage childhood lymphoblastic lymphoma diagnosis and pregnancy
__label__1	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and evidence with cns disease
__label__1	study interventions are Levoleucovorin . stage iiia colon cancer diagnosis and pleural pericardial effusion
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and major surgery within fourteen days before first dose of study drug
__label__1	study interventions are Prednisone . diffuse large cell lymphoma diagnosis and patients who have had more than one cycle of prior chemoimmunotherapy for diagnosis of nhl are not eligible note
__label__1	study interventions are Docetaxel . non small cell lung cancer nsclc locally advanced or metastatic second line diagnosis and mixed small cell or non small cell histology
__label__1	study interventions are Etoposide phosphate . diffuse large cell lymphoma diagnosis and serum cr less_than two gm dl
__label__1	study interventions are Antibodies, Monoclonal . melanoma ocular diagnosis and positive serum pregnancy test human chorionic gonadotropin within seven days prior to enrollment
__label__1	study interventions are Cyclosporins . testicular lymphoma diagnosis and patients with evidence of human immunodeficiency virus hiv seropositivity and or positive polymerase chain reaction pcr assay human lymphotropic virus htlv one htlvtwo_seropositivity the safety of allogeneic hsct is not yet well established for this population
__label__1	study interventions are Anastrozole . recurrent breast carcinoma diagnosis and receiving any other investigational agents
__label__1	study interventions are Vatalanib . recurrent renal cell cancer diagnosis and known standard therapy for the patient disease that is potentially curative or definitely capable of extending life expectancy
__label__1	study interventions are Etoposide . lymphoma non hodgkin diagnosis and patients with active infection requiring oral or intravenous antibiotics are excluded
__label__1	study interventions are Letrozole . stage iv breast cancer diagnosis and history of interstitial lung disease
__label__1	study interventions are Endo GIA Reinforced Reload with Tri-Staple technology . pancreatic neoplasms diagnosis and patients requiring other organ resection
__label__1	study interventions are Antibodies, Monoclonal . recurrent breast carcinoma diagnosis and patients using any of the following drugs known to inhibit platelet function are not eligible
__label__1	study interventions are Melphalan . ds stage ii plasma cell myeloma diagnosis and prior to study entry any electrocardiogram ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are Sorafenib . advanced cancer diagnosis and for paclitaxel treatment arm
__label__1	study interventions are Bevacizumab . prior adjuvant treatment for stage ii iii colorectal cancer completed within six months prior to randomisation
__label__1	study interventions are Pharmacological Study . renal cell carcinoma diagnosis and previous treatment with cabozantinib or another specific met hgf inhibitor tivantinib crizotinib
__label__1	study interventions are Immunoglobulins . recurrent childhood large cell lymphoma diagnosis and patients receiving chronic systemic corticosteroids are not eligible
__label__1	study interventions are Dexamethasone . stage b lymphoblastic lymphoma diagnosis and female patients of childbearing potential are not eligible unless negative pregnancy test result has been obtained
__label__1	study interventions are 111In-DAC . breast cancer diagnosis and have taken drugs that may damage the kidneys within two weeks of start of study
__label__1	study interventions are Fluorouracil . intestinal adenocarcinoma of the stomach diagnosis and active acute or chronic or uncontrolled severe infections
__label__1	study interventions are Trastuzumab . locally advanced hertwo positive breast cancer diagnosis and lvef value below institutional limits of normal range
__label__1	study interventions are Ethanol . pancreas cancer diagnosis and previous preoperative celiac nerve block
__label__1	study interventions are Hydroxocobalamin . brain imaging is required in symptomatic patients to rule out brain metastases but is not required in asymptomatic patients
__label__1	study interventions are Bevacizumab . recurrent fallopian tube carcinoma diagnosis and patients with active tuberculosis tb are excluded
__label__1	study interventions are Liposomal doxorubicin . undifferentiated high grade pleomorphic sarcoma of bone diagnosis and patients with known central nervous system cns metastases are not eligible note
__label__1	study interventions are Carboplatin . solid tumors diagnosis and left ventricular ejection fraction
__label__1	study interventions are Bevacizumab . ovarian cancer diagnosis and current clinically relevant bowel obstruction including sub occlusive disease related to underlying disease
__label__1	study interventions are ZD6474 . malignant gliomas diagnosis and patients who in the view of the treating physician have significant active hepatic renal or psychiatric diseases are ineligible
__label__1	study interventions are Antibodies . lung cancer diagnosis and granulocyte growth factors csf within three weeks of study entry
__label__1	study interventions are Androgens . prostate cancer diagnosis and renal failure serum creatinine greater_than two hundred umol l
__label__1	study interventions are Ifosfamide . previous or current malignancy with the exception of curatively treated no negative melanoma skin cancer or cervical carcinoma in situ
__label__1	study interventions are Hespecta . history of second malignancy except curatively treated low stage tumors with histology that can be differentiated from the current tumor or premalignant lesion
__label__1	study interventions are Cyclosporine . stage iii adult burkitt lymphoma diagnosis and donor
__label__1	study interventions are Lapatinib . brain cancer diagnosis and history of stroke myocardial infarction or unstable angina in the previous six months
__label__1	study interventions are Epacadostat . stage iiib ovarian cancer diagnosis and therapy with monoamine_oxidase inhibitors maois and selective serotonin_reuptake inhibitor ssris within the last four weeks or history of serotonin syndrome
__label__1	study interventions are Rituximab . recurrent adult diffuse small cleaved cell lymphoma diagnosis and other active malignancy requiring therapy exceptions
__label__1	study interventions are Carboplatin . stage iiia fallopian tube cancer diagnosis and patients who are pregnant or nursing bevacizumab should not be administered to nursing women patients of childbearing potential must agree to use contraceptive measures during study therapy and for at least six months after completion of bevacizumab therapy
__label__1	study interventions are Pembrolizumab . follicular variant thyroid gland papillary carcinoma diagnosis and replacement therapy eg
__label__1	study interventions are Foscarnet . stage iii adult cell leukemia lymphoma diagnosis and no prior allogeneic hct allo hct autologous hct auto hct is allowed
__label__1	study interventions are Cyclophosphamide . diffuse large cell lymphoma diagnosis and patients had previous history of treatment with cinobufacini tablets
__label__1	study interventions are Liposomal doxorubicin . stage iii enteropathy associated cell lymphoma diagnosis and pregnant or breast feeding females
__label__1	study interventions are Hormones . hertwo negative breast cancer diagnosis and liver disease such as cirrhosis chronic active hepatitis or chronic persistent hepatitis
__label__1	study interventions are Carboplatin . gastric cancer diagnosis and uncontrolled angina pectoris cardiac failure or clinically significant arrhythmias
__label__1	study interventions are Doxycycline . advanced cancers diagnosis and ecog of four and life expectancy less_than equal_than two weeks
__label__1	study interventions are Tacrolimus . peripheral cell lymphoma diagnosis and donor
__label__1	study interventions are Antibodies, Monoclonal . recurrent adult diffuse large cell lymphoma diagnosis and patients with history of hemoptysis
__label__1	study interventions are Nitrogen Mustard Compounds . diffusing lung capacity for carbon monoxide dlco less_than fifty forced expiratory volume in one second fev less_than fifty and or receiving supplementary continuous oxygen the fred_hutchinson cancer research center fhcrc principle investigator pi of the study must approve of enrollment of all patients with pulmonary nodules
__label__1	study interventions are Cediranib . stage iiic rectal cancer diagnosis and history of risk factors for qt interval prolongation including but not limited to family or personal history of long qt syndrome history of torsades de pointes recurrent syncope without known etiology or sudden_unexpected death
__label__1	study interventions are Everolimus . head and neck cancer diagnosis and active acute or chronic or uncontrolled severe infection liver disease such as cirrhosis decompensated liver disease and chronic hepatitis quantifiable hepatitis virus test hepatitis virus hbv dna and or positive hepatitis surface antigen hbsag quantifiable hepatitis virus test hepatitis virus hcv rna b
__label__1	study interventions are Docetaxel . symptomatic peripheral neuropathy greater_than grade two according to the national cancer institute nci common toxicity criteria
__label__1	study interventions are Mycophenolic Acid . recurrent refractory childhood hodgkin lymphoma diagnosis and forty kidneys
__label__1	study interventions are Bicalutamide . prostate cancer diagnosis and previously received bicalutamide flutamide or nilutamide within the past twelve months except for period of use less than thirty days long
__label__1	study interventions are Fludarabine . recurrent adult cell leukemia lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are quality-of-life assessment . stage verrucous carcinoma of the oral cavity diagnosis and mandibular invasion
__label__1	study interventions are Lenograstim . stage iv breast cancer diagnosis and pregnant women are excluded from this study because gthree thousand, one hundred and thirty-nine is an oligonucleotide agent with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with gthree thousand, one hundred and thirty-nine breastfeeding should be discontinued if the mother is treated with gthree thousand, one hundred and thirty-nine these potential risks may also apply to other agents used in this study such as doxorubicin and docetaxel
__label__1	study interventions are Questionnaire Administration . cancer survivor diagnosis and patient is planning major surgery within the next six months
__label__1	study interventions are Mycophenolic Acid . childhood diffuse large cell lymphoma diagnosis and any leukemia with morphologic relapse or persistent disease in the bm with greater_than equal_than twenty blasts cytogenetic relapse without morphologic evidence of relapse or cytogenetic persistent disease is acceptable
__label__1	study interventions are Doxorubicin . primary breast cancer diagnosis and psychiatric illness or drug addiction that would preclude obtaining informed consent
__label__1	study interventions are Capecitabine . local advanced high risk nasopharyngeal carcinoma diagnosis and younger than eighteen years old or older than seventy years old
__label__1	study interventions are Cetuximab . squamous cell carcinoma of the head and neck diagnosis and patient must not be receiving any other investigational agents
__label__1	study interventions are Methylprednisolone acetate . prostate cancer diagnosis and known lesion at brain or leptomeninx
__label__1	study interventions are Cabozantinib . plexiform neurofibromas diagnosis and subject requires anticoagulants
__label__1	study interventions are Nivolumab . stage iiic hepatocellular carcinoma diagnosis and patients with untreated central nervous system cns metastatic disease including spinal cord and leptomeningeal disease are excluded
__label__1	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and any history of allergic reaction to paclitaxel or other taxanes or to carboplatin
__label__1	study interventions are Antibodies, Monoclonal . carcinoma non small cell lung diagnosis and participant with previous history of malignancy other than nsclc is eligible provided that he she has been free of disease for greater_than three years
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian clear cell adenocarcinoma diagnosis and receipt of an investigational study drug for any indication within thirty days or five half lives whichever is longer prior to day one of protocol therapy
__label__1	study interventions are SBRT with proton beam radiation . non small cell lung cancer diagnosis and uncontrolled intercurrent illness
__label__1	study interventions are Glucocorticoids . ependymoblastoma diagnosis and research participants being treated for severe infection or who are recovering from major surgery are ineligible until recovery is deemed complete by the investigator
__label__1	study interventions are BB 1101 . metastatic colorectal cancer diagnosis and prior treatment with hai fudr
__label__1	study interventions are Carboplatin . neoplasms ovarian diagnosis and is unable to discontinue prohibited medications as listed in section doc for fourteen days or five half lives of drug prior to visit one and for the duration of the study
__label__1	study interventions are Vincristine . more than one previous line of therapy for multiple myeloma
__label__1	study interventions are Docetaxel . breast neoplasms diagnosis and significant poorly controlled cardiac disorders such as unstable angina pectoris poorly controlled heart failure arrhythmia requiring treatment or myocardial infarction within the last three months
__label__1	study interventions are Irinotecan . unspecified adult solid tumor protocol specific diagnosis and nursing women
__label__1	study interventions are Carboplatin . metastatic cancer with impaired renal function diagnosis and administration of cyponeatwo and cypthreeafour five enzyme inducing or inhibiting drugs within onefour days prior to starting study drug
__label__1	study interventions are Liposomal doxorubicin . stage iv adult hodgkin lymphoma diagnosis and in addition if negative for hbsag but hbcab positive regardless of hbsab status hb dna test will be performed and if positive the subject will be excluded if unable to tolerate and or receive anti hepatitis therapy
__label__1	study interventions are surveys . colon cancer diagnosis and auditory visual or motor impairment that would preclude ability to use telephone and or computer
__label__1	study interventions are hetIL-15 . head and neck squamous cell carcinoma diagnosis and positive hepatitis or serology
__label__1	study interventions are ACE-011 - 30 mg . bladder cancer diagnosis and part two only history of prior regimen of platinum based chemotherapy for metastatic nsclc and or history of adjuvant platinum based chemotherapy with last dose received less than six months prior to the start of current first line platinum based chemotherapy for metastatic nsclc
__label__1	study interventions are Leuprolide . breast cancer diagnosis and women who are currently taking tamoxifen and are unwilling to stop this medication
__label__1	study interventions are Antibodies, Monoclonal . gastric cancer diagnosis and active or prior documented autoimmune disease requiring systemic treatment within the past two years
__label__1	study interventions are Pemetrexed . local advanced non small cell lung cancer diagnosis and stage iv
__label__1	study interventions are brivanib . transitional cell carcinoma diagnosis and subjects with known brain metastasis
__label__1	study interventions are Bendamustine Hydrochloride . malignant lymphoma diagnosis and written informed consent
__label__1	study interventions are Cetuximab . advanced cancer diagnosis and invasive procedures defined as follows
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and patients must not have active uncontrolled seizure disorder
__label__1	study interventions are Etoposide phosphate . recurrent adult immunoblastic large cell lymphoma diagnosis and patients known to be human immunodeficiency virus hiv positive
__label__1	study interventions are Rituximab . stage iii adult burkitt lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are management of therapy complications . other prior malignancy except nonmelanoma skin cancer
__label__1	study interventions are Temozolomide . glioblastoma multiforme diagnosis and use of avastin or another veg inhibitor prior to progression is not permitted
__label__1	study interventions are Dexamethasone 21-phosphate . mature cell and nk cell non hodgkin lymphoma diagnosis and patients receiving stable or decreasing doses of corticosteroids for equal_than less_than seven days prior to enrollment or who are receiving increasing doses of corticosteroids are not eligible for enrollment the exception to this is pulsed steroids used for maintenance chemotherapy
__label__1	study interventions are Endothelial Growth Factors . adult glioblastoma diagnosis and right bundle_branch block positive left anterior_hemiblock bi fascicular block
__label__1	study interventions are Clarithromycin . squamous cell lung cancer diagnosis and patients with known coronary artery disease congestive heart failure not meeting the above criteria or lvef less_than fifty must be on stable medical regimen
__label__1	study interventions are Methotrexate . lymphoma non hodgkin diagnosis and radiation therapy as outlined in protocol
__label__1	study interventions are Fed treatment: AXL1717 . solid tumors diagnosis and ongoing infection or other major recent or ongoing disease that according to the investigator poses an unacceptable risk to the patient
__label__1	study interventions are Vorinostat . triple negative breast cancer diagnosis and intent to receive additional neoadjuvant therapy prior to surgery
__label__1	study interventions are quality of life assessment . stage squamous cell carcinoma of the hypopharynx diagnosis and patient pregnancy
__label__1	study interventions are Immunoglobulins . fallopian tube mucinous adenocarcinoma diagnosis and protein concentration mg dl creatinine mg dl patients must have upcr less_than doc to allow participation in the study
__label__1	study interventions are Bortezomib . ovarian mucinous adenocarcinoma diagnosis and stage not greater than b no more than superficial myometrial invasion without vascular or lymphatic invasion no poorly differentiated subtypes including papillary serous clear cell or other international federation of gynecology and obstetrics_figo grade three lesions
__label__1	study interventions are Erlotinib Hydrochloride . tumors diagnosis and history of chronic hepatitis
__label__1	study interventions are Ado-trastuzumab emtansine . metastatic breast cancer diagnosis and clinically significant history of liver disease including cirrhosis current alcohol abuse autoimmune hepatic disorders sclerosis cholangitis or active infection with human immunodeficiency virus hepatitis virus or hepatitis virus
__label__1	study interventions are Doxorubicin . pretext stage one hepatoblastoma diagnosis and patients must not be receiving any of the following potent cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour inducers or inhibitors
__label__1	study interventions are Bendamustine Hydrochloride . b cell non hodgkin lymphoma diagnosis and screening laboratory values
__label__1	study interventions are Antibodies . recurrent adult brain tumor diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biological composition to gamma_secretase inhibitor rofour million, nine hundred and twenty-nine thousand and ninety-seven or bevacizumab
__label__1	study interventions are Hormones . adenocarcinoma of the prostate diagnosis and thirty days of antiandrogen therapy monotherapy without androgen deprivation therapy
__label__1	study interventions are Vincristine . mantle cell lymphoma diagnosis and ketoconazole nizoral
__label__1	study interventions are INSTILADRIN . history of malignancy of other organ system within past five years except treated basal cell carcinoma or squamous cell carcinoma of the skin and less_than pathological tumor two pttwo upper tract urothelial carcinoma at least two4 months after nephroureterectomy
__label__1	study interventions are Cyclosporine . recurrent adult burkitt lymphoma diagnosis and donor
__label__1	study interventions are Antibodies . ovarian endometrioid adenocarcinoma diagnosis and ribose_polymerase parp inhibitor
__label__1	study interventions are Irinotecan . stage iva colon cancer diagnosis and patients who are unable to reliably tolerate and or receive oral medications
__label__1	study interventions are pharmacological study . stage iv adult diffuse mixed cell lymphoma diagnosis and miscellaneous
__label__1	study interventions are Liposomal doxorubicin . stage iii ovarian epithelial cancer diagnosis and no other concurrent investigational agents
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib breast cancer diagnosis and history of mi within six months prior to first study treatment
__label__1	study interventions are Magnetic Resonance Imaging . brain tumor diagnosis and presence of genetic disorder other than nfone that effects cognition or is associated with mr imaging abnormalities tuberous sclerosis
__label__1	study interventions are Lapatinib . head and neck cancers diagnosis and known hypersensitivity to lapatinib or any of the excipients of this product quinazolines
__label__1	study interventions are Financial Incentive to Increase Ambulation . bladder cancer diagnosis and non english speakers
__label__1	study interventions are Modified Measles Virus Lumbar Puncture . medulloblastoma recurrent diagnosis and exposure to household contact with known immunodeficiency
__label__1	study interventions are Irinotecan . colorectal cancer metastatic diagnosis and any severe acute or chronic medical condition which could impair the ability of the participant to participate to the study or to interfere with interpretation of study results
__label__1	study interventions are BKM120 . high risk prostate cancer diagnosis and other concurrent severe and or uncontrolled concomitant medical conditions active or uncontrolled infection that could cause unacceptable safety risks or compromise compliance with the protocol
__label__1	study interventions are Calcium, Dietary . stage ivb colon cancer diagnosis and any condition that impairs patient ability to swallow whole pills
__label__1	study interventions are Fludarabine . diffuse large cell lymphoma diagnosis and donor
__label__1	study interventions are Cisplatin . uterine cervical neoplasms diagnosis and history of bowel obstruction or malabsorption syndromes
__label__1	study interventions are Cyclosporine . stage ii childhood anaplastic large cell lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Hormones . hormone receptor positive malignant neoplasm of breast diagnosis and subject is currently receiving any of the following substances and cannot be discontinued seven days prior to the start of the treatment
__label__1	study interventions are Everolimus . recurrent childhood lymphoblastic lymphoma diagnosis and no evidence of active graft versus vs
__label__1	study interventions are Mycophenolic Acid . childhood grade iii lymphomatoid granulomatosis diagnosis and adult
__label__1	study interventions are Antibodies . stage iia esophageal cancer diagnosis and patients with psychiatric or addictive disorders or other conditions that in the opinion of the investigator would preclude them from meeting the study requirements are not eligible
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and patients with known amyloidosis
__label__1	study interventions are Prednisolone . prostate neoplasms diagnosis and therapy with other hormonal therapy including any dose of megestrol acetate megace finasteride_proscar dutasteride avodart any herbal product known to decrease prostate specific antigen psa levels eg saw_palmetto and pc_spes or any systemic corticosteroid within four weeks prior to first dose of study drug
__label__1	study interventions are Sirolimus . cervical carcinoma in situ melanoma in situ and basal cell or squamous cell carcinoma of the skin
__label__1	study interventions are MAGE-A3 ASCI . bladder cancer diagnosis and the use of prednisone or equivalent less_than doc twenty-five mg kg day absolute maximum ten mg day or inhaled corticosteroids or topical steroids is permitted
__label__1	study interventions are Sorafenib . carcinoma hepatocellular diagnosis and patients unable to swallow oral medications
__label__1	study interventions are Everolimus . pretext stage four hepatoblastoma diagnosis and males and females of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method
__label__1	study interventions are Liposomal doxorubicin . recurrent primary peritoneal carcinoma diagnosis and immunocompromised patients and patients known to be human immunodeficiency virus hiv positive and currently receiving antiretroviral therapy note
__label__1	study interventions are Propofol . colon cancer diagnosis and neurological deficit
__label__1	study interventions are Vidarabine . progression of multiple myeloma or plasma cell leukemia diagnosis and history of brain metastases
__label__1	study interventions are Placebo . solid tumors diagnosis and regular work with ionizing radiation or radioactive material or treated with radiotherapy within three weeks prior to the first dose of study drug
__label__1	study interventions are Fludarabine . stage iv adult burkitt lymphoma diagnosis and patients with medical history of noncompliance with haart or medical therapy
__label__1	study interventions are Cyclophosphamide . recurrent childhood lymphoblastic lymphoma diagnosis and fertile men and women unwilling to use contraceptives during and for twelve months post transplant
__label__1	study interventions are Antibodies, Monoclonal . ovarian mucinous adenocarcinoma diagnosis and unwilling or unable to follow protocol requirements
__label__1	study interventions are Meditation Therapy . digestive system neoplasm diagnosis and patients
__label__1	study interventions are Levoleucovorin . adenocarcinoma of the gastroesophageal junction diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to study enrollment
__label__1	study interventions are Paclitaxel . carcinoma non small cell lung diagnosis and unstable angina history of myocardial infarction and or congestive heart failure requiring hospitalization within the last six months
__label__1	study interventions are Rituximab . stage iv follicular lymphoma diagnosis and has history of non infectious pneumonitis that required steroids or current pneumonitis
__label__1	study interventions are Cyclosporins . stage iii multiple myeloma diagnosis and inability to achieve adequate venous access
__label__1	study interventions are Vaccines . history of prior malignancies other than breast cancer within the past five years excluding basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
__label__1	study interventions are Cyclophosphamide . anaplastic large cell lymphoma diagnosis and patients who have had major surgical procedures or significant traumatic injury within twenty-eight days prior to study treatment
__label__1	study interventions are Cytarabine . stage ii contiguous adult lymphoblastic lymphoma diagnosis and six hundred cgy of chest irradiation if medically necessary
__label__1	study interventions are Total Marrow Irradiation . multiple myeloma diagnosis and subjects with history of non compliance in other studies
__label__1	study interventions are Aminopterin . non small cell lung cancer diagnosis and pregnant or breast feeding women
__label__1	study interventions are Antibodies, Monoclonal . metastatic neoplasm diagnosis and pregnancy or breast feeding female patients must be surgically sterile or be postmenopausal for two years or must agree to use effective contraception during the period of treatment and six months after all female patients with reproductive potential must have negative pregnancy test serum urine within twenty-four hours from starting the conditioning chemotherapy the definition of effective contraception will be based on the judgment of the study investigators patients who are breastfeeding are not allowed on study
__label__1	study interventions are Glycine . multiple myeloma diagnosis and diarrhea greater_than grade one
__label__1	study interventions are Fluorouracil . prior ischemic heart disease cerebrovascular disease peripheral vascular disease arterial or venous thromboembolic disease cardiac failure inflammatory bowel disease gastroduodenal ulcer symptomatic diverticulitis or bleeding diathesis
__label__1	study interventions are Ramucirumab . gastric adenocarcinoma diagnosis and the participant has history of inflammatory bowel disease or crohn disease requiring medical intervention within twelve months
__label__1	study interventions are Estradiol . estrogen receptor positive breast cancer diagnosis and rapidly progressive visceral disease not suitable for further endocrine therapy
__label__1	study interventions are Mycophenolate mofetil . stage iii adult diffuse large cell lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of hydroxyurea and imatinib mesylate will not be allowed within two weeks of the initiation of conditioning
__label__1	study interventions are Antibodies . stage iiia uterine corpus cancer diagnosis and significant cardiovascular disease defined as congestive heart failure new york heart association class ii iii or iv angina pectoris requiring nitrate therapy or recent myocardial infarction equal_than less_than six months prior to registration
__label__1	study interventions are Vaccines . malignant pleural mesothelioma diagnosis and pregnant and or lactating women will be excluded due to the unknown potentially harmful effects of immune response to ct antigens and stem cell proteins that may be expressed in placenta fetus and neonates
__label__1	study interventions are Sorafenib . myelodysplastic myeloproliferative neoplasms diagnosis and patients must not have unstable angina anginal symptoms at rest or new onset angina began within the last three months or myocardial infarction within the past six months
__label__1	study interventions are Carboplatin . head and neck cancer diagnosis and clinically significant history of liver disease including viral or other hepatitis current alcohol abuse or cirrhosis
__label__1	study interventions are Cyclosporins . retinoblastoma diagnosis and glomerular filtration rate gfr less_than one hundred ml min
__label__1	study interventions are Cyclophosphamide . recurrent adult diffuse large cell lymphoma diagnosis and prior extensive radiation therapy that the radiation oncologist feels precludes additional tbi
__label__1	study interventions are Paclitaxel . stage ii breast cancer diagnosis and known hypersensitivity to any component of avastin or gemcitabine or other required drugs in the study
__label__1	study interventions are Mycophenolic Acid . stage iv adult burkitt lymphoma diagnosis and presence of active central nervous system cns disease history of adequately treated cns disease is acceptable
__label__1	study interventions are Carboplatin . breast cancer diagnosis and one year since taxane and herceptin treatment
__label__1	study interventions are Antibodies, Monoclonal . noncontiguous stage ii grade two follicular lymphoma diagnosis and patients with poorly controlled hypertension on multiple antihypertensives
__label__1	study interventions are Topotecan . ovarian neoplasms diagnosis and clinically significant cardiac disease
__label__1	study interventions are Trastuzumab . metastatic breast cancer diagnosis and hiv positive individuals on combination antiretroviral therapy
__label__1	study interventions are Sorafenib . stage iva verrucous carcinoma of the larynx diagnosis and prior treatment with sorafenib or cetuximab
__label__1	study interventions are ADCT-402 . non hodgkin lymphoma diagnosis and patients who have any option for other treatment for cell nhl at the current state of disease
__label__1	study interventions are Immunoglobulins . stage iii adult lymphoblastic lymphoma diagnosis and corticosteroid therapy also is not permitted while subjects are receiving protocol therapy during the treatment phase of the study
__label__1	study interventions are Paclitaxel . solid tumors diagnosis and patients with mean qtcf interval greater_than four hundred and fifty msec at screening are excluded
__label__1	study interventions are Prednisolone hemisuccinate . adequately treated basal cell or squamous cell skin or superficial ptis pta and ptone bladder cancer were allowed as well as any other cancer for which chemotherapy had been completed greater_than five years ago and from which the participant had been disease free for greater_than five years
__label__1	study interventions are Mitogens . who have fresh tumor specimen with no evidence of fgf five expression on technically adequate rt pcr assessment
__label__1	study interventions are Prednisolone hemisuccinate . multiple myeloma diagnosis and acute active infection requiring systemic antibiotics antiviral except antiviral therapy directed at hbv or antifungal agents within fourteen days prior to first dose
__label__1	study interventions are Etoposide phosphate . stage iiia non small cell lung cancer diagnosis and documented or pathologically proven metastatic disease
__label__1	study interventions are Bevacizumab . squamous cell carcinoma of the esophagus diagnosis and patients with greater_than equal_than grade two neuropathy are not eligible
__label__1	study interventions are hyperfractionated radiation therapy . invasive lobular breast carcinoma diagnosis and acquired immune deficiency syndrome aids based upon current centers for disease control cdc definition note however that human immunodeficiency virus hiv testing is not required for entry into this protocol the need to exclude patients with aids from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive protocol specific requirements may also exclude immunocompromised patients
__label__1	study interventions are Tazemetostat and [14C] Tazemetostat . follicular lymphoma diagnosis and subjects with history of deep vein thrombosis greater_than three months prior to study enrollment who are on anticoagulation therapy with low molecular weight heparin are eligible for this study
__label__1	study interventions are Prednisone . cutaneous cell non hodgkin lymphoma diagnosis and inability to comply with study or follow up testing and procedures
__label__1	study interventions are Immunoglobulins . stage iv melanoma diagnosis and women of childbearing potential wocbp who
__label__1	study interventions are Poly ICLC . sarcoma of the skin diagnosis and aids defined as cdfour count less_than then two hundred in the context of hiv sero positivity or chronically is taking immunosuppressive medication such as steroids or transplant related medications
__label__1	study interventions are Liposomal doxorubicin . liver cancer diagnosis and due to the experimental nature of the therapy and the unknown risk to fetus pregnant and or lactating women are not eligible to participate in this study
__label__1	study interventions are Camptothecin . metastatic colorectal cancer diagnosis and previous irinotecan or anti egfr therapies
__label__1	study interventions are Ondansetron . metastatic breast cancer diagnosis and previous treatment with eribulin mesylate
__label__1	study interventions are Irinotecan . a minimum of three weeks four weeks for carboplatin or investigational anticancer agents and six weeks for nitrosoureas and mitomycin must have elapsed between the end of treatment and start of treatment
__label__1	study interventions are Tyrphostins . melanoma diagnosis and breastfeeding should be discontinued if the mother is treated with wpone hundred and sixty-six
__label__1	study interventions are Erythromycin Estolate . metastatic breast cancer diagnosis and patients who are pregnant or nursing will not be eligible for this protocol
__label__1	study interventions are Cyclophosphamide . stage iiia skin melanoma diagnosis and patients with active systemic infection requiring intravenous antibiotics
__label__1	study interventions are Tamoxifen . stage iiia uterine corpus cancer diagnosis and john wort as these may decrease temsirolimus levels use of agents that potently inhibit cypthreea and hence may raise temsirolimus levels such as ketoconazole is discouraged but not specifically prohibited the appropriateness of use of such agents is left to physician discretion
__label__1	study interventions are Romidepsin . hodgkin lymphoma diagnosis and congenital long qt syndrome or qtc interval greater_than four hundred and fifty milliseconds
__label__1	study interventions are Dacarbazine . cognitive side effects of cancer therapy diagnosis and prolonged corrected qtc interval greater_than four hundred and fifty msec
__label__1	study interventions are laboratory biomarker analysis . recurrent adult burkitt lymphoma diagnosis and antibiotics
__label__1	study interventions are Rituximab . recurrent marginal zone lymphoma diagnosis and patient or donor with history of hepatitis or and or positive serology consistent with previous hepatitis or infection patients and or donor who received hepatitis vaccination are acceptable
__label__1	study interventions are Mycophenolate mofetil . blood cancer diagnosis and psychiatric disorders or psychosocial problems which in the opinion of the primary physician or principal investigator would place the patient at unacceptable risk from this regimen
__label__1	study interventions are Aspirin . adenomas diagnosis and likelihood of nsaid use
__label__1	study interventions are Gefitinib . carcinoma non small cell lung diagnosis and patients who have any other life threatening illness or organ system dysfunction
__label__1	study interventions are Fluorouracil . cancer of larynx diagnosis and patients with grade greater_than two peripheral neuropathy
__label__1	study interventions are Chinese medical treatment-LCH1 . breast cancer diagnosis and before receiving operation and chemotherapy the patient already have other chronic diseases
__label__1	study interventions are Vitamin D . lymphoma diagnosis and hypersensitivity to risedronate or other bisphosphonates
__label__1	study interventions are Chemotherapy . patients with tumors less_than doc cm
__label__1	study interventions are Aromatase Inhibitors . breast cancer diagnosis and in combination with the vaccine against yellow fever
__label__1	study interventions are Sunitinib . stage iv renal cell cancer diagnosis and current or recent within ten days of enrollment use of aspirin greater_than three hundred and twenty-five mg day or chronic use of other nonsteroidal anti inflammatory drugs nsaids
__label__1	study interventions are Fludarabine . stage ii contiguous mantle cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than forty total lung capacity tlc less_than forty forced expiratory volume in one second fevone less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Liposomal doxorubicin . ovarian cancer diagnosis and clinically significant cardiovascular disease incl
__label__1	study interventions are Bortezomib . myeloma diagnosis and known history of allergy to captisol cyclodextrin_derivative used to solubilize_carfilzomib
__label__1	study interventions are relaxation therapy 2 . basal cell carcinoma diagnosis and subjects with known mental illness or other psychological conditions such as psychotic disorders mood disorders anxiety disorders cognitive disorders depression with psychotic features dissociative disorders
__label__1	study interventions are Thalidomide . cancer diagnosis and patients with currently untreated brain metastases or brain metastases on current therapy are not eligible
__label__1	study interventions are Folic Acid . primary cutaneous anaplastic large cell lymphoma diagnosis and use of oral retinoids except bexarotene within four weeks of study treatment or high dose vitamin once daily multi vitamin allowed
__label__1	study interventions are Gemcitabine . nonsmall cell lung cancer diagnosis and patients must be at least four weeks post brain radiation therapy
__label__1	study interventions are Veliparib . stage iiic breast cancer diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and patients refractory to high dose dexamethasone defined as experiencing less than pr to dexamethasone or pd within sixmonths after discontinuing dexamethasone or discontinued dexamethasone because of greater_than grade three dexamethasone related toxicity
__label__1	study interventions are Stereotactic Radiosurgery . stage iv or recurrent carcinoma or sarcoma diagnosis and distinct sites of disease greater_than four
__label__1	study interventions are Tricyclodecane-9-yl-xanthogenate . pancreatic acinar cell carcinoma diagnosis and evidence of immunodeficiency or immune suppression autoimmune diseases such as the following
__label__1	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the nasopharynx diagnosis and patient has poorly controlled diabetes mellitus or steroid induced diabetes mellitus hemoglobin aonec hbaonec greater_than doc
__label__1	study interventions are Mitomycin . bladder cancer diagnosis and urethral strictures that would prevent endoscopic procedures and repeated catheterisation
__label__1	study interventions are Cabozantinib . cholangiocarcinoma of the extrahepatic bile duct diagnosis and the subject has history of clinically significant hematemesis hemoptysis of greater_than doc ml of red blood radiation including brachytherapy to pulmonary lesions or signs indicative of significant pulmonary hemorrhage within three months before the first dose of study treatment
__label__1	study interventions are Immunoglobulins . adult non hodgkin lymphoma diagnosis and serious non malignant disease such as active infection or other condition which in the opinion of the investigator would compromise other protocol objectives
__label__1	study interventions are Antibodies . recurrent mantle cell lymphoma diagnosis and residual grade three or grade four non hematologic toxicity after asct
__label__1	study interventions are Cisplatin . stage iv gastric cancer diagnosis and inadequate hepatic or renal function which is defined as below
__label__1	study interventions are Exercise . stage iii colon cancer diagnosis and uncontrolled hypertension systolic greater_than one hundred and eighty mmhg or diastolic greater_than one hundred mmhg
__label__1	study interventions are Liposomal doxorubicin . multiple myeloma diagnosis and known hypersensitivity to bortezomib boron or mannitol
__label__1	study interventions are Cyclophosphamide . lymphoma diffuse large cell diagnosis and systemic cytotoxic therapy within three weeks of treatment
__label__1	study interventions are Misonidazole . stage iva pancreatic cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
__label__1	study interventions are Vaccines . squamous cell carcinoma diagnosis and men or women of childbearing potential who are unwilling to employ adequate contraception condoms diaphragm birth control pills injections intrauterine device iud or abstinence etc
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and treatment with an investigational agent within two weeks prior to planned initiation of study therapy is allowed provided that any drug related toxicity has completely resolved
__label__1	study interventions are Immunoglobulins . cutaneous cell non hodgkin lymphoma diagnosis and prior radiation greater_than twenty gy to any critical normal organ lung liver spinal cord or over twenty-five of red marrow
__label__1	study interventions are Pyridoxal . cancer diagnosis and patients may receive no other concurrent complementary medicines during this study
__label__1	study interventions are Oxaliplatin . stage ii gastric cancer diagnosis and patients with known hypersensitivity to any of the components of oxaliplatin
__label__1	study interventions are Surgical staging . carcinoma non small cell lung diagnosis and uncorrected coagulopathy
__label__1	study interventions are Antibodies . ovarian serous adenocarcinoma diagnosis and participant has clinically significant peripheral artery disease those with claudication within six months
__label__1	study interventions are Pembrolizumab . metastatic prostate carcinoma diagnosis and five alpha reductase inhibitors
__label__1	study interventions are Bevacizumab . somatostatinoma diagnosis and concurrent use of other investigational agents and patients who have received investigational drugs less_than equal_than four weeks prior to enrollment
__label__1	study interventions are ER plus APC . existing symptomatic stricture or one caused by the study diagnostic er unless this can be dilated and the patient is then judged to be suitable for endoscopic treatment by the expert endoscopist
__label__1	study interventions are Capecitabine . gastric cancer diagnosis and atients have history of organ transplantation
__label__1	study interventions are Bevacizumab . inflammatory breast cancer stage iv diagnosis and prior treatment must be stopped before study entry
__label__1	study interventions are Antibodies, Monoclonal . non hodgkin lymphoma diagnosis and creatinine greater_than doc mg dl
__label__1	study interventions are Avelumab . laryngeal papilloma recurrent diagnosis and post menopause is defined as amenorrhea greater than or equal to twelve consecutive months
__label__1	study interventions are Cyclophosphamide . progesterone receptor negative breast cancer diagnosis and major surgical procedure within four weeks twenty-eight days prior to enrollment port placement is not considered major surgical procedure
__label__1	study interventions are Etoposide . stage iii follicular lymphoma diagnosis and intractable severe diarrhea defined as greater_than doc zero cc diarrheal fluid per day or diarrhea causing persistent severe electrolyte abnormalities or hypoalbuminemia
__label__1	study interventions are Irinotecan . stage ivb rectal cancer diagnosis and patients may not be receiving nor have received any other investigational agent equal_than less_than four weeks prior to study registration
__label__1	study interventions are Gemcitabine . soft tissue sarcoma diagnosis and patients who will need valproic acid for any medical condition
__label__1	study interventions are Trabedersen . melanoma diagnosis and patient participation in another clinical trial with investigational medication within thirty days prior to study entry
__label__1	study interventions are Anastrozole . breast cancer diagnosis and presence of metastatic disease
__label__1	study interventions are Pharmacological Study . recurrent childhood central nervous system neoplasm diagnosis and patients who have an uncontrolled infection are not eligible
__label__1	study interventions are Immunoglobulins . stage iv melanoma diagnosis and aspartate aminotransferase ast alanine aminotransferase alt greater_than doc uln
__label__1	study interventions are Endothelial Growth Factors . endometrial clear cell adenocarcinoma diagnosis and uncontrolled asthma or oxygen otwo saturation less_than ninety by abg arterial blood gas analysis or pulse_oximetry on room air
__label__1	study interventions are Fludarabine phosphate . noncontiguous stage ii grade two follicular lymphoma diagnosis and poorly controlled hypertension
__label__1	study interventions are Docetaxel . stage iiic breast cancer diagnosis and patients must not have bleeding diathesis hereditary of acquired bleeding disorder or coagulopathy
__label__1	study interventions are Sirolimus . multiple myeloma diagnosis and note
__label__1	study interventions are AFP464 . recurrent primary peritoneal cavity cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to afpfour hundred and sixty-four
__label__1	study interventions are cabozantinib-s-malate . stage iv melanoma diagnosis and hemoptysis of greater_than equal_than doc teaspoon doc ml of red blood within three months before the first dose of study treatment
__label__1	study interventions are Camptothecin . unresectable metastatic colo rectal cancer diagnosis and contraindicated for mri or ct
__label__1	study interventions are Mycophenolic Acid . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and treatment with rituximab for any reason in the twelve months preceding hct
__label__1	study interventions are Gemcitabine . urinary bladder cancer diagnosis and any previous exposure to intravesical gemcitabine instillations within the past twelve months
__label__1	study interventions are Buparlisib (BKM120) . patient has received chemotherapy or targeted anticancer therapy monoclonal antibodies less_than four weeks or five half lives whichever is shorter or six weeks for nitrosourea or mitomycin prior to starting the study drug or the patient has not recovered side the side effects of such therapy
__label__1	study interventions are Fludarabine phosphate . cervical cancer diagnosis and women of child bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
__label__1	study interventions are Paclitaxel . treatment with any anticancer therapy or investigational agent within thirty days prior to registration for protocol therapy
__label__1	study interventions are Mycophenolate mofetil . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Antibodies . recurrent hodgkin lymphoma diagnosis and known history of human immunodeficiency virus hiv or active with hepatitis virus hcv or hepatitis virus hbv subjects who are positive for hepatitis core antibody or hepatitis surface antigen must have negative polymerase chain reaction pcr result before enrollment those who are pcr positive will be excluded subjects who have an undetectable human immunodeficiency virus hiv viral load with cdfour greater_than equal_than two hundred and are on highly active antiretroviral therapy haart medication are allowed
__label__1	study interventions are Mycophenolic Acid . lymphoblastic lymphoma diagnosis and patient weight greater_than equal_than one hundred kg patients greater_than equal_than seventy kg with muds must be discussed with the principal investigator
__label__1	study interventions are Piperazine citrate . medulloblastoma diagnosis and because it is not known if mebendazole is excreted in breast milk breastfeeding should be discontinued if the mother is treated with mebendazole
__label__1	study interventions are Dihydrotestosterone . prior diagnosis of cancer except non melanoma skin cancer
__label__1	study interventions are Antibodies, Monoclonal . mucosal melanoma diagnosis and patients with untreated brain metastases leptomeningeal disease or seizure disorders are ineligible
__label__1	study interventions are Antilymphocyte Serum . stage iii marginal zone lymphoma diagnosis and uncontrolled diabetes mellitus cardiovascular disease active serious infection or other condition which in the opinion of treating physician would make this protocol unreasonably_hazardous for the patient
__label__1	study interventions are Cisplatin . head and neck cancer diagnosis and has an active autoimmune disease that has required systemic treatment in the past two years with use of disease modifying agents corticosteroids or immunosuppressive drugs
__label__1	study interventions are Capecitabine . locally advanced malignant neoplasm diagnosis and concurrent chronic systemic immune therapy
__label__1	study interventions are Cryoablation . renal cancers diagnosis and evidence of metastatic disease
__label__1	study interventions are Poly ICLC . head and neck cancer diagnosis and persistent toxicity from recent therapy that has not sufficiently resolved in the judgment of the study physician
__label__1	study interventions are Pertuzumab . stage iiic breast cancer diagnosis and palliative radiation therapy involving equal_than less_than twenty-five of marrow bearing bone is allowed if completed within greater_than equal_than fourteen days prior to first study treatment
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and treatment with thiazolidinedione tzds within four weeks prior to start of study treatment
__label__1	study interventions are Trametinib . melanoma diagnosis and active known suspected or documented history of autoimmune disease
__label__1	study interventions are First line systemic treatment . carcinoma non small cell lung diagnosis and patients with malignant pleural or pericardial effusion
__label__1	study interventions are Pancreatin . non metastatic pancreas cancer diagnosis and pregnant or lactating female
__label__1	study interventions are Bevacizumab . cervical adenosquamous carcinoma diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess for which an interval of three to six months must pass before study entry in addition the patient must have undergone correction or spontaneous healing of the perforation fistula and or the underlying process causing the fistula perforation patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are Nelfinavir . cervical cancer diagnosis and patients with stage ia ib or ivb disease
__label__1	study interventions are Levoleucovorin . stage ii lymphoblastic lymphoma diagnosis and patients with central nervous system three cnsthree leukemia
__label__1	study interventions are Antibodies, Monoclonal . stage iva laryngeal verrucous carcinoma diagnosis and patients with diseases which with reasonable certainty do not limit life expectancy to twelve months or less are eligible assessment of such concurrent illnesses should be by the principal investigator
__label__1	study interventions are Darbepoetin alfa . diffuse large cell lymphoma diagnosis and known hypersensitivity to erythropoietin
__label__1	study interventions are Panobinostat . enteropath negative type cell lymphoma diagnosis and concomitant use of any other investigational agent
__label__1	study interventions are Chloroquine . chondrosarcoma diagnosis and myocardial infarction
__label__1	study interventions are Cetuximab . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Interleukin-2 . metastatic melanoma diagnosis and active autoimmune disease
__label__1	study interventions are Dexamethasone acetate . refractory plasma cell myeloma diagnosis and have grade two or greater neuropathy at the time of screening
__label__1	study interventions are Carboplatin . endometrial adenosquamous carcinoma diagnosis and patients who have had radiotherapy within four weeks prior to entering the study or those who have not recovered from adverse events ctcae vfour grade two or greater excluding alopecia due to agents administered more than four weeks earlier
__label__1	study interventions are Nurse phone call . cancer diagnosis and patient residing outside the rhône alpes area
__label__1	study interventions are Docetaxel . undifferentiated carcinoma diagnosis and patients whom have already undergone secondary cytoreduction for recurrent disease are excluded
__label__1	study interventions are Rituximab . t lymphoblastic lymphoma diagnosis and systemic therapy for the acute management of hyperleukocytosis or acute symptoms corticosteroids cytarabine etc
__label__1	study interventions are Antibodies, Monoclonal . melanoma diagnosis and known history of human immunodeficiency virus hiv
__label__1	study interventions are Sirolimus . recurrent pancreatic neuroendocrine carcinoma diagnosis and not recovered from adverse events related to previous treatment excluding alopecia to active common terminology criteria for adverse events ctcae equal_than less_than grade one
__label__1	study interventions are Dexamethasone acetate . extranodal nk cell lymphoma diagnosis and patients who have serious medical condition abnormal laboratory results or psychiatric problems
__label__1	study interventions are Cyclophosphamide . stage iv ovarian germ cell tumor diagnosis and patients with any clinically significant autoimmune disease uncontrolled with treatment
__label__1	study interventions are Prednisone . hormone resistant prostate cancer diagnosis and prior therapy with cabazitaxel or to other drugs formulated with polysorbate eighty
__label__1	study interventions are Bevacizumab . angiosarcoma diagnosis and patients that have received more than two regimens of chemotherapy whatever the indication
__label__1	study interventions are Fluorouracil . rectal adenocarcinoma diagnosis and combination of the following positive or positive or positive c
__label__1	study interventions are Bortezomib . stage iv pancreatic cancer diagnosis and patients must not have significant history of cardiac disease unstable angina congestive heart failure with new york heart association class three or four and myocardial infarction within the last six months
__label__1	study interventions are Vinorelbine . hertwo negative locally advanced breast cancer diagnosis and patients who have received prior radiotherapy to greater_than two5 of the bone marrow
__label__1	study interventions are Maleic acid . stage iiia non small cell lung cancer diagnosis and patients may not have evidence of coagulopathy or bleeding diathesis therapeutic anticoagulation for prior thromboembolic events is permitted the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the given the increased risk of serious bleeding from cediranib patients who are on greater than or equal to two anti thrombotic agents including but not limited to anti platelet agents non steroidal anti inflammatory drugs nsaids aspirin clopidogrel heparin low molecular weight heparin lmwh warfarin and direct thrombin inhibitor will be excluded
__label__1	study interventions are Cyclosporine . stage iii adult lymphoblastic lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Rituximab . follicular lymphoma diagnosis and any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form
__label__1	study interventions are Ketoconazole . cancer diagnosis and clinically significant gi abnormalities that may affect absorption of investigational product including but not limited to
__label__1	study interventions are magnetic resonance spectroscopic imaging . prostate cancer diagnosis and acute renal dysfunction due to the hepato renal syndrome or in the perioperative liver transplantation period
__label__1	study interventions are Pembrolizumab . transitional cell carcinoma diagnosis and if subject received major surgery they must have recovered adequately from the toxicity and or complications from the intervention prior to starting therapy
__label__1	study interventions are Dexamethasone acetate . recurrent childhood lymphoblastic lymphoma diagnosis and shortening fraction of greater_than equal_than twenty-seven by echocardiogram or ejection fraction of greater_than equal_than fifty by gated radionuclide study
__label__1	study interventions are Pembrolizumab . penile cancer diagnosis and the following patients will undergo cardiac evaluations
__label__1	study interventions are laboratory biomarker analysis . stage ivc salivary gland cancer diagnosis and nefazodone_fluovoxamine
__label__1	study interventions are Bevacizumab . colorectal neoplasms diagnosis and history of organ transplants
__label__1	study interventions are MART-1 Antigen . stage iib skin melanoma diagnosis and chemotherapy equal_than less_than four weeks prior to registration
__label__1	study interventions are Rituximab . noncontiguous stage ii mantle cell lymphoma diagnosis and presence of active central nervous system cns disease history of adequately treated cns disease is acceptable
__label__1	study interventions are Tremelimumab . malignant melanoma diagnosis and history of treated hepatitis is not exclusionary
__label__1	study interventions are Antibodies . recurrent childhood large cell lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Nivolumab . renal cell carcinoma diagnosis and active known or suspected exclusionary autoimmune disease
__label__1	study interventions are Antibodies . ovarian serous cystadenocarcinoma diagnosis and new york heart association nyha grade ii or greater congestive heart failure
__label__1	study interventions are endoscopic submucosal dissection . esophageal neoplasm diagnosis and esophageal varices grade three or of any grade with signs of recent bleeding
__label__1	study interventions are GDC-0349 . non hodgkin lymphoma solid tumor diagnosis and known untreated central nervous system cns malignancies or treated brain metastases that are not radiographically stable for greater_than equal_than three months prior to initiation of study treatment
__label__1	study interventions are Mycophenolic Acid . stage iii adult hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and acute or chronic liver disease or renal disease
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and patients with any underlying medical condition which cannot be adequately controlled
__label__1	study interventions are Mycophenolic Acid . stage mantle cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than forty total lung capacity tlc less_than forty forced expiratory volume in one second fevone less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Cyclophosphamide . ovarian serous adenocarcinoma diagnosis and participant requires or is likely to require more than two week course of corticosteroids for intercurrent illness participant must complete the course of corticosteroids two weeks before screening to meet eligibility
__label__1	study interventions are Gemcitabine . non small cell lung cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Anti-Inflammatory Agents, Non-Steroidal . multiple myeloma diagnosis and patients who have had recent gi bleed less than two weeks ago will be excluded
__label__1	study interventions are Aldesleukin . symptomatic cardiac disease
__label__1	study interventions are Fluorouracil . carcinoma diagnosis and entry to the other clinical trial within four weeks prior to entry to this study
__label__1	study interventions are pharmacological study . recurrent islet cell carcinoma diagnosis and nursing women
__label__1	study interventions are briciclib . neoplasms diagnosis and ascites requiring active medical management including paracentesis
__label__1	study interventions are Etoposide . stage iv cutaneous cell non hodgkin lymphoma diagnosis and pregnant or breastfeeding women are excluded from this study breastfeeding should be discontinued if the mother is treated with busulfan cyclophosphamide and etoposide
__label__1	study interventions are Nodal Radiation Therapy . history of prior or concurrent contralateral invasive breast cancer
__label__1	study interventions are CM082 Tablet . advanced cancer diagnosis and patients with known gi disorders such as vomiting diarrhea
__label__1	study interventions are Podophyllotoxin . grade threeb follicular lymphoma diagnosis and absolute cdfour count of less_than fifty cells mm three
__label__1	study interventions are Phosphoramide Mustards . high grade glioma diagnosis and non bevacizumab systemic therapy including investigational agents and small molecule kinase inhibitors or non cytotoxic hormonal therapy eg tamoxifen within seven days or five half lives whichever is shorter prior first dose of study drug
__label__1	study interventions are Mesna . hodgkin lymphoma diagnosis and impaired cardiac function or clinically significant cardiac diseases including any one of the following
__label__1	study interventions are Antibodies, Monoclonal . stage iv melanoma diagnosis and patients with cns lesions that have been treated and who have no evidence of progression in the brain on ct mri for
__label__1	study interventions are Fludarabine . childhood diffuse large cell lymphoma diagnosis and disease resulting in severely limited performance status less_than seventy
__label__1	study interventions are Azacitidine . advanced or metastatic solid tumors diagnosis and major surgery radiotherapy chemotherapy or investigational agents within four weeks of treatment day one
__label__1	study interventions are Antibodies . neoplasm nerve tissue diagnosis and pregnant or nursing females
__label__1	study interventions are Dexrazoxane . fibrosarcoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to dexrazoxane or other agents used in the study
__label__1	study interventions are Progressive Stretching . breast cancer diagnosis and acute pulmonary embolus or pulmonary infarction within three months of any planned study procedures
__label__1	study interventions are Cetuximab . stage iv colon cancer diagnosis and uncontrolled hypertension
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and current peripheral neuropathy by chemotherapy diabetes mellitus alcoholic disease and relative symptoms with relevant treatment
__label__1	study interventions are Vaccines . stage iia ovarian cancer diagnosis and other serious illnesses serious infections requiring antibiotics bleeding disorders
__label__1	study interventions are Alemtuzumab . recurrent childhood lymphoblastic lymphoma diagnosis and donor
__label__1	study interventions are Tremelimumab . prostate cancer diagnosis and no prior treatment with an lhrh agonist or nonsteroidal antiandrogen such as casodex or flutamide
__label__1	study interventions are Oxaliplatin . ovarian neoplasms diagnosis and active or prior documented autoimmune or inflammatory disorders
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and investigational therapy within twenty-eight days prior to day one
__label__1	study interventions are Sirolimus . neuroendocrine tumors diagnosis and adults of reproductive potential not willing to use effective methods of birth control during tx and greater_than eight wks after completing tx
__label__1	study interventions are Olaparib . metastatic castration resistant prostate cancer diagnosis and current disease or condition known to interfere with absorption distribution metabolism or excretion of drugs at the investigator discretion
__label__1	study interventions are selumetinib . stage iva gallbladder cancer diagnosis and preclinical studies demonstrated the potential of mk two thousand, two hundred and six for induction of hyperglycemia in all preclinical_species tested patients with diabetes or in risk for hyperglycemia should not be excluded from trials with mk two thousand, two hundred and six but the hyperglycemia should be well controlled on oral agents before the patient enters the trial
__label__1	study interventions are Romidepsin . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and men or women of childbearing potential who are unwilling to employ adequate contraception
__label__1	study interventions are Gemcitabine . borderline resectable pancreatic cancer treated with chemoradiotherapy diagnosis and pregnant women women planning to become pregnant and women that are nursing
__label__1	study interventions are Idelalisib . small lymphocytic lymphoma diagnosis and positive serology for hepatitis hb defined as positive test for hbsag
__label__1	study interventions are Oxaliplatin . rectal cancer diagnosis and lymph node is considered malignant when
__label__1	study interventions are N-monoacetylcystine . stage ivc squamous cell carcinoma of the larynx diagnosis and pregnant women
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and evidence of any other medical conditions such as psychiatric illness peptic ulcer etc
__label__1	study interventions are Rituximab . nodal marginal zone cell lymphoma diagnosis and other active malignancy requiring therapy exceptions
__label__1	study interventions are Paclitaxel . metastatic melanoma diagnosis and however presence of controlled brain metastases evaluated as sd of pr after radiotherapy is allowed
__label__1	study interventions are Dexamethasone 21-phosphate . diffuse large cell lymphoma diagnosis and patients with serious cardiac illness or condition including but not limited to
__label__1	study interventions are Immunoglobulin G . malignant glioma diagnosis and psychiatric illness social situations that would limit compliance with study requirements or compromise the ability of the subject to give written informed consent
__label__1	study interventions are Cisplatin . ovarian cancer diagnosis and subjects who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
__label__1	study interventions are Cyclophosphamide . stage iv adult hodgkin lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to busulfan other agents used in this study
__label__1	study interventions are Prednisolone hemisuccinate . recurrent childhood anaplastic large cell lymphoma diagnosis and active extramedullary leukemia including cns disease
__label__1	study interventions are Letrozole . stage iiib breast cancer diagnosis and unwillingness to give informed consent
__label__1	study interventions are Vorinostat . stage iiib non small cell lung cancer diagnosis and prior therapy with paclitaxel
__label__1	study interventions are Antibodies, Monoclonal . gliosarcoma diagnosis and serious non healing wound ulcer or bone fracture patients with any wound requiring surgical intervention including scalp wounds requiring cranioplasty will be allowed to resume the study if the wound is clean and without further infection post surgical intervention
__label__1	study interventions are Immunoconjugates . stage iib breast cancer diagnosis and uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of study treatment
__label__1	study interventions are Sunitinib . endometrial adenocarcinoma diagnosis and low molecular weight heparin is permitted provided the patient prothrombin time pt international normalized ratio inr is equal_than less_than doc
__label__1	study interventions are Motexafin gadolinium . non small cell lung carcinoma diagnosis and myocardial infarction within six months of enrollment or congestive heart failure rated new york heart association nyha class iii or iv
__label__1	study interventions are Irinotecan . adult anaplastic astrocytoma diagnosis and patient with another active malignancy is ineligible for this study
__label__1	study interventions are Estrogens . triple negative breast carcinoma diagnosis and has had prior chemotherapy targeted small molecule therapy or radiation therapy within two weeks prior to study day one or who has not recovered equal_than less_than grade one or at baseline from adverse events due to previously administered agent note
__label__1	study interventions are Escalated Dose . malignant neoplasm of oropharynx stage iva diagnosis and previous or concurrent illness which in the investigator opinion would interfere with either completion of therapy or follow up
__label__1	study interventions are Veliparib . ovarian mucinous adenocarcinoma diagnosis and patients with invasive procedures or anticipation of invasive procedures within the following timeframes as defined below
__label__1	study interventions are Melphalan . patients must not have prior malignancy except for adequately treated basal cell or squamous cell skin cancer in situ cervical cancer or other cancer for which the patient has not received treatment for one year prior to enrollment
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and active or recent hemoptysis greater_than equal_than ½_teaspoon of bright red blood per episode equal_than less_than thirty days prior to randomization
__label__1	study interventions are Carotenoids . stage iii prostate cancer diagnosis and concurrent use of any vitamin herb or mineral supplements for at least fourteen days prior to start of therapy
__label__1	study interventions are Capecitabine . recurrent fallopian tube carcinoma diagnosis and previous history of malabsorption or other conditions preventing oral treatment
__label__1	study interventions are Melphalan . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and positive serology for toxoplasma_gondii and requiring treatment or with evidence of active infection
__label__1	study interventions are Metformin . breast cancer prevention diagnosis and have received other investigational agents within the past three months preceding the time of registration
__label__1	study interventions are RTA 744 . brain tumor diagnosis and two active or uncontrolled infection
__label__1	study interventions are Capecitabine . colorectal cancer diagnosis and prior chemotherapy for liver metastasis
__label__1	study interventions are Prosigna . at the time of enrollment subjects may not have had any prior systemic therapy for breast cancer including chemotherapy hormonal therapy or targeted biologic therapy
__label__1	study interventions are Dacarbazine . adult giant cell glioblastoma diagnosis and valproic acid another histone_deacetylase inhibitor equal_than less_than two weeks prior to registration and during treatment
__label__1	study interventions are Etoposide . cytologic or radiographic evidence of cns lymphoma
__label__1	study interventions are Etoposide . relapsed cell lymphoblastic lymphoma diagnosis and patients with prior seizure disorder requiring anti convulsant therapy are not eligible to receive nelarabine
__label__1	study interventions are Camptothecin . known cns metastases or carcinomatous_meningitis
__label__1	study interventions are Paclitaxel . esophageal neoplasm diagnosis and any un expected reason for patients can get operation
__label__1	study interventions are Fludarabine phosphate . recurrent mantle cell lymphoma diagnosis and active or recent prior six months invasive fungal infection without id consult and approval
__label__1	study interventions are CHI3L1 protein, human . malignant ovarian clear cell tumor diagnosis and patients who receive neoadjuvant chemotherapy prior to surgical staging
__label__1	study interventions are Gossypol acetic acid . carcinoma non small cell lung diagnosis and current treatment on other therapeutic clinical trials
__label__1	study interventions are Folic Acid . malignant neoplasm of stomach diagnosis and actively evolutive inflammatory bowel disease or any other intestinal disease causing chronic diarrhea greater_than grade two
__label__1	study interventions are Fluorouracil . stage iva rectal cancer diagnosis and impaired cardiovascular function or clinically significant cardiovascular diseases including any of the following
__label__1	study interventions are Romidepsin . mature cell lymphoma diagnosis and pre existing motor or sensory neuropathy greater_than grade three
__label__1	study interventions are Picosulfate sodium . colorectal cancer diagnosis and patient has condition clinically significant laboratory results or is in situation which in the investigator opinion may put the patient at significant risk may confound the study results or may interfere significantly
__label__1	study interventions are Trifluridine . squamous cell lung carcinoma diagnosis and subjects demonstrating an inability to comply with the study and or follow up procedures
__label__1	study interventions are Rituximab . burkitt lymphoma diagnosis and steroids of less than seventy-two hours duration for impending oncologic emergency are allowed
__label__1	study interventions are Antibodies . testicular lymphoma diagnosis and history of autoimmune disease requiring systemic therapy with immunosuppressive drugs including but not limited to rheumatoid arthritis inflammatory bowel disease systemic lupus erythematosus multiple sclerosis or psoriasis
__label__1	study interventions are Fludarabine . recurrent adult lymphoblastic lymphoma diagnosis and donor
__label__1	study interventions are Fludarabine . recurrent adult immunoblastic large cell lymphoma diagnosis and patients with known hypersensitivity to fludarabine or history of purine analog associated autoimmune hemolytic anemia or idiopathic thrombocytopenic_purpura
__label__1	study interventions are Docetaxel . gastric carcinoma diagnosis and prior chemotherapy regimen have included taxane docetaxel or paclitaxel uncontrolled hypertension
__label__1	study interventions are Abiraterone Acetate . castration resistant prostate cancer diagnosis and any prior treatment with cabozantinib or participation in prior clinical trial of cabozantinib
__label__1	study interventions are Iodine-131 anti-B1 antibody . clinical evidence of central nervous system cns involvement by lymphoma
__label__1	study interventions are Liposomal doxorubicin . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and lactating females who plan to breastfeed
__label__1	study interventions are Chloroquine diphosphate . breast cancer diagnosis and concurrent use of potent cypthreeafour inhibitors such as ketoconazole itraconazole clarithromycin indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin and voriconazole
__label__1	study interventions are Liposomal doxorubicin . ovarian cancer diagnosis and concomitant diseases conditions
__label__1	study interventions are Vincristine . stage iii diffuse large cell lymphoma diagnosis and has history of non infectious pneumonitis that required steroids or current pneumonitis
__label__1	study interventions are GSK2820151 . cancer diagnosis and history of or current untreated clinically significant uncontrolled arrhythmias clinically significant conduction abnormalities or arrhythmias presence of cardiac pacemaker history or evidence of current greater_than equal_than class ii congestive heart failure as defined by new york heart association nyha history of acute coronary syndromes including unstable angina and myocardial infarction coronary angioplasty or stenting within the past three months
__label__1	study interventions are Bevacizumab . breast cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to day zero
__label__1	study interventions are Albumin-Bound Paclitaxel . prior chemotherapy for advanced non small cell lung cancer
__label__1	study interventions are Cisplatin . stage ivb squamous cell carcinoma of the larynx diagnosis and serious concomitant systemic disorders including active infections that would compromise the safety of the patient or compromise the patient ability to complete the study at the discretion of the investigator this includes scleroderma
__label__1	study interventions are Folic Acid . glioblastoma diagnosis and non operable gbm
__label__1	study interventions are Gemcitabine . patients with symptomatic brain metastases or with leptomeningeal disease
__label__1	study interventions are Glucocorticoids . wegener granulomatosis diagnosis and have limited disease that would not normally be treated with cyc
__label__1	study interventions are Immunoglobulin G . stage iv fallopian tube cancer diagnosis and patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration and or nutrition
__label__1	study interventions are Oxaliplatin . patients with extensive symptomatic fibrosis of the lungs
__label__1	study interventions are Paclitaxel . endometrial cancer diagnosis and new york heart association nyha class ii or greater congestive heart failure
__label__1	study interventions are Mitogens . non squamous non small cell lung cancer diagnosis and progressive or uncontrolled brain metastases
__label__1	study interventions are Pioglitazone . stage oral cavity squamous cell carcinoma diagnosis and ten inter limb discrepancy in volume or circumference at point of greatest visible difference swelling or obscuration of anatomic architecture on close inspection
__label__1	study interventions are Cytarabine . myeloid sarcoma diagnosis and patients with acute promyelocytic leukemia apl as diagnosed by morphologic criteria flow cytometric characteristics and rapid cytogenetics or fluorescence in situ hybridization fish or molecular testing
__label__1	study interventions are Nelarabine . adult lymphoblastic lymphoma diagnosis and active hiv or hepatitis or infection
__label__1	study interventions are Endothelial Growth Factors . stage iiia primary peritoneal cancer diagnosis and patients with clinically significant proteinuria urine protein creatinine ratio greater or equal to doc
__label__1	study interventions are Sorafenib . non small cell lung cancer diagnosis and any other non pulmonary hemorrhage bleeding event greater_than equal_than grade three within twenty-eight days of initial study treatment
__label__1	study interventions are Lenalidomide . adult nasal type extranodal nk cell lymphoma diagnosis and cell prolymphocytic leukemia
__label__1	study interventions are BCG Vaccine . urinary bladder neoplasms diagnosis and kidney or liver function disorders more than doc times upper normal limit
__label__1	study interventions are Sorafenib . glioblastoma multiforme diagnosis and john wort or rifampicin
__label__1	study interventions are Vaccines . pancreatic acinar cell carcinoma diagnosis and evidence of immunodeficiency or immune suppression autoimmune diseases such as the following
__label__1	study interventions are Poly ICLC . unresectable stage iii or stage iv melanoma diagnosis and systemic radiation therapy within four weeks focal radiotherapy within two weeks and radiopharmaceuticals strontium samarium within eight weeks prior to first dose of study treatment
__label__1	study interventions are Docetaxel . stomach cancer diagnosis and uncontrolled serious medical or psychiatric illness
__label__1	study interventions are Cyclophosphamide . lymphoma diagnosis and transaminase ast alt greater_than three times the upper normal value or ii
__label__1	study interventions are Cyclophosphamide . lymphoma large cell diffuse diagnosis and significant active cardiac disease within the previous six months from the signing of the icd including
__label__1	study interventions are Antibodies, Monoclonal . colorectal cancer diagnosis and history of bone marrow or stem cell transplant
__label__1	study interventions are EMD 525797 . colorectal and ovarian cancer patients with liver metastases diagnosis and legal incapacity or limited legal capacity not applicable only in rare cases
__label__1	study interventions are Hormones . recurrent fallopian tube carcinoma diagnosis and patients who have received live attenuated vaccines equal_than less_than one week prior to registration and during the study note
__label__1	study interventions are Gemcitabine . non small cell lung cancer diagnosis and interstitial pneumonia or lung fibrosis
__label__1	study interventions are Mycophenolate mofetil . stage iii grade three follicular lymphoma diagnosis and current serious systemic illness that would result in increased risk for csf mobilization and harvest of peripheral blood stem cells pbsc
__label__1	study interventions are Cetuximab . signet ring adenocarcinoma of the colon diagnosis and new york heart association grade ii or greater congestive heart failure serious cardiac arrhythmia requiring medication unstable angina pectoris
__label__1	study interventions are Poly I-C . participants who have another cancer diagnosis except that the following diagnoses will be allowed
__label__1	study interventions are Pharmacological Study . recurrent melanoma diagnosis and patients who are currently receiving another investigational drug are not eligible
__label__1	study interventions are Therapeutic Conventional Surgery . stage iib skin melanoma diagnosis and any condition which in the investigator opinion deems the subject an unsuitable candidate to undergo observational study may also include preoperative testing results including electrocardiogram ekg chest ray or pulmonary function tests that preclude wide excision in the operating room
__label__1	study interventions are Antibodies, Monoclonal . colorectal cancer diagnosis and patients who have had an organ transplant
__label__1	study interventions are Pharmacological Study . endometrial adenosquamous carcinoma diagnosis and cardiovascular disorders including
__label__1	study interventions are Gemcitabine . non small cell lung carcinoma diagnosis and heart insufficiency nyha iii and iv
__label__1	study interventions are Cyclosporine . recurrent adult diffuse mixed cell lymphoma diagnosis and current serious systemic illness
__label__1	study interventions are Prednisone . hormone refractory prostate cancer diagnosis and major gi surgery or gi disease affecting absorption
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . breast cancer diagnosis and patients with diabetes type or uncontrolled type ii hbaonec greater_than eight assessed locally as judged by the investigator
__label__1	study interventions are Cyclosporins . stage iii adult diffuse mixed cell lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and patients known to be hiv positive
__label__1	study interventions are Leucovorin . locally advanced malignant neoplasm diagnosis and doc
__label__1	study interventions are Everolimus . metastatic clear cell renal cancer diagnosis and patients who are currently receiving anticoagulation treatment with therapeutic doses of warfarin
__label__1	study interventions are Liposomal doxorubicin . tubular breast cancer stage iii diagnosis and currently active infection
__label__1	study interventions are Carboplatin . hodgkin lymphoma diagnosis and patient with other medical or psychiatric illness that is likely to interfere with participation in this clinical study
__label__1	study interventions are Etoposide . non hodgkin lymphoma diagnosis and psychiatric disorder or mental deficiency severe as to make compliance with the treatment unlike and making informed consent impossible
__label__1	study interventions are Vorinostat . unspecified adult solid tumor protocol specific diagnosis and poorly controlled type one or two diabetes defined as hemoglobin aonec greater than eight or fasting glucose of greater_than one60 mg dl
__label__1	study interventions are Cisplatin . unspecified adult solid tumor protocol specific diagnosis and known diagnosis of hiv infection
__label__1	study interventions are Hypoperfusion of renal artery . renal cell carcinoma diagnosis and no prior diagnosis of renal artery disease
__label__1	study interventions are Lenvatinib . refractory solid tumors diagnosis and that may affect pk profiles of lenvatinib
__label__1	study interventions are Antibodies . gastric cancer diagnosis and active or uncontrolled infection
__label__1	study interventions are Capecitabine . stage ii esophageal squamous cell carcinoma diagnosis and history of organ transplantation
__label__1	study interventions are Paclitaxel . cancer ovarian diagnosis and history or evidence of central nervous system cns disorders unless properly treated with standard medical treatment
__label__1	study interventions are Open Surgery . free cancer cells
__label__1	study interventions are Mycophenolic Acid . recurrent indolent adult non hodgkin lymphoma diagnosis and fertile females who are unwilling to use contraceptive techniques during and for the twelve months following treatment as well as females who are pregnant or actively breast feeding
__label__1	study interventions are Interleukin-12 . pancreatic polypeptide tumor diagnosis and exposure to any investigational drug within three weeks prior to the start of dosing
__label__1	study interventions are Cyclosporins . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and infection with hiv
__label__1	study interventions are Polygenic Risk Score . breast cancer diagnosis and at risk due to prior radiation therapy to the chest
__label__1	study interventions are Analgesics, Opioid . cancer diagnosis and taking opioids for management of drug addiction
__label__1	study interventions are Doxorubicin . cutaneous lymphoma diagnosis and any known cardiac abnormalities including
__label__1	study interventions are Prednisone . lymphoma that is clearly restricted to the cns or originating from the gastrointestinal tract
__label__1	study interventions are Procarbazine . newly diagnosed non methylated glioblastoma multiforme grade four diagnosis and prior chemotherapy within the last five years
__label__1	study interventions are Pomalidomide . in situ squamous cell carcinoma of the cervix or anus
__label__1	study interventions are Trastuzumab . pregnant or lactating woman of childbearing potential with either positive or no pregnancy test at baseline are excluded postmenopausal woman must have been amenorrheic for at least twelve months to be considered of non childbearing potential patients must agree to continue contraception for thirty days from the date of the last study drug administration woman of childbearing potential not using reliable and appropriate contraceptive method are excluded
__label__1	study interventions are INC280 . melanoma diagnosis and patients with uncontrolled hypertension please refer to who ishguidelines are excluded from study
__label__1	study interventions are Etoposide . stage adult lymphoblastic lymphoma diagnosis and pregnant or breastfeeding women are excluded from this study breastfeeding should be discontinued if the mother is treated with busulfan cyclophosphamide and etoposide
__label__1	study interventions are Positron Emission Tomography . stage iiib ovarian cancer diagnosis and pregnant and breastfeeding
__label__1	study interventions are Etoposide phosphate . refractory diffuse large cell lymphoma diagnosis and history of myocardial infarction equal_than less_than one hundred and eighty days prior to registration or congestive heart failure requiring use of ongoing maintenance therapy for life threatening ventricular arrhythmias
__label__1	study interventions are Paclitaxel . stage iiib non small cell lung cancer diagnosis and patients who are participating in concurrent treatment protocol
__label__1	study interventions are Hormones . adenocarcinoma of the prostate diagnosis and at least two months must have elapsed from time of dosing with vaccines to the time of prescreening
__label__1	study interventions are Calcium, Dietary . stage iiia rectal cancer diagnosis and history of abdominal fistula gastrointestinal gi perforation or intra abdominal abscess within six months of randomization
__label__1	study interventions are Ramucirumab . stomach neoplasms diagnosis and exclude patient from this study if any of the following conditions are observed
__label__1	study interventions are PankoMab-GEX . primary peritoneal cancer with high grade grade two or three serous features or serous component diagnosis and clinically active infections greater_than grade two using nci ctcae doc
__label__1	study interventions are Sorafenib . untreated metastatic squamous neck cancer with occult primary diagnosis and subjects with thrombotic embolic venous or arterial events such as cerebrovascular accident including transient ischemic attacks within six months of informed consent
__label__1	study interventions are Mycophenolate mofetil . small intestine lymphoma diagnosis and cardiac ejection fraction less_than forty ejection fraction is required if the patient has history of anthracyclines or history of cardiac disease
__label__1	study interventions are questionnaire administration . neoplasm metastases diagnosis and patients having another severe or uncontrolled pathology which could compromise the participation at the study such as infection cardiovascular digestive renal or pulmonary disease
__label__1	study interventions are Interleukin-2 . previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study except cervical carcinoma in situ treated basal cell carcinoma superficial bladder tumors ta_tis ti or any cancer curatively treated less_than five years prior to study entry
__label__1	study interventions are Dactinomycin . alveolar rhabdomyosarcoma diagnosis and female patients who are pregnant are not eligible note
__label__1	study interventions are Antibodies, Monoclonal . stage iiib ovarian cancer diagnosis and pregnant women
__label__1	study interventions are Liposomal doxorubicin . patient has symptomatic metastasis to brain
__label__1	study interventions are Mycophenolate mofetil . stage ii multiple myeloma diagnosis and have progressive disease at the time of transplant
__label__1	study interventions are Immunoglobulins . recurrent adult immunoblastic large cell lymphoma diagnosis and known human immunodeficiency virus hiv infection
__label__1	study interventions are B-mode US . hepatocellular carcinoma diagnosis and age under twenty
__label__1	study interventions are western blotting . adult anaplastic ependymoma diagnosis and clinically evident congestive heart failure greater_than class ii of the new york heart association nyha guidelines
__label__1	study interventions are Immunoglobulin G . fallopian tube mucinous adenocarcinoma diagnosis and note
__label__1	study interventions are Gentamicins . nasopharyngeal neoplasms diagnosis and known allergic reaction to any component of oral ulcer gargle forrad or quadruple mixture which is composed of dexamethasone gentamicin vitamin btwelve and procaine or severe allergic constitution
__label__1	study interventions are Vidarabine . recurrent grade three follicular lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Liposomal doxorubicin . recurrent fallopian tube carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab
__label__1	study interventions are Cyclophosphamide . breast neoplasms diagnosis and any documented myocardial infarction
__label__1	study interventions are Abiraterone Acetate . prostate cancer diagnosis and clinically significant laboratory findings except as related to hepatic impairment
__label__1	study interventions are Peginterferon alfa-2b . childhood craniopharyngioma diagnosis and serum creatinine equal_than less_than doc the upper limit of normal for age or calculated creatinine clearance or nuclear glomerular filtration rate gfr greater_than equal_than seventy ml min doc three two
__label__1	study interventions are ExAblate 2000 . targeted tumor is at an impending fracture site greater_than seven on fracture risk score see section doc
__label__1	study interventions are Cyclosporins . multiple myeloma diagnosis and pregnant or breast feeding
__label__1	study interventions are FLC removal HD (Gambro HCO 1100) . multiple myeloma diagnosis and inability to give informed consent
__label__1	study interventions are Paclitaxel . stage iiia ovarian cancer diagnosis and patients with clinically significant proteinuria urine protein creatinine ratio greater or equal to doc
__label__1	study interventions are Imatinib Mesylate . lung cancer diagnosis and patient has known diagnosis of human immunodeficiency virus hiv infection
__label__1	study interventions are Daratumumab . multiple myeloma diagnosis and clinically significant abnormal electrocardiogram ecg finding at screening
__label__1	study interventions are Palbociclib . recurrent extragonadal non seminomatous germ cell tumor diagnosis and the subject has received cytotoxic chemotherapy including investigational cytotoxic chemotherapy within three weeks or nitrosoureas or mitomycin within six weeks before the first dose of pd
__label__1	study interventions are Immunoglobulin G . recurrent digestive system neuroendocrine tumor gone diagnosis and clinical evidence of encephalopathy
__label__1	study interventions are Pixantrone . malignant lymphoma diagnosis and at least six months response duration since last given course of treatment
__label__1	study interventions are Paclitaxel . stage iiib breast cancer diagnosis and patients suffering from psychiatric impairment are not eligible
__label__1	study interventions are ImmuniCell® . renal cell cancer diagnosis and pregnancy or lactation before or during the trial
__label__1	study interventions are Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and use of chronic immunosuppressive drugs
__label__1	study interventions are Antibodies, Monoclonal . metastatic malignant neoplasm in the brain diagnosis and the use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed and patients who previously required corticosteroids for symptom control must be off steroids for at least three days without recurrence of symptoms prior to starting trial therapy corticosteroids for other indications is allowed
__label__1	study interventions are Cyclosporine . stage iv adult cell leukemia lymphoma diagnosis and the fhcrc pi of the study must approve of enrollment of all patients with pulmonary nodules
__label__1	study interventions are Ascorbic Acid . cancer of the pancreas diagnosis and patients who are on the following drugs and cannot have substitution or who decline the substitution
__label__1	study interventions are Esophagectomy . esophageal cancer diagnosis and these patients will undergo open resection
__label__1	study interventions are Everolimus . recurrent breast cancer diagnosis and uncontrolled diabetes as defined by fasting serum glucose greater_than doc uln
__label__1	study interventions are Camptothecin . tumors diagnosis and major surgery within one month of study day one
__label__1	study interventions are Carboplatin . breast cancer diagnosis and uncontrolled infectious disease or known human immunodeficiency virus hiv one or hiv two type patients
__label__1	study interventions are Questionnaire Administration . renal cell carcinoma diagnosis and prior radiation to the index spine
__label__1	study interventions are Antibodies, Monoclonal . nodal marginal zone cell lymphoma diagnosis and patients who have had or are planning to have the following invasive procedures are not eligible
__label__1	study interventions are Ursodeoxycholic Acid . colorectal cancer diagnosis and significant medical or psychiatric condition that would make treatment unsafe
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and history of heart disease with congestive heart failure
__label__1	study interventions are Docetaxel . lung neoplasms diagnosis and superior vena_cava syndrome contra indicating hydration
__label__1	study interventions are Doxorubicin . plexiform fibrohistiocytic tumor diagnosis and note
__label__1	study interventions are Fludarabine phosphate . stage iv grade two follicular lymphoma diagnosis and unrelated donor products received from the deutsche_knochenmarkspenderdatei dkms_registry are not eligible for the optional study
__label__1	study interventions are Bortezomib . recurrent cell non hodgkin lymphoma diagnosis and patients must be willing not drive operate dangerous tools or machinery or engage in any other potentially hazardous activity that requires full alertness and coordination if they experience excessive sedation if patient experiences excessive sedation believed to be related to mlneight thousand, two hundred and thirty-seven treatment with mlneight thousand, two hundred and thirty-seven should be interrupted
__label__1	study interventions are Mycophenolate mofetil . recurrent adult cell leukemia lymphoma diagnosis and patient or donor with active hepatitis or and or detectable viral ribonucleic acid rna
__label__1	study interventions are Antibodies, Monoclonal . cervical squamous cell carcinoma not otherwise specified diagnosis and significant vascular disease aortic aneurysm history of aortic dissection
__label__1	study interventions are Cyclosporins . cardiac insufficiency requiring treatment symptomatic coronary artery disease or lvef less than thirty-five
__label__1	study interventions are Paclitaxel . prior systemic cancer directed treatments or investigational modalities less_than five half lives or four weeks whichever is shorter prior to starting study drug or who have not recovered from side effects of such therapy
__label__1	study interventions are Vinorelbine . non small cell lung cancer stage iii diagnosis and uncontrolled eye inflammation or infection or any potential circumstances lead to eye inflammation or infection
__label__1	study interventions are Estrogens . breast cancer diagnosis and ischemic bowel
__label__1	study interventions are Vaccines . melanoma diagnosis and patients with active infections including viral hepatitis
__label__1	study interventions are Oxaliplatin . participants with known anaplastic lymphoma kinase alk fusion oncogene must have experienced disease progression during or after treatment with crizotinib
__label__1	study interventions are Cyclophosphamide . lymphoma diagnosis and hepatitis hcv
__label__1	study interventions are Pembrolizumab . lung cancer diagnosis and has evidence of interstitial lung disease or active non infectious pneumonitis
__label__1	study interventions are 4-Dimensional Computed Tomography . psychological impact of cancer diagnosis and phase ii
__label__1	study interventions are Iodine . refractory hodgkin lymphoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Docetaxel . squamous cell cancer diagnosis and unstable brain metastasis is defined as patients on steroid medication to control symptoms or patient with motor neurologic compromise due to brain metastasis
__label__1	study interventions are Hydroxyurea . advanced solid tumors diagnosis and female study participant is breast feeding pregnant or intends to become pregnant
__label__1	study interventions are Ibandronic acid . neoplasm metastasis diagnosis and patients who are pregnant or breast feeding
__label__1	study interventions are Levoleucovorin . colorectal adenocarcinoma diagnosis and disease is well controlled at baseline and only requiring low potency topical steroids hydrocortisone doc hydrocortisone_butyrate doc fluocinolone doc one desonide doc five alclometasone_dipropionate doc five
__label__1	study interventions are Everolimus . uveal melanoma diagnosis and pregnant women are excluded from this study because radone and somtwo hundred and thirty are agents with the potential for teratogenic or abortifacient effects
__label__1	study interventions are Vaccines . glioblastoma diagnosis and patients who cannot undergo mri or spect due to obesity or to having certain metal in their bodies specifically pacemakers infusion pumps metal aneurysm clips metal prostheses joints rods or plates
__label__1	study interventions are Carboplatin . metastatic malignant neoplasm in the brain diagnosis and prisoners or subjects who are compulsorily_detained involuntarily_incarcerated for treatment of either psychiatric or physical infectious illness
__label__1	study interventions are Ramucirumab . stomach cancer diagnosis and patients with involved retroperitoneal para aortal paracaval or interaortocaval lymph nodes or mesenterial lymph nodes distant metastases
__label__1	study interventions are Poly ICLC . melanoma diagnosis and have an active or history of autoimmune disease known or suspected
__label__1	study interventions are quality-of-life assessment . breast cancer diagnosis and any medical condition that restricts participation in physical activity program exercise induced angina uncontrolled hypertension dementia or major psychological problem
__label__1	study interventions are Ceritinib . solid neoplasm diagnosis and medications with low therapeutic index that are primarily metabolized by cypthreeafour five cytochrome pfourfive0 family two subfamily polypeptide eight cyptwoceight and or cytochrome pfourfive0 family two subfamily polypeptide nine cyptwocnine
__label__1	study interventions are Cabozantinib S-malate . stage iva uterine corpus cancer diagnosis and any history of congenital long qt syndrome
__label__1	study interventions are Bevacizumab . progressive breast cancer diagnosis and grade one or higher cns hemorrhage on baseline brain mri
__label__1	study interventions are Not relevant (there is no intervention in the present study) . hodgkin lymphoma treated with mediastinal irradiation diagnosis and known cad these patients will be excluded from the imaging study but will be analyzed as separate control group
__label__1	study interventions are Pharmaceutical Solutions . neoplasm diagnosis and patients who are pregnant or breast feeding at the time of admission for conditioning
__label__1	study interventions are Immunoglobulins . ewing sarcoma diagnosis and allergy
__label__1	study interventions are Thalidomide . stage iv grade three follicular lymphoma diagnosis and inability to collect adequate stem cells
__label__1	study interventions are Nutritional intervention with the Ketogenic diet . malignant tumors diagnosis and early termination
__label__1	study interventions are Cyclophosphamide . melanoma diagnosis and pi or his designee shall make the final determination regarding appropriateness of enrollment
__label__1	study interventions are Mycophenolic Acid . recurrent refractory childhood hodgkin lymphoma diagnosis and patients with conventional transplant options conventional transplant should be the priority for eligible patients equal_than less_than fifty yr of age who have related donor mismatched for single hla b or drbone antigen
__label__1	study interventions are Abiraterone Acetate . salivary glands tumors diagnosis and aspartate aminotransferase ast or alanine aminotransferase alt greater_than doc uln
__label__1	study interventions are Dexamethasone acetate . plasma cell myeloma diagnosis and any serious medical or psychiatric illness that could in the investigator opinion potentially interfere with the completion of treatment according to this protocol
__label__1	study interventions are Antibodies, Monoclonal . prior chemotherapy or immunotherapy for prostate cancer
__label__1	study interventions are Proton Pump Inhibitors . colorectal neoplasms diagnosis and non healing wound non healing ulcer or non healing bone fracture
__label__1	study interventions are Vitamins . adenocarcinoma diagnosis and taking medications called sterol binding resins such as cholestyramine questran which is for the treatment of high blood cholesterol
__label__1	study interventions are Pemetrexed . metastatic breast cancer diagnosis and ventricular arrhythmias requiring anti arrhythmic therapy other than beta blockers
__label__1	study interventions are Docetaxel . cancer diagnosis and johns wort or macrolide antibiotics as erythromycin and clarithromycin
__label__1	study interventions are Cisplatin . transitional cell carcinoma of ureter diagnosis and patients with poor performance status or co morbidities that would make them unfit for chemotherapy are ineligible for the trial
__label__1	study interventions are Immunoconjugates . stage iia breast cancer diagnosis and note
__label__1	study interventions are Tumor tissue analysis of circulating cell free DNA . history of other malignancy within the previous five years except for appropriately treated carcinoma in situ of the cervix and non melanoma skin carcinoma
__label__1	study interventions are Sargramostim . recurrent childhood brain neoplasm diagnosis and radiation therapy
__label__1	study interventions are Immunoglobulins . stage iii verrucous carcinoma of the oral cavity diagnosis and transmural myocardial infarction within six months prior to registration
__label__1	study interventions are Sorafenib . stage ivb salivary gland cancer diagnosis and known hiv positive patients will be excluded from trial due to the potential immune modulation that these agents may cause
__label__1	study interventions are Immunoglobulins . breast cancer diagnosis and pre existing motor or sensory neuropathy of severity greater_than equal_than grade two by nci ctc criteria doc
__label__1	study interventions are Docetaxel . cervix neoplasm diagnosis and patients with para aortic disease
__label__1	study interventions are Endothelial Growth Factors . signet ring adenocarcinoma of the colon diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study
__label__1	study interventions are Lapatinib . stage iva salivary gland cancer diagnosis and pregnant women are excluded from this study because gwfive hundred and seventy-two thousand and sixteen is member of the four anilinoquinazoline class of kinase inhibitors with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with gwfive hundred and seventy-two thousand and sixteen breastfeeding should be discontinued if the mother is treated with gwfive hundred and seventy-two thousand and sixteen human immunodeficiency virus hiv positive patients receiving combination anti retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with gwfive hundred and seventy-two thousand and sixteen appropriate studies will be undertaken in patients receiving combination anti retroviral therapy when indicated
__label__1	study interventions are Etoposide . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and patients who have not recovered from adverse events due to agents administered more than four weeks earlier or
__label__1	study interventions are Axitinib . alveolar soft part sarcoma diagnosis and any serious medical or psychiatric illness condition including substance use disorders likely in the judgment of the investigator to interfere or limit compliance with study requirements treatment
__label__1	study interventions are Maleic acid . recurrent melanoma diagnosis and it is acceptable to use corrected calcium when interpreting calcium levels
__label__1	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and patients that have k ras mutation
__label__1	study interventions are DSP-7888 . diffuse intrinsic pontine glioma diagnosis and forty-two days
__label__1	study interventions are Axitinib . head and neck squamous cell carcinoma diagnosis and history of hemoptysis
__label__1	study interventions are Temozolomide . adult glioblastoma diagnosis and unstable angina and or congestive heart failure within the last six months
__label__1	study interventions are Fludrocortisone . melanoma diagnosis and prior stereotactic or highly conformal radiotherapy and or whole brain irradiation within fourteen days prior to start of ipilimumab dosing for this study
__label__1	study interventions are Psychosocial . uterine cervical neoplasms diagnosis and participants with deficient ability to read speak english
__label__1	study interventions are Docetaxel . advanced non small cell lung cancer diagnosis and prior surgery and or localised irradiation is permitted
__label__1	study interventions are Podophyllotoxin . follicular lymphoma diagnosis and prolonged corrected qt interval qtc on electrocardiogram ekg
__label__1	study interventions are Hormones . metastatic prostate cancer diagnosis and history of significant neurologic peripheral neuropathy grade greater_than two using nci ctc criteria doc
__label__1	study interventions are Adaptive dose-painting-by-numbers . primary non operated squamous cell carcinoma of the oral cavity oropharynx hypopharynx and larynx diagnosis and treatment combined with brachytherapy
__label__1	study interventions are Cediranib . primary peritoneal serous adenocarcinoma diagnosis and history of gastrointestinal perforation patients with history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed there has been no evidence of fistula for at least six months and patient is deemed to be at low risk of recurrent fistula
__label__1	study interventions are Prednisone . prior chemotherapy for prostate cancer with the exception of neoadjuvant adjuvant therapy as part of initial primary treatment for local disease that was completed two or more years before screening
__label__1	study interventions are DCR-MYC . ast or alt greater_than three the uln for the institution greater_than five if due to hepatic involvement by tumor
__label__1	study interventions are Cyclophosphamide . prior radiation therapy for breast cancer
__label__1	study interventions are Albumin-Bound Paclitaxel . primary peritoneal cancer diagnosis and patients with unstable angina
__label__1	study interventions are Citric Acid . brain tumors diagnosis and participants on concurrent external beam radiation therapy to the brain or spine during the planned nuclear imaging sessions
__label__1	study interventions are Trastuzumab . stage iiia breast cancer diagnosis and except for the following no other malignancy is allowed
__label__1	study interventions are BB 1101 . lung cancer diagnosis and females who are pregnant or breast feeding
__label__1	study interventions are Paclitaxel . ovarian brenner tumor diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are quality-of-life assessment . recurrent verrucous carcinoma of the oral cavity diagnosis and unexplained fever or untreated active infection
__label__1	study interventions are Tacrolimus . stage multiple myeloma diagnosis and patient with history of allergy to boron mannitol or bortezomib
__label__1	study interventions are Sirolimus . stage iva bladder cancer diagnosis and sub protocol aim a
__label__1	study interventions are Sunitinib . aids related small noncleaved cell lymphoma diagnosis and abnormal left ventricular ejection fraction per institutional standards
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood lymphoblastic lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than thirty
__label__1	study interventions are Antilymphocyte Serum . t lymphoblastic leukemia lymphoma diagnosis and an ekg recorded at screening showing evidence of cardiac ischemia st depression depression of greater_than equal_than two mm measured from isoelectric line to the st segment
__label__1	study interventions are FlexHD . breast neoplasm diagnosis and active smoker or recently quit less_than six weeks
__label__1	study interventions are Antibodies, Monoclonal . intraocular lymphoma diagnosis and patients who are receiving cyclosporine tacrolimus or other agents to prevent graft versus host disease post bone marrow transplant are not eligible for this trial
__label__1	study interventions are Trastuzumab . metastatic breast cancer diagnosis and erbbtwo negative and or er and pgr negative
__label__1	study interventions are MART-1 Antigen . stage iia skin melanoma diagnosis and history of brain metastases exception
__label__1	study interventions are Vinblastine . metastatic breast cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Estrogens . breast cancer diagnosis and use of any exogenous estrogen within the preceding four weeks
__label__1	study interventions are Dacarbazine . glioblastoma diagnosis and pregnant breast feeding women women men reproductive potential not practicing adequate contraception
__label__1	study interventions are Attention Control . stage ivb rectal cancer diagnosis and has self reported history of diagnosed sleep disorders obstructive sleep_apnea insomnia comorbidities associated with poor sleep or fatigue chronic fatigue syndrome or job with night_shifts
__label__1	study interventions are Mycophenolic Acid . small intestine lymphoma diagnosis and cross match positive with recipient
__label__1	study interventions are Sapanisertib . gliosarcoma diagnosis and placement of pacemaker for control of rhythm
__label__1	study interventions are Carboplatin . stage ivb vulvar cancer diagnosis and any other major illness which in the investigator judgment will substantially increase the risk associated with the patient participation in this study
__label__1	study interventions are TCR alfa beta T cell depletion . non hodgkin lymphoma diagnosis and current active infectious disease including positive hiv serology or viral rna
__label__1	study interventions are Rituximab . recurrent adult immunoblastic large cell lymphoma diagnosis and patient scheduled for cord blood transplantation
__label__1	study interventions are Fludarabine phosphate . stage iii adult diffuse large cell lymphoma diagnosis and active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Sirolimus . ovarian carcinosarcoma diagnosis and patients on anticoagulant therapy
__label__1	study interventions are Endothelial Growth Factors . recurrent colorectal carcinoma diagnosis and vaccination with live or attenuated vaccine equal_than less_than twenty-eight days prior to randomization note
__label__1	study interventions are ispinesib . stage iv grade one follicular lymphoma diagnosis and bitter_orange
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of the safety and adverse events of the prescribed regimens
__label__1	study interventions are Trametinib . papillary thyroid cancer diagnosis and patients are receiving any other investigational agents
__label__1	study interventions are Fludarabine . contiguous stage ii small lymphocytic lymphoma diagnosis and donor
__label__1	study interventions are Lamivudine . hepatocellular carcinoma diagnosis and hccs with radiological evidence of portal vein thrombus are not eligible
__label__1	study interventions are Capecitabine . rectal cancer diagnosis and previous pelvic irradiation therapy
__label__1	study interventions are Pertuzumab . breast cancer diagnosis and current known infection with hiv hepatitis virus or hepatitis virus
__label__1	study interventions are Letrozole . endometrial cancer diagnosis and patients with known history of cardiac disease uncontrolled hypertension systolic p greater_than equal_than one hundred and forty mm hg and or diastolic p greater_than equal_than ninety mm hg or unstable angina
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent mantle cell lymphoma diagnosis and barrier methods of contraception
__label__1	study interventions are Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells . lymphoma large cell diffuse diagnosis and frequent infection history and recent infection is uncontrolled
__label__1	study interventions are Sirolimus . unspecified adult solid tumor protocol specific diagnosis and any of the following because this study involves an investigational agent whose genotoxic_mutagenic and teratogenic effects on the developing fetus and newborn are unknown
__label__1	study interventions are Fluorouracil . co existing malignancies diagnosed within the last five years with the exception of basal cell carcinoma or cervical cancer in situ
__label__1	study interventions are Paclitaxel . stage iiib non small cell lung cancer diagnosis and pregnant or nursing
__label__1	study interventions are Androgens . prostate cancer diagnosis and unable to tolerate multiparametric mri or is contraindicated
__label__1	study interventions are Topotecan . lung cancer diagnosis and patients with cns metastases treated by neurosurgical resection or brain biopsy performed within three months prior to day one will be excluded
__label__1	study interventions are Paclitaxel . recurrent ovarian cancer diagnosis and patients who have history of small or large bowel obstruction within two weeks of screening or who have and active partial small bowel obstruction or percutaneous endoscopic gastrostomy peg tube
__label__1	study interventions are Antibodies . noncontiguous stage ii marginal zone lymphoma diagnosis and chemotherapy within four weeks of the first scheduled study treatment
__label__1	study interventions are 3-Iodobenzylguanidine . paraganglioma diagnosis and patients who are on hemodialysis
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and bilirubin total greater_than doc uln
__label__1	study interventions are Low dose computed tomography (CT) . lung cancer diagnosis and any evolutionary pathology classifying aids
__label__1	study interventions are Abiraterone Acetate . prostate cancer diagnosis and known allergies hypersensitivity or intolerance to abiraterone acetate prednisone or degarelix
__label__1	study interventions are Temozolomide . brain tumors diagnosis and patients changing from these anticonvulsants to other allowable drugs that are not enzyme inducing antiepileptic drugs eiaeds must be off the drugs listed above for at least seventy-two hours prior the initiation of treatment
__label__1	study interventions are Maytansine . more than one previous systemic anti cancer therapy line
__label__1	study interventions are Cisplatin . head and neck cancer diagnosis and coronary clinically significant arteriopathy or precedents of myocardial infarction in the last twelve months or high risk of not controlled arrhythmia or cardiac not controlled insufficiency
__label__1	study interventions are Hormone Antagonists . uncontrolled or symptomatic congestive heart failure
__label__1	study interventions are Paclitaxel . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and known seropositive for hiv antibody
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib primary peritoneal cancer diagnosis and major surgical procedure anticipated during the course of the study this includes but is not limited to abdominal surgery laparotomy or laparoscopy prior to disease progression such as colostomy or enterostomy_reversal interval or secondary cytoreductive surgery or second look surgery please consult with the study chair prior to patient entry for any questions related to the classification of surgical procedures
__label__1	study interventions are Mycophenolic Acid . recurrent grade one follicular lymphoma diagnosis and patients with creatinine clearance less_than fifty ml min
__label__1	study interventions are Capecitabine . metastatic breast cancer diagnosis and patients with signs of metastasis in the cns
__label__1	study interventions are Carboplatin . stage iv non small cell lung cancer diagnosis and known active untreated central nervous system cns metastases that require steroids subjects with cns metastases who have completed course of therapy would be eligible for the study provided they are clinically stable for at least four weeks before study entry defined as
__label__1	study interventions are Sorafenib . breast cancer diagnosis and active clinically serious infection greater_than nci ctcae grade two
__label__1	study interventions are Vidarabine . stage iii adult diffuse large cell lymphoma diagnosis and disease resulting in severely limited performance status less_than seventy
__label__1	study interventions are Rituximab . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and positive serology for hepatitis hb defined as positive test for hbsag
__label__1	study interventions are Albumin-Bound Paclitaxel . cervical adenosquamous carcinoma diagnosis and patients who have significant history of cardiac disease uncontrolled hypertension unstable angina congestive heart failure or uncontrolled arrhythmias within six months of registration
__label__1	study interventions are JM 3100 . stage ii multiple myeloma diagnosis and hiv seropositive
__label__1	study interventions are Gossypol acetic acid . adult nasal type extranodal nk cell lymphoma diagnosis and requirement for routine use of hematopoietic growth factors including granulocyte colony stimulating factor granulocyte macrophage colony stimulating factor or interleukin eleven or platelet transfusions to maintain absolute neutrophil counts or platelets counts above the required thresholds for study entry use of erythropoietin stimulating agents and rbcs prior to study enrollment is allowed
__label__1	study interventions are Thalidomide . melanoma diagnosis and prior desquamating_rash while taking thalidomide
__label__1	study interventions are Antibodies . stage iii small lymphocytic lymphoma diagnosis and use of hematopoietic growth factor including filgrastim pegfilgrastim sargramostim erythropoietin or darbepoetin within fourteen days prior to baseline
__label__1	study interventions are Dexamethasone . burkitt lymphoma diagnosis and pregnancy or nursing
__label__1	study interventions are Mitomycin . urinary bladder neoplasms diagnosis and women of childbearing potential unwilling or unable to use adequate contraception if sexually active
__label__1	study interventions are Niacinamide . carcinoma hepatocellular diagnosis and participation in another clinical trial within the past twenty-eight days
__label__1	study interventions are Niacinamide . acinar cell adenocarcinoma of the pancreas diagnosis and female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods if barrier contraceptives are being used these must be continued throughout the trial by both sexes hormonal contraceptives are not acceptable as sole method of contraception
__label__1	study interventions are Accelerated partial breast irradiation . breast cancer clinical grade tfour and or with major nodal involvement ntwo clinically us mri or pet ct
__label__1	study interventions are Erlotinib Hydrochloride . lung carcinoma diagnosis and serious concomitant systemic disorder that in the opinion of the investigator would compromise the patient ability to complete the study
__label__1	study interventions are Liposomal doxorubicin . ovarian clear cell adenocarcinoma diagnosis and patients with prior treatment with bevacizumab
__label__1	study interventions are Bevacizumab . recurrent primary peritoneal carcinoma diagnosis and severe infections within four weeks prior to cycle one day one including but not limited to hospitalization for complications of infection bacteremia or severe pneumonia
__label__1	study interventions are Antibodies . ovarian endometrioid adenocarcinoma diagnosis and has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Temozolomide . astrocytoma diagnosis and patients with prior bevacizumab exposure
__label__1	study interventions are Proton beam therapy . recurrent small hepatocellular carcinoma diagnosis and poor performance status of three to four on the eastern cooperative oncology group ecog score
__label__1	study interventions are Gefitinib . squamous cell carcinoma of bronchus diagnosis and exon twenty point mutation tseven hundred and ninetym or sseven hundred and sixty-eighti egfr or exon twenty insertion
__label__1	study interventions are Surgery . patients with history of treatment of other invasive cancers in the last five years
__label__1	study interventions are Poly ICLC . urothelial cancer diagnosis and has history or current evidence of any condition therapy or laboratory abnormality that might confound the results of the trial interfere with the subject participation for the full duration of the trial or is not the best interest of the subject to participate in the opinion of the treating investigator
__label__1	study interventions are Light Infusion Therapy . stage squamous cell carcinoma of the lip and oral cavity diagnosis and patients with porphyria or with known hypersensitivity to porphyrins or porphyrin like compounds
__label__1	study interventions are Epothilones . recurrent adult brain tumor diagnosis and miscellaneous
__label__1	study interventions are Fludarabine phosphate . stage ii cutaneous cell non hodgkin lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than thirty-five total lung capacity tlc less_than thirty-five or forced expiratory volume in one second fevone less_than thirty-five and or receiving supplementary continuous oxygen
__label__1	study interventions are Antibodies, Monoclonal . carcinoma hepatocellular diagnosis and pregnant female or nursing mother
__label__1	study interventions are Immunoglobulins . contiguous stage ii grade two follicular lymphoma diagnosis and donor
__label__1	study interventions are Radiation therapy . lobular breast carcinoma in situ diagnosis and prior radiotherapy to the ipsilateral breast or prior radiation to the region of the breast that would result in overlap of radiation therapy fields
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and previous serious allergic or unexpected reactions to trastuzumab treatment
__label__1	study interventions are Leucovorin . stage iib colon cancer diagnosis and any systemic or radiation therapy initiated for this malignancy
__label__1	study interventions are Liposomal doxorubicin . stage iii childhood anaplastic large cell lymphoma diagnosis and patients with central nervous system cns disease are not eligible
__label__1	study interventions are Vidarabine . stage iv adult cell leukemia lymphoma diagnosis and liver abnormalities
__label__1	study interventions are Lenalidomide . recurrent adult immunoblastic large cell lymphoma diagnosis and phenobarbital luminal
__label__1	study interventions are Antibodies, Monoclonal . metastatic solid neoplasm diagnosis and participants with known brain metastases or leptomeningeal metastases must be excluded unless they qualify for enrollment as described below because of poor prognosis and concerns regarding progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events participants with brain metastases are permitted if metastases have been treated and there is no magnetic resonance imaging mri evidence of progression for at least four weeks or more after treatment is complete and within four weeks prior to the first dose of nivolumab administration
__label__1	study interventions are CPI-0610 . systemic anti cancer treatment or radiotherapy less than two weeks before the first dose of cpi six hundred and ten
__label__1	study interventions are Expanded Prostate Cancer Index Composite Short Form 12 . transition cell cancer diagnosis and laboratory tests for liver function and coagulation parameters are not required for enrollment into this protocol
__label__1	study interventions are Bleomycin . germ cell tumors diagnosis and in addition patients who have an infection but without evidence of fever for forty-eight hours on antibiotics will be eligible
__label__1	study interventions are Gemcitabine . recurrent platinum sensitive ovarian cancer diagnosis and current or recent chronic use of aspirin greater_than three hundred and twenty-five mg day
__label__1	study interventions are Dihydrotestosterone . prostate cancer diagnosis and bicalutamide flutamide or enzalutamide during time of protocol scans
__label__1	study interventions are Selumetinib . recurrent adult diffuse large cell lymphoma diagnosis and cardiac conditions as follows
__label__1	study interventions are Dexamethasone acetate . have received treatment within thirty days of the initial dose of study drug with an experimental agent for non cancer indications that has not received regulatory approval for any indication
__label__1	study interventions are Dexamethasone 21-phosphate . prostate cancer less_than gleason score six with stable prostate specific antigen psa over twelve months
__label__1	study interventions are Antibodies . stage ivb squamous cell carcinoma of the oropharynx diagnosis and major surgery within the past four weeks prior to dosing with cetuximab or vtx two thousand, three hundred and thirty-seven
__label__1	study interventions are Pertuzumab . recurrent breast cancer diagnosis and active congestive heart failure or ventricular arrhythmia requiring medication
__label__1	study interventions are Epirubicin . breast cancer diagnosis and patients with alcohol abuse or drug addiction that may affect the compliance of the study
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and patients who are receiving bisphosphonate therapy or denosumab specifically to prevent skeletal events and who do not have history of clinically significant hypercalcemia are eligible
__label__1	study interventions are Capecitabine . gastrointestinal stromal tumor gist diagnosis and chronic renal disease
__label__1	study interventions are Irradiation of the chest-wall and supraclavicular fossa . breast cancer diagnosis and severe psychiatric disorder that may interfere with the process of informed consent and or treatment or follow up compliance
__label__1	study interventions are Vaccines . malignant melanoma diagnosis and participation in any other clinical trial involving another investigational agent within four weeks prior to enrollment
__label__1	study interventions are Mycophenolic Acid . recurrent grade one follicular lymphoma diagnosis and patients with chronic myelomonocytic leukemia cmml
__label__1	study interventions are Dendritic and Cytokine-induced Killer Cells . hepatocellular carcinoma hcc diagnosis and patients who were pregnant or lactating
__label__1	study interventions are Albumin-Bound Paclitaxel . head and neck cancer diagnosis and patient must have negative pregnancy test within seventy-two hours of start of study treatment
__label__1	study interventions are laboratory biomarker analysis . stage iv adult diffuse mixed cell lymphoma diagnosis and patients are ineligible for participation in the drug interaction study or can be deemed to be ineligible to receive certain drug probes if they have
__label__1	study interventions are Rituximab . recurrent grade two follicular lymphoma diagnosis and nefazodone serzone
__label__1	study interventions are Docetaxel . non small cell lung cancer diagnosis and uncontrollable seizure or psychotic patients without self control ability
__label__1	study interventions are Docetaxel . prior chemotherapy for prostate cancer
__label__1	study interventions are Fludarabine phosphate . noncontiguous stage ii marginal zone lymphoma diagnosis and positive serology for toxoplasma_gondii on treatment or with evidence of active infection
__label__1	study interventions are Thalidomide . peritoneal cavity cancer diagnosis and any condition including the presence of laboratory abnormalities which places the patient at unacceptable risk if she were to participate in the study or confounds the ability to interpret data from the study
__label__1	study interventions are Sorafenib . rectal cancer diagnosis and known or suspected allergy to sorafenib or any agent given in the course of this trial
__label__1	study interventions are Ibrutinib . classical hl chl or composite lymphoma
__label__1	study interventions are Oxaliplatin . pancreatic cancer diagnosis and albumin less_than two five dl
__label__1	study interventions are Fluorouracil . history of significant bleeding disorder unrelated to cancer including diagnosed congenital bleeding disorders diagnosed acquired bleeding disorder within one year or ongoing or recent less_than three months significant gastrointestinal bleeding
__label__1	study interventions are Vaccines . stage ii multiple myeloma diagnosis and acute myeloid leukemia beyond second remission
__label__1	study interventions are Pharmacological Study . metastatic endometrioid adenocarcinoma diagnosis and active uncontrolled infection requiring intravenous systemic treatment within fourteen days before the first dose of study treatment
__label__1	study interventions are Thalidomide . patients with localized carcinoma of the cervix non melanoma skin cancer or early stage prostate cancer requiring observation only are eligible regardless of timing of diagnosis
__label__1	study interventions are Estradiol . metastatic breast cancer diagnosis and see section doc
__label__1	study interventions are Capecitabine . rectal cancer diagnosis and active heart disease including blocked blood vessels recent heart attack history of congestive heart failure or abnormal heart beat
__label__1	study interventions are Cyclosporine . contiguous stage ii adult burkitt lymphoma diagnosis and donors for whom medical or psychologic reasons would make donor procedure intolerable
__label__1	study interventions are Paclitaxel . patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis other than for the treatment of uterine carcinosarcoma within the last five years are excluded
__label__1	study interventions are Fluorouracil . cancer of colon diagnosis and any chemotherapy related toxicities from prior treatment
__label__1	study interventions are Alemtuzumab . lymphoma diagnosis and pregnancy or lactation
__label__1	study interventions are FLT . large cell diffuse lymphoma diagnosis and subjects with significant concurrent medical complications that in the judgment of the principal investigator could affect the patient ability to complete the planned trial including the multiple imaging studies
__label__1	study interventions are Fluorouracil . pancreatic adenocarcinoma diagnosis and subjects with known metastases
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and significant neuropathy grade three or four or grade two with pain at the time of enrollment or within 1four days before enrollment
__label__1	study interventions are liquid chromatography . adult giant cell glioblastoma diagnosis and human immunodeficiency virus hiv positive patients receiving anti retroviral therapy are excluded from the study due to the possibility of pharmacokinetic pk interactions with bafetinib however patients will not be routinely screened for hiv
__label__1	study interventions are Doxorubicin . primary peritoneal high grade serous adenocarcinoma diagnosis and cluster of differentiation cd four count above two hundred and fifty cells mcl and an undetectable hiv viral load on standard pcr based tests
__label__1	study interventions are placebo . stage iii verrucous carcinoma of the larynx diagnosis and history of intolerance including hypersensitivity or allergy to berry or berry containing products
__label__1	study interventions are Immunoglobulins . recurrent salivary gland cancer diagnosis and john wort kava_ephedra ma_huang gingko_biloba dehydroepiandrosterone_dhea yohimbe_saw palmetto and ginseng fruits include the cytochrome pfour hundred and fifty family three subfamily cypthreea inhibitors seville_oranges grapefruit pummelos or exotic_citrus fruits
__label__1	study interventions are SNS01-T . multiple myeloma diagnosis and have an active infection or serious comorbid medical condition
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . primary peritoneal cancer diagnosis and clinically significant gi bleeding or hemoptysis within twenty-eight days prior to the start of the study
__label__1	study interventions are Ramucirumab . renal cell carcinoma diagnosis and have history of deep vein thrombosis pulmonary embolism or any other significant thromboembolic event during the three months prior to receiving study drugs
__label__1	study interventions are Fludarabine phosphate . metastatic melanoma diagnosis and active systemic infections coagulation disorders or other major medical illnesses of the cardiovascular respiratory or immune system myocardial infarction cardiac arrhythmias obstructive or restrictive pulmonary disease
__label__1	study interventions are Pazopanib Hydrochloride . stage ivb differentiated thyroid gland carcinoma diagnosis and anaplastic differentiated medullary
__label__1	study interventions are Erlotinib Hydrochloride . pancreatic cancer diagnosis and new york heart association class iv congestive heart failure
__label__1	study interventions are Vitamins . breast cancer diagnosis and unwilling or unable to provide informed consent
__label__1	study interventions are Cetuximab . colorectal cancer diagnosis and acute or chronic liver or pancreatic disease
__label__1	study interventions are Docetaxel . patient who have received hormone treatment for cancer within six weeks or five half lives of enrolment whichever is shorter
__label__1	study interventions are 6-Mercaptopurine . stage ii lymphoblastic lymphoma diagnosis and patients receiving prior steroid therapy may be eligible for aallnine hundred and thirty-two
__label__1	study interventions are Mitomycins . anal cancer diagnosis and doc
__label__1	study interventions are laboratory biomarker analysis . stage ivb squamous cell carcinoma of the larynx diagnosis and history of intolerance including hypersensitivity or allergy to berry or berry containing products
__label__1	study interventions are questionnaire administration . stage iib prostate cancer diagnosis and are taking certain medications no concurrent finasteride_proscar or other hormonal agents for chemoprevention treatment of benign prostate hyperplasia bph utilizing prescription medications for urinary outlet obstructive symptoms will not be permitted the use of non prescription substances to improve urinary tract symptoms will not be permitted saw_palmetto other herbal alternative products
__label__1	study interventions are Bendamustine Hydrochloride . intraocular lymphoma diagnosis and serious medical illness that would potentially increase patients risk for toxicity
__label__1	study interventions are Mycophenolate mofetil . stage iv adult immunoblastic large cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Cytarabine . stage ii lymphoblastic lymphoma diagnosis and the cns status must be determined based on sample obtained prior to administration of any systemic or intrathecal chemotherapy except for steroid pretreatment lly patients with cnsthree disease are not eligible for this protocol or the cog hr all protocol it is recommended that intrathecal cytarabine be administered at the time of the diagnostic lumbar_puncture this is usually done at the time of the diagnostic bone marrow or venous line placement to avoid second lumbar_puncture this is allowed prior to registration systemic chemotherapy must begin within seventy-two hours of the first dose of intrathecal therapy
__label__1	study interventions are Pharmacological Study . childhood soft tissue sarcoma diagnosis and patients who have an uncontrolled infection are not eligible
__label__1	study interventions are BioMega SDA® . head and neck cancer diagnosis and patients with known eating disorder eg anorexia_nervosa bulimia nervosa
__label__1	study interventions are Cyclosporine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Mitomycin . appendix cancer diagnosis and new york heart association nyha class ii or higher congestive heart failure
__label__1	study interventions are Fludarabine phosphate . stage ii childhood small noncleaved cell lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Paclitaxel . fallopian tube cancer diagnosis and one uncontrolled hypertension defined as systolic greater_than onefour0 mm hg or diastolic greater_than ninety mm hg two myocardial infarction or unstable angina less_than six months prior to registration three new york heart association nyha grade ii or greater congestive heart failure four serious cardiac arrhythmia requiring medication
__label__1	study interventions are Pembrolizumab . thymic carcinoma diagnosis and has known sensitivity to pembrolizumab or its formulation
__label__1	study interventions are Pembrolizumab . stage iva colorectal cancer diagnosis and is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with the pre screening or screening visit through one hundred and twenty days after the last dose of trial treatment
__label__1	study interventions are Cyclosporine . recurrent diffuse large cell lymphoma diagnosis and age greater_than equal_than eighteen years
__label__1	study interventions are IONIS-STAT3Rx . lymphoma diagnosis and nyha grade ii or greater congestive heart failure
__label__1	study interventions are Antibodies, Monoclonal . recurrent colon carcinoma diagnosis and prior treatment with irinotecan five fluoruracil or bevacizumab is allowed
__label__1	study interventions are Niacinamide . recurrent squamous cell carcinoma of the hypopharynx diagnosis and patients who have had chemotherapy or radiotherapy within three months prior to entering the study
__label__1	study interventions are Dacarbazine . glioblastoma diagnosis and prior rtx of the head
__label__1	study interventions are Antilymphocyte Serum . recurrent adult diffuse small cleaved cell lymphoma diagnosis and calculated creatinine clearance less_than forty cc min by the modified cockcroft gault formula for adults or the schwartz formula for pediatrics
__label__1	study interventions are Dexamethasone . treatment with steroid intended to treat myeloma within fourteen days prior to cycle one day one
__label__1	study interventions are Placebo . carcinoma renal cell diagnosis and significant cardiac event within three months of entry
__label__1	study interventions are Imiquimod . carcinoma non small cell lung diagnosis and active other malignancy
__label__1	study interventions are Estradiol . endometrial cancer diagnosis and active thrombophlebitis or current or past history of thromboembolic disorders or cerebral vascular disease
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and heart attack within the previous six months
__label__1	study interventions are Somatostatin . carcinoid tumors diagnosis and patients who have had chemotherapy within four weeks six weeks for nitrosoureas or mitomycin of study drug administration or those who have not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Vidarabine . recurrent indolent adult non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Immunoglobulins . recurrent cutaneous cell non hodgkin lymphoma diagnosis and patients with active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and subjects who are currently receiving anticoagulation treatment with therapeutic doses of warfarin
__label__1	study interventions are Thalidomide . lymphoma diagnosis and history of severe allergic or anaphylactic reactions to monoclonal antibody therapy
__label__1	study interventions are Immunoglobulins . stage ivc laryngeal verrucous carcinoma diagnosis and patient with confirmed history of interstitial lung disease
__label__1	study interventions are Antibodies . stage iib ovarian cancer diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer female diagnosis and known hypersensitivity to any of the study drugs or excipients
__label__1	study interventions are Dexamethasone . contiguous stage ii grade two follicular lymphoma diagnosis and patient requires supplemental oxygen
__label__1	study interventions are Nivolumab . lymphoma diagnosis and prior allogeneic stem cell transplant
__label__1	study interventions are BB 1101 . incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide
__label__1	study interventions are Fludarabine phosphate . symptomatic coronary artery disease
__label__1	study interventions are Albumin-Bound Paclitaxel . locally recurrent and metastatic breast cancer diagnosis and adjuvant or neoadjuvant taxane treatment within twelve months of randomization
__label__1	study interventions are Doxorubicin . myocardial infarction unstable angina symptomatic congestive heart failure serious uncontrolled cardiac arrhythmia less_than one year before enrolment
__label__1	study interventions are Antibodies . stage iiia primary peritoneal cancer diagnosis and qt interval corrected by fridericia formula qtcf greater_than four hundred and fifty msec on screening electrocardiogram ecg
__label__1	study interventions are Dexamethasone 21-phosphate . plasma cell myeloma diagnosis and note
__label__1	study interventions are Progress Reporting . cancer diagnosis and have history of seizure or loss of consciousness
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and prior treatment with lapatinib or capecitabine
__label__1	study interventions are Morphine . colonic neoplasms diagnosis and subjects with inflammatory bowel disease active colitis or pre existing intra abdominal inflammation
__label__1	study interventions are Hydrocortisone 17-butyrate 21-propionate . stage ii childhood lymphoblastic lymphoma diagnosis and lactating females who plan to breastfeed
__label__1	study interventions are Niacinamide . hepatocellular carcinoma diagnosis and patients with evidence of extrahepatic or metastatic disease
__label__1	study interventions are Cyclosporins . stage iii childhood hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Doxorubicin . patients with history of more than one primary cancer with the exception of
__label__1	study interventions are Tacrolimus . lymphoma diagnosis and history of stroke within six months
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and patients may not have received anthracycline based chemotherapy in the past
__label__1	study interventions are Sirolimus . human epidermal growth factor two negative carcinoma of breast diagnosis and the dosing of palbociclib should occur at least ten hours after htwo receptor antagonist evening dose and two hours before the htwo receptor antagonist morning dose
__label__1	study interventions are Paclitaxel . hereditary breast and ovarian cancer syndrome diagnosis and received greater_than three prior chemotherapy regimens for advanced stage disease for patients enrolled in stratum there is no upper limit on the number of prior regimens for patients enrolled in stratum ii added four seven nine
__label__1	study interventions are Trebananib . neoplasms advanced solid diagnosis and has minor surgery placement of central venous catheter or fine needle aspiration within seven days prior to enrollment
__label__1	study interventions are Oxaliplatin . colorectal carcinoma diagnosis and peripheral neuropathy greater_than grade one nci ctc
__label__1	study interventions are Niacinamide . symptomatic or uncontrolled brain metastasis
__label__1	study interventions are Carboplatin . cancer of the urethra diagnosis and due to the possibility of infection reactivation patients who are known seropositive for or who have active viral infection with human immunodeficiency virus hiv are not eligible
__label__1	study interventions are Hydroxyurea . glioblastoma diagnosis and patient greater_than five yrs free of another primary malignancy except
__label__1	study interventions are Cyclophosphamide . stage iii adult lymphoblastic lymphoma diagnosis and uncontrolled seizure disorder
__label__1	study interventions are Succinylcholine . stage iv pancreatic cancer diagnosis and patients must not have uncontrolled hypertension as defined by systolic blood pressure sbp greater_than equal_than one hundred and sixty mmhg or diastolic blood pressure dbp greater_than equal_than ninety mmhg patients whose blood pressure can be controlled medically are allowed to be rescreened once blood pressure bp is under control
__label__1	study interventions are Mycophenolate mofetil . recurrent grade one follicular lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for one2 months following treatment
__label__1	study interventions are Everolimus . stage iiia non small cell lung cancer diagnosis and use of st
__label__1	study interventions are Gadofosveset contrast agent enhanced MRI Axilla . breast neoplasms diagnosis and age less_than eighteen
__label__1	study interventions are Antibodies, Monoclonal . ovarian serous cystadenocarcinoma diagnosis and patients with clinically significant cardiovascular disease this includes
__label__1	study interventions are Vinblastine . neoplasm bladder diagnosis and current neuropathy greater or equal to ctc grade two
__label__1	study interventions are ispinesib . stage iiib rectal cancer diagnosis and john wort modafinil
__label__1	study interventions are Liposomal doxorubicin . gastrointestinal cancer diagnosis and left ventricular ejection fraction less than fifty-five
__label__1	study interventions are Hydrocortisone acetate . stage iv childhood lymphoblastic lymphoma diagnosis and pre existing greater_than equal_than grade two sensory or motor peripheral neurotoxicity
__label__1	study interventions are Octreotide . neuroendocrine tumors diagnosis and pregnancy breastfeeding pregnancy test not older than seven days is mandatory
__label__1	study interventions are Laboratory Biomarker Analysis . stage iva major salivary gland carcinoma diagnosis and patients with known brain metastases
__label__1	study interventions are Liposomal doxorubicin . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and unstable or severe uncontrolled medical psychological or social condition
__label__1	study interventions are Bronchoscopy . lung neoplasms diagnosis and bleeding disorder
__label__1	study interventions are TANDEM . hepatocellular carcinoma diagnosis and neutrophil less_than one thousand, five hundred cells mmthree
__label__1	study interventions are Etoposide . recurrent adult diffuse mixed cell lymphoma diagnosis and patient has greater_than grade two peripheral neuropathy within fourteen days before enrollment
__label__1	study interventions are Gemcitabine . hepatocellular carcinoma diagnosis and any other medical condition including mental illness or substance abuse deemed by the investigator likely to interfere with patient ability to sign informed consent cooperate and participate in the study or interfere with the interpretation of the results
__label__1	study interventions are Hormones . stage iiib breast cancer diagnosis and requirement for constant administration of proton_pump inhibitor histamine two htwo antagonist or pancreatic enzymes histamine two htwo receptor antagonists are not permitted from the day prior day one through to the end of alisertib dosing day seven except as required for premedication for protocol specific agent taxane neutralizing antacids and calcium containing supplements cannot be taken from two hours prior to alisertib dosing until up to two hours after dosing
__label__1	study interventions are Immunoglobulins . stage iv marginal zone lymphoma diagnosis and patients with poorly controlled hypertension on multiple antihypertensives
__label__1	study interventions are Mycophenolic Acid . stage iii grade one follicular lymphoma diagnosis and fertile men or women unwilling to use contraceptives during and for up to one2 months post treatment
__label__1	study interventions are Veliparib . stage iiic primary peritoneal cancer diagnosis and ctep ctcae version doc grade two or higher peripheral ischemia brief less_than two4 hours hrs episode of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Citric Acid . bladder cancer diagnosis and previous or concurrent treatment with serm and or hormonal replacement therapy within three months of the study
__label__1	study interventions are Mycophenolic Acid . stage ii cutaneous cell non hodgkin lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Antibodies, Monoclonal . adnexal carcinoma diagnosis and history or evidence of active autoimmune disease pneumonitis glomerulonephritis vasculitis or other or history of active autoimmune disease that has required systemic treatment use of corticosteroids immunosuppressive drugs or biological agents used for treatment of autoimmune diseases within two months of enrollment replacement therapy thyroxine for hypothyroidism insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is not considered form of systemic treatment for autoimmune disease
__label__1	study interventions are Botulinum Toxins, Type A . neoplasms diagnosis and previous breast surgery with implants
__label__1	study interventions are photodynamic therapy . stage ii verrucous carcinoma of the oral cavity diagnosis and prothrombin time doc times above the upper normal limit
__label__1	study interventions are Immunoglobulins . mixed adenocarcinoma of the stomach diagnosis and arterial thromboembolic events unstable angina
__label__1	study interventions are Melphalan . recurrent adult non hodgkin lymphoma diagnosis and any medical or physical contraindication or other inability to undergo hematopoietic progenitor cell hpc collection
__label__1	study interventions are VizAblate System . uterine fibroma diagnosis and presence of cardiac pacemaker or other active implant
__label__1	study interventions are Antibodies, Monoclonal . high grade ovarian serous adenocarcinoma diagnosis and no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
__label__1	study interventions are Conventional radiotherapy schedule . previous surgery for breast cancer
__label__1	study interventions are Acetylcysteine . stage ii lymphoepithelioma of the nasopharynx diagnosis and utilization of amifostine during radiotherapy
__label__1	study interventions are Liposomal doxorubicin . ovarian clear cell adenocarcinoma diagnosis and the use of inhaled corticosteroids and mineralocorticoids_fludrocortisone for patients with orthostatic_hypotension or adrenocortical insufficiency is allowed
__label__1	study interventions are Cisplatin . parotid gland cancer diagnosis and evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are Cyclophosphamide . ovarian carcinoma diagnosis and subjects with history of bowel obstruction including sub occlusive disease related to the underlying disease and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess
__label__1	study interventions are Antibodies, Monoclonal . stage iv skin melanoma diagnosis and history of grade greater_than three allergy to humanized monoclonal antibodies
__label__1	study interventions are Paclitaxel . invasive ductal breast cancer diagnosis and history of significant neurological or psychiatric disorders including psychotic disorders dementia or seizures that would prohibit the understanding and giving of informed consent
__label__1	study interventions are Etoposide phosphate . patients who have received any prior cytotoxic chemotherapy for the current diagnosis of alcl or any cancer diagnosed previously are not eligible
__label__1	study interventions are Dabrafenib . melanoma diagnosis and for cohort patients may not have any evidence of leptomeningeal disease
__label__1	study interventions are Carboplatin . ovarian epithelial cancer recurrent diagnosis and evidence of recto sigmoid involvement by pelvic examination or bowel involvement on ct scan or clinical symptoms of bowel obstruction
__label__1	study interventions are Oxaliplatin . mixed adenocarcinoma of the stomach diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to oxaliplatin irinotecan and capecitabine
__label__1	study interventions are Antibodies . stage iii verrucous carcinoma of the larynx diagnosis and active autoimmune disease
__label__1	study interventions are genetic sequencing . multiple myeloma diagnosis and women who are pregnant
__label__1	study interventions are Hormones . hertwo negative breast cancer diagnosis and uncontrolled central nervous system metastases
__label__1	study interventions are Etoposide . stage ii cutaneous cell non hodgkin lymphoma diagnosis and patients with untreated brain metastases should be excluded from this clinical trial
__label__1	study interventions are Cyclophosphamide . stage iiib breast cancer diagnosis and patients with history of seizure disorder requiring antiepileptics who have had seizure episode within the last six months
__label__1	study interventions are Carboplatin . other cancer curatively treated with no evidence of disease for at least five years
__label__1	study interventions are Niacinamide . hepatoma diagnosis and aspartate aminotransferase and or alanine transaminase greater_than five times upper limit of normal
__label__1	study interventions are Fludarabine . childhood nasal type extranodal nk cell lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Everolimus . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and patients with chronic active hepatitis or recent hepatitis infection hepatitis surface antigen hepb_sag or immunoglobulin igm antibody to hepatitis core antigen igm_antibc positive are ineligible because these patients are at increased risk of reactivation of the hepatitis virus which may be fatal due to the immunosuppressive properties of radone
__label__1	study interventions are Immunoglobulins . recurrent adult burkitt lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab_vedotin and or rituximab
__label__1	study interventions are Antibodies, Monoclonal . stage iiib uterine corpus cancer diagnosis and exceptions allowed for patients unable to tolerate the agent intolerance is defined in this protocol as discontinued agent due to side effects with an exposure less_than to four weeks of drug at any dose level
__label__1	study interventions are MEK 162 therapy or molecularly targeted therapy . stage iiia melanoma diagnosis and patients with acute gastrointestinal bleeding within one month of study entry
__label__1	study interventions are Cyclosporine . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and donor related risks to recipients
__label__1	study interventions are Immunoglobulin G . stage iiib primary peritoneal cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Cisplatin . gastric cancer diagnosis and legal incapacity
__label__1	study interventions are Aromatase Inhibitors . other malignancy within the past five years except adequately treated carcinoma in situ of the cervix contralateral breast cancer or nonmelanoma skin cancer
__label__1	study interventions are Mitomycin . solid neoplasm diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Ibrutinib . stage iv skin melanoma diagnosis and prior history of prostate provided that patient is not under active systemic treatment other than hormonal therapy and with documented undetectable prostate specific antigen psa less_than doc ng ml
__label__1	study interventions are counseling intervention . recurrent non small cell lung cancer diagnosis and other cognitive inability to complete informed consent process or study procedures
__label__1	study interventions are Immunoglobulin G . ovarian endometrioid adenocarcinoma diagnosis and carcinoid permanently closed to enrollment
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and history of active secondary malignancy
__label__1	study interventions are Vincristine . diffuse large cell lymphoma diagnosis and no serious active infection
__label__1	study interventions are Pembrolizumab . gastroesophageal junction adenocarcinoma diagnosis and known active hepatitis or hepatitis c
__label__1	study interventions are Antibodies, Monoclonal . undifferentiated ovarian carcinoma diagnosis and has received prior therapy with an anti pd one anti programmed cell death one ligand one pd lone or anti programmed cell death one ligand two pd ltwo agent
__label__1	study interventions are Tacrolimus . stage ii multiple myeloma diagnosis and left ventricular ejection fraction less_than thirty-five
__label__1	study interventions are Succinylcholine . stage iiaone cervical cancer diagnosis and patients receiving any other investigational agents
__label__1	study interventions are Vidarabine . hodgkin lymphoma diagnosis and alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt greater_than two institutional upper limit of normal
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian serous adenocarcinoma diagnosis and history of cva within six months
__label__1	study interventions are Fulvestrant . solid tumor diagnosis and history of leptomeningeal disease
__label__1	study interventions are DKN-01 . non small cell lung cancer diagnosis and have fridericia corrected qt interval qtcf greater_than four hundred and seventy millisecond msec female or greater_than four hundred and fifty male or history of congenital long qt syndrome
__label__1	study interventions are ImmuniCell® . malignant melanoma diagnosis and uncontrolled systemic infection
__label__1	study interventions are Valganciclovir . stage iii adult hodgkin lymphoma diagnosis and the recipient had prior polymerase chain reaction pcr positive cmv infection in blood or organ specific disease in the past twelve months
__label__1	study interventions are IV administration of gadolinium-containing contrast agent . adult gliosarcoma diagnosis and patients with metastatic disease
__label__1	study interventions are Vidarabine . concurrent immunotherapy to treat cancer
__label__1	study interventions are Immunoglobulins . recurrent gastric carcinoma diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Immunoconjugates . carcinoma non small cell lung diagnosis and uncontrolled significant non malignant disease congestive heart failure bleeding renal failure hepatic failure
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and patients must not have history of chronic obstructive or chronic restrictive pulmonary disease
__label__1	study interventions are Levoleucovorin . metastatic colorectal cancer diagnosis and prior treatment with anthracyclines or mitoxantrone
__label__1	study interventions are Lansoprazole . head and neck cancer diagnosis and patients who cannot complete study follow up and compliance with study protocol
__label__1	study interventions are Lumpectomy . breast carcinoma diagnosis and age less_than eighteen years
__label__1	study interventions are Vincristine . adult cell leukemia lymphoma diagnosis and may cause liver transplant rejection or serious side effects in patients on sirolimus
__label__1	study interventions are Nivolumab . exceptions include basal cell carcinoma of the skin squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy
__label__1	study interventions are Poly ICLC . stage iiia uveal melanoma diagnosis and the following will not be exclusionary
__label__1	study interventions are OPTICAL COLONOSCOPY ADHERENCE . colorectal cancer genetics of diagnosis and patients with swallowing problems dysphagia
__label__1	study interventions are AZD9150 . advanced adult hepatocellular carcinoma diagnosis and high likelihood of bleeding
__label__1	study interventions are Lapatinib . subjects receiving concurrent chemotherapy radiation therapy immunotherapy biologic therapy including an erbbone and or erbbtwo inhibitor or hormonal therapy for treatment of their cancer
__label__1	study interventions are Cisplatin . lung cancer non small cell diagnosis and prior use of bevacizumab is allowed
__label__1	study interventions are Histone Deacetylase Inhibitors . splenic marginal zone lymphoma diagnosis and patients with new york heart association nyha class ii iv heart failure
__label__1	study interventions are Trastuzumab . metastatic or locally advanced solid tumors diagnosis and four weeks before study treatment except treatment with trastuzumab both parts of the trial
__label__1	study interventions are pharmacological study . recurrent mantle cell lymphoma diagnosis and miscellaneous
__label__1	study interventions are Pharmacological Study . classical hodgkin lymphoma diagnosis and known cerebral meningeal disease
__label__1	study interventions are Levoleucovorin . stage iii childhood lymphoblastic lymphoma diagnosis and prednisone or methylprednisolone for equal_than less_than one hundred and twenty hours five days in the seven days prior to initiating induction chemotherapy or for equal_than less_than three hundred and thirty-six hours fourteen days in the twenty-eight days prior to initiating induction chemotherapy prior exposure to any steroids that occurred greater_than twenty-eight days before the initiation of protocol therapy does not affect eligibility the dose of prednisone or methylprednisolone does not affect eligibility
__label__1	study interventions are Paclitaxel . cancer of the head and neck diagnosis and prior chemotherapy prior egfr targeted therapy or prior radiation therapy for hnscc
__label__1	study interventions are Antibodies . recurrent squamous cell carcinoma of the larynx diagnosis and known untreated brain metastasis patients with neurological symptoms must undergo ct scan mri of the brain to exclude brain metastasis or progression of brain metastasis patients with treated brain metastasis are eligible for study as long as no evidence of progression of cns disease hemorrhagic brain metastases are not allowed on study
__label__1	study interventions are Antibodies . bone neoplasms diagnosis and patients must not be receiving denosumab on this study
__label__1	study interventions are Paclitaxel . non small cell lung cancer diagnosis and allergic to paclitaxel or platinum
__label__1	study interventions are Bortezomib . at least three weeks since prior chemotherapy radiation therapy immunotherapy systemic anticancer biologic therapy or anticancer hormonal therapy
__label__1	study interventions are Cyclosporins . recurrent adult lymphoblastic lymphoma diagnosis and donor
__label__1	study interventions are Erlotinib Hydrochloride . recurrent squamous cell carcinoma of the oropharynx diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to osi seven hundred and seventy-four
__label__1	study interventions are Mycophenolic Acid . recurrent mantle cell lymphoma diagnosis and bilirubin greater_than equal_than three upper limit of normal
__label__1	study interventions are Estrogen Antagonists . postmenopausal women with advanced breast cancer diagnosis and patients in whom one of the following is the sole manifestation of disease
__label__1	study interventions are Etoposide . diffuse large cell lymphoma diagnosis and female subject pregnant or breast feeding
__label__1	study interventions are Dutasteride . prostate neoplasms diagnosis and john wort
__label__1	study interventions are Paclitaxel . solid tumors diagnosis and other less potent cyponeatwo inhibitors inducers are not excluded
__label__1	study interventions are Pembrolizumab . refractory nodal marginal zone lymphoma diagnosis and intravenous immunoglobulin ivig can cause false positive hepatitis serology if patients receiving routine ivig have core antibody or surface antigen positivity without evidence of active viremia negative hepatitis dna they may still participate in the study but should have hepatitis serologies and hepatitis dna monitored periodically by the treating physician
__label__1	study interventions are Mycophenolic Acid . hepatocellular carcinoma fibrolamellar variant diagnosis and positive anti hepatitis hcv antibodies and positive serum hcv rna pcr
__label__1	study interventions are Docetaxel . stage ivb verrucous carcinoma of the oral cavity diagnosis and inability to comply with the protocol
__label__1	study interventions are Temozolomide . astrocytoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Paclitaxel . patients with recurrent endometrial cancer
__label__1	study interventions are Rituximab . lymphoma large cell diagnosis and patients who received syb five hundred and one in the past
__label__1	study interventions are BB 1101 . solid tumors diagnosis and chronic obstructive pulmonary disease copd exacerbation at the time of study enrollment
__label__1	study interventions are Etoposide phosphate . lung cancer diagnosis and may not be receiving any other study agents
__label__1	study interventions are Letrozole . neoplasm metastasis diagnosis and uncontrolled diabetes
__label__1	study interventions are Antibodies . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and clinically active hepatitis b or infections note
__label__1	study interventions are Topotecan . prior hormonal therapy leuprolide aromatase inhibitors tamoxifen will be allowed and not included as prior chemotherapy
__label__1	study interventions are Abiraterone Acetate . patient receiving an investigational treatment for prostate cancer of any kind before or at the time of initiation of abiraterone acetate or enzalutamide
__label__1	study interventions are Epirubicin . breast cancer diagnosis and administration of other investigational product in the thirty days prior to randomisation current participation in another clinical trial
__label__1	study interventions are Succinylcholine . stage iiib ovarian cancer diagnosis and stage not greater than ib
__label__1	study interventions are laboratory biomarker analysis . stage iv melanoma diagnosis and the subject has not recovered to baseline or common terminology criteria for adverse events ctcae equal_than less_than grade one from toxicity due to all prior therapies except alopecia rash and other non clinically significant adverse events aes
__label__1	study interventions are Levoleucovorin . stage iiib rectal cancer diagnosis and serious underlying medical or psychiatric illnesses that would in the opinion of the treating physician substantially increase the risk for complications related to treatment
__label__1	study interventions are Antibodies, Monoclonal . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and known hypersensitivity to rituximab
__label__1	study interventions are Dexamethasone 21-phosphate . intraocular lymphoma diagnosis and prior radioimmunotherapy within twelve weeks of registration
__label__1	study interventions are Antibodies . stage ic fallopian tube cancer diagnosis and patients with major surgical procedure anticipated during the course of the study this includes but is not limited to
__label__1	study interventions are Trametinib . stage iiib colorectal cancer diagnosis and subject has an underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding
__label__1	study interventions are Cisplatin . squamous cell carcinoma diagnosis and patients with history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate
__label__1	study interventions are Etoposide . diffuse large cell lymphoma diagnosis and previous chemotherapy or major surgery within twenty-one days prior to first study treatment or radiation therapy within six weeks
__label__1	study interventions are Valproic Acid . malignant mesothelioma diagnosis and history of prior hiv infection
__label__1	study interventions are TLR4 Agonist GLA-SE . stage iv adult soft tissue sarcoma diagnosis and patients with known systemic infections requiring antibiotics or chronic maintenance suppressive therapy
__label__1	study interventions are Olaparib . stage iv breast cancer diagnosis and history of hemoptysis within the last one month
__label__1	study interventions are Doxorubicin . ovarian neoplasms diagnosis and no patients with history of bevacizumab or other vegf or vegf receptor targeted agent use
__label__1	study interventions are Bevacizumab . adult anaplastic oligodendroglioma diagnosis and evidence or history of bleeding diathesis greater than normal risk of bleeding hereditary hemorrhagic telangiectasia type or hht one or coagulopathy in the absence of therapeutic anti coagulation or any hemorrhage bleeding event greater_than grade three within four weeks prior to registration note
__label__1	study interventions are Zoledronic acid . prostate cancer diagnosis and known history or present abuse of alcohol or drugs
__label__1	study interventions are Folic Acid . colorectal cancer diagnosis and concomitant radiotherapy
__label__1	study interventions are Propranolol . curatively resected non melanomatous skin cancer
__label__1	study interventions are circular stapler-assisted colostomy . colorectal carcinoma diagnosis and evidence of any other disease metabolic dysfunction physical examination finding or laboratory finding giving reasonable suspicion of disease or condition that puts the patient at high risk for treatment related complications
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the study therapy
__label__1	study interventions are dovitinib lactate . pancreatic polypeptide tumor diagnosis and fertile males not willing to use contraception fertile males must use condom with spermicide highly effective contraception as defined above must be used by both sexes male patients and their female partners during study treatment and for ninety days after the last dose of study medication and should not father child in this period condom is required to be used also by vasectomized men
__label__1	study interventions are Ifosfamide . stage iii diffuse large cell lymphoma diagnosis and pregnant or breastfeeding
__label__1	study interventions are Albumin-Bound Paclitaxel . inflammatory breast cancer diagnosis and participation in another clinical trial with any investigational not marketed drug within thirty days prior to study entry
__label__1	study interventions are Bevacizumab . locally recurrent and metastatic breast cancer diagnosis and treatment with immune modulators such as cyclosporine and tacrolimus within thirty days prior to randomization
__label__1	study interventions are Sirolimus . embolization or chemoembolization indicated for symptomatic control only
__label__1	study interventions are Mycophenolic Acid . recurrent small lymphocytic lymphoma diagnosis and liver function abnormalities
__label__1	study interventions are Endostatins . non small cell lung cancer diagnosis and patients with unexpected pathological patterns or those have received new adjuvant chemotherapy
__label__1	study interventions are Cyclophosphamide . non hodgkin lymphoma diagnosis and radiation oncology will evaluate all patients who have had previous radiation therapy
__label__1	study interventions are blood tests and muscular biopsies . lung cancer diagnosis and non caucasian
__label__1	study interventions are Everolimus . mixed oligoastrocytoma diagnosis and patients who have any severe and or uncontrolled medical conditions or other conditions that could affect their participation in the study such as
__label__1	study interventions are Sirolimus . aggressive non hodgkin lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Atorvastatin Calcium . aggressive non hodgkin lymphoma diagnosis and waldenstrom macroglobulinemia
__label__1	study interventions are Sirolimus . advanced cancers diagnosis and history of cva cerebrovascular accident within six months myocardial infarction or unstable angina within six months unstable angina pectoris
__label__1	study interventions are Docetaxel . fallopian tube endometrioid adenocarcinoma diagnosis and this criterion applies only to the patients enrolled before august twenty-nine two thousand and eleven and those enrolled after this date electing to receive bevacizumab patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Pentamidine . non small cell lung cancer diagnosis and active alcohol or drug abuse
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ii breast cancer diagnosis and clinically significant valvular disease
__label__1	study interventions are Anesthetics, Intravenous . brain neoplasms diagnosis and pregnancy
__label__1	study interventions are Calcium, Dietary . stage iia rectal cancer diagnosis and current or recent within ten days prior to first dose of bevacizumab use of aspirin greater_than three hundred and twenty-five mg day
__label__1	study interventions are Methotrexate . recurrent grade one follicular lymphoma diagnosis and known anaphylactic reaction to rituximab
__label__1	study interventions are Sorafenib . liver neoplasms diagnosis and any heart disease as follows
__label__1	study interventions are Sirolimus . anaplastic oligoastrocytoma diagnosis and any condition which in the investigator opinion deems the patient an unsuitable candidate to receive study drug any significant medical illness or abnormal laboratory finding that would in the investigator judgment increase the subject risk by participating in this study
__label__1	study interventions are Antilymphocyte Serum . metachromatic_leukodystrophy diagnosis and uncontrolled bacterial fungal or viral infections including hiv
__label__1	study interventions are Tacrolimus . b cell lymphoma diagnosis and previous irradiation that precludes the safe administration of an additional dose of two hundred cgy of tbi
__label__1	study interventions are Immunoglobulins . stage mantle cell lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Lapatinib . auditory tumor diagnosis and significant gastrointestinal disorder crohn disease ulcerative colitis extensive gastric resection
__label__1	study interventions are Alemtuzumab . recurrent adult immunoblastic large cell lymphoma diagnosis and patient received cytotoxic agents for cytoreduction within three weeks or the interval in which cycle of standard chemotherapy would be administered in non transplant setting prior to initiating the nonmyeloablative transplant conditioning exceptions are hydroxyurea and imatinib mesylate
__label__1	study interventions are Blood Tests . castration resistant prostate cancer metastatic to bone diagnosis and crohn disease or ulcerative colitis
__label__1	study interventions are Fludarabine . recurrent adult hodgkin lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Antibodies, Monoclonal . meningeal carcinomatosis uncontrolled seizures or disease that either causes or threatens neurologic compromise
__label__1	study interventions are laboratory biomarker analysis . recurrent marginal zone lymphoma diagnosis and baseline fredericia corrected qt interval qtcf greater_than four hundred and fifty msec male or qtcf greater_than four hundred and seventy msec female will exclude patients from entry on study
__label__1	study interventions are Fludarabine . recurrent follicular lymphoma diagnosis and hla matched or single allele mismatched donor able to donate
__label__1	study interventions are Ixazomib . prior systemic therapy for multiple myeloma including investigational drugs prior treatment with corticosteroids or localized radiation therapy dose not disqualify the patient
__label__1	study interventions are Vaccines . peritoneal cancer diagnosis and history of autoimmune disease
__label__1	study interventions are Exercise . non small cell lung cancer stage diagnosis and myocardial infarction diagnosed within the last three months
__label__1	study interventions are Fludarabine phosphate . refractory non hodgkin lymphoma diagnosis and inability to achieve adequate venous access
__label__1	study interventions are Alendronate . breast cancer diagnosis and clinical or radiological evidence of distant spread of disease
__label__1	study interventions are Iodine . follicular lymphoma diagnosis and patients with active obstructive hydronephrosis
__label__1	study interventions are Dendritic cell therapy . malignant melanoma stage iii diagnosis and inability to undergo fdg pet ct or mri examination
__label__1	study interventions are Fludarabine . recurrent mantle cell lymphoma diagnosis and low grade nhl
__label__1	study interventions are Albumin-Bound Paclitaxel . breast neoplasms diagnosis and participation in another clinical trial with any investigational not marketed drug within thirty days prior to study entry
__label__1	study interventions are Ibrutinib . recurrent diffuse large cell lymphoma diagnosis and major surgery or wound that has not fully healed within four weeks of enrollment
__label__1	study interventions are Endothelial Growth Factors . recurrent adult soft tissue sarcoma diagnosis and patients with uncontrolled hypertension are ineligible uncontrolled hypertension is defined as follows
__label__1	study interventions are Olaparib . ovarian endometrioid tumor diagnosis and unstable angina
__label__1	study interventions are Mesna . melanoma diagnosis and if subject received major surgery they must have recovered adequately from the toxicity and or complications from the intervention prior to starting therapy
__label__1	study interventions are Everolimus . head and neck neoplasms diagnosis and participants who meet any of the following criteria are not eligible for enrollment
__label__1	study interventions are Forodesine Hydrochloride Sterile Solution, 5 mg/mL . lymphoma diagnosis and rapidly progressive disease with compromised organ function judged to be life threatening by the investigator
__label__1	study interventions are Romidepsin . relapsed refractory cell lymphomas diagnosis and an ecg recorded at screening showing evidence of cardiac ischemia st depression of greater_than two mm measured from isoelectric line to the st segment
__label__1	study interventions are Antibodies, Monoclonal . anaplastic large cell lymphoma diagnosis and other serious medical conditions considered to represent contraindications to asct abnormally decreased cardiac ejection fraction diffusion capacity of the lung for carbon monoxide dlco less_than fifty predicted acquired immune deficiency syndrome aids etc
__label__1	study interventions are Placebo . prostate cancer diagnosis and chronic hepatitis with advanced decompensated hepatic disease or cirrhosis of the liver or history of chronic virus hepatitis or known viral hepatitis carrier patients recovered from hepatitis will be allowed to enter the study
__label__1	study interventions are Carboplatin . pancreatic neoplasms diagnosis and subject is pregnant or breast feeding
__label__1	study interventions are Attention Control . prostate cancer diagnosis and the patient has had previous treatment for pc
__label__1	study interventions are Citric Acid . plasma cell myeloma diagnosis and any serious medical or psychiatric illness that could in the investigator opinion potentially interfere with the completion of treatment according to this protocol
__label__1	study interventions are Dexamethasone 21-phosphate . lymphoblastic lymphoma in complete remission diagnosis and any serious medical or psychiatric illness that could in the investigator opinion potentially interfere with the treatment completion according to this protocol
__label__1	study interventions are Paclitaxel . malignant solid tumor diagnosis and aspirin use at doses up to three hundred and twenty-five milligrams day mg day and analgesic agents with no or low bleeding risk are permitted
__label__1	study interventions are Antibodies . non squamous non small cell lung cancer squamous non small cell lung cancer diagnosis and severe infection within four weeks prior to randomization
__label__1	study interventions are Oxaliplatin . stage ia esophageal cancer diagnosis and new york association nyha grade ii or greater congestive heart failure
__label__1	study interventions are Carboplatin . stage iii squamous cell carcinoma of the larynx diagnosis and active or unstable cardiovascular disease or cardiac disease requiring drug or device intervention history of coronary artery disease or congestive heart failure
__label__1	study interventions are Trastuzumab . prior systemic anticancer therapy for breast cancer immunotherapy hormonotherapy chemotherapy
__label__1	study interventions are Dacarbazine . fallopian tube cancer diagnosis and expanded safety cohorts only
__label__1	study interventions are Irinotecan . colorectal cancer diagnosis and radiotherapy or major abdominal or thoracic surgery excluding diagnostic biopsy or port implantation less_than four weeks before study entry
__label__1	study interventions are Peginterferon alfa-2b . history or clinical evidence of cns disease primary brain tumor or any brain metastasis
__label__1	study interventions are Immunoglobulin G . recurrent colorectal carcinoma diagnosis and patients who have had chemotherapy or radiotherapy within three weeks six weeks for nitrosoureas or mitomycin prior to entering the study
__label__1	study interventions are Lenalidomide . childhood grade iii meningioma diagnosis and patients with any significant medical illnesses that in the investigator opinion cannot be adequately controlled with appropriate therapy or would compromise patient ability to tolerate this therapy
__label__1	study interventions are Zoledronic acid . prostate cancer diagnosis and history of or current evidence of osteonecrosis of the jaw
__label__1	study interventions are Vidarabine . recurrent grade one follicular lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for one2 months following treatment
__label__1	study interventions are Gemcitabine . recurrent pancreatic carcinoma diagnosis and history of myocardial infarction equal_than less_than six months or congestive heart failure requiring use of ongoing maintenance therapy for life threatening ventricular arrhythmias
__label__1	study interventions are Prednisone . lymphoma diffuse large cell cell diagnosis and hiv positive patients
__label__1	study interventions are Immunoglobulins . gliosarcoma diagnosis and known hypersensitivity to any component of bevacizumab
__label__1	study interventions are Lapatinib . brain tumor diagnosis and patients must not have any significant medical illnesses that in the investigator opinion cannot be adequately controlled with appropriate therapy or would compromise the patient ability to tolerate this therapy
__label__1	study interventions are Sirolimus . with the exception of tumor common to single genetic cancer syndrome menone multiple endocrine neoplasia type two mentwo von hippel_lindau vhl tuberous sclerosis complex tsc etc patients with evidence of more than one active malignancy are excluded active malignancy is defined as the presence of primary regional nodal or distant metastatic neoplasm that has not undergone definitive therapy
__label__1	study interventions are Antibodies . hepatocellular carcinoma diagnosis and autoimmune disease that requires therapy
__label__1	study interventions are Everolimus . burkitt lymphoma diagnosis and patients with bacteremia must have documented negative blood cultures prior to study entry
__label__1	study interventions are Bevacizumab . kidney cancer diagnosis and pregnancy or breast feeding
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent adult immunoblastic large cell lymphoma diagnosis and any prior use of racemic_gossypol or at one hundred and one
__label__1	study interventions are Gefitinib . previous radiotherapy to the head or neck except for tone glottic cancer resulting in overlap of radiation fields
__label__1	study interventions are Soblidotin . other concurrent anticancer cytotoxic therapy
__label__1	study interventions are Trametinib . cancer diagnosis and taken an investigational drug within twenty-eight days or five half lives minimum fourteen days whichever is shorter prior to enrolment
__label__1	study interventions are Carboplatin . gastric cancer diagnosis and history of seizures or patients receiving anti epileptic prophylaxis
__label__1	study interventions are Methotrexate . recurrent grade one follicular lymphoma diagnosis and adult
__label__1	study interventions are Cytarabine . burkitt lymphoma diagnosis and uncontrolled infection
__label__1	study interventions are Cyclosporins . recurrent childhood lymphoblastic lymphoma diagnosis and patient has central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Retinol acetate . stage adult lymphoblastic lymphoma diagnosis and any condition gastrointestinal tract disease resulting in an inability to take oral medication or requirement for iv alimentation prior surgical procedures affecting absorption or active peptic ulcer disease that impairs their ability to swallow and retain at one hundred and one tablets
__label__1	study interventions are Paclitaxel . oesophageal cancer diagnosis and patients with known dihydropyrimidine_dehydrogenase dpd deficiency
__label__1	study interventions are Immunoglobulin G . primary peritoneal serous adenocarcinoma diagnosis and note
__label__1	study interventions are Paclitaxel . is receiving concurrent treatment with another anticancer therapy including chemotherapy immunotherapy hormonal therapy radiation therapy chemoembolization targeted or other investigational anticancer therapy
__label__1	study interventions are Endothelial Growth Factors . primary peritoneal serous adenocarcinoma diagnosis and brain metastases per mri or ct at any time prior to registration note
__label__1	study interventions are Pentostatin . follicular lymphoma diagnosis and major surgery other than diagnostic surgery within four weeks prior to study day one
__label__1	study interventions are Fosaprepitant . breast neoplasms diagnosis and patient will receive radiation to the abdomen or pelvis
__label__1	study interventions are Endothelial Growth Factors . stage ivb cervical cancer diagnosis and major surgical procedure within twenty-eight days prior to cycle one day one or anticipation of need for major surgical procedure during the course of the study
__label__1	study interventions are Busulfan . adult nasal type extranodal nk cell lymphoma diagnosis and patient unable to give informed consent
__label__1	study interventions are Etoposide . hodgkin lymphoma diagnosis and known hiv infection or aids
__label__1	study interventions are Immunoglobulin G . stage iiib primary peritoneal cancer diagnosis and subjects taking strong cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour and cytochrome pfour hundred and fifty family two subfamily polypeptide nineteen cyptwocnineteen inhibitors and or inducers should be considered with caution alternative treatments that are less likely to affect mln0onetwo8 metabolism if available should be considered if subject requires treatment with one or more of the strong cypthreeafour and cyptwocnineteen inhibitors and or inducers the principal investigator should be consulted
__label__1	study interventions are Cetuximab . recurrent squamous cell carcinoma of the oropharynx diagnosis and any malabsorption problem
__label__1	study interventions are Carboplatin . neoplasms diagnosis and active alcohol or drug abuse
__label__1	study interventions are Epothilones . kidney cancer diagnosis and prior systemic chemotherapy immunotherapy or biological therapy is allowed however prior use of either pazopanib or ixabepilone alone or in combination is not allowed
__label__1	study interventions are Screening Questionnaire Administration . colon carcinoma diagnosis and individuals with previous surgical removal of the entire colon one lung or the entire prostate men only
__label__1	study interventions are Cyclophosphamide . extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and patient has received other investigational drugs less_than fourteen days prior to registration
__label__1	study interventions are Deferasirox . stage iv adult diffuse mixed cell lymphoma diagnosis and patients with sepsis or acute illness
__label__1	study interventions are CX5461 . cancer diagnosis and patients with known photosensitivity disorders xeroderma pigmentosa porphyria etc
__label__1	study interventions are Guarana extract . neoplasms by site diagnosis and severe fatigue
__label__1	study interventions are Maleic acid . recurrent fallopian tube carcinoma diagnosis and known human immunodeficiency virus hiv positive individuals are ineligible
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian endometrioid adenocarcinoma diagnosis and stage not greater than b
__label__1	study interventions are Camptothecin . stage iiia colon cancer diagnosis and unstable angina pectoris
__label__1	study interventions are Albumin-Bound Paclitaxel . urologic neoplasms diagnosis and patients who have received wide field radiation cytotoxic chemotherapy or hormonal therapy within four weeks of study entry or mitomycin or nitrosoureas within six weeks of study entry
__label__1	study interventions are NBTXR3, IL or IA injection + SBRT . hepatocellular carcinoma diagnosis and auto immune hemolytic anemia
__label__1	study interventions are Irinotecan . stage iva rectal cancer diagnosis and history of intracranial bleeding
__label__1	study interventions are Goserelin . breast cancer diagnosis and nervous system disorders caused by diseases or obvious mental disorder which would affect patients right to consent and compliance or make patients in critical condition
__label__1	study interventions are Cisplatin . gastric cancer diagnosis and plateletless_than one hundred one hundred and nine l
__label__1	study interventions are Everolimus . transformed lymphoma dlbcl pmbcl diagnosis and examples of live attenuated vaccines include intranasal influenza measles_mumps rubella oral polio bcg yellow fever varicella and tytwenty-onea_typhoid vaccines
__label__1	study interventions are AlloStim . solid tumors stage ii stage iii and stage iv diagnosis and concomitant active autoimmune disease rheumatoid arthritis multiple sclerosis autoimmune thyroid disease uveitis
__label__1	study interventions are Endothelial Growth Factors . recurrent melanoma diagnosis and congestive heart failure requiring use of ongoing maintenance therapy for life threatening ventricular arrhythmias
__label__1	study interventions are Cisplatin . stage ib cervical cancer diagnosis and history of bowel obstruction or malabsorption syndromes
__label__1	study interventions are Doxorubicin . undifferentiated high grade pleomorphic sarcoma of bone diagnosis and brain imaging is not an eligibility requirement
__label__1	study interventions are PF-04691502 . cancer diagnosis and diagnosed or suspected congenital long qt syndrome
__label__1	study interventions are Immunoglobulin G . stage iib fallopian tube cancer diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and therapeutic anticoagulation is allowed if the anticoagulant dosing is stable
__label__1	study interventions are Cyclosporins . recurrent follicular lymphoma diagnosis and any cord blood units without the full maternal testing and negative results for hepatitis b hiv and human lymphotropic virus htlv one viruses
__label__1	study interventions are Paclitaxel . uterine carcinosarcoma diagnosis and absolute neutrophil count anc less_than one thousand, five hundred mmthree
__label__1	study interventions are Cortisone . hormone resistant prostate cancer diagnosis and patients requiring therapeutic anticoagulation warfarin dabigatran heparin or low molecular weight heparins lovenox dalteparin
__label__1	study interventions are enzalutamide . metastatic prostate cancer diagnosis and previous treatment with ipilimumab
__label__1	study interventions are Methotrexate . lymphoma diagnosis and pregnancy
__label__1	study interventions are Antibodies . stage ivc verrucous carcinoma of the larynx diagnosis and patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and known history of allergy to captisol cyclodextrin_derivative used to solubilize_carfilzomib
__label__1	study interventions are BBI503 . gastrointestinal stromal tumors diagnosis and qtc greater_than four hundred and eighty msec clinically significant cardiac enlargement or hypertrophy new bundle_branch block or signs of active ischemia
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and patient has not recovered from dexamethasone related toxicity experienced during mpi study mthirty-four thousand, one hundred and one thirty-nine
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian serous cystadenocarcinoma diagnosis and uncontrolled hypertension defined as systolic greater_than one hundred and fifty mm hg or diastolic greater_than ninety mmhg
__label__1	study interventions are Oxaliplatin . rectal cancer stage iii diagnosis and prior or concurrent malignancy less_than three years prior to enrolment in study exception
__label__1	study interventions are Bevacizumab . primary peritoneal serous adenocarcinoma diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Nedaplatin . woman in pregnancy and breast feeding
__label__1	study interventions are Ropidoxuridine . stage iiib rectal cancer diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Home Based Exercise . prostate cancer diagnosis and already meeting guidelines for moderate to vigorous physical activity mvpa
__label__1	study interventions are Simvastatin . active breast cancer with known metastatic involvement
__label__1	study interventions are Gadobutrol . adult mixed glioma diagnosis and cardiac pacemaker
__label__1	study interventions are Navitoclax . recurrent colorectal carcinoma diagnosis and the following concomitant medications are not allowed during navitoclax administration
__label__1	study interventions are Fecal Immunochemical Test . colorectal cancer diagnosis and prisoners
__label__1	study interventions are Albumin-Bound Paclitaxel . unresectable pancreatic carcinoma diagnosis and no known or suspected allergy to the investigational agents or any agents given in association with this trial
__label__1	study interventions are Vinorelbine . breast cancer diagnosis and major surgery within four weeks of the start of study treatment without complete recovery
__label__1	study interventions are TACE . hepatocellular carcinoma diagnosis and the patients would not sign the consent to the trial
__label__1	study interventions are Neoadjuvant chemotherapy . breast cancer diagnosis and cardiac thrombotic events in the past twelve months
__label__1	study interventions are 10-hydroxycamptothecin . gliosarcoma diagnosis and john wort modafinil
__label__1	study interventions are Bryostatin 1 . recurrent adult immunoblastic large cell lymphoma diagnosis and hemoglobin equal_than less_than doc dl
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Paclitaxel . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and any prior use of racemic_gossypol or at one hundred and one
__label__1	study interventions are Mycophenolic Acid . stage iii adult diffuse small cleaved cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Dexamethasone . refractory plasma cell myeloma diagnosis and rifabutin
__label__1	study interventions are Antibodies, Monoclonal . metastatic solid neoplasm diagnosis and patients who have received acute low dose systemic immunosuppressant medications one time dose of dexamethasone for nausea premedication for radiologic contrast allergy may be enrolled
__label__1	study interventions are BB 1101 . stage iii grade two follicular lymphoma diagnosis and marked limitation of physical activity comfortable at rest but less than ordinary activity causes fatigue or dyspnea iv
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and known human immunodeficiency virus positivity
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and known allergic sensitivity to leucovorin
__label__1	study interventions are Cyclosporins . myeloproliferative neoplasm diagnosis and unrelated donor
__label__1	study interventions are Cure Tape covering T 7 and T 8 dermatomes . cancer related problem condition diagnosis and to shower inability to report nausea and or vomiting
__label__1	study interventions are Irinotecan . lung carcinoma diagnosis and any patient requiring cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour isoform inducing drugs phenytoin phenobarbital carbamazepine rifampin rifabutin ketoconazole st
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ivb vulvar cancer diagnosis and active or unstable cardiovascular disease or cardiac disease requiring drug or device intervention history of coronary artery disease or congestive heart failure
__label__1	study interventions are Regorafenib . cancer of the bile duct diagnosis and other investigational treatment during or within twenty-one days before starting study treatment
__label__1	study interventions are Paclitaxel . endometrial clear cell adenocarcinoma diagnosis and patients with history of serious co morbid illness or uncontrolled illnesses that would preclude protocol therapy
__label__1	study interventions are Everolimus . pancreatic delta cell adenoma diagnosis and major surgical procedure open biopsy or significant traumatic injury equal_than less_than four weeks prior to registration
__label__1	study interventions are management of therapy complications . recurrent ovarian germ cell tumor diagnosis and body mass index bmi less_than leightkg two
__label__1	study interventions are Naloxegol . cancer diagnosis and any other significant and or progressive condition medical neurological psychiatric or metabolic or symptom that could increase the risk of participation in the study or affect the interpretation of study data as determined by the investigator uncontrolled hypothyroidism inadequately controlled clinical depression poorly controlled seizure disorder
__label__1	study interventions are Fluorouracil . symptomatic disease of the inferior artery
__label__1	study interventions are Cadexomer iodine . non hodgkin lymphoma diagnosis and patients who are pregnant
__label__1	study interventions are Mycophenolic Acid . non hodgkin lymphoma diagnosis and human immunodeficiency virus hiv or human lymphotrophic virus htlv infection
__label__1	study interventions are comprehensive geriatric assessment (CGA) . cancer diagnosis and patient for whom surgery is performed under local anaesthesia
__label__1	study interventions are Vinblastine . other active malignancies including other hematologic malignancies or other malignancies except for cured nonmelanoma skin cancer or cervical intraepithelial_neoplasia
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian endometrioid adenocarcinoma diagnosis and no poorly differentiated subtypes including papillary serous clear cell or other international federation of gynecology and obstetrics_figo grade three lesions
__label__1	study interventions are Fludarabine phosphate . recurrent grade three follicular lymphoma diagnosis and patient or donor with history of hepatitis or and or positive serology consistent with previous hepatitis or infection patients and or donor who received hepatitis vaccination are acceptable
__label__1	study interventions are Vaccines . prostate cancer diagnosis and history of or active autoimmune disease such as autoimmune neutropenia thrombocytopenia or hemolytic anemia systemic lupus erythematosis sjogrens syndrome scleroderma myasthenia_gravis goodpasture syndrome addisons disease hashimotos thyroiditis crohns or graves disease
__label__1	study interventions are Epothilone B . male breast cancer diagnosis and prior ixabepilone and or vorinostat are not allowed
__label__1	study interventions are anti-mesothelin CAR T cells . mesothelin positive tumors diagnosis and patients with prior history of autoimmune disease or other diseases who need long term use of systemic hormone drug or immunosuppressive therapy
__label__1	study interventions are Carboplatin . stage iv non small cell lung cancer diagnosis and history or signs of active coronary artery disease with or without angina pectoris myocardial infarction with six months prior to enrollment uncontrolled angina electrocardiographic evidence of acute ischemia
__label__1	study interventions are Bevacizumab . fallopian tube cancer diagnosis and stage not greater than ia grade one or two no more than superficial myometrial invasion without vascular or lymphatic invasion no poorly differentiated subtypes including papillary serous clear cell or other figo grade three lesions
__label__1	study interventions are Bleomycin . presence of other concomitant diseases neoplasia excluding cutaneous tumors with limited extension and without diagnosis of melanoma or any other life threatening clinical condition that would compromise its compliance to the protocol
__label__1	study interventions are HPPH . stage iii squamous cell carcinoma of the oropharynx diagnosis and white blood cells wbc less_than four zero
__label__1	study interventions are Vidarabine . peripheral cell lymphoma diagnosis and donor
__label__1	study interventions are Bevacizumab . stage iiib ovarian cancer diagnosis and invasive procedures defined as follows
__label__1	study interventions are Immunoglobulins . stage iva verrucous carcinoma of the oral cavity diagnosis and patients who have taken herbal medications and certain fruits within seven days prior to starting study drug herbal medications include but are not limited to st
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and minimum of two weeks should elapse between prior minor surgical procedures such as chemotherapy infusion port placement or core visceral organ biopsy and enrollment in the study
__label__1	study interventions are Immunoglobulins . fallopian tube mucinous adenocarcinoma diagnosis and patients with known allergy to cremophor or polysorbate eighty
__label__1	study interventions are 3-Iodobenzylguanidine . neuroblastoma diagnosis and patients and or families who are physically and psychologically unable to cooperate with the radiation safety isolation
__label__1	study interventions are Pembrolizumab . melanoma diagnosis and haematological
__label__1	study interventions are Cisplatin . stage iii oral cavity squamous cell carcinoma diagnosis and severe active co morbidity defined as follows
__label__1	study interventions are Levoleucovorin . other malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix
__label__1	study interventions are Melphalan . ewing sarcoma diagnosis and bone marrow involvement
__label__1	study interventions are Bendamustine Hydrochloride . intraocular lymphoma diagnosis and patients with history of myocardial infarction that is less_than three months prior to registration
__label__1	study interventions are Sirolimus . stage iv bladder urothelial carcinoma diagnosis and mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
__label__1	study interventions are Everolimus . colorectal carcinoma diagnosis and any uncontrolled clinically significant cardiac disease arrhythmias or angina pectoris
__label__1	study interventions are omaveloxolone . relapsed refractory melanoma diagnosis and known or suspected active drug or alcohol abuse
__label__1	study interventions are Fluorouracil . stage ii rectal cancer diagnosis and sensory or motor neuropathy greater_than equal_than grade two
__label__1	study interventions are Carmustine . patients who have had prior cytoreductive surgery for high grade glioma patients who have had diagnostic stereotactic biopsy are eligible
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and women who are pregnant positive pregnancy test or breast feeding
__label__1	study interventions are Antibodies, Monoclonal . testicular lymphoma diagnosis and positive crossmatch between donor and recipients
__label__1	study interventions are GLA-SE . merkel cell carcinoma diagnosis and pregnant or nursing
__label__1	study interventions are Dacarbazine . gliosarcoma diagnosis and patients must not have evidence of recent hemorrhage on baseline mri of the brain with the following exceptions
__label__1	study interventions are Vinorelbine . stage ib lung carcinoma diagnosis and patients with sensitivity to vinorelbine or cisplatin
__label__1	study interventions are Mycophenolic Acid . adult grade iii lymphomatoid granulomatosis diagnosis and marrow donors
__label__1	study interventions are Placebo . tenosynovial giant cell tumor localized or diffused type diagnosis and pregnant or nursing lactating women
__label__1	study interventions are [I-124]-CPD-1028 Injection . cancer diagnosis and subjects with known or suspected allergies or contraindications to the investigational agents and iodine
__label__1	study interventions are Prednisolone hemisuccinate . myeloma diagnosis and history of hypersensitivity reactions attributed to simvastatin bortezomib bendamustine or zoledronic acid
__label__1	study interventions are Podophyllotoxin . b cell lymphoma unclassifiable with features intermediate between diffuse large cell lymphoma and burkitt lymphoma diagnosis and research participants receiving any other investigational agents or concurrent biological chemotherapy or radiation therapy
__label__1	study interventions are Lenograstim . prostate cancer diagnosis and patients with severe psychiatric illness social situations that would limit compliance with study requirements in the judgment of study investigator
__label__1	study interventions are Docetaxel . advanced breast cancer diagnosis and have received more than three prior chemotherapy regimens for abc
__label__1	study interventions are Prednisone . prostate cancer metastatic diagnosis and history of hypersensitivity to docetaxel or polysorbate eighty
__label__1	study interventions are Sirolimus . stage iii childhood anaplastic large cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are BPX-501 . lymphomas diagnosis and positive hiv serology or viral rna
__label__1	study interventions are Cyclosporins . stage ii cutaneous cell non hodgkin lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Mycophenolic Acid . recurrent grade two follicular lymphoma diagnosis and known allergy to csf
__label__1	study interventions are laboratory biomarker analysis . previous within five years of enrollment or current malignancies at other sites except adequately treated basal cell or squamous cell skin cancers and carcinoma in situ of the cervix
__label__1	study interventions are Levoleucovorin . intestinal adenocarcinoma of the stomach diagnosis and patients with an active bleeding diathesis history of noncompliance to medical regimens
__label__1	study interventions are Gemcitabine . recurrent fallopian tube carcinoma diagnosis and patients who require parenteral hydration or nutrition and have evidence of partial bowel obstruction or perforation
__label__1	study interventions are Aldesleukin . refractory multiple myeloma diagnosis and pleural effusion pericardial effusion or ascites
__label__1	study interventions are Mitogens . stage iii mantle cell lymphoma diagnosis and history of thymectomy
__label__1	study interventions are Albumin-Bound Paclitaxel . gastroesophageal junction adenocarcinoma diagnosis and the participant underwent major surgery within twenty-eight days
__label__1	study interventions are Questionnaires . cancer diagnosis and dementia psychosis hallucinations delusions that interferes with cognitive processing verbal and music
__label__1	study interventions are Fludarabine . refractory plasma cell myeloma diagnosis and patients with primary idiopathic myelofibrosis
__label__1	study interventions are Aldesleukin . inflammatory breast cancer diagnosis and patients with karnofsky performance score less than seventy
__label__1	study interventions are Aldesleukin . metastatic pancreatic adenocarcinoma diagnosis and uncontrolled systemic disease like active infections
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and inability to access study site for clinical visits
__label__1	study interventions are Paclitaxel . stage ib breast cancer diagnosis and uncontrolled hypertension diastolic greater than one hundred mm hg or systolic greater_than two hundred mm hg
__label__1	study interventions are Thalidomide . small lymphocytic lymphoma diagnosis and patients with recent history of deep vein thrombosis dvt or pulmonary embolus pe in the six months prior to enrollment are not eligible for this study
__label__1	study interventions are JM 3100 . non hodgkin lymphoma diagnosis and documented history of ventricular arrhythmias during the last three years
__label__1	study interventions are Raltitrexed . colorectal cancer metastatic diagnosis and patients with severe organ dysfunction or failure
__label__1	study interventions are Ifosfamide . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and patients with prior treatment with myeloablative therapy are excluded
__label__1	study interventions are Topotecan . recurrent adult soft tissue sarcoma diagnosis and patients must not have an active secondary malignancy
__label__1	study interventions are Dexamethasone . colon cancer diagnosis and patients who have diagnosis of gilbert disease
__label__1	study interventions are Donor Lymphocyte Infusion (DLI) . hodgkin lymphoma diagnosis and pregnant or lactating
__label__1	study interventions are Cetuximab . head and neck neoplasms diagnosis and progressive disease within three months after completion of curative intent treatment for localized locoregionally advanced disease
__label__1	study interventions are Niacinamide . locally metastatic malignant neoplasm diagnosis and chronic treatment with systemic steroids or other immunosuppressive agent
__label__1	study interventions are Dihydrotachysterol . advanced malignant glioma diagnosis and known allergy or sensitivity to any of the excipients in the investigational product
__label__1	study interventions are Fludarabine . anaplastic large cell lymphoma diagnosis and marrow donors
__label__1	study interventions are Epothilones . renal cell carcinoma diagnosis and serious or non healing wound ulcer or bone fracture
__label__1	study interventions are eribulin mesylate . stage ii pancreatic cancer diagnosis and may not be receiving other investigational agents
__label__1	study interventions are Paclitaxel . pancreatic cancer diagnosis and known or suspected allergy to study drugs
__label__1	study interventions are Maleic acid . stage iv breast cancer diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Fludarabine . refractory plasma cell myeloma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are ViewRay MRI . previous systemic chemotherapy for any cancer or pelvic radiation therapy
__label__1	study interventions are 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography. . islet cell tumor diagnosis and any additional medical condition serious intercurrent illness or other extenuating_circumstance that in the opinion of the investigator may significantly interfere with study compliance
__label__1	study interventions are Carboplatin . stage iv fallopian tube cancer diagnosis and patients with known allergy to cremophor or polysorbate eighty
__label__1	study interventions are Cyclosporins . recurrent renal cell cancer diagnosis and donor
__label__1	study interventions are Cyclophosphamide . lymphoma diagnosis and patients with gastrointestinal conditions that might predispose for drug intolerability or poor drug absorption inability to take oral medication or requirement for iv alimentation prior surgical procedures affecting absorption malabsorption syndrome active peptic ulcer disease are excluded
__label__1	study interventions are western blotting . adult glioblastoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Sirolimus . hertwo neu negative carcinoma of breast diagnosis and prior palliative cytotoxic chemotherapies
__label__1	study interventions are Niacinamide . recurrent salivary gland cancer diagnosis and known hiv positive patients will be excluded from trial due to the potential immune modulation that these agents may cause
__label__1	study interventions are Everolimus . stage iv renal cell cancer diagnosis and uncontrolled brain or leptomeningeal metastases including patients who continue to require glucocorticoids for brain or leptomeningeal metastases
__label__1	study interventions are Tacrolimus . hematopoietic lymphoid cancer diagnosis and major anticipated illness or organ failure incompatible with survival form transplant
__label__1	study interventions are Sodium Glycididazole . esophageal neoplasms diagnosis and patients with distant metastasis
__label__1	study interventions are Antibodies . melanoma diagnosis and note
__label__1	study interventions are Antibodies, Monoclonal . unspecified childhood solid tumor protocol specific diagnosis and patients with history of clinically significant bleeding risk including evidence of active bleeding
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and acute or subacute intestinal occlusion
__label__1	study interventions are Paclitaxel . pancreatic carcinoma non resectable diagnosis and previous use of any chemotherapy or radiation therapy for metastatic disease
__label__1	study interventions are Antibodies, Monoclonal . stage iv childhood anaplastic large cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than thirty-five total lung capacity tlc less_than thirty-five or forced expiratory volume in one second fevone less_than thirty-five and or receiving supplementary continuous oxygen
__label__1	study interventions are LOP628 . ckit positive solid tumors diagnosis and patient has been previously treated with ckit directed antibodies
__label__1	study interventions are Bortezomib . recurrent adult diffuse large cell lymphoma diagnosis and ps three hundred and forty-one treatment
__label__1	study interventions are Antibodies, Monoclonal . gallbladder cancer diagnosis and subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
__label__1	study interventions are Everolimus . stage iv breast cancer diagnosis and chronic treatment with corticosteroids or other immunosuppressive agents topical or inhaled corticosteroids are allowed
__label__1	study interventions are Dexamethasone 21-phosphate . extranodal nk cell lymphoma nasal type diagnosis and mental disorders
__label__1	study interventions are Endostatins . esophageal squamous cell carcinoma diagnosis and patients have received radiotherapy in three months
__label__1	study interventions are Sunitinib . gastrointestinal stromal tumors diagnosis and this does not include patients with history of these events with adequate control by pacemaker
__label__1	study interventions are Ixazomib . multiple myeloma diagnosis and female participants who are lactating and breastfeeding or have positive serum pregnancy test during the screening period
__label__1	study interventions are Mifepristone . ovarian epithelial cancer recurrent diagnosis and patients who require treatment with systemic corticosteroids for serious medical conditions or illnesses immunosuppression after organ transplantation
__label__1	study interventions are Dacarbazine . resection of the brain tumor complete on mri exploration
__label__1	study interventions are Endothelial Growth Factors . cervical squamous cell carcinoma diagnosis and new york heart association nyha grade ii or greater congestive heart failure
__label__1	study interventions are Dacarbazine . recurrent central nervous system neoplasm diagnosis and patients must not be pregnant breast feeding and must agree to practice adequate contraception
__label__1	study interventions are Oxaliplatin . rectal adenocarcinoma diagnosis and transmural myocardial infarction within the last six months
__label__1	study interventions are Niacinamide . stage iva colon cancer diagnosis and other concurrent chemotherapy immunotherapy radiotherapy or any ancillary therapy considered investigational utilized for non food and drug administration fda approved indication and in the context of research investigation
__label__1	study interventions are Capecitabine . colon cancer diagnosis and other investigational treatment within thirty days prior to treatment start
__label__1	study interventions are cytology specimen collection procedure . stage iiib melanoma diagnosis and to participate in the study or which could jeopardize compliance with protocol requirements including but not limited to
__label__1	study interventions are Floxuridine . stomach cancer diagnosis and active ongoing infection which antibiotic treatment is needed
__label__1	study interventions are Cisplatin . histology other than squamous cell carcinoma
__label__1	study interventions are Acyclovir . prostate cancer diagnosis and known hiv positive patients
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and concurrent severe illness such as active infection or psychiatric illness social situations that would limit safety and compliance with study requirements
__label__1	study interventions are Pemetrexed . colorectal cancer diagnosis and systemic chemotherapy within three weeks after the administration of the last before the test treatment radiation therapy patients who had been administered
__label__1	study interventions are Niacinamide . stage iv hepatocellular carcinoma diagnosis and current use of certain concomitant medications due to mechanistic based platelet toxicities from navitoclax
__label__1	study interventions are Methylprednisolone acetate . prostate cancer diagnosis and e
__label__1	study interventions are Temozolomide . brain and central nervous system tumors diagnosis and pre surgery tissue acquisition
__label__1	study interventions are Carboplatin . human papilloma virus infection diagnosis and patient is enrolled in another investigational trial
__label__1	study interventions are Prednisone . prostate cancer diagnosis and known strong inducers or inhibitors of cypthreeafour five including grapefruit grapefruit hybrids_pummelos star_fruit and seville_oranges
__label__1	study interventions are Cytarabine . diffuse large cell lymphoma diagnosis and left ventricular ejection fraction less than forty-five
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and patients who are receiving any other investigational agents not included in this trial within twenty-one days of the start of this trial and throughout the duration of this trial
__label__1	study interventions are Dacarbazine . anaplastic astrocytoma diagnosis and uncontrolled or significant cardiovascular disease clinically significant ventricular arrhythmia such as ventricular tachycardia ventricular fibrillation or torsades des pointes clinically significant pulmonary disease such as greater_than grade two dyspnea according to ctcae doc three
__label__1	study interventions are Nintedanib . carcinoma non small cell lung diagnosis and total bilirubin greater_than doc mg dl twenty-six µmole si unit equivalent alanine amino_transferase alt and or aspartate amino_transferase ast greater_than doc upper limit of normal uln
__label__1	study interventions are Abiraterone Acetate . stage iv prostate cancer diagnosis and patients with known active hepatitis or hepatitis c
__label__1	study interventions are Liposomal doxorubicin . low grade myofibroblastic sarcoma diagnosis and the use of fentanyl is permitted
__label__1	study interventions are Propranolol . infantile_hemangioma diagnosis and allergic rhinitis
__label__1	study interventions are Olaparib . metastatic pancreatic adenocarcinoma diagnosis and history of stroke or transient ischemic attack within six months
__label__1	study interventions are Rituximab . lymphoma follicular diagnosis and receiving any other investigational agents
__label__1	study interventions are Radiation Therapy . digestive system neoplasm diagnosis and phase i
__label__1	study interventions are Epirubicin . esophageal neoplasms diagnosis and chemotherapy with epirubicin oxaliplatin carboplatin cisplatin or docetaxel less than six months before study entry
__label__1	study interventions are Mycophenolate mofetil . lymphoma diagnosis and severe organ dysfunction
__label__1	study interventions are Bevacizumab . previous or current malignancies within the last three years with the exception of cervical cancer and adequately treated basal cell or squamous cell carcinoma of the skin
__label__1	study interventions are Docetaxel . lung neoplasms diagnosis and controlled disease after first line treatment
__label__1	study interventions are Laboratory Biomarker Analysis . gastrin_producing neuroendocrine tumor diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days of treatment
__label__1	study interventions are peripheral blood stem cell transplantation . lymphoma diagnosis and concomitant malignancy that has not been curatively treated
__label__1	study interventions are Tacrolimus . recurrent marginal zone lymphoma diagnosis and patient has poorly controlled hypertension and on multiple antihypertensives
__label__1	study interventions are Nivolumab . lung cancer nonsmall cell stage diagnosis and known history of human immunodeficiency virus hiv or active hepatitis virus or active hepatitis virus infection or any uncontrolled active systemic infection
__label__1	study interventions are Veno-veno-arterial ECMO . lymphangioleiomyomatosis diagnosis and patients with arrhythmia
__label__1	study interventions are Ice-Sense . fibroadenoma diagnosis and patients carrying contagious diseases such as tuberculosis hepatitis or aids
__label__1	study interventions are Ibrutinib . recurrent grade two follicular lymphoma diagnosis and active central nervous system cns involvement
__label__1	study interventions are Internet-Based Intervention . evidence of cancer recurrence
__label__1	study interventions are tape measurement of arm . active cancer
__label__1	study interventions are Methyltestosterone . prostate cancer diagnosis and existing major cardiovascular grade iii
__label__1	study interventions are Etoposide . diffuse large cell lymphoma diagnosis and note
__label__1	study interventions are Cisplatin . uncontrolled intercurrent illness including but not limited to ongoing or active serious infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or serious psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Vitamins . breast tumors diagnosis and major surgery within fourteen days of enrollment
__label__1	study interventions are Antibodies, Monoclonal . anaplastic large cell lymphoma diagnosis and pregnant or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
__label__1	study interventions are Paclitaxel . preexisted peripheral toxicity greater_than grade two of the national cancer institute common toxicity criteria
__label__1	study interventions are Rituximab . for an indolent lymphoma histology follicular lymphoma sll cll or mantle cell lymphoma the patient should not have an hla matched sibling who would be an eligible donor available
__label__1	study interventions are Vaccines . other concurrent chemotherapy for pancreatic cancer
__label__1	study interventions are Carboplatin . solid tumors diagnosis and steroids given as part of pre medications for imaging studies are not exclusionary
__label__1	study interventions are FOLFOX . previous malignancy in the last five years except basal cell carcinoma of the skin or in situ cervical carcinoma
__label__1	study interventions are Prednisone . currently active other malignancy excluding controlled non melanoma skin cancer
__label__1	study interventions are Carboxymethylcellulose Sodium . non invasive non melanoma skin cancer such as superficial basal cell carcinoma or squamous cell carcinoma
__label__1	study interventions are Cyclosporins . recurrent mantle cell lymphoma diagnosis and coli derived proteins
__label__1	study interventions are Docetaxel . head and neck neoplasms diagnosis and pregnant or breast feeding women
__label__1	study interventions are Antibodies . stage iii grade one follicular lymphoma diagnosis and chemotherapy within four weeks of the first scheduled study treatment
__label__1	study interventions are Thalidomide . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and the development of erythema_nodosum if characterized by desquamating_rash while taking thalidomide or similar drugs
__label__1	study interventions are Digoxin . solid tumors diagnosis and inability to swallow oral medications that could interfere with the absorption of tivantinib
__label__1	study interventions are Everolimus . stage iv small lymphocytic lymphoma diagnosis and karnofsky score less_than sixty or lansky score less_than fifty
__label__1	study interventions are Idelalisib . pancreatic ductal adenocarcinoma diagnosis and documented myocardial infarction or unstable uncontrolled cardiac disease eg unstable angina congestive heart failure new york heart association greater_than class iii within six months or enrollment
__label__1	study interventions are Eicosapentaenoic acid ethyl ester . metastatic colorectal cancer diagnosis and evidence or history of bleeding diathesis or coagulopathy
__label__1	study interventions are Alpha cyclodextrin . stage prostate cancer diagnosis and use of any medication including over the counter otc medication within two weeks prior to admission day one or within one0 times the elimination half life of the respective drug or anticipated concomitant medication during the treatment periods
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and any sex hormonal therapy birth control pills ovarian hormone replacement therapy etc
__label__1	study interventions are Bevacizumab . stage ivb colorectal cancer diagnosis and history of arterial thromboembolic events
__label__1	study interventions are Aromatase Inhibitors . male breast cancer diagnosis and no indication for endocrine treatment
__label__1	study interventions are Immunoglobulins . childhood diffuse large cell lymphoma diagnosis and patients receiving chronic systemic corticosteroids are not eligible
__label__1	study interventions are Doxorubicin . recurrent ovarian carcinoma diagnosis and signs or symptoms of infection within two weeks prior to cycle one day one
__label__1	study interventions are Cyclophosphamide . contiguous stage ii adult burkitt lymphoma diagnosis and active or recent prior six months invasive fungal infection without id consult and approval
__label__1	study interventions are Ramucirumab . esophageal cancer diagnosis and aspirin use at doses up to three hundred and twenty-five milligrams per day mg day is permitted
__label__1	study interventions are Rituximab . nodal marginal zone cell lymphoma diagnosis and pregnant or nursing women
__label__1	study interventions are Albumin-Bound Paclitaxel . pancreatic neoplasms diagnosis and patient must not have previously received nab paclitaxel
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and peripheral neuropathy of greater_than grade two severity
__label__1	study interventions are Cyclosporins . childhood burkitt lymphoma diagnosis and donor
__label__1	study interventions are Fludarabine . stage grade three follicular lymphoma diagnosis and current serious systemic illness that would result in increased risk for csf mobilization and harvest of peripheral blood stem cells pbsc
__label__1	study interventions are Telephone Coaching Sessions . cancer diagnosis and patients with relapse or recurrence of disease within the past month or those with progressive disease
__label__1	study interventions are photodynamic therapy . recurrent verrucous carcinoma of the larynx diagnosis and patients who have received radiation therapy chemotherapy or other biological therapy during the past thirty days
__label__1	study interventions are Dichloroacetate (DCA) . metastatic breast cancer diagnosis and patients who have had chemotherapy hormonal therapy molecular targeted therapy or radiotherapy within four weeks prior to receiving first dose of dca
__label__1	study interventions are Lenvatinib . stage iv thyroid gland papillary carcinoma diagnosis and female subjects of childbearing potential
__label__1	study interventions are Fosbretabulin . neoplasms ovarian diagnosis and at high medical risk because of non malignant systemic disease including active uncontrolled infection
__label__1	study interventions are Fludarabine . stage iv adult burkitt lymphoma diagnosis and left ventricular ejection fraction less_than thirty-five
__label__1	study interventions are Sevoflurane . colorectal cancer diagnosis and significant hepatic alat and or asat greater_than two normal values or renal plasma creatinine greater_than two mg dl disorders
__label__1	study interventions are Immunoglobulin G . undifferentiated ovarian carcinoma diagnosis and history of diverticulitis or pancreatitis within twelve weeks of registration
__label__1	study interventions are laboratory biomarker analysis . recurrent adult lymphoblastic lymphoma diagnosis and research participants will be excluded who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
__label__1	study interventions are Sorafenib . malignant neoplasm of stomach diagnosis and known or suspected allergy or hypersensitivity to any of the study drugs study drug classes or excipients in the formulation given during the course of this trial
__label__1	study interventions are Capecitabine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and patients with known dihydropyrimidine_dehydrogenase dpd deficiency enzyme are excluded
__label__1	study interventions are Technetium Tc 99m Medronate . cancer diagnosis and cannot lie still for the necessary time
__label__1	study interventions are CX-4945 oral formulation . active symptomatic fungal bacterial and or viral infection including active hiv or viral hepatitis
__label__1	study interventions are Fludarabine phosphate . testicular lymphoma diagnosis and donor
__label__1	study interventions are Paclitaxel . stage ii breast cancer diagnosis and pre existing grade three or four sensory neuropathy
__label__1	study interventions are Cisplatin . history of other cancer
__label__1	study interventions are Doxorubicin . fallopian tube neoplasms diagnosis and one mg doxorubicin equal_than one mg doxil_caelyx equal_than doc mg epirubicin equal_than doc mg mitoxantrone equal_than doc five mg idarubicin
__label__1	study interventions are Lenograstim . stage iiic breast cancer diagnosis and phase i
__label__1	study interventions are Vincristine . patients with past or current history of liver parenchymal or hepatobiliary disease unrelated to cancer including but not limited to conditions such as liver cirrhosis acute chronic hepatitis ascending cholangitis etc
__label__1	study interventions are Prednisone . lymphoma diagnosis and one
__label__1	study interventions are Fludarabine phosphate . stage iii adult immunoblastic large cell lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Everolimus . adenocarcinoma of the esophagus diagnosis and patients with known hypersensitivity to everolimus or other rapamycins_sirolimus temsirolimus or to its excipients
__label__1	study interventions are Levoleucovorin . gastric cancer diagnosis and prior unanticipated severe reaction to fluoropyrimidine therapy with or without documented dpd deficiency or patients with known dihydropyrimidine_dehydrogenase dpd deficiency
__label__1	study interventions are Cyclosporine . splenic marginal zone lymphoma diagnosis and donor
__label__1	study interventions are Pembrolizumab . colorectal cancer diagnosis and has evidence of interstitial lung disease or active non infectious pneumonitis
__label__1	study interventions are Cyclosporine . blood cancer diagnosis and patients who have undergone prior allogeneic hematopoietic cell transplantation will not be eligible for this study
__label__1	study interventions are Rituximab . recurrent adult burkitt lymphoma diagnosis and patient or donor infected with human immunodeficiency virus hiv
__label__1	study interventions are Methamphetamine . stage iiic hepatocellular carcinoma diagnosis and patients with untreated central nervous system cns metastatic disease including spinal cord and leptomeningeal disease are excluded
__label__1	study interventions are Cisplatin . nasopharyngeal carcinoma diagnosis and evidence of metastases below the clavicle or distant by clinical or radiographic examinations
__label__1	study interventions are White light endoscopy . gastric cancer diagnosis and severe bone marrow dysfunction
__label__1	study interventions are Vismodegib . stage iv uterine sarcoma diagnosis and patients may not receive other investigational agents within two weeks of enrollment in this study patients treated with bevacizumab should be off therapy for four weeks other experimental or immuno therapies should wait for four half lives or four weeks whichever is longer prior exposure to notch or hedgehog inhibitors is not allowed patients who have not recovered to less than ctcae grade two from prior therapies are ineligible
__label__1	study interventions are Everolimus . duct cell adenocarcinoma of the pancreas diagnosis and cohort dose escalation
__label__1	study interventions are Gemcitabine . peripheral vascular disease greater_than grade three symptomatic and interfering with activities of daily living requiring repair or revision
__label__1	study interventions are Fludarabine phosphate . lymphoma diagnosis and patients with chronic active hepatitis or cirrhosis
__label__1	study interventions are Dextrans . papillary carcinoma of thyroid metastatic to regional lymph node diagnosis and guidelines and procedures pertinent to this requirement are available at
__label__1	study interventions are Poly I-C . melanoma diagnosis and use of any investigational or non registered product drug or vaccine other than the study treatment within thirty days preceding the randomization or planned use during the study period
__label__1	study interventions are Cyclosporins . stage iii adult diffuse small cleaved cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than thirty-five total lung capacity tlc less_than thirty-five or forced expiratory volume in one second fevone less_than thirty-five and or receiving supplementary continuous oxygen
__label__1	study interventions are Camptothecin . other concurrent anticancer therapy
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and concomitant use of phenytoin carbamazepine barbiturates rifampicin phenobarbital or st john wort preparations
__label__1	study interventions are Vorinostat . noncontiguous stage ii small lymphocytic lymphoma diagnosis and patients with history of prolonged corrected qt interval qtc syndrome
__label__1	study interventions are Flucytosine . anaplastic oligoastrocytoma diagnosis and is the subject hiv positive
__label__1	study interventions are Oxaliplatin . stage iva colon cancer diagnosis and patients who have neuromuscular disorders that are associated with elevated creatine kinase ck inflammatory myopathies_muscular dystrophy amyotrophic_lateral sclerosis spinal muscular_atrophy
__label__1	study interventions are Albumin-Bound Paclitaxel . gastroesophageal junction adenocarcinoma diagnosis and the patient has known alcohol or drug dependency
__label__1	study interventions are Mycophenolic Acid . recurrent refractory childhood hodgkin lymphoma diagnosis and adult
__label__1	study interventions are Pharmacological Study . recurrent adult diffuse large cell lymphoma diagnosis and psychiatric illness that would limit compliance
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and previous treatment with bortezomib thalidomide or lenalidomide
__label__1	study interventions are Cyclophosphamide . recurrent adult diffuse mixed cell lymphoma diagnosis and active bacterial viral or fungal infection
__label__1	study interventions are Podophyllotoxin . stage ii contiguous adult lymphoblastic lymphoma diagnosis and participation in clinical trials with other investigational agents not included in this trial within fourteen days of the start of this trial and within thirty days of any dose of bortezomib
__label__1	study interventions are Mitoxantrone . neoplasms diagnosis and pregnancy and breast feeding women
__label__1	study interventions are Tamoxifen . er positive breast cancer diagnosis and less than twelve months since stopping tamoxifen in the adjuvant setting
__label__1	study interventions are Peginterferon alfa-2b . carcinoma hepatocellular diagnosis and autoimmune hepatitis or history of autoimmune disease
__label__1	study interventions are Epirubicin . symptomatic peripheral neuropathy grade two or greater
__label__1	study interventions are Irinotecan . stage iiia non small cell lung cancer diagnosis and patients with uncontrolled brain metastases patients with brain metastases must have stable neurologic status following local therapy surgery or radiation for at least four weeks and must be without neurologic dysfunction that would confound the evaluation of neurologic and other adverse events patients may be treated with steroids as clinically indicated
__label__1	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and patients unable to comply with the protocol
__label__1	study interventions are Rituximab . lymphoma diagnosis and platelets less_than one hundred zero l
__label__1	study interventions are Prednisone . prostate cancer diagnosis and concurrent use of acid lowering drugs histamine antagonists proton_pump inhibitors
__label__1	study interventions are Rituximab . stage grade one follicular lymphoma diagnosis and any premalignant myeloid condition or any malignancy with myeloid characteristics myelodysplastic syndromes acute or chronic myelogenous leukemia
__label__1	study interventions are Sirolimus . evidence greater_than equal_than five years of prior malignancies except successfully treated basal cell or squamous cell carcinoma of the skin
__label__1	study interventions are Navitoclax . recurrent pancreatic carcinoma diagnosis and use of other investigational drugs within twenty-eight days or five half lives whichever is shorter with minimum of fourteen days from the last dose preceding the first dose of study drug and during the study
__label__1	study interventions are Vorinostat . non small cell lung carcinoma diagnosis and patients may not be receiving any other investigational agents nor had prior treatment with histone_deacetylase hdac inhibitors valproic acid pxd one depsipeptide ms two hundred and seventy-five and laq eight hundred and twenty-four
__label__1	study interventions are TdT-mediated dUTP nick end labeling assay . stage iv melanoma diagnosis and prior to study entry any ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are Ado-trastuzumab emtansine . any chemotherapy hormonal therapy radiotherapy immunotherapy or biologic therapy for the treatment of breast cancer within four weeks of first study treatment
__label__1	study interventions are Gemcitabine . metastatic neoplasm diagnosis and history of clinically significant cardiovascular disease
__label__1	study interventions are Proteasome Inhibitors . non hodgkin lymphoma diagnosis and subjects in whom the required program of oral and intravenous fluid hydration is contraindicated due to pre existing pulmonary cardiac or renal impairment
__label__1	study interventions are Cabozantinib . refractory soft tissue sarcomas diagnosis and the subject has uncontrolled significant intercurrent or recent illness including but not limited to the following conditions
__label__1	study interventions are AZD 4547 . breast cancer diagnosis and treatment potent inhibitors or inducers of cypthreeafour twoceight or twodsix or substrates of cypthreeafour within specified durations prior to the first dose of study treatment
__label__1	study interventions are Regorafenib . metastatic colorectal cancer diagnosis and patients must have recovered from all therapy related toxicities
__label__1	study interventions are Liposomal doxorubicin . soft tissue sarcoma diagnosis and palliative radiotherapy to non target lesions is allowed is completed at least two weeks prior to study entry
__label__1	study interventions are Cyclosporine . hepatosplenic cell lymphoma diagnosis and donor is hiv positive and or has medical condition that would result in increased risk for filgrastim csf mobilization and harvest of pbsc
__label__1	study interventions are Liposomal doxorubicin . prior radiation therapy for breast cancer or any radiotherapy to the chest wall for any other malignancy
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and patients with predisposing colonic or small bowel disorders in which symptoms are uncontrolled as indicated by pre treatment baseline pattern of greater_than three loose_stools daily in patients without colostomy or ileostomy
__label__1	study interventions are Folic Acid . stage iic ovarian cancer diagnosis and receiving any other investigational agent
__label__1	study interventions are Vaccines . melanoma diagnosis and however patients who develop new metastases during treatment may continue on treatment as long as no systemic treatment is indicated and any local treatment such as surgical resection or radiation would not cause delay in vaccination or two weeks or more
__label__1	study interventions are INXN-2001 . glioblastoma multiforme diagnosis and unstable or clinically significant concurrent medical condition that would in the opinion of the investigator or medical monitor jeopardize the safety of subject and or their compliance with the protocol
__label__1	study interventions are Sirolimus . all other participants who have had systemic anti cancer therapy within three weeks eight weeks for nitrosoureas or mitomycin prior to study entry
__label__1	study interventions are Mitoxantrone . diffuse large cell lymphoma diagnosis and stage disease
__label__1	study interventions are Ilio-inguinal Lymphadenectomy . those with thin less_than equal_than one mm regionally unrelated melanoma greater_than five years ago
__label__1	study interventions are Diketopiperazines . concurrent active second malignancy for which the patient is receiving therapy excluding basal cell carcinoma of the skin or carcinoma in situ of the cervix
__label__1	study interventions are L 647318 . malignant melanoma diagnosis and less than eighteen years of age
__label__1	study interventions are Maleic acid . ovarian serous cystadenocarcinoma diagnosis and clinical significant peripheral vascular disease or vascular disease aortic aneurysm or aortic dissection
__label__1	study interventions are Fluorouracil . metastatic colorectal cancer diagnosis and patient with poorly controlled hypertension
__label__1	study interventions are Fludarabine phosphate . lymphoma diagnosis and chemotherapy refractory large cell and high grade nhl
__label__1	study interventions are Vidarabine . type one papillary renal cell carcinoma diagnosis and history of brain metastases
__label__1	study interventions are Gemcitabine . bladder cancer diagnosis and replacement therapy eg
__label__1	study interventions are Carboplatin . pulmonary carcinoid tumors
__label__1	study interventions are PF-06801591 . hodgkin lymphoma diagnosis and active brain or leptomeningeal metastases
__label__1	study interventions are Paclitaxel . epithelial ovarian cancer diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Bevacizumab . metastatic breast cancer diagnosis and women of childbearing potential defined as those who have had their last menstrual period less_than two years and are not surgically sterilized who are not using hormonal contraceptives or highly effective birth control intrauterine device during the study
__label__1	study interventions are PF-00337210 . neoplasm diagnosis and any acute cardiovascular incident within the past twelve months
__label__1	study interventions are Nivolumab . ovarian cancer diagnosis and surgery within the last twenty-eight days
__label__1	study interventions are Aminolevulinic Acid . subjects with uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Albumin-Bound Paclitaxel . history of prior malignancy in the past five years except basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix active infection requiring antibiotics history of allergic reaction to drugs utilizing the vehicle cremophor not pregnant or nursing fertile patients must use effective contraception
__label__1	study interventions are Tacrolimus . recurrent adult diffuse small cleaved cell lymphoma diagnosis and patients with known human immunodeficiency virus hiv are excluded due to side effects of the therapy on the immune system
__label__1	study interventions are Liposomal doxorubicin . stage iv non hodgkin lymphoma diagnosis and amiodarone
__label__1	study interventions are Citric Acid . plasmacytoma diagnosis and other co morbidity which would interfere with patient ability to participate in trial uncontrolled infection uncompensated heart or lung disease
__label__1	study interventions are Sulindac . cancer diagnosis and blood pressure greater_than one hundred and forty ninety at baseline by home monitoring
__label__1	study interventions are Immunoglobulins . stage iiib fallopian tube cancer diagnosis and note
__label__1	study interventions are HP 3He . mesothelioma diagnosis and female exclusion only
__label__1	study interventions are Hormones . hormone receptor positive malignant neoplasm of breast diagnosis and any serious cardiovascular diseases in the previous six months
__label__1	study interventions are Rituximab . presence of any other malignancy or history of prior malignancy except non melanoma skin tumors or stage zero in situ cervical carcinoma
__label__1	study interventions are Lenograstim . recurrent adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__1	study interventions are BB 1101 . patients with previous history of cancer are excluded unless they have had curative treatment completed greater_than five years prior to entry onto study or have one of the following
__label__1	study interventions are Propofol . lung neoplasms diagnosis and suspect severe pleural or diaphragmatic adhesions
__label__1	study interventions are Sunitinib . renal cell carcinoma diagnosis and uncontrolled pleural effusion pericardial effusion or ascites requiring recurrent drainage procedures once monthly or more frequently
__label__1	study interventions are Pertuzumab . hertwo positive breast cancer diagnosis and stable regimen of antidepressants of the ssri class is allowed common ssris include escitalopram oxalate citalopram fluvoxamine paroxetine sertraline and fluoxetine
__label__1	study interventions are Maytansine . any other diseases active or uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris pulmonary dysfunction metabolic dysfunction psychiatric illness social situations physical examination finding or clinical laboratory finding that would limit compliance with study requirements
__label__1	study interventions are pharmacological study . adenocarcinoma of the prostate diagnosis and the subject has received any other type of investigational agent within twenty-eight days before the first dose of study treatment
__label__1	study interventions are Simvastatin . rhabdomyosarcoma diagnosis and subjects receiving known cytochrome pfour hundred and fifty threeafour cypthreeafour inhibitors or inducers
__label__1	study interventions are Immunosuppressive Agents . recurrent mantle cell lymphoma diagnosis and presence of active central nervous system cns disease history of adequately treated cns disease is acceptable
__label__1	study interventions are Etoposide phosphate . stage iii adult immunoblastic large cell lymphoma diagnosis and known hiv positive status
__label__1	study interventions are Carboxymethylcellulose Sodium . melanoma diagnosis and patients who have had prior treatment with ipilimumab or interleukin two will be allowed as long as this two8 day wash out period is followed
__label__1	study interventions are Romidepsin . subjects with history of myocardial infarction between six and twelve months prior to transplant who are asymptomatic and have had negative cardiac risk assessment treadmill stress test nuclear medicine stress test or stress echocardiogram since the event may participate
__label__1	study interventions are cabozantinib-s-malate . stage iiib melanoma diagnosis and any of the following within six months before the first dose of study treatment
__label__1	study interventions are Rituximab . lymphoma large cell diffuse diagnosis and patients who are undergoing active treatment for another malignancy exceptions include
__label__1	study interventions are Cyclosporine . recurrent cell non hodgkin lymphoma diagnosis and pregnancy
__label__1	study interventions are Endothelial Growth Factors . recurrent primary peritoneal carcinoma diagnosis and cerebral vascular accident cva or transient ischemic attack tia within six months
__label__1	study interventions are Mycophenolate mofetil . refractory plasma cell myeloma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Interleukin-2 . head and neck cancer diagnosis and treatment with immune suppressive drugs experimental drugs or antineoplastic drugs
__label__1	study interventions are Acyclovir . metastatic non small cell lung cancer diagnosis and history of or current alcohol misuse abuse within the past twelve months
__label__1	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and if hbsag negative but hbcab positive whatever hbsab status should check hbv dna dna positive patients cannot be enrolled
__label__1	study interventions are Carboplatin . stage iic fallopian tube cancer diagnosis and stage not greater than ib no more than superficial myometrial invasion without vascular or lymphatic invasion no poorly differentiated subtypes including papillary serous clear cell or other figo grade three lesions
__label__1	study interventions are Lenograstim . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and human immunodeficiency virus hiv seropositive
__label__1	study interventions are Paclitaxel . stage iv bladder cancer diagnosis and no chronic liver disease
__label__1	study interventions are Mycophenolic Acid . recurrent adult hodgkin lymphoma diagnosis and patients with renal failure are eligible however patients with renal compromise serum creatinine greater than doc will likely have further compromise in renal function and may require hemodialysis which may be permanent due to the need to maintain adequate serum cyclosporine levels
__label__1	study interventions are Vaccines . glioblastoma diagnosis and use of any experimental drug for any reason within the thirty days or standard of care drug therapy within twenty-eight days prior to randomization or failure to fully recover from hematological effects of prior chemotherapy
__label__1	study interventions are Capecitabine . rectal cancer diagnosis and life expectancy less_than three months
__label__1	study interventions are Antibodies . stage iiia fallopian tube cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies patients with known allergy to cremophor or polysorbate eighty
__label__1	study interventions are Dexrazoxane . noncutaneous extranodal lymphoma diagnosis and patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
__label__1	study interventions are Capecitabine . stage iiia breast cancer diagnosis and patients who have not recovered to less_than ctcae grade two toxicities related to prior therapy are not eligible to participate in this study
__label__1	study interventions are Lenalidomide . cancer of the urethra diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one
__label__1	study interventions are Doxorubicin . burkitt lymphoma diagnosis and john wor negative may decrease the effects of sirolimus by decreasing the amount of sirolimus in the body
__label__1	study interventions are Cytarabine . diffuse large cell lymphoma diagnosis and cardiac ef less_than fifty by two echogram
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and subjects taking chronic systemic corticosteroid therapy for any reason are not eligible
__label__1	study interventions are Bevacizumab . lung carcinoma of squamous cell histology or any histology in close proximity to major vessel cavitation or history of hemoptysis bright red blood of one two teaspoon or more non small cell lung cancer trials only
__label__1	study interventions are Carboplatin . stage iia cervical cancer diagnosis and patients who have received previous pelvic or abdominal radiation cytotoxic chemotherapy or previous therapy of any kind for this malignancy
__label__1	study interventions are Rituximab . non hodgkin lymphoma diagnosis and for the phase ii portion of the study once mtd has been determined bulky disease ie any single mass greater_than tencm or circulating malignant cells of twenty-five zero ul or more
__label__1	study interventions are Dexamethasone acetate . multiple myeloma in relapse diagnosis and patients who received allogenic stem cell transplantation less_than twelve months prior to entering the study or show evidence of active graft versus host disease that requires immunosuppressive therapy
__label__1	study interventions are Cetuximab . stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and history of documented congestive heart failure new york heart association functional classification iii iv
__label__1	study interventions are Antibodies, Monoclonal . adult oligodendroglioma diagnosis and prior therapy with thalidomide and lenalidomide is allowed as long as treatment has not occurred within thirty days prior to enrollment
__label__1	study interventions are Oxaliplatin . stage iva rectal cancer diagnosis and impairment of gastrointestinal function or gastrointestinal disease active ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome small bowel resection
__label__1	study interventions are Capecitabine . breast cancer diagnosis and pregnant or lactating females at anytime during the study
__label__1	study interventions are Paclitaxel . esophageal adenocarcinoma diagnosis and wocbp include
__label__1	study interventions are Docetaxel . breast neoplasms diagnosis and concurrent use of potent cypthreeafour inhibitors such as ketoconazole itraconazole clarithromycin indinavir nefazodone nelfinavir ritonavir saquinavir telithromycin and voriconazole
__label__1	study interventions are Cyclosporine . stage iv cutaneous cell non hodgkin lymphoma diagnosis and donors who are hiv positive
__label__1	study interventions are neoadjuvant chemotherapy . patients may have received prior adjuvant chemotherapy for localized breast cancer provided that it was completed more than three years prior to registration and that the patient remains free of recurrent or metastatic disease
__label__1	study interventions are Hydrocortisone . breast cancer diagnosis and person less than twenty-one years of age
__label__1	study interventions are Magnetic Tracking System (MTS) and radio-opaque markers . neuroendocrine tumor diagnosis and severe diabetes with late complications or known metabolic disorder
__label__1	study interventions are Gemcitabine . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia chronic indwelling drains history of interstitial pneumonitis or pulmonary fibrosis or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Carboplatin . non small cell lung cancer diagnosis and patients who have received prior treatment with an mtor inhibitor sirolimus temsirolimus everolimus
__label__1	study interventions are Antibodies . gastroesophageal junction adenocarcinoma diagnosis and recurrent laryngeal or phrenic nerve paralysis
__label__1	study interventions are Tacrolimus . childhood diffuse large cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than forty total lung capacity tlc less_than forty forced expiratory volume in one second fevone less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Dacarbazine . adult giant cell glioblastoma diagnosis and severe active co morbidity defined as follows
__label__1	study interventions are Cisplatin . cervical cancer diagnosis and prior radiotherapy to the pelvis or abdomen that would result in overlap of radiation therapy fields
__label__1	study interventions are Endothelial Growth Factors . high grade fallopian tube serous adenocarcinoma diagnosis and radiographic demonstration of improvement upon the completion of cns directed therapy and no evidence of interim progression between the completion of cns directed therapy and the screening radiographic study
__label__1	study interventions are Lucitanib . stage iv lung cancer diagnosis and uncontrolled hypertension defined as sbp greater_than one hundred and forty mmhg and or dbp greater_than ninety mmhg with optimized anti hypertensive therapy
__label__1	study interventions are Antibodies . adenocarcinoma of the rectum diagnosis and cva within six months of study entry
__label__1	study interventions are Antineoplastic Agents . indolent non hodgkin lymphoma diagnosis and patients may receive prophylactic antibiotics and antiviral therapy at the discretion of the investigator
__label__1	study interventions are Fondaparinux . cancer diagnosis and has ever received or is scheduled to receive an allogeneic hematopoietic stem cell transplantation allohsct
__label__1	study interventions are Cabozantinib . bile duct cancer diagnosis and abdominal fistula
__label__1	study interventions are Antibodies, Monoclonal . urothelial carcinoma diagnosis and major surgical procedure within twenty-eight days prior to cycle one day one or anticipation of need for major surgical procedure during the course of the study
__label__1	study interventions are Antibodies, Monoclonal . melanoma part diagnosis and criterion does not apply to subjects with right or left bundle_branch block
__label__1	study interventions are Bevacizumab . stage ivb rectal cancer diagnosis and prior history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Docetaxel . past or concurrent history of neoplasm other than gastric adenocarcinoma except for curatively treated non melanoma skin cancer or in situ carcinoma of the cervix uteri
__label__1	study interventions are Freund's Adjuvant . glioblastoma diagnosis and known history of an autoimmune disorder
__label__1	study interventions are Iodine . ovarian cancer diagnosis and therefore negative pregnancy test is required for all women of child bearing age and appropriate contraception is required during the study period
__label__1	study interventions are Interleukin-2 . lymphoma mantle cell diagnosis and donor unfit to receive csf and undergo apheresis uncontrolled hypertension history of heart failure or unstable angina platelet count less than ninety zero cu mm
__label__1	study interventions are Selinexor . recurrent mantle cell lymphoma diagnosis and immunotherapy or targeted therapy such as kinase inhibitors equal_than less_than two weeks prior to cycle one day one except patients already on ibrutinib
__label__1	study interventions are Antibodies . stage ib breast cancer diagnosis and other non malignant systemic disease that would preclude the patient from receiving study treatment or would prevent required follow up
__label__1	study interventions are Aldesleukin . non hodgkin lymphoma diagnosis and previously received solid organ transplant
__label__1	study interventions are Ursodeoxycholic Acid . t cell lymphoma diagnosis and eligibility to proceed to allogeneic transplant cannot be admitted for allogeneic transplant earlier than forty days and no later than one hundred and eighty days after autologous stem cell transplant
__label__1	study interventions are tumor antigen loaded autologous dendritic cells . advanced renal cell carcinoma diagnosis and patients with other significant illness including severe allergy asthma angina pectoris or congestive heart failure
__label__1	study interventions are Etoposide . small cell lung cancer diagnosis and major surgery within four weeks prior to treatment
__label__1	study interventions are Vaccines . brain tumors diagnosis and no alcohol or drug use or dependence that in the opinion of the investigator would interfere with adherence to study requirements
__label__1	study interventions are Nivolumab . pancreatic cancer diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Fluorouracil . colorectal cancer diagnosis and women with positive pregnancy test
__label__1	study interventions are Doxorubicin . recurrent ovarian carcinoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to starting cediranib
__label__1	study interventions are Exemestane . significant symptomatic deterioration of lung function
__label__1	study interventions are Cediranib . stage iv non small cell lung cancer diagnosis and although the following medications are not contra indicated on this study each should be used with extreme caution due to potential nephrotoxic effects
__label__1	study interventions are MEK 162 therapy or molecularly targeted therapy . stage iiia melanoma diagnosis and patients who have received organ transplant
__label__1	study interventions are Erlotinib Hydrochloride . brain cancer diagnosis and active infection disease that will obscure toxicity or dangerously alter drug metabolism especially liver disease including cirrhosis or hepatic dysfunction serious intercurrent medical illness
__label__1	study interventions are Irinotecan . colorectal neoplasms diagnosis and acute or chronic severe infection
__label__1	study interventions are Inositol . rectal carcinoma diagnosis and chronic renal insufficiency
__label__1	study interventions are Mycophenolate mofetil . recurrent small lymphocytic lymphoma diagnosis and patients with poorly controlled hypertension despite hypertensive medication
__label__1	study interventions are Sinotecean . advanced cancer diagnosis and have immunodeficiency history
__label__1	study interventions are Niacinamide . stage iva verrucous carcinoma of the oral cavity diagnosis and subjects with thrombotic embolic venous or arterial events such as cerebrovascular accident including transient ischemic attacks within six months of informed consent
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and pregnant or breast feeding women
__label__1	study interventions are Immunoglobulins . recurrent cervical carcinoma diagnosis and cdfour count above two hundred and fifty cells mcl and an undetectable hiv viral load on standard pcr based tests
__label__1	study interventions are Sirolimus . unspecified childhood solid tumor protocol specific diagnosis and patients who are currently receiving another investigational drug are not eligible
__label__1	study interventions are Fludarabine . diffuse large cell lymphoma transformed from follicular lymphoma diagnosis and active systemic infections coagulation disorders or other major medical illnesses of the cardiovascular respiratory or immune system myocardial infarction cardiac arrhythmias obstructive or restrictive pulmonary disease
__label__1	study interventions are Imatinib Mesylate . t cell non hodgkin lymphoma diagnosis and receiving any other study agents
__label__1	study interventions are Cyclosporine . relapsed non hodgkin lymphoma diagnosis and pregnant or breastfeeding women are excluded from this study
__label__1	study interventions are Camptothecin . colorectal cancer diagnosis and history of allergic reaction to tetracycline or doxycycline
__label__1	study interventions are Immunoglobulin G . type one papillary renal cell carcinoma diagnosis and serious or non healing wound ulcer or bone fracture or history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to day one
__label__1	study interventions are Antibodies, Monoclonal . diffuse large cell lymphoma lymphoma follicular diagnosis and history of severe allergic or anaphylactic reaction or known sensitivity to humanized or murine monoclonal antibodies
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and arrhythmia
__label__1	study interventions are self-expandable biliary nitinol alloys stent . gallbladder cancer diagnosis and noncooperation or no authorization and signature
__label__1	study interventions are Quality-of-life assessment . invasive ductal breast carcinoma diagnosis and unstable angina and or congestive heart failure requiring hospitalization within the last six months
__label__1	study interventions are Isophosphamide mustard . malignant triton tumor diagnosis and subjects with any condition that may impair the ability to swallow or absorb oral medications investigational product including
__label__1	study interventions are Ferrous fumarate . cervical cancer diagnosis and patient with known allergy to ferrous fumarate
__label__1	study interventions are BB 1101 . myeloma diagnosis and prior local radiotherapy within one week of treatment
__label__1	study interventions are Antibodies, Monoclonal . recurrent ovarian carcinoma diagnosis and patients with an active bleeding diathesis or on concurrent or prior within seven days of enrollment therapeutic anti coagulation therapy with warfarin heparin or low molecular weight heparin the use of low dose warfarin equal_than less_than two mg orally po daily for prophylaxis against central venous catheter thrombosis is allowed
__label__1	study interventions are Antibodies . stage ivc major salivary gland carcinoma diagnosis and patients who have had chemotherapy or radiotherapy within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events greater_than equal_than grade three due to agents administered more than four weeks earlier
__label__1	study interventions are Doxorubicin . stage iii marginal zone lymphoma diagnosis and inability to comply with study or follow up testing and procedures
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib fallopian tube cancer diagnosis and patients with acute hepatitis or active infection that requires parenteral antibiotics
__label__1	study interventions are Thalidomide . adult cell leukemia lymphoma diagnosis and in case hepatitis core antibody and or hepatitis surface antibody is positive even if hepatitis surface antigen negative hepatitis virus deoxyribonucleic acid test should be performed and if positive the subject will be excluded
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and evidence of transmural infarction on ecg
__label__1	study interventions are ASP2215 . advanced solid tumors diagnosis and subject requires treatment with concomitant drugs that are strong inducers of cytochrome pfour hundred and fifty cyp threeafour or strong inhibitors or inducers of p_glycoprotein p_gp or substrates of multidrug and toxin extrusion protein one mateone with the exception of drugs that are considered absolutely essential for the care of the subject
__label__1	study interventions are Immunoglobulins . stage ivb rectal cancer diagnosis and patients who are serologically positive for hepatitis or or have history of liver disease other forms of hepatitis or cirrhosis are ineligible
__label__1	study interventions are Leuprolide . breast cancer diagnosis and women with known deleterious brca one or brca two mutation
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and this includes
__label__1	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and have not recovered sufficiently from the adverse toxic effects of prior therapies
__label__1	study interventions are Vidarabine . recurrent marginal zone lymphoma diagnosis and karnofsky adult or lansky for equal_than less_than sixteen years performance status equal_than less_than fifty
__label__1	study interventions are Everolimus . stage iv childhood burkitt lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of tyrosine kinase inhibitors such as imatinib cytokine therapy hydroxyurea low dose cytarabine_chlorambucil or rituxan will not be allowed within three weeks of the initiation of conditioning
__label__1	study interventions are Vitamin D . breast neoplasms diagnosis and normal twenty-five oh vitamin level greater_than thirty ng ml
__label__1	study interventions are Fludarabine phosphate . stage iv adult lymphoblastic lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Cediranib . undifferentiated ovarian carcinoma diagnosis and clinically significant peripheral vascular disease or vascular disease including aortic aneurysm or aortic dissection
__label__1	study interventions are Laboratory Biomarker Analysis . stage ivb thyroid gland follicular carcinoma diagnosis and any of the following
__label__1	study interventions are Cisplatin . gastroesophageal cancer diagnosis and uncontrolled arterial hypertension systolic bp
__label__1	study interventions are Stereotactic radiosurgery (SRS) . extensive stage small cell lung cancer diagnosis and requirement for antiarrhythmics or other medications known to prolong qtc
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and hypersensitivity to clarithromycin or any of its excipients erythromycin or any of the macrolide antibiotics
__label__1	study interventions are PDR Brachytherapy . carcinoma in situ and stages less_than b
__label__1	study interventions are Lenalidomide . follicular lymphoma diagnosis and serum total bilirubin greater_than doc mg dl thirty-four µmol except in case of hemolytic anemia
__label__1	study interventions are Trametinib . metastatic malignant neoplasm in the brain diagnosis and history or evidence of current greater_than equal_than class ii congestive heart failure as defined by the new york heart association nyha functional classification system
__label__1	study interventions are Dexamethasone acetate . diffuse large cells non hodgkin lymphoma diagnosis and any other co existing medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent
__label__1	study interventions are Cisplatin . neoplasms diagnosis and bilirubin more than doc upper limit of institutional norm
__label__1	study interventions are Dexamethasone acetate . diagnosis or treatment of malignancy other than multiple myeloma or nhl within one year of randomization or who have previously been diagnosed with malignancy other than multiple myeloma or nhl and have any radiographic or biochemical marker evidence of malignancy
__label__1	study interventions are Etoposide phosphate . testicular cancer diagnosis and patients who have had previous autologous or allogeneic stem cell transplant in the previous twelve months
__label__1	study interventions are Panobinostat . recurrent colon cancer diagnosis and male patients whose sexual partners are wocbp not using effective birth control
__label__1	study interventions are Mycophenolic Acid . stage ii contiguous adult diffuse small cleaved cell lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Radiopharmaceuticals . neuroendocrine tumors diagnosis and surgery within four weeks of study drug administration
__label__1	study interventions are Doxorubicin . high grade ovarian serous adenocarcinoma diagnosis and baseline ejection fraction equal_than less_than fifty as assessed by echocardiogram or multi gated acquisition muga
__label__1	study interventions are Nivolumab . primary cutaneous mucinous carcinoma diagnosis and viral infections requiring intermittent or chronic systemic intravenous or oral treatment with an antiherpetic drug acyclovir other than intermittent topical use
__label__1	study interventions are Ifosfamide . non small cell lung cancer diagnosis and major surgery within four weeks prior to treatment
__label__1	study interventions are Aprepitant . sarcoma diagnosis and domperidone five cannabinoids six nkone antagonist aprepitant seven benzodiazepines lorazepam alprazolam etc eight herbal medications or preparations in doses designed to ameliorate nausea or emesis
__label__1	study interventions are Dabrafenib . malignant melanoma diagnosis and current use of prohibited medication as described in section six or requires any of these medications during treatment
__label__1	study interventions are chemoprevention . stage zero laryngeal cancer diagnosis and pregnant women
__label__1	study interventions are Parenteral nutrition . any disorder preventing oral ingestion cancer of the upper aerodigestive tract oesophagus or stomach
__label__1	study interventions are Gadoxetate . liver neoplasms diagnosis and pediatric patients less_than eighteen years old
__label__1	study interventions are Irinotecan . recurrent childhood supratentorial embryonal tumor not otherwise specified diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__1	study interventions are Docetaxel . non small cell lung cancer nsclc diagnosis and prior treatment with docetaxel containing therapy
__label__1	study interventions are Carboplatin . stage iv breast cancer diagnosis and serious intercurrent medical or psychiatric illness including serious active infection
__label__1	study interventions are Etoposide phosphate . diffuse large cell lymphoma diagnosis and pregnancy
__label__1	study interventions are Dexamethasone acetate . brain neoplasms diagnosis and subjects unable to undergo an mri with contrast
__label__1	study interventions are Immunoglobulins . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and angina pectoris that requires the use of anti anginal medication
__label__1	study interventions are Rituximab . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and positive serology for hepatitis hc defined as positive test for hcab
__label__1	study interventions are Antibodies . stage iiib gastric cancer diagnosis and known hypersensitivity to any component of bevacizumab
__label__1	study interventions are Vitamin B Complex . metastatic colorectal cancer diagnosis and pre existing neuropathy greater_than grade one nci ctcae except for loss of tendon reflex
__label__1	study interventions are Dabrafenib . unresectable thyroid gland carcinoma diagnosis and ritonavir saquinavir atazanavir
__label__1	study interventions are Paclitaxel . bladder carcinoma diagnosis and prior chemotherapy in the neoadjuvant adjuvant setting is allowed if completed at least twelve months prior to registration for protocol therapy
__label__1	study interventions are Fludarabine phosphate . stage ii cutaneous cell non hodgkin lymphoma diagnosis and marrow donors who have increased anesthetic risk
__label__1	study interventions are Olaparib . squamous cell carcinoma of the head and neck diagnosis and pregnant or breastfeeding women
__label__1	study interventions are JM 3100 . multiple myeloma diagnosis and serum ast alt or total bilirubin greater_than fivex upper limit of normal
__label__1	study interventions are Nivolumab . anti cancer therapy less than twenty-eight days prior to the first dose of study drug or palliative focal radiation therapy less than fourteen days prior to the first dose of study drug
__label__1	study interventions are Oxaliplatin . has history of other malignancies with the exception of curatively treated non melanoma skin cancer or carcinoma in situ of the cervix
__label__1	study interventions are Prednisolone . fallopian tube cancer diagnosis and participants of childbearing potential must have blood test or urine study within fourteen days prior to registration to rule out pregnancy and agree to use adequate birth control during study treatment
__label__1	study interventions are Immunoglobulins . stage iii grade one follicular lymphoma diagnosis and pregnant women
__label__1	study interventions are Fludarabine . recurrent childhood small noncleaved cell lymphoma diagnosis and donors who are allergic to filgrastim or escherichia e
__label__1	study interventions are ROR1 CAR-specific Autologous T-Lymphocytes . recurrent non small cell lung carcinoma diagnosis and patients who have contraindication to cyclophosphamide chemotherapy
__label__1	study interventions are Cyclosporine . recurrent grade two follicular lymphoma diagnosis and prior hematopoietic stem cell transplant autologous or allogeneic
__label__1	study interventions are Paclitaxel . patients had clinically apparent cns disease primary brain tumors tumor related apoplexy cns metastases carcinomatous_meningitis
__label__1	study interventions are Ceritinib . cholangiocarcinoma diagnosis and exceptions to this exclusion include the following
__label__1	study interventions are Gemcitabine . pancreatic ductal adenocarcinoma diagnosis and patients with history of interstitial pneumoniaslowly progressive difficulty in breathing and hoose sarcoidosissilicosis fibrose pulmonaire idiopathiquehylactic pneumonia or variety of allergy
__label__1	study interventions are Everolimus . advanced cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Docetaxel . lung cancer diagnosis and because patients with immune deficiency are at increased risk of lethal infections when treated with marrow suppressive therapy hiv positive patients are excluded from the study
__label__1	study interventions are Camptothecin . astrocytoma oligoastrocytoma mixed diagnosis and patient must not have received bevacizumab or other anti vegf inhibitor in the last three months
__label__1	study interventions are Dexamethasone acetate . recurrent plasma cell myeloma diagnosis and other malignancy requiring active therapy exceptions
__label__1	study interventions are Lenalidomide . stage ii multiple myeloma diagnosis and no coverage or not acceptable by patient co pay for lenalidomide
__label__1	study interventions are Paclitaxel . fallopian tube clear cell adenocarcinoma diagnosis and uncontrolled hypertension defined as systolic greater_than one hundred and fifty mm hg or diastolic greater_than ninety mm hg
__label__1	study interventions are Paclitaxel . non small cell lung cancer diagnosis and calculated creatinine clearance less_than fifty ml min
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv pancreatic cancer diagnosis and patients must not have uncontrolled intercurrent illness including but not limited to ongoing or active infection or known psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Antilymphocyte Serum . stage iv adult burkitt lymphoma diagnosis and uncontrolled diabetes mellitus cardiovascular disease active serious infection or other condition which in the opinion of treating physician would make this protocol unreasonably_hazardous for the patient
__label__1	study interventions are Albumin-Bound Paclitaxel . prior cancer treatment that would contraindicate study treatment
__label__1	study interventions are Lenalidomide . recurrent diffuse large cell lymphoma diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are TPI 287 . neuroblastoma diagnosis and patients with known hypersensitivity to any of the components of the drugs to be administered on study
__label__1	study interventions are Paclitaxel . locally recurrent and metastatic breast cancer diagnosis and uncontrolled hypertension defined as diastolic blood pressure greater_than ninety mmhg or systolic blood pressure greater_than one hundred and forty mmhg
__label__1	study interventions are Carboplatin . a history of other malignancy less_than five years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only
__label__1	study interventions are Prednisone . prostatic neoplasms diagnosis and subject is unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel
__label__1	study interventions are Vincristine . lymphoma diagnosis and patients with psychiatric illness and or social situations that would limit compliance with the study medication and requirements
__label__1	study interventions are Fosaprepitant . myeloma plasma cell diagnosis and patients with known active hepatitis and or hepatitis infections are excluded
__label__1	study interventions are Cytarabine . anaplastic large cell lymphoma diagnosis and any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form
__label__1	study interventions are BB 1101 . lymphoma non hodgkin diagnosis and participants with inherited or acquired bleeding disorders
__label__1	study interventions are Albumin-Bound Paclitaxel . tumors diagnosis and since bgjthree hundred and ninety-eight is likely inhibitor of cypthreeafour patients who are currently receiving treatment with agents that are known sting inducers or inhibitors cypthreeafour are not allowed
__label__1	study interventions are Simvastatin . breast cancer diagnosis and women currently taking drugs which are strong inhibitors or inducers of cypthreeafour are not eligible
__label__1	study interventions are Gemcitabine . cholangiocarcinoma diagnosis and heart failure nyha class ii or above
__label__1	study interventions are Trametinib . recurrent lung carcinoma diagnosis and history of interstitial lung disease or pneumonitis
__label__1	study interventions are Irinotecan . malignant gliomas diagnosis and phase ii surgical post operative
__label__1	study interventions are Cyclosporins . recurrent adult lymphoblastic lymphoma diagnosis and marrow donors
__label__1	study interventions are Lenalidomide . mantle cell lymphoma diagnosis and patients with hbcab serology will not be excluded from the study and be given lamivudine as prophylaxis starting one week before chemotherapy
__label__1	study interventions are pharmacological study . lymphoma diagnosis and clinically significant electrocardiogram abnormalities
__label__1	study interventions are Methylprednisolone . recurrent grade three follicular lymphoma diagnosis and any leukemia with morphologic relapse or persistent disease in the bm with greater_than equal_than twenty blasts cytogenetic relapse without morphologic evidence of relapse or cytogenetic persistent disease is acceptable
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and inability to swallow tablets or use of feeding tube
__label__1	study interventions are Fludarabine phosphate . prostate cancer diagnosis and contraindications to pegfilgrastim
__label__1	study interventions are Apaziquone . bladder cancer diagnosis and is the patient breast feeding
__label__1	study interventions are PG2 . cancer diagnosis and female patients are pregnant or breast feeding
__label__1	study interventions are Tamoxifen . recurrent uterine corpus carcinoma diagnosis and patients known to have congestive heart failure patients with baseline requirement for oxygen patients with serious concomitant illness that in the opinion of the treating physician will place patient at unreasonable risk from therapy on this protocol
__label__1	study interventions are Fludarabine . stage iv cutaneous cell non hodgkin lymphoma diagnosis and presence of active serious infection mucormycosis uncontrolled aspergillosis tuberculosis
__label__1	study interventions are Vorinostat . stage iv breast cancer diagnosis and patient has history or current evidence of any condition therapy or laboratory lab abnormality that might confound the results of the study interfere with the patient participation for the full duration of the study or is not in the best interest of the patient to participate
__label__1	study interventions are Docetaxel . recurrent salivary gland cancer diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Patient Navigator matched with subject . rectal cancer diagnosis and prior navigation
__label__1	study interventions are Sirolimus . adenocarcinoma diagnosis and pregnant or breastfeeding
__label__1	study interventions are Rituximab . aids related primary effusion lymphoma diagnosis and pregnant or nursing women
__label__1	study interventions are Fludarabine phosphate . recurrent childhood lymphoblastic lymphoma diagnosis and small bowel any volume forty-six gy
__label__1	study interventions are Deoxyglucose . prostate cancer diagnosis and active clinically significant infection requiring antibiotics
__label__1	study interventions are Axitinib . renal cell carcinoma diagnosis and the following are not considered to be major procedures and are permitted up to seven days before therapy initiation
__label__1	study interventions are Poly ICLC . glioblastoma diagnosis and subjects who have an uncontrolled systemic malignancy that is not in remission
__label__1	study interventions are CKD-516 inj. . unspecified adult solid tumor protocol specific diagnosis and history of ischemic heart disease myocardial infarction unstable angina pectoris or clinically significant heart disease such as nyha class iii and iv congestive atrial arrhythmias within six months prior to first dose of study drug
__label__1	study interventions are Ifosfamide . neoplasms diagnosis and serum creatinine greater_than two mg dl
__label__1	study interventions are Salvia hispanica Seed . t lymphoblastic leukemia lymphoma diagnosis and co morbid systemic illnesses such as active infection or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens note
__label__1	study interventions are Recombinant adenovirus- Ad/L523S . non small cell lung cancer diagnosis and received antibiotics within two weeks of day zero visit
__label__1	study interventions are Afatinib . brain cancer diagnosis and any other reason which in the opinion of the investigator interferes with the ability of the patient to participate in the study
__label__1	study interventions are Bleomycin . patients with second active tumor other than nonmelanomatous skin cancer or kaposi sarcoma
__label__1	study interventions are Lapatinib . uncontrolled or symptomatic congestive heart failure
__label__1	study interventions are Sunitinib . glioblastoma multiforme diagnosis and current treatment with therapeutic doses of marcoumar sintrom excluding thrombosis prophylaxis with low dose heparin
__label__1	study interventions are Levoleucovorin . adenocarcinoma of the esophagus diagnosis and will not exclude patient prior dilatation is also allowed
__label__1	study interventions are Letrozole . other carcinoma within the past five years except nonmelanoma skin cancer and treated in situ cervical cancer
__label__1	study interventions are Capecitabine . stage iv breast cancer diagnosis and major surgery chemotherapy or immunologic therapy equal_than less_than four weeks prior to registration
__label__1	study interventions are Gemcitabine . lung cancer non small cell diagnosis and for prior bevacizumab therapy at least forty days should have elapsed since last dose
__label__1	study interventions are Immunoglobulins . advanced adult hepatocellular carcinoma diagnosis and current therapy with cytochrome pfour hundred and fifty threeafour cypthreeafour inhibitor or inducer note
__label__1	study interventions are Mycophenolate mofetil . recurrent marginal zone lymphoma diagnosis and any patient who is unable to provide informed consent or comply with the requirements of the protocol
__label__1	study interventions are Immunoglobulins . recurrent adult diffuse small cleaved cell lymphoma diagnosis and corticosteroid therapy also is not permitted while subjects are receiving protocol therapy during the treatment phase of the study
__label__1	study interventions are Stereotactic Body Radiotherapy (SBRT) . pancoast tumors
__label__1	study interventions are linifanib . stage iva rectal cancer diagnosis and subjects with known human immunodeficiency virus hiv infection are excluded
__label__1	study interventions are dacarbazine plus Genasense . significant medical disease other than cancer
__label__1	study interventions are Laboratory Biomarker Analysis . invasive breast carcinoma diagnosis and allergy to measles vaccine or history of severe reaction to prior measles vaccination
__label__1	study interventions are Sirolimus . risk factors for torsades de pointes such as hypokalemia hypomagnesemia cardiac failure clinically significant symptomatic bradycardia or high grade atrioventricular_av block
__label__1	study interventions are Sorafenib . non small cell lung cancer diagnosis and cardiomegaly on chest imaging or ventricular hypertrophy on electrocardiogram ecg unless the left ventricular ejection fraction lvef is within normal range for the institution
__label__1	study interventions are Bevacizumab . administration of other simultaneous chemotherapy drugs any other anticancer therapy or anti neoplastic hormonal therapy or simultaneous radiotherapy during the trial treatment period hormonal replacement therapy is permitted
__label__1	study interventions are Azacitidine . stage iiia non small cell lung cancer diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Gemcitabine . stage iii renal cell cancer diagnosis and prior treatment with sorafenib
__label__1	study interventions are laboratory biomarker analysis . adult giant cell glioblastoma diagnosis and patients who have serious medical or psychiatric illness that could in the investigator opinion potentially interfere with the completion of treatment according to this protocol or may not be able to comply with the safety monitoring requirements of the study
__label__1	study interventions are carfilzomib . hematopoietic lymphoid cancer diagnosis and patients who have had treatment for chronic lymphocytic leukemia cll within two weeks although palliative steroids are acceptable
__label__1	study interventions are Sunitinib . non small cell lung cancer diagnosis and adjuvant chemotherapy or prior combined modality neoadjuvant therapy chemotherapy plus radiotherapy with or without surgery within six months prior to day one of cycle one
__label__1	study interventions are Dacarbazine . malignant glioma diagnosis and evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation
__label__1	study interventions are laboratory biomarker analysis . stage iv prostate cancer diagnosis and no prior malignancy is allowed except for the following
__label__1	study interventions are Fludarabine phosphate . stage iv small lymphocytic lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are contrast-enhanced magnetic resonance imaging . unspecified adult solid tumor protocol specific diagnosis and known allergic reaction to contrast or shellfish
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent osteosarcoma diagnosis and malabsorption syndrome
__label__1	study interventions are Cetuximab . prior doxorubicin or liposomal doxorubicin at doses greater_than three hundred and sixty mg two epirubicin at doses greater_than 7two0 mg two mitoxantrone at doses greater_than 1two0 mg two or idarubicin at doses greater_than ninety mg two
__label__1	study interventions are Maleic acid . tumors metastatic to brain diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with azdtwo thousand, one hundred and seventy-one
__label__1	study interventions are Prednisone . prostate cancer diagnosis and history of gastrointestinal disorders medical disorders or extensive surgery which may interfere with the absorption of the study drug
__label__1	study interventions are Bendamustine Hydrochloride . non hodgkin lymphoma diagnosis and participants with seronegative occult hbv infection or past hbv infection defined as anti hbc positive and hbv dna negative could be eligible if they were willing to be followed according to the protocol for hbv dna testing
__label__1	study interventions are Doxorubicin . mantle cell lymphoma diagnosis and exceptions include the following
__label__1	study interventions are Gemcitabine . breast cancer diagnosis and patients with pre existing peripheral neuropathy greater_than grade one
__label__1	study interventions are Bevacizumab . breast cancer diagnosis and valvular disease with documented cardiac function compromise and
__label__1	study interventions are quality of life assessment . stage iva verrucous carcinoma of the larynx diagnosis and previous head and neck surgery that would preclude transoral robotic procedures
__label__1	study interventions are Vidarabine . primary mediastinal cell lymphoma diagnosis and anti cmv antibody titer hsv serology and ebv panel note
__label__1	study interventions are Vincristine . double hit lymphoma confirmed by fluorescence in situ hybridization fish
__label__1	study interventions are Melphalan . recurrent adult burkitt lymphoma diagnosis and serum glutamic oxaloacetic transaminase sgot or serum glutamic pyruvate transaminase sgpt greater_than equal_than three upper limit of normal
__label__1	study interventions are Tamoxifen . glioma diagnosis and patients who are pregnant or breast feeding
__label__1	study interventions are Erlotinib Hydrochloride . recurrent or refractory pediatric ependymoma diagnosis and participating in another investigational drug trial
__label__1	study interventions are Pancrelipase . pancreatic cancer metastatic diagnosis and impairment of gastrointestinal function or gastrointestinal disease ulcerative disease uncontrolled nausea vomiting or diarrhea
__label__1	study interventions are Gemcitabine . fallopian tube transitional cell carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib or olaparib
__label__1	study interventions are Fludarabine phosphate . adult nasal type extranodal nk cell lymphoma diagnosis and patients with life expectancy of less_than six months for reasons other than their underlying hematologic oncologic disorder
__label__1	study interventions are Pemetrexed . non small cell lung cancer nsclc diagnosis and known positivity for human immunodeficiency virus hiv or hepatitis baseline testing for hiv and hepatitis is not required
__label__1	study interventions are Niacinamide . stage iv renal cell cancer diagnosis and patients who have not yet completed at least twenty-one days thirty days for prior monoclonal antibody therapy since ending other investigational device or drug trials or who are currently receiving other investigational treatments
__label__1	study interventions are Etoposide phosphate . transformed recurrent non hodgkin lymphoma diagnosis and receiving erythroid stimulating agents epoetin_alfa epo
__label__1	study interventions are Bevacizumab . fallopian tube carcinosarcoma diagnosis and core biopsy within seven days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are 7-hydroxystaurosporine . recurrent small cell lung cancer diagnosis and because patients with immune deficiency are at increased risk of lethal infections when treated with marrow suppressive therapy hiv positive patients receiving combination anti retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with ucn one or other agents administered during the study appropriate studies will be undertaken in patients receiving combination anti retroviral therapy when indicated
__label__1	study interventions are Liposomal doxorubicin . sarcoma kaposi diagnosis and all known marrow suppressive agents
__label__1	study interventions are Misonidazole . pancreatic adenocarcinoma diagnosis and nyha classification of iii or iv
__label__1	study interventions are Histone Deacetylase Inhibitors . unspecified adult solid tumor protocol specific diagnosis and patients with history of arrhythmia must be greater_than twelve months since last treatment with no recurrence of arrhythmia in the interval
__label__1	study interventions are Lenalidomide . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and inability to comply with study or follow up testing and procedures
__label__1	study interventions are Carboplatin . recurrent gastric cancer diagnosis and clinically significant autoimmune disease rheumatoid arthritis
__label__1	study interventions are Pembrolizumab . small cell lung cancer diagnosis and subjects with previously treated brain metastases may participate provided therapy are stable without evidence of progression by imagining for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline have no evidence of new or enlarging brain metastases and are not using steroids for at least seven days prior to trial treatment
__label__1	study interventions are Chemotherapy . intestinal neoplasms diagnosis and pregnant or lactating patients
__label__1	study interventions are Fludarabine . intraocular lymphoma diagnosis and patients with poorly controlled hypertension
__label__1	study interventions are Etoposide . testicular lymphoma diagnosis and active bacterial viral or fungal infection
__label__1	study interventions are Cyclophosphamide . cutaneous cell non hodgkin lymphoma diagnosis and patients with uncontrolled seizures as defined by having any seizure activity within the three months prior to screening
__label__1	study interventions are Mitomycin . neoplasms diagnosis and kidney or liver function disorders more than doc times upper normal limit
__label__1	study interventions are Liposomal doxorubicin . sarcoma kaposi diagnosis and ks therapy other than haart within three weeks
__label__1	study interventions are Denosumab . breast cancer diagnosis and active infection with hepatitis virus or hepatitis virus
__label__1	study interventions are Vincristine . lymphoma non hodgkin diagnosis and participants with inherited or acquired bleeding disorders
__label__1	study interventions are Abiraterone Acetate . symptomatic liver or visceral organ metastasis
__label__1	study interventions are Carboplatin . cancer metastatic diagnosis and coronary artery bypass graft surgery
__label__1	study interventions are Tacrolimus . recurrent childhood large cell lymphoma diagnosis and adult thirty pediatric
__label__1	study interventions are Immunoglobulins . recurrent ovarian carcinoma diagnosis and has active autoimmune disease that has required systemic treatment in the past six months with use of disease modifying agents corticosteroids or immunosuppressive drugs replacement therapy thyroxine insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is not considered form of systemic treatment
__label__1	study interventions are Green tea . diagnosis of internal cancer within the last five years or chemotherapy or radiation for an internal cancer within the last five years
__label__1	study interventions are Gemcitabine . confirmation that the subject is not pregnant must be established by negative serum beta human chorionic gonadotropin beta hcg pregnancy test unless there is reasonable certainty that beta hcg is coming from the tumor
__label__1	study interventions are Antibodies, Monoclonal . clear cell metastatic renal cell carcinoma diagnosis and neutrophiles less_than one five hundred mmthree
__label__1	study interventions are Prednisolone acetate . overt transformation to diffuse large cell lymphoma
__label__1	study interventions are Mycophenolic Acid . stage iii adult burkitt lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml mds all or cml
__label__1	study interventions are Immunoglobulins . stage iii childhood anaplastic large cell lymphoma diagnosis and patients who are homozygous at the mismatched major histocompatibility_complex mhc class locus
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and any condition that confounds the ability to interpret data from the study
__label__1	study interventions are Sunitinib . advanced renal cell carcinoma diagnosis and general medical
__label__1	study interventions are Fludarabine phosphate . stage iii marginal zone lymphoma diagnosis and donor
__label__1	study interventions are Carboplatin . stage mantle cell lymphoma diagnosis and patients with history of impaired cardiac status including history of severe coronary artery disease cardiomyopathy congestive heart failure or arrhythmia if the patient history is questionable measurement of left ventricular ejection fraction should be obtained within forty-two days prior to registration patients with left ventricular ejection fraction less_than fifty are not eligible
__label__1	study interventions are Cisplatin . head and neck squamous cell carcinoma diagnosis and any social personal medical and or psychologic factor that could interfere with the observance of the patient to the protocol and or the follow up and or the signature of the informed consent
__label__1	study interventions are Etoposide phosphate . stage iii grade three follicular lymphoma diagnosis and serious ongoing non malignant disease or infection which in the opinion of the investigator and or the sponsor would compromise other protocol objectives participants with active opportunistic infections are ineligible
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiic uterine corpus cancer diagnosis and patients undergoing invasive procedures as defined below
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and creatinine ratio less than or equal to doc at screening
__label__1	study interventions are Etoposide . lymphoma mantle cell diagnosis and cardiac manifest heart failure coronary heart disease uncontrolled hypertension
__label__1	study interventions are JM 3100 . adult supratentorial primitive neuroectodermal tumor pnet diagnosis and prior sensitivity to plerixafor
__label__1	study interventions are Bevacizumab . stage iiia fallopian tube cancer diagnosis and pulmonary hypertension
__label__1	study interventions are Gemcitabine . tumor of borderline malignancy
__label__1	study interventions are Dexamethasone . patients who relapsed from multiple myeloma with signs of organ damage related to disease crab
__label__1	study interventions are Antibodies, Monoclonal . cutaneous cell lymphoma diagnosis and patients with history of another primary malignancy not in remission for at least three years
__label__1	study interventions are Fludarabine . recurrent grade one follicular lymphoma diagnosis and adult thirty pediatric
__label__1	study interventions are Immunoglobulins . borderline ovarian mucinous tumor diagnosis and history of pulmonary embolism or deep vein thrombosis in the past six months
__label__1	study interventions are thoracoscopy . carcinoma non small cell lung diagnosis and previous history of malignancy in any organ
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian clear cell adenocarcinofibroma diagnosis and patients receiving concurrent immunotherapy or radiotherapy
__label__1	study interventions are Oxaliplatin . colorectal neoplasms diagnosis and grade two or higher peripheral neuropathy
__label__1	study interventions are Dasatinib . solid tumors diagnosis and failure to recover from any prior surgery within four weeks of study entry
__label__1	study interventions are Levoleucovorin . other medical illness unrelated to non hodgkin lymphoma including any of the following
__label__1	study interventions are Paclitaxel . breast neoplasms diagnosis and history of stroke or transient ischemic attack within six months prior to study enrollment
__label__1	study interventions are Ramucirumab . gastroesophageal cancer diagnosis and anticoagulation with low molecular weight heparin or anti factor xa agents will be allowed
__label__1	study interventions are Erlotinib Hydrochloride . neuroendocrine tumors diagnosis and known hypersensitivity to radone or other rapamycins
__label__1	study interventions are Interleukin-2 . metastatic kidney cancer diagnosis and prior history of psychiatric disorder which could be exacerbated by interleukin two
__label__1	study interventions are Laboratory Biomarker Analysis . refractory mantle cell lymphoma diagnosis and congestive heart failure new york heart association nyha class iii or iv or history of congestive heart failure nyha class iii or iv in the past unless screening echocardiogram echo or multi gated acquisition scan muga within three months results in left ventricular ejection fraction greater_than equal_than forty-five
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and iii
__label__1	study interventions are Gossypol . carcinoma non small cell lung diagnosis and or psychiatric conditions that would impart in the judgment of the investigator excess risk associated with study participation or study drug administration
__label__1	study interventions are Doxorubicin . hodgkin lymphoma diagnosis and inability to comply with study procedures
__label__1	study interventions are Succinylcholine . stage iiia fallopian tube cancer diagnosis and patients with clinically significant proteinuria urine protein should be screened by urine protein creatinine ratio upcr patients must have upcr less_than doc to allow participation in the study
__label__1	study interventions are Vidarabine . hepatosplenic cell lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are BMI group (successive patients) . gastric cancer diagnosis and after signature the clinical trial agreement patients and their agent will quit the trial
__label__1	study interventions are Antibodies . stage iiia ovarian cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to mlnone hundred and twenty-eight or bevacizumab
__label__1	study interventions are (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) . stage iiia primary peritoneal cancer diagnosis and ct of chest abdomen pelvis demonstrates
__label__1	study interventions are Leucovorin . stage iva colorectal cancer diagnosis and clinically significant uncontrolled illness or active infections
__label__1	study interventions are Vaccines . lymphoma diagnosis and patients with serious underlying medical conditions active infections requiring the use of antimicrobial drugs or active bleeding
__label__1	study interventions are Octreotide . neuroendocrine carcinoma diagnosis and patients with serious non healing wound active ulcer or untreated bone fracture
__label__1	study interventions are Immunoglobulin G . stage iiib ovarian cancer diagnosis and evidence of any significant intracranial hemorrhage as determined by the treating investigator within six weeks from registration or as seen on most recent mri prior to screening baseline mri
__label__1	study interventions are Fludarabine phosphate . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and pregnancy
__label__1	study interventions are Calcium, Dietary . coronary insufficiency or symptomatic cardiac disease
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and has an invasive fungal infection
__label__1	study interventions are Mycophenolic Acid . recurrent adult burkitt lymphoma diagnosis and serum glutamate pyruvate transaminase sgpt and serum glutamic oxaloacetic transaminase sgot four the upper limit of normal
__label__1	study interventions are Methotrexate . brain cancer diagnosis and pregnancy
__label__1	study interventions are Cyclosporins . recurrent mantle cell lymphoma diagnosis and donor
__label__1	study interventions are therapeutic allogeneic lymphocytes . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and unlikely to be able to procure additional donor lymphocytes
__label__1	study interventions are Endothelial Growth Factors . sarcoma diagnosis and patients who have received chemotherapy less than four weeks prior to entry into this study or who have not recovered from side effects of such therapy
__label__1	study interventions are Immunoglobulins . stage iia breast cancer diagnosis and valvular disease with documented compromise in cardiac function and
__label__1	study interventions are GS-9901 . marginal zone lymphoma diagnosis and history of non lymphoid malignancy except for the following
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iva vaginal cancer diagnosis and brain or central nervous system metastasis at entry
__label__1	study interventions are Doxorubicin . ovarian clear cell adenocarcinoma diagnosis and patients who require parental hydration and or nutrition
__label__1	study interventions are Mycophenolic Acid . diffuse large cell lymphoma diagnosis and patients with rapidly progressive aggressive nhl unless in minimal disease state
__label__1	study interventions are Tesevatinib . non small cell lung cancer diagnosis and treatment with erlotinib must be discontinued at least three days prior to first dose of tesevatinib and treatment with afatinib or other tyrosine kinase inhibitor must be discontinued at least three days prior to first dose of tesevatinib
__label__1	study interventions are Vinblastine . bladder cancer diagnosis and incidence of or uncontrolled medical illness active cardiac symptoms active systemic infection etc
__label__1	study interventions are Bevacizumab . advanced gastrointestinal cancer diagnosis and major surgical procedure within twenty-eight days or anticipation of the need for major surgical procedure during the course of the study as well as minor surgical procedure within seven days prior to study enrollment
__label__1	study interventions are Busulfan . ovarian cancer diagnosis and simultaneous radiotherapy
__label__1	study interventions are Vaccines . glioblastoma multiforme diagnosis and prior treatment with gliadel_wafers
__label__1	study interventions are Temozolomide . metastatic colorectal cancer diagnosis and inability to take oral medications
__label__1	study interventions are Succinylcholine . prostatic neoplasms diagnosis and history of seizures taking not taking anticonvulsants arteriovenous_malformation in the brain head trauma with loss of consciousness
__label__1	study interventions are Pharmacological Study . stage ivb rectal cancer diagnosis and patients who have had chemotherapy or radiotherapy within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Fludarabine phosphate . recurrent childhood small noncleaved cell lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less than forty predicted corrected for hemoglobin hb and or alveolar ventilation
__label__1	study interventions are Osimertinib . advanced non small cell lung cancer diagnosis and anc less_than doc ten nine platelet count less_than ten0 ten nine haemoglobin less_than nine0 l alt greater_than doc the institutional uln if no demonstrable liver metastases or greater_than five institutional uln in the presence of liver metastases ast greater_than doc institutional uln if no demonstrable liver metastases or greater_than five institutional uln in the presence of liver metastases total bilirubin greater_than doc institutional uln if no liver metastases or greater_than three institutional uln in the presence of documented gilbert syndrome or liver metastases creatinine greater_than doc institutional uln concurrent with creatinine clearance less_than five0 ml min measured or calculated by cockcroft gault formula confirmation of creatinine clearance is only required when creatinine is greater_than doc institutional uln
__label__1	study interventions are Bevacizumab . ovarian clear cell cystadenocarcinoma diagnosis and ctcae grade two or greater peripheral vascular disease at least brief less_than two4 hrs episodes of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Imatinib Mesylate . gliosarcoma diagnosis and other clinically significant cardiac diseases
__label__1	study interventions are Indocyanine Green . colorectal cancer diagnosis and history of allergy or hypersensitivity against the investigational product its active substance or ingredients to iodine or to shellfish
__label__1	study interventions are Lenalidomide . recurrent grade one follicular lymphoma diagnosis and prior therapy with histone_deacetylase hdac inhibitors or immunomodulatory drugs imds lenalidomide or thalidomide
__label__1	study interventions are Cyberknife . lung cancer diagnosis and women who are pregnant
__label__1	study interventions are laboratory biomarker analysis . testicular lymphoma diagnosis and patients who have received gonadotropin release hormone agonist or antagonist lupron prior to study entry are not eligible
__label__1	study interventions are Folic Acid . stage iia gastric cancer diagnosis and celiac adenopathy greater_than equal_than two cm in size
__label__1	study interventions are Immunoglobulin G . ovarian mucinous cystadenocarcinoma diagnosis and requirement of inotropic support excluding digoxin
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with palbociclib
__label__1	study interventions are Immunoconjugates . stage iv grade three follicular lymphoma diagnosis and known human immunodeficiency virus hiv infection
__label__1	study interventions are Regorafenib . sarcoma diagnosis and any hemorrhage or bleeding event greater_than common toxicity criteria for adverse effects grade three
__label__1	study interventions are Sirolimus . stage iv ovarian cancer diagnosis and clinically significant heart disease new york heart association nyha class iii or iv within six months
__label__1	study interventions are BB 1101 . systemic chemotherapy with approved or investigational anticancer therapeutics including steroid therapy intended to treat underlying malignancy within three weeks before the first dose or six weeks for antibody therapy
__label__1	study interventions are OGX-427 . neoplasms diagnosis and for patients in cohorts six and seven prior history of serious allergic reaction to docetaxel any chemotherapy containing cremophor_el used in drugs such as cyclosporine etoposide teniposide or polysorbate eighty the diluent for docetaxel
__label__1	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and significant co morbid central nervous system disease including but not limited to multiple sclerosis
__label__1	study interventions are Lenograstim . recurrent marginal zone lymphoma diagnosis and known allergy or intolerance to bendamustine mannitol gcsf or dexamethasone
__label__1	study interventions are Everolimus . recurrent squamous cell carcinoma of the oropharynx diagnosis and liver disease such as cirrhosis chronic active hepatitis or chronic persistent hepatitis note
__label__1	study interventions are Rituximab . malignancy within the past three years except for adequately treated carcinoma in situ of the cervix or localized nonmelanoma skin cancer
__label__1	study interventions are Lenalidomide . adult cell lymphoma diagnosis and the development of erythema nodorum if characterized by desquamating_rash while taking thalidomide or similar drugs
__label__1	study interventions are Nitrogen Mustard Compounds . adult diffuse large cell lymphoma diagnosis and previous history of hypersensitivity to bortezomib boron or mannitol known hypersensitivity to the components of study drug or its analogs
__label__1	study interventions are Cyclosporins . hepatosplenic cell lymphoma diagnosis and donor
__label__1	study interventions are Etoposide . recurrent non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are regorafenib . pulmonary carcinoid tumor diagnosis and unstable angina anginal symptoms at rest new onset angina within three months before randomization or myocardial infarction within six months before randomization
__label__1	study interventions are Bevacizumab . metastatic digestive system neuroendocrine tumor gone diagnosis and clinical signs and symptoms of gastrointestinal gi obstruction and require parental hydration nutrition or tube feeding
__label__1	study interventions are Antibodies . stage ii diffuse large cell lymphoma diagnosis and has known active hepatitis hepatitis virus surface protein antigen hbsag reactive or hepatitis virus hbv deoxyribonucleic acid dna detectable or hepatitis hepatitis virus hcv ribonucleic acid rna qualitative is detected
__label__1	study interventions are transoral robotic surgery . stage iii lymphoepithelioma of the oropharynx diagnosis and the presence of medical conditions which contraindicate general anesthesia
__label__1	study interventions are JM 3100 . non hodgkin lymphoma diagnosis and pregnant or breast feeding females or females not willing or able to use adequate contraception if sexually active
__label__1	study interventions are Vaccines . stage iiia esophageal cancer diagnosis and any condition which in the investigator opinion deems the patient an unsuitable candidate to receive study drug any significant medical illness or abnormal laboratory finding that would in the investigator judgment increase the subject risk by participating in this study
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and active congestive heart failure or ventricular arrhythmia requiring medication
__label__1	study interventions are Fludarabine phosphate . anaplastic large cell lymphoma diagnosis and total serum bilirubin more than twice upper normal limit
__label__1	study interventions are Fluorouracil . non metastatic pancreas cancer diagnosis and patient is enrolled in any outside outside baylor university medical center or texas oncology clinical protocol or investigational trial
__label__1	study interventions are Sampling of blood . melanoma diagnosis and pregnant women or nursing
__label__1	study interventions are Navigational Bronchoscopy . lung cancer diagnosis and patients with significant coagulopathy having international ratio inr greater_than doc or prothrombin time ptt greater_than twox normal
__label__1	study interventions are dynamic contrast-enhanced magnetic resonance imaging . duct cell adenocarcinoma of the pancreas diagnosis and presence of ventricular tachyarrhythmias
__label__1	study interventions are Fludarabine . hodgkin lymphoma diagnosis and bilirubin greater_than two mg dl not due to hemolysis gilbert or primary malignancy
__label__1	study interventions are Melphalan . recurrent childhood lymphoblastic lymphoma diagnosis and active bacterial viral or fungal infection
__label__1	study interventions are Pazopanib Hydrochloride . metastatic renal cell cancer diagnosis and medications or substances on the list drugs with risk of torsades de pointes are prohibited medications or substances on the list drugs with possible or conditional risk of torsades de pointes may be used while on study with extreme caution and careful monitoring
__label__1	study interventions are Mycophenolate mofetil . testicular lymphoma diagnosis and donor
__label__1	study interventions are Fludarabine . diffuse large cell lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Nitrous Oxide . cancer diagnosis and patient already included in another incompatible study with this protocol
__label__1	study interventions are Carboplatin . cancer diagnosis and history of kidney allograft
__label__1	study interventions are Sorafenib . stage iii renal cell cancer diagnosis and subject not consenting to the use of highly effective contraceptive precautions double barrier method condom plus diaphragm during the course of the study and for six months after administration of the last study medication
__label__1	study interventions are Antibodies, Monoclonal . solid tumors diagnosis and absolute neutrophil count anc less_than three one hundred and nine for cohorts
__label__1	study interventions are Fludarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Carboplatin . glioblastoma multiforme diagnosis and pregnancy tests with negative result must be obtained in all post menarchal females
__label__1	study interventions are Antilymphocyte Serum . recurrent grade two follicular lymphoma diagnosis and patient or donor infected with human immunodeficiency virus hiv
__label__1	study interventions are Cisplatin . dissemination of the tumor confirmed by ct of the lung and the abdomen
__label__1	study interventions are Trastuzumab . neoplasms diagnosis and previous treatment with vismodegib or any other hedgehog pathway inhibitor
__label__1	study interventions are Nintedanib . solid tumors diagnosis and pregnancy or breast feeding
__label__1	study interventions are Whole breast RT on prone position . breast cancer diagnosis and status of pregnant or brest feeding
__label__1	study interventions are Capecitabine . breast cancer diagnosis and concomitant requirement for medication classified as cypthreeafour inducers or inhibitors
__label__1	study interventions are Sirolimus . hepatosplenic cell lymphoma diagnosis and thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past six months
__label__1	study interventions are Triptorelin Pamoate . none patients are ineligible as are those with pelvic lymph nodes greater_than equal_than one cm in short axis diameter defined as pathologically enlarged per response evaluation criteria in solid tumors recist doc by ct or mri of the abdomen and pelvis unless the enlarged lymph nodes are negative after sampling
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma squamous cell of the head and neck diagnosis and all treatments should have been completed six months prior to signing the consent form
__label__1	study interventions are Rituximab . diffuse large cell lymphoma lymphoma follicular diagnosis and history of other malignancy that could affect compliance with the protocol or interpretation of results
__label__1	study interventions are Bortezomib . myeloma diagnosis and history of hypersensitivity to bevacizumab murine products or any component of the formulation
__label__1	study interventions are Carboxyamido-triazole . history or evidence upon physical neurological examination of central nervous system disease for example seizures unrelated to cancer unless adequately controlled by medication or potentially interfering with protocol treatment
__label__1	study interventions are Cyclosporine . hepatosplenic cell lymphoma diagnosis and patients with renal failure are eligible however patients with renal compromise serum creatinine greater than doc will likely have further compromise in renal function and may require hemodialysis which may be permanent due to the need to maintain adequate serum cyclosporine levels
__label__1	study interventions are Antibodies, Monoclonal . ovarian cancer diagnosis and any condition that in the clinical judgment of the treating physician is likely to prevent the subject from complying with any aspect of the protocol or that may put the subject at unacceptable risk
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and intranasal inhaled topical or local steroid injections eg intra articular injection
__label__1	study interventions are Tacrolimus . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Vinblastine . breast cancer diagnosis and disease significantly affecting absorption
__label__1	study interventions are Bevacizumab . ovarian seromucinous tumor diagnosis and patients with gog performance status of three or four
__label__1	study interventions are Dexamethasone acetate . myeloma diagnosis and known history of allergy to captisol cyclodextrin_derivative used to solubilize_carfilzomib
__label__1	study interventions are Tacrolimus . lymphoma diagnosis and five comorbidity points on the hct ci index see appendix b
__label__1	study interventions are Gossypol . stage iv marginal zone lymphoma diagnosis and requirement for routine use of hematopoietic growth factors including granulocyte colony stimulating factor granulocyte macrophage colony stimulating factor or interleukin eleven or platelet transfusions to maintain absolute neutrophil counts or platelets counts above the required thresholds for study entry use of erythropoietin stimulating agents and rbcs prior to study enrollment is allowed
__label__1	study interventions are Methylprednisolone acetate . childhood nasal type extranodal nk cell lymphoma diagnosis and uncontrolled infection
__label__1	study interventions are Cabozantinib . ureteral neoplasms diagnosis and because the lists of these agents are constantly_changing it is important to regularly consult frequently_updated list such as http
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and evidence of distant metastasis judged clinically and at least by chest ray liver sonography and bone scan
__label__1	study interventions are SPECT/CT guided LM/SL . cervical cancer diagnosis and patients with clinically and or radiologically evident regional lymph node metastases
__label__1	study interventions are Docetaxel . pulmonary neoplasms diagnosis and active concomitant malignancy
__label__1	study interventions are Erlotinib Hydrochloride . concurrent systemic corticosteroids except for treatment of increased intracranial pressure or symptomatic tumor edema in patients with cns tumors
__label__1	study interventions are Fludarabine phosphate . recurrent childhood anaplastic large cell lymphoma diagnosis and active involvement of the central nervous system with malignancy
__label__1	study interventions are Rituximab . lymphoma low grade diagnosis and patients known to have an allergic reaction to rituximab or murine derived proteins
__label__1	study interventions are Melphalan . regional neuroblastoma diagnosis and lactating females are not eligible unless they have agreed not to breastfeed their infants
__label__1	study interventions are Cyclophosphamide . recurrent adult diffuse large cell lymphoma diagnosis and patients who have received alemtuzumab within eight weeks of the transplant admission or who have recently received horse or rabbit ant thymocyte_globulin and have an atg level of greater_than two ugm ml
__label__1	study interventions are Fludarabine phosphate . stage iv childhood lymphoblastic lymphoma diagnosis and karnofsky score less_than fifty for adult patients
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . breast cancer diagnosis and patients with known brain metastases diagnosed within one year will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Fluorodeoxyglucose F18 . recurrent cervical carcinoma diagnosis and life expectancy of less than six months
__label__1	study interventions are Pemetrexed . non small cell lung carcinoma diagnosis and patients who have received radiation therapy
__label__1	study interventions are Fludarabine phosphate . t cell lymphomas diagnosis and severe peptic ulceration or bleeding contra indicative for corticosteroids
__label__1	study interventions are Temozolomide . glioblastoma diagnosis and patients must not have elevated liver transaminase levels
__label__1	study interventions are Doxorubicin . stage grade three follicular lymphoma diagnosis and participants who have received more than one one prior cycle of chemotherapy similar to cyclophosphamide doxorubicin hydrochloride vincristine sulfate and prednisone chop or epoch with or without rituximab
__label__1	study interventions are Panobinostat . potential participants who have purely non secretory multiple myeloma the absence of measurable protein in serum by electrophoresis and immunofixation and the absence of bence_jones protein in the urine defined by use of electrophoresis and immunofixation
__label__1	study interventions are Neoadjuvant Chemoradiotherapy . non small cell lung cancer stage iiia diagnosis and with acute infection or other serious underlying disease
__label__1	study interventions are Stent insertion . esophageal neoplasm diagnosis and tumour location not suited for stent or brachytherapy the upper three cm of oesophagus or major component in the cardia
__label__1	study interventions are Interferon-alpha . cancer diagnosis and concurrent receipt of radiotherapy for the metastatic disease unless for palliative purposes
__label__1	study interventions are Camptothecin . biliary cancer diagnosis and known hypersensibility or previous therapy with cisplatin gemcitabine or irinotecan
__label__1	study interventions are Rituximab . burkitt lymphoma bl diagnosis and known hiv positivity
__label__1	study interventions are DCR-MYC . pancreatic neuroendocrine tumors diagnosis and patients with any other serious active uncontrolled infection any infection requiring parenteral antibiotics or unexplained fever greater_than thirty-eightºc within two weeks prior to first study drug administration
__label__1	study interventions are Gemcitabine . history of other malignancies within five years of day one except for adequately treated carcinoma in situ of the cervix ductal carcinoma in situ dcis of breast basal or squamous cell skin cancer
__label__1	study interventions are Epacadostat . stage iiia primary peritoneal cancer diagnosis and any underlying medical or psychiatric condition which in the opinion of the investigator will make the administration of incbtwenty-four thousand, three hundred and sixty hazardous or obscure the interpretation of adverse events
__label__1	study interventions are Bevacizumab . endometrial endometrioid adenocarcinoma diagnosis and any of the following
__label__1	study interventions are Azacitidine . non hodgkin lymphoma diagnosis and patients with severe intercurrent infection
__label__1	study interventions are Estrogens, Conjugated (USP) . stage iii prostate adenocarcinoma diagnosis and investigational drug use within twenty-eight days of the first dose of plxthree thousand, three hundred and ninety-seven or concurrently
__label__1	study interventions are Cyclosporins . stage iii adult immunoblastic large cell lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Sirolimus . patients with poorly differentiated neuroendocrine carcinoma high grade neuroendocrine carcinoma adenocarcinoid pancreatic islet cell carcinoma insulinoma glucagonoma gastrinoma goblet cell carcinoid large cell neuroendocrine carcinoma and small cell carcinoma
__label__1	study interventions are Mitomycin . liver cancer diagnosis and patients with active hepatitis will be placed on lamivudine
__label__1	study interventions are Pembrolizumab . non hodgkin lymphoma diagnosis and any therapeutic antibody within four weeks of first dose of study drugs
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and contraindication to thalidomide
__label__1	study interventions are Pharmacological Study . stage iiic skin melanoma diagnosis and class ii or greater congestive heart failure as described in the new york heart association functional classification criteria
__label__1	study interventions are Cyclophosphamide . malignant neoplasm diagnosis and psychiatric disorder that would preclude patients from signing an informed consent
__label__1	study interventions are Cytarabine . multiple myeloma diagnosis and ongoing or active infection
__label__1	study interventions are Dexamethasone acetate . diffuse large cell lymphoma diagnosis and rapidly progressive disease or organ function threatened by disease
__label__1	study interventions are laboratory biomarker analysis . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and co morbid disease or incurrent illness that could affect patients immune status or ability to comply with the study but not limited to
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and c
__label__1	study interventions are Sirolimus . recurrent mantle cell lymphoma diagnosis and any history of ventricular fibrillation or torsade de pointes
__label__1	study interventions are placebo . uveal melanoma diagnosis and canadian cardiovascular society grade ii iv despite medical therapy
__label__1	study interventions are Sirolimus . any malignant neoplasia in the last five years except for adequately treated melanoma skin cancer
__label__1	study interventions are Everolimus . receiving any other investigational agent which would be considered as treatment for the primary neoplasm
__label__1	study interventions are Eurofarma's pegfilgrastim . breast cancer diagnosis and participation in clinical trial within thirty days prior to the screening visit
__label__1	study interventions are Paclitaxel . head and neck cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in this study
__label__1	study interventions are Fludarabine phosphate . stage iv small lymphocytic lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Stereotactic radiosurgery (SRS) . hertwo positive breast cancer diagnosis and patients with malabsorption syndrome or other condition that would interfere with intestinal absorption patients must be able to swallow tablets
__label__1	study interventions are Endothelial Growth Factors . recurrent colorectal carcinoma diagnosis and colonoscopy sigmoidoscopy or proctoscopy equal_than less_than seven days prior to randomization
__label__1	study interventions are Crizotinib . non small cell lung cancer diagnosis and active or chronic infection of hepatitis virus or hepatitis c
__label__1	study interventions are Immunoglobulins . stage iv prostate cancer diagnosis and enzalutamide
__label__1	study interventions are Sorafenib . history of lymphoma leukemia or high dose chemotherapy with hematopoietic stem cell rescue
__label__1	study interventions are Immunoglobulin G . high grade fallopian tube serous adenocarcinoma diagnosis and no metastases to brain stem midbrain_pons medulla_cerebellum or within ten mm of the optic apparatus optic nerves and chiasm
__label__1	study interventions are Vemurafenib . stage iv melanoma diagnosis and craniotomy within two weeks of protocol treatment
__label__1	study interventions are Cetuximab . clinically significant active cardiac disease congestive heart failure symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication or myocardial infarction within the last six months
__label__1	study interventions are Everolimus . progesterone receptor positive breast cancer diagnosis and taking any of the following agents
__label__1	study interventions are Liposomal doxorubicin . relapsed or refractory lymphoblastic lymphoma diagnosis and failure to have fully recovered ie less_than grade two toxicity from the effects of prior chemotherapy regardless of the interval since last treatment
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and patients known to be hep surface antigen positive will be not be eligible even if on antiviral treatment
__label__1	study interventions are Carboplatin . hepatocellular carcinoma diagnosis and severe coagulopathy prothrombin activity less_than forty or platelet count ofless_than forty zero mmthree
__label__1	study interventions are Icotinib . previous systemic anticancer therapy
__label__1	study interventions are Dabrafenib . metastatic melanoma diagnosis and prior braf or mek directed therapy patients who have received prior interferon are eligible
__label__1	study interventions are Heparin . metastatic pancreatic cancer diagnosis and patient has brain metastases
__label__1	study interventions are Oxaliplatin . stage iiib gastric cancer diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with gdc four hundred and forty-nine
__label__1	study interventions are Albumin-Bound Paclitaxel . small cell lung cancer diagnosis and testing is not required in the absence of clinical findings or suspicion
__label__1	study interventions are Albumin-Bound Paclitaxel . neoplasms breast diagnosis and peripheral neuropathy of grade two or greater
__label__1	study interventions are Folic Acid . endometrial cancer diagnosis and pregnancy
__label__1	study interventions are Placebo . gastrointestinal stromal tumors diagnosis and any hemorrhage or bleeding event nci ctcae version doc grade three or higher within four weeks prior to the start of study drug
__label__1	study interventions are Paclitaxel . patient has known symptomatic brain metastases
__label__1	study interventions are Cetuximab . head and neck cancer diagnosis and uncontrolled diabetes
__label__1	study interventions are SNX-5422 . cancer diagnosis and gastrointestinal diseases that could alter the assessment of safety including irritable bowel syndrome ulcerative colitis crohn disease or hemorrhagic coloproctitis
__label__1	study interventions are Carboplatin . squamous cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature
__label__1	study interventions are Albumin-Bound Paclitaxel . cervical cancer version doc fifteen
__label__1	study interventions are Levoleucovorin . adenocarcinoma of the esophagus diagnosis and patients with clinically apparent active infection will not be eligible please note an isolated elevation in the white blood cell count by itself does not constitute evidence of an infection
__label__1	study interventions are Maytansine . recurrent malignant peripheral nerve sheath tumor diagnosis and patients who have an uncontrolled infection are not eligible
__label__1	study interventions are Carboplatin . adenocarcinoma diagnosis and females who one have not undergone hysterectomy the surgical removal of the uterus or bilateral oophorectomy the surgical removal of both ovaries or two have not been naturally postmenopausal for at least two4 consecutive months ie has had menses at any time during the preceding two4 consecutive months
__label__1	study interventions are Antibodies, Monoclonal . metastatic cancer diagnosis and patients receiving or participating on any other experimental agents clinical trials are not eligible for participation
__label__1	study interventions are ESD - Endoscopic Submucosal Dissection . rectal neoplasms diagnosis and contraindications to general anaesthesia
__label__1	study interventions are Everolimus . lung neuroendocrine neoplasm diagnosis and prior therapy with radone or other mtor inhibitors sirolimus temsirolimus everolimus
__label__1	study interventions are Albumin-Bound Paclitaxel . advanced solid cancers diagnosis and requirement for treatment with warfarin coumadin immunosuppressive agents or chronic steroids
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and any other hemorrhage bleeding event greater_than ctcae grade three within four weeks of first dose of study drug
__label__1	study interventions are Regorafenib/placebo . cholangiocarcinoma diagnosis and unstable angina congestive heart failure greater_than nyha class ii
__label__1	study interventions are Estradiol . stage iv breast cancer diagnosis and chemotherapy equal_than less_than twenty-one days prior to registration
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube carcinoma diagnosis and known active acute hepatitis and confirmed diagnosis of hiv
__label__1	study interventions are Docetaxel . recurrent fallopian tube carcinoma diagnosis and patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
__label__1	study interventions are Antibodies, Monoclonal . recurrent adult burkitt lymphoma diagnosis and inability to understand or give an informed consent
__label__1	study interventions are Mycophenolic Acid . lymphoma diagnosis and pregnant or breast feeding women
__label__1	study interventions are pharmacological study . recurrent adult immunoblastic large cell lymphoma diagnosis and acidosis
__label__1	study interventions are Pembrolizumab . non small cell lung cancer diagnosis and note
__label__1	study interventions are Antibodies, Monoclonal . non hodgkin lymphoma diagnosis and uncontrolled bacterial viral or fungal infection currently taking medication and with progression or no clinical improvement
__label__1	study interventions are Triptorelin Pamoate . present or past history of cancer
__label__1	study interventions are Fluorouracil . rectal adenocarcinoma diagnosis and cardiac disease that would preclude the use of any of the drugs included in the gitwo treatment regimen this includes but is not limited to
__label__1	study interventions are Lapatinib . unspecified adult solid tumor protocol specific diagnosis and diagnosed congenital long qt syndrome
__label__1	study interventions are Docetaxel . recurrent uterine corpus sarcoma diagnosis and myocardial infarction or unstable angina within six months of the first date of bevacizumab placebo therapy
__label__1	study interventions are Doxorubicin . ovarian cancer diagnosis and patients who require antifolate therapy for the management of comorbid conditions rheumatoid arthritis will be excluded from the trial
__label__1	study interventions are Immunoglobulin G . stage iiia fallopian tube cancer diagnosis and patients with clinical symptoms or signs of gastrointestinal obstruction and or those who require parenteral hydration and or nutrition patients with history or current diagnosis of inflammatory bowel disease are not eligible twelve twenty ten
__label__1	study interventions are Immunoglobulins . stage iiia primary peritoneal cancer diagnosis and only applies to patients who elect to receive bevacizumab
__label__1	study interventions are Nivolumab . stage iiic skin melanoma diagnosis and known history of testing positive for human immunodeficiency virus hiv or known acquired immunodeficiency syndrome aids
__label__1	study interventions are Immunoglobulins . adult anaplastic oligodendroglioma diagnosis and four grade three or greater within three0 days prior to study entry
__label__1	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and inability to obtain informed consent
__label__1	study interventions are tissue bonding . basal cell carcinoma diagnosis and history of underlying photosensitivity condition skin phototypes vi use of photosensitizing medication history of accutane use within the past twelve months history of underlying bleeding disorder or use of anticoagulant coumadin active smoker known pregnancy or lactating mother allergies or reactions to lidocaine or epinephrine underlying immunodeficiency inability to comply with study requirements pacemaker or defibrillator in place
__label__1	study interventions are Bendamustine Hydrochloride . organ confined prostate cancer with no evidence of recurrent or progressive disease based on prostate specific antigen psa values are also eligible for this study if hormonal therapy has been initiated or radical prostatectomy or definitive prostate irradiation has been performed
__label__1	study interventions are Bevacizumab . recurrent colon cancer diagnosis and if patient is on full dose anticoagulants the following criteria should be met for enrollment
__label__1	study interventions are Aspirin . patients with rectal cancer are excluded except for transanal excision without radiation
__label__1	study interventions are Educational Intervention . stage colorectal cancer diagnosis and any individual considered to be that of vulnerable group including pregnant women and prisoners
__label__1	study interventions are Albumin-Bound Paclitaxel . symptomatic peripheral neuropathy greater_than grade two by ncic_ctg criteria
__label__1	study interventions are Vincristine . patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
__label__1	study interventions are Poly ICLC . astrocytoma diagnosis and growth factors
__label__1	study interventions are Endothelial Growth Factors . primary peritoneal serous adenocarcinoma diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Cetuximab . stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and cardiac disease
__label__1	study interventions are Cyclosporine . stage small lymphocytic lymphoma diagnosis and donor
__label__1	study interventions are Antibodies, Monoclonal . metastatic bladder cancer diagnosis and however stable atrial fibrillation controlled medically or with device pacemaker or prior ablation is allowed
__label__1	study interventions are Irinotecan . recurrent rectal cancer diagnosis and prior exposure to cetuximab in the metastatic stage iv setting
__label__1	study interventions are Niacinamide . fallopian tube cancer diagnosis and thrombotic or embolic events within the past six months such as cerebrovascular accident including transient ischemic attacks pulmonary embolism unstable angina or myocardial infarction
__label__1	study interventions are Maleic acid . stage iiia rectal cancer diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with rofour million, nine hundred and twenty-nine thousand and ninety-seven with or without cediranib
__label__1	study interventions are Acyclovir . known active central nervous system metastases and or carcinomatous_meningitis
__label__1	study interventions are Bevacizumab . cancer diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Nintedanib . endometrial squamous cell carcinoma diagnosis and known active hepatitis or infection known human immunodeficiency virus hiv infection
__label__1	study interventions are Doxorubicin . solid tumors diagnosis and patient has hypersensitivity to bortezomib boron mannitol doxorubicin or gemcitabine
__label__1	study interventions are Antibodies, Monoclonal . lymphoma diagnosis and patients with clinically significant unexplained bleeding within twenty-eight days prior to entering the study
__label__1	study interventions are Bendamustine Hydrochloride . grey zone lymphoma diagnosis and prior allogeneic transplant
__label__1	study interventions are Mycophenolate mofetil . small lymphocytic lymphoma diagnosis and myocardial infarction within six months prior to enrollment or new york heart association nyha class iii or iv heart failure see appendix uncontrolled angina severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
__label__1	study interventions are Chlorambucil . small cell lymphoma diagnosis and major surgery within four weeks of randomization
__label__1	study interventions are Methotrexate . stage ii non contiguous mantle cell lymphoma diagnosis and positive serology for hepatitis hb defined as positive test for hbsag in addition if negative for hbsag but hbcab positive regardless of hbsab status hepatitis dna test will be performed and if positive the patient will be excluded
__label__1	study interventions are CDX-1127 . marginal zone cell lymphoma diagnosis and among other criteria patients who meet the following conditions are not eligible for the study
__label__1	study interventions are Propofol . rectal cancer diagnosis and on anticoagulation agents
__label__1	study interventions are Everolimus . stage iiia fallopian tube cancer diagnosis and lack of availability of patient for immunological and clinical follow up assessment
__label__1	study interventions are Pemetrexed . non small cell lung cancer diagnosis and hiv positive patients on active treatment
__label__1	study interventions are Pembrolizumab . refractory extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and nursing women
__label__1	study interventions are Everolimus . second primary malignancy except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than five years ago without recurrence
__label__1	study interventions are Bevacizumab . recurrent grade two follicular lymphoma diagnosis and conditions requiring concurrent use of drugs or biologics with proarrythmic potential these drugs are prohibited during studies with azdtwo171 refer to appendix for listing of these agents
__label__1	study interventions are Sorafenib . recurrent rectal carcinoma diagnosis and radiation therapy equal_than less_than twenty-eight days prior to registration
__label__1	study interventions are Albumin-Bound Paclitaxel . her two positive advanced gastric cancer diagnosis and patients with history of hypersensitivity to trastuzumab and who have been treated with medicine including cremophor_el
__label__1	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the nasopharynx diagnosis and valvular disease with document compromise in cardiac function
__label__1	study interventions are Endothelial Growth Factors . recurrent ovarian carcinoma diagnosis and major surgery within twenty-eight days prior to the first date of study treatment
__label__1	study interventions are questionnaire administration . recurrent verrucous carcinoma of the larynx diagnosis and contraindication to full course chemoradiotherapy
__label__1	study interventions are Bevacizumab . head and neck cancer diagnosis and patients with incidental blood mixed with phlegm are not excluded
__label__1	study interventions are Paclitaxel . a history of other malignancy within the last five years which could affect the diagnosis or assessment of breast cancer recurrence or which could shorten patient survival
__label__1	study interventions are Lenograstim . other concurrent anticancer agents
__label__1	study interventions are questionnaire administration . intraocular lymphoma diagnosis and patients in whom planned therapy includes
__label__1	study interventions are Antibodies . breast neoplasm diagnosis and pregnant positive pregnancy test or lactating
__label__1	study interventions are Oxaliplatin . metastatic colorectal cancer diagnosis and subjects with known allergy to the study drugs or to any of its excipients
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and any history of treatment as follows
__label__1	study interventions are Everolimus . triple negative breast cancer diagnosis and for cytotoxic agents that have major delayed toxicity and ctla four antagonists washout period is six weeks
__label__1	study interventions are Vitamins . stage iv colon cancer with resectable liver metastases diagnosis and participants with these infections are ineligible because they are at increased risk of significant complications in the perioperative period particularly for active hepatitis or patients undergoing liver resection
__label__1	study interventions are Lenalidomide . advanced cancers diagnosis and history of hypersensitivity to lenalidomide
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and iii
__label__1	study interventions are Antibodies . ovarian clear cell adenocarcinoma diagnosis and history of hemoptysis greater_than equal_than one two teaspoon of bright red blood per episode within one month of study enrollment
__label__1	study interventions are Everolimus . recurrent adult liver carcinoma diagnosis and known human immunodeficiency virus hiv positive
__label__1	study interventions are Busulfan . estrogen receptor negative breast cancer diagnosis and patient is seropositive for the human immunodeficiency virus
__label__1	study interventions are Somatostatin . carcinoid tumors diagnosis and acute myocardial infarction
__label__1	study interventions are Etoposide phosphate . nodal marginal zone cell lymphoma diagnosis and serum bilirubin greater than three times the upper limits of normal unless determined to be result of the primary hematologic malignancy or attributed to gilbert syndrome
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and patients with history of treatment for clinically significant ventricular cardiac arrhythmias
__label__1	study interventions are multiple beams utilizing either intensity-modulated or 3D-conformal techniques . breast cancer diagnosis and patients are not considered to have currently active malignancies if they have completed therapy and are considered by their physicians to be at less_than five risk of relapse within three years
__label__1	study interventions are Antibodies, Monoclonal . adenocarcinoma of the colon diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Intensity-Modulated Radiotherapy . soft tissue sarcoma diagnosis and pregnant women
__label__1	study interventions are CD19-targeting CAR T Cells infusion . b cell lymphoma diagnosis and treatment with an investigational product within thirty days prior to enrollment or at least five half lives of that drug which is longest
__label__1	study interventions are Endothelial Growth Factors . stage ivb colorectal cancer diagnosis and no acute exacerbations of underlying condition within the last twelve months not requiring psoralen plus ultraviolet radiation puva methotrexate retinoids biologic agents oral calcineurin inhibitors high potency or oral steroids
__label__1	study interventions are Immunoglobulins . glioblastoma diagnosis and myocardial infarction or unstable angina within six months
__label__1	study interventions are Cisplatin . non small cell lung cancer diagnosis and have ever received bone marrow or peripheral blood stem cell infusion within one year of screening
__label__1	study interventions are Fludarabine . primary peritoneal cancer diagnosis and active infection
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and prior irinotecan chemotherapy
__label__1	study interventions are Cediranib . stage iv adult diffuse large cell lymphoma diagnosis and patients with bleeding diathesis clinical bleeding prothrombin time greater_than equal_than doc upper institutional normal value inr greater_than equal_than doc activated partial thromboplastin time aptt greater_than equal_than doc upper institutional normal value active gastric or duodenal ulcer
__label__1	study interventions are Leucovorin . stage iiic colon cancer diagnosis and leptomeningeal disease
__label__1	study interventions are Mycophenolic Acid . cutaneous cell non hodgkin lymphoma diagnosis and patient has fungal infection with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Lumpectomy . bilateral breast cancer
__label__1	study interventions are Cyclosporins . recurrent childhood small noncleaved cell lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Study sample collection . colorectal cancer diagnosis and in subjects who require intraoperative transfusions of greater_than four units of red packed blood cells rpbcs no further blood will be drawn for ctc dtc cfdna analysis during surgery or on postoperative day one
__label__1	study interventions are ispinesib . recurrent small lymphocytic lymphoma diagnosis and amiodarone grapefruit juice use of amiodarone within six months prior to the administration of the first dose of sb seven hundred and fifteen thousand, nine hundred and ninety-two is prohibited use of grapefruit juice within seven days prior to administration of the first dose of sb seven hundred and fifteen thousand, nine hundred and ninety-two is prohibited
__label__1	study interventions are Antibodies . recurrent uterine corpus carcinoma diagnosis and impairment of gastrointestinal gi function or gi disease that may significantly alter the absorption of oral mlnone hundred and twenty-eight ulcerative diseases uncontrolled nausea vomiting diarrhea malabsorption syndrome small bowel resection that requires nutritional support
__label__1	study interventions are Irinotecan . stage iva rectal cancer diagnosis and pregnant or nursing women may not participate in this trial
__label__1	study interventions are Rituximab . b cell small lymphocytic lymphoma recurrent diagnosis and prior autologous bone marrow transplant within twelve months prior to the first dose of study drug
__label__1	study interventions are Carboplatin . small cell lung carcinoma diagnosis and significant cardiovascular disease
__label__1	study interventions are Rituximab . b cell non hodgkin lymphoma diagnosis and female patients who are lactating or have positive serum pregnancy test during the screening period or positive urine pregnancy test on day one before first dose of study drug if applicable
__label__1	study interventions are Hormones . metastatic prostate carcinoma diagnosis and refuses to give informed consent
__label__1	study interventions are Ceritinib . metastatic pancreatic adenocarcinoma diagnosis and herbal supplements
__label__1	study interventions are Mycophenolic Acid . stage iv childhood burkitt lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Poly I-C . t cell lymphoma diagnosis and significant cardiovascular disease nyha class three congestive heart failure myocardial infarction within the past six months unstable angina coronary angioplasty within the past six months uncontrolled atrial or ventricular cardiac arrhythmias
__label__1	study interventions are Mycophenolic Acid . stage iv adult cell leukemia lymphoma diagnosis and donor
__label__1	study interventions are Etoposide . history of treated or non treated indolent lymphoma
__label__1	study interventions are Panobinostat . prostatic neoplasms diagnosis and patients with unresolved diarrhea greater than ctcae grade one
__label__1	study interventions are Methotrexate . refractory recurrent secondary central nervous system lymphoma scnsl diagnosis and patient is known to have human immunodeficiency virus hiv infection
__label__1	study interventions are Antibodies . ovarian seromucinous tumor diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and cardiac arrhythmia
__label__1	study interventions are Temozolomide . pancreatic delta cell carcinoma diagnosis and active peptic ulcer disease
__label__1	study interventions are Antibodies . noncontiguous stage ii marginal zone lymphoma diagnosis and any other condition not defined above including the presence of laboratory abnormalities which in the opinion of the investigator would place the subject at unacceptable risk if he she were to participate in the study or would confound the ability to interpret data from the study
__label__1	study interventions are Antibodies . fallopian tube adenocarcinoma diagnosis and new york heart association class ii iv congestive heart failure serious cardiac arrhythmia requiring medication
__label__1	study interventions are Liposomal doxorubicin . lymphoma diagnosis and hepatitis hcv
__label__1	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and known or suspected hypersensitivity to any of the agents of the treatment under evaluation
__label__1	study interventions are Pembrolizumab . advanced melanoma diagnosis and subjects with vitiligo or resolved childhood asthma atopy would be an exception to this rule
__label__1	study interventions are Lapatinib . cancer diagnosis and history of significant neurologic or psychiatric disorder which would impair the ability to obtain consent or limit compliance with study requirements
__label__1	study interventions are Liposomal doxorubicin . nerve sheath neoplasm diagnosis and brain imaging is not an eligibility requirement
__label__1	study interventions are Interferons . fallopian tube cancer diagnosis and patients with known hypersensitivity to interferon
__label__1	study interventions are Niacinamide . carcinoma renal cell diagnosis and history of organ allograft
__label__1	study interventions are Vitamin B Complex . ovarian cancer diagnosis and not post menopausal or not rendered surgically infertile
__label__1	study interventions are Digital foot candle datalogging light meter (Extech Instrument, Model SDL400) . cancer of breast diagnosis and concurrent malignancy
__label__1	study interventions are Vidarabine . stage iv grade two follicular lymphoma diagnosis and karnofsky score less_than fifty for adult patients
__label__1	study interventions are Fludarabine phosphate . stage adult lymphoblastic lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Aminopterin . hodgkin lymphoma diagnosis and systemic steroids that have not been stabilized to the equivalent of less_than ten mg day prednisone prior to the start of the study drugs
__label__1	study interventions are Epirubicin . breast cancer diagnosis and previous treatment with docetaxel paclitaxel epirubicin cyclophosphamide trastuzumab pertuzumab or tocotrienol
__label__1	study interventions are Folic Acid . stage iiia fallopian tube cancer diagnosis and known history of autoimmune disease
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and active autoimmune disease or documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents
__label__1	study interventions are Albumin-Bound Paclitaxel . melanoma diagnosis and the patient has any condition including the presence of laboratory abnormalities that places the patient at unacceptable risk if he she were to participate in the study
__label__1	study interventions are Laboratory Biomarker Analysis . splenic marginal zone lymphoma diagnosis and on prophylactic antibiotics such as trimethoprim_sulfamethoxazole for pneumocystis prophylaxis or post transplant penicillin prophylaxis
__label__1	study interventions are Meloxicam . multiple myeloma diagnosis and cardiac disease
__label__1	study interventions are Bevacizumab . fallopian tube mucinous adenocarcinoma diagnosis and patients with clinically significant cardiovascular disease this includes
__label__1	study interventions are Trametinib . stage iv skin melanoma diagnosis and carbamazepine oxcarbazepine phenobarbital phenytoin mephenytoin
__label__1	study interventions are Cyclophosphamide . non hodgkin lymphoma diagnosis and uncontrolled intercurrent disease including arrhythmias angina pectoris class iii iv congestive heart failure chf symptoms on less than ordinary exertion or at rest or active infection
__label__1	study interventions are ispinesib . recurrent rectal cancer diagnosis and patients may not have received any other investigational agents within twenty-eight days of study entry
__label__1	study interventions are Therapeutic Conventional Surgery . stage hypopharyngeal squamous cell carcinoma diagnosis and use of medications that have been linked to the occurrence of torsades de pointes
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube cancer diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are cabozantinib-s-malate . recurrent prostate cancer diagnosis and cytotoxic chemotherapy or biologic agents within three weeks of study treatment
__label__1	study interventions are Mycophenolic Acid . stage iii marginal zone lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for granulocyte colony stimulating factor csf mobilization and harvest of peripheral blood stem cell pbsc
__label__1	study interventions are Doxorubicin . breast cancer diagnosis and cardiac disease that would preclude the use of adriamycin taxol or herceptin
__label__1	study interventions are siRNA-transfected peripheral blood mononuclear cells APN401 . stage iii renal cell cancer diagnosis and women must not be pregnant or breastfeeding all women of childbearing potential must have blood test within seventy-two hours prior to randomization to rule out pregnancy women of childbearing potential and sexually active males must be strongly advised to use an accepted and effective method of contraception women of childbearing potential wocbp must be using an adequate method of contraception to avoid pregnancy throughout the study and for twelve weeks after the last dose of investigational product in such manner that the risk of pregnancy is minimized sexually mature females who have not undergone hysterectomy or who have not been postmenopausal naturally for at least twenty-four consecutive months who have had menses at some time in the preceding twenty-four consecutive months are considered to be of childbearing potential women who are using oral contraceptives other hormonal contraceptives vaginal products skin patches or implanted or injectable products or mechanical products such as an intrauterine device or barrier methods diaphragm condoms spermicides to prevent pregnancy or are practicing abstinence or where their partner is sterile vasectomy should be considered to be of childbearing potential
__label__1	study interventions are Fulvestrant . breast cancer diagnosis and active bleeding diathesis or on oral anti vitamin medication except cases
__label__1	study interventions are Valproic Acid . brainstem glioma diagnosis and patients on any anti convulsant with the exception of vpa are eligible for study entry
__label__1	study interventions are Akt inhibitor MK2206 . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and any serious active disease or co morbid condition which in the opinion of the principal investigator will interfere with the safety or with compliance with the study
__label__1	study interventions are LJM716 . hertwo positive gastric cancer diagnosis and pregnant or nursing lactating women
__label__1	study interventions are Gemcitabine . stage ia pancreatic cancer diagnosis and immunosuppressants such as tacrolimus leflunomide or tofacitinib roflumilast pimecrolimus
__label__1	study interventions are Secoisolariciresinol . breast cancer diagnosis and any other condition or intercurrent illness that in the opinion of the investigator makes the subject poor candidate for rpfna or the trial
__label__1	study interventions are Etoposide phosphate . angioimmunoblastic cell lymphoma aitl diagnosis and age less_than eighteen greater_than sixty-five years
__label__1	study interventions are Albumin-Bound Paclitaxel . advanced breast cancer diagnosis and pregnancy or breast feeding
__label__1	study interventions are SCIO-469 . bone marrow neoplasms diagnosis and patients who have received lenalidomide revlimidtm steroids erythropoietin hydroxyurea or growth factors within four weeks before study drug administration
__label__1	study interventions are Axitinib . carcinoma renal cell diagnosis and gastrointestinal abnormalities
__label__1	study interventions are Simvastatin . prostate carcinoma diagnosis and subjects who need to take cypthreeafour inducers such as phenobarbital dexamethasone carbamazepine phenytoin rifampicin or non nucleoside_reverse transcriptase inhibitors efavirenz nevirapine etravirine will be excluded
__label__1	study interventions are Diphosphonates . pain bone neoplasms neoplasm metastasis diagnosis and severe or concomitant infection
__label__1	study interventions are Liposomal doxorubicin . malignant triton tumor diagnosis and brain imaging is not an eligibility requirement
__label__1	study interventions are Oxaliplatin . non small cell lung cancer diagnosis and malignant secondary disease dated back less_than five years exception
__label__1	study interventions are Irinotecan . small cell lung cancer diagnosis and failed to meet the entry criteria of pathology and clinical stage
__label__1	study interventions are Surgery . history of cancer except cutaneous basocellular epithelioma or epithelioma of the uterine cervix having recurred in the five years preceding entry in the trial and no relapse in the last three years
__label__1	study interventions are Antibodies, Monoclonal . adult hepatocellular carcinoma diagnosis and carcinoid permanently closed to enrollment
__label__1	study interventions are counseling intervention . multiple myeloma diagnosis and patients
__label__1	study interventions are Oxaliplatin . previous chemotherapy for metastatic esophagogastric cancer diagnosis and age eighteen years or older
__label__1	study interventions are Lenograstim . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and contraindication or hypersensitivity to filgrastim or plerixafor
__label__1	study interventions are sipuleucel-T . cutaneous squamous cell and basal carcinomas
__label__1	study interventions are Pembrolizumab . rectal cancer diagnosis and has received an investigational drug within four weeks prior to study drug administration or unless other has been agreed with the medical monitor
__label__1	study interventions are Nivolumab . stage iii urethral cancer diagnosis and prior treatment with any therapy on the programmed cell death one pd one pd lone axis or anti cytotoxic lymphocyte associated protein four ctla four inhibitors
__label__1	study interventions are Sunitinib . stage iiic ovarian epithelial cancer diagnosis and are ineligible
__label__1	study interventions are Carboplatin . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and no compatible donor identified
__label__1	study interventions are Cephalosporins . adult immunoblastic large cell lymphoma diagnosis and estimated creatinine clearance less_than fifty milliliters minute
__label__1	study interventions are Bendamustine Hydrochloride . lymphoma follicular diagnosis and active infection or documented fungal infection within three months of bmt
__label__1	study interventions are Sirolimus . radiotherapy to primary tumor in lung lesions prior to enrollment
__label__1	study interventions are Carboplatin . prior radiation for head and neck cancer
__label__1	study interventions are Antibodies . recurrent breast carcinoma diagnosis and absolute neutrophil count anc less_than doc
__label__1	study interventions are Fluorouracil . colorectal carcinoma diagnosis and the participant has participated in clinical studies of non approved experimental agents or procedures within twelve weeks of study entry
__label__1	study interventions are Sirolimus . neuroendocrine tumors diagnosis and known impairment of gastrointestinal gi function or gi disease that may significantly alter the absorption of oral everolimus
__label__1	study interventions are Mycophenolate mofetil . stage cutaneous cell non hodgkin lymphoma diagnosis and patients with medical history of noncompliance with haart or medical therapy
__label__1	study interventions are aflibercept + FOLFIRI . metastatic colorectal cancer diagnosis and female patients who are pregnant or breastfeeding
__label__1	study interventions are Dexamethasone acetate . subjects with non controlled diabetes hypertension digestive ulcer or glaucoma
__label__1	study interventions are Trastuzumab . pancreatic neoplasms diagnosis and poor organ function as defined by one of the following
__label__1	study interventions are Sirolimus . sporadic_angiomyolipomas amls diagnosis and history of tuberous sclerosis lam or any active malignancy
__label__1	study interventions are Docetaxel . non small cell lung cancer diagnosis and treatment with another investigational drug biological agent or device within four weeks six weeks for biological agents before screening or five half lives of study agent whichever is longer
__label__1	study interventions are Prednisone . stage marginal zone lymphoma diagnosis and pregnant females
__label__1	study interventions are Cetuximab . recurrent squamous cell carcinoma of the larynx diagnosis and use of st
__label__1	study interventions are Fludarabine . solid tumor diagnosis and previous extensive radiotherapy to the lung or liver during the last four months prior to lymphodepletion regimen
__label__1	study interventions are Isophosphamide mustard . low grade fibromyxoid sarcoma diagnosis and patients with known central nervous system cns metastases are not eligible note
__label__1	study interventions are Hydrocortisone . plasmablastic lymphoma diagnosis and john wort are not eligible
__label__1	study interventions are Couples-Based Behavioral Weight and Symptom Management . male breast cancer survivors
__label__1	study interventions are Chemotherapy- scheme . colonic cancer diagnosis and cases of rectal tumours below twelvecm from anal verge or locally advanced tumours invading blood vessels nerves or bone
__label__1	study interventions are Bevacizumab . liver cancer diagnosis and core biopsy fine needle aspiration or other minor surgical procedure excluding placement of vascular access device within seven days prior to day one
__label__1	study interventions are therapeutic allogeneic lymphocytes . childhood burkitt lymphoma diagnosis and psychiatric illness that may make compliance to the clinical protocol unmanageable or may compromise the ability of the patient to give informed consent
__label__1	study interventions are Interferon-alpha . neuroendocrine tumors diagnosis and hypersensitivity against interferon or cyclophosphamide
__label__1	study interventions are Aprepitant . breast cancer diagnosis and patient is taking or will be taking within twenty-eight days of day one of cycle two cycle in which patients will start taking aprepitant the following cypthreeafour inducers
__label__1	study interventions are Antibodies, Monoclonal . stage iv mantle cell lymphoma diagnosis and serious non malignant disease active uncontrolled bacterial viral or fungal infections or other medical conditions including psychiatric which in the opinion of the principal investigator pi would compromise other protocol objectives
__label__1	study interventions are Metformin . adenomatous polyp diagnosis and participants with any medical psychosocial condition that in the opinion of the investigator could jeopardize participation in and compliance with the study criteria
__label__1	study interventions are Mocetinostat . breast cancer diagnosis and subjects meeting any of the following criteria will not be included in the study
__label__1	study interventions are Antibodies . anaplastic large cell lymphoma diagnosis and karnofsky performance score less_than seventy for adult patients
__label__1	study interventions are Paclitaxel . lung cancer diagnosis and known sensitivity to e
__label__1	study interventions are ASP3026 . solid tumor diagnosis and use of an investigational drug or device within twenty-one days prior to the scheduled initial dosing
__label__1	study interventions are FOLFIR + Aflibercept . metastatic colorectal cancer diagnosis and hypertension not kept under control sbp greater_than one hundred and fifty mmhg and dbp greater_than one hundred mmhg or history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Vitamin B Complex . stage iiib fallopian tube cancer diagnosis and receiving thyroid replacement therapy
__label__1	study interventions are Sirolimus . localized gallbladder cancer diagnosis and impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome or small bowel resection
__label__1	study interventions are Antibodies, Monoclonal . cervical squamous cell carcinoma diagnosis and patients with or with anticipation of invasive procedures as defined below
__label__1	study interventions are Capecitabine . stage iv grade two follicular lymphoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued
__label__1	study interventions are Ketorolac Tromethamine . rectum cancer diagnosis and allergy to any protocol medication
__label__1	study interventions are Azacitidine . indolent cell lymphoma diagnosis and appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
__label__1	study interventions are Immunoglobulins . stage ii grade two contiguous follicular lymphoma diagnosis and seropositive for or active viral infection with hepatitis virus hbv
__label__1	study interventions are Somatostatin . neuroendocrine tumors diagnosis and metabolic disorders clinical examination or laboratory investigations which contraindicate the use of drugs to study or patients at high risk of complications from the treatment
__label__1	study interventions are Ramucirumab . previous treatment with an egfr monoclonal antibody except for past treatment for squamous cell carcinoma of head and neck or metastatic colorectal cancer
__label__1	study interventions are Sorafenib . liver cancer diagnosis and uncontrolled asthma or otwo saturation less_than ninety by abg arterial blood gas analysis or pulse_oximetry on room air
__label__1	study interventions are Digital Rectal Exam . recurrent prostate cancer diagnosis and use of finasteride within thirty days prior to registration psa should not be obtained prior to thirty days after stopping finasteride
__label__1	study interventions are Smoked Cannabis High CBD/low THC . lung cancer diagnosis and current weekly use of cannabis
__label__1	study interventions are Liposomal doxorubicin . ovarian seromucinous carcinoma diagnosis and anticipation of need for major surgical procedures during the course of the study
__label__1	study interventions are Fludarabine . recurrent childhood anaplastic large cell lymphoma diagnosis and any vertebral instability
__label__1	study interventions are Everolimus . stage iiia endometrial carcinoma diagnosis and active uncontrolled infection
__label__1	study interventions are Natalizumab . multiple myeloma diagnosis and subjects who cannot undergo brain magnetic resonance imaging mri study
__label__1	study interventions are Twice daily radiotherapy . lung cancer diagnosis and platelets greater_than one hundred one hundred and nine l
__label__1	study interventions are Immunoglobulins . stage iiib fallopian tube cancer diagnosis and patients who have received prior therapy with any anti vascular endothelial growth factor vegf drug including bevacizumab
__label__1	study interventions are Aromatase Inhibitors . early stage breast carcinoma diagnosis and age less_than forty years
__label__1	study interventions are Doxorubicin . stage adult diffuse large cell lymphoma diagnosis and history of significant cerebrovascular disease in the past three months or ongoing event with active symptoms or sequelae
__label__1	study interventions are Cisplatin . stage iv squamous cell carcinoma of the oropharynx diagnosis and strong inhibitors of cypthreeafour
__label__1	study interventions are Pemetrexed . previous systemic chemotherapy for lung cancer
__label__1	study interventions are Nivolumab . recurrent urothelial carcinoma of the renal pelvis and ureter diagnosis and major surgery within three months of the first dose of cabozantinib if there were no wound healing complications or within six months of the first dose of cabozantinib if there were wound complications
__label__1	study interventions are Antibodies, Monoclonal . stage ii grade one contiguous follicular lymphoma diagnosis and seropositive for or active viral infection with hepatitis virus hbv
__label__1	study interventions are Immunoglobulins . neoplasm metastasis diagnosis and current active infection
__label__1	study interventions are Liposomal doxorubicin . ovarian neoplasms diagnosis and inclusion criterion eight
__label__1	study interventions are Blood collection . stage iv ovarian cancer diagnosis and not planned for surgical intervention
__label__1	study interventions are Fluorouracil . esophageal squamous cell carcinoma diagnosis and previous radiotherapy history
__label__1	study interventions are Fludarabine phosphate . recurrent mantle cell lymphoma diagnosis and patients who have received prior allogeneic hct must have no active gvhd requiring immunosuppressive therapy for at least twenty-one days prior to start of conditioning
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and any uncontrolled or severe cardiovascular disease
__label__1	study interventions are Niacinamide . pancreatic cancer diagnosis and uncontrolled hypertension
__label__1	study interventions are Intrathecal Resiniferatoxin . pain cancer diagnosis and anatomic abnormality or pathology of the spinal cord and or intrathecal space on magnetic resonance imaging mri that could increase the risk of adverse effects of intrathecal catheter placement or interfere with csf flow
__label__1	study interventions are Vidarabine . burkitt lymphoma diagnosis and uncontrolled diabetes mellitus cardiovascular disease active serious infection or other condition which in the opinion of treating physician would make this protocol unreasonably_hazardous for the patient
__label__1	study interventions are Freund's Adjuvant . partial response of multiple myeloma or plasma cell leukemia diagnosis and any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he she were to participate in the study or confounds the ability to interpret data from the study
__label__1	study interventions are Mechlorethamine . non hodgkin lymphoma diagnosis and patient is at the time of signing informed consent regular user including recreational use of any illicit drugs substance abuse or had recent history within the last year of drug or alcohol abuse
__label__1	study interventions are Panobinostat . recurrent renal cell cancer diagnosis and female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods adequate contraception must be used throughout the trial and for eight weeks after the last dose of study drug by both sexes
__label__1	study interventions are Cediranib . primary peritoneal serous adenocarcinoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with cediranib and olaparib
__label__1	study interventions are Mitogens . stage iv mantle cell lymphoma diagnosis and participation in another study with chronic gvhd as the primary endpoint
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . ovarian cancer diagnosis and patients who were treated with other parp inhibitors greater than twenty-eight days prior to study are eligible
__label__1	study interventions are Gemcitabine . prior invasive malignancy unless disease free for minimum of one thousand and ninety-five days three years non melanomatous skin cancer and previous early prostate cancer that had non rising prostate specific antigen psa are eligible
__label__1	study interventions are Fibrin Tissue Adhesive . breast cancer diagnosis and subjects with immunodeficiency
__label__1	study interventions are Sorafenib . subjects with locally advanced disease who are considered by the treating investigator to be appropriate candidates for radiation therapy as current treatment for locally advanced breast cancer
__label__1	study interventions are Hydroxychloroquine . colorectal cancer diagnosis and patients who do not demonstrate the ability to understand or the willingness to sign the written informed consent document will be excluded from study entry
__label__1	study interventions are Therapeutic Conventional Surgery . stage iv non small cell lung cancer diagnosis and patients with one three brain metastases each less_than three cm by contrast magnetic resonance imaging mri with stable systemic disease and ecog score of zero two who would otherwise be eligible for srs alone should not be enrolled into this study unless srs is not feasible due to any medical or logistic limitations as determined by the treating physician however patients who develop recurrence post srs or surgery alone and are recommended wbrt will be eligible for the protocol
__label__1	study interventions are Antibodies, Monoclonal . patients with history of inflammatory bowel disease including ulcerative colitis and crohn disease are excluded from this study as are patients with history of symptomatic disease eg rheumatoid arthritis systemic progressive sclerosis scleroderma systemic lupus erythematosus autoimmune vasculitis eg wegener granulomatosis motor neuropathy considered of autoimmune origin guillain_barre syndrome and myasthenia_gravis
__label__1	study interventions are Sirolimus . recurrent grade one follicular lymphoma diagnosis and receiving corticosteroids greater_than twenty mg of prednisone per day or equivalent note
__label__1	study interventions are fostamatinib . lymphoma diagnosis and hgb less_than doc dl anc less_than one thousand, five hundred µl platelets less_than seventy-five zero µl
__label__1	study interventions are Lenvatinib . clinically significant hemoptysis or tumor bleeding within two weeks prior to the first dose of study drug
__label__1	study interventions are Sirolimus . stage iii grade two follicular lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Iodine . stage ivb papillary thyroid cancer diagnosis and cardiac angioplasty or stenting
__label__1	study interventions are Linsitinib . chondrosarcoma diagnosis and use of drugs that have known risk of causing torsades de pointes tdp are prohibited within fourteen days prior to initiation of linsitinib osi nine hundred and six
__label__1	study interventions are Ifosfamide . extraosseous ewing sarcoma diagnosis and patients should not have any uncontrolled illness including ongoing or active infection
__label__1	study interventions are Hormones . stage iii prostate cancer diagnosis and patients with history of gastrointestinal gi bleeding and peptic ulcer disease
__label__1	study interventions are Iodine . stage iva thyroid gland follicular carcinoma diagnosis and left ventricular ejection fraction less_than fifty-five measured by echocardiography
__label__1	study interventions are Paclitaxel . stage ib breast cancer diagnosis and current use of digitalis or beta blockers for chf
__label__1	study interventions are Mycophenolate mofetil . stage ii grade three non contiguous follicular lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Immunoglobulins . stage iia gastric cancer diagnosis and patients must not have serious or non healing wound skin ulcers or unhealed bone fracture or known human immunodeficiency virus hiv infection
__label__1	study interventions are Metronidazole . stage ia ovarian epithelial cancer diagnosis and known hepatitis hepatitis or human immunodeficiency virus hiv
__label__1	study interventions are Prolactin Release-Inhibiting Factors . metastatic cancer diagnosis and because patients with immune deficiency are at increased risk of lethal infections when treated with marrow suppressive therapy hiv positive patients receiving combination anti retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with strontium eighty-nine or other agents administered during the study
__label__1	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and hepatitis or positive
__label__1	study interventions are Reconstructive Surgery . stage ia breast cancer diagnosis and acquired immune deficiency syndrome aids based upon current centers for disease control and prevention cdc definition note however that human immunodeficiency virus hiv testing is not required for entry into this protocol
__label__1	study interventions are Calcium Carbonate . stage iiic breast cancer diagnosis and inability to understand or cooperate with study procedures
__label__1	study interventions are Bevacizumab . adult nasal type extranodal nk cell lymphoma diagnosis and core biopsy within seven days prior to day one of therapy
__label__1	study interventions are Pemetrexed . non small cell lung cancer diagnosis and interstitial pneumoni ericardial effusion pleural effusion is uncontrolled
__label__1	study interventions are LDE225 . pancreatic ductal adenocarcinoma diagnosis and patients who have taken part in an experimental drug study within four weeks of initiating treatment with ldetwo hundred and twenty-five
__label__1	study interventions are Etoposide phosphate . recurrent burkitt lymphoma diagnosis and any history of hiv one associated encephalopathy
__label__1	study interventions are Vadimezan . metastatic cancer diagnosis and weeks prior to starting study drug
__label__1	study interventions are Doxorubicin . other previous or concomitant malignancy except for basal cell carcinoma and or cervical carcinoma in situ
__label__1	study interventions are Erlotinib Hydrochloride . squamous cell carcinoma of the head and neck scchn diagnosis and minor surgical procedures such as fine needle aspiration or core biopsy within five days prior to day one
__label__1	study interventions are Levoleucovorin . colorectal neoplasms diagnosis and impossibility of undergoing medical monitoring during the trial for geographic social or psychological reasons
__label__1	study interventions are Everolimus . adult cell leukemia lymphoma diagnosis and patients must not have evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with ara administration
__label__1	study interventions are Docetaxel . sarcoma diagnosis and evidence of bleeding diathesis or significant coagulopathy in the absence of therapeutic anticoagulation
__label__1	study interventions are Vitamins . neoplasm metastasis diagnosis and one prior regimen up to four cycles of neoadjuvant or adjuvant therapy for early stage disease will also be allowed
__label__1	study interventions are Mycophenolate mofetil . cutaneous cell non hodgkin lymphoma diagnosis and patients who are human immunodeficiency virus hiv positive
__label__1	study interventions are BB 1101 . stage iib non small cell lung carcinoma diagnosis and patients who report hearing deficit at baseline even if it does not require hearing aid or intervention or interfere with activities of daily life common terminology criteria for adverse events ctcae grade two or higher
__label__1	study interventions are Cisplatin . stage iiib non small cell lung cancer diagnosis and ovarian radiation or treatment with luteinizing hormone releasing hormone lh_rh agonist goserelin acetate or leuprolide acetate is not permitted for induction of ovarian suppression
__label__1	study interventions are Hormones . prostate cancer diagnosis and impending untreated spinal cord compression or urinary outlet obstruction
__label__1	study interventions are Fludarabine . stage iv cutaneous cell non hodgkin lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Methylprednisolone acetate . childhood diffuse large cell lymphoma diagnosis and for the phase iii trial patient without known history of hepatitis could be randomized in the study if the serology results are not available at the time of the randomization however if the serology results are positive or not available at day six the first day would be due to receive rituximab if so randomized the patient must be withdrawn from the study whatever the allocated treatment arm the data center must be informed immediately for the phase ii trial the hepatitis serology results must be available before registration in each case indicating carrier status or history for hepatitis infection the patients must not receive rituximab and therefore must not be included in the rituximab trials on any treatment arm in case of high risk patients the recommendation is to treat these patients with the standard lmb regimen corresponding to the patient prognostic group in the case of pmlbl the physician is left to choose the most appropriate therapy
__label__1	study interventions are Prednisone . hormone resistant prostate cancer diagnosis and history of pituitary or adrenal dysfunction
__label__1	study interventions are Dose 2 . patients with history metastatic melanoma involving the brain will be excluded if they have active disease or have had active disease within the prior six months that was not controlled with surgery or radiotherapy
__label__1	study interventions are BB 1101 . cancer diagnosis and platelet count less_than one hundred ten nine l
__label__1	study interventions are Dacarbazine . glioma diagnosis and patients or their legal guardians not willing or able to sign the informed consent document
__label__1	study interventions are Gemcitabine . recurrent fallopian tube carcinoma diagnosis and concurrent use of corticosteroids exceptions
__label__1	study interventions are Clarithromycin . non small cell lung cancer diagnosis and history of intracranial hemorrhage
__label__1	study interventions are Akt inhibitor MK2206 . primary central nervous system non hodgkin lymphoma diagnosis and patients receiving insulin or growth hormone therapy are not eligible
__label__1	study interventions are Auranofin . lung adenocarcinoma diagnosis and patients with treated cns metastases without evidence of progression and without uncontrolled symptoms or need for steroids may enroll
__label__1	study interventions are Albumin-Bound Paclitaxel . in countries where anaplastic lymphoma kinase alk inhibitors are available for the treatment of nsclc subjects need to have been screened for alk fusion gene rearrangements and excluded if positive unless previously treated and progressed on an appropriate tyrosine kinase inhibitor tki therapy
__label__1	study interventions are targeted therapy . recurrent non small cell lung cancer diagnosis and inability to comply with study and or follow up procedures
__label__1	study interventions are Endothelial Growth Factors . recurrent colon cancer diagnosis and pt inr greater_than doc unless the patient is on full dose warfarin
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and phase two part and part c
__label__1	study interventions are Camptothecin . pancreatic adenocarcinoma diagnosis and placement of an intrauterine device iud or intrauterine system ius
__label__1	study interventions are Fludarabine . sll small lymphocytic lymphoma diagnosis and known hypersensitivity to any component of ibrutinib or fludarabine
__label__1	study interventions are Antibodies . stage iv squamous cell carcinoma of the nasopharynx diagnosis and gastrointestinal tract disease resulting in an inability to take oral medication or requirement for iv alimentation prior surgical procedures affecting absorption or active peptic ulcer disease
__label__1	study interventions are Antibodies, Monoclonal . stage iiic primary peritoneal cancer diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and patient with myelodysplastic syndrome mds acute myeloid leukaemia aml or with features suggestive of mds aml
__label__1	study interventions are Anti-Bacterial Agents . non small cell lung cancer diagnosis and patients with two or more deep vein thromboses or an active deep vein thrombosis
__label__1	study interventions are Belinostat . stage iii marginal zone lymphoma diagnosis and pregnant women are excluded from this study because pxdone hundred and one is an hdac inhibitor with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with pxdone hundred and one breastfeeding should be discontinued if the mother is treated with pxdone hundred and one these potential risks may also apply to other agents used in this study
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and in such cases patient will be eligible for inclusion if the gleason score is less_than six and the prostate specific antigen psa less_than ten ng ml if the patient would be on hormonal treatment the psa must be undetectable
__label__1	study interventions are Cyclosporins . aggressive non hodgkin lymphoma diagnosis and failed flu cyclophosphamide cy rituximab fcr combination chemotherapy at any time point or
__label__1	study interventions are Carvedilol . multiple myeloma diagnosis and systolic blood pressure less_than ninety mmhg
__label__1	study interventions are Fludarabine . recurrent mantle cell lymphoma diagnosis and eligible for high priority curative autologous transplant
__label__1	study interventions are Ritonavir . hodgkin lymphoma diagnosis and current treatment with immunosuppressive agent systemic glucocorticoid cyclosporine mycophenolate azathioprine sirolimus rituximab infliximab adalimumab
__label__1	study interventions are Vaccines . primary central nervous system hodgkin lymphoma diagnosis and receipt of the following substances
__label__1	study interventions are Bevacizumab . rectal cancer diagnosis and urine dipstick for proteinuria greater_than equal_than two positive patients discovered to have greater_than equal_than two positive proteinuria on dipstick urinalysis at baseline should undergo two4 hour urine collection and must demonstrate less_than equal_than oneg of protein in two4 hours to be eligible
__label__1	study interventions are Diphosphonates . bone metastases in men with hormone refractory prostate cancer diagnosis and subjects must be surgically sterile postmenopausal or must agree to use effective contraception during the study
__label__1	study interventions are Capecitabine . rectal cancer diagnosis and prior unanticipated severe reaction to fluoropyrimidine therapy or known hypersensitivity to five fluorouracil or capecitabine or curcumin
__label__1	study interventions are Isophosphamide mustard . lymphoma non hodgkin diagnosis and known hepatitis virus infection
__label__1	study interventions are Immunosuppressive Agents . stage iii adult immunoblastic large cell lymphoma diagnosis and presence of active central nervous system cns disease history of adequately treated cns disease is acceptable
__label__1	study interventions are Cyclosporine . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and donor
__label__1	study interventions are Vidarabine . recurrent mantle cell lymphoma diagnosis and pregnancy
__label__1	study interventions are Thalidomide . stage iii adult diffuse large cell lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Pemetrexed . non small cell lung cancer diagnosis and concomitant disease or condition that could interfere with the conduct of the study or that would in the opinion of the investigator pose an unacceptable risk to the subject in this study
__label__1	study interventions are Tamoxifen . breast cancer diagnosis and world health organisation performance index greater_than three
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv breast cancer diagnosis and patients with uncontrolled hypertension defined as systolic blood pressure greater_than one hundred and fifty and or diastolic blood pressure greater_than ninety mm mg
__label__1	study interventions are Liposomal doxorubicin . metastatic malignant peripheral nerve sheath tumor diagnosis and pregnant or nursing lactating women breastfeeding should be discontinued
__label__1	study interventions are Everolimus . advanced cancer diagnosis and history of hypersensitivity to doxil doxorubicin hcl temsirolimus or it metabolites including sirolimus polysorbate eighty bevacizumab or murine products
__label__1	study interventions are educational intervention . stage iiib breast cancer diagnosis and there are no restrictions regarding use of other investigational agents
__label__1	study interventions are Tamoxifen . breast cancer diagnosis and chronic oral treatment with corticosteroids unless initiated greater_than six months prior to study entry and at low dose less_than twenty mg methylprednisolone or equivalent
__label__1	study interventions are Sunitinib . prostate cancer diagnosis and low molecular weight heparin is permitted
__label__1	study interventions are Everolimus . renal cell carcinoma diagnosis and clear cell type rcc
__label__1	study interventions are Interleukin-2 . stage iiic melanoma diagnosis and significant cardiovascular impairment history of congestive heart failure new york heart association nyha grade greater than two see appendix five unstable angina or myocardial infarction within the past six months or serious cardiac arrhythmia
__label__1	study interventions are Docetaxel . paranasal sinus neoplasms diagnosis and men and women of childbearing potential wocbp who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to three months after the study
__label__1	study interventions are Vincristine . grade one two or threea follicular lymphoma
__label__1	study interventions are EPIC SF-12 Questionnaire . prostate adenocarcinoma diagnosis and for example
__label__1	study interventions are Antibodies, Monoclonal . stage iiia non small cell lung cancer diagnosis and subject has active known or suspected autoimmune disease including systemic lupus erythematodes hashimoto thyroiditis scleroderma polyarteritis nodosa or autoimmune hepatitis
__label__1	study interventions are Paclitaxel . carcinoma non small cell lung diagnosis and inadequate hematologic function defined as anc less_than one five hundred mmthree platelet count less_than one00 zero mmthree or hemoglobin level less_than nine dl
__label__1	study interventions are Everyday experiences writing . cancer survivors diagnosis and patients with limited ability to produce saliva patients that received radiation or surgery on the face region or on salivary glands or patient suffering from dry mouth sjögren syndrome
__label__1	study interventions are Nimotuzumab . previous or concurrent malignancy other than pancreatic cancer except adequately treated carcinoma in situ of the cervix or non melanoma skin cancer
__label__1	study interventions are Niacinamide . stage iv pancreatic cancer diagnosis and cardiac disease
__label__1	study interventions are DSC-MRI . recurrent adult brain tumor diagnosis and prisoners or other individuals deemed to be susceptible to coercion
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and current chronic daily treatment with corticosteroids greater_than equal_than ten mg day methylprednisolone or equivalent excluding inhaled steroids
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and roteinuria greater_than two positive with reactive stick dipstick
__label__1	study interventions are Gefitinib . non small cell lung cancer diagnosis and patients in whose medical objection was recorded to use the existing data from medical practice for scientific research
__label__1	study interventions are Cyclosporine . recurrent adult lymphoblastic lymphoma diagnosis and patients with poorly controlled hypertension who are unable to have blood pressure kept below one hundred and fifty ninety on standard medication
__label__1	study interventions are Camptothecin . ewing sarcoma diagnosis and known history of mds
__label__1	study interventions are Endothelial Growth Factors . solid neoplasm diagnosis and known central nervous system cns disease except for treated brain metastasis treated brain metastases are defined as having no ongoing requirement for steroids and no evidence of progression or hemorrhage after treatment for at least three months as ascertained by clinical examination and brain imaging magnetic resonance imaging mri or computed tomography ct stable dose of non enzyme inducing anticonvulsants are allowed treatment for brain metastases may include whole brain radiotherapy wbrt radiosurgery rs gamma_knife linear_accelerator linac or equivalent or combination as deemed appropriate by the treating physician patients with cns metastases treated by neurosurgical resection or brain biopsy performed within three months prior to day one will be excluded
__label__1	study interventions are Tesmilifene . metastatic breast cancer diagnosis and patients with clinically significant cardiovascular pulmonary renal endocrine hepatic respiratory neurologic psychiatric immunologic gastrointestinal haematologic metabolic or any other condition or laboratory abnormality that in the opinion of the investigator or medical director of ym biosciences inc
__label__1	study interventions are Sirolimus . stage ivc lip and oral cavity squamous cell carcinoma diagnosis and patients with known active brain metastases should be excluded from this clinical trial patients with treated brain metastases stable for greater_than equal_than twelve weeks are eligible
__label__1	study interventions are Bevacizumab . clear cell renal cell carcinoma diagnosis and patients with known brain metastases should be excluded because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Fluorouracil . breast cancer diagnosis and patients with other concurrent severe and or uncontrolled medical disease or infection which could compromise participation in the study
__label__1	study interventions are Gemcitabine . sarcoma diagnosis and patients with previous exposure to therapy with gemcitabine are allowed in the study
__label__1	study interventions are Etoposide phosphate . recurrent small lymphocytic lymphoma diagnosis and current serious systemic illness
__label__1	study interventions are Immunoglobulins . stage iii adult lymphoblastic lymphoma diagnosis and pregnancy or active nursing of an infant
__label__1	study interventions are Carotenoids . allergy to tomato based products
__label__1	study interventions are study of high risk factors . active invasive malignancy in any site except basal cell or squamous cell skin cancer
__label__1	study interventions are Interferon-alpha . carcinoma renal cell diagnosis and patients who have previously received systemic mtor inhibitors
__label__1	study interventions are Fludarabine phosphate . recurrent adult hodgkin lymphoma diagnosis and pregnancy
__label__1	study interventions are Ureteral Stent . tumor diagnosis and patients requiring ureteral stents bilaterally same reason as above
__label__1	study interventions are Carboplatin . ovarian serous cystadenocarcinoma diagnosis and patients who have received more than one previous regimen of chemotherapy maintenance is not considered second regimen
__label__1	study interventions are Bendamustine Hydrochloride . recurrent small lymphocytic lymphoma diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens including but not limited to the following
__label__1	study interventions are Sunitinib . advanced solid tumors diagnosis and cardiac arrhythmias requiring anti arrhythmic therapy beta blockers or digoxin are permitted
__label__1	study interventions are Poly ICLC . cutaneous cell lymphoma diagnosis and uncontrolled hypertension defined as systolic blood pressure bp greater_than one hundred and fifty mmhg or diastolic bp greater_than ninety mmhg
__label__1	study interventions are Cyclosporine . small intestine lymphoma diagnosis and patient has central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and liver diseases combined with an elevation of transaminases and of bilirubin of three times above normal
__label__1	study interventions are Cediranib . endometrial adenosquamous carcinoma diagnosis and patients undergoing invasive procedures as defined below
__label__1	study interventions are Ribociclib . stage iv prostate cancer diagnosis and administration of antifungal agents itraconazole fluconazole etc within four weeks of enrollment or unrecovered aes due to agents administered more than four weeks of enrollment
__label__1	study interventions are Paclitaxel . solid tumors diagnosis and clinically significant resting bradycardia less_than fifty bpm
__label__1	study interventions are Aromatase Inhibitors . metastatic breast cancer diagnosis and known human immunodeficiency virus infection
__label__1	study interventions are Bortezomib . small lymphocytic lymphoma diagnosis and patients with hypersensitivity to bortezomib boron or mannitol
__label__1	study interventions are therapeutic conventional surgery . stage iva squamous cell carcinoma of the oropharynx diagnosis and serum creatinine greater_than two mg dl
__label__1	study interventions are Pembrolizumab . soft tissue sarcoma diagnosis and patients with previous exposure to anti programmed cell death pd one or anti programmed cell death ligand one pdl one will not be eligible
__label__1	study interventions are Questionnaire Administration . primary cutaneous anaplastic large cell lymphoma diagnosis and patients with any form of feeding tube or swallowing disorder are not eligible
__label__1	study interventions are BB 1101 . stage iii multiple myeloma diagnosis and grade three neuropathy
__label__1	study interventions are Cetuximab . stage iii squamous cell carcinoma of the nasopharynx diagnosis and clinically significant ophthalmologic disease defined as
__label__1	study interventions are Docetaxel . recurrent prostate carcinoma diagnosis and currently receiving active therapy for other neoplastic disorders
__label__1	study interventions are Cyclosporine . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Alovudine . stage iv squamous cell carcinoma of the hypopharynx diagnosis and patients with known syndromes that alter radiosensitivity
__label__1	study interventions are Sorafenib . recurrent squamous cell carcinoma of the nasopharynx diagnosis and known hiv positive patients will be excluded from trial due to the potential immune modulation that these agents may cause
__label__1	study interventions are Vinorelbine . uncontrolled inter current illness including but not limited to ongoing or active infection symptomatic congestive heart failure uncontrolled hypertension unstable angina pectoris cardiac arrhythmia serious non healing wound ulcer bone fracture or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Carboplatin . triple negative breast cancer diagnosis and history of major organ allograft or condition requiring chronic immunosuppression kidney liver lung heart bone marrow transplant or autoimmune diseases this includes treatment with corticosteroids within one month dose of greater_than equal_than ten mg day methylprednisolone equivalent excluding inhaled steroids patients who have received corneal transplants cadaver skin or bone transplants are eligible
__label__1	study interventions are educational intervention . endometrial carcinoma diagnosis and severe musculoskeletal disease
__label__1	study interventions are Capecitabine . breast cancer diagnosis and clinically significant electrocardiogram ecg abnormality including marked baseline prolongation of qt qtc interval time between the start of the q_wave and the end of the wave qt interval corrected for heart rate repeated demonstration of qtc interval greater than five hundred ms
__label__1	study interventions are Dexamethasone 21-phosphate . plasmacytoma diagnosis and ongoing or active systemic infection or active hepatitis or virus infection
__label__1	study interventions are Etoposide phosphate . recurrent childhood non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Mycophenolate mofetil . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and liver function abnormalities
__label__1	study interventions are Short-term fasting . breast cancer diagnosis and medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent
__label__1	study interventions are Bevacizumab . esophageal cancer diagnosis and pregnant or breast feeding
__label__1	study interventions are Fludarabine . refractory multiple myeloma diagnosis and pregnancy
__label__1	study interventions are Pembrolizumab . thyroid gland oncocytic follicular carcinoma diagnosis and known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Vinblastine . neoplasms connective and soft tissue diagnosis and does not satisfy the criteria of eligibility
__label__1	study interventions are Antibodies, Monoclonal . stage ivb squamous cell carcinoma of the larynx diagnosis and note
__label__1	study interventions are Mycophenolic Acid . lymphoma non hodgkin diagnosis and patients known to be human immunodeficiency virus hiv positive are ineligible because the concern for opportunistic infection and hematologic reserve are considered to be significantly greater in this population
__label__1	study interventions are Immunoglobulins . stage iiib uterine corpus cancer diagnosis and prior treatment with sorafenib or other vascular endothelial growth factor vegf inhibitors note
__label__1	study interventions are Lenograstim . recurrent diffuse large cell lymphoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Ceritinib . in case of oophorectomy alone only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
__label__1	study interventions are Evaluation of the Tomosynthesis . mammary tumor diagnosis and patients with indications against the achievement of mri mammography and tomosynthesis
__label__1	study interventions are Fluorouracil . stage iva colon cancer diagnosis and inadequately controlled hypertension systolic blood pressure of greater_than one hundred and fifty mmhg or diastolic pressure greater_than one hundred mmhg on anti hypertensive medications
__label__1	study interventions are pegfilgrastim . non hodgkin lymphoma diagnosis and active infection requiring treatment with systemic anti infectives within seventy-two hours of chemotherapy
__label__1	study interventions are Bevacizumab . stage iiic esophageal cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to study enrollment
__label__1	study interventions are Trametinib . melanoma and brain metastases diagnosis and specific criteria have to be met
__label__1	study interventions are Prednisolone acetate . neoplasm of the breast diagnosis and patient has history of another primary malignancy with the exceptions of
__label__1	study interventions are Leuprolide . prostatic neoplasm diagnosis and systemic immunosuppressive therapy
__label__1	study interventions are Endothelial Growth Factors . malignant pancreatic insulinoma diagnosis and patients on an active liver transplant list and considered likely to receive liver transplant equal_than less_than six months following registration
__label__1	study interventions are musculoskeletal complications management/prevention . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and current or previous bisphosphonate use
__label__1	study interventions are Cyclosporins . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and patients with evidence of hepatitis or hepatitis pcr positivity hepatitis reactivation following myelosuppressive therapy can lead to fatal complications
__label__1	study interventions are Tacrolimus . noncontiguous stage ii grade two follicular lymphoma diagnosis and patients with active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Vidarabine . aggressive non hodgkin lymphoma diagnosis and any prior myeloablative transplant within the last six months
__label__1	study interventions are Cyclophosphamide . childhood pleomorphic rhabdomyosarcoma diagnosis and patients with uncontrolled hypertension are ineligible uncontrolled hypertension is defined as follows
__label__1	study interventions are Letrozole . endometrial carcinoma diagnosis and patients receiving chronic systemic treatment with corticosteroids or another immunosuppressive agent
__label__1	study interventions are Mitomycins . anal canal cancer diagnosis and hiv positive with result of cdfour less_than two hundred
__label__1	study interventions are Mitogens . male breast cancer diagnosis and uncontrolled systemic disease clinically significant cardiac pulmonary or metabolic disease
__label__1	study interventions are Tamoxifen . chemotherapy or endocrine therapy for breast cancer in last five years
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and have an active infection or ongoing treatment for systemic infection ongoing treatment does not include prophylactic anti infectives chest ray suggestive of tuberculosis or history risk of chronic latent infection that may reactivate in the presence of study therapy
__label__1	study interventions are Dihydromevinolin . ovarian cancer diagnosis and other serious illnesses which would limit survival to less_than two years or psychiatric condition which would prevent compliance with treatment or informed consent
__label__1	study interventions are Trastuzumab . advanced breast cancer diagnosis and cardiomyopathy congestive hypertrophic or restrictive
__label__1	study interventions are Immunosuppressive Agents . stage mantle cell lymphoma diagnosis and patient or donor with history of hepatitis or and or positive serology consistent with previous hepatitis or infection patients and or donor who received hepatitis vaccination are acceptable
__label__1	study interventions are tumor tissue samples will be requested . pancreatic ductal adenocarcinoma diagnosis and not willing to provide blood samples for correlative studies
__label__1	study interventions are Antibodies . pancreatic alpha cell adenoma diagnosis and untreated central nervous system cns metastases exceptions
__label__1	study interventions are Misonidazole . metastatic pancreatic adenocarcinoma diagnosis and patients who have received prior inhibitor of vegf signaling and poly_adp ribose_polymerases parp inhibitor administered in combination unless administered in combination patients who received prior parp inhibitor or prior vegf signaling inhibitor agent are allowed after discussing with the pi
__label__1	study interventions are Cyclosporine . noncontiguous stage ii adult burkitt lymphoma diagnosis and donor
__label__1	study interventions are Prehabilitation (PREHAB) . prostate cancer patients undergoing radical prostatectomy diagnosis and severe coronary artery disease canadian cardiovascular society class iii or greater
__label__1	study interventions are Bortezomib . ovarian endometrioid adenocarcinoma diagnosis and concomitant medications known to inhibit or induce cytochrome pfour hundred and fifty family three subfamily polypeptide four threeafour are to be avoided
__label__1	study interventions are nasal brushing . lung cancer diagnosis and minors
__label__1	study interventions are Nivolumab . melanoma diagnosis and history of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibody
__label__1	study interventions are Fludarabine phosphate . stage adult diffuse mixed cell lymphoma diagnosis and patient with rapidly progressive aggressive nhl unless in minimal disease state
__label__1	study interventions are Paclitaxel . ovarian neoplasms diagnosis and have hepatic dysfunction eg bilirubin more than doc times higher than normal levels lactate dehydrogenase ldh serum glutamic oxaloacetic transaminase sgot and serum glutamic pyruvic transaminase sgpt doubled compared to normal or albumin less_than doc dl
__label__1	study interventions are OTX015/MK-8628 . triple negative breast cancer diagnosis and other serious illness or medical conditions such as active infection unresolved bowel obstruction or psychiatric disorders
__label__1	study interventions are Retroviral vector-transduced autologous T cells to express CD22-specific CARs . recurrent adult diffuse large cell lymphoma diagnosis and female study participants of reproductive potential must have negative serum or urine pregnancy test performed within forty-eight hours before infusion
__label__1	study interventions are Carboplatin . gastric stomach cancer diagnosis and any prior history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Tremelimumab . recurrent ovarian carcinoma diagnosis and known history of previous clinical diagnosis of tuberculosis
__label__1	study interventions are Bevacizumab . fallopian tube clear cell adenocarcinoma diagnosis and cerebral vascular accident cva or transient ischemic attack tia within six months
__label__1	study interventions are Letrozole . recurrent ovarian carcinoma diagnosis and history or evidence of current clinically significant uncontrolled arrhythmias
__label__1	study interventions are Vaccines . prevention of human papillomavirus infection diagnosis and allergy to any component of the hpv vaccine including yeast and aluminum
__label__1	study interventions are Light touch therapy . cancer related fatigue diagnosis and people unable to read and understand the informed consent document because of language difficulties
__label__1	study interventions are Fotemustine . symptomatic brain metastases requiring immediate local intervention radiotherapy rt and or surgery
__label__1	study interventions are Prednisolone acetate . other prior malignancies except curatively treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
__label__1	study interventions are Liposomal doxorubicin . metastatic cancer diagnosis and any contraindication for hepatic embolization procedures including any of the following
__label__1	study interventions are Vidarabine . recurrent marginal zone lymphoma diagnosis and active central nervous system malignancy
__label__1	study interventions are Interferons . ovarian cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Immunoglobulins . stage ivb oral cavity squamous cell carcinoma diagnosis and patients with body weight less_than equal_than thirty kg
__label__1	study interventions are Vidarabine . stage iv adult diffuse large cell lymphoma diagnosis and known allergy to filgrastim csf
__label__1	study interventions are Docetaxel . stage iiib breast cancer diagnosis and phase i
__label__1	study interventions are Pertuzumab . breast cancer female nos diagnosis and currently active infection
__label__1	study interventions are Fluorouracil . bladder cancer diagnosis and overt psychosis or mental disability or otherwise incompetent to give informed consent
__label__1	study interventions are proton beam therapy . postoperative residual or recurrent tumor evidence of distant metastases previous irradiation for the tumor in the same location adjuvant anti androgenic hormonal therapy high risk group nccn guide line
__label__1	study interventions are Vatalanib . recurrent non small cell lung cancer diagnosis and unstable angina myocardial infarction equal_than less_than six months prior to registration serious uncontrolled cardiac arrhythmia uncontrolled diabetes
__label__1	study interventions are Carboplatin . stage iiib uterine corpus cancer diagnosis and hemoglobin less_than doc dl the patient may be transfused prior to study entry
__label__1	study interventions are Theliatinib . cancer diagnosis and patients unable to comply with the protocol since significant psychological or psychogenic abnormal
__label__1	study interventions are Antibodies . previously treated childhood rhabdomyosarcoma diagnosis and systolic blood pressure greater_than equal_than one hundred and sixty mm hg and or diastolic blood pressure greater_than equal_than ninety mm hg that is not controlled by one antihypertensive medication
__label__1	study interventions are Ergocalciferols . adenomas diagnosis and any diagnosis of severe liver disease cirrhosis
__label__1	study interventions are Cisplatin . non small cell lung carcinoma diagnosis and presence of fluid retention that cannot be controlled by drainage
__label__1	study interventions are Hemostatics . benign ovarian tumor diagnosis and serious concomitant systemic disorders incompatible with the study at the discretion of the investigator
__label__1	study interventions are Veliparib . gastric cancer diagnosis and subjects that are being treated with ketoconazole enzyme inducing anticonvulsants and or st
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and poems polyneuropathy_organomegaly endocrinopathy monoclonal gammopathy and skin changes syndrome
__label__1	study interventions are Doxorubicin . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and known hiv infection due to expected frequent occurrence of myelo suppression and immunosuppression
__label__1	study interventions are Cisplatin . urothelial carcinoma diagnosis and has history or current evidence of any condition therapy or laboratory abnormality that might confound the results of the trial interfere with the subject participation for the full duration of the trial or is not in the best interest of the subject to participate in the opinion of the treating investigator
__label__1	study interventions are Gemcitabine . has nonsquamous nsclc adenocarcinoma large cell or other
__label__1	study interventions are Docetaxel . head and neck squamous cell carcinoma diagnosis and active infection
__label__1	study interventions are Vidarabine . peripheral cell lymphoma diagnosis and cardiac ejection fraction less_than forty ejection fraction is required if the patient has history of anthracyclines or history of cardiac disease
__label__1	study interventions are AZD6244 . non squamous cell lung cancer with kras mutations diagnosis and john wort carbamazepine dexamethasone primidone griseofulvin carbamazepine barbiturates troglitazone pioglitazone oxcarbazepine nevirapine efavirenz rifabutin three week minimum wash out period and phenobarbitone five week minimum wash out period
__label__1	study interventions are Levoleucovorin . advanced adult primary liver cancer diagnosis and pregnancy or breastfeeding
__label__1	study interventions are Radiation and chemotherapy . previous systemic chemotherapy for any cancer or pelvic radiation therapy
__label__1	study interventions are Bevacizumab . metastatic renal cell carcinoma diagnosis and patients with brain metastasis treated or untreated or other cns disease
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and pregnant or nursing women
__label__1	study interventions are CT Abdomen and Pelvis scan . squamous cell carcinoma diagnosis and inability to lie supine for imaging with pet ct
__label__1	study interventions are Acetylcysteine . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and greater than or equal to grade two dry mouth prior to chemoradiotherapy or greater than or equal to grade two mucositis
__label__1	study interventions are Aldesleukin . anal cancer diagnosis and history of severe immediate hypersensitivity reaction to any of the agents used in this study
__label__1	study interventions are Isophosphamide mustard . inflammatory myofibroblastic tumor diagnosis and patients chronically receiving medications known to be metabolized by cypthreeafour and with narrow therapeutic indices within seven days prior to study enrollment including but not limited to pimozide_aripiprazole triazolam_ergotamine and halofantrine are not eligible note
__label__1	study interventions are IPOP (post-operative) . non muscle invasive bladder cancer diagnosis and pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study hormonal mechanical contraceptive
__label__1	study interventions are Antibodies, Monoclonal . contiguous stage ii marginal zone lymphoma diagnosis and patient is currently enrolled in or has not yet completed at least thirty days since ending another investigational device or drug trial
__label__1	study interventions are Illinois bone marrow aspiration neddle . non small cell lung cancer diagnosis and patients receiving immunomodulatory drugs tacrolimus
__label__1	study interventions are Everolimus . advanced gastric cancer diagnosis and any other severe and or uncontrolled medical conditions
__label__1	study interventions are Pancrelipase . twond line threerd line and greater metastatic pancreatic cancer diagnosis and valvular heart disease that requires antibiotic prophylaxis for prevention of endocarditis
__label__1	study interventions are Paclitaxel . ovarian cancer diagnosis and active infection or other serious underlying medical condition which might prevent the patient from receiving treatment or to be followed
__label__1	study interventions are Cyclophosphamide . stage adult diffuse large cell lymphoma diagnosis and patient or donor with active hepatitis or and or detectable viral ribonucleic acid rna
__label__1	study interventions are SAR260301 . neoplasm malignant diagnosis and mean qtc interval greater_than four hundred and seventy msec using qtcf formula or any clinically significant qtc prolongation history of torsade de pointes or malignant arrhythmias or conduction disturbances
__label__1	study interventions are Rituximab . lymphoma diagnosis and acute infection requiring treatment iv antibiotics antivirals or antifungals within fourteen days prior to initiation of study
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are Cisplatin . stage iv squamous cell carcinoma of the oropharynx diagnosis and evidence of clinically significant congestive heart failure patients must be able to tolerate hydration with cisplatin
__label__1	study interventions are Iodine . non hodgkin lymphoma diagnosis and disease better treated with limited field therapy
__label__1	study interventions are TKI258 . advanced metastatic renal cell cancer diagnosis and diabetes mellitus with signs of clinically significant peripheral vascular disease
__label__1	study interventions are Ifosfamide . lymphoma large cell diffuse diagnosis and not previously treated with anthracycline containing regimens
__label__1	study interventions are Antibodies . recurrent small lymphocytic lymphoma diagnosis and failed stem cell collection
__label__1	study interventions are As usual . lung cancer diagnosis and seventy-nine years
__label__1	study interventions are Irinotecan . recurrent adult brain tumor diagnosis and patient is homozygous or heterozygous for the udp glycosyltransferase one family polypeptide aone twenty-eight allele ugt oneaone twenty-eight allele and or has gilbert disease
__label__1	study interventions are Sorafenib . stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and subject with any pulmonary hemorrhage bleeding event of nci ctcae doc grade two or higher within four weeks before randomization any other hemorrhage bleeding event of nci ctcae doc grade three or higher within four weeks before randomization
__label__1	study interventions are Immunoglobulin G . stage iiib uterine corpus cancer diagnosis and patients who had surgical resection of cns metastases or brain biopsy equal_than less_than three months prior to registration will be excluded
__label__1	study interventions are Mocetinostat . squamous cell carcinoma head and neck diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Ixazomib . diagnosis of smoldering multiple myeloma waldenstrom macroglobulinemia poems syndrome plasma cell leukemia primary amyloidosis myelodysplastic syndrome or myeloproliferative syndrome
__label__1	study interventions are Liposomal doxorubicin . metastatic malignant peripheral nerve sheath tumor diagnosis and histologic diagnosis for which single agent doxorubicin is not appropriate therapy including but not limited to
__label__1	study interventions are Prednisone . multiple myeloma diagnosis and if the test is positive the patient must be excluded from the study
__label__1	study interventions are Cyclosporine . peripheral cell lymphoma diagnosis and lansky play performance score less_than fifty for pediatric patients
__label__1	study interventions are Paclitaxel . esophageal cancer diagnosis and history of hypersensitivity to nab paclitaxel capecitabine or oxaliplatin
__label__1	study interventions are Liposomal doxorubicin . follicular lymphoma diagnosis and patient has calculated or measured creatinine clearance of less_than twenty ml minute within fourteen days before enrollment
__label__1	study interventions are DCE MRI . metastatic liver cancer diagnosis and presence of mri incompatible metallic objects or implanted medical devices in body
__label__1	study interventions are Vaccines . infections papillomavirus diagnosis and previous vaccination against hpv or planned administration of any hpv vaccine other than that foreseen by the study protocol during the study period up to month twenty-four
__label__1	study interventions are Dacarbazine . stage iv skin melanoma diagnosis and patients must be able to swallow tablets
__label__1	study interventions are Paclitaxel . epithelial ovarian cancer diagnosis and evidence of interstitial lung disease or active non infectious pneumonitis
__label__1	study interventions are ispinesib . stage iva colon cancer diagnosis and nefazodone_fluovoxamine
__label__1	study interventions are Camptothecin . stage iiib colon cancer diagnosis and unstable angina pectoris
__label__1	study interventions are Fludarabine phosphate . stage iv adult immunoblastic lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than forty total lung capacity tlc less_than forty forced expiratory volume in one second fevone less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Fluorodeoxyglucose F18 . esophageal carcinoma squamous cell carcinoma adenocarcinoma diagnosis and distant metastases organ
__label__1	study interventions are SBRT . metastatic renal cell carcinoma diagnosis and grade three and four toxicity of targeted therapy
__label__1	study interventions are Albumin-Bound Paclitaxel . melanoma diagnosis and radiation therapy within fourteen days prior to day one
__label__1	study interventions are Fluphenazine . multiple myeloma diagnosis and treatment with hematopoietic growth factors may be started during the study with development or worsening of cytopenia
__label__1	study interventions are Bevacizumab . stage iiib colon cancer diagnosis and leptomeningeal disease
__label__1	study interventions are Estrogens . inflammatory carcinoma defined as peau orange affecting at least one third of the breast
__label__1	study interventions are Cisplatin . nasal and nasal type nk cell lymphoma diagnosis and serious infection
__label__1	study interventions are Fluorouracil . colorectal carcinoma diagnosis and has an acute subacute bowel obstruction or history of clinically significant chronic diarrhea
__label__1	study interventions are Vidarabine . anaplastic large cell lymphoma diagnosis and uncontrolled viral or bacterial infection at the time of study enrollment
__label__1	study interventions are Bevacizumab . fallopian tube serous adenocarcinoma diagnosis and serious cardiac arrhythmia requiring medication
__label__1	study interventions are Veliparib . ovarian serous cystadenocarcinoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with bevacizumab
__label__1	study interventions are Peginterferon alfa-2b . melanoma diagnosis and autoimmune or immunosuppressive disorders hiv or aids related illness
__label__1	study interventions are Cyclosporine . contiguous stage ii grade three follicular lymphoma diagnosis and pregnant women are excluded from this study because vorinostat is histone_deacetylase inhibitor agent with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat breastfeeding should be discontinued if the mother is treated with vorinostat
__label__1	study interventions are Everolimus . hormone receptor positive tumor diagnosis and patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cypthreea within the last five days prior to enrollment
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and prior resection of the papilla of vater whipple procedure or bile duct stent across the papilla
__label__1	study interventions are Immunoglobulins . stage iic fallopian tube cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Mycophenolate mofetil . recurrent mantle cell lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for granulocyte colony stimulating factor csf mobilization and harvest of peripheral blood stem cell pbsc
__label__1	study interventions are Bevacizumab . advanced gastrointestinal cancer diagnosis and evidence of bleeding diathesis or clinically significant coagulopathy
__label__1	study interventions are Antibodies, Bispecific . gastric adenocarcinoma with peritoneal carcinomatosis diagnosis and women of childbearing potential must have negative pregnancy test performed within seven days of the start of treatment
__label__1	study interventions are Sorafenib . stage ivb squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and evidence or history of bleeding diathesis or coagulopathy
__label__1	study interventions are Nivolumab . metastatic melanoma diagnosis and subjects are permitted to enroll if they have vitiligo type diabetes mellitus residual hypothyroidism due to autoimmune condition only requiring hormone replacement psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and hemoglobin
__label__1	study interventions are Metformin . lung neoplasms diagnosis and similarly any unstable medical condition that in the opinion of the treating physician or study investigators would interfere with the study objectives
__label__1	study interventions are Sirolimus . solid tumors diagnosis and impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption inflammatory bowel disease uncontrolled nausea vomiting diarrhea malabsorption syndrome or significant small bowel resection
__label__1	study interventions are Liposomal doxorubicin . ovarian tumor diagnosis and are pregnant or nursing
__label__1	study interventions are Dacarbazine . advanced milignant gliomas diagnosis and progressed while on temozolomide
__label__1	study interventions are Epothilones . recurrent adult soft tissue sarcoma diagnosis and any of the following as the effects of epothilone analog bms two hundred and forty-seven thousand, five hundred and fifty on the developing fetus or nursing child at the recommended therapeutic dose are unknown
__label__1	study interventions are Cyclosporine . stage iii marginal zone lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Etoposide phosphate . lung cancer diagnosis and is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with the pre screening or screening visit through one hundred and twenty days after the last dose of trial treatment
__label__1	study interventions are Maytansine . stage ib breast cancer diagnosis and four weeks of tamoxifen therapy or other hormonal therapy for adjuvant therapy for this malignancy
__label__1	study interventions are Pemetrexed . mesothelioma diagnosis and pemetrexed cisplatin and sorafenib are pregnancy category d
__label__1	study interventions are Cisplatin . head and neck cancer diagnosis and major surgery open biopsy or significant traumatic injury within four weeks of first study drug
__label__1	study interventions are Antibodies, Monoclonal . metastatic melanoma diagnosis and creatinine greater_than twox uln bilirubin greater_than three wbc less_than three500 platelets less_than one hundred zero hgb less_than nine
__label__1	study interventions are Mycophenolate mofetil . stage iii mantle cell lymphoma diagnosis and age greater_than seventy-five years
__label__1	study interventions are Oxaliplatin . stage ?b pancreatic cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biological composition to the drugs
__label__1	study interventions are Cediranib . primary peritoneal serous adenocarcinoma diagnosis and prior use of parp inhibitors
__label__1	study interventions are Dexamethasone acetate . lymphoma non hodgkin diagnosis and active heart disease congestive heart failure or heart block greater than first degree on ekg
__label__1	study interventions are Immunoglobulins . refractory lymphoblastic lymphoma diagnosis and hiv antibody positive
__label__1	study interventions are Cyclosporine . childhood burkitt lymphoma diagnosis and patient has central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Busulfan . stage ii childhood hodgkin lymphoma diagnosis and patients receiving any medications or substances that are inhibitors or inducers of specify cytochrome pfour hundred and fifty cypfour hundred and fifty enzyme will be eligible for the study at the discretion of the consenting physician
__label__1	study interventions are Get up and Go test . bladder cancer requiring cystectomy diagnosis and pregnancy
__label__1	study interventions are Carboplatin . melanoma diagnosis and organ transplantation history
__label__1	study interventions are 10-deazaaminopterin . peripheral cell lymphoma diagnosis and cell
__label__1	study interventions are Dexamethasone . myeloma diagnosis and known hypersensitivity to thalidomide lenalidomide and dexamethasone
__label__1	study interventions are 851B . papillomavirus infections diagnosis and the subject has history of alcoholism or substance abuse within one year or has current alcohol or substance abuse as assessed by the investigator
__label__1	study interventions are Dexamethasone . stage ii lymphoblastic lymphoma diagnosis and patients receiving prior steroid therapy may be eligible for aallnine hundred and thirty-two
__label__1	study interventions are Fludarabine . relapsed or refractory neuroblastoma diagnosis and airway compromise by direct tumoural invasion or compression
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent thyroid gland carcinoma diagnosis and minor surgery equal_than less_than one months of the first dose of cabozantinib if there were no wound healing complications or equal_than less_than three months of the first dose of cabozantinib if there were wound complications
__label__1	study interventions are SM04755 . colorectal cancer diagnosis and subjects with certain medical conditions
__label__1	study interventions are Vincristine . multiple myeloma diagnosis and or unstable angina uncontrolled hypertension or cardiac arrythmias or myocardial infarction within the last six months
__label__1	study interventions are Liposomal doxorubicin . inflammatory breast cancer diagnosis and inadequate general condition not fit for dose dense dose intensified anthracycline taxane targeted agents based chemotherapy
__label__1	study interventions are Albumin-Bound Paclitaxel . squamous non small cell lung cancer diagnosis and chest irradiation within twelve weeks prior to randomization except palliative irradiation of bone lesions which is allowed
__label__1	study interventions are Isophosphamide mustard . brain and central nervous system tumors diagnosis and infection
__label__1	study interventions are Paclitaxel . pulmonary large cell neuroendocrine carcinoma diagnosis and pregnant or lactating
__label__1	study interventions are Prednisone . other concurrent anticancer agents or treatments
__label__1	study interventions are Cyclosporins . recurrent mantle cell lymphoma diagnosis and donor
__label__1	study interventions are Antibodies . recurrent primary peritoneal carcinoma diagnosis and participant has clinically significant cardiovascular disease including
__label__1	study interventions are Sunitinib . platinum refractory epithelial ovarian cancer diagnosis and ongoing cardiac dysrhythmias of nci ctcae grade greater_than equal_than two atrial fibrillation of any grade or prolongation of the qtc interval to greater_than four hundred and seventy msec for females
__label__1	study interventions are Prednisolone phosphate . prostate cancer diagnosis and treatment within four weeks before randomization and or whilst on study treatment with the following
__label__1	study interventions are Saracatinib . stage iv colon cancer diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are GSK690693 . cancer diagnosis and any serious or unstable pre existing medical psychiatric or other condition including lab abnormalities that could interfere with subject safety or with obtaining informed consent
__label__1	study interventions are Olaparib . non small cell lung cancer diagnosis and patients receiving the following classes of inhibitors of cypthreeafour see appendix five for guidelines and wash out periods
__label__1	study interventions are Binimetinib . relapsed or refractory multiple myeloma diagnosis and serum creatinine greater_than two uln or calculated or directly measured crcl less_than forty-five ml min patients with creatinin clearance between thirty forty-five ml min can be enrolled with approval by the coordinating investigator
__label__1	study interventions are Gemcitabine . breast cancer diagnosis and if you do not qualify for the trial study personnel will explain the reasons
__label__1	study interventions are Gefitinib . pancreatic polypeptide tumor diagnosis and congenital abnormality
__label__1	study interventions are Binimetinib . relapsed or refractory multiple myeloma diagnosis and impaired cardiovascular function or clinical significant cardiovascular disease including any of the following
__label__1	study interventions are Immunoglobulins . clear cell renal cell carcinoma diagnosis and inadequately controlled hypertension htn systolic blood pressure sbp greater_than one hundred and sixty mmhg and or diastolic blood pressure dbp greater_than ninety mmhg despite antihypertensive medication
__label__1	study interventions are Poly I-C . non melanoma skin cancers diagnosis and aids defined as cdfour cluster of differentiation four count less then two hundred in the context of hiv sero positivity or chronically is taking immunosuppressive medication such as steroids or transplant related medications
__label__1	study interventions are Niacinamide . colorectal neoplasms diagnosis and patients taking chronic erythropoietin are permitted provided no dose adjustment is undertaken within two months prior to the study or during the study
__label__1	study interventions are Thalidomide . stage small lymphocytic lymphoma diagnosis and new york heart association classification iii or iv cardiovascular disease
__label__1	study interventions are Antibodies, Monoclonal . stage iii prostate cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury within
__label__1	study interventions are Albumin-Bound Paclitaxel . triple negative breast carcinoma diagnosis and any continued use of sex hormonal therapy birth control pills ovarian hormone replacement therapy patients are eligible if these medications are discontinued prior to randomization
__label__1	study interventions are Trastuzumab . gastric cancer diagnosis and unwillingness to give written informed consent unwillingness to participate or inability to comply with the protocol for the duration of the study
__label__1	study interventions are Cyclophosphamide . t cell non hodgkin lymphoma diagnosis and active or recent prior six month invasive fungal infection without infectious disease id consult and approval
__label__1	study interventions are Epirubicin . gastric cancer diagnosis and alat or aspat or alp greater_than doc
__label__1	study interventions are WBI . breast cancer diagnosis and unable to commence within eight weeks of the last dose of chemotherapy
__label__1	study interventions are laboratory biomarker analysis . recurrent renal cell cancer diagnosis and known or suspected primary muscular or neuromuscular disease muscular dystrophy myasthenia_gravis
__label__1	study interventions are Bevacizumab . mucinous adenocarcinoma of the colon diagnosis and less than one hundred and twenty days elapsed time between chemotherapy treatment for adjuvant disease and enrollment onto this protocol or less than twenty-eight days between therapy for metastatic disease and enrollment onto this protocol
__label__1	study interventions are Sirolimus . soft tissue sarcoma diagnosis and uncontrolled systemic vascular hypertension
__label__1	study interventions are Antilymphocyte Serum . small lymphocytic lymphoma diagnosis and active central nervous system cns involvement by malignant cells
__label__1	study interventions are Bevacizumab . stage iia colon cancer diagnosis and isolated distant or non contiguous intra abdominal metastases even if resected
__label__1	study interventions are Antibodies, Monoclonal . stage iii hypopharyngeal squamous cell carcinoma diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Tacrolimus . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and cross match positive with recipient
__label__1	study interventions are Immunoglobulins . ovarian serous adenocarcinoma diagnosis and has known history of human immunodeficiency virus hiv hiv one two antibodies
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma non small cell lung diagnosis and patients requiring daily finger stick blood glucose measurements
__label__1	study interventions are Aminopterin . human mammary carcinoma diagnosis and prior radiation therapy on more than thirty of bone marrow reserve or prior bone marrow stem cell transplantation
__label__1	study interventions are BKM120 . melanoma diagnosis and clinically significant resting bradycardia
__label__1	study interventions are Capecitabine . breast cancer diagnosis and previous chemotherapy for metastatic disease concurrent immunotherapy or hormonal therapy antihormonal contraceptive and or replacement therapy
__label__1	study interventions are Carboplatin . stage iiib breast cancer diagnosis and definitive clinical or radiologic evidence of metastatic disease chest imaging mandatory for all patients and other imaging if required must have been performed within ninety days prior to randomization
__label__1	study interventions are Paclitaxel . early primary breast cancer in the elderly diagnosis and previous or concurrent treatment with cytotoxic agents for any reason after consultation with the sponsor
__label__1	study interventions are Docetaxel . esophageal cancer diagnosis and interstitial lung diseases for example
__label__1	study interventions are Etoposide phosphate . aids related diffuse mixed cell lymphoma diagnosis and history of hiv associated encephalopathy dementia of any kind seizures in the past twelve months any perceived inability to directly provide informed consent note
__label__1	study interventions are Mycophenolic Acid . stage ii multiple myeloma diagnosis and donor
__label__1	study interventions are Carmustine . stage iii grade three follicular lymphoma diagnosis and patient has greater_than grade two peripheral neuropathy within fourteen days before enrollment
__label__1	study interventions are Temozolomide . recurrent childhood medulloblastoma diagnosis and patients must not have evidence of new cns hemorrhage on baseline mri obtained within fourteen days prior to study enrollment
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma in relapse diagnosis and known seropositive for or active viral infection with human immunodeficiency virus hiv
__label__1	study interventions are Brivanab . tumor spread to the brain
__label__1	study interventions are Vidarabine . peripheral cell lymphoma diagnosis and any current central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Antibodies . stage iv marginal zone lymphoma diagnosis and clinically active hepatitis b or infections note
__label__1	study interventions are Fludarabine phosphate . plasma cell myeloma diagnosis and cardiac ejection fraction less_than thirty-five or if unable to obtain ejection fraction shortening fraction of less_than twenty-six ejection fraction is required if the patient is greater_than fifty years of age or history of cardiac disease or anthracycline exposure patients with shortening fraction less_than twenty-six may be enrolled if approved by cardiologist
__label__1	study interventions are Doxorubicin . epithelioid malignant peripheral nerve sheath tumor diagnosis and pulmonary embolism untreated deep venous thrombosis dvt or dvt which has been treated with therapeutic anticoagulation for less than six weeks
__label__1	study interventions are Cetuximab . stage iv squamous cell carcinoma of the hypopharynx diagnosis and known hiv positive patients will be excluded from trial due to the potential immune modulation that these agents may cause
__label__1	study interventions are Vinblastine . solid tumors diagnosis and patients must have fully recovered from the effects of prior chemotherapy generally at least three weeks from the most recent administration six weeks for nitrosoureas
__label__1	study interventions are Levoleucovorin . stage ib gastric cancer diagnosis and major surgery equal_than less_than four weeks prior to registration
__label__1	study interventions are annual CT screening . lung cancer diagnosis and serious co morbidity with life expectancy below ten years
__label__1	study interventions are Endothelial Growth Factors . stage iib fallopian tube cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Endothelial Growth Factors . fallopian tube mucinous adenocarcinoma diagnosis and this criterion applies only to the patients enrolled before august twenty-nine two thousand and eleven and those enrolled after this date electing to receive bevacizumab patients who have had major surgical procedure open biopsy dental extractions or other dental surgery procedure that results in an open wound or significant traumatic injury within twenty-eight days prior to the first date of treatment on this study or anticipation of need for major surgical procedure during the course of the study patients with placement of vascular access device or core biopsy within seven days prior to the first date of treatment on this study
__label__1	study interventions are Gemcitabine . colorectal cancer diagnosis and patients should not have any immediate life threatening complications of their malignancies
__label__1	study interventions are Laboratory Biomarker Analysis . adult soft tissue sarcoma diagnosis and patients must not be receiving any of the following potent cypthreeafour inducers or inhibitors
__label__1	study interventions are Paclitaxel . non small cell lung cancer diagnosis and history of previous bone marrow and or stem cell transplantation
__label__1	study interventions are allogeneic hematopoietic stem cell transplantation . lymphoma diagnosis and not pregnant or nursing
__label__1	study interventions are Everolimus . malignant advanced solid tumors diagnosis and hypersensitivity to axitinib or everolimus
__label__1	study interventions are laboratory biomarker analysis . stage grade three follicular lymphoma diagnosis and removal or uterus or ovary ies pelvic irradiation cranial irradiation or hematopoietic stem cell transplantation are not eligible
__label__1	study interventions are Axitinib . stage iiib intraocular melanoma diagnosis and requirement of therapeutic anticoagulant therapy with oral vitamin antagonists low dose anticoagulants for maintenance of patency of central venous access devise or prevention of deep venous thrombosis is allowed therapeutic use of low molecular weight heparin or similar parenteral drug for venous thromboembolic disease is allowed
__label__1	study interventions are Carmustine . stage iii grade one follicular lymphoma diagnosis and prior to study entry any electrocardiogram ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are Niacinamide . recurrent verrucous carcinoma of the oral cavity diagnosis and any malabsorption condition
__label__1	study interventions are regorafenib . pulmonary carcinoid tumor diagnosis and presence of non healing wound non healing ulcer or bone fracture
__label__1	study interventions are Doxorubicin . lymphoma diagnosis and concurrent valproic acid
__label__1	study interventions are Maleic acid . nodal marginal zone cell lymphoma diagnosis and anticipation of need for major surgical procedures during the course of the study
__label__1	study interventions are Palbociclib . ovarian cancer diagnosis and ongoing or active infection requiring intravenous antibiotics at the time of treatment initiation
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . astrocytoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Ceritinib . metastatic pancreatic adenocarcinoma diagnosis and corrected qt qtc greater_than four hundred and fifty msec using fridericia correction on the screening electrocardiogram ecg
__label__1	study interventions are Trastuzumab . progesterone receptor negative breast cancer diagnosis and patients with cardiac disease that would preclude the use of adriamycin taxol or herceptin are not eligible
__label__1	study interventions are Tasquinimod . prostate cancer diagnosis and has received external radiotherapy within the last four weeks prior to start of study treatment
__label__1	study interventions are Etoposide . lymphoma diagnosis and see disease characteristics
__label__1	study interventions are Antilymphocyte Serum . multiple myeloma and plasma cell neoplasm diagnosis and diagnosis of cervical dysplasia cin iii
__label__1	study interventions are Fludarabine . multiple myeloma diagnosis and if donors do not meet institutional guidelines exclusion will be considered
__label__1	study interventions are Methotrexate . head and neck squamous cell cancer diagnosis and currently participating in or has participated in study of an investigational agent or using an investigational device within four weeks prior to randomization
__label__1	study interventions are Bevacizumab . solid tumors diagnosis and however if subject is at risk for having undiagnosed hepatitis virus hcv due to history of injection drug use or due to geographic location for example testing at screening should be considered
__label__1	study interventions are Isophosphamide mustard . refractory mediastinal thymic large cell cell lymphoma diagnosis and these patients are usually treated with cns directed therapy screening for cerebrospinal fluid csf cns involvement is not required but can be performed per treating medical doctor md discretion
__label__1	study interventions are Cetuximab . any concurrent malignancy other than non melanoma skin cancer or carcinoma in situ of the cervix
__label__1	study interventions are Bleomycin . therapy for kaposi sarcoma including interferons immunomodulators antiretroviral agents
__label__1	study interventions are Pembrolizumab . stage iv merkel cell carcinoma diagnosis and patient has had live vaccines within thirty days before the first dose of trial treatment and while participating in the trial examples of live vaccines include but are not limited to the following
__label__1	study interventions are Immunoglobulins . clear cell renal cell carcinoma diagnosis and current or recent within ten days of enrollment use of aspirin greater_than three hundred and twenty-five mg day or chronic use of other nonsteroidal anti inflammatory drugs nsaids
__label__1	study interventions are Niacinamide . recurrent adult primary liver cancer diagnosis and substance abuse medical psychological or social conditions that may interfere with the patient participation in the study or evaluation of the study results
__label__1	study interventions are Aromatase Inhibitors . breast cancer diagnosis and patient has participated in prior investigational study within thirty days prior to enrollment or within five half lives of the investigational product whichever is longer
__label__1	study interventions are Testosterone . prostate cancer diagnosis and any condition or situation which in the opinion of the investigator would put the subject at risk may confound study results or interfere with the subject participation in this study
__label__1	study interventions are Androgens . prostatic neoplasms diagnosis and subject has history of congestive heart failure new york heart association class ii or greater
__label__1	study interventions are Strattice . fibromatosis abdominal diagnosis and patients presenting for emergent hernia repair in the setting of bowel strangulation necrosis penetrating trauma as it will be difficult to consent those patients for the study preoperatively
__label__1	study interventions are Cyclosporins . stage childhood small noncleaved cell lymphoma diagnosis and history of brain metastases
__label__1	study interventions are Vaccines . non small cell lung carcinoma diagnosis and history of immune suppression or autoimmune disorder
__label__1	study interventions are Isophosphamide mustard . extraskeletal osteosarcoma diagnosis and inflammatory bowel disease ulcerative colitis crohn disease or other gastrointestinal conditions which increase the risk of perforation
__label__1	study interventions are Thalidomide . relapsed hodgkin lymphoma diagnosis and replacement therapy eg
__label__1	study interventions are Whole Brain Radiation Therapy . brain cancer diagnosis and post entry exclusion
__label__1	study interventions are Podophyllotoxin . mantle cell lymphoma diagnosis and patient has history of gastrointestinal surgery or other procedures that might in the opinion of the investigator interfere with the absorption or swallowing of the study drugs
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and major surgery within four weeks before randomization
__label__1	study interventions are Stereotactic body radiotherapy . carcinoma non small cell lung diagnosis and patients with mental illness considered as can fully understand the issues of this research
__label__1	study interventions are Dasatinib . endometrial mucinous adenocarcinoma diagnosis and patients who have an active pleural or pericardial effusion of any grade
__label__1	study interventions are Pharmacological Study . triple negative breast carcinoma diagnosis and they have no active bleeding or pathological condition that carries high risk of bleeding
__label__1	study interventions are Trastuzumab . recurrent colon cancer diagnosis and clinically significant autoimmune disease rheumatoid arthritis
__label__1	study interventions are Everolimus . advanced cancer diagnosis and uncontrolled brain metastases or malignancy
__label__1	study interventions are Imiquimod . colorectal carcinoma diagnosis and radiotherapy during and or following the twelve week first line oxaliplatin based standard chemotherapy palliative radiotherapy for bone metastasis is allowed
__label__1	study interventions are Cyclophosphamide . recurrent grade one follicular lymphoma diagnosis and lansky play performance score less_than sixty for pediatric patients
__label__1	study interventions are Antibodies . stage iii pancreatic cancer diagnosis and inadequately controlled hypertension defined as systolic blood pressure greater_than one hundred and fifty mmhg and or diastolic blood pressure greater_than one hundred mmhg
__label__1	study interventions are laboratory biomarker analysis . recurrent squamous cell carcinoma of the oropharynx diagnosis and the presence of medical conditions which contraindicate general anesthesia
__label__1	study interventions are Vorinostat . stage iv mantle cell lymphoma diagnosis and patients undergoing total body irradiation tbi based conditioning regimen tbi one thousand, two hundred centigray_cgy
__label__1	study interventions are Hormones . stage ii breast cancer diagnosis and unwillingness to give informed consent
__label__1	study interventions are Cabozantinib S-malate . stage ii thyroid gland papillary carcinoma diagnosis and any of the following equal_than less_than six months before the first dose of study treatment
__label__1	study interventions are Cyclosporins . diffuse large cell lymphoma diagnosis and patients with refractory anemia with excess blasts raeb who have not received myelosuppressive chemotherapy induction chemotherapy
__label__1	study interventions are [131I]-SGMIB Anti-HER2 VHH1 . breast cancer diagnosis and subjects who cannot communicate reliably with the investigator
__label__1	study interventions are Fludarabine phosphate . refractory non hodgkin lymphoma diagnosis and patients with fungal infection and radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Post-operative radiotherapy . breast cancer diagnosis and previous history of malignant disease does not preclude entry if the expectation of relapse free survival at ten years is ninety or greater
__label__1	study interventions are Cytarabine . recurrent adult hodgkin lymphoma diagnosis and seizures within the past twelve months
__label__1	study interventions are Dexamethasone . recurrent childhood gliomatosis_cerebri diagnosis and patients with history of prior hsv encephalitis or encephalitis due to other etiologies
__label__1	study interventions are Meditation Therapy . lung neoplasm diagnosis and prior radiotherapy to the abdomen lung
__label__1	study interventions are Vaccines . stage ic primary peritoneal cavity cancer diagnosis and other serious illnesses serious infections requiring antibiotics bleeding disorders
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and daily requirement for corticosteroids greater_than ten mg prednisone daily or equivalent inhaled corticosteroids are permitted
__label__1	study interventions are Fludarabine . stage iii marginal zone lymphoma diagnosis and treatment with rituximab for any reason in the twelve months preceding hct
__label__1	study interventions are Immunoglobulins . lymphoma non hodgkin diagnosis and the mean of bilateral biopsies must be no more than twenty-five
__label__1	study interventions are Ergocalciferols . fallopian tube cancer diagnosis and patients who are pregnant or breastfeeding are not eligible
__label__1	study interventions are Cisplatin . the following histological tumor types are excluded
__label__1	study interventions are Immunoglobulin G . recurrent uterine corpus carcinoma diagnosis and untreated central nervous system cns metastases exceptions
__label__1	study interventions are Temozolomide . glioblastoma multiforme diagnosis and pregnant or lactating women men and women of childbearing potential must agree to practice an effective method of birth control
__label__1	study interventions are Cadexomer iodine . lymphoma non hodgkin diagnosis and prior chemotherapy biologic therapy radiation therapy or steroid therapy for nhl within eight weeks prior to screening procedures
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and treatment with biologic therapy within twenty-one days of registration
__label__1	study interventions are Retinol palmitate . untreated childhood myeloid neoplasm diagnosis and patients who have received treatment with any other cytotoxic chemotherapy prior to beginning protocol therapy other than allowed in above criteria are excluded
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and the development of erythema_nodosum if characterized by desquamating_rash while taking thalidomide or similar drugs
__label__1	study interventions are Immunoglobulins . non hodgkin lymphoma diagnosis and patients with previous allergic reactions to iodine
__label__1	study interventions are Cediranib . peripheral cell lymphoma diagnosis and urine protein should be screened by dipstick or urine analysis for proteinuria greater_than one positive or urine protein
__label__1	study interventions are Lenalidomide . recurrent adult immunoblastic large cell lymphoma diagnosis and phenytoin dilantin_phenytek
__label__1	study interventions are Belinostat . stage iv grade one follicular lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to pxdone0one there are no known allergic reactions attributed to compounds of similar chemical or biological composition to one7aag patients with known egg allergy should be excluded as the agent is diluted in epl_diluent
__label__1	study interventions are Docetaxel . advanced breast cancer diagnosis and patients who have received wide field radiotherapy including therapeutic radioisotopes such as strontium eighty-nine less_than four weeks or limited field radiation for palliation less_than two weeks prior to starting study drug or who have not recovered from side effects of such therapy
__label__1	study interventions are Niacinamide . known history or presence of metastatic brain or meningeal tumors
__label__1	study interventions are Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination . kaposi sarcoma diagnosis and in the opinion of the site investigator any psychological or social condition or addictive disorder that would preclude compliance with the protocol
__label__1	study interventions are Pentostatin . prior cytotoxic therapy or rituximab for this cancer
__label__1	study interventions are Carboplatin . recurrent fallopian tube cancer diagnosis and any patient with active crohn disease or active ulcerative colitis is excluded patients having these conditions are at an excessive risk of organ function impairing fibrosis
__label__1	study interventions are Olaparib . ovarian seromucinous carcinoma diagnosis and participants receiving any medications or substances that are strong inhibitors or inducers of cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour are ineligible strong inhibitors and inducers of ugt_pgp should be used with caution
__label__1	study interventions are Belinostat . stage iii adult lymphoblastic lymphoma diagnosis and patients who have history of serious ventricular arrhythmia vt or vf greater_than equal_than three beats in row or qtc greater_than equal_than four hundred and fifty msec for men and four hundred and seventy msec for women or history of long qt syndrome
__label__1	study interventions are Vemurafenib . skin cancer diagnosis and history of or evidence of retinal pathology on ophthalmologic examination that is considered risk factor for neurosensory retinal detachment retinal vein occlusion rvo or neovascular macular_degeneration
__label__1	study interventions are Endothelial Growth Factors . recurrent rectal carcinoma diagnosis and prior treatment with sorafenib is not allowed
__label__1	study interventions are BB 1101 . colorectal cancer diagnosis and treatment with antiemetics within twenty-four hr prior to chemotherapy
__label__1	study interventions are Ferrosoferric Oxide . papillary carcinoma of thyroid metastatic to regional lymph node diagnosis and suggested text is provided below and may be modified as necessary
__label__1	study interventions are Poly ICLC . ovarian carcinoma diagnosis and diclofenac imipramine and ketoconazole
__label__1	study interventions are Mindfulness-Based Stress Reduction . cancer diagnosis and shift work
__label__1	study interventions are A-dmDT390-bisFv(UCHT1) (Resimmune®) . melanoma diagnosis and congestive heart failure atrial fibrillation pulmonary hypertension anticoagulant drug therapy thromboembolic events cardiomyopathy or myocardial infarction within the past eight months
__label__1	study interventions are AG-120 . metastatic cholangiocarcinoma diagnosis and received prior idh inhibitor
__label__1	study interventions are Cisplatin . stage iiia primary peritoneal cancer diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are Liposomal doxorubicin . concomitant treatment with other therapy for cancer
__label__1	study interventions are Iodine . symptomatic peripheral vascular disease
__label__1	study interventions are Antibodies, Monoclonal . recurrent small intestine cancer diagnosis and prior treatment with egfr targeting therapies
__label__1	study interventions are Docetaxel . prior malignancies except cured non melanoma skin cancer curatively treated in situ carcinoma of the cervix or other cancer curatively treated and with non evidence of disease for at least three years
__label__1	study interventions are Alendronate . ovarian cancer diagnosis and hypersensitivity to any component of the drug product
__label__1	study interventions are Methotrexate . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and patients undergoing total body irradiation tbi based conditioning regimen tbi one thousand, two hundred centigray_cgy
__label__1	study interventions are Carmustine . recurrent childhood non hodgkin lymphoma diagnosis and patient with poorly controlled hypertension despite multiple antihypertensives
__label__1	study interventions are Veliparib . hereditary breast ovarian cancer brcaone diagnosis and active uncontrolled infection
__label__1	study interventions are Pembrolizumab . melanoma diagnosis and diagnosis of immunodeficiency
__label__1	study interventions are Antibodies, Monoclonal . ovarian neoplasms diagnosis and history of hypersensitivity or infusion reaction to any of the proposed chemotherapy arm agents that could not be controlled with pre medication and or infusion rate adjustment
__label__1	study interventions are Antibodies, Monoclonal . patient must not have an uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Aprepitant . stage iv squamous cell carcinoma of the larynx diagnosis and patients may be enrolled in additional clinical trials as long as no additional investigational agents are being used
__label__1	study interventions are Mycophenolic Acid . plasma cell myeloma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Cisplatin . recurrent cholangiocarcinoma diagnosis and any of the following
__label__1	study interventions are Fludarabine . stage iv marginal zone lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Immunoglobulins . neoplasms diagnosis and history of arterial thromboembolic event
__label__1	study interventions are Sunitinib . endometrial endometrioid adenocarcinoma diagnosis and class iii or iv heart failure as defined by the nyha functional classification system
__label__1	study interventions are Ado-trastuzumab emtansine . stage iib breast cancer diagnosis and another anthracycline or more than one anthracycline used in cumulative dose exceeding the equivalent of doxorubicin five hundred mg two
__label__1	study interventions are Fluorouracil . colon cancer diagnosis and women who test positive for serum or urine pregnancy test less_than seventy-two hours before randomization or are breast feeding
__label__1	study interventions are Dexrazoxane . synovial sarcoma diagnosis and systolic heart failure defined as left ventricular ejection fraction less_than forty-five
__label__1	study interventions are Lenograstim . myeloma diagnosis and prior stem cell transplantation allogeneic or autologous
__label__1	study interventions are Sorafenib . recurrent verrucous carcinoma of the oral cavity diagnosis and congestive heart failure greater_than class ii nyha patients must not have unstable angina anginal symptoms at rest or new onset angina began within the last three months or myocardial infarction within the past six months significant history of uncontrolled cardiac disease uncontrolled hypertension defined as defined as systolic blood pressure greater_than one hundred and fifty mmhg or diastolic pressure greater_than ninety mmhg despite optimal medical management uncontrolled congestive heart failure and cardiomyopathy with decreased ejection fraction will also be excluded from study cardiac ventricular arrhythmias requiring anti arrhythmic therapy will also be excluded from study
__label__1	study interventions are Eribulin . breast cancer diagnosis and concomitant use within fourteen days prior to commencement of study treatment of any investigational agent
__label__1	study interventions are Trametinib . colorectal cancer diagnosis and history of severe hypersensitivity reactions to other monoclonal antibodies
__label__1	study interventions are Tipifarnib . recurrent grade one follicular lymphoma diagnosis and any of the following as this regimen may be harmful to developing fetus or nursing child
__label__1	study interventions are Gemcitabine . prior cytokine therapy for epithelial tumors of mullerian origin chemotherapy
__label__1	study interventions are Bevacizumab . adult grade iii lymphomatoid granulomatosis diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one registration
__label__1	study interventions are Albumin-Bound Paclitaxel . resectable pancreatic adenocarcinoma diagnosis and pregnant women are excluded
__label__1	study interventions are Fluorouracil . rectal cancer diagnosis and patients with history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to day zero
__label__1	study interventions are Antibodies, Monoclonal . triple negative breast cancer diagnosis and known alcohol or drug abuse
__label__1	study interventions are Antibodies, Monoclonal . primary peritoneal serous adenocarcinoma diagnosis and ctcae grade two or greater peripheral vascular disease at least brief less_than two4 hrs episodes of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Interleukin-2 . esophageal cancer diagnosis and cardiopulmonary insufficiency
__label__1	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and investigational therapy within four weeks of study entry
__label__1	study interventions are Mycophenolic Acid . stage ii multiple myeloma diagnosis and donor
__label__1	study interventions are Fludarabine . diffuse large cell lymphoma diagnosis and hcg pregnancy test serum or urine on all women of child bearing potential
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and patient having history of clinically significant cardiovascular hepatic respiratory or renal diseases clinically significant hematological and endocrinal abnormalities clinically significant neurological or psychiatric conditions
__label__1	study interventions are Docetaxel . tumors harboring isocitrate dehydrogenase one idhone and idhtwo mutations diagnosis and active infection requiring within two weeks prior to first dose of study drug
__label__1	study interventions are Cisplatin . liver cancer diagnosis and pregnancy or breast feeding
__label__1	study interventions are Decitabine . myelodysplastic myeloproliferative neoplasm diagnosis and targeted therapies kinase inhibitors equal_than less_than seven days or five half life whichever is shorter
__label__1	study interventions are Doxorubicin . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and history of significant cerebrovascular disease in the past three months or ongoing event with active symptoms or sequelae
__label__1	study interventions are Cyclosporine . childhood burkitt lymphoma diagnosis and donor
__label__1	study interventions are Albumin-Bound Paclitaxel . endometrial adenocarcinoma diagnosis and three grade two or greater hypoxemia
__label__1	study interventions are Prednisolone . hemangioma diagnosis and cardiovascular disease impossible to use propranolol
__label__1	study interventions are Antibodies, Monoclonal . metastatic melanoma diagnosis and inability to regularly access centre facilities for logistical or other reasons
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and severe inpatient care is needed lung disease ex
__label__1	study interventions are Mitogens . recurrent adult hodgkin lymphoma diagnosis and use of rabbit_antithymocyte globulin in the pretransplant conditioning regimen
__label__1	study interventions are Antibodies . active bleeding or pathologic condition that would confer high risk of bleeding tumor involving major blood vessels or known varices
__label__1	study interventions are Melphalan . stage aids related lymphoma diagnosis and consent may not be obtained by means of legal guardian
__label__1	study interventions are Etoposide phosphate . recurrent childhood anaplastic large cell lymphoma diagnosis and total cd thirty-four positive greater_than equal_than two ten six kg or if unable to collect this dose total nucleated cell bone marrow dose of greater_than equal_than x ten eight kg
__label__1	study interventions are Pemetrexed . pancreatic neoplasms diagnosis and pregnant or breastfeeding
__label__1	study interventions are Triptorelin Pamoate . active second malignancy during the last five years except non melanomatous skin cancer or carcinoma in situ of the cervix
__label__1	study interventions are Sirolimus . stage iic primary peritoneal cavity cancer diagnosis and participation in any other clinical trial involving another investigational agent within four weeks prior to first dosing of study drug
__label__1	study interventions are Immunoglobulins . ovarian serous cystadenocarcinoma diagnosis and angina pectoris equal_than less_than twelve months prior to starting drug
__label__1	study interventions are Personalized titanium plate . benign tumor
__label__1	study interventions are ExAblate 2000 . uterine leiomyomas diagnosis and pedunculated fibroids
__label__1	study interventions are Sirolimus . renal cell carcinoma diagnosis and contraindication for surgical intervention
__label__1	study interventions are Doxorubicin . ovarian seromucinous carcinoma diagnosis and patients with prior treatment with pld
__label__1	study interventions are Dasatinib . high grade glioma diagnosis and metastatic disease for stratum only
__label__1	study interventions are Antibodies, Monoclonal . history of active malignancy during the past five years except squamous cell and basal cell carcinomas of the skin and carcinoma in situ of the cervix or malignancy that in the opinion of the local investigator with concurrence with the principal investigator is considered cured with minimal risk of recurrence within five years
__label__1	study interventions are Vincristine . isolated extramedullary relapse leukemia or isolated cns lymphoma
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and liver function
__label__1	study interventions are Tacrolimus . recurrent childhood anaplastic large cell lymphoma diagnosis and pregnancy
__label__1	study interventions are Niacinamide . hepatosplenic cell lymphoma diagnosis and uncontrolled intercurrent illness including but not limited to
__label__1	study interventions are Indomethacin . esophageal neoplasms diagnosis and chronic renal disease defined as gfr mdrd less_than sixty ml min
__label__1	study interventions are Liposomal doxorubicin . breast neoplasms diagnosis and wall motion abnormalities are present on initial echocardiograms
__label__1	study interventions are Pharmacological Study . recurrent adult soft tissue sarcoma diagnosis and patients who have had significant traumatic injury within twenty-eight days prior to enrollment are not eligible
__label__1	study interventions are Pentostatin . lymphoma hodgkins diagnosis and anemia hb less_than nine gm dl that cannot be corrected with transfusion
__label__1	study interventions are Etoposide . lymphoma diagnosis and patients should not have received more than six cycles of fludarabine therapy
__label__1	study interventions are Androgens . recurrent breast carcinoma diagnosis and female
__label__1	study interventions are Fosaprepitant . breast cancer diagnosis and ketoconazole itraconazole
__label__1	study interventions are Fluorouracil . rectal cancer diagnosis and female patients who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control
__label__1	study interventions are Metronidazole . prostatic neoplasms diagnosis and d
__label__1	study interventions are Carboplatin . refractory diffuse large cell lymphoma diagnosis and received anticoagulation therapy with coumadin or equivalent vitamin antagonists within the last twenty-eight days
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and known human immunodeficiency virus hiv infection or active hepatitis b or c
__label__1	study interventions are Antibodies, Monoclonal . lymphoblastic lymphoma diagnosis and the patient is pregnant or unwilling to practice appropriate birth control
__label__1	study interventions are Bevacizumab . malignant glioma who grade iii or iv diagnosis and treated with alkylating agents within four weeks before enrollment or treated within one week before enrollment with daily or metronomic chemotherapy unless the patient has recovered from the expected toxic effects of such therapy
__label__1	study interventions are CT scan . precancerous condition diagnosis and evidence of severe or uncontrolled systemic diseases that in the view of the investigator makes it undesirable for the patient to participate in this trial
__label__1	study interventions are Mycophenolate mofetil . fibrolamellar hepatocellular carcinoma diagnosis and participants with positive hcv antibodies but undetectable serum hcv rna may be considered for eligibility
__label__1	study interventions are Etoposide . recurrent childhood lymphoblastic lymphoma diagnosis and hepatitis or hiv infection
__label__1	study interventions are Epigallocatechin gallate . stage colon cancer diagnosis and pregnant women nursing women men or women of childbearing potential who are unwilling to employ adequate contraception note
__label__1	study interventions are Immunoglobulins . stage iiia primary peritoneal cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to day one
__label__1	study interventions are Ultrasound . liver neoplasms diagnosis and plt sixty thousand mmthree prothrombin activityprothrombin time activity seventy
__label__1	study interventions are Sunitinib . glioblastoma diagnosis and prolonged qtc interval on baseline ekg
__label__1	study interventions are Cetuximab . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and grade three four electrolyte abnormalities common terminology criteria for adverse events ctcae v
__label__1	study interventions are Pharmacological Study . neurofibromatosis type one diagnosis and have had recent major surgery within minimum of four weeks prior to starting study treatment with the exception of surgical placement for vascular access
__label__1	study interventions are Bleomycin . active uncontrolled infection active second malignancy within five years except adequately treated nonmelanoma skin cancer or adequately treated carcinoma in situ of the cervix not pregnant or nursing fertile patients must use effective contraception
__label__1	study interventions are Cisplatin . adenocarcinoma diagnosis and known acute or chronic active infection with hepatitis virus hbv or hepatitis virus hcv
__label__1	study interventions are Enoblituzumab . osteosarcoma diagnosis and history of clinically significant cardiovascular disease
__label__1	study interventions are Gefitinib . head and neck cancer diagnosis and known severe hypersensitivity to zdone thousand, eight hundred and thirty-nine or any of the excipients of this product
__label__1	study interventions are Gemcitabine . advanced hodgkin lymphoma diagnosis and group one and two
__label__1	study interventions are Mitomycins . pseudomyxoma_peritonei diagnosis and active systemic infections coagulation disorders or other major medical illnesses precluding major surgery
__label__1	study interventions are Endothelial Growth Factors . type one papillary renal cell carcinoma diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and affiliated with social security regime
__label__1	study interventions are Carboplatin . primary peritoneal cancer diagnosis and cns central nervous system disease
__label__1	study interventions are Hyaluronic Acid . prostate cancer diagnosis and allergy to avian products
__label__1	study interventions are Gemcitabine . pancreatic adenocarcinoma diagnosis and last dose of radiotherapy received within four weeks before the start of study treatment excluding palliative radiotherapy
__label__1	study interventions are Oxaliplatin . carcinoma squamous diagnosis and prior malignancy within five years
__label__1	study interventions are REGN2810 . melanoma diagnosis and untreated brain metastasis es that may be considered active
__label__1	study interventions are Bevacizumab . stage iia gastric cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to study enrollment
__label__1	study interventions are Fludarabine phosphate . stage iv adult hodgkin lymphoma diagnosis and patients with conventional transplant options conventional transplant should be the priority for eligible patients equal_than less_than fifty yr of age who have related donor mismatched for single hla b or drbone antigen
__label__1	study interventions are Cyclophosphamide . ovarian serous adenocarcinoma diagnosis and participant has clinically significant cardiovascular disease including
__label__1	study interventions are Prednisolone . neuroma human forefoot diagnosis and hepatic impairment and coagulation disorders
__label__1	study interventions are Antibodies . recurrent grade three follicular lymphoma diagnosis and use of zidovudine or cobicistat as part of the haart regimen drug substitution at the time of study entry is allowed
__label__1	study interventions are Biospecimen Collection . urothelial carcinoma diagnosis and affected by dementia altered mental status or any psychiatric or co morbid condition that would prohibit the understanding or rendering of informed consent as determined by treating physician
__label__1	study interventions are Carboplatin . non small cell lung cancer diagnosis and any gastrointestinal tract disease or other medical condition resulting in the inability to take oral medications
__label__1	study interventions are Fulvestrant . cervical cancer diagnosis and evidence of severe or uncontrolled systemic diseases including active bleeding diatheses or active infections including hepatitis c and hiv
__label__1	study interventions are Irinotecan . prior systemic anticancer therapy for mcrc
__label__1	study interventions are EMD 521873 . non small cell lung cancer diagnosis and any psychiatric condition that would prohibit the understanding or rendering of the informed consent
__label__1	study interventions are Alkylating Agents . neuroblastoma recurrent diagnosis and patients with cardiac arrhythmias especially prolonged qt
__label__1	study interventions are Niacinamide . metastatic solid tumor diagnosis and subject has been previously treated with pithreek inhibitor or mek inhibitor and taken off treatment due to treatment related adverse events
__label__1	study interventions are Vincristine . lymphoma diagnosis and this includes
__label__1	study interventions are Fluorouracil . colorectal cancer metastatic diagnosis and known acquired immunodeficiency syndrome aids related illnesses or known human deficiency virus hiv disease requiring antiretroviral treatment
__label__1	study interventions are hyperfractionated radiation therapy . invasive ductal breast carcinoma diagnosis and prior treatment with anti angiogenic therapy
__label__1	study interventions are Calcium, Dietary . mixed adenocarcinoma of the stomach diagnosis and severely impaired lung function as defined as spirometry and diffusion lung capacity of carbon monoxide dlco that is fifty of the normal predicted value and or two saturation that is eighty-eight or less at rest on room air
__label__1	study interventions are Tipifarnib . once patient begins fti tipifarnib treatment the addition of other cancer treatment will confound the assessment of efficacy and therefore is not allowed this restriction precludes the addition of cytotoxic immunologic agents radiotherapy or an increase in corticosteroid dose while the patient is in the treatment phase of this protocol
__label__1	study interventions are Everolimus . malignant neoplasms of female genital organs diagnosis and oncomitant use of medication with known risk to prolong the qt interval and or known to cause torsades de pointe that cannot be discontinued within five half lives or seven days prior to starting study drug or replaced by safe alternative medication
__label__1	study interventions are Vaccines . human papillomavirus infection diagnosis and heart disease
__label__1	study interventions are Antibodies, Bispecific . metastatic colorectal cancer diagnosis and women who are pregnant or lactating
__label__1	study interventions are Nintedanib . neuroendocrine neoplasm diagnosis and severe or uncontrolled medical conditions
__label__1	study interventions are IV administration of gadolinium-containing contrast agent . recurrent adult brain tumor diagnosis and patients who are pregnant or breast feeding urine pregnancy test will be performed on women of child bearing potential
__label__1	study interventions are Paclitaxel . stage iiia uterine corpus cancer diagnosis and serum creatinine greater_than doc mg dl
__label__1	study interventions are Dexamethasone 21-phosphate . t cell lymphoblastic lymphoma diagnosis and have evidence of uncontrolled active infection less_than seven days prior to administration of study medication
__label__1	study interventions are Busulfan . lymphoma non hodgkin diagnosis and it would be eligible following the judgment of the investigator
__label__1	study interventions are Decitabine . myelodysplastic myeloproliferative neoplasm diagnosis and muscular activities such as strenuous exercise that can result in significant increases in plasma creatine kinase ck levels should be avoided whilst on ldetwo hundred and twenty-five treatment
__label__1	study interventions are Thiotepa . non hodgkins lymphoma diagnosis and presence of leukemia in the cns
__label__1	study interventions are Carboplatin . non small cell lung cancer diagnosis and patients with grade two constipation within the past fourteen days could be re screened if constipation decreases to less_than grade one with optimal management of constipation
__label__1	study interventions are Estrogens . breast neoplasms diagnosis and women and members of all races and ethnic groups are eligible for this trial
__label__1	study interventions are Albumin-Bound Paclitaxel . mucinous breast cancer stage ii diagnosis and chronic corticosteroids unless initiated greater_than six months prior to study entry and at low dose less_than ten mg methylprednisolone or equivalent
__label__1	study interventions are Sorafenib . metastatic breast cancer diagnosis and polyoxyethylated_castor oil or drug formulated in
__label__1	study interventions are Cyclophosphamide . any history of cancer or cancer treatment during the last three years with the exception of non melanoma skin cancer or stage zero in situ carcinoma of any type if they have undergone complete resection
__label__1	study interventions are Bevacizumab . small cell lung cancer diagnosis and bevacizumab thalidomide cp five hundred and forty-seven thousand, six hundred and thirty-two sunitinib sorafenib
__label__1	study interventions are Melphalan . recurrent childhood hodgkin lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Everolimus . metastatic pancreatic adenocarcinoma diagnosis and clinically significant cardiac arrhythmias ventricular tachycardia complete left bundle_branch block high grade atrioventricular block av block bifascicular block mobitz type ii and third degree av block
__label__1	study interventions are Everolimus . carcinoid tumor diagnosis and any severe and or uncontrolled medical condition or other conditions that could affect their participation in the study such as
__label__1	study interventions are Bevacizumab . stage iib fallopian tube cancer diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study examples of this would be
__label__1	study interventions are Radiation Therapy . positive lymph nodes or metastatic disease from prostate cancer
__label__1	study interventions are Cyclophosphamide . cervical cancer diagnosis and patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities
__label__1	study interventions are Cetuximab . stage ivb verrucous carcinoma of the larynx diagnosis and pregnancy or women of childbearing potential and men who are sexually active and not willing able to use medically acceptable forms of contraception this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
__label__1	study interventions are Whole Brain Radiation Therapy . neoplasm metastasis diagnosis and additional history of significant neurological or psychiatric disorder
__label__1	study interventions are Liposomal doxorubicin . human epidermal growth factor two negative carcinoma of breast diagnosis and prior therapy with bevacizumab sorafenib sunitinib or other vegf pathway targeted therapy
__label__1	study interventions are Niacinamide . metastatic breast cancer diagnosis and thrombolic or embolic events such as cerebrovascular accident
__label__1	study interventions are Histone Deacetylase Inhibitors . endocrine gland neoplasms diagnosis and if the patient has brain metastasis they must have stable neurologic status without the use of steroids or on stable or decreasing dose of steroids
__label__1	study interventions are Antibodies, Monoclonal . fallopian tube serous adenocarcinoma diagnosis and participant has clinical symptoms or signs of partial or complete gastrointestinal obstruction or requires parenteral hydration and or nutrition
__label__1	study interventions are Paclitaxel . duct cell adenocarcinoma of the pancreas diagnosis and any active gastrointestinal gi impairment which in the opinion of the investigator would impair or alter the absorption of dovitinib ulcerative colitis or crohn disease
__label__1	study interventions are Veliparib . childhood mixed glioma diagnosis and hgb greater_than eight gm dl transfusion independent
__label__1	study interventions are Cyclophosphamide . stage iv adult immunoblastic large cell lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to busulfan other agents used in this study
__label__1	study interventions are Antibodies . stage iiib breast cancer diagnosis and angina pectoris that requires the use of anti anginal medication
__label__1	study interventions are Irinotecan . stage iiic colon cancer diagnosis and serious underlying medical or psychiatric illnesses that would in the opinion of the treating physician substantially increase the risk for complications related to treatment
__label__1	study interventions are Prednisone . currently active second malignancy other than non melanoma skin cancer
__label__1	study interventions are transoral robotic surgery . recurrent adenoid cystic carcinoma of the oral cavity diagnosis and unexplained fever or untreated active infection
__label__1	study interventions are Lenograstim . blood cancer diagnosis and cardiac function
__label__1	study interventions are 2-Aminopurine . childhood lymphoblastic lymphoma diagnosis and female patients who are pregnant are ineligible
__label__1	study interventions are Liposomal doxorubicin . cancer diagnosis and have serious nonmalignant disease hydronephrosis liver failure significantly impaired hepatic function or other conditions that could compromise protocol objectives in the opinion of the investigator and or the sponsor
__label__1	study interventions are Liposomal doxorubicin . diffuse large cell lymphoma diagnosis and researchers determine unsuited to participate in this trial
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and prior treatment with pertuzumab and or dmone
__label__1	study interventions are Bevacizumab . prior anticancer therapy that would preclude study entry
__label__1	study interventions are Vincristine . adult cell leukemia lymphoma diagnosis and tacrolimus prograf
__label__1	study interventions are Lenalidomide . myeloma diagnosis and patients with diarrhea greater_than common terminology criteria for adverse events ctcae version four grade two at the time of signing consent
__label__1	study interventions are Daclizumab . hodgkin lymphoma diagnosis and doc
__label__1	study interventions are placebo . stage iva oral cavity squamous cell carcinoma diagnosis and although there are no known adverse effects of black_raspberries upon the fetus if patients become pregnant during period of lyophilized_black raspberries_lbr administration then lbr will be discontinued and patient will be removed from the study we should however emphasize given this is food based study that risks are likely extremely low even though participant should become pregnant as such we are not recommending active contraception for women but rather if participants become pregnant that they notify their study doctor and that they will likely be removed from study there are no expected or logical risks if men were to father child and as such no contraception will be recommended for men
__label__1	study interventions are Maleic acid . recurrent ovarian epithelial cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to azdtwo thousand, one hundred and seventy-one
__label__1	study interventions are photodynamic therapy . stage ii adenoid cystic carcinoma of the oral cavity diagnosis and platelet count less_than one hundred zero
__label__1	study interventions are Carboplatin . uterine carcinosarcoma diagnosis and patients who have had radiotherapy within four weeks prior to entering the study or those who have not recovered from adverse events ctcae vfour grade two or greater excluding alopecia due to agents administered more than four weeks earlier
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent mantle cell lymphoma diagnosis and radiation or chemotherapy equal_than less_than four weeks
__label__1	study interventions are Gemcitabine . sarcoma diagnosis and if patients have positive serologic markers viral load markers hbv dna and hepatitis rna pcr will be performed during screening to confirm disease as well as screening for hepatitis via quantitative rna pcr
__label__1	study interventions are Cisplatin . stage iiia non small cell lung cancer diagnosis and arm cohort three
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and limitation of the patient ability to comply with the treatment or follow up protocol
__label__1	study interventions are Everolimus . stage iiic ovarian cancer diagnosis and sub protocol aim a
__label__1	study interventions are Molecular Mechanisms of Pharmacological Action . carcinoma non small cell lung diagnosis and known or suspected allergy hypersensitivity to any agent given in the course of this trial
__label__1	study interventions are biopsy with 25 gauge needle . pancreatic cancer diagnosis and age less_than nineteen years
__label__1	study interventions are Cyclophosphamide . breast adenocarcinoma diagnosis and uncontrolled hypertension defined as sustained systolic blood pressure bp greater_than one hundred and fifty mmhg or diastolic bp greater_than ninety mmhg patients with initial bp elevations are eligible if initiation or adjustment of bp medication lowers pressure to meet entry criteria
__label__1	study interventions are Ganciclovir triphosphate . contiguous stage ii grade two follicular lymphoma diagnosis and no prior allogeneic hct allo hct autologous hct auto hct is allowed
__label__1	study interventions are Lenalidomide . recurrent childhood visual pathway glioma diagnosis and hormonal prescription birth control pills injections implants
__label__1	study interventions are Prednisone . stage iii prostate adenocarcinoma diagnosis and cytochrome pfour hundred and fifty cyp seventeen inhibitors ketoconazole
__label__1	study interventions are Bevacizumab . head and neck cancer diagnosis and unstable angina
__label__1	study interventions are Laboratory Biomarker Analysis . stage iv breast cancer diagnosis and patients with known brain metastases should be excluded from this clinical trial patients will not undergo pre treatment imaging of the brain unless clinically indicated
__label__1	study interventions are Gemcitabine . multiple myeloma diagnosis and impairment of gi function or gi disease that may significantly alter the absorption of panobinostat
__label__1	study interventions are Mechlorethamine . ewing sarcoma diagnosis and prior allogeneic hematopoietic stem cell transplant
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiia gastric cancer diagnosis and any of the following are excluded
__label__1	study interventions are Vaccines . infections papillomavirus diagnosis and planned administration administration of vaccine not foreseen by the study protocol within thirty days before and thirty days after the first dose of vaccine
__label__1	study interventions are Trastuzumab . participants showing histologically confirmed focal hertwo expression less than less_than thirty of positively stained tumor cells
__label__1	study interventions are Iodine-131 anti-B1 antibody . non hodgkin lymphoma diagnosis and patients who are pregnant or breast feeding
__label__1	study interventions are Mycophenolate mofetil . stage childhood anaplastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Vinorelbine . her two positive breast cancer diagnosis and hbv dna and hcv rna pcr testing are required at screening for all patients with positive medical history based on risk factors and or confirmation of prior hbv hcv infection
__label__1	study interventions are Erlotinib Hydrochloride . lung cancer diagnosis and erythromycin clarithromycin iv
__label__1	study interventions are Cabozantinib . urinary bladder neoplasms diagnosis and low dose aspirin less than or equal to eighty-one mg day lowdose warfarin less than or equal to one mg day and low molecular weight heparin lmwh are permitted
__label__1	study interventions are Lenvatinib . participants who have received any anticancer treatment within three weeks or any investigational agent within threezero days before the first dose of study drug or who have not recovered from any acute toxicity greater than grade zero or one related to previous anticancer treatment
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and acute bacterial or fungal infection requiring intravenous antibiotics at the time of randomization
__label__1	study interventions are Antibodies, Monoclonal . melanoma diagnosis and any major surgery within four weeks or diagnostic procedure incision needle biopsy within one day of study drug administration
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv primary peritoneal cancer diagnosis and patients with unstable angina or those who have had myocardial infarction within the past six months patients with evidence of abnormal cardiac conduction bundle_branch block heart block are eligible if their disease has been stable for the past six months
__label__1	study interventions are Etoposide phosphate . ovarian steroid cell tumor diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study the investigator can consult the study chair or study co chairs for uncertainty in this regard
__label__1	study interventions are Educational materials . colon cancer diagnosis and planning to move within the next year
__label__1	study interventions are Computed Tomography . recurrent renal cell carcinoma diagnosis and for normal subject arm
__label__1	study interventions are Etoposide phosphate . history of cardiomyopathy or symptomatic congestive heart failure
__label__1	study interventions are Vincristine . follicular lymphoma grade threeb diagnosis and history of progressive multifocal_leukoencephalopathy
__label__1	study interventions are Fluorouracil . paranasal sinus neoplasms diagnosis and subjects who are men must also agree to use effective contraception
__label__1	study interventions are Vorinostat . adult gliosarcoma diagnosis and other active malignancy equal_than less_than three years prior to registration exception
__label__1	study interventions are Axitinib . colorectal neoplasms diagnosis and minor surgeries should be completed greater_than two weeks of enrollment and be fully recovered from any procedure
__label__1	study interventions are Cyclosporins . refractory multiple myeloma diagnosis and current serious systemic illness
__label__1	study interventions are Doxorubicin . previous treatment for lymphoma
__label__1	study interventions are Laboratory Biomarker Analysis . stage iv adult soft tissue sarcoma diagnosis and known untreated central nervous system cns metastasis
__label__1	study interventions are Levoleucovorin . tfour tumors or incomplete resection rtwo
__label__1	study interventions are Cetuximab . recurrent salivary gland cancer diagnosis and chemotherapy therapy or palliative radiation therapy within the previous two weeks prior to dosing with cetuximab or vtx_two337 patients should have recovered from major toxicities of prior therapy if deemed reversible toxicities should return to baseline or equal_than less_than grade two in severity
__label__1	study interventions are Cisplatin . stage iib fallopian tube cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Methylprednisolone acetate . lymphoma cell diagnosis and hypersensitivity to bortezomib boron or mannitol
__label__1	study interventions are Cytarabine . lymphoma large cell diffuse diagnosis and prior transplantation
__label__1	study interventions are Endothelial Growth Factors . glioblastoma diagnosis and any other clinically significant medical disease or condition laboratory abnormality or psychiatric illness that in the investigator opinion may interfere with protocol adherence or subject ability to give informed consent
__label__1	study interventions are Gemcitabine . stage iv breast cancer diagnosis and history of seropositive human immunodeficiency virus hiv
__label__1	study interventions are Genistein . stage prostate cancer diagnosis and carbamazepine clarithromycin fluconazole fosphenytoin itraconazole ketoconazole phenobarbital phenytoin rifabutin rifampin
__label__1	study interventions are Cyberknife . prior surgery chemotherapy or radiation for the pancreatic cancer
__label__1	study interventions are Hydroxyitraconazole . advanced solid tumors diagnosis and participants must have no history of amiodarone use in the six months before the first dose of mlnfour thousand, nine hundred and twenty-four
__label__1	study interventions are Sodium Bicarbonate . cancer diagnosis and patients unable to ingest sodium bicarbonate capsules such as patients with dysphagia or severe nausea
__label__1	study interventions are Immunoglobulins . primary peritoneal high grade serous adenocarcinoma diagnosis and patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
__label__1	study interventions are Fluorouracil . solid tumor diagnosis and patients taking valproic acid
__label__1	study interventions are PET/CT scan . non small cell lung cancer diagnosis and of oncology aarhus university hospital
__label__1	study interventions are Oxaliplatin . gastrointestinal cancer diagnosis and greater than doc times the uln if no demonstrable liver metastases or
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv prostate cancer diagnosis and serious concurrent infection requiring intravenous antibiotic therapy
__label__1	study interventions are Pembrolizumab . stage iva major salivary gland carcinoma diagnosis and has received live vaccine within thirty days prior to the first dose of trial treatment
__label__1	study interventions are Doxorubicin . primary peritoneal carcinoma diagnosis and pregnant or breast feeding females
__label__1	study interventions are Antibodies . refractory cell non hodgkin lymphoma diagnosis and patients with history of prior treatment with an anti programmed cell death pd one antibody cdone37 agonist or other immune activating therapy such as anti cd forty antibody are excluded unless five half lives of the agent minimum of eight weeks have intervened since the therapy patients who have received prior vaccine therapy are eligible
__label__1	study interventions are Testosterone enanthate . breast neoplasms diagnosis and pregnant women and women who are breast feeding are excluded from this study because it is limited to post menopausal women
__label__1	study interventions are Immunoglobulins . ductal breast carcinoma in situ diagnosis and supraventricular and nodal arrhythmias requiring pacemaker or not controlled with medication and
__label__1	study interventions are Oxaliplatin . serious stricture exclude the patients who are put in stoma
__label__1	study interventions are Lapatinib . neoplasms breast diagnosis and women with ulcerative colitis are also excluded
__label__1	study interventions are Taxane . triple negative breast cancer diagnosis and is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and patients who have had prior allogeneic stem cell transplantation and show evidence of active graft versus host disease that requires immunosuppressive therapy
__label__1	study interventions are Carboplatin . melanoma skin diagnosis and patients that have had primary therapy for brain metastasis surgical resection whole brain radiation or stereotactic radiation therapy srt even if stable are not eligible
__label__1	study interventions are Albumin-Bound Paclitaxel . platinum resistant ovarian cancer diagnosis and history of myocardial infarction or unstable angina within six months prior to study day one
__label__1	study interventions are Atorvastatin Calcium . malignant neoplasm diagnosis and donor
__label__1	study interventions are Prednisolone phosphate . multiple myeloma diagnosis and history of hypersensitivity to thalidomide or any component of the medications
__label__1	study interventions are Famotidine . cancer diagnosis and wocbp unable or unwilling to use birth control during study and for up to four weeks after study completion
__label__1	study interventions are Hormones . breast cancer diagnosis and known severe hypersensitivity reactions to compounds similar to palbociclib or palbociclib placebo excipients or to endocrine treatments
__label__1	study interventions are Lenalidomide . mature cell lymphoma diagnosis and patients with known hepatitis infection
__label__1	study interventions are Immunoglobulins . solid neoplasm diagnosis and serious and inadequately controlled cardiac arrhythmia
__label__1	study interventions are Misonidazole . stage iiib non small cell lung cancer diagnosis and history of myocardial infarction within six months
__label__1	study interventions are Antibodies, Monoclonal . recurrent mantle cell lymphoma diagnosis and history of aes with prior il two or interferon will not preclude subjects from entering the current study
__label__1	study interventions are Radiopharmaceuticals . glioma diagnosis and breast feeding pregnancy
__label__1	study interventions are Albumin-Bound Paclitaxel . advanced cancer diagnosis and exclusion
__label__1	study interventions are Lapatinib . metastatic breast cancer diagnosis and peripheral neuropathy greater_than grade two
__label__1	study interventions are Prednisone . metastatic prostate carcinoma diagnosis and patients requiring therapeutic anticoagulation warfarin dabigatran heparin or low molecular weight heparins lovenox dalteparin
__label__1	study interventions are Immunoglobulins . endometrial adenosquamous carcinoma diagnosis and three grade two or greater hypoxemia
__label__1	study interventions are poly(I).poly(c12,U) . primary peritoneal cancer diagnosis and wbc less_than two five hundred mmthree
__label__1	study interventions are Liposomal doxorubicin . diffuse large cell lymphoma diagnosis and dlbcl transformed from other low grade nhl types
__label__1	study interventions are X . breast cancer diagnosis and non palpable lesions manifested only by nipple discharge or skin rash paget disease
__label__1	study interventions are Cyclosporine . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and patient is female who is pregnant or breastfeeding
__label__1	study interventions are Calcium, Dietary . adenomatous polyps diagnosis and patients with known gastro duodenal ulcer at time of inclusion
__label__1	study interventions are Carmustine . stage iv adult diffuse large cell lymphoma diagnosis and active infection at the start of lenalidomide
__label__1	study interventions are FUFA . colorectal cancer diagnosis and patients older than seventy-five years not fulfilling these criteria
__label__1	study interventions are Cetuximab . colorectal cancer diagnosis and concurrent antihypertensive therapies allowed
__label__1	study interventions are Fludarabine . stage iv grade one follicular lymphoma diagnosis and donor
__label__1	study interventions are Ifosfamide . non hodgkin lymphoma diagnosis and pregnancy testing is not required for post menopausal or surgically sterilized women
__label__1	study interventions are Immunoglobulins . stage iiia primary peritoneal cancer diagnosis and exceptions allowed for patients unable to tolerate the agent intolerance is defined in this protocol as discontinued agent due to side effects with an exposure less_than to four weeks of drug at any dose level
__label__1	study interventions are Vorinostat . stage iii marginal zone lymphoma diagnosis and patients who are not candidate for an unrelated donor allogeneic hsct based on the current institutional bone marrow transplant bmt program clinical practice guidelines organ function criteria will be utilized per the current institutional bmt program clinical practice guidelines there will be no restriction to study entry based on hematological parameters
__label__1	study interventions are Vinblastine . high risk urothelial carcinoma of the upper urinary tracts diagnosis and pregnant women are excluded from this study due to the potential for teratogenic or abortifacient effects of cytotoxic chemotherapy
__label__1	study interventions are Fludarabine phosphate . diffuse large cell lymphoma diagnosis and may be performed within eight weeks of treatment
__label__1	study interventions are poly(I).poly(c12,U) . fallopian tube cancer diagnosis and subject has known allergies to reagents used in this study
__label__1	study interventions are Cyclophosphamide . transformed lymphomas
__label__1	study interventions are Hormones . prior or concurrent diagnosis of basal cell or non invasive squamous cell cancer of the skin is allowed
__label__1	study interventions are Vaccines . stage iiia fallopian tube cancer diagnosis and other serious illnesses serious infections requiring antibiotics bleeding disorders
__label__1	study interventions are Dasatinib . glioblastoma diagnosis and patients with the following invasive procedures
__label__1	study interventions are Doxorubicin . recurrent childhood large cell lymphoma diagnosis and patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
__label__1	study interventions are Oxaliplatin . stage iva rectal cancer diagnosis and patients who have had chemotherapy biologic targeted or radiotherapy within four weeks prior to entering the study or those who have not recovered from grade two and above adverse events due to agents administered more than four weeks earlier with the exception of alopecia or neuropathy
__label__1	study interventions are Dexamethasone . neoplasm metastases diagnosis and patients with previous exposure to trabectedin
__label__1	study interventions are Delay procedure of SIEA flap. . breast neoplasms diagnosis and patients who previously underwent operations of the lower abdomen abdominoplasty and inguinal hernia repair
__label__1	study interventions are Immunoglobulins . stage ib fallopian tube cancer diagnosis and previous history of malabsorption or other conditions preventing oral treatment
__label__1	study interventions are Camptothecin . triple negative breast carcinoma diagnosis and any ingredients contained within the liquid irinotecan solution_sorbitol or
__label__1	study interventions are Dexamethasone . stage iii multiple myeloma diagnosis and participants must not have life threatening co morbidities
__label__1	study interventions are laboratory biomarker analysis . stage iv adult diffuse large cell lymphoma diagnosis and concurrent antifungal medications or within the past four weeks
__label__1	study interventions are Bevacizumab . stage ic fallopian tube cancer diagnosis and patients may have minor surgical procedures mediport insertion fine needle aspiration or core biopsies as long as it is performed greater_than seven days prior to the first date of bevacizumab therapy and there is no evidence of wound disruption or impaired healing
__label__1	study interventions are Pembrolizumab . metastatic colorectal cancer diagnosis and has evidence of interstitial lung disease or active non infectious pneumonitis
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent laryngeal verrucous carcinoma diagnosis and medical or psychiatric illness which would compromise the patient ability to tolerate this treatment or comply with administration of study drug
__label__1	study interventions are Toremifene . prostate cancer diagnosis and ast and alt less_than twox upper limit of normal
__label__1	study interventions are Decitabine . pleural mesotheliomas diagnosis and uncontrolled arrhythmias
__label__1	study interventions are Pembrolizumab . refractory lymphoplasmacytic lymphoma diagnosis and subjects with equal_than less_than grade two neuropathy are an exception to this criterion and may qualify for the study
__label__1	study interventions are Cyclosporins . contiguous stage ii grade two follicular lymphoma diagnosis and patients asking or who have had prior treatment with drug like vorinostat valproic acid within the last thirty days
__label__1	study interventions are Regorafenib . gastrointestinal stromal tumors gists diagnosis and patients with brain metastases as assessed by radiologic imaging ct mri
__label__1	study interventions are Pomalidomide . multiple myeloma diagnosis and has received prior therapy with an anti programmed cell death one receptor anti pd one antiprogrammed death ligand one anti pd lone anti pd ltwo anti cdone37 or anti cytotoxic lymphocyte associated antigen four ctla four antibody including ipilimumab or any other antibody or drug specifically targeting cell costimulation or checkpoint_pathways
__label__1	study interventions are Antibodies, Monoclonal . hormone resistant prostate cancer diagnosis and receipt of live attenuated vaccination within thirty days prior to study entry or within thirty days of receiving durvalumab
__label__1	study interventions are Capecitabine . solid tumor diagnosis and patients on full dose anticoagulation are permitted to enroll provided that they have been clinically stable on ant negative coagulation
__label__1	study interventions are Iodine-131 anti-B1 antibody . follicular lymphoma diagnosis and confirmation that the subject is not pregnant must be established by negative serum pregnancy test result obtained during screening
__label__1	study interventions are Lenalidomide . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and known hiv positive status
__label__1	study interventions are Paclitaxel . epithelial ovarian cancer diagnosis and history of concurrent second malignancy
__label__1	study interventions are Erlotinib Hydrochloride . prior chemotherapy or therapy with systemic anti tumor therapy monoclonal antibody therapy or prior exposure to agents directed at the her axis egfr tk inhibitors herceptin
__label__1	study interventions are External Beam Radiation Therapy . medium large size posterior uveal melanoma diagnosis and history of prior irradiation to the thorax or abdomen
__label__1	study interventions are Immunoglobulin G . fallopian tube endometrioid adenocarcinoma diagnosis and no history of intracranial hemorrhage or spinal cord hemorrhage
__label__1	study interventions are Bevacizumab . kidney cancer diagnosis and patients must not be scheduled to receive another experimental drug while on this study
__label__1	study interventions are Levoleucovorin . signet ring adenocarcinoma of the rectum diagnosis and inflammatory bowel disease crohn disease ulcerative colitis
__label__1	study interventions are 852A . neoplasms diagnosis and use of investigational agent in the four weeks prior to onest dose of the study drug
__label__1	study interventions are Dexamethasone acetate . other concurrent anticancer agents including chemotherapy except for hydroxyurea radiotherapy immunotherapy or biologic therapy
__label__1	study interventions are Cisplatin . neck cancer diagnosis and patients should have the ability to understand and the willingness to sign written informed consent document
__label__1	study interventions are Aplidin (plitidepsin) . prostate cancer diagnosis and uncontrolled arterial hypertension despite optimal medical therapy
__label__1	study interventions are Vaccines . stage iii colon cancer diagnosis and prior radiation to more than fifty of all nodal groups
__label__1	study interventions are Antibodies, Monoclonal . stage iia colon cancer diagnosis and core biopsy or other minor procedure excluding placement of vascular access device within seven days prior to randomization
__label__1	study interventions are APE with intersphincteric dissection . rectal cancer diagnosis and asa iv or worse
__label__1	study interventions are Paclitaxel . stage iiib fallopian tube cancer diagnosis and partial or complete gastrointestinal obstruction
__label__1	study interventions are Ado-trastuzumab emtansine . stage iii breast cancer diagnosis and other concurrent serious diseases that may interfere with planned treatment including severe pulmonary conditions illness uncontrolled infections uncontrolled diabetes
__label__1	study interventions are Camptothecin . pancreatic cancer diagnosis and history of congestive heart failure
__label__1	study interventions are Rituximab . stage iii grade three follicular lymphoma diagnosis and myocardial infarction within six months prior to enrollment or has new york heart association nyha class iii or iv heart failure uncontrolled angina severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
__label__1	study interventions are Melphalan . anti cancer therapy started within three weeks prior to study initiation and fully recovered from all toxicities associated with prior surgery radiation treatments chemotherapy or immunotherapy
__label__1	study interventions are Oxaliplatin . colon cancer liver metastasis diagnosis and hiv infection or the presence of aids related illness or severe acute and chronic diseases
__label__1	study interventions are Cyclosporins . myeloproliferative neoplasm diagnosis and active bacterial infection
__label__1	study interventions are Lenalidomide . uncontrolled inter current illness that would limit compliance with the study including uncontrolled hypertension symptomatic congestive heart failure unstable angina uncontrolled cardiac arrhythmia uncontrolled psychiatric illness or social situation prior history of stevens_johnson syndrome
__label__1	study interventions are Cyclophosphamide . esophageal cancer diagnosis and patients receiving warfarin anticoagulation who cannot be transferred to other agents such as enoxaparin or dabigatran and for whom anticoagulants cannot be held for up to twenty-four hours will be excluded
__label__1	study interventions are Osimertinib . advanced inoperable non small cell lung cancer diagnosis and any of the following cardiac criteria
__label__1	study interventions are Antibodies, Monoclonal . recurrent breast cancer or other malignancy
__label__1	study interventions are Glycine . smoldering multiple myeloma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to ixazomib or lenalidomide
__label__1	study interventions are Cyclosporine . recurrent childhood anaplastic large cell lymphoma diagnosis and karnofsky score less_than seventy for adult patients
__label__1	study interventions are Irinotecan . stage iiic colon cancer diagnosis and ongoing or active infection
__label__1	study interventions are survey instrument . uterine cancer diagnosis and patients with psychiatric disorder precluding response to the survey
__label__1	study interventions are Bryostatin 1 . recurrent mantle cell lymphoma diagnosis and creatinine greater_than doc mg dl and or actual creatinine clearance less_than forty ml min doc three two all patients are required to have two4 hr creatinine clearance
__label__1	study interventions are intervention by caregiver . recurrent refractory childhood hodgkin lymphoma diagnosis and parents caregivers who have previously provided consistent massage for their child will be excluded from the study child is receiving radiation only
__label__1	study interventions are Ginseng . colorectal cancer diagnosis and subjects permanently withdrawn from study participation will not be allowed to re enter study
__label__1	study interventions are Antibodies . malignant melanoma diagnosis and known hypersensitivity reaction to any of the components of study treatment
__label__1	study interventions are Camptothecin . stage ivb colon cancer diagnosis and current evidence of corneal or retinal disorder keratopathy including but not limited to bullous band keratopathy corneal abrasion inflammation ulceration keratoconjunctivitis confirmed by ophthalmologic examination
__label__1	study interventions are Sigmoidoscopy . rectal carcinoma diagnosis and men who are taking tamoxifen are not excluded from any part of the plco screening trial
__label__1	study interventions are Gemcitabine . any prior anti cancer chemotherapy biologic or investigational therapy for pdac
__label__1	study interventions are Saracatinib . stage ivc squamous cell carcinoma of the larynx diagnosis and history of myocardial infarction within the past year
__label__1	study interventions are Albumin-Bound Paclitaxel . urethral cancer associated with invasive bladder cancer diagnosis and prior therapy with herceptin
__label__1	study interventions are Vidarabine . recurrent small lymphocytic lymphoma diagnosis and cross match positive with recipient
__label__1	study interventions are Antimitotic Agents . peritoneal cancer diagnosis and history or concurrent evidence of retinal vein occlusion rvo or current risk factors for rvo
__label__1	study interventions are Isotretinoin . neuroblastoma diagnosis and another investigational drug within four weeks of study drug administration
__label__1	study interventions are Bevacizumab . ovarian carcinosarcoma diagnosis and other medical conditions including but not limited to
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and known hypersensitivity to cyclophosphamide thalidomide or dexamethasone
__label__1	study interventions are Mycophenolate mofetil . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and age greater_than seventy-five years
__label__1	study interventions are Methylprednisolone Hemisuccinate . prostate cancer metastatic diagnosis and uncontrolled severe illness or medical condition including uncontrolled diabetes mellitus
__label__1	study interventions are Paclitaxel . stage iii squamous cell carcinoma of the hypopharynx diagnosis and patient is enrolled in another investigational trial
__label__1	study interventions are Sirolimus . advanced adult hepatocellular carcinoma diagnosis and patients with an active bleeding diathesis or on oral anti vitamin medication except warfarin as long as the goal inr is less_than doc
__label__1	study interventions are Paclitaxel . stage iia ovarian cancer diagnosis and note
__label__1	study interventions are Pomalidomide . refractory plasma cell myeloma diagnosis and john wort
__label__1	study interventions are Laboratory Biomarker Analysis . stage iii fallopian tube cancer diagnosis and medical or psychiatric illness that would in the opinion of the investigator preclude participation in the study or the ability of patients to provide informed consent for themselves
__label__1	study interventions are Pembrolizumab . stage iv non small cell lung cancer diagnosis and patients who are undergoing first month of therapy ripe or equivalent for active tb
__label__1	study interventions are Albumin-Bound Paclitaxel . germ cell tumors diagnosis and patients with hiv infection hepatitis and c
__label__1	study interventions are Mycophenolic Acid . stage mantle cell lymphoma diagnosis and karnofsky score less_than seventy for adult patients
__label__1	study interventions are Letrozole . endometrial cancer diagnosis and gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug
__label__1	study interventions are sotrastaurin acetate . recurrent small lymphocytic lymphoma diagnosis and severe systemic infections requiring intravenous antibiotics within the two weeks prior to initiation of aebseventy-one
__label__1	study interventions are Tissue Collection . ovarian cancer diagnosis and women who are pregnant
__label__1	study interventions are Antibodies . recurrent squamous cell carcinoma of the nasopharynx diagnosis and supraventricular and nodal arrhythmias requiring pacemaker or not controlled with medication
__label__1	study interventions are Antibodies . stage iv squamous cell carcinoma of the hypopharynx diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Epacadostat . stage iiib ovarian cancer diagnosis and malabsorption syndrome or chronic nausea that might hinder absorption and assessment of oral medication
__label__1	study interventions are Pemetrexed . is now undergoing and or has undergone in the twenty-eight days immediately prior to first dose of study drug any cancer therapy surgery tumor embolization chemotherapy radiation therapy immunotherapy biological therapy or hormonal therapy
__label__1	study interventions are Cediranib . recurrent thyroid gland carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to cediranib lenalidomide or other agents used in this study
__label__1	study interventions are PM01183 . symptomatic and progressive or corticosteroid requiring documented brain metastases
__label__1	study interventions are L-lysine . stage iii squamous cell carcinoma of the larynx diagnosis and inability or unwillingness to take daily lysine supplementation as prescribed
__label__1	study interventions are Lenograstim . contiguous stage ii mantle cell lymphoma diagnosis and fever temp greater_than thirty-eight degrees_celsius ten doc degrees_fahrenheit f
__label__1	study interventions are Sodium thiosulfate . gastric cancer diagnosis and solid organ metastases liver central nervous system lung
__label__1	study interventions are Trastuzumab . stage iv breast cancer diagnosis and patients have an active infection and require intravenous iv or oral antibiotics
__label__1	study interventions are Fluorouracil . pancreatic carcinoma non resectable diagnosis and patients with remote history of asthma or mild active asthma are eligible
__label__1	study interventions are laboratory biomarker analysis . stage iv pancreatic cancer diagnosis and active infections or oral temperature greater_than three doc celsius within forty-eight hours of study entry
__label__1	study interventions are Pembrolizumab . gastrointestinal cancer metastatic diagnosis and if positive results are not indicative of true active or chronic infection the patient can be treated
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ib uterine sarcoma diagnosis and patients with known hypersensitivity to mesna or other thiol compounds
__label__1	study interventions are Levoleucovorin . prior therapy for metastatic cancer
__label__1	study interventions are Bacitracin . breast cancer diagnosis and allergy to chg
__label__1	study interventions are Dexamethasone acetate . anaplastic large cell lymphoma alk positive diagnosis and patients with disease limited to the skin are not eligible regardless of how wide spread
__label__1	study interventions are Docetaxel . unspecified adult solid tumor protocol specific diagnosis and barrier methods of contraception
__label__1	study interventions are Cyclophosphamide . recurrent mantle cell lymphoma diagnosis and donor
__label__1	study interventions are Cyclosporine . primary central nervous system lymphoma diagnosis and donor
__label__1	study interventions are Vidarabine . refractory multiple myeloma diagnosis and mediastinum forty gy
__label__1	study interventions are Regorafenib . metastatic biliary tract carcinoma diagnosis and unstable angina angina symptoms at rest new onset angina within three months before randomization or myocardial infarction within six months before randomization
__label__1	study interventions are Lapatinib . stage iva verrucous carcinoma of the larynx diagnosis and patients who have not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are personalized coaching . breast cancer diagnosis and patients do not have sufficient understanding of the french language
__label__1	study interventions are Immunoglobulin G . ovarian seromucinous carcinoma diagnosis and no stereotactic radiation or whole brain radiation within twenty-eight days prior to cycle one day one
__label__1	study interventions are Cyclosporins . small lymphocytic lymphoma diagnosis and if less_than eighteen years old prior myeloablative transplant within the last six months
__label__1	study interventions are Tacrolimus . fibrolamellar hepatocellular carcinoma diagnosis and autoimmune disease requiring immunosuppressive drugs for maintenance
__label__1	study interventions are XL184 . lymphoma diagnosis and administration of an investigational drug within thirty days of the first dose of xlone hundred and eighty-four
__label__1	study interventions are Carboplatin . past or current history of neoplasm other than breast carcinoma except for
__label__1	study interventions are Antilymphocyte Serum . multiple myeloma diagnosis and congenital bone marrow failure syndrome
__label__1	study interventions are Iodine . thyroid cancer diagnosis and poorly differentiated
__label__1	study interventions are Cytarabine . recurrent grade three follicular lymphoma diagnosis and patient has greater_than grade two peripheral neuropathy within fourteen days before enrollment
__label__1	study interventions are Cervarix . infections papillomavirus diagnosis and subject who at the ncttwo hundred and ninety-four thousand and forty-seven concluding study visit had cervical lesion at that visit or who had cervical lesion that required treatment at her ncttwo hundred and ninety-four thousand and forty-seven exit colposcopy
__label__1	study interventions are NovoTTF-100A plus chemotherapy . small cell lung cancer diagnosis and shunt
__label__1	study interventions are Methylprednisolone Hemisuccinate . diffuse large cell lymphoma diagnosis and history of significant neurological or psychiatric disorders including dementia or seizures
__label__1	study interventions are Cyclophosphamide . recurrent primary peritoneal carcinoma diagnosis and use of systemic steroid equal_than less_than thirty days prior to registration
__label__1	study interventions are Antibodies, Monoclonal . recurrent adult diffuse large cell lymphoma diagnosis and new york heart association classification iii or iv or history of angina pectoris requiring active treatment
__label__1	study interventions are Lenograstim . metastatic pancreatic cancer diagnosis and recent less_than three months history of partial or complete bowel obstruction
__label__1	study interventions are Rituximab . refractory diffuse large cell lymphoma diagnosis and history of allogeneic stem cell or other organ transplantation
__label__1	study interventions are Prednisone . mature cell non hodgkin lymphoma diagnosis and prior exposure to rituximab
__label__1	study interventions are Sirolimus . insulinoma diagnosis and treatment with medications listed in appendix for which no safer or more efficacious alternative is available
__label__1	study interventions are Entinostat . stage ib non small cell lung carcinoma diagnosis and wedge resection or segmentectomy
__label__1	study interventions are Vidarabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and patients who have received alemtuzumab within eight weeks of the transplant admission or who have recently received horse or rabbit anti thymocyte_globulin and have an anti thymocyte_globulin level of greater_than two ugm ml
__label__1	study interventions are Thalidomide . stage ii thyroid gland follicular carcinoma diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Irinotecan . adenocarcinoma of the colon diagnosis and patients with any active or uncontrolled infection
__label__1	study interventions are ispinesib . stage iv adult immunoblastic large cell lymphoma diagnosis and miscellaneous
__label__1	study interventions are Computed Tomography and Mammography and Tomosynthesis . breast cancer diagnosis and multiple food and or drug allergy
__label__1	study interventions are Antilymphocyte Serum . lymphoma non hodgkin diagnosis and active infection requiring oral or intravenous antibiotics
__label__1	study interventions are Therapeutic Conventional Surgery . stage iv non small cell lung cancer diagnosis and concomitant administration with strong inhibitors or inducers of cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour should be avoided because the lists of these agents are constantly_changing it is important to regularly consult frequently_updated medical reference for list of drugs to avoid or minimize use of ongoing phenytoin should be either discontinued if clinically safe or transitioned to non enzyme inducing antiepileptics like keppra levetiracetam with eight day washout period half life 1eight twenty-two hours time to steady state four eight days prior to first dose of vx nine hundred and seventy seven days prior to wbrt
__label__1	study interventions are Fludarabine phosphate . hepatosplenic cell lymphoma diagnosis and coli derived proteins
__label__1	study interventions are Laboratory Biomarker Analysis . stage iv breast cancer diagnosis and treatment with other investigational agent within thirty days of planned lymphodepletion
__label__1	study interventions are Fludarabine phosphate . myeloproliferative neoplasm diagnosis and bone marrow documenting blast count greater_than equal_than ten or greater_than equal_than five in cmml patients who have progressed beyond cmmlone and received myelosuppressive chemotherapy
__label__1	study interventions are Lapatinib . infiltrative bladder carcinoma diagnosis and ejection fraction below the institutional normal limit
__label__1	study interventions are Antibodies, Monoclonal . glioblastoma multiforme diagnosis and inability to comply with study and or follow up procedure
__label__1	study interventions are Vinblastine . sarcoma soft tissue diagnosis and another primary malignancy
__label__1	study interventions are Endothelial Growth Factors . adult rhabdomyosarcoma diagnosis and patients with history of central venous catheter cvc associated thrombosis requiring systemic anticoagulation are ineligible note
__label__1	study interventions are Cetuximab . squamous cell carcinoma of the head and neck diagnosis and patient who has received radiotherapy less_than four weeks or limited field radiation for palliation less_than two weeks prior to starting study drug and who has not recovered to grade one or better from related side effects of such therapy with the exception of alopecia and or from whom greater_than two5 r
__label__1	study interventions are Antibodies, Monoclonal . stage marginal zone lymphoma diagnosis and patient is unwilling or unable to practice contraception during treatment and for one year thereafter
__label__1	study interventions are Laboratory Biomarker Analysis . stage iiib fallopian tube cancer diagnosis and cirrhosis or chronic hepatitis virus positivity or chronic hepatitis infection subjects who may not tolerate immune mediated hepatitis due to compromised hepatic reserve are also excluded from participation including
__label__1	study interventions are Endothelial Growth Factors . solid neoplasm diagnosis and history of any of the following within six months prior to start of mlnone hundred and twenty-eight
__label__1	study interventions are Paclitaxel . endometrial undifferentiated carcinoma diagnosis and patients who have an active pleural or pericardial effusion of any grade
__label__1	study interventions are Lapatinib . glioma diagnosis and hiv positive patients receiving combination anti retroviral therapy are excluded from the study due to possible retro viral drug interactions
__label__1	study interventions are Bevacizumab . glial cell tumors diagnosis and patients with history of serious non healing wound ulcer or bone fracture are not eligible
__label__1	study interventions are Capsaicin . prostate cancer diagnosis and non steroidal anti androgens bicalutamide nilutamide flutamide etc
__label__1	study interventions are Cabozantinib S-malate . stage iii thyroid gland papillary carcinoma diagnosis and the subject requires chronic concomitant treatment of strong cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour inducers dexamethasone phenytoin carbamazepine rifampin rifabutin rifapentin phenobarbital and st
__label__1	study interventions are Ibrutinib . nodal marginal zone lymphoma diagnosis and history of stroke or intracranial hemorrhage within six months prior to enrollment
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and participants who had received bortezomib in previous clinical trial and best response was progressive disease or experienced one or more serious events
__label__1	study interventions are Carboplatin . lymphoma diagnosis and uncontrolled angina
__label__1	study interventions are Paclitaxel . recurrent breast cancer diagnosis and hormone therapy
__label__1	study interventions are Mycophenolic Acid . recurrent cutaneous cell non hodgkin lymphoma diagnosis and any vertebral instability
__label__1	study interventions are Antibodies, Monoclonal . recurrent metastatic squamous neck cancer with occult primary diagnosis and clinically significant cardiac disease congestive heart failure unstable or uncontrolled angina myocardial infarction within six months of dosing with vtx two thousand, three hundred and thirty-seven
__label__1	study interventions are Melphalan . stage iv adult lymphoblastic lymphoma diagnosis and prior to study entry any electrocardiogram ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are Pembrolizumab . recurrent non hodgkin lymphoma diagnosis and pregnancy or nursing or unwilling to take adequate birth control during therapy
__label__1	study interventions are Tasigna . neurofibromatosis diagnosis and qtc greater_than four hundred and fifty msec on baseline ecg
__label__1	study interventions are Capecitabine . hertwo negative breast cancer diagnosis and any other life threatening illness serious uncontrolled concurrent infection or clinically significant cardiac disease
__label__1	study interventions are Bevacizumab . symptomatic peripheral vascular disease
__label__1	study interventions are Vorinostat . stage iii pancreatic cancer diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Tamoxifen . estrogen receptor positive breast cancer diagnosis and confirmed diagnosis of hertwo positive disease
__label__1	study interventions are Therapeutic conventional surgery . recurrent breast cancer diagnosis and bmi less_than twenty-one
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and patients with ongoing abdominal infections or bowel obstruction
__label__1	study interventions are Fludarabine phosphate . stage ii grade two contiguous follicular lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for 1two months following treatment
__label__1	study interventions are Stereotactic radiosurgery (SRS) . recurrent breast cancer diagnosis and preclinical studies indicate that rofour million, nine hundred and twenty-nine thousand and ninety-seven is substrate of cypfour hundred and fifty family three subfamily polypeptide four cypthreeafour and inducer of cypthreeafour enzyme activity caution should be exercised when dosing rofour million, nine hundred and twenty-nine thousand and ninety-seven concurrently with cypthreeafour substrates inducers and or inhibitors furthermore patients who are taking concurrent medications that are strong inducers inhibitors or substrates of cypthreeafour should be switched to alternative medications to minimize any potential risk if such patients cannot be switched to alternative medications they will be ineligible to participate in this study
__label__1	study interventions are Paclitaxel . stage iiia breast cancer diagnosis and patients who have had chemotherapy or radiotherapy within four weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Paclitaxel . symptomatic coronary artery disease
__label__1	study interventions are PF-299804 (Dacomitinib) . glioblastoma diagnosis and because there is an unknown risk of potential adverse effects in infants secondary to maternal treatment with pf two hundred and ninety-nine thousand, eight hundred and four breastfeeding should be discontinued if mother is treated with pf two hundred and ninety-nine thousand, eight hundred and four
__label__1	study interventions are Ascorbic Acid . prostatic adenocarcinoma diagnosis and the use of the five alpha reductase inhibitor dutasteride must be discontinued within four weeks of degarelix injection for cohort one two and four and within four weeks of surgery for cohort three
__label__1	study interventions are Carmustine . refractory childhood hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Antibodies . stage iva salivary gland cancer diagnosis and patients may not be receiving any other investigational agents in addition patients must not have received investigational treatment equal_than less_than thirty days prior to registration
__label__1	study interventions are Fludarabine phosphate . angioimmunoblastic cell lymphoma diagnosis and donor
__label__1	study interventions are Bevacizumab . glioblastoma diagnosis and pregnant or breastfeeding patients
__label__1	study interventions are Cediranib . lung cancer diagnosis and patient with inappropriate laboratory tests values
__label__1	study interventions are video fluoroscopy . primary non operated squamous cell carcinoma of larynx diagnosis and patient unlikely to comply with protocol uncooperative_attitude inability to return for follow up visits and unlikely to complete the study
__label__1	study interventions are Paclitaxel . metastatic breast cancer diagnosis and mean resting corrected qt interval qtc greater_than four hundred and eightymsec or qtcf greater_than four hundred and fifty msec obtained from three consecutive ecgs
__label__1	study interventions are Doxorubicin . fallopian tube cancer diagnosis and have had any investigational agent within four weeks before enrollment into the study
__label__1	study interventions are Endothelial Growth Factors . metastatic solid neoplasm diagnosis and uncontrolled high blood pressure systolic blood pressure greater_than one hundred and fifty mm hg diastolic blood pressure greater_than ninety-five mm hg
__label__1	study interventions are Thalidomide . waldenstrom macroglobulinemia or immunoglobin ig myeloma
__label__1	study interventions are Aluminum Hydroxide . stomatitis diagnosis and current smokers or alcohol users
__label__1	study interventions are Cyclophosphamide . neoplasms diagnosis and patients with history of cns metastases who have received treatment and whose cns metastatic disease status has remained stable for greater than or equal to three months without steroids or anti seizure medications may be eligible
__label__1	study interventions are Dexamethasone 21-phosphate . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and marked limitation of physical activity comfortable at rest but less than ordinary activity causes fatigue or dyspnea iv
__label__1	study interventions are Antibodies, Monoclonal . stage ivb squamous cell carcinoma of the oropharynx diagnosis and unstable angina and or congestive heart failure requiring hospitalization within six months prior to registration
__label__1	study interventions are Fludarabine . noncutaneous extranodal lymphoma diagnosis and marrow donors who have increased anesthetic risk
__label__1	study interventions are Estrogens . invasive breast carcinoma diagnosis and clinical nodal staging of ntwo or nthree disease
__label__1	study interventions are Immunoglobulins . stage ivb squamous cell carcinoma of the larynx diagnosis and previous or current uveitis
__label__1	study interventions are Mycophenolate mofetil . recurrent adult diffuse mixed cell lymphoma diagnosis and donor
__label__1	study interventions are Armodafinil . triple negative breast cancer diagnosis and provided the lung is not in the radiation field
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and anticoagulant therapy except for warfarin of less than twomg per day
__label__1	study interventions are Bevacizumab . advanced colorectal cancer diagnosis and ascertained hypersensitivity to any component of investigational product or folfox positive bevacizumab cetuximab that the subject will be treated
__label__1	study interventions are Freund's Adjuvant . recurrent ovarian epithelial cancer diagnosis and other serious illnesses serious infections requiring antibiotics bleeding disorders
__label__1	study interventions are Albumin-Bound Paclitaxel . bladder urothelial transitional cell cancer resectable pre cystectomy diagnosis and myocardial infarction
__label__1	study interventions are Liposomal doxorubicin . any chemotherapy external beam radiation therapy or anti cancer antibodies within two weeks
__label__1	study interventions are Survey . one diagnosed with cancers other than central nervous system tumors sarcomas leukemia or lymphoma two diagnosed with cancer either prior to one99two or after two00seven three currently on treatment four currently diagnosed with progressive cancer five deceased six under age eight or over age threefour or seven non english speaking or reading
__label__1	study interventions are Epoetin Alfa . diagnosis of down syndrome tumor of the central nervous system cns or symptomatic metastatic cns disease for the solid tumor hodgkin disease stratum or presence of symptomatic cns disease at diagnosis for the acute lymphocytic leukemia non hodgkin lymphoma stratum
__label__1	study interventions are Sorafenib . advanced adult hepatocellular carcinoma diagnosis and clinically significant cardiovascular risk
__label__1	study interventions are Pembrolizumab . esophageal adenocarcinoma diagnosis and has active autoimmune disease that has required systemic treatment in the past two years with use of disease modifying agents corticosteroids or immunosuppressive drugs
__label__1	study interventions are Paclitaxel . rhabdomyosarcoma diagnosis and the metabolism of paclitaxel is catalyzed by cyptwoceight and cypthreeafour
__label__1	study interventions are Pembrolizumab . prostate adenocarcinoma diagnosis and patients may not have been treated with prior sipuleucel t
__label__1	study interventions are Immunoglobulin G . stage iv fallopian tube cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are BB 1101 . prior treatment with pomalidomide
__label__1	study interventions are Fludarabine phosphate . splenic marginal zone lymphoma diagnosis and patients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening
__label__1	study interventions are Immunoglobulin G . adult glioblastoma diagnosis and pulmonary hypertension
__label__1	study interventions are Lanreotide . autosomal_dominant diagnosis and use of oral anticonceptives or estrogen suppletion
__label__1	study interventions are MRI scanner . cerebellar neoplasm diagnosis and participants that require anesthesia to complete an mri scan
__label__1	study interventions are questionnaire administration . stage iva squamous cell carcinoma of the lip and oral cavity diagnosis and presence of distant metastatic disease
__label__1	study interventions are Paclitaxel . her two positive gastric cancer diagnosis and baseline less than one month before treatment cardiac left ventricular function with resting ejection fraction of less than fifty percent measured by multigated blood pool imaging of the heart muga scan or echocardiogram
__label__1	study interventions are Antibodies . childhood embryonal rhabdomyosarcoma diagnosis and patients with known type or type ii diabetes mellitus are not eligible for enrollment on pilot one
__label__1	study interventions are Calorimetry . unresectable colorectal tumor with without synchronous metastases
__label__1	study interventions are Albumin-Bound Paclitaxel . sarcoma kaposi diagnosis and serious uncontrolled infection
__label__1	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and significant thrombotic or embolic events within three months prior to randomization significant thrombotic or embolic events include but are not limited to stroke or transient ischemic attack
__label__1	study interventions are Bendamustine Hydrochloride . refractory relapsed indolent non hodgkin lymphoma diagnosis and men or women of childbearing potential who are unwilling to employ adequate contraception
__label__1	study interventions are Dexamethasone acetate . solid tumors diagnosis and that requires wound healing within last two weeks
__label__1	study interventions are Sirolimus . unresectable gallbladder cancer diagnosis and other concurrent chemotherapy immunotherapy radiotherapy or any ancillary therapy considered investigational utilized for non food and drug administration fda approved indication and in the context of research investigation
__label__1	study interventions are Docetaxel . breast cancer diagnosis and has used an investigational drug within one month before the screening visit
__label__1	study interventions are LEE011 . melanoma diagnosis and lgxeight hundred and eighteen mekone hundred and sixty-two bkmone hundred and twenty
__label__1	study interventions are Bortezomib . metastatic renal cell carcinoma diagnosis and patients with poorly controlled diabetes mellitus
__label__1	study interventions are placebo . colorectal cancer diagnosis and brain metastasis
__label__1	study interventions are Glycosylated Recombinant Human Interleukin-7 . hormone resistant prostate cancer diagnosis and patients who have received prior immunosuppressive therapy within thirty days prior to enrollment
__label__1	study interventions are PV-10 (10% rose bengal disodium) . melanoma diagnosis and female subjects who have positive serum ßhcg pregnancy test taken within seven days of pv ten treatment
__label__1	study interventions are Liposomal doxorubicin . stage iii diffuse large cell lymphoma diagnosis and is currently participating and receiving study therapy or has participated in study of an investigational agent and received study drug or using an investigation device within four weeks of the first dose of treatment
__label__1	study interventions are Immunoglobulins . stage iiic primary peritoneal cancer diagnosis and core biopsy within seven days prior to day one therapy
__label__1	study interventions are Ramucirumab . advanced cancer diagnosis and previous systemic therapy for locally advanced or metastatic disease is not allowed
__label__1	study interventions are Veliparib . ovarian clear cell adenocarcinoma diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and concurrent treatment with ovarian hormonal replacement therapy
__label__1	study interventions are Paclitaxel . stage iv adult burkitt lymphoma diagnosis and patients with myocardial infarction mi or cardiac heart surgery within the past three months
__label__1	study interventions are Cyclophosphamide . anaplastic large cell lymphoma diagnosis and hct ci score greater_than four points for patients greater_than sixty years old or greater_than five points for patients less_than sixty
__label__1	study interventions are Antibodies . recurrent rectal cancer diagnosis and patients with history of brain metastases are eligible provided that the metastases have been surgically resected and or are radiographically and clinically stable for two months following the completion of radiation therapy
__label__1	study interventions are Niacinamide . cancer diagnosis and patients on rifampin st
__label__1	study interventions are Cediranib . ovarian endometrioid adenocarcinoma diagnosis and no prior allogeneic bone marrow transplant or double umbilical cord blood transplantation dubct
__label__1	study interventions are Ramucirumab . stage iv gastric cancer diagnosis and patients with untreated brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Mycophenolic Acid . recurrent grade two follicular lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Zidovudine . sarcoma kaposi diagnosis and significant pulmonary exertional dyspnea with minimal exercise or cardiac insufficiency new york heart association status greater_than two
__label__1	study interventions are Fludarabine phosphate . stage iv adult diffuse large cell lymphoma diagnosis and bone marrow bm donors
__label__1	study interventions are Antibodies . stage iii verrucous carcinoma of the larynx diagnosis and magnesium less_than doc mg dl less_than doc mmol or greater_than three mg dl greater_than doc three mmol despite intervention to normalize levels
__label__1	study interventions are Dasatinib . stage iva squamous cell carcinoma of the larynx diagnosis and pregnant women and women who are currently breast feeding may not participate in this study all women of childbearing potential must have negative pregnancy test within seventy-two hours prior to enrolling in the study postmenopausal women must be amenorrheic for at least twelve months to be considered of non childbearing potential
__label__1	study interventions are Ponatinib . adenocarcinoma of the lung diagnosis and history of allergic or severe reactions attributed to compounds of similar chemical or biologic composition to ponatinib
__label__1	study interventions are Liposomal doxorubicin . triple negative breast cancer diagnosis and uncontrolled hypertension bp greater_than one hundred and fifty ninety-five mmhg despite medical therapy b
__label__1	study interventions are Melphalan . stage iii small lymphocytic lymphoma diagnosis and any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form
__label__1	study interventions are Halt Procedure . uterine myomas diagnosis and in the medical judgment of the investigator should not participate in the study
__label__1	study interventions are Methotrexate . symptomatic pulmonary disease
__label__1	study interventions are Cadexomer iodine . non hodgkin lymphoma diagnosis and patients of child bearing potential must undergo serum pregnancy test within seven days prior to study entry and radiolabeled antibody is not to be administered until negative result is obtained
__label__1	study interventions are Rituximab . contiguous stage ii small lymphocytic lymphoma diagnosis and known cns involvement
__label__1	study interventions are Levoleucovorin . lymphoma diagnosis and no prior cytotoxic chemotherapy
__label__1	study interventions are Tacrolimus . stage iv grade one follicular lymphoma diagnosis and patient or donor infected with human immunodeficiency virus hiv
__label__1	study interventions are Sorafenib . solid neoplasm diagnosis and women of childbearing potential who are unwilling to employ adequate contraception note
__label__1	study interventions are pharmacological study . stage iiib non small cell lung cancer diagnosis and patients with malabsorption syndrome or other condition that would interfere with intestinal absorption
__label__1	study interventions are Laboratory Biomarker Analysis . stage iia breast cancer diagnosis and recent use within past month of more than three days of antibiotics use
__label__1	study interventions are Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength) . squamous cell carcinoma diagnosis and known hypersensitivity to adhesive rings
__label__1	study interventions are Androgens . non metastatic hormone naïve prostate cancer diagnosis and uncontrolled cardiac arrhythmias
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic carcinoma to the uterine cervix diagnosis and impaired renal liver functions as indicated by
__label__1	study interventions are Everolimus . cancer within the past five years except basal cell skin cancer
__label__1	study interventions are Iodine-131 anti-B1 antibody . multiple myeloma diagnosis and prior anti cdtwenty therapy
__label__1	study interventions are ispinesib . stage iv grade three follicular lymphoma diagnosis and john wort modafinil oxcarbazepine
__label__1	study interventions are Capecitabine . other primary solid tumor curatively treated with no known active disease present and no treatment administered for the last three years
__label__1	study interventions are questionnaire administration . stage ii childhood anaplastic large cell lymphoma diagnosis and patients who have received gonadotropin release hormone agonist or antagonist lupron prior to study entry are not eligible
__label__1	study interventions are Etoposide phosphate . small cell lung cancer diagnosis and active hepatitis or hepatitis c
__label__1	study interventions are Cyclosporins . refractory multiple myeloma diagnosis and known allergy to csf
__label__1	study interventions are Fostamatinib disodium . carcinoma renal cell diagnosis and erythromycin
__label__1	study interventions are Methotrexate . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and breakpoint cluster region abelson positive bcr_abl positive patients will be excluded from the study
__label__1	study interventions are Dexamethasone . lymphoma diagnosis and patients previously randomized in any other onyx sponsored phase three trial
__label__1	study interventions are Laboratory Biomarker Analysis . refractory plasma cell myeloma diagnosis and as part of the enrollment informed consent procedures the patient will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the patient is considering new over the counter product
__label__1	study interventions are Interleukin-2 . skin cancer diagnosis and prior systemic therapy with pd one blocking antibody
__label__1	study interventions are Lapatinib . stage iii bladder cancer diagnosis and presence of left bundle_branch blocks lbbb
__label__1	study interventions are Sunitinib . neoplasms by histologic type diagnosis and active diverticulitis
__label__1	study interventions are Vinorelbine . a history of other tumors or combined with other tumor patients
__label__1	study interventions are placebo . stage iva oral cavity squamous cell carcinoma diagnosis and although there are no known adverse effects of black_raspberries upon the fetus if patients become pregnant during period of lyophilized_black raspberries_lbr administration then lbr will be discontinued and patient will be removed from the study we should however emphasize given this is food based study that risks are likely extremely low even though participant should become pregnant as such we are not recommending active contraception for women but rather if participants become pregnant that they notify their study doctor and that they will likely be removed from study there are no expected or logical risks if men were to father child and as such no contraception will be recommended for men
__label__1	study interventions are Thalidomide . peripheral cell lymphoma diagnosis and ongoing or active infection
__label__1	study interventions are Sirolimus . hertwo negative locally advanced breast cancer diagnosis and clinical or radiological detection of cns metastases
__label__1	study interventions are Misonidazole . stage iv breast cancer diagnosis and an ultrasound us within the last six months will be required to document that it is less_than fivecm
__label__1	study interventions are Doxorubicin . prior chemotherapy for breast cancer
__label__1	study interventions are Fludarabine phosphate . stage marginal zone lymphoma diagnosis and positive cross match exists between the donor and recipient
__label__1	study interventions are Palonosetron . multiple myeloma diagnosis and phenothiazine antiemetics prochlorperazine thiethylperazine and perphenazine
__label__1	study interventions are Vitamin B Complex . hodgkin lymphoma diagnosis and patients treated with an fda approved monoclonal antibody therapy may be enrolled at any time after the therapy if they have pd
__label__1	study interventions are Dexamethasone acetate . mantle cell lymphoma diagnosis and serious surgery within thirty days
__label__1	study interventions are Capecitabine . colorectal cancer diagnosis and creatinine ratio greater_than equal_than doc impaired renal function with estimated creatinine clearance less_than thirty ml min as calculated with cockroft et gault equation
__label__1	study interventions are Laser diode . melanoma uveal diagnosis and patients for whom follow up will be difficult due to geographical social or psychological reasons
__label__1	study interventions are Fludarabine phosphate . recurrent adult lymphoblastic lymphoma diagnosis and donor or centers who will exclusively donate marrow
__label__1	study interventions are (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) . stage iiib fallopian tube cancer diagnosis and pregnant and breastfeeding
__label__1	study interventions are Endothelial Growth Factors . recurrent primary peritoneal carcinoma diagnosis and prior treatment with sorafenib or other vascular endothelial growth factor vegf inhibitors note
__label__1	study interventions are Fludarabine phosphate . stage iii adult diffuse small cleaved cell lymphoma diagnosis and donors for whom medical or psychologic reasons would make donor procedure intolerable
__label__1	study interventions are Bevacizumab . renal cell carcinoma diagnosis and malignancies other than rcc within five years prior to cycle one day one with the exception of those with negligible risk of metastasis or death treated with expected curative outcome
__label__1	study interventions are Fludarabine phosphate . noncontiguous stage ii grade two follicular lymphoma diagnosis and bilirubin greater_than equal_than three upper limit of normal
__label__1	study interventions are Godin Leisure-Time Exercise Questionnaire (GLTEQ) . prostate cancer diagnosis and previously undergone major pelvic surgery
__label__1	study interventions are Imatinib Mesylate . lung cancer diagnosis and limited stage disease includes ia ib iia iib and iiia
__label__1	study interventions are Antibodies, Monoclonal . stage ivb rectal cancer diagnosis and patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are 10-deazaaminopterin . b cell lymphoma diagnosis and receipt of systemic corticosteroids within seven days of study treatment unless on continuous dose of no more than ten mg day of prednisone for at least one month
__label__1	study interventions are Laboratory Biomarker Analysis . stage iva laryngeal squamous cell carcinoma diagnosis and documented evidence of distant metastases
__label__1	study interventions are Lenograstim . breast neoplasms diagnosis and had mental condition or psychiatric disorder rendering her unable to understand the nature scope and possible consequences of the study
__label__1	study interventions are Trastuzumab . symptomatic angina pectoris within the past ninety days that required the initiation of or increase in anti anginal medication or other intervention ventricular arrhythmias except for benign premature ventricular contractions supraventricular and nodal arrhythmias requiring pacemaker or not controlled with medication conduction abnormality requiring pacemaker valvular disease with documented compromise in cardiac function and symptomatic pericarditis
__label__1	study interventions are Hormones . solid tumors diagnosis and history of cva within six months myocardial infarction or unstable angina within six months or unstable angina pectoris
__label__1	study interventions are Irinotecan . metastatic colorectal cancer diagnosis and subject unwilling or unable to comply with study requirements
__label__1	study interventions are Immunoglobulins . stage iva squamous cell carcinoma of the oropharynx diagnosis and patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator
__label__1	study interventions are Pharmaceutical Solutions . breast cancer diagnosis and known diagnoses possibly underlying or contributing to the state of the eyebrows including but not limited to telogen effluvium or anagen effluvium group two
__label__1	study interventions are Capecitabine . atients combined antitumor drug outside the research program
__label__1	study interventions are Antibodies . stage ivc squamous cell carcinoma of the oropharynx diagnosis and uncontrolled comorbid illness
__label__1	study interventions are Vaccines . undifferentiated ovarian carcinoma diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Vaccines . lung cancer diagnosis and healthy controls exclusion
__label__1	study interventions are Lenograstim . aids related burkitt lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to csf filgrastim e
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and patients receiving warfarin
__label__1	study interventions are Quality Of Life questionnaires . bladder cancer diagnosis and metastatic disease at diagnosis
__label__1	study interventions are 14C-labeled AC0010 oral . carcinoma non small cell lung diagnosis and any severe and or uncontrolled active infections
__label__1	study interventions are Immunoglobulin Fc Fragments . metabolic bone disease such as hyperparathyroidism paget disease or osteomalacia
__label__1	study interventions are Folic Acid . pancreatic adenocarcinoma diagnosis and john wort hypericum_perforatum
__label__1	study interventions are Poly ICLC . bladder cancer diagnosis and myocardial infarction or unstable angina within six months of the first date of treatment on this study
__label__1	study interventions are Carboxymethylcellulose Sodium . carcinoma in situ of the breast dcis or lcis
__label__1	study interventions are Dabrafenib . symptomatic or untreated or not stable for three months must be documented by imaging or requiring corticosteroids
__label__1	study interventions are Hormones . stage iii prostate cancer diagnosis and subjects with serious non healing wound ulcer or bone fracture are not eligible
__label__1	study interventions are Mycophenolic Acid . cutaneous cell non hodgkin lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Camptothecin . neuroblastoma diagnosis and history of abdominal fistula gastrointestinal perforation intra abdominal abscess or active gastrointestinal bleeding within six months prior to study enrolment
__label__1	study interventions are Dexamethasone . plasmacytoma diagnosis and men or women of childbearing potential who are unwilling to employ adequate contraception
__label__1	study interventions are Antibodies, Monoclonal . neurofibromatosis type two diagnosis and new york heart association grade ii or greater congestive heart failure
__label__1	study interventions are Whole blood sample . prostate adenocarcinoma diagnosis and patient with disease worsening and in incapacity to move about to chjm
__label__1	study interventions are Fludarabine phosphate . splenic marginal zone lymphoma diagnosis and fungal infections with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Bortezomib . refractory multiple myeloma diagnosis and these potential risks may also apply to other agents used in this study
__label__1	study interventions are Mitogens . renal cell carcinoma diagnosis and patients diagnosed with another malignancy
__label__1	study interventions are Gemcitabine . stage ia pancreatic cancer diagnosis and methadone dosage of methadone may need to be increased when coadministered with viracept
__label__1	study interventions are Doxorubicin . lymphoma non hodgkin diagnosis and ddi is allowed except when also taking allopurinol
__label__1	study interventions are Etoposide phosphate . intraocular lymphoma diagnosis and prior pelvic or spinal irradiation
__label__1	study interventions are Dasatinib . significant vascular disease aortic aneurysm aortic dissection and symptomatic peripheral vascular disease
__label__1	study interventions are Antibodies, Monoclonal . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements patients with chronic hepatitis or hepatitis infections should be excluded
__label__1	study interventions are Fludarabine . adult nasal type extranodal nk cell lymphoma diagnosis and cross match positive with recipient
__label__1	study interventions are Antibodies . recurrent squamous cell carcinoma of the larynx diagnosis and use of the following medications will not be allowed within four weeks prior to enrollment on the study and during the study
__label__1	study interventions are Triptorelin Pamoate . prostate cancer diagnosis and has history or current use of over the counter medications dietary supplements or drugs including nicotine and alcohol outside protocol specified parameters
__label__1	study interventions are Antibodies . recurrent colon cancer diagnosis and prisoners or subjects who are compulsorily_detained involuntarily_incarcerated for treatment of either psychiatric or physical eg infectious illness
__label__1	study interventions are Aromatase Inhibitors . stage iiia breast cancer diagnosis and any of the following
__label__1	study interventions are Capecitabine . symptomatic malignant ascites requiring palliative paracentesis
__label__1	study interventions are Hyperfractionated radiation therapy . adult pilocytic astrocytoma diagnosis and pregnancy testing is not required for post menopausal or surgically sterilized women
__label__1	study interventions are Hydroxyurea . uncontrolled diabetes active abuse of ethanol allergies to study medication active infection or other serious medical condition that precludes protocol treatment dementia or significantly altered mental status that precludes informed consent prior melanoma or malignancy of the following sites
__label__1	study interventions are Vitamin D . breast cancer diagnosis and undergone prior subaeolar breast surgery
__label__1	study interventions are Navitoclax . prostate cancer diagnosis and patients without prior hiv testing will not be required to be tested
__label__1	study interventions are Pancreatin . adenocarcinoma diagnosis and major cardiovascular disease
__label__1	study interventions are Liposomal doxorubicin . dose escalation solid tumors diagnosis and a
__label__1	study interventions are Rituximab . adequately treated local basal cell or squamous cell carcinoma of the skin cervical carcinoma in situ superficial bladder cancer asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate specific antigen for greater_than one year prior to study entry other adequately treated stage one or two cancer currently in complete remission or any other cancer that has been in complete remission for greater_than five years
__label__1	study interventions are Paclitaxel . oesophageal cancer diagnosis and known peripheral neuropathy greater_than grade one absence of deep tendon_reflexes as the sole neurological abnormality does not render the patient ineligible
__label__1	study interventions are Mycophenolate mofetil . indolent non hodgkin lymphoma diagnosis and pregnancy or breastfeeding
__label__1	study interventions are Pulmonary Function Testing . hodgkin lymphoma diagnosis and currently pregnant
__label__1	study interventions are 10 mg/kg humanized anti-PD-1 mAb . esophageal squamous cell carcinoma diagnosis and patients received treatment for brain or meningeal metastasis previously can be included if they have remained stable clinically for at least two months and systemic glucocorticoid treatment prednisone with dose greater_than ten mg day or other equivalent formulations has been discontinued for more than four weeks
__label__1	study interventions are Bortezomib . stage ii multiple myeloma diagnosis and patients with systemic fungal bacterial viral or other infection not controlled defined as exhibiting ongoing signs symptoms related to the infection on antiviral antibiotic and antifungal treatment
__label__1	study interventions are Mycophenolic Acid . stage adult immunoblastic large cell lymphoma diagnosis and lansky play performance score less_than fifty for pediatric patients
__label__1	study interventions are Antibodies, Monoclonal . stage iiib breast cancer diagnosis and no requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
__label__1	study interventions are Prednisolone phosphate . prostate cancer diagnosis and in addition any clinically relevant sequel from the surgery must have resolved prior to cycle one day one
__label__1	study interventions are Trametinib . solid tumors diagnosis and prior vegf targeted tki therapy
__label__1	study interventions are Bevacizumab . neoplasm metastasis diagnosis and hypertension high blood pressure or significant cardiovascular disease
__label__1	study interventions are Mycophenolate mofetil . stage iv adult burkitt lymphoma diagnosis and patient unable to give informed consent
__label__1	study interventions are Fluorouracil . signet ring adenocarcinoma of the rectum diagnosis and prior radiotherapy to the region of the body that would result in overlap of rt fields with the current protocol treatment
__label__1	study interventions are Thiotepa . recurrent childhood anaplastic large cell lymphoma diagnosis and patients who have received alemtuzumab within eight weeks of the transplant admission or who have recently received horse or rabbit ant thymocyte_globulin and have an atg level of greater_than two ugm ml
__label__1	study interventions are Methoxsalen . prior systemic anticancer alkaloid chemotherapy
__label__1	study interventions are Poly I-C . small size posterior uveal melanoma diagnosis and positive hepatitis serology indicative of previous immunization hepatitis surface antibody hbsab positive and hepatitis core antibody hbcab negative or fully resolved acute hepatitis virus infection is not an exclusion criterion
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and general
__label__1	study interventions are Cyclophosphamide . noninvasive cancer
__label__1	study interventions are Rituximab . recurrent small lymphocytic lymphoma diagnosis and concerns for the subject compliance with the protocol
__label__1	study interventions are Sirolimus . breast cancer diagnosis and uncompensated diabetes mellitus fasting value of blood sugar of greater_than one hundred and twenty mg dl
__label__1	study interventions are Thioguanine . anaplastic glioma of brain diagnosis and patients of childbearing potential must not be pregnant or become pregnant
__label__1	study interventions are Epothilones . adult solid neoplasm diagnosis and nursing women
__label__1	study interventions are Oxaliplatin . hepatocellular carcinoma diagnosis and patients unable to swallow oral medications
__label__1	study interventions are Dexamethasone . stage iib non small cell lung carcinoma diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Trastuzumab . history of non breast malignancies except for in situ cancers treated only by local excision and basal cell and squamous cell carcinomas of the skin within five years prior to randomization
__label__1	study interventions are Endothelial Growth Factors . stage iiib ovarian cancer diagnosis and patients with or with anticipation of invasive procedures as defined below
__label__1	study interventions are Etoposide . recurrent adult burkitt lymphoma diagnosis and patients known positive for human immunodeficiency virus hiv or infectious hepatitis type or c
__label__1	study interventions are Paclitaxel . advanced or metastatic breast cancer diagnosis and patients who have had myocardial infarction or cardiac surgery should be at least six months from the event and free of active symptoms
__label__1	study interventions are Etoposide . recurrent mantle cell lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Alovudine . stage iib breast cancer diagnosis and condition requiring anesthesia for pet scanning and or unable to lie still for doc hours
__label__1	study interventions are Mannitol . adult anaplastic oligodendroglioma diagnosis and subject is pregnant has positive serum human chorionic gonadotropin hcg or is lactating
__label__1	study interventions are Erlotinib Hydrochloride . tumor invading the gi tract esophagus stomach small or large bowel rectum or anus or any evidence of endotracheal or endobronchial tumor cavitating pulmonary lesion tumor in contact with invading or encasing any major blood vessels
__label__1	study interventions are Rituximab . grade threea follicular lymphoma diagnosis and history prior malignancy except
__label__1	study interventions are Bevacizumab . ovarian endometrioid adenocarcinoma diagnosis and patients with known allergy to cremophor or polysorbate eighty
__label__1	study interventions are Liposomal doxorubicin . metastatic breast cancer diagnosis and contraindication to the use of corticosteroids as premedication
__label__1	study interventions are Antibodies, Monoclonal . ovarian endometrioid adenocarcinoma diagnosis and known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__1	study interventions are Buparlisib . basal cell carcinoma of the skin diagnosis and women of child bearing potential defined as all women physiologically capable of becoming pregnant must use highly effective contraception during the study and through twenty months after the final dose of study treatment for males with partners with childbearing potential highly effective contraception is required for six months the highly effective contraception is defined as either
__label__1	study interventions are Mechlorethamine . refractory plasma cell myeloma diagnosis and patients with fungal infection and radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Aminopterin . b cell lymphoma diagnosis and progression of disease pd after at least one prior treatment any number of prior therapies allowed
__label__1	study interventions are Temozolomide . primary central nervious system lymphoma diagnosis and within twenty-eight days of the first dose of study drug
__label__1	study interventions are Alemtuzumab . stage iv small lymphocytic lymphoma diagnosis and participation in any investigational drug study within twenty-eight days before study entry
__label__1	study interventions are Vincristine . stage iii childhood lymphoblastic lymphoma diagnosis and serious medical or psychiatric illness likely to interfere with participation in this clinical study
__label__1	study interventions are JM 3100 . recurrent adult lymphoblastic lymphoma diagnosis and have had previous radiation of the pelvic area
__label__1	study interventions are Antibodies . adult oligodendroglioma diagnosis and four grade two or greater or evidence of significant hemorrhage regardless of ctcae v
__label__1	study interventions are Mycophenolic Acid . recurrent childhood anaplastic large cell lymphoma diagnosis and active central nervous system cns involvement with disease
__label__1	study interventions are Ranitidine bismuth citrate . prostate cancer diagnosis and patients with reproductive potential who do not agree to use an accepted and effective method of contraception during the study treatment period
__label__1	study interventions are Bevacizumab . stage iiib ovarian cancer diagnosis and clinical evidence of encephalopathy
__label__1	study interventions are Dextrans . the patient has tumor with breslow depth less than doc fivemm
__label__1	study interventions are Bevacizumab . advanced cancer diagnosis and doc patients with clinically significant unexplained bleeding within twenty-eight days prior to entering the study
__label__1	study interventions are Fluorouracil . administration of the last dose of any previous adjuvant therapy for colorectal cancer within six months previous to randomization
__label__1	study interventions are Letrozole . patients who have no indication for an aromatase inhibitor or have known hypersensitivity to letrozole
__label__1	study interventions are Vidarabine . contiguous stage ii adult immunoblastic large cell lymphoma diagnosis and use of any other experimental drug within twenty-eight days of baseline
__label__1	study interventions are regional nodal XRT . stage ib breast cancer diagnosis and patients with microscopic positive margins after definitive surgery
__label__1	study interventions are Pembrolizumab . breast cancer diagnosis and completed
__label__1	study interventions are Trastuzumab . tubular breast cancer stage iii diagnosis and known or suspected congestive heart failure greater_than nyha and or coronary heart disease angina pectoris requiring antianginal medication previous history of myocardial infarction evidence of transmural infarction on ecg uncontrolled or poorly controlled arterial hypertension bp greater_than one hundred and forty ninety mm hg under treatment with two antihypertensive drugs rhythm abnormalities requiring permanent treatment clinically significant valvular heart disease
__label__1	study interventions are Mycophenolic Acid . stage iii adult diffuse mixed cell lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Dexamethasone acetate . ds stage iii plasma cell myeloma diagnosis and left ventricular ejection fraction less than forty-five immediately pre transplant patients with congestive heart disease with transplant history of myocardial infarction mi or history of coronary artery disease
__label__1	study interventions are Capecitabine . stomach neoplasms diagnosis and major surgery within four weeks of start of study treatment without complete recovery
__label__1	study interventions are VMAT with CBCT . head and neck carcinoma diagnosis and patient has systemic lupus erythematosis or scleroderma
__label__1	study interventions are Everolimus . cholangiocarcinoma diagnosis and if barrier contraceptives are being used these must be continued throughout the trial by both sexes
__label__1	study interventions are Hormones . estrogen receptor positive breast cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to tipifarnib rone hundred and fifteen thousand, seven hundred and seventy-seven zarnestra or other agents used in the study imidazoles quinolones
__label__1	study interventions are Albumin-Bound Paclitaxel . peritoneal neoplasms diagnosis and parenchymal brain metastases unless documented to be clinically and radiographically stable for at least six months after treatment for the disease
__label__1	study interventions are Therapeutic Conventional Surgery . stage iva oropharyngeal squamous cell carcinoma diagnosis and documented evidence of distant metastases or brain metastases
__label__1	study interventions are Mycophenolate mofetil . stage iii adult immunoblastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and serious intercurrent medical or psychiatric illnesses or any other conditions that in the opinion of the investigator would impair the ability to give informed consent or unacceptably reduce protocol compliance or safety of the study treatment
__label__1	study interventions are Ifosfamide . lymphoma diagnosis and abnormal liver function
__label__1	study interventions are Cyclosporine . hiv associated hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Pembrolizumab . skin basal cell carcinoma diagnosis and aspartate aminotransferase ast serum glutamic oxaloacetic transaminase sgot and alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than doc uln or equal_than less_than five uln for subjects with liver metastases
__label__1	study interventions are Doxorubicin . kaposi sarcoma diagnosis and screening serum creatinine greater_than doc upper limit of normal uln alanine aminotransferase alt greater_than doc uln total bilirubin greater_than doc uln absolute neutrophil count anc less_than one five hundred mmthree platelet concentration less_than seventy-five zero mmthree absolute lymphocyte count less_than onezero mmthree hematocrit level less_than twenty-five for females or less_than twenty-seven for males serum albumin less_than doc dl
__label__1	study interventions are Antibodies, Monoclonal . carcinoma non small cell lung diagnosis and patient has untreated brain metastases
__label__1	study interventions are Glycine . recurrent plasma cell myeloma diagnosis and recent prior chemotherapy
__label__1	study interventions are Azacitidine . brain tumor recurrent diagnosis and has received another investigational or chemotherapy agent or radiation therapy within seven days prior to five azacytidine infusion into the fourth_ventricle
__label__1	study interventions are Pegaspargase . tumors diagnosis and has coagulopathy or history of coagulopathy
__label__1	study interventions are Gemcitabine . ovarian cancer diagnosis and avastin administration within ninety days of screening
__label__1	study interventions are Tacrolimus . recurrent small lymphocytic lymphoma diagnosis and women of childbearing potential who are pregnant beta hcg positive or breast feeding
__label__1	study interventions are Albumin-Bound Paclitaxel . triple negative breast cancer diagnosis and subjects who have received an investigational product within the previous four weeks prior to randomization
__label__1	study interventions are Immunoglobulins . metastatic melanoma diagnosis and note
__label__1	study interventions are Panobinostat . solid tumors diagnosis and known diagnosis of human immunodeficiency virus hiv infection
__label__1	study interventions are Fluorouracil . nasopharyngeal neoplasms diagnosis and age greater_than equal_than seventy
__label__1	study interventions are Anamorelin HCl . cancer cachexia diagnosis and aids
__label__1	study interventions are questionnaire administration . stage iii squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and contraindication to full course chemoradiotherapy
__label__1	study interventions are Polyphenon E and Placebo . non melanomatous skin cancer diagnosis and within two weeks
__label__1	study interventions are Rituximab . evolutive malignancy within five years with the exception of localized non melanomatous skin cancer
__label__1	study interventions are Enzalutamide . prior chemotherapy for metastatic disease in castration resistant prostate cancer
__label__1	study interventions are Temozolomide . non melanoma skin cancer and carcinoma in situ of the cervix uterus or breast unless the patient has been disease free for greater_than three years
__label__1	study interventions are Carboplatin . stage iiib breast cancer diagnosis and minimum of twelve weeks from the first dose of anti ctla four and greater_than six weeks from the last dose
__label__1	study interventions are Laboratory Biomarker Analysis . skin kaposi sarcoma diagnosis and cardiac related illnesses including but not limited to
__label__1	study interventions are Group C - Usual Breathing Control Group . lung cancer diagnosis and unstable angina
__label__1	study interventions are Irinotecan . other concurrent investigational anticancer drugs
__label__1	study interventions are Paclitaxel . recurrent endometrial cancer diagnosis and central nervous system metastasis note
__label__1	study interventions are Temozolomide . anaplastic astrocytoma diagnosis and women of childbearing potential must have negative serum pregnancy test within seventy-two hours prior to administration of study regimen
__label__1	study interventions are Nintedanib . stage iv non small cell lung cancer diagnosis and active hemoptysis or history of clinically relevant hemoptysis as determined by the treating physician patients who had history of transient minor hemoptysis after bronchoscopic biopsy are eligible unless deemed otherwise by the treating physician
__label__1	study interventions are quality-of-life assessment . stage iv salivary gland cancer diagnosis and subjects may not be receiving other investigational agents
__label__1	study interventions are Albumin-Bound Paclitaxel . squamous cell carcinoma of lung diagnosis and allergic to study drug
__label__1	study interventions are Cyclosporins . stage iv grade three follicular lymphoma diagnosis and prior autologous or allogeneic stem cell transplant with myeloablative preparative regimen if equal_than less_than eighteen years old prior myeloablative transplant within the last six months
__label__1	study interventions are Docetaxel . prostatic neoplasms diagnosis and is currently receiving strong or moderate inhibitors of cypthreeafour including azole_antifungals macrolide antibiotics or protease inhibitors
__label__1	study interventions are Antibodies . patients with known allergy to murine proteins or have had documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol oregovomab or to antiemetics appropriate for administration in conjunction with protocol directed therapy
__label__1	study interventions are N-monoacetylcystine . stage ivc verrucous carcinoma of the larynx diagnosis and nursing women
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and patients with known hiv positivity
__label__1	study interventions are Collaborative Care . hepatocellular carcinoma diagnosis and current suicidal or homicidal_ideation
__label__1	study interventions are Pembrolizumab . recurrent merkel cell carcinoma diagnosis and subjects who are breast feeding are not eligible for enrollment
__label__1	study interventions are Gemcitabine . pancreatic adenocarcinoma diagnosis and history of primary immunodeficiency history of organ transplant that requires therapeutic immunosuppression or prior history of severe grade three or four immune mediated toxicity from other immune therapy
__label__1	study interventions are Wooden spatula . oral cancer diagnosis and any patient who has no subjective tightening of the jaw
__label__1	study interventions are Antibodies . recurrent primary peritoneal carcinoma diagnosis and patients with greater_than equal_than grade two peripheral neuropathy
__label__1	study interventions are Docetaxel . non small cell lung cancer diagnosis and known human immunodeficiency virus or acquired immunodeficiency syndrome related illness
__label__1	study interventions are Immunoglobulins . ovarian cancer diagnosis and patients must not have received bevacizumab as part of their treatment on relapse
__label__1	study interventions are ExAblate MRgFUS . microcalcifications as the only sign of breast cancer on imaging studies
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and male subjects must agree to practice contraception
__label__1	study interventions are Ergocalciferols . breast cancer diagnosis and prior history or current evidence of osteomyelitis osteonecrosis of the jaw
__label__1	study interventions are Everolimus . metastatic breast cancer hr positive her negative diagnosis and concurrent malignancy or malignancy within three years prior to start of study treatment
__label__1	study interventions are N-monoacetylcystine . stage ivc adenoid cystic carcinoma of the oral cavity diagnosis and greater than or equal to grade two dry mouth prior to chemoradiotherapy or greater than or equal to grade two mucositis
__label__1	study interventions are quality-of-life assessment . stage ii squamous cell carcinoma of the oropharynx diagnosis and use of arginine supplementation
__label__1	study interventions are Paclitaxel . ovarian cancer diagnosis and patients requiring drainage gastrostomy drainage peg tube and or parenteral hydration and or nutrition
__label__1	study interventions are Fludarabine phosphate . stage cutaneous cell non hodgkin lymphoma diagnosis and donors for whom medical or psychologic reasons would make donor procedure intolerable
__label__1	study interventions are Cisplatin . stage iii pancreatic cancer diagnosis and patients with known history of extensive disseminated bilateral interstitial fibrosis or interstitial lung disease including history of pneumonitis hypersensitivity pneumonitis interstitial pneumonia obliterative_bronchiolitis and clinically significant radiation pneumonitis affecting activities of daily living or requiring therapeutic intervention
__label__1	study interventions are Antibodies, Monoclonal . unresectable solid neoplasm diagnosis and cdfour count above two hundred and fifty cells mcl and an undetectable hiv viral load on standard pcr based tests
__label__1	study interventions are Antibiotics, Antitubercular . brain tumor diagnosis and have an immunodeficiency disease or immunocompromised state use of immunosuppressive agents chemotherapy or radiation therapy within fourteen days of study treatment
__label__1	study interventions are Niclosamide . stage iv prostate adenocarcinoma diagnosis and any psychological familial sociological or geographical condition that could potentially interfere with compliance with the study protocol and follow up schedule
__label__1	study interventions are Mycophenolate mofetil . aids related peripheral systemic lymphoma diagnosis and marrow donors who have increased anesthetic risk
__label__1	study interventions are Carboplatin . ovarian neoplasms diagnosis and subject with history of severe hypersensitivity reactions to products containing cremophor_el
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and known cns disease
__label__1	study interventions are Prednisolone hemisuccinate . angioimmunoblastic cell lymphoma diagnosis and patient is pregnant or breastfeeding or expecting to conceive or father children within one year of finishing study treatment
__label__1	study interventions are Insulin . estraosseous ewing tumor diagnosis and disease related
__label__1	study interventions are Carboplatin . other concurrent experimental drugs anticancer treatment or investigational therapy
__label__1	study interventions are Cisplatin . unresectable intrahepatic cholangiocarcinoma diagnosis and these potential risks may also apply to other agents used in this study
__label__1	study interventions are Antibodies, Monoclonal . pancreatic polypeptide tumor diagnosis and the patient has poorly controlled diabetes mellitus patients with history of diabetes mellitus are allowed to participate providing that their blood glucose is within doc institutional upper limit of normal and that they are on stable dietary or therapeutic regimen for this condition
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and inability to comply with an anti thrombotic treatment regimen
__label__1	study interventions are MRI . prostate cancer diagnosis and patients with history of allergic reaction to latex or gadolinium containing intravenous contrast agents
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and history of allergy to boron or mannitol
__label__1	study interventions are Radium Ra 223 dichloride . prostate carcinoma metastatic to the bone diagnosis and subject has known malignant pleural effusion or known lung liver or brain metastasis lymph node only metastasis less_than six cm in short axis diameter is allowed
__label__1	study interventions are Pancreatin . pancreas cancer diagnosis and external biliary drain
__label__1	study interventions are Pembrolizumab . stage iii thyroid gland papillary carcinoma diagnosis and active infection requiring systemic therapy
__label__1	study interventions are questionnaire administration . recurrent verrucous carcinoma of the oral cavity diagnosis and requirement of chronic steroid therapy except when given for laryngeal edema
__label__1	study interventions are Dihydromevinolin . breast cancer diagnosis and patients with history of severe hypersensitivity reaction to taxotere or other drugs formulated with polysorbate eighty
__label__1	study interventions are Somatostatin . neuroendocrine tumors diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to one hundred and seventy-sevenlu dota jreleven as assessed from medical records
__label__1	study interventions are Defactinib . non hematologic cancers diagnosis and known history of malignant hypertension
__label__1	study interventions are Fludarabine phosphate . diffuse large cell lymphoma diagnosis and susceptible to its toxicities
__label__1	study interventions are Immunoglobulins . other malignancy within the past five years except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer
__label__1	study interventions are Mycophenolic Acid . recurrent adult immunoblastic large cell lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of hydroxyurea and imatinib mesylate will not be allowed within two weeks of the initiation of conditioning
__label__1	study interventions are Survivorship Care Plan . current treatment for another cancer
__label__1	study interventions are Vidarabine . recurrent grade three follicular lymphoma diagnosis and patients with greater_than grade ii hypertension by common toxicity criteria ctc
__label__1	study interventions are Exemestane . stage iv breast cancer diagnosis and type diabetes mellitus patients with type ii diabetes mellitus will be included as long as their glucose can be controlled to under two hundred mg dl
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and use of any investigational drugs within thirty days before randomization
__label__1	study interventions are Vincristine . b cell lymphoma diagnosis and ageless_than eighteen and greater_than seventy-five years
__label__1	study interventions are Training group . oesophagus cancer diagnosis and serious untreated cardiac disease that may be critical
__label__1	study interventions are ixabepilone . other concurrent experimental anticancer medications
__label__1	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and patients who have received more than two therapeutic previous lines
__label__1	study interventions are Temozolomide . glioblastoma multiforme diagnosis and prior history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Cetuximab . carcinoma squamous cell of head and neck diagnosis and patients with history of hypersensitivity to other monoclonal antibodies or to the active or inactive excipients of study drug
__label__1	study interventions are Mycophenolic Acid . recurrent marginal zone lymphoma diagnosis and twelve pediatric
__label__1	study interventions are Fludarabine . recurrent adult burkitt lymphoma diagnosis and left ventricular ejection fraction less than forty
__label__1	study interventions are Liposomal doxorubicin . metastatic liposarcoma diagnosis and impairment of gastrointestinal gi function or gi disease that may significantly alter the absorption of the study drugs ulcerative diseases uncontrolled nausea vomiting diarrhea malabsorption syndrome or major small bowel resection
__label__1	study interventions are Camptothecin . prior anticancer therapy that would preclude study therapy
__label__1	study interventions are Zoledronic acid . prostate cancer diagnosis and no other prior or concurrent bisphosphonates excluding zoledronic acid
__label__1	study interventions are Erlotinib Hydrochloride . pancreatic cancer diagnosis and no prior anti epidermal growth factor receptor therapy
__label__1	study interventions are Romidepsin . cutaneous cell lymphoma diagnosis and total bilirubin greater_than doc five upper limit of normal uln for institution
__label__1	study interventions are Fludarabine . recurrent adult immunoblastic large cell lymphoma diagnosis and identical twin
__label__1	study interventions are Paclitaxel . uterine cancer diagnosis and patient has severe or uncontrolled concurrent medical disease eg
__label__1	study interventions are Everolimus . hamartoma syndrome multiple diagnosis and patients taking immuno suppressive agents other than prescribed corticosteroids which must not exceed the equivalent of twenty mg of prednisone
__label__1	study interventions are EGF816 . advanced non small cell lung cancer nsclc diagnosis and magnesium
__label__1	study interventions are quality-of-life assessment . recurrent small cell lung cancer diagnosis and uncontrolled coagulopathy or bleeding disorders
__label__1	study interventions are Carboplatin . stage iiic breast cancer diagnosis and known or active hepatitis or with abnormal liver function tests
__label__1	study interventions are Gossypol . locally advanced esophageal or ge junction cancer diagnosis and prior radiotherapy that would overlap the anticipated study treatment fields or radiotherapy to greater_than thirty of the marrow cavity no prior chest irradiation
__label__1	study interventions are Antibodies, Monoclonal . invasive ductal breast carcinoma diagnosis and cases with an histology different from invasive ductal nos of high proliferation or grade
__label__1	study interventions are Vidarabine . recurrent adult lymphoblastic lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Immunoglobulin G . recurrent fallopian tube carcinoma diagnosis and patient is on angiotensin_converting enzyme ace inhibitors benazapril_captopril enalopril_fosonopril lisinopril_moexipril perindopril_quinopril ramipril and trandolapril patients may have an alternate antihypertensive substituted note
__label__1	study interventions are Lenograstim . glioblastoma diagnosis and previous chemotherapy for any malignancy including temozolomide dacarbazine_dtic or prior nitrosourea
__label__1	study interventions are Bevacizumab . patients with history or evidence upon physical examination of cns disease including primary brain tumor seizures not controlled with standard medical therapy any brain metastases or history of cerebrovascular accident cva stroke transient ischemic attack tia or subarachnoid hemorrhage within six months of the first date of treatment on this study
__label__1	study interventions are Third Eye Retroscope . colorectal neoplasms diagnosis and patients with history of colonic resection
__label__1	study interventions are Cryoablation . renal cancers diagnosis and unable to have general anesthetic
__label__1	study interventions are Temozolomide . anaplastic astrocytoma diagnosis and thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past six months
__label__1	study interventions are Fluorouracil . metastatic colorectal cancer diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Mycophenolic Acid . refractory multiple myeloma diagnosis and current serious systemic illness
__label__1	study interventions are Prednisolone . prostate cancer diagnosis and uncontrolled cardiac arrhythmias angina pectoris and or hypertension
__label__1	study interventions are Sirolimus . pancreatic polypeptide tumor diagnosis and any of the following as this regimen may be harmful to developing fetus or nursing child
__label__1	study interventions are quality-of-life assessment . recurrent verrucous carcinoma of the oral cavity diagnosis and surgery with significant defect or flap in the oral cavity
__label__1	study interventions are Immunoglobulins . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
__label__1	study interventions are Antibodies . stage iiia fallopian tube cancer diagnosis and prior therapy with vascular endothelial growth factor receptor vegfr targeting agents or mammalian target of rapamycin mtor inhibitors except as in hcc and in the islet cell single agent bevacizumab alone cohort where prior mtor inhibitor is allowed note
__label__1	study interventions are Estradiol . breast cancer diagnosis and known brain metastases
__label__1	study interventions are Rituximab . nodal marginal zone cell lymphoma diagnosis and medically documented history of or active major depressive episode requiring inpatient or intensive outpatient therapy bipolar disorder or ii obsessive_compulsive disorder schizophrenia history of suicidal attempt or active ideation or homicidal_ideation immediate risk of doing_harm to others patients under the care of primary care physician who are treated with one oral agent and who have not required dose adjustments or new medications within two months prior to study enrollment and who otherwise meet eligibility requirements may be enrolled
__label__1	study interventions are Cholecalciferol . stage iia prostate cancer diagnosis and participants requires thyroid replacement therapy note
__label__1	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and patients with platelet count less_than seventy-five zero mmthree and anc less_than one thousand, five hundred mmthree within seventy-two hours prior to itv depocyt and or oral temozolomide treatment
__label__1	study interventions are Thalidomide . stage multiple myeloma diagnosis and uncontrolled hypertension
__label__1	study interventions are Cyclosporine . recurrent adult lymphoblastic lymphoma diagnosis and patients with evidence of hepatitis or hepatitis pcr positivity hepatitis reactivation following myelosuppressive therapy can lead to fatal complications
__label__1	study interventions are Pemetrexed . non small cell lung cancer diagnosis and presence of cns central nervous system except for treated brain metastases
__label__1	study interventions are Poly ICLC . astrocytoma diagnosis and allergy desensitization injections
__label__1	study interventions are Mycophenolate mofetil . stage grade one follicular lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than thirty total lung capacity tlc less_than thirty forced expiratory volume in one second fevone less_than thirty and or receiving supplementary continuous oxygen the fhcrc principal investigator pi of the study must approve enrollment of all patients with pulmonary nodules
__label__1	study interventions are Camptothecin . pretext stage four hepatoblastoma diagnosis and patients must not be receiving any of the following potent cytochrome pfour50 family three subfamily polypeptide four cypthreeafour inducers or inhibitors
__label__1	study interventions are Abiraterone Acetate . hormone resistant prostate cancer diagnosis and note
__label__1	study interventions are Triptorelin Pamoate . adenocarcinoma of the prostate diagnosis and have any condition that in the opinion of the investigator would compromise the well being of the subject or the study or prevent the subject from meeting or performing study requirements
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and patients of childbearing potential must implement adequate non hormonal contraceptive measures barrier methods intrauterine contraceptive devices sterilization during study treatment
__label__1	study interventions are Antibodies, Monoclonal . non squamous non small cell lung cancer diagnosis and concurrent estrogens anti estrogens or progesterone compounds
__label__1	study interventions are Cetuximab . head and neck cancer diagnosis and patients who have undergone surgery within the last one month
__label__1	study interventions are Fludarabine . aggressive non hodgkin lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of tyrosine kinase inhibitors such as imatinib cytokine therapy hydroxyurea low dose cytarabine_chlorambucil or rituxan will not be allowed within three weeks of the initiation of conditioning
__label__1	study interventions are Gefitinib . concurrent use of hormones for non cancer related conditions eg insulin for diabetes and hormone replacement therapy is acceptable
__label__1	study interventions are Fludarabine phosphate . stage iii childhood anaplastic large cell lymphoma diagnosis and lansky play performance score less_than fifty for pediatric patients
__label__1	study interventions are Cabergoline . prolactinomas diagnosis and patients who have any current or prior medical condition that can interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator
__label__1	study interventions are Polystyrene sulfonic acid . advanced inoperable non small cell lung cancer diagnosis and patients unable to swallow orally administered medication or patients with gastrointestinal disorders or significant gastrointestinal resection likely to interfere with the absorption of azdnine thousand, two hundred and ninety-one
__label__1	study interventions are Glycine . plasma cell myeloma diagnosis and nursing women
__label__1	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and thirty-six pediatric
__label__1	study interventions are Antibodies, Monoclonal . patients receiving concurrent treatment with other anti cancer therapy or other investigational anticancer agents
__label__1	study interventions are Histone Deacetylase Inhibitors . neoplasms by histologic type diagnosis and completed study sndx two hundred and seventy-five one hundred and forty ncttwo million, eight hundred and ninety-seven thousand, seven hundred and seventy-eight more than thirty days prior to cycle one day one of this study
__label__1	study interventions are Calcium, Dietary . stage iii childhood lymphoblastic lymphoma diagnosis and sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
__label__1	study interventions are Vaccines . multiple myeloma diagnosis and total bilirubin greater than or equal to two uln or ast alt greater than or equal to three uln
__label__1	study interventions are Antibodies . stage iva squamous cell carcinoma of the larynx diagnosis and clinically significant ophthalmologic disease defined as
__label__1	study interventions are Paclitaxel . fallopian tube neoplasms diagnosis and non healing wound active ulcer or bone fracture
__label__1	study interventions are Fluorouracil . gastric junction adenocarcinoma diagnosis and significant hearing impairment as judged by the need for or use of hearing aid
__label__1	study interventions are Peginterferon alfa-2b . multiple mieloma diagnosis and subjects with severe cardiovascular disease
__label__1	study interventions are Floxuridine . colorectal neoplasms diagnosis and pregnant or lactating women
__label__1	study interventions are Formyltetrahydrofolates . mucinous adenocarcinoma of the rectum diagnosis and prior allergic reaction to five fluorouracil or oxaliplatin
__label__1	study interventions are Cisplatin . diffuse large cell lymphoma diagnosis and patients who are pregnant or breast feeding
__label__1	study interventions are Cisplatin . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Carboplatin . other prior cancer therapy that would preclude study therapy
__label__1	study interventions are Endoscopic ultrasound guided needle based confocal endomicroscopy . cystadenocarcinoma diagnosis and histological and immunohistochemical findings final diagnosis
__label__1	study interventions are Rituximab . recurrent adult diffuse large cell lymphoma diagnosis and transfusion requirement red blood cells or platelets within fourteen days prior to baseline
__label__1	study interventions are Communication Intervention . malignant neoplasm diagnosis and stakeholder and usability study
__label__1	study interventions are Immunoglobulin G . stage iiic uterine corpus cancer diagnosis and evidence of bleeding diathesis or coagulopathy in the absence of therapeutic anticoagulation
__label__1	study interventions are Immunoglobulins . pancreatic cell adenoma diagnosis and grade greater_than equal_than three hemorrhage equal_than less_than four weeks prior to registration
__label__1	study interventions are Methotrexate . diffuse large cell lymphoma diagnosis and patient who has received any prior anthracyclines
__label__1	study interventions are Lapatinib . breast cancer diagnosis and been treated with any hematopoietic colony stimulating growth factors less_than two weeks prior to starting study drug
__label__1	study interventions are Bortezomib . ds stage ii plasma cell myeloma diagnosis and patient is already on dual anti hepatitis therapy
__label__1	study interventions are Poly I-C . the tumor tissue of such case would be brought to the lab before the pathological diagnosis is made and thus would be processed before the lab is informed of the final hgg diagnosis
__label__1	study interventions are Carboplatin . localized unresectable neuroblastoma diagnosis and group and patients who do not enroll on anblone thousand, two hundred and thirty-two within four weeks of definitive diagnostic procedure
__label__1	study interventions are Antibodies . recurrent adult diffuse small cleaved cell lymphoma diagnosis and donor is hiv positive and or has medical condition that would result in increased risk for filgrastim csf mobilization and harvest of pbsc
__label__1	study interventions are Docetaxel . prostate cancer metastatic disease diagnosis and history of myocardial infarction or unstable angina within six months prior to study enrollment
__label__1	study interventions are Sunitinib . urinary tract urothelial carcinoma diagnosis and major incisional surgery within four weeks of study enrollment
__label__1	study interventions are Albumin-Bound Paclitaxel . advanced pancreatic cancer diagnosis and no untreated central nervous system metastases or if treated must be neurologically stable for at least two weeks prior to enrollment
__label__1	study interventions are Temozolomide . solid tumors diagnosis and must not be known to have human immunodeficiency virus hiv infection or known hiv related malignancy
__label__1	study interventions are Antibodies, Monoclonal . recurrent esophageal cancer diagnosis and human immunodeficiency virus hiv positive patients receiving combination anti retroviral therapy are excluded from the study
__label__1	study interventions are Aromatase Inhibitors . male breast cancer diagnosis and concurrent neuronal or cardiac disease poorly controlled arterial hypertension
__label__1	study interventions are Antilymphocyte Serum . t lymphoblastic leukemia lymphoma diagnosis and pregnancy testing is not required for post menopausal or surgically sterilized women
__label__1	study interventions are Lenograstim . stage iii marginal zone lymphoma diagnosis and contraindication or hypersensitivity to filgrastim or plerixafor
__label__1	study interventions are PLX3397 capsule . prostate and breast cancer in remission not receiving active therapy for greater_than five years will be allowed
__label__1	study interventions are Sirolimus . hepatosplenic cell lymphoma diagnosis and therapy with myelosuppressive chemotherapy or biologic therapy less_than three weeks unless the patient has recovered from the nadir of the previous treatment to level that meets the inclusion eligibility criteria of this protocol note
__label__1	study interventions are Romidepsin . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements note
__label__1	study interventions are Vidarabine . recurrent adult cell leukemia lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Endobronchial ultrasound miniprobe . lung cancer diagnosis and patients not able to be investigated by bronchoscopy
__label__1	study interventions are Fluconazole . advanced solid tumors diagnosis and however participants with less_than grade three atrial fibrillation for period of at least six months may enroll
__label__1	study interventions are Cediranib . pancreatic adenocarcinoma diagnosis and patients may not have evidence of coagulopathy or bleeding diathesis therapeutic anticoagulation for prior thromboembolic events is permitted the clinical indication for therapeutic anticoagulation must be clearly documented prior to enrollment and must be discussed with the given the increased risk of serious bleeding from cediranib patients who are on greater than or equal to two anti thrombotic agents including but not limited to anti platelet agents non steroidal anti inflammatory drugs nsaids aspirin clopidogrel heparin low molecular weight heparin lmwh warfarin and direct thrombin inhibitor will be excluded
__label__1	study interventions are Fludarabine phosphate . noncontiguous stage ii small lymphocytic lymphoma diagnosis and fungal infections with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ib fallopian tube cancer diagnosis and patients with surgery including open biopsy within four weeks prior to anticipated first dose of bevacizumab allowing for fact that bevacizumab can be omitted from first cycle of chemotherapy
__label__1	study interventions are HIV Protease Inhibitors . pancreatic adenocarcinoma diagnosis and amiodarone quinidine
__label__1	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one of study drug treatment
__label__1	study interventions are Androgens . prostate cancer diagnosis and prior seizures while on enzalutamide therapy
__label__1	study interventions are Paclitaxel . ovarian neoplasms diagnosis and prior chemo radiotherapy
__label__1	study interventions are Immunoglobulins . recurrent childhood hodgkin lymphoma diagnosis and active hepatitis or with uncontrolled disease
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and individuals unable to provide informed consent
__label__1	study interventions are Carboplatin . ovarian clear cell adenocarcinoma diagnosis and note
__label__1	study interventions are BB 1101 . refractory multiple myeloma diagnosis and patients who have any other concurrent severe and or uncontrolled medical condition including but not limited to
__label__1	study interventions are Fludarabine . stage childhood anaplastic large cell lymphoma diagnosis and females who are pregnant or breast feeding
__label__1	study interventions are Leuprolide . prostate cancer diagnosis and administration of five reductase inhibitors finasteride dutasteride within three months before baseline rationale
__label__1	study interventions are BLZ-100 . skin neoplasms diagnosis and life expectancy less_than six months
__label__1	study interventions are Mycophenolic Acid . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and pregnancy
__label__1	study interventions are Tremelimumab . non small cell lung cancer diagnosis and non leukocyte depleted whole blood transfusion within one hundred and twenty days of the date of the genetic sample collection
__label__1	study interventions are neoadjuvant Photonradiation . primarily resectable pancreatic cancer diagnosis and major surgery excluding laparoscopy within four weeks of the start of study treatment without complete recovery
__label__1	study interventions are Trabectedin . recurrent childhood soft tissue sarcoma diagnosis and patients newly diagnosed or in first relapse
__label__1	study interventions are Trastuzumab . spinal cord ependymoma
__label__1	study interventions are Capecitabine . metastatic breast cancer diagnosis and evidence of cardiovascular disease myocardial infection unstable angina pectoris or arrhythmia
__label__1	study interventions are Mycophenolic Acid . noncontiguous stage ii grade three follicular lymphoma diagnosis and patient unable to give informed consent
__label__1	study interventions are Cisplatin . cancer diagnosis and liver disease bilirubin greater_than two mg dl transaminase levels greater_than doc times the upper limit normal
__label__1	study interventions are Antibodies . stage adult diffuse large cell lymphoma diagnosis and prior use of lenalidomide either concurrently with rituximab or within eight weeks following dose of rituximab
__label__1	study interventions are Paclitaxel . fallopian tube clear cell adenocarcinoma diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Imatinib Mesylate . adult anaplastic oligodendroglioma diagnosis and patients with no limitation of activities they suffer no symptoms from ordinary activities class ii
__label__1	study interventions are Vaccines . mesolthelioma diagnosis and patients with uncontrolled hypertension greater_than one hundred and sixty ninety-five unstable coronary disease evidenced by uncontrolled arrhythmias unstable angina decompensated chf greater_than nyha class ii or myocardial infarction within six months of study will be excluded
__label__1	study interventions are Lenograstim . refractory multiple myeloma diagnosis and prior radioimmunotherapy within twelve weeks of registration
__label__1	study interventions are Fludarabine . stage adult diffuse mixed cell lymphoma diagnosis and identical twin
__label__1	study interventions are Hsp90 . colorectal cancer diagnosis and patients who previously accepted radiotherapy
__label__1	study interventions are Cyclosporins . refractory hodgkin lymphoma diagnosis and known allergy to filgrastim
__label__1	study interventions are Fludarabine phosphate . stage iii grade one follicular lymphoma diagnosis and donor
__label__1	study interventions are Fludarabine . recurrent grade two follicular lymphoma diagnosis and patients or their partners unwilling to use contraception
__label__1	study interventions are SCH66336 . head and neck cancer diagnosis and patient has history of uncontrolled heart disease including arrhythmia angina congestive heart failure or any heart condition that cannot be controlled with regular ongoing medication
__label__1	study interventions are Dutasteride . prostate cancer diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Vaccines . cutaneous cell non hodgkin lymphoma diagnosis and prior autologous bone marrow or peripheral blood stem cell support within one year
__label__1	study interventions are Promethazine . breast cancer diagnosis and patients with nyha class three or four congestive heart failure
__label__1	study interventions are Mitomycins . tumor progression observed with the current line of treatment when under twond line
__label__1	study interventions are Sorafenib . brain tumors diagnosis and patients with known or suspected allergy to any agent given in the course of this trial
__label__1	study interventions are Mycophenolic Acid . recurrent small lymphocytic lymphoma diagnosis and presence of active serious infection mucormycosis uncontrolled aspergillosis tuberculosis
__label__1	study interventions are Letrozole . prior treatment with an aromatase inhibitor
__label__1	study interventions are Melphalan . non hodgkin lymphoma diagnosis and neurologic disease
__label__1	study interventions are Copper . stage iia gastric cancer diagnosis and uncontrolled hypertension mmhg greater_than one hundred and sixty systolic or greater_than ninety diastolic
__label__1	study interventions are Pemetrexed . pleural mesothelioma diagnosis and thyroxine insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc
__label__1	study interventions are GX-051 . head and neck cancer diagnosis and child pugh class hepatic impairment
__label__1	study interventions are Vidarabine . stage iii cutaneous cell non hodgkin lymphoma diagnosis and infection with hiv
__label__1	study interventions are stereotactic radiosurgery . stage iiia non small cell lung cancer diagnosis and contraindication to sbrt or temla this includes the inability to cooperate with any aspect of sbrt such as the inability to lie still and breathe reproducibly
__label__1	study interventions are Vidarabine . recurrent mantle cell lymphoma diagnosis and twenty spinal cord
__label__1	study interventions are Carboplatin . adenosquamous cell carcinoma diagnosis and other serious illness or medical conditions including but not limited to
__label__1	study interventions are Selumetinib . recurrent childhood pilocytic astrocytoma diagnosis and stratum five
__label__1	study interventions are Immunoglobulins . stage iiic breast cancer diagnosis and documented cardiomyopathy
__label__1	study interventions are Immunoconjugates . stage iii grade three follicular lymphoma diagnosis and patients with chronic hepatitis hcv or hepatitis hbv infection may enroll if other laboratory criteria are met those with hbv surface antigen positivity may enroll only if maintained on appropriate suppressive antiviral therapy per treating investigator discretion for the duration of enrollment in the trial
__label__1	study interventions are Mycophenolic Acid . multiple myeloma diagnosis and serologic evidence of hiv
__label__1	study interventions are Cyclin-Dependent Kinase Inhibitor Proteins . estrogen receptor positive breast cancer diagnosis and the subject has baseline corrected qt interval qtc greater_than four hundred and seventy ms
__label__1	study interventions are Cisplatin . pregnant or lactation woman
__label__1	study interventions are Antibodies, Monoclonal . head and neck cancer diagnosis and the subject is known to be positive for the human immunodeficiency virus hiv hepbsag or hcv rna
__label__1	study interventions are Hormones . stage iiic breast cancer diagnosis and radiation therapy equal_than less_than twenty-one days prior to registration
__label__1	study interventions are Vaccines . metastatic breast cancer diagnosis and cyclosporine antithymocyte_globulin or tacrolimus within one month of study entry
__label__1	study interventions are To perform RT-PCR on the tissue obtained during surgery . clinical or laboratory evidence of pituitary hormone oversecretion non functioning pituitary macroadenoma
__label__1	study interventions are Ketoconazole . solid tumors diagnosis and unstable angina pectoris or cardiac arrhythmia
__label__1	study interventions are Oxaliplatin . solid tumor diagnosis and no prior oxaliplatin or pemetrexed_disodium
__label__1	study interventions are Dacarbazine . stage iva hodgkin lymphoma diagnosis and patients with prior anthracycline therapy will be excluded
__label__1	study interventions are Endothelial Growth Factors . stage iiia ovarian cancer diagnosis and current therapy with cytochrome pfour hundred and fifty threeafour cypthreeafour inhibitor or inducer note
__label__1	study interventions are Alvocidib . other concurrent anticancer agents or therapies
__label__1	study interventions are Etoposide . recurrent mantle cell lymphoma diagnosis and not pregnant
__label__1	study interventions are Antibodies, Monoclonal . refractory childhood hodgkin lymphoma diagnosis and patients who have an uncontrolled infection are not eligible
__label__1	study interventions are Vidarabine . recurrent adult burkitt lymphoma diagnosis and eligible for radioimmunotherapy based autologous transplant trial
__label__1	study interventions are Antibodies . stage iiic primary peritoneal cancer diagnosis and other than low molecular weight heparin lmwh medication must be stopped before time of registration if patient has recently been on anti coagulants other than lmwh patient must have international normalized ratio inr equal_than less_than two
__label__1	study interventions are Carboplatin . other concomitant malignancies with the exception of nonmelanoma skin cancer who had or have any evidence of other cancer present within the last five years
__label__1	study interventions are Mindfulness-Based Stress Reduction (MBSR) . cancer diagnosis and prior experience with mbsr
__label__1	study interventions are whey protein supplement . lung cancer diagnosis and milk protein allergy
__label__1	study interventions are Laboratory Biomarker Analysis . stage ivb thyroid gland medullary carcinoma diagnosis and any history of cerebrovascular accident cva equal_than less_than six months
__label__1	study interventions are Ibrutinib . recurrent melanoma of the skin diagnosis and unable to swallow capsules or disease significantly affecting gastrointestinal function and or inhibiting small intestine absorption such as malabsorption syndrome resection of portions of small bowel larger than three feet or poorly controlled inflammatory bowel disease affecting the small intestine
__label__1	study interventions are therapeutic conventional surgery . adult glioblastoma diagnosis and patients with history of being serologically positive for hepatitis or or who have history of cirrhosis are ineligible
__label__1	study interventions are Bevacizumab . stage iia esophageal cancer diagnosis and patients with psychiatric or addictive disorders or other conditions that in the opinion of the investigator would preclude them from meeting the study requirements are not eligible
__label__1	study interventions are Fluorouracil . colorectal neoplasms diagnosis and uncontrolled hypercalcemia
__label__1	study interventions are Fludarabine . stage ii childhood lymphoblastic lymphoma diagnosis and fungal infections with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Cediranib . patients who have not recovered from side effects of previous systemic anticancer therapy to less_than common terminology criteria for adverse events ctcae grade two except alopecia prior to the first dose of combination
__label__1	study interventions are Cyclosporine . hodgkin lymphoma diagnosis and alanine aminotransferase alt or aspartate aminotransferase ast three times or greater than the institutional upper limit of normal
__label__1	study interventions are Vitamin B Complex . undifferentiated ovarian carcinoma diagnosis and multiple sclerosis ms
__label__1	study interventions are Bevacizumab . gliosarcoma diagnosis and cerebrovascular accident cva transient ischemic attack tia within the last six months prior to registration
__label__1	study interventions are Diphosphonates . first or second line hertwo negative breast cancer diagnosis and patients who have undergone major surgery intra thoracic intra abdominal or intra pelvic less_than four weeks prior to study enrollment or who have not recovered from side effects of such therapy
__label__1	study interventions are Fluorouracil . gastric cancer diagnosis and childs or cirrhosis or with evidence of severe portal hypertension by history endoscopy or radiologic studies
__label__1	study interventions are No-touch RFA . maximum tumor diameter greater than doc cm
__label__1	study interventions are Lenalidomide . fallopian tube carcinoma diagnosis and pregnant or breast feeding females
__label__1	study interventions are Tomosynthesis . breast neoplasms diagnosis and breast prostheses
__label__1	study interventions are Temozolomide . histologically proven diagnosis of glioblastoma or gliosarcoma who grade iv diagnosis and unstable angina and or congestive heart failure within the last six months
__label__1	study interventions are Paclitaxel . metastatic pancreatic adenocarcinoma diagnosis and viral syndrome diagnosed during the two weeks before inclusion
__label__1	study interventions are HDR brachytherapy + hypofractionated EBRT . prostatic neoplasms diagnosis and prior pelvic radiotherapy
__label__1	study interventions are Etoposide phosphate . peripheral cell lymphoma diagnosis and blood counts are not required to be normal prior to enrollment on trial
__label__1	study interventions are Exemestane . breast cancer diagnosis and biotherapy
__label__1	study interventions are FDG PET/CT imaging . clinical stage iii nodal or intransit disease or resectable stage iv melanoma diagnosis and all individuals will be told that their choice regarding study participation will in no way change their access to clinical care
__label__1	study interventions are Fludarabine phosphate . non hodgkin lymphoma diagnosis and active uncontrolled cns leukemia
__label__1	study interventions are Gemcitabine . advanced aggressive non hodgkin lymphoma diagnosis and received allogeneic hematopoietic stem cell transplant within the last six months or has active graft versus host disease gvhd following allogeneic transplant or is currently receiving immunosuppressive therapy following allogeneic transplant
__label__1	study interventions are Cyclosporine . stage iii adult diffuse small cleaved cell lymphoma diagnosis and fungal infections with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Quality-of-Life Assessment . soft tissue sarcoma diagnosis and patients who cannot obtain contrast enhanced mri or ct myelogram due to allergy renal failure or other medical contraindication
__label__1	study interventions are Laboratory Biomarker Analysis . chondrosarcoma diagnosis and patients with clinically active liver disease including active viral or other hepatitis or cirrhosis are ineligible
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and pregnant and lactating women are not eligible
__label__1	study interventions are Vidarabine . recurrent adult diffuse large cell lymphoma diagnosis and current serious systemic illness or infection
__label__1	study interventions are Veliparib . recurrent childhood visual pathway and hypothalamic glioma diagnosis and five to less_than ten years
__label__1	study interventions are Sirolimus . localized gallbladder cancer diagnosis and clinically significant cardiac disease especially history of myocardial infarction equal_than less_than six months or congestive heart failure new york heart association nyha classification iii or iv requiring use of ongoing maintenance therapy for life threatening ventricular arrhythmias
__label__1	study interventions are Antibodies, Monoclonal . fallopian tube cancer diagnosis and history of known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study
__label__1	study interventions are Everolimus . recurrent renal cell carcinoma diagnosis and sub protocol aim a
__label__1	study interventions are Mycophenolic Acid . non hodgkin lymphoma diagnosis and patients with any medical illness or concurrent psychiatric illness which in the investigators opinion cannot be adequately controlled with appropriate therapy
__label__1	study interventions are Carboplatin . stage iv prostate cancer diagnosis and patients who meet any of the following criteria will be excluded from the study
__label__1	study interventions are Irinotecan . stage ivb colon cancer diagnosis and prior treatment with sorafenib is not allowed
__label__1	study interventions are Antibodies, Monoclonal . b cell non hodgkin lymphoma diagnosis and radiation therapy within three weeks before randomization enrollment of subjects who require concurrent radiotherapy which must be localized in its field size should be deferred until the radiotherapy is completed and three weeks have elapsed since the last date of therapy
__label__1	study interventions are placebo . carcinoma renal cell diagnosis and note
__label__1	study interventions are Vaccines . central nervous system neoplasm diagnosis and patients unable to receive the influenza vaccine due to history of allergy to egg proteins allergy to influenza vaccine component acute febrile illness at the time of proposed vaccine administration history of clinically or virologically confirmed influenza infection in the previous six months contraindication to intramuscular injections guillan barré syndrome or other contraindication to the vaccine
__label__1	study interventions are Capecitabine . breast cancer diagnosis and male patients
__label__1	study interventions are Metformin . well differentiated pancreatic endocrine tumor diagnosis and surgeries performed within twenty-eight days prior to the start of treatment
__label__1	study interventions are Mycophenolate mofetil . adult hodgkin lymphoma diagnosis and patients who have received an investigational drug within thirty days of enrollment in study
__label__1	study interventions are Cytarabine . lymphoma diagnosis and psychological familial sociological or geographical conditions that do not permit treatment and or medical follow up required to comply with the study protocol
__label__1	study interventions are Lenalidomide . adult cell leukemia lymphoma diagnosis and any prior use of lenalidomide
__label__1	study interventions are Antibodies . recurrent mantle cell lymphoma diagnosis and central line placement or subcutaneous port placement is not considered major surgery but must be placed at least three days prior to enrollment for external lines hickman or broviac and at least seven days prior to enrollment for subcutaneous port
__label__1	study interventions are Immunoglobulins . stage marginal zone lymphoma diagnosis and any serious medical condition laboratory abnormality or psychiatric illness that in the opinion of the investigator would prevent the subject from providing written informed consent
__label__1	study interventions are Alemtuzumab . stage small lymphocytic lymphoma diagnosis and patients who are homozygous at the mismatched major histocompatibility_complex mhc class locus
__label__1	study interventions are Etoposide . stage iii childhood anaplastic large cell lymphoma diagnosis and patients with stage disease are not eligible
__label__1	study interventions are Irinotecan . brain tumor diagnosis and active infection requiring intravenous iv antibiotics
__label__1	study interventions are Everolimus . non small cell lung cancer diagnosis and patients who have any severe and or uncontrolled medical conditions or other conditions that could affect their participation
__label__1	study interventions are Tacrolimus . recurrent adult cell leukemia lymphoma diagnosis and human immunodeficiency virus hiv positive
__label__1	study interventions are Melphalan . stage multiple myeloma diagnosis and patients with positive pcr for hepatitis or hepatitis b
__label__1	study interventions are Immunoglobulins . stage ivb colon cancer diagnosis and prior treatment with irinotecan five fluoruracil or bevacizumab is allowed
__label__1	study interventions are Mitomycins . hepatocellular carcinoma diagnosis and the subject has history of study drug or similar drug allergy
__label__1	study interventions are High Dose Intracavitary Brachytherapy . breast cancer diagnosis and surgical margins which cannot be microscopically assessed or are positive at pathological evaluation
__label__1	study interventions are Busulfan . b cell lymphoma refractory diagnosis and cardiac function
__label__1	study interventions are MK-8628 Dose 1 . non small cell lung cancer nsclc diagnosis and must be stopped at least seven days prior to the first dose of mk
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv grade three follicular lymphoma diagnosis and pregnant women are excluded from this study because the effects of at one hundred and one on the developing human fetus are unknown but could potentially include teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with at one hundred and one breastfeeding should be discontinued if the mother is treated with at one hundred and one these potential risks may also apply to other agents used in this study
__label__1	study interventions are Philips Sonalleve MR-HIFU Breast Tumor Therapy System . breast cancer diagnosis and contraindications to administration of gadolinium based contrast agent including
__label__1	study interventions are Bevacizumab . recurrent fallopian tube carcinoma diagnosis and concurrent use of herbal supplements and other non traditional medications all herbal supplements and other non traditional medications must be stopped before time of registration
__label__1	study interventions are Antibodies, Monoclonal . fallopian tube cancer diagnosis and any patient with an allo transplant of any kind would be excluded as well including xenograft heart valve
__label__1	study interventions are Paclitaxel . carcinoma non small cell lung diagnosis and history of or suspected allergy to nab paclitaxel carboplatin and human albumin or any other platinum based therapy
__label__1	study interventions are Abiraterone Acetate . metastatic prostate cancer diagnosis and uncontrolled hypertension systolic bp greater_than equal_than one hundred and sixty mmhg or diastolic bp greater_than equal_than ninety-five mmhg
__label__1	study interventions are Vincristine . stage marginal zone lymphoma diagnosis and inability to comply with study or follow up testing and procedures
__label__1	study interventions are Erlotinib Hydrochloride . non small cell lung cancer nsclc recurrent diagnosis and cirrhosis chronic active hepatitis or chronic persistent hepatitis
__label__1	study interventions are Vidarabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and cardiac ejection fraction less_than forty
__label__1	study interventions are Dexamethasone acetate . lymphoma diagnosis and pregnant or breast feeding females
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and patient had major surgery within four weeks previous inclusion
__label__1	study interventions are Immunoglobulins . noncutaneous extranodal lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are placebo . colorectal cancer diagnosis and bone fracture or wounds that was not cured for long time
__label__1	study interventions are Tacrolimus . plasma cell neoplasms diagnosis and active involvement of the central nervous system with malignancy
__label__1	study interventions are Doxorubicin . metastatic undifferentiated pleomorphic sarcoma diagnosis and psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Antibodies . stage ii childhood anaplastic large cell lymphoma diagnosis and donor
__label__1	study interventions are DEB TACE . hepatocellular carcinoma diagnosis and infiltration or occlusion of the portal vein
__label__1	study interventions are Immunoglobulin G . stage ivb colorectal cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury equal_than less_than fifty-six days prior to randomization
__label__1	study interventions are Methotrexate . primary diagnosis predating the opening of siop ependymoma ii
__label__1	study interventions are Fluorouracil . rectal cancer diagnosis and history or evidence upon physical examination of cns disease unless adequately treated seizure not controlled with standard medical therapy or history of stroke
__label__1	study interventions are therapeutic allogeneic lymphocytes . recurrent adult lymphoblastic lymphoma diagnosis and human immune deficiency virus
__label__1	study interventions are Cetuximab . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and history of clinically significant heart failure previously assessed with left ventricular ejection fraction lvef of less_than fifty as determined by multiple grated acquisition muga scan or echocardiogram echo
__label__1	study interventions are Everolimus . stage childhood anaplastic large cell lymphoma diagnosis and all patients receiving antifungal therapy voriconazole posaconazole or fluconazole and who are then randomized to arm three must have rapamycin reduced according to the standard practice of antifungal therapy guidelines
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube mucinous adenocarcinoma diagnosis and patients are excluded who have had prior therapy with ct two thousand, one hundred and three
__label__1	study interventions are Docetaxel . prostate neoplasms diagnosis and uncontrolled hypertension systolic bp greater_than equal_than one hundred and sixty mmhg or diastolic bp greater_than equal_than ninety-five mmhg patients with history of hypertension are allowed provided blood pressure is controlled by anti hypertensive therapy
__label__1	study interventions are Paclitaxel . stage iv squamous cell carcinoma of the hypopharynx diagnosis and congestive heart failure with left ventricular ejection fraction less_than twenty
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent primary peritoneal carcinoma diagnosis and pregnant women
__label__1	study interventions are PDT-Deuteporfin(6 hour) . hilar cholangiocarcinoma diagnosis and patients with abnormal laboratory parameters
__label__1	study interventions are Temozolomide . gliosarcoma diagnosis and severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with participating in clinical trial
__label__1	study interventions are Epothilones . carcinoma diagnosis and known history of hypersensitivity reaction to drug formulated in cremophor_el
__label__1	study interventions are Interferons . solid tumors diagnosis and patients taking the following medications will not be eligible
__label__1	study interventions are Dideoxynucleosides . recurrent renal cell carcinoma diagnosis and patients who have had chemotherapy radiotherapy experimental therapy or major surgery within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered to grade less_than one or baseline from clinically significant adverse events due to agents administered more than four weeks earlier alopecia and fatigue excluded clinical significance to be determined by investigator
__label__1	study interventions are Capecitabine . triple negative breast cancer diagnosis and has diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within seven days prior to the first dose of trial treatment
__label__1	study interventions are Bevacizumab . fallopian tube mucinous adenocarcinoma diagnosis and patients with clinically significant proteinuria urine protein should be screened by urine protein creatinine ratio upcr the upcr has been found to correlate_directly with the amount of protein excreted in twenty-four hour urine collection specifically upcr of doc is equivalent to doc gram of protein in twenty-four hour urine collection obtain at least four ml of random urine sample in sterile container does not have to be twenty-four hour urine send sample to lab with request for urine protein and creatinine levels separate requests the lab will measure protein concentration mg dl and creatinine concentration mg dl the upcr is derived as follows
__label__1	study interventions are Dasatinib . endometrioid adenocarcinoma diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Antibodies . malignant pancreatic glucagonoma diagnosis and men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception diaphragm birth control pills injections intrauterine device iud surgical sterilization subcutaneous implants or abstinence etc
__label__1	study interventions are Cyclosporins . stage childhood hodgkin lymphoma diagnosis and donors who are hiv positive
__label__1	study interventions are Dexamethasone . lymphoma mantle cell diagnosis and known or suspected inability to comply with study protocol
__label__1	study interventions are Mycophenolate mofetil . stage iv childhood anaplastic large cell lymphoma diagnosis and fungal infections with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Mycophenolate mofetil . childhood diffuse large cell lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are TAK-901 . lymphoma diagnosis and infection requiring systemic anti infective therapy within fourteen days before the start of study drug
__label__1	study interventions are Topotecan . disseminated neuroblastoma diagnosis and lactating females are not eligible unless they have agreed not to breastfeed their infants
__label__1	study interventions are OSNA Breast Cancer System . breast neoplasms diagnosis and subjects who have been judged to be an inappropriate candidate by any medical care provider surgeon oncologist or pathologist
__label__1	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and is currently participating in or has participated in study of an investigational agent or using an investigational device
__label__1	study interventions are Antibodies, Monoclonal . recurrent mantle cell lymphoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one registration
__label__1	study interventions are pharmacological study . colorectal cancer diagnosis and history of celiac disease
__label__1	study interventions are Carboplatin . stage iia fallopian tube cancer diagnosis and patients with clinically significant proteinuria urine protein should be screened by urine protein creatinine ratio upcr patients must have upcr less_than doc to allow participation in the study
__label__1	study interventions are Pembrolizumab . squamous cell carcinoma of the head and neck diagnosis and replacement therapy eg
__label__1	study interventions are Leucovorin . stage ib esophageal cancer diagnosis and patients with non malignant systemic disease cardiovascular renal hepatic etc
__label__1	study interventions are Sirolimus . stage iv fallopian tube cancer diagnosis and note
__label__1	study interventions are Mycophenolate mofetil . recurrent grade three follicular lymphoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Valproic Acid . solid tumor diagnosis and female patients who are pregnant
__label__1	study interventions are Paclitaxel . solid tumors diagnosis and significant gastrointestinal disorder that could in the opinion of the investigator interfere with the absorption metabolism or excretion of arq ninety-two crohn disease ulcerative colitis extensive gastric resection
__label__1	study interventions are Carboplatin . any woman who has experienced menarche and who has not undergone surgical sterilization hysterectomy bilateral tubal ligation or oophorectomy or who is not post menopausal defined as amenorrheic greater_than twelve consecutive months
__label__1	study interventions are Lithium Carbonate . recurrent adult diffuse mixed cell lymphoma diagnosis and patients with any psychological familial sociological or geographical condition potentially hampering compliance with the study protocol will be excluded
__label__1	study interventions are AZD9496 Variant A . breast cancer diagnosis and known or suspected history of drug abuse as judged by the investigator
__label__1	study interventions are Antibodies, Monoclonal . recurrent marginal zone lymphoma diagnosis and marrow cellularity equal_than less_than fifteen as determined on all bone marrow samples
__label__1	study interventions are Genistein . bladder cancer diagnosis and hiv positive or immunocompromised
__label__1	study interventions are Leuprolide . symptomatic bulky lymphadenopathy causing scrotal or pedal edema or significant local invasive disease in bladder invasion
__label__1	study interventions are Mycophenolic Acid . recurrent adult immunoblastic large cell lymphoma diagnosis and current serious systemic illness
__label__1	study interventions are FACIT-Fatigue 52-point questionnaire . breast cancer diagnosis and score on the facit fatigue questionnaire of twenty-three twenty-nine
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and patients with remote histories greater_than five years of other cured malignancies may be entered
__label__1	study interventions are Sirolimus . neurofibromatoses diagnosis and known history of hiv seropositivity
__label__1	study interventions are Tacrolimus . stage iii grade two follicular lymphoma diagnosis and donor
__label__1	study interventions are CD19 or CD20 CAR T cells briging HSCT . lymphoma large cell diffuse diagnosis and participation in prior investigational study within four weeks prior to enrollment or longer if required by local regulation
__label__1	study interventions are Sirolimus . stage iii childhood lymphoblastic lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml mds all or cml
__label__1	study interventions are Fludarabine phosphate . recurrent adult immunoblastic large cell lymphoma diagnosis and patients with known human immunodeficiency virus hiv are excluded due to side effects of the therapy on the immune system
__label__1	study interventions are Immunoglobulin G . endometrial cancers with fgfrtwo mutations diagnosis and any eligibility questions related to prior therapies including the timing from prior therapies should be discussed and decision agreed on by the investigator and the sponsor in writing prior to the subject entering the study
__label__1	study interventions are fatigue and depressive symptom assessment and management . stage iib colon cancer diagnosis and has self reported history of diagnosed sleep disorders obstructive sleep_apnea insomnia comorbidities associated with poor sleep or fatigue chronic fatigue syndrome or job with night_shifts
__label__1	study interventions are Prednisone . prostate cancer metastatic diagnosis and daily multi vitamin calcium and vitamin is allowed
__label__1	study interventions are Epirubicin . tubular breast cancer diagnosis and patients with medical conditions taht indicate intolerant to neoadjuvant therapy including uncontrolled cardiovascular disease severe infection
__label__1	study interventions are Antibodies, Monoclonal . stage iv breast cancer diagnosis and patients who have had chemotherapy or other systemic therapy or radiotherapy or those who have not recovered from adverse events due to prior administered agents as follows
__label__1	study interventions are Tecogalan sodium . sarcoma kaposi diagnosis and active heart disease such as uncontrolled angina uncompensated congestive heart failure or dysrhythmias requiring antiarrhythmics
__label__1	study interventions are Collection of biological samples . pancreatic adenocarcinoma diagnosis and no informed consent
__label__1	study interventions are API 31510 Topical Cream . superficial basal cell carcinoma diagnosis and levulanic acid five fluorouracil coricosteroids retinoids diclofenac hyaluronic acid imiquimod
__label__1	study interventions are Pomalidomide . cancer treated with curative intent greater_than five years before study enrollment and without evidence of recurrence will be allowed
__label__1	study interventions are Imidazole . stage iib hodgkin lymphoma diagnosis and female participants who are pregnant or breast feeding confirmation that the subject is not pregnant must be established by negative serum beta human chorionic gonadotropin hcg pregnancy test result obtained during screening pregnancy testing is not required for post menopausal or surgically sterilized women
__label__1	study interventions are Zidovudine . epstein_barr virus associated hodgkin lymphoma diagnosis and patients refusing to take any anti hepatitis therapy during study will also be excluded
__label__1	study interventions are Endothelial Growth Factors . stage iiia fallopian tube cancer diagnosis and new york heart association nyha grade ii or greater congestive heart failure
__label__1	study interventions are Fulvestrant . breast cancer diagnosis and active heart cardiac disease as defined in the protocol
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and patients with concomitant or previous malignancies within the last five years are excluded from the study
__label__1	study interventions are Phase 2 . relapsed or refractory hodgkin lymphoma diagnosis and known brain metastases or leptomeningeal disease
__label__1	study interventions are Sunitinib . recurrent fallopian tube cancer diagnosis and azole_antifungals ketoconazole itraconazole miconazole verapamil clarithromycin human immunodeficiency virus hiv protease inhibitors indinavir saquinavir ritonavir atazanavir nelfinavir erythromycin delavirdine diltiazem
__label__1	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and prior treatment with monoclonal antibodies
__label__1	study interventions are Lenalidomide . peripheral cell lymphoma diagnosis and known hypersensitivity to thalidomide
__label__1	study interventions are Irreversible electroporation (IRE) . extremities neoplasms diagnosis and cardiac insufficiency ongoing coronary artery disease or arrhythmia
__label__1	study interventions are Docetaxel . non small cell lung cancer diagnosis and no eliminated acute or chronic infection or other serious concomitant diseases
__label__1	study interventions are Antibodies . refractory hodgkin lymphoma diagnosis and erythropoietin or darbepoetin therapy if initiated at least two weeks prior to study registration may be continued
__label__1	study interventions are CTL019 . diffuse large cell lymphoma dlbcl diagnosis and any immunosuppressive medication must be stopped greater_than four weeks prior to enrollment
__label__1	study interventions are Radiation with photons . very small tumors for example acoustic neuromas very small recurrences for this is proton therapy from medical point of view no alternative to stereotactic radiotherapy
__label__1	study interventions are Cisplatin . histologic confirmed squamous cell carcinoma
__label__1	study interventions are Anticonvulsants . anaplastic astrocytoma diagnosis and drugs that are generally accepted to have risk of causing torsades de pointes including
__label__1	study interventions are Sirolimus . pancreatic neuroendocrine tumors pnet diagnosis and hepatic artery embolization or cryoablation radiofrequency ablation of hepatic metastasis within two months of study treatment start
__label__1	study interventions are Rituximab . noncontiguous stage ii mantle cell lymphoma diagnosis and patients that have other medical conditions that would contraindicate treatment with aggressive chemotherapy including active infection uncontrolled hypertension congestive heart failure unstable angina pectoris or myocardial infarction within the past six months or uncontrolled arrhythmia
__label__1	study interventions are Rituximab . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and patient unable to give informed consent
__label__1	study interventions are Niacinamide . advanced adult hepatocellular carcinoma diagnosis and child pugh cirrhosis or child pugh cirrhosis with more than seven points
__label__1	study interventions are Saccharomyces boulardii . colorectal cancer diagnosis and patients who had previously taken any probiotic or prebiotic
__label__1	study interventions are Everolimus . prostate cancer diagnosis and the use of agents that significantly prolong the corrected qt interval and who are unable to stop medications prior to study initiation
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and in any patient in whom there is doubt the patient should have stress imaging study and if abnormal angiography to define whether or not cad is present
__label__1	study interventions are Capecitabine . malignant neoplasms of mesothelial and soft tissue diagnosis and proteinuria greater_than one positive on urine dipstick testing or thirty mg dl
__label__1	study interventions are Tramadol . eye neoplasms diagnosis and patients less than eighteen years of age
__label__1	study interventions are EMD525797 . solid tumor diagnosis and current history of chronic daily acetylsalicylic acid ass therapy ass at doses less_than equal_than one hundred mg is permitted
__label__1	study interventions are Arsenic trioxide . lung cancer diagnosis and patient is unable or unwilling to abide by the study protocol
__label__1	study interventions are Laboratory Biomarker Analysis . thyroid gland oncocytic follicular carcinoma diagnosis and any of the following equal_than less_than six months before the first dose of study treatment
__label__1	study interventions are Sunitinib . non small cell lung cancer diagnosis and treatment within the last twenty-eight days with any investigational drug
__label__1	study interventions are cognitive intervention . leydig cell tumor diagnosis and progressive neurological or chronic progressive debilitating condition dementia
__label__1	study interventions are Albumin-Bound Paclitaxel . epithelial ovarian cancer diagnosis and new york heart association nyha grade ii or greater congestive heart failure
__label__1	study interventions are Gemcitabine . pancreatic adenocarcinoma diagnosis and inability to lie supine for thirty to sixty minutes
__label__1	study interventions are Cognitive Rehabilitation . breast cancer diagnosis and doc
__label__1	study interventions are Laboratory biomarker analysis . recurrent intraocular melanoma diagnosis and patients with poorly controlled diabetes mellitus patients with history of diabetes mellitus are allowed to participate provided that their blood glucose is within normal range fasting less_than one hundred and twenty mg dl or below institutional uln and that they are on stable dietary or therapeutic regimen for this condition
__label__1	study interventions are Leucovorin . stage iiia rectal cancer diagnosis and clinical evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are Methotrexate . nodal marginal zone cell lymphoma diagnosis and adult forty pediatric equal_than less_than eighteen yrs
__label__1	study interventions are Immunoglobulin G . stage iiia fallopian tube cancer diagnosis and persistent gastrointestinal symptoms resulting from clostridia_difficile enterocolitis or bowel surgery which may increase gastrointestinal toxicity from bevacizumab or hearing loss or neuropathy which would prevent tolerance to cisplatin and paclitaxel administration the investigator should feel free to consult the study chair or study co chairs for uncertainty in this regard twelve twenty ten
__label__1	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and if the involved field is small seven days will be considered sufficient interval between treatment and administration of the ixazomib
__label__1	study interventions are Niacinamide . stage iii prostate cancer diagnosis and any condition that impairs patient ability to swallow whole pills
__label__1	study interventions are Alemtuzumab . hodgkin lymphoma diagnosis and known to be positive for hiv
__label__1	study interventions are Antibodies, Monoclonal . stage iiia breast cancer diagnosis and known hypersensitivity to any of the study drugs or any of the ingredients or excipients of these drugs polysorbate eighty including sensitivity to benzyl alcohol
__label__1	study interventions are Trastuzumab . past or current history of neoplasm other than curatively treated
__label__1	study interventions are Pegaspargase . b precursor lymphoblastic lymphoma
__label__1	study interventions are Levoleucovorin . gastric cancer diagnosis and prior treatment with investigational drugs that target the hepatocyte growth factor hgf or met pathway
__label__1	study interventions are Etoposide . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and pregnant or nursing women men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
__label__1	study interventions are Bevacizumab . hormone sensitive prostate cancer
__label__1	study interventions are AZD2014 . neurofibromatosis two diagnosis and angina pectoris
__label__1	study interventions are Melphalan . ocular melanoma diagnosis and child b or cirrhosis or clinical evidence of portal hypertension
__label__1	study interventions are Pembrolizumab . recurrent hodgkin lymphoma diagnosis and patients with tb immune reconstitution syndrome iris requiring corticosteroids
__label__1	study interventions are Camptothecin . advanced cancers diagnosis and medical psychological or social conditions that may interfere with the patient participation in the study or evaluation of the study results
__label__1	study interventions are Fludarabine . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Liposomal doxorubicin . pilocytic astrocytoma diagnosis and arm b
__label__1	study interventions are Fludarabine phosphate . childhood burkitt lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Biopsies taken . familial adenomatous polyposis coli diagnosis and subjects who are taking warfarin or other anticoagulants
__label__1	study interventions are Epirubicin . breast cancer diagnosis and treatment with any drug within the last thirty days that has not received regulatory approval
__label__1	study interventions are Vaccines . patients with known active or symptomatic brain metastases
__label__1	study interventions are BB 1101 . lymphoma cell cutaneous diagnosis and known hiv infection
__label__1	study interventions are Etoposide phosphate . stage ii childhood anaplastic large cell lymphoma diagnosis and patients with down syndrome are not eligible
__label__1	study interventions are Ibrutinib . relapsed follicular lymphoma diagnosis and those who are pcr positive will be excluded
__label__1	study interventions are Dacarbazine . a history of other malignancy less_than five years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix
__label__1	study interventions are Mitogens . severe or uncontrolled systemic disease active infection concomitant malignancy or second primary malignancy except for in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin
__label__1	study interventions are Dacarbazine . metastatic malignant melanoma diagnosis and evidence of brain metastases
__label__1	study interventions are Mitogens . recurrent adult lymphoblastic lymphoma diagnosis and use of graft depleted of cells
__label__1	study interventions are Fludarabine . patients with non hematological tumors
__label__1	study interventions are Mesna . lymphoma diagnosis and patient has an absolute neutrophil count of anc eg less_than doc ten nine for studies with bortezomib alone greater_than within fourteen days before enrollment
__label__1	study interventions are Prednisone . stage iv grade three follicular lymphoma diagnosis and treatment with any known non marketed drug substance or experimental therapy within four weeks prior to enrollment or currently participating in any other interventional clinical study for nhl or any other illness except observational prevention and or registry trials
__label__1	study interventions are Lenalidomide . carcinoma in situ of the cervix
__label__1	study interventions are Exemestane . her two positive breast cancer diagnosis and patients with clinically significant history of liver disease including viral or other known hepatitis current alcohol abuse or cirrhosis
__label__1	study interventions are Nivolumab . colorectal cancer diagnosis and subjects with brain metastases are eligible if these have been locally treated surgery radiotherapy
__label__1	study interventions are Antibodies, Monoclonal . follicular lymphoma diagnosis and prior exposure to ofatumumab or other targeted anti cdtwenty therapies including rituximab
__label__1	study interventions are Carboplatin . carcinoma pancreatic ductal diagnosis and any peripheral neuropathy greater_than nci ctcae grade two
__label__1	study interventions are Cyclosporins . recurrent adult immunoblastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Valproic Acid . brainstem glioma diagnosis and prior ischemic events
__label__1	study interventions are Azacitidine . adequately treated carcinoma in situ without evidence of disease
__label__1	study interventions are Pembrolizumab . bone sarcoma diagnosis and patients that require inhaled steroids or local steroid injections would not be excluded from the study
__label__1	study interventions are BCG Vaccine . bladder carcinoma diagnosis and patients with implantable or wearable electrical devices will be excluded from this study
__label__1	study interventions are 9.6 mg/kg a-TEA . metastatic sarcoma diagnosis and patients requiring steroids for management of cns metastatic disease are not eligible
__label__1	study interventions are Vaccines . human papillomavirus positive oropharyngeal squamous cell carcinoma diagnosis and patients who have history of listeriosis or prior adxseleven one therapy
__label__1	study interventions are Antibodies . refractory multiple myeloma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Erlotinib Hydrochloride . cancer diagnosis and history of chronic hepatitis
__label__1	study interventions are Fludarabine phosphate . recurrent adult immunoblastic large cell lymphoma diagnosis and eligible for other therapeutic options that will be more likely to have better long term disease free survival with lower potential toxicity non transplant therapy autologous transplants etc
__label__1	study interventions are Bevacizumab . endometrial serous adenocarcinoma diagnosis and patients with peripheral neuropathy greater_than ctcae grade one
__label__1	study interventions are PET/CT . prostate cancer diagnosis and performed pet ct before randomisation
__label__1	study interventions are Questionnaires . breast cancer diagnosis and present with any of american college of sports medicine absolute contraindications to exercise testing
__label__1	study interventions are Liposomal doxorubicin . triple negative breast carcinoma diagnosis and has history of non infectious pneumonitis that required steroids or currently has pneumonitis
__label__1	study interventions are Cyclophosphamide . aggressive non hodgkin lymphoma diagnosis and patients who have received prior allogeneic hct must have no active gvhd requiring immunosuppressive therapy for at least twenty-one days prior to start of conditioning
__label__1	study interventions are Albumin-Bound Paclitaxel . neuroblastoma diagnosis and the patient has known history or current diagnosis of human immunodeficiency virus hiv infection regardless of treatment status
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and history of myocardial infarction or unstable angina within twelve months prior to study enrollment
__label__1	study interventions are Carboplatin . fallopian tube carcinoma diagnosis and a
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and karnofsky performance status seventy one hundred
__label__1	study interventions are Thiotepa . patients with diagnosis of atypical_teratoid rhabdoid tumor atrt by histology immunohistochemistry and or molecular analysis and desmoplastic mzero medulloblastoma will be excluded from the study
__label__1	study interventions are Cyclosporins . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and identical twin
__label__1	study interventions are Leucovorin . stage iiia gastric cancer diagnosis and patients with clinically active liver disease including viral or other hepatitis or cirrhosis are ineligible
__label__1	study interventions are Megestrol . stage iiictwo uterine corpus cancer diagnosis and john wort as these may decrease temsirolimus levels use of agents that potently inhibit cypthreea and hence may raise temsirolimus levels such as ketoconazole is discouraged but not specifically prohibited the appropriateness of use of such agents is left to physician discretion
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and hormonal therapy for locally recurrent or metastatic disease must have been discontinued at least two weeks prior to study entry
__label__1	study interventions are Etoposide . peripheral cell lymphomas ptcl diagnosis and any active uncontrolled infection
__label__1	study interventions are Albumin-Bound Paclitaxel . primary peritoneal cavity cancer diagnosis and clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer disease
__label__1	study interventions are Fluorouracil . solid tumors diagnosis and male subject with pregnant partner who is not willing to use condom during treatment and for an additional six months after the last dose of protocol specified therapy administration
__label__1	study interventions are Sirolimus . recurrent ovarian carcinoma diagnosis and evidence of current drug or alcohol abuse or psychiatric impairment which in the investigator opinion will prevent completion of the protocol therapy or follow up
__label__1	study interventions are Mycophenolic Acid . noncutaneous extranodal lymphoma diagnosis and current serious systemic illness
__label__1	study interventions are Melphalan . stage iv adult diffuse small cleaved cell lymphoma diagnosis and inability to collect adequate stem cells
__label__1	study interventions are Doxorubicin . endometrial cancer diagnosis and table one
__label__1	study interventions are Immunoglobulins . presence of second active tumor other than non melanoma skin cancer carcinoma in situ of the cervix or kaposi sarcoma ks that requires systemic therapy
__label__1	study interventions are questionnaire administration . stage iiib breast cancer diagnosis and patients who have been previously treated with cytotoxic chemotherapy
__label__1	study interventions are Mycophenolate mofetil . splenic marginal zone lymphoma diagnosis and donor
__label__1	study interventions are Cyclophosphamide . metastatic cancer that express the mage_athree hla aone antigen diagnosis and age greater than or equal to sixty years old
__label__1	study interventions are Metformin . stage iiic ovarian germ cell tumor diagnosis and concurrent active invasive malignancy or one previously diagnosed with greater than thirty chance of recurrence in the next two years
__label__1	study interventions are Camptothecin . pediatric solid tumors diagnosis and patients with evidence of bleeding diathesis are not eligible
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and known hypersensitivity to bevacizumab or any of its excipients and any of the chemotherapies
__label__1	study interventions are Interleukin-12 . stage ivb cervical cancer diagnosis and history of significant peripheral neuropathy or significant central nervous system disease
__label__1	study interventions are Apatinib single agent arm . non small cell lung cancer diagnosis and thrombosis in twelve months including pulmonary thrombosis stroke or deep venous thrombosis
__label__1	study interventions are laboratory biomarker analysis . uncontrolled brain metastases including symptomatic lesions or lesions requiring glucocorticoids and or anticonvulsants to suppress symptoms
__label__1	study interventions are Ketoconazole . recurrent prostate carcinoma diagnosis and inability to swallow oral capsules
__label__1	study interventions are Fludarabine . recurrent childhood lymphoblastic lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Azacitidine . has history of other malignancy within the last five years except cured basal cell carcinoma of skin which could affect the diagnosis or assessment of any of the study drugs
__label__1	study interventions are Tacrolimus . stage adult diffuse large cell lymphoma diagnosis and pregnant women are excluded from this study because vorinostat is histone_deacetylase inhibitor agent with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat breastfeeding should be discontinued if the mother is treated with vorinostat
__label__1	study interventions are Cyclophosphamide . recurrent grade two follicular lymphoma diagnosis and no compatible donor identified
__label__1	study interventions are Bevacizumab . solid tumors diagnosis and inadequately controlled hypertension defined as systolic blood pressure greater_than one hundred and fifty and or diastolic blood pressure greater_than one hundred mmhg
__label__1	study interventions are Vaccines . stage iia lung carcinoma diagnosis and known hypersensitivity to sirolimus
__label__1	study interventions are Vinorelbine . hertwo positive breast cancer diagnosis and pregnant or breast feeding
__label__1	study interventions are alpha-Tocopherol . cancer of the prostate diagnosis and current use of finasteride or dutasteride
__label__1	study interventions are Endothelial Growth Factors . stage iiia fallopian tube cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube carcinoma diagnosis and history of non malignant gi bleeding gastric stress ulcerations or peptic ulcer disease within the past three months that in the opinion of the investigator may place the patient at risk of side effects on an anti angiogenesis product
__label__1	study interventions are Robotic single port surgery and NOTES . oral neoplasms diagnosis and noncorrectable coagulopathy
__label__1	study interventions are Estradiol . breast cancer diagnosis and if you do qualify study personnel will explain the trial in detail and answer any questions you may have
__label__1	study interventions are Mycophenolic Acid . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and patient has the following organ dysfunction
__label__1	study interventions are Carboplatin . stage iic fallopian tube cancer diagnosis and hemoptysis liver rupture
__label__1	study interventions are PG2 . cancer diagnosis and patients who require preoperative nutritional support
__label__1	study interventions are Gemcitabine . patients currently treated for metastatic pancreatic cancer with other therapy than nab paclitaxel plus gemcitabine
__label__1	study interventions are Tranexamic Acid . hematologic neoplasms diagnosis and coagulopathy defined as prothrombin time or activated partial thromboplastin time greater_than doc times the upper limit of normal or fibrinogen less than two l
__label__1	study interventions are Bevacizumab . colon cancer diagnosis and subjects who are men must also agree to use effective contraception
__label__1	study interventions are Sorafenib . stage iib adult soft tissue sarcoma diagnosis and thrombolic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past six months
__label__1	study interventions are 851B . papillomavirus infections diagnosis and in the four weeks prior to the screening visit the subject has received
__label__1	study interventions are survey administration . solid tumor diagnosis and prior concurrent therapy
__label__1	study interventions are Antibodies . hodgkin lymphoma diagnosis and known hepatitis surface antigen positive or known or suspected active hepatitis infection
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and hiv infection
__label__1	study interventions are Central Nervous System Stimulants . malnourished children with cancer diagnosis and subjects with previous or current thromboembolic conditions excluding central venous thrombosis related to the placement of central venous catheter
__label__1	study interventions are Cyclosporins . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and seropositive for human immunodeficiency virus hiv
__label__1	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and known allergy to csf
__label__1	study interventions are Mycophenolate mofetil . lymphoma non hodgkin diagnosis and patients with an available five six six hla b drbone matched sibling donor or one0 one0 unrelated bone marrow donor
__label__1	study interventions are Trastuzumab . solid tumors diagnosis and central nervous system metastasis
__label__1	study interventions are Folic Acid Antagonists . lung cancer diagnosis and patients must have recovered from the acute toxic effects prior to day one of cycle one to grade less_than equal_than one or baseline
__label__1	study interventions are Cyclophosphamide . stage iv non small cell lung cancer diagnosis and patients with any of the following cardiac conditions
__label__1	study interventions are Lenvatinib . stage ivc thyroid gland papillary carcinoma diagnosis and male subjects
__label__1	study interventions are Antilymphocyte Serum . contiguous stage ii adult diffuse mixed cell lymphoma diagnosis and more than twenty zero circulating cdtwenty positive cells ul
__label__1	study interventions are Pomalidomide . diffuse large cell lymphoma dlbcl diagnosis and unable to receive medications by mouth
__label__1	study interventions are Cisplatin . head and neck cancer diagnosis and serious concomitant diseases preventing the safe administration of chemotherapy and or radiotherapy or likely to interfere with the study assessments
__label__1	study interventions are Antibodies, Monoclonal . cutaneous cell lymphoma ctcl diagnosis and grade two or greater neuropathy
__label__1	study interventions are Busulfan . non small cell lung cancer diagnosis and history of idiopathic pulmonary fibrosis including pneumonitis history of drug induced pneumonitis
__label__1	study interventions are Hormones . neoplasms breast diagnosis and documented myocardial infarction less_than six months from study entry
__label__1	study interventions are Megestrol Acetate . progesterone receptor positive breast cancer diagnosis and hypersensitivity to trial medications everolimus
__label__1	study interventions are Cyclophosphamide . recurrent small lymphocytic lymphoma diagnosis and seropositive for the human immunodeficiency virus hiv
__label__1	study interventions are Aromatase Inhibitors . prior anti cancer therapy or radiotherapy within two weeks prior to day one of cycle one
__label__1	study interventions are Sirolimus . ovarian seromucinous carcinoma diagnosis and major surgical procedure open biopsy or significant traumatic injury equal_than less_than four weeks prior to registration
__label__1	study interventions are Antibodies, Monoclonal . uncontrolled intercurrent illness including but not limited to ongoing or active infection uncontrolled diabetes clinically significant pneumonitis symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Cyclophosphamide . localized unresectable neuroblastoma diagnosis and lactating females are not eligible unless they have agreed not to breastfeed their infants
__label__1	study interventions are Fludarabine . noncontiguous stage ii mantle cell lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Antibodies . stage adult diffuse large cell lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab_vedotin and or rituximab
__label__1	study interventions are Immunoglobulin G . stage iiic primary peritoneal cancer diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study examples of this would be
__label__1	study interventions are Antibodies . carcinoma diagnosis and known portal vein obstruction
__label__1	study interventions are Fludarabine . recurrent adult diffuse mixed cell lymphoma diagnosis and cardiac ejection fraction less_than forty
__label__1	study interventions are Semi-structured interview . colorectal cancer diagnosis and patient unwilling or unable to provide informed consent
__label__1	study interventions are Fludarabine phosphate . recurrent adult diffuse mixed cell lymphoma diagnosis and cardiac ejection fraction less_than forty ejection fraction is required if the patient has history of anthracyclines or history of cardiac disease
__label__1	study interventions are Endothelial Growth Factors . fallopian tube carcinosarcoma diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Pembrolizumab . solid tumors diagnosis and patients who have received any other investigational agents within thirty days of first dose of study drug
__label__1	study interventions are Docetaxel . patients whose tumor is deemed by the doctor to be difficult to evaluate
__label__1	study interventions are Etoposide phosphate . intraocular lymphoma diagnosis and positive serology because of prior vaccination is allowed
__label__1	study interventions are Mycophenolate mofetil . recurrent adult diffuse small cleaved cell lymphoma diagnosis and female of childbearing potential with positive pregnancy test
__label__1	study interventions are Paclitaxel . a man or woman of childbearing potential who has no willingness to use contraceptive measure during the study
__label__1	study interventions are Bortezomib . lymphoma diagnosis and myocardial infarction within the past six months
__label__1	study interventions are Vatalanib . unspecified adult solid tumor protocol specific diagnosis and other chemotherapy immunotherapy hormonal therapy radiotherapy or any ancillary therapy considered investigational utilized for non fda approved indication and in the context of research investigation equal_than less_than four weeks prior to registration
__label__1	study interventions are Trastuzumab . neoplasms breast diagnosis and subjects with ulcerative colitis are also excluded
__label__1	study interventions are Capecitabine . breast cancer diagnosis and preexisting motor sensory peripheral neuropathy
__label__1	study interventions are Cyclosporine . recurrent grade one follicular lymphoma diagnosis and any leukemia with morphologic relapse or persistent disease in the bm with greater_than equal_than twenty blasts cytogenetic relapse without morphologic evidence of relapse or cytogenetic persistent disease is acceptable
__label__1	study interventions are Laboratory Biomarker Analysis . solid neoplasm diagnosis and known standard therapy for the patient disease that is potentially curative or definitely capable of extending life expectancy
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and active cns malignancy
__label__1	study interventions are Cetuximab . gastric cancer diagnosis and impaired renal function estimated creatinine clearance less_than thirty ml min as calculated with cockroft gault equation and serum creatinine greater_than doc upper normal limit
__label__1	study interventions are Cyclosporins . hodgkin lymphoma diagnosis and the effects upon breast milk are also unknown and may be harmful to the infant
__label__1	study interventions are Doxorubicin . carcinoma hepatocellular diagnosis and other serious illness or medical conditions
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iia ovarian cancer diagnosis and patients with gog performance grade of three or four
__label__1	study interventions are Irinotecan . prior history of breast cancer or ovarian cancer in female patients or any cancer except cured cervical carcinoma in situ or skin cancer
__label__1	study interventions are Lapatinib . recurrent thyroid gland carcinoma diagnosis and history of hepatitis virus hbv or hepatitis virus hcv infection with the exception of cleared hbv and hcv infection which will be allowed
__label__1	study interventions are Cisplatin . epithelial ovarian cancer diagnosis and patients known to be serologically positive for hepatitis c or hiv
__label__1	study interventions are Loperamide . carcinoma non small cell lung diagnosis and major surgery within four weeks before starting study treatment or scheduled for surgery during the projected course of the study
__label__1	study interventions are Antibodies . splenic marginal zone lymphoma diagnosis and use of hematopoietic growth factor including filgrastim pegfilgrastim sargramostim erythropoietin or darbepoetin within fourteen days prior to baseline
__label__1	study interventions are Sirolimus . castrate resistant prostate cancer crpc diagnosis and fivex uln
__label__1	study interventions are Everolimus . stage iv marginal zone lymphoma diagnosis and the fhcrc pi of the study must approve of enrollment of all patients with pulmonary nodules
__label__1	study interventions are Antibodies . stage iiic fallopian tube cancer diagnosis and pulmonary hypertension
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and evidence of current uncontrolled cardiovascular conditions
__label__1	study interventions are Laboratory Biomarker Analysis . advanced malignant neoplasm diagnosis and gastrointestinal gi
__label__1	study interventions are Cisplatin . tongue cancer diagnosis and pregnancy or women of childbearing potential and men who are sexually active and not willing able to use medically acceptable forms of contraception this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
__label__1	study interventions are Antibodies, Monoclonal . current use of systemic corticosteroids greater than greater_than twenty milligrams mg prednisone per day or equivalent or prior anti cancer therapy to include
__label__1	study interventions are Fludarabine . recurrent childhood lymphoblastic lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Oxaliplatin . malignant tumor of colon diagnosis and positive hbsag
__label__1	study interventions are Dacarbazine . childhood grade iii meningioma diagnosis and sgpt alt less_than doc times institutional uln for age
__label__1	study interventions are Bevacizumab . carcinoma of the ovary diagnosis and patients receiving other chemotherapy taxol carboplatin associated or not to avastin
__label__1	study interventions are Etoposide . neoplasms diagnosis and must not have known hypersensitivity to other antibodies or any accompanying excipients associated with these medications
__label__1	study interventions are Fludarabine . recurrent refractory childhood hodgkin lymphoma diagnosis and calculated cockcroft gault or appropriate calculation for pediatric patients serum creatinine clearance equal_than less_than sixty ml min if the calculated crcl is fifty sixty ml min but measured crcl by twenty-four hour urine collection is greater_than sixty ml min this measurement is acceptable
__label__1	study interventions are Zalypsis (PM00104) . lymphoma diagnosis and uncontrolled arterial hypertension despite optimal medical therapy
__label__1	study interventions are Cisplatin . esophageal adenocarcinomas diagnosis and patients with history of severe hypersensitivity reaction to docetaxel cisplatin or drugs formulated with polysorbate tween eighty
__label__1	study interventions are BB 1101 . breast cancer diagnosis and patients under the age of eighteen or over the age of seventy-nine
__label__1	study interventions are Panobinostat . multiple myeloma diagnosis and eight
__label__1	study interventions are Reconstructive surgery . cancer diagnosis and the subject is diabetic
__label__1	study interventions are Vincristine . primary effusion lymphoma diagnosis and participants with viral hepatitis who do not meet the criteria will not be eligible all participants who present with acute hepatitis including those with normal transaminases who are hbsag positive and igm positive for hepatitis core antigen will not be eligible participants who are hepatitis core antibody positive are eligible only if they start or are on prophylactic therapy hepatitis viral load should be confirmed negative on all participants who are hepatitis core antibody positive participants refusing to take any anti hepatitis therapy during study will also be excluded participants diagnosed with hepatitis are eligible if they meet criteria
__label__1	study interventions are Mycophenolic Acid . recurrent adult diffuse small cleaved cell lymphoma diagnosis and severe defects in pulmonary function testing defects are currently categorized as mild moderate and severe as defined by the pulmonary consultant or receiving supplementary continuous oxygen
__label__1	study interventions are Ergocalciferols . glioblastoma multiforme diagnosis and platelet count less_than one hundred one hundred and nine l
__label__1	study interventions are Antibodies . stage ivc laryngeal squamous cell carcinoma diagnosis and patient with confirmed history of interstitial lung disease
__label__1	study interventions are Vaccines . infections papillomavirus diagnosis and chronic administration defined as more than fourteen days of immunosuppressants or other immune modifying drugs within six months prior to the first vaccine dose
__label__1	study interventions are Tryptophan . malignant brain tumor diagnosis and other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results or in the judgment of the investigator would make the patient inappropriate for entry into this study
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and john wort within fourteen days before randomization in the study
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma renal cell diagnosis and low dose coumadin one mg for maintenance of catheter patency or daily prophylactic aspirin is allowed
__label__1	study interventions are Prednisone . significant hepatic dysfunction unless related to myeloma
__label__1	study interventions are Maleic acid . stage iv grade three follicular lymphoma diagnosis and uncontrolled intercurrent illness including but not limited to ongoing or active infection requiring parenteral antibiotics on day one
__label__1	study interventions are Mitogens . stage iib breast cancer diagnosis and positive hepatitis hepatitis surface antigen and antibody and or hepatitis hepatitis antibody test as indicated by serologies conducted equal_than less_than three months prior to starting study if liver function tests are outside of the normal institutional range
__label__1	study interventions are Everolimus . adult hepatocellular carcinoma diagnosis and untreated central nervous system cns metastases exceptions
__label__1	study interventions are Carboplatin . stage iiic uterine corpus cancer diagnosis and total serum bilirubin greater_than doc mg dl
__label__1	study interventions are Iodine . other malignancy within the past three years except basal cell carcinoma or squamous cell carcinoma of the skin or in situ carcinoma of the cervix
__label__1	study interventions are Ixazomib . multiple myeloma diagnosis and bilirubin greater_than doc mg dl not due to hemolysis gilbert or primary malignancy ast alt greater_than threex uln
__label__1	study interventions are MLN8237 . prostate adenocarcinoma plus greater_than fifty immunohistochemical staining for neuroendocrine markers diagnosis and patient has received other investigational drugs with fourteen days before enrollment
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are Cyclophosphamide . sarcoma diagnosis and fev less_than thirty predicted dlco less_than thirty predicted post bronchodilator oxygen saturation less than ninety-two on room air
__label__1	study interventions are Calcium, Dietary . colorectal adenomatous polyps diagnosis and unable to be off aspirin for seven days
__label__1	study interventions are PQR309 . other concomitant anti tumor therapy as determined by the study team
__label__1	study interventions are Isophosphamide mustard . ovarian carcinosarcoma diagnosis and patients with known hypersensitivity to e
__label__1	study interventions are Bortezomib . non hodgkin lymphoma diagnosis and confirmation that the subject is not pregnant must be established by negative serum pregnancy test result obtained during screening
__label__1	study interventions are Quercetin . stage iii prostate cancer diagnosis and allergies to multiple food items or nutritional supplements
__label__1	study interventions are Letrozole . non hodgkin lymphoma solid cancers diagnosis and major surgery less_than equal_than four weeks before study treatment
__label__1	study interventions are Gemcitabine . pancreatic acinar cell carcinoma diagnosis and any of the following prior therapies
__label__1	study interventions are Everolimus . history of prior malignancy within the past five years except for curatively treated basal cell carcinoma of the skin or cervical intra epithelial neoplasia with two consecutive normal pap smears six months apart
__label__1	study interventions are Albumin-Bound Paclitaxel . patients with variant histologies ductal or small cell carcinoma are excluded from the phase ii part of the trial are eligible for the phase part
__label__1	study interventions are X-Ray . lung carcinoma diagnosis and males who have taken proscar propecia finasteride in the past six months
__label__1	study interventions are Liposomal doxorubicin . peritoneal cancer diagnosis and has known history of active tb_bacillus tuberculosis
__label__1	study interventions are Immunoglobulin G . recurrent primary peritoneal carcinoma diagnosis and participant has grade ii or greater peripheral vascular disease
__label__1	study interventions are Everolimus . male breast carcinoma diagnosis and patients may not be receiving any other investigational agents or herbal preparations patients may not be taking corticosteroids except in low doses as replacement for adrenal insufficiency or for short term less than five days use for other reasons
__label__1	study interventions are Sorafenib . stage iva salivary gland cancer diagnosis and any condition which in the investigator opinion makes the subject unsuitable for trial participation
__label__1	study interventions are Albumin-Bound Paclitaxel . neoplasms diagnosis and patients with history of unstable or newly diagnosed angina pectoris recent myocardial infarction within six months of enrollment or new york heart assoc
__label__1	study interventions are Mycophenolate mofetil . splenic marginal zone lymphoma diagnosis and child class and liver failure
__label__1	study interventions are Cyclosporine . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Prednisone . prostate cancer diagnosis and history of central nervous system cns or brain metastases
__label__1	study interventions are Gemcitabine . non squamous non small cell lung cancer diagnosis and recent history of poorly controlled hypertension systolic greater_than one hundred and eighty mmhg or diastolic greater_than one hundred mmhg
__label__1	study interventions are Tacrolimus . recurrent grade one follicular lymphoma diagnosis and liver abnormalities
__label__1	study interventions are Pharmacological Study . gastrointestinal stromal tumor diagnosis and prior treatment with another kinase inhibitor targeting insulin like growth factor one receptor igf_oner pathway including monoclonal antibodies targeting igf_oner
__label__1	study interventions are Letrozole . triple negative breast carcinoma diagnosis and has history of active pneumonitis requiring treatment with steroids or history of active interstitial lung disease
__label__1	study interventions are Dacarbazine . pleomorphic_xanthoastrocytoma diagnosis and patients with history or current condition that would preclude the use of bevacizumab
__label__1	study interventions are Trametinib . cancer diagnosis and prior systemic treatment in the adjuvant setting is allowed
__label__1	study interventions are Antibodies . mucinous adenocarcinoma of the colon diagnosis and core biopsy within seven days prior to done therapy
__label__1	study interventions are Bevacizumab . glioblastoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to first avastin infusion during xrt temodar or anticipation of need for major surgical procedure during the course of the study
__label__1	study interventions are Dasatinib . non hodgkin lymphoma diagnosis and cisapride_bepridil droperidol_methadone arsenic_chloroquine domperidone_halofantrine levomethadyl_pentamidine sparfloxacin_lidoflazine
__label__1	study interventions are Naloxone . lymphoma cell cutaneous diagnosis and topical alpha hydroxy acids to any skin surface
__label__1	study interventions are Histone Deacetylase Inhibitors . recurrent adult cell leukemia lymphoma diagnosis and right bundle_branch block positive left anterior_hemiblock bifascicular block
__label__1	study interventions are Rituximab . nodal marginal zone cell lymphoma diagnosis and pregnant women and women of childbearing age who are not practicing adequate contraception men who are not willing to use an effective method of contraception
__label__1	study interventions are Vidarabine . stage mantle cell lymphoma diagnosis and karnofsky score less_than seventy for adult patients
__label__1	study interventions are Albumin-Bound Paclitaxel . advanced breast cancer diagnosis and the subject is unable or unwilling to abide by the study protocol or cooperate fully with the investigator or designee
__label__1	study interventions are Docetaxel . inflammatory breast cancer bilateral breast cancer or breast cancer already with distant metastasis
__label__1	study interventions are Antibodies . recurrent squamous cell carcinoma of the nasopharynx diagnosis and known human immunodeficiency virus hiv positive patients are ineligible because these patients are at increased risk of lethal infections when treated with marrow suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agents
__label__1	study interventions are Immunoglobulin G . endometrial clear cell adenocarcinoma diagnosis and known standard therapy for the patient disease that is potentially curative or definitely capable of extending life expectancy exception
__label__1	study interventions are Immunoglobulins . undifferentiated fallopian tube carcinoma diagnosis and patients with gog performance status of three or four
__label__1	study interventions are regorafenib . gastrinoma diagnosis and active or clinically significant cardiac disease including
__label__1	study interventions are AZD6244 . triple negative breast cancer diagnosis and gemfibrozil trimethoprim glitazones montelukast quercetin one week minimum wash out period
__label__1	study interventions are Cytarabine . recurrent childhood hodgkin lymphoma diagnosis and positive anti donor cytotoxic crossmatch
__label__1	study interventions are Olaparib . ovarian transitional cell carcinoma diagnosis and prior treatment with trastuzumab
__label__1	study interventions are Pembrolizumab . subject has severe cardiovascular disease arrhythmias requiring chronic treatment congestive heart failure nyha class iii or iv or symptomatic ischemic heart disease
__label__1	study interventions are Rituximab . non hodgkin lymphoma diagnosis and malignancy treated with curative intent and with no known active disease present for greater_than five years before the first dose of study drug and felt to be at low risk for recurrence by treating physician
__label__1	study interventions are Irinotecan . other concurrent anticancer therapy
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and aspartate aminotransferase ast or alanine aminotransferase alt greater_than doc upper limit of normal
__label__1	study interventions are Cetuximab . endometrial cancer diagnosis and patients may be on maintenance anticoagulation therapy
__label__1	study interventions are ADI-PEG 20 . malignant pleural mesothelioma diagnosis and patients that are surgically sterile are also eligible to participate in this study
__label__1	study interventions are Deferasirox . stage iv adult diffuse small cleaved cell lymphoma diagnosis and patient who have been treated with rituximab or immunomodulating drugs equal_than less_than one month prior to enrollment
__label__1	study interventions are Paclitaxel . ovarian undifferentiated adenocarcinoma diagnosis and patient currently requires lithium due to drug interaction with gm csf leukine
__label__1	study interventions are Hormones . prostate cancer diagnosis and previous or current treatment with chemotherapy
__label__1	study interventions are Cisplatin . non resectable cholangiocarcinoma diagnosis and patients must not have prior exposure to docetaxel
__label__1	study interventions are Etoposide phosphate . aids related primary effusion lymphoma diagnosis and unable to comply with the requirements of the protocol or unable to provide adequate informed consent in the opinion of the principal investigator
__label__1	study interventions are Immunoglobulin G . stage iva uterine corpus cancer diagnosis and patients with ctcae v
__label__1	study interventions are Fluorodeoxyglucose F18 . stage iia prostate cancer diagnosis and cardiac ejection fraction measurement of less_than fifty
__label__1	study interventions are Gemcitabine . metastatic pancreatic cancer diagnosis and allergy to anyone of the included drugs
__label__1	study interventions are Exemestane . human epidermal growth factor two negative carcinoma of breast diagnosis and patients being treated with drugs recognized as being strong inhibitors or inducers of the isoenzyme cypthreea within the last five days prior to enrollment
__label__1	study interventions are Fludarabine phosphate . recurrent plasma cell myeloma diagnosis and current uncontrolled bacterial viral or fungal infection currently taking medication with evidence of progression of clinical symptoms or radiologic findings
__label__1	study interventions are Docetaxel . adenocarcinoma of the prostate diagnosis and ongoing oral steroid use
__label__1	study interventions are BB 1101 . cutaneous cell non hodgkin lymphoma diagnosis and patient has received systemic steroid therapy within one month of entry into protocol
__label__1	study interventions are Telephone-Based Intervention . esophageal cancer diagnosis and patients who are unable to successfully respond to the pmsa alarm and properly enter their data
__label__1	study interventions are 131-I-TM-601 . glioblastoma multiforme diagnosis and patient with the potential for pregnancy or impregnating their partner and who do not agree to follow an acceptable birth control method to avoid conception
__label__1	study interventions are Immunoglobulin G . recurrent colorectal carcinoma diagnosis and any investigational agent equal_than less_than twenty-eight days or five half lives prior to randomization whichever is longer
__label__1	study interventions are Melphalan . recurrent refractory childhood hodgkin lymphoma diagnosis and whole brain thirty gy enrollment of patients who previously receive higher than allowed dose of radiation to small volume of lungs liver and brain will be determine by the discretion of the radiation oncologist on the study
__label__1	study interventions are Fosaprepitant . patients with brain tumor brain metastasis or seizure
__label__1	study interventions are Camptothecin . other concurrent anticancer therapy
__label__1	study interventions are Antibodies . stage iiia ovarian cancer diagnosis and patient is on angiotensin_converting enzyme ace inhibitors benazapril_captopril enalopril_fosonopril lisinopril_moexipril perindopril_quinopril ramipril and trandolapril patients may have an alternate antihypertensive substituted note
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and this includes greater_than grade three rash during prior thalidomide or lenalidomide therapy
__label__1	study interventions are Cisplatin . squamous cell carcinoma diagnosis and the female in pregnancy or feeding
__label__1	study interventions are CYT004-MelQbG10 . melanoma diagnosis and pregnant or nursing
__label__1	study interventions are JS-001 . lung cancer diagnosis and active known or suspected autoimmune disease
__label__1	study interventions are Immunoglobulins . stage iib prostate cancer diagnosis and use of neoadjuvant hormonal manipulation
__label__1	study interventions are Bevacizumab . stage iia fallopian tube cancer diagnosis and new york heart association nyha class ii or higher congestive heart failure
__label__1	study interventions are Cyclosporins . stage ii cutaneous cell non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and subject has diabetes mellitus or steroid induced diabetes mellitus
__label__1	study interventions are Capecitabine . metastatic colorectal cancer diagnosis and patients who have received any other investigational agents within the twenty-eight days prior to day one of study drug treatment
__label__1	study interventions are Cyclosporine . refractory follicular lymphoma diagnosis and any cord blood units without the full maternal testing and negative results for hepatitis b hiv and human lymphotropic virus htlv one viruses
__label__1	study interventions are Cisplatin . stage ivb laryngeal squamous cell carcinoma diagnosis and patients with nasopharyngeal paranasal sinus skin or unknown primary site disease
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and serious medical or psychiatric illness likely to interfere with participation in this clinical study
__label__1	study interventions are Immunoglobulins . stage iib pancreatic cancer diagnosis and st
__label__1	study interventions are Thalidomide . recurrent marginal zone lymphoma diagnosis and known hypersensitivity to rituximab
__label__1	study interventions are Prexasertib . advanced cancer diagnosis and must not have taken an unapproved drug as treatment for any indication within the last twenty-eight days prior to starting study treatment
__label__1	study interventions are Ganciclovir triphosphate . stage iv adult hodgkin lymphoma diagnosis and no prior allogeneic hct allo hct autologous hct auto hct is allowed
__label__1	study interventions are Pomalidomide . multiple myeloma diagnosis and participation in other clinical trials including those with other investigational agents not included in this trial within twenty-one days of the start of this trial and throughout the duration of this trial
__label__1	study interventions are Trastuzumab . invasive ductal breast cancer diagnosis and sex hormones
__label__1	study interventions are Sirolimus . stage ivb major salivary gland carcinoma diagnosis and concurrent use of warfarin is allowed but requires close monitoring of prothrombin time pt international normalized ratio inr
__label__1	study interventions are Octreotide . recurrent merkel cell carcinoma diagnosis and unstable angina or pectoris myocardial infarction within six months of start of study drug
__label__1	study interventions are Immunoglobulins . ovarian transitional cell carcinoma diagnosis and patients with clinically significant cardiovascular disease this includes
__label__1	study interventions are Cetuximab . colorectal cancer diagnosis and severe hypercalcemia
__label__1	study interventions are Veliparib . breast cancer diagnosis and subject has significant history of cardiovascular disease
__label__1	study interventions are Paclitaxel . stage iiia primary peritoneal cancer diagnosis and severe active co morbidity defined as follows
__label__1	study interventions are Melphalan . stage ii multiple myeloma diagnosis and bilirubin greater than two the upper limit of normal
__label__1	study interventions are GSK1363089 (formerly XL880) . neoplasms gastrointestinal tract diagnosis and the subject is pregnant or breastfeeding
__label__1	study interventions are Analgesics . advanced cancers diagnosis and memorial delirium assessment scale greater_than thirteen thirty
__label__1	study interventions are placebo . recurrent squamous cell carcinoma of the hypopharynx diagnosis and contraindication to full course chemoradiotherapy
__label__1	study interventions are Survey . human papillomaviru negative six eleven 1six eighteen diagnosis and doc zero any clinically significant diseases other than hiv infection or findings during study screening that in the opinion of the principal investigator or lead associate investigator may interfere with the study
__label__1	study interventions are Carboplatin . small cell lung cancer diagnosis and grade two peripheral neuropathy motor or sensory
__label__1	study interventions are Sunitinib . stage renal cell cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to day one
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian transitional cell carcinoma diagnosis and core biopsy within seven days prior to the first date of bevacizumab placebo therapy cycle two
__label__1	study interventions are Thalidomide . anaplastic large cell lymphoma diagnosis and serum creatinine greater_than equal_than doc mg dl or calculated creatinine clearance equal_than less_than fiftyml min
__label__1	study interventions are Sunitinib . recurrent ovarian epithelial cancer diagnosis and azole_antifungals ketoconazole itraconazole miconazole verapamil clarithromycin human immunodeficiency virus hiv protease inhibitors indinavir saquinavir ritonavir atazanavir nelfinavir erythromycin delavirdine diltiazem
__label__1	study interventions are Bevacizumab . melanoma diagnosis and autoimmune disease
__label__1	study interventions are fatigue assessment and management . stage iii adult immunoblastic large cell lymphoma diagnosis and does not complete the baseline assessment through the hads hospital anxiety and depression scale
__label__1	study interventions are Vaccines . recurrent epithelial ovarian cancer diagnosis and anti hormonal treatment such as tamoxifen may continue until first study treatment administration
__label__1	study interventions are Etoposide phosphate . recurrent small lymphocytic lymphoma diagnosis and active infection requiring systemic antibiotic therapy with antibacterial antifungal or antiviral agents excluding hiv
__label__1	study interventions are Rituximab . known central nervous system cns lymphoma or cerebrospinal fluid involvement with malignant lymphoma cells these patients are usually treated with cns directed therapy screening for cerebrospinal fluid csf cns involvement is not required but can be performed per treating medical doctor md discretion intrathecal it methotrexate or it cytarabine prophylaxis in patients with negative csf who are felt to be at high risk of cns relapse is allowed per local md discretion this should be noted on the treatment form
__label__1	study interventions are Melphalan . recurrent childhood anaplastic large cell lymphoma diagnosis and adult
__label__1	study interventions are Estradiol . history of or active ventricular dysrhythmias or congestive heart failure requiring medication or symptomatic coronary heart disease
__label__1	study interventions are Bevacizumab . recurrent colon cancer diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Mitogens . head and neck squamous cell carcinoma diagnosis and past or current malignancy other than hnscc
__label__1	study interventions are Methylprednisolone acetate . neoplasm metastasis diagnosis and prior treatment with vascular endothelial growth factor vegf inhibitors or vegf receptor inhibitors
__label__1	study interventions are Bleomycin . lymphoma non hodgkin diagnosis and immunomodulating agents
__label__1	study interventions are Gemcitabine . refractory aggressive non hodgkin lymphoma diagnosis and hiv positive patients and those with hepatitis or will be excluded from this protocol
__label__1	study interventions are Paclitaxel . fallopian tube mucinous adenocarcinoma diagnosis and patients who have had chemotherapy or radiotherapy within four weeks six weeks for nitrosoureas or mitomycin of starting treatment or those who have not recovered from adverse events due to agents administered more than four weeks earlier patients may not have had hormonal therapy within two weeks prior to entering the study patients receiving raloxifene for bone health as per food and drug administration fda indication may remain on raloxifene absent other drug interactions
__label__1	study interventions are Cisplatin . recurrent verrucous carcinoma of the oral cavity diagnosis and patients with an active infection or with fever greater_than equal_than three doc ºc within three days of the first scheduled day of dosing patients who are registered but develop fever of greater_than equal_than three doc ºc may remain in the study if the fever abates prior to the expiration of the screening procedures if the screening procedures have expired the patient may be re screened once afebrile
__label__1	study interventions are Paclitaxel . fallopian tube cancer diagnosis and patients who have had hypersensitivity reaction to polyoxyethylated or hydrogenated castor_oil
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and any condition including laboratory abnormalities that in the opinion of the investigator places the subject at unacceptable risk if he she were to participate in the study
__label__1	study interventions are Bevacizumab . advanced cancer diagnosis and radiotherapy within fourteen days of study start
__label__1	study interventions are Vidarabine . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and serum glutamic oxaloacetic transaminase sgot or serum glutamic pyruvate transaminase sgpt greater_than equal_than three upper limit of normal
__label__1	study interventions are Cediranib . recurrent ovarian carcinoma diagnosis and history of myocardial infarction within six months
__label__1	study interventions are Bevacizumab . head and neck cancer diagnosis and patients with hearing loss requiring hearing aid or intervention interfering in clinically significant way with activities of daily living
__label__1	study interventions are Oxaliplatin . colorectal carcinoma diagnosis and severe pulmonary dysfunction
__label__1	study interventions are Methotrexate . stage iii adult cell leukemia lymphoma diagnosis and cnsthree positive or testicular involvement
__label__1	study interventions are Sorafenib . breast cancer diagnosis and patients who have experienced any type of bone fracture within twelve months or who have undergone joint replacement surgery within six months
__label__1	study interventions are Immunoglobulin G . advanced metastatic solid tumors diagnosis and history of autoimmune disease or known inflammatory bowel disease
__label__1	study interventions are Azacitidine . non small cell lung cancer diagnosis and appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated
__label__1	study interventions are Estradiol valerate . cancer diagnosis and has life expectancy of less_than three months
__label__1	study interventions are Mycophenolate mofetil . stage ii childhood lymphoblastic lymphoma diagnosis and positive serology for toxoplasma_gondii on treatment or with evidence of active infection
__label__1	study interventions are Antibodies, Monoclonal . hepatocellular cancer diagnosis and have serious or nonhealing wound peptic ulcer or bone fracture within twenty-eight days prior to receiving study drugs
__label__1	study interventions are Dasatinib . patient has had any treatment specific for tumor control within three weeks of dosing with investigational drugs and cytotoxic agents or within two weeks of cytotoxic agent given weekly or within six weeks of nitrosoureas or mitomycin or within five half lives of biological targeted agents
__label__1	study interventions are Immunoglobulins . stage iv colon cancer diagnosis and subjects unwilling or unable to comply with study requirements
__label__1	study interventions are Pertuzumab . breast cancer diagnosis and clinical or radiographic evidence of central nervous system cns metastases or significant cv disease
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and refer to the revlimid risk evaluation and management strategy rems program for more information
__label__1	study interventions are Rituximab . recurrent grade three follicular lymphoma diagnosis and marrow cellularity equal_than less_than fifteen as determined on all bone marrow samples
__label__1	study interventions are Epothilone B . stage iv breast cancer diagnosis and fertile patients must use effective contraception
__label__1	study interventions are Portal triad clamping . liver neoplasms diagnosis and contraindication for surgery severe disorders of circulation respiratory or renal system
__label__1	study interventions are Sorafenib . kidney cancer diagnosis and patients with neurological symptoms must undergo ct scan mri of the brain to exclude brain metastasis
__label__1	study interventions are Pancreatin . non metastatic pancreas cancer diagnosis and eighteen years of age
__label__1	study interventions are Bevacizumab . primary peritoneal cancer diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Lenalidomide . peripheral neuropathy of greater_than grade two severity according to the national cancer institute common terminology criteria for adverse events version doc
__label__1	study interventions are hypofractionated radiation therapy . women who are pregnant women of childbearing age must agree to undergo urine pregnancy test prior to therapy and to use adequate contraception hormonal or barrier method of birth control abstinence prior to study entry for the duration of study participation and for six months after should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__1	study interventions are Antibodies . stage ii grade one non contiguous follicular lymphoma diagnosis and abnormal renal function serum creatinine greater_than two uln
__label__1	study interventions are Bortezomib . mantle cell lymphoma diagnosis and twenty-four hour urine test is not required per study
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv skin melanoma diagnosis and any of the following
__label__1	study interventions are Paclitaxel . undifferentiated ovarian carcinoma diagnosis and allergy to iodine note
__label__1	study interventions are Carboplatin . adult anaplastic oligodendroglioma diagnosis and patients with unstable or serious concurrent illness including but not limited to ongoing or active infections requiring iv antibiotics or psychiatric illness social situations that would limit compliance with study requirements are ineligible if patient has stable chronic infection requiring oral antibiotics the patient may be treated at the investigators discretion however clinical note must include the justification regarding the safety of treating the patient
__label__1	study interventions are Vaccines . stage iiic skin melanoma diagnosis and concomitant systemic treatment with anti histamine or non steroidal anti inflammatory drugs specific cyclooxygenase_cox two inhibitors are permitted
__label__1	study interventions are Sirolimus . head and neck cancer diagnosis and impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of study agents ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome or small bowel resection
__label__1	study interventions are Cisplatin . non small cell lung cancer metastatic diagnosis and uncontrolled brain metastatic disease
__label__1	study interventions are Bevacizumab . renal cell carcinoma diagnosis and known cns disease except for treated brain metastasis
__label__1	study interventions are Placebo Capsule . the central cavity of squamous cell carcinoma and hemoptysis with nsclc
__label__1	study interventions are Rituximab . small lymphocytic lymphoma diagnosis and altered hepatic function bilirubin got gpt or gammagt greater_than two times upper limit of normal not attributable to cll sll
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ii breast cancer diagnosis and documented congestive heart failure
__label__1	study interventions are Endothelial Growth Factors . colorectal cancer diagnosis and history of other disease metabolic dysfunction physical examination finding or clinical laboratory finding giving reasonable suspicion of disease or condition that contraindicates the use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications
__label__1	study interventions are Immunoglobulins . malignant ovarian mixed epithelial tumor diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study the investigator should feel free to consult the study chair or study co chairs for uncertainty in this regard
__label__1	study interventions are Irinotecan . triple negative breast carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib mm three hundred and ninety-eight and ferumoxytol
__label__1	study interventions are Erlotinib Hydrochloride . cholangiocarcinoma of the extrahepatic bile duct diagnosis and immunotherapy less_than four weeks prior to study entry
__label__1	study interventions are Oral nutritional supplement . cancer diagnosis and eastern cooperative oncology group ecog performance status greater_than two
__label__1	study interventions are Hormones . recurrent prostate cancer diagnosis and myocardial infarction within six months of screening uncontrolled angina within three months of screening new york heart association nyha class three or four congestive heart failure clinically significant ventricular arrhythmia mobitz ii twond degree or threerd degree heart block without pacemaker in place uncontrolled hypertension htn systolic greater_than one hundred and eighty mmhg or diastolic greater_than one hundred and five mmhg at screening
__label__1	study interventions are placebo . carcinoma renal cell diagnosis and note
__label__1	study interventions are Calcium heparin . pancreatic cancer diagnosis and pre existing indication for anticoagulation
__label__1	study interventions are Dexamethasone 21-phosphate . those with solitary bone or solitary extramedullary plasmacytoma
__label__1	study interventions are Antibodies, Monoclonal . stage iv renal cell cancer diagnosis and patients on full dose anticoagulation will be excluded antiplatelet therapy will not be exclusionary
__label__1	study interventions are Gemcitabine . collecting duct carcinoma kidney diagnosis and patients who underwent according to the investigator significant surgery such as but not limited to abdominal thoracic or neurologic surgery within twenty-eight days before the first treatment administration or patient with wound that is not already healed at the first treatment administration or patients who underwent minor surgical procedure including placement of vascular access device within two days of the first study treatment
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and corrected serum calcium greater_than one doc mg dl greater_than doc mmol l
__label__1	study interventions are Capecitabine . history or evidence upon physical neurological examination of cns disease unrelated to cancer unless adequately treated with standard medical therapy uncontrolled seizures
__label__1	study interventions are Simvastatin . smoldering multiple myeloma diagnosis and patients on statin treatment on the day of recruitment
__label__1	study interventions are Antibodies, Monoclonal . stage iv fallopian tube cancer diagnosis and anticonvulsants stable dose are allowed
__label__1	study interventions are Bevacizumab . non small cell lung carcinoma diagnosis and mean resting corrected qt interval fridericia correction formula qtcf greater_than four hundred and seventy ms using fredericia formula
__label__1	study interventions are Bevacizumab . cervical adenosquamous carcinoma diagnosis and prior therapy with an angiogenesis inhibitor
__label__1	study interventions are Cyclosporins . refractory multiple myeloma diagnosis and consenting five of six or six of six hla matched related donor available
__label__1	study interventions are Vorinostat . recurrent metastatic squamous neck cancer with occult primary diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to the study agents used in study including hypersensitivity to paclitaxel cremophor or platins
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent adult lymphoblastic lymphoma diagnosis and pregnancy or breastfeeding pregnancy test must be performed within seven days prior to ibrutinib initiation in women of childbearing potential pregnant women are excluded breastfeeding must be discontinued
__label__1	study interventions are Docetaxel . hepatocellular carcinoma diagnosis and midazolam anti mycotic agents ketoconazole and related compounds macrolide antibiotics erythromycin and related compounds nifedipine phenobarbital phenytoin carbamazepine and rifampin induction and anti retrovirals including ritonavir saquinavir
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and pts receiving active treatment or intervention for any other malignancy or pts who at the investigator discretion may require active treatment or intervention for any other malignancy within eight months of starting study treatment
__label__1	study interventions are Idelalisib . mantle cell lymphoma diagnosis and history of prior allogeneic bone marrow progenitor cell or solid organ transplantation
__label__1	study interventions are Immunoglobulin G . solid neoplasm diagnosis and core biopsy within seven days prior to day one therapy
__label__1	study interventions are Bevacizumab . stage iv adult burkitt lymphoma diagnosis and creatinine ratio greater_than doc twenty-four hour urine protein should be obtained and the level should be less_than one thousand mg for patient enrollment
__label__1	study interventions are Fenofibrate . multiple myeloma diagnosis and subject is receiving corticosteroid therapy greater_than ten mg of prednisone or equivalent
__label__1	study interventions are Valganciclovir . stage ii cutaneous cell non hodgkin lymphoma diagnosis and concomitant anti graft versus host disease gvd treatment includes in vivo cell depletion
__label__1	study interventions are Dacarbazine . adult grade meningioma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with rofour million, nine hundred and twenty-nine thousand and ninety-seven or temozolomide these potential risks may also apply to other agents used in this study
__label__1	study interventions are Bendamustine Hydrochloride . refractory multiple myeloma diagnosis and prior radioimmunotherapy within twelve weeks of registration
__label__1	study interventions are Cabozantinib . solid tumor not breast or prostate cancers diagnosis and received prior treatment with small molecule kinase inhibitor or hormonal therapy within fourteen days five half lives
__label__1	study interventions are Zoledronic acid . adenocarcinoma of the prostate diagnosis and other therapy or supportive care that is considered investigational
__label__1	study interventions are Antibodies, Monoclonal . recurrent refractory childhood hodgkin lymphoma diagnosis and patients who are currently receiving another investigation drug are not eligible
__label__1	study interventions are Antibodies . stage iiib fallopian tube cancer diagnosis and for all stage two participants no prior treatment with mtor pithree kinase or akt inhibitors prior treatment with mtor pithree kinase or akt inhibitors allowed in stage one only
__label__1	study interventions are Fludarabine . peripheral cell lymphoma diagnosis and hct ci score greater_than four points for patients greater_than sixty years old or greater_than five points for patients less_than sixty
__label__1	study interventions are Plasma/Serum Sample for biomarkers . prostate adenocarcinoma diagnosis and greater than ttwoa disease based on digital rectal exam
__label__1	study interventions are Plicamycin . lung cancer diagnosis and patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
__label__1	study interventions are Fludarabine . recurrent adult immunoblastic large cell lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Fludarabine phosphate . stage iv grade one follicular lymphoma diagnosis and more than twenty zero circulating cdtwenty positive cells ul
__label__1	study interventions are Vatalanib . pancreatic cancer diagnosis and exception
__label__1	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and patients with the following mood disorders as judged by the investigator or psychiatrist or as result of patient mood assessment questionnaire treating physician to decide on whether to administer questionnaire
__label__1	study interventions are Etoposide . small cell lung cancer diagnosis and documented side effects to chloroquine or related agents
__label__1	study interventions are conventional surgery . stage ii lymphoepithelioma of the oropharynx diagnosis and platelet count less_than one hundred zero
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and patients with liver involvement
__label__1	study interventions are Everolimus . thyroid cancer diagnosis and topical or inhaled corticosteroids are allowed
__label__1	study interventions are Antibodies, Monoclonal . stage iib fallopian tube cancer diagnosis and patients with history or evidence upon physical examination of major central nervous system cns disease for example
__label__1	study interventions are Lapatinib . cancer diagnosis and currently receiving treatment with any medications listed on the prohibited medication list see section doc
__label__1	study interventions are Everolimus . metastatic breast cancer diagnosis and if clinically indicated pulmonary function tests including measures of predicted lung volumes dlco diffusing capacity of lung for carbon monoxide otwo saturation at rest on room air should be considered to exclude restrictive pulmonary disease pneumonitis or pulmonary infiltrates
__label__1	study interventions are Folic Acid . ineligible were patients not fulfilling these criteria or having history of cancer except for adequately treated superficial basal or squamous cell skin cancer or in situ carcinoma of the cervix getting previous radi negative or chemotherapy pregnant or nursing women other having severe concomitant diseases limiting life expectancy or not allowing chemotherapy and with social conditions not allowing five year follow up
__label__1	study interventions are Doxorubicin . marginal zone lymphomas diagnosis and patients not establishing all above mentioned prerequisites
__label__1	study interventions are Immunoglobulins . stage iib ovarian cancer diagnosis and patients with invasive procedures or anticipation of invasive procedures within the following timeframes as defined below
__label__1	study interventions are Clopidogrel . metastatic pancreatic cancer diagnosis and previous radiotherapy for measurable lesions
__label__1	study interventions are Irinotecan . glioblastoma diagnosis and urine dipstick for proteinuria greater_than two positive
__label__1	study interventions are Camptothecin . metastatic pancreatic adenocarcinoma diagnosis and uncontrolled hypertension defined as systolic blood pressure bp greater_than equal_than one hundred and sixty mmhg or diastolic bp greater_than equal_than one hundred mmhg despite maximal anti hypertensive medications
__label__1	study interventions are Palbociclib . any other anti cancer agents eg hormonal biological investigational within five times the half life prior to investigational product
__label__1	study interventions are Irinotecan . stage iiic rectal cancer diagnosis and pregnant or nursing women negative pregnancy test serum or urine equal_than less_than three days prior to starting study treatment
__label__1	study interventions are Erlotinib Hydrochloride . metastatic breast cancer diagnosis and other baseline laboratory values
__label__1	study interventions are Imatinib Mesylate . neurofibromatosis diagnosis and non specific cns changes on mri ct characteristic of nfone are allowed but not known cns malignancies
__label__1	study interventions are Paclitaxel . stage iiic breast cancer diagnosis and pregnant and lactating women are not eligible all participants of reproductive age must have negative serum pregnancy test at baseline and agree to use an effective barrier method of contraception during the entire period of treatment on the study
__label__1	study interventions are Everolimus . stage iva oral cavity verrucous carcinoma diagnosis and breastfeeding should be discontinued if the mother is treated with temsirolimus
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and uncontrolled hypertension defined as bp greater than one hundred and fifty ninety on antihypertensive therapy
__label__1	study interventions are Retinol acetate . stage adult immunoblastic large cell lymphoma diagnosis and pregnant women are excluded from this study because the effects of at one hundred and one on the developing human fetus are unknown but could potentially include teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with at one hundred and one breastfeeding should be discontinued if the mother is treated with at one hundred and one these potential risks may also apply to other agents used in this study
__label__1	study interventions are Interleukin-2 . skin cancer diagnosis and documented forced expiratory volume one fevone less than or equal to sixty predicted tested in patients with
__label__1	study interventions are Cabozantinib S-malate . metastatic osteosarcoma diagnosis and the subject is unable to swallow tablets
__label__1	study interventions are Paclitaxel . ovarian mucinous cystadenocarcinoma diagnosis and patients with surgery including open biopsy within four weeks prior to anticipated first dose of bevacizumab allowing for fact that bevacizumab can be omitted from first cycle of chemotherapy
__label__1	study interventions are Antibodies, Monoclonal . recurrent uterine corpus carcinoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one therapy
__label__1	study interventions are Four and two time schedule . colorectal cancer diagnosis and lifelong anticoagulant therapy with warfarin
__label__1	study interventions are Metronidazole . stage iv primary peritoneal cavity cancer diagnosis and pregnant or nursing female patients
__label__1	study interventions are Acetylcysteine . stage ii mucoepidermoid carcinoma of the oral cavity diagnosis and patients known to be hiv positive but without clinical evidence of an immunocompromised state are eligible for this trial
__label__1	study interventions are Pemetrexed . lymphoma diagnosis and ecog performance status zero two
__label__1	study interventions are Topoisomerase I Inhibitors . neuroblastoma recurrent diagnosis and any contraindications or known hypersensitivity to the imps or to any of the other components
__label__1	study interventions are Poly ICLC . transitional cell carcinoma of the bladder diagnosis and pregnant women are excluded from this study because nivolumab personalized_neoantigen peptides and poly_iclc are agents with unknown risks to the developing fetus
__label__1	study interventions are Fludarabine phosphate . recurrent small lymphocytic lymphoma diagnosis and uncontrolled viral or bacterial infection at the time of study enrollment
__label__1	study interventions are Gemcitabine . gallbladder cancer diagnosis and history of stroke or transient ischemic attack within six months
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv esophageal cancer diagnosis and patients have received prior taxane or anti insulin growth factor receptor igfr therapy
__label__1	study interventions are Ascorbic Acid . cancer of pancreas diagnosis and chlorpropamide
__label__1	study interventions are Vaccines . melanoma diagnosis and prior malignancy except for the following
__label__1	study interventions are Fludarabine phosphate . stage iii cutaneous cell non hodgkin lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Vaccines . sarcoma diagnosis and known hypersensitivity to sirolimus
__label__1	study interventions are Paclitaxel . melanoma diagnosis and serious medical risk factors determine by the investigator
__label__1	study interventions are Nivolumab . recurrent breast carcinoma diagnosis and patients are permitted to enroll if they have vitiligo type diabetes mellitus residual hypothyroidism due to autoimmune condition only requiring hormone replacement psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger_precipitating event
__label__1	study interventions are Axitinib . stage iv melanoma diagnosis and current congestive heart failure new york heart association nyha class ii iii or iv
__label__1	study interventions are fatigue assessment and management . stage iv adult hodgkin lymphoma diagnosis and these survivors will however have full access to the website if they have completed the required baseline assessment they will be asked to also complete follow up assessments
__label__1	study interventions are Proteasome Inhibitors . multiple myeloma diagnosis and known allergy to any component of vorinostat
__label__1	study interventions are Gossypol . contiguous stage ii adult burkitt lymphoma diagnosis and pregnant women are excluded from this study because the effects of at one hundred and one on the developing human fetus are unknown but could potentially include teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with at one hundred and one breastfeeding should be discontinued if the mother is treated with at one hundred and one these potential risks may also apply to other agents used in this study
__label__1	study interventions are Azacitidine . recurrent nasopharyngeal undifferentiated carcinoma diagnosis and patients should not have taken sodium valproate for at least two weeks prior to enrollment
__label__1	study interventions are Prednisone . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and pregnant females
__label__1	study interventions are Antibodies . undifferentiated ovarian carcinoma diagnosis and stage not greater than ib no more than superficial myometrial invasion without vascular or lymphatic invasion no poorly differentiated subtypes including papillary serous clear cell or other figo grade three lesions
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and prior taxanes
__label__1	study interventions are Everolimus . head and neck neoplasms diagnosis and inadequate hematologic renal or liver function within lfour days prior to the first rapamycin dosing visit as defined by
__label__1	study interventions are Gossypol acetic acid . contiguous stage ii adult diffuse large cell lymphoma diagnosis and patients with myocardial infarction mi or cardiac heart surgery within the past three months
__label__1	study interventions are Everolimus . non small cell lung cancer diagnosis and midazolam buspirone felodipine
__label__1	study interventions are Niacinamide . hepatocellular cancer diagnosis and inability to perform yninety tare due to
__label__1	study interventions are support group therapy . stage iiib breast cancer diagnosis and there are no therapy restrictions
__label__1	study interventions are questionnaire administration . stage iii adult diffuse large cell lymphoma diagnosis and does not complete the baseline assessment through the hads hospital anxiety and depression scale
__label__1	study interventions are Antibodies, Monoclonal . anaplastic large cell lymphoma diagnosis and known active cerebral meningeal disease including signs or symptoms of progressive multifocal_leukoencephalopathy pml or any history of pml
__label__1	study interventions are RP6530 . lymphoma cell diagnosis and patients with hbv hcv or hiv infection
__label__1	study interventions are Melphalan . stage iv adult immunoblastic large cell lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less than forty predicted corrected for hemoglobin hb and or alveolar ventilation
__label__1	study interventions are Gemcitabine . sarcoma diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Mycophenolic Acid . recurrent grade two follicular lymphoma diagnosis and patients with active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and baseline corrected qt interval qtc greater_than four hundred and seventy msec or previous history of qt prolongation while taking other medications
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and women of child bearing potential wocbp defined as all women physiologically capable of becoming pregnant must use highly effective methods of contraception during the study and eight weeks after
__label__1	study interventions are Irinotecan . pancreatic neoplasms diagnosis and known hypersensitivity to ipi nine hundred and twenty-six or any of the excipients in ipi nine hundred and twenty-six capsules
__label__1	study interventions are Bevacizumab . advanced solid tumors diagnosis and patients who have any severe and or uncontrolled medical conditions or other conditions that could affect their participation in the study as so judged by the treating physician
__label__1	study interventions are Antibodies, Monoclonal . recurrent adult diffuse small cleaved cell lymphoma diagnosis and donors less_than twelve years of age
__label__1	study interventions are Veliparib . ovarian brenner tumor diagnosis and patients with clinical symptoms or signs of gastrointestinal obstruction and who require parenteral hydration or nutrition
__label__1	study interventions are Antibodies . cancer diagnosis and uncontrolled diabetes or hypertension
__label__1	study interventions are Pembrolizumab . ovarian mucinous adenocarcinoma diagnosis and has had prior chemotherapy targeted small molecule therapy or radiation therapy within two weeks prior to study day one or who has not recovered equal_than less_than grade one or at baseline from adverse events due to previously administered agent
__label__1	study interventions are Vaccines . human papillomavirus infection diagnosis and who have previously been immunized with meningococcal vaccine
__label__1	study interventions are Tipifarnib . mature cell and nk cell non hodgkin lymphoma diagnosis and ongoing radiation therapy or radiation therapy equal_than less_than three weeks prior to study registration unless the acute side effects associated with such therapy are resolved
__label__1	study interventions are Toremifene . breast neoplasms diagnosis and history of known cns metastases significant neurological dysfunction including active seizures or clinical signs of other significant neurological diseases
__label__1	study interventions are Prednisolone acetate . prostate cancer diagnosis and patients with contra indications to prednisolone including active peptic ulceration or history of gastrointestinal bleeding
__label__1	study interventions are AZD9150 . gastrointestinal cancer diagnosis and any clinically important abnormalities in rhythm conduction or morphology of resting ecg complete left bundle_branch block third degree heart block
__label__1	study interventions are Metronidazole . stage iib ovarian epithelial cancer diagnosis and other serious illnesses serious infections requiring antibiotics bleeding disorders
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and uncontrolled diabetes
__label__1	study interventions are SNX-5422 plus ibrutinib . cancer diagnosis and active hepatitis or b
__label__1	study interventions are Antibodies . intraocular lymphoma diagnosis and positive crossmatch between donor and recipient
__label__1	study interventions are Cyclophosphamide . diffuse large cell lymphoma diagnosis and clinical symptoms suggesting unresolved hiv hbv or hcv infection
__label__1	study interventions are Pioglitazone . squamous cell lung cancer diagnosis and creatinine greater_than doc mg dl
__label__1	study interventions are Trastuzumab . stage iiib breast cancer diagnosis and surgery radiotherapy or lesion ablative procedure to the only area of measurable evaluable disease
__label__1	study interventions are Immunoglobulin G . cancer diagnosis and abnormal cardiac valve morphology greater_than equal_than grade two documented by echocardiogram subjects with grade one abnormalities mild regurgitation_stenosis can be entered on study
__label__1	study interventions are Cisplatin . prior chemotherapy or surgery except fine needle aspiration biopsy to primary tumor or nodes
__label__1	study interventions are Everolimus . diffuse adenocarcinoma of the stomach diagnosis and severely impaired lung function as defined as spirometry and diffusion lung capacity of carbon monoxide dlco that is fifty of the normal predicted value and or two saturation that is eighty-eight or less at rest on room air
__label__1	study interventions are Antibodies . kidney cancer diagnosis and active serious infection
__label__1	study interventions are Iodine . recurrent thyroid gland carcinoma diagnosis and patients unable to follow low iodine diet or requiring medication with high content in iodide amiodarone
__label__1	study interventions are Methotrexate . lymphoma diagnosis and clearance letter from primary physician required
__label__1	study interventions are Paclitaxel . stage iii endometrial carcinoma diagnosis and prior therapy with herceptin
__label__1	study interventions are Niacinamide . ovarian cancer diagnosis and history of hiv infection or chronic hepatitis or c
__label__1	study interventions are Vidarabine . nodal marginal zone cell lymphoma diagnosis and infection with hiv
__label__1	study interventions are Epoetin Alfa . lymphoma non hodgkin diagnosis and fifteen years greater_than doc mg dl for children older than fifteen years
__label__1	study interventions are Antibodies, Monoclonal . stage iib pancreatic cancer diagnosis and phenytoin phenytoin plasma serum concentrations should be monitored phenytoin dose may require adjustment to compensate for altered phenytoin concentration
__label__1	study interventions are Etoposide . symptomatic respiratory compromise
__label__1	study interventions are Cetuximab . recurrent mucoepidermoid carcinoma of the oral cavity diagnosis and known human immunodeficiency virus hiv positive patients are ineligible because these patients are at increased risk of lethal infections when treated with marrow suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agents
__label__1	study interventions are Sorafenib . stage ivb squamous cell carcinoma of the oropharynx diagnosis and patient has received other investigational drugs within twenty-eight days before enrollment
__label__1	study interventions are Capecitabine . carcinoma renal cell diagnosis and pregnant or breastfeeding women
__label__1	study interventions are Vaccines . stage iiic skin melanoma diagnosis and systemic immunoglobulin therapy within the last thirty days
__label__1	study interventions are Vinorelbine . breast cancer diagnosis and chronic treatment with corticosteroids unless initiated greater_than six months prior to study entry and at low dose less_than equal_than twenty mg methylprednisolone or equivalent
__label__1	study interventions are Paclitaxel . prior systemic chemotherapy with advanced stere negative tumor before the recruitment recidivist metastatic without perioperative chemotherapy at least sixm
__label__1	study interventions are Pazopanib Hydrochloride . stage ivb thyroid gland medullary carcinoma diagnosis and radiotherapy to greater_than equal_than twenty-five of bone marrow
__label__1	study interventions are Albumin-Bound Paclitaxel . triple negative breast cancer diagnosis and clinically significant bleeding such as gross hematuria gastrointestinal bleeding before screening if clinically significant bleeding has occurred within six months of screening but the cause has been identified and adequately treated cystitis ulcer then this exclusion criterion does not apply
__label__1	study interventions are Bevacizumab . stage iva rectal cancer diagnosis and other active malignancy equal_than less_than three years prior to registration exceptions
__label__1	study interventions are Immunoglobulin G . fallopian tube serous adenocarcinoma diagnosis and has known history of or any evidence of active non infectious pneumonitis
__label__1	study interventions are TAA-Specific CTLs . bladder cancer diagnosis and patients in remission who are enrolled on another study where time to progression or disease free survival is primary endpoint
__label__1	study interventions are Antibodies . high grade ovarian serous adenocarcinoma diagnosis and patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
__label__1	study interventions are Cixutumumab . stage iv intraocular melanoma diagnosis and patients with one or more of the following as the only manifestations of disease are ineligible
__label__1	study interventions are Etoposide phosphate . recurrent adult diffuse mixed cell lymphoma diagnosis and prior radioimmunotherapy within twelve weeks of registration
__label__1	study interventions are IN2005E . breast cancer diagnosis and mental incapacity
__label__1	study interventions are Hydrocortisone . peripheral cell lymphoma diagnosis and host disease and at least eighty-four days must have elapsed after transplant or stem cell infusion
__label__1	study interventions are Endothelial Growth Factors . stage iv colorectal cancer diagnosis and known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies fluoropyrimidines folic acid derivatives or oxaliplatin
__label__1	study interventions are Pemetrexed . carcinoma non small cell lung diagnosis and sanguinous pleural effusion due to disease or pericardial effusion suspicious for disease
__label__1	study interventions are Everolimus . stage ivb cervical cancer diagnosis and active uncontrolled infection or non healing wounds
__label__1	study interventions are Cyclophosphamide . adult rhabdomyosarcoma diagnosis and patients aged greater_than seventeen years
__label__1	study interventions are Paclitaxel . liver cancer diagnosis and history of significant liver pathology other than metastases cirrhosis of the liver psc pbc or liver transplantation
__label__1	study interventions are Nivolumab . malignant solid tumor diagnosis and prior therapy with any antibody drug that targets the cell coregulatory proteins including but not limited to anti pd one anti pd lone anti pd ltwo anti cdone37 anti ox forty and anti cdforty antibodies
__label__1	study interventions are Ifosfamide . hodgkin lymphoma diagnosis and patient has with myelodysplasia polycythemia_vera idiopathic thrombocythemia myelofibrosis or acute leukemia
__label__1	study interventions are Paclitaxel . stage iv pancreatic cancer diagnosis and surgery radiotherapy chemotherapy or hormonal therapy during the three weeks prior to the initiation of therapy
__label__1	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and patients who are taking metronidazole and cannot be safely moved to different antibiotic greater than seven days prior to starting mebendazole therapy
__label__1	study interventions are Docetaxel . breast cancer diagnosis and the who performance status greater_than one
__label__1	study interventions are therapeutic conventional surgery . stage iii renal cell cancer diagnosis and cardiac arrhythmias requiring anti arrhythmic medications except for atrial fibrillation that is well controlled with anti arrhythmic medication
__label__1	study interventions are Etoposide phosphate . extensive stage small cell lung cancer diagnosis and requirement for routine use of hematopoietic growth factors including granulocyte colony stimulating factor granulocyte macrophage colony stimulating factor or interleukin eleven or platelet transfusions to maintain absolute neutrophil counts or platelets counts above the required thresholds for study entry if patient requires routine use of erythropoietin eligibility at investigator discretion
__label__1	study interventions are Immunoglobulins . multiple myeloma diagnosis and patient is pregnant or unwilling to take contraceptive treatment for three months after treatment
__label__1	study interventions are Vorinostat . brain cancer diagnosis and however prior treatment with dose dense regimens of temozolomide seven days on seven days off twenty-one days twenty-eight days or continuous low dose daily dosing not with chemoradiation and hdac inhibitors other than valproic acid such as depsipeptide lbh five hundred and eighty-nine or vorinostat are not permitted
__label__1	study interventions are Rituximab . testicular lymphoma diagnosis and posaconazole noxafil
__label__1	study interventions are Thalidomide . recurrent central nervous system neoplasm diagnosis and female child young adult of childbearing potential as female who has
__label__1	study interventions are BB 1101 . plasmacytoma diagnosis and patients at high risk of venous thromboembolism due to
__label__1	study interventions are Pharmacological Study . hertwo positive breast carcinoma diagnosis and inability to take oral medication
__label__1	study interventions are Mechlorethamine . refractory plasma cell myeloma diagnosis and this exclusion does not apply to patients with non hematologic malignancies that do not require therapy
__label__1	study interventions are Aldesleukin . metastatic cancer diagnosis and patients with known brain metastases
__label__1	study interventions are Prednisone . castrate resistant prostate cancer diagnosis and inability to comply with protocol or study procedures
__label__1	study interventions are Levoleucovorin . stage ivb rectal cancer diagnosis and impairment of gastrointestinal function or gastrointestinal disease active ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome small bowel resection
__label__1	study interventions are Liposomal doxorubicin . undifferentiated ovarian carcinoma diagnosis and rash must cover less than ten of body surface area bsa
__label__1	study interventions are Etoposide . merkel cell carcinoma diagnosis and previous chemotherapy in the past five years or prior radiotherapy to the area of concern
__label__1	study interventions are Veliparib . stage ii rectal cancer diagnosis and co morbid illnesses or other concurrent disease that in the judgement of the clinician obtaining informed consent would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens or prevent required follow up
__label__1	study interventions are Interleukin-2 . penile cancer diagnosis and women of child bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the preparative chemotherapy treatment on the fetus or infant
__label__1	study interventions are Proton Radiotherapy . breast cancer diagnosis and prior radiation to the breast or thorax
__label__1	study interventions are Cyclophosphamide . stage iii multiple myeloma diagnosis and total serum bilirubin more than twice upper normal limit
__label__1	study interventions are Cisplatin . stage iia fallopian tube cancer diagnosis and no more than superficial myometrial invasion
__label__1	study interventions are Temozolomide . ovarian cancer diagnosis and clinically significant and uncontrolled major medical condition including but not limited to
__label__1	study interventions are Antibodies, Bispecific . history of malignancy other than cell lymphoma within five years prior to study entry with the exception of basal cell carcinoma of the skin or carcinoma in situ of the cervix
__label__1	study interventions are Recombinant Human Adenovirus Type 5 Injection . hepatocellular carcinoma diagnosis and others
__label__1	study interventions are Lenalidomide . stage multiple myeloma diagnosis and poems syndrome polyneuropathy_organomegaly endocrinopathy monoclonal protein and skin changes
__label__1	study interventions are ADCT-301 . small lymphocytic lymphoma diagnosis and evidence of myelodysplasia or myeloid leukemia by morphology immunostains flow cytometry or cytogenetics on bone marrow aspirate or biopsy
__label__1	study interventions are Fludarabine phosphate . stage iii childhood burkitt lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are N-monoacetylcystine . stage ivc lymphoepithelioma of the oropharynx diagnosis and utilization of amifostine during radiotherapy
__label__1	study interventions are Interleukin-2 . stage iv skin melanoma diagnosis and has history of significant congestive heart failure or significant pulmonary disease
__label__1	study interventions are Cisplatin . ovarian seromucinous tumor diagnosis and core biopsy within seven days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Camptothecin . adenocarcinoma of unknown primary diagnosis and serious underlying medical or psychiatric illnesses that would in the opinion of the treating physician substantially increase the risk for complications related to treatment
__label__1	study interventions are Robotic single port surgery and NOTES . oropharyngeal neoplasms diagnosis and vulnerable population mentally disabled pregnancy
__label__1	study interventions are Crizotinib . cholangiocarcinoma of the extrahepatic bile duct diagnosis and other serious illness considered not suitable for this study by investigators
__label__1	study interventions are Capecitabine . colorectal cancer diagnosis and previous systemic treatment for advanced disease
__label__1	study interventions are Olaparib . ovarian endometrioid adenocarcinoma diagnosis and if cardiac function assessment is clinically indicated or performed
__label__1	study interventions are Romidepsin . recurrent solid neoplasm diagnosis and note
__label__1	study interventions are 4Dimensional Phase Contrast Magnetic Resonance Angiography . cancer of the liver diagnosis and documented or reported contrast allergy
__label__1	study interventions are Isophosphamide mustard . myxoinflammatory_fibroblastic sarcoma diagnosis and cypthreeafour inhibitors
__label__1	study interventions are Sirolimus . locally advanced cervical cancer diagnosis and patients using other agents under investigation or receiving investigational medications less_than four weeks before the study treatment starting
__label__1	study interventions are Bortezomib . non small cell lung cancer diagnosis and previous treatment with docetaxel prior treatment with paclitaxel will be allowed
__label__1	study interventions are Iodine . stage ivc thyroid gland follicular carcinoma diagnosis and external beam radiation therapy equal_than less_than twenty-eight days prior to registration note
__label__1	study interventions are Busulfan . stage iii marginal zone lymphoma diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Pembrolizumab . recurrent diffuse large cell lymphoma diagnosis and has known history of human immunodeficiency virus hiv hiv one two antibodies
__label__1	study interventions are Topotecan . undifferentiated ovarian carcinoma diagnosis and exposure to household_contacts equal_than less_than fifteen months old or household contact with known immunodeficiency
__label__1	study interventions are TLR4 Agonist GLA-SE . stage iv skin melanoma diagnosis and known standard therapy for the patient disease that is potentially curative or proven capable of extending life expectancy
__label__1	study interventions are Antibodies, Monoclonal . unresectable solid neoplasm diagnosis and patients with previously treated brain metastases must have stable neurologic status and magnetic resonance imaging mri imaging following local therapy surgery or radiation for at least four weeks with no requirement for immunosuppressive doses of systemic corticosteroids greater_than ten mg day prednisone equivalents for at least two weeks prior to study drug administration stable low dose dexamethasone allowed at discretion of protocol chair
__label__1	study interventions are Tacrolimus . contiguous stage ii adult burkitt lymphoma diagnosis and current serious systemic illness that would result in increased risk for csf mobilization and harvest of peripheral blood stem cells pbsc
__label__1	study interventions are Pembrolizumab . adrenocortical carcinoma diagnosis and has known additional malignancy that is progressing or requires active treatment
__label__1	study interventions are Trastuzumab . cancer diagnosis and adequate contraception includes intra uterine device barrier methods with spermicide or oral contraceptives unless clinically contraindicated for the subject population or per local practice refer to protocol for further details
__label__1	study interventions are Dexamethasone 21-phosphate . has received any myeloma directed therapy after asct
__label__1	study interventions are Alisertib . adult brain stem glioma diagnosis and john wort within fourteen days prior to the first dose of mlneight thousand, two hundred and thirty-seven and during the study
__label__1	study interventions are TargomiRs . non small cell lung cancer diagnosis and cardiac arrhythmias requiring anti arrhythmic therapy beta blockers or digoxin are permitted
__label__1	study interventions are Doxorubicin . adenocarcinoma of colon diagnosis and carries the human immunodeficiency virus hiv
__label__1	study interventions are Endothelial Growth Factors . fallopian tube mucinous adenocarcinoma diagnosis and ctep ctcae version doc grade two or higher peripheral ischemia brief less_than two4 hours hrs episode of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Eflornithine . colorectal cancer diagnosis and women greater_than eighty-eight cm greater_than thirty-five in
__label__1	study interventions are guiding equipments . lung neoplasms diagnosis and patient has uncontrollable hypertension sbp greater_than one hundred and eightymmhg
__label__1	study interventions are Bevacizumab . if history of other primary cancer subject will be eligible only if she or he has
__label__1	study interventions are Cetuximab . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Doxorubicin . breast cancer diagnosis and the presence of any other medical or psychiatric disorder that in the opinion of the treating physician would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications
__label__1	study interventions are Pembrolizumab . stage iib gastric cancer diagnosis and celiac adenopathy greater_than equal_than two cm in size
__label__1	study interventions are Vinorelbine . lung cancer diagnosis and patients who are not candidates for surgical resection
__label__1	study interventions are Etoposide . stage iv childhood large cell lymphoma diagnosis and evidence of pregnancy or lactation period
__label__1	study interventions are Bevacizumab . glioblastoma multiforme diagnosis and proteinuria as demonstrated by urine protein creatinine ratios upc ratio greater_than doc at screening appendix a
__label__1	study interventions are therapeutic autologous dendritic cells . stage iv renal cell cancer diagnosis and presence of untreated active central nervous system cns metastases
__label__1	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the nasopharynx diagnosis and myocardial infraction within the last six months documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of lvef function
__label__1	study interventions are Levoleucovorin . stage ib gastric cancer diagnosis and respiratory condition that required any oxygen supplementation equal_than less_than six months prior to registration
__label__1	study interventions are Levoleucovorin . stage iv childhood lymphoblastic lymphoma diagnosis and pre treatment with dexamethasone in the twenty-eight days prior to initiation of protocol therapy is not allowed with the exception of single dose of dexamethasone use during sedation to prevent or treat airway edema
__label__1	study interventions are AuroShell particle infusion . neoplasms of the prostate diagnosis and patients who are receiving concurrent investigational therapy or who have received investigational therapy within period of five half lives of the investigational therapy in question prior to the day of dosing with the pegylated auroshell particles investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication
__label__1	study interventions are Doxorubicin . undifferentiated fallopian tube carcinoma diagnosis and patients positive for human immunodeficiency virus hiv are not excluded from this study but hiv positive patients must have
__label__1	study interventions are Panobinostat . chordoma diagnosis and myocardial infarction within twelve months prior to starting study
__label__1	study interventions are Oxaliplatin . patients from whom tumor tissue for correlative studies cannot be safely obtained
__label__1	study interventions are Fluorouracil . metastatic pancreatic adenocarcinoma diagnosis and barrier methods of contraception
__label__1	study interventions are Zalypsis . primitive neuroectodermal tumor pnet diagnosis and new york heart association nyha grade ii or greater congestive heart failure
__label__1	study interventions are Metronidazole . recurrent primary peritoneal cavity cancer diagnosis and participation in any other clinical trial involving another investigational agent within four weeks prior to first dosing of study drug
__label__1	study interventions are Sunitinib . greater than or equal to ttwonzeromzero transitional cell carcinoma of the bladder on current pathology or in the past
__label__1	study interventions are Vidarabine . stage childhood large cell lymphoma diagnosis and donor
__label__1	study interventions are Pembrolizumab . head and neck squamous cell carcinoma diagnosis and patients may not be receiving any additional investigational agents or radiation therapy
__label__1	study interventions are Letrozole . advanced metastatic breast cancer diagnosis and patient who received any cdkfour six inhibitor
__label__1	study interventions are Tacrolimus . childhood nasal type extranodal nk cell lymphoma diagnosis and cross match positive with donor
__label__1	study interventions are Topotecan . fallopian tube mucinous adenocarcinoma diagnosis and history of intra abdominal abscess within the past three months
__label__1	study interventions are Mycophenolate mofetil . recurrent adult cell leukemia lymphoma diagnosis and twenty-one heart
__label__1	study interventions are Etoposide phosphate . recurrent adult hodgkin lymphoma diagnosis and left ventricular ejection fraction lvef less_than fifty or coronary artery disease requiring treatment
__label__1	study interventions are Oxaliplatin . rectal neoplasms diagnosis and any prior therapy with oxaliplatin or allergy to platinum containing drugs
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and patients with total bilirubin greater than doc mg dl and sgot or sgpt greater than two and half times normal unless due to primary malignancy or history of severe hepatic dysfunction are ineligible
__label__1	study interventions are Dexamethasone 21-phosphate . cholangiocarcinoma diagnosis and patient must not be pregnant or breastfeeding
__label__1	study interventions are Mycophenolate mofetil . stage adult lymphoblastic lymphoma diagnosis and donors for whom medical or psychologic reasons would make donor procedure intolerable
__label__1	study interventions are Pharmaceutical Solutions . colorectal cancer screening diagnosis and subject has participated in an investigational drug or device research study within thirty days of enrollment that may interfere with the subject safety or ability to participate in this study
__label__1	study interventions are Cyclosporins . childhood immunoblastic large cell lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasm diagnosis and may be treated in first complete remission cr diagnostic lumbar_puncture lp required pre transplant
__label__1	study interventions are Erlotinib Hydrochloride . patients must have discontinued the above cancer therapies for one week prior to the first dose of study medication as well as recovered from toxicity to less_than than grade one except for alopecia neuropathy and anc which should be greater_than one250 mmthree induced by previous treatments
__label__1	study interventions are Acupuncture . breast cancer diagnosis and patients on prophylactic antibiotics
__label__1	study interventions are Mycophenolate mofetil . stage grade three follicular lymphoma diagnosis and donor
__label__1	study interventions are Androgens . prior cryotherapy for prostate cancer
__label__1	study interventions are Hormones . ovarian serous cystadenocarcinoma diagnosis and nursing women
__label__1	study interventions are 2-methoxyestradiol . history of prior malignancy except basal cell carcinoma resected with curative intent unless resected or treated with curative intent and disease free for greater than or equal to five years
__label__1	study interventions are AZD2014 . prior chemotherapy biological therapy radiation therapy immunotherapy other anticancer agents and any investigational agents within fourteen days of starting study treatment not including palliative radiotherapy at focal sites
__label__1	study interventions are Paclitaxel . advanced non small cell lung cancer diagnosis and any prior history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Denosumab . multiple myeloma diagnosis and known sensitivity to any of the products to be administered during the study eg mammalian derived products
__label__1	study interventions are Laboratory Biomarker Analysis . childhood clear cell sarcoma of soft parts diagnosis and patients who have had or are planning to have the following invasive procedures are not eligible
__label__1	study interventions are Hormones . recurrent prostate cancer diagnosis and life expectancy less_than six months
__label__1	study interventions are Antibodies, Monoclonal . recurrent adult diffuse large cell lymphoma diagnosis and fertile men or women unwilling to use contraceptives during and for up to twelve months post treatment
__label__1	study interventions are Imatinib Mesylate . b lymphoblastic lymphoma diagnosis and human immunodeficiency virus hiv positive or evidence of infection with hepatitis or virus as defined by any of the following criteria if patients have not previously been tested for the following these will be conducted during screening
__label__1	study interventions are Camptothecin . rectal adenocarcinoma diagnosis and known hypersensitivity to bgjthree hundred and ninety-eight fluorouracil oxaliplatin irinotecan or to any of the excipients
__label__1	study interventions are Antibodies, Monoclonal . stage iiib breast cancer diagnosis and known human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible patients who have positive test for hepatitis virus surface antigen hbv sag or hepatitis antibody hepatitis virus hcv ab ribonucleic acid hcv rna indicating acute or chronic infection are also ineligible baseline testing required
__label__1	study interventions are Bortezomib . prior malignancy except for adequately treated basal cell or squamous cell skin cancer in situ cervical cancer in situ breast cancer in situ prostate cancer or other cancer for which the patient has been disease free for at least three years
__label__1	study interventions are Antibodies, Monoclonal . stage ivb hepatocellular carcinoma diagnosis and crohn s
__label__1	study interventions are Epothilones . breast cancer diagnosis and evidence of metastatic disease
__label__1	study interventions are Rituximab . lymphoma diagnosis and known hypersensitivity to lenalidomide or thalidomide ibrutinib rituximab etoposide vincristine doxorubicin cyclophosphamide or prednisone
__label__1	study interventions are 34 Gy in a single fraction . neoplasm metastasis diagnosis and prior thoracic radiation treatment wich dose contribution can be expected in the new sbrt plan
__label__1	study interventions are Everolimus . endometrial cancer diagnosis and patients who have had chemotherapy radiotherapy or major surgery within three weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events due to agents administered more than three weeks earlier
__label__1	study interventions are Rituximab . stage iii marginal zone lymphoma diagnosis and pregnant or breast feeding
__label__1	study interventions are Albumin-Bound Paclitaxel . malignant airway obstruction secondary to non small cell lung cancer diagnosis and uncontrolled hypertension
__label__1	study interventions are Prednisolone . lymphoma large cell diffuse diagnosis and current or prior use of immunosuppressive medication within twenty-eight days before start of treatment
__label__1	study interventions are Paclitaxel . any anti cancer chinese medicine herbal remedies within fourteen days prior to study enrollment
__label__1	study interventions are Liposomal doxorubicin . stage ib breast cancer diagnosis and for patients less_than fifty years old who will receive ac
__label__1	study interventions are Rituximab . lymphoma non hodgkin diagnosis and note
__label__1	study interventions are Diphosphonates . breast neoplasms diagnosis and patients received medical treatment which can affect bone metabolism such as calcitonin_mithramycin or gallium_nitrate within two weeks before enrollment
__label__1	study interventions are DS-3078a . advanced solid tumor diagnosis and prolongation of corrected qt interval by fridericia method qtcf at rest where the mean qtcf interval is greater_than four hundred and fifty msec based on triplicate electrocardiogram ecg
__label__1	study interventions are Immunoglobulins . recurrent grade two follicular lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Vaccines . non small cell lung cancer diagnosis and prior history or uveitis or autoimmune inflammatory eye disease
__label__1	study interventions are Estrogens . breast cancer diagnosis and patient has been treated with all fda approved endocrine therapies or has been treated with all fda approved endocrine therapies except for tamoxifen tamoxifen is excluded from the trial
__label__1	study interventions are Gemcitabine . multiple myeloma diagnosis and screening ecg with qtc greater_than four hundred and seventy msec
__label__1	study interventions are Cyclosporins . recurrent adult diffuse large cell lymphoma diagnosis and marrow donors
__label__1	study interventions are MRI-guided stereotactive body radiation therapy . liver cancer diagnosis and medical contraindication to undergoing mr imaging
__label__1	study interventions are Antibodies, Monoclonal . skin basosquamous cell carcinoma diagnosis and history or evidence of active autoimmune disease pneumonitis glomerulonephritis vasculitis or other or history of active autoimmune disease that has required systemic treatment use of corticosteroids immunosuppressive drugs or biological agents used for treatment of autoimmune diseases within two months of enrollment replacement therapy thyroxine for hypothyroidism insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is not considered form of systemic treatment for autoimmune disease
__label__1	study interventions are Antibodies, Monoclonal . stage ia fallopian tube cancer diagnosis and uncontrolled hypertension defined as systolic greater_than one hundred and fifty mm hg or diastolic greater_than one hundred mm hg patients with history of hypertension are permitted
__label__1	study interventions are Lifestyle counseling . prostate cancer diagnosis and has received high dose radiotherapy or brachytherapy in place of surgery as primary treatment
__label__1	study interventions are AT13387 . metastatic solid tumors diagnosis and male and female patients of childbearing potential must use appropriate birth control barrier methods oral contraceptives and or intrauterine devices during the entire duration of the study or the patient must be surgically sterile with documentation in the patient medical records
__label__1	study interventions are 18F-FACBC Radiotracer . lung cancer diagnosis and cannot provide written informed consent
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and history of cardiac disease
__label__1	study interventions are Fludarabine . stage ii adult cell leukemia lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Romidepsin . recurrent adult diffuse mixed cell lymphoma diagnosis and providers should use caution with drugs with possible increased risk for torsades de pointes patient will be eligible if they can be taken off these medications prior to initiation of therapy and no less than four half life of the medication
__label__1	study interventions are Etoposide phosphate . lung cancer diagnosis and medications that are strong cypthreeafour five inhibitors should be discontinued at least seven days and strong cypthreea five inducers should be discontinued for at least 1four days prior to starting treatment with lde22five some of these medications are recognized to cause rhabdomyolysis
__label__1	study interventions are Lenvatinib . recurrent ovarian cancer diagnosis and systolic blood pressure of greater_than one hundred and forty mmhg or diastolic blood pressure of greater_than ninety mmhg documented on two consecutive measurements taken at least two4 hours apart
__label__1	study interventions are Mycophenolate mofetil . small lymphocytic lymphoma diagnosis and cardiac ejection fraction less_than thirty-five or if unable to obtain ejection fraction shortening fraction of less_than twenty-six ejection fraction is required if age greater_than fifty years or there is history of anthracycline exposure or history of cardiac disease patients with shortening fraction less_than twenty-six may be enrolled if approved by cardiologist
__label__1	study interventions are Azacitidine . fltthree tyrosine kinase domain point mutation diagnosis and clarithromycin biaxin_biaxin xl
__label__1	study interventions are Paclitaxel . stage ib ovarian cancer diagnosis and patients may have minor surgical procedures mediport insertion fine needle aspiration or core biopsies as long as it is performed greater_than seven days prior to the first date of bevacizumab therapy and there is no evidence of wound disruption or impaired healing
__label__1	study interventions are Docetaxel . melanoma diagnosis and no known allergies to any of the drug therapies being used in this protocol
__label__1	study interventions are Immunoconjugates . hertwo positive breast carcinoma diagnosis and patients with hepatitis or serologies indicating active infection without known active disease must meet the eligibility requirements for alt ast total bilirubin inr ptt and alkaline phosphatase on at least two consecutive occasions separated by at least one week
__label__1	study interventions are Idelalisib . recurrent small lymphocytic lymphoma diagnosis and known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Lenograstim . stage adult non hodgkin lymphoma diagnosis and medical history of noncompliance with art or medical therapy
__label__1	study interventions are Docetaxel . stage iv gallbladder cancer diagnosis and patients must not have untreated central nervous system cns metastases patients whose cns metastases have been treated by surgery or radiotherapy who are no longer on corticosteroids and who are neurologically stable may be enrolled
__label__1	study interventions are Rituximab . follicular lymphoma diagnosis and prior allogeneic stem cell transplantation
__label__1	study interventions are Trastuzumab . known active cns metastases and or carcinomatous_meningitis
__label__1	study interventions are Fludarabine . cutaneous cell non hodgkin lymphoma diagnosis and prior autologous or allogeneic stem cell transplant
__label__1	study interventions are Dexamethasone 21-phosphate . stage multiple myeloma diagnosis and subjects in whom the required program of po and iv fluid hydration is contraindicated eg due to pre existing pulmonary cardiac or renal impairment
__label__1	study interventions are Shear wave elastography . cholangiocellular carcinoma diagnosis and obstructive jaundice
__label__1	study interventions are Vaccines . recurrent melanoma diagnosis and lack of availability of patient for immunological and clinical follow up assessment
__label__1	study interventions are Doxorubicin . noncutaneous extranodal lymphoma diagnosis and patients who are currently receiving another investigational drug are not eligible
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and pre existing neuropathy greater_than gtwo
__label__1	study interventions are Irinotecan . colorectal neoplasms diagnosis and pregnant or lactating women
__label__1	study interventions are Carmustine . aids related lymphoblastic lymphoma diagnosis and positive serology for toxoplasma_gondii and requiring treatment or with evidence of active infection
__label__1	study interventions are Immunoglobulin G . stage iv ovarian cancer diagnosis and history of arrhythmia requiring an implantable cardiac defibrillator
__label__1	study interventions are Cyclosporins . adult nasal type extranodal nk cell lymphoma diagnosis and any vertebral instability
__label__1	study interventions are NKT cells . squamous cell lung cancer diagnosis and subject has any other medical condition that in the opinion of the investigator might significantly affect the ability to safely participate in the study or affect the conduct of the study
__label__1	study interventions are CCT3833 . cancer diagnosis and major surgery within the last four weeks
__label__1	study interventions are Tremelimumab . multiple myeloma diagnosis and major surgical procedure within thirty days prior to day thirty-one or still recovering from prior surgery
__label__1	study interventions are Antibodies, Monoclonal . stage diffuse large cell lymphoma diagnosis and chemotherapy within three weeks of the first scheduled study treatment
__label__1	study interventions are Cisplatin . head neck neoplasms diagnosis and in addition all wocbp should be instructed to contact the investigator immediately if they suspect they might be pregnant missed or late menstrual period at any time during study participation
__label__1	study interventions are Sirolimus . lymphoma diagnosis and active congestive heart failure from any cause
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and clinically significant cardiovascular disease
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv non small cell lung cancer diagnosis and any of the following within four weeks prior to randomization
__label__1	study interventions are Therapeutic Conventional Surgery . stage iv primary peritoneal cancer diagnosis and history of pulmonary disease such as emphysema or chronic obstructive pulmonary disease copd forced expiratory volume of the lung in one second fevone greater_than sixty of predicted for height and age pulmonary function tests pfts are required in patients with prolonged smoking history or signs symptoms or history of respiratory dysfunction
__label__1	study interventions are Gemcitabine . recurrent primary peritoneal cancer diagnosis and patients whose circumstances do not permit completion of the study or the required follow up
__label__1	study interventions are Antibodies, Monoclonal . refractory mature cell and nk cell non hodgkin lymphoma diagnosis and active hepatitis or viral infection or hepatitis surface antigen positive
__label__1	study interventions are Antibodies, Monoclonal . endometrial serous adenocarcinoma diagnosis and left ventricular ejection fraction lvef equal_than less_than fifty-five as determined by multi gated acquisition muga scan or echocardiogram echo
__label__1	study interventions are Vitamin E . breast carcinoma diagnosis and heart failure nyha classgreater_than one
__label__1	study interventions are radiotherapy . hepatocellular carcinoma diagnosis and doc
__label__1	study interventions are Immunoglobulins . childhood burkitt lymphoma diagnosis and positive cross match exists between the donor and recipient
__label__1	study interventions are Temozolomide . neoplasms diagnosis and patients receiving concurrent antibody or immunotherapy
__label__1	study interventions are Etoposide phosphate . recurrent adult burkitt lymphoma diagnosis and prior to study entry any electrocardiogram ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are Vaccines . melanoma diagnosis and brain metastases
__label__1	study interventions are Estrogens . breast cancer diagnosis and less than ordinary physical activity that causes fatigue palpitation dyspnea or anginal pain
__label__1	study interventions are Carboplatin . hormone resistant prostate cancer diagnosis and any medical conditions which in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained are not eligible
__label__1	study interventions are Veliparib . stage iiic breast cancer diagnosis and pre existing grade three or four sensory neuropathy
__label__1	study interventions are Tc+blue dye . breast cancer diagnosis and the axilla is clinically and radiologically by ultrasound positive ycnone postchemotherapy
__label__1	study interventions are therapeutic allogeneic lymphocytes . recurrent adult hodgkin lymphoma diagnosis and creatinine greater_than equal_than doc mg dl
__label__1	study interventions are Antibodies, Monoclonal . recurrent verrucous carcinoma of the larynx diagnosis and patients with an active bleeding diathesis or on therapeutic anticoagulation except low dose coumadin
__label__1	study interventions are Liposomal doxorubicin . stage iii soft tissue sarcoma diagnosis and known strong inducers or inhibitors of cypthreeafour five including grapefruit grapefruit hybrids_pummelos star_fruit and seville_oranges
__label__1	study interventions are Interferons . recurrent adult liver carcinoma diagnosis and patient for whom surgical resection or liver transplantation would be more appropriate
__label__1	study interventions are Everolimus . stage iii adult diffuse large cell lymphoma diagnosis and females who are pregnant or breast feeding
__label__1	study interventions are Trametinib . solid tumors diagnosis and history of retinal vein occlusion rvo
__label__1	study interventions are Temozolomide . stage iv pancreatic cancer diagnosis and history of myocardial infarction or unstable angina within six months prior to day one
__label__1	study interventions are Cyclosporine . nodal marginal zone cell lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Interleukin-2 . metastatic melanoma diagnosis and brain metastases
__label__1	study interventions are Carboplatin . estrogen recepto negative negative breast cancer diagnosis and subject is currently enrolled or will enroll in different clinical study in which investigational therapeutic procedures are performed or investigational therapies are administered while participating in this study
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic pancreas adenocarcinoma diagnosis and subject will not be eligible for inclusion in this study if any of the following criteria apply
__label__1	study interventions are Azacitidine . osteosarcoma diagnosis and uncontrolled systemic fungal bacterial or viral infection defined as ongoing signs symptoms related to the infection without improvement despite appropriate antibiotics antiviral therapy and or other treatment
__label__1	study interventions are Bendamustine Hydrochloride . recurrent adult diffuse large cell lymphoma diagnosis and patients who are refractory not responded or progressed within six months to carboplatin cisplatin bendamustine or etoposide based regimen
__label__1	study interventions are Estradiol . breast carcinoma diagnosis and in addition this includes grapefruit grapefruit hybrids_pummelos star_fruit and seville_oranges
__label__1	study interventions are Lenalidomide . lymphoma non hodgkin diagnosis and new york heart association class three four heart failure
__label__1	study interventions are quality-of-life assessment . stage iib prostate cancer diagnosis and acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and uncontrolled hypertension defined as blood pressure bp that is consistently greater_than one hundred and fifty ninety on antihypertensive therapy at the time of registration patients with hypertension that is well controlled on medication are eligible
__label__1	study interventions are Antibodies, Monoclonal . cancer diagnosis and minor surgical procedure open biopsy less_than equal_than seven days before first dose of study treatment or not yet recovered from prior minor surgery note
__label__1	study interventions are Personalized dose redistribution . previous neoplastic disease of less than five years duration or progressive without basal cell carcinoma of the skin in situ carcinoma of the cervix
__label__1	study interventions are Cabozantinib S-malate . recurrent osteosarcoma diagnosis and minor surgery including uncomplicated tooth extractions within twenty-eight days before the first dose of study treatment with complete wound healing at least ten days before the first dose of study treatment subjects with clinically relevant ongoing complications from prior surgery are not eligible
__label__1	study interventions are Prednisolone phosphate . previous treatment for cell lymphoma except low dose radiotherapy for follicular lymphoma and glucocorticoids no more than fourteen days before inclusion one mg kg day maximum dose
__label__1	study interventions are E7777 . cutaneous cell lymphoma diagnosis and women of childbearing potential or man of impregnate potential who don agree to use medically effective method for contraception
__label__1	study interventions are BB 1101 . stage ii multiple myeloma diagnosis and uncontrolled hypertension or diabetes
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and impaired cardiac function or clinically significant cardiac diseases including any one of the following
__label__1	study interventions are Gabapentin . subjects are excluded from the gprd cohort if they have cancer diagnosis or history of cancer prior to the cohort entry date
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and ten ninety-six will be potential candidates
__label__1	study interventions are Radium Ra 223 dichloride . prostatic neoplasms diagnosis and imminent or history of spinal cord compression based on clinical findings and or magnetic resonance imaging mri
__label__1	study interventions are Antibodies, Monoclonal . stage iva colorectal cancer diagnosis and vaccination with live or attenuated vaccine equal_than less_than twenty-eight days prior to randomization note
__label__1	study interventions are Vincristine . stage iv mantle cell lymphoma diagnosis and grade two or higher baseline peripheral neuropathy
__label__1	study interventions are Aminopterin . undifferentiated gastric carcinoma diagnosis and undergone an allogeneic stem cell transplant
__label__1	study interventions are Dexamethasone 21-phosphate . lymphoma large cell diffuse diagnosis and pregnant women
__label__1	study interventions are Pembrolizumab . stage iv breast cancer diagnosis and known history of human immunodeficiency virus hiv hiv one two antibodies
__label__1	study interventions are Cyclosporins . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and acute leukemia in relapse greater_than equal_than five marrow blasts by morphology
__label__1	study interventions are Dacarbazine . astrocytoma diagnosis and prisoners will be excluded from this study
__label__1	study interventions are Antibodies, Monoclonal . solid cancers diagnosis and leptomeningeal disease
__label__1	study interventions are Cyclophosphamide . metastatic neoplasm diagnosis and patients will be excluded if they have history of clinically significant electrocardiogram ecg abnormalities symptoms of cardiac ischemia or arrhythmias and have left ventricular ejection fraction lvef less_than forty-five on cardiac stress test stress thallium stress multi gated acquisition scan muga dobutamine echocardiogram or other stress test
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and prior neo adjuvant chemotherapy radiotherapy completed within six months prior to study entry
__label__1	study interventions are Computed Tomography . stage iii nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and patients with tonenzeromzero stage disease
__label__1	study interventions are Laboratory Biomarker Analysis . evidence of cancer within twenty-eight days prior to start of study treatment this should be determined by imaging of the chest abdomen and pelvis by computed tomography ct and or magnetic resonance imaging mri staging of the chest using chest ray in lieu of ct and or mri should not be used for this purpose
__label__1	study interventions are Antibodies . lung cancer diagnosis and the patient has history of stroke or transient ischemic attack within six months prior to day one of cycle one
__label__1	study interventions are Ascorbic Acid . prostate cancer diagnosis and prostatectomy hyperthermia and cryosurgery
__label__1	study interventions are Vaccines . stage iiib skin melanoma diagnosis and clinical evidence of vitiligo
__label__1	study interventions are Cisplatin . esophageal cancer diagnosis and patients with serious diseases such as congestive heart failure uncontrolled myocardial infarction and arrhythmia liver failure and renal failure
__label__1	study interventions are Immunoglobulin G . fallopian tube mucinous adenocarcinoma diagnosis and history of inflammatory bowel disease requiring ongoing therapy
__label__1	study interventions are Cyclosporine . hepatosplenic cell lymphoma diagnosis and cardiac ejection fraction less_than forty ejection fraction is required if the patient has history of anthracyclines or history of cardiac disease
__label__1	study interventions are AVL-292 . b cell non hodgkin lymphoma diagnosis and active uncontrolled infection
__label__1	study interventions are Cyclosporins . stage iii childhood large cell lymphoma diagnosis and donors for whom medical or psychologic reasons would make donor procedure intolerable
__label__1	study interventions are Cisplatin . adenocarcinoma diagnosis and presence of active infection
__label__1	study interventions are Paclitaxel . squamous cell carcinoma diagnosis and known to be human immunodeficiency virus hiv positive have hepatitis surface antigen hbsag or hepatitis antibodies hcab unless hcv rna is undetected negative
__label__1	study interventions are Everolimus . squamous cell skin carcinoma diagnosis and currently receiving any investigational agents
__label__1	study interventions are Immunoglobulins . adenocarcinoma of the rectum diagnosis and patients must not be receiving any other investigational agents
__label__1	study interventions are dynamic contrast-enhanced magnetic resonance imaging . stage iv breast cancer diagnosis and complete left bundle_branch block or use of permanent cardiac pacemaker
__label__1	study interventions are Selumetinib . aids related kaposi sarcoma diagnosis and refractory nausea vomiting chronic gastrointestinal diseases inflammatory bowel disease or significant bowel resection that would preclude adequate absorption
__label__1	study interventions are Trastuzumab . stage ib breast cancer diagnosis and current use of digitalis or beta blockers for congestive heart failure chf
__label__1	study interventions are Rituximab . multiple myleoma diagnosis and patient may be hepatitis core antibody positive
__label__1	study interventions are Cyclophosphamide . stage iiia breast cancer diagnosis and evidence of distant metastatic disease
__label__1	study interventions are Doxorubicin . male breast cancer
__label__1	study interventions are Paclitaxel . esophageal neoplasms diagnosis and have had myocardial infarction less_than six months prior to start of study treatment
__label__1	study interventions are Levoleucovorin . lymphoma non hodgkin diagnosis and patients with recurrent infection that may interfere with the planned protocol
__label__1	study interventions are Bicalutamide . prostatic neoplasms diagnosis and prior use of systemic glucocorticoids the equivalent of ten mg of prednisone within three months prior to randomization or expectation of their use during the study
__label__1	study interventions are Vaccines . adult mixed glioma diagnosis and inability to obtain informed consent because of psychiatric or complicating medical problems
__label__1	study interventions are Methotrexate . primary non hodgkin lymphoma of the central nervous system diagnosis and creatinine greater_than one five mg or creatinine clearance less_than five0ml min
__label__1	study interventions are PET/CT Scan . ovarian cancer diagnosis and patients who have received neoadjuvant chemotherapy prior to their initial debulking are excluded
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . recurrent childhood visual pathway and hypothalamic glioma diagnosis and patients with uncontrolled seizures are not eligible for study entry
__label__1	study interventions are SHR-1210 . gastric cancer diagnosis and note
__label__1	study interventions are cabozantinib-s-malate . unspecified adult solid tumor protocol specific diagnosis and gastrointestinal perforation
__label__1	study interventions are Talazoparib . brca mutated solid tumor diagnosis and history of myocardial infraction mi within six month prior to starting study treatment
__label__1	study interventions are Busulfan . refractory multiple myeloma diagnosis and no psychiatric conditions which would prevent delivery of care psychology clearance is necessary
__label__1	study interventions are Fludarabine phosphate . stage iv adult burkitt lymphoma diagnosis and serum glutamic oxaloacetic transaminase sgot or serum glutamic pyruvate transaminase sgpt greater_than equal_than three upper limit of normal
__label__1	study interventions are Antibodies . adult anaplastic oligodendroglioma diagnosis and at least six weeks since prior nitrosourea
__label__1	study interventions are Lapatinib . neoplasm metastasis diagnosis and previous or current systemic malignancy within the past three years other than the following
__label__1	study interventions are Doxorubicin . peritoneal cancer diagnosis and if participant underwent major surgery they must have recovered adequately from the toxicity and or complications from the intervention prior to starting therapy
__label__1	study interventions are Cyclophosphamide . multiple myeloma diagnosis and serum hcg pregnancy test must be performed at the screening visit for female subjects of childbearing potential
__label__1	study interventions are Pembrolizumab . hormone resistant prostate cancer diagnosis and has known history of human immunodeficiency virus hiv hiv one two antibodies
__label__1	study interventions are laboratory biomarker analysis . splenic marginal zone lymphoma diagnosis and st
__label__1	study interventions are Antilymphocyte Serum . marginal zone lymphoma diagnosis and active central nervous system cns involvement by malignant cells
__label__1	study interventions are Busulfan . stage adult diffuse mixed cell lymphoma diagnosis and patient unable to give informed consent
__label__1	study interventions are Testosterone . history of nonskin cancer other than prostate cancer requiring active treatment within two years of screening
__label__1	study interventions are Etoposide phosphate . lymphoma diagnosis and recovered from prior adverse effects due to agents administered more than three weeks earlier
__label__1	study interventions are Androgens . prostate cancer diagnosis and bilirubin less_than doc mg dl
__label__1	study interventions are Everolimus . breast cancer diagnosis and topical or inhaled corticosteroids are allowed
__label__1	study interventions are Sirolimus . recurrent lymphoepithelioma of the oropharynx diagnosis and patients with an active bleeding diathesis or on therapeutic anticoagulation except low dose coumadin
__label__1	study interventions are Vincristine . refractory lymphoblastic lymphoma diagnosis and routine systemic maintenance therapy abelson murine leukemia viral oncogene_homolog one abl kinase inhibitor methotrexate six mercaptopurine vincristine etc
__label__1	study interventions are Sunitinib . fallopian tube cancer diagnosis and other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration
__label__1	study interventions are Vinorelbine . breast cancer diagnosis and no breast feeding
__label__1	study interventions are Immunoglobulins . fallopian tube clear cell adenocarcinoma diagnosis and new york heart association nyha grade ii or greater congestive heart failure
__label__1	study interventions are Magnetic Nanoparticle Injection . prostate cancer diagnosis and unable to have mri scan or ct scan or in whom artefact would reduce scan quality
__label__1	study interventions are Dexamethasone acetate . malignant neoplasms of male genital organs diagnosis and low molecular weight heparin less than thirty-six hours prior to surgery
__label__1	study interventions are Dexamethasone acetate . stage iii multiple myeloma diagnosis and inability to give voluntary written informed consent before performance of any study related procedure not part of normal medical care with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
__label__1	study interventions are Erythromycin Estolate . ras wildtype colorectal cancer diagnosis and history of interstitial lung disease pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest ct scan
__label__1	study interventions are Part B: Expansion Cohort of Cantrixil . peritoneal neoplasms diagnosis and screening for chronic conditions is not required
__label__1	study interventions are Rituximab . follicular lymphoma diagnosis and active infections bacterial fungal or viral
__label__1	study interventions are Immunoglobulins . recurrent mantle cell lymphoma diagnosis and skin rash such as stevens_johnson syndrome or toxic epidermal necrolysis with prior rituximab therapy should not be entered on this study because of the risk of reoccurrence of that skin toxicity
__label__1	study interventions are Irinotecan . gallbladder cancer diagnosis and more than two weeks since completion of prior radiotherapy
__label__1	study interventions are PDR001 . triple negative breast cancer diagnosis and malignant disease other than that being treated in this study
__label__1	study interventions are Nintedanib . genital neoplasms female diagnosis and patients with known brain metastases
__label__1	study interventions are Capecitabine . colorectal carcinoma diagnosis and patients who have tested positive for hiv
__label__1	study interventions are Thiotepa . testicular lymphoma diagnosis and allogeneic bmt not possible or not desirable
__label__1	study interventions are Methotrexate . gynecologic cancers diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days prior to beginning study treatment
__label__1	study interventions are Hormones . metastatic breast cancer diagnosis and known hypersensitivity to the components of study drug or its analogs
__label__1	study interventions are Dexamethasone 21-phosphate . myeloma proteins diagnosis and or unstable angina uncontrolled hypertension or cardiac arrythmias or myocardial infarction within the last six months
__label__1	study interventions are Single arm, open-label . glioblastoma diagnosis and human immunodeficiency virus hiv infection
__label__1	study interventions are Antibodies, Monoclonal . hepatocellular carcinoma diagnosis and history of peptic ulcer disease within three months of treatment
__label__1	study interventions are Docetaxel . fallopian tube mucinous adenocarcinoma diagnosis and patients whom have already undergone secondary cytoreduction for recurrent disease are excluded
__label__1	study interventions are Everolimus . recurrent adult lymphoblastic lymphoma diagnosis and if the medication is deemed essential and cannot be discontinued sirolimus dosing will be adjusted following discussion with the study pharmacologist dr
__label__1	study interventions are DS-3078a . advanced solid tumor diagnosis and use of chronic systemic corticosteroids use of nasal or inhaled steroids is permitted
__label__1	study interventions are Mitogens . stage iii multiple myeloma diagnosis and use of rabbit_antithymocyte globulin in the pretransplant conditioning regimen
__label__1	study interventions are Bevacizumab . stage iva uterine corpus cancer diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal pelvic fistula gastrointestinal perforation or intra abdominal abscess within three months prior to the first date of study therapy patients with underlying lesions that caused the fistula or perforation in the past that have not been corrected
__label__1	study interventions are Doxorubicin . t lymphoblastic lymphoma diagnosis and for patients with philadelphia_chromosome positive ph positive all they must not have progressed within three months of receiving imatinib or have documented abl kinase mutation known to confer resistance to imatinib tthree15i
__label__1	study interventions are Carboplatin . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and no prior treatment with histone_deacetylase inhibitors
__label__1	study interventions are Thalidomide . relapse refratory peripheral cell lymphoma diagnosis and any psychological conditions which may disturb consent
__label__1	study interventions are Docetaxel . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and patients who are felt to be poorly compliant
__label__1	study interventions are Pembrolizumab . pancreatic cancer diagnosis and has history or current evidence of any condition therapy or laboratory abnormality that might confound the results of the trial interfere with the subject participation for the full duration of the trial or is not in the best interest of the subject to participate in the opinion of the treating investigator including dialysis
__label__1	study interventions are Sirolimus . other malignancies within the past three years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin
__label__1	study interventions are Paclitaxel . head and neck cancer diagnosis and known active hepatitis or c
__label__1	study interventions are Levoleucovorin . colorectal cancer diagnosis and uncontrolled high blood pressure systolic blood pressure greater_than equal_than one hundred and forty and diastolic blood pressure greater_than equal_than ninety history of labile hypertension or history of poor compliance with an antihypertensive regimen
__label__1	study interventions are Mycophenolic Acid . stage iv grade one follicular lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of tyrosine kinase inhibitors such as imatinib cytokine therapy hydroxyurea low dose cytarabine_chlorambucil or rituxan will not be allowed within three weeks of the initiation of conditioning
__label__1	study interventions are placebo . colorectal cancer diagnosis and kidney failure receiving renal dialysis or serum creatinine greater_than two mg dl
__label__1	study interventions are Pharmaceutical Solutions . colon cancer diagnosis and known hypersensitivity to polyethylene glycols ascorbic acid and sulfates or any other component of the investigational product or comparator
__label__1	study interventions are Paclitaxel . recurrent fallopian tube carcinoma diagnosis and patients with known hypersensitivity to chinese_hamster cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Antibodies . recurrent adult lymphoblastic lymphoma diagnosis and pregnancy
__label__1	study interventions are Prednisone . prostate cancer metastatic castration resistant diagnosis and patients must stop taking all strong cypthreeafour inhibitors including clarithromycin telithromycin nefazodone itraconazole ketoconazole atazanavir darunavir indinavir lopinavir nelfinavir ritonavir saquinavir and tipranavir prior to registration
__label__1	study interventions are Immunoglobulins . breast neoplasm diagnosis and any patient with need for chronic steroids or anticoagulation will be ineligible
__label__1	study interventions are Mycophenolate mofetil . lymphoma diagnosis and current active infection
__label__1	study interventions are Quality-of-Life Assessment . cancer survivor diagnosis and have practiced_yoga greater_than equal_than one day week within the three months prior to enrolling in the study
__label__1	study interventions are Ganetespib . stage oropharyngeal squamous cell carcinoma diagnosis and pregnancy or lactation patients of child bearing age must agree to use adequate contraception
__label__1	study interventions are Maleic acid . adult gliosarcoma diagnosis and it is acceptable to use corrected calcium when interpreting calcium levels
__label__1	study interventions are Liposomal doxorubicin . metastatic liposarcoma diagnosis and at least fourteen days since last dose prior to first dose of ribociclib
__label__1	study interventions are Antibodies, Monoclonal . non squamous non small cell lung cancer diagnosis and uncontrolled intercurrent disease diabetes hypertension thyroid disease
__label__1	study interventions are Fludarabine . contiguous stage ii adult diffuse large cell lymphoma diagnosis and age greater_than seventy-five years
__label__1	study interventions are Bendamustine Hydrochloride . high grade cell lymphoma diagnosis and requires treatment with strong cytochrome cypthreeafour five inhibitors
__label__1	study interventions are Carboplatin . non small cell lung cancer diagnosis and patients who are at risk in the investigator opinion of transmitting human immunodeficiency virus hiv through blood or other body fluids
__label__1	study interventions are Dexamethasone 21-phosphate . refractory plasma cell myeloma diagnosis and john wort
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and patients who have had myocardial infarction or cardiac surgery should be at lease six months from the event and free of active symptoms
__label__1	study interventions are Immunoglobulins . refractory cell non hodgkin lymphoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with mlneight thousand, two hundred and thirty-seven
__label__1	study interventions are TLR9 Agonist SD-101 . grade one follicular lymphoma diagnosis and patients with active infection or with fever greater_than three doc zero degrees_celsius within three days prior to the first scheduled treatment
__label__1	study interventions are dovitinib lactate . pancreatic polypeptide tumor diagnosis and unwilling or unable to comply with the protocol
__label__1	study interventions are Docetaxel . nasopharyngeal carcinoma diagnosis and prior radiotherapy to the head and neck region for any reason
__label__1	study interventions are Ketoconazole . solid tumors diagnosis and has undergone an allogeneic stem cell transplant
__label__1	study interventions are Vincristine . intraocular lymphoma diagnosis and inability to comply with study or follow up testing and procedures
__label__1	study interventions are Carboplatin . stage iv non small cell lung cancer diagnosis and has an active infection requiring systemic therapy
__label__1	study interventions are Oxaliplatin . melanoma skin diagnosis and active infection
__label__1	study interventions are Doxorubicin . stage ii adult hodgkin lymphoma diagnosis and positive serology for hepatitis hb defined as positive test for hbsag
__label__1	study interventions are Cisplatin . ovarian cancer diagnosis and has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Bevacizumab . somatostatinoma diagnosis and known cns metastases
__label__1	study interventions are Gemcitabine . leiomyosarcoma diagnosis and calcium and magnesium levels inferior to standard levels measured within fourteen days before the first pazopanib dose and potassium levels inferior to standard levels measured within seventy-two hours before the first pazopanib dose
__label__1	study interventions are Lenalidomide . recurrent cutaneous cell non hodgkin lymphoma diagnosis and intranasal inhaled topical or local steroid injections intra articular injection and are on stable dose for at least twenty-eight days
__label__1	study interventions are Antibodies, Monoclonal . small cell lung cancer diagnosis and severe infections at the time of enrollment
__label__1	study interventions are Ergocalciferols . colorectal cancer diagnosis and any diagnosis of osteoporosis with physician recommendation for treatment of low bone mass
__label__1	study interventions are Letrozole . previous or concurrent cancer that is distinct in primary site or histology from breast cancer except carcinoma in situ of the cervix treated basal cell skin cancer superficial bladder tumors ta and tis or any cancer curatively treated within the past five years
__label__1	study interventions are Lenalidomide . adult grade iii lymphomatoid granulomatosis diagnosis and history of significant cerebrovascular disease in the past three months or ongoing event with active symptoms or sequelae
__label__1	study interventions are Hormones . stage iiic breast cancer diagnosis and plans to begin bisphosphonates or denosumab after registration or began therapy regiment equal_than less_than thirty days from registration
__label__1	study interventions are Rituximab . stage iii adult diffuse large cell lymphoma diagnosis and current or chronic hepatitis or hepatitis infection as detected by positive testing for hepatitis surface antigen hbs ag or antibody to hepatitis virus anti hcv respectively patients must be tested for hepatitis surface antigen and anti hcv equal_than less_than twenty-one days prior to registration
__label__1	study interventions are Oxaliplatin . recurrent childhood lymphoblastic lymphoma diagnosis and no history of life threatening hypersensitivity to platinum containing agents
__label__1	study interventions are Doxorubicin . primary central nervous system cns lymphoma and secondary cns involvement by lymphoma mantle cell lymphoma mcl or histologic evidence of transformation to burkitt lymphoma primary mediastinal dlbcl primary effusion lymphoma plasmablastic lymphoma and primary cutaneous dlbcl
__label__1	study interventions are Albumin-Bound Paclitaxel . invasive breast carcinoma diagnosis and patients positive for hepatitis virus hcv antibody are eligible only if polymerase chain reaction pcr is negative for hcv ribonucleic acid rna
__label__1	study interventions are Antibodies . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and patient is female who is pregnant or breastfeeding
__label__1	study interventions are Glycine . multiple myeloma diagnosis and co morbid systemic illnesses or other severe concurrent disease that in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Azacitidine . hodgkin lymphoma diagnosis and pregnant or breastfeeding females
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy breastfeeding should be discontinued if the mother is treated with chemotherapy
__label__1	study interventions are Androgens . prostate cancer diagnosis and patients on therapeutic anticoagulation are at increased risk from bleeding while on bay_forty-three nine thousand and six sorafenib
__label__1	study interventions are Paclitaxel . peritoneal cancer diagnosis and urine dipstick for proteinuria greater_than equal_than two positive patients discovered to have greater_than equal_than two positive proteinuria on dipstick urinalysis at baseline should undergo two4 hour urine collection and must demonstrate less_than equal_than oneg of protein in two4 hours to be eligible
__label__1	study interventions are Deoxyglucose . lung cancer diagnosis and total bilirubin greater_than doc mg dl
__label__1	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and other organic disorders preventing inclusion in the trial
__label__1	study interventions are Cytarabine . evolving malignancy within three years with the exception of localized non melanomatous skin cancer
__label__1	study interventions are Docetaxel . breast cancer diagnosis and the only exception is hormonal therapy which may have been given for up to total of twenty-eight days anytime after diagnosis and before study entry
__label__1	study interventions are Questionnaire Administration . stage iiic breast cancer diagnosis and immunotherapy equal_than less_than three weeks
__label__1	study interventions are Bortezomib . stage iv adult lymphoblastic lymphoma diagnosis and intrathecal cytarabine the cns status must be determined based on sample obtained prior to administration of any systemic or intrathecal chemotherapy except for steroid pretreatment system chemotherapy must begin with seventy-two hours of this it therapy or
__label__1	study interventions are Cyclophosphamide . breast neoplasm diagnosis and hypersensitivity to irx two cyclophosphamide indomethacin aspirin or ciprofloxacin
__label__1	study interventions are Paclitaxel . pancreatic cancer diagnosis and impaired gi function or gi disease that may significantly alter the absorption of oral bylseven hundred and nineteen ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome or small bowel resection
__label__1	study interventions are Ado-trastuzumab emtansine . malabsorption syndrome resection of the small bowel or stomach and ulcerative colitis
__label__1	study interventions are Oxaliplatin . localized unresectable adult primary liver cancer diagnosis and pregnancy or breastfeeding
__label__1	study interventions are Melphalan . adult nasal type extranodal nk cell lymphoma diagnosis and twelve pediatric
__label__1	study interventions are Cyclophosphamide . invasive adenocarcinoma of the breast diagnosis and conduction abnormality requiring pacemaker
__label__1	study interventions are Olaparib . ovarian serous cystadenocarcinoma diagnosis and condition requiring concurrent use of drugs or biologics with pro arrhythmic potential
__label__1	study interventions are Busulfan . squamous cell lung cancer diagnosis and major surgical procedure within four weeks prior to randomization or expected need for major surgical procedure during the course of the study other than for diagnosis
__label__1	study interventions are Vidarabine . recurrent adult immunoblastic large cell lymphoma diagnosis and diffusion capacity of the lung for carbon monoxide dlco less_than thirty-five total lung capacity tlc less_than thirty-five forced expiratory volume of the lung in one second fevone less_than thirty-five and or receiving supplementary continuous oxygen the fhcrc study principal investigator pi must approve enrollment of all patients with pulmonary nodules
__label__1	study interventions are Mycophenolate mofetil . stage iii childhood large cell lymphoma diagnosis and liver function abnormalities
__label__1	study interventions are Prexasertib . carcinoma non small cell lung diagnosis and must not have family history of long qtc syndrome or be taking drugs known to cause qtc prolongation or torsades de pointes
__label__1	study interventions are Lenalidomide . urethral neoplasms diagnosis and due to the possibility of infection reactivation patients who are known seropositive for or who have active viral infection with human immunodeficiency virus hiv are not eligible
__label__1	study interventions are Goserelin . breast neoplasms diagnosis and total bilirubin less_than uln
__label__1	study interventions are Vidarabine . splenic marginal zone lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Cyclophosphamide . recurrent mantle cell lymphoma diagnosis and pregnancy
__label__1	study interventions are Cisplatin . stage iii nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and patients who are receiving adjuvant chemoradiation after surgical resection of the primary site of disease
__label__1	study interventions are Hormones . prostate cancer diagnosis and prior therapy with strontium ninety samarium one hundred and fifty or other injectable therapeutic radioisotopes
__label__1	study interventions are Near infra red sentinel node biopsy . previous surgery or scar in the lymph node basin or primary tumor except primary tumor biopsy
__label__1	study interventions are Podophyllotoxin . adult diffuse large cell lymphoma diagnosis and prior history of human immunodeficiency virus hiv positivity or known history of hepatitis or c
__label__1	study interventions are Antibodies, Monoclonal . head and neck neoplasm diagnosis and seasonal influenza vaccines for injection are generally_inactivated vaccines and are allowed however intranasal influenza vaccines flu_mist are live attenuated vaccines and are not allowed
__label__1	study interventions are Carboplatin . stage iii ovarian cancer diagnosis and previous treatment with an mtor inhibitor sirolimus temsirolimus everolimus paclitaxel or carboplatin
__label__1	study interventions are Melphalan . recurrent marginal zone lymphoma diagnosis and no serious medical or psychiatric illness
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and prior history of uncontrollable side effects to dexamethasone therapy
__label__1	study interventions are Conventional T cells (Tcon) and Regulatory T cells (Treg) . lymphoma non hodgkin diagnosis and lactating female
__label__1	study interventions are Immunoglobulin G . stage iib ovarian cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Albumin-Bound Paclitaxel . bladder cancer diagnosis and bowel obstruction or impending bowel obstruction
__label__1	study interventions are Deoxyglucose . lung cancer diagnosis and subjects who live alone
__label__1	study interventions are TAK-901 . advanced solid tumors diagnosis and treatment with any investigational products within twenty-eight days before the first dose of study drug
__label__1	study interventions are Sorafenib . stage iv squamous cell carcinoma of the nasopharynx diagnosis and history of organ allograft including corneal transplant
__label__1	study interventions are Carboxymethylcellulose Sodium . myeloma diagnosis and known history of chronic active hepatitis or liver cirrhosis if suspected by laboratory studies should be confirmed by liver biopsy
__label__1	study interventions are Camptothecin . stage iva pancreatic cancer diagnosis and john wort will be excluded cypthreeafour inducing drugs should be discontinued at least two weeks prior to the first cycle of irinotecan
__label__1	study interventions are Interferon-alpha . the time requirement also does not apply to patients who underwent successful definitive resection of basal or squamous cell carcinoma of the skin superficial bladder cancer in situ cancers including cervical cancer breast cancer melanoma or other in situ cancers
__label__1	study interventions are Albumin-Bound Paclitaxel . breast neoplasms diagnosis and this includes
__label__1	study interventions are Sorafenib . kidney cancer diagnosis and you can then decide if you wish to participate
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and non active diverticulitis and crohn disease not affecting the rectum are allowed
__label__1	study interventions are Bevacizumab . pancreatic cancer diagnosis and urine dipstick for proteinuria greater_than two positive patients discovered to have greater_than two positive proteinuria on dipstick urinalysis at baseline should undergo two4 hour urine collection and must demonstrate less_than oneg of protein in two4 hours to be eligible
__label__1	study interventions are Sirolimus . adult mixed glioma diagnosis and patients with prior therapy that included stereotactic radiosurgery including gamma_knife or cyber knife during therapy for newly diagnosed or recurrent disease or re irradiation of any type must have confirmation of true progressive disease rather than radiation necrosis based upon surgical documentation of recurrent progressive disease imaging with magnetic resonance mr spectroscopy pet or other techniques is not adequate to exclude radiation necrosis for this study such prior therapy is allowed for the phase component and does not require surgical documentation of disease
__label__1	study interventions are Docetaxel . breast neoplasms diagnosis and had concurrent treatment with ovarian hormonal replacement therapy
__label__1	study interventions are Sorafenib . uveal melanoma diagnosis and patient simultaneously participating in another clinical trial
__label__1	study interventions are Doxorubicin . endometrial clear cell carcinoma diagnosis and known uncontrolled hypersensitivity to the investigational drugs or their excipients
__label__1	study interventions are Diphosphonates . osteosarcoma diagnosis and unstable cardiac disease pulse_oximetry saturation less_than ninety at rest
__label__1	study interventions are Paclitaxel . tumors harboring amplifications in the cmyc gene diagnosis and patients who have hiv hepatitis b or or cmv reactivation
__label__1	study interventions are Mycophenolic Acid . stage iv cutaneous cell non hodgkin lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than thirty total lung capacity tlc less_than thirty forced expiratory volume in one second fevone less_than thirty and or receiving supplementary continuous oxygen the fhcrc principal investigator pi of the study must approve enrollment of all patients with pulmonary nodules
__label__1	study interventions are Laboratory Biomarker Analysis . endometrial clear cell adenocarcinoma diagnosis and the subject has prothrombin time pt international normalized ratio inr or partial thromboplastin time ptt test greater_than equal_than doc the laboratory uln equal_than less_than seven days before the first dose of study treatment
__label__1	study interventions are Irinotecan . non small cell lung cancer diagnosis and positive pregnancy test
__label__1	study interventions are Cyclosporins . stage iv adult lymphoblastic lymphoma diagnosis and age greater_than seventy-five years
__label__1	study interventions are Sirolimus . pancreatic beta cell adenoma diagnosis and patient is on angiotensin_converting enzyme ace inhibitors benazapril_captopril enalopril_fosonopril lisinopril_moexipril perindopril_quinopril ramipril and trandolapril patients may have an alternate antihypertensive substituted note
__label__1	study interventions are Fludarabine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and donor age less_than twelve years
__label__1	study interventions are Thalidomide . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Antibodies . recurrent adult hodgkin lymphoma diagnosis and patients who have known human immunodeficiency virus hiv viral hepatitis or an uncontrolled infection are not eligible
__label__1	study interventions are Fludarabine . criteria for exclusion are human immunodeficiency virus hiv or human lymphotropic virus htlv seropositivity pregnancy cardiac ejection fraction by echo cardiogram less than forty active central nervous system involvement serum creatinine greater than doc mg dl or serum bilirubin greater than doc mg dl unless due to tumor absolute neutrophil count anc less than one zero mmthree and platelets less than one00 zero mmthree unless due to tumor performance status ecog scale greater than two pulmonary function tes negative diffusing capacity of the lung for carbon monoxide dlco less than forty of predicted and severe concomitant medical or psychiatric illnesses
__label__1	study interventions are Natural Killer (NK) Cells . soft tissue sarcoma diagnosis and chronic active untreated hepatitis or infection
__label__1	study interventions are Heparin . brain tumor diagnosis and anticoagulant medication
__label__1	study interventions are Immunoglobulins . fallopian tube clear cell adenocarcinoma diagnosis and baseline ejection fraction equal_than less_than fifty as assessed by echocardiogram or multi gated acquisition muga
__label__1	study interventions are Topotecan . tumors diagnosis and patient has received another investigational agent within four weeks prior to study enrollment
__label__1	study interventions are Melphalan . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than forty predicted corrected for hemoglobin and or alveolar ventilation
__label__1	study interventions are Deferasirox . peripheral cell lymphoma diagnosis and hiv positive patients
__label__1	study interventions are Dexamethasone . incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide
__label__1	study interventions are Rituximab . diffuse large cell lymphoma diagnosis and absolute neutrophil count less_than doc ten nine without gcsf gmcsf support
__label__1	study interventions are Mycophenolate mofetil . recurrent adult diffuse mixed cell lymphoma diagnosis and severe defects in pulmonary function testing defects are currently categorized as mild moderate and severe as defined by the pulmonary consultant or receiving supplementary continuous oxygen
__label__1	study interventions are Cisplatin . stage iii squamous cell carcinoma of the oropharynx diagnosis and acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
__label__1	study interventions are Mitomycins . adults with unresectable liver dominant neuroendocrine tumor metastases that are are symptomatic progressive or involve twenty-five of the liver volume diagnosis and newly diagnosed and or requiring treatment
__label__1	study interventions are Antibodies, Monoclonal . stage iva verrucous carcinoma of the larynx diagnosis and ketoconazole itraconazole ritonavir cyclosporine carbamazepine phenytoin phenobarbital products containing grapefruit juice will not be allowed while on study
__label__1	study interventions are Dexamethasone 21-phosphate . recurrent grade one follicular lymphoma diagnosis and confirmation that the subject is not pregnant must be established by negative serum human chorionic gonadotropin hcg pregnancy test result obtained during screening
__label__1	study interventions are Fludarabine phosphate . noncontiguous stage ii grade three follicular lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are ATN-161 . carcinoma renal cell diagnosis and patients known to be human immunodeficiency virus hiv positive are excluded
__label__1	study interventions are Alkylating Agents . osteosarcoma diagnosis and hypersensitivity to any component of gnrha
__label__1	study interventions are Everolimus . kidney cancer diagnosis and uncontrolled hypertension
__label__1	study interventions are Taxane . breast neoplasms diagnosis and pregnancy breast feeding fertile women refusing to use reliable contraceptive methods
__label__1	study interventions are Leucovorin . stage ivb colon cancer diagnosis and history of arterial thromboembolic events
__label__1	study interventions are Irinotecan . metastatic colorectal cancer mcrc diagnosis and no prior history of blood clots requiring anti coagulation
__label__1	study interventions are Pancrelipase . previously treated metastatic adenocarcinoma of the pancreas diagnosis and use more than three day of acetaminophen
__label__1	study interventions are Capecitabine . breast neoplasm diagnosis and subject must not have rapidly progressing visceral involvement liver lymphangitic lung
__label__1	study interventions are Paclitaxel . mixed tumor mullerian diagnosis and patients with an active systemic infection
__label__1	study interventions are Vaccines . breast cancer diagnosis and any active autoimmune disease requiring treatment with the exception of vitiligo
__label__1	study interventions are Cisplatin . squamous cell carcinoma of the head and neck diagnosis and patients with in the best judgment of the investigator psychosocial family sociological or geographical limitations which could impact the patient ability to comply with study procedures
__label__1	study interventions are Vincristine . stage follicular lymphoma diagnosis and is currently participating and receiving study therapy or has participated in study of an investigational agent and received study drug or using an investigation device within four weeks of the first dose of treatment
__label__1	study interventions are Docetaxel . breast neoplasms diagnosis and pre existing motor or sensory neurologic toxicity of severity greater_than than or equal_than to grade two according to nci ctc ae criteria version doc
__label__1	study interventions are Vinorelbine . metastatic breast cancer diagnosis and abnormal coagulation contraindicating biopsy
__label__1	study interventions are Niacinamide . patients with known symptomatic brain metastases should be excluded from this clinical trial patients with stable or asymptomatic brain metastases are eligible but should not be taking enzyme inducing anticonvulsants and should be maintained on stable steroid doses
__label__1	study interventions are Cisplatin . carcinoma diagnosis and female patients of childbearing potential who wish to become pregnant or are unwilling as well as their partners to use an appropriate contraceptive method throughout the study period
__label__1	study interventions are Pembrolizumab . recurrent urothelial carcinoma of the renal pelvis and ureter diagnosis and is currently participating in or has participated in study of an investigational agent or using an investigational device within four weeks of the first dose of treatment
__label__1	study interventions are Cediranib . recurrent uterine corpus carcinoma diagnosis and myocardial infarction or unstable angina within six months of the first date of cediranib azd two thousand, one hundred and seventy-one therapy
__label__1	study interventions are Maleic acid . stage iiia skin melanoma diagnosis and patients taking medications with narrow therapeutic indices that are metabolized by cytochrome pfour hundred and fifty cypfour hundred and fifty including warfarin sodium coumadin are ineligible except low dose warfarin for prophylaxis for central catheters
__label__1	study interventions are Doxorubicin . breast neoplasm diagnosis and active malignancy diagnosed within the last five years
__label__1	study interventions are Azacitidine . estrogen receptor positive and hertwo negative breast cancer diagnosis and history of hypersensitivity to study drug formulations including azacitidine mannitol or durvalumab its constituents or to any other humanized monoclonal antibody
__label__1	study interventions are Capecitabine . gastro_entero pancreatic neuroendocrine tumors diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition
__label__1	study interventions are Oxaliplatin . non small cell lung cancer diagnosis and participants with extrathoracic only squamous cell nsclc were eligible
__label__1	study interventions are Cyclosporine . recurrent childhood large cell lymphoma diagnosis and donors who are positive for hiv
__label__1	study interventions are Sorafenib . unresectable hepatocellular carcinoma diagnosis and have received sorafenib or other systemic therapies for treatment of hcc in the past
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and exceptions if treated and not active include the following
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and angina pectoris within three months acute myocardial infarction within three months qtcf greater_than four hundred and fifty msec for males and greater_than four hundred and seventy msec for females on the screening ecg past medical history of clinically significant ecg abnormalities or family history of prolonged qt interval syndrome other clinically significant heart disease congestive heart failure uncontrolled hypertension history of labile hypertension or history of poor compliance with an antihypertensive regimen
__label__1	study interventions are Everolimus . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure of nyha class iii or iv active coronary artery disease unstable angina pectoris cardiac arrhythmia myocardia infraction less_than six months prior to start of everolimus uncontrolled hypertension systolic pressure greater_than one hundred and fifty mmhg or diastolic pressure greater_than ninety mmhg uncontrolled seizure disorder liver disease such as cirrhosis decompensated liver disease active and chronic hepatitis known severely impaired lung function spirometry and dlco fifty or less of normal and two saturation eighty-eight or less at rest on room air active bleeding diathesis or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Lenograstim . lymphoma diagnosis and patients should not have received more than six cycles of fludarabine therapy
__label__1	study interventions are Placebo . symptomatic metastatic brain or meningeal tumors
__label__1	study interventions are Immunoglobulins . stage iv fallopian tube cancer diagnosis and stage not greater than ib
__label__1	study interventions are Sargramostim . smoldering multiple myeloma smm diagnosis and received any investigational treatment in thirty days
__label__1	study interventions are Antibodies . recurrent adult hodgkin lymphoma diagnosis and failure to fully recover from acute reversible effects of prior chemotherapy regardless of interval since last treatment
__label__1	study interventions are Fludarabine . recurrent adult cell leukemia lymphoma diagnosis and active central nervous system cns involvement with disease
__label__1	study interventions are Asparaginase . mature cell and nk cell non hodgkin lymphoma diagnosis and patients must not be known to be refractory to red cell or platelet transfusion
__label__1	study interventions are Laboratory Biomarker Analysis . stage iiic primary peritoneal cancer diagnosis and history of pulmonary embolus and or substantial deep vein thrombosis
__label__1	study interventions are Fludarabine . peripheral cell lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than thirty-five and or receiving supplemental continuous oxygen
__label__1	study interventions are Fludarabine phosphate . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and uncontrolled central nervous system cns disease for hematologic malignancies
__label__1	study interventions are Cetuximab . prior cytotoxic therapy for cervical cancer
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and subjects with signs or symptoms or history of brain metastasis must have ct or mri scan of the brain within one month prior to the start of protocol therapy
__label__1	study interventions are Antibodies, Monoclonal . stage iva midline lethal granuloma of the paranasal sinus and nasal cavity diagnosis and patients with chronic active hepatitis or recent hepatitis infection hepatitis surface antigen hepb_sag or immunoglobulin igm antibody to hepatitis core antigen igm_antibc positive are ineligible because these patients are at increased risk of reactivation of the hepatitis virus which may be fatal due to the immunosuppressive properties of radone
__label__1	study interventions are HPPH . carcinoma of the oropharynx diagnosis and patients on concurrent chemotherapy or radiation therapy or less than four weeks after the last dose of chemotherapy or radiation therapy
__label__1	study interventions are Trebananib . recurrent uterine corpus sarcoma diagnosis and minor surgical procedures except placement of tunneled central venous access device within three days seven days if with vegf inhibitor prior to randomization enrollment
__label__1	study interventions are Immunoglobulin G . fallopian tube mucinous adenocarcinoma diagnosis and patients with acute hepatitis or active infection that requires parenteral antibiotics
__label__1	study interventions are brachytherapy . other pathological invasive tumor or dcis
__label__1	study interventions are Lenalidomide . adult cell leukemia lymphoma diagnosis and mycosis_fungoides
__label__1	study interventions are Fludarabine phosphate . noncutaneous extranodal lymphoma diagnosis and lansky play performance score less_than seventy for pediatric patients
__label__1	study interventions are quality-of-life assessment . recurrent squamous cell carcinoma of the nasopharynx diagnosis and other medical conditions that could make the patient not able to comply with the treatment
__label__1	study interventions are Immunoglobulins . ovarian mucinous adenocarcinoma diagnosis and acrin six thousand, six hundred and ninety-five ineligible patients
__label__1	study interventions are Trametinib . cancer diagnosis and subject who
__label__1	study interventions are Gabapentin . rectum neoplasm diagnosis and mental illness mental retardation or inability to participate in informed consent due to mental status
__label__1	study interventions are Oxaliplatin . stomach neoplasms diagnosis and distant metastasis such as six and three lymphnode liver lung brain bones or peritoneal metastasis
__label__1	study interventions are Levulinic acid . glioblastoma diagnosis and pregnant or lactating women
__label__1	study interventions are Fulvestrant . stage iiia breast cancer diagnosis and premenopausal status
__label__1	study interventions are Dexamethasone . clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias congestive heart failure or myocardial infarction within six months of screening or any class three moderate or class four severe cardiac disease as defined by the new york heart association functional classification
__label__1	study interventions are Carboplatin . stage iii ovarian epithelial cancer diagnosis and exposure to any investigational drug within three weeks prior to the start of dosing
__label__1	study interventions are Immunoglobulin G . stage iiia primary peritoneal cancer diagnosis and known hypersensitivity to other recombinant human antibodies or chinese_hamster ovary cell products
__label__1	study interventions are Antibodies . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and patient life expectancy is severely limited by diseases other than malignancy
__label__1	study interventions are Dextromethorphan . prostate neoplasms diagnosis and clinically significant heart disease as evidenced by myocardial infarction or arterial thrombotic events in the past six months severe or unstable angina or new york heart association class iii or iv heart disease or cardiac ejection fraction measurement of less_than fifty at baseline
__label__1	study interventions are Doxorubicin . breast cancer diagnosis and metastatic disease mone
__label__1	study interventions are Levoleucovorin . stage iiia gastric cancer diagnosis and prior significant ventricular arrhythmia requiring medication
__label__1	study interventions are Mitomycin . neoplasms squamous cell diagnosis and previous neuropathy two or higher
__label__1	study interventions are Capecitabine . rectal cancer diagnosis and myocardial infarction within the past year
__label__1	study interventions are Cortisone . hormone resistant prostate cancer diagnosis and patients may not have received any other investigational agents within the last fourteen days at the time of treatment start
__label__1	study interventions are Mycophenolate mofetil . recurrent adult diffuse large cell lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Bevacizumab . stage iv ovarian cancer diagnosis and protein concentration mg dl creatinine mg dl patients must have upcr less_than doc to allow participation in the study
__label__1	study interventions are Cediranib . stage iiic colon cancer diagnosis and blood pressure needs to be optimally controlled and less_than one hundred and fifty one hundred for period of at least two weeks prior to enrollment into the study
__label__1	study interventions are Sunitinib . nasopharyngeal carcinoma diagnosis and women of childbearing potential not employing adequate contraception
__label__1	study interventions are Hormones . prostate cancer diagnosis and the study center will determine if you meet all of the criteria
__label__1	study interventions are laboratory biomarker analysis . patients with central tumors within the proximal tree or touching the mediastinal pleura
__label__1	study interventions are Podophyllotoxin . classical hodgkin lymphoma diagnosis and lactating females who plan to breastfeed
__label__1	study interventions are Paclitaxel . non small cell lung cancer diagnosis and women who are pregnant or breastfeeding
__label__1	study interventions are Immunoglobulins . stage iiia primary peritoneal cancer diagnosis and serious or non healing wound ulcer or bone fracture
__label__1	study interventions are Nivolumab . subjects with brain metastases are eligible if these have been treated or if they are asymptomatic and there is no clinical evidence of progression within twenty-eight days prior to first dose of study drug administration
__label__1	study interventions are Vidarabine . lymphoma diagnosis and patients who have received cranial radiation therapy must still be eligible to receive total lymphoid irradiation to seven gy
__label__1	study interventions are Docetaxel . stage ib breast cancer diagnosis and documented cardiomyopathy
__label__1	study interventions are Paclitaxel . breast neoplasms diagnosis and patients with any medical or psychological disorder which in the investigator opinion might compromise the ability of the patient to give their informed consent
__label__1	study interventions are Subjects are mailed informational/educational materials . colon cancer diagnosis and living in nursing home
__label__1	study interventions are Paclitaxel . stage iib cervical cancer diagnosis and any previous pelvic radiotherapy
__label__1	study interventions are Pembrolizumab . recurrent thyroid gland carcinoma diagnosis and unwilling or unable to use two methods of birth control or be surgically sterile or abstain from heterosexual activity for the course of the study through 1two0 days after the last dose of study medication note
__label__1	study interventions are Saporin . histologically confirmed advanced cancer diagnosis and male patients must agree to use effective contraception or be surgically sterile
__label__1	study interventions are Bevacizumab . rectal cancer diagnosis and patients who have diagnosis of gilbert disease
__label__1	study interventions are Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging . stage renal cell cancer diagnosis and women who are pregnant or breastfeeding
__label__1	study interventions are Rituximab . lymphoma diagnosis and arm only
__label__1	study interventions are Sirolimus . metastatic renal cancer diagnosis and patients with any medical or psychiatric condition or disease
__label__1	study interventions are Paclitaxel . fallopian tube transitional cell carcinoma diagnosis and patients with clinically significant proteinuria urine protein should be screened by urine protein creatinine ratio upcr the upcr has been found to correlate_directly with the amount of protein excreted in twenty-four hour urine collection specifically upcr of doc is equivalent to doc gram of protein in twenty-four hour urine collection obtain at least four ml of random urine sample in sterile container does not have to be twenty-four hour urine send sample to lab with request for urine protein and creatinine levels separate requests the lab will measure protein concentration mg dl and creatinine concentration mg dl the upcr is derived as follows
__label__1	study interventions are Tremelimumab . liver cancer diagnosis and doc
__label__1	study interventions are quality-of-life assessment . recurrent small cell lung cancer diagnosis and central nervous system cns metastases that results in impaired ability to participate in an exercise program at the discretion of the study physician
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and wbc less_than three zero 1zero nine platelets greater_than 1zerozero 1zero nine l
__label__1	study interventions are Nivolumab . stage iiib breast cancer diagnosis and patients with previously treated brain metastases must have stable neurologic status and magnetic resonance imaging mri imaging following local therapy surgery or radiation for at least four weeks with no requirement for immunosuppressive doses of systemic corticosteroids greater_than ten mg day prednisone equivalents for at least two weeks prior to study drug administration stable low dose dexamethasone allowed at discretion of protocol chair
__label__1	study interventions are Placebo . basal cell carcinomas diagnosis and subjects who have gorlins syndrome
__label__1	study interventions are Immunoglobulins . patients with unrelated prior malignancies must have undergone potentially curative therapy for their prior malignancy have no evidence of that disease for three years or be deemed at low risk for recurrence of their prior malignancy by her his treating physician patients with dermal squamous cell carcinoma basal cell carcinoma or melanoma in situ that has been completely excised will be eligible following excision
__label__1	study interventions are Functional Imaging previous the second course . ovarian cancer diagnosis and other uncontrolled medical conditions as thyroid pathology neuropsychiatric disease infection coronary insufficiency or grade three
__label__1	study interventions are Levoleucovorin . rectal cancer stage iii diagnosis and psychological familial sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule these conditions should be discussed with the patient before registration in the trial
__label__1	study interventions are Antineoplastic Agents, Phytogenic . ovarian cancer diagnosis and any serious and or unstable pre existing medical psychiatric or other condition that could interfere with subject safety provision of informed consent or compliance to study procedures
__label__1	study interventions are Dexamethasone . relapse refractory multiple myeloma diagnosis and subject has history of thromboembolic event within the past four weeks prior to enrollment
__label__1	study interventions are Bendamustine Hydrochloride . gray zone lymphoma diagnosis and untreated or progressive central nervous system leukemia
__label__1	study interventions are Vidarabine . stage ii childhood small noncleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Immunoglobulins . stage ivc nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and patients with clinically significant pneumonitis pulmonary infiltrates unless there is known and treatable cause for the condition
__label__1	study interventions are Sunitinib . glioblastoma multiforme diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to sunitinib
__label__1	study interventions are Vaccines . prostate cancer diagnosis and l
__label__1	study interventions are Cetuximab . colorectal cancer diagnosis and patient with known allergy or hypersensitivity to monoclonal antibodies bevacizumab cetuximab
__label__1	study interventions are different volume aspiration . pancreatic cancer diagnosis and pregnancy
__label__1	study interventions are Dexamethasone 21-phosphate . received anti cancer medications or investigational therapy in the past twenty-eight days
__label__1	study interventions are Vorinostat . glioblastoma multiforme diagnosis and however vorinostat may potentially suppress cyp threeafour activity
__label__1	study interventions are Albumin-Bound Paclitaxel . endometrial squamous cell carcinoma diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Fludarabine phosphate . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and eligible for high priority curative autologous transplant
__label__1	study interventions are Vidarabine . noncontiguous stage ii grade three follicular lymphoma diagnosis and patients with chronic myelomonocytic leukemia cmml
__label__1	study interventions are Dabrafenib . cancer diagnosis and presence of active gastrointestinal disease or other condition small bowel or large bowel resection that will interfere significantly with the absorption of drugs
__label__1	study interventions are Bevacizumab . undifferentiated ovarian carcinoma diagnosis and patients positive for hepatitis virus hcv antibody are eligible only if polymerase chain reaction pcr is negative for hcv ribonucleic acid rna
__label__1	study interventions are Nivolumab . metastatic urothelial carcinoma of the renal pelvis and ureter diagnosis and the subject has not recovered to baseline or common terminology criteria for adverse events ctcae equal_than less_than grade one from toxicity due to all prior therapies except alopecia and other non clinically significant adverse events aes defined as lab elevation with no associated symptoms or sequelae
__label__1	study interventions are Immunoglobulins . stage adult burkitt lymphoma diagnosis and transfusion requirement red blood cells or platelets within fourteen days prior to baseline
__label__1	study interventions are Doxorubicin . prior systemic anticancer therapy for breast cancer immunotherapy hormonotherapy chemotherapy
__label__1	study interventions are Camptothecin . colorectal neoplasms diagnosis and patients cannot have concurrent malignancies at study entry
__label__1	study interventions are Gemcitabine . hodgkin lymphoma diagnosis and congestive heart failure class iii iv
__label__1	study interventions are Nintedanib . current symptomatic brain metastases or if previously present must have been treated at least two months before randomization
__label__1	study interventions are Cyclophosphamide . breast cancer stage iii diagnosis and active autoimmune disease requiring systemic treatment within the past two years ie with use of disease modifying agents corticosteroids or immunosuppressive drugs or documented history of clinically severe autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents note
__label__1	study interventions are Sevoflurane . breast cancer diagnosis and pregnant women
__label__1	study interventions are Antibodies . contiguous stage ii adult immunoblastic large cell lymphoma diagnosis and use of hematopoietic growth factor including filgrastim pegfilgrastim sargramostim erythropoietin or darbepoetin within fourteen days prior to baseline
__label__1	study interventions are Melanocyte-Stimulating Hormones . breast cancer diagnosis and endocrine disorders that can cause fatigue
__label__1	study interventions are Cadexomer iodine . poorly differentiated thyroid gland carcinoma diagnosis and unable to follow low iodine diet or requiring medication with high content in iodide amiodarone
__label__1	study interventions are Vidarabine . stage ii childhood large cell lymphoma diagnosis and eligible for high priority curative autologous transplant
__label__1	study interventions are Metformin . renal cell carcinoma diagnosis and sixteen history of qt prolongation associated with other medications that required discontinuation of that medication
__label__1	study interventions are Sunitinib . urinary tract urothelial carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to bcg and sunitinib
__label__1	study interventions are Capecitabine . cancer of the pancreas diagnosis and presence of clinically significant valvular heart disease
__label__1	study interventions are Aldesleukin . metastatic cancer that express the mage_athree dpfour antigen diagnosis and concurrent opportunistic infections the experimental treatment being evaluated in this protocol depends on an intact immune system
__label__1	study interventions are Vinca Alkaloids . advanced cancer diagnosis and prior whole abdominal or whole pelvis radiation therapy or radiation therapy to greater_than ten of the bone marrow at any time in the past or prior radiation therapy within the last three years to the breast sternum head or neck
__label__1	study interventions are Veliparib . recurrent marginal zone lymphoma diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are eligible if their hiv is under adequate control with an antiretroviral regimen that has been stable for greater_than equal_than four weeks as long as the cdfour count is greater_than three hundred appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated patients on zidovudine or stavudine would not be eligible
__label__1	study interventions are Mycophenolic Acid . stage iv grade three follicular lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Ibrutinib . refractory follicular lymphoma diagnosis and planned use of post hematopoietic cell transplant cyclophosphamide for graft versus host disease prophylaxis
__label__1	study interventions are Albumin-Bound Paclitaxel . metastatic breast cancer diagnosis and any patient who is pregnant or lactating
__label__1	study interventions are Gemcitabine . peripheral cell lymphoma diagnosis and cell
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and known positive serology for the human immunodeficiency virus hiv hepatitis and or active hepatitis c
__label__1	study interventions are Fludarabine phosphate . childhood renal cell carcinoma diagnosis and any vertebral instability
__label__1	study interventions are chemoprevention . stage zero oropharyngeal cancer diagnosis and inability to take oral nutrition liquids or history of aspiration pneumonia
__label__1	study interventions are Gemcitabine . ovarian transitional cell carcinoma diagnosis and human immunodeficiency virus hiv positive test result or history of other immunodeficiency
__label__1	study interventions are Palbociclib . hormone receptor positive tumor diagnosis and prior adjuvant therapy with letrozole if last intake less_than twelve months prior to entering the study
__label__1	study interventions are First line systemic treatment . intercurrent malignant diseases except basal cell carcinoma in skin inactive carcinoma in situ of the cervix when completely resected
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and have received sorafenib or other systemic therapies for treatment of hcc in the past
__label__1	study interventions are Nitrogen Mustard Compounds . t cell non hodgkin lymphoma diagnosis and patient who has had chemotherapy radiotherapy or biological therapy within thirty days forty-two days for nitrosoureas or mitomycin or who has not recovered from adverse events due to agents administered more than thirty days earlier
__label__1	study interventions are Imatinib Mesylate . fibromatosis diagnosis and evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
__label__1	study interventions are Paclitaxel . metastatic breast cancer triple negative breast cancer diagnosis and active hepatitis or hepatitis c
__label__1	study interventions are Doxorubicin . hepatoma diagnosis and cardiac exclusion for
__label__1	study interventions are Vidarabine . nodal marginal zone cell lymphoma diagnosis and donor
__label__1	study interventions are Lenalidomide . stage adult diffuse small cleaved cell lymphoma diagnosis and chronic or current infectious disease requiring systemic antibiotics antifungal or antiviral treatment such as but not limited to chronic renal infection chronic chest infection with bronchiectasis tuberculosis and active hepatitis c
__label__1	study interventions are Paclitaxel . ovarian cancer diagnosis and patients with any evidence of severe or uncontrolled systemic disease severe hepatic impairment interstitial lung disease bilateral diffuse parenchymal lung disease uncontrolled chronic renal disease glomerulonephritis nephritic syndrome fanconi syndrome or renal tubular acidosis or current unstable or uncompensated respiratory or cardiac conditions or uncontrolled hypertension blood pressure greater_than equal_than one hundred and forty ninety active bleeding diatheses or active infection
__label__1	study interventions are Heparin, Low-Molecular-Weight . bone cancer diagnosis and severe liver or renal insufficiency
__label__1	study interventions are X-Linked Inhibitor of Apoptosis Protein . should woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately
__label__1	study interventions are Dacarbazine . adult gliosarcoma diagnosis and pregnancy or women of childbearing potential and men who are sexually active and not willing able to use medically acceptable forms of contraception
__label__1	study interventions are Paclitaxel . triple negative breast carcinoma diagnosis and history of cardiac disease
__label__1	study interventions are Prednisolone hemisuccinate . diffuse large cell lymphoma diagnosis and baseline hearing impairment which in the opinion of the investigator may significantly worsen with treatment with cisplatin
__label__1	study interventions are Sunitinib . symptomatic coronary artery disease myocardial infarction within the past six months congestive cardiac failure nyha class iii iv disease or uncontrolled or symptomatic cardiac arrhythmia
__label__1	study interventions are Albumin-Bound Paclitaxel . patients with neuroendocrine carcinoma
__label__1	study interventions are Temozolomide . neuroblastoma diagnosis and therefore negative pregnancy test is required for all women of child bearing age and appropriate contraception is used during the study period
__label__1	study interventions are Pembrolizumab . recurrent endometrial cancer diagnosis and has known history of active tb_bacillus tuberculosis
__label__1	study interventions are colposcopic biopsy . cervical cancer diagnosis and pregnant individuals will be excluded
__label__1	study interventions are Vitamin B Complex . lung cancer diagnosis and pregnant positive pregnancy test or lactating women
__label__1	study interventions are Prednisolone . renal cell carcinoma diagnosis and subjects treated with systemic corticosteroid cst within one week before randomization and subjects treated with infliximab within seven weeks before randomization
__label__1	study interventions are CART-EGFR . advanced egfr positive solid tumors diagnosis and patients who are participating or participated any other clinical trials in latest thirty days will be excluded
__label__1	study interventions are Leucovorin . stage iic rectal cancer diagnosis and extension of malignant disease into the anal canal
__label__1	study interventions are biopsy . sarcoma diagnosis and alpha one antitrypsin deficiency
__label__1	study interventions are Vorinostat . extranodal marginal zone lymphoma of mucosa associated lymphoid tissue diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma thymic diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to lapatinib
__label__1	study interventions are Asparaginase . recurrent adult lymphoblastic lymphoma diagnosis and extramedullary disease status
__label__1	study interventions are Bendamustine Hydrochloride . extensive stage lung cancer diagnosis and psychiatric disorder that prevents patients from providing informed consent or following protocol instructions
__label__1	study interventions are Cisplatin . lymphoma non hodgkin diagnosis and patients with history of other malignancies except
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and pregnant or lactating
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and heart rate less_than fifty minute on pre entry electrocardiogram
__label__1	study interventions are Mycophenolic Acid . cutaneous cell non hodgkin lymphoma diagnosis and total bilirubin greater_than twox the upper limit of normal
__label__1	study interventions are galeterone . prostate cancer diagnosis and severe systemic diseases or active uncontrolled illnesses
__label__1	study interventions are Folic Acid . recurrent colorectal cancer diagnosis and patients undergoing treatment with curative intent
__label__1	study interventions are Vatalanib . unspecified adult solid tumor protocol specific diagnosis and any of the following prior therapies
__label__1	study interventions are Erlotinib Hydrochloride . stage ivb verrucous carcinoma of the oral cavity diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and patient has any condition for which in the opinion of the investigator participation would not be in the best interest of the patient compromise the well being or that could prevent limit or confound the protocol specified assessments
__label__1	study interventions are Rituximab . nodal marginal zone cell lymphoma diagnosis and rifabutin mycobutin
__label__1	study interventions are Veliparib . stage iic ovarian cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ia breast cancer diagnosis and patients who are pregnant or breastfeeding are not eligible women of child bearing potential must agree to practice adequate contraception
__label__1	study interventions are Bortezomib . fallopian tube serous adenocarcinoma diagnosis and patients with insulin dependent diabetes will be excluded
__label__1	study interventions are Carboplatin . breast carcinoma diagnosis and patients with both hepatic and renal dysfunction will also be excluded
__label__1	study interventions are Simvastatin . stage ii breast cancer diagnosis and http
__label__1	study interventions are Fludarabine phosphate . fallopian tube carcinoma diagnosis and have ever had serotonin syndrome after receiving one or more serotonergic drugs
__label__1	study interventions are Paclitaxel . stage iiic fallopian tube cancer diagnosis and patients with known allergy to cremophor or polysorbate eighty
__label__1	study interventions are Nivolumab . stage iv breast cancer diagnosis and patients who have an uncontrolled intercurrent illness including but not limited to any of the following are not eligible
__label__1	study interventions are Erlotinib Hydrochloride . recurrent non small cell lung carcinoma diagnosis and to the thoracic cavity abdomen or pelvis within two weeks before the first dose of study treatment or has ongoing complications or is without complete recovery and healing from prior radiation therapy
__label__1	study interventions are Rituximab . non hodgkin lymphoma diagnosis and prior use of any investigational monoclonal antibody within six months of study start
__label__1	study interventions are Doxorubicin . breast cancer diagnosis and you cannot participate in this study if any of the following apply to you
__label__1	study interventions are Axitinib . active seizure disorder spinal cord compression or carcinomatous_meningitis
__label__1	study interventions are Salvia hispanica Seed . diffuse large cell lymphoma diagnosis and patients with any form of feeding tube or swallowing disorder are not eligible
__label__1	study interventions are Liposomal doxorubicin . prior history of hypersensitivity reaction to pld doxorubicin bortezomib carfilzomib or liposomal drug formulations other than pld history of reactions to liposomal drug formulations other than pld should be evaluated individually and if their reactions were felt to have been due to the encapsulated agent rather than the liposomal component itself they should be excluded at the discretion of the investigators
__label__1	study interventions are Tacrolimus . nodal marginal zone cell lymphoma diagnosis and patient or donor with history of hepatitis or and or positive serology consistent with previous hepatitis or infection patients and or donor who received hepatitis vaccination are acceptable
__label__1	study interventions are Bortezomib . recurrent marginal zone lymphoma diagnosis and mitomycin nitrosoureas less_than six weeks
__label__1	study interventions are Aminopterin . relapsed peripheral cell lymphoma diagnosis and prophylactic cns treatment are eligible
__label__1	study interventions are Vaccines . melanoma diagnosis and exceptions
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and unable or unwilling to undergo antithrombotic prophylactic treatment
__label__1	study interventions are Oxaliplatin . adenocarcinoma of the gastroesophageal junction diagnosis and patients with history of the following within twelve months of study entry are not eligible
__label__1	study interventions are Goserelin . metastatic cancer diagnosis and prior radioisotope treatment consisting of strontium eighty-nine or samarium one hundred and fifty-three
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iib breast cancer diagnosis and bilateral malignancy or mass in the opposite breast suspicious for malignancy unless there is biopsy proof that the mass is not malignant
__label__1	study interventions are Capecitabine . advanced gastrointestinal cancer diagnosis and persistent proteinuria of ctcae grade three greater_than doc twenty-four hours
__label__1	study interventions are Regorafenib . adenoid cystic carcinoma diagnosis and subjects with thrombotic embolic venous or arterial events such as cerebrovascular accident including transient ischemic attacks deep vein thrombosis or pulmonary embolism within six months of start of study treatment
__label__1	study interventions are Isophosphamide mustard . stage iii soft tissue sarcoma diagnosis and patients with known central nervous system cns metastases are not eligible note
__label__1	study interventions are HuMax-CD4 . cutaneous cell lymphoma diagnosis and pregnant or breast feeding women
__label__1	study interventions are Mechlorethamine . refractory hodgkin lymphoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Lenalidomide . must not have active bleeding or pathological conditions that carry high risk of bleeding tumor involving major vessels known varices
__label__1	study interventions are Antibodies, Monoclonal . fallopian tube mucinous adenocarcinoma diagnosis and patients with clinically significant cardiovascular disease this includes
__label__1	study interventions are Dexamethasone . sarcoma diagnosis and patients receiving any medication for pre existing nausea vomiting will be excluded
__label__1	study interventions are Fludarabine . stage iii grade three follicular lymphoma diagnosis and karnofsky adult or lansky for equal_than less_than sixteen years performance status equal_than less_than fifty
__label__1	study interventions are Niacinamide . liver cancer diagnosis and exceptions
__label__1	study interventions are Carboplatin . recurrent adult immunoblastic large cell lymphoma diagnosis and adequate bone marrow or blood stem cell dose obtained
__label__1	study interventions are Everolimus . recurrent adult diffuse mixed cell lymphoma diagnosis and karnofsky score less_than sixty or lansky score less_than fifty
__label__1	study interventions are Antibodies, Monoclonal . stage adult diffuse large cell lymphoma diagnosis and participants should not have taken valproic acid or another histone_deacetylase inhibitor for at least two weeks prior to study enrollment
__label__1	study interventions are Ascorbic Acid . glioblastoma multiforme diagnosis and pregnant women are excluded from this study because ionizing radiation is known teratogen and temozolomide is class agent with the potential for teratogenic or abortifacient effects
__label__1	study interventions are Liposomal doxorubicin . subjects with history of myocardial infarction between six and twelve months prior to conedone who are asymptomatic and have had negative cardiac risk assessment treadmill stress test nuclear medicine stress test or stress echocardiogram since the event may participate
__label__1	study interventions are Sunitinib . recurrent renal cell cancer diagnosis and patients with clinically significant cardiovascular disease are excluded
__label__1	study interventions are Lenvatinib . kiffiveb_ret positive adenocarcinoma of the lung diagnosis and subjects with urine protein greater than or equal to one twenty-four hour will be ineligible
__label__1	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and flecainide methadone amphetamines quinidine and chlorpropamide
__label__1	study interventions are Liposomal doxorubicin . stage iiia breast cancer diagnosis and conduction abnormality requiring pacemaker
__label__1	study interventions are Gefitinib . peritoneal neoplasms diagnosis and patients with overt psychosis or mental disability or otherwise incompetent to give informed consent
__label__1	study interventions are Venlafaxine Hydrochloride . diagnosis of metastatic breast cancer stage iv
__label__1	study interventions are Bevacizumab . pancreatic alpha cell adenoma diagnosis and radiation therapy to greater_than twenty-five of marrow bearing areas
__label__1	study interventions are Liposomal doxorubicin . stage iib breast cancer diagnosis and angina pectoris that requires the current use of anti anginal medication
__label__1	study interventions are Testosterone . breast cancer diagnosis and prolonged systemic corticosteroid treatment except for topical applications for rash inhaled sprays for obstructive airway diseases eye drops or local insertion intra articular
__label__1	study interventions are Endothelial Growth Factors . advanced solid tumors diagnosis and history of allergic reactions to monoclonal antibodies or other therapeutic proteins
__label__1	study interventions are Cetuximab . head and neck squamous cell carcinoma diagnosis and any prior treatment with radiotherapy or chemotherapy is an exclusion criterion
__label__1	study interventions are Preoperative hyperbaric oxygen . duodenal neoplasms diagnosis and cisplatin therapy some evidence that this drug retards wound healing when combined with hbot
__label__1	study interventions are Thalidomide . recurrent childhood visual pathway glioma diagnosis and one mg dl
__label__1	study interventions are Oxaliplatin . pancreatic cancer diagnosis and ctc grade three hyperlipidaemia greater_than one doc four mmol in spite of treatment
__label__1	study interventions are Epothilones . endometrial clear cell adenocarcinoma diagnosis and new york heart association nyha class ii or greater congestive heart failure
__label__1	study interventions are Fludarabine phosphate . recurrent childhood large cell lymphoma diagnosis and uncontrolled infection the protocol principal investigator pi will be final arbiter if there is uncertainty regarding whether previous infection is under adequate control to allow enrollment in the study
__label__1	study interventions are Cyclosporine . stage iv marginal zone lymphoma diagnosis and pregnant women are excluded from this study because vorinostat is histone_deacetylase inhibitor agent with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat breastfeeding should be discontinued if the mother is treated with vorinostat
__label__1	study interventions are Docetaxel . non small cell lung cancer diagnosis and history of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility
__label__1	study interventions are Bevacizumab . adult glioblastoma diagnosis and hepatic insufficiency resulting in clinical jaundice and or coagulation defects
__label__1	study interventions are Fludarabine . recurrent grade one follicular lymphoma diagnosis and adult
__label__1	study interventions are Vincristine . recurrent adult lymphoblastic lymphoma diagnosis and patients with known optic nerve and or retinal involvement are not eligible patients presenting with visual disturbances should have an ophthalmological exam and if indicated an magnetic resonance imaging mri to determine optic nerve or retinal involvement
__label__1	study interventions are Paclitaxel . invasive breast cancer diagnosis and definitive clinical or radiologic evidence of metastatic disease
__label__1	study interventions are Oxaliplatin . stage iva rectal cancer diagnosis and serious underlying medical or psychiatric illnesses that would in the opinion of the treating physician substantially increase the risk for complications related to treatment
__label__1	study interventions are Cyclosporine . nodal marginal zone cell lymphoma diagnosis and bulky disease resulting in severely limited performance status less_than seventy
__label__1	study interventions are Entinostat . neoplasms glandular and epithelial diagnosis and if the patient has brain metastasis they must have stable neurologic status without the use of steroids or on stable or decreasing dose of steroids
__label__1	study interventions are Everolimus . advanced malignant neoplasm diagnosis and immunosuppressive agents within three weeks before treatment with nab rapamycin except corticosteroids used as antiemetics
__label__1	study interventions are Rituximab . recurrent grade three follicular lymphoma diagnosis and prior autologous or allogeneic hsct
__label__1	study interventions are pharmacological study . stage iv squamous cell carcinoma of the oropharynx diagnosis and itraconazole ketoconazole fluconazole doses greater_than two hundred mg day voriconazole
__label__1	study interventions are Antibodies, Monoclonal . stage ivb colorectal cancer diagnosis and the use of inhaled corticosteroids and mineralocorticoids_fludrocortisone for patients with orthostatic_hypotension or adrenocortical insufficiency is allowed
__label__1	study interventions are Paclitaxel . undifferentiated ovarian carcinoma diagnosis and history of grade three or four bowel toxicity from immune checkpoint inhibitor within twelve weeks of registration
__label__1	study interventions are Fludarabine . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Immunoglobulins . patients who do not have resolution of the predisposing risk factor resection of bleeding tumor treatment and endoscopic documentation of resolved ulcer will also be excluded
__label__1	study interventions are Cisplatin . gastric cancer diagnosis and clinically significant upper gastro intestinal bleeding less_than thirty days prior to enrollment or randomization
__label__1	study interventions are Cortisone acetate . stage iv prostate adenocarcinoma diagnosis and patients with history of gastrointestinal disorders medical disorders or extensive surgery that may interfere with the absorption of the study agents
__label__1	study interventions are Folic Acid . unilateral breast carcinoma diagnosis and immunocompromised patients and patients known to be human immunodeficiency virus hiv positive and currently receiving antiretroviral therapy
__label__1	study interventions are Antibodies . localized unresectable adult primary liver cancer diagnosis and no ongoing psychiatric or social situation that would preclude study compliance
__label__1	study interventions are Panobinostat . hodgkin lymphoma diagnosis and screening ekg with qt fiftymsec
__label__1	study interventions are Interferons . solid tumors diagnosis and these must be continued for three months after study initiation
__label__1	study interventions are Etoposide . ovarian sex cord stromal tumor diagnosis and unable or unwilling to sign informed consents
__label__1	study interventions are Alemtuzumab . peripheral cell lymphoma diagnosis and serious accompanying disorder or impaired organ function
__label__1	study interventions are Rituximab . primary central nervious system lymphoma diagnosis and concurrent systemic immunosuppressant therapy other than corticosteroids cyclosporine tacrolimus etc
__label__1	study interventions are Distal ureterectomy . high grade upper tract urothelial carcinoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Succinylcholine . stage ivb oropharyngeal squamous cell carcinoma diagnosis and supraclavicular nodes defined as nodes visualized on the same axial imaging slice as the clavicle
__label__1	study interventions are Dasatinib . malignant pleural mesothelioma diagnosis and all wocbp must have negative pregnancy test prior to first receiving dasatinib
__label__1	study interventions are Iodine-131 anti-B1 antibody . non hodgkin lymphoma diagnosis and males and females must agree to use contraceptive method from enrollment to six months after receiving iodine one hundred and thirty-one anti bone antibody
__label__1	study interventions are Oxaliplatin . stage iiib rectal cancer diagnosis and psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Capecitabine . prior abdomipelvic radiotherapy with the exception of short course pre operative radiotherapy for rectal cancer
__label__1	study interventions are Cyclosporins . adult nasal type extranodal nk cell lymphoma diagnosis and severe defects in pulmonary function testing defects are currently categorized as mild moderate and severe as defined by the pulmonary consultant or receiving supplementary continuous oxygen
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv non small cell lung cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biological composition to cixutumumab
__label__1	study interventions are Antibodies . lung cancer diagnosis and patient has signs or symptoms of acute infection requiring systemic therapy
__label__1	study interventions are Axitinib . colorectal carcinoma diagnosis and any of the following within the twelve months prior to study drug administration
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and no prior chemotherapy for hormone refractory disease is allowed
__label__1	study interventions are Nintedanib . stage iib non small cell lung carcinoma diagnosis and common terminology criteria for adverse events ctcae grade two or higher proteinuria
__label__1	study interventions are Mycophenolic Acid . refractory childhood hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Antibodies, Monoclonal . stage iiic breast cancer diagnosis and myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular lv function
__label__1	study interventions are Imatinib Mesylate . recurrent uterine sarcoma diagnosis and patients receiving therapeutic corticosteroids
__label__1	study interventions are Succinylcholine . stage iiib primary peritoneal cancer diagnosis and stage not greater than ib
__label__1	study interventions are Lapatinib . patients with current active hepatic or biliary disease with exception of patients with gilbert syndrome asymptomatic gallstones liver metastases or stable chronic liver disease per investigator assessment
__label__1	study interventions are Leucovorin . symptomatic arrhythmia
__label__1	study interventions are Irinotecan . colorectal cancer diagnosis and no oral or parenteral anticoagulant therapy within the past ten days
__label__1	study interventions are Urine Sample Collection . prostate cancer diagnosis and gleason score less_than six
__label__1	study interventions are Busulfan . contiguous stage ii adult diffuse large cell lymphoma diagnosis and presence of active central nervous system cns disease history of adequately treated cns disease is acceptable
__label__1	study interventions are Etoposide phosphate . unspecified adult solid tumor protocol specific diagnosis and other concurrent severe and or uncontrolled concomitant medical conditions
__label__1	study interventions are Busulfan . malignant melanoma diagnosis and inability to find suitable donor for the patient
__label__1	study interventions are Oxaliplatin . colon cancer diagnosis and current or recent within ten days prior to study treatment start use of full dose oral or parenteral anticoagulants or thrombolytic agent for therapeutic purposes
__label__1	study interventions are cilengitide . childhood grade ii meningioma diagnosis and patient must have no uncontrolled infection
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and absolute neutrophil count of less_than one thousand cells mmthree doc one hundred and nine l
__label__1	study interventions are Leucovorin . cancer of rectum diagnosis and known hiv positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study drugs
__label__1	study interventions are pharmacological study . unspecified adult solid tumor protocol specific diagnosis and serious non healing wound ulcer bone fracture within twenty-eight days before the first dose of study treatment
__label__1	study interventions are Montelukast . fallopian tube cancer diagnosis and patients with hiv disease will be permitted only if they are on effective antiretroviral therapy have cdfour count greater than four00 and have had no opportunistic infections within the past six months
__label__1	study interventions are Prednisolone phosphate . any other malignancies within the past five years except skin basal cell carcinoma or carcinoma in situ of cervix
__label__1	study interventions are Doxorubicin . peritoneal neoplasms diagnosis and has any condition that in the opinion of the investigator would compromise the well being of the participant or the study or prevent the participant from meeting or performing study requirements
__label__1	study interventions are Gemcitabine . regional transitional cell cancer of the renal pelvis and ureter diagnosis and no uncontrolled severe hypertension
__label__1	study interventions are Selenium . stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and non regional metastatic disease stage ivc
__label__1	study interventions are Laboratory Biomarker Analysis . neurofibromatosis type one diagnosis and current exposure to household_contacts equal_than less_than one5 months old or household contact with known immunodeficiency note
__label__1	study interventions are Tacrolimus . stage iii adult diffuse mixed cell lymphoma diagnosis and patients who are not candidate for an unrelated donor allogeneic hsct based on the current institutional bone marrow transplant bmt program clinical practice guidelines organ function criteria will be utilized per the current institutional bmt program clinical practice guidelines there will be no restriction to study entry based on hematological parameters
__label__1	study interventions are Docetaxel . prostate carcinoma metastatic in the bone diagnosis and any medical conditions which in the opinion of the investigators would jeopardize either the patient or the integrity of the data obtained are not eligible
__label__1	study interventions are Cholecalciferol . adenocarcinoma diagnosis and this includes untreated hyperparathyroidism increase in parathyroid function and history of milk alkali syndrome type of calcium metabolism disease
__label__1	study interventions are Epirubicin . stomach neoplasms diagnosis and the following laboratory values
__label__1	study interventions are Antibodies . prostate cancer diagnosis and active angina pectoris or ny heart association class iii iv heart disease
__label__1	study interventions are intensity-modulated radiation therapy . patient with hodgkin lymphoma are not eligible for this study
__label__1	study interventions are Cyclosporins . stage iii multiple myeloma diagnosis and performance status greater_than two eastern cooperative oncology group ecog or less_than fifty lansky for patients less_than sixteen years old
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent primary peritoneal carcinoma diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days prior to the first date of study treatment
__label__1	study interventions are MEDI1873 . unresolved toxicities from prior anticancer therapy
__label__1	study interventions are Antibodies, Monoclonal . colorectal cancer diagnosis and serious uncontrolled cardiac arrhythmia
__label__1	study interventions are Laparotomy . melanoma diagnosis and patients with chronic active hepatitis based on positive serology test for surface antigen or will be excluded if there is evidence of cirrhosis on pathology
__label__1	study interventions are Cyclophosphamide . esophageal cancer diagnosis and patients with active infections including hiv will be excluded due to unknown effects of the vaccine on lymphoid precursors
__label__1	study interventions are Enadenotucirev . metastatic bladder cancer diagnosis and any condition or illness that in the opinion of the investigator or the medical monitor would compromise patient safety or interfere with the evaluation of the safety of the drug
__label__1	study interventions are Curettage . carcinoma basal cell diagnosis and five bccs at presentation
__label__1	study interventions are Mycophenolic Acid . stage childhood large cell lymphoma diagnosis and known allergy to filgrastim csf
__label__1	study interventions are external fractionated radiotherapy . tumor in close proximity to the skin
__label__1	study interventions are Etoposide phosphate . recurrent childhood lymphoblastic lymphoma diagnosis and pregnant or breastfeeding women are excluded from this study breastfeeding should be discontinued if the mother is treated with busulfan cyclophosphamide and etoposide
__label__1	study interventions are Antibodies . recurrent adult diffuse mixed cell lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to abt eight hundred and eighty-eight bendamustine or mannitol patients enrolling in the cohort expansion or phase two portions of the study who have been intolerant of repeated doses of rituximab in the past will be excluded patients who have had infusion reactions to their initial dose of rituximab will not be excluded
__label__1	study interventions are Progesterone . breast neoplasms diagnosis and for spine dxa
__label__1	study interventions are Albumin-Bound Paclitaxel . patients must have recovered from side effects from prior cancer directed therapy to grade one or less unless deemed not clinically significant by study investigator
__label__1	study interventions are Carboplatin . recurrent adult primary liver cancer diagnosis and pregnant or nursing women
__label__1	study interventions are Cancer education . breast cancer diagnosis and medicare part enrolled
__label__1	study interventions are Nivolumab . squamous cell carcinoma of the head and neck diagnosis and inhaled or topical steroids and adrenal replacement steroid doses are permitted in the absence of autoimmune disease
__label__1	study interventions are Active-breathing-controlled deep-inspiratory breathhold . breast cancer diagnosis and requirement for nodal irradiation
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and not willing to accept punch biopsy before treatment and neoadjuvant therapy
__label__1	study interventions are Sorafenib . recurrent adult primary liver cancer diagnosis and congestive heart failure greater_than new york heart association nyha class two active coronary artery disease cad cardiac arrhythmias requiring anti arrhythmic therapy other than beta blockers ordigoxin or uncontrolled hypertension myocardial infarction more than sixmonths prior to study entry is permitted
__label__1	study interventions are Methotrexate . hertwo positive breast cancer diagnosis and documented cardiomyopathy
__label__1	study interventions are Mitogens . hertwo positive breast cancer diagnosis and history of intolerance or hypersensitivity to trastuzumab and or pertuzumab
__label__1	study interventions are Cyclophosphamide . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and host disease complications greater than risk of recurrence after autologous bmt
__label__1	study interventions are Albumin-Bound Paclitaxel . small cell lung cancer diagnosis and severe or uncontrolled cardiac disease defined as uncontrolled or unstable angina myocardial infarction in the last month uncontrolled congestive heart failure greater_than three admissions for congestive heart failure in the three months prior to diagnosis
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and if the test is positive the patient must be excluded from the study
__label__1	study interventions are Cyclophosphamide . non hodgkin lymphoma diagnosis and they are excluded given the potential teratogenic effects of chemotherapy and agents used in the transplant
__label__1	study interventions are Trastuzumab . metastatic breast cancer diagnosis and current unstable angina
__label__1	study interventions are Vidarabine . noncontiguous stage ii adult burkitt lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Immunoglobulins . refractory childhood hodgkin lymphoma diagnosis and patients who have an uncontrolled infection are not eligible
__label__1	study interventions are questionnaire administration . colorectal cancer diagnosis and cognitive impairment
__label__1	study interventions are Cyclophosphamide . patients who have received greater_than eight cycles of cytotoxic chemotherapy or metastatic melanoma
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and any unstable systemic disease including active infection grade four hypertension unstable angina congestive heart failure liver and kidney or metabolic disease
__label__1	study interventions are Vidarabine . childhood nasal type extranodal nk cell lymphoma diagnosis and whole lungs twelve gy
__label__1	study interventions are Paclitaxel . ovarian cancer diagnosis and active peptic ulcer disease
__label__1	study interventions are ileostoma closure . ileostomy closure in rectal cancer diagnosis and emptied urinary bladder
__label__1	study interventions are Liposomal doxorubicin . stage ii grade three non contiguous follicular lymphoma diagnosis and participants with viral hepatitis who do not meet the criteria will not be eligible all participants who present with acute hepatitis including those with normal transaminases who are hbsag positive and igm positive for hepatitis core antigen will not be eligible participants who are hepatitis core antibody positive are eligible only if they start or are on prophylactic therapy hepatitis viral load should be confirmed negative on all participants who are hepatitis core antibody positive participants refusing to take any anti hepatitis therapy during study will also be excluded participants diagnosed with hepatitis are eligible if they meet criteria
__label__1	study interventions are Avelumab . hodgkins lymphoma diagnosis and prior allogeneic stem cell transplantation for patients in dose expansion cohorts only
__label__1	study interventions are Docetaxel . prostatic neoplasms diagnosis and any history of congenital long qt syndrome
__label__1	study interventions are Methotrexate . recurrent cutaneous cell non hodgkin lymphoma diagnosis and karnofsky adult or lansky for equal_than less_than sixteen years performance status less_than fifty
__label__1	study interventions are Vilaprisan (BAY1002670) . leiomyoma diagnosis and abuse of alcohol drugs or medicines laxatives
__label__1	study interventions are Carboplatin . stage iiic breast cancer diagnosis and patients on therapeutic doses of coumadin or lovenox are ineligible to participate in study
__label__1	study interventions are Irinotecan . colorectal carcinoma diagnosis and neutrophil less_than one thousand, five hundred cells mmthree
__label__1	study interventions are Cisplatin . gastroesophageal cancer diagnosis and circulating anticoagulant baseline platelet count less_than fifty zero mmthree activated partial thromboplastin time aptt value doc the upper limit of normal or international normalized ratio inr greater_than doc
__label__1	study interventions are Pembrolizumab . recurrent grade three follicular lymphoma diagnosis and has received an allogeneic stem cell transplant
__label__1	study interventions are Melphalan . adult nasal type extranodal nk cell lymphoma diagnosis and uncontrolled diabetes mellitus
__label__1	study interventions are Dexamethasone acetate . patients with smoldering myeloma or monoclonal gammopathy of unknown significance are not eligible
__label__1	study interventions are Questionnaire Administration . stage iiia primary peritoneal cancer diagnosis and patients diagnosed with chronic disease illness precluding their participation diabetics receiving insulin myocardial infarction or unstable angina within previous six months chronic hepatitis rheumatoid disease renal or hepatic disease dysfunction
__label__1	study interventions are Leucovorin . cancer of the rectum diagnosis and women of childbearing potential must have negative serum pregnancy test within fourteen days of study entry
__label__1	study interventions are Temozolomide . glioblastoma multiforme diagnosis and asat or alat levels more than three times the upper limit of normal
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and squamous small cell carcinoid adenosquamous large cell neuroendocrine or mixed histology containing small cell or squamous cell nsclc
__label__1	study interventions are Paclitaxel . triple negative breast carcinoma diagnosis and patient who has undergone major surgery equal_than less_than four weeks prior to starting study treatment or who has not recovered from side effects of such procedure
__label__1	study interventions are Dacarbazine . recurrent childhood cerebral astrocytoma diagnosis and serum albumin greater_than two dl
__label__1	study interventions are Endothelial Growth Factors . fallopian tube serous adenocarcinoma diagnosis and this criterion applies only to the patients enrolled before august twenty-nine two thousand and eleven and those enrolled after this date electing to receive bevacizumab patients who have had major surgical procedure open biopsy dental extractions or other dental surgery procedure that results in an open wound or significant traumatic injury within twenty-eight days prior to the first date of treatment on this study or anticipation of need for major surgical procedure during the course of the study patients with placement of vascular access device or core biopsy within seven days prior to the first date of treatment on this study
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and known severe hypersensitivity to any drugs in this study
__label__1	study interventions are Everolimus . regional digestive system neuroendocrine tumor gone diagnosis and prior liver transplant with evidence of recurrent or metastatic disease
__label__1	study interventions are Carboplatin . urethral cancer diagnosis and females of childbearing potential fcbp must have negative serum or urine pregnancy test with sensitivity of at least twenty-five miu ml within ten fourteen days and again within twenty-four hours prior to starting cycle one of lenalidomide
__label__1	study interventions are quality-of-life assessment . stage iv non small cell lung cancer diagnosis and any condition which the investigator opinion deems the patient ineligible
__label__1	study interventions are Adaptive Radiotherapy . oropharyngeal cancer diagnosis and patients unable or unwilling to give written informed consent or to undergo mri imaging
__label__1	study interventions are Distal Gastrectomy with D2 LND . gastric cancer diagnosis and inadequate organ function as below
__label__1	study interventions are Cisplatin . stage iiia ovarian cancer diagnosis and ctep ctcae version doc grade two or higher peripheral ischemia brief less_than two4 hours hrs episode of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Sirolimus . stage iiic primary peritoneal cancer diagnosis and known hypersensitivity to sirolimus
__label__1	study interventions are Lapatinib . brain cancer diagnosis and history of an abdominal fistula gi perforation or intra abdominal abscess within previous six months
__label__1	study interventions are Carboplatin . ovarian brenner tumor diagnosis and this criterion applies only to the patients enrolled before august twenty-nine two thousand and eleven and those enrolled after this date electing to receive bevacizumab patients who have had major surgical procedure open biopsy dental extractions or other dental surgery procedure that results in an open wound or significant traumatic injury within twenty-eight days prior to the first date of treatment on this study or anticipation of need for major surgical procedure during the course of the study patients with placement of vascular access device or core biopsy within seven days prior to the first date of treatment on this study
__label__1	study interventions are Cisplatin . stomach neoplasm diagnosis and neuropathy of grade two or higher
__label__1	study interventions are Antibodies, Monoclonal . metastatic solid neoplasm diagnosis and patients with controlled type one diabetes mellitus on stable insulin regimen may be eligible
__label__1	study interventions are Lenograstim . myeloma diagnosis and female patient is pregnant or breast feeding
__label__1	study interventions are Delanzomib . solid tumors diagnosis and any of the following hematologic values
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and significant neuropathy grades greater_than two within fourteen days prior to enrollment
__label__1	study interventions are Dexamethasone . cancer diagnosis and scheduled to receive chemotherapy with any cytotoxic agents irinotecan gemcitabine or biological agents cetuximab panitumimab other than the protocol allowed chemotherapy described in inclusion criterion three
__label__1	study interventions are Doxorubicin . ovarian clear cell cystadenocarcinoma diagnosis and ribose_polymerase parp inhibitor
__label__1	study interventions are Cyclosporine . nodal marginal zone cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than thirty-five total lung capacity tlc less_than thirty-five or forced expiratory volume in one second fevone less_than thirty-five and or receiving supplementary continuous oxygen
__label__1	study interventions are Immunoglobulins . adult diffuse large cell lymphoma diagnosis and uncontrolled bacterial viral or fungal infection currently taking medication and with progression or no clinical improvement
__label__1	study interventions are Cyclophosphamide . pancreatic cancer diagnosis and is pregnant
__label__1	study interventions are Antibodies . stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and ketoconazole itraconazole ritonavir cyclosporine carbamazepine phenytoin phenobarbital products containing grapefruit juice will not be allowed while on study
__label__1	study interventions are Carmustine . recurrent follicular lymphoma diagnosis and participants with greater_than five involvement of bone marrow by malignant cells either by manual count or flow cytometry prior to stem cell collection
__label__1	study interventions are Captopril . glioblastoma diagnosis and patients who have been treated with any investigational agent within twenty-eight days of the first day of administration of study drugs
__label__1	study interventions are Denileukin diftitox . stage iv melanoma diagnosis and diphtheria_toxin il two or excipients
__label__1	study interventions are Paclitaxel . stage iv pancreatic cancer diagnosis and arm cohort two
__label__1	study interventions are Helical Tomotherapy treatment . head and neck cancer diagnosis and lymph node involvement level iii or proximity of disease to submandibular gland on the side chosen for salivary gland transfer on frozen section or permanent pathological evaluation
__label__1	study interventions are Transarterial Chemoembolization . stage iiib hepatocellular carcinoma diagnosis and must not have any evidence of bleeding diathesis or active gastrointestinal bleeding
__label__1	study interventions are Arsenic trioxide . carcinoma small cell diagnosis and pregnant women are excluded from this study because trisenox is category agent with the potential to cause fetal harm
__label__1	study interventions are Fludarabine phosphate . stage iii adult diffuse mixed cell lymphoma diagnosis and pregnancy
__label__1	study interventions are Alisertib . malignant neoplasms of female genital organs diagnosis and other clinically significant co morbidities such as uncontrolled pulmonary disease active central nervous system disease active infection or any other condition that could compromise the patient participation in the study
__label__1	study interventions are Immunoglobulins . stage iii grade one follicular lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab_vedotin and or rituximab
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and or
__label__1	study interventions are Antibodies, Monoclonal . platinum sensitive ovarian cancer second line third line or fourth line diagnosis and history of toxic epidermal necrolysis
__label__1	study interventions are Antibodies, Monoclonal . sweat gland carcinoma diagnosis and previous treatment with vec or other herpes virus based therapy prior therapy with checkpoint inhibitors and or other immunotherapy is allowed
__label__1	study interventions are Vinblastine . non small cell lung cancer diagnosis and any of the following within the twelve months prior to starting the study treatment
__label__1	study interventions are Lenalidomide . noncontiguous stage ii grade one follicular lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Fluorouracil . stage iiib gastric cancer diagnosis and documented brain metastases
__label__1	study interventions are Antibodies . endometrial squamous cell carcinoma diagnosis and history of inflammatory bowel disease requiring ongoing therapy
__label__1	study interventions are Lenalidomide . stage multiple myeloma diagnosis and be currently enrolled in another investigational treatment protocol
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and breast feeder
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood large cell lymphoma diagnosis and cross match positive with recipient
__label__1	study interventions are Tamoxifen . ovarian cancer diagnosis and history of clinically significant cardiac or pulmonary dysfunction the patient has type one or two diabetes requiring daily anti hyperglycemic medication
__label__1	study interventions are Vaccines . tumor diagnosis and hematocrit less than or equal to thirty percent
__label__1	study interventions are Fludarabine . adult diffuse large cell lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Liposomal doxorubicin . stage iib breast cancer diagnosis and poorly controlled diabetes mellitus
__label__1	study interventions are TargomiRs . malignant pleural mesothelioma diagnosis and myocardial infarction less than six months before eligibility screening
__label__1	study interventions are Lenalidomide . recurrent grade three follicular lymphoma diagnosis and mibefradil
__label__1	study interventions are the first pass is made with 5ml suction technique . neoplasm metastases diagnosis and the patients who suffered from acute pancreatitis in the past two weeks
__label__1	study interventions are Antibodies, Monoclonal . systemic anaplastic large cell lymphoma diagnosis and known hypersensitivity to any of the excipients of ceritinib microcrystalline_cellulose mannitol crospovidone_colloidal silicon_dioxide and magnesium stearate
__label__1	study interventions are Carmustine . recurrent adult non hodgkin lymphoma diagnosis and active psychosocial condition that would hinder study compliance and follow up
__label__1	study interventions are Docetaxel . breast cancer diagnosis and male
__label__1	study interventions are Erlotinib Hydrochloride . lung cancer diagnosis and patients cannot take non steroidal anti inflammatory agents nsaids or salicylates two days prior and two days following five days pre and post for long acting nsaids administration of pemetrexed due to concerns of increased risk of renal toxicity
__label__1	study interventions are Axitinib . stage iii prostate cancer diagnosis and current use or anticipated need for treatment with drugs that are known cypthreeafour or cytochrome pfour50 oneatwo_cyponeatwo inducers ie carbamazepine dexamethasone felbamate omeprazole phenobarbital phenytoin amobarbital_nevirapine primidone rifabutin rifampin and st
__label__1	study interventions are Vaccines . ocular melanoma with extraocular extension diagnosis and the presence of laboratory evidence of autoimmune disease positive ana_titer without associated symptoms
__label__1	study interventions are Fludarabine . lymphoma diagnosis and the standard cord blood graft for this protocol will consist of two units as double unit graft although single units are permitted
__label__1	study interventions are Dihematoporphyrin Ether . epitheliod malignant pleural mesothelioma diagnosis and patients that have been treated with prior mantle field radiation
__label__1	study interventions are Carboplatin . triple negative metastatic breast cancer diagnosis and any significant medical condition laboratory abnormalities which places the subject at unacceptable risk if he she were to participate in the study
__label__1	study interventions are Antibodies . stage iva colon cancer diagnosis and other concurrent chemotherapy immunotherapy radiotherapy or any ancillary therapy considered investigational utilized for non food and drug administration fda approved indication and in the context of research investigation
__label__1	study interventions are Capecitabine . gastric cancer diagnosis and prior oral or intravenous chemotherapy for metastatic disease
__label__1	study interventions are Tacrolimus . recurrent adult diffuse small cleaved cell lymphoma diagnosis and infection with hiv
__label__1	study interventions are Rituximab . immunocytomas diagnosis and patients not establishing all above mentioned prerequisites
__label__1	study interventions are TLR9 Agonist SD-101 . grade two follicular lymphoma diagnosis and major surgery or wound that has not fully healed within four weeks of enrollment
__label__1	study interventions are Cervical Cancer Screening and Diagnosis . breast neoplasms diagnosis and women under the age of thirty
__label__1	study interventions are Icotinib . large cell lung cancer diagnosis and eye inflammation not fully controlled or conditions predisposing the subject to this
__label__1	study interventions are Pembrolizumab . refractory follicular lymphoma diagnosis and requires therapeutic anticoagulation with warfarin or other vitamin antagonists
__label__1	study interventions are Prednisone . more than three weeks since prior chemotherapy for cancer other than hydroxyurea for patients with wbc greater_than ten zero mm³
__label__1	study interventions are Lenvatinib . advanced solid tumors diagnosis and any signs and or symptoms of brain metastases those were stable for at least four weeks
__label__1	study interventions are Cetuximab . use of anti cancer treatments within twenty-eight days
__label__1	study interventions are vemurafenib . thyroid cancer diagnosis and history of cerebrovascular attack or transient ischemic attack within six months prior to the initiation of therapy on this protocol
__label__1	study interventions are Sirolimus . stage iii merkel cell carcinoma diagnosis and detailed assessment of hepatitis c medical history and risk factors must be done at screening for all patients
__label__1	study interventions are Mycophenolic Acid . refractory burkitt lymphoma diagnosis and pregnancy
__label__1	study interventions are Flucytosine . adult glioblastoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Cyclophosphamide . refractory plasma cell myeloma diagnosis and diltiazem
__label__1	study interventions are Etoposide phosphate . stage ii grade three contiguous follicular lymphoma diagnosis and any acute inter current infection that may interfere with planned protocol treatment participants with mycobacterium_avium will not be excluded from study entry chronic therapy with potentially myelosuppressive agents is allowed provided that entry hematologic criteria are met
__label__1	study interventions are Melphalan . recurrent adult immunoblastic large cell lymphoma diagnosis and left ventricular ejection fraction less_than forty
__label__1	study interventions are Etoposide . previous diagnosis of other malignant neoplasm in the last three years in situ cervical cancer or completely excised basocellular squamocellular skin cancer are always admitted
__label__1	study interventions are Immunoglobulin G . ovarian seromucinous carcinoma diagnosis and invasive procedures defined as follows
__label__1	study interventions are Immunoglobulins . metastatic triple negative breast cancer diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are HIV Protease Inhibitors . stage iib pancreatic cancer diagnosis and carbamazepine phenobarbital
__label__1	study interventions are Laboratory Biomarker Analysis . stage iic skin melanoma diagnosis and renal dysfunction as defined as glomerular filtration rate gfr less_than seventy
__label__1	study interventions are Alemtuzumab . stage iv grade one follicular lymphoma diagnosis and fertile men or women unwilling to use contraceptives during and for up to one2 months post treatment
__label__1	study interventions are Vorinostat . stage adult diffuse large cell lymphoma diagnosis and participants should not have taken valproic acid or another histone_deacetylase inhibitor for at least two weeks prior to study enrollment
__label__1	study interventions are Antibodies, Monoclonal . recurrent cervical carcinoma diagnosis and patients with pre existing grade two or greater peripheral neuropathy
__label__1	study interventions are Cyclosporine . testicular lymphoma diagnosis and identical twin
__label__1	study interventions are Cyclosporine . anaplastic large cell lymphoma diagnosis and marrow donors
__label__1	study interventions are photodynamic therapy . stage verrucous carcinoma of the oral cavity diagnosis and serum creatinine greater_than two mg
__label__1	study interventions are IPdR . neoplasms diagnosis and inclusion of women and minorities
__label__1	study interventions are Mycophenolate mofetil . stage childhood anaplastic large cell lymphoma diagnosis and karnofsky score less_than sixty or lansky score less_than fifty
__label__1	study interventions are Cetuximab . advanced cancers diagnosis and utilization of capecitabine for the six weeks preceding sir_spheres therapy and indefinitely following sir_spheres therapy as per manufacturer recommendations due to the increased risk of radiation hepatitis
__label__1	study interventions are Cisplatin . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and patients with known brain metastases will be excluded from this clinical trial
__label__1	study interventions are LEE011 . malignant rhabdoid tumors mrt neuroblastoma diagnosis and in particular enzyme inducing antiepileptic drugs eiaeds
__label__1	study interventions are Gamma-Secretase Inhibitor RO4929097 . recurrent uterine corpus sarcoma diagnosis and patients may not receive other investigational agents within two weeks of enrollment in this study patients treated with bevacizumab should be off therapy for four weeks other experimental or immuno therapies should wait for four half lives or four weeks whichever is longer prior exposure to notch or hedgehog inhibitors is not allowed patients who have not recovered to less than ctcae grade two from prior therapies are ineligible
__label__1	study interventions are Dexamethasone . relapsed or refractory multiple myeloma diagnosis and the development of desquamating_rash while taking thalidomide
__label__1	study interventions are Hydroxocobalamin . breast cancer diagnosis and prior treatment with anti angiogenics within six months prior to enrollment
__label__1	study interventions are 10-deazaaminopterin . breast tumors diagnosis and females who are pregnant or breastfeeding
__label__1	study interventions are Cisplatin . solid tumors or mantle cell lymphoma diagnosis and the patient has any malabsorption syndrome and or prior gastrectomy
__label__1	study interventions are Immunoglobulins . angioimmunoblastic cell lymphoma diagnosis and circulating human anti mouse antibody hama to be determined before each infusion
__label__1	study interventions are Mesna . lymphoma low grade diagnosis and renal cardiac pulmonary and hepatic function meet standard criteria for nonmyeloablative sct as listed below
__label__1	study interventions are Rituximab . lymphoplasmacytic lymphoma diagnosis and systemic treatment within fourteen days before the first dose of ixazomib with strong inhibitors of cytochrome pfour hundred and fifty family one subfamily polypeptide two cyponeatwo fluvoxamine_enoxacin ciprofloxacin strong inhibitors of cytochrome pfour hundred and fifty family three subfamily cypthreea clarithromycin telithromycin itraconazole voriconazole ketoconazole nefazodone posaconazole or strong cypthreea inducers rifampin rifapentine rifabutin carbamazepine phenytoin phenobarbital or use of ginkgo_biloba or st
__label__1	study interventions are Antibodies, Monoclonal . stage iva squamous cell carcinoma of the larynx diagnosis and glucose less_than forty mg dl less_than doc mmol or greater_than two hundred and fifty mg dl greater_than fourteenmmol l
__label__1	study interventions are Mobilan (M-VM3) . prostate cancer diagnosis and unstable stenocardia within three months prior the screening
__label__1	study interventions are Niacinamide . neoplasms diagnosis and pregnant or breast feeding women
__label__1	study interventions are Dexamethasone acetate . lymphoma diagnosis and concurrent conditions
__label__1	study interventions are Sunitinib . kidney cancer diagnosis and hormonal contraceptives are not acceptable as sole method of contraception
__label__1	study interventions are Everolimus . dental braces or prosthesis that interfere with volumetric analysis of the neurofibroma s
__label__1	study interventions are IMRT . endometrial cancer diagnosis and surgery not in accordance with recommendations of inca
__label__1	study interventions are Capecitabine . cancer of liver diagnosis and protocol specific laboratory values as described below in section doc numberfifteen
__label__1	study interventions are Antibodies . recurrent cell non hodgkin lymphoma diagnosis and co administration of enzyme inducing antiepileptic drugs rifampin rifabutin rifapentine or st
__label__1	study interventions are Dexamethasone . breast cancer diagnosis and cardiac pacemakers
__label__1	study interventions are Tacrolimus . diffuse large cell lymphoma diagnosis and hla identical b and dr related or unrelated donor available
__label__1	study interventions are incobotulinumtoxinA . neoplasms diagnosis and patients with known hypersensitivity to botulinum toxin a
__label__1	study interventions are Dexamethasone . patients with history of active malignancy during the past five years with the exception of basal cell carcinoma of the skin or stage zero cervical carcinoma treated with curative intent
__label__1	study interventions are Rituximab . non hodgkins lymphoma diagnosis and major surgery within the previous two weeks
__label__1	study interventions are Docetaxel . mouth neoplasms diagnosis and can not tolerate the treatment protocol with systematic diseases such as history of severe pulmonary or cardiac diseases
__label__1	study interventions are Lapatinib . hertwo positive breast cancer diagnosis and if the medication cannot be monitored clinically they discontinue all such medications at least five days prior to start of therapy and no further doses are anticipated for the duration of investigational therapy
__label__1	study interventions are Liver Extracts . secondary malignant neoplasm of liver diagnosis and patients with baseline flr of less than fifteen
__label__1	study interventions are Antibodies, Monoclonal . stage iv mantle cell lymphoma diagnosis and donor
__label__1	study interventions are Dihematoporphyrin Ether . cholangiocarcinoma diagnosis and patient under eighteen
__label__1	study interventions are Thalidomide . contiguous stage ii adult diffuse mixed cell lymphoma diagnosis and known hypersensitivity to rituximab
__label__1	study interventions are Nivolumab . advanced non small cell lung cancer diagnosis and patients meeting any of the following criteria are not eligible for tissue procurement for the vigil manufacturing
__label__1	study interventions are Antibodies, Monoclonal . tumor involving major vessels
__label__1	study interventions are Cyclosporins . multiple myeloma diagnosis and fractional_shortening by echocardiogram not within normal limits per institution
__label__1	study interventions are Carboplatin . advanced cancer diagnosis and untreated brain metastasis es that may be considered active
__label__1	study interventions are Levoleucovorin . stage iiia rectal cancer diagnosis and patients without sufficient central venous access for therapy
__label__1	study interventions are Busulfan . lymphoma malignant diagnosis and major anticipated illness or organ failure incompatible with survival from bone marrow transplant
__label__1	study interventions are O(6)-benzylguanine . recurrent grade two follicular lymphoma diagnosis and medical history of noncompliance with highly active anti retroviral therapy haart or medical therapy
__label__1	study interventions are Sirolimus . facial_angiofibromas diagnosis and systemic treatment by sirolimus everolimus or any other immunosuppressive drug during the previous six months
__label__1	study interventions are Tacrolimus . stage ii multiple myeloma diagnosis and grade greater_than neuropathy
__label__1	study interventions are Rituximab . nodal marginal zone cell lymphoma diagnosis and known hypersensitivity to thalidomide
__label__1	study interventions are Oxaliplatin . advanced colorectal cancer diagnosis and doublebarrier method oral contraceptive implant dermal contraception long term injectable contraceptive intrauterine device or tubal ligation during the study
__label__1	study interventions are TNFerade . previous chemotherapy or radiation for pancreatic cancer or previous radiation to the target field
__label__1	study interventions are Dabrafenib . stage iiia skin melanoma diagnosis and exception
__label__1	study interventions are Blood and respiratory fluids sampling . lung cancer diagnosis and persons referred to in articles lone thousand, one hundred and twenty-one five to lone thousand, one hundred and twenty-one eight of csp protected people
__label__1	study interventions are TRX-818 capsules . advanced cancer diagnosis and myocardial infarction severe unstable angina coronary peripheral artery bypass graft congestive heart failure or cerebrovascular accident including transient ischemic attack within six months prior to starting study treatment for pulmonary embolus
__label__1	study interventions are Paclitaxel . stage iii squamous cell carcinoma of the lip and oral cavity diagnosis and exposure to any investigational drug within three weeks prior to the start of dosing
__label__1	study interventions are Vaccines . melanoma diagnosis and inhaled or topical steroids and adrenal replacement doses less_than ten mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
__label__1	study interventions are ARQ 197 . renal cell carcinoma rcc diagnosis and known human immunodeficiency virus hiv hepatitis virus hbv or hepatitis virus hcv infection
__label__1	study interventions are Pemetrexed . head and neck neoplasms diagnosis and exception
__label__1	study interventions are Tamoxifen . breast cancer diagnosis and ast and or alt greater_than three times the value of upper normal limit with clinical and laboratory findings that indicate grade of hepatic insufficiency that could potentially increase the risk of assuming letrozole
__label__1	study interventions are Bevacizumab . recurrent glioblastoma multiforme diagnosis and proteinuria at screening as demonstrated by either
__label__1	study interventions are Antibodies, Monoclonal . stage ivb oral cavity verrucous carcinoma diagnosis and patients with clinically significant pneumonitis pulmonary infiltrates unless there is known and treatable cause for the condition
__label__1	study interventions are Liver Extracts . hepatocellular carcinoma fibrolamellar variant diagnosis and ineligible for liver transplantation per institutional criteria see appendix one
__label__1	study interventions are Mycophenolate mofetil . stage iii childhood anaplastic large cell lymphoma diagnosis and donor or centers who will exclusively donate marrow
__label__1	study interventions are Mycophenolate mofetil . recurrent small lymphocytic lymphoma diagnosis and active or recent prior six months invasive fungal infection without id consult and approval
__label__1	study interventions are Pharmacological Study . stage iv skin melanoma diagnosis and inability to home monitor blood pressure
__label__1	study interventions are questionnaire administration . noncontiguous stage ii marginal zone lymphoma diagnosis and turner syndrome or polycystic ovarian syndrome are not eligible
__label__1	study interventions are Melphalan . recurrent plasma cell myeloma diagnosis and other serious medical or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol
__label__1	study interventions are Ganetespib . stage ii hypopharyngeal squamous cell carcinoma diagnosis and history of severe allergic or hypersensitivity reactions to excipients polyethylene_glycol peg three hundred and polysorbate eighty
__label__1	study interventions are Vaccines . breast cancer diagnosis and patients who have received an autologous or allogeneic hct
__label__1	study interventions are Lenalidomide . histiocytic sarcoma hs diagnosis and in addition these participants are at increased risk of lethal infections when treated with marrow suppressive therapy
__label__1	study interventions are Dalteparin . ovarian cancer diagnosis and uncontrolled hypertension despite optimal medical therapy
__label__1	study interventions are Lapatinib . recurrent breast carcinoma diagnosis and alanine aminotransferase alt and aspartate aminotransferase ast greater_than equal_than three uln with or without liver metastasis mets
__label__1	study interventions are Busulfan . myelodysplastic myeloproliferative neoplasm diagnosis and with human immunodeficiency virus hiv positivity or active infectious hepatitis
__label__1	study interventions are Celecoxib . breast cancer diagnosis and no history of gastrointestinal ulcer or ulcerative colitis requiring treatment
__label__1	study interventions are Compliance Monitoring . stage iiib ovarian cancer diagnosis and patients with gog performance grade of three or four
__label__1	study interventions are BB 1101 . diffuse large cell lymphoma diagnosis and vaccinated with live attenuated vaccines within four weeks of randomization
__label__1	study interventions are Riluzole . myocardial infarction symptomatic coronary artery disease severe or unstable angina artery bypass graft uncontrolled arrhythmias symptomatic congestive heart failure cerebrovascular accident or transient ischemic attack or pulmonary embolus
__label__1	study interventions are Vaccines . multiple myeloma diagnosis and clinically significant autoimmune disease
__label__1	study interventions are Belinostat . stage iv grade one follicular lymphoma diagnosis and patients who have had chemotherapy or radiotherapy within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered less_than grade one from clinically significant adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Interleukin-12 . thyroid gland medullary carcinoma diagnosis and exposure to any investigational drug within three weeks prior to the start of dosing
__label__1	study interventions are behavioral, psychological or informational intervention . stage iia fallopian tube cancer diagnosis and non ambulatory
__label__1	study interventions are Palbociclib . stage iii malignant testicular germ cell tumor diagnosis and the subject has received any other type of investigational agent within twenty-eight days before the first dose of study treatment
__label__1	study interventions are Antibodies . metastatic melanoma diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are Iodine . stage iii small lymphocytic lymphoma diagnosis and patients with active hemolysis
__label__1	study interventions are Mycophenolate mofetil . recurrent small lymphocytic lymphoma diagnosis and any cord blood units without the full maternal testing and negative results for hepatitis b hiv and human lymphotropic virus htlv one viruses
__label__1	study interventions are Antibodies, Monoclonal . glioma diagnosis and patients with full dose anticoagulants are eligible provided the patient has been on stable dose for at least two weeks of low molecular weight heparin therapeutic coumadin and aspirin doses greater_than 3two5 mg daily are not allowed
__label__1	study interventions are Mycophenolate mofetil . stage multiple myeloma diagnosis and seropositive for the human immunodeficiency virus
__label__1	study interventions are Pembrolizumab . peritoneal cancer diagnosis and hypersensitivity to pembrolizumab or any of its excipients
__label__1	study interventions are Vorinostat . patient with currently active malignancy other than non melanoma skin cancer and carcinoma in situ of the cervix
__label__1	study interventions are Gemcitabine . patients with history of lobular carcinoma in situ lcis are eligible
__label__1	study interventions are Metformin . cancer of kidney diagnosis and in such cases venous blood ph would be checked to confirm or exclude acidosis
__label__1	study interventions are 3-Iodobenzylguanidine . phaeochromocytoma diagnosis and evidence of severe or uncontrolled systemic diseases or laboratory finding that in the view of the investigator makes it undesirable for the patient to participate in the trial
__label__1	study interventions are Sirolimus . stage iv childhood anaplastic large cell lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Vaccines . stage iiia breast cancer diagnosis and patients with any seizure disorder
__label__1	study interventions are Allogeneic Bone Marrow Transplant . multiple myeloma diagnosis and severe psychiatric illness
__label__1	study interventions are Antibodies, Monoclonal . lymphoma follicular diagnosis and active infection requiring intravenous antibiotics at the time of study enrollment
__label__1	study interventions are SOM230 LAR . patients with additional active malignant disease within the last five years with the exception of basal cell carcinoma or carcinoma in situ of the cervix
__label__1	study interventions are Sorafenib . sarcoma diagnosis and pulmonary hemorrhage or bleeding event greater_than ctcae grade two within the past four weeks
__label__1	study interventions are Capecitabine . glioblastoma multiforme diagnosis and patients of childbearing potential must not be pregnant or become pregnant
__label__1	study interventions are Arsenic trioxide . untreated symptomatic cardiac ischemia
__label__1	study interventions are Cadexomer iodine . stage iva follicular thyroid cancer diagnosis and any serious and or unstable pre existing medical psychiatric or other condition that could interfere with subject safety provision of informed consent or compliance to study procedures
__label__1	study interventions are cabozantinib-s-malate . adenocarcinoma of the prostate diagnosis and the subject has uncontrolled significant intercurrent or recent illness including but not limited to the following conditions
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood large cell lymphoma diagnosis and karnofsky score less_than fifty
__label__1	study interventions are Isophosphamide mustard . adult nasal type extranodal nk cell lymphoma diagnosis and patients known to be human immunodeficiency virus hiv positive
__label__1	study interventions are Busulfan . lymphoma diagnosis and evidence of acute or chronic active hepatitis or cirrhosis
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and subjects with history of acute myocardial infarction within the past six months before starting the study drugs
__label__1	study interventions are Metronidazole . stage ic fallopian tube cancer diagnosis and evidence of current drug or alcohol abuse or psychiatric impairment which in the investigator opinion will prevent completion of the protocol therapy or follow up
__label__1	study interventions are Mitogens . stage iii adult diffuse small cleaved cell lymphoma diagnosis and any infection that is not improving during appropriate treatment
__label__1	study interventions are GV1001 . carcinoma hepatocellular diagnosis and known history of human immunodeficiency virus hiv
__label__1	study interventions are Carboplatin . is pregnant or breast feeding woman
__label__1	study interventions are Nivolumab . squamous cell lung cancer diagnosis and chronic hypopotassemia
__label__1	study interventions are Immunoglobulins . stage iiic breast cancer diagnosis and cardiac disease history of and or active disease that would preclude the use of the drugs included in the treatment regimens this includes but is not confined to
__label__1	study interventions are Liver Extracts . colorectal neoplasms diagnosis and fertile patient must use effective contraception during participation in the study
__label__1	study interventions are Vorinostat . patient had prior treatment with an histone_deacetylase hdac inhibitor romidespin depsipeptide nsc six hundred and thirty thousand, one hundred and seventy-six ms two hundred and seventy-five laq eight hundred and twenty-four belinostat pxd one hundred and one lbhfive hundred and eighty-nine mgcdone hundred and three cratwenty-four thousand, seven hundred and eighty-one etc patients who have received compounds with hdac inhibitor like activity such as valproic acid as anti tumor therapy should not enroll in this study patients who have received such compounds for other indications valproic acid for epilepsy may enroll after thirty day washout period
__label__1	study interventions are Gadopentetate Dimeglumine . adult choroid_plexus neoplasm diagnosis and subject is claustrophobic and cannot cooperate for the mri
__label__1	study interventions are Vincristine . recurrent mantle cell lymphoma diagnosis and bilirubin greater_than doc mg dl
__label__1	study interventions are Gefitinib . is targeted therapy increasing survival inoperable nonsmall cell lung cancer with spinal metastasis diagnosis and brain metastasis and expected survival less_than three months
__label__1	study interventions are Ifosfamide . refractory diffuse large cell lymphoma diagnosis and current life threatening illness medical condition or organ system dysfunction which in the investigator opinion could compromise the patient safety or put the study at risk
__label__1	study interventions are Lenalidomide . noncontiguous stage ii grade two follicular lymphoma diagnosis and positive serology for hepatitis hc defined as positive test for hcab
__label__1	study interventions are Relaxing Music (RM) Therapy . unspecified adult solid tumor protocol specific diagnosis and have known psychotic diagnosis
__label__1	study interventions are Morphine . cancer pain diagnosis and lack of informed consent
__label__1	study interventions are Cyclophosphamide . stage ia breast cancer diagnosis and previous therapy with anthracyclines taxanes or trastuzumab for any malignancy
__label__1	study interventions are Epothilone B . stage iv adult soft tissue sarcoma diagnosis and inflammatory breast disease
__label__1	study interventions are specimen samples . urinary cancer diagnosis and history of prior intravenous chemotherapy or radiation therapy
__label__1	study interventions are Sirolimus . stage ii bladder cancer diagnosis and known parenchymal brain metastasis
__label__1	study interventions are Sirolimus . other malignancies within the past three years except for adequately treated carcinoma of teh cervix or basal or squamous cell carcinoma of the skin
__label__1	study interventions are Pembrolizumab . stage iv melanoma diagnosis and has known psychiatric or substance abuse disorders that would interfere with the requirements of the trial
__label__1	study interventions are Antibodies, Monoclonal . fallopian tube transitional cell carcinoma diagnosis and patients known to be hiv positive but without clinical evidence of an immunocompromised state are eligible for this trial
__label__1	study interventions are Rezum System . prostatic adenoma diagnosis and subjects interested in maintaining fertility
__label__1	study interventions are Sirolimus . refractory central nervous system neoplasm diagnosis and patients who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study are not eligible
__label__1	study interventions are Antibodies, Monoclonal . undifferentiated ovarian carcinoma diagnosis and any of the following
__label__1	study interventions are Hematoporphyrin Derivative . duct cell adenocarcinoma of the pancreas diagnosis and total bilirubin greater_than equal_than three uln
__label__1	study interventions are Cisplatin . esophageal cancer diagnosis and active or uncontrolled other malignancy
__label__1	study interventions are Docetaxel . gastric cancer diagnosis and cardiac ejection fraction forty-five or greater
__label__1	study interventions are Etoposide . extranodal nk cell lymphoma nasal type diagnosis and bone marrow transplantation before
__label__1	study interventions are Bevacizumab . anaplastic astrocytoma diagnosis and patients with history of serious non healing wound ulcer or bone fracture are not eligible
__label__1	study interventions are Cyclophosphamide . stage iv adult diffuse large cell lymphoma diagnosis and patient or donor with active hepatitis or and or detectable viral ribonucleic acid rna
__label__1	study interventions are Complete Cardiac Magnetic Resonance Imaging (MRI) . breast cancer diagnosis and patients with contraindications to mri examination gadolinium allergies reactions metallic implants incompatible implanted electronic cardiac devices over scanner weight tolerance etc
__label__1	study interventions are quality-of-life assessment . stage ii squamous cell carcinoma of the hypopharynx diagnosis and mandibular invasion
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube carcinosarcoma diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Akt Inhibitor MK2206 . stage iva major salivary gland carcinoma diagnosis and other active malignancy other than indolent malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis
__label__1	study interventions are Melphalan . recurrent small lymphocytic lymphoma diagnosis and whole lungs twelve gy
__label__1	study interventions are Dacarbazine . glioblastoma diagnosis and patients requiring aprepitant dolasetron and tropisetron as antiemetics are excluded
__label__1	study interventions are Study of High Risk Factors . stage ib cervical cancer diagnosis and vulvar patients from june nine two thousand and fourteen on
__label__1	study interventions are Dexamethasone . lymphoma non hodgkin diagnosis and previous treatment with sch seven hundred and twenty-seven thousand, nine hundred and sixty-five
__label__1	study interventions are Docetaxel . stage prostate cancer diagnosis and subjects with known history of pulmonary embolus are not eligible
__label__1	study interventions are Doxorubicin . mediastinal thymic large cell lymphoma diagnosis and unimmunized and hepatitis surface antigen hbsag and or anti hbs antibody and or ant negative hbc antibody positive
__label__1	study interventions are Antibodies, Monoclonal . metastatic squamous neck cancer with occult primary squamous cell carcinoma diagnosis and history of allogeneic transplant
__label__1	study interventions are Antibodies . stage iva colorectal cancer diagnosis and inadequately controlled hypertension defined as average systolic blood pressure greater_than one hundred and fifty mmhg and or diastolic blood pressure greater_than one hundred mmhg
__label__1	study interventions are Oxaliplatin . prior chemotherapy radiotherapy and immunotherapy except preoperative chemoradiation for rectal cancer
__label__1	study interventions are Cyclosporins . stage iii adult diffuse small cleaved cell lymphoma diagnosis and patients with history of prolonged corrected qt interval qtc syndrome
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma of unknown primary origin diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Vorinostat . stage iiia non small cell lung cancer diagnosis and hiv positive patients receiving combination antiretroviral therapy are ineligible
__label__1	study interventions are ExAblate 2000 . multiple myeloma diagnosis and need surgical stabilization of the affected bony structure greater_than seven fracture risk score see section doc or
__label__1	study interventions are 2-Aminopurine . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and participation in clinical trials with other investigational agents not included in this trial within fourteen days of the start of this trial and within thirty days of any dose of bortezomib
__label__1	study interventions are Antibodies, Monoclonal . stage iva squamous cell carcinoma of the oropharynx diagnosis and uncontrolled comorbid illness
__label__1	study interventions are Nivolumab . carcinoma renal cell diagnosis and history of severe hypersensitivity reaction to any monoclonal antibody or any constituent of the product
__label__1	study interventions are Levoleucovorin . metastatic cancer diagnosis and new york heart association grade ii iv cardiac insufficiency
__label__1	study interventions are Fluorodeoxyglucose F18 . adult supratentorial primitive neuroectodermal tumor pnet diagnosis and unable to undergo eighteenf flt pet scan
__label__1	study interventions are Amrubicin . lung cancer diagnosis and interstitial pneumonia or pulmonary fibrosis
__label__1	study interventions are Prednisolone acetate . lymphoma diagnosis and serum creatinine level less_than two mg dl one hundred and seventy-seven µmol l
__label__1	study interventions are ACE-011 - 30 mg . carcinoma non small cell lung diagnosis and clinically significant pulmonary endocrine neurologic gastrointestinal hepatic or genitourinary disease unrelated to underlying malignancy
__label__1	study interventions are Everolimus . stage ivc laryngeal squamous cell carcinoma diagnosis and use of strong inhibitors inducers of cypthreeafour is not permitted
__label__1	study interventions are Omeprazole . malt lymphoma diagnosis and patients who have disease beyond stage iie two
__label__1	study interventions are Sunitinib . renal cell carcinoma diagnosis and psychiatric or addictive disorders that may compromise the ability to give informed consent
__label__1	study interventions are INNO-105 . tumors diagnosis and have psychiatric disorder that would interfere with consent study participation or follow up
__label__1	study interventions are Capecitabine . rectal cancer diagnosis and hypersensitivity to fluoropyrimidine
__label__1	study interventions are Processed Human Nerve Tissue Scaffold . prostate cancer diagnosis and currently receiving or planned treatment with chemotherapy or radiation therapy
__label__1	study interventions are Carboplatin . stage iiib primary peritoneal cancer diagnosis and patients with history of cerebrovascular accident cva stroke transient ischemic attack tia or subarachnoid hemorrhage within six months of the first date of treatment on this study are ineligible
__label__1	study interventions are Dacarbazine . history of carcinomatous_meningitis
__label__1	study interventions are HTIMRT . prostate adenocarcinoma diagnosis and if prior malignancy is in remission for less_than five years then the patient is not eligible
__label__1	study interventions are Flt3 ligand protein . stage iib uveal melanoma diagnosis and breastfeeding should be discontinued if the mother is treated with cdx one thousand, four hundred and one or cdx three hundred and one and poly_iclc
__label__1	study interventions are TB-403 =175mg/kg . have not fully recovered from the acute toxic effects of prior anticancer therapy chemotherapy immunotherapy radiation therapy or are currently receiving cytotoxic chemotherapy immunotherapy or radiation therapy
__label__1	study interventions are Dasatinib . stage iva squamous cell carcinoma of the larynx diagnosis and major conduction abnormality unless cardiac pacemaker is present
__label__1	study interventions are Cisplatin . previous diagnosis of other malignant neoplasm in the last three years in situ cervical cancer or completely excised basocellular squamocellular skin cancer are always admitted
__label__1	study interventions are Placebo . colon cancer diagnosis and current history of inflammatory or infectious disease
__label__1	study interventions are Antibodies, Monoclonal . myeloma diagnosis and patients with hemoptysis within twenty-eight days prior to entering the study
__label__1	study interventions are Antibodies . recurrent adult diffuse mixed cell lymphoma diagnosis and new york heart association classification iii or iv or history of angina pectoris requiring active treatment
__label__1	study interventions are Busulfan . childhood immunoblastic large cell lymphoma diagnosis and not pregnant
__label__1	study interventions are Vaccines . breast cancer diagnosis and history of autoimmune disease
__label__1	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and subject has qtcf interval greater_than four hundred and fifty ms on twelve lead ecg at screening
__label__1	study interventions are Fluorouracil . stage ivb colon cancer diagnosis and fertile men unwilling to practice contraceptive methods during the study period
__label__1	study interventions are Methamphetamine . adult primary hepatocellular carcinoma diagnosis and evidence of pulmonary insufficiency
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and have had serious or non healing wound ulcer or bone fracture within twenty-eight days prior to enrollment
__label__1	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and has received prior therapy with an anti pd one anti pd lone anti pd ltwo anti cdone37 or anti cytotoxic lymphocyte associated antigen four ctla four antibody including ipilimumab or any other antibody or drug specifically targeting cell co stimulation or checkpoint_pathways
__label__1	study interventions are Epothilones . active bleeding or pathological conditions that carry high risk of bleeding tumor involving major vessels known varices
__label__1	study interventions are Bevacizumab . melanoma diagnosis and prior therapy with bevacizumab sorafenib sunitinib or other vascular endothelial growth factor vegf pathway targeted therapy
__label__1	study interventions are Sirolimus . breast cancer diagnosis and history of jaundice
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib primary peritoneal cancer diagnosis and patients who have received prior therapy with any anti vascular endothelial growth factor vegf drug including bevacizumab
__label__1	study interventions are Antineoplastic Agents, Phytogenic . endometrial cancer diagnosis and chemotherapy immunotherapy biologic therapy investigational therapy or hormonal therapy within fourteen days or five half lives of drug whichever is longer prior to the first dose of study drug
__label__1	study interventions are Dihydroxycholecalciferols . prostate cancer diagnosis and no known brain metastases
__label__1	study interventions are Immunoglobulins . signet ring adenocarcinoma of the rectum diagnosis and patients receiving any other investigational agents
__label__1	study interventions are Buparlisib . nevoid basal cell carcinoma syndrome diagnosis and patients who are currently taking therapeutic doses of warfarin sodium or any other coumadin derivative anticoagulant low molecular weight heparin is allowed
__label__1	study interventions are Bevacizumab . primary peritoneal carcinoma diagnosis and bleeding diathesis or coagulopathy
__label__1	study interventions are Vadimezan . non small cell lung cancer diagnosis and right bundle_branch block rbbb and either left anterior_hemiblock or left posterior hemiblock bifasicular block
__label__1	study interventions are Antibodies . non small cell lung carcinoma diagnosis and history of clinically significant interstitial lung disease ild including drug induced ild radiation pneumonitis requiring steroid treatment or any evidence of clinically active ild
__label__1	study interventions are Cisplatin . non small cell lung cancer diagnosis and cardiovascular concerns
__label__1	study interventions are Fludarabine . stage small lymphocytic lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than forty total lung capacity tlc less_than forty forced expiratory volume in one second fevone less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Sirolimus . malignant pancreatic somatostatinoma diagnosis and evidence of free abdominal air not explained by paracentesis or recent surgical procedures
__label__1	study interventions are Quality-of-Life Assessment . stage ii nasopharyngeal keratinizing squamous cell carcinoma diagnosis and patients with tonenzeromzero stage disease
__label__1	study interventions are Docetaxel . metastatic prostate carcinoma diagnosis and seville_oranges grapefruit or grapefruit juice and or pummelos_star fruit exotic_citrus fruits or grapefruit hybrids
__label__1	study interventions are Antibodies . stage iiib fallopian tube cancer diagnosis and ischemic cerebrovascular event including transient ischemic attack tia and artery revascularization procedures
__label__1	study interventions are Erlotinib Hydrochloride . stage iiic colon cancer diagnosis and patients without sufficient central venous access for therapy
__label__1	study interventions are High-Dose Rate Brachytherapy . invasive breast carcinoma diagnosis and positive axillary node s
__label__1	study interventions are MEK 162 therapy or molecularly targeted therapy . stage iiib melanoma diagnosis and myocardial infarction
__label__1	study interventions are Cyclosporine . myeloproliferative neoplasm diagnosis and active central nervous system malignancy
__label__1	study interventions are Prednisone . radiation therapy will be afterwards permitted during the treatment period if it is indicated due to the presence of plasmacytomas
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and patients with immune deficiency who are at increased risk of lethal infections when treated with marrow suppressive therapy or hiv positive patients receiving anti retroviral therapy
__label__1	study interventions are Nivolumab . nonhodgkin lymphoma diagnosis and current use of systemic corticosteroids greater_than doc mg kg day
__label__1	study interventions are Bevacizumab . brain cancer diagnosis and known hypersensitivity to any component of bevacizumab
__label__1	study interventions are Busulfan . estrogen receptor negative breast cancer diagnosis and are on steroids
__label__1	study interventions are Leuprolide . prostate cancer diagnosis and has an intellectual incapacity or language barriers precluding adequate understanding or co operation
__label__1	study interventions are Peginterferon alfa-2b . melanoma diagnosis and history of severe psychiatric disorders eg
__label__1	study interventions are Temozolomide . glioblastoma multiforme grade iv of cerebellum diagnosis and prolonged corrected qt qtc interval on pre entry electrocardiogram greater_than four hundred and seventy msec
__label__1	study interventions are Rituximab . stage cutaneous cell non hodgkin lymphoma diagnosis and no concurrent treatment with valproic acid or on valproic acid within two weeks of study enrollment
__label__1	study interventions are Vinorelbine . breast cancer diagnosis and evidence of distant metastasis
__label__1	study interventions are Vinorelbine . childhood pleomorphic rhabdomyosarcoma diagnosis and patients with history of sluggish flow from cvc or cvc associated thrombosis treated with tissue plasminogen activator tpa only are not excluded
__label__1	study interventions are Levoleucovorin . arterial thromboembolic events or hemorrhage within six months prior to study entry except tumor bleeding surgically treated by tumor resection
__label__1	study interventions are Paclitaxel . advanced or metastatic non small cell lung cancer diagnosis and the subject is pregnant or breast feeding
__label__1	study interventions are Exemestane . hertwo neu negative carcinoma of breast diagnosis and known dihydropyrimidine_dehydrogenase dpd deficiency
__label__1	study interventions are Melphalan . myeloma diagnosis and have positive pregnancy test at baseline or
__label__1	study interventions are Temozolomide . anaplastic astrocytoma diagnosis and patients taking immuno suppressive agents other than prescribed corticosteroids
__label__1	study interventions are Doxorubicin . history of other malignant diseases except cured basal cell carcinoma of skin and cured carcinoma in situ of uterine cervix
__label__1	study interventions are Antibodies, Monoclonal . adult glioblastoma diagnosis and patients with cirrhosis or active viral or nonviral hepatitis
__label__1	study interventions are Bevacizumab . stage ic fallopian tube cancer diagnosis and patients with acute hepatitis or active infection that requires parenteral antibiotics
__label__1	study interventions are Immunoconjugates . refractory hodgkin lymphoma diagnosis and patient has hypersensitivity to brentuximab_vedotin
__label__1	study interventions are Mitomycins . neoplasms diagnosis and previous chemotherapy or radiotherapy
__label__1	study interventions are Comparator: Menactra (Concomitant) . human papillomavirus infection diagnosis and subject has history of hpv
__label__1	study interventions are Nitrogen Mustard Compounds . refractory small lymphocytic lymphoma diagnosis and donor
__label__1	study interventions are Vidarabine . anaplastic large cell lymphoma diagnosis and whole brain thirty gy enrollment of patients who previously receive higher than allowed dose of radiation to small volume of lungs liver and brain will be determine by the discretion of the radiation oncologist on the study
__label__1	study interventions are Dacarbazine . pancreatic delta cell carcinoma diagnosis and untreated deep venous thrombosis dvt subjects with recent dvt who have been therapeutically coagulated for at least six weeks are eligible
__label__1	study interventions are Hippocampal avoidance WBRT . metastatic malignant neoplasm to brain diagnosis and uncontrolled active infection requiring intravenous antibiotics at the time of registration
__label__1	study interventions are Liposomal doxorubicin . peritoneal carcinomatosis diagnosis and severe renal impairment myelosuppression severe hepatic impairment severe myocardial insufficiency recent myocardial infarction severe arrhythmias
__label__1	study interventions are Echinocandins . cancer diagnosis and this will avoid the possibility of reducing effective antifungal coverage for the purpose of the study
__label__1	study interventions are Epirubicin . breast cancer diagnosis and patients received major surgery or suffered from severe trauma within two months of first administration
__label__1	study interventions are Carboplatin . uterine cancer diagnosis and patient has impairment of hepatic renal or hematologic function as defined by the following baseline laboratory values
__label__1	study interventions are Fluorouracil . prior therapy for metastatic cancer
__label__1	study interventions are Questionnaires . brain neoplasms diagnosis and female patients of childbearing age will be excluded if they are pregnant as assessed by serum hcg or urine pregnancy test
__label__1	study interventions are placebo . stage ii squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and although there are no known adverse effects of black_raspberries upon the fetus if patients become pregnant during period of lyophilized_black raspberries_lbr administration then lbr will be discontinued and patient will be removed from the study we should however emphasize given this is food based study that risks are likely extremely low even though participant should become pregnant as such we are not recommending active contraception for women but rather if participants become pregnant that they notify their study doctor and that they will likely be removed from study there are no expected or logical risks if men were to father child and as such no contraception will be recommended for men
__label__1	study interventions are Belinostat . stage iv mantle cell lymphoma diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with pxdone hundred and one in addition these patients are at increased risk of lethal infections when treated with marrow suppressive therapy appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated
__label__1	study interventions are Oxandrolone . leukemia lymphoma myeloma or other hematologic malignancies
__label__1	study interventions are ThermoDox in combination with Microwave Hyperthermia (heat) . breast cancer diagnosis and ecog zubrod performance status greater_than two
__label__1	study interventions are Octreotide . the following endocrine tumor types may not be included
__label__1	study interventions are Maleic acid . recurrent ovarian carcinoma diagnosis and history of stroke or transient ischemic attack within six months
__label__1	study interventions are HBV Screening - Small group educational session . liver cancer diagnosis and adults over the age of sixty-four years
__label__1	study interventions are Docetaxel . stage iv breast cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to gthree thousand, one hundred and thirty-nine or other agents used in the study patients are excluded if known hypersensitivity to drugs formulated in polysorbate eighty tween eighty
__label__1	study interventions are Oxaliplatin . prior anti cancer therapy that fulfills the following criteria
__label__1	study interventions are Niacinamide . pancreatic adenocarcinoma diagnosis and any investigational agent within four weeks of study treatment initiation
__label__1	study interventions are S-adenosyl-L-methionine disulfate p-toluene-sulfonate . adult primary liver cancer diagnosis and hospitalization within the past five years for mania or for bipolar disease
__label__1	study interventions are Liposomal doxorubicin . clinical evidence of central nervous system cns involvement by lymphoma
__label__1	study interventions are Isophosphamide mustard . solid tumors diagnosis and host disease and or patients wiht allogeneic stem cell transplant sct less_than six months
__label__1	study interventions are Ascorbic Acid . pancreatic cancer diagnosis and life expectancy less than three months
__label__1	study interventions are Metformin . squamous cell carcinoma diagnosis and taking drug disulfiram antabuse
__label__1	study interventions are Vorinostat . solid tumors diagnosis and patients with prior history of treatment with hdac inhibitors sndx two hundred and seventy-five entinostat laq eight hundred and twenty-four lbhfive hundred and eighty-nine pxd one hundred and one belinostat etc
__label__1	study interventions are Dexamethasone acetate . lymphoma non hodgkin diagnosis and pregnancy or lactation
__label__1	study interventions are Fludarabine phosphate . recurrent adult diffuse mixed cell lymphoma diagnosis and bilirubin greater_than equal_than three upper limit of normal
__label__1	study interventions are Vidarabine . stage iv mantle cell lymphoma diagnosis and patients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening
__label__1	study interventions are Mycophenolate mofetil . recurrent small lymphocytic lymphoma diagnosis and females who are pregnant
__label__1	study interventions are binimetinib . recurrent melanoma diagnosis and patients who have neuromuscular disorders that are associated with elevated creatine kinase ck inflammatory myopathies_muscular dystrophy amyotrophic_lateral sclerosis spinal muscular_atrophy
__label__1	study interventions are Dacarbazine . metastatic malignant melanoma diagnosis and any of the following within the six months prior to study drug administration
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and known diagnosis of human immunodeficiency virus hiv infection hiv testing is not mandatory
__label__1	study interventions are AZD6244 . non squamous cell lung cancer with wild type kras diagnosis and inducers
__label__1	study interventions are Entinostat . stage iiic breast cancer diagnosis and psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Trastuzumab . neoplasms diagnosis and erlotinib
__label__1	study interventions are Romidepsin . ds stage iii plasma cell myeloma diagnosis and patients may not be receiving any other investigational agent
__label__1	study interventions are ECO-4601 . prostate cancer diagnosis and csf gm csf and other growth factors may not be used as substitute for scheduled dose reduction however they may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated at the discretion of the investigator
__label__1	study interventions are Etoposide . solid tumors diagnosis and must not have history of another malignancy
__label__1	study interventions are AV-412 . refractory cancer diagnosis and known history of significant ophthalmologic abnormalities including
__label__1	study interventions are Sorafenib . neoplasms by site diagnosis and uncontrolled hypertension
__label__1	study interventions are Deferasirox . stage adult cell leukemia lymphoma diagnosis and hiv positive patients
__label__1	study interventions are ispinesib . recurrent grade three follicular lymphoma diagnosis and john wort modafinil oxcarbazepine
__label__1	study interventions are Dacarbazine . recurrent childhood subependymal giant cell astrocytoma diagnosis and patients with history of hypersensitivity to dacarbazine temozolomide or polyethylene_glycol are excluded
__label__1	study interventions are Antibodies . other concurrent anticancer therapy
__label__1	study interventions are Etoposide . refractory lymphoblastic lymphoma diagnosis and other medical or psychiatric conditions that in the opinion of the investigator would preclude safe participation in the protocol
__label__1	study interventions are Bortezomib . lung cancer diagnosis and minor surgical procedure such as fine needle aspirations or core biopsies within seven days prior to day zero
__label__1	study interventions are Placebo . hepatocellular carcinoma diagnosis and administered with any anti hbv drugs within four weeks of entering this study
__label__1	study interventions are Raltitrexed . cerebral metastasis or meningeal carcinomatosis
__label__1	study interventions are Thalidomide . refractory diffuse large cell lymphoma diagnosis and history of allergic reactions attributed to lenalidomide or compounds of similar chemical or biologic composition to lenalidomide including thalidomide
__label__1	study interventions are Methyltestosterone . active cns or epidural tumor
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib breast cancer diagnosis and patients must not have received any prior taxane treatments
__label__1	study interventions are oral nutritional supplement . duodenal cancer diagnosis and when investigator judged that the patient is not eligible to the trial
__label__1	study interventions are Cortisone . diffuse large cell lymphoma diagnosis and patients who have had major surgery within four weeks prior to registration are not eligible
__label__1	study interventions are Vidarabine . refractory multiple myeloma diagnosis and age less than twelve years
__label__1	study interventions are Dexamethasone acetate . diffuse large cell lymphoma diagnosis and drug addiction history or alcoholism which may interfere the experimental results
__label__1	study interventions are Hydroxychloroquine . recurrent plasma cell myeloma diagnosis and itraconazole
__label__1	study interventions are Darinaparsin . non hodgkin lymphoma diagnosis and significant neuropathology defined as grade greater_than two per ctcae version doc
__label__1	study interventions are Maleic acid . receiving any other investigational agent which would be considered as treatment for the primary neoplasm
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and other concurrent severe and or uncontrolled medical conditions uncontrolled diabetes or active or uncontrolled infection including abnormal laboratory values that could cause unacceptable safety risks or compromise compliance with the protocol
__label__1	study interventions are Glycine . multiple myeloma diagnosis and serious medical or psychiatric illness that could in the investigator opinion potentially interfere with the completion of treatment according to the protocol
__label__1	study interventions are Doxorubicin . adult cell leukemia lymphoma diagnosis and patients must not have evidence of cerebellar dysfunction or prior history of cerebellar dysfunction with ara administration
__label__1	study interventions are Nivolumab . gliosarcoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with these agents
__label__1	study interventions are Physical Training . pediatric cancer diagnosis and pregnancy test will be provided for participants of ages fourteen and older
__label__1	study interventions are Antibodies . contiguous stage ii small lymphocytic lymphoma diagnosis and corticosteroid therapy also is not permitted while subjects are receiving protocol therapy during the treatment phase of the study
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and significant cardiovascular disease such as new york heart association cardiac disease class ii or greater myocardial infarction within the previous three months unstable arrhythmias or unstable angina
__label__1	study interventions are Paclitaxel . fallopian tube clear cell adenocarcinoma diagnosis and patients known to be hiv positive but without clinical evidence of an immunocompromised state are eligible for this trial
__label__1	study interventions are Carboxymethylcellulose Sodium . melanoma diagnosis and known immunodeficiency or hiv hepatitis or hepatitis positivity
__label__1	study interventions are laboratory biomarker analysis . adenocarcinoma of the prostate diagnosis and the subject requires concomitant treatment in therapeutic doses with anticoagulants such as warfarin or warfarin related agents heparin thrombin or factor xa inhibitors or antiplatelet agents eg clopidogrel low dose aspirin equal_than less_than eighty-one mg day low dose warfarin equal_than less_than one mg day and prophylactic low molecular weight heparin lmwh are permitted
__label__1	study interventions are Vaccines . small cell lung cancer diagnosis and bilirubin less_than doc mg dl
__label__1	study interventions are Interferon-alpha . anus neoplasms diagnosis and history of ventricular arrhythmias or myocardial infarction
__label__1	study interventions are Sirolimus . neuroendocrine tumor grade three and disease progression as measured by response evaluation criteria in solid tumors recist one one diagnosis and concurrent treatment with inhibitors itraconazole ketoconazole and inducers phenytoin rifampicin of cytochrome pfour hundred and fifty threeafour cypthreeafour and or the multidrug efflux pump p_glycoprotein pgp
__label__1	study interventions are Antibodies, Monoclonal . cancer diagnosis and known positive test for human immunodeficiency virus hiv infection hepatitis virus acute or chronic hepatitis infection
__label__1	study interventions are Fludarabine . childhood grade iii lymphomatoid granulomatosis diagnosis and adult thirty pediatric
__label__1	study interventions are Fluorouracil . adenocarcinoma of the gallbladder diagnosis and neuropathy grade two or greater by nci ctcae v
__label__1	study interventions are Epirubicin . tubular breast cancer stage ii diagnosis and pre existing motor or sensory neuropathy of severity grade two by nci ctc criteria doc
__label__1	study interventions are Lenalidomide . central nervous system or meningeal involvement by lymphoma
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and uncontrolled hypertension or diabetes
__label__1	study interventions are Paclitaxel . hrpos breast neoplasms diagnosis and patients of childbearing potential must implement adequate non hormonal contraceptive measures barrier methods intrauterine contraceptive devices sterilization during study treatment
__label__1	study interventions are Aveeno cream . urogenital neoplasms diagnosis and sometimes mild burn gradually tans
__label__1	study interventions are Trastuzumab . neoplasms breast diagnosis and the patient has other concurrent severe medical problems unrelated to the malignancy that would significantly limit full compliance with the study or expose the patient to unacceptable risk
__label__1	study interventions are Capecitabine . colorectal cancer diagnosis and known brain metastases
__label__1	study interventions are Carboplatin . ovarian carcinoma diagnosis and pulmonary hemorrhage bleeding event greater_than ctcae grade two within four weeks of first dose of study drug
__label__1	study interventions are Sirolimus . stage iiib ovarian cancer diagnosis and metastatic disease to the central nervous system for which other therapeutic options including radiotherapy may be available
__label__1	study interventions are Lenograstim . recurrent adult diffuse small cleaved cell lymphoma diagnosis and previous systemic chemotherapy immunotherapy within three weeks before study entry
__label__1	study interventions are Cisplatin . head and neck squamous cell carcinoma diagnosis and patients must not have active clinically significant hemoptysis
__label__1	study interventions are Vaccines . stage iiic breast cancer diagnosis and pregnant or nursing female patients
__label__1	study interventions are onabotulinumtoxinA . neoplasms by site diagnosis and patient declines inclusion in the study
__label__1	study interventions are Prednisone . contiguous stage ii marginal zone lymphoma diagnosis and known hypersensitivity to lenalidomide or thalidomide
__label__1	study interventions are Vidarabine . intraocular lymphoma diagnosis and patient has central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Sunitinib . metastatic renal cell carcinoma diagnosis and subjects with vitiligo or type diabetes mellitus or residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement are permitted to enroll
__label__1	study interventions are Rituximab . non hodgkin follicular lymphoma diagnosis and other investigational drug within twenty-eight days before enrollment
__label__1	study interventions are Thiotepa . primary central nervous system lymphoma diagnosis and severe renal or hepatic disease
__label__1	study interventions are Clindamycin . breast cancer diagnosis and allergy to any of the antibiotic drugs used
__label__1	study interventions are Paclitaxel . pancreatic adenocarcinoma diagnosis and patients with locally advanced surgically unresectable pdac
__label__1	study interventions are Cyclosporins . stage ii childhood anaplastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Buprenorphine . cancer pain diagnosis and participation in other research projects that are in conflict or could confound the results of the study
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and previous radiation therapy to target lesion
__label__1	study interventions are Dexamethasone 21-phosphate . lymphoma large cell diffuse diagnosis and pregnant or lactating women
__label__1	study interventions are Dexamethasone . other malignancy within the past five years except for adequately treated basal cell or squamous cell skin cancer in situ cervical cancer or other cancer for which the patient has not received treatment within the past year note
__label__1	study interventions are Rituximab . grade one follicular lymphoma diagnosis and history of human immunodeficiency virus hiv infection or active hepatitis or c
__label__1	study interventions are Cetuximab . recurrent non small cell lung carcinoma diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Bevacizumab . cholangiocarcinoma diagnosis and subjects meeting any of the following criteria are ineligible for study entry
__label__1	study interventions are Tacrolimus . stage ii multiple myeloma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Endothelial Growth Factors . stage iiib skin melanoma diagnosis and patients who have had chemotherapy or radiotherapy within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and intolerance to bortezomib or cc five thousand and thirteen in the past or significant allergy to either compound boron or mannitol
__label__1	study interventions are Pembrolizumab . recurrent fallopian tube carcinoma diagnosis and has received live vaccine within thirty days of planned start of study therapy
__label__1	study interventions are Retinol acetate . contiguous stage ii small lymphocytic lymphoma diagnosis and concurrent treatment with an investigational agent other than the investigational agent used in this study or treatment within four weeks of study entry with any investigational agent or device s
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma and plasma cell neoplasm diagnosis and known hepatitis or obligatory testing is not necessary
__label__1	study interventions are Vidarabine . noncutaneous extranodal lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than thirty total lung capacity tlc less_than thirty forced expiratory volume in one second fevone less_than thirty and or receiving supplementary continuous oxygen the fhcrc principal investigator pi of the study must approve enrollment of all patients with pulmonary nodules
__label__1	study interventions are Prednisone . contiguous stage ii mantle cell lymphoma diagnosis and positive serology because of prior vaccination is allowed
__label__1	study interventions are Dacarbazine . patients with significant cardiac illness such as symptomatic coronary artery disease or previous history of myocardial infarction impaired left ventricle function or serious cardiac arrhythmias requiring therapy
__label__1	study interventions are Dynamic Contrast-Enhanced Magnetic Resonance Imaging . adult medulloblastoma diagnosis and serious concurrent infection illness or medical condition
__label__1	study interventions are Molgramostim . sarcoma kaposi diagnosis and other antiviral agents immunotherapy hormonal therapy chemotherapy directed at treatment of viral infection or malignancy
__label__1	study interventions are Melphalan . recurrent adult burkitt lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than forty predicted corrected for hemoglobin and or alveolar ventilation
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and pregnant women are excluded from this study because pembrolizumab has the potential for teratogenic or abortifacient effects
__label__1	study interventions are Cisplatin . other malignancy within the past five years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
__label__1	study interventions are Carboplatin . stage iva vaginal cancer diagnosis and known seropositive for hiv antibody
__label__1	study interventions are Gemcitabine . stage ib pancreatic cancer diagnosis and use of pancreatic enzyme supplements is allowed to control malabsorption
__label__1	study interventions are laboratory biomarker analysis . childhood nasal type extranodal nk cell lymphoma diagnosis and pregnant or lactating females
__label__1	study interventions are Laboratory Biomarker Analysis . stage iii thyroid gland follicular carcinoma diagnosis and myocardial infarction
__label__1	study interventions are Pharmacological Study . unresectable pancreatic carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to dinaciclib or to mk two thousand, two hundred and six
__label__1	study interventions are Paclitaxel . proximal urethral cancer diagnosis and no persistently uncontrolled diabetes mellitus
__label__1	study interventions are Doxorubicin . stage iii non hodgkin lymphoma diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated note
__label__1	study interventions are Fludarabine phosphate . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and patients with poorly controlled hypertension on multiple antihypertensives
__label__1	study interventions are Bevacizumab . esophageal neoplasms diagnosis and history of stroke within the last six months
__label__1	study interventions are Immunoglobulins . colorectal neoplasm diagnosis and recipient of vaccines within one month of or during study drug treatment
__label__1	study interventions are Tacrolimus . stage grade one follicular lymphoma diagnosis and donor
__label__1	study interventions are Tamoxifen . stage iib breast cancer diagnosis and definitive clinical or radiologic evidence of metastatic disease note
__label__1	study interventions are regorafenib . recurrent islet cell carcinoma diagnosis and persistent proteinuria greater_than equal_than grade three nci ctcae doc greater_than doc twenty-four hrs measured by urine protein
__label__1	study interventions are Radiofrequency Ablation . primary liver cancer diagnosis is not clear
__label__1	study interventions are Capecitabine . metastatic breast cancer diagnosis and history of severe and unexpected reactions to fluoropyrimidine therapy
__label__1	study interventions are Mycophenolate mofetil . aids related peripheral systemic lymphoma diagnosis and donor
__label__1	study interventions are Gossypol acetic acid . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to at one hundred and one or other agents used in study
__label__1	study interventions are Sirolimus . kidney neoplasms diagnosis and active infection or fever greater_than three doc within three days of starting treatment
__label__1	study interventions are Tacrolimus . stage iii cutaneous cell non hodgkin lymphoma diagnosis and patients with suitably matched related or unrelated donors
__label__1	study interventions are Carboplatin . recurrent verrucous carcinoma of the oral cavity diagnosis and patients who have had chemotherapy within four weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Paclitaxel . ovarian serous tumor diagnosis and prior treatment with trastuzumab
__label__1	study interventions are Placebo administration. . colorectal cancer diagnosis and evidence of other disease metabolic dysfunction physical examination finding or clinical laboratory finding giving reasonable suspicion of disease or condition that contraindicates the treatment or patient at high risk from treatment complications
__label__1	study interventions are Mesna . small cell lung cancer diagnosis and additional malignancies
__label__1	study interventions are Bevacizumab . endometrial serous adenocarcinoma diagnosis and patient is on angiotensin_converting enzyme ace inhibitors benazapril_captopril enalopril_fosonopril lisinopril_moexipril perindopril_quinopril ramipril and trandolapril patients may have an alternate antihypertensive substituted note
__label__1	study interventions are Etoposide phosphate . germ cell tumors diagnosis and associated pathology may prevent the patient to receive treatment creatinine clearance less_than fifty ml min calculated by cockcroft gault
__label__1	study interventions are 851B . papillomavirus infections diagnosis and cytotoxic drugs
__label__1	study interventions are Cholecalciferol . ovarian cancer diagnosis and negative pregnancy test is required within seven days of registration if pr negative or perimenopausal last menstrual period within one year of registration
__label__1	study interventions are Cisplatin . esophageal cancer diagnosis and evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are Pertuzumab . breast cancer diagnosis and currently receiving pmab or lapatinib for treatment of mbc
__label__1	study interventions are Vidarabine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and left ventricular ejection fraction less_than thirty-five
__label__1	study interventions are Iodine-131 anti-B1 antibody . recurrent adult diffuse small cleaved cell lymphoma diagnosis and other serious medical conditions considered to represent contraindications to autologous stem cell transplant asct active coronary artery disease pulmonary dysfunction forced expiratory volume in one second fevone less_than seventy expected vital capacity less_than seventy expected diffusing capacity of the lung for carbon monoxide dlco less_than fifty patient on supplemental oxygen aids etc
__label__1	study interventions are Rituximab . stage iii small lymphocytic lymphoma diagnosis and patients requiring daily corticosteroids at prednisone equivalent of greater_than equal_than twenty mg daily should not be enrolled if corticosteroids can be discontinued or reduced to less_than twenty mg per day of prednisone or equivalent the discontinuation or dose reduction should be done at least seven days prior to first dose
__label__1	study interventions are Antibodies . stage ivb nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Erlotinib Hydrochloride . stage iv non small cell lung cancer diagnosis and to any other site within twenty-eight days before the first dose of study treatment
__label__1	study interventions are Tacrolimus . stage adult diffuse mixed cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and women who are pregnant and or breast feeding
__label__1	study interventions are Dihydromevinolin . neurofibromatosis type one diagnosis and overall the measures below remain appropriate to capture the necessary data to make determination about adhd diagnosis and the investigator will also have the continuous data which may be the most pertinent for our research questions
__label__1	study interventions are Etoposide . splenic marginal zone lymphoma diagnosis and no prior treatment with histone_deacetylase inhibitors
__label__1	study interventions are Levoleucovorin . squamous cell carcinoma histology
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and female participant who is pregnant lactating or planning pregnancy during the course of the trial or the female partner of male participant planning pregnancy during the course of the trial
__label__1	study interventions are Cyclosporins . stage iii adult burkitt lymphoma diagnosis and patients asking or who have had prior treatment with drug like vorinostat valproic acid within the last thirty days
__label__1	study interventions are CAR-T cell immunotherapy . prostate cancer diagnosis and mods
__label__1	study interventions are Mycophenolate mofetil . recurrent grade two follicular lymphoma diagnosis and prior autologous or allogeneic stem cell transplant with myeloablative preparative regimen if equal_than less_than eighteen years old prior myeloablative transplant within the last six months
__label__1	study interventions are 8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one . sarcoma diagnosis and any current treatment medical history or uncontrolled condition other than malignancy alcoholism or signs of alcohol abuse seizure disorder medical or psychiatric condition that in the opinion of the investigator would confound the results of the study or pose any unwarranted risk in administering study drug to the subject
__label__1	study interventions are Antibodies, Monoclonal . lymphoma non hodgkin diagnosis and patients with new york heart association class iii or iv heart disease or other serious illness that would preclude evaluation
__label__1	study interventions are radiotherapy weekly verification standard safety margins . prostatic neoplasms diagnosis and any pre existing condition making the patient unsuitable for radiotherapy
__label__1	study interventions are Celecoxib . colorectal adenoma diagnosis and the dose schedule and indications of the medications would be reviewed with the patient and decision regarding entry into the study would be made by the enlisting physician
__label__1	study interventions are Akt Inhibitor MK2206 . endometrial clear cell adenocarcinoma diagnosis and hgbaonec greater_than doc or fasting glucose greater than one30mg dl will exclude patients from entry on study patients requiring insulin for control of their hyperglycemia are excluded from entry on this study
__label__1	study interventions are Olaparib . cancer diagnosis and patients with previously treated brain metastases are eligible provided that the patient has not experienced seizure or had clinically significant change in neurological status within the three months prior to registration
__label__1	study interventions are Mycophenolic Acid . stage ii childhood anaplastic large cell lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Niacinamide . recurrent breast cancer diagnosis and nsaids must be discontinued within five days prior to initiating study treatment
__label__1	study interventions are Irinotecan . patients with known brain metastases are not eligible unless brain metastases are treated and stable on radiographic follow up and without significant symptomatology
__label__1	study interventions are Voriconazole . hematopoietic lymphoid cancer diagnosis and sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation
__label__1	study interventions are Doxorubicin . recurrent primary peritoneal carcinoma diagnosis and patients with active severe infection known infection with human immunodeficiency virus hiv hepatitis virus hepatitis virus or severe concurrent illness
__label__1	study interventions are Taxane . recurrent breast cancer diagnosis and left ventricular ejection fraction lvef less_than fifty as determined by multi gated acquisition muga scan or echocardiogram echo
__label__1	study interventions are Irinotecan . stage iva pancreatic cancer diagnosis and patients may not have received any other investigational agents within four weeks of study entry
__label__1	study interventions are Radiofrequency ablation . esophageal cancer diagnosis and participant suffers from psychiatric or other illness deemed by the investigator as an inability to comply with protocol
__label__1	study interventions are Immunoglobulin G . recurrent adult soft tissue sarcoma diagnosis and patients with cns metastases treated within three months prior to enrollment by neurosurgical resection or brain biopsy are ineligible
__label__1	study interventions are Erlotinib Hydrochloride . non squamous non small cell lung cancer diagnosis and use of coumarins
__label__1	study interventions are Valganciclovir . contiguous stage ii adult lymphoblastic lymphoma diagnosis and no prior allogeneic hct allo hct autologous hct auto hct is allowed
__label__1	study interventions are Mycophenolate mofetil . recurrent adult hodgkin lymphoma diagnosis and age less than twelve years
__label__1	study interventions are Bevacizumab . esophageal neoplasms diagnosis and unstable angina or history of myocardial infarction within the last six months
__label__1	study interventions are NCCN Guidelines: Distress management . have not completed cancer treatment within the past three months
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and subject is pregnant or breast feeding or planning to become pregnant within six months after the last dose of protocol specified therapy administration
__label__1	study interventions are Poly(ADP-ribose) Polymerase Inhibitors . cervical cancer diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with azdtwo thousand, two hundred and eighty-one
__label__1	study interventions are Antiviral Agents . noncontiguous stage ii adult burkitt lymphoma diagnosis and concomitant anti graft versus host disease gvd treatment includes in vivo cell depletion
__label__1	study interventions are Cisplatin . transitional cell carcinoma diagnosis and clinically significant arrhythmia electrocardiogram qtc greater than five hundred msec
__label__1	study interventions are Gemcitabine . patients with currently active second malignancy other than non melanoma skin cancer or carcinoma in situ of the cervix are not to be registered
__label__1	study interventions are Piperazine . malignant glioma diagnosis and seven patients with human immunodeficiency virus hiv hepatitis surface antigen or hepatitis positive or with history of chronic active hepatitis or cirrhosis
__label__1	study interventions are Cytarabine . recurrent plasma cell myeloma diagnosis and patient with poorly controlled hypertension despite multiple antihypertensives
__label__1	study interventions are Fludarabine phosphate . indolent non hodgkin lymphoma diagnosis and has active hepatitis or confirmed by rna test
__label__1	study interventions are Trebananib . recurrent renal cell carcinoma diagnosis and history of allergic reactions to bacterially_produced proteins
__label__1	study interventions are Paclitaxel . esophageal squamous cell carcinoma diagnosis and active infection
__label__1	study interventions are Antibodies . ovarian carcinosarcoma diagnosis and known hypersensitivity to other recombinant human antibodies or chinese_hamster ovary cell products
__label__1	study interventions are Lapatinib . hertwo neu positive breast cancer diagnosis and medications that are specifically prohibited can be found in appendix c
__label__1	study interventions are Cyclosporins . anaplastic large cell lymphoma diagnosis and donors
__label__1	study interventions are Everolimus . advanced cancer diagnosis and major surgery open biopsy or traumatic injury within four weeks of starting study drug
__label__1	study interventions are Epoetin Alfa . cancer diagnosis and no uncontrolled hypertension
__label__1	study interventions are Etoposide . stage adult diffuse large cell lymphoma diagnosis and positive serology for hepatitis hc defined as positive test for hcab
__label__1	study interventions are Octreotide . polycystic kidney autosomal_dominant diagnosis and uncontrolled hypertension systolic blood pressure greater than one hundred and sixty mmhg diastolic blood pressure greater than one hundred mmhg
__label__1	study interventions are Lenalidomide . stage cutaneous cell non hodgkin lymphoma diagnosis and patients who received chemotherapy including monoclonal antibodies or radiotherapy administered for any condition within four weeks prior to registration are not eligible
__label__1	study interventions are Motexafin gadolinium . lung neoplasms diagnosis and creatinine greater_than doc mg dl
__label__1	study interventions are Prednisolone phosphate . multiple myeloma diagnosis and patients with congestive heart failure nyha iii iv
__label__1	study interventions are Paclitaxel . stage iiib primary peritoneal cancer diagnosis and ctep ctcae version doc grade two or higher peripheral ischemia brief less_than two4 hours hrs episode of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Pembrolizumab . metastatic non small cell lung cancer diagnosis and is not considered form of systemic treatment
__label__1	study interventions are Cyclophosphamide . non hodgkins lymphoma diagnosis and diagnosis
__label__1	study interventions are Acetylcysteine . stage ii squamous cell carcinoma of the lip and oral cavity diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Oxaliplatin . recurrent colon cancer diagnosis and patients who have undergone major surgery equal_than less_than three weeks prior to starting study drug or who have not recovered from side effects of such procedure
__label__1	study interventions are Bevacizumab . primary peritoneal serous adenocarcinoma diagnosis and stage not greater than b no more than superficial myometrial invasion without vascular or lymphatic invasion no poorly differentiated subtypes including papillary serous clear cell or other figo grade three lesions
__label__1	study interventions are Docetaxel . stage iiic breast cancer diagnosis and patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Lenvatinib . solid malignant tumors diagnosis and previous treatment with lenvatinib except for participants previously enrolled into cohorts one or twob of this study
__label__1	study interventions are Immunoglobulins . lymphoma non hodgkin diagnosis and cytotoxic chemotherapy radiation therapy immunosuppressants or cytokine treatment within four weeks of study entry
__label__1	study interventions are Accelerated Partial Breast Irradiation . t stage of ttwo with the tumor greater_than three cm in maximum diameter or t stage greater_than equal_than three
__label__1	study interventions are Fludarabine . recurrent childhood anaplastic large cell lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and participation in another clinical trial with any investigational drug within thirty days prior to study entry
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and seropositive for human immunodeficiency virus hepatitis or hepatitis c
__label__1	study interventions are Leucovorin . stage iib pancreatic cancer diagnosis and ethinyl estradiol alternative or additional contraceptive measures should be used when oral contraceptives and viracept are coadministered
__label__1	study interventions are TNFerade . pancreatic cancer diagnosis and pancreatic pseudocyst
__label__1	study interventions are Liposomal doxorubicin . stage iv soft tissue sarcoma diagnosis and cerebrovascular accident cva or transient ischemic attack tia
__label__1	study interventions are Exemestane . kidney neoplasms diagnosis and patient with known positive serology for human immunodeficiency virus
__label__1	study interventions are Iodine-131 anti-B1 antibody . lymphoma non hodgkin diagnosis and patients with known hiv infection
__label__1	study interventions are E-NOTES . myoma diagnosis and greater than five fibroids sized of threecm or more
__label__1	study interventions are Antibodies, Monoclonal . not recovered from side effects of prior therapy to less_than grade one according to national cancer institute nci common terminology criteria for adverse events ctcae v
__label__1	study interventions are Veliparib . childhood supratentorial ependymoma diagnosis and patients with any clinically significant unrelated systemic illness serious infections or significant cardiac pulmonary hepatic or other organ dysfunction that would compromise the patient ability to tolerate protocol therapy or would likely interfere with the study procedures or results
__label__1	study interventions are Mycophenolate mofetil . stage iii adult diffuse small cleaved cell lymphoma diagnosis and patients with poorly controlled hypertension on multiple antihypertensives
__label__1	study interventions are Liposomal doxorubicin . stage adult hodgkin lymphoma diagnosis and known cns involvement
__label__1	study interventions are KLH, peptides plus Montanide . melanoma diagnosis and patients with known allergy to gentamicin tobramycin streptomycin and amikacin risk of cross reaction between aminoglycosides
__label__1	study interventions are Pembrolizumab . stage iiib hepatocellular carcinoma diagnosis and note
__label__1	study interventions are Antibodies, Monoclonal . stage ib pancreatic cancer diagnosis and john wort hypericum_perforatum
__label__1	study interventions are Bevacizumab . neoplasm metastasis diagnosis and creatinine ratio greater than or equal to doc at screening
__label__1	study interventions are Diphosphonates . prostate cancer diagnosis and patients with history of unilateral fracture of hip due to trauma or unilateral hip surgery and the other hip and lumbar spine are not evaluable
__label__1	study interventions are Fluorouracil . stage iv colon cancer diagnosis and major surgery within twenty-eight days prior to enrollment or still recovering from prior surgery
__label__1	study interventions are photodynamic therapy . adenocarcinoma of the lung diagnosis and prothrombin time exceeding doc times the upper normal limit
__label__1	study interventions are Antibodies, Monoclonal . cutaneous cell non hodgkin lymphoma diagnosis and patient is unwilling or unable to practice contraception during treatment and for one year thereafter
__label__1	study interventions are management of therapy complications . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and any screws_pins rods or other metal objects in the body
__label__1	study interventions are Calcium Carbonate . stage ii breast cancer diagnosis and pre existing myalgias arthralgias and or joint stiffness greater_than equal_than grade one as defined using ctep ctc identified during baseline physical exam
__label__1	study interventions are Nivolumab . neuroblastoma diagnosis and patients previously treated with nivolumab or any other pd one or pd lone targeting antibodies will be excluded from the study
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iib breast cancer diagnosis and pregnant women
__label__1	study interventions are Succinylcholine . stage iiib ovarian cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Complement System Proteins . lymphoma diagnosis and myeloproliferative syndromes diseases
__label__1	study interventions are Mycophenolate mofetil . stage iv adult immunoblastic lymphoma diagnosis and donor
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and any of the following cardiac conditions
__label__1	study interventions are Docetaxel . stage iiic breast cancer diagnosis and myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricle lv function
__label__1	study interventions are Carboplatin . ovarian cancer diagnosis and radiotherapy within twenty-one days prior to registration or to greater than fifteen of the bone marrow
__label__1	study interventions are Erlotinib Hydrochloride . any other malignancies in the preceding five years except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer
__label__1	study interventions are Carboplatin . carcinoma non small cell lung diagnosis and has received previous chemotherapy for stage iv nsclc participants who have received adjuvant chemotherapy are eligible if the last administration of the prior adjuvant regimen occurred at least six months prior to randomization
__label__1	study interventions are Lymphadenectomy . stage iiib vulvar cancer diagnosis and patients who are going to receive another elective surgery during the same operative event as their inguinal lymphadenectomy and vulvar surgery
__label__1	study interventions are Fluorouracil . metastatic colorectal cancer diagnosis and peripheral neuropathy of grade greater_than two
__label__1	study interventions are Vidarabine . lymphoma diagnosis and patients with an antecedent malignancy whose prognosis is poor less_than ninety probability of surviving for five yrs
__label__1	study interventions are Fluorouracil . recurrent esophageal cancer diagnosis and patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period
__label__1	study interventions are Metformin . advanced cancers diagnosis and patients with major surgery within thirty days prior to entering the study
__label__1	study interventions are Iodine . brain and central nervous system tumors diagnosis and therefore negative pregnancy test is required for all women of child bearing age and appropriate contraception is required during the study period
__label__1	study interventions are Stereotactic radiosurgery (SRS) . male breast cancer diagnosis and patients with malabsorption syndrome or other condition that would interfere with intestinal absorption patients must be able to swallow tablets
__label__1	study interventions are Stretching/Flexibility exercise . endometrial cancer diagnosis and six having been told by physician to only do exercise prescribed by physician
__label__1	study interventions are Tacrolimus . stage iii grade three follicular lymphoma diagnosis and identical twin
__label__1	study interventions are Sunitinib . stage iii renal cell cancer diagnosis and non healing wound ulcer including gastrointestinal or fracture
__label__1	study interventions are Lapatinib . metastatic breast cancer diagnosis and patient with hiv and pos negative transplant associated lymphoproliferative disorders
__label__1	study interventions are Esomeprazole . advanced or metastatic erbbtwo overexpressing breast cancer diagnosis and clinically significant electrocardiogram abnormality
__label__1	study interventions are Capecitabine . breast cancer diagnosis and history of myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of lv function
__label__1	study interventions are Bortezomib . non hodgkin lymphoma diagnosis and patient has hypersensitivity to boron or mannitol
__label__1	study interventions are Docetaxel . locally advanced malignant neoplasm diagnosis and acute or subacute intestinal occlusion
__label__1	study interventions are Paclitaxel . metastatic breast cancer diagnosis and central nervous system metastasis including leptomeningeal involvement
__label__1	study interventions are Pegaspargase . recurrent childhood lymphoblastic lymphoma diagnosis and serum glutamate pyruvate transaminase sgpt alanine aminotransferase alt equal_than less_than two hundred and twenty-five l for the purpose of this study the uln for sgpt is forty-five l
__label__1	study interventions are Carboplatin . recurrent cutaneous cell non hodgkin lymphoma diagnosis and pregnant or nursing women men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
__label__1	study interventions are Carboplatin . low grade glioma diagnosis and pregnancy tests with negative result must be obtained in all post menarchal females
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and major surgery kyphoplasty is not considered major surgery
__label__1	study interventions are Triptorelin Pamoate . breast cancer diagnosis and inability to comply with followup
__label__1	study interventions are Polyestradiol phosphate . cancer diagnosis and patients with evidence of active angina as evidenced by chest pain responsive to sublingual nitroglycerin or other anginal equivalent
__label__1	study interventions are Hydrocortisone . recurrent pancreatic cancer diagnosis and patients may not be receiving or received prior to enrollment any other investigational agents for metastatic disease
__label__1	study interventions are Laboratory Biomarker Analysis . ovarian transitional cell carcinoma diagnosis and patients enrolled in weight loss program or who are taking weight loss medications or dietary supplements and are unwilling to discontinue
__label__1	study interventions are Fluorodeoxyglucose F18 . signet ring adenocarcinoma of the rectum diagnosis and known chronic infectious disease including human immunodeficiency virus hiv acquired immune deficiency syndrome aids
__label__1	study interventions are Aromatase Inhibitors . neoplasms diagnosis and rapidly progressive visceral disease not suitable for further endocrine therapy
__label__1	study interventions are Antibodies, Monoclonal . stage iv mantle cell lymphoma diagnosis and donors less_than twelve years of age
__label__1	study interventions are laboratory biomarker analysis . recurrent adult brain tumor diagnosis and patients with history of being serologically positive for hepatitis or or who have history of cirrhosis are ineligible
__label__1	study interventions are Anastrozole . breast carcinoma diagnosis and therapeutic or traumatic metal implant in the skin or muscle of either deltoid region
__label__1	study interventions are Lenalidomide . intraocular lymphoma diagnosis and the development of erythema_nodosum if characterized by desquamating_rash while taking thalidomide or similar drugs
__label__1	study interventions are Magnetic Resonance Spectroscopic Imaging . glioblastoma diagnosis and research participant requires supplemental oxygen to keep saturation greater than ninety-five and the situation is not expected to resolve within two weeks
__label__1	study interventions are Tacrolimus . angioimmunoblastic cell lymphoma diagnosis and patient with rapidly progressive aggressive nhl unless in minimal disease state
__label__1	study interventions are Pimonidazole . hypoxia in rectal cancer diagnosis and previous pelvic radiotherapy
__label__1	study interventions are Sirolimus . adult non hodgkin lymphoma diagnosis and one and donor is homozygous two
__label__1	study interventions are SNS01-T . multiple myeloma diagnosis and be receiving or have received heparin therapeutically within two days before and after treatment with snsone t
__label__1	study interventions are Vidarabine . stage iii multiple myeloma diagnosis and eligible for high priority curative autologous transplant
__label__1	study interventions are Epirubicin . exceptions include basocellular carcinoma in situ cancer of the cervix of the uterus or any curatively treated other malignancies without evidence of disease for more than five years
__label__1	study interventions are Bevacizumab . primary peritoneal carcinoma diagnosis and life expectancy of less than twelve weeks
__label__1	study interventions are Antibodies, Monoclonal . metastatic breast cancer diagnosis and human anti murine antibody positive or hypersensitivity to murine proteins and any other component of the study drug
__label__1	study interventions are Immunoglobulins . stage ivb salivary gland cancer diagnosis and any malabsorption problem
__label__1	study interventions are Liposomal doxorubicin . have platelet count less_than seventy-five zero mmthree absolute neutrophil count less_than one thousand, five hundred mmthree or hgb less_than one doc dl unless the hemoglobin value has been stable the subject is cardiovascularly stable asymptomatic and judged able to withstand the rfa procedure
__label__1	study interventions are Oxaliplatin . stage iva rectal cancer diagnosis and history of retinal degenerative disease
__label__1	study interventions are Cisplatin . gastric cancer diagnosis and radiotherapy within two weeks before the study entry
__label__1	study interventions are MGD009 . clear cell renal cell carcinoma diagnosis and active viral bacterial or systemic fungal infection requiring parenteral treatment within seven days of first study drug administration
__label__1	study interventions are Lapatinib . prostate cancer diagnosis and patients may not go on heparin during this time
__label__1	study interventions are GD0-994 . history of glaucoma
__label__1	study interventions are Paclitaxel . patients with myocardial infarction within the preceding six months or symptomatic heart disease including uncontrolled or unstable angina uncontrolled congestive heart failure and uncontrolled arrhythmia
__label__1	study interventions are Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination . ovarian cancer risk diagnosis and ischemic heart disease
__label__1	study interventions are Denileukin diftitox . ovarian undifferentiated adenocarcinoma diagnosis and known history of pulmonary disease except controlled asthma
__label__1	study interventions are Trabectedin . sarcoma diagnosis and uncontrolled infection active viral hepatitis
__label__1	study interventions are Bevacizumab . peritoneal carcinoma diagnosis and pulmonary hemorrhage bleeding event greater_than ctcae grade two within four weeks of first dose of study drug
__label__1	study interventions are Docetaxel . non small cell lung cancer stage iiib diagnosis and serious cardiac illness or medical conditions
__label__1	study interventions are Brachytherapy . biliary cancer diagnosis and patients inappropriate for standard breast conservation therapy multicentric disease inability to achieve clear margins
__label__1	study interventions are Metformin . stage ivb oropharyngeal squamous cell carcinoma diagnosis and participant is an active alcoholic or consumes excessive amounts of alcohol per the following definitions
__label__1	study interventions are Dihematoporphyrin Ether . recurrent oral cavity verrucous carcinoma diagnosis and total serum bilirubin greater_than doc mg dl
__label__1	study interventions are Vitamin B 12 . hodgkin lymphoma diagnosis and phase twoa
__label__1	study interventions are Carmustine . t cell non hodgkin lymphoma diagnosis and inadequate performance status organ function defined by dlco less_than fifty adjusted for hgb cardiac function as defined below kps less_than sixty
__label__1	study interventions are Laboratory Biomarker Analysis . malignant ovarian brenner tumor diagnosis and patients who have had surgery for weight loss
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma pancreatic ductal diagnosis and known acute or chronic pancreatitis
__label__1	study interventions are Sirolimus . pten_overgrowth syndrome with vascular anomaly diagnosis and patients who have received prior treatment with an mtor inhibitor
__label__1	study interventions are Emetics . cancer diagnosis and the anti diabetic agent repaglinide or the diuretic torsemide
__label__1	study interventions are Veliparib . stage iii pancreatic cancer diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with abt eight hundred and eighty-eight
__label__1	study interventions are Bortezomib . non hodgkin lymphoma diagnosis and any drugs or agents that inhibit cimetidine erythromycin fluoxetine ketoconazole paroxetine or induce carbamazepine glucocorticoids phenobarbital phenytoin st
__label__1	study interventions are Vaccines . primary central nervous system non hodgkin lymphoma diagnosis and had relapse
__label__1	study interventions are Breast IMRT . breast neoplasms diagnosis and patient being pregnant
__label__1	study interventions are Gold Sodium Thiomalate . stage iv non small cell lung cancer diagnosis and patients with known diabetes mellitus unless well controlled fasting blood sugar fbs equal_than less_than one hundred and twenty-sixmg dl and hemoglobin hb aonec equal_than less_than doc
__label__1	study interventions are selumetinib . advanced adult primary liver cancer diagnosis and patients requiring strong inhibitors or inducers of cytochrome pfour hundred and fifty threeafour cypthreeafour or those receiving any medications or substances that are inhibitors or inducers of cyp four hundred and fifty threeafour are ineligible
__label__1	study interventions are Oxaliplatin . a history of other malignancy less_than three years previous with the exception of basal cell or squamous cell carcinoma of the skin which were treated with local resection only or carcinoma in situ of the cervix or prostate cancer treated without radiotherapy
__label__1	study interventions are Trastuzumab . adenocarcinoma of the stomach diagnosis and patients with known history of hypersensitivity to trastuzumab or any of its components are excluded
__label__1	study interventions are Bevacizumab . melanoma diagnosis and patients should be excluded if they have the following conditions
__label__1	study interventions are Oxaliplatin . gastric cancer diagnosis and history of another malignancy within the last five years
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and previous treatment with docetaxel paclitaxel epirubicin cyclophosphamide trastuzumab pertuzumab or tocotrienol
__label__1	study interventions are Antibodies . ovarian mucinous adenocarcinoma diagnosis and stage not greater than ib
__label__1	study interventions are Capecitabine . patients with symptomatic brain metastasis
__label__1	study interventions are Cisplatin . stage iii squamous cell carcinoma of the hypopharynx diagnosis and pregnant lactating or unwilling to use adequate contraception
__label__1	study interventions are Abiraterone Acetate . prostatic neoplasm diagnosis and have uncontrolled hypertension
__label__1	study interventions are Bendamustine Hydrochloride . extensive stage lung cancer diagnosis and neuropathy at baseline greater_than grade two
__label__1	study interventions are Folic Acid . colorectal cancer diagnosis and known leptomeningeal disease or brain metastases or uncontrolled spinal cord compression currently or in the past
__label__1	study interventions are Fentanyl . primary breakthrough pain is not related to cancer in any way
__label__1	study interventions are Nintedanib . renal cell carcinoma diagnosis and known hypersensitivity to nintedanib peanut or soya or any other trial drug their excipients or to contrast media
__label__1	study interventions are Paclitaxel . neuroendocrine tumors diagnosis and history of an allergic reaction to previous received platinum doublet or history of having to discontinue previous exposed chemotherapy secondary to toxicity to previous chemotherapy
__label__1	study interventions are Carboplatin . bronchioloalveolar lung carcinoma diagnosis and aspirin greater_than three hundred and twenty-five mg day nsaid and or anti platelet drugs patient must have discontinued its use greater_than one week prior to randomization
__label__1	study interventions are Pomalidomide . relapsed or refractory multiple myeloma diagnosis and hypersensitivity to thalidomide lenalidomide or dexamethasone this includes greater_than grade three rash during prior thalidomide or lenalidomide therapy
__label__1	study interventions are Bendamustine Hydrochloride . non hodgkin lymphoma diagnosis and for r participants recruited in obinutuzumab positive fc regimen immediate prior treatment should not have contained fludarabine or fluoropyrimidines
__label__1	study interventions are Dexamethasone 21-phosphate . ovarian neoplasm diagnosis and current usage of vpa or dex if patient has been on these medications in the past but is not currently taking them she is still candidate for the study
__label__1	study interventions are Gossypol acetic acid . stage iii adult diffuse small cleaved cell lymphoma diagnosis and requirement for routine use of hematopoietic growth factors including granulocyte colony stimulating factor granulocyte macrophage colony stimulating factor or interleukin eleven or platelet transfusions to maintain absolute neutrophil counts or platelets counts above the required thresholds for study entry use of erythropoietin stimulating agents and rbcs prior to study enrollment is allowed
__label__1	study interventions are Antibodies, Monoclonal . colorectal cancer diagnosis and known positive test for human immunodeficiency virus infection hepatitis virus chronic active hepatitis infection
__label__1	study interventions are Oxaliplatin . adenocarcinoma of the rectum diagnosis and subject is receiving therapeutic anticoagulation therapy
__label__1	study interventions are Stenting with neoadjuvant chemotherapy . patients with suspected or proven metastatic adenocarcinoma
__label__1	study interventions are Panobinostat . recurrent grade two follicular lymphoma diagnosis and screening electrocardiogram ecg with qtcfredericia qtcf greater_than four hundred and fifty msec
__label__1	study interventions are Carboplatin . advanced ovarian cancer diagnosis and history of severe allergy
__label__1	study interventions are Anastrozole . ovarian cancer diagnosis and known hypersensitivity to iressa or any of the excipients of this product
__label__1	study interventions are Obinutuzumab . indolent non hodgkin lymphoma diagnosis and known sensitivity to murine products
__label__1	study interventions are Antibodies, Monoclonal . stage iiia fallopian tube cancer diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are Pembrolizumab . stage iv skin melanoma diagnosis and has diagnosis of immunodeficiency or is receiving systemic immunosuppressive steroid therapy or any other form of systemic immunosuppressive therapy within seven days prior to the first dose of trial treatment exception
__label__1	study interventions are Cediranib . stage iiia rectal cancer diagnosis and human immunodeficiency virus hiv positive patients on combination antiretroviral therapy are ineligible
__label__1	study interventions are Trastuzumab . metastatic breast cancer diagnosis and significant cardiovascular disease such as
__label__1	study interventions are Carmustine . recurrent adult hodgkin lymphoma diagnosis and no compatible donor identified
__label__1	study interventions are Dexamethasone 21-phosphate . refractory cell lymphoma diagnosis and patients with cutaneous disease only are not eligible
__label__1	study interventions are Cyclophosphamide . hertwo negative breast cancer diagnosis and known hiv or active hepatitis or infection
__label__1	study interventions are Dihydroxycholecalciferols . prostate cancer diagnosis and must not have urinary protein greater_than fourgm 2four hours
__label__1	study interventions are Cetuximab . recurrent head and neck cancer diagnosis and patients receiving radiation within four weeks prior to the first dose of study drug
__label__1	study interventions are Cisplatin . her two positive advanced gastric cancer diagnosis and baseline lvef left ventricular ejection fraction less_than fifty
__label__1	study interventions are Cediranib . cutaneous cell non hodgkin lymphoma diagnosis and creatinine ratio greater_than doc twenty-four hour urine protein should be obtained and the level should be less_than one thousand mg for patient enrollment
__label__1	study interventions are Adrenergic Agents . cervical cancer diagnosis and must have had treatment for first line recurrence
__label__1	study interventions are Rosiglitazone . huerthle cell thyroid cancer diagnosis and allergy or hypersensitivity to components of either of the study treatment xlone hundred and eighty-four and rosiglitazone formulations
__label__1	study interventions are Aromatase Inhibitors . metastatic breast cancer diagnosis and extensive visceral metastases requiring chemotherapy
__label__1	study interventions are Ado-trastuzumab emtansine . investigational therapy or any other anticancer therapy less_than equal_than twenty-eight days before first study treatment
__label__1	study interventions are Endothelial Growth Factors . recurrent ovarian carcinoma diagnosis and active infection requiring parenteral antibiotics
__label__1	study interventions are Oxaliplatin . stage iiib gastric cancer diagnosis and arterial thromboembolic events unstable angina
__label__1	study interventions are PAC-1 . gastrointestinal cancers diagnosis and has history of blood clots pulmonary embolism or dvt unless controlled by anticoagulant treatment
__label__1	study interventions are pharmacological study . recurrent small lymphocytic lymphoma diagnosis and rifampin rifabutin rifapentine
__label__1	study interventions are Paclitaxel . peritoneal cancer diagnosis and known hypersensitivity to cremophor_el paclitaxel or its components
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent urothelial carcinoma of the renal pelvis and ureter diagnosis and prior therapy with eseven thousand, three hundred and eighty-nine halichondrin analog eribulin
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib cervical cancer diagnosis and patients with renal abnormalities such as pelvic kidney horseshoe kidney or renal transplantation that would require modification of radiation fields
__label__1	study interventions are Carboplatin . epithelial ovarian cancer diagnosis and prior chemotherapy targeted small molecule therapy or radiation therapy within two weeks prior to study day one or has not recovered less_than grade one or at baseline from adverse events due to previously administered event
__label__1	study interventions are Gemcitabine . kidney cancer diagnosis and serious concurrent infections or other serious medical conditions including uncontrolled diabetes
__label__1	study interventions are CT/CBCT thermometry method . neoplasms liver diagnosis and subjects have body weight in excess of three hundred and seventy-five lbs
__label__1	study interventions are Liposomal doxorubicin . undifferentiated fallopian tube carcinoma diagnosis and patients with prior treatment with bevacizumab
__label__1	study interventions are Docetaxel . metastatic breast cancer diagnosis and age less than eighteen years
__label__1	study interventions are Carmustine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and patients with active infection
__label__1	study interventions are Endothelial Growth Factors . recurrent ovarian carcinoma diagnosis and pregnant women
__label__1	study interventions are Rituximab . stage marginal zone lymphoma diagnosis and known hypersensitivity to lenalidomide or thalidomide
__label__1	study interventions are Bevacizumab . lung cancer diagnosis and you can then decide if you wish to participate
__label__1	study interventions are Antibodies, Monoclonal . pediatric cancers diagnosis and patients are excluded if they have greater_than five hundred mg protein on twenty-four hour urine collection
__label__1	study interventions are Dexamethasone 21-phosphate . fallopian tube cancer diagnosis and myocardial infarction within six months prior to entry
__label__1	study interventions are Fluorouracil . adenocarcinoma of the gastroesophageal junction diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Dasatinib . breast cancer diagnosis and newly diagnosed within three months before enrollment or poorly controlled defined as fasting serum glucose greater_than one hundred and sixty mg dl or hemoglobin aonec greater_than eight at screening type one or two diabetes mellitus
__label__1	study interventions are Immunoglobulin G . solid neoplasm diagnosis and significant st depression of greater_than equal_than doc mm in two or more leads and or wave_inversions in greater_than equal_than two leads
__label__1	study interventions are Bevacizumab . adult giant cell glioblastoma diagnosis and at least six weeks since prior nitrosourea
__label__1	study interventions are Busulfan . unspecified adult solid tumor protocol specific diagnosis and estimated risk of graft vs
__label__1	study interventions are Interferon-beta . merkel cell polyomavirus infection diagnosis and aspartate aminotransferase ast alanine aminotransferase alt greater_than doc uln for patients with liver metastases
__label__1	study interventions are Thiotepa . other malignancy within the past five years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ
__label__1	study interventions are Cyclophosphamide . hepatocellular carcinoma fibrolamellar variant diagnosis and active substance abuse
__label__1	study interventions are Testosterone undecanoate . ovarian tumors sertoli_leydig cell tumor or androgen secreting tumors of the ovary or adrenal gland
__label__1	study interventions are EPZ-6438 . have measurable disease as defined by international working group non hodgkin lymphoma iwg nhl cheson two thousand and seven
__label__1	study interventions are cytology specimen collection procedure . recurrent breast cancer diagnosis and have serious uncontrolled intercurrent medical or psychiatric illness including serious infection
__label__1	study interventions are Fiducial marker placement . prostate cancer diagnosis and artificial heart valve
__label__1	study interventions are Vidarabine . refractory multiple myeloma diagnosis and patients with greater_than grade ii hypertension by common toxicity criteria ctc
__label__1	study interventions are Carboplatin . newly diagnosed carcinoma of unknown primary diagnosis and prior therapy with herceptin
__label__1	study interventions are Cisplatin . unresectable gallbladder carcinoma diagnosis and arm cohort three
__label__1	study interventions are quality-of-life assessment . breast cancer diagnosis and known to be pregnant or breastfeeding
__label__1	study interventions are Goserelin . breast cancer diagnosis and four poorly controlled hypertension systolic bp greater_than one hundred and eighty mmhg or diastolic bp greater_than one hundred mmhg
__label__1	study interventions are Therapeutic Conventional Surgery . stage iii laryngeal squamous cell carcinoma diagnosis and secon negative or third degree atrioventricular_av block unless treated with permanent pacemaker
__label__1	study interventions are Interferon-alpha . melanoma diagnosis and uveal or ocular mel
__label__1	study interventions are Antibodies, Monoclonal . stage iv adrenal cortex carcinoma diagnosis and any known positive test for hepatitis or hepatitis virus indicating acute or chronic infection is not permitted
__label__1	study interventions are Nintedanib . peritoneal cancer diagnosis and uncontrolled hypertension
__label__1	study interventions are Camptothecin . adenocarcinoma of unknown primary diagnosis and history of interstitial lung disease idiopathic pulmonary fibrosis silicosis or connective tissue disorders
__label__1	study interventions are pharmacological study . stage ivc squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and antifungals
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent primary peritoneal carcinoma diagnosis and this criterion applies only to the patients enrolled before august twenty-nine two thousand and eleven and those enrolled after this date electing to receive bevacizumab patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Sorafenib . stage ivc squamous cell carcinoma of the oropharynx diagnosis and use of the following medications will not be allowed within four weeks prior to enrollment on the study and during the study
__label__1	study interventions are enzalutamide . advanced hepatocellular carcinoma diagnosis and congestive heart failure new york heart association nyha class iii or iv or history of congestive heart failure nyha class iii or iv in the past unless screening echocardiogram or multi gated acquisition scan performed within three months before the day one visit reveals left ventricular ejection fraction that is greater_than forty-five
__label__1	study interventions are Oxaliplatin . pancreatic carcinoma non resectable diagnosis and subjects receiving inhaled or topical corticosteroids are eligible
__label__1	study interventions are Mycophenolic Acid . stage adult cell leukemia lymphoma diagnosis and presence of active uncontrolled infection at start of conditioning
__label__1	study interventions are Irinotecan . stage iiic rectal cancer diagnosis and history or presence of clinically significant ventricular arrhythmias atrial fibrillation resting bradycardia or conduction abnormality
__label__1	study interventions are Bevacizumab . mixed adenocarcinoma of the stomach diagnosis and patients with non malignant systemic disease cardiovascular renal hepatic etc
__label__1	study interventions are Antibodies, Monoclonal . nodal marginal zone cell lymphoma diagnosis and patient has poorly controlled hypertension and on multiple antihypertensives
__label__1	study interventions are Gemcitabine . malignancies within the past five years other than non melanoma skin cancer or insitu cervical cancer status post treatment
__label__1	study interventions are Paclitaxel . osteosarcoma diagnosis and rifampicin carbamazepine phenytoin efavirenz and nevirapine
__label__1	study interventions are BB 1101 . chemotherapy with approved or investigational anticancer therapeutics including steroid therapy within three weeks prior to first dose or six weeks for antibody therapy
__label__1	study interventions are Liposomal doxorubicin . active infection or fever greater_than three doc degrees unless due to lymphoma
__label__1	study interventions are Carboplatin . stage iiia uterine corpus cancer diagnosis and patients with peripheral neuropathy greater_than ctcae grade one
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and anygreater_than grade two toxicity unresolved
__label__1	study interventions are Veliparib . stage iiic breast cancer diagnosis and active infection
__label__1	study interventions are Antibodies . stage iv melanoma diagnosis and patients with active infections or oral temperature greater_than three doc within seventy-two hours prior to planned leukapheresis the procedure may be deferred
__label__1	study interventions are Citric Acid . ovarian serous adenocarcinoma diagnosis and patients with previous or current malignancy at other sites should be excluded with the exception of
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and taking any known pfour hundred and fifty cytochrome inducers or inhibitors
__label__1	study interventions are Cyclophosphamide . diffuse large cell lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Paclitaxel . fallopian tube transitional cell carcinoma diagnosis and no more than superficial myometrial invasion
__label__1	study interventions are SNS-314 . previous cancer treatment up to twenty-one days before first dose
__label__1	study interventions are Everolimus . estrogen receptor positive breast cancer diagnosis and female patients who are pregnant or breast feeding or adults of reproductive potential who are not using effective birth control methods if barrier contraceptives are being used these must be continued throughout the trial by both sexes hormonal contraceptives are not acceptable as sole method of contraception women of childbearing potential must have negative urine or serum pregnancy test within seven days prior to administration of everolimus
__label__1	study interventions are Therapeutic Conventional Surgery . stage laryngeal squamous cell carcinoma diagnosis and secon negative or third degree atrioventricular_av block unless treated with permanent pacemaker
__label__1	study interventions are Methotrexate . second primary cancer other than kaposi sarcoma non melanoma skin cancer or carcinoma in situ of the cervix
__label__1	study interventions are S-1 . advanced non small cell lung cancer diagnosis and phenytoin one may enhance phenytoin activity
__label__1	study interventions are Cisplatin . transitional cell carcinoma of the bladder diagnosis and for cisplatin only
__label__1	study interventions are Fludarabine . stage iv adult diffuse large cell lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Niacinamide . ocular melanoma diagnosis and history of hiv infection or chronic hepatitis or c
__label__1	study interventions are Endothelial Growth Factors . stage iiia fallopian tube cancer diagnosis and patients with history of cva within six months
__label__1	study interventions are Olaparib . ovarian epithelial cancer diagnosis and known hypersensitivity to olaparib
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and psychological or sociological conditions addictive disorders or family problems that would preclude adherence with study drug or compliance with the protocol
__label__1	study interventions are Mitogens . recurrent breast cancer diagnosis and have required any type of therapy including radiation surgery or steroids to control symptoms from brain metastases within sixty days prior to the first study treatment
__label__1	study interventions are Doxorubicin . adenocarcinoma of colon diagnosis and patients with hypertension or diabetes mellitus is countable if at the time of inclusion deemed medically controlled
__label__1	study interventions are Antibodies . stage iii adult lymphoblastic lymphoma diagnosis and known human immunodeficiency virus hiv infection
__label__1	study interventions are Questionnaires . advanced cancers diagnosis and patients who are currently receiving ultraviolet light ultraviolet light uva uvb therapy or tanning sessions at salons
__label__1	study interventions are Succinylcholine . stage iii pancreatic cancer diagnosis and arms two twoe three threee
__label__1	study interventions are Rituximab . adult lymphoblastic lymphoma diagnosis and known hiv positivity
__label__1	study interventions are Radium-223 . prostate cancer diagnosis and previous treatment with chemotherapy for mcrpc adjuvant chemotherapy is permitted or chemotherapy for any reason within two years prior to registration
__label__1	study interventions are Ganciclovir . noncontiguous stage ii marginal zone lymphoma diagnosis and recipient is human immunodeficiency virus hiv one positive
__label__1	study interventions are BLZ-100 . central nervous system tumors diagnosis and bleeding and thrombosis
__label__1	study interventions are Oxaliplatin . stage iib pancreatic cancer diagnosis and aortic invasion
__label__1	study interventions are Antibodies, Monoclonal . glucagonoma diagnosis and serious non healing wound active ulcer or untreated bone fracture
__label__1	study interventions are Methotrexate . progesterone receptor positive breast cancer diagnosis and prior unanticipated severe reaction to fluoropyrimidine therapy or known sensitivity to five fluorouracil
__label__1	study interventions are Ifosfamide . lymphoma diagnosis and receipt of another investigational drug within fourteen days of enrollment
__label__1	study interventions are Sorafenib . neoplasms diagnosis and gastrointestinal disease that may affect to the absorption of drug or pharmacokinetics
__label__1	study interventions are Pazopanib Hydrochloride . gastrin_producing neuroendocrine tumor diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Antibodies, Monoclonal . stage iii breast cancer diagnosis and chemotherapy less_than three weeks prior to registration
__label__1	study interventions are Thalidomide . carcinoma non small cell lung diagnosis and duration of five half lives must have elapsed before the study registration if the patient was on systemic steroids or other immunosuppressive drugs
__label__1	study interventions are Phenobarbital . breast cancer diagnosis and known severe hypersensitivity to trastuzumab
__label__1	study interventions are gamma-secretase/Notch signalling pathway inhibitor RO4929097 . estrogen receptor negative breast cancer diagnosis and history of risk factors for qt interval prolongation including but not limited to family or personal history of long qt syndrome recurrent syncope without known etiology or sudden_unexpected death
__label__1	study interventions are Vidarabine . angioimmunoblastic cell lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less than forty predicted corrected for hemoglobin hb and or alveolar ventilation
__label__1	study interventions are Fludarabine . multiple myeloma diagnosis and organ function
__label__1	study interventions are Cadexomer iodine . patients who have been disease free of another cancer for greater than five years must be carefully assessed at the time of study entry to rule out recurrent disease
__label__1	study interventions are Specialized tumor board recommendation . diffuse intrinsic pontine glioma dipg diagnosis and female patients of childbearing potential must not be pregnant or breast feeding
__label__1	study interventions are pharmacological study . adult gliosarcoma diagnosis and active clinically significant serious infection requiring treatment with antibiotics anti virals or anti fungals
__label__1	study interventions are Antibodies, Monoclonal . ovarian cancer diagnosis and more than three lines of systemic chemotherapy for recurrent or advanced disease
__label__1	study interventions are Antibodies, Monoclonal . advanced non clear cell kidney cancer diagnosis and treatment with systemic immunosuppressive medications including but not limited to
__label__1	study interventions are Antibodies . stage iva uterine corpus cancer diagnosis and known hypersensitivity to other recombinant human antibodies or chinese_hamster ovary cell products
__label__1	study interventions are Dexamethasone 21-phosphate . presence of symptomatic cns lymphoma
__label__1	study interventions are Mycophenolic Acid . stage ii childhood anaplastic large cell lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Fludarabine phosphate . recurrent childhood lymphoblastic lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Androgens . human epidermal growth factor two negative carcinoma of breast diagnosis and patients who have received pithreek akt inhibitors previously for less_than four weeks will be eligible
__label__1	study interventions are Paclitaxel . cervical adenosquamous carcinoma diagnosis and patients who have received previous pelvic or abdominal radiation cytotoxic chemotherapy or previous therapy of any kind for this malignancy
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and less than three weeks since the last radiotherapy dose
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and history of inflammatory bowel disease
__label__1	study interventions are Oxaliplatin . woman with positive pregnancy test in urine or serum during recruitment prior to the administration of the study medication or within seventy-two hours of beginning to take the study medication or woman who is nursing
__label__1	study interventions are Antibodies, Monoclonal . stage grade two follicular lymphoma diagnosis and known human immunodeficiency virus hiv infection
__label__1	study interventions are AS1409 . metastatic malignant melanoma diagnosis and any concurrent medical or psychological condition that would limit the ability of the patient to provide informed consent or to comply with the obligations of the study
__label__1	study interventions are Dexamethasone acetate . nodal marginal zone cell lymphoma diagnosis and patients with active hepatitis virus hbv infection or hepatitis
__label__1	study interventions are Dasatinib . hormone refractory prostate cancer diagnosis and prior localized radiotherapy for metastatic disease is permitted provided the treatment volume is less thantwenty-five of potential marrow space the radiotherapy must have been completed six weeks prior to enrollment
__label__1	study interventions are Cytarabine . stage iv adult lymphoblastic lymphoma diagnosis and known history of allergy to captisol
__label__1	study interventions are Letrozole . progesterone receptor positive breast cancer diagnosis and uncontrolled central nervous system metastases
__label__1	study interventions are Sirolimus . malignant peripheral nerve sheath tumors diagnosis and patients taking enzyme inducing anticonvulsants
__label__1	study interventions are Fludarabine . recurrent adult immunoblastic large cell lymphoma diagnosis and bilirubin greater_than equal_than three upper limit of normal
__label__1	study interventions are Topoisomerase I Inhibitors . neuroblastoma recurrent diagnosis and patients with cardiac arrhythmias especially prolonged qt
__label__1	study interventions are Vandetanib, Selumetinib . cancer diagnosis and superior vena_cava syndrome
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent fallopian tube carcinoma diagnosis and stage not greater than b no more than superficial myometrial invasion without vascular or lymphatic invasion no poorly differentiated subtypes including papillary serious clear cell or other international federation of gynecology and obstetrics_figo grade three lesions
__label__1	study interventions are Antibodies, Monoclonal . aids related plasmablastic lymphoma diagnosis and use of zidovudine or cobicistat as part of the haart regimen drug substitution at the time of study entry is allowed
__label__1	study interventions are Educational Intervention . breast carcinoma diagnosis and medical history or devices which make an mri unsafe or uncomfortable magnetic rods or pins metal plates or screws pacemaker
__label__1	study interventions are Mycophenolic Acid . recurrent adult diffuse small cleaved cell lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than forty predicted corrected for hemoglobin and or alveolar ventilation
__label__1	study interventions are Albumin-Bound Paclitaxel . melanoma diagnosis and history of hemoptysis or bleeding from gi tract
__label__1	study interventions are Clevudine . malignant neoplasm diagnosis and have undergone chemotherapy or radiation therapy within the previous one month
__label__1	study interventions are Male ER(+) BC Patients . triple negative breast cancer diagnosis and class iii or iv heart failure as defined by the new york heart association nyha functional classification system
__label__1	study interventions are Plicamycin . lung neoplasms diagnosis and dipyridamole
__label__1	study interventions are Cetuximab . stage iv squamous cell carcinoma of the lip and oral cavity diagnosis and impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of radone ulcerative disease uncontrolled nausea vomiting diarrhea malabsorption syndrome or small bowel resection
__label__1	study interventions are Paclitaxel . recurrent fallopian tube cancer diagnosis and history of allergic reactions to cremophor_el paclitaxel or its components
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and mone metastatic disease
__label__1	study interventions are Cetuximab . colorectal cancer diagnosis and active or history of autoimmune disease
__label__1	study interventions are Gamma-Secretase Inhibitor RO4929097 . chondrosarcoma diagnosis and patients must be able to swallow pills patients with malabsorption syndrome or other condition that would interfere with intestinal absorption
__label__1	study interventions are Thalidomide . contiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Abiraterone Acetate . prostate cancer diagnosis and any chronic medical condition requiring higher dose of corticosteroid than five mg prednisone twice daily
__label__1	study interventions are Vidarabine . myelodysplastic myeloproliferative neoplasm diagnosis and pregnancy
__label__1	study interventions are Vidarabine . stage iv marginal zone lymphoma diagnosis and bilirubin greater_than equal_than three upper limit of normal
__label__1	study interventions are Regorafenib . rectal adenocarcinoma diagnosis and gastrointestinal conditions that may significantly affect the absorption of regorafenib
__label__1	study interventions are Bevacizumab . glioblastoma multiforme diagnosis and patients with known sensitivity to any of the products to be administered during treatment
__label__1	study interventions are Prednisolone . prostatic neoplasms diagnosis and rior isotope therapy and or brachytherapy
__label__1	study interventions are Bortezomib . brain and central nervous system tumors diagnosis and hiv positive patients on antiretroviral therapy
__label__1	study interventions are Cisplatin . metastatic breast cancer diagnosis and have qt corrected interval of greater_than four hundred and fifty milliseconds msec on screening electrocardiogram ecg
__label__1	study interventions are JM 3100 . stage iii grade one follicular lymphoma diagnosis and pregnant or lactating females
__label__1	study interventions are Placebo . patients with documentation of well differentiated liposarcoma only of the well differentiated dedifferentiated liposarcoma family are specifically excluded owing to its characteristically slow growth
__label__1	study interventions are Antibodies, Monoclonal . brain neoplasm diagnosis and uncontrolled blood sugar levels defined as hbaonec greater_than seven on two separate measurements
__label__1	study interventions are Dabrafenib . recurrent melanoma diagnosis and history of glucose six phosphate dehydrogenase gsixpd deficiency
__label__1	study interventions are Fluorouracil . malignant neoplasm of stomach stage iv diagnosis and history of stroke or cva within six months
__label__1	study interventions are Prednisolone . recurrent adult diffuse mixed cell lymphoma diagnosis and uncontrolled infection
__label__1	study interventions are Antibodies, Monoclonal . mucinous adenocarcinoma of the rectum diagnosis and patient is more than six months since the last dose of folfiri
__label__1	study interventions are Oxandrolone . unspecified adult solid tumor protocol specific diagnosis and because of the interaction between oxandrin and coumadin oxandrin elevates the inr patients will subsequently require much lower dose of coumadin
__label__1	study interventions are Antibodies, Bispecific . gastric cancer diagnosis and treatment with another investigational product during this study or during the last thirty days prior to study start
__label__1	study interventions are Mycophenolate mofetil . recurrent refractory childhood hodgkin lymphoma diagnosis and cardiac ejection fraction less_than forty
__label__1	study interventions are quality-of-life assessment . prior therapy for breast cancer
__label__1	study interventions are BB 1101 . neoplasms diagnosis and pregnant or lactated women
__label__1	study interventions are Cabozantinib S-malate . stage iva osteosarcoma diagnosis and any of the following within six months before the first dose of study treatment
__label__1	study interventions are Educational Intervention . undifferentiated fallopian tube carcinoma diagnosis and patients with life expectancy of less than one year
__label__1	study interventions are Fluorouracil . any previous or concurrent malignancy withih five years other than non melanoma skin cancer in situ cancer of uterine cervix early gastric cancer thyroid cancer of low risk
__label__1	study interventions are Epothilone B . symptomatic pleural effusions
__label__1	study interventions are Cyclosporine . stage iii adult burkitt lymphoma diagnosis and patients with other disease or organ dysfunction that would limit survival to less than thirty days
__label__1	study interventions are Dacarbazine . brain and central nervous system tumors diagnosis and history of stroke within the past six months
__label__1	study interventions are Cisplatin . gastric cancer diagnosis and severe or uncontrolled cardiovascular disease congestive heart failure nyha iii or iv no myocardial infarction within the last twelve months unstable angina pectoris or significant arrhythmia
__label__1	study interventions are Lenograstim . stage iv adult immunoblastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Everolimus . bladder cancer diagnosis and patients who have any severe and or uncontrolled medical conditions or other conditions that could affect their participation in the study such as
__label__1	study interventions are Celecoxib . brain cancer diagnosis and patients who received only temozolomide during radiation therapy and did not receive adjuvant chemotherapy with temozolomide and or those who received gliadel bcnu wafers at surgery without adjuvant chemotherapy with bcnu or ccnu are eligible if six months has passed since the treatment s
__label__1	study interventions are Vidarabine . metastatic renal cell cancer diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Cisplatin . non small cell lung cancer diagnosis and concomitant treatment with prohibited medications other chemotherapy radiation hormonal treatment excepting corticosteroids or immunotherapy less_than fourteen days prior to negative doc one treatment
__label__1	study interventions are Cetuximab . ovarian cancer diagnosis and women with positive pregnancy test on enrollment or prior to study drug administration
__label__1	study interventions are Camptothecin . recurrent small intestine cancer diagnosis and preexisting sensory neuropathy greater_than equal_than grade two from any cause interfering with function
__label__1	study interventions are Gemcitabine . ovarian cancer diagnosis and concurrent radiation therapy to treat primary disease throughout the course of the study
__label__1	study interventions are Vincristine . untreated childhood medulloblastoma diagnosis and patients with inability to return for follow up visits or obtain follow up studies required to assess toxicity to therapy
__label__1	study interventions are Sorafenib . carcinoma hepatocellular diagnosis and complete left bundle_branch or bifascicular block
__label__1	study interventions are Cabozantinib S-malate . endometrial serous adenocarcinoma diagnosis and other disorders associated with high risk of fistula formation including percutaneous endoscopic gastrostomy peg tube placement within three months before the first dose of study therapy
__label__1	study interventions are Isophosphamide mustard . refractory mediastinal thymic large cell cell lymphoma diagnosis and pregnant women
__label__1	study interventions are Dexamethasone acetate . hx of ventricular arrhythmia or symptomatic conduction abnormality within twelvem
__label__1	study interventions are Mycophenolate mofetil . stage iv adult burkitt lymphoma diagnosis and patients with conventional transplant options conventional transplant should be the priority for eligible patients equal_than less_than fifty yr of age who have related donor mismatched for single hla b or drbone antigen
__label__1	study interventions are Rimiducid . lymphomas diagnosis and pregnancy positive serum human chorionic gonadotropin hcg test or breast feeding
__label__1	study interventions are Therapeutic Conventional Surgery . anaplastic oligodendroglioma diagnosis and any of the following therapies
__label__1	study interventions are Mycophenolic Acid . stage ii childhood small noncleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Lenalidomide . childhood mixed glioma diagnosis and patients who have had thromboembolic event that is not line related are excluded
__label__1	study interventions are Antibodies . recurrent renal cell cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to day one
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and plasma cell dyscrasia with polyneuropathy_organomegaly endocrinopathy monoclonal protein protein and skin changes poems syndrom
__label__1	study interventions are Sunitinib . cervical squamous cell carcinoma diagnosis and active uncontrolled infection
__label__1	study interventions are Sorafenib . history of another primary cancer with the exception of
__label__1	study interventions are Nivolumab . smoldering multiple myeloma diagnosis and patients with hashimoto thyroiditis are eligible to go on study
__label__1	study interventions are Pembrolizumab . recurrent ovarian carcinoma diagnosis and patients with previously treated brain metastases may participate provided they are stable without evidence of progression by imaging for at least three months prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline have no evidence of new or enlarging brain metastases and are not using steroids for at least seven days prior to trial treatment
__label__1	study interventions are Rituximab . non hodgkin lymphoma diagnosis and patient has received other investigational drugs or cytotoxic chemotherapy within fourteen days of enrollment
__label__1	study interventions are Methotrexate . stage iiia breast cancer diagnosis and uncontrolled hypertension diastolic greater than one hundred mm hg or systolic greater_than two hundred mm hg
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and prior treatment with an hdac inhibitor
__label__1	study interventions are Niacinamide . stage iiia skin melanoma diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are Capecitabine . stomach cancer diagnosis and general medical exclusions
__label__1	study interventions are quality-of-life assessment . unspecified adult solid tumor protocol specific diagnosis and not fluent in english because not all questionnaires have been validated in other languages
__label__1	study interventions are Antibodies, Monoclonal . metastatic solid tumors diagnosis and history of arterial or venous thrombosis
__label__1	study interventions are Bevacizumab . breast cancer diagnosis and proteinuria at baseline or clinically significant impairment of renal function
__label__1	study interventions are Valproic Acid . glioma diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Albumin-Bound Paclitaxel . urinary bladder neoplasms diagnosis and pregnant or breast feeding
__label__1	study interventions are Ergocalciferols . lung cancer diagnosis and expected to die within next two months
__label__1	study interventions are TNFerade . rectal cancer diagnosis and concurrent second malignancy requiring systemic therapy
__label__1	study interventions are Propofol . auto immune disease hiv other active cancer agegreater_than eighty-five asa iv or v
__label__1	study interventions are Antibodies, Monoclonal . history of autoimmune disease including but not limited to systemic lupus erythematosus sle sjögren syndrome glomerulonephritis multiple sclerosis rheumatoid arthritis vasculitis systemic immune activation inflammatory bowel disease vascular thrombosis associated with antiphospholipid syndrome wegener granulomatosis guillain_barré syndrome bell palsy
__label__1	study interventions are Tremelimumab . ovarian cancer diagnosis and history of autoimmune disorders other than vitiligo psoriasis extensive atopic_dermatitis asthma inflammatory bowel disease multiple sclerosis uveitis vasculitis chronic inflammatory condition or any condition requiring concurrent use of any systemic immunosuppressants or steroids for any reason are excluded from the study
__label__1	study interventions are Lucitanib . ongoing aes from prior anticancer therapies
__label__1	study interventions are Paclitaxel . fallopian tube clear cell adenocarcinoma diagnosis and new york heart association class ii iv congestive heart failure serious cardiac arrhythmia requiring medication
__label__1	study interventions are Antibodies . recurrent grade two follicular lymphoma diagnosis and history of inflammatory bowel disease crohn disease or ulcerative colitis celiac disease or other chronic gastrointestinal conditions associated with diarrhea or current acute colitis of any origin
__label__1	study interventions are Carboplatin . squamous cell carcinoma of the head and neck diagnosis and pulmonary fibrosis acute lung injury or interstitial pneumonia or with previous medical history of these states
__label__1	study interventions are Abiraterone Acetate . stage iv prostate cancer diagnosis and history of peptic ulcer disease requiring treatment within the last five years
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and history of cardiac disease
__label__1	study interventions are MC: Autologous PBMCs in GM-CSF . stage iv ovarian carcinoma diagnosis and active infection or other active medical condition that could be eminently life threatening including active blood clotting or bleeding diathesis
__label__1	study interventions are N-monoacetylcystine . stage mucoepidermoid carcinoma of the oral cavity diagnosis and immunocompromised patients and patients known to be human immunodeficiency virus hiv positive and currently receiving antiretroviral therapy note
__label__1	study interventions are Cetuximab . gastric cancer diagnosis and concomitant or previous hormonal therapy or immunotherapy
__label__1	study interventions are Albumin-Bound Paclitaxel . disease free period of other malignant tumor is less than five years except cured basal cell skin cancer and cervical carcinoma in situ
__label__1	study interventions are Antibodies, Monoclonal . gastrointestinal stromal tumor diagnosis and subjects who active hepatitis or or human immunodeficiency virus hiv
__label__1	study interventions are Cetuximab . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and uncontrolled inter current illness pre planned surgery or procedure requiring hospitalization during the study period or any other condition or circumstance that could interfere with adherence to the study procedures or requirements or otherwise compromise the study objectives
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and inadequately controlled hypertension defined as systolic blood pressure greater_than one hundred and fifty mmhg and or diastolic blood pressure greater_than one hundred mmhg
__label__1	study interventions are Fludarabine . stage grade three follicular lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Gemcitabine . evidence of another active cancer that may influence patient outcome as determined by the principal investigator except for non melanoma skin carcinoma melanoma in situ in situ carcinoma of the cervix curatively treated treated superficial bladder cancer and adenocarcinoma of the prostate that has been surgically treated with post treatment psa that is non detectable
__label__1	study interventions are 4Dimensional Phase Contrast Magnetic Resonance Angiography . liver cancer diagnosis and documented or reported contrast allergy
__label__1	study interventions are Bevacizumab . malignant ovarian mixed epithelial tumor diagnosis and acrin six thousand, six hundred and ninety-five ineligible patients
__label__1	study interventions are Oxaliplatin . malabsorption syndrome disease significantly affecting gastrointestinal function or resection of the stomach or small bowel or ulcerative colitis symptomatic inflammatory bowel disease or partial or complete bowel obstruction
__label__1	study interventions are Levoleucovorin . malignant neoplasm of esophagus diagnosis and peripheral neuropathy greater_than grade one
__label__1	study interventions are laboratory biomarker analysis . stage iva salivary gland cancer diagnosis and new york heart association nyha grade iii or greater congestive heart failure
__label__1	study interventions are Fludarabine phosphate . recurrent adult burkitt lymphoma diagnosis and inability to understand or give an informed consent
__label__1	study interventions are laboratory biomarker analysis . chemotherapy surgery excluding transurethral resection of bladder tumor turbt bcg or radiotherapy in the prior four weeks six weeks for mitomycin or interferon
__label__1	study interventions are Antibodies, Monoclonal . stage iiic fallopian tube cancer diagnosis and carcinoid permanently closed to enrollment
__label__1	study interventions are Gemcitabine . urethral cancer diagnosis and men must agree to use latex condom during sexual contact with fcbp even if they have had successful vasectomy
__label__1	study interventions are Antibodies . stage iva uterine corpus cancer diagnosis and history of serious ventricular arrhythmia ventricular tachycardia or ventricular fibrillation or cardiac arrhythmias requiring anti arrhythmic medications except for atrial fibrillation that is well controlled with anti arrhythmic medication
__label__1	study interventions are Lapatinib . reccurent metastatic solid tumor disease diagnosis and ecog performance status of zero or one
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and major surgery less than twenty-eight days prior
__label__1	study interventions are Metronidazole . stage iv primary peritoneal cavity cancer diagnosis and metastatic disease to the central nervous system for which other therapeutic options including radiotherapy may be available
__label__1	study interventions are Lactoferrin . carcinoma renal cell diagnosis and pregnant or lactating patients or fertile female patients with positive pregnancy test serum human chorionic gonadotropin hcg at screening and on day one prior to the first dose or fertile female patients unwilling to use adequate contraception prior to study entry during treatment and thirty days after completion of treatment
__label__1	study interventions are Trastuzumab . resolution of all specific toxicities excluding alopecia related to any prior anticancer therapy to grade two according to the national cancer institute common terminology criteria for adverse events nci ctcae v
__label__1	study interventions are Paclitaxel . stage iib gastric cancer diagnosis and pregnant or breastfeeding
__label__1	study interventions are Palbociclib . estrogen receptor positive breast cancer diagnosis and any condition that in the opinion of the investigator might jeopardize the safety of the subject or interfere with protocol compliance
__label__1	study interventions are Pharmacological Study . recurrent malignant neoplasm diagnosis and abdominal fistula
__label__1	study interventions are Etoposide phosphate . angioimmunoblastic cell lymphoma diagnosis and no other concurrent investigational agents
__label__1	study interventions are Diketopiperazines . cancer diagnosis and pregnant or breast feeding women
__label__1	study interventions are Tazemetostat and [14C] Tazemetostat . marginal zone lymphoma diagnosis and is unable to take oral medications malabsorption syndrome or any other uncontrolled gastrointestinal condition nausea diarrhea or vomiting that might impair the bioavailability of study drug
__label__1	study interventions are Saracatinib . recurrent squamous cell carcinoma of the larynx diagnosis and patients who have had chemotherapy or radiotherapy within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study
__label__1	study interventions are Sorafenib . pediatric solid tumors diagnosis and women of childbearing potential must have negative serum or urine pregnancy test within seven days of study entry
__label__1	study interventions are Maleic acid . superficial spreading malignant melanoma diagnosis and mean qtcgreater_than four hundred and seventymsec bazett correction in screening electrocardiogram or history of familial long qt syndrome
__label__1	study interventions are Doxorubicin . stage ia breast cancer diagnosis and uncontrolled hypertension diastolic greater than one hundred mm hg or systolic greater_than two hundred mm hg
__label__1	study interventions are mFOLFOX6 regimen . gastric cancer diagnosis and patients with second malignancies or evidence of severe or uncontrolled systemic disease were excluded
__label__1	study interventions are Radiotherapy . cancer diagnosis and participation in another clinical study or observation period of competing trials
__label__1	study interventions are Vitamins . metastatic breast cancer diagnosis and history of hyperparathyroidism
__label__1	study interventions are Carboplatin . lungcancer diagnosis and total abstinence or two barrier methods or barrier method plus hormonal method from visit one to onetwo0 days after the last dose of treatment
__label__1	study interventions are Endothelial Growth Factors . regional digestive system neuroendocrine tumor gone diagnosis and breastfeeding women
__label__1	study interventions are Paclitaxel . gastric adenocarcinoma diagnosis and active infection requiring systemic therapy
__label__1	study interventions are Bendamustine Hydrochloride . recurrent adult diffuse small cleaved cell lymphoma diagnosis and prior autologous or allogeneic transplantation
__label__1	study interventions are Rituximab . recurrent adult diffuse small cleaved cell lymphoma diagnosis and females who are pregnant or breast feeding
__label__1	study interventions are Immunoglobulins . fallopian tube clear cell adenocarcinoma diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study the investigator should feel free to consult the study chair or study co chairs for uncertainty in this regard
__label__1	study interventions are Docetaxel . fallopian tube endometrioid adenocarcinoma diagnosis and serious cardiac arrhythmia requiring medication
__label__1	study interventions are Immunoglobulins . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and pregnant or breast feeding women will not be entered on this study pregnancy tests must be obtained in girls who are post menarchal males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
__label__1	study interventions are Mebendazole . glioblastoma multiforme diagnosis and lactating females must agree they will not breastfeed child while on this study
__label__1	study interventions are Mycophenolic Acid . recurrent adult cell leukemia lymphoma diagnosis and positive crossmatch between donor and recipient
__label__1	study interventions are Temozolomide . any site of distant disease for example drop metastases from the gbm tumor site
__label__1	study interventions are Bevacizumab . ependymoma diagnosis and patients must not be pregnant because animal studies show that carboplatin and bevacizumab are teratogenic
__label__1	study interventions are Immunoglobulins . follicular lymphoma diagnosis and infection requiring systemic antibiotic therapy or other serious infection within fourteen days before study enrollment
__label__1	study interventions are Dexamethasone acetate . recurrent grade one follicular lymphoma diagnosis and patient has received other investigational drugs less_than one4 days prior to registration
__label__1	study interventions are Carboplatin . neoplasms diagnosis and history of hypersensitivity or infusion reaction to any of the proposed chemotherapy arm agents that could not be controlled with pre medication and or infusion rate adjustment
__label__1	study interventions are Everolimus . gastrointestinal stromal tumor diagnosis and any of the following
__label__1	study interventions are Immunoglobulins . childhood rhabdomyosarcoma with mixed embryonal and alveolar features diagnosis and patients who previously received vinorelbine bevacizumab temsirolimus or any other direct vascular endothelial growth factor vegf vascular endothelial growth factor receptor vegf negative or mammalian target of rapamycin mto negative targeting agents are ineligible
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiic uterine corpus cancer diagnosis and coli derived drug preparations
__label__1	study interventions are Axitinib . metastatic renal cell carcinoma diagnosis and investigational product ags sixteencthreef and or
__label__1	study interventions are Vincristine . neuroblastoma diagnosis and neutrophil count less_than one zero microl or platelet count of less_than fifty zero microl except for the expanded all cohort where there is no blood count requirement
__label__1	study interventions are Saline . glioblastoma multiforme diagnosis and severe active co morbidity
__label__1	study interventions are Immunoglobulins . high grade ovarian serous adenocarcinoma diagnosis and new york heart association functional classification ii iii or iv
__label__1	study interventions are Fludarabine phosphate . recurrent adult immunoblastic large cell lymphoma diagnosis and donor recipient pairs in which the hla mismatch is only in the hvg_direction
__label__1	study interventions are Rituximab . recurrent adult burkitt lymphoma diagnosis and patients who are on daily proton_pump inhibitor therapy must be able to discontinue use or only require use of antacid or hydrogen htwo antagonist intermittently patients who require daily administration of proton_pump inhibitor htwo antagonist or pancreatic enzymes are not eligible intermittent uses of antacids or htwo antagonists are allowed
__label__1	study interventions are Carboplatin . malignant melanoma diagnosis and chronic systemic steroid therapy within two weeks before the planned date for first dose randomized treatment or on any other form of immunosuppressive medication
__label__1	study interventions are Sirolimus . stage iv renal cell cancer diagnosis and major surgery intra thoracic intra abdominal or intra pelvic equal_than less_than four weeks prior to registration or failure to recover from side effects of such surgery exceptions
__label__1	study interventions are Endothelial Growth Factors . stage iv uterine sarcoma diagnosis and fourweeks since prior chemotherapy less_than six weeks for nitrosoureas carmustine mitomycin prior investigational treatment radiotherapy and major surgery open biopsy
__label__1	study interventions are Etoposide phosphate . recurrent diffuse large cell lymphoma diagnosis and psychiatric conditions disease that impair the ability to give informed consent or to adequately co operate
__label__1	study interventions are (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) . stage iiib ovarian cancer diagnosis and extension to the pelvic sidewall this criteria may also be assessed on physical examination
__label__1	study interventions are Cabozantinib S-malate . hepatoblastoma diagnosis and patients who have an uncontrolled infection are not eligible
__label__1	study interventions are Antibodies, Monoclonal . childhood diffuse large cell lymphoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Exercise Intervention . stage iib breast cancer diagnosis and patient is taking medications or supplements for weight loss currently or within the past three months
__label__1	study interventions are Mesna . solid tumors diagnosis and evidence of hiv infection or positive hiv serology
__label__1	study interventions are Docetaxel . resected advanced gastric cancer diagnosis and presence of distant metastasis
__label__1	study interventions are Maytansine . stage iv breast cancer diagnosis and the last fraction of radiotherapy has been administered within fourteen days prior to randomization
__label__1	study interventions are Trastuzumab . stage iiic breast cancer diagnosis and current unstable ventricular arrhythmia requiring treatment
__label__1	study interventions are Dexamethasone . participants with history of other malignancies within five years before the date of study entry exceptions are squamous and basal cell carcinomas of the skin carcinoma in situ of the cervix or breast or other non invasive lesion that is considered cured with minimal risk of recurrence within five years
__label__1	study interventions are Laboratory Biomarker Analysis . endometrial serous adenocarcinoma diagnosis and history of major surgery as follows
__label__1	study interventions are Aldesleukin . recurrent melanoma diagnosis and pt inr greater_than doc unless the patient is on full dose warfarin
__label__1	study interventions are vismodegib . recurrent adult brain tumor diagnosis and pregnant women are excluded from this study because gdc four hundred and forty-nine is an hh pathway inhibiting agent with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with gdc four hundred and forty-nine breastfeeding should be discontinued if the mother is treated with gdc four hundred and forty-nine
__label__1	study interventions are Sonidegib . nevoid basal cell carcinoma syndrome diagnosis and ventricular arrhythmias except for benign premature ventricular contractions
__label__1	study interventions are Fluorouracil . metastatic colorectal cancer diagnosis and uncontrolled cns metastases
__label__1	study interventions are Maytansine . non small cell lung cancer diagnosis and use also not permitted while on trial
__label__1	study interventions are Diphosphonates . giant cell tumor of bone diagnosis and known hypersensitivity reaction to any of the components of the treatment
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and disease
__label__1	study interventions are Gossypol acetic acid . recurrent small lymphocytic lymphoma diagnosis and requirement for routine use of hematopoietic growth factors including granulocyte colony stimulating factor granulocyte macrophage colony stimulating factor or interleukin eleven or platelet transfusions to maintain absolute neutrophil counts or platelets counts above the required thresholds for study entry use of erythropoietin stimulating agents and rbcs prior to study enrollment is allowed
__label__1	study interventions are N-monoacetylcystine . recurrent verrucous carcinoma of the oral cavity diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Sorafenib . recurrent ewing sarcoma peripheral primitive neuroectodermal tumor diagnosis and patients receiving other investigational agents
__label__1	study interventions are Antineoplastic Agents . mantle cell lymphoma diagnosis and has serum aspartate aminotransferase ast alanine aminotransferase alt greater_than two upper limit of normal
__label__1	study interventions are Sirolimus . recurrent laryngeal squamous cell carcinoma diagnosis and pregnant women are excluded from this study
__label__1	study interventions are ADXS11-001 . stage ivb cervical cancer diagnosis and has implanted medical device that pose high risk for colonization and or cannot be easily removed prosthetic joints artificial heart valves pacemakers orthopedic_screw metal plate bone graft or other exogenous implant s
__label__1	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and major surgery within six weeks
__label__1	study interventions are Phone Call . breast cancer diagnosis and known or suspected
__label__1	study interventions are Protein Kinase Inhibitors . symptomatic brain metastases
__label__1	study interventions are Doxorubicin . ovarian cancer diagnosis and is known to be human immunodeficiency virus hiv positive
__label__1	study interventions are Cetuximab . recurrent squamous cell carcinoma of the nasopharynx diagnosis and gastrointestinal tract disease resulting in an inability to take oral medication or requirement for iv alimentation prior surgical procedures affecting absorption or active peptic ulcer disease
__label__1	study interventions are Antibodies, Monoclonal . stage iv grade one follicular lymphoma diagnosis and patient is currently enrolled in or has not yet completed at least thirty days since ending another investigational device or drug trial
__label__1	study interventions are Cisplatin . solid tumors diagnosis and unstable angina or unstable cardiac arrhythmia requiring medication
__label__1	study interventions are Vidarabine . recurrent small lymphocytic lymphoma diagnosis and karnofsky score less_than seventy for adult patients
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and patient has grade two peripheral neuropathy within fourteen days before enrollment
__label__1	study interventions are Irinotecan . recurrent central nervous system neoplasm diagnosis and patients who are receiving cyclosporine tacrolimus or other agents to prevent graft versus host disease post bone marrow transplant are not eligible for this trial
__label__1	study interventions are Goserelin . breast cancer diagnosis and prior cdk four six inhibitor exposure
__label__1	study interventions are Pancrelipase . cholangiocarcinoma diagnosis and eipl lavage vs
__label__1	study interventions are Cyclosporins . stage iv renal cell cancer diagnosis and any active central nervous system cns involvement with disease
__label__1	study interventions are Cytarabine . recurrent non hodgkin lymphoma diagnosis and prior autologous hematopoietic stem cell transplant
__label__1	study interventions are Paclitaxel . metastatic breast cancer diagnosis and psychiatric disorders or other conditions rendering the participant incapable of complying with the requirements of the protocol
__label__1	study interventions are Melphalan . recurrent adult diffuse mixed cell lymphoma diagnosis and estimated risk of graft vs
__label__1	study interventions are Methotrexate . other lymphoma categories other than diffuse large cell lymphoma
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiic breast cancer diagnosis and active hepatitis or hepatitis with abnormal liver function tests
__label__1	study interventions are Dexamethasone . refractory multiple myeloma diagnosis and no treatment with cytotoxic therapy or monoclonal antibodies within twenty-one days prior to cycle one day one
__label__1	study interventions are Paclitaxel . adult solid neoplasm diagnosis and known standard therapy for the patient disease that is potentially curative or definitely capable of extending life expectancy
__label__1	study interventions are Cyclosporine . stage ii childhood anaplastic large cell lymphoma diagnosis and history of brain metastases
__label__1	study interventions are Antibodies, Monoclonal . advanced non clear cell kidney cancer diagnosis and current or recent use of dipyramidole ticlopidine clopidogrel cilostazol is excluded
__label__1	study interventions are Antibodies . recurrent squamous cell carcinoma of the nasopharynx diagnosis and valvular disease with document compromise in cardiac function
__label__1	study interventions are Antibodies . stage iv breast cancer diagnosis and known hypersensitivity reaction to mushroom products
__label__1	study interventions are Paclitaxel . ovarian neoplasms diagnosis and patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
__label__1	study interventions are IGIMRT 27 Gy in 3 fractions . sarcoma diagnosis and prior radiotherapy delivered to the target region
__label__1	study interventions are Cyclophosphamide . recurrent adult hodgkin lymphoma diagnosis and patients with life expectancy of less_than six months for reasons other than their underlying hematologic oncologic disorder
__label__1	study interventions are HPV-16/18 L1 VLP AS04 . infections papillomavirus diagnosis and known acute or chronic clinically significant neurologic pulmonary cardiovascular hepatic or renal functional abnormality as determined by previous physical examination or laboratory tests
__label__1	study interventions are Antibodies, Monoclonal . undifferentiated ovarian carcinoma diagnosis and other active malignancy equal_than less_than three years prior to registration exceptions
__label__1	study interventions are Cobimetinib . melanoma diagnosis and pregnant or breastfeeding
__label__1	study interventions are Antibodies, Monoclonal . ovarian sex cord stromal tumor diagnosis and patients with clinically significant peripheral arterial disease claudication within six months
__label__1	study interventions are Cobimetinib . melanoma diagnosis and the following foods supplements are prohibited at least seven days prior to initiation of and during study treatment
__label__1	study interventions are Maleic acid . recurrent breast carcinoma diagnosis and participants who have had chemotherapy or radiotherapy within three weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events due to agents administered more than three weeks earlier
__label__1	study interventions are Carmustine . central nervous system cns lymphoma
__label__1	study interventions are Fludarabine . cdseventy expressing cancers diagnosis and history of coronary revascularization or ischemic symptoms
__label__1	study interventions are Liposomal doxorubicin . fallopian tube mucinous adenocarcinoma diagnosis and resting electrocardiogram ecg with clinically significant abnormal findings
__label__1	study interventions are Fludarabine . refractory multiple myeloma diagnosis and active viral bacterial or fungal infection unless adequately treated
__label__1	study interventions are Antibodies, Monoclonal . malignant pancreatic gastrinoma diagnosis and anticipation of need for major surgical procedures during the course of the study
__label__1	study interventions are Irinotecan . metastatic colorectal cancer diagnosis and absolute neutrophils count anc less_than doc one hundred and nine l
__label__1	study interventions are Estradiol . breast cancer diagnosis and impaired kidney function
__label__1	study interventions are Sirolimus . kidney cancer diagnosis and history of hypersensitivity to the medications under investigation
__label__1	study interventions are Antibodies, Monoclonal . primary peritoneal serous adenocarcinoma diagnosis and has received live vaccine within thirty days of planned start of study therapy
__label__1	study interventions are Immunoglobulins . stage iv small lymphocytic lymphoma diagnosis and transfusion requirement red blood cells or platelets within fourteen days prior to baseline
__label__1	study interventions are Thalidomide . stage iii grade three follicular lymphoma diagnosis and known hypersensitivity to thalidomide
__label__1	study interventions are Everolimus . renal pelvis cancer diagnosis and adults of reproductive potential who are not using effective birth control methods
__label__1	study interventions are Sorafenib . stage iva verrucous carcinoma of the larynx diagnosis and any condition which in the investigator opinion makes the subject unsuitable for trial participation
__label__1	study interventions are Antibodies . noncontiguous stage ii mantle cell lymphoma diagnosis and prior use of lenalidomide either concurrently with rituximab or within eight weeks following dose of rituximab
__label__1	study interventions are Erlotinib Hydrochloride . signet ring adenocarcinoma of the rectum diagnosis and ascites
__label__1	study interventions are Irinotecan . biopsy proven tumor invasion of the tracheobronchial_tree or tracheoesophageal fistula
__label__1	study interventions are Mycophenolate mofetil . recurrent adult diffuse large cell lymphoma diagnosis and prior hematopoietic stem cell transplant autologous or allogeneic
__label__1	study interventions are Mifepristone . breast cancer diagnosis and in addition these patients are at increased risk of lethal infections when treated with marrow suppressive therapy
__label__1	study interventions are HPPH . stage verrucous carcinoma of the oral cavity diagnosis and patients with known brain metastases should be excluded from this clinical trial
__label__1	study interventions are Liposomal doxorubicin . lymphoma large cell diffuse diagnosis and history of allergic reaction to substances containing boron or mannitol
__label__1	study interventions are Sirolimus . refractory plasma cell myeloma diagnosis and serum phosphorus less_than doc mg dl
__label__1	study interventions are Doxorubicin . stage adult lymphoblastic lymphoma diagnosis and any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he she were to participate in the study or confounds the ability to interpret data from the study
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiia breast cancer diagnosis and any prior history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Endothelial Growth Factors . primary peritoneal serous adenocarcinoma diagnosis and patients with uncontrolled infection
__label__1	study interventions are Neoadjuvant Chemotherapy . high grade upper tract urothelial carcinoma diagnosis and uncontrolled hypertension greater_than one hundred and fifty one hundred mmhg despite optimal medical therapy
__label__1	study interventions are photodynamic therapy . stage ii squamous cell carcinoma of the oropharynx diagnosis and patients on concurrent chemotherapy or radiation therapy will be excluded
__label__1	study interventions are Erlotinib Hydrochloride . papillary serous mullerian tumor diagnosis and no more than one cycle of first line chemotherapy with carboplatin and paclitaxel
__label__1	study interventions are Liposomal doxorubicin . tumors breast diagnosis and serious uncontrolled concurrent infection s
__label__1	study interventions are Vaccines . cervical adenocarcinoma diagnosis and patients with uncontrolled intercurrent illness including but not limited to
__label__1	study interventions are Nivolumab . stage iv bladder urothelial carcinoma diagnosis and prior treatment with any therapy on the programmed cell death one pd one pd lone axis or anti cytotoxic lymphocyte associated protein four ctla four inhibitors
__label__1	study interventions are Androgens . prostate cancer diagnosis and known hiv positive status
__label__1	study interventions are Niacinamide . myelodysplastic myeloproliferative neoplasms diagnosis and have had diagnosis of another malignancy unless the participant has been disease free for at least three years following the completion of curative intent therapy with the following exceptions
__label__1	study interventions are Rituximab . adult grade iii lymphomatoid granulomatosis diagnosis and residual grade three or grade four non hematologic toxicity after asct
__label__1	study interventions are Fludarabine . refractory childhood hodgkin lymphoma diagnosis and patients with greater_than grade ii hypertension by common toxicity criteria ctc
__label__1	study interventions are Testosterone enanthate . advanced cancer diagnosis and uncontrolled thyroid disease
__label__1	study interventions are Cisplatin . stage ivc squamous cell carcinoma of the oropharynx diagnosis and patients who have received an investigational therapy within four weeks of signing the informed consent for the current study
__label__1	study interventions are Extraperitoneal laparoscopic lymphadenectomy (EPLND) . cervical squamous cell carcinoma diagnosis and women with planned treatment of radiotherapy only without chemotherapy
__label__1	study interventions are Olaparib . malignant female reproductive system neoplasm diagnosis and reference and use of the appendix with the list of agents that can be updated and is more inclusive will be used for determining eligibility
__label__1	study interventions are Doxorubicin . metastatic malignant neoplasm in the lung diagnosis and female patients of childbearing potential are not eligible unless negative pregnancy test result has been obtained lactating females are not eligible unless they have agreed not to breastfeed their infants for the duration of protocol therapy sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of protocol therapy
__label__1	study interventions are F-18 RGD-K5 . breast cancer diagnosis and subject has known hyper or hypo coagulation syndromes
__label__1	study interventions are Prednisone . hormone resistant prostate cancer diagnosis and patients with history of active seizures are not eligible
__label__1	study interventions are biopsy . unspecified adult solid tumor protocol specific diagnosis and no other concurrent investigational procedures
__label__1	study interventions are Histone Deacetylase Inhibitors . angioimmunoblastic cell lymphoma diagnosis and known history of uncontrolled sleep_apnea syndrome and other conditions that could result in excessive_daytime sleepiness such as severe chronic obstructive pulmonary disease requirement for supplemental oxygen or any conditions that could result in excessive toxicity associated with the benzodiazepine like effects of mlneight thousand, two hundred and thirty-seven
__label__1	study interventions are educational intervention . cancer survivor diagnosis and develop distant metastases or progressive disease
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent digestive system neuroendocrine tumor gone diagnosis and current use of therapeutic warfarin note
__label__1	study interventions are Fludarabine . recurrent adult diffuse large cell lymphoma diagnosis and inability to achieve adequate venous access
__label__1	study interventions are Maleic acid . stage ovarian epithelial cancer diagnosis and patients may not be receiving any other investigational agents nor have participated in an investigational trial within the past three weeks subjects may not have received prior treatment affecting the vegf pathway subjects may not have received prior treatment with antibodies that may interfere with ca one hundred and twenty-five measurements subjects may not have received intraperitoneal therapy within the four weeks prior to starting azdtwo thousand, one hundred and seventy-one and or the treating physician must confirm the patient has recurrent disease
__label__1	study interventions are Placebo . gastrointestinal neoplasms diagnosis and diseases of the blood system
__label__1	study interventions are Erlotinib Hydrochloride . patients with inflammatory breast cancer will be excluded
__label__1	study interventions are Immunoconjugates . refractory hodgkin lymphoma diagnosis and men of childbearing potential are defined as all males physiologically capable of conceiving_offspring
__label__1	study interventions are HCQ . hepatocellular carcinoma diagnosis and contraindication to receiving hcq or tace
__label__1	study interventions are Avelumab . human papilloma virus diagnosis and women of childbearing potential must have negative pregnancy test at screening
__label__1	study interventions are Abiraterone Acetate . metastatic castration resistant prostate cancer diagnosis and any previous treatment with parp inhibitor including olaparib
__label__1	study interventions are Endothelial Growth Factors . fallopian tube mucinous adenocarcinoma diagnosis and no more than superficial myometrial invasion
__label__1	study interventions are Corticotropin-Releasing Hormone . brain tumor diagnosis and central nervous system infection
__label__1	study interventions are Diphosphonates . non small cell lung cancer diagnosis and current active dental problems including infection of the teeth or jawbone_maxilla or mandibular dental or fixture_trauma or current or prior diagnosis of osteonecrosis of the jaw_onj of exposed bone in the mouth or of slow healing after dental procedures
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and known hypersensitivity to thalidomide or dexamethasone
__label__1	study interventions are Cisplatin . clinically measurable distant disease or has asymptomatic small distant lesions outside the radiation field less_than three cm in individual or aggregate diameter for which palliation of local and regional disease is clearly warranted
__label__1	study interventions are Immunoglobulin G . stage iiib ovarian cancer diagnosis and patients with clinically significant proteinuria urine protein creatinine ratio greater or equal to doc
__label__1	study interventions are Enzalutamide . a second active malignancy except adequately treated non melanoma skin cancer or other non invasive or in situ neoplasm
__label__1	study interventions are Hormones . stage prostate cancer diagnosis and prior history of lactic_acidosis or metabolic acidosis
__label__1	study interventions are Vaccines . recurrent primary peritoneal carcinoma diagnosis and nursing women unwilling to stop breast feeding
__label__1	study interventions are Mycophenolic Acid . noncontiguous stage ii small lymphocytic lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than thirty-five total lung capacity tlc less_than thirty-five or forced expiratory volume in one second fevone less_than thirty-five and or receiving supplementary continuous oxygen
__label__1	study interventions are Methadone . colon cancer diagnosis and nelfinavir
__label__1	study interventions are Cisplatin . malignant salivary gland tumors diagnosis and doc acquired immune deficiency syndrome aids doc
__label__1	study interventions are Gemcitabine . regional transitional cell cancer of the renal pelvis and ureter diagnosis and no hiv positivity
__label__1	study interventions are Immunoglobulins . stage iva major salivary gland carcinoma diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Mycophenolate mofetil . refractory plasma cell myeloma diagnosis and patient with poorly controlled hypertension and on multiple antihypertensives
__label__1	study interventions are Antibodies . noncontiguous stage ii grade two follicular lymphoma diagnosis and clinically active hepatitis b or infections note
__label__1	study interventions are Carboplatin . recurrent ovarian epithelial cancer diagnosis and patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Ergocalciferols . ductal carcinoma in situ diagnosis and patients receiving medications that are incompatible with vd
__label__1	study interventions are Colposcopy . human papilloma virus infection diagnosis and women with hysterectomy or known destructive therapy to the cervix
__label__1	study interventions are Cyclophosphamide . aids related small noncleaved cell lymphoma diagnosis and inability to swallow oral medications
__label__1	study interventions are Placebo . adrenocortical carcinoma diagnosis and prior igf_oner inhibitor therapy
__label__1	study interventions are Prednisone . follicular non hodgkin lymphoma diagnosis and evidence of any severe active acute or chronic infection
__label__1	study interventions are Aromatase Inhibitors . neoplasms diagnosis and evidence of dementia altered mental status or any psychiatric condition that would prohibit understanding or rendering of informed consent
__label__1	study interventions are Antibodies, Monoclonal . recurrent marginal zone lymphoma diagnosis and major surgery other than diagnostic surgery within four weeks
__label__1	study interventions are Doxorubicin . localized unresectable neuroblastoma diagnosis and female patients who are lactating must agree to stop breast feeding
__label__1	study interventions are Fludarabine phosphate . stage iv adult diffuse mixed cell lymphoma diagnosis and current serious systemic illness that would result in increased risk for csf mobilization and harvest of peripheral blood stem cells pbsc
__label__1	study interventions are Cyclosporins . splenic marginal zone lymphoma diagnosis and prior autologous or allogeneic stem cell transplant with myeloablative preparative regimen if equal_than less_than eighteen years old prior myeloablative transplant within the last six months
__label__1	study interventions are Hydroxocobalamin . peripheral cell lymphoma diagnosis and cell
__label__1	study interventions are laboratory biomarker analysis . splenic marginal zone lymphoma diagnosis and pregnant women are excluded from this study because sb seven hundred and fifteen thousand, nine hundred and ninety-two is mitotic inhibitor with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sb seven hundred and fifteen thousand, nine hundred and ninety-two breastfeeding should be discontinued if the mother is treated with sb seven hundred and fifteen thousand, nine hundred and ninety-two
__label__1	study interventions are computed tomography . stage ii malignant mesothelioma diagnosis and other active malignancy equal_than less_than two years prior to pre registration exceptions
__label__1	study interventions are Cyclosporine . recurrent adult lymphoblastic lymphoma diagnosis and donors
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and pregnancy or breast feeding
__label__1	study interventions are WST11 . prostate cancer diagnosis and if the results are within normal ranges then the patient can be included
__label__1	study interventions are Positron Emission Tomography . stage ia breast cancer diagnosis and inability to tolerate scanning
__label__1	study interventions are Pioglitazone . squamous cell lung cancer diagnosis and patients with uncontrolled hypertension respiratory rate continuously greater_than one hundred and forty ninety mm hg
__label__1	study interventions are Antibodies, Monoclonal . noncontiguous stage ii adult diffuse large cell lymphoma diagnosis and clinically active hepatitis b or infections note
__label__1	study interventions are Camptothecin . stage iiia ovarian cancer diagnosis and ongoing or active infection
__label__1	study interventions are Paclitaxel . carcinoma non small cell lung diagnosis and subjects who have used previous antisense oligonucleotide in the last ninety days will be excluded
__label__1	study interventions are Paclitaxel . borderline ovarian mucinous tumor diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and absolute neutrophil count less_than doc one hundred and nine l
__label__1	study interventions are Erlotinib Hydrochloride . stage iv squamous cell carcinoma of the hypopharynx diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to osi seven hundred and seventy-four
__label__1	study interventions are Tc+SPIO . tfour tumors cnthree or cmone
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and patients with an active bacterial viral or fungal infection
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube serous adenocarcinoma diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study the investigator should feel free to consult the study chair or study co chairs for uncertainty in this regard
__label__1	study interventions are Cetuximab . stage ivc verrucous carcinoma of the larynx diagnosis and major active psychiatric disorders which would limit compliance
__label__1	study interventions are Immunoglobulin G . undifferentiated ovarian carcinoma diagnosis and only applies to patients who elect to receive bevacizumab
__label__1	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and patients with renal failure are eligible however patients with renal compromise serum creatinine greater than doc will likely have further compromise in renal function and may require hemodialysis which may be permanent due to the need to maintain adequate serum cyclosporine levels
__label__1	study interventions are Veliparib . triple negative breast cancer diagnosis and any medical condition which in the opinion of the investigator places the patient at an unacceptably high risk for toxicities
__label__1	study interventions are Erlotinib Hydrochloride . clear cell renal cell carcinoma diagnosis and history of stroke or other serious disorders of the nervous system
__label__1	study interventions are Saracatinib . stage iii squamous cell carcinoma of the hypopharynx diagnosis and history of myocardial infarction within the past year
__label__1	study interventions are Bevacizumab . recurrent fallopian tube carcinoma diagnosis and known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__1	study interventions are Pembrolizumab . transitional cell carcinoma diagnosis and note
__label__1	study interventions are Mycophenolate mofetil . recurrent adult diffuse mixed cell lymphoma diagnosis and female of childbearing potential with positive pregnancy test
__label__1	study interventions are Melphalan . ovarian cancer diagnosis and asthma
__label__1	study interventions are HomMed Telemonitor . lung cancer diagnosis and are discharged to hospice
__label__1	study interventions are Leucovorin . colorectal cancer diagnosis and evidence of bleeding diathesis or significant coagulopathy in the absence of therapeutic anticoagulation
__label__1	study interventions are Immunoglobulin G . fallopian tube clear cell adenocarcinoma diagnosis and patients with history of autoimmune hypothyroidism on stable dose of thyroid replacement hormone are eligible
__label__1	study interventions are Ursodeoxycholic Acid . duodenal neoplasms diagnosis and risk factors
__label__1	study interventions are Bortezomib . recurrent small lymphocytic lymphoma diagnosis and patients who have deterioration of their clinical status or laboratory parameters between the time of enrollment and transplant such that they no longer meet entry criteria may be removed from study at the discretion of the treating physician or principal investigator
__label__1	study interventions are Bevacizumab . metastatic pancreas adenocarcinoma diagnosis and any significant medical condition laboratory abnormality or psychiatric illness that would prevent the subject from participating in the study
__label__1	study interventions are Fludarabine . recurrent adult diffuse small cleaved cell lymphoma diagnosis and left ventricular ejection fraction less_than forty
__label__1	study interventions are Cyclosporine . stage iv adult hodgkin lymphoma diagnosis and patients with history of prolonged corrected qt interval qtc syndrome
__label__1	study interventions are Immunoglobulins . stage iiib primary peritoneal cancer diagnosis and patients with acute hepatitis or active infection that requires parenteral antibiotics
__label__1	study interventions are Immunoglobulins . recurrent fallopian tube carcinoma diagnosis and significant st depression of greater_than equal_than doc mm in two or more leads and or wave_inversions in greater_than equal_than two leads
__label__1	study interventions are Fludarabine . non hodgkin lymphoma diagnosis and serum bilirubin greater_than doc mg dl except in the case of gilbert syndrome or hemolytic anemia in which the bilirubin can be elevated greater than doc mg dl
__label__1	study interventions are questionnaire administration . stage iva verrucous carcinoma of the oral cavity diagnosis and although there are no known adverse effects of black_raspberries upon the fetus if patients become pregnant during period of lyophilized_black raspberries_lbr administration then lbr will be discontinued and patient will be removed from the study we should however emphasize given this is food based study that risks are likely extremely low even though participant should become pregnant as such we are not recommending active contraception for women but rather if participants become pregnant that they notify their study doctor and that they will likely be removed from study there are no expected or logical risks if men were to father child and as such no contraception will be recommended for men
__label__1	study interventions are Temozolomide . giant cell glioblastoma diagnosis and subject is pregnant or breastfeeding
__label__1	study interventions are Irinotecan . neoplasm diagnosis and carinii pneumonia prophylaxis
__label__1	study interventions are Bortezomib . cancer diagnosis and patient has hypersensitivity to bortezomib boron or mannitol
__label__1	study interventions are Recombinant human interleukin-15 (rhIL-15) . pediatric cancers diagnosis and patients who require systemic corticosteroid or other systemic immunosuppressive therapy
__label__1	study interventions are Androgens . prostate cancer diagnosis and this is to allow enrollment of those who have been given bicalutamide as bridge for lhrh agonist antagonist
__label__1	study interventions are Cyclosporins . stage iii adult lymphoblastic lymphoma diagnosis and patients with medical history of noncompliance with haart or medical therapy
__label__1	study interventions are Sirolimus . breast cancer diagnosis and inability to swallow or digest oral medications
__label__1	study interventions are Cisplatin . previous or current malignancies other than gastric adenocarcinoma with the exception of adequately treated in situ carcinoma of the cervix uteri or nonmelanoma skin cancer
__label__1	study interventions are Immunoglobulins . stage iiia fallopian tube cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__1	study interventions are Rituximab . small intestine lymphoma diagnosis and known hiv positive status
__label__1	study interventions are Capecitabine . prior malignant tumors with detectable signs of recurrence or distant metastasis
__label__1	study interventions are Antibodies, Monoclonal . peritoneal neoplasms diagnosis and known hypersensitivity to murine or chimeric antibodies
__label__1	study interventions are Dasatinib . brain and central nervous system tumors diagnosis and other investigational agents
__label__1	study interventions are Cyclophosphamide . neuroblastoma diagnosis and patients with known aspirin hypersensitivity triad asthma allergic rhinitis asa hypersensitivity
__label__1	study interventions are Mycophenolate mofetil . stage iv childhood lymphoblastic lymphoma diagnosis and seropositive for human immunodeficiency virus hiv
__label__1	study interventions are Nivolumab . non small cell lung cancer diagnosis and active known or suspected autoimmune disease except for type diabetes mellitus hypothyroidism only requiring hormone replacement skin disorders such as vitiligo psoriasis or alopecia
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and history of stroke or transient ischemic attack within six months prior to day one
__label__1	study interventions are Fludarabine phosphate . history of other neoplasms either active or treated within five years
__label__1	study interventions are Immunoglobulins . metastatic pancreatic adenocarcinoma diagnosis and active liver disease such as cirrhosis chronic active hepatitis or chronic persistent hepatitis
__label__1	study interventions are Fluorouracil . tumor relapse progression within six months of completion of cisplatin based chemoradiotherapy regimen for the treatment of early stage tumors
__label__1	study interventions are Albumin-Bound Paclitaxel . pancreatic ductal adenocarcinoma diagnosis and idelalisib positive nab paclitaxel their metabolites or formulation excipients
__label__1	study interventions are Doxorubicin . metastatic malignant peripheral nerve sheath tumor diagnosis and prior systemic therapy with an anthracycline for any indication
__label__1	study interventions are computed tomography . cancer survivor diagnosis and abnormal renal function glomerular filtration rate gfr less_than sixty ml min doc threemtwo
__label__1	study interventions are Sirolimus . prostate cancer diagnosis and gastrointestinal gi disease condition or symptoms that may significantly impair gi function and alter the absorption of everolimus including any of the following
__label__1	study interventions are Lenalidomide . lymphoma diagnosis and none of the following should be present
__label__1	study interventions are Cisplatin . larynx cancer diagnosis and has diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within seven days prior to the first dose of trial treatment
__label__1	study interventions are Antibodies . recurrent squamous cell carcinoma of the larynx diagnosis and any malabsorption problem
__label__1	study interventions are ispinesib . recurrent marginal zone lymphoma diagnosis and sb seven hundred and fifteen thousand, nine hundred and ninety-two is moderate to significant in vitro inhibitor of cypthreeafour the following lists of medications substances are moderate to significant inhibitors inducers of cypthreeafour that if administered concomitantly with sb seven hundred and fifteen thousand, nine hundred and ninety-two may alter study drug exposure the use of these medications substances within 1four days greater_than equal_than six months for amiodarone prior to the administration of the first dose of sb seven hundred and fifteen thousand, nine hundred and ninety-two through discontinuation from the study is prohibited
__label__1	study interventions are Estradiol 17 beta-cypionate . cancer diagnosis and has an eastern cooperative oncology group ecog performance status of zero or one
__label__1	study interventions are Camptothecin . glioblastoma diagnosis and impairment of gi function gi disease that may significantly alter absorption of sunitinib malate sutent
__label__1	study interventions are questionnaire administration . uterine sarcoma diagnosis and planned surgery for urinary incontinence in the next three months
__label__1	study interventions are Doxorubicin . mantle cell lymphoma diagnosis and prior greater_than grade three rash or any desquamating blistering rash while taking thalidomide
__label__1	study interventions are Ganetespib . stage ii laryngeal squamous cell carcinoma diagnosis and other medications or severe acute chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and in the judgment of the investigator would make the subject inappropriate for entry into this study
__label__1	study interventions are Niacinamide . recurrent melanoma diagnosis and the eligibility of patients taking medications that are potent modulators of cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour cytochrome pfour hundred and fifty family two subfamily polypeptide six cyptwobsix subfamily two polypeptide eight twoceight will be determined following review of their case by the principal investigator every effort should be made to switch patients taking such agents or substances to other medications
__label__1	study interventions are Dacarbazine . melanoma diagnosis and patients with known brain metastases or history of cns metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Erlotinib Hydrochloride . stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and abnormalities of the cornea based on history dry eye syndrome sjogren syndrome congenital abnormality fuch dystrophy abnormal slit_lamp examination using vital dye_fluorescein bengal_rose and or an abnormal corneal sensitivity test schirmer test or similar tear_production test
__label__1	study interventions are Carboplatin . recurrent fallopian tube carcinoma diagnosis and history of pulmonary embolism or deep vein thrombosis in the past six months
__label__1	study interventions are Cyclophosphamide . stage iii childhood small noncleaved cell lymphoma diagnosis and patients who have not recovered from adverse events due to agents administered more than four weeks earlier or
__label__1	study interventions are Fludarabine phosphate . recurrent grade one follicular lymphoma diagnosis and prior radiation greater_than twenty gy to any critical normal organ lung liver spinal cord greater_than twenty-five of red marrow
__label__1	study interventions are Sirolimus . tumors diagnosis and cardiac ejection fraction below institutional lower limit of normal
__label__1	study interventions are Antibodies, Monoclonal . adult giant cell glioblastoma diagnosis and history of torsades de pointes or other significant cardiac arrhythmias other than chronic stable atrial fibrillation
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood anaplastic large cell lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Carboplatin . urethral cancer associated with invasive bladder cancer diagnosis and known seropositive for hepatitis surface antigen
__label__1	study interventions are Liposomal doxorubicin . stage iv grade three follicular lymphoma diagnosis and treatment with any known non marketed drug substance or experimental therapy within four weeks prior to enrollment or currently participating in any other interventional clinical study for nhl or any other illness except observational prevention and or registry trials
__label__1	study interventions are Lenograstim . nodal marginal zone cell lymphoma diagnosis and radiation therapy within three weeks before randomization enrollment of subjects who require concurrent radiotherapy which must be localized in its field size should be deferred until the radiotherapy is completed and three weeks have elapsed since the last date of therapy
__label__1	study interventions are Questionnaire Administration . stage iiic breast cancer diagnosis and patients that have cataracts that do not require surgery are eligible
__label__1	study interventions are Immunoglobulin G . metastatic carcinoma in the liver diagnosis and participation in another clinical study with an investigational product during the last four weeks
__label__1	study interventions are Cyclosporins . cutaneous cell non hodgkin lymphoma diagnosis and age less than twelve years
__label__1	study interventions are PF-00337210 . neoplasm diagnosis and any acute cardiovascular incident within the past twelve months
__label__1	study interventions are Capecitabine . pancreatic cancer diagnosis and evidence of cns metastases or history of uncontrolled seizures central nervous system disorders or psychiatric disability
__label__1	study interventions are Liposomal doxorubicin . stage iii enteropathy associated cell lymphoma diagnosis and major surgery within two weeks of study drug administration
__label__1	study interventions are Immunoconjugates . stage iii cutaneous cell non hodgkin lymphoma diagnosis and known john cunningham_jc virus infection and or progressive multifocal_leukoencephalopathy pml
__label__1	study interventions are Vismodegib . stage iv breast cancer diagnosis and patients with clinically active liver disease including active viral or other hepatitis or cirrhosis are ineligible
__label__1	study interventions are Computed Tomography Perfusion Imaging . metastatic malignant neoplasm in the lung diagnosis and patients with renal failure defined as glomerular filtration rate gfr less_than sixty at the time of the radiation treatment planning rtp scan will be excluded
__label__1	study interventions are Antibodies, Monoclonal . recurrent mantle cell lymphoma diagnosis and failed stem cell collection
__label__1	study interventions are Bevacizumab . colorectal neoplasms diagnosis and legal incapacity or limited legal capacity
__label__1	study interventions are Mycophenolate mofetil . stage small lymphocytic lymphoma diagnosis and donor
__label__1	study interventions are Cisplatin . history of another cancer other than head and neck unless treated with curative intent and with no evidence of disease for more than three years with the exception of non melanoma skin cancer or in situ cervical cancer
__label__1	study interventions are Epothilones . other malignancy within the past five years except curatively treated nonmelanoma skin cancer
__label__1	study interventions are Oxaliplatin . adenocarcinoma of the esophagogastric junction diagnosis and khk cardiomyopathy or cardiac insufficiency
__label__1	study interventions are PI-88 . cancer diagnosis and subjects with uncontrolled infection or serious infection within the past four weeks
__label__1	study interventions are Fludarabine phosphate . recurrent mantle cell lymphoma diagnosis and patients who are homozygous at the mismatched major histocompatibility_complex mhc class locus
__label__1	study interventions are Lamivudine . kaposi sarcoma diagnosis and life expectancy of less_than three months
__label__1	study interventions are Pemetrexed . malignant pleural mesothelioma diagnosis and serious or uncontrolled concomitant systemic disorders
__label__1	study interventions are Chlorambucil . small lymphocytic lymphoma diagnosis and major surgery within four weeks prior to randomization
__label__1	study interventions are Docetaxel . esophageal neoplasms diagnosis and prior cumulative dose of greater_than three hundred mg mtwo of epirubicin
__label__1	study interventions are Sirolimus . squamous cell cancer diagnosis and history of any brain metastases
__label__1	study interventions are Talaporfin . neoplasm metastasis diagnosis and neutrophils less than two thousand mm
__label__1	study interventions are Hormones . breast cancer diagnosis and received neoadjuvant endocrine therapy
__label__1	study interventions are Cisplatin . esophageal squamous cell carcinoma diagnosis and patients with distant metastases
__label__1	study interventions are Albumin-Bound Paclitaxel . concurrent enrollment in another clinical study using an investigational anti cancer treatment within twenty-eight days before the first doses of trastuzumab and pertuzumab
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and prior radiation therapy less_than four weeks or limited field radiotherapy less_than two weeks prior start of study
__label__1	study interventions are Sirolimus . recurrent grade one follicular lymphoma diagnosis and the fhcrc pi of the study must approve of enrollment of all patients with pulmonary nodules
__label__1	study interventions are Fluorouracil . biliary tract cancer diagnosis and major surgery chemotherapy immunotherapy or radiotherapy during the twenty-eight days preceding the first study treatment
__label__1	study interventions are Antibodies, Monoclonal . recurrent nasopharyngeal keratinizing squamous cell carcinoma diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Oxaliplatin . advanced gastric cancer diagnosis and clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding or the absorption of investigational product
__label__1	study interventions are Interleukin-2 . liver cancer diagnosis and cardiopulmonary insufficiency
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent breast cancer diagnosis and pertuzumab given in the neoadjuvant and or adjuvant setting is allowed
__label__1	study interventions are Thiotepa . progesterone receptor positive breast cancer diagnosis and if the patient does not wish to receive the therapy
__label__1	study interventions are Contraceptive Agents . ovarian cancer risk diagnosis and severe
__label__1	study interventions are Albumin-Bound Paclitaxel . resectable pancreatic cancers diagnosis and anticoagulation with warfarin
__label__1	study interventions are Docetaxel . head and neck cancer diagnosis and concurrent investigational agent or intervention within ninety days of screening visit
__label__1	study interventions are huC242-DM4 . metastatic or locally advanced gastric cancer diagnosis and known history hepatitis or hiv or history of alcoholic liver disease
__label__1	study interventions are Bevacizumab . fallopian tube cancer diagnosis and patients who have received prior therapy with anti vegf vascular endothelial growth factor
__label__1	study interventions are Immunoglobulins . recurrent pancreatic neuroendocrine carcinoma diagnosis and evidence of history bleeding equal_than less_than six months such as hemoptysis or cerebrovascular accident equal_than less_than previous six months or peripheral vascular disease with claudication on less_than one block or history of clinically significant bleeding because of the potential bleeding and or clotting risk with bevacizumab
__label__1	study interventions are Vaccines . advanced melanoma diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Carboplatin . previous surgery to remove lung tumor
__label__1	study interventions are Docetaxel . breast neoplasms diagnosis and the above information is not intended to contain all considerations relevant to patient potential participation in clinical trial
__label__1	study interventions are Cyclosporine . recurrent mantle cell lymphoma diagnosis and karnofsky score less_than sixty for adult patients
__label__1	study interventions are Fulvestrant . metastatic breast cancer diagnosis and patients who are treated with fulvestrant
__label__1	study interventions are Cisplatin . carcinoma non small cell lung diagnosis and history of organ allograft
__label__1	study interventions are Carboplatin . uncontrolled electrolyte abnormalities including hypocalcemia hypomagnesemia and hypokalemia symptomatic congestive heart failure unstable angina pectoris and history of torsades de pointes or other significant cardiac arrhythmias
__label__1	study interventions are Bevacizumab . undifferentiated carcinoma diagnosis and this criterion applies only to the patients enrolled before august twenty-nine two thousand and eleven and those enrolled after this date electing to receive bevacizumab patients with clinically significant cardiovascular disease this includes
__label__1	study interventions are Docetaxel . stage iiib breast cancer diagnosis and patients on therapeutic doses of coumadin or lovenox are ineligible to participate in study
__label__1	study interventions are Mycophenolic Acid . stage adult lymphoblastic lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of tyrosine kinase inhibitors such as imatinib cytokine therapy hydroxyurea low dose cytarabine_chlorambucil or rituxan will not be allowed within three weeks of the initiation of conditioning
__label__1	study interventions are Pharmacological Study . paraganglioma diagnosis and note
__label__1	study interventions are Esophagogastroduodenoscopy (EGD) . esophageal adenocarcinoma diagnosis and prior esophageal or gastro esophageal junction surgery
__label__1	study interventions are Gemcitabine . ureter cancer diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are Methylprednisolone acetate . prostatic neoplasms diagnosis and any chronic medical condition requiring higher dose of corticosteroid than five mg prednisone prednisolone bid
__label__1	study interventions are Dexamethasone . morphologically unclassifiable lymphoma
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and pregnant or breastfeeding females
__label__1	study interventions are Gemcitabine . nasopharyngeal carcinoma diagnosis and pregnancy or lactation consider pregnancy test in women of child bearing age and emphasize effective contraception during the treatment period
__label__1	study interventions are Pembrolizumab . melanoma diagnosis and if it is the opinion of the investigator that subject may be unable to comply with the safety monitoring requirements of the study they will be excluded
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and use of venous access devices made of materials other than silicone for the infusion of ganetespib
__label__1	study interventions are Endothelial Growth Factors . stage iv renal cell cancer diagnosis and invasive procedures defined as follows
__label__1	study interventions are Cisplatin . head and neck neoplasms diagnosis and prior history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are JM 3100 . recurrent adult diffuse small cleaved cell lymphoma diagnosis and hiv seropositive
__label__1	study interventions are Antibodies, Monoclonal . cutaneous lymphomas diagnosis and patients with dementia or altered mental status that would preclude understanding and rendering of informed consent
__label__1	study interventions are BCG Vaccine . recurrent bladder carcinoma diagnosis and psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Preoperative MRI scan . cancer diagnosis and presence of irresectable distant metastases
__label__1	study interventions are Etoposide phosphate . noncutaneous extranodal lymphoma diagnosis and medical history of noncompliance with highly active anti retroviral therapy haart or medical therapy
__label__1	study interventions are Proton radiation therapy . adenoid cystic carcinoma diagnosis and history of different malignancy unless disease free for at least two years and are deemed by the investigator to be at low risk for recurrence
__label__1	study interventions are Simotinib Hydrochloride . non small cell lung cancer diagnosis and the known hypersensitivity to simotinib or any of the excipients
__label__1	study interventions are Dexamethasone . hodgkins lymphoma diagnosis and pregnant or potential for pregnancy
__label__1	study interventions are Antibodies . stage iib ovarian cancer diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Lapatinib . mucinous breast cancer stage ii diagnosis and history of significant neurological or psychiatric disorders including psychotic disorders dementia or seizures that would prohibit the understanding and giving of informed consent
__label__1	study interventions are Pazopanib Hydrochloride . uterine carcinosarcoma diagnosis and myocardial infarction or unstable angina within six months of the first date of pazopanib therapy
__label__1	study interventions are Bendamustine Hydrochloride . malignant lymphoma diagnosis and deemed frail by the treating physician
__label__1	study interventions are ARQ 197 . neoplasms diagnosis and patients with less than one positive proteinuria are eligible following initial determination by urinalysis within one week prior to enrollment and do not need the urinalysis repeated
__label__1	study interventions are laboratory biomarker analysis . stage ii bladder cancer diagnosis and have had major surgery within four weeks of starting therapy not including placement of vascular access device or turbt
__label__1	study interventions are Cyclophosphamide . squamous cell carcinoma diagnosis and history of severe immediate hypersensitivity reaction to any of the agents used in this study
__label__1	study interventions are Cisplatin . malignant pleural mesothelioma diagnosis and uncontrolled hypertension
__label__1	study interventions are Antibodies, Monoclonal . stage iv mucoepidermoid carcinoma of the oral cavity diagnosis and known human immunodeficiency virus hiv positive patients are ineligible because these patients are at increased risk of lethal infections when treated with marrow suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agents
__label__1	study interventions are Liposomal doxorubicin . stage adult immunoblastic large cell lymphoma diagnosis and in addition if negative for hbsag but hbcab positive regardless of hbsab status hb dna test will be performed and if positive the subject will be excluded if unable to tolerate and or receive anti hepatitis therapy
__label__1	study interventions are Oxaliplatin . adenocarcinoma of the gastroesophageal junction diagnosis and patients who have received prior treatment with an mammalian target of rapamycin mtor inhibitor sirolimus temsirolimus everolimus
__label__1	study interventions are Irinotecan . gastric cancer diagnosis and men and women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on treatment and for at least three months thereafter
__label__1	study interventions are Methotrexate . localized transitional cell cancer of the renal pelvis and ureter diagnosis and the presence of active heart disease such as congestive heart failure or unstable angina
__label__1	study interventions are Sirolimus . metastatic digestive system neuroendocrine tumor gone diagnosis and other uncontrolled serious medical or psychiatric condition cardiac arrhythmias diabetes etc
__label__1	study interventions are Ursodeoxycholic Acid . polycystic kidney autosomal_dominant diagnosis and acute cholecystitis or frequent biliary colic attacks
__label__1	study interventions are Rituximab . stage iv adult lymphoblastic lymphoma diagnosis and use of any other experimental drug or therapy within twenty-eight days of baseline
__label__1	study interventions are Vinorelbine . history or presence of another cancer
__label__1	study interventions are Bevacizumab . stage iii rectal cancer diagnosis and arterial thromboembolic event unstable angina or myocardial infarction within the past twelve months
__label__1	study interventions are Octreotide . thyroid gland medullary carcinoma diagnosis and patients who have received prior treatment with imc_atwelve everolimus other agents targeting the insulin like growth factor receptor igfr or an mtor inhibitor sirolimus temsirolimus everolimus
__label__1	study interventions are Bendamustine Hydrochloride . mantle cell lymphoma diagnosis and central nervous system localization in particular meninge
__label__1	study interventions are Sorafenib . tumors metastatic to brain diagnosis and any pulmonary hemorrhage ctcae doc grade two or higher within four weeks of first study drug
__label__1	study interventions are Melphalan . multiple myeloma patients who candidate for autologous peripheral blood stem cell transplantation diagnosis and patient has known clinically active hepatitis or c
__label__1	study interventions are Interferon-gamma . fallopian tube cancer diagnosis and weight loss greater_than ten over four months
__label__1	study interventions are placebo . stage verrucous carcinoma of the larynx diagnosis and inability to grant informed consent
__label__1	study interventions are Lenograstim . lymphoma diagnosis and previous myeloablative autologous transplant is permitted but not required
__label__1	study interventions are Antibodies . endometrial squamous cell carcinoma diagnosis and other medical conditions including but not limited to
__label__1	study interventions are Mycophenolate mofetil . testicular lymphoma diagnosis and donor is hiv positive and or has medical condition that would result in increased risk for filgrastim csf mobilization and harvest of pbsc
__label__1	study interventions are Vitamin D . early stage breast cancer diagnosis and renal failure creatinine greater_than one hundred and ninety mmol l
__label__1	study interventions are Erlotinib Hydrochloride . metastatic pancreatic carcinoma diagnosis and ecog ps three four
__label__1	study interventions are Sirolimus . malignant solid neoplasms diagnosis and efour
__label__1	study interventions are Anastrozole . human epidermal growth factor two negative carcinoma of breast diagnosis and coronary artery bypass graft surgery
__label__1	study interventions are Aspirin . stage iib prostate cancer diagnosis and patients taking aspirin for previously diagnosed cardiovascular disease
__label__1	study interventions are Trametinib . stage iia rectal cancer diagnosis and history or evidence of current greater_than equal_than class ii congestive heart failure as defined by new york heart association nyha
__label__1	study interventions are Antibodies, Monoclonal . cervical cancer diagnosis and known active or chronic viral hepatitis or history of any type of hepatitis within the last six months
__label__1	study interventions are Vinblastine . metastatic breast cancer diagnosis and uncontrolled bacterial viral or fungal infection
__label__1	study interventions are Pembrolizumab . melanoma diagnosis and has been vaccinated previously with any of the synthetic peptides included in this protocol
__label__1	study interventions are Histone Deacetylase Inhibitors . recurrent grade three follicular lymphoma diagnosis and patients with new york heart association nyha class ii iv heart failure
__label__1	study interventions are Pembrolizumab . melanoma diagnosis and patients with vitiligo or other non serious autoimmune diseases based on the investigator assessment are not excluded
__label__1	study interventions are Antibodies . rectal cancer diagnosis and patients must not have received prior chemotherapy or radiation for greater_than equal_than two weeks before study enrollment
__label__1	study interventions are Camptothecin . colorectal cancer diagnosis and any of the following within one year before randomization
__label__1	study interventions are Sirolimus . stage iii merkel cell carcinoma diagnosis and known history of human immunodeficiency virus hiv seropositivity
__label__1	study interventions are Dimethyl Fumarate . small lymphocytic lymphoma diagnosis and myocardial infarction within six months of starting study drug
__label__1	study interventions are Docetaxel . breast cancer diagnosis and poorly controlled diabetes mellitus
__label__1	study interventions are Capecitabine . adenocarcinoma of the gastroesophageal junction diagnosis and prior radiation to greater_than thirty of the marrow cavity
__label__1	study interventions are Etoposide phosphate . refractory mantle cell lymphoma diagnosis and prior radiation therapy rt greater_than twenty gray gy to critical organ within one year of enrollment
__label__1	study interventions are Vinblastine . previous malignancies are allowed if disease free survival is superior to five years except for renal carcinoma or melanoma
__label__1	study interventions are Antibodies, Monoclonal . melanoma diagnosis and is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with the pre screening or screening visit through one hundred and twenty days after the last dose of trial treatment
__label__1	study interventions are Gemcitabine . recurrent ovarian carcinoma diagnosis and patients with primary platinum refractory disease defined as progression while first line platinum based chemotherapy
__label__1	study interventions are Cortisone acetate . stage ii follicular lymphoma diagnosis and has received live vaccine within thirty days prior to the first dose of trial treatment
__label__1	study interventions are Pomalidomide . recurrent childhood visual pathway glioma diagnosis and alanine aminotransferase alt serum glutamate pyruvate transaminase sgpt equal_than less_than three institutional upper limit of normal
__label__1	study interventions are Fludarabine phosphate . recurrent childhood lymphoblastic lymphoma diagnosis and current serious systemic illness
__label__1	study interventions are Lacosamide . brain cancer diagnosis and there is insufficient information to determine if lacosamide is safe during lactation
__label__1	study interventions are Docetaxel . patients with advanced inoperable or metastatic esophageal carcinoma
__label__1	study interventions are Bupivacaine . thyroid neoplasms diagnosis and patient with chronic pain syndromes
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ib breast cancer diagnosis and history of hospitalization in past twelve months for diabetic ketoacidosis dka or hyperosmolar hyperglycemic nonketotic syndrome hhns
__label__1	study interventions are Antibodies, Monoclonal . stage ib cervical cancer diagnosis and patients who have significant history of cardiac disease uncontrolled hypertension unstable angina congestive heart failure or uncontrolled arrhythmias within six months of registration
__label__1	study interventions are MSB0010445 (1.0 mg/kg) . treatment with systemic anti cancer therapy within the thirty days before the first dose of sbrt
__label__1	study interventions are Docetaxel . pancreatic cancer diagnosis and females who are pregnant or breast feeding
__label__1	study interventions are Osimertinib . nonsmall cell lung cancer diagnosis and diagnosed congenital bleeding disorders von_willebrand disease
__label__1	study interventions are Antibodies . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Tacrolimus . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and patients who are not candidate for an unrelated donor allogeneic hsct based on the current institutional bone marrow transplant bmt program clinical practice guidelines organ function criteria will be utilized per the current institutional bmt program clinical practice guidelines there will be no restriction to study entry based on hematological parameters
__label__1	study interventions are Immunoglobulin G . stage ivb rectal cancer diagnosis and other active malignancy equal_than less_than three years prior to registration exceptions
__label__1	study interventions are Oxaliplatin . rectal cancer that is unlikely to be operable even after neoadjuvant treatment tumor involving the internal iliac vessels
__label__1	study interventions are Chloroquine diphosphate . invasive breast cancer diagnosis and abnormal hepatic function serum ast or alt greater_than threex upper limit of normal
__label__1	study interventions are Lenalidomide . advanced cancer diagnosis and prior receipt of jakone inhibitor phase onea only
__label__1	study interventions are Liposomal doxorubicin . contiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and positive serology because of prior vaccination is allowed
__label__1	study interventions are Prednisolone phosphate . extramedullary plasmacytoma or solitary plasmacytoma
__label__1	study interventions are Sirolimus . lymphoma diagnosis and prior to study entry any ecg abnormality at screening must be documented by the investigator as not medically relevant
__label__1	study interventions are Daratumumab . multiple myeloma diagnosis and subject is known to be seropositive for human immunodeficiency virus hiv or have active hepatitis or hepatitis c
__label__1	study interventions are Dexamethasone 21-phosphate . relapse refractory multiple myeloma diagnosis and patient has impaired cardiac function or prolonged qtc interval at screening ecg
__label__1	study interventions are Albumin-Bound Paclitaxel . locally advanced breast cancer diagnosis and angina pectoris that requires the current use of anti anginal medication
__label__1	study interventions are Tacrolimus . stage iv adult diffuse mixed cell lymphoma diagnosis and donor
__label__1	study interventions are Temozolomide . pancreatic cell carcinoma diagnosis and class iii or iv congestive heart failure as defined by the new york heart association
__label__1	study interventions are positron emission tomography . adenocarcinoma of the prostate diagnosis and the subject has received radiation therapy
__label__1	study interventions are Etoposide . stage iv childhood small noncleaved cell lymphoma diagnosis and patients with uncontrolled seizures as defined by having any seizure activity within the three months prior to screening
__label__1	study interventions are Vidarabine . noncontiguous stage ii adult burkitt lymphoma diagnosis and disease resulting in severely limited performance status less_than seventy
__label__1	study interventions are Vidarabine . recurrent adult cell leukemia lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Bevacizumab . leiomyosarcoma diagnosis and inability to comply with study and or follow up procedures
__label__1	study interventions are laboratory biomarker analysis . female sterilization have had surgical bilateral oophorectomy with or without hysterectomy or tubal ligation at least six weeks before taking study treatment in case of oophorectomy alone only when the reproductive status of the woman has been confirmed by follow up hormone level assessment
__label__1	study interventions are Hormones . metastatic breast cancer diagnosis and note
__label__1	study interventions are Fluorouracil . colorectal cancer metastatic diagnosis and persistence of clinically relevant treatment related toxicities from previous chemotherapy and or radiotherapy adjuvant or neo adjuvant setting
__label__1	study interventions are Sirolimus . head and neck cancer diagnosis and mini dose anticoagulation may be used to assist in patency of central venous lines
__label__1	study interventions are Mycophenolic Acid . contiguous stage ii small lymphocytic lymphoma diagnosis and marrow donors who have increased anesthetic risk
__label__1	study interventions are Fludarabine . noncontiguous stage ii small lymphocytic lymphoma diagnosis and donor
__label__1	study interventions are Bevacizumab . regional digestive system neuroendocrine tumor gone diagnosis and grade greater_than equal_than three hemorrhage equal_than less_than four weeks prior to registration
__label__1	study interventions are Albumin-Bound Paclitaxel . inflammatory breast cancer diagnosis and inadequate general condition not fit for anthracycline taxane targeted agents based chemotherapy
__label__1	study interventions are Epothilone B . non small cell lung cancer diagnosis and clinical evidence of leptomeningeal disease
__label__1	study interventions are Cetuximab . recurrent salivary gland cancer diagnosis and topical applications rash inhaled sprays obstructive airways diseases eye drops or local injections intra articular are allowed patients with previously treated brain metastases who are on stable low dose corticosteroids treatment eg
__label__1	study interventions are CT perfusion . hepatobiliary cancers diagnosis and doc
__label__1	study interventions are Folic Acid . recurrent rectal carcinoma diagnosis and note
__label__1	study interventions are Regorafenib . metastatic biliary tract carcinoma diagnosis and renal failure requiring hemo or peritoneal dialysis
__label__1	study interventions are Mesna . advanced stage diffuse large cell non hodgkin lymphoma diagnosis and any medical condition that in the opinion of the investigator would compromise treatment delivery add toxicity or impair assessment
__label__1	study interventions are Progesterone . progesterone receptor positive tumor max one line of prior chemotherapy no prior hormone therapy diagnosis and chronic adrenal failure or is receiving concurrent long term corticosteroid therapy
__label__1	study interventions are Ubiquinone . breast cancer diagnosis and currently using any investigational agent
__label__1	study interventions are Everolimus . multiple myeloma diagnosis and patients with uncontrolled diabetes mellitus
__label__1	study interventions are Ondansetron . advanced stage diffuse large cell non hodgkin lymphoma diagnosis and any medical condition that in the opinion of the investigator would compromise treatment delivery add toxicity or impair assessment
__label__1	study interventions are conventional surgery . stage ii mucoepidermoid carcinoma of the oral cavity diagnosis and porphyria or hypersensitivity to porphyrin or porphyrin like compounds
__label__1	study interventions are Nivolumab . lung carcinoma diagnosis and repeat imaging demonstrates no new sites of bone metastases
__label__1	study interventions are Carmustine . refractory hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Immunoglobulin G . exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or cervical cancer in situ that has undergone potentially curative therapy
__label__1	study interventions are Capecitabine . metastatic breast cancer diagnosis and uncontrolled diabetes as defined by fasting serum glucose greater_than doc uln
__label__1	study interventions are Doxorubicin . classical hodgkin lymphoma diagnosis and patients who received systemic corticosteroids within twenty-eight days of enrollment on this protocol except as specified are not eligible
__label__1	study interventions are Dasatinib . chondrosarcoma diagnosis and erythromycins clarithromycin
__label__1	study interventions are Immunoglobulin G . ovarian clear cell adenocarcinoma diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study the investigator should feel free to consult the study chair or study co chairs for uncertainty in this regard
__label__1	study interventions are Fludarabine . recurrent childhood large cell lymphoma diagnosis and positive crossmatch between donor and recipients
__label__1	study interventions are Poly ICLC . stage breast cancer diagnosis and previous splenectomy or radiotherapy to spleen
__label__1	study interventions are Trifluridine . previously treated metastatic colorectal cancer diagnosis and hospitalization for an acute medical issue within four weeks prior to screening visit that would not otherwise be managed in an infusion center or outpatient clinic setting patient admitted to complete transfusion would not be ineligible
__label__1	study interventions are Antibodies, Monoclonal . treatment with systemic corticosteroids or other systemic immunosuppressive medications including but not limited to prednisone dexamethasone cyclophosphamide azathioprine methotrexate thalidomide and anti tumor necrosis factor tnf agents within two weeks prior to initiation of study drug or anticipated requirement for systemic immunosuppressive medications during the trial
__label__1	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and subjects allergic to any component that is part of the treatment regimen
__label__1	study interventions are Fluorodeoxyglucose F18 . stage iva cervical cancer diagnosis and patients unable to receive intravenous chemotherapies as consequence of poor vascular access are ineligible
__label__1	study interventions are Prednisone . metastatic renal cancer diagnosis and patients with an active bleeding diathesis
__label__1	study interventions are Antibodies . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure uncontrolled hypertension prior cardiomyopathy lvef less_than fifty unstable angina pectoris cardiac arrhythmia atrial fibrillation or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Rituximab . splenic marginal zone lymphoma diagnosis and inability to achieve adequate venous access
__label__1	study interventions are Antibodies, Monoclonal . mucosal melanoma diagnosis and patients with inadequate tissue for analysis
__label__1	study interventions are Chloroquine . carcinoma intraductal_noninfiltrating diagnosis and history of hiv disease and or treatment with anti hiv agents
__label__1	study interventions are Carboplatin . stage iv ovarian epithelial cancer diagnosis and this criterion does not apply to subjects treated on the expansion cohort accruals post february one 20one3
__label__1	study interventions are Rucaparib . peritoneal cancer diagnosis and required drainage of ascites during the final two cycles of their last platinum based regimen and or during the period between the last dose of chemotherapy of that regimen and randomization to maintenance treatment in this study
__label__1	study interventions are Vidarabine . recurrent grade three follicular lymphoma diagnosis and inability to understand or give an informed consent
__label__1	study interventions are Registry . pancreatic cancer diagnosis and any patient that will not undergo ablation
__label__1	study interventions are Rituximab . stage iv adult diffuse mixed cell lymphoma diagnosis and clinically active hepatitis b or infections note
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and known gi disease or gi procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing
__label__1	study interventions are Beta-lapachone . carcinoma diagnosis and have received any chemotherapy immunotherapy vaccines monoclonal antibodies major surgery or irradiation whether conventional or investigational within two weeks of treatment in this study
__label__1	study interventions are Lenograstim . other concurrent anticancer agents or therapies
__label__1	study interventions are Brivanib Placebo . hepatocellular carcinoma diagnosis and history of human immunodeficiency virus hiv infection
__label__1	study interventions are Foscarnet . stage iv adult diffuse large cell lymphoma diagnosis and the source of hematopoietic stem cells is cell depleted
__label__1	study interventions are Navitoclax . stage iiic colorectal cancer diagnosis and history or evidence of cardiovascular risk including any of the following
__label__1	study interventions are Placebo . cancer patients with cachexia diagnosis and other clinical diagnosis ongoing or intercurrent illness that in the investigator opinion would prevent the patient participation
__label__1	study interventions are Nitrogen Mustard Compounds . recurrent follicular lymphoma diagnosis and intractable severe diarrhea defined as greater_than doc zero cc diarrheal fluid per day or diarrhea causing persistent severe electrolyte abnormalities or hypoalbuminemia
__label__1	study interventions are Radiofrequency Ablation(RFA) by HALO device. . esophageal neoplasms diagnosis and any previous esophageal surgery including fundoplication
__label__1	study interventions are Pirfenidone . neurofibroma plexiform diagnosis and patients with gilbert syndrome are excluded from the requirement of normal bilirubin
__label__1	study interventions are Bevacizumab . lung cancer diagnosis and concomitant chemotherapy radiotherapy or investigational agents
__label__1	study interventions are Vaccines . melanoma diagnosis and allergic skin diseases including eczema psoriasis and neurodermitis
__label__1	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and known brain and or leptomeningeal metastases
__label__1	study interventions are Cisplatin . patients who have residual toxicity ities from previous anti cancer treatment that is are clinically significant or greater_than grade one are excluded those whose toxicity ities improved to grade one or better will be eligible
__label__1	study interventions are Veliparib . other concurrent anticancer therapies or agents
__label__1	study interventions are Pemetrexed . stage iiib lung adenocarcinoma diagnosis and patients receiving any medications or substances that are inhibitors or inducers of nonsteroidal anti inflammatory drugs nsaids probenecid salisylates sulfonamides are ineligible concomitant drugs that are sensitive cytochrome pfour hundred and fifty cypfour hundred and fifty substrates or strong and moderate cypfour hundred and fifty inducers and inhibitors should be avoided as part of the enrollment informed consent procedures the patient will be counseled on the risk of interactions with other agents and what to do if new medications need to be prescribed or if the patient is considering new over the counter medicine or herbal product
__label__1	study interventions are Epothilones . metastatic breast cancer diagnosis and patient has concurrent medical condition which may increase the risk of toxicity
__label__1	study interventions are Lenograstim . stage mantle cell lymphoma diagnosis and myocardial infarction within six months prior to enrollment or has new york heart association nyha class iii or iv heart failure uncontrolled angina severe uncontrolled ventricular arrhythmias or electrocardiographic evidence of acute ischemia or active conduction system abnormalities prior to study entry any electrocardiogram ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and other active malignancy equal_than less_than three years prior to randomization exceptions
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib breast cancer diagnosis and patients with known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol or to antiemetics appropriate for administration in conjunction with protocol directed therapy
__label__1	study interventions are Resistance Training and Nutrition Counseling . laryngeal cancer diagnosis and severe emotional distress
__label__1	study interventions are Antibodies, Monoclonal . malignancies other than colorectal cancer within five years prior to cycle one day one
__label__1	study interventions are Dexamethasone . stage ii multiple myeloma diagnosis and have had diagnosis of another malignancy unless the patient has been disease free for at least three years following the completion of curative intent therapy including the following
__label__1	study interventions are Dacarbazine . other malignancies within the past three years except for adequately treated carcinoma in situ of the cervix or basal cell or superficial squamous skin cell carcinomas
__label__1	study interventions are blood draw . liver cancer diagnosis and history of second active malignancy with evidence of metastatic disease
__label__1	study interventions are Axitinib . malignant pleural mesothelioma diagnosis and impaired renal function
__label__1	study interventions are Nintedanib . stage iib non small cell lung carcinoma diagnosis and active hemoptysis or history of clinically relevant hemoptysis as determined by the treating physician patients who had history of transient minor hemoptysis after bronchoscopic biopsy are eligible unless deemed otherwise by the treating physician
__label__1	study interventions are Tamoxifen . reccurent metastatic solid tumor disease diagnosis and pregnant and or breastfeeding women
__label__1	study interventions are Capecitabine . tumor relapse progression within six months of completion of cisplatin based chemoradiotherapy regimen for the treatment of early stage tumors
__label__1	study interventions are Etoposide . stage ii grade three contiguous follicular lymphoma diagnosis and serious ongoing non malignant disease or infection which in the opinion of the investigator and or the sponsor would compromise other protocol objectives participants with active opportunistic infections are ineligible
__label__1	study interventions are Epothilones . stage iv adult soft tissue sarcoma diagnosis and prior other neoadjuvant or adjuvant chemotherapy less than or equal to four weeks prior to study entry
__label__1	study interventions are Dexamethasone . mantle cell lymphoma diagnosis and peripheral neuropathy of grade three or higher
__label__1	study interventions are Floxuridine . stage iv ovarian cancer diagnosis and failure to fully recover from acute reversible effects of prior chemotherapy regardless of interval since last treatment
__label__1	study interventions are Fosaprepitant . stage iiic primary peritoneal cancer diagnosis and patients who are known to be hypersensitive to aprepitant granisetron or any of the components of the patch or to dexamethasone
__label__1	study interventions are Lapatinib . brain tumor diagnosis and patients must not be pregnant because no studies with this drug have been performed to evaluate safety
__label__1	study interventions are Lapatinib . stage iva verrucous carcinoma of the larynx diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to gwfive hundred and seventy-two thousand and sixteen
__label__1	study interventions are Etoposide . recurrent plasma cell myeloma diagnosis and life expectancy severely limited by disease other than malignancy
__label__1	study interventions are Fludarabine phosphate . testicular lymphoma diagnosis and pregnancy
__label__1	study interventions are Antibodies, Monoclonal . stage iv adult cell leukemia lymphoma diagnosis and urine protein should be screened by dipstick or urine analysis for proteinuria greater_than one positive or urine protein
__label__1	study interventions are Pemetrexed . head and neck cancer diagnosis and patients with neurological symptoms or previously treated cns metastases must undergo ct scan mri of the brain within fourteen days of study enrollment to rule out brain metastasis
__label__1	study interventions are Antibodies . high grade ovarian serous adenocarcinoma diagnosis and new york heart association functional classification ii iii or iv
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and known hypersensitivity to thalidomide or purine analogues
__label__1	study interventions are JCAR017 single-dose schedule . non hodgkin lymphoma diagnosis and radiation within six weeks of leukapheresis
__label__1	study interventions are Albumin-Bound Paclitaxel . small cell lung cancer diagnosis and grade two peripheral neuropathy motor or sensory
__label__1	study interventions are Dexamethasone . prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer in situ cervical cancer or other cancer for which the patient has been disease free for at least three years
__label__1	study interventions are Cyclosporins . relapsed non hodgkin or hodgkin lymphoma diagnosis and patients with known hypersensitivity to e
__label__1	study interventions are Recombinant human apolipoprotein(a) Kringle V . solid tumors diagnosis and history of idiopathic or hereditary angioedema
__label__1	study interventions are Bevacizumab . metastatic renal cell carcinoma diagnosis and uncontrolled hypercalcemia while receiving appropriate treatment
__label__1	study interventions are Lenvatinib . malignant neoplasms of thyroid and other endocrine glands diagnosis and history of gastrointestinal malabsorption or having undergone surgery requiring gastrointestinal anastomoses within four weeks of starting therapy or who have not recovered from major surgery within three weeks of starting therapy
__label__1	study interventions are Mycophenolate mofetil . stage iii grade three follicular lymphoma diagnosis and karnofsky performance status less_than seventy adults or lanksy score less_than fifty pediatrics
__label__1	study interventions are Sunitinib . prostate cancer diagnosis and recent cardiovascular event within twelve months including unstable angina myocardial infarction severe or at rest claudication or stroke cva
__label__1	study interventions are Dexamethasone . refractory plasma cell myeloma diagnosis and any of the following
__label__1	study interventions are Sorafenib . recurrent adult primary liver cancer diagnosis and prior radiotherapy to the region of the liver that would result in overlap of radiation therapy fields
__label__1	study interventions are Mycophenolate mofetil . recurrent adult cell leukemia lymphoma diagnosis and cardiac ejection fraction less_than forty or cardiac failure requiring therapy
__label__1	study interventions are Antibodies . stage grade one follicular lymphoma diagnosis and donors less_than one2 years of age
__label__1	study interventions are Mycophenolic Acid . refractory hodgkin lymphoma diagnosis and current serious systemic illness
__label__1	study interventions are Dacarbazine . pontine glioma diagnosis and age greater than ten years but less than fifteen
__label__1	study interventions are Vitamins . breast cancer diagnosis and five recent history of excessive alcohol or drug use
__label__1	study interventions are One-on-one interview . stage iiic breast cancer diagnosis and inability to understand english
__label__1	study interventions are Mycophenolic Acid . stage iv childhood burkitt lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Trabectedin . solid tumors diagnosis and pregnant or breast feeding females
__label__1	study interventions are Lansoprazole . oropharyngeal cancer diagnosis and subjects with allergies or sensitivities to proton_pump inhibitors
__label__1	study interventions are Pharmacogenomic Study . stage iiic breast cancer diagnosis and patients with prior history of seizures
__label__1	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and any significant ophthalmologic abnormality especially severe dry eye syndrome keratoconjunctivitis_sicca sjögren syndrome severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions
__label__1	study interventions are Olaparib . melanoma neoplasms diagnosis and major surgery within four weeks of starting the study
__label__1	study interventions are Bevacizumab . non small cell lung cancer diagnosis and evidence of confusion or disorientation or history of major psychiatric illness that may impair the patient understanding of the informed consent form or their ability to comply with study requirements
__label__1	study interventions are Epirubicin . male breast carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition as epirubicin or dinaciclib
__label__1	study interventions are Ifosfamide . recurrent diffuse large cell lymphoma diagnosis and pregnant or breastfeeding
__label__1	study interventions are Oxaliplatin . stage iiib gastric cancer diagnosis and neuropathy grade two or greater by nci ctcae v
__label__1	study interventions are Capecitabine . advanced gastrointestinal cancer diagnosis and known hypersensitivity to any component of bevacizumab
__label__1	study interventions are Standard support . cervical cancer diagnosis and transgender status
__label__1	study interventions are Pembrolizumab . known active central nervous system cns metastases and or carcinomatous_meningitis
__label__1	study interventions are pegfilgrastim . non hodgkin lymphoma diagnosis and central nervous system cns involvement
__label__1	study interventions are tanespimycin . brain metastases unless previously treated with radiotherapy or surgery and asymptomatic with active brain metastases detectable by ct scan or mri for greater_than six months
__label__1	study interventions are Antibodies, Monoclonal . urothelial carcinoma diagnosis and cardiac arrhythmias of nci ctcae grade greater than or equal to two within the last month
__label__1	study interventions are Albumin-Bound Paclitaxel . esophageal cancer diagnosis and prior radiation to the chest or abdomen
__label__1	study interventions are Pembrolizumab . refractory lymphoplasmacytic lymphoma diagnosis and previous use of corticosteroids is allowed
__label__1	study interventions are Pembrolizumab . adenocarcinoma diagnosis and clinically significant greater_than grade two peripheral neuropathy at the time of study entry
__label__1	study interventions are Prednisone . diffuse large cell lymphoma lymphoma follicular diagnosis and positive for hepatitis surface antigen hbsag total hepatitis core antibody hbcab or hepatitis virus hcv antibody at screening
__label__1	study interventions are Busulfan . kidney cancer diagnosis and prior bone marrow transplantation
__label__1	study interventions are Pioglitazone . stage iva oropharyngeal squamous cell carcinoma diagnosis and actoplus met avandamet avandaryl duetact glucovance invokamet janumet jentadueto komboglyze metaglip prandimet synjardy xigudo
__label__1	study interventions are Immunoglobulins . endometrial clear cell adenocarcinoma diagnosis and history of diverticulitis or pancreatitis within twelve weeks of registration
__label__1	study interventions are Mycophenolic Acid . recurrent grade two follicular lymphoma diagnosis and donor
__label__1	study interventions are Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter . recurrent ovarian carcinoma diagnosis and any of the following prior therapies
__label__1	study interventions are Carboplatin . ovarian nonepithelial cancer including malignant mixed mullerian tumors and borderline tumors tumors of low malignant potential
__label__1	study interventions are Antibodies, Monoclonal . recurrent adult diffuse large cell lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Vinblastine . lung cancer diagnosis and patients with third space fluid which cannot be adequately controlled with drainage
__label__1	study interventions are SGM-101 . rectum cancer diagnosis and serum creatinine above doc times the uln or
__label__1	study interventions are Sirolimus . stage iiib breast cancer diagnosis and active bleeding diathesis
__label__1	study interventions are Fludarabine phosphate . contiguous stage ii grade one follicular lymphoma diagnosis and patient scheduled for cord blood transplantation
__label__1	study interventions are Fludarabine . metastatic gastric cancer diagnosis and any patient known to have an lvef less than or equal to forty-five
__label__1	study interventions are Busulfan . ewing sarcoma peripheral primitive neuroectodermal tumor pnet diagnosis and age greater_than sixty-five years
__label__1	study interventions are Sulfatinib . neuroendocrine tumors diagnosis and palliative radiotherapy for bone metastasis lesion within two weeks prior to the initiation of the investigational treatment
__label__1	study interventions are Nivolumab . solid neoplasm diagnosis and history of organ transplant
__label__1	study interventions are Albumin-Bound Paclitaxel . invasive adenocarcinoma of the breast diagnosis and angina pectoris that requires the current use of anti anginal medication
__label__1	study interventions are Fludarabine phosphate . recurrent childhood lymphoblastic lymphoma diagnosis and donor related risks to recipients
__label__1	study interventions are Immunoglobulins . ovarian endometrioid adenocarcinoma diagnosis and other active malignancy equal_than less_than three years prior to registration exceptions
__label__1	study interventions are Everolimus . stage mantle cell lymphoma diagnosis and donor
__label__1	study interventions are Fluorouracil . stage iib colon cancer diagnosis and pregnancy or lactation at the time of proposed randomization eligible patients of reproductive potential both sexes must agree to use adequate contraceptive methods during study therapy and for at least three months after the completion of bevacizumab
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and absolute neutrophil count less_than doc one hundred and nine within fourteen days of enrolment
__label__1	study interventions are Bevacizumab . malignant brain tumor diagnosis and other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study
__label__1	study interventions are Veliparib . stage iiia ovarian cancer diagnosis and ongoing or active infection
__label__1	study interventions are Megestrol Acetate . unspecified adult solid tumor protocol specific diagnosis and pt inr results should be monitored frequently with dosage adjustment as needed
__label__1	study interventions are Pancrelipase . pancreatic ductal adenocarcinoma diagnosis and individuals with active or history of eczema or atopic_dermatitis or darier disease those with other acute chronic or exfoliative skin conditions burns_impetigo varicella_zoster severe acne contact dermatitis psoriasis herpes or other open rashes or wounds until the condition resolves
__label__1	study interventions are Pemetrexed . lung cancer small cell diagnosis and note
__label__1	study interventions are Fludarabine . metastatic renal cell cancer diagnosis and any form of primary immunodeficiency such as severe combined immunodeficiency disease
__label__1	study interventions are Cyclosporine . noncutaneous extranodal lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of hydroxyurea and imatinib mesylate will not be allowed within two weeks of the initiation of conditioning
__label__1	study interventions are Paclitaxel . triple negative breast cancer diagnosis and patients with known human immunodeficiency virus hiv infection infectious hepatitis type b or active hepatitis or hepatic insufficiency
__label__1	study interventions are Fludarabine . refractory multiple myeloma diagnosis and active central nervous system cns leukemia involvement at the time of study enrollment cerebrospinal fluid with greater_than five white blood cells wbc mm three and malignant cells on cytospin
__label__1	study interventions are Paclitaxel . adenosquamous cell lung cancer diagnosis and refusal to sign the informed consent
__label__1	study interventions are Standard therapy . subjects with curatively treated cervical carcinoma in situ or basal cell carcinoma of the skin or subjects who have been free of other malignancies for greater_than five years are eligible for this study
__label__1	study interventions are Fludarabine . recurrent adult burkitt lymphoma diagnosis and calculated creatinine clearance less_than forty cc min by the modified cockroft gault formula for adults or the schwartz formula for pediatrics
__label__1	study interventions are Interferon-gamma . ovarian cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Isophosphamide mustard . germ cell tumors diagnosis and patients with hiv infection hepatitis and c
__label__1	study interventions are BB 1101 . subject has received anti myeloma treatment within two weeks of cycle one day
__label__1	study interventions are Antibodies, Monoclonal . solid tumor cancers diagnosis and prior radiation therapy within two weeks before the first dose of study treatment
__label__1	study interventions are Dexamethasone . multiple myeloma diagnosis and serum sgot ast or sgpt alt greater_than doc upper limit of normal uln
__label__1	study interventions are Quality of life . choroid melanoma
__label__1	study interventions are Oxaliplatin . colorectal neoplasms diagnosis and concomitant treatments with drugs ingredients reported to have potential activity in preventing psn
__label__1	study interventions are HPV Specific T Cells . human papillomavirus positive penile carcinoma diagnosis and pregnancy or lactation
__label__1	study interventions are Vaccines . metastatic melanoma diagnosis and patients currently taking medications that inhibit platelet function aspirin dipyridamole epoprostenol eptifibatide clopidogrel cilostazol abciximab ticlopidine and any non steroidal anti inflammatory drug because of potential increased risk of bleeding from dasatinib
__label__1	study interventions are Docetaxel . breast cancer diagnosis and clinically significant cardiovascular disease hypertension bp greater_than one hundred and fifty one hundred myocardial infarction or stroke within six months unstable angina new york heart association nyha grade ii or greater congestive heart failure or serious cardiac arrhythmia requiring medication
__label__1	study interventions are Nivolumab . stage iii urethral cancer diagnosis and the subject has prothrombin time pt international normalized ratio inr or partial thromboplastin time ptt test greater_than equal_than doc the laboratory uln within seven days before the first dose of study treatment
__label__1	study interventions are Antibodies . malignant melanoma diagnosis and history of retinal degenerative disease
__label__1	study interventions are Erlotinib Hydrochloride . pancreatic cancer diagnosis and pt ptt international normalized ratio inr within normal limits
__label__1	study interventions are Tamoxifen . recurrent breast cancer or second primary cancer
__label__1	study interventions are Bevacizumab . cancer diagnosis and history of visceral arterial ischemia less_than twenty-four weeks before randomization
__label__1	study interventions are Cisplatin . non squamous non small cell lung cancer stage iiia diagnosis and pre existing neuropathic greater_than grade two
__label__1	study interventions are Immunoglobulins . adequately treated non melanoma skin cancer or lentigo maligns without evidence of disease
__label__1	study interventions are Goserelin . metastatic breast cancer diagnosis and however patients with cns metastases who have completed course of therapy would be eligible for the study provided they are clinically stable for at least one month prior to entry as defined as
__label__1	study interventions are Oxaliplatin . stage iii pancreatic cancer diagnosis and major surgery intra thoracic intra abdominal or intra pelvic open biopsy or significant traumatic injury equal_than less_than four weeks and minor procedures including percutaneous biopsies placement of vascular access device laparoscopy positive
__label__1	study interventions are Trametinib . stage iiia skin melanoma diagnosis and strong inhibitors of cypthreea or cyptwoceight
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma diagnosis and known hypersensitivity to any component of bevacizumab
__label__1	study interventions are Hydrocortisone 17-butyrate 21-propionate . prostate cancer diagnosis and evidence of cns brain or leptomeningeal metastases or large pleural pericardial effusions
__label__1	study interventions are Cisplatin . stage iiia ovarian cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Fludarabine . renal cancer diagnosis and patients receiving full dose anticoagulative therapy
__label__1	study interventions are Cabozantinib . ureteral neoplasms diagnosis and the subject is unable to swallow tablets
__label__1	study interventions are Palbociclib . breast carcinoma diagnosis and condition that would interfere with enteric absorption
__label__1	study interventions are Antibodies . stage ivb colorectal cancer diagnosis and administration of live attenuated vaccine within twenty-eight days prior to randomization
__label__1	study interventions are Antibodies . lymphoma non hodgkin diagnosis and patients with known hiv infection
__label__1	study interventions are Paclitaxel . cervical adenosarcoma diagnosis and brain metastases per mri or ct at any time prior to registration note
__label__1	study interventions are Trametinib . recurrent non small cell lung carcinoma diagnosis and any major surgery extensive radiotherapy chemotherapy with delayed toxicity biologic therapy or immunotherapy within twenty-one days prior to enrollment
__label__1	study interventions are pp65-shLAMP DC with GM-CSF . glioblastoma diagnosis and more than forty-five days after completion of radiation therapy and temozolomide
__label__1	study interventions are Lenograstim . stage iii adult diffuse mixed cell lymphoma diagnosis and patient has platelet count of less_than one hundredx ten nine within fourteen days before enrollment
__label__1	study interventions are Oxaliplatin . adenocarcinoma of the esophagus diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to study enrollment
__label__1	study interventions are placebo . non small cell lung cancer diagnosis and within six months before the first treatment occurs artery venous thromboembolic events such as cerebral vascular accident including transient ischemic attack deep vein thrombosis and pulmonary embolism etc
__label__1	study interventions are Vorinostat . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and patients with history of impaired cardiac status including history of severe coronary artery disease cardiomyopathy congestive heart failure or arrhythmia if the patient history is questionable measurement of left ventricular ejection fraction should be obtained within forty-two days prior to registration patients with left ventricular ejection fraction less_than fifty are not eligible
__label__1	study interventions are management of therapy complications . stage ivb rectal cancer diagnosis and unable to read or understand english
__label__1	study interventions are Antibodies, Monoclonal . carcinoma non small cell lung diagnosis and therapeutic or experimental monoclonal antibodies within twenty-eight day or prior radiation therapy within fourteen days of the first dose of study drug
__label__1	study interventions are Liposomal doxorubicin . neoplasm metastasis diagnosis and uncontrolled significant heart disease such as unstable angina
__label__1	study interventions are Abiraterone Acetate . metastatic castrate resistant prostate cancer diagnosis and uncontrolled medical conditions such as myocardial infarction uncontrolled hypertension stroke or treatment of major active infection within three months of randomization as well as any significant concurrent medical illness that in the opinion of the investigator would preclude protocol therapy
__label__1	study interventions are Immunoglobulins . undifferentiated fallopian tube carcinoma diagnosis and no metastases to brain stem midbrain_pons medulla_cerebellum or within ten mm of the optic apparatus optic nerves and chiasm
__label__1	study interventions are Mesenchymal Stem Cell Transplantation . malignant ovarian brenner tumor diagnosis and other cardiac or pulmonary disease that at the investigators discretion can impair treatment safety
__label__1	study interventions are Carboplatin . stage iv non small cell lung cancer diagnosis and patients with untreated brain metastases should be excluded from this clinical trial however patients who have stable brain disease should be off corticosteroids at least three weeks after completion of appropriate therapy are eligible
__label__1	study interventions are Thioguanine . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and patients who are pregnant pregnancy test is required for female patients of childbearing potential
__label__1	study interventions are Calcium, Dietary . metastatic colorectal cancer diagnosis and malignant coelomic fluid required drainage
__label__1	study interventions are Fludarabine phosphate . recurrent cutaneous cell non hodgkin lymphoma diagnosis and pregnancy
__label__1	study interventions are PROAPOPTOTIC PEPTIDE CIGB 300 . recurrent condyloma diagnosis and having received surgery treatment ablative or immunomodulator treatment during the thirty days prior to inclusion
__label__1	study interventions are Sorafenib . non small cell lung cancer nsclc diagnosis and patients with unresolved diarrhea greater_than ctcae grade one
__label__1	study interventions are Carboplatin . undifferentiated fallopian tube carcinoma diagnosis and note
__label__1	study interventions are Fludarabine phosphate . recurrent mantle cell lymphoma diagnosis and twenty spinal cord
__label__1	study interventions are Sorafenib . hepatocellular carcinoma diagnosis and major surgery open biopsy or significant traumatic injury within four weeks of first study drug
__label__1	study interventions are Mitogens . prostate cancer diagnosis and hepatic malignancy
__label__1	study interventions are Progesterone . breast cancer diagnosis and unstable diabetes mellitus
__label__1	study interventions are Cyclophosphamide . melanoma diagnosis and participants classified according to the new york heart association classification as having class iii or iv heart disease appendix four
__label__1	study interventions are Osimertinib . lung cancer diagnosis and all patients must try to avoid concomitant use of any medications herbal supplements and or ingestion of foods with known inducer inhibitory effects on cypthreeafour
__label__1	study interventions are Cisplatin . stage ivb hypopharyngeal squamous cell carcinoma diagnosis and breastfeeding patients are ineligible
__label__1	study interventions are Immunoglobulin G . stage iv skin melanoma diagnosis and clinically significant stroke or transient ischemic attack tia equal_than less_than six months prior to registration randomization seizures not controlled with standard medical therapy
__label__1	study interventions are Nivolumab . non squamous cell non small cell lung cancer diagnosis and in addition subjects must be either off corticosteroids or on stable or decreasing dose of less_than tenmg daily prednisone or equivalent
__label__1	study interventions are hand gauge . pancreatic cancer diagnosis and minor patients
__label__1	study interventions are Sirolimus . malignant pancreatic insulinoma diagnosis and untreated central nervous system cns metastases exceptions
__label__1	study interventions are Mycophenolate mofetil . stage ii adult contiguous immunoblastic lymphoma diagnosis and patients with diagnosis of chronic myelomonocytic leukemia cmml
__label__1	study interventions are Erlotinib Hydrochloride . non small cell lung cancer diagnosis and history of any of the following autoimmune skin disorders
__label__1	study interventions are questionnaire administration . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and patients who previously have had their uterus or ovary ies removed are not eligible
__label__1	study interventions are Mycophenolate mofetil . recurrent grade three follicular lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of hydroxyurea and imatinib mesylate will not be allowed within two weeks of the initiation of conditioning
__label__1	study interventions are Cyclosporine . recurrent adult diffuse large cell lymphoma diagnosis and donor
__label__1	study interventions are Everolimus . stage adult lymphoblastic lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Isophosphamide mustard . lymphoma large cell diffuse diagnosis and poor renal function creatinine level greater_than one hundred and fiftyµmol or doc
__label__1	study interventions are Temozolomide . pancreatic alpha cell carcinoma diagnosis and inflammatory bowel disease ulcerative colitis crohn disease
__label__1	study interventions are radiofrequency ablation . liver cancer diagnosis and known history of human immunodeficiency virus hiv infection
__label__1	study interventions are Antibodies . stage grade three follicular lymphoma diagnosis and prior history of human immunodeficiency virus hiv positivity routine hiv testing is required pretreatment
__label__1	study interventions are Paclitaxel . metastatic breast cancer diagnosis and medical or psychological conditions that would not permit the subject to complete the study or sign informed consent
__label__1	study interventions are Capecitabine . stage iv adult diffuse small cleaved cell lymphoma diagnosis and requirement for antiarrhythmics or other medications known to prolong qtc
__label__1	study interventions are Tipifarnib . thyroid cancer diagnosis and controlled brain metastases that require continuous high dose corticosteroid use within four weeks of day one
__label__1	study interventions are Paclitaxel . stage iiia breast cancer diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to rofour million, nine hundred and twenty-nine thousand and ninety-seven or other agents used in the study
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent plasma cell myeloma diagnosis and planned concurrent treatment with any other investigational agents
__label__1	study interventions are Cefepime . plasma cell neoplasm diagnosis and diagnostic criteria suggestive of sepsis
__label__1	study interventions are Paclitaxel . cancer of the pancreas diagnosis and patients actively receiving insulin
__label__1	study interventions are Liposomal doxorubicin . lymphoma diagnosis and women who are pregnant or breastfeeding
__label__1	study interventions are Everolimus . kidney cancer diagnosis and treatment with strong cypthreeafour inhibitors
__label__1	study interventions are Oxaliplatin . colon cancer high risk stage iii ptfournone or ptone to four ntwo diagnosis and regnancy absence to be confirmed by hcg test or breast feeding period
__label__1	study interventions are Anastrozole . estrogen receptor positive breast cancer diagnosis and corrected qt interval qtc greater_than four hundred and eighty msecs using bazett formula
__label__1	study interventions are Heparin, Low-Molecular-Weight . ovarian cancer diagnosis and eastern cooperative oncology group ecog performance score of three or four
__label__1	study interventions are Navitoclax . small cell lung carcinoma diagnosis and currently receiving or requires anticoagulation therapy or any drug or herbal supplements that affect platelet function with exception of low dose anticoagulation medications that are used to maintain the patency of central intravenous catheter
__label__1	study interventions are orthogonal polarization spectral (OPS) imaging . colorectal cancer diagnosis and any patient who refuses enrolment
__label__1	study interventions are Donor Lymphocyte Infusion (DLI) . multiple myeloma with plasmacytoma diagnosis and absolute neutrophil count of less than five hundred cells microl
__label__1	study interventions are Antineoplastic Agents . lymphoma diagnosis and acute or chronic condition that in the opinion of the investigator would render vaccination unsafe or would interfere with the evaluation of responses including but not limited to the following
__label__1	study interventions are BB 1101 . subject has immeasurable mm no measurable monoclonal protein free light chains in blood or urine or measureable plasmacytoma on radiologic scanning
__label__1	study interventions are Antibodies, Monoclonal . cancer of head and neck diagnosis and uncontrolled intercurrent illness including but not limited to ongoing or active infection or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Antibodies, Monoclonal . a ongoing or planned administration of anti cancer therapies other than those specified in this study
__label__1	study interventions are Paclitaxel . ovarian mucinous adenocarcinoma diagnosis and patients who have received prior therapy with any anti vascular endothelial growth factor vegf drug including bevacizumab
__label__1	study interventions are Immunoglobulins . recurrent marginal zone lymphoma diagnosis and other serious medical conditions considered to represent contraindications to bone marrow transplant bmt abnormally decreased cardiac ejection fraction diffusing capacity dlco less_than fifty predicted patient on supplemental oxygen acquired immunodeficiency syndrome aids etc
__label__1	study interventions are Epirubicin . breast cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood lymphoblastic lymphoma diagnosis and cross match positive with donor
__label__1	study interventions are Valproic Acid . soft tissue sarcoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one or anticipation of need for major surgical procedure during the course of the study
__label__1	study interventions are Endothelial Growth Factors . recurrent uterine corpus sarcoma diagnosis and cardiovascular function specifically patient may not have
__label__1	study interventions are Endothelial Growth Factors . undifferentiated fallopian tube carcinoma diagnosis and grade ii or greater peripheral vascular disease exception
__label__1	study interventions are Camptothecin . colorectal cancer diagnosis and partial or complete bowel obstruction known chronic malabsorption total colectomy or other major abdominal surgery that might result in substantial alteration in transit to absorption of oral medication
__label__1	study interventions are Microdialysis . primary brain tumor diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Methotrexate . recurrent grade one follicular lymphoma diagnosis and thirty
__label__1	study interventions are Cyclophosphamide . hodgkin lymphoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are F-18-ISO . patients with other invasive malignancies with the exception of non melanoma skin cancer who had or have any evidence of the other cancer present within the last five years
__label__1	study interventions are protein vaccination . neoplasms diagnosis and pregnancy and breastfeeding
__label__1	study interventions are Paclitaxel . fallopian tube transitional cell carcinoma diagnosis and patients with medical history or conditions not otherwise previously specified which in the opinion of the investigator should exclude participation in this study the investigator should feel free to consult the study chair or study co chairs for uncertainty in this regard
__label__1	study interventions are Dasatinib . triple negative breast neoplasms diagnosis and aspirin are not allowed
__label__1	study interventions are Vitamin B Complex . stage iiic breast cancer diagnosis and receiving any other investigational agent
__label__1	study interventions are pharmacological study . history of myocardial infarction severe unstable angina or symptomatic congestive heart failure within the six months prior to study drug administration
__label__1	study interventions are Questionnaire Administration . stage iia cervical cancer diagnosis and patients with prior history of chronic lower extremity swelling
__label__1	study interventions are Contraceptive Agents . ovarian cancer risk diagnosis and oc related
__label__1	study interventions are Fludarabine phosphate . recurrent marginal zone lymphoma diagnosis and patients who are homozygous at the mismatched major histocompatibility_complex mhc class locus
__label__1	study interventions are STAT 3 DECOY . subjects with tumors that are too small to biopsy prior to resection and reserve portion of the resected specimen for research purposes
__label__1	study interventions are Fludarabine phosphate . metastatic melanoma diagnosis and symptoms of respiratory dysfunction
__label__1	study interventions are Cabozantinib S-malate . inflammatory bowel disease including ulcerative colitis and crohn disease diverticulitis cholecystitis symptomatic cholangitis or appendicitis
__label__1	study interventions are FDA-Approved HPV DNA Test . human papillomavirus infection diagnosis and having an illness or medical condition that could interfere with or affect the conduct results and or completion of the clinical trial
__label__1	study interventions are Epothilones . lung cancer diagnosis and women who are pregnant or nursing
__label__1	study interventions are Light Physical Activity . lung cancer diagnosis and presence of metastatic disease
__label__1	study interventions are Dexamethasone acetate . myeloma diagnosis and female patient is pregnant or breast feeding
__label__1	study interventions are Bevacizumab . supratentorial meningioma diagnosis and patients with serious non healing wound active ulcer or untreated bone fracture
__label__1	study interventions are Bortezomib . medullary thyroid carcinoma diagnosis and concomitant medications that are potent inducers rifampicin rifabutin phenytoin carbamazepine phenobarbital and st
__label__1	study interventions are Pioglitazone . non small cell lung cancer diagnosis and patients with past hepatitis virus hbv infection or resolved hbv are eligible
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and known or suspected allergy to any investigational drug in this study
__label__1	study interventions are Saracatinib . recurrent rectal cancer diagnosis and patients with greater than positive one proteinuria on two consecutive readings taken no less than twenty-four hours apart are ineligible
__label__1	study interventions are Fludarabine phosphate . contiguous stage ii marginal zone lymphoma diagnosis and patients with other disease or organ dysfunction that would limit survival to less than thirty days
__label__1	study interventions are Everolimus . breast neoplasms diagnosis and patient with an history of significant cardiovascular impairment congestive heart failuregreater_than nyha grade ii unstable angina or myocardial infraction within the past six months or serious cardiac arrhythmia
__label__1	study interventions are Cetuximab . metastatic squamous neck cancer with occult primary squamous cell carcinoma diagnosis and investigational therapy within four weeks of study entry
__label__1	study interventions are Erlotinib Hydrochloride . stage iiia non small cell lung cancer diagnosis and serious condition that in the opinion of the investigator would compromise the patient ability to complete the study or increase the risk for serious adverse events
__label__1	study interventions are Camptothecin . stage iiic esophageal adenocarcinoma diagnosis and major surgery within four weeks
__label__1	study interventions are management of therapy complications . recurrent adult diffuse small cleaved cell lymphoma diagnosis and doc
__label__1	study interventions are Pembrolizumab . non small cell lung cancer diagnosis and subjects with neurological symptoms must undergo head ct scan or brain mri to exclude brain metastasis
__label__1	study interventions are Doxorubicin . primary peritoneal high grade serous adenocarcinoma diagnosis and unstable angina
__label__1	study interventions are Bevacizumab . mixed adenocarcinoma of the stomach diagnosis and patients must not have had significant traumatic injury within twenty-eight days prior to randomization
__label__1	study interventions are Olaparib . ovarian cancer diagnosis and pregnant or breastfeeding
__label__1	study interventions are quality-of-life assessment . stage iv lymphoepithelioma of the oropharynx diagnosis and radiation
__label__1	study interventions are Pembrolizumab . stage iv uveal melanoma diagnosis and has an active autoimmune disease requiring systemic treatment within the past three months or documented history of clinically severe autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents subjects with vitiligo or resolved childhood asthma atopy would be an exception to this rule subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study subjects with hypothyroidism stable on hormone replacement or sjögren syndrome will not be excluded from the study
__label__1	study interventions are Blinatumomab . non hodgkin lymphoma diagnosis and autologous stem cell transplantation within twelve weeks prior to study entry
__label__1	study interventions are Mycophenolate mofetil . stage iii small lymphocytic lymphoma diagnosis and fertile men or women unwilling to use contraceptives during and for up to twelve months post treatment
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and any known central nervous system cns disease
__label__1	study interventions are gamma secretase inhibitor PF-03084014 . aids related kaposi sarcoma diagnosis and concurrent neoplasia requiring cytotoxic therapy
__label__1	study interventions are Niacinamide . recurrent cutaneous cell non hodgkin lymphoma diagnosis and currently taking the cytochrome pfour hundred and fifty enzyme inducing anti epileptic drugs phenytoin carbamazepine and phenobarbital rifampin or st
__label__1	study interventions are Antilymphocyte Serum . contiguous stage ii adult diffuse large cell lymphoma diagnosis and presence of active uncontrolled infection at start of conditioning
__label__1	study interventions are ALXN6000 . multiple myeloma diagnosis and positive coombs test neither direct or indirect
__label__1	study interventions are Fluorouracil . stage iiib rectal cancer diagnosis and acquired immune deficiency syndrome aids based upon current centers for disease control and prevention cdc definition note however that human immunodeficiency virus hiv testing is not required for entry into this protocol
__label__1	study interventions are Cyclosporins . stage iv adult lymphoblastic lymphoma diagnosis and donor
__label__1	study interventions are Vidarabine . primary mediastinal cell lymphoma diagnosis and chest ray
__label__1	study interventions are Cyclophosphamide . thymic carcinoma diagnosis and these potential risks may also apply to other agents used in this study
__label__1	study interventions are Aromatase Inhibitors . breast cancer metastatic diagnosis and previous treatment with mammalian target of rapamycin mtor inhibitors
__label__1	study interventions are Mycophenolic Acid . cutaneous cell non hodgkin lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Antibodies, Monoclonal . stage iv grade three follicular lymphoma diagnosis and qtc prolongation greater_than five hundredmsec or other significant ecg abnormality noted within fourteen days of registration
__label__1	study interventions are Antibodies . stage iv ovarian cancer diagnosis and prior liver transplant with evidence of recurrent or metastatic disease
__label__1	study interventions are Antibodies . stage grade three follicular lymphoma diagnosis and use of hematopoietic growth factor including filgrastim pegfilgrastim sargramostim erythropoietin or darbepoetin within fourteen days prior to baseline
__label__1	study interventions are Trastuzumab . proximal urethral cancer diagnosis and prior therapy with herceptin
__label__1	study interventions are Fludarabine phosphate . stage ii multiple myeloma diagnosis and identical twin
__label__1	study interventions are Everolimus . stage iv adult immunoblastic lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Everolimus . malignant neoplasms of female genital organs diagnosis and therapy with heparin low molecular weight heparin lmwh or fondaparinux is allowed
__label__1	study interventions are Cyclophosphamide . recurrent renal cell carcinoma diagnosis and history of central nervous system cns metastases unless previously treated and stable for greater_than eight weeks prior to study initiation
__label__1	study interventions are Interferons . glioblastoma multiforme diagnosis and prothrombin time pt greater_than two seconds above the uln
__label__1	study interventions are EktoTherix . basal cell carcinoma diagnosis and does the patient know of any allergy to any of the device materials to be used in the trial
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent uterine corpus carcinoma diagnosis and other disorders associated with high risk of fistula formation including percutaneous endoscopic gastrostomy peg tube placement within three months before the first dose of study therapy
__label__1	study interventions are Immunoglobulin G . metastatic malignant neoplasm in the bone diagnosis and enzalutamide
__label__1	study interventions are Entinostat . stage iiia breast cancer diagnosis and patients requiring concurrent administration of valproic acid are also excluded
__label__1	study interventions are Epothilones . metastatic breast cancer diagnosis and treatment with immune modulators such as cyclosporine and tacrolimus within seven days prior to study enrollment
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and any serious uncontrolled intercurrent infections or other serious uncontrolled concomitant disease
__label__1	study interventions are Methotrexate . cutaneous cell lymphoma diagnosis and oral retinoid therapy for any indication within three weeks of study entry
__label__1	study interventions are Cisplatin . urothelial carcinoma diagnosis and currently receiving treatment with therapeutic doses of warfarin sodium
__label__1	study interventions are Autologous hematopoietic and immune cell rescue (transplantation) . anal colon and rectal cancers diagnosis and history or presence of autoimmune disorders requiring treatment
__label__1	study interventions are Tacrolimus . intraocular lymphoma diagnosis and identical twin
__label__1	study interventions are Bevacizumab . invasive ductal breast cancer diagnosis and history of abdominal fistula or any grade four non gastrointestinal fistula gastrointestinal perforation or intra abdominal abscess within six months of enrolment
__label__1	study interventions are Phenelzine . hormone resistant prostate cancer diagnosis and known or suspected brain metastases
__label__1	study interventions are Sunitinib . stage ivc thyroid gland papillary carcinoma diagnosis and low molecular weight heparin is permitted provided the patient prothrombin time pt international normalized ratio inr is equal_than less_than doc
__label__1	study interventions are Temozolomide . giant cell glioblastoma diagnosis and co medication that may interfere with study results immuno suppressive agents other than corticosteroids
__label__1	study interventions are Etoposide phosphate . stage iv grade two follicular lymphoma diagnosis and patients who have not recovered from adverse events due to agents administered more than four weeks earlier or
__label__1	study interventions are Laboratory Biomarker Analysis . stage iv skin melanoma diagnosis and current or recent equal_than less_than four weeks use of immunosuppressive medications including systemic inhaled oral or intravenous iv corticosteroids note
__label__1	study interventions are Carmustine . refractory cell non hodgkin lymphoma diagnosis and other serious medical conditions considered to represent contraindications to asct abnormally decreased cardiac ejection fraction diffusion capacity of carbon monoxide dlco less_than fifty predicted etc
__label__1	study interventions are Olaparib . patients who have received prior chemotherapy for any abdominal or pelvic tumor are excluded
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and prior gemcitabine will be therapy
__label__1	study interventions are IPI-504 . stage iv lung cancer diagnosis and patients with clinically stable brain metastasis are eligible
__label__1	study interventions are Etoposide phosphate . mantle cell lymphoma diagnosis and fvc or dlco of less than fifty of predicted dlco corrected for hemoglobin level
__label__1	study interventions are serological examination and gastroscope . stomach neoplasms diagnosis and informed consent cannot be attained
__label__1	study interventions are Antibodies . stage iiic ovarian cancer diagnosis and concurrent use of herbal supplements and other non traditional medications all herbal supplements and other non traditional medications must be stopped before time of registration
__label__1	study interventions are Leucovorin . spindle cell sarcoma of bone diagnosis and previous treatment with glucarpidase pregnant or breast feeding women patients with reproductive potential of either gender must use contraception concomitant treatment with agents which interact with methotrexate metabolism or excretion serous effusions including ascites and pleural effusions
__label__1	study interventions are Etoposide . recurrent grade one follicular lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to busulfan other agents used in this study
__label__1	study interventions are Pegaspargase . mature cell and nk cell non hodgkin lymphoma diagnosis and creatinine clearance or radioisotope glomerular filtration rate gfr greater_than equal_than seventyml min doc three two or serum creatinine based on age gender as follows
__label__1	study interventions are Pembrolizumab . grade threeb follicular lymphoma diagnosis and no active autoimmune disease that has required systemic treatment in past two years with use of disease modifying agents corticosteroids or immunosuppressive drugs replacement therapy thyroxine insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency etc
__label__1	study interventions are Oncoplastic Approach Excisional Breast Biopsy . breast neoplasms diagnosis diagnosis and patients who do not want to be photographed for cosmetic evaluations
__label__1	study interventions are Bupropion . lung cancer diagnosis and currently taking bupropion for depression
__label__1	study interventions are Epothilones . breast neoplasms diagnosis and hiv positive patients
__label__1	study interventions are Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus) . neoplasms diagnosis and colonoscopy performed during last ten years
__label__1	study interventions are BB 1101 . extranodal nk cell lymphoma nasal type diagnosis and history of pancreatitis
__label__1	study interventions are Paclitaxel . adenocarcinoma of the esophagus diagnosis and allergies to any of the active or inactive components of oncogel ie allergies to degradable plga poly lactide co glycolide sutures
__label__1	study interventions are Sorafenib . advanced solid tumors diagnosis and pregnant or breastfeeding
__label__1	study interventions are Methotrexate . lymphoma non hodgkin diagnosis and zidovudine azt or any antiretroviral agent unless allowed by investigator
__label__1	study interventions are Cisplatin . cancer from an oral cavity site oral tongue floor mouth alveolar ridge buccal or lip nasopharynx hypopharynx or larynx even if psixteen positive
__label__1	study interventions are Sitagliptin Phosphate . symptomatic uncontrolled coronary artery disease or congestive heart failure
__label__1	study interventions are Cetuximab . oropharyngeal carcinoma diagnosis and creatinine clearance less_than thirty ml min
__label__1	study interventions are Irinotecan . pancreatic cancer diagnosis and life expectancy less than three months
__label__1	study interventions are Fludarabine . recurrent adult diffuse large cell lymphoma diagnosis and patients with active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Pentostatin . renal cell carcinoma diagnosis and the risk benefit profile of transplant and hepatitis will be discussed with the patient and eligibility determined by the principal investigator and protocol chairperson
__label__1	study interventions are Everolimus . pediatric progressive low grade gliomas diagnosis and detailed assessment of hepatitis c medical history and risk factors must be done at screening for all patients
__label__1	study interventions are Antibodies . non hodgkin lymphoma diagnosis and patients who previously received radioimmunotherapy
__label__1	study interventions are Everolimus . breast cancer diagnosis and major surgery significant traumatic injury within four weeks of start of study drug
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and patient is hiv positive
__label__1	study interventions are Rituximab . recurrent adult diffuse large cell lymphoma diagnosis and participants with viral hepatitis who do not meet the criteria will not be eligible all participants who present with acute hepatitis including those with normal transaminases who are hbsag positive and igm positive for hepatitis core antigen will not be eligible participants who are hepatitis core antibody positive are eligible only if they start or are on prophylactic therapy hepatitis viral load should be confirmed negative on all participants who are hepatitis core antibody positive participants refusing to take any anti hepatitis therapy during study will also be excluded participants diagnosed with hepatitis are eligible if they meet criteria
__label__1	study interventions are Fludarabine phosphate . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and donor
__label__1	study interventions are Paclitaxel . tumors harboring amplifications in the cmyc gene diagnosis and chemotherapy radiation therapy hormonal therapy immunotherapy or biological therapy or investigational agent within twenty-one days
__label__1	study interventions are Bendamustine Hydrochloride . mantle cell lymphoma diagnosis and patient who has not signed the informed consent
__label__1	study interventions are Cyclosporins . childhood nasal type extranodal nk cell lymphoma diagnosis and donors
__label__1	study interventions are Modafinil . malignant glioma diagnosis and currently receiving ritalin or tricyclic_antidepressants
__label__1	study interventions are Molecular Mechanisms of Pharmacological Action . oestrogen receptor positive advanced breast cancer diagnosis and hertwo overexpressing patients by local laboratory testing ihc three positive staining or in situ hybridization positive
__label__1	study interventions are Carboplatin . recurrent adult diffuse large cell lymphoma diagnosis and autologous or allogeneic transplantation within twelve months or radioimmunotherapy within six months of registration prior failed less_than five ten six cdthirty-four kg peripheral blood stem cell pbsc collection
__label__1	study interventions are Podophyllotoxin . stage ii contiguous adult lymphoblastic lymphoma diagnosis and prednisone or methylprednisolone for equal_than less_than one hundred and twenty hours five days in the seven days prior to initiating induction chemotherapy or for equal_than less_than three hundred and thirty-six hours fourteen days in the twenty-eight days prior to initiating induction chemotherapy prior exposure to any steroids that occurred greater_than twenty-eight days before the initiation of protocol therapy does not affect eligibility the dose of prednisone or methylprednisolone does not affect eligibility
__label__1	study interventions are Doxorubicin . breast cancer diagnosis and active uncontrolled infection
__label__1	study interventions are Nivolumab . uveal melanoma diagnosis and concomitant therapy with any of the following
__label__1	study interventions are Bevacizumab . head and neck cancer diagnosis and platelets less_than one hundred zero
__label__1	study interventions are Cyclophosphamide . metastatic pancreatic cancer diagnosis and history of severe immediate hypersensitivity reaction to any of the agents used in this study
__label__1	study interventions are Vaccines . vulvar cancer diagnosis and received marketed hpv vaccine or participated in an hpv trial
__label__1	study interventions are MSB0010445 (1.0 mg/kg) . melanoma diagnosis and concurrent systemic therapy with steroids or other immunosuppressive agents except short term systemic steroids for allergic reactions
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiic ovarian cancer diagnosis and protein concentration mg dl creatinine mg dl patients must have upcr less_than doc to allow participation in the study
__label__1	study interventions are L 647318 . any cancer diagnosis and patients with history of severe hypersensitivity reaction to taxotere or other drugs formulated with polysorbate eighty
__label__1	study interventions are Vidarabine . cancer diagnosis and history of hypersensitivity to cyclophosphamide fludarabine or il two
__label__1	study interventions are Endothelial Growth Factors . stage ivb cervical cancer diagnosis and patients who have received concurrent paclitaxel and or concurrent topotecan with radiation therapy are ineligible
__label__1	study interventions are Paclitaxel . stage iiib breast cancer diagnosis and have uncontrolled hypertension greater_than one hundred and fifty one hundred mm hg despite optimal medical therapy
__label__1	study interventions are AFM11 . refractory cell non hodgkin lymphoma diagnosis and peripheral lymphocyte count greater_than twenty ten nine l
__label__1	study interventions are Antibodies, Monoclonal . small intestine lymphoma diagnosis and anticipation of need for major surgical procedures during the course of the study
__label__1	study interventions are 18F-FSPG . brain cancer diagnosis and however participation in clinical studies involving other investigational pet or spect tracers will not be excluded if in the opinion of the investigator
__label__1	study interventions are Fludarabine . stage iv cutaneous cell non hodgkin lymphoma diagnosis and patients with chronic myelomonocytic leukemia cmml
__label__1	study interventions are Gemcitabine . other concurrent chemotherapy for cancer
__label__1	study interventions are Maleic acid . noncutaneous extranodal lymphoma diagnosis and urine protein should be screened by dipstick or urine analysis for proteinuria greater_than one positive or urine protein
__label__1	study interventions are Embosphere® Microspheres . leiomyoma diagnosis and presence of one or more submucosal fibroid with more than fifty growth into the uterine cavity
__label__1	study interventions are Vorinostat . stage iva major salivary gland carcinoma diagnosis and is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with the pre screening or screening visit through one hundred and twenty days after the last dose of trial treatment
__label__1	study interventions are Administration of hyperbaric oxygen . hodgkins lymphoma diagnosis and claustrophobia
__label__1	study interventions are Antibodies, Monoclonal . biliary tract neoplasms diagnosis and any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his her compliance in the study
__label__1	study interventions are BB 1101 . prior history of malignancies other than multiple myeloma unless the patient has been free of the disease for greater_than three years
__label__1	study interventions are Antibodies . stage ivb rectal cancer diagnosis and abdominal masses that are not confirmed and followed by imaging techniques
__label__1	study interventions are Thalidomide . recurrent laryngeal squamous cell carcinoma diagnosis and patients with history of toxicity greater_than equal_than grade three with prior egfr directed therapy
__label__1	study interventions are Etoposide phosphate . small intestine lymphoma diagnosis and left ventricular ejection fraction lvef less_than fifty or coronary artery disease requiring treatment
__label__1	study interventions are Everolimus . stage iva colon cancer diagnosis and chronic treatment with systemic steroids or another immunosuppressive agent
__label__1	study interventions are Gemcitabine . metastatic pancreatic cancer diagnosis and use of oral injected or implanted hormonal methods of contraception
__label__1	study interventions are Cyclophosphamide . stage iii adult cell leukemia lymphoma diagnosis and patients who have not recovered from adverse events due to agents administered more than four weeks earlier or
__label__1	study interventions are Rituximab . b cell non hodgkin lymphoma diagnosis and participation in another investigational drug clinical trial
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma non small cell lung diagnosis and symptoms of esophageal dysfunction dysphagia odynophagia or inability to swallow solid food within four weeks prior to study randomization
__label__1	study interventions are Vitamin B 12 . known history of prior malignancy except if participant has undergone potentially curative therapy with no evidence of that disease recurrence for five years since initiation of that therapy except for successful definitive resection of basal cell carcinoma of the skin superficial bladder cancer squamous cell carcinoma of the skin in situ cervical cancer or other in situ cancers
__label__1	study interventions are Temozolomide . malignant adult intracranial hemangiopericytoma diagnosis and patients with known history of hepatitis or or who have history of liver disease other forms of hepatitis or cirrhosis are ineligible hepatitis and serology should be obtained as part of pre treatment evaluation but are not required for eligibility
__label__1	study interventions are Cisplatin . cancer diagnosis and has known hypersensitivity or contraindication to ondansetron another five htthree receptor antagonist dexamethasone or any component of casopitant
__label__1	study interventions are Rituximab . has received prior therapy with an anti pd one anti programmed cell death ligand one pd lone anti programmed cell death ligand two pd ltwo anti tumor necrosis factor receptor superfamily member nine cdone37 or anti cytotoxic lymphocyte associated antigen four ctla four antibody including ipilimumab or any other antibody or drug specifically targeting cell co stimulation or checkpoint_pathways
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and must have stable inr between two three
__label__1	study interventions are Sirolimus . non mantle cell low grade cell lymphomas sll cll diagnosis and patients who are pre terminal or moribund
__label__1	study interventions are Paclitaxel . ovarian neoplasms diagnosis and subjects with known history of interstitial lung disease or pulmonary fibrosis
__label__1	study interventions are Bevacizumab . stage iv renal cell cancer diagnosis and patients with known brain metastases should be excluded because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Cisplatin . patients with symptomatic neuropathy
__label__1	study interventions are Cisplatin . stage iii hypopharyngeal squamous cell carcinoma diagnosis and previous head and neck radiation therapy
__label__1	study interventions are Cisplatin . bile duct cancer diagnosis and patients with prior treatment or known hypersensitivity to any of the components of oxaliplatin or gemcitabine
__label__1	study interventions are manual lymph drainage . breast cancer diagnosis and involved other diseases may cause extremity edema ex
__label__1	study interventions are Albumin-Bound Paclitaxel . primary breast cancer diagnosis and known or suspected hypersensitivity to anthracycline or paclitaxel
__label__1	study interventions are Erlotinib Hydrochloride . metastatic colorectal cancer diagnosis and medical or psychiatric conditions that compromise the patient ability to give informed consent or to complete the protocol
__label__1	study interventions are Simvastatin . renal cell carcinoma diagnosis and subjects who received prior solid organ transplantation
__label__1	study interventions are Cyclophosphamide . lung cancer diagnosis and patients with active infections including hiv will be excluded due to unknown effects of the vaccine on lymphoid precursors
__label__1	study interventions are Vitamin B Complex . stage ii breast cancer diagnosis and history of auto immune disease per physician discretion
__label__1	study interventions are Irinotecan . advanced cancer diagnosis and active clinically serious infection greater_than ctcae version doc three grade two
__label__1	study interventions are Tacrolimus . recurrent adult diffuse large cell lymphoma diagnosis and adult forty pediatric equal_than less_than eighteen yrs
__label__1	study interventions are Rituximab . stage iii marginal zone lymphoma diagnosis and unrelated donor products received from the deutsche_knochenmarkspenderdatei dkms_registry are not eligible for the optional study
__label__1	study interventions are Smoking cessation treatment plus moderate intensity exercise . lung cancer diagnosis and peripheral vascular disease such as claudication
__label__1	study interventions are Gemcitabine . stage iii pancreatic cancer diagnosis and patients with symptoms of partial or complete bowel obstruction and recent within six month history of fistula intra abdominal abscess or bowel perforation
__label__1	study interventions are Histone Deacetylase Inhibitors . splenic marginal zone lymphoma diagnosis and patients with myocardial infarction or unstable angina equal_than less_than six months prior to starting study drug
__label__1	study interventions are Erlotinib Hydrochloride . non squamous non small cell lung cancer diagnosis and clinically unstable central nervous system cns metastasis to be enrolled in the study subjects must have confirmation of stable disease by mri or computed tomography ct scan within four weeks of randomization and have cns metastases well controlled by steroids anti epileptics or other symptom relieving medications
__label__1	study interventions are Everolimus . adenocarcinoma diagnosis and patients with uncontrolled central nervous system cns metastases
__label__1	study interventions are Maleic acid . carcinoma in situ of the breast or cervix
__label__1	study interventions are Immunoglobulin G . stage iv breast cancer diagnosis and proteinuria at baseline subjects unexpectedly discovered to have greater_than equal_than one positive proteinuria should undergo twenty-four hour urine collection which must be an adequate collection and must demonstrate equal_than less_than five hundred mg protein twenty-four hours to allow participation in the study
__label__1	study interventions are Cisplatin . esophageal squamous cell carcinoma diagnosis and uncontrolled angina and heart failure have history of hospitalization in three months
__label__1	study interventions are Immunoglobulins . high grade ovarian serous adenocarcinoma diagnosis and rash must cover less than ten of body surface area bsa
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and known hypersensitivity to lenalidomide or other thalidomide derivatives previous monoclonal antibody therapy or maytansinoids
__label__1	study interventions are Tecogalan sodium . sarcoma kaposi diagnosis and co existing condition
__label__1	study interventions are Rituximab . recurrent grade two follicular lymphoma diagnosis and identical twin
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and serious cardiac illness uncontrolled hypertension or medical condition that would affect administration of chemotherapy and compliance to study procedures
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib non small cell lung cancer diagnosis and if subject received major surgery they must have recovered adequately from the toxicity and or complications from the intervention prior to starting therapy
__label__1	study interventions are Tamoxifen . existence of an increased risk of thromboembolic event apart from the metastatic cancer condition such as
__label__1	study interventions are Etoposide . peripheral cell lymphoma diagnosis and no serious medical or psychiatric illness
__label__1	study interventions are Oxaliplatin . esophageal cancer diagnosis and participation in another clinical study with an investigational product during the last six weeks
__label__1	study interventions are Palbociclib . breast neoplasms diagnosis and in premenopausal women serum estradiol level in postmenopausal range less_than seven days prior to registration
__label__1	study interventions are Endothelial Growth Factors . stage iv colorectal cancer diagnosis and patients who have received acute low dose systemic immunosuppressant medications one time dose of dexamethasone for nausea or chronic daily treatment with corticosteroids with dose of equal_than less_than ten mg day methylprednisolone equivalent may be enrolled
__label__1	study interventions are Everolimus . glucagonoma diagnosis and highly effective contraception methods include combination of any two of the following
__label__1	study interventions are Oxaliplatin . pancreatic adenocarcinoma diagnosis and known historical positive human immunodeficiency virus hiv serology active hepatitis or active hepatitis infection
__label__1	study interventions are Anti-Bacterial Agents . anaplastic astrocytoma diagnosis and use of more than four grams per day of acetaminophen
__label__1	study interventions are Oxaliplatin . concurrent major surgery unrelated to intact primary colon cancer
__label__1	study interventions are Pembrolizumab . small cell lung cancer diagnosis and has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Paclitaxel . stage iva uterine sarcoma diagnosis and serum glutamic oxaloacetic transaminase sgot and or serum glutamate pyruvate transaminase sgpt greater_than doc times the institutional upper limit of normal
__label__1	study interventions are Chemo . triple negative breast neoplasms diagnosis and people who are pregnant or unwilling to use contraception during treatment
__label__1	study interventions are Panobinostat . stage iii renal cell cancer diagnosis and patients who have received prior treatment with an mtor inhibitor sirolimus temsirolimus everolimus
__label__1	study interventions are Hydrocortisone acetate . stage iv childhood large cell lymphoma diagnosis and prior exposure to rituximab
__label__1	study interventions are Liposomal doxorubicin . clear cell sarcoma of soft tissue diagnosis and patients chronically receiving medications known to be metabolized by cypthreeafour and with narrow therapeutic indices within seven days prior to study enrollment including but not limited to pimozide_aripiprazole triazolam_ergotamine and halofantrine are not eligible note
__label__1	study interventions are Delanzomib . solid tumors diagnosis and concomitant treatment with steroids
__label__1	study interventions are dietary intervention (red tomato juice) . stage iib prostate cancer diagnosis and have plasma total cholesterol greater_than two hundred mg dl
__label__1	study interventions are placebo . recurrent squamous cell carcinoma of the oropharynx diagnosis and brachytherapy or interstitial implantation treatment
__label__1	study interventions are BCG Vaccine . neoplasms by site diagnosis and bleeding disorder
__label__1	study interventions are TAK-228 . soft tissue sarcoma diagnosis and known human immunodeficiency virus infection
__label__1	study interventions are Dexamethasone . cancer diagnosis and contraindication to dexamethasone
__label__1	study interventions are Ophthalmic Solutions . hemangioma diagnosis and any infant who in the opinion of his or her pediatrician or the investigators has major medical problem such as cardiac pathology or airway obstruction that makes participation in the study difficult
__label__1	study interventions are Lenalidomide . mantle cell lymphoma diagnosis and uncontrolled hypertension systolic blood pressure bp greater_than one hundred and eighty or diastolic bp greater_than one hundredmm hg or uncontrolled cardiac arrhythmias
__label__1	study interventions are Fludarabine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and donors
__label__1	study interventions are Antibodies . noncontiguous stage ii grade three follicular lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab_vedotin and or rituximab
__label__1	study interventions are Vidarabine . peripheral cell lymphoma diagnosis and donor
__label__1	study interventions are Androgens . prostate cancer diagnosis and gastrointestinal disorder affecting absorption or the ability to swallow tablets
__label__1	study interventions are Laboratory Biomarker Analysis . fallopian tube endometrioid adenocarcinoma diagnosis and patients with gog performance grade of three or four
__label__1	study interventions are Sirolimus . advanced cancers diagnosis and patients who are pregnant or breastfeeding
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and iv
__label__1	study interventions are Cabozantinib S-malate . childhood hepatocellular carcinoma diagnosis and patients who have had significant traumatic injury within twenty-eight days prior to enrollment are not eligible
__label__1	study interventions are Immunoglobulins . stage ivb verrucous carcinoma of the larynx diagnosis and patients with diarrhea greater_than equal_than ctcae vfour grade two
__label__1	study interventions are Rituximab . recurrent adult burkitt lymphoma diagnosis and patient has received other investigational drugs with fourteen days before enrollment
__label__1	study interventions are EMD 521873 . non hodgkin lymphoma diagnosis and presence of medically significant third space fluid pericardial effusion or ascites pleural infusion requiring repetitive paracentesis
__label__1	study interventions are Vaccines . non small cell lung carcinoma diagnosis and patients with previous exposure to anti programmed cell death pd one or anti programmed cell death ligand one pdl one will not be eligible
__label__1	study interventions are Breast Cancer Locator (BCL) . breast cancer diagnosis and pregnancy
__label__1	study interventions are Antibodies, Monoclonal . stage ivb laryngeal verrucous carcinoma diagnosis and concurrent life threatening diseases
__label__1	study interventions are Sirolimus . multiple myeloma diagnosis and drugs and other treatments to be excluded either during or within four weeks prior to study entry unless otherwise noted
__label__1	study interventions are Gemcitabine . stage iii pancreatic cancer diagnosis and amiodarone quinidine
__label__1	study interventions are Cisplatin . solid tumors diagnosis and evidence of peripheral neuropathy greater_than grade one according to nci ctcae version three
__label__1	study interventions are Oxaliplatin . esophageal cancer diagnosis and history of hiv positivity or hepatitis or c
__label__1	study interventions are Antibodies, Monoclonal . supratentorial meningioma diagnosis and patients with proteinuria within fourteen days of registration as demonstrated by either
__label__1	study interventions are laparoscopic surgery . other tumors and without liver metastases
__label__1	study interventions are Vatalanib . symptomatic congestive heart failure
__label__1	study interventions are Dexamethasone 21-phosphate . unspecified adult solid tumor protocol specific diagnosis and recent history of unexplained nausea or vomiting or history of frequent nausea or vomiting
__label__1	study interventions are Fludarabine phosphate . stage ii childhood lymphoblastic lymphoma diagnosis and fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold active azoles for greater than one month
__label__1	study interventions are Bortezomib . stage iv marginal zone lymphoma diagnosis and chemotherapy less_than four weeks
__label__1	study interventions are Albumin-Bound Paclitaxel . esophageal neoplasms diagnosis and severe cardiac comorbidities including congestive heart failure uncontrolled cardiac arrhythmia unstable angina pectoris myocardial infarction within six months severe heart valve disease or intractable hypertension
__label__1	study interventions are Gefitinib . carcinoma non small cell lung diagnosis and previous radiation therapy is allowed but should have been limited and must not have included whole pelvis radiation
__label__1	study interventions are Morphine . neoplasms diagnosis and must not have had treatment with radiotherapy chemotherapy or radionuclides in the last thirty days
__label__1	study interventions are Liposomal doxorubicin . brain metastases or primary brain tumors
__label__1	study interventions are Sunitinib . uterine corpus carcinosarcoma diagnosis and patients with known brain metastases should be excluded
__label__1	study interventions are Sodium Pertechnetate Tc 99m . head and neck neoplasms diagnosis and nursing or pregnant females
__label__1	study interventions are Antibodies . recurrent cutaneous cell non hodgkin lymphoma diagnosis and inability to understand or give an informed consent
__label__1	study interventions are Paclitaxel . gastroesophageal junction adenocarcinoma diagnosis and the following are exceptions to this criterion
__label__1	study interventions are MLN8237 . precursor lymphoblastic leukemia lymphoma diagnosis and patients who have received treatment with nitrosoureas mitomycin rituximab alemtuzumab or other unconjugated antibody treatment within forty-two days
__label__1	study interventions are Antibodies, Monoclonal . undifferentiated ovarian carcinoma diagnosis and any tissue biopsy such as core biopsy within seven days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Vaccines . stage iv small lymphocytic lymphoma diagnosis and in vitro cell depleted graft
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube clear cell adenocarcinoma diagnosis and stage not greater than ib
__label__1	study interventions are Melphalan . noncontiguous stage ii mantle cell lymphoma diagnosis and whole lungs twelve gy
__label__1	study interventions are Paclitaxel . advanced cancer diagnosis and has received more than two prior cytotoxic regimens for metastatic disease
__label__1	study interventions are Hormones . papillary thyroid cancer diagnosis and history of drug or alcohol abuse within the last year current use of illicit drugs or alcohol abuse cagegreater_than three
__label__1	study interventions are Antibodies, Monoclonal . solid tumors diagnosis and examples of such agents include but are not limited to
__label__1	study interventions are Prednisone . stage iv prostate cancer diagnosis and atypical antipsychotics clozapine olanzapine risperidone ziprasidone
__label__1	study interventions are Sertraline . glioblastoma diagnosis and known hiv infection active hepatitis or infection
__label__1	study interventions are Fludarabine . stage iii adult lymphoblastic lymphoma diagnosis and poorly controlled hypertension
__label__1	study interventions are pharmacological study . stage iv breast cancer diagnosis and subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study
__label__1	study interventions are Irinotecan . stomach neoplasm diagnosis and active infection
__label__1	study interventions are Immunoglobulins . stage iv grade two follicular lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for granulocyte colony stimulating factor csf mobilization and harvest of peripheral blood stem cell pbsc
__label__1	study interventions are Irinotecan . active secondary malignancies twond cancer not treated present
__label__1	study interventions are Vatalanib . multiple myeloma diagnosis and prior biologic or immunotherapy less than or equal to two weeks prior to registration and or randomization
__label__1	study interventions are OTL38 . ovarian cancer diagnosis and impaired renal function defined as egfrless_than fifty ml min doc threemtwo
__label__1	study interventions are Lenalidomide . refractory diffuse large cell lymphoma diagnosis and unable or unwilling to take any prophylaxis patients with history of or new active deep vein thrombosis embolism thrombophilia are allowed to participate if they are on appropriate therapeutic anticoagulation during the treatment on the trial these patients would not need the aspirin with the lenalidomide unless clinically indicated therefore patients must be able and willing to receive anticoagulation prophylaxis versus therapeutic as clinically indicated
__label__1	study interventions are Home-based upper-body rehabilitation with online support . breast cancer diagnosis and severe depression anxiety dementia poor physical health with likely possibility of hospitalization within the next twelve weeks
__label__1	study interventions are Anastrozole . breast cancer diagnosis and the exceptions are patients with the following and only the following malignancies previous or concomitant who are eligible if adequately treated
__label__1	study interventions are Cetuximab . head and neck neoplasms diagnosis and history of significant neurologic or psychiatric disorders including dementia or seizures
__label__1	study interventions are Methylprednisolone Hemisuccinate . metastatic castration resistant prostate cancer diagnosis and as judged by the investigator any evidence of severe or uncontrolled systemic diseases including uncontrolled hypertension active bleeding diatheses or active infection including hepatitis hepatitis and human immunodeficiency virus hiv
__label__1	study interventions are Succinylcholine . stage iiib ovarian cancer diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Fludarabine . childhood nasal type extranodal nk cell lymphoma diagnosis and females who are pregnant
__label__1	study interventions are Sorafenib . metastatic colorectal cancer diagnosis and evidence or history of bleeding diathesis or coagulopathy
__label__1	study interventions are Cyclosporins . childhood burkitt lymphoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Doxorubicin . stage iii childhood large cell lymphoma diagnosis and in phase ii study pmlbl patients with cns involvement are not eligible
__label__1	study interventions are Heptavalent Pneumococcal Conjugate Vaccine . stage small lymphocytic lymphoma diagnosis and patients known to be hiv positive but without clinical evidence of an immunocompromised state are eligible for this trial
__label__1	study interventions are Fludarabine phosphate . stage iv childhood large cell lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Paclitaxel . stage iv fallopian tube cancer diagnosis and patients who are pregnant or nursing are excluded patients who may become pregnant must practice an effective method of birth control
__label__1	study interventions are Melphalan . metastatic melanoma diagnosis and pregnant or nursing
__label__1	study interventions are Albumin-Bound Paclitaxel . micropapillary serous carcinoma diagnosis and history of within six months prior to randomization acute coronary syndromes including myocardial infarction and unstable angina coronary angioplasty or stenting
__label__1	study interventions are Capecitabine . stage iib pancreatic cancer diagnosis and human immunodeficiency virus hiv positive patients receiving combination anti retroviral therapy
__label__1	study interventions are Radiation therapy . chordoma diagnosis and impaired cardiac function
__label__1	study interventions are BB 1101 . rectal cancer diagnosis and cerebral metastases or history of such
__label__1	study interventions are Aldesleukin . tumors with the following characteristics
__label__1	study interventions are Sorafenib . differentiated thyroid cancer diagnosis and organ allografts
__label__1	study interventions are Methotrexate . symptomatic coronary artery disease or ejection fraction less_than thirty-five
__label__1	study interventions are Bevacizumab . recurrent renal cell carcinoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother wishes to participate in the study
__label__1	study interventions are Endothelial Growth Factors . recurrent pancreatic neuroendocrine carcinoma diagnosis and men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception diaphragm birth control pills injections intrauterine device iud surgical sterilization subcutaneous implants or abstinence etc
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and one fna or core biopsy of an axillary node for any patient and two although not recommended pre neoadjuvant therapy sentinal node sn biopsy for patients with clinically negative axillary nodes
__label__1	study interventions are Vaccines . stage iii ovarian epithelial cancer diagnosis and subjects cannot have active immunodeficiency disorder hiv
__label__1	study interventions are Everolimus . endometrial cancer diagnosis and examples of live attenuated vaccines include intranasal influenza measles_mumps rubella oral polio_bacillus calmette_guérin bcg yellow fever varicella and tytwenty-onea_typhoid vaccines
__label__1	study interventions are Trametinib . stage iv melanoma diagnosis and if study subject has history of brain metastasis but currently has no evidence of disease in brain ned confirmation by two consecutive scans separated by greater_than six weeks prior to done of treatment is required
__label__1	study interventions are Pembrolizumab . cancer diagnosis and patients are allowed to be on stable dose of corticosteroids up to ten mg daily prednisolone or equivalent for at least two weeks prior to study drug administration please see appendix iv for prohibited medications
__label__1	study interventions are Nivolumab . head and neck neoplasms diagnosis and inhaled or topical corticosteroids and adrenal replacement doses greater_than ten mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
__label__1	study interventions are Liposomal doxorubicin . other cancer for which the patient has been disease free for greater_than three years
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiia breast cancer diagnosis and patients who have received prior treatment with anti cytotoxic lymphocyte associated protein four anti ctla four may be enrolled provided the following requirements are met
__label__1	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and peripheral neuropathy
__label__1	study interventions are Androgens . prostate cancer diagnosis and diagnosed congenital long qt syndrome
__label__1	study interventions are Pharmacological Study . gastrointestinal stromal tumor diagnosis and women of childbearing potential include both pre menopausal women and women within the first two years of the onset of menopause
__label__1	study interventions are Surgery . rectal adenocarcinoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Etoposide . small cell lung cancer diagnosis and patients with history of hypertension must be well controlled less_than one hundred and forty ninety on stable regimen of anti hypertensive therapy
__label__1	study interventions are Trastuzumab . malignant tumor of the breast diagnosis and patient is pregnant or lactating
__label__1	study interventions are Tacrolimus . stage iii adult lymphoblastic lymphoma diagnosis and patient or donor infected with human immunodeficiency virus hiv
__label__1	study interventions are photodynamic therapy . recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity diagnosis and alkaline phosphatase hepatic greater_than three times the upper normal limit
__label__1	study interventions are Selenious Acid . prostate cancer metastatic disease diagnosis and inadequate organ function as evidenced by any of the following at screening
__label__1	study interventions are Pembrolizumab . adequately treated with curative intent basal or squamous cell carcinoma in situ carcinoma of the cervix in situ ductal adenocarcinoma of the breast in situ prostate cancer or limited stage bladder cancer
__label__1	study interventions are selumetinib . adult primary cholangiocellular carcinoma diagnosis and patients who have had chemotherapy biologic therapy or immunotherapy within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events to grade one or less due to agents administered more than four weeks earlier
__label__1	study interventions are Mycophenolate mofetil . stage grade one follicular lymphoma diagnosis and positive serology for toxoplasma_gondii on treatment or with evidence of active infection
__label__1	study interventions are Tamoxifen . breast neoplasms diagnosis and for parts b d and g
__label__1	study interventions are Fludarabine phosphate . mantle cell lymphoma diagnosis and has active serious infection requiring systemic therapy
__label__1	study interventions are Bevacizumab . rectal cancer diagnosis and patients may not have received prior radiotherapy to greater than twenty-five of bone marrow
__label__1	study interventions are SSR411298 . cancer related surgery within four weeks before study entry or cancer related surgery planned during the study
__label__1	study interventions are Topotecan . recurrent small cell lung cancer sclc diagnosis and anticipation of need for major surgical procedure during the study
__label__1	study interventions are Immunoglobulins . small intestine lymphoma diagnosis and inability to understand or give an informed consent
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and patients with primary systemic amyloidosis
__label__1	study interventions are Fludarabine . childhood nasal type extranodal nk cell lymphoma diagnosis and twenty pediatric
__label__1	study interventions are AZD8055 . glioblastoma multiforme diagnosis and evidence of active infection or active bleeding diatheses
__label__1	study interventions are Keyhole-limpet hemocyanin . prior antibody therapy for lymphoma
__label__1	study interventions are Farnesyl Protein Transferase Inhibitor . carcinoma squamous cell diagnosis and known hiv positivity or aids related illness
__label__1	study interventions are Antibodies, Monoclonal . recurrent grade three follicular lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to ofatumumab or bortezomib
__label__1	study interventions are Immunoglobulins . with the exception of non melanoma skin cancer patients with other invasive malignancies who had or have any evidence of the other cancer present within the last five years or whose previous cancer treatment contraindicates this protocol therapy
__label__1	study interventions are Sirolimus . childhood alveolar rhabdomyosarcoma diagnosis and systolic blood pressure greater_than equal_than one hundred and sixty mm hg and or diastolic blood pressure greater_than equal_than ninety mm hg that is not controlled by one antihypertensive medication
__label__1	study interventions are laboratory biomarker analysis . recurrent verrucous carcinoma of the larynx diagnosis and pregnant women are excluded from this study because sb seven hundred and fifteen thousand, nine hundred and ninety-two is mitotic inhibitor with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sb seven hundred and fifteen thousand, nine hundred and ninety-two breastfeeding should be discontinued if the mother is treated with sb seven hundred and fifteen thousand, nine hundred and ninety-two
__label__1	study interventions are AUY922 . patients who have not recovered from side effects of previous systemic anticancer therapy to less than grade two ctcae prior to the first dose
__label__1	study interventions are BI 6727 . neoplasms diagnosis and absolute neutrophil count less than one thousand, five hundred mmthree
__label__1	study interventions are MLN0264 . adenocarcinoma of the stomach diagnosis and radiotherapy within four weeks before enrollment
__label__1	study interventions are Vidarabine . stage iv childhood anaplastic large cell lymphoma diagnosis and marrow donors
__label__1	study interventions are Quality-of-Life Assessment . stage iiic breast cancer diagnosis and any physical or mental health condition that would interfere with full participation in the study including individuals who are unable to read consent materials or appear to lack the capacity to consent
__label__1	study interventions are Rituximab . stage iii grade two follicular lymphoma diagnosis and hepatitis surface antigen hbsag positive
__label__1	study interventions are Fulvestrant . her two positive breast cancer diagnosis and concurrent therapy with other investigational products
__label__1	study interventions are Antibodies, Monoclonal . stage ivc squamous cell carcinoma of the larynx diagnosis and chemotherapy therapy or palliative radiation therapy within the previous two weeks prior to dosing with cetuximab or vtx_two337 patients should have recovered from major toxicities of prior therapy if deemed reversible toxicities should return to baseline or equal_than less_than grade two in severity
__label__1	study interventions are Fludarabine . stage ii adult cell leukemia lymphoma diagnosis and liver function abnormalities
__label__1	study interventions are Mycophenolic Acid . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and patient received cytotoxic agents for cytoreduction within three weeks or the interval in which cycle of standard chemotherapy would be administered in non transplant setting prior to initiating the nonmyeloablative transplant conditioning exceptions are hydroxyurea and imatinib mesylate
__label__1	study interventions are Pazopanib . adenocarcinoma of the prostate diagnosis and any serious and or unstable pre existing medical psychiatric or other condition that could interfere with subject safety provision of informed consent or compliance to study procedures
__label__1	study interventions are Etoposide phosphate . small cell lung cancer diagnosis and severe or uncontrolled systemic diseases the investigator found incompatible with the proposed protocol
__label__1	study interventions are Stem cell transplantation . multiple myeloma diagnosis and any of the following
__label__1	study interventions are Fludarabine phosphate . non hodgkin lymphoma diagnosis and prior allogeneic transplantation
__label__1	study interventions are Doxorubicin . multiple myeloma in relapse diagnosis and patient has had prior treatment with vorinostat or hdac inhibitors
__label__1	study interventions are Nivolumab . melanoma skin diagnosis and concurrent medical condition requiring the use of immunosuppressive medications or immunosuppressive doses of systemic or absorbable topical corticosteroids
__label__1	study interventions are Carboplatin . fallopian tube carcinoma diagnosis and known hypersensitivity to althree thousand, eight hundred and eighteen or components of the formulation
__label__1	study interventions are BB 1101 . stage iv fallopian tube cancer diagnosis and patients who are pregnant or nursing to date no fetal studies in animals or humans have been performed the possibility of harm to fetus is likely
__label__1	study interventions are Vincristine . burkitt lymphoma diagnosis and prior administration of an aurora kinase targeted agent including alisertib
__label__1	study interventions are Doxorubicin . locally advanced breast cancer diagnosis and vitiligo
__label__1	study interventions are Daratumumab . a malignancy treated with curative intent and with no known active disease present for more than equal to greater_than equal_than three years before randomization adequately treated non melanoma skin cancer or lentigo_maligna without evidence of disease adequately treated carcinoma in situ for example cervical breast with no evidence of disease
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and peripheral neuropathy greater_than ctcae grade two
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and impaired gi function that may affect the absorption of lclone hundred and sixty-one
__label__1	study interventions are Deoxyglucose . stage iiib melanoma diagnosis and limited ability to give informed consent due to mental disability altered mental status confusion or psychiatric disorders
__label__1	study interventions are Anlotinib . non small cell lung cancer diagnosis and patients has many influence factors toward oral medications
__label__1	study interventions are Cortisone . hormone resistant prostate cancer diagnosis and must be discontinued before registration patients must not be planning to receive any concurrent cytotoxic chemotherapy surgery or radiation therapy during protocol treatment hormonal acting agents including diethylstilbestrol_des aldosterone and spironolactone are forbidden during the trial and must be stopped prior to registration no washout period will be required for any of these agents patients on megestrol acetate for hot_flashes are allowed to continue therapy
__label__1	study interventions are Pazopanib . stomach neoplasms diagnosis and inclusion of women and minorities
__label__1	study interventions are Carboplatin . recurrent breast cancer diagnosis and due to potential toxicity associated with study therapy particularly with paclitaxel patients with peripheral neuropathy greater_than grade one will be excluded from study participation
__label__1	study interventions are Folic Acid . metastatic colorectal cancer diagnosis and known history of alcohol or drug abuse
__label__1	study interventions are Camptothecin . hepatoma diagnosis and prior receipt of on one hundred and ninety-one or prior participation in this protocol
__label__1	study interventions are Liposomal doxorubicin . advanced solid tumors amenable to anthracycline therapy diagnosis and presence of known brain metastases
__label__1	study interventions are Mycophenolate mofetil . myelodysplastic myeloproliferative neoplasm diagnosis and age less_than eighteen years
__label__1	study interventions are Melphalan . extranodal nk cell lymphoma diagnosis and history of significant neurologic or psychiatric disorders including dementia or seizures iii
__label__1	study interventions are Antibodies, Monoclonal . non squamous non small cell lung cancer diagnosis and positive for hiv infection
__label__1	study interventions are Nivolumab . malignant female reproductive system neoplasm diagnosis and sex and reproductive status
__label__1	study interventions are Cisplatin . stomach cancer diagnosis and blood pressure of greater_than one hundred and fifty one hundred mmhg
__label__1	study interventions are Sunitinib . ovarian clear cell adenocarcinoma diagnosis and poorly controlled hypertension systolic blood pressure of greater_than equal_than one hundred and forty mm hg or diastolic blood pressure of greater_than equal_than ninety mm hg are ineligible
__label__1	study interventions are Everolimus . recurrent marginal zone lymphoma diagnosis and history or presence of sustained ventricular tachyarrhythmia patients with history of atrial arrhythmia are eligible but should be discussed with the sponsor prior to enrollment
__label__1	study interventions are Dacarbazine . central nervous system neoplasms diagnosis and patients with history of myocardial infarction within the preceding six months significant arrhythmia within the preceding three months or uncontrolled hypertension or congestive heart failure are ineligible
__label__1	study interventions are Erlotinib Hydrochloride . glioma diagnosis and women of childbearing potential must have negative serum or urine pregnancy test within seven days of study entry
__label__1	study interventions are Bexarotene . cutaneous cell lymphoma diagnosis and monoclonal antibody within three months without evidence of pd
__label__1	study interventions are Capecitabine . functional pancreatic neuroendocrine tumor diagnosis and patients with uncontrolled seizures or any neurological conditions resulting in increased risk for seizures are not eligible for study entry
__label__1	study interventions are Erlotinib Hydrochloride . metastatic colorectal cancer diagnosis and current or recent within ten days prior to study treatment start use of full dose oral anticoagulant warfarin or thrombolytic agent
__label__1	study interventions are Irinotecan . rhabdomyosarcomas diagnosis and known history of life threatening allergy or hypersensitivity to camptothecin active interstitial lung disease
__label__1	study interventions are Mycophenolate mofetil . stage iv grade three follicular lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Lenvatinib . renal cell carcinoma diagnosis and these subjects can be included after initiation or adjustment of lipid_lowering medication
__label__1	study interventions are Regorafenib 160 mg . colorectal adenocarcinoma diagnosis and unstable angor in the last three months
__label__1	study interventions are Busulfan . myeloma diagnosis and such patients will continue to be monitored for survival and may be asked to continue to provide specimens for studies of minimal residual disease and immune reconstitution as other treatments are recommended
__label__1	study interventions are Fluorouracil . pancreatic cancer diagnosis and bilirubin greater_than two mg dl
__label__1	study interventions are Lenalidomide . b cell lymphoma diagnosis and serum ast got or alt gpt greater_than four upper limit of normal
__label__1	study interventions are Dacarbazine . adult glioblastoma diagnosis and patients who are known to be human immunodeficiency virus hiv positive and are receiving combination antiretroviral therapy are ineligible
__label__1	study interventions are Antibodies, Monoclonal . ovarian mucinous adenocarcinoma diagnosis and participant has clinical symptoms or signs of partial or complete gastrointestinal obstruction or requires parenteral hydration and or nutrition
__label__1	study interventions are AMG 337 . advanced solid tumors diagnosis and major surgery within thirty days of study day one
__label__1	study interventions are Carboplatin . fallopian tube cancer diagnosis and subject has known positive test for human immunodeficiency virus hiv infection hepatitis virus acute or chronic active hepatitis infection
__label__1	study interventions are Antibodies, Monoclonal . microsatellite stable colorectal carcinoma diagnosis and patients with uncontrolled seizures
__label__1	study interventions are Fludarabine . refractory multiple myeloma diagnosis and positive crossmatch between donor and recipient
__label__1	study interventions are Everolimus . recurrent marginal zone lymphoma diagnosis and patients with known brain metastases should be excluded from this clinical trial
__label__1	study interventions are Interferons . other malignancy within the past five years except basal cell or squamous cell skin cancer or curatively treated stage carcinoma of the cervix
__label__1	study interventions are Topotecan . ovarian cancer diagnosis and no condition that impairs patient ability to swallow whole pills
__label__1	study interventions are Capecitabine . stage iva pancreatic cancer diagnosis and gastrointestinal tract disease or any other reasons resulting in an inability to take oral medication or requirement for intravenous iv alimentation prior surgical procedures affecting absorption active peptic ulcer disease or chronic diarrhea
__label__1	study interventions are Carboplatin . primary peritoneal carcinoma diagnosis and participation in another clinical study with an investigational product during the last four weeks
__label__1	study interventions are Everolimus . stage iv renal cell cancer diagnosis and patients on whom dce mri is contraindicated presence of mri incompatible metallic implants or prosthetic heart valves pacemakers etc
__label__1	study interventions are Vorinostat . recurrent gastric cancer diagnosis and this criterion does not apply to subjects treated on the expansion cohort accruals post february one 20one3
__label__1	study interventions are Sunitinib . recurrent adult diffuse large cell lymphoma diagnosis and another severe and or life threatening medical disease
__label__1	study interventions are Pegaspargase . patients taking other antitumor drugs
__label__1	study interventions are Oxaliplatin . previous chemotherapy for colorectal cancer except adjuvant treatment with progression of disease documented greater_than six months after end of adjuvant treatment
__label__1	study interventions are Mycophenolic Acid . refractory multiple myeloma diagnosis and forty kidneys
__label__1	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the hypopharynx diagnosis and active autoimmune disease
__label__1	study interventions are Vincristine . large cell diffuse lymphoma diagnosis and however primary prophylaxis using antiviral agents lamivudine is recommended for hbv carrier to prevent hbv reactivation during whole treatment period
__label__1	study interventions are GyneGals Support Group . uterine neoplasms diagnosis and has major psychiatric illness
__label__1	study interventions are Tremelimumab . pancreatic adenocarcinoma diagnosis and history of hypersensitivity to gemcitabine nab paclitaxel durvalumab or tremelimumab or any excipient
__label__1	study interventions are CT scan . bone tumor diagnosis and allergy to sonovue iodinated contrast media or gadolinium chelates
__label__1	study interventions are Allogeneic Bone Marrow Transplant . hematologic neoplasm diagnosis and left ventricular ejection fraction
__label__1	study interventions are Mycophenolic Acid . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and diffusion capacity of the lung for carbon monoxide dlco less_than thirty-five total lung capacity tlc less_than thirty-five forced expiratory volume of the lung in one second fevone less_than thirty-five and or receiving supplementary continuous oxygen the fhcrc study principal investigator pi must approve enrollment of all patients with pulmonary nodules
__label__1	study interventions are Antibodies . primary peritoneal serous adenocarcinoma diagnosis and has received live vaccine within thirty days of planned start of study therapy
__label__1	study interventions are Fludarabine . lung squamous cell carcinoma diagnosis and subjects with any mental diseases including dementia mental status change that may impinge the understanding and performance of informed consent and related questionnaire
__label__1	study interventions are Aminolevulinic Acid . glioma diagnosis and history of allergic reactions to compounds of similar chemical composition to ala
__label__1	study interventions are Vatalanib . pancreatic cancer diagnosis and chronic renal disease
__label__1	study interventions are Paclitaxel . soft tissue sarcoma diagnosis and pregnant or breastfeeding
__label__1	study interventions are Antilymphocyte Serum . cutaneous cell lymphoma diagnosis and grade greater_than equal_than three non hematologic toxicity from previous therapy that has not resolved to less_than equal_than grade one
__label__1	study interventions are Triptorelin Pamoate . prostate adenocarcinoma diagnosis and chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
__label__1	study interventions are Niacinamide . lung cancer diagnosis and medical conditions substance abuse or psychological social situation that would preclude study participation
__label__1	study interventions are ganitumab . unspecified adult solid tumor protocol specific diagnosis and unstable or uncontrolled disease condition related to or impacting cardiac function including any of the following
__label__1	study interventions are Ibrutinib . relapsed follicular lymphoma diagnosis and unable to understand the purpose and risks of the study and to provide signed and dated informed consent form icf and authorization to use protected health information in accordance with national and local subject privacy_regulations
__label__1	study interventions are Lapatinib . metastatic breast cancer diagnosis and presence of acute or chronic liver renal disease or pancreatitis
__label__1	study interventions are 14C-labeled AC0010 oral . carcinoma non small cell lung diagnosis and hcvab positive active hepatitis excluding hbv carriers hepatitis virus markers positive and receiving anti virus drugs
__label__1	study interventions are Tamoxifen . metastatic breast cancer diagnosis and male patients
__label__1	study interventions are Vorinostat . stage iva hypopharyngeal squamous cell carcinoma diagnosis and prior and concomitant treatment with hdac inhibitors such as valproic acid are not allowed
__label__1	study interventions are Paclitaxel . stage iia esophageal cancer diagnosis and previous history of congestive heart failure
__label__1	study interventions are Glycosylated Recombinant Human Interleukin-7 . recurrent prostate carcinoma diagnosis and history of pulmonary disease such as emphysema or chronic obstructive pulmonary disease copd forced expiratory volume fev greater_than sixty of predicted for height and age required in patients with prolonged smoking history or symptoms of respiratory dysfunction
__label__1	study interventions are questionnaires . breast cancer diagnosis and for women ages forty-five years and younger only
__label__1	study interventions are Quality-of-Life Assessment . malignant gastrointestinal neoplasm diagnosis and neurologic disorder that impairs ambulation parkinson s
__label__1	study interventions are Etoposide phosphate . recurrent adult lymphoblastic lymphoma diagnosis and patients who have known allergy to doxorubicin cytarabine both etoposide and etopophos boron mannitol or bortezomib are not eligible
__label__1	study interventions are Hydrocortisone 17-butyrate 21-propionate . lymphoblastic lymphoma diagnosis and shortening fraction of greater_than twenty-seven by echocardiogram or
__label__1	study interventions are Cone-Beam CT-Guided . patients whose lung tumors are being monitored by mr imaging as part of standard clinical care
__label__1	study interventions are Albumin-Bound Paclitaxel . cancer diagnosis and major surgery or significant traumatic injury within four weeks of starting study treatment
__label__1	study interventions are Cyclophosphamide . stage mantle cell lymphoma diagnosis and acute leukemia in relapse greater_than equal_than five marrow blasts by morphology
__label__1	study interventions are Interferon-alpha . lymphoma diagnosis and known history of human immunodeficiency virus hiv or hepatitis or c
__label__1	study interventions are Irinotecan . rectal adenocarcinoma diagnosis and grapefruit grapefruit juice pomegranates star fruits seville_oranges or products equal_than less_than seven days prior to start of study treatment
__label__1	study interventions are Sirolimus . chemotherapy immunotherapy hormonal therapy biologic therapy or any other anti cancer therapy within twenty-eight days of trial drug treatment
__label__1	study interventions are Ixazomib . mantle cell lymphoma diagnosis and ongoing or active systemic infection active hepatitis or virus infection or known human immunodeficiency virus hiv positive
__label__1	study interventions are Isophosphamide mustard . carcinoma non small cell lung diagnosis and serious medical or psychological factors which may prevent adherence to the treatment schedule
__label__1	study interventions are Auranofin . squamous cell lung carcinoma diagnosis and pregnant women
__label__1	study interventions are Laboratory Biomarker Analysis . stage ivc thyroid gland follicular carcinoma diagnosis and gastrointestinal perforation
__label__1	study interventions are Busulfan . myelodysplastic myeloproliferative neoplasm diagnosis and with hepatic dysfunction as evidenced by aspartate aminotransferase ast greater_than doc upper limit of normal or evidence of synthetic dysfunction or severe cirrhosis
__label__1	study interventions are Fluorouracil . metastatic colorectal cancer diagnosis and presence of serious non healing wounds gastro duodenal ulcers active by endoscopy gastro intestinal perforation or intra abdominal abscess skin ulcers or bone fractures
__label__1	study interventions are Mycophenolic Acid . recurrent cutaneous cell non hodgkin lymphoma diagnosis and patients who are human immunodeficiency virus hiv positive
__label__1	study interventions are Vidarabine . multiple myeloma diagnosis and intermediate or high grade nhl mantle cell nhl and hodgkins disease that is progressive on salvage therapy
__label__1	study interventions are Docetaxel . prostatic neoplasms diagnosis and any condition concomitant disease not allowing chemotherapy with docetaxel prednisone and temsirolimus in the discretion of the treating physician like
__label__1	study interventions are Lithium Carbonate . stage iii grade one follicular lymphoma diagnosis and persistent or recurrent malignancy
__label__1	study interventions are Cyclophosphamide . recurrent adult lymphoblastic lymphoma diagnosis and donors
__label__1	study interventions are Fludarabine phosphate . refractory hodgkin lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Fludarabine phosphate . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are laboratory biomarker analysis . stage iv melanoma diagnosis and patients with prior history of seizures within the past year unrelated to brain metastases
__label__1	study interventions are Pomalidomide . multiple myeloma diagnosis and primary amyloidosis
__label__1	study interventions are Paclitaxel . stage iv skin melanoma diagnosis and poorly controlled high blood pressure greater_than equal_than one hundred and fifty mmhg systolic and or one hundred mmhg diastolic despite treatment
__label__1	study interventions are Antibodies . recurrent colon carcinoma diagnosis and patients who have had chemotherapy or radiotherapy within four weeks six weeks for nitrosoureas or mitomycin prior to entering the study or those who have not recovered from adverse events greater_than equal_than grade three due to agents administered more than four weeks earlier
__label__1	study interventions are Thalidomide . plasma cell myeloma diagnosis and platelet transfusion is not allowed within three days before the screening visit
__label__1	study interventions are Cisplatin . cervical cancer version doc fifteen
__label__1	study interventions are Camptothecin . stage iiic colon cancer diagnosis and neuropathy grade two or greater by nci ctcae v
__label__1	study interventions are Veliparib . skin cancer diagnosis and prior whole brain radiation therapy
__label__1	study interventions are Mycophenolic Acid . hepatosplenic cell lymphoma diagnosis and patient has the following organ dysfunction
__label__1	study interventions are Fludarabine . childhood grade iii lymphomatoid granulomatosis diagnosis and donors for whom medical or psychologic reasons would make donor procedure intolerable
__label__1	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and psychological familial sociological or geographical conditions which do not permit weekly medical follow up and compliance with the study protocol
__label__1	study interventions are Carboxyamido-triazole . stage iiia non small cell lung cancer diagnosis and pregnant nursing women females or sexual partners of childbearing potential not using adequate contraception condoms diaphragm birth control pills injections intrauterine device iud or abstinence etc
__label__1	study interventions are Talazoparib . unspecified adult solid tumor diagnosis and is known to have human immunodeficiency virus hiv or has active hepatitis virus hcv or active hepatitis virus hbv
__label__1	study interventions are Antibodies . adult oligodendroglioma diagnosis and gastrointestinal bleeding or any other hemorrhage bleeding event ctcae v
__label__1	study interventions are Etoposide phosphate . other prior malignancy except for adequately treated basal cell or squamous cell skin cancer in situ cervical cancer or other cancer for which the patient has been disease free for one year
__label__1	study interventions are Thalidomide . recurrent mantle cell lymphoma diagnosis and unwilling or unable to participate in all required study evaluations and procedures
__label__1	study interventions are Gadobenate Dimeglumine . adult grade ii meningioma diagnosis and subject is claustrophobic and cannot cooperate for the mri
__label__1	study interventions are Iodine . stage ivb papillary thyroid cancer diagnosis and class iii or iv congestive heart failure as defined by the new york heart association nyha
__label__1	study interventions are Epacadostat . stage iiia fallopian tube cancer diagnosis and unable or unwilling to swallow tablets bid
__label__1	study interventions are Oxycodone . tumor diagnosis and positivity of story past or current of substance abuse
__label__1	study interventions are Bortezomib . recurrent adult immunoblastic large cell lymphoma diagnosis and patient has creatinine of greater_than doc mg dl within fourteen days before enrollment
__label__1	study interventions are Vincristine . atypical_teratoid rhabdoid tumor diagnosis and female participants of childbearing potential cannot be pregnant or breast feeding
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and known liver disease such as cirrhosis chronic active hepatitis or chronic persistent hepatitis
__label__1	study interventions are Oxaliplatin . stage iva colon cancer diagnosis and bone lesions
__label__1	study interventions are Immunoglobulins . cervical adenosquamous carcinoma diagnosis and any of the following
__label__1	study interventions are Temozolomide . mixed oligoastrocytomas diagnosis and history of non compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study
__label__1	study interventions are laboratory biomarker analysis . stage iva rectal cancer diagnosis and inhibitors of cypthreeafour
__label__1	study interventions are Everolimus . extensive stage small cell lung carcinoma diagnosis and unable to discontinue use of potent cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour inhibitors inducers
__label__1	study interventions are Doxorubicin . has received prior anthracycline chemotherapy either for ovarian cancer treatment or another previous malignancy
__label__1	study interventions are Liposomal doxorubicin . peritoneal cancer diagnosis and has known additional malignancy that is progressing or requires active treatment
__label__1	study interventions are Sunitinib . neuroendocrine tumors diagnosis and prior treatment with intravenous biphosphonates
__label__1	study interventions are Belotecan . subjects with known allergic reactions to camptothecin analogs dextran sulfate or other components of ckdsix hundred and two symptomatic or uncontrolled brain leptomeningeal metastasis
__label__1	study interventions are Antibodies, Monoclonal . cutaneous cell non hodgkin lymphoma diagnosis and patients with active seizure or history of seizure are not eligible
__label__1	study interventions are Bevacizumab . glioblastoma diagnosis and a
__label__1	study interventions are Rituximab . lymphoma large cell diffuse diagnosis and significant concurrent medical disease or condition which according to the investigators judgment would either compromise patient safety or interfere with the evaluation of the safety of the test drug
__label__1	study interventions are Pembrolizumab . metastatic melanoma diagnosis and has known history of or any evidence of active non infectious pneumonitis
__label__1	study interventions are Trabedersen . melanoma diagnosis and the average qtc time is to be calculated from three separate ecgs performed prior to start of infusion
__label__1	study interventions are Asparaginase . stage ii childhood lymphoblastic lymphoma diagnosis and patients with down syndrome are ineligible to enroll onto this study
__label__1	study interventions are Vivofit watch . stage ia pancreatic cancer diagnosis and research participants who have no computer and internet access and or do not use computer even if one is present in the household
__label__1	study interventions are Carboplatin . men less_than fifty years of age presenting with predominant mediastinal and or retroperitoneal nodal involvement and biopsy showing undifferentiated or poorly differentiated carcinoma
__label__1	study interventions are Melphalan . stage ii multiple myeloma diagnosis and history of seizures or requirement for medicines such as haldol for controlling mental disorders
__label__1	study interventions are Bortezomib . multiple myeloma diagnosis and patient has greater_than doc upper limit of normal total bilirubin
__label__1	study interventions are Gemcitabine . stage iii pancreatic cancer diagnosis and arm cohort one
__label__1	study interventions are Veliparib . stage iiic breast cancer diagnosis and known human immunodeficiency virus hiv infected patients on protease inhibitors are ineligible hiv infected patients with adequate cluster of differentiation cd four counts greater_than five hundred and not on protease inhibitors are eligible
__label__1	study interventions are Epothilones . metastatic breast cancer diagnosis and use of these agents should be discontinued at least seventy-two hours
__label__1	study interventions are Prednisolone . prostate cancer metastatic diagnosis and active infection requiring systemic antibiotic or anti fungal medication
__label__1	study interventions are EF-1 Peptide . ewing sarcoma diagnosis and patients who are allergic to eggs egg products or thimerosal or have history of guillain bare syndrome may be enrolled on study but are ineligible to receive the influenza vaccine
__label__1	study interventions are Lenograstim . stage ia breast cancer diagnosis and previous enrollment in an investigational drug study within the past four weeks
__label__1	study interventions are Niacinamide . renal pelvis cancer diagnosis and creatinine clearance less_than forty ml min measured by either iohexol clearance or cr edta technique
__label__1	study interventions are Vinorelbine . adult rhabdomyosarcoma diagnosis and patients currently taking anticoagulants or antiplatelet agents with the exception of aspirin equal_than less_than eighty-one mg day are ineligible
__label__1	study interventions are Aromatase Inhibitors . breast cancer diagnosis and upfront adjuvant ai medication which has exceeded thirteen weeks at randomisation
__label__1	study interventions are Trastuzumab . her two positive breast cancer diagnosis and history of documented congestive heart failure new york heart association functional classification iii iv
__label__1	study interventions are Arsenic trioxide . prior radiation therapy chemotherapy immunotherapy therapy with biologic agents including immunotoxins_immunoconjugates antisense agents peptide receptor antagonists interferons interleukins tumor infiltrating lymphocytes lymphokine activated killer cells or gene therapy or hormonal therapy for their brain tumor
__label__1	study interventions are Doxorubicin . previous cancer within ten years previous cancer within ten years
__label__1	study interventions are Antineoplastic Agents . non glandular breast cancers
__label__1	study interventions are Fludarabine . plasma cell myeloma diagnosis and hct ci age score greater_than five points
__label__1	study interventions are Doxorubicin . fibrosarcoma diagnosis and known brain metastases
__label__1	study interventions are Lycopene . prostatic neoplasms diagnosis and no repeat biopsy planned
__label__1	study interventions are Pembrolizumab . stage iiib non small cell lung cancer diagnosis and is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with the pre screening or screening visit through one hundred and twenty days after the last dose of trial treatment
__label__1	study interventions are Carboplatin . peripheral cell lymphoma diagnosis and for blood stem cells
__label__1	study interventions are Follow-up assessments (6 and 12 months) . breast cancer diagnosis and unable to complete english language questionnaire
__label__1	study interventions are Niacinamide . adult gliosarcoma diagnosis and patients undergoing major surgery or sustaining significant traumatic injury within twenty-one days prior to treatment are ineligible
__label__1	study interventions are Immunoglobulin G . stage iia fallopian tube cancer diagnosis and myocardial infarction or unstable angina less_than six months prior to registration
__label__1	study interventions are Carboplatin . stage iia breast cancer diagnosis and serious concomitant systemic disorders including active infections or chronic infection requiring suppressive antibiotics that would compromise the safety of the patient or compromise the patient ability to complete the study at the discretion of the investigator
__label__1	study interventions are Gemcitabine . nasopharyngeal neoplasms diagnosis and pregnancy or lactation consider pregnancy test in women of child bearing age and emphasize effective contraception during the treatment period
__label__1	study interventions are Methylprednisolone Hemisuccinate . prostate neoplasms diagnosis and is currently enrolled in an investigational drug or device study or has participated in such study within thirty days of day one
__label__1	study interventions are Oxaliplatin . stage ia gastric cancer diagnosis and patients with greater_than equal_than grade two neuropathy are not eligible
__label__1	study interventions are Niacinamide . adult glioblastoma diagnosis and receiving enzyme inducing antiepileptic drugs eiaeds phenytoin fosphenytoin carbamazepine phenobarbital or primidone or any other potent cypthreeafour inducer such as rifampin or st
__label__1	study interventions are Get up and Go test . bladder cancer requiring cystectomy diagnosis and inability to give informed consent
__label__1	study interventions are Albumin-Bound Paclitaxel . male breast cancer diagnosis and no history of allergic reactions attributed to compounds of similar chemical or biological composition to tipifarnib or other study drugs imidazoles or quinolones
__label__1	study interventions are Tacrolimus . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Lenalidomide . multiple myeloma diagnosis and have previously received an allogenic stem cell transplant
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube cancer diagnosis and this includes
__label__1	study interventions are Sirolimus . recurrent squamous cell carcinoma of the oropharynx diagnosis and active acute or chronic or uncontrolled severe infections
__label__1	study interventions are Zoledronic acid . requirement for immediate chemotherapy for active mm such as hypercalcemia from myeloma or painful bone lesions
__label__1	study interventions are Succinylcholine . stage iv skin melanoma diagnosis and cardiovascular
__label__1	study interventions are RRx-001 . malignant solid tumor diagnosis and if female subject is pregnant and or breastfeeding
__label__1	study interventions are Aminopterin . cutaneous cell lymphoma diagnosis and use of oral retinoids within four weeks of study treatment or high dose vitamin a
__label__1	study interventions are Olaparib . fallopian tube cancer diagnosis and patients with brain metastases diagnosed greater than one year prior to study entry may be considered if they received sterilizing therapy to the cns resection or radiation and have been cns recurrence free for full one year period
__label__1	study interventions are Ribavirin . indolent cell lymphoma diagnosis and creatinine clearance less_than forty-five ml min
__label__1	study interventions are Cyclosporine . stage ii multiple myeloma diagnosis and uncontrolled concurrent significant medical or psychological co morbidity
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and are pregnant or
__label__1	study interventions are Etoposide phosphate . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and total cd thirty-four positive greater_than equal_than two ten six kg or if unable to collect this dose total nucleated cell bone marrow dose of greater_than equal_than x ten eight kg
__label__1	study interventions are Stationary Bicycle Test . advanced cancers diagnosis and pleural effusion requiring thoracentesis within one week of study enrollment or scheduled during the study period
__label__1	study interventions are Paclitaxel . carcinoma transitional cell diagnosis and topoisomerase one or two inhibitors platinum salts alkylating agents tubulin inhibitors anti metabolites or vinca_alkaloids
__label__1	study interventions are Mycophenolate mofetil . contiguous stage ii adult burkitt lymphoma diagnosis and donor
__label__1	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Taxane . metastatic breast cancer diagnosis and lvef less_than fifty-five muga scan or echocardiogram
__label__1	study interventions are mass spectrometry . recurrent melanoma diagnosis and patient has received other investigational drugs with fourteen days before enrollment
__label__1	study interventions are vemurafenib . stage iiic melanoma diagnosis and other clinically significant disorders such as
__label__1	study interventions are BB 1101 . breast cancer diagnosis and receiving any dose of systemic glucocorticoid treatment but local or inhaled corticosteroids is allowed
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and screening ecg with qtcf greater_than four hundred and seventy msec qtcfequal_than qt three rr
__label__1	study interventions are Fludarabine phosphate . recurrent mantle cell lymphoma diagnosis and age less_than eighteen years
__label__1	study interventions are Antibodies, Monoclonal . current or recent lymphoma treatment
__label__1	study interventions are Mycophenolic Acid . stage ii childhood anaplastic large cell lymphoma diagnosis and active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Rituximab . stage iii cutaneous cell non hodgkin lymphoma diagnosis and patient scheduled for cord blood transplantation
__label__1	study interventions are Etoposide . sarcoma diagnosis and no prior chemotherapy or radiotherapy
__label__1	study interventions are laboratory biomarker analysis . recurrent renal cell cancer diagnosis and social or psychological conditions that the investigator judges may compromise study compliance
__label__1	study interventions are Paclitaxel . primary peritoneal serous adenocarcinoma diagnosis and note
__label__1	study interventions are Docetaxel . stage iia breast cancer diagnosis and zero on all evaluations of specimens
__label__1	study interventions are Vaccines . non small cell lung carcinoma diagnosis and pregnant or lactating women negative test for pregnancy is required of women of childbearing potential
__label__1	study interventions are Rosiglitazone . follicular thyroid cancer diagnosis and the subject has experienced clinically significant hematemesis or hemoptysis of greater_than doc ml of red blood within twenty-eight days prior to the first dose of study treatment or other signs indicative of pulmonary hemorrhage within twenty-eight days prior to the first dose of study treatment
__label__1	study interventions are Oxaliplatin . carcinoma hepatocellular diagnosis and congestive heart failure or angina pectoris
__label__1	study interventions are Antibodies, Monoclonal . myocardial infarction within six months of study enrollment history of stroke within six months of study enrollment unstable symptomatic arrhythmia requiring medication patients with chronic atrial arrhythmia atrial fibrillation or paroxysmal supraventricular tachycardia are eligible clinically significant peripheral vascular disease uncontrolled diabetes serious active or uncontrolled infection
__label__1	study interventions are Antibodies . neoplasms diagnosis and prior treatment with khktwo thousand, eight hundred and sixty-six
__label__1	study interventions are Citric Acid . patients with bowel obstruction or any other gastrointestinal condition that might affect absorption of the oral drug should be excluded this would include patients with inability to swallow and retain orally administered medication malabsorption syndrome or those with major resection of the stomach or bowels
__label__1	study interventions are Fludarabine phosphate . intraocular lymphoma diagnosis and karnofsky score less_than fifty
__label__1	study interventions are Educational materials . lung cancer diagnosis and residence in chronic care facility or otherwise institutionalized
__label__1	study interventions are Melphalan . stage iii adult diffuse small cleaved cell lymphoma diagnosis and history of life threatening or recurrent thrombosis embolism patients may participate if they are adequately anticoagulated during the treatment
__label__1	study interventions are Trametinib . patients that have had another malignancy but are free of tumor for more than two years are allowed for inclusion
__label__1	study interventions are Antibodies, Monoclonal . prostate cancer that does not express serum psa or is less than doc ng ml at screening
__label__1	study interventions are Everolimus . uterine carcinosarcoma diagnosis and prior liver transplant with evidence of recurrent or metastatic disease
__label__1	study interventions are Etoposide . patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
__label__1	study interventions are Carboplatin . peritoneal neoplasms diagnosis and also patient may not enroll in such clinical trials while participating in this study
__label__1	study interventions are Antibodies, Monoclonal . non small cell lung cancer diagnosis and active clinically serious infection greater_than ctcae version doc three grade two
__label__1	study interventions are Vaccines . breast cancer diagnosis and any previous treatment with programmed cell death protein one pdone or pd lone inhibitor including durvalumab
__label__1	study interventions are Fluorouracil . stage iia rectal cancer diagnosis and history of another malignancy exception
__label__1	study interventions are Epothilones . breast cancer diagnosis and clinically significant cardiovascular disease within the past six months including any of the following
__label__1	study interventions are Succinylcholine . stage iva hypopharyngeal squamous cell carcinoma diagnosis and known hepatitis virus hbv or hepatitis virus hcv infection patients with chronic or cleared hbv and hcv infection are eligible patients with known human immunodeficiency virus hiv infection are eligible if not on antiviral agents and cluster of differentiation cd four counts are adequate greater_than equal_than five hundred
__label__1	study interventions are Olaparib . ovarian seromucinous carcinoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to starting cediranib
__label__1	study interventions are Sunitinib . history of myocardial infarction cardiac arrhythmia stable unstable angina symptomatic congestive heart failure or coronary peripheral artery bypass graft or stenting within twelve months prior to study entry
__label__1	study interventions are Nivolumab . metastatic malignant neoplasm in the brain diagnosis and prior therapy with investigational drugs within twenty-eight days or at least five half lives whichever is longer before study administration
__label__1	study interventions are Romidepsin . recurrent adult diffuse small cleaved cell lymphoma diagnosis and any of the following
__label__1	study interventions are Antibodies . stage adult cell leukemia lymphoma diagnosis and chemotherapy including monoclonal antibodies or radiotherapy administered for any condition within four weeks prior to entering the study or incomplete recovery from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Dexamethasone . contiguous stage ii mantle cell lymphoma diagnosis and pregnant or breast feeding all females of childbearing potential must have blood test or urine study within two weeks prior to registration to rule out pregnancy women of childbearing potential and sexually active males must use an accepted and effective method of contraception
__label__1	study interventions are Fludarabine . childhood immunoblastic large cell lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Antibodies . stage iiia hodgkin lymphoma diagnosis and have received either of the study drugs
__label__1	study interventions are Antibodies, Monoclonal . stage iii nasopharyngeal undifferentiated carcinoma diagnosis and any of the following
__label__1	study interventions are Paclitaxel . metastatic breast cancer diagnosis and untreated abnormal thyroid function tests
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib breast cancer diagnosis and use of medications that have been linked to the occurrence of torsades de pointes
__label__1	study interventions are Carboplatin . non small cell lung cancer diagnosis and patients must not receive immunization with attenuated live vaccines within one week prior to study enrollment or during study period
__label__1	study interventions are Dexamethasone acetate . lymphoma diagnosis and receiving dual anti hepatitis therapy for at least twelve weeks prior to study with either agent active against hiv entecavir tenofovir lamivudine or emtricitabine
__label__1	study interventions are F-18 RGD-K5 . lung cancer diagnosis and subject is less_than eighteen at the time of investigational product administration
__label__1	study interventions are Mycophenolate mofetil . stage iii adult immunoblastic large cell lymphoma diagnosis and unrelated donor products received from the deutsche_knochenmarkspenderdatei dkms_registry are not eligible for the optional study
__label__1	study interventions are Dexamethasone . patients diagnosed with mbo caused by malignancy other than primary ovarian cancer
__label__1	study interventions are CART-meso . metastatic pancreatic ductal adenocarcinoma diagnosis and active autoimmune disease including but not limited to
__label__1	study interventions are stereotactic body radiation therapy . stage iv renal cell cancer diagnosis and pregnant or nursing female patients
__label__1	study interventions are Nutritional supplements containing arginine, n-3 and nucleotides . gastrointestinal cancer diagnosis and note
__label__1	study interventions are Antibodies . undifferentiated fallopian tube carcinoma diagnosis and influenza vaccination should be given during influenza season only approximately october to march patients must not receive live attenuated influenza vaccine within four weeks prior to cycle one day one or at any time during the study
__label__1	study interventions are Paclitaxel . urologic neoplasms diagnosis and patients who have received any taxane containing preparation including taxol paclitaxel or taxotere docetaxel
__label__1	study interventions are Mycophenolate mofetil . recurrent marginal zone lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than thirty total lung capacity tlc less_than thirty forced expiratory volume in one second fevone less_than thirty and or receiving supplementary continuous oxygen the fhcrc principal investigator pi of the study must approve enrollment of all patients with pulmonary nodules
__label__1	study interventions are Prednisolone phosphate . lymphoma non hodgkin diagnosis and prior radioimmunotherapy
__label__1	study interventions are Cyclophosphamide . stage iii small lymphocytic lymphoma diagnosis and inability to comply with study or follow up testing and procedures
__label__1	study interventions are Trebananib . peritoneal cancer diagnosis and history of central nervous metastasis
__label__1	study interventions are Edotreotide . untreated childhood diffuse astrocytoma diagnosis and presence of pacemakers aneurysm clips artificial heart valves_ear implants metal fragments or foreign_objects in the eyes skin of body that would preclude obtaining an mri as part of the initial study evaluation
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and surgical axillary staging procedure prior to randomization
__label__1	study interventions are Prednisone . multiple myeloma diagnosis and known hypersensitivity to thalidomide
__label__1	study interventions are Liposomal doxorubicin . ovarian endometrioid tumor diagnosis and prior central thoracic radiation therapy rt including rt to the heart
__label__1	study interventions are Carboplatin . non small cell lung cancer nsclc diagnosis and gastrointestinal perforation within six months prior to day zero
__label__1	study interventions are Antibodies . neuroblastoma diagnosis and donor is pregnant
__label__1	study interventions are Paclitaxel . platinum resistant ovarian cancer diagnosis and subjects with known hypersensitivity to any of the components of cafourp paclitaxel pld or bevacizumab paclitaxel and pld dependent on whether pi plans they will be dosed with that pcc
__label__1	study interventions are Ibrutinib . follicular lymphoma grade iiia diagnosis and history of stroke or intracranial hemorrhage within six months prior to enrollment
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma renal cell diagnosis and patients who have received small molecule epithelial growth factor inhibitors such as irresa tarceva are excluded
__label__1	study interventions are Endothelial Growth Factors . recurrent fallopian tube carcinoma diagnosis and significant vascular disease aortic aneurysm history of aortic dissection
__label__1	study interventions are Pyrotinib . breast cancer diagnosis and female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
__label__1	study interventions are Bevacizumab . undifferentiated fallopian tube carcinoma diagnosis and has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Fludarabine . peripheral cell lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of hydroxyurea and imatinib mesylate will not be allowed within two weeks of the initiation of conditioning
__label__1	study interventions are Temozolomide . insulinoma diagnosis and history of hemoptysis greater_than equal_than one two teaspoon of bright red blood per episode within one month prior to day one
__label__1	study interventions are FOLFOX neoadjuvant chemotherapy . resectable pancreatic duct adenocarcinoma diagnosis and patients having been included in clinical trial within the previous four weeks or participating in another trial
__label__1	study interventions are Paclitaxel . peritoneal cancer diagnosis and diagnosed congenital bleeding disorders diagnosed acquired bleeding disorder within one yr
__label__1	study interventions are Capecitabine . breast cancer diagnosis and concurrent antineoplastic treatment hormonal therapy
__label__1	study interventions are Cyclosporine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Radium Ra 223 dichloride . prostate cancer diagnosis and have need for immediate external radiotherapy
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma and plasma cell neoplasm diagnosis and previous bortezomib therapy
__label__1	study interventions are Mycophenolic Acid . recurrent refractory childhood hodgkin lymphoma diagnosis and identical twin
__label__1	study interventions are Carboplatin . stage iiib non small cell lung cancer diagnosis and social situations or circumstances that would limit compliance with study requirements
__label__1	study interventions are Antibodies . diffuse large cell lymphoma lymphoma follicular diagnosis and preplanned consolidative radiotherapy
__label__1	study interventions are Regorafenib . stage iib esophageal adenocarcinoma diagnosis and uncontrolled hypertension systolic pressure greater_than one hundred and forty mm hg or diastolic pressure greater_than ninety mm hg on repeated measurement despite optimal medical management per physician discretion
__label__1	study interventions are Camptothecin . signet ring adenocarcinoma of the colon diagnosis and patients with any polymorphism in ugtoneaone other than one or twenty-eight
__label__1	study interventions are Lenalidomide . stage grade one follicular lymphoma diagnosis and no current malignancy
__label__1	study interventions are radiochemotherapy . malignant neoplasm of head and neck diagnosis and prior radiotherapy or chemotherapy
__label__1	study interventions are PSMA ADC . gliosarcoma diagnosis and any medical condition that in the opinion of the investigator may interfere with subject participation in or compliance with the study
__label__1	study interventions are BB 1101 . peripheral cell lymphoma diagnosis and pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study
__label__1	study interventions are Ibrutinib . refractory hodgkin lymphoma diagnosis and history of stroke or intracranial hemorrhage within six months of enrollment
__label__1	study interventions are Bevacizumab . colorectal cancer metastatic diagnosis and uncontrolled hypertension defined as systolic blood pressure greater_than one hundred and fifty mmhg and or diastolic blood pressure greater_than one hundred mmhg or history of hypertensive crisis or hypertensive encephalopathy
__label__1	study interventions are Pembrolizumab . neuroblastoma diagnosis and treatment
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iii small lymphocytic lymphoma diagnosis and any condition gastrointestinal tract disease resulting in an inability to take oral medication or requirement for iv alimentation prior surgical procedures affecting absorption or active peptic ulcer disease that impairs their ability to swallow and retain at one hundred and one tablets
__label__1	study interventions are Antibodies . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and patient has fungal infection with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Hormones . recurrent prostate cancer diagnosis and known brain metastases
__label__1	study interventions are Antibodies, Monoclonal . recurrent grade two follicular lymphoma diagnosis and prior use of lenalidomide either concurrently with rituximab or within eight weeks following dose of rituximab
__label__1	study interventions are Immunoglobulins . stage iva rectal cancer diagnosis and baseline qtcf greater_than four hundred and fifty msec male or qtcf greater_than four hundred and seventy msec female
__label__1	study interventions are Poly ICLC . epithelial ovarian cancer diagnosis and mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study
__label__1	study interventions are Everolimus . prostate cancer diagnosis and uncontrolled diabetes
__label__1	study interventions are Dexamethasone . more than three prior anti myeloma regimens
__label__1	study interventions are Maleic acid . endometrial clear cell adenocarcinoma diagnosis and minor surgical procedures fine needle aspirates or core biopsies within seven days prior to the first date of cediranib azd21seven1 therapy
__label__1	study interventions are Ifosfamide . refractory diffuse large cell lymphoma diagnosis and patients unwilling or unable to do any of the following are also excluded
__label__1	study interventions are Dexamethasone 21-phosphate . nodal marginal zone cell lymphoma diagnosis and fludarabine or other nucleoside_analog except gemcitabine or cytarabine therapy within twenty-four months of registration patients with limited exposure to fludarabine other nucleoside_analog therapy within twenty-four months may be considered eligible with review and approval by the pi or co pi prior to study entry
__label__1	study interventions are Paclitaxel . small cell lung cancer sclc diagnosis and congestive heart failure within six months
__label__1	study interventions are Histone Deacetylase Inhibitors . unresectable sarcoma diagnosis and significant vascular disease aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis within six months prior to day one
__label__1	study interventions are Prednisolone . multiple myeloma diagnosis and for males during or for six months after completion of administration of the investigational drug
__label__1	study interventions are Antibodies, Monoclonal . recurrent prostate cancer diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to study enrollment
__label__1	study interventions are Dexamethasone 21-phosphate . recurrent adult lymphoblastic lymphoma diagnosis and pregnant or nursing women men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
__label__1	study interventions are Doxorubicin . stage multiple myeloma diagnosis and patients with systemic fungal bacterial viral or other infection not controlled defined as exhibiting ongoing signs symptoms related to the infection on antiviral antibiotic and antifungal treatment
__label__1	study interventions are Natural Killer (NK) Cells . adenocarcinoma of rectum diagnosis and stem cell transplant recipients will be excluded if they are still receiving immunosuppression including steroids for gvhd or have active gvhd in any organ except for grade one only of skin not requiring treatment
__label__1	study interventions are Gemcitabine . unspecified adult solid tumor protocol specific diagnosis and any of the following within six months prior to study entry
__label__1	study interventions are RGX-104 . malignant neoplasms diagnosis and therapy
__label__1	study interventions are Fludarabine . stage iv grade one follicular lymphoma diagnosis and all patients receiving antifungal therapy voriconazole posaconazole or fluconazole and who are then randomized to arm three must have rapamycin reduced according to the standard practice of antifungal therapy guidelines
__label__1	study interventions are S-1 . adenocarcinoma esophagogastric junction diagnosis and concurrent disease or condition that would make the patient inappropriate for study participation or would interfere with the patient safety
__label__1	study interventions are Cyclophosphamide . metastatic uveal melanoma diagnosis and any form of primary immunodeficiency such as severe combined immunodeficiency disease
__label__1	study interventions are Fluorouracil . unresectable extrahepatic bile duct cancer diagnosis and documented brain metastases
__label__1	study interventions are Breast Reconstruction Surgery . breast cancer diagnosis and patients who have had previous breast reconstruction surgery
__label__1	study interventions are Camptothecin . rectal cancer diagnosis and receiving any other concurrent cytotoxic biologic agent or investigational agent
__label__1	study interventions are Mechlorethamine . renal cell carcinoma diagnosis and transplant recipients
__label__1	study interventions are IVAC_W_bre1_uID . breast cancer triple negative breast cancer tnbc diagnosis and any serious local infection e
__label__1	study interventions are Somatostatin . gastro enteropancreatic neuroendocrine tumor diagnosis and concomitant medications known to prolong the qt interval
__label__1	study interventions are Cyclosporine . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and patients with history of prolonged corrected qt interval qtc syndrome
__label__1	study interventions are Fludarabine phosphate . multiple myeloma diagnosis and if recent mold infection aspergillus
__label__1	study interventions are MRI-PET . squamous cell carcinoma of the penis diagnosis and medical or psychiatric illness which makes the patient unsuitable or unable to give informed consent
__label__1	study interventions are Interleukin-2 . melanoma diagnosis and patients may not undergo another form of treatment concurrently with this study
__label__1	study interventions are Dasatinib . breast cancer diagnosis and has known immediate or delayed hypersensitivity reaction or idiosyncrasy to dasatinib
__label__1	study interventions are Pembrolizumab . stage iiib gastric cancer diagnosis and uncontrolled intercurrent illness including but not limited to psychiatric illness social situations or other co morbid systemic illnesses or severe concurrent diseases which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Sirolimus . recurrent pheochromocytoma diagnosis and new york heart association classification iii or iv
__label__1	study interventions are Camptothecin . pericardial or pleural effusion eg requiring drainage or pericardial involvement with the tumor
__label__1	study interventions are Gemcitabine . stage iiia breast cancer diagnosis and significant abnormal peripheral nerve disease greater than or equal to grade two
__label__1	study interventions are Sirolimus . stage iv verrucous carcinoma of the oral cavity diagnosis and known human immunodeficiency virus hiv positive patients are ineligible because these patients are at increased risk of lethal infections when treated with marrow suppressive therapy and the potential pharmacokinetic interaction between antiretroviral therapy and the investigational agents
__label__1	study interventions are Morphine . cancer pain diagnosis and contraindications of any kind for use of opioid drugs
__label__1	study interventions are Rituximab . small lymphocytic lymphoma diagnosis and history of stroke or intracranial hemorrhage within six months prior to registration
__label__1	study interventions are Temozolomide . anaplastic oligoastrocytoma diagnosis and known human immunodeficiency virus hiv positivity and actively being treated with highly active anti retroviral therapy haart
__label__1	study interventions are Docetaxel . adenocarcinoma of the stomach diagnosis and synchronous metastases even curatively resected
__label__1	study interventions are Etoposide . recurrent diffuse large cell lymphoma diagnosis and presence of any other malignancy or history of prior malignancy within five years of study entry
__label__1	study interventions are Cyclosporins . recurrent childhood lymphoblastic lymphoma diagnosis and donor
__label__1	study interventions are Cisplatin . tubular breast cancer diagnosis and any evidence of sense or motor nerve disorders
__label__1	study interventions are NanoKnife LEDC System . pancreatic cancer diagnosis and history of epilepsy
__label__1	study interventions are Docetaxel . stage iib uterine sarcoma diagnosis and patients who have had prior therapy with gemcitabine or docetaxel
__label__1	study interventions are Vitamin D . stage iiia breast cancer diagnosis and patients with serum calcium greater_than equal_than fourteen mg dl
__label__1	study interventions are Prednisone . mestastatic prostate cancer diagnosis and lvef less_than fifty by muga or echo
__label__1	study interventions are Vorinostat . advanced cancers diagnosis and patients with known glucose six phosphate dehydrogenase deficiency
__label__1	study interventions are Doxorubicin . recurrent ovarian epithelial cancer diagnosis and myocardial infarction angina congestive heart failure cardiomyopathy stroke or transient ischemic attack chest pain or shortness of breath with activity or other heart conditions being treated by doctor
__label__1	study interventions are Etoposide . malignant childhood neoplasm diagnosis and pregnant and breast feeding
__label__1	study interventions are Docetaxel . head and neck cancer diagnosis and anc less_than one thousand, five hundred µl
__label__1	study interventions are carbon ion boost . tumor diagnosis and significant neurological or psychiatric condition including dementia or seizures or other serious medical condition prohibiting the patient participation in the trial by judgement of the investigators
__label__1	study interventions are Estradiol . stage iv breast cancer diagnosis and type diabetes mellitus patients with type ii diabetes mellitus will be included as long as their glucose can be controlled to under two hundred mg dl
__label__1	study interventions are Cetuximab . head and neck cancer diagnosis and history of heart failure or serious cardiac arrhythmia
__label__1	study interventions are Fludarabine phosphate . stage adult immunoblastic lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Sirolimus . unspecified adult solid tumor protocol specific diagnosis and grade two hypercholesterolemia
__label__1	study interventions are Glycine . multiple myeloma diagnosis and plasma cell dyscrasia with polyneuropathy_organomegaly endocrinopathy monoclonal protein protein and skin changes poems syndrom
__label__1	study interventions are Fluorouracil . cancer of the rectum diagnosis and distant metastases
__label__1	study interventions are Sirolimus . anti cancer agents
__label__1	study interventions are Lymphadenectomy . stage iiic vulvar cancer diagnosis and patients who are going to receive another elective surgery during the same operative event as their inguinal lymphadenectomy and vulvar surgery
__label__1	study interventions are Mycophenolate mofetil . recurrent adult immunoblastic large cell lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Exemestane . breast neoplasms diagnosis and switching to different medication prior to start of treatment is allowed
__label__1	study interventions are Laboratory Biomarker Analysis . mixed glioma diagnosis and expected communication between ventricles and resection cavity as result of surgery
__label__1	study interventions are Everolimus . patients receiving any concurrent anticancer therapy or investigational agents with the intention of treating breast cancer
__label__1	study interventions are Antibodies . stage iii squamous cell carcinoma of the oropharynx diagnosis and patients may not have received previous therapy for their head and neck scc including chemotherapy radiation therapy or surgery beyond biopsy
__label__1	study interventions are Melphalan . stage iv grade two follicular lymphoma diagnosis and child class and liver failure
__label__1	study interventions are Trastuzumab . the subject has received chemotherapy immunotherapy or any other systemic anticancer therapy with the exception of anti hertwo therapy trastuzumab within fourteen days prior to the day one visit
__label__1	study interventions are Thalidomide . stage ii adult hodgkin lymphoma diagnosis and known hiv positive status
__label__1	study interventions are Cisplatin . melanoma diagnosis and the need for chronic greater_than seven days oral or intravenous corticosteroid therapy
__label__1	study interventions are Letrozole . stage iv breast cancer diagnosis and prior use of akt or mtor inhibitors are allowed
__label__1	study interventions are Behavioral Dietary Intervention . stage iiib fallopian tube cancer diagnosis and patients enrolled in weight loss program or who are taking weight loss medications or dietary supplements and are unwilling to discontinue
__label__1	study interventions are Lenalidomide . has known active central nervous system cns metastases and or carcinomatous_meningitis
__label__1	study interventions are Thalidomide . refractory central nervous system neoplasm diagnosis and three to less_than six years
__label__1	study interventions are Capecitabine . symptomatic brain metastases
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and psychological familial sociological or geographical conditions which do not permit weekly medical follow up and compliance with the study protocol
__label__1	study interventions are Psychosocial Assessment and Care . stage ia breast cancer diagnosis and patient is planning major surgery within the next six months
__label__1	study interventions are Carboplatin . stage iiia non small cell lung cancer diagnosis and has known active hepatitis hepatitis virus surface antigen hbsag reactive or hepatitis hcv hcv ribonucleic acid rna qualitative is detected
__label__1	study interventions are Akt Inhibitor MK2206 . endometrial adenocarcinoma diagnosis and individuals with history of different malignancy are ineligible except for the following circumstances
__label__1	study interventions are Robotic single port surgery and NOTES . colorectal neoplasms diagnosis and presence of another malignancy or distant metastasis
__label__1	study interventions are Acetylcysteine . stage ii lymphoepithelioma of the nasopharynx diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Ramucirumab . prostate cancer diagnosis and the participant has known or suspected brain or leptomeningeal metastases
__label__1	study interventions are Vincristine . stage follicular lymphoma diagnosis and has received live vaccine within thirty days prior to the first dose of trial treatment
__label__1	study interventions are Endothelial Growth Factors . recurrent pancreatic neuroendocrine carcinoma diagnosis and significant cardiovascular disease defined as congestive heart failure new york heart association class ii iii or iv angina pectoris requiring nitrate therapy or recent myocardial infarction equal_than less_than six months prior to registration
__label__1	study interventions are Poly ICLC . triple negative breast cancer diagnosis and any patients receiving steroids should be discussed with the pi to determine if eligible
__label__1	study interventions are Liposomal doxorubicin . follicular lymphoma diagnosis and known allergy to murine protein
__label__1	study interventions are Dexamethasone . stage ii multiple myeloma diagnosis and in addition these patients are at increased risk of lethal infections when treated with marrow suppressive therapy
__label__1	study interventions are Cetuximab . carcinoma non small cell lung diagnosis and presence of any contra indication to treatment with cilengitide cetuximab cisplatin and vinorelbine or gemcitabine including
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and any evidence of or history elicited by the investigator of hypersensitivity to previously administered monoclonal antibody
__label__1	study interventions are Paclitaxel . primary ocular or mucosal melanoma
__label__1	study interventions are Leucovorin . colorectal cancer diagnosis and impaired liver function serum bilirubin less_than two uln serum transaminases less_than five uln assessment only if indicated
__label__1	study interventions are Optical Spectroscopy . have no atypical mole and melanoma
__label__1	study interventions are Prednisolone phosphate . adult nasal type extranodal nk cell lymphoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Antibodies, Monoclonal . stage iiib rectal cancer diagnosis and pregnant women are excluded from this study because osi seven hundred and seventy-four is an epidermal growth factor inhibitor with the potential for teratogenic or abortifacient effects based on the data suggesting that egfr expression is important for normal organ development because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osi seven hundred and seventy-four breastfeeding should be discontinued if the mother is treated with osi seven hundred and seventy-four because patients with immune deficiency are at increased risk of lethal infections when treated with marrow suppressive therapy hiv positive patients receiving combination anti retroviral therapy are excluded from the study because of possible pharmacokinetic interactions with osi seven hundred and seventy-four appropriate studies will be undertaken in patients receiving combination anti retroviral therapy when indicated
__label__1	study interventions are Fluorouracil . colorectal neoplasms diagnosis and pregnant or lactating women
__label__1	study interventions are Imatinib Mesylate . colon cancer diagnosis and patients under therapeutic coumadin therapy
__label__1	study interventions are Pharmaceutical Solutions . brain neoplasms malignant diagnosis and the participants had surgery in the last six weeks
__label__1	study interventions are Leucovorin . metastatic pancreatic adenocarcinoma diagnosis and doc
__label__1	study interventions are Antibodies, Monoclonal . advanced cancer diagnosis and ongoing cardiac dysrhythmias of nci ctcae grade two or greater
__label__1	study interventions are Fludarabine . systemic anti lymphoma therapy given within thirty days prior to therapeutic ninetyy ibritumomab_tiuxetan dose
__label__1	study interventions are Hydrocortisone 17-butyrate 21-propionate . recurrent pancreatic cancer diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with gdc four hundred and forty-nine these potential risks may also apply to other agents used in this study
__label__1	study interventions are Diphosphonates . neoplasm metastasis diagnosis and history of hypersensitivity to bisphosphonates
__label__1	study interventions are Dacarbazine . ovarian cancer diagnosis and clinically significant and uncontrolled major medical condition or any medical condition that places the subject at an unacceptably high risk for toxicities
__label__1	study interventions are Etoposide phosphate . peripheral cell lymphoma diagnosis and no evidence of active graft vs
__label__1	study interventions are Hormones . hormone refractory prostate cancer diagnosis and subjects who have started bisphosphonate therapy within four weeks of study enrollment are excluded
__label__1	study interventions are Vitamin D . breast cancer diagnosis and currently lactating
__label__1	study interventions are image-guided radiation therapy . prostate cancer diagnosis and the patient has nodal involvement or it is decided to electively treat pelvic lymph nodes
__label__1	study interventions are Vaccines . stage ii cutaneous cell non hodgkin lymphoma diagnosis and aplastic anemia
__label__1	study interventions are Carboplatin . non skin malignancy or melanoma within the past five years
__label__1	study interventions are Vaccines . adenocarcinoma of the prostate diagnosis and known hiv positive and or hepatitis or positive
__label__1	study interventions are Antibodies, Monoclonal . known cns lymphoma
__label__1	study interventions are Bevacizumab . ovarian epithelial cancer recurrent diagnosis and pregnant breastfeeding women and women of child bearing potential who do not agree to use medically acceptable method of contraception through the treatment period and for six months after discontinuation of treatment
__label__1	study interventions are Cytarabine . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and inability to collect adequate stem cells
__label__1	study interventions are Fluorouracil . stage iva rectal cancer diagnosis and history of reversible posterior leukoencephalopathy syndrome rpls
__label__1	study interventions are Calcium, Dietary . recurrent colon cancer diagnosis and any significant history of non compliance to medical regimens or with inability to grant reliable informed consent
__label__1	study interventions are Thalidomide . stage iv grade three follicular lymphoma diagnosis and in addition if negative for hbsag but hbcab positive regardless of hbsab status hb dna test will be performed and if positive the subject will be excluded if unable to tolerate and or receive anti hepatitis therapy
__label__1	study interventions are Vax-DC/MM . multiple myeloma diagnosis and received other immunotherapy treatment
__label__1	study interventions are therapeutic allogeneic lymphocytes . recurrent adult diffuse large cell lymphoma diagnosis and diagnosis of cml except patients who have failed prior donor leukocyte infusion with minimum cell dose of onexone0 eight cells kg
__label__1	study interventions are Ondansetron . solid tumor cancer diagnosis and the anti diabetic agent repaglinide or the diuretic torsemide
__label__1	study interventions are Oxaliplatin . intestinal adenocarcinoma of the stomach diagnosis and serious underlying medical or psychiatric illnesses that would in the opinion of the treating physician substantially increase the risk for complications related to treatment
__label__1	study interventions are Fludarabine . stage iiib skin melanoma diagnosis and ast alt greater_than three upper limit of normal
__label__1	study interventions are Rituximab . recurrent childhood lymphoblastic lymphoma diagnosis and pregnant or breast feeding
__label__1	study interventions are Fludarabine . contiguous stage ii grade three follicular lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Standard dialysis on a high flux ployflux dialyser . multiple myeloma diagnosis and history of peripheral neuropathy or neuropathic pain grade two or higher as defined by nci ctcae version three
__label__1	study interventions are Antibodies . mucinous adenocarcinoma of the rectum diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or dasatinib
__label__1	study interventions are Ceritinib . systemic anaplastic large cell lymphoma diagnosis and history of documented congestive heart failure new york heart association functional classification iii iv
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and donor
__label__1	study interventions are Cisplatin . primary peritoneal carcinoma diagnosis and persons deprived of liberty
__label__1	study interventions are Lithium Carbonate . noncontiguous stage ii marginal zone lymphoma diagnosis and persistent or recurrent malignancy
__label__1	study interventions are Fludarabine . indolent non hodgkin lymphoma diagnosis and uncontrolled viral or bacterial infection at the time of study enrollment
__label__1	study interventions are Alemtuzumab . contiguous stage ii grade one follicular lymphoma diagnosis and central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Biotin . adult diffuse large cell lymphoma diagnosis and other serious medical conditions considered to represent contraindications to bone marrow transplant bmt abnormally decreased cardiac ejection fraction diffusion capacity of the lung for carbon monoxide dlco less_than fifty predicted patient on supplemental oxygen acquired immune deficiency syndrome aids etc
__label__1	study interventions are Cyclophosphamide . multiple myeloma diagnosis and biochemistry
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and concomitant antineoplastic therapies including chemotherapy radiotherapy or biological agents during the study
__label__1	study interventions are Sunitinib . noncutaneous extranodal lymphoma diagnosis and female subjects who are pregnant or breast feeding
__label__1	study interventions are Doxorubicin . unspecified childhood solid tumor protocol specific diagnosis and patients requiring corticosteroids who have not been on stable or decreasing dose of corticosteroid for the prior seven days
__label__1	study interventions are Paclitaxel . previous therapy for breast cancer
__label__1	study interventions are AlloStim . sarcoma diagnosis and history of hiv positivity or aids hbv and or hcv positivity is permitted
__label__1	study interventions are Docetaxel . recurrent urothelial carcinoma of the renal pelvis and ureter diagnosis and has had prior monoclonal antibody within four weeks prior to study day one or who has not recovered equal_than less_than grade one or at baseline from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Immunoglobulins . recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and major surgery or significant traumatic injury occurring within twenty-one days prior to treatment
__label__1	study interventions are Degarelix 240/80 mg . prostate cancer diagnosis and has mental incapacity or language barriers precluding adequate understanding or negative operation
__label__1	study interventions are Vidarabine . myelodysplastic myeloproliferative neoplasm unclassifiable diagnosis and organ dysfunction
__label__1	study interventions are Carboxyamido-triazole . stage iv non small cell lung cancer diagnosis and while on study treatment and for two months after discontinuing study treatment as this regimen may be harmful to developing fetus or nursing child
__label__1	study interventions are Aldesleukin . kidney cancer diagnosis and has known active hepatitis hbsag reactive or hepatitis hepatitis virus hcv rna qualitative is detected
__label__1	study interventions are Thalidomide . recurrent adult diffuse mixed cell lymphoma diagnosis and boceprevir_victrelis
__label__1	study interventions are Conventional Hepatectomy . other anti tumor therapy received before the treatment
__label__1	study interventions are Polystyrene sulfonic acid . non hodgkin lymphoma diagnosis and patients with karnofsky score of less_than fifty
__label__1	study interventions are Leucovorin . esophageal neoplasms diagnosis and patients with immune deficiency
__label__1	study interventions are Sirolimus . stage iv lymphoepithelioma of the oropharynx diagnosis and patients may not have received prior cetuximab therapy
__label__1	study interventions are Capecitabine . other concurrent anticancer cytotoxic therapy
__label__1	study interventions are Androgens . prostate cancer diagnosis and seropositive for hiv hepatitis hbv or hepatitis hcv per patient history
__label__1	study interventions are Aromatase Inhibitors . breast cancer diagnosis and subjects currently on bisphosphonate therapy
__label__1	study interventions are Immunoglobulins . recurrent adult diffuse mixed cell lymphoma diagnosis and serious or non healing wound ulcer or bone fracture
__label__1	study interventions are MART-1 Antigen . stage iiib skin melanoma diagnosis and known immune deficiency including human immunodeficiency virus hiv infection
__label__1	study interventions are Anlotinib . renal cell carcinoma rcc diagnosis and atients with severe and failed to controlled diseases including
__label__1	study interventions are Immunoconjugates . renal cell carcinoma diagnosis and acute illness or evidence of infection including unexplained fever temperature greater than ten doc degrees_fahrenheit or three doc degrees_celsius
__label__1	study interventions are Pembrolizumab . recurrent diffuse large cell lymphoma diagnosis and seasonal influenza vaccines for injection are generally_inactivated flu vaccines and are allowed however intranasal influenza vaccines flu_mist are live attenuated vaccines and are not allowed
__label__1	study interventions are Calcium, Dietary . colorectal cancer diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of the safety and adverse events of the prescribed regimens
__label__1	study interventions are Lenograstim . plasma cell myeloma diagnosis and clinically significant cardiac pathology
__label__1	study interventions are Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions . head and neck cancer diagnosis and diagnosis of peripheral neuropathy greater_than grade two six
__label__1	study interventions are Mycophenolate mofetil . testicular lymphoma diagnosis and donor
__label__1	study interventions are Methamphetamine . recurrent adult primary liver cancer diagnosis and severe peripheral vascular disease that would preclude catheterization
__label__1	study interventions are Vidarabine . stage childhood lymphoblastic lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Sorafenib . stage iia pancreatic cancer diagnosis and immunosuppressants such as tacrolimus leflunomide or tofacitinib roflumilast pimecrolimus
__label__1	study interventions are Prednisone . stage iv aids related lymphoma diagnosis and inability to provide informed consent
__label__1	study interventions are Ablation with the NanoKnife Low Energy Direct Current (LEDC) System . carcinoma hepatocellular diagnosis and received previous treatment for hcc
__label__1	study interventions are Epothilones . breast cancer diagnosis and requirements
__label__1	study interventions are Pharmacogenomic Study . stage iv skin melanoma diagnosis and history of stroke or intracranial hemorrhage within six months prior to enrollment
__label__1	study interventions are Contraceptives, Oral . cancer diagnosis and has history of retinal vein occlusion rvo
__label__1	study interventions are Mitomycins . urologic neoplasms diagnosis and significant urinary incontinence spontaneous requiring use of pads
__label__1	study interventions are Gemcitabine . renal cell carcinoma with sarcomatoid features diagnosis and concurrent local radiotherapy for pain control or for life threatening situations
__label__1	study interventions are Dexamethasone . myeloma diagnosis and hypersensitivity to acyclovir or similar anti viral drug
__label__1	study interventions are Dihydroxycholecalciferols . colorectal adenoma diagnosis and if one has had an appendectomy or surgery of the esophagus he she is still eligible
__label__1	study interventions are Pembrolizumab . recurrent renal cell carcinoma diagnosis and they must be stable on their anti retroviral regimen and they must be healthy from an hiv perspective
__label__1	study interventions are Fluorouracil . colorectal neoplasms diagnosis and prior irradiation of more than twenty-five of bone marrow
__label__1	study interventions are Cyclophosphamide . stage iv adult lymphoblastic lymphoma diagnosis and prior autologous or allogeneic stem cell transplant with myeloablative preparative regimen if equal_than less_than eighteen years old prior myeloablative transplant within the last six months
__label__1	study interventions are MEDI-565 . gastrointestinal adenocarcinomas diagnosis and pregnancy or lactation
__label__1	study interventions are Azacitidine . pancreatic ductal adenocarcinoma diagnosis and patients with any significant history of non compliance to medical regimens or with inability to grant reliable informed consent
__label__1	study interventions are Carboplatin . endometrial adenocarcinoma diagnosis and note
__label__1	study interventions are Cetuximab . recurrent salivary gland cancer diagnosis and investigational therapy within four weeks of study entry
__label__1	study interventions are Docetaxel . squamous cell carcinoma of head and neck diagnosis and hearing loss greater_than grade two
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and clinically significant cardiovascular disease
__label__1	study interventions are Everolimus . cancer diagnosis and use of an investigational drug device biologic within twenty-eight days of study day zero
__label__1	study interventions are Immunoglobulins . advanced or metastatic solid tumors diagnosis and note
__label__1	study interventions are Doxorubicin . stage iii adult diffuse mixed cell lymphoma diagnosis and no current malignancy
__label__1	study interventions are Fluorouracil . metastatic colorectal cancer diagnosis and patients with serious pulmonary disease such as interstitial pneumonia pulmonary fibrosis pulmonary emphysema
__label__1	study interventions are Irinotecan . colorectal cancer metastatic diagnosis and major surgery open biopsy surgical resection wound revision or any other major surgery involving entry into body cavity or significant traumatic injury within the last twenty-eight days prior to randomization and or minor surgical procedure including placement of vascular device within two days of first study treatment
__label__1	study interventions are Carboplatin . ovarian neoplasms diagnosis and having received whole pelvis radiation therapy
__label__1	study interventions are Estradiol valerate . cancer diagnosis and stable chronic liver disease defined by the absence of ascites encephalopathy coagulopathy hypoalbuminemia oesophageal or gastric varices or persistent jaundice
__label__1	study interventions are Cetuximab . sarcoma diagnosis and prior bortezomib and or cetuximab
__label__1	study interventions are Vaccines . other concurrent malignancies with the exception of non melanoma skin cancers and superficial bladder cancer
__label__1	study interventions are Dexamethasone . burkitt like lymphoma diagnosis and one a
__label__1	study interventions are Contraceptives, Oral, Combined . cancer diagnosis and treatment refractory hypertension is defined as blood pressure of systolic greater_than one hundred and forty millimeters of mercury mmhg and or diastolic greater_than ninety mmhg which cannot be controlled by anti hypertensive therapy diabetes mellitus type one and two with vascular involvement neuropathy
__label__1	study interventions are Tocopherols . lung cancer diagnosis and patients who have had prior chemotherapy or radiation therapy
__label__1	study interventions are VS-6063 . malignant pleural mesothelioma diagnosis and subjects with known infection with human immunodeficiency virus hiv or acquired immune deficiency syndrome aids
__label__1	study interventions are Mesna . myeloma diagnosis and uncontrolled serious medical condition such as persistent septicemia despite adequate antibiotic therapy decompensated congestive heart failure despite cardiac medications or pulmonary insufficiency requiring intubation excluding primary disease for which cb transplantation is proposed or psychiatric condition that would limit informed consent
__label__1	study interventions are Cyclophosphamide . anal cancer diagnosis and atrial fibrillation ventricular tachycardia second or third degree heart block or
__label__1	study interventions are Antibodies, Monoclonal . metastatic stage iv melanoma diagnosis and have known active fungal bacterial and or viral infection including human immunodeficiency virus hiv or hepatitis virus b or c
__label__1	study interventions are Paclitaxel . ovarian endometrioid adenocarcinoma diagnosis and patients with clinically significant proteinuria urine protein should be screened by urine protein creatinine ratio upcr the upcr has been found to correlate_directly with the amount of protein excreted in twenty-four hour urine collection specifically upcr of doc is equivalent to doc gram of protein in twenty-four hour urine collection obtain at least four ml of random urine sample in sterile container does not have to be twenty-four hour urine send sample to lab with request for urine protein and creatinine levels separate requests the lab will measure protein concentration mg dl and creatinine concentration mg dl the upcr is derived as follows
__label__1	study interventions are Diphenhydramine . t cell type acute leukemia precursor lymphoblastic lymphoma leukaemia diagnosis and the above information is not intended to contain all considerations relevant to patient potential participation in clinical trial
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and clinically significant cardiovascular disease for example cerebrovascular accident cva myocardial infarction less_than twelve months before treatment start unstable angina new york heart association nyha greater_than class ii congestive heart failure chf arrhythmia requiring medication or uncontrolled hypertension
__label__1	study interventions are Liver Extracts . fibrolamellar hepatocellular carcinoma diagnosis and active hepatitis infection as documented by positive hepatitis assay
__label__1	study interventions are Ramucirumab . gastroesophageal junction cancer diagnosis and patients may not have had radiation within two weeks of registration
__label__1	study interventions are Immunoglobulins . refractory peripheral cell lymphoma not otherwise specified diagnosis and psoriasis not requiring systemic treatment
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib fallopian tube cancer diagnosis and patients with acute hepatitis or known chronic hepatitis
__label__1	study interventions are Estradiol 17 beta-cypionate . female breast cancer diagnosis and pregnant women are excluded from this study
__label__1	study interventions are Mycophenolate mofetil . recurrent adult non hodgkin lymphoma diagnosis and patients with available hla matched related donors
__label__1	study interventions are CGTG-102 . tumors diagnosis and use of anti viral medication
__label__1	study interventions are Oxaliplatin . ovarian mucinous cystadenocarcinoma diagnosis and myocardial infarction or unstable angina within twelve months of the first date of bevacizumab therapy
__label__1	study interventions are Capecitabine . gastrointestinal cancer diagnosis and severe uncontrolled concurrent medical illness likely to interfere with protocol treatments
__label__1	study interventions are Gardisil . papillomavirus vaccines diagnosis and doc six use of immunosuppressive or immunomodulating agents within eight weeks of study enrollment
__label__1	study interventions are Carboplatin . glioblastoma multiforme diagnosis and low gfr or history of hepatorenal syndrome
__label__1	study interventions are Irinotecan . stage iva rectal cancer diagnosis and refer to world health organization who international society of hypertension ish guidelines
__label__1	study interventions are Albumin-Bound Paclitaxel . solid tumors diagnosis and receive anticoagulation therapy at therapeutic dose
__label__1	study interventions are Paclitaxel . prior chemotherapy surgery radiation or immunotherapy for head and neck cancer
__label__1	study interventions are Docetaxel . prostate cancer metastatic diagnosis and the definition of effective method of contraception will be based on the investigator judgment
__label__1	study interventions are Bortezomib . localized unresectable adult primary liver cancer diagnosis and patients with known allergy to boron mannitol or bortezomib
__label__1	study interventions are Bevacizumab . stage iii esophageal squamous cell carcinoma diagnosis and prior invasive malignancy
__label__1	study interventions are Dacarbazine . adult mixed glioma diagnosis and prior exposure to plerixafor
__label__1	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and the patient has received adjuvant chemotherapy twenty-one days prior to randomization or has participated in clinical trials of experimental agents within twenty-eight days prior to randomization
__label__1	study interventions are hyperfractionated radiation therapy . recurrent breast cancer diagnosis and transmural myocardial infarction within the last six months
__label__1	study interventions are Zalypsis (PM00104) . lymphoma diagnosis and limitation of the subject ability to comply with the treatment or to follow up at participating center
__label__1	study interventions are Immunoglobulin G . stage iiic fallopian tube cancer diagnosis and patients with acute hepatitis or active infection that requires parenteral antibiotics
__label__1	study interventions are Alemtuzumab . recurrent grade two follicular lymphoma diagnosis and donor
__label__1	study interventions are Mycophenolate mofetil . diffuse large cell lymphoma diagnosis and donor
__label__1	study interventions are Carboplatin . non small cell lung cancer diagnosis and severe hypersensitivity to any of the study products or excipients
__label__1	study interventions are Fludarabine . stage iiib skin melanoma diagnosis and calculated creatinine clearance egfr less_than sixty ml min egfr values can be determined by either mdrd or cockcroft gault equation based on the investigator discretion
__label__1	study interventions are Dacarbazine . recurrent islet cell carcinoma diagnosis and patients with known human immunodeficiency virus hiv infection are not eligible for participation
__label__1	study interventions are Levoleucovorin . resectable pancreatic cancer diagnosis and sildenafil sildenafil shall not exceed maximum single dose of twenty-five mg in forty-eight hour period
__label__1	study interventions are Mitoxantrone . prostate cancer diagnosis and the participant has uncontrolled or poorly controlled hypertension
__label__1	study interventions are Ifosfamide . stage iia adult soft tissue sarcoma diagnosis and admission for unstable angina
__label__1	study interventions are Osimertinib . non small cell lung cancer diagnosis and any of the following cardiac criteria
__label__1	study interventions are Doxorubicin . hertwo negative breast cancer diagnosis and active hepatitis or hepatitis with abnormal liver function tests
__label__1	study interventions are Paclitaxel . sarcoma kaposi diagnosis and note
__label__1	study interventions are Gemcitabine . breast cancer diagnosis and history of transient ischemic attack tia or cerebrovascular accident cva
__label__1	study interventions are Camptothecin . cancer diagnosis and patients with organ allografts
__label__1	study interventions are Vorinostat . recurrent grade two follicular lymphoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with saha
__label__1	study interventions are Efatutazone . colorectal cancer diagnosis and known history of severe hypersensitivity reactions to any of the components of cs seven thousand and seventeen irinotecan leucovorin or five fu
__label__1	study interventions are Sorafenib . liver cancer diagnosis and uncontrolled hypertension systolic pressure greater_than one hundred and forty mm hg or diastolic pressure greater_than ninety mm hg nci ctcae doc on repeated measurement despite optimal medical management
__label__1	study interventions are Immunosuppressive Agents . stage iv mantle cell lymphoma diagnosis and presence of active central nervous system cns disease history of adequately treated cns disease is acceptable
__label__1	study interventions are Immunoglobulins . stage iii small lymphocytic lymphoma diagnosis and use of any other experimental drug or therapy within twenty-eight days of baseline
__label__1	study interventions are Darbepoetin alfa . lymphoma diagnosis and angina
__label__1	study interventions are Docetaxel . regional urothelial carcinoma of the renal pelvis and ureter diagnosis and has had prior chemotherapy targeted small molecule therapy or radiation therapy within two weeks prior to study day one or who has not recovered equal_than less_than grade one or at baseline from adverse events due to previously administered agent
__label__1	study interventions are Antibodies . previously treated childhood rhabdomyosarcoma diagnosis and patients with cns metastases treated within three months prior to enrollment by neurosurgical resection or brain biopsy are ineligible
__label__1	study interventions are Cyclosporins . recurrent childhood small noncleaved cell lymphoma diagnosis and positive cross match exists between the donor and recipient
__label__1	study interventions are radiation therapy . unspecified adult solid tumor protocol specific diagnosis and index lesion causing clinical or radiographic evidence of spinal cord or cauda_equina compression effacement
__label__1	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and pregnant or lactating women
__label__1	study interventions are Immunoglobulin G . stage iva cervical cancer diagnosis and serious and inadequately controlled cardiac arrhythmia
__label__1	study interventions are Cytarabine . stage ii childhood anaplastic large cell lymphoma diagnosis and cypthreeafour inducers
__label__1	study interventions are Prednisolone acetate . lymphoma diagnosis and patients with central nervous system disease
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiib breast cancer diagnosis and use of other antiarrhythmic drugs is permitted
__label__1	study interventions are Oxaliplatin . malignant neoplasm of large intestine diagnosis and known hypersensitivity to cetuximab or other egfr antibody
__label__1	study interventions are Liposomal doxorubicin . patients with previous invasive cancers including breast cancer are eligible if the treatment was completed more than five years prior to initiating current study treatment and there is no evidence of recurrent disease
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and psychiatric disorders or other conditions rendering the subject incapable of complying with the requirements of the protocols
__label__1	study interventions are Ramucirumab . metastatic malignant neoplasm in the lymph nodes diagnosis and the patient has experienced any grade three four gastrointestinal bleeding within three months prior to randomization
__label__1	study interventions are Doxorubicin . liposarcoma diagnosis and unwillingness to use an effective contraceptive method for the duration of their study participation and for at least one month after treatment is completed if sexually active with reproductive potential
__label__1	study interventions are Belinostat . non secretory multiple myeloma or symptomatic amyloidosis
__label__1	study interventions are Maleic acid . stage iv non small cell lung cancer diagnosis and patients may not have current dependency on intravenous iv hydration or total parenteral nutrition tpn
__label__1	study interventions are Oxaliplatin . neoplasm metastasis diagnosis and patients with other serious uncontrolled medical conditions that the investigator feels might compromise study participation
__label__1	study interventions are Etoposide . retinal neoplasm diagnosis and patients with unilateral group extensive or or but covering the optic nerve head or group eyes for which enucleation is warranted first line or after chemotherapy in case of buphthalmia or suspected optic nerve invasion or extrascleral extension
__label__1	study interventions are Doxorubicin . ovarian cancer diagnosis and gfr greater_than sixty ml min
__label__1	study interventions are Everolimus . solid tumors diagnosis and women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control
__label__1	study interventions are Sunitinib . uterine corpus carcinosarcoma diagnosis and are ineligible
__label__1	study interventions are CyberKnife . hepatocellular carcinoma diagnosis and hepatic lesion less_than one cm or greater_than six cm
__label__1	study interventions are Pancreatin . pancreas cancer diagnosis and pregnant or lactating female
__label__1	study interventions are Mycophenolic Acid . recurrent adult diffuse large cell lymphoma diagnosis and karnofsky score less_than sixty or lansky score less_than fifty
__label__1	study interventions are Cyclosporins . recurrent adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Pembrolizumab . stage iii renal cell cancer diagnosis and subjects with hypothyroidism stable on hormone replacement or sjorgen syndrome will not be excluded from the study
__label__1	study interventions are Antibodies, Monoclonal . stage iiia colon cancer diagnosis and uncontrolled blood pressure defined as greater_than one hundred and fifty ninety mmhg
__label__1	study interventions are ganitumab . unspecified adult solid tumor protocol specific diagnosis and alpha one antitrypsin deficiency
__label__1	study interventions are Veliparib . childhood high grade cerebral astrocytoma diagnosis and patients receiving any of the following medications are not eligible for study entry
__label__1	study interventions are Ifosfamide . childhood central nervous system germinoma diagnosis and total bilirubin less_than doc times upper limit of normal uln
__label__1	study interventions are Thalidomide . diffuse intrinsic pontine glioma diagnosis and patients who have had thromboembolic event that is not line related are excluded
__label__1	study interventions are musculoskeletal complications management/prevention . recurrent adult lymphoblastic lymphoma diagnosis and current or previous bisphosphonate use
__label__1	study interventions are Immunoglobulin G . hodgkin lymphoma diagnosis and doc
__label__1	study interventions are Goserelin . metastatic breast cancer diagnosis and patients with discrete pulmonary parenchymal metastases are eligible provided their respiratory function is not compromised as result of disease
__label__1	study interventions are Albumin-Bound Paclitaxel . stage ivb uterine sarcoma diagnosis and serum glutamic oxaloacetic transaminase sgot and or serum glutamate pyruvate transaminase sgpt greater_than doc times the institutional upper limit of normal
__label__1	study interventions are Oxaliplatin . gastroesophageal cancer diagnosis and phase ii only
__label__1	study interventions are Dacarbazine . childhood high grade cerebral astrocytoma diagnosis and patients with uncontrolled seizures are not eligible for study entry
__label__1	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and oral birth control methods alone will not be considered adequate on this study because of the potential pharmacokinetic interaction between study drug and oral contraceptives
__label__1	study interventions are musculoskeletal complications management/prevention . recurrent neuroblastoma diagnosis and pre transplant weight greater_than equal_than two hundred and eighty lbs
__label__1	study interventions are Paclitaxel . recurrent fallopian tube carcinoma diagnosis and history of organ transplantation
__label__1	study interventions are Mycophenolic Acid . childhood grade iii lymphomatoid granulomatosis diagnosis and cardiac ejection fraction less_than forty
__label__1	study interventions are Albumin-Bound Paclitaxel . hormonal therapy with gonadotropin releasing hormone agonists or antagonists for prostate cancer hormone replacement therapy and palliative radiotherapy for bone metastases greater than greater_than two weeks prior to day one
__label__1	study interventions are Niacinamide . advanced hepatocarcinoma diagnosis and pregnant or breastfeeding women
__label__1	study interventions are Allopurinol . b cell lymphoma diagnosis and pregnant or breast feeding
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and subject has previously been treated for mm
__label__1	study interventions are Romidepsin . virally_mediated cancers and liposarcoma diagnosis and uncontrolled intercurrent illness
__label__1	study interventions are Capecitabine . colorectal cancer liver metastases diagnosis and body mass index greater_than thirty-five
__label__1	study interventions are Sorafenib . liver neoplasms diagnosis and pregnancy or breastfeeding
__label__1	study interventions are Bendamustine Hydrochloride . immunocytomas diagnosis and option of primary potential curative radiation therapy
__label__1	study interventions are Mycophenolate mofetil . adult diffuse large cell lymphoma diagnosis and patients for whom the best available donor is mismatched at both hla class and class ii
__label__1	study interventions are Paclitaxel . breast carcinoma diagnosis and prior to study entry any ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are Irinotecan . any other active malignancy or previous malignancies within the last five years except adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ
__label__1	study interventions are Liposomal doxorubicin . small intestine lymphoma diagnosis and history of significant cerebrovascular disease in the past three months or ongoing event with active symptoms or sequelae
__label__1	study interventions are Mycophenolate mofetil . refractory plasma cell myeloma diagnosis and donor
__label__1	study interventions are Vidarabine . recurrent childhood small noncleaved cell lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and known human immunodeficiency virus infection or known active acute or chronic viral hepatitis
__label__1	study interventions are Fludarabine phosphate . bladder carcinoma diagnosis and history of coronary revascularization or ischemic symptoms
__label__1	study interventions are Immunoglobulins . stage iv verrucous carcinoma of the oral cavity diagnosis and chronic treatment with systemic steroids or another immunosuppressive agent
__label__1	study interventions are Capecitabine . estrogen receptor positive tumor diagnosis and clinically significant electrocardiogram ecg abnormality including marked baseline prolongation of qt qtc interval time between the start of the q_wave and the end of the wave qt interval corrected for heart rate repeated demonstration of qtc interval greater than five hundred ms
__label__1	study interventions are Letrozole . metastatic breast cancer diagnosis and pleural or pericardial effusion
__label__1	study interventions are Etoposide . b cell lymphoma unclassifiable with features intermediate between diffuse large cell lymphoma and burkitt lymphoma diagnosis and study specific exclusions
__label__1	study interventions are Docetaxel . second primary malignancy except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin or prior malignancy treated more than five years ago without recurrence
__label__1	study interventions are NovoTTF-100A device . one five brain metastases from non small cell lung cancer diagnosis and infratentorial metastases
__label__1	study interventions are Mitogens . noncontiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and use of rabbit_antithymocyte globulin in the pretransplant conditioning regimen
__label__1	study interventions are Group-based Intervention . breast cancer survivors diagnosis and fasting triglycerides greater_than five hundred mg dl
__label__1	study interventions are Alisertib . advanced solid tumors diagnosis and known gastrointestinal gi disease or procedures that could interfere with the oral absorption or tolerance of alisertib
__label__1	study interventions are Pembrolizumab . carcinoma transitional cell diagnosis and has active autoimmune disease that has required systemic treatment in the past two years with use of disease modifying agents corticosteroids or immunosuppressive drugs
__label__1	study interventions are Everolimus . cholangiocarcinoma diagnosis and uncontrolled diabetes mellitus or hyperlipidaemia
__label__1	study interventions are Monitoring Device . stage iia colorectal cancer diagnosis and survivors must not be performing greater_than equal_than sixty minute min week of moderate vigorous physical activity
__label__1	study interventions are Fluorouracil . colorectal cancer diagnosis and primary surgeon indicates need for abdominoperineal apr at baseline
__label__1	study interventions are Cetuximab . metastatic colorectal cancer diagnosis and prior myocardial infarction severe renal insufficiency creatinine clearance thirtyml min
__label__1	study interventions are Bevacizumab . anaplastic oligo astrocytoma aoa diagnosis and craniotomy wound that has not sufficiently healed
__label__1	study interventions are Veliparib . nervous system neoplasms diagnosis and history of immediate or delayed hypersensitivity reaction or other contraindication to contrast agents including but not limited to gadolinium and iodine
__label__1	study interventions are Lenograstim . contiguous stage ii marginal zone lymphoma diagnosis and patient has greater_than doc uln total bilirubin
__label__1	study interventions are Antibodies, Monoclonal . childhood diffuse large cell lymphoma diagnosis and lansky play performance score less_than fifty for pediatric patients
__label__1	study interventions are Epirubicin . breast cancer diagnosis and low risk patient according to risk assessment
__label__1	study interventions are Doxorubicin . alveolar soft part sarcoma diagnosis and patients chronically receiving drugs that are known potent cypthreeafour inhibitors within seven days prior to study enrollment including but not limited to itraconazole clarithromycin erythromycin many non nucleoside_reverse transcriptase inhibitors nnrtis_diltiazem verapamil and grapefruit juice are not eligible
__label__1	study interventions are Vaccines . lung cancer diagnosis and systemic steroids at doses greater than ten mg day of prednisone or the equivalent
__label__1	study interventions are Antibodies . ovarian transitional cell carcinoma diagnosis and patients with gog performance status of three or four
__label__1	study interventions are Immunoglobulin G . recurrent fallopian tube carcinoma diagnosis and concomitant use of strong cypthreea inducers phenytoin rifampicin carbamazepine st
__label__1	study interventions are 131I-TM601 . melanoma diagnosis and examples of medical illnesses include but are not limited to the following
__label__1	study interventions are Gemcitabine . ovarian cancer diagnosis and vascular disease or bleeding problems
__label__1	study interventions are Placebo . squamous cell carcinoma of head and neck diagnosis and other concomitant antineoplastic treatment
__label__1	study interventions are Fludarabine phosphate . intraocular lymphoma diagnosis and donor
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iii adult diffuse large cell lymphoma diagnosis and pregnant women are excluded from this study because the effects of at one hundred and one on the developing human fetus are unknown but could potentially include teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with at one hundred and one breastfeeding should be discontinued if the mother is treated with at one hundred and one these potential risks may also apply to other agents used in this study
__label__1	study interventions are Trametinib . cancer diagnosis and has an eastern cooperative oncology group ecog performance status of zero or one
__label__1	study interventions are Assessment of therapy complications . stage iiia breast cancer diagnosis and current use of warfarin or other anticoagulants
__label__1	study interventions are Antibodies, Monoclonal . stage iii bladder urothelial carcinoma diagnosis and to any other site within twenty-eight days before the first dose of study treatment
__label__1	study interventions are Sirolimus . bladder cancer diagnosis and patients who have undergone major surgery within four weeks prior to starting study drug open biopsy or significant traumatic injury or who have not recovered from the side effects of any of the above
__label__1	study interventions are Prednisone . prostate cancer diagnosis and history of acute or chronic gastrointestinal bleeding within the last two years inflammatory bowel disease or other abnormal bleeding tendency
__label__1	study interventions are Immunoglobulins . stage iv renal cell cancer diagnosis and patients who have had systemic biologic therapy or radiotherapy within two weeks prior to entering the study or those who have not recovered from adverse events related to their prior therapy
__label__1	study interventions are VB-111 . radiotherapy or chemotherapy less_than four weeks prior to baseline visit concurrent and or prior therapy with octreotide will be allowed provided tumor progression on this therapy has been demonstrated concurrent and or prior therapy with biphosphonates will be allowed
__label__1	study interventions are Cyclophosphamide . diffuse tumors by mammography that would not be surgically amenable to lumpectomy
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent cell non hodgkin lymphoma diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are Melphalan . multiple myeloma and plasma cell neoplasm diagnosis and female patients who are pregnant or lactating
__label__1	study interventions are Celecoxib . colorectal cancer diagnosis and discrete gastric or duodenal ulcer of size greater_than five mm patients with helicobacter_pylori related peptic ulcers of greater_than five mm at the time of the baseline endoscopy will become eligible upon endoscopically documented successful treatment of helicobacter_pylori and of the ulcer s
__label__1	study interventions are Lenograstim . stage ib breast cancer diagnosis and cardiac arrhythmia requiring medication
__label__1	study interventions are Laboratory Biomarker Analysis . stage iv breast cancer diagnosis and allergy to iodine note
__label__1	study interventions are Valganciclovir . stage iv adult cell leukemia lymphoma diagnosis and concomitant anti graft versus host disease gvd treatment includes in vivo cell depletion
__label__1	study interventions are Laboratory Biomarker Analysis . glioma diagnosis and stratum four
__label__1	study interventions are Paclitaxel . primary peritoneal serous adenocarcinoma diagnosis and patients with clinically significant proteinuria urine protein should be screened by urine protein creatinine ratio upcr the upcr has been found to correlate_directly with the amount of protein excreted in twenty-four hour urine collection specifically upcr of doc is equivalent to doc gram of protein in twenty-four hour urine collection obtain at least four ml of random urine sample in sterile container does not have to be twenty-four hour urine send sample to lab with request for urine protein and creatinine levels separate requests the lab will measure protein concentration mg dl and creatinine concentration mg dl the upcr is derived as follows
__label__1	study interventions are Antibodies, Monoclonal . composite lymphoma diagnosis and has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Fludarabine . stage iv adult diffuse mixed cell lymphoma diagnosis and all patients receiving antifungal therapy voriconazole posaconazole or fluconazole and who are then randomized to arm three must have rapamycin reduced according to the standard practice of antifungal therapy guidelines
__label__1	study interventions are Tamoxifen . er positive breast cancer diagnosis and life threatening disease requiring quick response eg extensive hepatic or pulmonary involvement
__label__1	study interventions are TPI 287 . prostate cancer diagnosis and active infection or with fever greater than or equal to three doc degrees centigrade within three days of first scheduled day of dosing
__label__1	study interventions are Irinotecan . malignant gastrointestinal neoplasm diagnosis and neuropathy grade two or greater by nci ctcae v
__label__1	study interventions are Dasatinib . recurrent adult brain neoplasm diagnosis and patients who require concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour are ineligible
__label__1	study interventions are TaTME . rectal carcinoma diagnosis and planned synchronous abdominal organ resections
__label__1	study interventions are Folic Acid . stage iii pancreatic cancer diagnosis and patients with active duodenal ulcer or bleeding or history of gastrointestinal fistula or perforation or other significant bowel problems severe nausea vomiting inflammatory bowel disease and significant bowel resection
__label__1	study interventions are EPIC SF-12 Questionnaire . prostate adenocarcinoma diagnosis and unable to obtain doc or doc multiparametric mri of the pelvis and prostate with contrast
__label__1	study interventions are Thiotepa . primary non hodgkin lymphoma of the central nervous system diagnosis and women with childbearing potential without sufficient contraception
__label__1	study interventions are Epirubicin . stage iv adult soft tissue sarcoma diagnosis and patients with known brain metastases patients with neurological symptoms must undergo computed tomography ct scan magnetic resonance imaging mri of the brain to exclude brain metastases
__label__1	study interventions are Tinzaparin . uncontrolled severe intercurrent illness including ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Ferrosoferric Oxide . adult brain glioblastoma diagnosis and patients with renal insufficiency glomerular filtration rate gfr less_than fifty
__label__1	study interventions are Sirolimus . patients who have history of another primary malignancy less_than three years with the exception of non melanoma skin cancer and carcinoma in situ of uterine cervix
__label__1	study interventions are Cetuximab . stage iva squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and prior treatment with sorafenib or cetuximab
__label__1	study interventions are Carboplatin . mantle cell lymphoma mcl blastoid_variant diagnosis and suspicion that patient compliance will be poor especially that rules for effective contraception will not be followed
__label__1	study interventions are Dexamethasone . myeloma diagnosis and pregnant or breast feeding females
__label__1	study interventions are Ado-trastuzumab emtansine . metastatic breast cancer diagnosis and current severe uncontrolled systemic disease
__label__1	study interventions are Cisplatin . history of any other cancer except non melanoma skin cancer or carcinoma in situ of the cervix unless in complete remission and off all therapy for that cancer for at least five years
__label__1	study interventions are Mycophenolic Acid . non hodgkin lymphoma diagnosis and evidence of relapse or progression of disease after transplantation
__label__1	study interventions are Immunoglobulin G . ovarian sex cord tumor with annular_tubules diagnosis and myocardial infarction or unstable angina within six months prior to registration
__label__1	study interventions are Valproic Acid . glioblastoma multiforme diagnosis and it is strongly recommended that neurology consult be obtained to enable discontinuation of all anti convulsant other than vpa whenever possible
__label__1	study interventions are Bevacizumab . colorectal cancer diagnosis and active cardiac disease
__label__1	study interventions are Isophosphamide mustard . osteosarcoma diagnosis and men or women of childbearing potential unless effective methods of contraception are used during study treatment and for at least seven days after the last mifamurtide dose see section doc informed consent
__label__1	study interventions are Bevacizumab . metastatic colorectal cancer diagnosis and absolute neutrophils count anc less_than doc one hundred and nine l
__label__1	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the hypopharynx diagnosis and major surgery within the past four weeks prior to dosing with cetuximab or vtx two thousand, three hundred and thirty-seven
__label__1	study interventions are Immunoglobulins . adult nodular sclerosis hodgkin lymphoma diagnosis and previous treatment with brentuximab_vedotin or any other prior anti cdthirty based antibody therapy
__label__1	study interventions are Dexamethasone 21-phosphate . adult cell leukemia lymphoma diagnosis and history of allogeneic transplant
__label__1	study interventions are Antibodies, Monoclonal . stage iiib breast cancer diagnosis and may not be receiving any other investigational agents
__label__1	study interventions are Peginterferon alfa-2b . diffuse intrinsic pontine glioma diagnosis and patients with known hypersensitivity to interferon alpha
__label__1	study interventions are Cyclosporine . recurrent grade two follicular lymphoma diagnosis and patients who are homozygous at the mismatched major histocompatibility_complex mhc class locus
__label__1	study interventions are Dacarbazine . glioblastoma multiforme of brain diagnosis and active infection or serious intercurrent medical illness
__label__1	study interventions are Antibodies, Monoclonal . malignant pancreatic glucagonoma diagnosis and patients on anticoagulant therapy
__label__1	study interventions are Dexamethasone acetate . lymphoma non hodgkin diagnosis and patients with history of other malignancies except
__label__1	study interventions are Rituximab . multiple myeloma diagnosis and pregnant women are excluded from this study because palifermin has been shown to be embrytoxic and fetotoxic in animal studies
__label__1	study interventions are laboratory biomarker analysis . recurrent adult hodgkin lymphoma diagnosis and cardiovascular
__label__1	study interventions are Fludarabine . serum total bilirubin greater_than doc uln except in case of gilbert syndrome and documented liver involvement by lymphoma
__label__1	study interventions are Esomeprazole . colorectal neoplasms diagnosis and known hypersensitivity to any of the study drugs study drug classes or excipients in the formulation
__label__1	study interventions are Bevacizumab . colon cancer diagnosis and ore biopsy or other minor procedure excluding placement of vascular access device less_than seven days before randomization
__label__1	study interventions are Docetaxel . pancreatic cancer diagnosis and unwillingness or inability to comply with the study protocol for any other reason
__label__1	study interventions are Daunorubicin . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and pregnant or lactating females are ineligible
__label__1	study interventions are Cediranib . stage iv childhood small noncleaved cell lymphoma diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Temozolomide . grade four malignant glioma diagnosis and history of intracranial abscess within six months prior to first study treatment
__label__1	study interventions are Belinostat . cutaneous cell lymphoma diagnosis and clinically significant central nervous system disorders with altered mental status or psychiatric disorders precluding understanding of the informed consent process and or completion of the necessary studies
__label__1	study interventions are BKM120 . glioblastoma diagnosis and phenobarbital phenytoin fosphenytoin primidone carbamazepine oxcarbazepine eslicarbazepine rufinamide and felbamate
__label__1	study interventions are Glycine . lymphomas diagnosis and infection requiring systemic antibiotic therapy or other serious infection within fourteen days before study enrollment
__label__1	study interventions are Acetaminophen . uterine cervical cancer diagnosis and severe undernutrition
__label__1	study interventions are Hydroxocobalamin . human mammary carcinoma diagnosis and dementia or other altered mental status that would prevent the patient from understanding and giving informed consent or limit her ability to follow the study requirements
__label__1	study interventions are management of therapy complications . noncontiguous stage ii marginal zone lymphoma diagnosis and any artificial_limbs
__label__1	study interventions are musculoskeletal complications management/prevention . stage iiib breast cancer diagnosis and unwilling or unable to follow protocol requirements
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and serum total bilirubin greater_than doc mg dl
__label__1	study interventions are Immunoglobulins . systemic anaplastic large cell lymphoma diagnosis and medication with known risk of prolonging the qt interval or inducing torsades de pointes
__label__1	study interventions are Panobinostat . multiple myeloma diagnosis and women who are pregnant or breast feeding or women of childbearing potential wocbp not using an effective method of birth control
__label__1	study interventions are Vaccines . stage iiib primary peritoneal cavity cancer diagnosis and other serious illnesses serious infections requiring antibiotics bleeding disorders
__label__1	study interventions are Immunoglobulins . recurrent fallopian tube carcinoma diagnosis and invasive procedures defined as follows
__label__1	study interventions are Oxaliplatin . gastric cancer diagnosis and intolerable operation or neoadjuvant chemotherapy
__label__1	study interventions are Antibodies . sarcoma diagnosis and patients who are pregnant
__label__1	study interventions are Cisplatin . esophageal neoplasms diagnosis and patients with history of severe hypersensitivity reaction to taxotere or other drugs formulated with polysorbate eighty
__label__1	study interventions are Liposomal doxorubicin . hepatocellular carcinoma diagnosis and impaired clotting test platelet count less_than five one hundred and four mmthree pt inr greater_than doc
__label__1	study interventions are Survivor Survey (3): 3 Month Post-Visit . cancer diagnosis and not providing services for eligible survivors
__label__1	study interventions are Thalidomide . recurrent adult immunoblastic large cell lymphoma diagnosis and known hypersensitivity to thalidomide
__label__1	study interventions are Mycophenolate mofetil . hematopoietic lymphoid cancer diagnosis and five comorbidity points on the hct ci index see appendix b
__label__1	study interventions are Dacarbazine . recurrent childhood pineoblastoma diagnosis and sexually active patients of childbearing potential must agree to use an effective method of contraception during the study and for at least six months after the completion of bevacizumab therapy
__label__1	study interventions are Antibodies, Monoclonal . stage iiic breast cancer diagnosis and pregnancy testing must be performed within two weeks prior to randomization according to institutional standards for women of childbearing potential
__label__1	study interventions are Sirolimus . refractory multiple myeloma diagnosis and impaired cardiac function or clinically significant cardiac diseases including any one of the following
__label__1	study interventions are Rituximab . recurrent adult diffuse mixed cell lymphoma diagnosis and prior to study entry any electrocardiogram ecg abnormality at screening has to be documented by the investigator as not medically relevant
__label__1	study interventions are GM-CSF . malignant melanoma diagnosis and no concurrent antineoplastic treatments including chemotherapy biologic response modifiers radiation vaccines or other experimental therapies
__label__1	study interventions are Mycophenolate mofetil . refractory small lymphocytic lymphoma diagnosis and patients with fungal infection and radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Eicosapentanoic acid and docosahexanoic acid . colorectal adenomatous polyps diagnosis and coronary artery disease or congestive heart failure
__label__1	study interventions are Vidarabine . stage ii childhood large cell lymphoma diagnosis and any current central nervous system cns involvement with disease refractory to intrathecal chemotherapy
__label__1	study interventions are Dexamethasone 21-phosphate . nasal type extranodal nk cell lymphoma diagnosis and other uncontrollable medical condition that may that may interfere the participation of the study
__label__1	study interventions are Bevacizumab . glioblastoma diagnosis and significant active systemic illness including infections requiring intravenous antibiotics
__label__1	study interventions are Etoposide phosphate . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and in addition if negative for hbsag but hbcab positive regardless of hbsab status hb dna test will be performed and if positive the subject will be excluded if unable to tolerate and or receive anti hepatitis therapy
__label__1	study interventions are Fluorouracil . hepatocellular carcinoma non resectable diagnosis and if the alt ast level exceeds doc five times the normal upper limit in liver function tests
__label__1	study interventions are Oxaliplatin . intrahepatic cholangiocarcinoma diagnosis and prior external beam radiation therapy to the liver
__label__1	study interventions are Anastrozole . other concurrent anticancer agents or therapies
__label__1	study interventions are placebo . recurrent squamous cell carcinoma of the lip and oral cavity diagnosis and presence of distant metastatic disease
__label__1	study interventions are Topoisomerase I Inhibitors . recurrent small cell lung carcinoma diagnosis and major surgery less_than four weeks or minor surgery talc pleurodesis excisional biopsy etc less_than two weeks prior to the first day of study defined treatment
__label__1	study interventions are Liposomal doxorubicin . endometrial cancer diagnosis and radiotherapy including pr negative or post operative brachytherapy within four weeks prior to randomization
__label__1	study interventions are Mycophenolate mofetil . stage childhood anaplastic large cell lymphoma diagnosis and positive serology for toxoplasma_gondii on treatment or with evidence of active infection
__label__1	study interventions are Antibodies, Monoclonal . advanced or metastatic medically or surgically unresectable clear cell renal cell carcinoma diagnosis and any active known or suspected autoimmune disease
__label__1	study interventions are Pemetrexed . non small cell lung cancer diagnosis and pregnant or nursing women are not eligible to participate in this trial due to the potential teratogenic or abortifacient effects of the study drug on the fetus or nursing infant
__label__1	study interventions are Laboratory Biomarker Analysis . stage iia skin melanoma diagnosis and any condition that excludes sln biopsy as the standard of care lymphadenectomy indicated
__label__1	study interventions are Albumin-Bound Paclitaxel . gastroesophageal junction adenocarcinoma diagnosis and the patient has undergone major surgery within twenty-eight days prior to enrollment or subcutaneous venous access device placement within seven days prior to enrollment
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and valproic acid
__label__1	study interventions are Paclitaxel . recurrent ovarian cancer diagnosis and cardiac arrhythmias requiring anti arrhythmic medications except for atrial fibrillation that is well controlled with anti arrhythmic medication
__label__1	study interventions are Cyclophosphamide . stage ii non contiguous adult diffuse large cell lymphoma diagnosis and unable to comply with the requirements of the protocol or unable to provide adequate informed consent in the opinion of the principal investigator
__label__1	study interventions are Levoleucovorin . diffuse adenocarcinoma of the stomach diagnosis and any history of stroke or transient ischemic attack
__label__1	study interventions are Prednisone . recurrent lymphoblastic leukemia lymphoma diagnosis and hepatitis surface antigen or core antibody positive
__label__1	study interventions are Standard . colon cancer diagnosis and prior surgical resection of any portion of colon
__label__1	study interventions are Cetuximab . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and major active psychiatric disorders which would limit compliance
__label__1	study interventions are Antibodies, Monoclonal . stage iva hodgkin lymphoma diagnosis and lactating females who plan to breastfeed
__label__1	study interventions are Interleukin-12 . stage iv squamous cell carcinoma of the larynx diagnosis and any other major illness which in the investigator judgment will substantially increase the risk associated with the patient participation in this study
__label__1	study interventions are Sirolimus . endometrial adenosquamous carcinoma diagnosis and myocardial infarction or unstable angina within six months of the first date of study therapy
__label__1	study interventions are Gemcitabine . metastatic breast cancer diagnosis and patients using non substitutable drugs that are known to prolong qt interval or induce torsades de pointes when they are supposed to be treated with vandetanib azdfive thousand, three hundred and sixty-three or azdeight thousand, nine hundred and thirty-one
__label__1	study interventions are Epothilones . non small cell lung cancer diagnosis and patients with evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are HylaCare . breast cancer diagnosis and planned relocation which would make follow up visits impossible during the course of the study
__label__1	study interventions are Laparotomy+ HIPEC +/- CRS . colorectal carcinoma diagnosis and childs or cirrhosis or with evidence of severe portal hypertension by history endoscopy or radiologic studies or with evidence of moderate to severe ascites
__label__1	study interventions are Sirolimus . stage iva uterine sarcoma diagnosis and patients with pre existing clinically significant pulmonary infiltrates of unknown origin
__label__1	study interventions are Rituximab . non hodgkin lymphoma diagnosis and prior anaphylactoid or other serious reaction to rituximab that resulted in hospitalization or discontinuation of therapy or both
__label__1	study interventions are Exercise . cancer diagnosis and not have engaged in regular exercise in the past year five positive days wk twenty positive min three positive months
__label__1	study interventions are Trastuzumab . gastric cancer diagnosis and is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial starting with the pre screening or screening visit through one hundred and twenty days after the last dose of trial treatment
__label__1	study interventions are Paclitaxel . small cell lung cancer diagnosis and last steroid dose must have been given at least two weeks prior to the first vaccine administration
__label__1	study interventions are Cyclosporine . refractory childhood hodgkin lymphoma diagnosis and patients with rapidly progressive intermediate or high grade nhl
__label__1	study interventions are Dalteparin . gynecologic neoplasms diagnosis and vascular injury
__label__1	study interventions are Antibodies, Monoclonal . advanced solid tumors diagnosis and major surgery excluding biopsy or significant trauma within four weeks prior to enrollment
__label__1	study interventions are CI-1040 . breast neoplasms diagnosis and unstable medical condition
__label__1	study interventions are Maleic acid . ovarian clear cell adenocarcinoma diagnosis and patients with the following risk factors should have baseline cardiac function assessment
__label__1	study interventions are Mycophenolate mofetil . noncontiguous stage ii adult diffuse mixed cell lymphoma diagnosis and uncontrolled viral or bacterial infection at the time of study enrollment
__label__1	study interventions are Metformin . stage breast carcinoma diagnosis and if participants are consuming any of these items and would like to participate in this study then thirty day washout period will be required
__label__1	study interventions are Androgens . prostatic neoplasms diagnosis and prior radiation therapy to the prostate
__label__1	study interventions are Dasatinib . metastatic pancreatic adenocarcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib erlotinib or gemcitabine
__label__1	study interventions are management of therapy complications . stage iv ovarian germ cell tumor diagnosis and currently treated with therapeutic dose of anti coagulation for recent pulmonary embolism or deep vein thrombosis
__label__1	study interventions are Sorafenib . carcinoma renal cell diagnosis and hypersensitivity to sorafenib or to any of the excipients
__label__1	study interventions are CAR-T cell . colorectal cancer metastatic diagnosis and pregnant or lactating women
__label__1	study interventions are Etoposide . stage ii childhood anaplastic large cell lymphoma diagnosis and cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour substrates with narrow therapeutic indices
__label__1	study interventions are Irinotecan . colorectal cancer diagnosis and participation in clinical trials with investigational agents within thirty days before start of the treatment in study
__label__1	study interventions are Cyclophosphamide . triple negative breast cancer diagnosis and has known history of or any evidence of active non infectious pneumonitis requiring treatment with steroids has history of or any evidence of active interstitial lung disease
__label__1	study interventions are Vitamin B Complex . recurrent primary peritoneal carcinoma diagnosis and co morbid systemic illnesses or other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
__label__1	study interventions are Veliparib . fallopian tube carcinosarcoma diagnosis and patients with gog performance status of three or four
__label__1	study interventions are Aldesleukin . recurrent pleural malignant mesothelioma diagnosis and hiv or htlv infection
__label__1	study interventions are Bevacizumab . anaplastic ependymoma diagnosis and history of abdominal fistula or gastrointestinal perforation within six months prior to day one
__label__1	study interventions are Camptothecin . esophageal cancer diagnosis and peripheral neuropathy greater_than grade one
__label__1	study interventions are laboratory biomarker analysis . stage iii adult burkitt lymphoma diagnosis and patients who have received gonadotropin release hormone agonist or antagonist lupron prior to study entry are not eligible
__label__1	study interventions are Cisplatin . esophageal neoplasms diagnosis and severe cardiac comorbidities including congestive heart failure uncontrolled cardiac arrhythmia unstable angina pectoris myocardial infarction within six months severe heart valve disease or intractable hypertension
__label__1	study interventions are Stereotactic Body Radiation Therapy . psychological impact of cancer diagnosis and phase ii
__label__1	study interventions are Calcitonin . thyroid carcinoma diagnosis and unwillingness or inability to comply with study and follow up procedures
__label__1	study interventions are Irinotecan . stage iv gallbladder cancer diagnosis and history of interstitial lung disease idiopathic pulmonary fibrosis silicosis or connective tissue disorders
__label__1	study interventions are Antibodies . recurrent mantle cell lymphoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one registration
__label__1	study interventions are Histone Deacetylase Inhibitors . recurrent adult immunoblastic lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to mlneight thousand, two hundred and thirty-seven including but not limited to established allergic reaction to benzodiazepines
__label__1	study interventions are Vaccines . colorectal neoplasms diagnosis and immunosuppressant treatment
__label__1	study interventions are Antibodies, Monoclonal . salivary gland squamous cell carcinoma diagnosis and uncontrolled inter current illness pre planned surgery or procedure requiring hospitalization during the study period or any other condition or circumstance that could interfere with adherence to the study procedures or requirements or otherwise compromise the study objectives
__label__1	study interventions are Fludarabine . aggressive non hodgkin lymphoma diagnosis and positive cross match exists between the donor and recipient
__label__1	study interventions are Thalidomide . stage ii small lymphocytic lymphoma diagnosis and pregnant females
__label__1	study interventions are Hormones . progesterone receptor negative breast cancer diagnosis and patient weight greater than four hundred lbs exceeds weight limit for tomograph table
__label__1	study interventions are Antibodies, Monoclonal . stage iii pancreatic cancer diagnosis and amiodarone quinidine
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and participation in another clinical trial
__label__1	study interventions are Androgens . tumors diagnosis and known hypocalcemia
__label__1	study interventions are Antibodies . fallopian tube endometrioid adenocarcinoma diagnosis and known hypersensitivity to chinese_hamster ovary cell products or other recombinant human antibodies
__label__1	study interventions are MK-8628 Dose 3 . nut midline carcinoma nmc diagnosis and have other serious illness or medical condition such as active infection unresolved bowel obstruction psychiatric disorders or cerebrovascular accident within one year of study start
__label__1	study interventions are Podophyllotoxin . refractory mediastinal thymic large cell cell lymphoma diagnosis and subjects with hepatitis antibody will be eligible provided that they do not have elevated liver transaminases or other evidence of active hepatitis
__label__1	study interventions are Paclitaxel . gastric carcinoma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Trastuzumab . recurrent prostate cancer diagnosis and known seropositive for hepatitis surface antigen
__label__1	study interventions are Fludarabine . recurrent adult diffuse mixed cell lymphoma diagnosis and adult
__label__1	study interventions are Dexamethasone acetate . incidence of gastrointestinal disease that may significantly alter the absorption of pomalidomide
__label__1	study interventions are JM 3100 . recurrent adult immunoblastic large cell lymphoma diagnosis and be currently enrolled in another investigational protocol
__label__1	study interventions are Carboplatin . breast neoplasms diagnosis and participants with the following criteria were excluded from this study
__label__1	study interventions are Leukotriene Antagonists . breast cancer diagnosis and ast sgot greater_than doc institutional uln and alt sgpt greater_than doc institutional uln
__label__1	study interventions are Everolimus . non clear cell renal cell cancer diagnosis and pulmonary function tests need only to be performed if abnormal pulmonary function present in medical history
__label__1	study interventions are Paclitaxel . adenocarcinoma of the proximal stomach diagnosis and known positive test for human immunodeficiency virus infection hepatitis virus acute or chronic active hepatitis infection
__label__1	study interventions are Antibodies, Monoclonal . has received prior therapy for hodgkin lymphoma except as noted above
__label__1	study interventions are Beta-lapachone . adenocarcinoma diagnosis and have any other severe concurrent disease which in the judgment of the investigator would make the patient inappropriate for entry into this study
__label__1	study interventions are Irinotecan . colorectal cancer diagnosis and patients who have received previous irinotecan based therapy
__label__1	study interventions are behavioral, psychological or informational intervention . stage iiia primary peritoneal cavity cancer diagnosis and concurrent diagnosis of organic brain syndrome dementia mental retardation or significant sensory deficit
__label__1	study interventions are Sorafenib . metastatic breast cancer diagnosis and hemorrhage or bleeding event greater_than grade three within four weeks of the
__label__1	study interventions are Angiogenesis Inhibitors . metastatic colon rectum cancer diagnosis and iud oral contraceptives depo_provera or norplant
__label__1	study interventions are Camptothecin . gliosarcoma diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within six months prior to first avastin infusion during xrt temodar
__label__1	study interventions are Dovitinib (TKI258) . tumor pathway activations_inhibited by dovitinib diagnosis and acute or chronic infection as depicted by positive hcv rna testing note
__label__1	study interventions are Vidarabine . stage iii childhood anaplastic large cell lymphoma diagnosis and infection with hiv
__label__1	study interventions are Lenalidomide . advanced cancer diagnosis and patient with history of psychiatric diagnosis of depression or clinical diagnosis of depression as determined by the treating physician or hospital anxiety depression scale total score of thirteen or greater
__label__1	study interventions are MLN8237 . prostate adenocarcinoma plus greater_than fifty immunohistochemical staining for neuroendocrine markers diagnosis and requirement for constant administration of proton_pump inhibitor htwo antagonist or pancreatic enzymes
__label__1	study interventions are Vincristine . stage iii adult diffuse large cell lymphoma diagnosis and pregnant females
__label__1	study interventions are Trovax . clear cell renal carcinoma diagnosis and previous history of major psychiatric disorder requiring hospitalization or any current psychiatric disorder that would impede the patient ability to provide informed consent or to comply with the protocol
__label__1	study interventions are Sunitinib . recurrent prostate cancer diagnosis and subjects with history of severe hypersensitivity reaction to docetaxel or other drugs formulated with polysorbate eighty will be excluded
__label__1	study interventions are Oxaliplatin . rectal cancer diagnosis and peg tube tube or external biliary stents
__label__1	study interventions are Albumin-Bound Paclitaxel . esophageal cancer diagnosis and patients with history of seizures or are receiving phenytoin phenobarbital or other antiepileptic prophylaxis
__label__1	study interventions are Folic Acid . recurrent colon carcinoma diagnosis and history of abdominal fistula gastrointestinal perforation or intra abdominal abscess equal_than less_than six months prior to registration
__label__1	study interventions are Tacrolimus . recurrent refractory childhood hodgkin lymphoma diagnosis and adult
__label__1	study interventions are Prednisolone acetate . diffuse large cell lymphoma diagnosis and hypersensitivity or contraindication to any of the study drugs as stated in the smpcs for each of the study drugs
__label__1	study interventions are Sirolimus . unspecified childhood solid tumor protocol specific diagnosis and patients who are currently receiving enzyme inducing anticonvulsants are not eligible
__label__1	study interventions are Carboplatin . stage iiia gastric cancer diagnosis and pre existing motor or sensory neurotoxicity greater than common terminology criteria for adverse events ctcae grade one
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and patients with any significant history of non compliance to medical regimens or with inability to grant reliable informed consent
__label__1	study interventions are Cetuximab . squamous cell carcinoma of the head and neck diagnosis and blood pressure must be re assessed on two occasions that are separated by minimum of one hour on each of these occasions the mean of three readings from each assessment must be less_than one hundred and forty ninety mmhg for patient to be eligible for this study
__label__1	study interventions are Cyclophosphamide . stage iv adult diffuse small cleaved cell lymphoma diagnosis and patients who have not recovered from adverse events due to agents administered more than four weeks earlier or
__label__1	study interventions are alpha-Tocopherol . non small cell lung cancers diagnosis and pregnant women or lactating women
__label__1	study interventions are Temozolomide . malignant melanoma diagnosis and active hepatitis or hepatitis c
__label__1	study interventions are Cyclosporine . recurrent adult diffuse mixed cell lymphoma diagnosis and donor
__label__1	study interventions are Panobinostat . recurrent adult cell leukemia lymphoma diagnosis and thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past six months
__label__1	study interventions are The Cancer Home Life Intervention . cancer diagnosis and live in nursing home or hospice
__label__1	study interventions are Olaparib . prostate cancer diagnosis and doc
__label__1	study interventions are Lenograstim . stage ib breast cancer diagnosis and uncontrolled hypertension diastolic greater than one hundred mm hg or systolic greater_than two hundred mm hg
__label__1	study interventions are Temozolomide . glioblastoma multiforme diagnosis and significant cardiac disease including any of the following
__label__1	study interventions are Concurrent Boost RT . breast cancer diagnosis and unable to commence radiation therapy within twelve weeks of the last surgical procedure on the breast
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiic breast cancer diagnosis and not pregnant or nursing
__label__1	study interventions are Isoflurane . pancreatic neoplasms diagnosis and breast feeding
__label__1	study interventions are Sorafenib . rhabdomyosarcoma and other soft tissue sarcomas diagnosis and johns wort
__label__1	study interventions are Liposomal doxorubicin . cancer diagnosis and first line chemotherapy completed at least one month prior to start of treatment
__label__1	study interventions are N-monoacetylcystine . stage lymphoepithelioma of the nasopharynx diagnosis and any of the following
__label__1	study interventions are Laboratory Biomarker Analysis . stage iiia primary peritoneal cancer diagnosis and therapy with monoamine_oxidase inhibitors maois and selective serotonin_reuptake inhibitor ssris within the last four weeks or history of serotonin syndrome
__label__1	study interventions are Cyclosporins . recurrent marginal zone lymphoma diagnosis and eligible for autologous transplantation
__label__1	study interventions are Ramucirumab . the patient has concurrent active malignancy other than treated non melanoma skin cancers or in situ neoplasm patient with prior history of malignancy is eligible provided that they have been free of disease for greater_than three years
__label__1	study interventions are PF-3512676 . lymphoma non hodgkin diagnosis and in this case note to file must be generated to explain the inclusion of the patient
__label__1	study interventions are Gabapentin . rectum cancer diagnosis and history of constipation
__label__1	study interventions are Antibodies . lung carcinoid tumor diagnosis and any of the following as this regimen may be harmful to developing fetus or nursing child
__label__1	study interventions are Antibodies, Monoclonal . recurrent non small cell lung carcinoma diagnosis and active tuberculosis
__label__1	study interventions are Bevacizumab . prior systemic chemotherapy for advanced colorectal cancer fluorouracil containing adjuvant therapy in previous six months
__label__1	study interventions are Bevacizumab . recurrent childhood large cell lymphoma diagnosis and clinically significant peripheral vascular disease
__label__1	study interventions are TSR-011 . solid tumors diagnosis and patient must stop taking any prescription over the counter or herbal remedy known to be an inhibitor or inducer of cypthreeafour five
__label__1	study interventions are Everolimus . recurrent renal cell carcinoma diagnosis and concomitant systemic treatment with corticosteroids anti histamine or non steroidal anti inflammatory drugs aspirin greater_than three hundred and twenty-five mg specific cyclooxygenase_cox two inhibitors are permitted
__label__1	study interventions are psychosocial assessment and care . recurrent mantle cell lymphoma diagnosis and does not complete the baseline assessment through the hads hospital anxiety and depression scale
__label__1	study interventions are Angiogenesis Inhibitors . central nervous system neoplasms diagnosis and initiation or adjustment of antihypertensive medication is permitted prior to study entry
__label__1	study interventions are Antibodies, Monoclonal . non hodgkin lymphomas diagnosis and if hbcab positive and hbsab positive which is indicative of past infection subject can be included
__label__1	study interventions are Fludarabine . stage iv small lymphocytic lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than thirty total lung capacity tlc less_than thirty forced expiratory volume in one second fevone less_than thirty and or receiving supplementary continuous oxygen the fhcrc principal investigator pi of the study must approve enrollment of all patients with pulmonary nodules
__label__1	study interventions are Etoposide phosphate . unspecified childhood solid tumor protocol specific diagnosis and no other concurrent investigational agents
__label__1	study interventions are V503 . papilloma viral infection diagnosis and subject has had fever within the twenty-four hour period prior to the day one vaccination
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and patient has known hypersensitivity to ribociclib or any of its excipients or prior treatment with cdk four six inhibitor
__label__1	study interventions are Cyclophosphamide . pancreatic cancer diagnosis and patients who have known history of infection with hiv hepatitis or hepatitis c
__label__1	study interventions are Pembrolizumab . advanced cancers diagnosis and if subject received major surgery they must have recovered adequately from the toxicity and or complications from the intervention prior to starting therapy
__label__1	study interventions are 3-Iodobenzylguanidine . pheochromocytoma diagnosis and subjects will be excluded if any of the following conditions are observed
__label__1	study interventions are Cisplatin . digestive system neoplasms diagnosis and pregnant or lactating patients
__label__1	study interventions are anti-CD20-CAR vector-transduced autologous T cells . stage iv grade two follicular lymphoma diagnosis and feasibility assessment during screening demonstrates less_than thirty transduction of target lymphocytes or insufficient expansion less_than five fold in response to cdthree cdtwo8 costimulation
__label__1	study interventions are Paclitaxel . endometrial cancer diagnosis and patients with zubrod status of three or greater
__label__1	study interventions are Antibodies, Monoclonal . metastatic colorectal cancer diagnosis and history of abdominal fistula gastrointestinal perforation abdominal abscess within six months prior to enrollment
__label__1	study interventions are Antibodies, Monoclonal . metastatic clear cell renal cell carcinoma diagnosis and psychiatric illness social situations that would limit consenting and compliance with study requirements
__label__1	study interventions are Focus Group Sessions . colon cancer diagnosis and participants who don speak english
__label__1	study interventions are Dexamethasone 21-phosphate . diagnosed or treated for another malignancy within three years prior to enrollment with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin an in situ malignancy or low risk prostate cancer after curative therapy
__label__1	study interventions are Thalidomide . recurrent adult diffuse mixed cell lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Dalteparin . asymptomatic routine post operative blood products in post surgical cavity are not an exclusion
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv ampulla of vater cancer diagnosis and major surgery within four weeks
__label__1	study interventions are Antibodies, Monoclonal . stage ivb squamous cell carcinoma of the larynx diagnosis and potassium less_than doc mmol or greater_than six mmol despite intervention to normalize levels
__label__1	study interventions are Vaccines . male breast cancer diagnosis and patients who are pregnant or breast feeding
__label__1	study interventions are Antibodies . fallopian tube endometrioid adenocarcinoma diagnosis and if participant received major surgery they must have recovered adequately from the toxicity and or complications from the intervention prior to starting therapy and has to be at least twenty-eight days after the surgery
__label__1	study interventions are Fludarabine phosphate . stage childhood large cell lymphoma diagnosis and fungal infections with radiological progression after receipt of amphotericin or active triazole for greater than one month
__label__1	study interventions are Niacinamide . carcinoma renal cell diagnosis and significant cardiovascular disease defined as congestive heart failure new york heart association class ii ii or iv
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma thymic diagnosis and lvef less_than fifty
__label__1	study interventions are Fluorouracil . colorectal adenocarcinoma diagnosis and patients positive for human immunodeficiency virus hiv are not excluded from this study but hiv positive patients must have
__label__1	study interventions are Levoleucovorin . signet ring adenocarcinoma of the colon diagnosis and history of arterial thromboembolic events
__label__1	study interventions are Dexamethasone . any currently active second malignancy other than non melanoma skin cancer
__label__1	study interventions are Doxorubicin . tubular breast cancer stage iii diagnosis and major surgery within the last twenty-eight days or anticipation of the need for major surgery during study treatment with bevacizumab
__label__1	study interventions are Capecitabine . stage iv cutaneous cell non hodgkin lymphoma diagnosis and baseline qtcf greater_than four hundred and fifty msec
__label__1	study interventions are Bevacizumab . advanced colorectal cancer diagnosis and any of the following serum chemistry abnormalities
__label__1	study interventions are Carboplatin . neoplasms diagnosis and participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial
__label__1	study interventions are Oxaliplatin . metastatic colorectal cancer diagnosis and patient with uncontrolled brain metastases
__label__1	study interventions are Capecitabine . stage iiib merkel cell carcinoma diagnosis and patients with uncontrolled seizures or any neurological conditions resulting in increased risk for seizures are not eligible for study entry
__label__1	study interventions are PBI 05204 . pancreatic cancer diagnosis and patients with pacemakers may be eligible
__label__1	study interventions are Paclitaxel . stage iiib breast cancer diagnosis and biologic therapy equal_than less_than fourteen days prior to registration
__label__1	study interventions are Sirolimus . pineoblastoma diagnosis and sexually active patients who refuse to use contraception according to the institutional requirements
__label__1	study interventions are Antibodies . contiguous stage ii marginal zone lymphoma diagnosis and pregnancy or active nursing of an infant
__label__1	study interventions are Oxaliplatin . stage iv ovarian cancer diagnosis and history of pulmonary embolism or deep vein thrombosis in the past six months
__label__1	study interventions are BKM120 . advanced endometrial cancer diagnosis and previous treatment with pithreek and or mtor inhibitors
__label__1	study interventions are Interleukin-2 . fallopian tube cancer diagnosis and responses will be recorded and reported to the fda as part of the annual report
__label__1	study interventions are Fludarabine . noncontiguous stage ii adult immunoblastic large cell lymphoma diagnosis and fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold active azoles for greater than one month
__label__1	study interventions are Busulfan . non hodgkin lymphoma diagnosis and any preexisting medical condition of sufficient severity to prevent full compliance with the study
__label__1	study interventions are Deoxyglucose . breast neoplasms diagnosis and patient has diabetes
__label__1	study interventions are Daunorubicin . other prior malignancy within the past five years except adequately treated basal cell or squamous cell skin cancer carcinoma in situ of the cervix or other adequately treated stage or ii cancer in complete remission
__label__1	study interventions are Cyclophosphamide . solid tumor diagnosis and known hypersensitivity to any involved study drug or any of its formulation components
__label__1	study interventions are Etoposide phosphate . non hodgkins lymphoma diagnosis and you cannot participate in this study if any of the following apply to you
__label__1	study interventions are Immunotoxins . non hodgkin lymphoma diagnosis and prior radiation therapy will not be excluded providing the volume of bone marrow treated is less than twenty-five
__label__1	study interventions are Cortisone acetate . stage iii grade three follicular lymphoma diagnosis and use of zidovudine or cobicistat as part of the haart regimen drug substitution at the time of study entry is allowed
__label__1	study interventions are Vorinostat . ds stage plasma cell myeloma diagnosis and previous history of hypersensitivity to bortezomib boron or mannitol known hypersensitivity to the components of study drug or its analogs
__label__1	study interventions are MEDI3726 Post-Chemo . subjects with previous radiotherapy for the treatment of unresectable locally advanced or metastatic prostate cancer are excluded if
__label__1	study interventions are Antibodies . salivary gland squamous cell carcinoma diagnosis and supraventricular and nodal arrhythmias requiring pacemaker or not controlled with medication
__label__1	study interventions are Everolimus . renal pelvis cancer diagnosis and severely impaired lung function as evidenced by
__label__1	study interventions are AZD6244 . thyroid cancer diagnosis and patient with chronic renal insufficiency as defined initially by an estimated creatinine clearance of less_than thirty ml minute calculated using the cockcroft and gault equation
__label__1	study interventions are Gemcitabine . kidney cancer diagnosis and patients who have had an organ allograft
__label__1	study interventions are Sorafenib . adult giant cell glioblastoma diagnosis and hypertension with systolic blood pressure of greater_than one hundred and forty mmhg or diastolic pressure greater_than ninety mmhg
__label__1	study interventions are Immunoglobulins . stage iv adult diffuse mixed cell lymphoma diagnosis and uncontrolled systemic vascular hypertension systolic blood pressure greater_than one hundred and forty mmhg diastolic blood pressure greater_than ninety mmhg
__label__1	study interventions are Surgical excision . basal cell carcinoma diagnosis and earlier treatments at the same site
__label__1	study interventions are Everolimus . stage iv non small cell lung cancer diagnosis and immunocompromised patients other than that related to the use of corticosteroids including patients known to be human immunodeficiency virus hiv positive
__label__1	study interventions are Bevacizumab . astrocytoma diagnosis and myocardial infarction within six months prior to enrollment
__label__1	study interventions are Ursodeoxycholic Acid . familial adenomatous polyposis diagnosis and renal dysfunction
__label__1	study interventions are Tacrolimus . multiple myeloma diagnosis and ast alt greater_than three normal or bilirubin greater_than doc normal unless due to gilbert syndrome
__label__1	study interventions are Methyltestosterone . prostate cancer diagnosis and undergone orchiectomy adrenalectomy hypophysectomy or be receiving any product which could alter the function of these organs
__label__1	study interventions are Bleomycin . hodgkin lymphoma diagnosis and serious non healing wound ulcer or bone fracture
__label__1	study interventions are Albumin-Bound Paclitaxel . fallopian tube carcinoma diagnosis and the use of concomitant medications that prolong the qt qtc interval
__label__1	study interventions are Sirolimus . stage iv pancreatic cancer diagnosis and nursing women
__label__1	study interventions are Cisplatin . lymphomatous or acute subtype subject with greater_than two prior systemic therapy regimens and who has not achieved response cr or pr or maintained stable disease for at least 1two weeks on last immediate prior therapy
__label__1	study interventions are Antibodies, Monoclonal . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and prisoners or subjects who are compulsorily_detained involuntarily_incarcerated for treatment of either psychiatric or physical eg infectious illness
__label__1	study interventions are Dexamethasone 21-phosphate . plasma cell myeloma diagnosis and prior radiation therapy or major surgical procedure within four weeks of the first dose of study treatment
__label__1	study interventions are Capecitabine . stage iii adult diffuse mixed cell lymphoma diagnosis and patients who have not recovered to less_than ctcae grade two toxicities related to prior therapy are not eligible to participate in this study
__label__1	study interventions are Vorinostat . soft tissue sarcoma diagnosis and concurrent radi negative or chemotherapy
__label__1	study interventions are Docetaxel . non small cell lung cancer diagnosis and untreated brain metastases or spinal cord compression
__label__1	study interventions are Dexamethasone 21-phosphate . uterine myoma diagnosis and liver or kidney dysfuntion
__label__1	study interventions are Antibodies, Monoclonal . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and pregnancy or breast feeding
__label__1	study interventions are Doxorubicin . stage iib hodgkin lymphoma diagnosis and patients who have received any previous chemotherapy or radiation therapy are not eligible
__label__1	study interventions are Zoledronic acid . previous or concurrent malignancies at other sites with the exception of surgically cured carcinoma in situ of the cervix and basal or squamous cell carcinoma of the skin
__label__1	study interventions are laboratory biomarker analysis . adenocarcinoma of the prostate diagnosis and patients whom are planned to receive pelvic nodal radiation are excluded
__label__1	study interventions are ispinesib . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and clarithromycin erythromycin troleandomycin
__label__1	study interventions are Paclitaxel . peritoneal neoplasms diagnosis and any condition that confounds the ability to interpret data from the study
__label__1	study interventions are Nivolumab . melanoma part diagnosis and major surgery within four weeks prior to screening
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and inability to swallow oral medication or inability or unwillingness to comply with the administration requirements related to alisertib
__label__1	study interventions are Paclitaxel . neoplasm metastasis diagnosis and patient with only local metastatic disease with the exception of axillary lymph nodes
__label__1	study interventions are Ramucirumab . malignant solid tumor diagnosis and has serious or nonhealing wound peptic ulcer or bone fracture within twenty-eight days prior to first dose of study medication
__label__1	study interventions are Fludarabine phosphate . recurrent adult diffuse mixed cell lymphoma diagnosis and patient scheduled for cord blood transplantation
__label__1	study interventions are MG4101 . hepatocellular carcinoma diagnosis and patients who have participated in other clinical trials within four weeks prior to this study
__label__1	study interventions are Carboplatin . stage iiic primary peritoneal cancer diagnosis and patients who in the opinion of the investigator are unable or unlikely to comply with the dosing schedule and study evaluations
__label__1	study interventions are Aminolevulinic Acid . non melanoma skin cancer diagnosis and use of retinoids within one month
__label__1	study interventions are Decipher Genomics Resource Information Database (GRID) . prostate cancer diagnosis and required patient clinical data is not available for evaluation of eligibility criteria
__label__1	study interventions are Irinotecan . esophageal cancer diagnosis and no known brain or other cns metastasis by history or clinical examination
__label__1	study interventions are MLN8237 . angioimmunoblastic cell lymphoma aitl diagnosis and radiotherapy involving greater_than twenty-five of the hematopoietically active bone marrow within forty-two days preceding first dose of study treatment
__label__1	study interventions are Antibodies . stage iiib esophageal cancer diagnosis and known hypersensitivity to any component of bevacizumab
__label__1	study interventions are Dexamethasone acetate . recurrent grade one follicular lymphoma diagnosis and any of the following because this study involves an investigational agent whose genotoxic_mutagenic and teratogenic effects on the developing fetus and newborn are unknown
__label__1	study interventions are Fludarabine . recurrent adult diffuse large cell lymphoma diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iiic ovarian cancer diagnosis and nursing women
__label__1	study interventions are Doxorubicin . pleomorphic rhabdomyosarcoma diagnosis and at least twenty-one days since last dose prior to first dose of ribociclib
__label__1	study interventions are breast biopsy . breast cancer diagnosis and major medical condition
__label__1	study interventions are Sorafenib . head and neck cancer diagnosis and evidence or history of bleeding diathesis or coagulopathy
__label__1	study interventions are Ramucirumab . recurrent tumor diagnosis and history of solid organ transplant
__label__1	study interventions are Erlotinib Hydrochloride . lung cancer diagnosis and concomitant radiation therapy to the lungs
__label__1	study interventions are Cyclosporins . recurrent follicular lymphoma diagnosis and prior myeloablative transplant containing full dose tbi greater than eight gray gy
__label__1	study interventions are Calcium, Dietary . stage ivb rectal cancer diagnosis and patients taking cytochrome pfour hundred and fifty enzyme inducing antiepileptic drugs equal_than less_than four weeks prior to registration will be excluded phenytoin carbamazepine phenobarbital rifampin or st
__label__1	study interventions are Vaccines . stage iv adult lymphoblastic lymphoma diagnosis and had relapse
__label__1	study interventions are JM 3100 . lymphoma non hodgkin diagnosis and failed previous stem cell collection
__label__1	study interventions are Calcitriol . ovarian cancer diagnosis and patients who have been managed with bisphosphonates or calcium lowering therapy for three months or greater prior to the start of the trial and have demonstrated evidence for stability of calcium metabolism would be considered eligible for participation in the trial
__label__1	study interventions are Cyclosporine . recurrent mantle cell lymphoma diagnosis and donor
__label__1	study interventions are Immunoglobulins . stage iia breast cancer diagnosis and cumulative dose of doxorubicin or equivalent of greater_than three hundred and sixty mg two during prior adjuvant therapy
__label__1	study interventions are ctDNA analysis . non small cell lung cancer metastatic diagnosis and patient with no histologic or cytological diagnosis
__label__1	study interventions are Everolimus . stage iiic ovarian cancer diagnosis and clinical signs and symptoms of gastrointestinal gi obstruction and require parental hydration nutrition or tube feeding
__label__1	study interventions are Antibodies, Monoclonal . recurrent fallopian tube carcinoma diagnosis and patients with peripheral edema or lymphedema greater_than grade two
__label__1	study interventions are Mitoxantrone . mestastatic prostate cancer diagnosis and other investigational procedures are excluded
__label__1	study interventions are Fludarabine . stage iii multiple myeloma diagnosis and forced vital capacity fvc less_than fifty predicted
__label__1	study interventions are Heparin, Low-Molecular-Weight . cervical cancer diagnosis and concurrent high dose chemotherapy with stem cell transplantation
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and cardiac disease history of and or active disease that would preclude the use of any of the drugs included in the treatment regimen
__label__1	study interventions are Carboplatin . stage iiia ovarian cancer diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Vincristine . lymphoma non hodgkin diagnosis and uncontrolled intercurrent illness
__label__1	study interventions are Lapatinib . recurrent squamous cell carcinoma of the oropharynx diagnosis and prior treatment
__label__1	study interventions are oregovomab . patients with known refractory or recurrent epithelial adenocarcinoma of ovarian tubal or peritoneal origin requiring chemotherapy
__label__1	study interventions are Sunitinib . aids related diffuse large cell lymphoma diagnosis and pre existing thyroid abnormality that cannot be maintained with medication to keep measures of thyroid stimulating hormone within the normal range
__label__1	study interventions are Bendamustine Hydrochloride . recurrent adult lymphoblastic lymphoma diagnosis and unwilling or unable to follow protocol requirements
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and women currently pregnant or breastfeeding
__label__1	study interventions are CD45RA-depleted peripheral blood mononuclear cells . lymphoma diagnosis and patients who can perform pulmonary function tests will be excluded if they have diffusing capacity of the lung for carbon monoxide dlco corrected for hemoglobin of less_than fifty predicted patients who are unable to perform pulmonary function tests will be excluded if the oxygen otwo saturation is less_than 9two on room air
__label__1	study interventions are Camptothecin . carcinoma neuroendocrine diagnosis and patients with known gilbert syndrome are ineligible
__label__1	study interventions are Heparin, Low-Molecular-Weight . malignant neoplasm diagnosis and investigators shall counsel wocbp and male subjects who are sexually active with wocbp on the importance of pregnancy prevention and the implications of an unexpected pregnancy investigators shall advise wocbp and male subjects who are sexually active with wocbp on the use of highly effective methods of contraception highly effective methods of contraception have failure rate of less_than one when used consistently and correctly
__label__1	study interventions are Antibodies, Monoclonal . recurrent refractory childhood hodgkin lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Abiraterone Acetate . prostate cancer diagnosis and documented hypersensitivity ctcae grade greater_than two to any drug containing polysorbate eighty
__label__1	study interventions are Antibodies . metastatic colorectal cancer diagnosis and patients can not complete this study for any other reason
__label__1	study interventions are Paclitaxel . other prior malignancy within the past five years except adequately treated basal cell or squamous cell skin cancer carcinoma in situ of the cervix or adequately treated stage or ii cancer in complete remission
__label__1	study interventions are Vinorelbine . non small cell lung cancer nsclc diagnosis and active or prior documented inflammatory bowel disease eg crohn disease ulcerative colitis
__label__1	study interventions are Fludarabine phosphate . mesothelioma diagnosis and women of child bearing potential who are pregnant or breastfeeding because of the potentially dangerous effects of the treatment on the fetus or infant
__label__1	study interventions are Myomectomy . myomas diagnosis and have known or suspected endometriosis or adenomyosis
__label__1	study interventions are 6-Mercaptopurine . recurrent childhood lymphoblastic lymphoma diagnosis and hepatitis or hiv infection
__label__1	study interventions are Paclitaxel . non small cell lung cancer diagnosis and patients will be excluded from the study if they meet any of the following criteria
__label__1	study interventions are Hydroxyurea . glioblastoma diagnosis and serum bilirubin greater_than doc uln of reference range
__label__1	study interventions are Bortezomib . multiple myeloma and plasma cell neoplasm diagnosis and cardiac amyloidosis with hypotension systolic blood pressure less_than one hundred mm hg
__label__1	study interventions are Isophosphamide mustard . recurrent grade two follicular lymphoma diagnosis and pregnant or nursing women men or women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method
__label__1	study interventions are Cancer early detection . cancer diagnosis and bmigreater_than forty
__label__1	study interventions are Bevacizumab . primary peritoneal cancer diagnosis and evidence of bleeding diathesis
__label__1	study interventions are Sirolimus . nephroid carcinoma diagnosis and patients who have received prior systemic treatment for their metastatic rcc
__label__1	study interventions are Leucovorin . intestinal adenocarcinoma of the stomach diagnosis and significant vascular disease aortic dissection aortic aneurysm
__label__1	study interventions are Liposomal doxorubicin . ovarian seromucinous carcinoma diagnosis and major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day one therapy
__label__1	study interventions are Tissue Collection . uncontrolled concomitant illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would limit compliance with study requirements
__label__1	study interventions are Carboplatin . primary peritoneal serous adenocarcinoma diagnosis and patients with or with anticipation of invasive procedures as defined below
__label__1	study interventions are Fluorouracil . anal cancer diagnosis and more common devices and prosthetics which include arterial and venous stents dental and breast implants and venous access devices port cath or mediport are permitted
__label__1	study interventions are Antibodies, Monoclonal . noncontiguous stage ii adult lymphoblastic lymphoma diagnosis and the development of erythema_nodosum if characterized by desquamating_rash while taking thalidomide or similar drugs
__label__1	study interventions are Bendamustine Hydrochloride . multiple myeloma diagnosis and known positive for hiv or infectious hepatitis type b or c
__label__1	study interventions are Doxorubicin . patient has already undergone hepatic arterial embolization for the hepatocellular cancer for which they are currently being evaluated
__label__1	study interventions are Antibodies, Monoclonal . urothelial carcinoma diagnosis and prior monoclonal antibody within four weeks before study day one or has not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Antibodies, Monoclonal . solid neoplasm diagnosis and the subject has uncontrolled significant intercurrent or recent illness including but not limited to the following conditions
__label__1	study interventions are Hydrocortisone 17-butyrate 21-propionate . stage iv prostate cancer diagnosis and known severe hypersensitivity to ketoconazole calcitriol or any of the excipients of these products
__label__1	study interventions are Antibodies . stage iiia primary peritoneal cancer diagnosis and core biopsy equal_than less_than seven days prior to registration
__label__1	study interventions are Valproic Acid . sarcoma diagnosis and evidence of bleeding diathesis or significant coagulopathy in the absence of therapeutic anticoagulation
__label__1	study interventions are Paclitaxel . carcinoma non small cell lung diagnosis and uncontrolled intercurrent illness
__label__1	study interventions are Topotecan . gynecologic tumors diagnosis and known intraluminal metastatic lesion with risk of bleeding
__label__1	study interventions are Tacrolimus . stage iii adult burkitt lymphoma diagnosis and pregnant women are excluded from this study because vorinostat is histone_deacetylase inhibitor agent with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with vorinostat breastfeeding should be discontinued if the mother is treated with vorinostat
__label__1	study interventions are Fluorouracil . colon cancer diagnosis and radiation therapy within six weeks of cycle one week one or any radiation therapy which encompasses target lesions selected for this study unless those lesions have documented progression of disease
__label__1	study interventions are Carboplatin . breast cancer diagnosis and patients with any significant non traumatic bleeding within six months prior to study entry are ineligible
__label__1	study interventions are Sirolimus . stage iii marginal zone lymphoma diagnosis and females who are pregnant or breast feeding
__label__1	study interventions are Epirubicin . breast cancer diagnosis and age less_than eighteen
__label__1	study interventions are Trametinib . endometrial adenocarcinoma diagnosis and drugs that potently inhibit cytochrome pfour hundred and fifty family three subfamily polypeptide four cypthreeafour should be prohibited or used with caution drugs which are strong inducers of cypthreea and may result in lower exposures of gsktwo1four1795 should also be prohibited drugs that are substrates of cypthreeafour or cytochrome pfour hundred and fifty family two subfamily polypeptide eight cyptwoceight with narrow therapeutic index may be prohibited drugs that are sensitive substrates of cypthreeafour or cyptwoceight should be used with caution
__label__1	study interventions are Paclitaxel . breast cancer diagnosis and uncontrolled hypertension defined as systolic bp greater than one hundred and fifty mmhg or diastolic bp greater than ninety mmhg with or without anti hypertensive medications
__label__1	study interventions are Nivolumab . fallopian tube cancer diagnosis and history of documented congestive heart failure nyha classification of iii or iv or documented cardiomyopathy
__label__1	study interventions are Immunoglobulins . fallopian tube serous adenocarcinoma diagnosis and patients with significant cardiac conduction abnormalities pr interval greater_than doc four seconds sec or twond or threerd degree atrioventricular_av block
__label__1	study interventions are Paclitaxel . non small cell lung cancer diagnosis and previous radiotherapy of the primary tumour
__label__1	study interventions are Ibrutinib . recurrent indolent adult non hodgkin lymphoma diagnosis and history of stroke or intracranial hemorrhage within six months of screening
__label__1	study interventions are Antibodies, Monoclonal . splenic marginal zone lymphoma diagnosis and infection with hiv
__label__1	study interventions are Antibodies . stage iva verrucous carcinoma of the larynx diagnosis and active autoimmune disease
__label__1	study interventions are No Loco-regional treatment . cancer of the breast diagnosis and expected survival of less than six months after completion of chemotherapy
__label__1	study interventions are Lidocaine . breast cancer diagnosis and female military healthcare beneficiaries with chronic pain syndrome fibromyalgia undergoing active narcotic based treatment
__label__1	study interventions are placebo . stage ii squamous cell carcinoma of the larynx diagnosis and although there are no known adverse effects of black_raspberries upon the fetus if patients become pregnant during period of lyophilized_black raspberries_lbr administration then lbr will be discontinued and patient will be removed from the study we should however emphasize given this is food based study that risks are likely extremely low even though participant should become pregnant as such we are not recommending active contraception for women but rather if participants become pregnant that they notify their study doctor and that they will likely be removed from study there are no expected or logical risks if men were to father child and as such no contraception will be recommended for men
__label__1	study interventions are Tivozanib . prostate cancer diagnosis and history of genetic or acquired immune suppression disease such as hiv subjects on immune suppressive therapy for organ transplant
__label__1	study interventions are Trastuzumab . neoplasms breast diagnosis and evidence of transmural infarction on ecg
__label__1	study interventions are Cholecalciferol . stage iii colon cancer diagnosis and history of prior or synchronous malignancy except
__label__1	study interventions are perifosine . stage iv adult soft tissue sarcoma diagnosis and men or women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception condoms diaphragm birth control pills injections intrauterine device iud surgical sterilization subcutaneous implants or abstinence etc
__label__1	study interventions are Pemetrexed . known anaplastic lymphoma kinase alk translocations
__label__1	study interventions are Cyclosporins . recurrent adult hodgkin lymphoma diagnosis and patients with greater_than grade ii hypertension by common toxicity criteria ctc
__label__1	study interventions are Cetuximab . colorectal cancer metastatic diagnosis and known or suspected allergy or hypersensitivity to any component of bevacizumab cetuximab irinotecan or five fu lv
__label__1	study interventions are Cediranib . stage iva pancreatic cancer diagnosis and history of hemoptysis within the last one month
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and if machine reading is above this value the ekg should be reviewed by qualified reader and confirmed on subsequent ekg
__label__1	study interventions are Immunoglobulin G . stage iv primary peritoneal cancer diagnosis and significant cardiovascular disease defined as congestive heart failure new york heart association class ii iii or iv angina pectoris requiring nitrate therapy or recent myocardial infarction equal_than less_than six months prior to registration
__label__1	study interventions are Tacrolimus . stage grade two follicular lymphoma diagnosis and treatment with rituximab for any reason in the 1two months preceding hct
__label__1	study interventions are Glycine . receiving any other investigational agent which would be considered as treatment for the primary neoplasm
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and positive for hbs antigen or hcv antibody
__label__1	study interventions are Paclitaxel . known history of uncontrolled or symptomatic angina clinically significant arrhythmias congestive heart failure transmural myocardial infarction uncontrolled hypertension
__label__1	study interventions are Cyclosporine . recurrent adult immunoblastic large cell lymphoma diagnosis and donor
__label__1	study interventions are Succinylcholine . cervical squamous cell carcinoma diagnosis and figo two thousand and eight stage iiia disease
__label__1	study interventions are Antibodies, Monoclonal . recurrent primary peritoneal carcinoma diagnosis and any of the following as this regimen may be harmful to developing fetus or nursing child
__label__1	study interventions are Gemcitabine . pancreatic adenocarcinoma diagnosis and active infection or other serious illness or autoimmune disease
__label__1	study interventions are Laboratory Biomarker Analysis . metastatic adrenal gland pheochromocytoma diagnosis and frequent ventricular ectopy
__label__1	study interventions are Gemcitabine . recurrent breast carcinoma diagnosis and any other known concurrent infectious disease requiring iv antibiotics with two weeks of study enrollment
__label__1	study interventions are Central Nervous System Stimulants . malnourished children with cancer diagnosis and pre study random chemstrip or venous blood glucose greater_than ten mmol with confirmation by fasting blood glucose the next morning greater than the normal limits defined for this study
__label__1	study interventions are BB 1101 . stage mantle cell lymphoma diagnosis and any condition which in the investigator opinion deems the patient an unsuitable candidate to receive study drug
__label__1	study interventions are Interleukin-12 . stage iii cervical cancer diagnosis and any other major illness which in the investigator judgment will substantially increase the risk associated with the patient participation in this study
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood lymphoblastic lymphoma diagnosis and karnofsky score less_than fifty for adult patients
__label__1	study interventions are Gossypol acetic acid . recurrent adult immunoblastic large cell lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to at one hundred and one or other agents used in study
__label__1	study interventions are N-monoacetylcystine . stage verrucous carcinoma of the oral cavity diagnosis and any of the following
__label__1	study interventions are Cyclosporins . stage grade three follicular lymphoma diagnosis and diffusing capacity of the lung for carbon monoxide dlco less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Endothelial Growth Factors . ovarian neoplasms diagnosis and patients with active infection will not be eligible but may become eligible once infection has resolved and they are at least seven days from completion of antibiotics
__label__1	study interventions are DS-3201b . lymphoma follicular diagnosis and has received radiation therapy within four weeks twenty-eight days of the start of study treatment
__label__1	study interventions are Fludarabine phosphate . stage childhood large cell lymphoma diagnosis and patients with other disease or organ dysfunction that would limit survival to less than thirty days
__label__1	study interventions are Intravenous Patient-Controlled Analgesia (IVPCA) . pancreatic cancer diagnosis and inability to comply with study and or follow up procedures
__label__1	study interventions are Sorafenib . cancer other than nsclc within five years prior to start of study treatment except cervical cancer in situ treated basal cell carcinoma or superficial bladder tumors
__label__1	study interventions are AUY922 . adenocarcinoma of the pancreas diagnosis and within four weeks
__label__1	study interventions are Letrozole . breast cancer diagnosis and history of another pathology that may affect the development of the protocol or the interpretation of results
__label__1	study interventions are Dabrafenib . exceptions include basal cell carcinoma of the skin squamous cell carcinoma of the skin or in situ cervical cancer that has undergone potentially curative therapy
__label__1	study interventions are Cetuximab . colorectal cancer diagnosis and contraindications to angiography and selective visceral catheterization
__label__1	study interventions are Food Record . lymphoma diagnosis and subject has been scheduled to withhold oral intake or parenteral nutrition support for more than four days during the week of dietary record week two four and six
__label__1	study interventions are Docetaxel . locally recurrent and metastatic breast cancer diagnosis and unable to take oral medications
__label__1	study interventions are Immunoglobulins . recurrent fallopian tube carcinoma diagnosis and clinically significant stroke or transient ischemic attack tia equal_than less_than six months prior to registration seizures not controlled with standard medical therapy
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood large cell lymphoma diagnosis and identical twin
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and brain metastases
__label__1	study interventions are Sirolimus . head and neck neoplasms diagnosis and prior severe infusion reaction to monoclonal antibody
__label__1	study interventions are Staurosporine . recurrent melanoma diagnosis and pregnant women are excluded from this study because ucn one is serine_threonine kinase inhibitor with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse effects in nursing infants secondary to treatment of the mother with ucn one breastfeeding should be discontinued if the mother is treated with ucn one
__label__1	study interventions are Dexamethasone acetate . high risk smoldering multiple myeloma diagnosis and radiotherapy within fourteen days before enrollment
__label__1	study interventions are Levoleucovorin . stage ii childhood lymphoblastic lymphoma diagnosis and pre existing greater_than equal_than grade two sensory or motor peripheral neurotoxicity
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and absolute neutrophil count less_than one zero cells mmthree
__label__1	study interventions are Antibodies . melanoma diagnosis and systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism patients receiving inhaled or topical corticosteroids may participate
__label__1	study interventions are Doxorubicin . stage iiia uterine corpus cancer diagnosis and patients with active extra abdominal disease including active malignant pleural effusion patients who have been successfully treated with neoadjuvant chemotherapy and no longer have malignant pleural effusions may be included
__label__1	study interventions are Bexarotene . advanced malignant aerodigestive tract tumor lung head and neck and esophagus diagnosis and systemic vitamin in doses exceeding fifteen zero iu day within fourteen days prior to initiating study medications
__label__1	study interventions are Tumor delineation . oropharyngeal squamous cell carcinoma diagnosis and primary surgical management
__label__1	study interventions are Thalidomide . diffuse large cell lymphoma diagnosis and all patients must be counseled at minimum of every twenty-one days about pregnancy precautions and risks of fetal exposure
__label__1	study interventions are Pemetrexed . previously untreated stage iv non squamous non small cell lung cancer diagnosis and subject has had prescription or non prescription drugs or other products grapefruit juice known to be sensitive cypthreeafour substrates
__label__1	study interventions are Antibodies, Monoclonal . stage ivc squamous cell carcinoma of the lip and oral cavity diagnosis and use of the following medications will not be allowed within four weeks prior to enrollment on the study and during the study
__label__1	study interventions are Everolimus . stage ivb colon cancer diagnosis and patients with chronic active hepatitis or recent hepatitis infection hepatitis surface antigen hepb_sag or immunoglobulin igm antibody to hepatitis core antigen igm_antibc positive are ineligible because these patients are at increased risk of reactivation of the hepatitis virus which may be fatal due to the immunosuppressive properties of radone
__label__1	study interventions are Thalidomide . b cell lymphoma unclassifiable with features intermediate between diffuse large cell lymphoma and burkitt lymphoma diagnosis and clinically significant history of liver disease including viral or other hepatitis current alcohol abuse or cirrhosis
__label__1	study interventions are Paclitaxel . pancreatic adenocarcinoma diagnosis and concurrent malignant hematologic or solid disease
__label__1	study interventions are Immunoglobulins . glioblastoma diagnosis and patients with full dose anticoagulants are eligible provided the patient has been on stable dose for at least two weeks of low molecular weight heparin therapeutic coumadin and aspirin doses greater_than 3two5 mg daily are not allowed
__label__1	study interventions are Tacrolimus . recurrent childhood lymphoblastic lymphoma diagnosis and fungal pneumonia with radiological progression after receipt of amphotericin formulation or mold active azoles for greater than one month
__label__1	study interventions are Cyclophosphamide . stage adult diffuse large cell lymphoma diagnosis and any evidence of serious active uncontrolled infection requiring an iv antibiotic or antiviral agent
__label__1	study interventions are Paclitaxel . mixed tumor mesodermal diagnosis and history of prior malignancy that required prior systemic therapy
__label__1	study interventions are Everolimus . unstable angina pectoris symptomatic congestive heart failure myocardial infarction within six months of start of study drug serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease
__label__1	study interventions are Vaccines . intraocular melanoma diagnosis and clinical history of hiv hepb hepc and or htlv i
__label__1	study interventions are Aprepitant . stage iv squamous cell carcinoma of the oropharynx diagnosis and patients with hypersensitivity to fosaprepitant aprepitant polysorbate and any other components of the emend product
__label__1	study interventions are Etoposide phosphate . stage grade three follicular lymphoma diagnosis and patients with uncontrolled seizures as defined by having any seizure activity within the three months prior to screening
__label__1	study interventions are Fludarabine . nodal marginal zone cell lymphoma diagnosis and patients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening
__label__1	study interventions are Educational Intervention . stage ia breast cancer diagnosis and self report or have medical record of an unstable comorbid medical or psychiatric condition that would make it unsafe or impossible to adhere to the study protocol
__label__1	study interventions are Cytology Specimen Collection Procedure . esophageal squamous cell carcinoma diagnosis and subjects that are unable to swallow tablet pill
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and patient has greater_than grade two peripheral neuropathy on clinical examination within fourteen days before enrolment
__label__1	study interventions are laboratory biomarker analysis . recurrent squamous cell carcinoma of the hypopharynx diagnosis and pregnant women are excluded from this study because sb seven hundred and fifteen thousand, nine hundred and ninety-two is mitotic inhibitor with the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sb seven hundred and fifteen thousand, nine hundred and ninety-two breastfeeding should be discontinued if the mother is treated with sb seven hundred and fifteen thousand, nine hundred and ninety-two
__label__1	study interventions are Antibodies . gastric cancer diagnosis and receipt of other pd one inhibitors or pd lone inhibitors is allowed
__label__1	study interventions are Sorafenib . liver neoplasms diagnosis and no bleeding diathesis
__label__1	study interventions are Liposomal doxorubicin . ovarian serous tumor diagnosis and prior central thoracic radiation therapy rt including rt to the heart
__label__1	study interventions are ID-LV305 . sarcoma enrollment completed diagnosis and marrow
__label__1	study interventions are Tremelimumab . renal cell carcinoma diagnosis and at screening single ecg will be obtained on which qtcf must be less_than four hundred and seventy ms
__label__1	study interventions are Temozolomide . childhood solid neoplasm diagnosis and core biopsy within seven days prior to enrollment
__label__1	study interventions are Etoposide . lymphoma hodgkin diagnosis and no chemotherapy other than corticosteroids should be administered within two weeks of the initiation of protocol therapy
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and subject has received an experimental drug or used and experimental medical device within four weeks before enrollment
__label__1	study interventions are Dacarbazine . glioblastoma multiforme diagnosis and ongoing or recent less_than three months significant gastrointestinal bleeding untreated or recurring
__label__1	study interventions are Paclitaxel . metastatic breast cancer diagnosis and prior therapy for metastatic tnbc chemotherapy hormone therapy or biological therapy patients may receive bisphosphonates and other therapies to treat bone metastases however if used bone lesions will not be considered as measurable disease
__label__1	study interventions are Fludarabine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and eligible for radioimmunotherapy based autologous transplant trial
__label__1	study interventions are Thalidomide . multiple myeloma in relapse diagnosis and bradycardia defined as hr less_than fifty bpm
__label__1	study interventions are Dabrafenib . melanoma diagnosis and participants must not have had prior autoimmune disorders requiring cytotoxic or immunosuppressive therapy or autoimmune disorders with visceral involvement
__label__1	study interventions are Doxorubicin . endometrial undifferentiated carcinoma diagnosis and history of intra abdominal abscess within the past three months
__label__1	study interventions are Freund's Adjuvant . gliosarcoma diagnosis and any of the following
__label__1	study interventions are Estradiol . breast neoplasms diagnosis and clinically significant uncontrolled heart disease and or cardiac repolarization abnormality
__label__1	study interventions are Carboplatin . prior cytotoxic chemotherapy or targeted therapy for advanced or metastatic disease prior adjuvant therapy for lung cancer allowed if completed greater_than one year prior to registration
__label__1	study interventions are Fludarabine phosphate . small lymphocytic lymphoma diagnosis and prolonged qtc interval on pre entry ecg
__label__1	study interventions are Immunoglobulins . clear cell renal cell carcinoma diagnosis and history of cerebrovascular accidents including transient ischemic attacks tia
__label__1	study interventions are Cetuximab . stage ivb salivary gland cancer diagnosis and pregnant or lactating sexually active women of childbearing potential must use an effective method of birth control during the course of the study in manner such that risk of failure is minimized
__label__1	study interventions are Mycophenolate mofetil . stage ii childhood small noncleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Hydroxyitraconazole . non small cell lung cancer metastatic diagnosis and hiv positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with subatm itraconazole gemcitabine or cisplatin with these essential mediations
__label__1	study interventions are Immunoglobulin G . malignant ovarian epithelial tumor diagnosis and other medical conditions including but not limited to
__label__1	study interventions are Interleukin-2 . neuroblastoma diagnosis and seizure activity clinically detectable encephalopathy or new focal neurologic deficits within prior seventy-two hour period
__label__1	study interventions are Hormones . estrogen receptor positive breast cancer diagnosis and known strong inducers or inhibitors of cypthreeafour five including grapefruit grapefruit hybrids pomelos star_fruit and seville_oranges
__label__1	study interventions are Mitogens . stage iii adult hodgkin lymphoma diagnosis and positive pregnancy test women of child bearing potential
__label__1	study interventions are Antibodies, Monoclonal . refractory diffuse large cell lymphoma diagnosis and psoriasis not requiring systemic treatment
__label__1	study interventions are Pembrolizumab . urothelial bladder carcinoma diagnosis and patients taking regular oral steroids above the allowed limit of tenmg day methylprednisolone or analogues for any reason
__label__1	study interventions are Immunoglobulins . stage iib breast cancer diagnosis and cumulative dose of doxorubicin or equivalent of greater_than three hundred and sixty mg two during prior adjuvant therapy
__label__1	study interventions are Niacinamide . lung cancer diagnosis and pregnant positive pregnancy test or breast feeding
__label__1	study interventions are Sunitinib . glioblastoma multiforme diagnosis and concurrent use of anticoagulant or antiplatelet drugs
__label__1	study interventions are Mycophenolic Acid . stage iv childhood anaplastic large cell lymphoma diagnosis and lansky play performance score less_than fifty for pediatric patients
__label__1	study interventions are Mycophenolic Acid . recurrent small lymphocytic lymphoma diagnosis and karnofsky score less_than seventy for adult patients
__label__1	study interventions are Cediranib . recurrent adult diffuse mixed cell lymphoma diagnosis and conditions requiring concurrent use of drugs or biologics with proarrythmic potential these drugs are prohibited during studies with azdtwo thousand, one hundred and seventy-one refer to appendix for listing of these agents
__label__1	study interventions are Bevacizumab . clear cell renal cell carcinoma diagnosis and clinical history of coughing or vomiting blood within the past three months
__label__1	study interventions are Minocycline . lung cancer diagnosis and patients who currently have bile duct obstruction or cholelithiasis
__label__1	study interventions are Dacarbazine . cancer of brain and nervous system diagnosis and creatinine upc ratio greater than or equal to doc at screening or urine dipstick for proteinuria greater than or equal to two or more patients discovered to have greater than or equal to two or greater proteinuria on dipstick urinalysis at baseline should undergo two4 hour urine collection and must demonstrate less than or equal to oneg of protein in two4 hours to be eligible
__label__1	study interventions are Cetuximab . head and neck cancer diagnosis and active infection at needs endovenous antibiotics including active tuberculosis and diagnosed hiv
__label__1	study interventions are Antibodies, Monoclonal . stage iiic rectal cancer diagnosis and treatment with any other investigational agent or participation in another investigational drug trial within twenty-eight days prior to randomization
__label__1	study interventions are Exemestane . breast neoplasms diagnosis and significant gastrointestinal abnormalities which may impair intake transit or absorption of the study drugs
__label__1	study interventions are Prednisolone hemisuccinate . lung cancer diagnosis and pregnant nursing
__label__1	study interventions are Cisplatin . locally advanced head and neck hpv negative squamous cell cancers diagnosis and current participation in any other interventional clinical study
__label__1	study interventions are Pembrolizumab . recurrent non small cell lung carcinoma diagnosis and the presence of laboratory evidence of autoimmune disease positive antinuclear antibody ana_titer or lupus anticoagulant without associated symptoms
__label__1	study interventions are Sirolimus . breast cancer diagnosis and women of child bearing potential wocbp defined as all women physiologically capable of becoming pregnant must use highly effective methods of contraception during the study and eight weeks after
__label__1	study interventions are Camptothecin . stage iva rectal cancer diagnosis and inadequately controlled hypertension systolic blood pressure of greater_than one hundred and fifty mmhg or diastolic pressure greater_than one hundred mmhg on anti hypertensive medications
__label__1	study interventions are Antibodies . stage ivc squamous cell carcinoma of the lip and oral cavity diagnosis and major surgery open biopsy or significant traumatic injury within four weeks of first study drug
__label__1	study interventions are Rituximab . lymphoma large cell diffuse diagnosis and subjects with treatment related myelodysplastic syndrome
__label__1	study interventions are Paclitaxel . her two positive breast cancer diagnosis and serum creatinine greater_than doc uln
__label__1	study interventions are Assess Surgical Site Occurrences at 1 year postoperatively . fibromatosis abdominal diagnosis and patients with severe systemic sepsis
__label__1	study interventions are Cetuximab . advanced colorectal cancer diagnosis and patients who have not recovered from any clinically significant grade three or four chemotherapy immunotherapy or radiotherapy related toxicity at study entry excluding neuropathy infertility or alopecia
__label__1	study interventions are Prednisone . diffuse large cell lymphoma diagnosis and diagnosed or treated for malignancy other than nhl with some exceptions
__label__1	study interventions are Antibodies, Monoclonal . stage iii squamous cell carcinoma of the paranasal sinus and nasal cavity diagnosis and clinically significant cardiac disease congestive heart failure unstable or uncontrolled angina myocardial infarction within six months of dosing with vtx two thousand, three hundred and thirty-seven
__label__1	study interventions are Irinotecan . cancer diagnosis and proteinuria greater_than one positive or total quantitative protein greater_than five hundred mg protein day as determined by twenty-four hr urine collection
__label__1	study interventions are Immunoglobulins . recurrent hodgkin lymphoma diagnosis and inability to understand or give an informed consent
__label__1	study interventions are Vidarabine . recurrent small lymphocytic lymphoma diagnosis and bulky disease
__label__1	study interventions are Fludarabine . childhood nasal type extranodal nk cell lymphoma diagnosis and life expectancy severely limited by diseases other than malignancy
__label__1	study interventions are Antibodies . signet ring adenocarcinoma of the rectum diagnosis and serious non healing wound active peptic ulcer or untreated bone fracture
__label__1	study interventions are Etoposide phosphate . recurrent childhood hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Deferasirox . recurrent adult diffuse large cell lymphoma diagnosis and patients with active disease undergoing chemotherapy treatment
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and presence of measurable or evaluable disease outside of the cns
__label__1	study interventions are Paclitaxel . stage iiib primary peritoneal cancer diagnosis and patients who in the opinion of the investigator are unable or unlikely to comply with the dosing schedule and study evaluations
__label__1	study interventions are Immunoglobulin G . stage iv ovarian cancer diagnosis and prior use of bevacizumab is not allowed in any cohort
__label__1	study interventions are Rituximab . stage iii adult immunoblastic large cell lymphoma diagnosis and presence of active uncontrolled infection at start of conditioning
__label__1	study interventions are Cyclophosphamide . mesothelioma diagnosis and age greater than or equal to sixty years old
__label__1	study interventions are Fludarabine phosphate . glioblastoma diagnosis and prior history of gliadel implantation in the past six months
__label__1	study interventions are Taxane . breast neoplasms diagnosis and evidence of new york heart association class iii or greater cardiac disease
__label__1	study interventions are pharmacological study . stage iv verrucous carcinoma of the larynx diagnosis and antibiotics
__label__1	study interventions are [131I]-SGMIB Anti-HER2 VHH1 . breast cancer diagnosis and pregnant patients
__label__1	study interventions are No lung plug . lung cancer diagnosis and patients with fungal infections patients with known or imaging evidence highly suggestive of pulmonary fungal infection
__label__1	study interventions are Liposomal doxorubicin . sarcoma diagnosis and uncontrolled fungal infection
__label__1	study interventions are Methylprednisolone acetate . prostate cancer diagnosis and clinically significant cardiac failure requiring treatment nyha ii iv
__label__1	study interventions are Niacinamide . renal cell carcinoma diagnosis and use of megestrol acetate and medroxyprogesterone
__label__1	study interventions are Vaccinia virus (vvDD-CDSR) . colorectal cancer diagnosis and clinically significant active infection or uncontrolled medical condition pulmonary neurological cardiovascular gastrointestinal genitourinary considered high risk for investigational new drug treatment
__label__1	study interventions are Albumin-Bound Paclitaxel . mucinous cystadenocarcinoma of pancreas diagnosis and active pancreatitis or pancreatic infection
__label__1	study interventions are Panobinostat . primary central nervous system non hodgkin lymphoma diagnosis and patients who have received prior radone therapy will be allowed but must meet above requirements
__label__1	study interventions are Capecitabine . gastroesophageal junction adenocarcinoma diagnosis and patients with evidence of metastatic disease are not eligible
__label__1	study interventions are FOLFIR + Aflibercept . metastatic colorectal cancer diagnosis and gilbert syndrome
__label__1	study interventions are Everolimus . advanced cancer diagnosis and current use of any herbal supplements or rifampin rifampicin
__label__1	study interventions are Cisplatin . stage ivc squamous cell carcinoma of the oropharynx diagnosis and patients with history of significant cardiovascular neurological endocrine gastrointestinal respiratory or inflammatory illness that could preclude their participation in the study pose an undue medical hazard or interfere with the interpretation of the study results including but not limited to patients with congestive heart failure new york heart association nyha class three or class four unstable angina cardiac arrhythmia recent within the preceding six months myocardial infarction or stroke hypertension requiring greater_than two medications for adequate control diabetes mellitus with greater_than two episodes of ketoacidosis in the preceding 1two months chronic obstructive pulmonary disease copd requiring greater_than two hospitalizations in the preceding 1two months
__label__1	study interventions are Antibodies, Monoclonal . recurrent diffuse large cell lymphoma diagnosis and history of prior malignancy with the exception of the following
__label__1	study interventions are Bupivacaine . neuroma diagnosis and subject is claustrophobic
__label__1	study interventions are Plasma Analysis of circulating cell free DNA . colorectal cancer diagnosis and patients with psychological familial sociological or geographical condition potentially hampering compliance with the study protocol and follow up schedule
__label__1	study interventions are Liposomal doxorubicin . liver cancer diagnosis and poor renal function ack of arterial access eg femoral artery occlusion
__label__1	study interventions are Vincristine . stage marginal zone lymphoma diagnosis and history of significant cerebrovascular disease in the past three months or ongoing event with active symptoms or sequelae
__label__1	study interventions are Minocycline . lung cancer diagnosis and patients with pre existing tourette syndrome
__label__1	study interventions are Quality-of-life assessment . adult subependymal giant cell astrocytoma diagnosis and whole pelvic radiation is considered to be over twenty-five
__label__1	study interventions are Sirolimus . metastatic renal cell cancer diagnosis and prior treatment with everolimus or any other specific or selective torcone pithreek akt inhibitor eg temsirolimus
__label__1	study interventions are Gemcitabine . fallopian tube cancer diagnosis and patients taking valproic acid unless valproic acid is stopped at least thirty days prior to enrollment
__label__1	study interventions are Technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane . glioma diagnosis diagnosis and less thaneighteen years
__label__1	study interventions are Angiogenesis Inhibitors . stage iiic melanoma diagnosis and active seizure disorder or evidence of brain metastases
__label__1	study interventions are Hormones . estrogen receptor positive breast cancer diagnosis and patients who have received prior radiotherapy must have recovered from toxicity less_than grade one induced by this treatment
__label__1	study interventions are Pharmacological Study . unresectable malignant neoplasm diagnosis and new york heart association nyha class iii moderate or class iv severe at the time of screening
__label__1	study interventions are Fludarabine . hodgkin lymphoma diagnosis and hiv positive
__label__1	study interventions are Pancrelipase . adenocarcinoma of the pancreas diagnosis and external biliary drain
__label__1	study interventions are Gemcitabine . stage iv primary peritoneal cavity cancer diagnosis and patients whose disease has progressed following at least three cycles of neoadjuvant chemotherapy as defined by at least one of the following
__label__1	study interventions are Prednisone . peripheral cell lymphoma diagnosis and these patients are excluded because the effects of this treatment on the fetus and young children are unknown
__label__1	study interventions are Somatostatin . anti cancer therapy with the exception of lanreotide or another somatostatin analogue within twenty-one days or five half lives whichever is shorter of starting study treatment
__label__1	study interventions are Pertuzumab . hertwo positive breast cancer diagnosis and indwelling temporary pacemaker
__label__1	study interventions are Cyclosporins . recurrent adult burkitt lymphoma diagnosis and positive cross match exists between the donor and recipient
__label__1	study interventions are Erlotinib Hydrochloride . carcinoma non small cell lung diagnosis and known pre existing interstitial lung disease
__label__1	study interventions are Azacitidine . carcinoma non small cell lung diagnosis and fourteen
__label__1	study interventions are Cyclosporine . clear cell renal cell carcinoma diagnosis and fertile men or women unwilling to use contraceptive techniques during and for twelve months following treatment
__label__1	study interventions are Erlotinib Hydrochloride . lymphomas diagnosis and known human immunodeficiency virus hiv infection or known hiv related malignancy
__label__1	study interventions are Aldesleukin . stage iv melanoma diagnosis and serum creatinine greater_than doc mg dl or creatinine clearance less_than seventy-five ml min
__label__1	study interventions are Sorafenib . gliosarcoma diagnosis and severe active co morbidity defined as follows
__label__1	study interventions are Fludarabine . recurrent adult diffuse large cell lymphoma diagnosis and research participants receiving any other investigational agents or concurrent biological chemotherapy or radiation therapy
__label__1	study interventions are Paclitaxel . cervical adenosarcoma diagnosis and pregnant women
__label__1	study interventions are Rituximab . mantle cell lymphoma diagnosis and cardiac status as described in protocol
__label__1	study interventions are 10-deazaaminopterin . lymphoma cell diagnosis and uncontrolled hypertension
__label__1	study interventions are Cetuximab . carcinoma squamous diagnosis and active infection or fever within three days of treatment
__label__1	study interventions are Antibodies, Monoclonal . mixed adenocarcinoma of the stomach diagnosis and that would preclude any of the study therapy drugs are not eligible specifically excluded are the following conditions
__label__1	study interventions are LY3039478 . lymphoma diagnosis and have active or uncontrolled clinically serious hepatitis virus or hepatitis virus infection
__label__1	study interventions are Prednisolone hemisuccinate . prostate cancer less_than gleason score six with stable prostate specific antigen psa over twelve months
__label__1	study interventions are Immunoglobulins . history of acute diverticulitis intra abdominal abscess gastrointestinal obstruction or abdominal carcinomatosis
__label__1	study interventions are Semaxinib . concurrent anti cancer radiotherapy
__label__1	study interventions are Melphalan . absolute neutrophil count anc less_than one zero cells ml doc one09 platelet count less_than fifty zero cells ml fifty one09 for patients in whom less_than fifty of bone marrow nucleated cells are plasma cells but platelet count less_than thirty zero cells ml for patients in whom fifty of bone marrow nucleated cells are plasma cells serum sgpt alt greater_than doc upper limit of normal uln bilirubin greater_than two uln alt more specific to liver creatinine clearance less_than thirty ml min cockcroft gault calculation five prior history of malignancies other than multiple myeloma unless the subject has been free of the disease for three years
__label__1	study interventions are Lenograstim . contiguous stage ii adult diffuse large cell lymphoma diagnosis and patient has an absolute neutrophil count of anc less_than doc ten nine within fourteen days before enrollment
__label__1	study interventions are Etoposide . breast cancer diagnosis and pregnancy or lactation
__label__1	study interventions are Bevacizumab . hepatosplenic cell lymphoma diagnosis and patients with history of hemoptysis
__label__1	study interventions are Antibodies, Monoclonal . solid neoplasm diagnosis and patients who have been previously treated with met proto_oncogene met or vascular endothelial growth factor receptor vegfr inhibitors are not eligible for phase ii but can enroll in the phase portion
__label__1	study interventions are Fludarabine . recurrent cutaneous cell non hodgkin lymphoma diagnosis and hiv positive
__label__1	study interventions are Mycophenolate mofetil . adult grade iii lymphomatoid granulomatosis diagnosis and patients who previously have received higher than allowed dose of radiation to small lung liver and brain volume will be evaluated by the radiation oncologist to determine if the patient is eligible for study
__label__1	study interventions are Antibodies . stage ivc verrucous carcinoma of the larynx diagnosis and previous or current uveitis
__label__1	study interventions are Docetaxel . cancer diagnosis and prior major surgery or trauma within twenty-eight days before first dose of study drug
__label__1	study interventions are 10-Meter Walk Test . head and neck cancer diagnosis and medical comorbidities which limit the safe completion of the sixmwt gait speed and strength testing
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian carcinoma diagnosis and hiv positive
__label__1	study interventions are Ulipristal . leiomyoma diagnosis and abuse of alcohol drugs or medicines laxatives
__label__1	study interventions are precision cells . advanced lung cancer diagnosis and other serious diseases
__label__1	study interventions are Cisplatin . stage iv adult soft tissue sarcoma diagnosis and evidence of pulmonary toxicity from previous or ongoing chemotherapy
__label__1	study interventions are Recombinant Human Interleukin-15 . stage iiib non small cell lung cancer diagnosis and patients who have received prior anti ctlafour or anti pdone therapy less than eight weeks prior to enrollment
__label__1	study interventions are Albumin-Bound Paclitaxel . epithelial ovarian cancer diagnosis and the investigator should consult the study chair
__label__1	study interventions are Etoposide phosphate . recurrent cutaneous cell non hodgkin lymphoma diagnosis and fertile patients must use effective contraception
__label__1	study interventions are Oxaliplatin . stage iv pancreatic cancer diagnosis and pregnancy or breastfeeding
__label__1	study interventions are gas chromatography-mass spectrometry . prostate cancer diagnosis and patients who have received prior cytotoxic chemotherapy or androgen ablative therapy for recurrent disease
__label__1	study interventions are Gefitinib . non small cell lung cancer diagnosis and known severe hypersensitivity to gefitinib or any of the excipients of this product
__label__1	study interventions are Cyclosporine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Carboplatin . tubular breast cancer stage ii diagnosis and currently active infection
__label__1	study interventions are Lenograstim . stage iii adult diffuse large cell lymphoma diagnosis and hiv seropositive
__label__1	study interventions are Sorafenib . metastatic breast cancer diagnosis and prior chemotherapy for metastatic disease
__label__1	study interventions are Antibodies, Monoclonal . stage ivb oropharyngeal squamous cell carcinoma diagnosis and patients with distant metastatic disease stage ivc
__label__1	study interventions are Sunitinib . colorectal carcinoma diagnosis and uncontrolled hypertension
__label__1	study interventions are Antibodies, Monoclonal . recurrent mantle cell lymphoma diagnosis and human immunodeficiency virus hiv positive
__label__1	study interventions are Immunoglobulin G . stage iib fallopian tube cancer diagnosis and note
__label__1	study interventions are Antibodies, Monoclonal . peripheral cell lymphoma diagnosis and persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least eight weeks after ipilimumab is stopped sexually active wocbp must use an effective method of birth control during the course of the study in manner such that risk of failure is minimized before study enrollment wocbp must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy all wocbp must have negative pregnancy test before first receiving ipilimumab if the pregnancy test is positive the patient must not receive ipilimumab and must not be enrolled in the study
__label__1	study interventions are Placebo . head and neck cancer diagnosis and had curative surgery more than six weeks prior to the initiation of radiotherapy
__label__1	study interventions are Gossypol acetic acid . stage iv prostate cancer diagnosis and patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
__label__1	study interventions are Dexamethasone acetate . lymphoblastic lymphoma diagnosis and inability or unwillingness of research participant or legal guardian representative to give written informed consent
__label__1	study interventions are neoadjuvant chemotherapy . fallopian tube carcinoma diagnosis and patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis are excluded
__label__1	study interventions are Diphosphonates . adenocarcinoma of the prostate diagnosis and any of the following
__label__1	study interventions are Gemcitabine . unresectable sarcoma diagnosis and concomitant use of drugs with risk of causing torsades de pointes
__label__1	study interventions are Iodine-131 anti-B1 antibody . chronic lymphocytic leukemia or small lymphocytic lymphoma well differentiated lymphocytic lymphoma
__label__1	study interventions are Carboplatin . breast cancer diagnosis and peripheral neuropathy of common toxicity criteria ctc grade greater than
__label__1	study interventions are Dabrafenib . stage iiib skin melanoma diagnosis and herbal remedies st
__label__1	study interventions are Niacinamide . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and patients who have had chemotherapy or radiotherapy within three months prior to entering the study
__label__1	study interventions are Immunoglobulin G . stage iv fallopian tube cancer diagnosis and clinical evidence of encephalopathy
__label__1	study interventions are Leucovorin . metastatic colorectal cancer diagnosis and history of thrombotic or hemorrhagic disorder patients with elevated international normalized ratio inr doc to doc on stable doses of therapeutic anticoagulation are eligible
__label__1	study interventions are Lenograstim . stage iii grade three follicular lymphoma diagnosis and female subject is pregnant or breast feeding confirmation that the subject is not pregnant must be established by negative serum beta human chorionic gonadotropin hcg pregnancy test result obtained during screening pregnancy testing is not required for post menopausal or surgically sterilized women
__label__1	study interventions are Stereotactic radiosurgery . adult oligodendroglioma diagnosis and radiation therapy to more than twenty-five of the bone marrow
__label__1	study interventions are Aminolevulinic Acid . colon cancer diagnosis and patients with any acute or chronic illness including cardiovascular disease history of atrial fibrillation or ventricular arrhythmias or history of myocardial infarction autoimmune state or any psychiatric illness that in the opinion of the investigators would compromise treatment
__label__1	study interventions are Cabozantinib S-malate . stage ivb osteosarcoma diagnosis and the subject is unable to swallow tablets
__label__1	study interventions are Dexamethasone acetate . plasma cell myeloma diagnosis and other concurrent chemotherapy or any ancillary therapy considered investigational
__label__1	study interventions are Fludarabine phosphate . stage ii childhood small noncleaved cell lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for csf mobilization and harvest of pbmc
__label__1	study interventions are Pembrolizumab . stage iiib breast cancer diagnosis and hormone replacement therapies estrogens megestrol acetate within fourteen days prior to day one of protocol therapy
__label__1	study interventions are Endothelial Growth Factors . recurrent primary peritoneal carcinoma diagnosis and child pugh or classification
__label__1	study interventions are Fludarabine . hepatosplenic cell lymphoma diagnosis and new york heart association nyha classification iii or iv heart disease
__label__1	study interventions are Tacrolimus . recurrent marginal zone lymphoma diagnosis and patients who in the opinion of the treating physician are unlikely to comply with the restrictions of allogeneic stem cell transplantation based on formal psychosocial screening
__label__1	study interventions are Gemcitabine . advanced cancer diagnosis and have previously completed or withdrawn from this study or any other study investigating lytwo million, six hundred and three thousand, six hundred and eighteen or any other checkpoint kinase one chkone inhibitor
__label__1	study interventions are Sorafenib . stage iva squamous cell carcinoma of the larynx diagnosis and john wort hypericum_perforatum or rifampin rifampicin and or rifabutin within twenty-eight days before randomization
__label__1	study interventions are Albumin-Bound Paclitaxel . carcinoma non small cell lung diagnosis and palliative radiation therapy
__label__1	study interventions are Rituximab . uncontrolled intercurrent illness including but not limited to ongoing or active infection symptomatic congestive heart failure unstable angina pectoris cardiac arrhythmia or psychiatric illness social situations that would in the judgment of the investigator limit compliance with study requirements
__label__1	study interventions are Metformin . subjects with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection
__label__1	study interventions are Ifosfamide . clear cell sarcoma of soft tissue diagnosis and cerebrovascular accident cva or transient ischemic attack tia
__label__1	study interventions are Albumin-Bound Paclitaxel . small cell lung cancer diagnosis and received treatment within the last thirty days with drug that has not received food and drug administration fda approval for any indication at the time of study entry
__label__1	study interventions are Etoposide . recurrent adult diffuse large cell lymphoma diagnosis and host disease complications greater than risk of recurrence after autologous bmt
__label__1	study interventions are Sirolimus . prostate cancer diagnosis and uncontrolled diabetes mellitus despite adequate therapy
__label__1	study interventions are Mycophenolate mofetil . angioimmunoblastic cell lymphoma diagnosis and donor
__label__1	study interventions are management of therapy complications . stage iii malignant testicular germ cell tumor diagnosis and any artificial_limbs
__label__1	study interventions are Gossypol . squamous cell carcinoma of the head and neck scchn diagnosis and treatment of scchn with erlotinib within fourteen days of the first dose of study treatment
__label__1	study interventions are Mitomycins . bladder cancer transitional cell grade diagnosis and previous radiotherapy to the pelvis
__label__1	study interventions are Pretend Reiki . prostate cancer diagnosis and any patient whose medical intervention could not wait the four weeks for intervention for medical reasons
__label__1	study interventions are Fludarabine . adult grade iii lymphomatoid granulomatosis diagnosis and child class and liver failure
__label__1	study interventions are Sirolimus . advanced solid cancers diagnosis and because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with these agents breastfeeding should be discontinued if the mother is treated
__label__1	study interventions are Prednisone . burkitt lymphoma diagnosis and administration of myeloid growth factors or platelet transfusion within fourteen days prior to the first dose of study treatment
__label__1	study interventions are Antibodies, Monoclonal . history or active secondary cancer within the last five years except for superficial basal cell skin cancers curatively resected non melanoma skin cancer
__label__1	study interventions are Bevacizumab . significant vascular disease or symptomatic peripheral vascular disease
__label__1	study interventions are Eicosapentaenoic acid ethyl ester . malignant neoplasms of independent primary multiple sites diagnosis and major contraindication to fish oil hypersensitivity to fish oil or physical activity
__label__1	study interventions are Mycophenolic Acid . stage adult lymphoblastic lymphoma diagnosis and cardiac ejection fraction less_than thirty-five ejection fraction is required if age greater_than fifty years or there is history of anthracycline exposure or history of cardiac disease
__label__1	study interventions are Cisplatin . stage iva intrahepatic cholangiocarcinoma diagnosis and adjuvant chemotherapy is allowed if completed greater_than six months prior to the start of registration
__label__1	study interventions are Sonidegib . recurrent skin cancer diagnosis and note
__label__1	study interventions are Antibodies, Monoclonal . stage iv uveal melanoma diagnosis and active infection requiring parenteral antibiotics
__label__1	study interventions are Counseling Intervention . lung cancer diagnosis and one high risk pregnancy or known negative birth outcome
__label__1	study interventions are Doxorubicin . regional neuroblastoma diagnosis and group and patients who do not enroll on anblone thousand, two hundred and thirty-two within four weeks of definitive diagnostic procedure
__label__1	study interventions are Talaporfin . liver neoplasms diagnosis and any concurrent disease or condition that in the opinion of the investigator impairs the patient ability to complete the trial such as psychological familial sociological geographical or medical conditions which in the principal investigator opinion could compromise compliance with the objectives and procedures of this protocol or obscure interpretation of the trial data are excluded
__label__1	study interventions are Bevacizumab . insulinoma diagnosis and serious non healing wound active ulcer or untreated bone fracture
__label__1	study interventions are Cisplatin . stomach neoplasms diagnosis and post menopausal women must have been amenorrheic for at least twelve months to be considered of non child bearing potential
__label__1	study interventions are Sirolimus . stage iiic uterine corpus cancer diagnosis and patients undergoing invasive procedures as defined below
__label__1	study interventions are Tacrolimus . intraocular lymphoma diagnosis and liver abnormalities
__label__1	study interventions are Liposomal doxorubicin . stage ii angioimmunoblastic cell lymphoma diagnosis and known seropositive for or active viral infection with human immunodeficiency virus hiv hepatitis virus hbv or hepatitis virus hcv patients who are seropositive because of hepatitis virus vaccine are eligible
__label__1	study interventions are Paclitaxel . non small cell lung carcinoma diagnosis and patient has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the patient to receive an experimental research drug
__label__1	study interventions are Everolimus . squamous cell lung carcinoma diagnosis and any of the following concurrent severe and or uncontrolled medical conditions
__label__1	study interventions are Fludarabine phosphate . stage ii non contiguous adult lymphoblastic lymphoma diagnosis and patient has poorly controlled hypertension and on multiple antihypertensives
__label__1	study interventions are Carboplatin . stage iv pancreatic cancer diagnosis and patients with untreated brain metastases will be excluded from this clinical trial however patients with resected oligometastasis are eligible if postresection magnetic resonance imaging mri demonstrates resolution gamma_knife treated patients are also eligible if there are no more than two treated metastases confined to the same area of the brain and post treatment mri shows decrease in the metastases
__label__1	study interventions are Tacrolimus . stage iii adult diffuse mixed cell lymphoma diagnosis and women of childbearing potential who are pregnant beta hcg positive or breast feeding
__label__1	study interventions are Laboratory Biomarker Analysis . stage laryngeal squamous cell carcinoma diagnosis and magnesium less_than doc or greater_than doc mg dl
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and known positive for hiv human immunodeficiency virus or infectious hepatitis type or c
__label__1	study interventions are Melanocyte-Stimulating Hormones . breast cancer diagnosis and prior radiation therapy to the chest or brain
__label__1	study interventions are Cetuximab . carcinoma squamous cell of the head and neck diagnosis and if currently taking either of these medications patient must discontinue for one week before receiving treatment with nab paclitaxel
__label__1	study interventions are Albumin-Bound Paclitaxel . tubular breast cancer stage ii diagnosis and concurrent treatment with
__label__1	study interventions are Maleic acid . fallopian tube clear cell adenocarcinoma diagnosis and history of myocardial infarction within six to twelve months patients with history of myocardial infarction within six months are excluded from the study
__label__1	study interventions are Pharmacological Study . adult rhabdomyosarcoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to gdc four hundred and forty-nine or rofour million, nine hundred and twenty-nine thousand and ninety-seven used in the study
__label__1	study interventions are Docetaxel . carcinoma non small cell lung diagnosis and patients with uncontrolled peptic ulcer disease will be excluded
__label__1	study interventions are Albumin-Bound Paclitaxel . tubular breast cancer stage ii diagnosis and pre existing motor or sensory neuropathy of severity grade two by nci ctc criteria doc
__label__1	study interventions are Nivolumab . recurrent prostate carcinoma diagnosis and patients should be excluded if they have condition requiring systemic treatment with either corticosteroids greater_than ten mg daily prednisone equivalents or other immunosuppressive medications within fourteen days of study drug administration inhaled or topical steroids and adrenal replacement doses greater_than ten mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
__label__1	study interventions are Androgens . prostate cancer diagnosis and hormone therapy within twelve months
__label__1	study interventions are Endothelial Growth Factors . fallopian tube endometrioid adenocarcinoma diagnosis and new york heart association nyha class ii or higher congestive heart failure
__label__1	study interventions are Antibodies, Monoclonal . hertwo negative breast cancer diagnosis and known hypersensitivity to any component of avastin or gemcitabine or other required drugs in the study
__label__1	study interventions are Sirolimus . lymphoblastic lymphoma diagnosis and gabapentin or levetiracetam prior to study entry is acceptable
__label__1	study interventions are Disulfiram . glioblastoma diagnosis and radiation implants
__label__1	study interventions are Mycophenolate mofetil . recurrent refractory childhood hodgkin lymphoma diagnosis and donor
__label__1	study interventions are Hydroxyurea . recurrent squamous cell carcinoma of the nasopharynx diagnosis and patients who have had chemotherapy within four weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Antibodies, Monoclonal . stage ivb hepatocellular carcinoma diagnosis and patients with active autoimmune disease or history of autoimmune disease that might recur which may affect vital organ function or require immune suppressive treatment including chronic prolonged systemic corticosteroids defined as corticosteroid use of duration one month or greater should be excluded these include but are not limited to patients with history of
__label__1	study interventions are Niacinamide . stage ivb squamous cell carcinoma of the lip and oral cavity diagnosis and john wort hypericum_perforatum or rifampin rifampicin and or rifabutin within twenty-eight days before randomization
__label__1	study interventions are Carboplatin . stage iib fallopian tube cancer diagnosis and ctep ctcae version doc grade two or higher peripheral ischemia brief less_than two4 hours hrs episode of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Irinotecan . adenocarcinoma diagnosis and blood pressure of greater_than one hundred and fifty one hundred mmhg
__label__1	study interventions are Methylprednisolone Hemisuccinate . wegener granulomatosis diagnosis and history of severe allergic reactions to human or chimeric monoclonal antibodies
__label__1	study interventions are Mycophenolic Acid . recurrent adult diffuse large cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are dietary intervention . colon cancer diagnosis and currently taking more than three antihypertensive medications
__label__1	study interventions are Oxaliplatin . rectal neoplasms diagnosis and female patients who are pregnant or breast feeding
__label__1	study interventions are Sonidegib . nevoid basal cell carcinoma syndrome diagnosis and other concurrent severe and or uncontrolled concomitant medical conditions eg active or uncontrolled infection that could cause unacceptable safety risks or compromise compliance with the protocol
__label__1	study interventions are BB 1101 . multiple myeloma diagnosis and degenerative changes of the hip joint are not exclusionary
__label__1	study interventions are Doxorubicin . advanced solid tumors phase one population diagnosis and patient has received an anthracycline within six months prior to entry into the study
__label__1	study interventions are Estradiol . prostate neoplasms diagnosis and aprepitant bexarotene clarithromycin itraconazole ketoconazole st
__label__1	study interventions are Antibodies, Monoclonal . stage iiia fallopian tube cancer diagnosis and exceptions allowed for patients unable to tolerate the agent intolerance is defined in this protocol as discontinued agent due to side effects with an exposure less_than to four weeks of drug at any dose level
__label__1	study interventions are pharmacological study . recurrent prostate cancer diagnosis and the subject has received cytotoxic chemotherapy including investigational cytotoxic chemotherapy or biologic agents eg cytokines or antibodies within three weeks or nitrosoureas mitomycin within six weeks before the first dose of study treatment
__label__1	study interventions are Antibodies . childhood nasal type extranodal nk cell lymphoma diagnosis and donors who are hiv positive and or medical conditions that would result in increased risk for granulocyte colony stimulating factor csf mobilization and harvest of peripheral blood stem cell pbsc
__label__1	study interventions are Laboratory Biomarker Analysis . nodal marginal zone lymphoma diagnosis and patients with any form of feeding tube or swallowing disorder are not eligible
__label__1	study interventions are Interleukin-2 . metastatic malignant neoplasm diagnosis and any form of primary immunodeficiency such as severe combined immunodeficiency disease
__label__1	study interventions are Cortisone acetate . recurrent prostate carcinoma diagnosis and concurrent or planned treatment with strong inhibitors or strong inducers of cytochrome pfour hundred and fifty family three subfamily polypeptide four five threeafour five one week wash out period is necessary for patients who are already on these treatments
__label__1	study interventions are Camptothecin . stage iiic rectal cancer diagnosis and total abstinence when this is in line with the preferred and usual_lifestyle of the subject periodic abstinence calendar_ovulation symptothermal post ovulation methods and withdrawal are not acceptable methods of contraception
__label__1	study interventions are Mechlorethamine . recurrent adult non hodgkin lymphoma diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued these potential risks may also apply to other agents used in this study
__label__1	study interventions are Interleukin-2 . stage iv breast cancer diagnosis and patients who have had cdthirty-four positive selection of their pbsc products
__label__1	study interventions are Pembrolizumab . recurrent malignant glioma diagnosis and is not considered form of systemic treatment
__label__1	study interventions are Cyclosporine . recurrent adult diffuse mixed cell lymphoma diagnosis and donor is hiv positive and or has medical condition that would result in increased risk for filgrastim csf mobilization and harvest of pbsc
__label__1	study interventions are Liposomal doxorubicin . multiple myeloma diagnosis and significant infection
__label__1	study interventions are Oxaliplatin . history of other malignancy within last five years except for cured basal cell cancer of the skin or in situ cancer of the cervix
__label__1	study interventions are Imatinib Mesylate . prostatic neoplasms diagnosis and patient with any significant history of non compliance to medical regimens or with inability to grant reliable informed consent
__label__1	study interventions are Tamoxifen . fallopian tube cancer diagnosis and subjects with any evidence of new disease greater_than one cm including new ascites as confirmed by imaging
__label__1	study interventions are Methotrexate . relapsed non hodgkin or hodgkin lymphoma diagnosis and lvef less_than forty
__label__1	study interventions are Paclitaxel . untreated metastatic pancreatic ductal adenocarcinoma diagnosis and prior pd one or pd lone therapy
__label__1	study interventions are Rituximab . contiguous stage ii mantle cell lymphoma diagnosis and chronic or current infectious disease requiring systemic antibiotics antifungal or antiviral treatment such as but not limited to chronic renal infection chronic chest infection with bronchiectasis tuberculosis and active hepatitis c
__label__1	study interventions are Irinotecan . gastric cancer diagnosis and patients with infection intestinal palsy or intestinal occlusion
__label__1	study interventions are Capecitabine . breast cancer diagnosis and active peptic ulcer incomplete wound healing or unhealed bone fracture
__label__1	study interventions are Hydrocortisone 17-butyrate 21-propionate . colorectal cancer diagnosis and prior cetuximab treatment within the six months of study initiation
__label__1	study interventions are Dacarbazine . recurrent childhood medulloblastoma diagnosis and patients must not have had significant vascular disease eg aortic aneurysm requiring surgical repair deep venous or arterial thrombosis within the last six months prior to study entry
__label__1	study interventions are Open colectomy . colorectal cancer diagnosis and chronic diseases
__label__1	study interventions are Fludarabine phosphate . lymphoma diagnosis and stable disease is acceptable to move forward provided it is non bulky
__label__1	study interventions are Antibodies, Monoclonal . stage iii oropharyngeal squamous cell carcinoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to cetuximab or ipilimumab
__label__1	study interventions are Calcium Carbonate . ovarian cancer diagnosis and hyperparathyroidism hyperthyroidism
__label__1	study interventions are Fluorouracil . squamous carcinoma of esophagus diagnosis and presence of bowel obstruction within the last thirty days
__label__1	study interventions are Doxorubicin . undifferentiated fallopian tube carcinoma diagnosis and significant cardiovascular or cerebrovascular disease including
__label__1	study interventions are Surgery . glioblastoma diagnosis and list of eiaed and other inducers of cypthreeafour is provided in table three of appendix of the protocol
__label__1	study interventions are Liposomal doxorubicin . advanced cancer diagnosis and bilirubin greater_than doc mg dl
__label__1	study interventions are Veliparib . recurrent epithelial ovarian cancer diagnosis and pregnant or breast feeding patients
__label__1	study interventions are Sirolimus . stage iv renal cell cancer diagnosis and sub protocol aim a
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent gallbladder carcinoma diagnosis and patients must not have any other condition including mental illness or substance abuse deemed by the investigator to be likely to interfere with patient ability to sign informed consent cooperate and participate in the study or interferes with the interpretation of the results
__label__1	study interventions are Immunoglobulins . recurrent fallopian tube carcinoma diagnosis and brain metastases per mri or ct at any time prior to registration note
__label__1	study interventions are Nitrogen Mustard Compounds . ds stage ii plasma cell myeloma diagnosis and known allergies to any of the components of the investigational treatment regimen or required ancillary treatments
__label__1	study interventions are Dexamethasone acetate . patients who have had any prior chemotherapy for mm with the exception of pulse steroids for any myeloma related acute events
__label__1	study interventions are Tacrolimus . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and current serious systemic illness that would result in increased risk for csf mobilization and harvest of peripheral blood stem cells pbsc
__label__1	study interventions are Cyclosporine . stage iv adult burkitt lymphoma diagnosis and the addition of cytotoxic agents for cytoreduction with the exception of hydroxyurea and imatinib mesylate will not be allowed within two weeks of the initiation of conditioning
__label__1	study interventions are Sirolimus . stage childhood anaplastic large cell lymphoma diagnosis and human immunodeficiency virus hiv positive patients
__label__1	study interventions are Antibodies, Monoclonal . stage iiib primary peritoneal cancer diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are IV administration of gadolinium-containing contrast agent . adult anaplastic oligodendroglioma diagnosis and inability to adhere to the experimental protocols for any reason
__label__1	study interventions are Norethindrone . cancer diagnosis and exception
__label__1	study interventions are Doxorubicin . metastatic childhood soft tissue sarcoma diagnosis and female patients who are pregnant are not eligible
__label__1	study interventions are Antibodies . testicular lymphoma diagnosis and prior autologous bone marrow or stem cell transplant within one year of enrollment
__label__1	study interventions are Cetuximab . stage ivb squamous cell carcinoma of the oropharynx diagnosis and note
__label__1	study interventions are Basiliximab . glioblastoma multiforme diagnosis and active connective tissue disorders such as lupus or scleroderma that in the opinion of the treating physician may put the patient at high risk for radiation toxicity
__label__1	study interventions are Epirubicin . patients with advanced or metastatic solid tumors diagnosis and has known hypersensitivity to five fu epirubicin oxaliplatin or other platinum compounds
__label__1	study interventions are Etoposide . anaplastic lymphoma large cell lymphoma or small noncleaved cell lymphoma
__label__1	study interventions are Bevacizumab . esophageal cancer diagnosis and urine protein
__label__1	study interventions are Paclitaxel . ovarian cancer recurrent diagnosis and uncontrolled hypertension within three months prior to study treatment or patient with organ damage related to hypertension
__label__1	study interventions are Dexamethasone 21-phosphate . multiple myeloma diagnosis and known or suspected al amyloidosis
__label__1	study interventions are Doxorubicin . metastatic leiomyosarcoma diagnosis and history of non compliance to medical regimen or inability to grant consent
__label__1	study interventions are Pembrolizumab . epithelial ovarian cancer diagnosis and is pregnant or breastfeeding or expecting to conceive within the projected duration of the study starting with the pre screening or screening visit through one hundred and twenty days after the last dose of study treatment
__label__1	study interventions are Antibodies . recurrent adult diffuse large cell lymphoma diagnosis and other significant medical diseases
__label__1	study interventions are Dabrafenib . solid neoplasm diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to navitoclax dabrafenib or trametinib or excipients or to dimethyl_sulfoxide dmso
__label__1	study interventions are Carboplatin . recurrent primary peritoneal cavity cancer diagnosis and any patient with active crohn disease or active ulcerative colitis is excluded patients having these conditions are at an excessive risk of organ function impairing fibrosis
__label__1	study interventions are Bevacizumab . gallbladder adenocarcinoma diagnosis and evidence of bleeding diathesis or coagulopathy
__label__1	study interventions are Oxaliplatin . stage iiic colon cancer diagnosis and unstable angina within twelve months before study entry and
__label__1	study interventions are Doxorubicin . fallopian tube transitional cell carcinoma diagnosis and prior treatment with trastuzumab
__label__1	study interventions are Vinblastine . history or clinical evidence of central nervous system cns metastases or leptomeningeal carcinomatosis
__label__1	study interventions are Everolimus . breast cancer diagnosis and premenopausal status
__label__1	study interventions are Exemestane . metastatic breast cancer diagnosis and known or possible hypersensitivity to goserelin during the adjuvant setting
__label__1	study interventions are Mechlorethamine . medulloepithelioma diagnosis and subject is pregnant or is lactating
__label__1	study interventions are Niacinamide . unresectable hepatocellular carcinoma diagnosis and esophageal and or gastric varices which has high risk of bleeding
__label__1	study interventions are Oxaliplatin . rectal cancer diagnosis and has undergone major surgery within twenty-eight days prior to randomization
__label__1	study interventions are The imaging biomarkers determined by MR-PET . esophageal cancer diagnosis and for the safety reason patients with the following conditions are contraindicated to enter magnetic resonance imaging mri machine due to the high magnetic field including
__label__1	study interventions are Rituximab . contiguous stage ii marginal zone lymphoma diagnosis and chronic or current infectious disease requiring systemic antibiotics antifungal or antiviral treatment such as but not limited to chronic renal infection chronic chest infection with bronchiectasis tuberculosis and active hepatitis c
__label__1	study interventions are Cyclophosphamide . splenic marginal zone lymphoma diagnosis and no serious medical or psychiatric illness
__label__1	study interventions are Vidarabine . hematopoietic lymphoid cancer diagnosis and male
__label__1	study interventions are Fluorouracil . stage iva colon cancer diagnosis and pregnancy or breastfeeding
__label__1	study interventions are Testosterone enanthate . localized prostate cancer diagnosis and adt consists of chemical castration degarelix to remove endogenous dht
__label__1	study interventions are Vidarabine . recurrent childhood large cell lymphoma diagnosis and donor recipient pairs in which the hla mismatch is only in the hvg_direction
__label__1	study interventions are Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years . pharynx cancer diagnosis and head and neck clinical examination during the past six months
__label__1	study interventions are Liposomal doxorubicin . progesterone receptor positive breast cancer diagnosis and inability to cooperate with treatment protocol
__label__1	study interventions are Immunoglobulins . hepatosplenic cell lymphoma diagnosis and patients with poorly controlled hypertension on multiple antihypertensives
__label__1	study interventions are Game-based intervention . cancer diagnosis and unable to walk for exercise self report
__label__1	study interventions are Antibodies, Monoclonal . recurrent melanoma diagnosis and use of topical or inhaled corticosteroids will not render patient ineligible
__label__1	study interventions are Trametinib . cancer diagnosis and known immediate or delayed hypersensitivity to any of the components of the study treatment s
__label__1	study interventions are Gemcitabine . symptomatic or any uncontrolled arrhythmia
__label__1	study interventions are Therapeutic Conventional Surgery . stage iiib fallopian tube cancer diagnosis and one subjects with extensive liver metastasis as judged by the investigator two subjects who drink more than two standard alcoholic_beverages per day on regular basis three subjects who consume more than two grams of acetaminophen per day on regular basis
__label__1	study interventions are Sorafenib . hepatoma diagnosis and vascular anatomy that precludes catheter placement or injection of lc bead microspheres
__label__1	study interventions are Capecitabine . colorectal tumors diagnosis and systemic metastases liver lung
__label__1	study interventions are Docetaxel . prostate cancer diagnosis and doc
__label__1	study interventions are Yoga . breast cancer diagnosis and have regularly engaged in moderate activity that makes you breathe somewhat harder than normal may include carrying light loads bicycling at regular pace fast walking tennis easy swimming or popular or folk dancing or vigorous activity that causes heavy breathing sweating rapid fatigue it can only be sustained for very short periods of time like running or swimming strongly physical activity at least three five days per week on average within the past four weeks
__label__1	study interventions are Piracetam . brain tumor without the potential need for chemotherapy meningioma without anaplastic features
__label__1	study interventions are Albumin-Bound Paclitaxel . breast cancer diagnosis and male patients
__label__1	study interventions are Prednisone . prostate cancer diagnosis and known brain metastases or uncontrolled epidural disease
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iia fallopian tube cancer diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies
__label__1	study interventions are Sirolimus . neurofibromatosis type one diagnosis and with an active bleeding diathesis
__label__1	study interventions are Rituximab . adult diffuse large cell lymphoma diagnosis and uncontrolled bacterial viral or fungal infection currently taking medication and with progression or no clinical improvement
__label__1	study interventions are Female AR(+) TNBC Enzalutamide Treated . advanced breast cancer diagnosis and class iii or iv heart failure as defined by the new york heart association nyha functional classification system
__label__1	study interventions are ASN001: Dose 2 Part B . prostate cancer diagnosis and part only prior chemotherapy or radiotherapy within four weeks prior to day one
__label__1	study interventions are Interleukin-2 . metastatic melanoma diagnosis and need for immunosuppressive treatment corticosteroids or methotrexate
__label__1	study interventions are Gemcitabine . carcinoma non small cell lung diagnosis and recent myocardial infarction within six months
__label__1	study interventions are Pembrolizumab . refractory malignant neoplasm diagnosis and pregnancy or nursing or unwilling to take adequate birth control during therapy
__label__1	study interventions are Gefitinib . lung neoplasms diagnosis and any prohibited concomitant medications for therapy with afatinib or gefitinib
__label__1	study interventions are Cediranib . stage ivb thyroid gland follicular carcinoma diagnosis and history of pulmonary embolism within the past twelve months
__label__1	study interventions are Cisplatin . non small cell lung cancer metastatic diagnosis and cons indication of bevacizumab
__label__1	study interventions are Goserelin . previous treatment for prostate cancer
__label__1	study interventions are Regorafenib 160 mg . colorectal adenocarcinoma diagnosis and cirrhosis
__label__1	study interventions are Pentetic Acid . patients with symptomatic disease that is due to malignant involvement of the central nervous system
__label__1	study interventions are Glycine . triple negative breast cancer diagnosis and radiation of the target lesion within the last four weeks prior to randomization
__label__1	study interventions are Expanded Prostate Cancer Index Composite . stage iia prostate cancer diagnosis and evidence of distant metastases
__label__1	study interventions are Etoposide . stage iii adult diffuse large cell lymphoma diagnosis and no current malignancy
__label__1	study interventions are Bevacizumab . anticancer chemotherapy or immunotherapy
__label__1	study interventions are Rituximab . stage small lymphocytic lymphoma diagnosis and patient is currently enrolled in or has not yet completed at least thirty days since ending another investigational device or drug trial
__label__1	study interventions are Antibodies . childhood pleomorphic rhabdomyosarcoma diagnosis and myocardial infarction or unstable angina within the prior six months
__label__1	study interventions are Laboratory Biomarker Analysis . recurrent childhood hepatocellular carcinoma diagnosis and major surgical procedure laparoscopic procedure or open biopsy within twenty-eight days prior to enrollment
__label__1	study interventions are Mycophenolic Acid . recurrent plasma cell myeloma diagnosis and donor
__label__1	study interventions are Oxaliplatin . pancreatic neoplasms diagnosis and for example biliary derivation
__label__1	study interventions are Paclitaxel . symptomatic brain metastasis
__label__1	study interventions are Levoleucovorin . mucinous adenocarcinoma of the rectum diagnosis and myocardial infarction severe unstable angina pectoris coronary peripheral artery bypass graft new york heart association nyha class iii or iv congestive heart failure stroke or transient ischemic attack
__label__1	study interventions are Paclitaxel . active malignancy other than non melanoma skin cancer within five years of enrollment
__label__1	study interventions are Gossypol . recurrent plasma cell myeloma diagnosis and nursing women
__label__1	study interventions are Pembrolizumab . diffuse large cell lymphoma diagnosis and has known clinically active central nervous system cns involvement
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian cancer diagnosis and psychiatric illness social situation that would limit compliance with study requirements
__label__1	study interventions are Cyclophosphamide . adult nasal type extranodal nk cell lymphoma diagnosis and performance status greater_than two eastern cooperative oncology group ecog or less_than fifty lansky for patients less_than sixteen years old
__label__1	study interventions are Dexamethasone . myeloma diagnosis and patients with grade greater_than equal_than three non hematologic toxicity from previous therapy that has not resolved to less_than equal_than grade one
__label__1	study interventions are Camptothecin . duct cell adenocarcinoma of the pancreas diagnosis and pregnancy or breastfeeding
__label__1	study interventions are MABp1 . advanced cancers diagnosis and immunocompromised including subjects know to be infected with hiv
__label__1	study interventions are Rituximab . small lymphocytic lymphoma diagnosis and inability to adhere to the study schedule or the required follow up
__label__1	study interventions are Laboratory Biomarker Analysis . endometrial undifferentiated carcinoma diagnosis and grapefruit and grapefruit juice cypthreeafour inhibitor seville_oranges and star_fruit consumption is not permitted during the study
__label__1	study interventions are Mycophenolic Acid . recurrent adult burkitt lymphoma diagnosis and age less than twelve years
__label__1	study interventions are laboratory biomarker analysis . recurrent adult lymphoblastic lymphoma diagnosis and hepatitis with positive viral load prior to transplant conditioning or hepatitis virus
__label__1	study interventions are Albumin-Bound Paclitaxel . breast adenocarcinoma diagnosis and any continued use of sex hormonal therapy birth control pills ovarian hormone replacement therapy patients are eligible if these medications are discontinued prior to randomization
__label__1	study interventions are Pembrolizumab . poorly differentiated thyroid gland carcinoma diagnosis and known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
__label__1	study interventions are Cisplatin . gastric cancer diagnosis and coagulopathies acquired or inherited
__label__1	study interventions are Carboplatin . carcinoma non small cell lung diagnosis and in case of hepatitis virus hcv antibody positive with hcv ribonucleic acid
__label__1	study interventions are Everolimus . stage ii contiguous adult diffuse small cleaved cell lymphoma diagnosis and diffusion capacity of carbon monoxide dlco less_than forty total lung capacity tlc less_than forty forced expiratory volume in one second fevone less_than forty and or receiving supplementary continuous oxygen
__label__1	study interventions are Interferon-alpha . melanoma diagnosis and patients with active autoimmune disorders or who are receiving immunosuppressive therapy including steroids or methotrexate for any indication are excluded
__label__1	study interventions are Emetics . cancer diagnosis and creatinine greater_than doc upper limit of normal
__label__1	study interventions are Prednisone . follicular lymphoma diagnosis and life expectancy less_than six months
__label__1	study interventions are Bortezomib . hodgkin lymphoma diagnosis and vorinostat cohorts only
__label__1	study interventions are Androgens . prostate cancer metastatic diagnosis and child pugh class or hepatic insufficiency
__label__1	study interventions are Deoxyglucose . recurrent non small cell lung cancer diagnosis and patients requiring continuous supplemental oxygen
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv breast cancer diagnosis and pregnant women are excluded from this study breastfeeding should be discontinued if the mother is treated with veliparib
__label__1	study interventions are Trastuzumab . known history of or clinical evidence of central nervous system cns metastases or leptomeningeal carcinomatosis
__label__1	study interventions are Lovastatin . prostate cancer diagnosis and currently taking an inhibitor of cytochrome pfour hundred and fifty threeafour
__label__1	study interventions are LEE011 . gastrointestinal cancer diagnosis and such patients must have no need for treatment with steroids or anti epileptic medications
__label__1	study interventions are Cyclophosphamide . invasive ductal breast cancer diagnosis and significant dental oral disease including prior history or current evidence of osteonecrosis osteomyelitis of the jaw active dental or jaw condition which requires oral surgery non healed dental oral surgery planned invasive dental procedure for the course of the study
__label__1	study interventions are Dexamethasone . refractory multiple myeloma diagnosis and serum alanine aminotransferase alt greater_than doc uln
__label__1	study interventions are Vorinostat . known brain metastases in patients with solid tumors or nhl
__label__1	study interventions are Trebananib . neoplasm prostatic diagnosis and inability to absorb abiraterone after oral administration previous major gastrointestinal surgery or gastrointestinal disease resulting in malabsorption
__label__1	study interventions are Fluorouracil . pretext stage two hepatoblastoma diagnosis and females who are pregnant or breast feeding are not eligible for this study
__label__1	study interventions are Bleomycin . posttransplantation hodgkin lymphoma
__label__1	study interventions are Carboplatin . stage iiib fallopian tube cancer diagnosis and patients who are receiving any other investigational agents
__label__1	study interventions are Vincristine . plasmablastic lymphoma diagnosis and patients who have undergone systemic treatment within fourteen days prior to registration with strong inhibitors of cytochrome pfour hundred and fifty superfamily cyp oneatwo fluvoxamine_enoxacin ciprofloxacin strong inhibitors of cypthreea clarithromycin telithromycin itraconazole voriconazole ketoconazole nefazodone posaconazole or strong cypthreea inducers rifampin rifapentine rifabutin carbamazepine phenytoin phenobarbital or use of ginkgo_biloba or st
__label__1	study interventions are Methotrexate . hepatosplenic cell lymphoma diagnosis and adult forty pediatric equal_than less_than eighteen yrs
__label__1	study interventions are HuMax-AXL-ADC . thyroid cancer diagnosis and grade two or higher peripheral neuropathy
__label__1	study interventions are Bevacizumab . carcinoma non small cell lung diagnosis and pregnant or lactating women
__label__1	study interventions are Veliparib . non small cell lung cancer diagnosis and clinically significant and uncontrolled major medical condition s
__label__1	study interventions are Antibodies, Monoclonal . breast cancer diagnosis and history of idiopathic pulmonary fibrosis organizing_pneumonia bronchiolitis_obliterans drug induced pneumonitis idiopathic pneumonitis or evidence of active pneumonitis on screening chest ct scan
__label__1	study interventions are Tremelimumab . cancer of pancreas diagnosis and history of hypersensitivity reaction to human or mouse antibody products
__label__1	study interventions are Vitamin B Complex . stage iv ovarian cancer diagnosis and known history of autoimmune disease
__label__1	study interventions are Metformin . stage iiib non small cell lung cancer diagnosis and chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within thirty days of registration
__label__1	study interventions are Gemcitabine . fallopian tube neoplasms diagnosis and pregnancy or lactation
__label__1	study interventions are Lenalidomide . recurrent adult diffuse small cleaved cell lymphoma diagnosis and boceprevir_victrelis
__label__1	study interventions are Liposomal doxorubicin . recurrent fallopian tube carcinoma diagnosis and pregnant or lactating patients
__label__1	study interventions are Etoposide . recurrent grade three follicular lymphoma diagnosis and no prior treatment with histone_deacetylase inhibitors
__label__1	study interventions are Tamoxifen . stage iia breast cancer diagnosis and patients with distant metastatic disease
__label__1	study interventions are Docetaxel . previous radiotherapy or chemotherapy for head and neck district tumors surgical treatment relapses are admitted
__label__1	study interventions are Abiraterone Acetate . a patient with controlled and asymptomatic cns metastases may participate in this trial
__label__1	study interventions are Vaccines . tumor diagnosis and subject has any underlying conditions which would contraindicate therapy with study treatment or allergies to reagents used in this study
__label__1	study interventions are AL3818 . ovarian cancer diagnosis and patients with acute or chronic liver disease active hepatitis or with known cirrhosis or liver dysfunction
__label__1	study interventions are Cyclosporine . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and donor
__label__1	study interventions are Mycophenolic Acid . recurrent mantle cell lymphoma diagnosis and infection with hiv
__label__1	study interventions are PLX73086 . tenosynovial giant cell tumor diagnosis and known hiv positive individuals on combination antiretroviral therapy
__label__1	study interventions are Histone Deacetylase Inhibitors . cutaneous lymphoma diagnosis and any serious medical condition laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form
__label__1	study interventions are Everolimus . metastatic transitional cell carcinoma diagnosis and patients with known hypersensitivity to everolimus radone or other rapamycins_sirolimus temsirolimus or to its excipients
__label__1	study interventions are Albumin-Bound Paclitaxel . ovarian serous cystadenocarcinoma diagnosis and core biopsy within seven days prior to the first date of bevacizumab therapy cycle two
__label__1	study interventions are Ferric Compounds . breast cancer female nos diagnosis and definite contraindications for the use of corticosteroids
__label__1	study interventions are Bleomycin . lymphoma non hodgkin diagnosis and patients with the following conditions or symptoms are excluded
__label__1	study interventions are immunological diagnostic method . cancer diagnosis and prior immunosuppressive therapy or radiotherapy for any disease healthy participant
__label__1	study interventions are Azathioprine . wegener granulomatosis diagnosis and malignancy
__label__1	study interventions are Vidarabine . noncutaneous extranodal lymphoma diagnosis and inability to achieve adequate venous access
__label__1	study interventions are Rituximab . non hodgkin lymphoma diagnosis and other major systemic disease such as active infection significant cardiac disease neurological deficit or psychiatric disorder that the investigators consider to be significant risk
__label__1	study interventions are Poly I-C . merkel cell carcinoma diagnosis and grade two or higher peripheral ischemia brief less_than two4 hours episode of ischemia managed non surgically and without permanent deficit
__label__1	study interventions are Sorafenib . metastatic renal cell carcinoma diagnosis and women of childbearing potential must have negative pregnancy test performed within seven days of the start of treatment
__label__1	study interventions are Dabrafenib . stage iv melanoma diagnosis and pulmonary embolism on active therapy history of interstitial lung disease or pneumonitis known hiv hepatitis or infection with the exception of chronic or cleared hbv and hcv infection which will be allowed provided the following tests are done at screening
__label__1	study interventions are Letrozole . breast cancer diagnosis and any psychological family sociological or geographical circumstance that could potentially represent an obstacle to compliance with the study protocol and the follow up schedule these circumstances will be discussed with the patient before enrolment in the trial
__label__1	study interventions are Ionizing radiation (IR) therapy . colorectal neoplasms diagnosis and patients who are pregnant
__label__1	study interventions are Cyclosporine . stage iv small lymphocytic lymphoma diagnosis and karnofsky score less_than sixty for adult patients
__label__1	study interventions are Romidepsin . lymphoma cell peripheral diagnosis and subjects for whom transfusion of red blood cells or platelets is impossible such as clinical state and religious beliefs
__label__1	study interventions are Afatinib . carcinoma non small cell lung diagnosis and men capable of fathering child who are unwilling to use adequate contraception prior to study entry for the duration of study participation and for at least twenty-eight days after treatment has ended
__label__1	study interventions are Sunitinib . esophageal cancer diagnosis and patient characteristics
__label__1	study interventions are Rituximab . lymphoma large cell diffuse diagnosis and inability to take oral medication or malabsorption syndrome or any other uncontrolled gastrointestinal condition that would harm ability to take tazemetostat
__label__1	study interventions are Tamoxifen . stage iiib breast cancer diagnosis and radiation therapy within two weeks of enrollment or surgery within four weeks
__label__1	study interventions are Carotenoids . squamous cell carcinoma diagnosis and clinically significant abnormal findings or conditions which might in the opinion of the principal investigator interfere with study evaluations or pose risk to subject safety during the study
__label__1	study interventions are Cyclosporins . stage ii childhood lymphoblastic lymphoma diagnosis and with expected survival of less than six months
__label__1	study interventions are Leuprolide . prostate cancer diagnosis and prostate specific antigen greater than one hundred and sixtyng dl
__label__1	study interventions are Rimiducid . multiple myeloma diagnosis and bovine product allergy
__label__1	study interventions are Dexamethasone . lymphoma diagnosis and unstable angina pectoris
__label__1	study interventions are Cyclophosphamide . recurrent plasma cell myeloma diagnosis and evidence of current uncontrolled cardiovascular conditions including cardiac arrhythmias congestive heart failure angina or myocardial infarction within the past six months note
__label__1	study interventions are Cyclosporins . refractory multiple myeloma diagnosis and current serious systemic illness
__label__1	study interventions are Anti-BCMA-CAR-transduced T cells . multiple myeloma diagnosis and participation in non therapeutic research studies is allowed
__label__1	study interventions are Cisplatin . prior chemotherapy for metastatic disease for patients with esophageal or gastric cancer
__label__1	study interventions are Pertuzumab . gastroesophageal junction cancer diagnosis and subject pregnant or breast feeding or planning to become pregnant within six months after the end of treatment
__label__1	study interventions are Ixazomib . life threatening illness unrelated to cancer
__label__1	study interventions are Everolimus . b cell lymphoma diagnosis and impaired hepatic or renal function as demonstrated by any of the following laboratory values
__label__1	study interventions are Liposomal doxorubicin . epithelioid malignant peripheral nerve sheath tumor diagnosis and patients aged greater_than seventeen years with excess of doc ml of hemoptysis are not eligible
__label__1	study interventions are MesoCancerVac . mesothelioma diagnosis and pregnant or lactating women
__label__1	study interventions are Abiraterone Acetate . stage iib prostate cancer diagnosis and patients with dementia psychiatric illness social situations that would limit compliance with study requirements or would prohibit the understanding and or giving of informed consent will not be eligible
__label__1	study interventions are Everolimus . lymphoma diagnosis and donor
__label__1	study interventions are Cisplatin . known ampulla of vater or pancreatic cancer involving the biliary tract
__label__1	study interventions are Prednisolone phosphate . prostate cancer metastatic diagnosis and active infection requiring systemic antibiotic or anti fungal medication
__label__1	study interventions are Tenofovir . kaposi sarcoma diagnosis and use of drugs within the prior twenty-eight days contraindicated while taking lopinavir ritonavir or efavirenz because of effects on the cytochrome pfour hundred and fifty system
__label__1	study interventions are Megestrol Acetate . stage iii esophageal squamous cell carcinoma diagnosis and radiotherapy contraindications
__label__1	study interventions are Daunorubicin . stage ii contiguous adult lymphoblastic lymphoma diagnosis and participation in clinical trials with other investigational agents not included in this trial within fourteen days of the start of this trial and within thirty days of any dose of bortezomib
__label__1	study interventions are Dacarbazine . growth factors that support platelet or white cell number or function administered within the past three days currently receiving investigational drugs or who have received an investigational drug within the last seven days currently receiving other anti cancer agents currently taking phenobarbital phenytoin carbamazepine oxcarbazepine trileptal rifampin voriconazole itraconazole ketoconazole or other systemically administered azole antifungal drugs aprepitant emend or st
__label__1	study interventions are Antibodies, Monoclonal . stage iii renal cell cancer diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Minocycline . head and neck cancer diagnosis and anorexia bulimia in past two months
__label__1	study interventions are Trastuzumab . synchronous ipsilateral breast cancer of the same subtype er pr her two neu adequately treated basal cell or squamous cell skin cancer in situcervical cancer or other stage or ii cancer from which the patient has been disease free for at least five years
__label__1	study interventions are Antibodies . stage iii diffuse large cell lymphoma diagnosis and pregnant or breastfeeding
__label__1	study interventions are Liposomal doxorubicin . follicular lymphoma grade threeb diagnosis and history of progressive multifocal_leukoencephalopathy
__label__1	study interventions are Endothelial Growth Factors . ovarian brenner tumor diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Transvaginal Ultrasound . currently receiving adjuvant chemotherapy or radiation therapy for cancer excluding tamoxifen
__label__1	study interventions are Cyclophosphamide . renal cell carcinoma diagnosis and severe coronary heart disease cardiac arrhythmia requiring medication or uncontrolled hypertension
__label__1	study interventions are A high-intensity interval exercise group . breast cancer diagnosis and complex ventricular arrhythmias
__label__1	study interventions are Mycophenolic Acid . progression of multiple myeloma or plasma cell leukemia diagnosis and seropositive for the human immunodeficiency virus
__label__1	study interventions are Gold Sodium Thiomalate . stage iiia non small cell lung cancer diagnosis and pregnant women
__label__1	study interventions are Cyclophosphamide . stage iiia non small cell lung cancer diagnosis and clinically significant pulmonary dysfunction as determined by medical history and physical exam patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second fevone less_than doc or diffusion capacity of the lungs for carbon monoxide dlco corrected for hb less_than fifty will be excluded
__label__1	study interventions are Capecitabine . gastric cancer diagnosis and previous history of adverse reactions suggestive of dihydropyrimidine_dehydrogenase dpd deficiency
__label__1	study interventions are Ponatinib . stage iiia non small cell lung cancer diagnosis and part b
__label__1	study interventions are Sunitinib . liver cancer diagnosis and ongoing cardiac dysrhythmias of nci ctcae grade greater than or equal to two
__label__1	study interventions are Pharmacological Study . stage iv non small cell lung cancer diagnosis and patients who have received prior biologic agents less than four weeks prior to enrollment
__label__1	study interventions are Antiviral Agents . stage adult cell leukemia lymphoma diagnosis and recipient is human immunodeficiency virus hiv one positive
__label__1	study interventions are L 647318 . malignant melanoma diagnosis and any condition psychiatric or otherwise which may preclude valid informed consent or consistent compliance with study requirements in the medical opinion of the investigator
__label__1	study interventions are Tin etiopurpurin . sarcoma kaposi diagnosis and active opportunistic infection or condition except thrush or herpes_simplex virus infections
__label__1	study interventions are Palbociclib . breast cancer diagnosis and pregnant women or women of childbearing potential without negative pregnancy test serum or urine within seven days prior to randomization irrespective of the method of contraception used are excluded from this study because the effect of palbociclib on developing fetus is unknown
__label__1	study interventions are Olaparib . patients with synchronous primary endometrial cancer or past history of endometrial cancer unless all of the following conditions are met
__label__1	study interventions are Immunoglobulins . stage iiib primary peritoneal cancer diagnosis and patients who have received prior therapy with any anti vascular endothelial growth factor vegf drug including bevacizumab
__label__1	study interventions are Everolimus . cutaneous cell lymphoma diagnosis and pregnancy or breastfeeding
__label__1	study interventions are Cabozantinib . neuroendocrine tumors diagnosis and the subject requires concomitant treatment in therapeutic doses with anticoagulants such as warfarin or warfarin related agents heparin thrombin or factor xa inhibitors or antiplatelet agents eg clopidogrel
__label__1	study interventions are Nivolumab . stage iiib hepatocellular carcinoma diagnosis and autoimmune demyelinating neuropathy
__label__1	study interventions are Cholecalciferol . newly diagnosed operative invasive ductal breast carcinoma stage ii diagnosis and known hiv positive
__label__1	study interventions are Paclitaxel . stage iva cervical cancer diagnosis and clinically significant gastrointestinal bleeding or uncontrolled peptic ulcer disease
__label__1	study interventions are Veliparib . stage iv breast cancer diagnosis and unstable angina pectoris or cardiac arrhythmia
__label__1	study interventions are Cyclophosphamide . breast cancer female nos diagnosis and known or suspected congestive heart failure greater_than nyha and or coronary heart disease angina pectoris requiring antianginal medication previous history of myocardial infarction evidence of transmural infarction on ecg uncontrolled or poorly controlled arterial hypertension bp greater_than one hundred and forty ninety mm hg under treatment with two antihypertensive drugs rhythm abnormalities requiring permanent treatment clinically significant valvular heart disease
__label__1	study interventions are Propranolol . ovarian cancer diagnosis and inability to accurately answer questions dementia brain metastases or speak english or spanish
__label__1	study interventions are Albumin-Bound Paclitaxel . stage iv fallopian tube cancer diagnosis and patients with serious non healing wound ulcer or bone fracture this includes history of abdominal fistula gastrointestinal perforation or intra abdominal abscess within twenty-eight days patients with granulating_incisions healing by secondary intention with no evidence of fascial_dehiscence or infection are eligible but require weekly wound examinations
__label__1	study interventions are JM 3100 . multiple myeloma diagnosis and despite screening of the patient enrollment randomization is stopped at the study level
__label__1	study interventions are Trastuzumab . breast cancer diagnosis and women who are pregnant or breast feeding
__label__1	study interventions are Pancrelipase . pancreatic cancer diagnosis and active second primary malignancy or history of second primary malignancy within the last three years
__label__1	study interventions are L 647318 . stage zero melanoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to lovastatin
__label__1	study interventions are Cisplatin . cancer of cervix diagnosis and damage to nerves such as being unable to distinguish hot and cold to touch
__label__1	study interventions are Erlotinib Hydrochloride . any concurrent anticancer therapy or radiation
__label__1	study interventions are Cyclosporine . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and infection with hiv
__label__1	study interventions are Protein Kinase Inhibitors . non small cell lung carcinoma diagnosis and abnormalities of the cornea based on history dry eye syndrome sjogrens syndrome congenital abnormality fuchs dystrophy abnormal slit_lamp examination using vital dye_fluorescein bengal_rose and or an abnormal corneal sensitivity test schirmer test or similar tear_production test
__label__1	study interventions are Immunoglobulins . unspecified adult solid tumor protocol specific diagnosis and this excludes placement of vascular access device
__label__1	study interventions are RO4929097 . non squamous non small cell lung cancer diagnosis and history of cns metastases or leptomeningeal metastases except for clinically stable disease
__label__1	study interventions are Fludarabine . recurrent childhood anaplastic large cell lymphoma diagnosis and adult thirty pediatric
__label__1	study interventions are Blinatumomab . history of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide and blinatumomab or other agents used in study
__label__1	study interventions are Androgens . primary peritoneal carcinoma diagnosis and patients with history of hypertension are allowed provided blood pressure is controlled by anti hypertensive treatment
__label__1	study interventions are Fludarabine phosphate . refractory multiple myeloma diagnosis and karnofsky performance score less_than seventy for adult patients
__label__1	study interventions are pharmacological study . primary central nervous system hodgkin lymphoma diagnosis and patients who are currently receiving another investigational drug are not eligible
__label__1	study interventions are CEP-11981 (kinase inhibitor) . cancer diagnosis and has any pre existing coagulopathy recent hemoptysis gross hematuria or gastrointestinal bleeding and history of clinically significant cardiovascular or cerebrovascular event within six months prior to study entry
__label__1	study interventions are Doxorubicin . recurrent ovarian carcinoma diagnosis and history of gastrointestinal perforation patients with history of abdominal fistula will be considered eligible if the fistula was surgically repaired or has healed there has been no evidence of fistula for at least six months and patient is deemed to be at low risk of recurrent fistula
__label__1	study interventions are Tivantinib . received anti cancer therapy including antibody retinoid or hormonal treatment except megestrol acetate as supportive care and radiation within three weeks before dosing
__label__1	study interventions are Etoposide phosphate . non small cell lung cancer diagnosis and had be treated by her targeting agents
__label__1	study interventions are Soy Isoflavones . stage iii hypopharyngeal squamous cell carcinoma diagnosis and pregnancy or lactation patients of child bearing age must agree to use adequate contraception hormonal or barrier method of birth control prior to study entry and for the duration of soy administration
__label__1	study interventions are Cytarabine . stage iii adult burkitt lymphoma diagnosis and any prior use of lenalidomide
__label__1	study interventions are Paclitaxel . breast neoplasms diagnosis and the subject has left ventricular ejection fraction lvef less_than fifty
__label__1	study interventions are Saracatinib . stage ivc verrucous carcinoma of the oral cavity diagnosis and history of allergic reactions attributed to compounds of similar chemical or biological composition to azdfive hundred and thirty
__label__1	study interventions are Huaier Granule . colorectal cancer diagnosis and those who can not take drugs by oral route
__label__1	study interventions are Cyclophosphamide . stage iiib skin melanoma diagnosis and cardiac ischemia or symptoms of coronary artery disease
__label__1	study interventions are Cyclosporins . contiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and donor
__label__1	study interventions are Rituximab . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and residual grade three or grade four non hematologic toxicity after asct
__label__1	study interventions are Dacarbazine . adult subependymoma diagnosis and requirement for antiarrhythmics or other medications known to prolong qtc
__label__1	study interventions are Vidarabine . splenic marginal zone lymphoma diagnosis and donor
__label__1	study interventions are Antibodies . mucinous adenocarcinoma of the colon diagnosis and myocardial infarction or unstable angina less_than six months prior to registration
__label__1	study interventions are Calcium, Dietary . stage iiib gastric cancer diagnosis and prior fistula within thorax including bronchoalveolar or esophageal
__label__1	study interventions are Androgens . prostate cancer diagnosis and prior bilateral orchiectomy
__label__1	study interventions are Letrozole . breast cancer diagnosis and scheduled date of surgical resection that would limit the amount of time taking the intervention to less than twenty-one days
__label__1	study interventions are Fludarabine phosphate . stage iv mantle cell lymphoma diagnosis and patients with other disease or organ dysfunction that would limit survival to less than thirty days
__label__1	study interventions are Laboratory Biomarker Analysis . stage iv non small cell lung cancer diagnosis and anticipated survival of less_than three months
__label__1	study interventions are ganetespib . triple negative breast cancer diagnosis and patients must have completed treatment and recovered from all acute treatment related toxicities prior to administration of first dose of ganetespib
__label__1	study interventions are Apatinib Mesylate . esophageal squamous cell carcinoma diagnosis and local active ulcer lesions with occult blood positive positive melena and haematemesis within two months possibilities of digestive tract hemorrhage
__label__1	study interventions are Succinylcholine . unresectable extrahepatic bile duct carcinoma diagnosis and prior biologic or immunologic therapy equal_than less_than four weeks prior to study entry
__label__1	study interventions are Cyclophosphamide . recurrent plasma cell myeloma diagnosis and pregnancy or breast feeding
__label__1	study interventions are Cholecalciferol . basal cell carcinoma diagnosis and use of oral vitamin containing supplements during the trial period or within thirty days before starting therapy
__label__1	study interventions are Pemetrexed . symptomatic cns metastases or cns metastases requiring steroids
__label__1	study interventions are Magnetic Resonance Imaging (MRI) . prostate cancer diagnosis and uncontrolled serious infection
__label__1	study interventions are Antilymphocyte Serum . recurrent adult diffuse large cell lymphoma diagnosis and any leukemia with morphologic relapse or persistent disease in the bm with greater_than equal_than twenty blasts cytogenetic relapse without morphologic evidence of relapse or cytogenetic persistent disease is acceptable
__label__1	study interventions are Antibodies, Monoclonal . recurrent squamous cell carcinoma of the larynx diagnosis and patients may not be receiving any other investigational agents
__label__1	study interventions are Nivolumab . head and neck cancer diagnosis and patients with abnormal serum chemistry values which in the opinion of the investigator is considered to be clinically significant will be excluded from the study
__label__1	study interventions are Sirolimus . refractory multiple myeloma diagnosis and patients with radiographic changes including pulmonary disease including but not limited to
__label__1	study interventions are Prednisolone . contiguous stage ii adult lymphoblastic lymphoma diagnosis and known history of allergy to captisol
__label__1	study interventions are BB 1101 . cancer diagnosis and severe hypertension severe heart disease kidney disease serum creatinine greater_than three mg dl liver disease ast alt greater_than three times of upper normal range alp greater_than two times of upper normal range
__label__1	study interventions are Etoposide phosphate . concurrent history of neoplasm other than non hodgkin with life expectancy less than three months except for curatively treated non melanoma skin cancer or in situ uterine cervix cancer
__label__1	study interventions are Optonuclear probe . squamous cell carcinoma skin diagnosis and adenopathy clinically suspicious or positively cytopenic
__label__1	study interventions are Oxaliplatin . colorectal cancer diagnosis and women of childbearing potential
__label__1	study interventions are Liposomal doxorubicin . breast cancer diagnosis and patients who have history of another primary malignancy with the exceptions of
__label__1	study interventions are Fludarabine phosphate . stage iii grade one follicular lymphoma diagnosis and presence of uncontrolled psychiatric disorder
__label__1	study interventions are Albumin-Bound Paclitaxel . non small cell lung cancer diagnosis and myocardial infarction within six months prior to day one cycle one
__label__1	study interventions are laboratory biomarker analysis . unspecified adult solid tumor protocol specific diagnosis and patients are excluded for any underlying medical or psychiatric condition which in the opinion of the investigator will make treatment hazardous or obscure the interpretation of adverse events such as condition associated with frequent rashes or diarrhea
__label__1	study interventions are Carboplatin . stage iiia fallopian tube cancer diagnosis and new york heart association nyha class ii or higher congestive heart failure
__label__1	study interventions are Lenalidomide . stage iv adult diffuse mixed cell lymphoma diagnosis and prior use of lenalidomide either concurrently with rituximab or within eight weeks following dose of rituximab
__label__1	study interventions are Everolimus . advanced gastric cancer diagnosis and major surgery within two weeks prior to randomization
__label__1	study interventions are Cytarabine . recurrent childhood lymphoblastic lymphoma diagnosis and pregnant or breast feeding
__label__1	study interventions are Melphalan . multiple myeloma diagnosis and impaired gastrointestinal gi function or gi disease that may significantly alter the absorption of panobinostat
__label__1	study interventions are ultrasound imaging . breast cancer diagnosis and no prior surgery to ipsilateral breast
__label__1	study interventions are Gemcitabine . pancreatic cancer diagnosis and prior radiotherapy or chemotherapy
__label__1	study interventions are Sunitinib . leiomyosarcoma diagnosis and coronary peripheral artery bypass graft
__label__1	study interventions are Rituximab . stage iv adult lymphoblastic lymphoma diagnosis and chemotherapy including monoclonal antibodies or radiotherapy administered for any condition within four weeks prior to entering the study or incomplete recovery from adverse events due to agents administered more than four weeks earlier
__label__1	study interventions are Liposomal doxorubicin . rhabdomyosarcoma extraosseous ewing sarcoma primitive neuroectodermal tumor osteosarcoma chondrosarcoma kaposi sarcoma or aggressive fibromatosis
__label__1	study interventions are Antibodies . stage grade three follicular lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to brentuximab_vedotin and or rituximab
__label__1	study interventions are Leucovorin . kras wild type colorectal cancer diagnosis and history or evidence of interstitial lung disease pneumonitis pulmonary fibrosis
__label__1	study interventions are Antibodies . stage iiib ovarian cancer diagnosis and clinical evidence of encephalopathy
__label__1	study interventions are Fluorouracil . metastatic gastric adenocarcinoma diagnosis and have an acute or subacute bowel obstruction or history of chronic diarrhea which is considered clinically significant in the opinion of the investigator
__label__1	study interventions are MLN0264 . gastroesophageal junction adenocarcinoma diagnosis and has positive test for hepatitis surface antigen
__label__1	study interventions are Immunoglobulin G . b cell small lymphocytic lymphoma recurrent diagnosis and an active infection viral bacterial or fungal requiring systemic therapy subjects receiving prophylactic therapy are eligible
__label__1	study interventions are Fulvestrant . breast cancer er positive her negative pikthreeca gene mutation diagnosis and patients in the combination arms
__label__1	study interventions are Sub Study - 18 FHBG PET/CT Scans . multiple myeloma diagnosis and patients who are unable to tolerate thirty forty-five minutes of imaging
__label__1	study interventions are Doxorubicin . ovarian transitional cell carcinoma diagnosis and note
__label__1	study interventions are Mycophenolate mofetil . childhood grade iii lymphomatoid granulomatosis diagnosis and pregnancy
__label__1	study interventions are Methyltestosterone . stage prostate adenocarcinoma diagnosis and aspartate aminotransferase ast alanine aminotransferase alt greater_than doc uln or greater_than five uln in the presence of liver metastases
__label__1	study interventions are Gelatin Sponge, Absorbable . hepatocellular carcinoma diagnosis and substance abuse current psychological or social conditions that may interfere with the patient participation in the study or evaluation of the study results
__label__1	study interventions are Fludarabine . hepatosplenic cell lymphoma diagnosis and patient has the following organ dysfunction
__label__1	study interventions are Cyclophosphamide . any previous history of ipsilateral invasive breast cancer or ipsilateral dcis patients with synchronous or previous ipsilateral lcis are eligible
__label__1	study interventions are BB 1101 . lymphoma non hodgkin diagnosis and excluded within thirty days of study entry
__label__1	study interventions are Carboxymethylcellulose Sodium . ocular melanoma with extraocular extension diagnosis and influenza vaccination inactivated is permitted during the flu season the preferred time is seven to fourteen days after cdx fourteen01 administration
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and frequent visits for bortezomib injections not feasible
__label__1	study interventions are Ballon implantation . prostate cancer diagnosis and transmural myocardial infarction within the last six months prior to screening
__label__1	study interventions are Prednisone . prostate cancer diagnosis and known history of human immunodeficiency virus hiv infection hepatitis or hepatitis c
__label__1	study interventions are N-monoacetylcystine . stage ivc salivary gland cancer diagnosis and previous receipt of head and neck irradiation
__label__1	study interventions are Fludarabine . stage iii small lymphocytic lymphoma diagnosis and patients with active bacterial or fungal infections unresponsive to medical therapy
__label__1	study interventions are Everolimus . advanced cancer diagnosis and history of hypersensitivity to sirolimus
__label__1	study interventions are Antibodies, Monoclonal . stage iiia esophageal cancer diagnosis and transmural myocardial infarction within the last six months
__label__1	study interventions are Chemotherapy . digestive system neoplasms diagnosis and patients who are suffering from serious autoimmune disease
__label__1	study interventions are Extended Follow up . breast cancer diagnosis and breast implants
__label__1	study interventions are Liposomal doxorubicin . recurrent lymphoblastic lymphoma diagnosis and systemic therapy for the acute management of hyperleukocytosis or acute symptoms corticosteroids cytarabine etc
__label__1	study interventions are Antibodies, Monoclonal . refractory childhood hodgkin lymphoma diagnosis and prior exposure to gemcitabine is not an exclusion criterion
__label__1	study interventions are Gemcitabine . distal urethral cancer diagnosis and patients who have undergone prior radiation to greater than or equal to twenty-five of the bone marrow within the past year are excluded
__label__1	study interventions are Niacinamide . melanoma diagnosis and patients who are pregnant because of possible side effects on the fetus effective contraception will be discussed with each patient
__label__1	study interventions are Leucovorin . stage ii rectal cancer diagnosis and corrected qt qtc greater_than equal_than four hundred and fiftyms
__label__1	study interventions are Vidarabine . contiguous stage ii adult diffuse small cleaved cell lymphoma diagnosis and donors less_than twelve years of age
__label__1	study interventions are Antibodies . stage iic fallopian tube cancer diagnosis and patients with clinical symptoms or signs of gastrointestinal obstruction and or those who require parenteral hydration and or nutrition patients with history or current diagnosis of inflammatory bowel disease are not eligible twelve twenty ten
__label__1	study interventions are Experimental arm . ovarian carcinoma diagnosis and contraindication for blood test
__label__1	study interventions are Succinylcholine . stage ivb nasal cavity and paranasal sinus squamous cell carcinoma diagnosis and patients taking the following prescription or non prescription drugs or other products grapefruit juice are ineligible
__label__1	study interventions are Capecitabine . breast cancer diagnosis and biologic therapy eg bevacizumab trastuzumab for the treatment of metastatic disease must be discontinued greater_than three weeks from the start of protocol treatment
__label__1	study interventions are SABR . lung cancer diagnosis and children are excluded because lung malignancies rarely occur in this age group
__label__1	study interventions are Cyclophosphamide . t cell lymphoma
__label__1	study interventions are Ferric Compounds . metastatic medullary thyroid cancer diagnosis and subjects who have known allergy to iron
__label__1	study interventions are Alemtuzumab . lymphoma diagnosis and known to be hiv
__label__1	study interventions are Pazopanib Hydrochloride . kidney medullary carcinoma diagnosis and prior history of receiving pazopanib treatments
__label__1	study interventions are Busulfan . lymphoma diagnosis and residual disease must be responsive and non bulky less_than fivecm largest diameter
__label__1	study interventions are Akt Inhibitor MK2206 . colon mucinous adenocarcinoma diagnosis and cardiovascular baseline corrected qt by fridericia qtcf greater_than four hundred and fifty msec male or qtcf greater_than four hundred and seventy msec female will exclude patients from entry on study
__label__1	study interventions are Isophosphamide mustard . thymoma diagnosis and currently pregnant or nursing
__label__1	study interventions are Rituximab . stage iv adult diffuse large cell lymphoma diagnosis and known hypersensitivity to phosphorothiate containing oligonucleotides
__label__1	study interventions are Etoposide phosphate . non hodgkin lymphoma diagnosis and pregnant or breastfeeding
__label__1	study interventions are Bevacizumab . glioblastoma multiforme diagnosis and inflammatory bowel disease ulcerative colitis crohn disease or other gastrointestinal conditions with increased risk of perforation
__label__1	study interventions are Hydroxychloroquine . glioblastoma diagnosis and alcoholic liver disease
__label__1	study interventions are Liposomal doxorubicin . splenic marginal zone lymphoma diagnosis and currently receiving hormone therapy or chemotherapy for another malignancy even if the treatment is being provided in the adjuvant treatment setting with no evidence of the original other malignancy
__label__1	study interventions are Laboratory Biomarker Analysis . childhood solid neoplasm diagnosis and patients who have had significant traumatic injury within twenty-eight days prior to enrollment are not eligible
__label__1	study interventions are Pemetrexed . mesothelioma diagnosis and ten major surgical procedure open biopsy or significant traumatic injury within twenty-eight days prior to day zero anticipation of need for major surgical procedure during the course of the study doc
__label__1	study interventions are Cisplatin . human papilloma virus diagnosis and advanced stage iii iv ntwoc nthree or surgically unresectable disease or disease that cannot be fully resected obvious radiologic ecs supraclavicular or matted metastatic disease greater_than three cervical nodes
__label__1	study interventions are Vaccines . recurrent adult diffuse large cell lymphoma diagnosis and there are ongoing non hematological post hct toxicities greater_than equal_than grade three non hematological hem adverse events ae with exception of grade three glucose intolerance and grade three non hem_labs cholesterol triglyceride and hyperglycemia
__label__1	study interventions are Cisplatin . cancer diagnosis and history of known arrhythmias except sinus arrhythmia and atrial fibrillation that is controlled within the past twenty-four weeks
__label__1	study interventions are Irinotecan . gastric cancer diagnosis and any previous treatment with taxane including paclitaxel and docetaxel or irinotecan in the metastatic or recurrent setting
__label__1	study interventions are Macimorelin . cancer cachexia diagnosis and confirmation that the patient is not pregnant will be established by negative serum hcg pregnancy test at the time of enrollment
__label__1	study interventions are Cyclophosphamide . progesterone receptor positive breast cancer diagnosis and evidence of distant metastatic disease
__label__1	study interventions are Cyclophosphamide . past or current history of neoplasm other than breast carcinoma except for
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and history of allergic reaction or intolerance to statin treatment
__label__1	study interventions are Image-guided brachytherapy . carcinoma of the vulva diagnosis and pacemaker brain aneurysm clip inner_ear implant neurostimulator or metal fragments in the eye
__label__1	study interventions are Cisplatin . mesothelioma diagnosis and active bacterial or fungal infection
__label__1	study interventions are Postoperative risk stratification . tumors diagnosis and any condition that might interfere with the subject participation in the study compliance with study requirements or in the evaluation of the study results
__label__1	study interventions are Dasatinib . prostate cancer diagnosis and anti coagulation and or anti platelet therapies
__label__1	study interventions are Liposomal doxorubicin . corticosteroids for treatment of lymphoma within twenty-eight days of study entry chronically administered low dose corticosteroids prednisone less_than twenty mg day for indications other than lymphoma or lymphoma related complications are permitted
__label__1	study interventions are Fludarabine phosphate . recurrent refractory childhood hodgkin lymphoma diagnosis and forced expiratory volume in one second fevone less_than thirty
__label__1	study interventions are Cyclophosphamide . metastatic breast cancer diagnosis and concomitant treatment with medicine containing phenytoin or medication received in the context of trial or participation in another therapeutic clinical trial within less_than thirty days prior treatment with chemotherapy
__label__1	study interventions are HPPH . stage ii adenoid cystic carcinoma of the oral cavity diagnosis and white blood cell wbc less_than four zero
__label__1	study interventions are Capecitabine . well differentiated adrenal cortex carcinoma diagnosis and major surgical procedure within four weeks of treatment
__label__1	study interventions are Thalidomide . contiguous stage ii grade one follicular lymphoma diagnosis and positive serology because of prior vaccination is allowed
__label__1	study interventions are Isophosphamide mustard . recurrent adult diffuse mixed cell lymphoma diagnosis and no concurrent treatment with valproic acid or on valproic acid within two weeks of study enrollment
__label__1	study interventions are PQR 309 . concomitant anticancer therapy chemotherapy radiotherapy hormonal immunotherapy
__label__1	study interventions are Fludarabine phosphate . stage iv adult diffuse large cell lymphoma diagnosis and patients with conventional transplant options conventional transplant should be the priority for eligible patients equal_than less_than fifty yr of age who have related donor mismatched for single hla b or drbone antigen
__label__1	study interventions are Magnetic Resonance Imaging . stage iiia breast cancer diagnosis and history of diabetes mellitus heart disease or tia stroke
__label__1	study interventions are Antibodies, Monoclonal . diffuse large cell lymphoma diagnosis and concurrent systemic corticosteroid use for any reason except as premedication in case of known or suspected allergies to contrast media or as premedication for potential side effects of rituximab treatment
__label__1	study interventions are Leucovorin . rectum neoplasms diagnosis and known hiv positivity and on combination antiretroviral therapy because of the potential for pharmacokinetic interactions with the study drugs
__label__1	study interventions are Ibrutinib . refractory follicular lymphoma diagnosis and treatment with an immunosuppressive regimen of corticosteroids or other immunosuppressive medication methotrexate rapamycin within thirty days of study treatment note
__label__1	study interventions are Flucytosine . neoplasms diagnosis and cerebrovascular accident including transient ischemic attacks within the past six months
__label__1	study interventions are Thiotepa . osteosarcoma diagnosis and patients with multiple relapses for whom surgical resection seems impossible even after chemotherapy
__label__1	study interventions are Antilymphocyte Serum . recurrent adult diffuse small cleaved cell lymphoma diagnosis and whole liver twenty gy
__label__1	study interventions are Interferons . stage iii multiple myeloma diagnosis and active connective tissue disease
__label__1	study interventions are Albumin-Bound Paclitaxel . advanced gastric cancer diagnosis and legal incapacity
__label__1	study interventions are Liposomal doxorubicin . ovarian serous adenocarcinoma diagnosis and patients with the following risk factors should have baseline cardiac function assessment
__label__1	study interventions are Immunoglobulins . stage ivb verrucous carcinoma of the oral cavity diagnosis and any other hemorrhage bleeding event greater_than ctcae grade three within four weeks of first dose of study drug
__label__1	study interventions are Oxaliplatin . gastric cardia adenocarcinoma diagnosis and prior radiation to chest or abdomen or to greater_than thirty of the marrow cavity
__label__1	study interventions are Trametinib . cancer diagnosis and history of acute coronary syndromes including unstable angina coronary angioplasty or stenting within the past twenty-four weeks
__label__1	study interventions are Irinotecan . metastatic colorectal cancer diagnosis and women who are pregnant or lactating
__label__1	study interventions are Antibodies . metastatic malignant neoplasm in the bone marrow diagnosis and patients with known pre existing diabetes mellitus will be excluded from study
__label__1	study interventions are Paclitaxel . progesterone receptor negative breast cancer diagnosis and receipt of taxane for adjuvant therapy or metastatic disease in the last twelve months
__label__1	study interventions are Thalidomide . multiple myeloma diagnosis and serious medical or psychiatric illness likely to interfere with participation in this clinical study
__label__1	study interventions are Albumin-Bound Paclitaxel . recurrent breast cancer diagnosis and pregnant or breast feeding women
__label__1	study interventions are Oxaliplatin . periampullary adenocarcinoma diagnosis and in case of the patients with short term use of steroids the enrollment is permitted if the administration is stopped two weeks before screening
__label__1	study interventions are tumor marker detection in lymph nodes . prostate cancer diagnosis and hiv antibody test hbs ag detected in serum and or chronic hepatitis
__label__1	study interventions are Estradiol . cancer of the breast diagnosis and chemotherapy or radiotherapy within one week of beginning treatment in the clinical trial
__label__1	study interventions are Dexamethasone 21-phosphate . other prior active malignancy within the past two years except currently treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast
__label__1	study interventions are Carboplatin . carcinoma non small cell lung diagnosis and peripheral neuropathy greater_than grade one
__label__1	study interventions are Antibodies . refractory multiple myeloma diagnosis and positive crossmatch between donor and recipient
__label__1	study interventions are Rituximab . extranodal marginal zone cell lymphoma of mucosa associated lymphoid tissue diagnosis and common terminology for adverse events ctcae version doc grade three anxiety
__label__1	study interventions are Cisplatin . ovarian mucinous cystadenocarcinoma diagnosis and patients with known hypersensitivity to chinese_hamster ovary cell products or other recombinant human or humanized antibodies patients with known allergy to cremophor or polysorbate eighty
__label__1	study interventions are Cetuximab . glioblastoma diagnosis and patients who completed chemo rt less than six months prior to enrollment
__label__1	study interventions are Cyclophosphamide . breast cancer diagnosis and laboratory assessments as outlined in the protocol
__label__1	study interventions are Mycophenolate mofetil . recurrent cutaneous cell non hodgkin lymphoma diagnosis and left ventricular ejection fraction less_than thirty-five
__label__1	study interventions are Paclitaxel . fallopian tube clear cell adenocarcinoma diagnosis and patients who are pregnant or nursing
__label__1	study interventions are G-202 . clear cell renal cell carcinoma diagnosis and uncontrolled cardiac hepatic renal or neurologic psychiatric disorder
__label__1	study interventions are Mycophenolate mofetil . recurrent mantle cell lymphoma diagnosis and current uncontrolled bacterial viral or fungal infection currently taking medication with evidence of progression of clinical symptoms or radiologic findings
__label__1	study interventions are AMG 228 . cancer diagnosis and active autoimmune disease history of autoimmune disease
__label__1	study interventions are Albumin-Bound Paclitaxel . hereditary breast and ovarian cancer syndrome diagnosis and unstable angina pectoris
__label__1	study interventions are Poly I-C . iris melanoma diagnosis and cirrhosis or chronic hepatitis virus positivity or chronic hepatitis infection
__label__1	study interventions are Cetuximab . colorectal cancer metastatic diagnosis and prior systemic chemotherapy for metastatic disease
__label__1	study interventions are Insulin . gastro enteropancreatic neuroendocrine tumor diagnosis and patients with history of non compliance to medical regimens
__label__1	study interventions are Vincristine . lymphoma diagnosis and history of cns involvement is not an exclusion criterion
__label__1	study interventions are Aldesleukin . metastatic colorectal cancer diagnosis and concurrent opportunistic infections the experimental treatment being evaluated in this protocol depends on an intact immune system
__label__1	study interventions are Doxorubicin . stage ia breast cancer diagnosis and note
__label__1	study interventions are Trastuzumab . reccurent metastatic solid tumor disease diagnosis and patients with other concurrent severe and or uncontrolled medical disease which could compromise participation in the study including uncontrolled diabetes cardiac disease uncontrolled hypertension congestive cardiac failure ventricular arrhythmias active ischemic heart disease myocardial infection within one year chronic liver or renal disease active gastrointestinal tract ulceration severely impaired lung function
__label__1	study interventions are Mycophenolic Acid . splenic marginal zone lymphoma diagnosis and liver alkaline phosphatase greater_than equal_than three upper limit of normal
__label__1	study interventions are Bicalutamide . prostate cancer diagnosis and men able to conceive and unwilling to practice an effective method of birth control
__label__1	study interventions are Estradiol . metastatic breast cancer diagnosis and prior stem cell or bone marrow transplantation
__label__1	study interventions are questionnaire administration . pre existing lymphedema prior to breast cancer diagnosis
__label__1	study interventions are pharmacological study . unspecified adult solid tumor protocol specific diagnosis and prior treatment with any heat_shock protein hsp ninety or histone_deacetylase hdac inhibitor compounds
__label__1	study interventions are Immunoglobulins . stage iv melanoma diagnosis and patients with underlying heart conditions who are deemed ineligible for surgery by cardiology consult patients with reversible ischemic changes on cardiac stress test
__label__1	study interventions are Fractionated Stem Cell Infusions . multiple myeloma diagnosis and pregnant or lactating females
__label__1	study interventions are Antibodies, Monoclonal . prostate cancer diagnosis and prior investigational immunotherapy
__label__1	study interventions are Fludarabine . metastatic renal cancer diagnosis and concurrent systemic steroid therapy
__label__1	study interventions are Albumin-Bound Paclitaxel . patients with current diagnosis of borderline epithelial ovarian tumor formerly tumors of low malignant potential or recurrent invasive epithelial ovarian primary peritoneal or fallopian tube cancer treated with surgery only such as patients with stage ia or ib low grade epithelial ovarian or fallopian tube cancers are not eligible patients with prior diagnosis of borderline tumor that was surgically resected and who subsequently develop an unrelated new invasive epithelial ovarian peritoneal primary or fallopian tube cancer are eligible provided that they have not received prior chemotherapy for any ovarian tumor
__label__1	study interventions are AZD8055 . glioblastoma multiforme diagnosis and patients with peripheral neuropathy ctcae greater_than one in the prior four weeks or active muscle diseases including dermatomyositis polymyositis inclusion body myositis muscular dystrophy and metabolic myopathy or family history of myopathy
__label__1	study interventions are Melphalan . gastrointestinal tumor diagnosis and newly diagnosed patients with no prior attempt at curative therapy
__label__1	study interventions are Fludarabine phosphate . recurrent adult cell leukemia lymphoma diagnosis and inability to obtain informed consent
__label__1	study interventions are Hormones . stage iv prostate cancer diagnosis and no concurrent strong inhibitors or inducers of cypthreeafour
__label__1	study interventions are Cyclosporins . recurrent childhood lymphoblastic lymphoma diagnosis and known allergy to csf
__label__1	study interventions are Mibefradil . glioblastoma multiforme gbm diagnosis and requirement for calcium channel blocker for blood pressure control that cannot be switched to an antihypertensive with an alternative mechanism of action
__label__1	study interventions are Sirolimus . stage ivb uterine corpus cancer diagnosis and patients who are pregnant or nursing
__label__1	study interventions are Fluorouracil . stage iv gastric cancer diagnosis and gdc four hundred and forty-nine inhibits cytochrome pfour hundred and fifty family two subfamily polypeptide eight cyptwoceight cytochrome pfour hundred and fifty family two subfamily polypeptide nine cyptwocnine and cytochrome pfour hundred and fifty family two subfamily polypeptide 1nine cyptwoc1nine drug metabolism enzymes in vitro at concentrations that may be clinically relevant therefore caution should be exercised when dosing gdc four hundred and forty-nine concurrently with medications that are substrates of cyptwoceight cyptwocnine and cyptwoc1nine and have narrow therapeutic windows
__label__1	study interventions are Antibodies, Monoclonal . lung cancer diagnosis and the patient is pregnant confirmed by serum hcg if applicable or is breastfeeding
__label__1	study interventions are Sorafenib . renal cancer diagnosis and patients with congenital long qt syndrome
__label__1	study interventions are Lenvatinib . lymphomas diagnosis and subjects who are unwilling or unable to abide by the requirements of the study
__label__1	study interventions are Cytarabine . myeloproliferative myelodysplastic neoplasm diagnosis and patient refuses to use adequate contraception
__label__1	study interventions are Thiotepa . recurrent adult lymphoblastic lymphoma diagnosis and no psychiatric conditions which would prevent delivery of care psychology clearance is necessary
__label__1	study interventions are Antineoplastic Agents, Hormonal . breast neoplasms diagnosis and patient refuses to sign consent
__label__1	study interventions are gamma secretase inhibitor PF-03084014 . aids related kaposi sarcoma diagnosis and participants requiring blood transfusions to maintain hemoglobin hgb eligibility
__label__1	study interventions are Paclitaxel . recurrent endometrial carcinoma diagnosis and history of significant peripheral neuropathy or significant central nervous system disease
__label__1	study interventions are Dacarbazine . adult mixed glioma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to vorinostat saha or other agents used in study
__label__1	study interventions are Vaccines . stage cutaneous cell non hodgkin lymphoma diagnosis and diagnosed with greater_than grade two graft versus host disease gvhd before day two8 post hct and diagnosed with greater_than grade two gvhd between day two8 post hct and administration of the twond vaccine at day fifty-six
__label__1	study interventions are Liposomal doxorubicin . refractory lymphomas diagnosis and patient has history or current evidence of any condition therapy or lab abnormality that might confound the results of the study interfere with the patient participation for the full duration of the study or is not in the best interest of the patient to participate
__label__1	study interventions are questionnaire administration . stage iii verrucous carcinoma of the larynx diagnosis and other medical conditions that could make the patient not able to comply with the treatment
__label__1	study interventions are Albumin-Bound Paclitaxel . brenner tumor diagnosis and pregnant women are excluded from this study because osi seven hundred and seventy-four has the potential for teratogenic or abortifacient effects because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with osi seven hundred and seventy-four breastfeeding should be discontinued if the mother is treated with osi seven hundred and seventy-four these potential risks may also apply to other agents used in this study
__label__1	study interventions are Buparlisib . recurrent mantle cell lymphoma diagnosis and barrier methods of contraception
__label__1	study interventions are Fulvestrant . breast cancer diagnosis and known severe hypersensitivity to everolimus or similar drugs or any of the excipients of this product
__label__1	study interventions are massage therapy . extramedullary plasmacytoma diagnosis and parents caregivers who have previously provided consistent massage for their child will be excluded from the study child is receiving radiation only
__label__1	study interventions are Antibodies, Monoclonal . stage iii melanoma diagnosis and patients with isolated vitiligo remain eligible
__label__1	study interventions are Dacarbazine . neoplasms diagnosis and prior radiation therapy irradiating more than ten of total bone marrow
__label__1	study interventions are Dexamethasone acetate . multiple myeloma diagnosis and participants with history of malignancy other than mm within five years before the date of the first daratumumab administration
__label__1	study interventions are BB 1101 . stage ii multiple myeloma diagnosis and referring physician not registered with s
__label__1	study interventions are ADCT-301 . non hodgkin lymphoma diagnosis and failure to recover to common terminology criteria for adverse events ctcae version doc grade zero or grade one from acute non hematologic toxicity except alopecia or grade two or lower neuropathy due to previous therapy prior to screening
__label__1	study interventions are Paclitaxel . large cell lung carcinoma diagnosis and transmural myocardial infarction within the last six months
__label__1	study interventions are Fludarabine phosphate . stage iii mantle cell lymphoma diagnosis and karnofsky adult or lansky for equal_than less_than sixteen years performance status equal_than less_than fifty
__label__1	study interventions are blood sampling . thyroid neoplasms diagnosis and severe immunodeficiency
__label__1	study interventions are Rituximab . recurrent grade three follicular lymphoma diagnosis and patients with fasting blood glucose greater_than equal_than one hundred and twenty mg dl doc mmol patients with diabetes mellitus are eligible if they require oral agents only and have fasting blood glucose equal_than less_than one hundred and twenty mg dl patients with history of diabetes mellitus who require daily long acting or mealtime insulin are not eligible patients who have previously required treatment for hyperglycemia due to steroids or other medications are eligible as long as they have not required insulin or any other oral agent within two months prior to study enrollment
__label__1	study interventions are Pyruvate (13C) . prostate cancer diagnosis and history of use of five reductase inhibitor is allowed provided it was discontinued at least one month prior to study entry
__label__1	study interventions are diffusion-weighted magnetic resonance imaging . tumors metastatic to brain diagnosis and patients with leptomeningeal disease
__label__1	study interventions are Antibodies . sarcoma diagnosis and women of child bearing potential who are pregnant as evidenced by positive serum pregnancy test minimum sensitivity twenty-five iu or equivalent units of hcg or nursing
__label__1	study interventions are Mycophenolate mofetil . recurrent childhood grade iii lymphomatoid granulomatosis diagnosis and history of brain metastases
__label__1	study interventions are Mycophenolate mofetil . contiguous stage ii mantle cell lymphoma diagnosis and presence of circulating leukemic blasts in the peripheral blood detected by standard pathology for patients with aml all or cml
__label__1	study interventions are Carmustine . recurrent diffuse large cell lymphoma diagnosis and creatinine greater_than doc mg dl
__label__1	study interventions are Sorafenib . other concurrent anticancer agents or therapies
__label__1	study interventions are Aromatase Inhibitors . hormone receptor positive tumor diagnosis and potent or moderate inhibitors or inducers of cypthreeafour five pgp_mdrone and bcrp see appendix five
__label__1	study interventions are Ramucirumab . pancreatic cancer diagnosis and acute or sub acute intestinal obstruction
__label__1	study interventions are Docetaxel . breast cancer diagnosis and hrt within four weeks of starting treatment
__label__1	study interventions are Dexamethasone 21-phosphate . hematologic cancer diagnosis and treatment with nitrosoureas such as carmustine bicnu nitrogen_mustard agents or melphalan within six weeks of first dose of elotuzumab
__label__1	study interventions are Docetaxel . advanced solid tumors diagnosis and low dose steroid for the control of nausea and vomiting topical steroid inhaled steroid or use of dexamethasone
__label__1	study interventions are Tazemetostat . renal medullary carcinoma diagnosis and is unwilling to exclude grapefruit juice seville_oranges and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
__label__1	study interventions are BPX-501 . hematologic neoplasms diagnosis and grade ii acute gvhd or chronic extensive gvhd due to previous allograft at the time of screening
__label__1	study interventions are Lenalidomide . stage iii adult lymphoblastic lymphoma diagnosis and pregnant or breast feeding females lactating females must agree not to breast feed while taking lenalidomide
__label__1	study interventions are Plyometric training program . neurofibromatosis type one diagnosis and participation in simultaneous medical intervention trial
__label__1	study interventions are Fludarabine phosphate . lymphoma diagnosis and female patients who are pregnant or lactating
__label__1	study interventions are Doxycycline . currently receiving anticancer agents other than erlotinib
__label__1	study interventions are Vinblastine . breast cancer diagnosis and have received chemotherapy after metastasis
__label__1	study interventions are Cisplatin . carcinoma non small cell lung diagnosis and palliative radiotherapy will be allowed as described in the prior and concomitant therapy section
__label__1	study interventions are Antilymphocyte Serum . noncontiguous stage ii marginal zone lymphoma diagnosis and females of childbearing potential with positive pregnancy test
__label__1	study interventions are Immunosuppressive Agents . contiguous stage ii adult lymphoblastic lymphoma diagnosis and patient unable to give informed consent
__label__1	study interventions are Mycophenolate mofetil . recurrent adult hodgkin lymphoma diagnosis and adult
__label__1	study interventions are Immunoglobulins . stage iv squamous cell carcinoma of the nasopharynx diagnosis and john wort kava_ephedra ma_huang gingko_biloba dehydroepiandrosterone_dhea yohimbe_saw palmetto and ginseng fruits include the cytochrome pfour hundred and fifty family three subfamily cypthreea inhibitors seville_oranges grapefruit pummelos or exotic_citrus fruits
__label__1	study interventions are Mycophenolic Acid . stage iv adult immunoblastic large cell lymphoma diagnosis and age greater_than seventy-five years
__label__1	study interventions are Fludarabine . stage iv adult diffuse large cell lymphoma diagnosis and consenting five of six or six of six hla matched related donor available
__label__1	study interventions are Mycophenolate mofetil . recurrent adult grade iii lymphomatoid granulomatosis diagnosis and donor
__label__1	study interventions are INO-3106, INO-9012 . aerodigestive precancerous lesions and malignancies diagnosis and administration of any vaccine within six weeks of enrollment
__label__1	study interventions are Antibodies . adenocarcinoma of the esophagus diagnosis and patients with history of the following within twelve months of study entry are not eligible
__label__1	study interventions are Dasatinib . giant cell tumor of bone diagnosis and subjects currently taking one or more of the following drugs that are generally accepted to have risk of causing torsades de pointes
__label__1	study interventions are Pemetrexed . malignant pleural mesothelioma diagnosis and any prior chemotherapy including intracavitary administration
__label__1	study interventions are oral JAK inhibitor INCB18424 . peripheral cell lymphoma diagnosis and any prior or concomitant use of another jak inhibitor
__label__1	study interventions are Niacinamide . solid tumors diagnosis and investigational drugs
__label__1	study interventions are KW-2450 . solid tumor diagnosis and subjects with inflammatory diseases of the gastrointestinal tract or malabsorption syndrome
__label__1	study interventions are Angiogenesis Inhibitors . glioblastoma multiforme diagnosis and class iii or iv congestive heart failure as defined by the new york heart association nyha see appendix one doc
__label__1	study interventions are Etoposide phosphate . intraocular lymphoma diagnosis and history of allergic reactions attributed to compounds of similar chemical or biologic composition to busulfan other agents used in this study
__label__1	study interventions are Pazopanib . carcinoma renal cell diagnosis and pregnant or lactating female
__label__1	study interventions are Dexamethasone 21-phosphate . uveal melanoma diagnosis and presence of any ocular condition that in the opinion of one of the investigators will prevent at least two lines of improvement in best corrected visual acuity
__label__1	study interventions are Camptothecin . rectal cancer diagnosis and creatinine clearance less_than fifty ml min
__label__1	study interventions are Cyclophosphamide . stage iii non hodgkin lymphoma diagnosis and concurrent administration of any other investigational agent s
__label__1	study interventions are Cyclophosphamide . lymphoma diagnosis and patients with active hepatitis or infection not including patients with prior hepatitis vaccination